PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Kumar, V; Misra, V; Chaurasiya, D; Verma, N				Kumar, Varsha; Misra, Vatsala; Chaurasiya, Dilip; Verma, Neelima			Collecting duct carcinoma kidney masquerading as hydatid cyst: A rare case report and review of literature	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Review						Bosniak; collecting duct; renal cyst		Cystic renal masses pose diagnostic challenge especially when they belong to Bosniak Type II and III. Septal and nodular enhancement on computed tomography (CT) is the strongest predictor of malignant process. A unilocular cyst with a calcified rim or a multilocular cystic lesion with heterogeneity on CT goes in favor of hydatid disease. We report a case in a 65-year-old female who presented with painless hematuria, was found to have a cystic mass in the right kidney. The mass turned out to be collecting duct carcinoma after histopathological examination though imaging studies were in favor of a hydatid cyst.	[Kumar, Varsha; Misra, Vatsala; Chaurasiya, Dilip; Verma, Neelima] MLN Med Coll, Dept Pathol, Allahabad 211002, Uttar Pradesh, India	Kumar, V (reprint author), MLN Med Coll, Dept Pathol, Allahabad 211002, Uttar Pradesh, India.	drvarshakumar1@gmail.com					BOSNIAK MA, 1986, RADIOLOGY, V158, P1; DIMOPOULOS MA, 1993, BRIT J UROL, V71, P388, DOI 10.1111/j.1464-410X.1993.tb15978.x; FOOT NC, 1949, JAMA-J AM MED ASSOC, V139, P356, DOI 10.1001/jama.1949.02900230010003; Harisinghani MG, 2003, AM J ROENTGENOL, V180, P755, DOI 10.2214/ajr.180.3.1800755; Li M, 2001, MODERN PATHOL, V14, P623, DOI 10.1038/modpathol.3880361; RUMPELT HJ, 1991, HISTOPATHOLOGY, V18, P115, DOI 10.1111/j.1365-2559.1991.tb01453.x; Siegel CL, 1997, AM J ROENTGENOL, V169, P813, DOI 10.2214/ajr.169.3.9275902; Silverman SG, 2008, RADIOLOGY, V249, P16, DOI 10.1148/radiol.2491070783; Srigley JR, 1998, SEMIN DIAGN PATHOL, V15, P54; Srigley JR, 2004, WHO CLASSIFICATION T, P33	10	1	1	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					410	413		10.4103/IJPM.IJPM_849_16			4	Pathology	Pathology	GN7CT	WOS:000439282500025	30004068	DOAJ Gold			2019-10-28	
J	He, R; Ding, W; Viswanatha, DS; Chen, D; Shi, M; Van Dyke, D; Tian, SL; Dao, LN; Parikh, SA; Shanafelt, TD; Call, TG; Ansell, SM; Leis, JF; Mai, M; Hanson, CA; Rech, KL				He, Rong; Ding, Wei; Viswanatha, David S.; Chen, Dong; Shi, Min; Van Dyke, Daniel; Tian, Shulan; Dao, Linda N.; Parikh, Sameer A.; Shanafelt, Tait D.; Call, Timothy G.; Ansell, Stephen M.; Leis, Jose F.; Mai, Ming; Hanson, Curtis A.; Rech, Karen L.			PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT) A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						PD-1; PD-L1; chronic lymphocytic leukemia; small lymphocytic lymphoma; Richter transformation; diffuse large B-cell lymphoma; clonal relatedness	DEATH LIGAND 1; PROLIFERATION CENTERS; T-CELLS; LYMPHOPROLIFERATIVE DISORDERS; PROGRAMMED DEATH-1; HODGKIN LYMPHOMAS; ADVANCED MELANOMA; PDL1 EXPRESSION; LUNG-CANCER; MOUSE MODEL	Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a low-grade B-cell neoplasm and similar to 2% to 9% patients develop an aggressive lymphoma, most commonly diffuse large B-cell lymphoma (Richter transformation, DLBCL-RT). Programmed death-1 (PD-1) pathway plays a crucial role in tumor host immunity evasion and its blockade has emerged as an effective anti-cancer immunotherapy. PD-L1 and PD-1 expression has shown predictive value in anti-PD cancer immunotherapy; however, it has not been well documented in CLL/SLL and DLBCL-RT. We evaluated PD-1 and PD-L1 expression by immunohistochemistry in 39 CLL/SLL, 15 DLBCL-RT, and 26 other DLBCL. In CLL/SLL, neoplastic B-cell PD-1 expression was weak and restricted to prolymphocytes/paraimmunoblasts within proliferation centers (PCs) and accentuated PCs of all sizes. Neoplastic B-cell PD-1 expression was highly prevalent and demonstrated increased intensity in DLBCL-RT, but in contrast was only rarely seen in other DLBCL (12/15 vs. 1/26; P<0.0001). An excellent correlation (90% concordance) was observed between neoplastic B-cell PD-1 immunohistochemistry positivity and molecularly defined CLL/SLL clonal relatedness in DLBCL-RT. PD-L1 expression was observed on the neoplastic B cells in rare DLBCL-RT and other DLBCL cases (1/15 vs. 1/26; P>0.05) as well as background histiocytes and dendritic cells. Overall survival of DLBCL-RT was significantly inferior to that of the other DLBCL (median, 16.9 vs. 106.1mo; P=0.002). Our findings suggest a biological continuum from prolymphocytes/paraimmunoblasts in CLL/SLL PCs to the neoplastic B-cells in DLBCL-RT. The characteristic PD-1 expression in DLBCL-RT makes it a potential surrogate marker for determining clonal relatedness to CLL/SLL, which may have important prognostic and therapeutic implications.	[He, Rong; Viswanatha, David S.; Chen, Dong; Shi, Min; Dao, Linda N.; Mai, Ming; Hanson, Curtis A.; Rech, Karen L.] Mayo Clin, Coll Med, Div Hematopathol, Rochester, MN 55905 USA; [Ding, Wei; Parikh, Sameer A.; Shanafelt, Tait D.; Call, Timothy G.; Ansell, Stephen M.] Mayo Clin, Coll Med, Div Hematol, Rochester, MN USA; [Van Dyke, Daniel] Mayo Clin, Coll Med, Lab Genet & Genom, Rochester, MN USA; [Tian, Shulan] Mayo Clin, Coll Med, Biomed Stat & Informat, Rochester, MN USA; [Leis, Jose F.] Mayo Clin, Coll Med, Div Hematol, Scottsdale, AZ USA	He, R (reprint author), Mayo Clin, Coll Med, Div Hematopathol, Rochester, MN 55905 USA.	he.rong@mayo.edu	Chen, Dong/V-8825-2019		MerckMerck & Company; GenentechRoche HoldingGenentech; Celgene; Pharmacyclics; Jansen; GlaxoSmithKlineGlaxoSmithKline; AbbVieAbbott Laboratories; Hospira; Cephalon	W.D. has received research funding from Merck and is an advisory board member of Alexion. T.D.S. has received research support from Genentech, Celgene, Pharmacyclics, Jansen, GlaxoSmithKline, AbbVie, Hospira, and Cephalon. S.A.P. has received research funding from Pharmacyclics and also participated in advisory boards at Pharmacyclics and AstraZeneca. He was not personally compensated for both the research funding and the advisory boards. The remaining authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Andorsky DJ, 2011, CLIN CANCER RES, V17, P4232, DOI 10.1158/1078-0432.CCR-10-2660; Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Berghoff AS, 2014, CLIN NEUROPATHOL, V33, P42, DOI 10.5414/NP300698; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Brusa D, 2013, HAEMATOLOGICA, V98, P953, DOI 10.3324/haematol.2012.077537; Chang K L, 1992, Diagn Mol Pathol, V1, P246, DOI 10.1097/00019606-199203000-00037; Chen BJ, 2013, CLIN CANCER RES, V19, P3462, DOI 10.1158/1078-0432.CCR-13-0855; Chen LP, 2015, J CLIN INVEST, V125, P3384, DOI 10.1172/JCI80011; Ciccone M, 2012, LEUKEMIA, V26, P499, DOI 10.1038/leu.2011.247; Ding W, 2017, BLOOD, V129, P3419, DOI 10.1182/blood-2017-02-765685; Dorfman DM, 2006, AM J SURG PATHOL, V30, P802, DOI 10.1097/01.pas.0000209855.28282.ce; Falchi L, 2014, BLOOD, V123, P2783, DOI 10.1182/blood-2013-11-536169; Fang X, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006398; FOON KA, 1993, ANN INTERN MED, V119, P63, DOI 10.7326/0003-4819-119-1-199307010-00011; Four M, 2017, HEMATOL ONCOL, V35, P487, DOI 10.1002/hon.2375; Francisco LM, 2010, IMMUNOL REV, V236, P219, DOI 10.1111/j.1600-065X.2010.00923.x; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gibson SE, 2016, BRIT J HAEMATOL, V175, P173, DOI 10.1111/bjh.13844; Gine E, 2010, HAEMATOL-HEMATOL J, V95, P1526, DOI 10.3324/haematol.2010.022277; Gradowski JF, 2012, AM J CLIN PATHOL, V138, P132, DOI 10.1309/AJCPIVKZRMPF93ET; Gravelle P, 2017, ONCOTARGET, V8, P44960, DOI 10.18632/oncotarget.16680; Green MR, 2012, CLIN CANCER RES, V18, P1611, DOI 10.1158/1078-0432.CCR-11-1942; Grzywnowicz M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035178; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Herreros B, 2010, LEUKEMIA, V24, P872, DOI 10.1038/leu.2009.285; Jain P, 2015, BLOOD, V125, P2062, DOI 10.1182/blood-2014-09-603670; Kiyasu J, 2015, BLOOD, V126, P2193, DOI 10.1182/blood-2015-02-629600; Kleffel S, 2015, CELL, V162, P1242, DOI 10.1016/j.cell.2015.08.052; Kroft SH, 2000, AM J CLIN PATHOL, V114, P523, DOI 10.1309/RM1Q-1T0B-WKQB-AF5A; Krysov S, 2012, BLOOD, V119, P170, DOI 10.1182/blood-2011-07-370403; Kwon D, 2016, HISTOPATHOLOGY, V68, P1079, DOI 10.1111/his.12882; Lesokhin AM, 2016, J CLIN ONCOL, V34, P2698, DOI 10.1200/JCO.2015.65.9789; Linderoth J, 2003, CLIN CANCER RES, V9, P722; Maddocks KJ, 2015, JAMA ONCOL, V1, P80, DOI 10.1001/jamaoncol.2014.218; Mao ZR, 2007, AM J SURG PATHOL, V31, P1605, DOI 10.1097/PAS.0b013e31804bdaf8; MATOLCSY A, 1995, AM J PATHOL, V147, P207; McClanahan F, 2015, BLOOD, V126, P212, DOI 10.1182/blood-2015-02-626754; McClanahan F, 2015, BLOOD, V126, P203, DOI 10.1182/blood-2015-01-622936; Menter T, 2016, HUM PATHOL, V54, P17, DOI 10.1016/j.humpath.2016.03.005; Muenst S, 2010, DIS MARKERS, V29, P47, DOI 10.3233/DMA-2010-0725; Packham G, 2010, SEMIN CANCER BIOL, V20, P391, DOI 10.1016/j.semcancer.2010.08.004; Parikh SA, 2013, BRIT J HAEMATOL, V162, P774, DOI 10.1111/bjh.12458; Ramsay AG, 2008, J CLIN INVEST, V118, P2427, DOI 10.1172/JCI35017; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257; ROBERTSON LE, 1993, J CLIN ONCOL, V11, P1985, DOI 10.1200/JCO.1993.11.10.1985; Rossi D, 2008, BRIT J HAEMATOL, V142, P202, DOI 10.1111/j.1365-2141.2008.07166.x; Rossi D, 2011, BLOOD, V117, P3391, DOI 10.1182/blood-2010-09-302174; Stevenson FK, 2011, BLOOD, V118, P4313, DOI 10.1182/blood-2011-06-338855; Swerdlow SH, 2008, WHO CLASSIFICATION T; Swerdlow SH, 2017, WHO CLASSIFICATION T; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tsimberidou AM, 2005, CANCER-AM CANCER SOC, V103, P216, DOI 10.1002/cncr.20773; Tsimberidou AM, 2002, LEUKEMIA LYMPHOMA, V43, P767, DOI 10.1080/10428190290016872; Wang HY, 2017, BLOOD, V129, P2592, DOI 10.1182/blood-2017-02-766857; Westin JR, 2014, LANCET ONCOL, V15, P69, DOI 10.1016/S1470-2045(13)70551-5; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Xerri L, 2008, HUM PATHOL, V39, P1050, DOI 10.1016/j.humpath.2007.11.012; Xia Y, 2016, BBA-REV CANCER, V1865, P58, DOI 10.1016/j.bbcan.2015.09.002; Xing W, 2016, ONCOTARGET, V7, P59976, DOI 10.18632/oncotarget.11045; Yee KW, 2005, CANCER J, V11, P161, DOI 10.1097/00130404-200505000-00001; Zou WP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7118	65	4	5	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUL	2018	42	7					843	854		10.1097/PAS.0000000000001077			12	Pathology; Surgery	Pathology; Surgery	GJ6CY	WOS:000435472600001	29762141				2019-10-28	
J	Roberts, DE; Kakar, S; Mehta, N; Gill, RM				Roberts, Daniel E.; Kakar, Sanjay; Mehta, Neil; Gill, Ryan M.			A Point-based Histologic Scoring System for Hepatocellular Carcinoma Can Stratify Risk of Posttransplant Tumor Recurrence	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						HCC; hepatocellular carcinoma; grading; scoring; recurrence	LIVER-TRANSPLANT RECIPIENTS; MICROVASCULAR INVASION; EXPANDED CRITERIA; IMPACT; CANCER; GRADE; ASSOCIATION; PREDICTORS; EXPRESSION; PROGNOSIS	Eligibility for liver transplant is most commonly decided by measuring tumor size and number on radiographic imaging. However, this method often underestimates the extent of disease. Evaluation of tumor histology has been shown to improve risk stratification when compared with imaging-based transplant criteria, but the World Health Organization (WHO) guidelines for grading hepatocellular carcinoma (HCC) are imprecise and require subjective interpretation by the pathologist. We performed a retrospective analysis of 190 explanted livers containing HCC and correlated histologic features with posttransplant recurrence to formulate a three-tiered, point-based scoring system that categorizes tumors as having a low, intermediate, or high risk of recurrence. Our Recurrence Risk Assessment Score (RRAS) evaluates tumor architecture and specific cytologic featuresnuclear pleomorphism, cytoplasmic amphophilia, and nuclear-to-cytoplasmic ratioshowing superior stratification of HCC recurrence risk compared with imaging criteria and grade assigned by WHO methodology. Stratifying tumors using RRAS criteria, the rate of recurrence after transplant was 0% among low-risk tumors (compared with 3% of well-differentiated tumors), 12% among intermediate-risk tumors (compared with 15% of moderately differentiated tumors), and 54% among high-risk tumors (compared with 29% of poorly differentiated tumors). Receiver operating characteristic analysis shows significantly improved performance of RRAS criteria in predicting HCC recurrence compared with WHO grade (area under curve of 0.841 and 0.671, respectively; P=0.0061). Our results indicate that evaluation of tumor histology offers superior prediction of recurrence risk following liver transplantation compared with radiographic criteria, and that the RRAS system better stratifies recurrence risk compared with HCC grading by WHO methodology.	[Roberts, Daniel E.; Kakar, Sanjay; Gill, Ryan M.] Univ Calif San Francisco, Dept Pathol, Room 559,505 Parnassus Ave, San Francisco, CA 94117 USA; [Mehta, Neil] Univ Calif San Francisco, Dept Med, Div Gastroenterol, San Francisco, CA USA	Roberts, DE (reprint author), Univ Calif San Francisco, Dept Pathol, Room 559,505 Parnassus Ave, San Francisco, CA 94117 USA.	daniel.roberts@ucsf.edu			NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30 DK026743]		Agopian VG, 2015, J AM COLL SURGEONS, V220, P416, DOI 10.1016/j.jamcollsurg.2014.12.025; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Budczies J, 2015, ONCOTARGET, V6, P570, DOI 10.18632/oncotarget.2677; Chung GE, 2012, ABDOM IMAGING, V37, P439, DOI 10.1007/s00261-011-9756-3; Cillo U, 2004, ANN SURG, V239, P150, DOI 10.1097/01.sla.0000109146.72827.76; Clavien PA, 2012, LANCET ONCOL, V13, pE11, DOI 10.1016/S1470-2045(11)70175-9; Colecchia A, 2011, J HEPATOL, V54, P300, DOI 10.1016/j.jhep.2010.06.037; D'Amico F, 2009, LIVER TRANSPLANT, V15, P1278, DOI [10.1002/lt.21842, 10.1002/It.21842]; DuBay D, 2011, ANN SURG, V253, P166, DOI 10.1097/SLA.0b013e31820508f1; Durnez A, 2006, HISTOPATHOLOGY, V49, P138, DOI 10.1111/j.1365-2559.2006.02468.x; Esnaola NF, 2002, J GASTROINTEST SURG, V6, P224, DOI 10.1016/S1091-255X(01)00015-4; Osorio FMF, 2015, EXP CLIN TRANSPLANT, V13, P421, DOI 10.6002/ect.2015.0045; Feng JL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151501; Fleiss J. L., 2003, STAT METHODS RATES P; Freeman RB, 2006, LIVER TRANSPLANT, V12, P1504, DOI 10.1002/lt.20847; Geissler EK, 2016, TRANSPLANTATION, V100, P116, DOI 10.1097/TP.0000000000000965; Halazun KJ, 2014, HEPATOLOGY, V60, P1957, DOI 10.1002/hep.27272; Harper AM, 2016, LIVER TRANSPLANT, V22, P757, DOI 10.1002/lt.24441; Herrero JI, 2001, LIVER TRANSPLANT, V7, P631, DOI 10.1053/jlts.2001.25458; KENMOCHI K, 1987, LIVER, V7, P18; Klintmalm GB, 1998, ANN SURG, V228, P479, DOI 10.1097/00000658-199810000-00005; Lee JI, 2012, WORLD J GASTROENTERO, V18, P4751, DOI 10.3748/wjg.v18.i34.4751; Massie AB, 2011, AM J TRANSPLANT, V11, P2362, DOI 10.1111/j.1600-6143.2011.03735.x; Matter MS, 2014, J HEPATOL, V60, P855, DOI 10.1016/j.jhep.2013.11.031; Matthai SM, 2015, INDIAN J MED RES, V142, P391, DOI 10.4103/0971-5916.169195; Mazzaferro V, 1996, NEW ENGL J MED, V334, P693, DOI 10.1056/NEJM199603143341104; Mazzaferro V, 2009, LANCET ONCOL, V10, P35, DOI 10.1016/S1470-2045(08)70284-5; Miltiadous O, 2015, J HEPATOL, V63, P1368, DOI [10.1016/j.jhep.2015.07.025, 10.1016/j.jhep.2015.07]; Molmenti EP, 2002, LIVER TRANSPLANT, V8, P736, DOI 10.1053/jlts.2002.34879; Pirisi M, 2010, ARCH PATHOL LAB MED, V134, P1818, DOI 10.1043/2009-0551-OAR1.1; Prasad KR, 2011, LIVER TRANSPLANT, V17, pS81, DOI 10.1002/lt.22380; Sharma P, 2012, DIGEST DIS SCI, V57, P806, DOI 10.1007/s10620-011-1910-9; Tamura S, 2001, ARCH SURG-CHICAGO, V136, P25, DOI 10.1001/archsurg.136.1.25; Theise N, 2010, WHO CLASSIFICATION T, P205; Torbenson M, 2015, HEPATOLOGY, V61, P431, DOI 10.1002/hep.27545; TROJANI M, 1984, INT J CANCER, V33, P37, DOI 10.1002/ijc.2910330108; Wang LJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144216; Wiesner RH, 2004, GASTROENTEROLOGY, V127, pS261, DOI 10.1053/j.gastro.2004.09.040; Yao FY, 2007, AM J TRANSPLANT, V7, P2587, DOI 10.1111/j.1600-6143.2007.01965.x; Yao FY, 2001, HEPATOLOGY, V33, P1394, DOI 10.1053/jhep.2001.24563; Zheng SS, 2008, TRANSPLANTATION, V85, P1726, DOI 10.1097/TP.0b013e31816b67e4; Zimmerman MA, 2008, ARCH SURG-CHICAGO, V143, P182, DOI 10.1001/archsurg.2007.39	42	0	0	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUL	2018	42	7					855	865		10.1097/PAS.0000000000001053			11	Pathology; Surgery	Pathology; Surgery	GJ6CY	WOS:000435472600002	29649017	Green Accepted			2019-10-28	
J	Louie, CY; DiMaio, MA; Charville, GW; Berry, GJ; Longacre, TA				Louie, Christine Y.; DiMaio, Michael A.; Charville, Gregory W.; Berry, Gerald J.; Longacre, Teri A.			Gastrointestinal Tract Vasculopathy Clinicopathology and Description of a Possible "New Entity" With Protean Features	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						gastrointestinal tract; vasculopathy; vasculitis; GI biopsy; phlebitis; autoimmune disease	SYSTEMIC-LUPUS-ERYTHEMATOSUS; IDIOPATHIC MYOINTIMAL HYPERPLASIA; INFLAMMATORY-BOWEL-DISEASE; CHURG-STRAUSS-SYNDROME; ENTEROCOLIC LYMPHOCYTIC PHLEBITIS; RHEUMATOLOGY 1990 CRITERIA; MESENTERIC VEINS; THE-LITERATURE; SMALL-INTESTINE; JUVENILE DERMATOMYOSITIS	Noninfectious gastrointestinal (GI) vasculopathic disorders are rare and are often overlooked in histopathologic examination or when forming differential diagnoses due to their rarity. However, involvement of the GI tract may lead to serious complications, including ischemia and perforation. Since awareness of the types of vasculopathy that may involve the GI tract is central to arriving at a correct diagnosis, we reviewed our institutional experience with GI tract vasculopathy in order to enhance diagnostic accuracy of these rare lesions. We report the clinical and histologic features of 16 cases (excluding 16 cases of immunoglobulin A vasculitis) diagnosed over a 20-year period. Of the 16 patients, 14 presented with symptoms related to the GI vasculopathy (including 2 presenting with a mass on endoscopic examination). The remaining 2 patients presented with incarcerated hernia and invasive adenocarcinoma. The vasculopathy was not associated with systemic disease and appeared limited to the GI tract in 8 patients. Eight had associated systemic disease, but only 6 had a prior diagnosis. The underlying diagnoses in these 6 patients included systemic lupus erythematosus (1), dermatomyositis (2), rheumatoid arthritis (1), eosinophilic granulomatosis with polyangiitis (1), and Crohn disease (1). One patient with granulomatous polyangiitis and 1 patient with systemic lupus erythematosus initially presented with GI symptoms. The 8 cases of isolated GI tract vasculopathy consisted of enterocolic lymphocytic phlebitis (4), idiopathic myointimal hyperplasia of the sigmoid colon (1), idiopathic myointimal hyperplasia of the ileum (1), granulomatous vasculitis (1), and polyarteritis nodosa-like arteritis (1). Isolated GI tract vasculopathy is rare, but appears to be almost as common as that associated with systemic disease. The chief primary vasculopathies are enterocolic lymphocytic colitis and idiopathic myointimal hyperplasia. Although the latter occurs predominantly in the left colon, rare examples occur in the small bowel and likely represent a complex, more protean disorder.	[Louie, Christine Y.; DiMaio, Michael A.] Vet Affairs Palo Alto Hlth Care Syst, Dept Pathol, Palo Alto, CA USA; [Charville, Gregory W.; Berry, Gerald J.; Longacre, Teri A.] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA	Longacre, TA (reprint author), Stanford Univ, Dept Pathol, Stanford, CA 94305 USA.	longacre@stanford.edu					Ahn E, 2009, SEMIN DIAGN PATHOL, V26, P77, DOI 10.1053/j.semdp.2009.06.001; Berarducci M, 1996, J Clin Rheumatol, V2, P221, DOI 10.1097/00124743-199608000-00011; Bollen L, 2016, EUR J GASTROEN HEPAT, V28, P1, DOI 10.1097/MEG.0000000000000495; Bryant J, 1998, J FORENSIC SCI, V43, P905; BURKE AP, 1995, AM J SURG PATHOL, V19, P338, DOI 10.1097/00000478-199503000-00012; Chetty R, 2017, J CLIN PATHOL, V70, P470, DOI 10.1136/jclinpath-2016-204308; Daniels J, 2017, PATHOLOGY, V49, P661, DOI 10.1016/j.pathol.2017.05.013; Drenkard C, 1997, LUPUS, V6, P235, DOI 10.1177/096120339700600304; Ebert EC, 2011, J CLIN GASTROENTEROL, V45, P436, DOI 10.1097/MCG.0b013e31820f81b8; Franco Diana L, 2014, Case Rep Gastroenterol, V8, P329, DOI 10.1159/000369129; GENTA RM, 1991, GASTROENTEROLOGY, V101, P533, DOI 10.1016/0016-5085(91)90035-J; Gitiaux C, 2016, RHEUMATOLOGY, V55, P470, DOI 10.1093/rheumatology/kev359; Grimbacher B, 1998, BRIT J RHEUMATOL, V37, P1023; Guadagno E, 2016, INT J SURG PATHOL, V24, P627, DOI 10.1177/1066896916642289; HABER MM, 1993, J CLIN GASTROENTEROL, V17, P327, DOI 10.1097/00004836-199312000-00014; Hatemi I, 2018, RHEUM DIS CLIN N AM, V44, P45, DOI 10.1016/j.rdc.2017.09.007; HELLIWELL TR, 1985, HISTOPATHOLOGY, V9, P1103; Jennette JC, 2013, ARTHRITIS RHEUM-US, V65, P1, DOI 10.1002/art.37715; Kao PC, 2005, J CLIN GASTROENTEROL, V39, P704, DOI 10.1097/00004836-200509000-00011; Kappelman MD, 2011, GUT, V60, P937, DOI 10.1136/gut.2010.228585; Kibbi Nour, 2016, BMJ Case Rep, V2016, DOI 10.1136/bcr-2015-213460; Kim KJ, 2013, BRIT J HAEMATOL, V161, P706, DOI 10.1111/bjh.12318; Kim YB, 2000, J KOREAN MED SCI, V15, P585, DOI 10.3346/jkms.2000.15.5.585; Kishore S, 2017, CURR RHEUMATOL REP, V19, DOI 10.1007/s11926-017-0667-3; Kohoutova D, 2015, J THROMB THROMBOLYS, V39, P489, DOI 10.1007/s11239-014-1129-7; Koklu S, 2010, DIGESTION, V81, P214, DOI 10.1159/000264643; KURITA M, 1994, J GASTROENTEROL, V29, P208, DOI 10.1007/BF02358685; Lanitis S, 2012, GASTROENTEROLOGY, V142, pE5, DOI 10.1053/j.gastro.2011.11.052; Laskaratos FM, 2015, GUT, V64, P214, DOI 10.1136/gutjnl-2014-308319; LEAVITT RY, 1990, ARTHRITIS RHEUM, V33, P1101, DOI 10.1002/art.1780330807; Lie JT, 1998, CARDIOVASC PATHOL, V7, P109, DOI 10.1016/S1054-8807(97)00113-0; Louie CY, 2018, AM J SURG PATHOL, V42, P529, DOI 10.1097/PAS.0000000000001036; Lundberg IE, 2017, ANN RHEUM DIS, V76, P1955, DOI 10.1136/annrheumdis-2017-211468; MAGILL HL, 1984, PEDIATR RADIOL, V14, P28, DOI 10.1007/BF02386727; MASI AT, 1990, ARTHRITIS RHEUM, V33, P1094, DOI 10.1002/art.1780330806; Medina F, 1997, AM J MED, V103, P100, DOI 10.1016/S0002-9343(97)80020-4; Murakami S, 2004, SURG TODAY, V34, P788, DOI 10.1007/s00595-004-2817-2; Nakamura Y, 2002, SURG TODAY, V32, P541, DOI 10.1007/s005950200094; Ngo N, 2007, ARCH PATHOL LAB MED, V131, P1130; Nguyen GC, 2014, GASTROENTEROLOGY, V146, P835, DOI 10.1053/j.gastro.2014.01.042; Pulham NJ, 2016, GASTROENTEROLOGY, V150, pE12, DOI 10.1053/j.gastro.2015.11.012; Purnak T, 2015, INFLAMM BOWEL DIS, V21, P1195, DOI 10.1097/MIB.0000000000000274; Saraga E, 2000, AM J SURG PATHOL, V24, P824, DOI 10.1097/00000478-200006000-00007; Shah IA, 1996, ARCH PATHOL LAB MED, V120, P872; Sinnott JD, 2013, BMJ CASE REP, V2013; Storesund B, 1998, BRIT J RHEUMATOL, V37, P387; Sultan SM, 1999, RHEUMATOLOGY, V38, P917, DOI 10.1093/rheumatology/38.10.917; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; Timmermann Sonja, 2013, J Med Case Rep, V7, P141, DOI 10.1186/1752-1947-7-141; Tweezer-Zaks N, 2006, AM J MED SCI, V332, P308, DOI 10.1097/00000441-200612000-00003; Wang IJ, 2001, J FORMOS MED ASSOC, V100, P844; Yantiss RK, 2017, AM J SURG PATHOL, V41, P1657, DOI 10.1097/PAS.0000000000000905	52	3	3	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUL	2018	42	7					866	876		10.1097/PAS.0000000000001060			11	Pathology; Surgery	Pathology; Surgery	GJ6CY	WOS:000435472600003	29624512				2019-10-28	
J	Agaimy, A; Fonseca, I; Martins, C; Thway, K; Barrette, R; Harrington, KJ; Hartmann, A; French, CA; Fisher, C				Agaimy, Abbas; Fonseca, Isabel; Martins, Carmo; Thway, Khin; Barrette, Ryan; Harrington, Kevin J.; Hartmann, Arndt; French, Christopher A.; Fisher, Cyril			NUT Carcinoma of the Salivary Glands Clinicopathologic and Molecular Analysis of 3 Cases and a Survey of NUT Expression in Salivary Gland Carcinomas	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						salivary glands; carcinoma; NUT carcinoma; midline carcinoma; poorly differentiated carcinoma; squamous cell carcinoma; BRD4; FISH	UPPER AERODIGESTIVE TRACT; MIDLINE CARCINOMA; PAROTID-GLAND; SUBLINGUAL GLAND; SINONASAL TRACT; REARRANGEMENT; FEATURES; OUTCOMES	NUT carcinoma (NC) represents a rare subset of highly aggressive poorly differentiated carcinomas characterized by rearrangement of the NUT (aka NUTM1, nuclear protein in testis) gene, most commonly fused to BRD4. Originally described as a mediastinal/thymic malignancy, NC has been reported at a variety of anatomic regions including the upper and lower aerodigestive tract. To date, only 7 NC cases of probable salivary gland origin have been reported. We herein describe 3 new cases (all affecting the parotid gland) in 2 women (39- and 55-y old) and 1 man (35-y old). Histologic examination showed poorly differentiated neoplasms composed of poorly cohesive small-sized to medium-sized cells with variable squamoid cell component that was focal and abrupt. Immunohistochemistry showed uniform expression of p63 and distinctive punctate expression of the NUT antigen in the tumor cell nuclei. Review of the reported salivary gland NC cases (total, 10) showed a male:female ratio of 1.5:1 and an age range of 12 to 55 years (median, 29y). Site of the primary tumor was the parotid (7), sublingual (2), and submandibular (1) glands. All presented as rapidly growing masses treated by surgery followed by adjuvant radiotherapy/chemotherapy. Initial nodal status was positive in 8/10. At last follow-up (1 to 24mo; median, 5mo), 7/10 patients died of disease at a median of 5.5 months (1 to 24mo) and only 2 were disease free at 7 and 14 months. Of 9 cases with genetic data, the fusion partner was BRD4 (n=7), non-BRD4/3 (n=1), or undetermined (n=1). None of 306 carcinomas spanning the spectrum of salivary carcinoma types screened by NUT immunohistochemistry was positive. This is the first small series on salivary NC highlighting the importance to include this rare disease in the differential diagnosis of poorly differentiated salivary gland carcinomas and in cases of presumable poorly differentiated carcinoma of unknown origin.	[Agaimy, Abbas; Hartmann, Arndt] Univ Hosp, Inst Pathol, Erlangen, Germany; [Fonseca, Isabel] Univ Lisbon, Inst Anat Patol, Fac Med, Lisbon, Portugal; [Fonseca, Isabel] Inst Portugues Oncol Francisco Gentil, Serv Anat Patol, Lisbon, Portugal; [Martins, Carmo] Inst Portugues Oncol Francisco Gentil, UIPM, Lisbon, Portugal; [Thway, Khin; Fisher, Cyril] Head & Neck Unit, Sarcoma Unit, London, England; [Harrington, Kevin J.] Royal Marsden Hosp, Head & Neck Unit, London, England; [Harrington, Kevin J.] Inst Canc Res, Targeted Therapy Team, London, England; [Barrette, Ryan; French, Christopher A.] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA	Agaimy, A (reprint author), Univ Klinikum Erlangen, Pathol Inst, Krankenhausstr 8-10, D-91054 Erlangen, Germany.	abbas.agaimy@uk-erlangen.de	Fonseca, Isabel/A-7396-2008	Fonseca, Isabel/0000-0002-1359-6494	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA124633]		Andreasen S, 2016, HEAD NECK PATHOL, V10, P362, DOI 10.1007/s12105-015-0672-7; Bauer DE, 2012, CLIN CANCER RES, V18, P5773, DOI 10.1158/1078-0432.CCR-12-1153; Bishop JA, 2012, AM J SURG PATHOL, V36, P1216, DOI 10.1097/PAS.0b013e318254ce54; Chau NG, 2016, CANCER-AM CANCER SOC, V122, P3632, DOI 10.1002/cncr.30242; Chirieac LR, 2015, WHO CLASSIFICATION T, P97; den Bakker MA, 2009, AM J SURG PATHOL, V33, P1253, DOI 10.1097/PAS.0b013e3181abe120; El-Naggar A, 2017, WHO CLASSIFICATION H; Fang W, 2013, INT J SURG PATHOL, V21, P102, DOI 10.1177/1066896912451651; French CA, 2013, HEAD NECK PATHOL, V7, P11, DOI 10.1007/s12105-013-0428-1; French CA, 2004, J CLIN ONCOL, V22, P4135, DOI 10.1200/JCO.2004.02.107; French CA, 2003, CANCER RES, V63, P304; French CA, 2015, WHO CLASSIFICATION T, P229; French CA, 2017, WHO CLASSIFICATION H, P20; French C, 2014, NAT REV CANCER, V14, P149, DOI 10.1038/nrc3659; Haack H, 2009, AM J SURG PATHOL, V33, P984, DOI 10.1097/PAS.0b013e318198d666; Kakkar A, 2018, HEAD NECK PATHOL, V12, P230, DOI 10.1007/s12105-017-0858-2; Klijanienko J, 2016, DIAGN CYTOPATHOL, V44, P753, DOI 10.1002/dc.23506; KUBONISHI I, 1991, CANCER RES, V51, P3327; Martins C, 2005, MODERN PATHOL, V18, P1048, DOI 10.1038/modpathol.3800386; Nagao T, 2013, HEAD NECK PATHOL, V7, pS37, DOI 10.1007/s12105-013-0458-8; Park Heae Surng, 2014, Korean J Pathol, V48, P335, DOI 10.4132/KoreanJPathol.2014.48.4.335; Seim NB, 2017, HEAD NECK PATHOL, V11, P460, DOI 10.1007/s12105-017-0809-y; Shehata BM, 2010, PEDIATR DEVEL PATHOL, V13, P481, DOI 10.2350/09-10-0727-CR.1; Stelow EB, 2008, AM J SURG PATHOL, V32A, P828, DOI 10.1097/PAS.0b013e31815a3900; Stelow EB, 2009, ADV ANAT PATHOL, V16, P92, DOI 10.1097/PAP.0b013e31819923e4; Vulsteke C, 2016, J CHEMOTHERAPY, V28, P242, DOI 10.1179/1973947815Y.0000000046; Ziai J, 2010, HEAD NECK PATHOL, V4, P163, DOI 10.1007/s12105-010-0174-6	27	2	2	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUL	2018	42	7					877	884		10.1097/PAS.0000000000001046			8	Pathology; Surgery	Pathology; Surgery	GJ6CY	WOS:000435472600004	29649019	Green Accepted			2019-10-28	
J	McGinnis, LM; Nybakken, G; Ma, L; Arber, DA				McGinnis, Lisa M.; Nybakken, Grant; Ma, Lisa; Arber, Daniel A.			Frequency of MAP2K1, TP53, and U2AF1 Mutations in BRAF-mutated Langerhans Cell Histiocytosis Further Characterizing the Genomic Landscape of LCH	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						LCH; myeloproliferative neoplasms; BRAF; Erk signaling; genomics; TP53	P53 EXPRESSION; INHIBITION; RESISTANCE; MEK; DISEASE; VEMURAFENIB; MELANOMA; DATABASE; CANCERS	Langerhans cell histiocytosis is a proliferative disorder of neoplastic Langerhans cells with activating mutations in the Erk signaling pathway. TP53 and U2AF1 mutations have been implicated in other myelomonocytic malignancies and we hypothesized that mutations in these genes may cosegregate in LCH patients according to BRAF mutation status. Towards this end, we collected cases with a pathologic diagnosis of Langerhans cell histiocytosis from Stanford University Hospital. We analyzed the status of known pathogenic alleles in BRAF, ARAF, TP53, U2AF1, and MAP2K1 on formalin-fixed, paraffin-embedded tissue by direct sequencing. A total of 41 cases (71%) had a BRAFV600E allele detected by sequencing. MAP2K1 mutations were also detected in 5 cases: 3 of 17 (18%) cases with wild-type BRAF and 2 of 41 (5%) cases with BRAFV600E mutations (P=0.14). No cases contained the previously reported ARAF mutation, Q347_A348del. All 10 cases with TP53 mutations contained mutant BRAFV600E allele (P=0.021). Of the 11 cases with U2AF1 mutated, 9 of 41 cases co-occurred with BRAFV600E mutations (P=0.31) and 2 of 17 with wild-type BRAF. Interestingly, we do not find that somatic activating MAP2K1 mutations are mutually exclusive with BRAFV600E mutations as has been reported previously. Instead, our data suggests that MAP2K1 mutations may be present along with BRAF either at diagnosis or may be acquired during disease progression. Furthermore, we demonstrated that likely deleterious TP53 mutations correlate with BRAF mutational status and may play a role in the underlying pathogenesis.	[McGinnis, Lisa M.; Ma, Lisa] Stanford Univ, Med Ctr, Dept Pathol, 300 Pasteur Dr,Room L235, Stanford, CA 94305 USA; [Nybakken, Grant] Kaiser Permanente, Santa Clara Med Ctr, Dept Pathol, Santa Clara, CA USA; [Arber, Daniel A.] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA	McGinnis, LM (reprint author), Stanford Univ, Med Ctr, Dept Pathol, 300 Pasteur Dr,Room L235, Stanford, CA 94305 USA.	lmmcgi@stanford.edu					Alayed K, 2016, HUM PATHOL, V52, P61, DOI 10.1016/j.humpath.2015.12.029; Badalian-Very G, 2010, BLOOD, V116, P1919, DOI 10.1182/blood-2010-04-279083; Bank MI, 2002, J PEDIAT HEMATOL ONC, V24, P733, DOI 10.1097/00043426-200212000-00010; Berres ML, 2014, J EXP MED, V211, P669, DOI 10.1084/jem.20130977; Bond CE, 2012, INT J CANCER, V130, P1567, DOI 10.1002/ijc.26175; Bouaoun L, 2016, HUM MUTAT, V37, P865, DOI 10.1002/humu.23035; Bromberg-White JL, 2012, BRIEF FUNCT GENOMICS, V11, P300, DOI 10.1093/bfgp/els022; Brown NA, 2014, BLOOD, V124, P1655, DOI 10.1182/blood-2014-05-577361; Chakraborty R, 2014, BLOOD, V124, P3007, DOI 10.1182/blood-2014-05-577825; da Costa CET, 2009, GENE CHROMOSOME CANC, V48, P239, DOI 10.1002/gcc.20634; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Haroche J, 2013, BLOOD, V121, P1495, DOI 10.1182/blood-2012-07-446286; Hatzivassiliou G, 2012, MOL CANCER THER, V11, P1143, DOI 10.1158/1535-7163.MCT-11-1010; Heritier S, 2016, J CLIN ONCOL, V34, P3023, DOI 10.1200/JCO.2015.65.9508; Heritier S, 2015, JAMA ONCOL, V1, P836, DOI 10.1001/jamaoncol.2015.0736; Ilagan JO, 2015, GENOME RES, V25, P14, DOI 10.1101/gr.181016.114; Liu XM, 2011, HUM MUTAT, V32, P894, DOI 10.1002/humu.21517; Nelson DS, 2014, BLOOD, V123, P3152, DOI 10.1182/blood-2013-06-511139; Ohgami RS, 2015, MODERN PATHOL, V28, P706, DOI 10.1038/modpathol.2014.160; Robles AI, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026294; Solit DB, 2011, NEW ENGL J MED, V364, P772, DOI 10.1056/NEJMcibr1013704; Waterfall JJ, 2014, NAT GENET, V46, P8, DOI 10.1038/ng.2828; Weintraub M, 1998, J PEDIAT HEMATOL ONC, V20, P12, DOI 10.1097/00043426-199801000-00002; WILLMAN CL, 1994, NEW ENGL J MED, V331, P154, DOI 10.1056/NEJM199407213310303; YU RC, 1994, LANCET, V343, P767, DOI 10.1016/S0140-6736(94)91842-2	27	0	1	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUL	2018	42	7					885	890		10.1097/PAS.0000000000001057			6	Pathology; Surgery	Pathology; Surgery	GJ6CY	WOS:000435472600005	29649018				2019-10-28	
J	Tanaka, M; Ushiku, T; Ikemura, M; Takazawa, Y; Igari, T; Shimizu, M; Yamaguchi, H; Fukushima, N; Sakuma, K; Arita, J; Sakamoto, Y; Hasegawa, K; Watadani, T; Nakai, Y; Koike, K; Fukayama, M				Tanaka, Mariko; Ushiku, Tetsuo; Ikemura, Masako; Takazawa, Yutaka; Igari, Toru; Shimizu, Michio; Yamaguchi, Hiroshi; Fukushima, Noriyoshi; Sakuma, Kei; Arita, Junichi; Sakamoto, Yoshihiro; Hasegawa, Kiyoshi; Watadani, Takeyuki; Nakai, Yousuke; Koike, Kazuhiko; Fukayama, Masashi			Pancreatic Lipomatous Hamartoma A Hitherto Unrecognized Variant	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						pancreatic hamartoma; lipomatous; HMGA2	PULMONARY CHONDROID HAMARTOMAS; MESENCHYMAL TUMORS; HMGA PROTEINS; CANCER; LESION; ENTITY	Pancreatic masses consisting of lipomatous components clinically include lipoma, liposarcoma, lipomatous pseudohypertrophy of the pancreas, fat-containing neoplasms such as perivascular epithelioid cell tumor, and malignant neoplasm with lipoid degeneration. We present pancreatic lipomatous hamartoma, which has not been reported hitherto. A solid pancreatic mass was detected from a computed tomographic scan check-up in each of 3 cases of Japanese men. Macroscopically, well-demarcated solid lipomatous masses were detected at the uncus, body, and tail of the pancreas, respectively. Microscopically, the masses predominantly consisted of mature adipocytes with no atypia, but contained characteristics components of pancreatic hamartoma, such as small ducts, a well-preserved acinar structure, and/or fibrous stroma. On the basis of the unique features, lack of islets and absence of periductal elastic fibers, these tumors are a distinct variant of pancreatic hamartoma. Furthermore, high-mobility group AT-hook 2 expression in the fibro-adipocytes of this tumor indicated that these cells are an integral component of the pancreatic lipomatous hamartoma. Consequently, the unique tumors described herein are pancreatic lipomatous hamartoma, which must be discriminated from other lipomatous lesions of the pancreas.	[Tanaka, Mariko; Ushiku, Tetsuo; Ikemura, Masako; Sakuma, Kei; Fukayama, Masashi] Univ Tokyo, Grad Sch Med, Dept Pathol, Tokyo, Japan; [Arita, Junichi; Sakamoto, Yoshihiro; Hasegawa, Kiyoshi] Univ Tokyo, Grad Sch Med, Dept Hepatobiliary Pancreat Surg, Tokyo, Japan; [Watadani, Takeyuki] Univ Tokyo, Grad Sch Med, Dept Radiol, Tokyo, Japan; [Nakai, Yousuke; Koike, Kazuhiko] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Tokyo, Japan; [Igari, Toru] Natl Ctr Global Hlth & Med, Div Pathol, Tokyo, Japan; [Shimizu, Michio] Hakujikai Mem Hosp, Diagnost Pathol Ctr, Tokyo, Japan; [Yamaguchi, Hiroshi] Tokyo Med Univ Hosp, Div Pathol, Tokyo, Japan; [Fukushima, Noriyoshi] Jichi Med Univ Hosp, Div Diagnost Pathol, Tokyo, Japan; [Takazawa, Yutaka] Canc Inst JFCR, Div Pathol, Tokyo, Japan	Fukayama, M (reprint author), Univ Tokyo, Grad Sch Med, Dept Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	mfukayama-tky@umin.ac.jp	Nakai, Yousuke/H-2964-2019	Nakai, Yousuke/0000-0001-7411-1385			Addeo P, 2014, SURGERY, V156, P1284, DOI 10.1016/j.surg.2013.02.021; Altinel D, 2010, PANCREAS, V39, P392, DOI 10.1097/MPA.0b013e3181bd2923; ANTHONY PP, 1977, BRIT MED J, V1, P814, DOI 10.1136/bmj.1.6064.814; Basak D, 1991, J Indian Med Assoc, V89, P265; BURT TB, 1983, PEDIATR RADIOL, V13, P287, DOI 10.1007/BF00973350; D'Angelo D, 2017, J MOL MED, V95, P353, DOI 10.1007/s00109-017-1520-x; Dreux N, 2010, MODERN PATHOL, V23, P1657, DOI 10.1038/modpathol.2010.174; Durczynski A, 2011, ARCH MED SCI, V7, P1082, DOI [10.5114/aoms.2011.26624, 10.5114/AOMS.2011.26624]; FLAHERTY MJ, 1992, HUM PATHOL, V23, P1309, DOI 10.1016/0046-8177(92)90301-I; Francisco A, 2014, CARDIOL YOUNG, V24, P923, DOI 10.1017/S1047951113001388; Fusco A, 2007, NAT REV CANCER, V7, P899, DOI 10.1038/nrc2271; Inoue H, 2014, ENDOSCOPY, V46, pE157, DOI 10.1055/s-0034-1364953; IZBICKI JR, 1994, AM J GASTROENTEROL, V89, P1261; Kawakami F, 2012, WORLD J GASTRO ONCOL, V4, P202, DOI 10.4251/wjgo.v4.i9.202; KAZMIERCZAK B, 1995, CANCER RES, V55, P2497; Kim HH, 2012, J KOREAN SURG SOC, V83, P330, DOI 10.4174/jkss.2012.83.5.330; Kim JY, 2014, PANCREAS, V43, P959, DOI 10.1097/MPA.0000000000000130; Kwon Wooil, 2012, Korean J Hepatobiliary Pancreat Surg, V16, P80, DOI 10.14701/kjhbps.2012.16.2.80; Matsushita D, 2016, BMC GASTROENTEROL, V16, DOI 10.1186/s12876-016-0419-2; McFaul CD, 2004, PANCREATOLOGY, V4, P533, DOI 10.1159/000080528; Murakami T, 2016, PANCREATOLOGY, V16, P464, DOI 10.1016/j.pan.2015.12.178; Nagata S, 2007, PATHOL INT, V57, P276, DOI 10.1111/j.1440-1827.2007.02090.x; Namiki Yoko, 2016, Radiol Case Rep, V11, P50, DOI 10.1016/j.radcr.2016.02.017; Pauser U, 2005, AM J SURG PATHOL, V29, P797, DOI 10.1097/01.pas.0000157748.18591.d7; Pauser U, 2005, MODERN PATHOL, V18, P1211, DOI 10.1038/modpathol.3800406; Piton N, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0603-x; Sampelean D, 2009, J GASTROINTEST LIVER, V18, P483; Sueyoshi R, 2013, INT J SURG CASE REP, V4, P98, DOI 10.1016/j.ijscr.2012.10.001; Tallini G, 2000, LAB INVEST, V80, P359, DOI 10.1038/labinvest.3780040; Tanaka M, 2011, J HISTOCHEM CYTOCHEM, V59, P942, DOI 10.1369/0022155411420569; Thrall M, 2008, PEDIATR DEVEL PATHOL, V11, P314, DOI 10.2350/07-04-0260.1; Yamaguchi H, 2013, AM J SURG PATHOL, V37, P1006, DOI 10.1097/PAS.0b013e318283ce4c; Zhang JW, 2016, ONCOL LETT, V11, P3925, DOI 10.3892/ol.2016.4535	33	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUL	2018	42	7					891	897		10.1097/PAS.0000000000001075			7	Pathology; Surgery	Pathology; Surgery	GJ6CY	WOS:000435472600006	29738363				2019-10-28	
J	Yozu, M; Johncilla, ME; Srivastava, A; Ryan, DP; Cusack, JC; Doyle, L; Setia, N; Yang, M; Lauwers, GY; Odze, RD; Misdraji, J				Yozu, Masato; Johncilla, Melanie E.; Srivastava, Amitabh; Ryan, David P.; Cusack, James C.; Doyle, Leona; Setia, Namrata; Yang, Michelle; Lauwers, Gregory Y.; Odze, Robert D.; Misdraji, Joseph			Histologic and Outcome Study Supports Reclassifying Appendiceal Goblet Cell Carcinoids as Goblet Cell Adenocarcinomas, and Grading and Staging Similarly to Colonic Adenocarcinomas	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						appendix; goblet cell carcinoid; adenocarcinoid; adenocarcinoma	VERMIFORM APPENDIX; PROGNOSTIC-SIGNIFICANCE; NEUROENDOCRINE CELLS; TUMORS; PREVALENCE; BEHAVIOR	Goblet cell carcinoid tumors are amphicrine tumors whose biological behavior ranges from indolent to highly aggressive, depending on tumor grade. Current grading systems for these tumors are based on identifying an adenocarcinoma arising in the setting of a goblet cell carcinoid tumor, which distinguishes this tumor from other gastrointestinal tract adenocarcinomas. Because goblet cell tumors are predominantly tumors of mucin secreting cells, we propose that they be classified as goblet cell adenocarcinomas, and graded using a methodology that has parallels in colorectal adenocarcinoma grading. We graded a large series of goblet cell adenocarcinomas by assessing the proportion of the tumor that demonstrates tubular or clustered growth. Histologic grade correlated with overall survival independent of stage, with median overall survival of 204, 86, and 29 months for low-grade, intermediate-grade, and high-grade goblet cell adenocarcinomas, respectively. Tumor stage also correlated with overall survival. We also graded the tumors according to previously proposed grading systems, and found that these systems are valid, in that they segregate patients according to prognosis.	[Misdraji, Joseph] Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St, Boston, MA 02114 USA; [Cusack, James C.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; [Srivastava, Amitabh; Cusack, James C.; Doyle, Leona; Odze, Robert D.] Harvard Med Sch, Boston, MA USA; [Srivastava, Amitabh; Doyle, Leona; Odze, Robert D.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Ryan, David P.] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA; [Yozu, Masato] Middlemore Hosp, Histopathol Dept, Auckland, New Zealand; [Lauwers, Gregory Y.] H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, Tampa, FL USA; [Yang, Michelle] Univ Vermont, Med Ctr, Dept Pathol & Lab Med, Burlington, VT USA; [Setia, Namrata] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Johncilla, Melanie E.] Weill Cornell Med, Dept Pathol, New York, NY USA	Misdraji, J (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St, Boston, MA 02114 USA.	jmisdraji@partners.org			Harvard Catalyst/The Harvard Clinical and Translational Science Center (National Center for Research Resources); Harvard Catalyst/The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health) [UL1 TR001102]; Harvard University	This work was conducted with support from Harvard Catalyst/The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award UL1 TR001102) and financial contributions from Harvard University and its affiliated academic health care centers.	BAK M, 1988, DIS COLON RECTUM, V31, P605, DOI 10.1007/BF02556796; BURKE AP, 1990, AM J CLIN PATHOL, V94, P27, DOI 10.1093/ajcp/94.1.27; Foley EF, 1998, ARCH PATHOL LAB MED, V122, P912; Hamilton K, 2000, MODERN PATHOL, V13, P475, DOI 10.1038/modpathol.3880081; Hristov AC, 2007, AM J SURG PATHOL, V31, P1502, DOI 10.1097/PAS.0b013e31804f7aa1; ISAACSON P, 1981, AM J SURG PATHOL, V5, P213, DOI 10.1097/00000478-198104000-00001; Johncilla M, 2018, MOD PATHOL; Lee LH, 2015, HUM PATHOL, V46, P1881, DOI 10.1016/j.humpath.2015.08.005; Liu E, 2011, AM J SURG, V202, P400, DOI 10.1016/j.amjsurg.2010.08.036; Madani A, 2015, ANN SURG ONCOL, V22, P959, DOI 10.1245/s10434-014-4023-9; Overman MJ, 2017, AJCC CANC STAGING MA, P237; Ramnani DM, 1999, CANCER, V86, P14, DOI 10.1002/(SICI)1097-0142(19990701)86:1<14::AID-CNCR4>3.0.CO;2-X; Reid MD, 2016, MODERN PATHOL, V29, P1243, DOI 10.1038/modpathol.2016.105; SMITH DM, 1984, AM J SURG PATHOL, V8, P123, DOI 10.1097/00000478-198402000-00006; Stancu M, 2003, MODERN PATHOL, V16, P1189, DOI 10.1097/01.MP.0000097362.10330.B1; SUBBUSWAMY SG, 1974, CANCER-AM CANCER SOC, V34, P338, DOI 10.1002/1097-0142(197408)34:2<338::AID-CNCR2820340218>3.0.CO;2-W; Taggart MW, 2015, ARCH PATHOL LAB MED, V139, P782, DOI 10.5858/arpa.2013-0047-OA; Tang LH, 2008, AM J SURG PATHOL, V32, P1429, DOI 10.1097/PAS.0b013e31817f1816; van Eeden S, 2007, HISTOPATHOLOGY, V51, P763, DOI 10.1111/j.1365-2559.2007.02883.x; Wang HLL, 2009, ADV ANAT PATHOL, V16, P247, DOI 10.1097/PAP.0b013e3181a9d49a; WARKEL RL, 1978, CANCER, V42, P2781, DOI 10.1002/1097-0142(197812)42:6<2781::AID-CNCR2820420638>3.0.CO;2-B; WATSON PH, 1987, VIRCHOWS ARCH A, V412, P175, DOI 10.1007/BF00716191	22	5	5	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUL	2018	42	7					898	910		10.1097/PAS.0000000000001056			13	Pathology; Surgery	Pathology; Surgery	GJ6CY	WOS:000435472600007	29579011				2019-10-28	
J	Parilla, M; Kadri, S; Patil, SA; Ritterhouse, L; Segal, J; Henriksen, KJ; Antic, T				Parilla, Megan; Kadri, Sabah; Patil, Sushant A.; Ritterhouse, Lauren; Segal, Jeremy; Henriksen, Kammi J.; Antic, Tatjana			Are Sporadic Eosinophilic Solid and Cystic Renal Cell Carcinomas Characterized by Somatic Tuberous Sclerosis Gene Mutations?	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						eosinophilic solid and cystic renal cell carcinoma; tuberous sclerosis complex; TSC2; next-generation sequencing	TSC2; COMPLEX	Eosinophilic solid and cystic renal cell carcinomas (ESC RCC) is a rare, unique tumor type not yet included in the World Health Organization classification of renal neoplasia. Separately, RCCs found in patients with tuberous sclerosis complex (TSC) have recently been categorized into 3 morphologic groups: RCC with a tubulopapillary architecture separated by smooth muscle stroma, chromophobe-like, and eosinophilic-microcytic type. The third classification has been identified in approximate to 11% of TSC-associated RCC and have histology identical to ESC RCCs. The sporadic form of ESC RCC, not associated with TSC, have only been characterized on the cytogenetic level and the full molecular underpinnings have yet to be examined. Using next-generation sequencing we present 2 cases of sporadic ESC RCC in patients without clinical features of tuberous sclerosis, which demonstrate pathogenic somatic TSC2 gene mutations. These mutations are without other alterations in any other genes associated with RCC, suggesting that sporadic ESC RCC may be characterized by somatic tuberous sclerosis gene mutations (TSC2).	[Parilla, Megan; Kadri, Sabah; Patil, Sushant A.; Ritterhouse, Lauren; Segal, Jeremy; Henriksen, Kammi J.; Antic, Tatjana] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA	Antic, T (reprint author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA.	Tatjana.Antic@uchospitals.edu			University of Chicago Faculty Diversity Career Advancement Grant	Supported by the University of Chicago Faculty Diversity Career Advancement Grant.	Cho J, 2016, TRANSL ONCOL, V9, P466, DOI 10.1016/j.tranon.2016.08.009; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Guo J, 2014, AM J SURG PATHOL, V38, P1457, DOI 10.1097/PAS.0000000000000248; Habib SL, 2016, J CANCER, V7, P1621, DOI 10.7150/jca.14747; Jones AC, 1999, AM J HUM GENET, V64, P1305, DOI 10.1086/302381; Kadri S, 2017, J MOL DIAGN, V19, P43, DOI 10.1016/j.jmoldx.2016.07.012; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li YJ, 2018, HISTOPATHOLOGY, V72, P588, DOI 10.1111/his.13395; Mose LE, 2014, BIOINFORMATICS, V30, P2813, DOI 10.1093/bioinformatics/btu376; Parilla M, 2017, AJSP-REV REP, V22, P164, DOI 10.1097/PCR.0000000000000199; Potter SL, 2017, PEDIAT BLOOD CANC, V64, P1; Rosset C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185713; Rosset C, 2017, GENET MOL BIOL, V40, P69, DOI [10.1590/1678-4685-GMB-2015-0321, 10.1590/1678-4685-gmb-2015-0321]; Trpkov K, 2017, AM J SURG PATHOL, V41, P1299, DOI 10.1097/PAS.0000000000000838; Trpkov K, 2016, AM J SURG PATHOL, V40, P60, DOI 10.1097/PAS.0000000000000508; Tyburczy ME, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005637; Urakami S, 1997, J UROLOGY, V158, P275, DOI 10.1097/00005392-199707000-00085; Yang P, 2014, AM J SURG PATHOL, V38, P895, DOI 10.1097/PAS.0000000000000237; You JB, 2013, INDIAN J DERMATOL VE, V79, P104, DOI 10.4103/0378-6323.104680	19	7	7	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUL	2018	42	7					911	917		10.1097/PAS.0000000000001067			7	Pathology; Surgery	Pathology; Surgery	GJ6CY	WOS:000435472600008	29668487				2019-10-28	
J	ten Kate, FJC; Nieboer, D; ten Kate, FJW; Doukas, M; Bruno, MJ; Spaander, MCW; Looijenga, LHJ; Biermann, K				ten Kate, Fiebo J. C.; Nieboer, Daan; ten Kate, Fiebo J. W.; Doukas, Michail; Bruno, Marco J.; Spaander, Manon C. W.; Looijenga, Leendert H. J.; Biermann, Katharina		ProBar Study Grp; Palga Grp	Improved Progression Prediction in Barrett's Esophagus With Low-grade Dysplasia Using Specific Histologic Criteria	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						Barrett's esophagus; low-grade dysplasia; interob-server agreement; progression rate; histology	P53 PROTEIN EXPRESSION; RADIOFREQUENCY ABLATION; NEOPLASTIC PROGRESSION; MALIGNANT PROGRESSION; INCREASED RISK; UPDATED GUIDELINES; BRITISH SOCIETY; DIAGNOSIS; SURVEILLANCE; MANAGEMENT	Risk stratification of patients with Barrett's esophagus (BE) is based on diagnosis of low-grade dysplasia (LGD). LGD has a poor interobserver agreement and a limited value for prediction of progression to high-grade dysplasia or esophageal adenocarcinoma. Specific reproducible histologic criteria may improve the predictive value of LGD. Four gastrointestinal pathologists examined 12 histologic criteria associated with LGD in 84 BE patients with LGD (15 progressors and 69 nonprogressors). The criteria with at least a moderate (kappa, 0.4 to 0.6) interobserver agreement were validated in an independent cohort of 98 BE patients with LGD (30 progressors and 68 nonprogressors). Hazard ratios (HR) were calculated by Cox proportional hazard regression analysis using time-dependent covariates correcting for multiple endoscopies during follow-up. Agreement was moderate or good for 4 criteria, that is, loss of maturation, mucin depletion, nuclear enlargement, and increase of mitosis. Combination of the criteria differentiated high-risk and low-risk group amongst patients with LGD diagnosis (P<0.001). When 2 criteria were present, a significantly higher progression rate to high-grade dysplasia or esophageal adenocarcinoma was observed (discovery set: HR, 5.47; 95% confidence interval [CI], 1.81-17; P=0.002; validation set: HR, 3.52; 95% CI, 1.56-7.97; P=0.003). Implementation of p53 immunohistochemistry and histologic criteria optimized the prediction of progression (area under the curve, 0.768; 95% CI, 0.656-0.881). We identified and validated a clinically applicable panel of 4 histologic criteria, segregating BE patients with LGD diagnosis into defined prognostic groups. This histologic panel can be used to improve clinical decision making, although additional studies are warranted.	[ten Kate, Fiebo J. C.; Doukas, Michail; Looijenga, Leendert H. J.; Biermann, Katharina] Erasmus Univ, Med Ctr, Dept Pathol, Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands; [Nieboer, Daan] Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands; [ten Kate, Fiebo J. W.] Erasmus Univ, Med Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands; [Bruno, Marco J.; Spaander, Manon C. W.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands	Biermann, K (reprint author), Erasmus Univ, Med Ctr, Dept Pathol, Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands.	k.biermann@erasmusmc.nl	Looijenga, Leendert/B-8145-2019	Looijenga, Leendert/0000-0002-8146-1911	Erasmus MC Fellowship	Supported by the Erasmus MC Fellowship appointed to K.B., entitled "Barrett esophagus: improved prediction of progression by targeted risk stratification."	Adams MA, 2014, GASTROENTEROLOGY, V146, pS553, DOI 10.1053/j.gastro.2014.02.015; Bennett C, 2015, AM J GASTROENTEROL, V110, P943, DOI 10.1038/ajg.2015.151; Contino G, 2017, GASTROENTEROLOGY, V153, P657, DOI 10.1053/j.gastro.2017.07.007; Curvers WL, 2010, AM J GASTROENTEROL, V105, P1523, DOI 10.1038/ajg.2010.171; de Jonge PJF, 2010, GUT, V59, P1030, DOI 10.1136/gut.2009.176701; de Jonge PJF, 2014, GUT, V63, P191, DOI 10.1136/gutjnl-2013-305490; di Pietro M, 2018, GUT, V67, P392, DOI 10.1136/gutjnl-2017-314135; Duits LC, 2017, GASTROENTEROLOGY, V152, P993, DOI 10.1053/j.gastro.2016.12.008; Duits LC, 2015, GUT, V64, P700, DOI 10.1136/gutjnl-2014-307278; Essink-Bot ML, 2007, QUAL LIFE RES, V16, P1309, DOI 10.1007/s11136-007-9239-8; Fitzgerald RC, 2014, GUT, V63, P7, DOI 10.1136/gutjnl-2013-305372; Hopcroft SA, 2014, HISTOPATHOLOGY, V65, P441, DOI 10.1111/his.12457; Hvid-Jensen F, 2011, NEW ENGL J MED, V365, P1375, DOI 10.1056/NEJMoa1103042; Kastelein F, 2016, GUT, V65, P548, DOI 10.1136/gutjnl-2014-308802; Kastelein F, 2013, GUT, V62, P1676, DOI 10.1136/gutjnl-2012-303594; Kastelein F, 2011, GASTROENTEROLOGY, V141, P2000, DOI 10.1053/j.gastro.2011.08.036; Kastelein F, 2011, GASTROENTEROLOGY, V140, pS137; Kaye PV, 2016, HISTOPATHOLOGY, V69, P431, DOI 10.1111/his.12956; Kaye PV, 2009, HISTOPATHOLOGY, V54, P699, DOI 10.1111/j.1365-2559.2009.03288.x; Kerkhof M, 2007, HISTOPATHOLOGY, V50, P920, DOI 10.1111/j.1365-2559.2007.02706.x; Kestens C, 2016, CLIN GASTROENTEROL H, V14, P956, DOI 10.1016/j.cgh.2015.12.027; KOCH GG, 1977, BIOMETRICS, V33, P133, DOI 10.2307/2529309; Levine DS, 2000, AM J GASTROENTEROL, V95, P1152; Lim CH, 2007, ENDOSCOPY, V39, P581, DOI 10.1055/s-2007-966592; Lim YC, 2013, BRIT MED BULL, V107, P117, DOI 10.1093/bmb/ldt025; MCGILCHRIST CA, 1991, BIOMETRICS, V47, P461, DOI 10.2307/2532138; Montgomery E, 2001, HUM PATHOL, V32, P379, DOI 10.1053/hupa.2001.23511; Moyes LH, 2016, GUT, V65, P360, DOI 10.1136/gutjnl-2015-309978; Nelson KP, 2015, STAT MED, V34, P3116, DOI 10.1002/sim.6546; Odze RD, 2011, CURR OPIN GASTROEN, V27, P389, DOI 10.1097/MOG.0b013e328346f551; Phoa KN, 2014, JAMA-J AM MED ASSOC, V311, P1209, DOI 10.1001/jama.2014.2511; Puli SR, 2006, GASTROINTEST ENDOSC, V63, pAB83; Qumseya BJ, 2017, AM J GASTROENTEROL, V112, P849, DOI 10.1038/ajg.2017.70; Sampliner RE, 2002, AM J GASTROENTEROL, V97, P1888; Senore C, 2016, BEST PRACT RES CL GA, V30, P855, DOI 10.1016/j.bpg.2016.08.002; Shaheen NJ, 2016, AM J GASTROENTEROL, V111, P30, DOI 10.1038/ajg.2015.322; Shaheen NJ, 2009, NEW ENGL J MED, V360, P2277, DOI 10.1056/NEJMoa0808145; Small AJ, 2015, GASTROENTEROLOGY, V149, P567, DOI 10.1053/j.gastro.2015.04.013; SUEYOSHI GT, 1992, J ECONOMETRICS, V51, P25, DOI 10.1016/0304-4076(92)90028-P; Ten Kate FJC, 2017, ONCOTARGET, V8, P104123, DOI 10.18632/oncotarget.22021; van der Wel MJ, 2018, HISTOPATHOLOGY, V72, P1015, DOI 10.1111/his.13462; van Olphen S, 2015, AM J GASTROENTEROL, V110, P1420, DOI 10.1038/ajg.2015.260; Vennalaganti P, 2017, GASTROENTEROLOGY, V152, P564, DOI 10.1053/j.gastro.2016.10.041; Wang KK, 2008, AM J GASTROENTEROL, V103, P788, DOI 10.1111/j.1572-0241.2008.01835.x; Wani S, 2016, GASTROENTEROLOGY, V151, P822, DOI 10.1053/j.gastro.2016.09.040; Wani S, 2010, CLIN GASTROENTEROL H, V8, P783, DOI 10.1016/j.cgh.2010.04.028; Wani S, 2009, AM J GASTROENTEROL, V104, P502, DOI 10.1038/ajg.2008.31; WANI SB, 2011, GASTROENTEROLOGY S1, V140, pS217; Younes M, 2017, HISTOPATHOLOGY, V71, P27, DOI 10.1111/his.13193	49	1	1	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUL	2018	42	7					918	926		10.1097/PAS.0000000000001066			9	Pathology; Surgery	Pathology; Surgery	GJ6CY	WOS:000435472600009	29697438				2019-10-28	
J	Carreras, J; Kikuti, YY; Miyaoka, M; Hiraiwa, S; Tomita, S; Ikoma, H; Kondo, Y; Shiraiwa, S; Ando, K; Sato, S; Suzuki, Y; Miura, I; Roncador, G; Nakamura, N				Carreras, Joaquim; Kikuti, Yara Yukie; Miyaoka, Masashi; Hiraiwa, Shinichiro; Tomita, Sakura; Ikoma, Haruka; Kondo, Yusuke; Shiraiwa, Sawako; Ando, Kiyoshi; Sato, Shinji; Suzuki, Yasuo; Miura, Ikuo; Roncador, Giovanna; Nakamura, Naoya			Genomic Profile and Pathologic Features of Diffuse Large B-Cell Lymphoma Subtype of Methotrexate-associated Lymphoproliferative Disorder in Rheumatoid Arthritis Patients	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						diffuse large B-cell lymphoma; methotrexate-associated lymphoproliferative disorder; rheumatoid arthritis; genome profile; FISH; immunohistochemistry; clinicopathologic characteristics	EPSTEIN-BARR-VIRUS; REGULATORY T-CELLS; SELECTIN GLYCOPROTEIN LIGAND-1; TUMOR-ASSOCIATED MACROPHAGES; FOLLICULAR LYMPHOMA; HIGH NUMBERS; CLINICOPATHOLOGICAL CHARACTERISTICS; ANALYSIS REVEALS; SURVIVAL; RISK	Rheumatoid arthritis patients often develop the diffuse large B-cell lymphoma subtype of methotrexate-associated lymphoproliferative disorder (DLBCLMTX-LPD). We characterized the genomic profile and pathologic characteristics of 20 biopsies using an integrative approach. DLBCLMTX-LPD was associated with extranodal involvement, a high/high-intermediate international prognostic index in 53% of cases, and responded to MTX withdrawal. The phenotype was nongerminal center B-cell in 85% of samples and Epstein-Barr encoding region positive (EBER+) in 65%, with a high proliferation index and intermediate MYC expression levels. The immune microenvironment showed high numbers of CD8(+) cytotoxic T lymphocytes and CD163(+) M2 macrophages with an (CD163/CD68) M2 ratio of 3.6. Its genomic profile was characterized by 3p12.1-q25.31, 6p25.3, 8q23.1-q24.3, and 12p13.33-q24.33 gains, 6q22.31-q24.1 and 13q21.33-q34 losses, and 1p36.11-p35.3 copy neutral loss-of-heterozygosity. This profile was closer to nongerminal center B-cell DLBCL not-otherwise-specified, but with characteristic 3q, 12q, and 20p gains and lower 9p losses (P<0.05). We successfully verified array results using fluorescent DNA in situ hybridization on PLOD2, MYC, WNT1, and BCL2. Protein immunohistochemistry revealed that DLBCLMTX-LPD expressed high IRF4 (6p25.3) and SELPLG (12q24.11) levels, intermediate TNFRSF14 (1p36.32; the exons 1 to 3 were unmutated), BTLA (3q13.2), PLOD2 (3q24), KLHL6 (3q27.1), and MYC (8q24.21) levels, and low AICDA (12p13.31) and EFNB2 (13q33.3) levels. The correlation between the DNA copy number and protein immunohistochemistry was confirmed for BTLA, PLOD2, and EFNB2. The characteristics of EBER+ versus EBER- cases were similar, with the exception of specific changes: EBER+ cases had higher numbers of CD163(+) M2 macrophages and FOXP3(+) regulatory T lymphocytes, high programmed cell death 1 ligand 1 expression levels, slightly fewer genomic changes, and 3q and 4p focal gains. In conclusion, DLBCLMTX-LPD has a characteristic genomic profile with 3q and 12 gains, 13q loss, different expression levels of relevant pathogenic biomarkers, and a microenvironment with high numbers of cytotoxic T lymphocytes and M2 macrophages.	[Carreras, Joaquim; Kikuti, Yara Yukie; Miyaoka, Masashi; Hiraiwa, Shinichiro; Tomita, Sakura; Ikoma, Haruka; Kondo, Yusuke; Nakamura, Naoya] Tokai Univ, Sch Med, Dept Pathol, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan; [Shiraiwa, Sawako; Ando, Kiyoshi] Tokai Univ, Sch Med, Dept Internal Med, Div Hematol Oncol, Hiratsuka, Kanagawa, Japan; [Sato, Shinji; Suzuki, Yasuo] Tokai Univ, Sch Med, Dept Internal Med, Div Rheumatol, Hiratsuka, Kanagawa, Japan; [Miura, Ikuo] St Marianna Univ, Sch Med, Div Hematol & Oncol, Kawasaki, Kanagawa, Japan; [Roncador, Giovanna] Spanish Natl Canc Res Ctr CNIO, Monoclonal Antibodies Unit, Madrid, Spain	Nakamura, N (reprint author), Tokai Univ, Sch Med, Dept Pathol, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.	naoya@is.icc.u-tokai.ac.jp	Sato, Shinji/V-7271-2019; Roncador, Giovanna/L-1764-2014	Roncador, Giovanna/0000-0002-9807-2875			Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Atalay F, 2015, CL LYMPH MYELOM LEUK, V15, P164, DOI 10.1016/j.clml.2014.09.005; Baecklund E, 2003, ARTHRITIS RHEUM-US, V48, P1543, DOI 10.1002/art.11144; Batlle-Lopez A, 2016, ONCOTARGET, V7, P18036, DOI 10.18632/oncotarget.7495; Berti A, 2018, JOINT BONE SPINE, V85, P32, DOI 10.1016/j.jbspin.2017.01.006; Carreras J, 2006, BLOOD, V108, P2957, DOI 10.1182/blood-2006-04-018218; Carreras J, 2017, HISTOPATHOLOGY, V70, P595, DOI 10.1111/his.13106; Carreras J, 2009, J CLIN ONCOL, V27, P1470, DOI 10.1200/JCO.2008.18.0513; Chapuy B, 2016, BLOOD, V127, P869, DOI 10.1182/blood-2015-10-673236; Chung IM, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060900; Coutinho R, 2015, HAEMATOLOGICA, V100, P363, DOI 10.3324/haematol.2014.110189; Du HZ, 2017, BIOMED PHARMACOTHER, V90, P670, DOI 10.1016/j.biopha.2017.04.023; Feng WH, 2004, JNCI-J NATL CANCER I, V96, P1691, DOI 10.1093/jnci/djh313; Flowers CR, 2010, CA-CANCER J CLIN, V60, P393, DOI 10.3322/caac.20087; GASTON JSH, 1986, ANN RHEUM DIS, V45, P932, DOI 10.1136/ard.45.11.932; Gaulard P, 2008, WHO CLASSIFICATION T, P350; Ghorbian S, 2017, ANN DIAGN PATHOL, V29, P28, DOI 10.1016/j.anndiagpath.2017.04.008; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; Harigai M, 2018, MOD RHEUMATOL, V28, P1, DOI 10.1080/14397595.2017.1352477; Hasselblom S, 2008, PATHOL INT, V58, P529, DOI 10.1111/j.1440-1827.2008.02268.x; Hasselblom S, 2007, BRIT J HAEMATOL, V137, P364, DOI 10.1111/j.1365-2141.2007.06593.x; Hellgren K, 2017, ARTHRITIS RHEUMATOL, V69, P700, DOI 10.1002/art.40017; Hoshida Y, 2007, J RHEUMATOL, V34, P322; Hsi ED, 2017, INT J LAB HEMATOL, V39, P14, DOI 10.1111/ijlh.12650; Hu SM, 2013, BLOOD, V121, P4021, DOI 10.1182/blood-2012-10-460063; Ichikawa A, 2013, EUR J HAEMATOL, V91, P20, DOI 10.1111/ejh.12116; Kameda T, 2014, ARTHRIT CARE RES, V66, P1302, DOI 10.1002/acr.22306; KAMEL OW, 1994, HUM PATHOL, V25, P638, DOI 10.1016/0046-8177(94)90295-X; KAMEL OW, 1993, NEW ENGL J MED, V328, P1317, DOI 10.1056/NEJM199305063281806; Karube K, 2018, LEUKEMIA, V32, P675, DOI 10.1038/leu.2017.251; Kim JA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167641; Klein U, 2006, NAT IMMUNOL, V7, P773, DOI 10.1038/ni1357; Kojima M, 2006, BIOMED PHARMACOTHER, V60, P663, DOI 10.1016/j.biopha.2006.09.004; Kuang SQ, 2010, BLOOD, V115, P2412, DOI 10.1182/blood-2009-05-222208; Kubuki Y, 2017, J CLIN EXP HEMATOP, V56, P145, DOI 10.3960/jslrt.56.145; Lan XW, 2017, ONCOTARGETS THER, V10, P919, DOI 10.2147/OTT.S128825; Langerak AW, 2012, LEUKEMIA, V26, P2159, DOI 10.1038/leu.2012.246; Laszik Z, 1996, BLOOD, V88, P3010, DOI 10.1182/blood.V88.8.3010.bloodjournal8883010; Lenz G, 2008, P NATL ACAD SCI USA, V105, P13520, DOI 10.1073/pnas.0804295105; Liersch-Lohn B, 2016, INT J CANCER, V138, P1220, DOI 10.1002/ijc.29865; Liu PF, 2015, GENET MOL RES, V14, P10288, DOI 10.4238/2015.August.28.14; Luan SL, 2010, J PATHOL, V222, P166, DOI 10.1002/path.2752; Lurier EB, 2017, IMMUNOBIOLOGY, V222, P847, DOI 10.1016/j.imbio.2017.02.006; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; MCCHESNEY MB, 1986, ANN RHEUM DIS, V45, P546, DOI 10.1136/ard.45.7.546; McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965; Meyer PN, 2011, AM J CLIN PATHOL, V135, P54, DOI 10.1309/AJCPJX4BJV9NLQHY; Miyaoka M, 2018, MODERN PATHOL, V31, P313, DOI 10.1038/modpathol.2017.134; Monti S, 2005, BLOOD, V105, P1851, DOI 10.1182/blood-2004-07-2947; Monti S, 2012, CANCER CELL, V22, P359, DOI 10.1016/j.ccr.2012.07.014; Muris JJF, 2004, LEUKEMIA, V18, P589, DOI 10.1038/sj.leu.2403240; Nagao R, 2016, AM J SURG PATHOL, V40, P1041, DOI 10.1097/PAS.0000000000000651; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; Nutt SL, 2015, NAT REV IMMUNOL, V15, P160, DOI 10.1038/nri3795; Okada Y, 2014, NATURE, V506, P376, DOI 10.1038/nature12873; Pasero C, 2013, IMMUNOL LETT, V151, P71, DOI 10.1016/j.imlet.2013.01.008; Puente XS, 2011, NATURE, V475, P101, DOI 10.1038/nature10113; Raes G, 2007, INT J CANCER, V121, P2646, DOI 10.1002/ijc.23067; Rimsza L, 2017, VIRCHOWS ARCH, V471, P453, DOI 10.1007/s00428-017-2199-7; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schmidt J, 2016, BLOOD, V128, P1101, DOI 10.1182/blood-2016-03-703819; Shi Y, 2014, ELIFE, V3, DOI 10.7554/eLife.02349; Shimizu Y, 2017, CLIN RHEUMATOL, V36, P1237, DOI 10.1007/s10067-017-3634-5; Simon TA, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0728-9; Smitten AL, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2404; Sutton LA, 2015, HAEMATOLOGICA, V100, P370, DOI 10.3324/haematol.2014.109777; Tomita S, 2015, MODERN PATHOL, V28, P1286, DOI 10.1038/modpathol.2015.85; Tzankov A, 2008, HAEMATOL-HEMATOL J, V93, P193, DOI 10.3324/haematol.11702; Vaidya R, 2014, ANN ONCOL, V25, P2124, DOI 10.1093/annonc/mdu109; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; Wada N, 2012, HISTOPATHOLOGY, V60, P313, DOI 10.1111/j.1365-2559.2011.04096.x; Walsh AM, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0948-6; Willis SN, 2014, J IMMUNOL, V192, P3200, DOI 10.4049/jimmunol.1303216; Wolfe F, 2007, ARTHRITIS RHEUM, V56, P2886, DOI 10.1002/art.22864; Wong AK, 2012, CLIN RHEUMATOL, V31, P631, DOI 10.1007/s10067-011-1895-y; Xu-Monette ZY, 2015, MODERN PATHOL, V28, P1555, DOI 10.1038/modpathol.2015.118; Yamada K, 2015, HISTOPATHOLOGY, V67, P70, DOI 10.1111/his.12627; Yamada T, 2011, RHEUMATOL INT, V31, P1487, DOI 10.1007/s00296-010-1524-0; Yamakawa N, 2014, J RHEUMATOL, V41, P293, DOI 10.3899/jrheum.130270; Yamamoto K, 2015, P JPN ACAD B-PHYS, V91, P410, DOI 10.2183/pjab.91.410; Yamanaka H, 2014, MOD RHEUMATOL, V24, P33, DOI 10.3109/14397595.2013.854059; Yarwood A, 2016, RHEUMATOLOGY, V55, P199, DOI 10.1093/rheumatology/keu323; Young RM, 2013, NAT REV DRUG DISCOV, V12, P229, DOI 10.1038/nrd3937	84	3	3	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUL	2018	42	7					936	950		10.1097/PAS.0000000000001071			15	Pathology; Surgery	Pathology; Surgery	GJ6CY	WOS:000435472600011	29738359				2019-10-28	
J	Al Hmada, Y; Schaefer, IM; Fletcher, CDM				Al Hmada, Youssef; Schaefer, Inga-Marie; Fletcher, Christopher D. M.			Hibernoma Mimicking Atypical Lipomatous Tumor 64 Cases of a Morphologically Distinct Subset	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						hibernoma; brown fat; atypical lipomatous tumor; liposarcoma	CLINICOPATHOLOGICAL FEATURES; INTRAOSSEOUS HIBERNOMA; MORPHOLOGY; ADULT; RARE; AIP	Hibernoma is a benign adipocytic tumor with predilection for subcutaneous tissue of the thigh, upper trunk, and neck of middle-aged adults. 11q13 rearrangement resulting in MEN1/AIP codeletion is characteristic. Hibernomas are composed, in varying proportions, of brown fat cells, mature adipocytes, and microvacuolated lipoblast-like cells. Examples containing predominantly multivacuolated lipoblast-like cells are uncommon and distinction from atypical lipomatous tumor (ALT) is important for clinical management. We herein present the clinicopathologic features of 64 hibernomas histologically mimicking ALT. MDM2 and CDK4 immunohistochemistry as well as MDM2 fluorescence in situ hybridization were performed in a subset of cases. Clinical and follow-up information were obtained from referring pathologists. Thirty-four patients were male and 30 female, with a median age of 43 years (range, 24 to 78y). The tumors were well circumscribed and mostly deeply located (53/64 cases, 83%) with a median tumor size of 12.9cm (range, 3.5 to 23cm) and predilection for the thigh (42/64 cases, 66%). Histologically, large cells with prominent lipoblast-like cytoplasmic fatty vacuoles and small central nuclei were present to a prominent degree in all cases, along with mature univacuolated adipocytes and smaller numbers of large, finely vacuolated cells with eosinophilic granular cytoplasm. Nuclear atypia and mitoses were absent. None of the 39 cases tested showed CDK4 and MDM2 overexpression or MDM2 amplification. Follow-up, available for 16/64 cases (median, 47mo; range, 1 to 165mo), revealed no recurrences or metastases. Hibernoma mimicking ALT shows predilection for deep soft tissue, especially in the thigh. These tumors behave in a benign manner and MDM2/CDK4 negativity may be useful in excluding ALT.	[Al Hmada, Youssef; Schaefer, Inga-Marie; Fletcher, Christopher D. M.] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA; [Al Hmada, Youssef] Univ Mississippi, Dept Pathol, Grad Sch Med, Jackson, MS USA	Fletcher, CDM (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	cfletcher@bwh.harvard.edu		, Inga-Marie/0000-0001-9710-5500	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32 HL007627]		Beals C, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0769-3; Cantisani V, 2003, ABDOM IMAGING, V28, P721, DOI 10.1007/s00261-002-0094-3; Chitoku S, 1998, SURG NEUROL, V49, P509, DOI 10.1016/S0090-3019(97)00304-2; Fletcher C, 2013, WHO CLASSIFICATION T; Fletcher CDM, 1996, AM J PATHOL, V148, P623; FLETCHER CDM, 1986, BRIT J UROL, V58, P99; Furlong MA, 2001, AM J SURG PATHOL, V25, P809, DOI 10.1097/00000478-200106000-00014; Gery L, 1914, B MEM SOC ANAT PARIS, V89, P111; Hallin M, 2016, INT J SURG PATHOL, V24, P620, DOI 10.1177/1066896916653213; Jaroszewski Dawn E, 2013, World J Clin Cases, V1, P143, DOI 10.12998/wjcc.v1.i4.143; Kim Hyun Su, 2012, Korean J Spine, V9, P362, DOI 10.14245/kjs.2012.9.4.362; Magnusson L, 2017, J PATHOL, V243, P160, DOI 10.1002/path.4945; Mavrogenis AF, 2011, ORTHOPEDICS, V34, pE755, DOI 10.3928/01477447-20110922-12; Merkel H, 1906, BEITR PATHOL ANAT AL, V39, P152; Minni A, 2008, ACTA OTORHINOLARYNGO, V28, P141; Naik R, 2015, J CLIN DIAGN RES, V9, pED1, DOI 10.7860/JCDR/2015/13500.6041; Neufeld Marilyn, 2005, Can J Plast Surg, V13, P33; Nord KH, 2010, P NATL ACAD SCI USA, V107, P21122, DOI 10.1073/pnas.1013512107; Schwartz BF, 2003, UROLOGY, V61, DOI 10.1016/S0090-4295(02)02586-4; Shackelford RE, 2017, CASE REP ONCOL, V10, P438, DOI 10.1159/000475708; Song B, 2017, J PATHOL TRANSL MED, V51, P499, DOI 10.4132/jptm.2017.07.28; Turaga KK, 2006, CANCER GENET CYTOGEN, V170, P163, DOI 10.1016/j.cancergencyto.2006.05.014; Ugalde PA, 2007, ANN THORAC SURG, V84, P1376, DOI 10.1016/j.athoracsur.2007.05.044; Westacott L, 2016, INT J SURG PATHOL, V24, P749, DOI 10.1177/1066896916657642	24	4	4	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUL	2018	42	7					951	957		10.1097/PAS.0000000000001061			7	Pathology; Surgery	Pathology; Surgery	GJ6CY	WOS:000435472600012	29629919	Green Accepted			2019-10-28	
J	Wong, RWC; Moore, M; Talia, KL; Ganesan, R; McCluggage, WG				Wong, Richard Wing-Cheuk; Moore, Michelle; Talia, Karen L.; Ganesan, Raji; McCluggage, W. Glenn			Primary Vaginal Gastric-type Adenocarcinoma and Vaginal Adenosis Exhibiting Gastric Differentiation Report of a Series With Detailed Immunohistochemical Analysis	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						vagina; adenocarcinoma; vaginal adenosis; gastric-type; immunohistochemistry	CLEAR-CELL ADENOCARCINOMA; PRIMARY MUCINOUS ADENOCARCINOMA; FEMALE GENITAL-TRACT; INTESTINAL-TYPE; UTERINE CERVIX; GLANDULAR LESIONS; DIETHYLSTILBESTROL EXPOSURE; IN-UTERO; METAPLASIA; STILBESTROL	So-called gastric-type adenocarcinoma and related premalignant lesions have been characterized in the cervix, but similar lesions are not widely recognized in the vagina. We report a series of 11 vaginal glandular lesions exhibiting gastric differentiation, comprising 5 cases of adenocarcinoma and 6 of adenosis. All cases occurred in adults (aged 33 to 69) with no known history of diethylstilboestrol exposure. The vaginal adenocarcinomas exhibited morphologic features identical to gastric-type adenocarcinoma of the cervix, but 1 case additionally demonstrated basaloid and sarcomatoid components, which have not been previously reported in cervical gastric-type adenocarcinoma. Immunohistochemically, the adenocarcinomas were positive for MUC6 (4/5), PAX8 (3/5), CK7 (5/5), CK20 (1/5), CDX2 (5/5), CA19.9 (5/5), CEA (4/5), CA125 (5/5), and hepatocyte nuclear factor 1 (5/5). p16, estrogen receptor, and Napsin A were negative in all cases tested, whereas p53 exhibited mutation-type staining in 3/5 cases. In all 5 adenocarcinomas, a component of adenosis with benign or atypical nuclear features was identified; the adenosis displayed gastric morphology in 4 cases and tuboendometrial morphology in 1. The 6 cases of pure vaginal adenosis (without associated adenocarcinoma) all contained gastric-type mucinous glands together with tuboendometrial glands in 2 cases. There was focal intestinal differentiation with goblet cells in all 6 cases and neuroendocrine cells with eosinophilic granules in 3. Cytologic atypia was observed in 4/6 cases of pure vaginal adenosis. Immunohistochemically, the gastric-type adenosis (10 cases) was positive for MUC6 (10/10), estrogen receptor (5/10), PAX8 (8/10), CK7 (9/9), CK20 (2/9), CDX2 (5/9), CA19.9 (8/9), CEA (6/9), CA125 (6/9), hepatocyte nuclear factor 1 (10/10), and Napsin A (1/10). p53 exhibited wild-type immunoreactivity in all 10 cases, whereas p16 was negative in all cases tested. Scattered individual chromogranin-positive cells were present in all 5 cases of pure adenosis tested. Follow-up was available in 4 of the adenocarcinoma cases, with 3 patients dead of disease within 1 to 3 years and 1 patient alive with disease at 1 year. The morphologic and immunohistochemical findings in our study suggest a close relationship between vaginal gastric-type adenocarcinoma and adenosis exhibiting gastric differentiation. This probably represents a distinct pathway of vaginal gastric-type carcinogenesis analogous to that occurring in the cervix. We propose that gastric-type adenocarcinoma be recognized as a distinct histologic subtype of vaginal adenocarcinoma while vaginal adenosis of gastric-type represents a novel subtype of adenosis that requires further study to clarify its biological potential.	[Wong, Richard Wing-Cheuk] Pamela Youde Nethersole Eastern Hosp, Dept Clin Pathol, Hong Kong, Hong Kong, Peoples R China; [Moore, Michelle; McCluggage, W. Glenn] Belfast Hlth & Social Care Trust, Dept Pathol, Belfast, Antrim, North Ireland; [Ganesan, Raji] Birmingham Womens NHS Fdn Trust, Dept Cellular Pathol, Mindelsohn Way, Birmingham, W Midlands, England; [Talia, Karen L.] Box Hill Hosp, Dept Pathol, Melbourne, Vic, Australia	McCluggage, WG (reprint author), Royal Grp Hosp Trust, Dept Pathol, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.	glenn.mccluggage@belfasttrust.hscni.net					Bartley AN, 2017, J CLIN ONCOL, V35, P446, DOI 10.1200/JCO.2016.69.4836; Bartman AE, 1998, J PATHOL, V186, P398; Carleton C, 2016, AM J SURG PATHOL, V40, P636, DOI 10.1097/PAS.0000000000000578; DEBOLOS C, 1995, GASTROENTEROLOGY, V109, P723, DOI 10.1016/0016-5085(95)90379-8; DEMARS LR, 1995, GYNECOL ONCOL, V58, P389, DOI 10.1006/gyno.1995.1249; Driss M, 2007, J OBSTET GYNAECOL, V27, P332, DOI 10.1080/01443610701269325; Ebrahim S, 2001, GYNECOL ONCOL, V80, P89, DOI 10.1006/gyno.2000.5963; Fadare O, 2014, AM J SURG PATHOL, V38, P189, DOI 10.1097/PAS.0000000000000085; FOX H, 1988, HISTOPATHOLOGY, V12, P167, DOI 10.1111/j.1365-2559.1988.tb01927.x; GOODMAN A, 1991, CANCER, V68, P1628, DOI 10.1002/1097-0142(19911001)68:7<1628::AID-CNCR2820680727>3.0.CO;2-R; HERBST AL, 1970, CANCER, V25, P745, DOI 10.1002/1097-0142(197004)25:4<745::AID-CNCR2820250402>3.0.CO;2-2; HERBST AL, 1972, OBSTET GYNECOL, V40, P287; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; Huang W, 2016, INT J GYNECOL PATHOL, V35, P66; Iwamoto M, 2015, HUM PATHOL, V46, P957, DOI 10.1016/j.humpath.2015.03.008; Kao YC, 2012, HISTOPATHOLOGY, V61, P760, DOI 10.1111/j.1365-2559.2012.04267.x; Karamurzin YS, 2015, AM J SURG PATHOL, V39, P1449, DOI 10.1097/PAS.0000000000000532; Kenny SL, 2012, AM J SURG PATHOL, V36, P799, DOI 10.1097/PAS.0b013e31824a72c6; Kojima A, 2007, AM J SURG PATHOL, V31, P664, DOI 10.1097/01.pas.0000213434.91868.b0; Kurman RJ, 2014, WHO CLASSIFICATION T; Laronda MM, 2012, DIFFERENTIATION, V84, P252, DOI 10.1016/j.diff.2012.05.004; McCluggage WG, 2016, ADV ANAT PATHOL, V23, P58, DOI 10.1097/PAP.0000000000000095; MERCHANT WJ, 1993, HISTOPATHOLOGY, V23, P373, DOI 10.1111/j.1365-2559.1993.tb01222.x; Mikami Y, 2004, MODERN PATHOL, V17, P962, DOI 10.1038/modpathol.3800148; Mikami Y, 1999, GYNECOL ONCOL, V74, P504, DOI 10.1006/gyno.1999.5462; Mikami Y, 2013, ADV ANAT PATHOL, V20, P227, DOI 10.1097/PAP.0b013e31829c2d66; Mikami Y, 2009, HISTOPATHOLOGY, V54, P184, DOI 10.1111/j.1365-2559.2008.03202.x; Mudhar HS, 2001, INT J GYNECOL PATHOL, V20, P204, DOI 10.1097/00004347-200104000-00016; Nasu K, 2010, EUR J GYNAECOL ONCOL, V31, P679; OTT MM, 1994, VIRCHOWS ARCH, V425, P445; Paczos TA, 2010, INT J GYNECOL PATHOL, V29, P193, DOI 10.1097/PGP.0b013e3181b6a7d7; Pirog EC, 2017, ARCH PATHOL LAB MED, V141, P1653, DOI 10.5858/arpa.2016-0356-RA; ROBBOY SJ, 1982, OBSTET GYNECOL, V60, P546; ROBBOY SJ, 1974, CANCER-AM CANCER SOC, V34, P606, DOI 10.1002/1097-0142(197409)34:3<606::AID-CNCR2820340318>3.0.CO;2-P; ROBBOY SJ, 1984, CANCER, V54, P869, DOI 10.1002/1097-0142(19840901)54:5<869::AID-CNCR2820540519>3.0.CO;2-I; Saitoh M, 2005, PATHOL INT, V55, P372, DOI 10.1111/j.1440-1827.2005.01839.x; SCULLY RE, 1974, ANN CLIN LAB SCI, V4, P222; Shah C, 2006, GYNECOL ONCOL, V103, P1130, DOI 10.1016/j.ygyno.2006.06.044; Shimao Y, 2000, VIRCHOWS ARCH, V436, P622, DOI 10.1007/s004289900166; Staats PN, 2007, AM J SURG PATHOL, V31, P1490, DOI 10.1097/PAS.0b013e31804a7e9a; Staats PN, 2014, AM J SURG PATHOL, V38, P593, DOI 10.1097/PAS.0000000000000157; Stolnicu S, 2018, AM J SURG PATHOL, V42, P214, DOI 10.1097/PAS.0000000000000986; Talia KL, 2018, PATHOLOGY, V50, P122, DOI 10.1016/j.pathol.2017.09.009; Talia KL, 2017, AM J SURG PATHOL, V41, P1023, DOI 10.1097/PAS.0000000000000855; Talia KL, 2012, INT J GYNECOL PATHOL, V31, P192, DOI 10.1097/PGP.0b013e31822c8036; Tatsumi K, 2015, AM J CLIN PATHOL, V144, P790, DOI 10.1309/AJCPVZ0QNLUO7OFE; Tjalma WAA, 2006, INT J GYNECOL CANCER, V16, P1461, DOI 10.1111/j.1525-1438.2006.00575.x; Uehara T, 2010, J OBSTET GYNAECOL RE, V36, P681, DOI 10.1111/j.1447-0756.2010.01178.x; Werner Dietrich, 2004, J Low Genit Tract Dis, V8, P38, DOI 10.1097/00128360-200401000-00009; Yamashita Y, 2015, MODERN PATHOL, V28, P111, DOI 10.1038/modpathol.2014.61; Yuan CT, 2016, VIRCHOWS ARCH, V469, P351, DOI 10.1007/s00428-016-1978-x; Zhao SM, 2003, INT J GYNECOL PATHOL, V22, P393, DOI 10.1097/01.pgp.0000092128.10100.17	52	0	0	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUL	2018	42	7					958	970		10.1097/PAS.0000000000001068			13	Pathology; Surgery	Pathology; Surgery	GJ6CY	WOS:000435472600013	29664741				2019-10-28	
J	Yang, ZM; Epstein, JI				Yang, Zhiming; Epstein, Jonathan I.			Urothelial Carcinoma In Situ of the Bladder With Glandular Differentiation Report of 92 Cases	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						carcinoma in situ; small cell carcinoma; urothelial carcinoma	URINARY-BLADDER; NATURAL-HISTORY	Urothelial carcinoma in situ (CIS) of the bladder with glandular differentiation (CIS-GL) is rare with some showing an association with small cell carcinoma. There is a paucity of data on whether CIS-GL diagnosed in the absence of invasive carcinoma is associated with an increased risk of developing small cell carcinoma of the bladder. Twenty-seven cases of CIS-GL were identified from the consult files of one of the authors from 2008 to 2015 without prior or coexisting invasive carcinoma at the time of diagnosis. Sixty-five additional cases were identified with concurrent CIS-GL and invasive carcinoma to assess the nature of the association. Of the 27 cases with only CIS-GL without invasive carcinoma at the time of diagnosis, follow-up time ranged from 11 to 91 months (mean, 41.1mo). Of 24/27 cases with follow-up information: 13 (54.2%) had no evidence of disease at last follow-up, typically treated with induction and maintenance Bacillus Calmette-Guerin; 3 (12.5%) patients underwent radical cystectomy due to disease progression; 2 (8.3%) patients had recurrent CIS, and 1 (4.2%) had recurrent noninvasive low-grade papillary urothelial carcinoma (UC) (these patients underwent transurethral resection of the bladder and Bacillus Calmette-Guerin treatment); 2 (8.3%) patients died of metastatic UC; and 3 (12.5%) died of other or unknown causes. Of note, none of these 24 patients developed small cell carcinoma. Of the 65 cases with concurrent CIS-GL and invasive carcinoma, the invasive carcinoma was: pure UC in 29/65 (45%); invasive UC with GL in 13/65 (20%); coexisting small cell carcinoma and invasive UC in 8/65 (12%); plasmacytoid UC in 7/65 (11%); sarcomatoid UC in 3/65 (5%); micropapillary UC in 2/65 (3%); squamous in 2/65 (3%); and signet ring with colloid features in 1/65 (1%). Patients with CIS-GL without invasive carcinoma are at significant risk for cancer progression and in a minority of cases at risk for death from bladder carcinoma, similar to usual CIS. Typically, subsequent invasive carcinoma is UC rather than adenocarcinoma. Similarly, the largest fraction of concurrent invasive carcinoma and CIS-GL is UC. However, this study for the first time demonstrates the wide spectrum of other UC variants that coexist with CIS-GL, including a sizeable minority of cases with invasive UC with GL. Although there is a disproportionately high fraction of CIS-GL with coexisting small cell carcinoma, small cell carcinoma does not seem to develop at high frequency following the diagnosis and treatment of CIS-GL.	[Yang, Zhiming; Epstein, Jonathan I.] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA; [Epstein, Jonathan I.] Johns Hopkins Univ Hosp, Dept Urol, Baltimore, MD 21287 USA; [Epstein, Jonathan I.] Johns Hopkins Univ Hosp, Dept Oncol, Baltimore, MD 21287 USA	Epstein, JI (reprint author), Johns Hopkins Univ Hosp, Weinberg Bldg,Rm 2242,401 N Broadway St, Baltimore, MD 21231 USA.	jepstein@jhmi.edu					Chan TY, 2001, AM J SURG PATHOL, V25, P892, DOI 10.1097/00000478-200107000-00007; Cheng L, 1999, CANCER-AM CANCER SOC, V85, P2469, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2469::AID-CNCR24>3.3.CO;2-L; Choong NWW, 2005, CANCER-AM CANCER SOC, V103, P1172, DOI 10.1002/cncr.20903; FARROW GM, 1992, J CELL BIOCHEM, P39; Gofrit ON, 2009, UROL ONCOL-SEMIN ORI, V27, P258, DOI 10.1016/j.urolonc.2007.12.011; Lee AHS, 1997, J PATHOL, V181, P200; Lim M, 2009, MODERN PATHOL, V22, P1280, DOI 10.1038/modpathol.2009.97; Lopez-Beltran A, 2011, HUM PATHOL, V42, P1653, DOI 10.1016/j.humpath.2010.12.024; MELAMED MR, 1964, CANCER, V17, P1533, DOI 10.1002/1097-0142(196412)17:12<1533::AID-CNCR2820171205>3.0.CO;2-7; Miller JS, 2009, AM J SURG PATHOL, V33, P1241, DOI 10.1097/PAS.0b013e3181a1ff41; Moch H, 2016, TUMOURS URINARY TRAC, P91; Moch H, 2016, TUMOURS PROSTATE, P169; OROZCO RE, 1994, CANCER-AM CANCER SOC, V74, P115, DOI 10.1002/1097-0142(19940701)74:1<115::AID-CNCR2820740120>3.0.CO;2-R; Sehgal Shailen S, 2010, Rev Urol, V12, pe197; Soria G, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-130; Sylvester RJ, 2005, UROLOGY, V66, P90, DOI 10.1016/j.urology.2005.06.135	16	4	4	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUL	2018	42	7					971	976		10.1097/PAS.0000000000001073			6	Pathology; Surgery	Pathology; Surgery	GJ6CY	WOS:000435472600014	29683821				2019-10-28	
J	Busca, A; Mirkovic, J; Parra-Herran, C				Busca, Aurelia; Mirkovic, Jelena; Parra-Herran, Carlos			Gastric-type Endocervical Adenocarcinoma Involving the Endometrium and Clinically Mimicking Endometrial Neoplasia A Diagnostic Challenge	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Letter							IMMUNOHISTOCHEMICAL ANALYSIS; GLANDULAR LESIONS; UTERINE CERVIX; IMMUNOPHENOTYPE		[Busca, Aurelia] Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON, Canada; [Mirkovic, Jelena; Parra-Herran, Carlos] Sunnybrook Hlth Sci Ctr, Dept Lab Med & Mol Diagnost, Toronto, ON, Canada; [Mirkovic, Jelena; Parra-Herran, Carlos] Univ Toronto, Toronto, ON, Canada	Busca, A (reprint author), Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON, Canada.			Parra-Herran, Carlos/0000-0003-1420-7291			Carleton C, 2016, AM J SURG PATHOL, V40, P636, DOI 10.1097/PAS.0000000000000578; Karamurzin YS, 2015, AM J SURG PATHOL, V39, P1449, DOI 10.1097/PAS.0000000000000532; Kojima A, 2007, AM J SURG PATHOL, V31, P664, DOI 10.1097/01.pas.0000213434.91868.b0; Liao SY, 2013, BRIT J CANCER, V108, P613, DOI 10.1038/bjc.2012.578; Matsubara A, 2014, AM J SURG PATHOL, V38, P370, DOI 10.1097/PAS.0000000000000093; Mikami Y, 2004, MODERN PATHOL, V17, P962, DOI 10.1038/modpathol.3800148; Mikami Y, 2013, ADV ANAT PATHOL, V20, P227, DOI 10.1097/PAP.0b013e31829c2d66; Park KJ, 2011, AM J SURG PATHOL, V35, P633, DOI 10.1097/PAS.0b013e31821534b9; Stolnicu S, 2018, AM J SURG PATHOL, V42, P214, DOI 10.1097/PAS.0000000000000986; Talia KL, 2017, AM J SURG PATHOL, V41, P1023, DOI 10.1097/PAS.0000000000000855	10	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUL	2018	42	7					983	985		10.1097/PAS.0000000000001063			3	Pathology; Surgery	Pathology; Surgery	GJ6CY	WOS:000435472600016	29683820				2019-10-28	
J	Andreasen, S; Kiss, K; Melchior, LC; Laco, J				Andreasen, Simon; Kiss, Katalin; Melchior, Linea C.; Laco, Jan			The ETV6-RET Gene Fusion Is Found in ETV6-rearranged Low-grade Sinonasal Adenocarcinoma Without NTRK3 Involvement	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Letter							ANALOG SECRETORY CARCINOMA; FIBROSARCOMA; SUBSET		[Andreasen, Simon] Copenhagen Univ Hosp, Rigshosp, Dept Otorhinolaryngol Head & Neck Surg, Copenhagen, Denmark; [Andreasen, Simon] Copenhagen Univ Hosp, Rigshosp, Dept Audiol, Copenhagen, Denmark; [Kiss, Katalin; Melchior, Linea C.] Copenhagen Univ Hosp, Rigshosp, Dept Pathol, Copenhagen, Denmark; [Andreasen, Simon] Zealand Univ Hosp, Dept Otorhinolaryngol & Maxillofacial Surg, Koge, Denmark; [Laco, Jan] Charles Univ Prague, Fac Med, Fingerland Dept Pathol, Hradec Kralove, Czech Republic; [Laco, Jan] Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic	Andreasen, S (reprint author), Copenhagen Univ Hosp, Rigshosp, Dept Otorhinolaryngol Head & Neck Surg, Copenhagen, Denmark.; Andreasen, S (reprint author), Copenhagen Univ Hosp, Rigshosp, Dept Audiol, Copenhagen, Denmark.; Andreasen, S (reprint author), Zealand Univ Hosp, Dept Otorhinolaryngol & Maxillofacial Surg, Koge, Denmark.		; Laco, Jan/L-9715-2017	Andreasen, Simon/0000-0002-1528-4988; Laco, Jan/0000-0002-9602-7501			Andreasen S, 2017, AM J SURG PATHOL, V41, P1552, DOI 10.1097/PAS.0000000000000912; Andreasen S, 2016, ONCOL REP, V35, P2177, DOI 10.3892/or.2016.4621; Eguchi M, 1999, BLOOD, V93, P1355, DOI 10.1182/blood.V93.4.1355.404k29_1355_1363; Ito Y, 2015, AM J SURG PATHOL, V39, P602, DOI 10.1097/PAS.0000000000000392; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Lurquin E, 2015, HISTOPATHOLOGY, V67, P749, DOI 10.1111/his.12702; Rubin BP, 1998, AM J PATHOL, V153, P1451, DOI 10.1016/S0002-9440(10)65732-X; Seethala RR, 2017, AM J SURG PATHOL, V41, P446, DOI 10.1097/PAS.0000000000000814; Skalova A, 2018, AM J SURG PATHOL, V42, P234, DOI 10.1097/PAS.0000000000000972; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Xu B, 2017, HEAD NECK PATHOL	11	6	6	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUL	2018	42	7					985	988		10.1097/PAS.0000000000001069			4	Pathology; Surgery	Pathology; Surgery	GJ6CY	WOS:000435472600017	29683817				2019-10-28	
J	Hameed, M; Mandelker, D				Hameed, Meera; Mandelker, Diana			Tumor Syndromes Predisposing to Osteosarcoma	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						osteosarcoma; hereditary syndromes; cancer predisposition	LI-FRAUMENI-SYNDROME; ROTHMUND-THOMSON-SYNDROME; SYNDROME ADULT PROGERIA; LONG-TERM SURVIVORS; RETINOBLASTOMA PATIENTS; CANCER PREDISPOSITION; MUTATION DETECTION; BLOOMS-SYNDROME; RB1 MUTATIONS; BREAST-CANCER	Osteosarcoma (OS) is the most common primary bone tumor affecting predominantly adolescents and young adults. It accounts for about 5% of all childhood cancers. Although the majority of OSs are sporadic, a small percentage occur as a component of hereditary cancer syndromes. Early onset, bilateral, multifocal, and metachronous tumors suggest genetic predisposition. The inheritance patterns can be autosomal dominant or recessive. These syndromes predispose to a wide variety of mesenchymal and epithelial cancers with propensity for certain mutations being prevalent in specific cancer subtypes. Li-Fraumeni syndrome, retinoblastoma, Rothmund-Thompson syndrome (type 2), Werner syndrome, and Bloom syndrome, constitute the majority of the tumor syndromes predisposing to OS and will be the focus for this review.	[Hameed, Meera; Mandelker, Diana] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA	Hameed, M (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA.	hameedm@mskcc.org			NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA008748]		Bougeard G, 2003, ONCOGENE, V22, P840, DOI 10.1038/sj.onc.1206155; Briccoli A, 2010, SURG ONCOL, V19, P193, DOI 10.1016/j.suronc.2009.05.002; Calvert George T., 2012, Sarcoma, P152382, DOI 10.1155/2012/152382; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen Z, 2014, HUM MUTAT, V35, P384, DOI 10.1002/humu.22488; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Correa H, 2016, J PEDIATR GENET, V5, P84, DOI 10.1055/s-0036-1579759; Dimaras H, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.21; Dommering CJ, 2014, J MED GENET, V51, P366, DOI 10.1136/jmedgenet-2014-102264; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Fletcher C, 2013, WHO CLASSIFICATION T, P281; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Fuchs B, 2002, CLIN ORTHOP RELAT R, P40; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; Garber JE, 2005, J CLIN ONCOL, V23, P276, DOI 10.1200/JCO.2005.10.042; German J, 1997, CANCER GENET CYTOGEN, V93, P100, DOI 10.1016/S0165-4608(96)00336-6; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; GOTO M, 1981, CLIN GENET, V19, P8; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; Harbour JW, 1998, OPHTHALMOLOGY, V105, P1442, DOI 10.1016/S0161-6420(98)98025-3; Hawkins MM, 1996, J NATL CANCER I, V88, P270, DOI 10.1093/jnci/88.5.270; Ishikawa Y, 2000, JPN J CANCER RES, V91, P1345, DOI 10.1111/j.1349-7006.2000.tb00924.x; Kivela T, 2009, BRIT J OPHTHALMOL, V93, P1129, DOI 10.1136/bjo.2008.150292; Kleinerman RA, 2005, J CLIN ONCOL, V23, P2272, DOI 10.1200/JCO.2005.05.054; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kratz CP, 2017, CLIN CANCER RES, V23, pE38, DOI 10.1158/1078-0432.CCR-17-0408; Larizza L, 2010, ORPHANET J RARE DIS, V5, DOI 10.1186/1750-1172-5-2; Lebel M, 2018, AGEING RES REV, V41, P82, DOI 10.1016/j.arr.2017.11.003; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Li L, 1998, MOL GENET METAB, V64, P286, DOI 10.1006/mgme.1998.2733; Liu JC, 2011, SKULL BASE-INTERD AP, V21, P103, DOI 10.1055/s-0031-1275256; LUSTBADER ED, 1992, AM J HUM GENET, V51, P344; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Mandelker D, 2017, JAMA-J AM MED ASSOC, V318, P825, DOI 10.1001/jama.2017.11137; Marees T, 2008, J NATL CANCER I, V100, P1771, DOI 10.1093/jnci/djn394; Mirabello L., 2015, JNCI-J NATL CANCER I, V107, P1; Mirabello L, 2009, INT J CANCER, V125, P229, DOI 10.1002/ijc.24320; Mohaghegh P, 2001, HUM MOL GENET, V10, P741, DOI 10.1093/hmg/10.7.741; Moore Drew D, 2014, Cancer Treat Res, V162, P65, DOI 10.1007/978-3-319-07323-1_4; Nakayama R, 2008, CANCER SCI, V99, P333, DOI 10.1111/j.1349-7006.2007.00692.x; Nishijo K, 2004, INT J CANCER, V111, P367, DOI 10.1002/ijc.20269; Ognjanovic S, 2012, CANCER-AM CANCER SOC, V118, P1387, DOI 10.1002/cncr.26390; Ottaviani G, 2009, CANC TREAT, V152, P15, DOI [10.1007/978-1-4419-0284-9_2, 10.1007/978-1-4419-0284-9_23]; Pinto Emilia M, 2011, Genes Cancer, V2, P485, DOI 10.1177/1947601911409745; Price EA, 2014, J MED GENET, V51, P208, DOI 10.1136/jmedgenet-2013-101821; Ruijs MWG, 2010, J MED GENET, V47, P421, DOI 10.1136/jmg.2009.073429; Savage Sharon A., 2011, Sarcoma, P548151, DOI 10.1155/2011/548151; Siitonen HA, 2009, EUR J HUM GENET, V17, P151, DOI 10.1038/ejhg.2008.154; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Stinco G, 2008, J DERMATOL, V35, P154, DOI 10.1111/j.1346-8138.2008.00436.x; Tabori U, 2007, CANCER RES, V67, P1415, DOI 10.1158/0008-5472.CAN-06-3682; Valverde JR, 2005, BMC GENET, V6, DOI 10.1186/1471-2156-6-53; Varley J, 2003, BREAST CANCER RES, V5, P123, DOI 10.1186/bcr582; Wang LL, 2003, J NATL CANCER I, V95, P669, DOI 10.1093/jnci/95.9.669; Wang LL, 2001, AM J MED GENET, V102, P11, DOI 10.1002/1096-8628(20010722)102:1<11::AID-AJMG1413>3.0.CO;2-A; Wong FL, 1997, JAMA-J AM MED ASSOC, V278, P1262, DOI 10.1001/jama.278.15.1262; Woo KI, 2010, ARCH OPHTHALMOL-CHIC, V128, P865, DOI 10.1001/archophthalmol.2010.126; Yu CL, 2009, JNCI-J NATL CANCER I, V101, P581, DOI 10.1093/jnci/djp046; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389; Zils K, 2015, PEDIATR HEMAT ONCOL, V32, P32, DOI 10.3109/08880018.2014.987939	64	3	3	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	JUL	2018	25	4					217	222		10.1097/PAP.0000000000000190			6	Pathology	Pathology	GJ4AY	WOS:000435290000001	29668499	Green Accepted			2019-10-28	
J	Yee, EU; Kuo, E; Goldsmith, JD				Yee, Eric U.; Kuo, Enoch; Goldsmith, Jeffrey D.			Pathologic Features of Infectious Gastritis	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						infectious gastritis; surgical pathology; stomach	EPSTEIN-BARR-VIRUS; HELICOBACTER-PYLORI INFECTION; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; POSTURAL EPIGASTRIC PAIN; HERPES-SIMPLEX-VIRUS; UPPER GASTROINTESTINAL-TRACT; STRONGYLOIDES-STERCORALIS INFECTION; LOSING HYPERTROPHIC GASTROPATHY; RENAL-TRANSPLANT RECIPIENTS; VARICELLA-ZOSTER GASTRITIS	This manuscript presents a review of infectious causes of gastritis aimed at the practicing anatomic pathologist. We shall highlight unique histologic findings and clinical attributes that will assist those analyzing endoscopically obtained mucosal biopsies of the stomach or resection specimens.	[Yee, Eric U.; Kuo, Enoch] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA; [Goldsmith, Jeffrey D.] Boston Childrens Hosp, Dept Pathol, BCH3027,300 Longwood Ave, Boston, MA 02115 USA; [Goldsmith, Jeffrey D.] Harvard Med Sch, Boston, MA USA	Goldsmith, JD (reprint author), Boston Childrens Hosp, Dept Pathol, BCH3027,300 Longwood Ave, Boston, MA 02115 USA.	jeffrey.goldsmith@childrens.harvard.edu					Agan BK, 2002, CLIN LAB MED, V22, P937, DOI 10.1016/S0272-2712(02)00017-3; Al Jarie A, 2003, PEDIATR INFECT DIS J, V22, P1007, DOI 10.1097/01.inf.0000095166.94823.11; Al-Obaidy K, 2015, BMC CLIN PATHOL, V15, DOI 10.1186/s12907-015-0002-8; Alpert L, 1996, GASTROENTEROLOGY, V110, P258, DOI 10.1053/gast.1996.v110.pm8536865; ANDRADE JD, 1983, AM J CLIN PATHOL, V79, P493, DOI 10.1093/ajcp/79.4.493; BAKER CJ, 1973, SOUTH MED J, V66, P539, DOI 10.1097/00007611-197305000-00006; Balkhair A, 2008, INT J INFECT DIS, V12, P111, DOI 10.1016/j.ijid.2007.04.009; Batts KP, 2013, AM J SURG PATHOL, V37, pE12, DOI 10.1097/PAS.0000000000000097; BAYERDORFFER E, 1994, GUT, V35, P701, DOI 10.1136/gut.35.5.701; Bento-Miranda M, 2014, WORLD J GASTROENTERO, V20, P17779, DOI 10.3748/wjg.v20.i47.17779; Bhalla Amarpreet, 2012, Conn Med, V76, P261; Bodmer T, 2000, FEMS MICROBIOL LETT, V182, P45, DOI 10.1111/j.1574-6968.2000.tb08871.x; Boettler Tobias, 2015, Gut, V64, P1453, DOI 10.1136/gutjnl-2014-308851; Boyanova L, 2007, J MED MICROBIOL, V56, P1081, DOI 10.1099/jmm.0.47181-0; Brandt LJ, 2011, GASTROINTEST ENDOSC, V74, P688, DOI 10.1016/j.gie.2011.04.021; BROWN JR, 1973, HUM PATHOL, V4, P319, DOI 10.1016/S0046-8177(73)80097-8; Caca K, 1995, Bildgebung, V62, P244; CAPPELL MS, 1991, AM J GASTROENTEROL, V86, P654; Cardenas-Mondragon MG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062850; Chan WY, 2001, DIAGN MOL PATHOL, V10, P153, DOI 10.1097/00019606-200109000-00002; Charles P, 2011, MEDICINE, V90, P223, DOI 10.1097/MD.0b013e318225ab89; Chen Y, 1998, Zhonghua Yi Xue Za Zhi, V78, P490; Chen ZME, 2007, AM J SURG PATHOL, V31, P1446, DOI 10.1097/PAS.0b013e318050072f; Chetty R, 2003, INT J SURG PATHOL, V11, P241, DOI 10.1177/106689690301100316; CHETTY R, 1994, J CLIN PATHOL, V47, P968, DOI 10.1136/jcp.47.11.968; Chhaya V, 2011, ENDOSCOPY, V43, pE289, DOI 10.1055/s-0030-1256425; Chitkara Y, 2015, AM J CLIN PATHOL, V143, P84, DOI 10.1309/AJCP0G6INEDBSXCN; Cimino RO, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0994-z; Clemente C M, 2000, Arq Gastroenterol, V37, P180; Colaiacovo R, 2011, ENDOSCOPY, V43, pE216, DOI 10.1055/s-0030-1256398; DAMSKER B, 1985, J INFECT DIS, V151, P179, DOI 10.1093/infdis/151.1.179; Daschner A, 2000, J ALLERGY CLIN IMMUN, V105, P176, DOI 10.1016/S0091-6749(00)90194-5; Daschner A, 2012, TRENDS PARASITOL, V28, P9, DOI 10.1016/j.pt.2011.10.001; Dayal R, 2015, INDIAN J PEDIATR, V82, P189, DOI 10.1007/s12098-014-1506-4; de Souza JN, 2015, INT J RHEUM DIS, P700; DEGIACOMO C, 1990, J PEDIATR GASTR NUTR, V11, P310; DIXON MF, 1988, J PATHOL, V154, P125, DOI 10.1002/path.1711540204; DOGLIONI C, 1992, J CLIN PATHOL, V45, P964, DOI 10.1136/jcp.45.11.964; Drut RM, 1995, MEDICINA-BUENOS AIRE, V55, P659; Dunn BE, 1997, CLIN MICROBIOL REV, V10, P720, DOI 10.1128/CMR.10.4.720; DUNN DL, 1991, TRANSPLANTATION, V51, P98, DOI 10.1097/00007890-199101000-00015; Ecka RS, 2013, CASE REP MED, DOI 10.1155/2013/169051; ECTORS NL, 1993, HISTOPATHOLOGY, V23, P55, DOI 10.1111/j.1365-2559.1993.tb01183.x; El-Shabrawi MHF, 2011, J MED MICROBIOL, V60, P871, DOI 10.1099/jmm.0.028670-0; Ensari A, 2005, VIRCHOWS ARCH, V446, P463, DOI 10.1007/s00428-005-1215-5; Fenkel JM, 2009, CLIN GASTROENTEROL H, V7, pXIV, DOI 10.1016/j.cgh.2009.01.019; Fernandez de la Puebla Gimenez R A, 1995, Gastroenterol Hepatol, V18, P125; Fernandez-Acenero MJ, 2004, OBES SURG, V14, P1012, DOI 10.1381/0960892041719572; FISHER JR, 1978, AM J DIG DIS, V23, P282, DOI 10.1007/BF01072330; FITZPATRICK TJ, 1953, ARCH INTERN MED, V91, P49, DOI 10.1001/archinte.1953.00240130057006; Franciosi CM, 2002, SURGERY, V131, P685, DOI 10.1067/msy.2002.116405; Fretzayas A, 2011, ANN TROP PAEDIATR, V31, P141, DOI 10.1179/146532811X13006353133876; FYFE B, 1993, ARCH PATHOL LAB MED, V117, P820; Ganji M, 2003, ARCH PATHOL LAB MED, V127, P732; GARCIA F, 1987, ARCH INTERN MED, V147, P787, DOI 10.1001/archinte.147.4.787; GENTA RM, 1993, HUM PATHOL, V24, P577, DOI 10.1016/0046-8177(93)90235-9; GENTA RM, 1994, ARCH PATHOL LAB MED, V118, P740; GENTA RM, 1988, AM J CLIN PATHOL, V89, P391, DOI 10.1093/ajcp/89.3.391; Geri G, 2015, INFECTION, V43, P691, DOI 10.1007/s15010-015-0799-1; Gholoobi A, 2014, JUNDISHAPUR J MICROB, V7, DOI 10.5812/jjm.8939; Giladi M, 1998, INFECTION, V26, P234, DOI 10.1007/BF02962370; GILLESPIE PE, 1978, MED J AUSTRALIA, V1, P228, DOI 10.5694/j.1326-5377.1978.tb107855.x; Goenka MK, 1996, J CLIN GASTROENTEROL, V23, P7, DOI 10.1097/00004836-199607000-00003; Goh S. H., 1994, Annals Academy of Medicine Singapore, V23, P903; Goldman H, 1996, GASTROINTESTINAL MUC; GOODWIN RA, 1980, MEDICINE, V59, P1, DOI 10.1097/00005792-198001000-00001; GRADONI L, 1995, APMIS, V103, P25, DOI 10.1111/j.1699-0463.1995.tb01075.x; GREENSTEIN DB, 1994, J CLIN GASTROENTEROL, V18, P4, DOI 10.1097/00004836-199401000-00003; Greiner A, 1996, HISTOPATHOLOGY, V29, P51, DOI 10.1046/j.1365-2559.1996.d01-482.x; Guarner Jeannette, 2004, Curr Gastroenterol Rep, V6, P441, DOI 10.1007/s11894-004-0065-7; Guimaraes AJ, 2006, BRAZ J MICROBIOL, V37, P1, DOI 10.1590/S1517-83822006000100001; GUPTA B, 1990, POSTGRAD MED J, V66, P63, DOI 10.1136/pgmj.66.771.63; Habas F, 2014, ARCH PEDIATRIE, V21, P903, DOI 10.1016/j.arcped.2014.05.015; Hansson LE, 1996, NEW ENGL J MED, V335, P242, DOI 10.1056/NEJM199607253350404; HAOT J, 1988, GUT, V29, P1258, DOI 10.1136/gut.29.9.1258; Hastings SM, 2012, GASTROENTEROLOGY, V142, P702, DOI 10.1053/j.gastro.2011.09.013; HEILMANN KL, 1991, GUT, V32, P137, DOI 10.1136/gut.32.2.137; Hindupur S, 2006, LANCET INFECT DIS, V6, P60, DOI 10.1016/S1473-3099(05)70328-5; Hirasaki S, 1999, J GASTROENTEROL, V34, P688, DOI 10.1007/s005350050320; Hisamatsu A, 2010, INTERNAL MED, V49, P2101, DOI 10.2169/internalmedicine.49.3789; Hoang MP, 2004, J CUTAN PATHOL, V31, P595, DOI 10.1111/j.0303-6987.2004.00236.x; Hokama A, 2010, WORLD J GASTRO ENDOS, V2, P379, DOI 10.4253/wjge.v2.i11.379; Horn B, 2000, AUST VET J, V78, P320, DOI 10.1111/j.1751-0813.2000.tb11781.x; Hsu PI, 2007, AM J GASTROENTEROL, V102, P725, DOI 10.1111/j.1572-0241.2006.01109.x; Huppmann AR, 2010, HUM PATHOL, V41, P1777, DOI 10.1016/j.humpath.2010.06.007; Hussein MR, 2007, MYCOL RES, V111, P926, DOI 10.1016/j.mycres.2007.06.009; Inagaki H, 1996, HUM PATHOL, V27, P761, DOI 10.1016/S0046-8177(96)90446-3; Ito Y, 2007, ASIAN J SURG, V30, P67, DOI 10.1016/S1015-9584(09)60131-7; Jain S, 2000, ACTA CYTOL, V44, P987, DOI 10.1159/000328621; Jaka H, 2013, TROP DOCT, V43, P46, DOI 10.1177/0049475512472438; Jhala D, 1999, MODERN PATHOL, V12, P534; Jun DW, 2007, GASTROINTEST ENDOSC, V65, P1092, DOI 10.1016/j.gie.2006.11.003; Kakugawa Y, 2010, WORLD J GASTROENTERO, V16, P2907, DOI 10.3748/wjg.v16.i23.2907; KAPLAN CS, 1989, ARCH INTERN MED, V149, P2095, DOI 10.1001/archinte.149.9.2095; Kato T, 2013, DIGEST ENDOSC, V25, P508, DOI 10.1111/den.12031; Kattoor J, 2002, J MED VIROL, V68, P384, DOI 10.1002/jmv.10215; Kawaguchi Y, 2008, J CLIN GASTROENTEROL, V42, P1063, DOI 10.1097/MCG.0b013e31805d7ef1; Kazan E, 2011, CLIN MICROBIOL INFEC, V17, P588, DOI 10.1111/j.1469-0691.2010.03310.x; KEMKER BP, 1992, AM SURGEON, V58, P775; Kijima Y, 2001, J MED VIROL, V64, P513, DOI 10.1002/jmv.1079; Kim DG, 2012, ENDOSCOPY         S2, V44, pE381; Kim Seoung-Gu, 2006, Korean Journal of Parasitology, V44, P81, DOI 10.3347/kjp.2006.44.1.81; Kim SH, 2013, CLIN ENDOSC, V46, P293, DOI 10.5946/ce.2013.46.3.293; KINOSHITA Y, 1993, GASTROENTEROL JPN, V28, P88; Kishihara Y, 1993, Kansenshogaku Zasshi, V67, P1223; Kitayama Y, 2000, GASTROINTEST ENDOSC, V52, P290, DOI 10.1067/mge.2000.107715; Koczka CP, 2012, EUR J GASTROEN HEPAT, V24, P860, DOI 10.1097/MEG.0b013e3283543ea0; KOMOROWSKI RA, 1991, AM J SURG PATHOL, V15, P577, DOI 10.1097/00000478-199106000-00006; Konjeti Venkata Rajesh, 2014, Conn Med, V78, P335; Konstantopoulos K, 2002, SCAND J INFECT DIS, V34, P148, DOI 10.1080/00365540110077281; Kordy F, 2015, PEDIATR INFECT DIS J, V34, P91, DOI 10.1097/INF.0000000000000498; Kulkarni RV, 2015, INDIAN J SURG, V77, pS87, DOI 10.1007/s12262-014-1164-9; Kumamoto CA, 2011, CURR OPIN MICROBIOL, V14, P386, DOI 10.1016/j.mib.2011.07.015; LAGUNA F, 1994, CLIN INFECT DIS, V19, P48, DOI 10.1093/clinids/19.1.48; Lamps LW, 2000, AM J CLIN PATHOL, V113, P64, DOI 10.1309/X0Y2-P3GY-TWE8-DM02; Lamps LW, 2009, SURG PATHOLOGY GASTR; Lass-Florl C, 2009, CLIN MICROBIOL INFEC, V15, P60, DOI 10.1111/j.1469-0691.2009.02999.x; Lauwers GY, 2010, J GASTROENTEROL, V45, P131, DOI 10.1007/s00535-009-0146-3; Lavery Eric A, 2008, Curr Gastroenterol Rep, V10, P417, DOI 10.1007/s11894-008-0078-8; Lee CM, 1996, J FORMOS MED ASSOC, V95, P66; Lee SH, 2004, GASTROINTEST ENDOSC, V59, P586, DOI 10.1016/S0016-5107(04)00009-4; Li W, 2009, TRANSPL P, V41, P3956, DOI 10.1016/j.transproceed.2009.05.034; Licci S, 2009, Z GASTROENTEROL, V47, P357, DOI 10.1055/s-2008-1027656; Lisby G, 1999, MOL BIOTECHNOL, V12, P75, DOI 10.1385/MB:12:1:75; LOHR JM, 1990, J VIROL, V64, P2168; LONG BW, 1995, AM J GASTROENTEROL, V90, P1504; Loutfy MR, 2002, AM J TROP MED HYG, V66, P749, DOI 10.4269/ajtmh.2002.66.749; Lyon GM, 2001, CLIN INFECT DIS, V32, P1448, DOI 10.1086/320161; Ma Zhi-Qiang, 2000, Journal of Medical and Dental Sciences, V47, P39; MacFie J, 1999, GUT, V45, P223, DOI 10.1136/gut.45.2.223; Maeng L, 2004, AM J SURG PATHOL, V28, P941, DOI 10.1097/00000478-200407000-00015; Maiorana A, 2003, HUM PATHOL, V34, P1331, DOI 10.1016/j.humpath.2003.08.005; Malakoutian T, 2015, IRAN J PARASITOL, V10, P141; Mallet E, 2006, EUR J PEDIATR, V165, P64, DOI 10.1007/s00431-005-1748-2; Manzelli Antonio, 2008, Journal of Infection and Chemotherapy, V14, P371, DOI 10.1007/s10156-008-0635-y; MARSHALL BJ, 1984, LANCET, V1, P1311; Matsumoto T, 2014, WORLD J GASTROENTERO, V20, P3376, DOI 10.3748/wjg.v20.i12.3376; MAYORAL JL, 1991, ARCH SURG-CHICAGO, V126, P202; MCCLUGGAGE WG, 1994, J CLIN PATHOL, V47, P1054, DOI 10.1136/jcp.47.11.1054; McGarvey JA, 2001, INFECT IMMUN, V69, P7242, DOI 10.1128/IAI.69.12.7242-7249.2001; McKinsey DS, 1997, CLIN INFECT DIS, V24, P1195, DOI 10.1086/513653; Megged O, 2008, EUR J PEDIATR, V167, P1217, DOI 10.1007/s00431-008-0791-1; Meining A, 1998, SCAND J GASTROENTERO, V33, P795; Merzianu M, 2005, ARCH PATHOL LAB MED, V129, pe87; Misra Vatsala, 2006, Indian J Pathol Microbiol, V49, P519; Mitropoulos P, 2010, J AM ACAD DERMATOL, V63, P309, DOI 10.1016/j.jaad.2009.06.088; Miyamoto M, 2002, VIRCHOWS ARCH, V440, P376, DOI 10.1007/s00428-001-0575-8; MIYAZAKI Y, 1991, APMIS, V99, P1001, DOI 10.1111/j.1699-0463.1991.tb01292.x; Montes H, 2008, ENDOSCOPY, V40, pE230, DOI 10.1055/s-2007-995497; Moorchung N, 2006, CLIN EXP MED, V6, P107, DOI 10.1007/s10238-006-0104-9; Moosmayer Stefan, 1992, Tidsskrift for den Norske Laegeforening, V112, P2857; Moustafellos P, 2006, TRANSPL P, V38, P1357, DOI 10.1016/j.transproceed.2006.05.067; Muller MJ, 2001, DIGEST DIS SCI, V46, P1784, DOI 10.1023/A:1010630326858; Mylona EE, 2010, SEX TRANSM DIS, V37, P177, DOI 10.1097/OLQ.0b013e3181c0d51f; Nagata N, 2012, INTERNAL MED, V51, P1433, DOI 10.2169/internalmedicine.51.7551; Nandwani A, 2015, Indian J Nephrol, V25, P373, DOI 10.4103/0971-4065.157428; Nemenqani D, 2009, ARCH PATHOL LAB MED, V133, P1938, DOI 10.1043/1543-2165-133.12.1938; Nielsen JA, 2014, HELICOBACTER, V19, P349, DOI 10.1111/hel.12139; Nishibayashi H, 2003, J GASTROEN HEPATOL, V18, P1384, DOI 10.1046/j.1440-1746.2003.03192.x; Nishimura So, 2011, Nihon Shokakibyo Gakkai Zasshi, V108, P1393; NUDELMAN HL, 1966, J AMER MED ASSOC, V195, P44; OEHLERT W, 1980, DEUT MED WOCHENSCHR, V105, P1773, DOI 10.1055/s-2008-1070956; Osuz M, 2007, TURK J GASTROENTEROL, V18, P44; Owen DA, 2003, MODERN PATHOL, V16, P325, DOI 10.1097/01.MP.0000062995.72390.14; Ozaki T, 2013, CLIN RHEUMATOL, V32, P1683, DOI 10.1007/s10067-013-2363-7; Ozturk G, 2011, ULUS TRAVMA ACIL CER, V17, P90, DOI 10.5505/tjtes.2011.51196; Paik S, 2006, J CLIN PATHOL, V59, P1316, DOI 10.1136/jcp.2005.032185; Panarelli NC, 2015, HUM PATHOL, V46, P397, DOI 10.1016/j.humpath.2014.11.014; Papadopoulos AA, 2005, GUT, V54, P1822, DOI 10.1136/gut.2005.075077; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PARSONNET J, 1998, GUT               S1, V43, pS; Patel N, 2010, ENDOSCOPY, V42, pE218, DOI 10.1055/s-0030-1255721; Paydar S, 2010, Middle East J Dig Dis, V2, P46; Phelps RG, 2000, INT J DERMATOL, V39, P609, DOI 10.1046/j.1365-4362.2000.00029.x; PIKEN E, 1978, JAMA-J AM MED ASSOC, V240, P2181; Pirsch JD, 1999, TRANSPLANTATION, V68, P1203, DOI 10.1097/00007890-199910270-00024; Ramanan P, 2013, INFECT CHEMOTHER, V45, P260, DOI 10.3947/ic.2013.45.3.260; Ramsay DB, 2007, DIGEST DIS SCI, V52, P1364, DOI 10.1007/s10620-006-9380-1; Rathnaraj S, 1997, Indian J Gastroenterol, V16, P110; Ratnam Sam, 2005, Can J Infect Dis Med Microbiol, V16, P45; Reyna-Figueroa J, 2015, J INFECT DEV COUNTR, V9, P431, DOI 10.3855/jidc.5714; Ricci C, 2007, BEST PRACT RES CL GA, V21, P299, DOI 10.1016/j.bpg.2006.11.002; Ricci S, 1996, Pediatr Med Chir, V18, P269; Rivasi F, 1999, HISTOPATHOLOGY, V34, P405; Rivasi F, 2006, ARCH PATHOL LAB MED, V130, P1792; Rivera-Vaquerizo PA, 2001, GASTROINTEST ENDOSC, V53, P809, DOI 10.1067/mge.2001.114421; Rossi P, 1998, GUT, V43, P476, DOI 10.1136/gut.43.4.476; ROTTERDAM H, 1985, PATHOLOGY, V17, P181, DOI 10.3109/00313028509063754; Ryan JL, 2012, DIGEST DIS SCI, V57, P1887, DOI 10.1007/s10620-012-2116-5; SAKANARI JA, 1989, CLIN MICROBIOL REV, V2, P278; SAKR M, 1992, TRANSPLANTATION, V53, P786, DOI 10.1097/00007890-199204000-00016; Saltmarsh G, 2014, AM SURGEON, V80, pE293; Sanad Magda M., 1996, Journal of the Egyptian Society of Parasitology, V26, P481; Sanders DL, 2003, AM SURGEON, V69, P536; SATHAPATAYAVONGS B, 1983, MEDICINE, V62, P263, DOI 10.1097/00005792-198309000-00001; Scholl S, 2006, ACTA HAEMATOL-BASEL, V116, P58, DOI 10.1159/000092349; Seo AN, 2015, KOREAN J PARASITOL, V53, P95, DOI 10.3347/kjp.2015.53.1.95; Serris A, 2014, REV MED INTERNE, V35, P337, DOI 10.1016/j.revmed.2013.05.004; Shafaghi A, 2012, AM J CASE REP, V13, P7, DOI 10.12659/AJCR.882279; Shapiro JL, 1996, AM J SURG PATHOL, V20, P462, DOI 10.1097/00000478-199604000-00009; Sharma D, 2004, SURG TODAY, V34, P537, DOI 10.1007/s00595-004-2745-1; Sheth S, 2014, CASE REP MED, DOI 10.1155/2014/346256; Shibata E, 2014, ABDOM IMAGING, V39, P257, DOI 10.1007/s00261-014-0075-3; Shimizu T, 1996, Helicobacter, V1, P197, DOI 10.1111/j.1523-5378.1996.tb00040.x; Sinelnikov I, 2009, HUM PATHOL, V40, P323, DOI 10.1016/j.humpath.2008.07.015; Singh S, 2015, BMC MICROBIOL, V15, DOI 10.1186/s12866-015-0528-z; Singhal AV, 2005, AM J SURG PATHOL, V29, P1537, DOI 10.1097/01.pas.0000169499.96658.6e; SKOUTELIS A, 1995, SOUTHERN MED J, V88, P647, DOI 10.1097/00007611-199506000-00010; Soavi C, 2014, HELICOBACTER, V19, P237, DOI 10.1111/hel.12122; Sohn WM, 2015, KOREAN J PARASITOL, V53, P465, DOI 10.3347/kjp.2015.53.4.465; SOPER RT, 1970, J PEDIATR SURG, V5, P32, DOI 10.1016/0022-3468(70)90517-8; Spivak H, 1996, AM SURGEON, V62, P369; Stolte M, 1997, SCAND J GASTROENTERO, V32, P28, DOI 10.3109/00365529709025059; SUBEI I, 1987, AM J GASTROENTEROL, V82, P769; SUGIMACHI K, 1985, JAMA-J AM MED ASSOC, V253, P1012, DOI 10.1001/jama.253.7.1012; Suter WR, 2000, DIGESTION, V62, P276, DOI 10.1159/000007827; Sycuro LK, 2010, CELL, V141, P822, DOI 10.1016/j.cell.2010.03.046; Tajima S, 2015, INT J CLIN EXP PATHO, V8, P1013; Takabayashi T, 2014, AM J EMERG MED, V32, P1485, DOI 10.1016/j.ajem.2014.09.010; Takada K, 2000, J CLIN PATHOL-MOL PA, V53, P255; Takei H, 2007, ANN DIAGN PATHOL, V11, P350, DOI 10.1016/j.anndiagpath.2006.03.018; Tapan U, 2012, RENAL FAILURE, V34, P235, DOI 10.3109/0886022X.2011.646883; Tazawa K, 1998, PATHOL INT, V48, P242, DOI 10.1111/j.1440-1827.1998.tb03901.x; Thompson BF, 2004, GASTROINTEST ENDOSC, V59, P906, DOI 10.1016/S0016-5107(04)00337-2; Thompson MP, 2004, CLIN CANCER RES, V10, P803, DOI 10.1158/1078-0432.CCR-0670-3; Toledo R, 2015, ADV PARASIT, V88, P165, DOI 10.1016/bs.apar.2015.02.005; Tresallet C, 2010, SURGERY, V148, P158, DOI 10.1016/j.surg.2009.02.010; TROMBA JL, 1991, AM J GASTROENTEROL, V86, P1820; Tsamakidis K, 2005, WORLD J GASTROENTERO, V11, P6644, DOI 10.3748/wjg.v11.i42.6644; Ugras M, 2013, J CLIN VIROL, V56, P153, DOI 10.1016/j.jcv.2012.10.021; Valour F, 2014, INFECT DRUG RESIST, V7, P183, DOI 10.2147/IDR.S39601; van Ingen J, 2013, SEMIN RESP CRIT CARE, V34, P103, DOI 10.1055/s-0033-1333569; VANOLMEN G, 1984, AM J GASTROENTEROL, V79, P512; Ventura G, 1997, EUR J GASTROEN HEPAT, V9, P307, DOI 10.1097/00042737-199703000-00017; Vergara M, 1998, Gastroenterol Hepatol, V21, P332; Vikram HR, 2012, CLIN INFECT DIS, V54, P1685, DOI 10.1093/cid/cis250; VILOTTE J, 1981, NOUV PRESSE MED, V10, P1471; Warich-Eitel S, 2010, PATHOLOGE, V31, P205, DOI 10.1007/s00292-009-1272-7; WEESE WC, 1975, ARCH INTERN MED, V135, P1562, DOI 10.1001/archinte.135.12.1562; WEISSMAN D, 1990, AM J GASTROENTEROL, V85, P742; WHEAT LJ, 1990, MEDICINE, V69, P361, DOI 10.1097/00005792-199011000-00004; Wig JD, 2000, SURG TODAY, V30, P921, DOI 10.1007/s005950070046; WINTERS HA, 1992, ANN INTERN MED, V116, P314, DOI 10.7326/0003-4819-116-4-314; Wolk D, 2001, INFECT DIS CLIN N AM, V15, P1157, DOI 10.1016/S0891-5520(05)70190-2; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; Wu TT, 1999, AM J SURG PATHOL, V23, P153, DOI 10.1097/00000478-199902000-00003; Xiao SY, 2001, AM J GASTROENTEROL, V96, P223, DOI 10.1111/j.1572-0241.2001.03480.x; Xu WS, 1998, J MED VIROL, V56, P342, DOI 10.1002/(SICI)1096-9071(199812)56:4<342::AID-JMV10>3.0.CO;2-P; Yap R, 2014, ANZ J SURG, P614; Yong S, 2000, ARCH PATHOL LAB MED, V124, P619; Yousef OM, 1999, AM J CLIN PATHOL, V112, P610; Zhang HJ, 2014, CLIN RES HEPATOL GAS, V38, pE89, DOI 10.1016/j.clinre.2014.05.008; Zhang L, 2011, SCAND J GASTROENTERO, V46, P1074, DOI 10.3109/00365521.2011.579998; Zhang YL, 2003, ARCH PATHOL LAB MED, V127, P478; Zwolinska-Wcislo M, 2001, MED SCI MONITOR, V7, P266	255	1	1	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	JUL	2018	25	4					238	253		10.1097/PAP.0000000000000187			16	Pathology	Pathology	GJ4AY	WOS:000435290000003	29465420				2019-10-28	
J	Choi, WT; Kakar, S				Choi, Won-Tak; Kakar, Sanjay			Atypical Hepatocellular Neoplasms: Review of Clinical, Morphologic, Immunohistochemical, Molecular, and Cytogenetic Features	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						atypical hepatocellular neoplasm; hepatocellular adenoma; hepatocellular carcinoma; hepatocellular neoplasm of uncertain malignant potential	BETA-CATENIN MUTATIONS; FOCAL NODULAR HYPERPLASIA; COMPARATIVE GENOMIC HYBRIDIZATION; MALIGNANT POTENTIAL PROPOSAL; GLYCOGEN-STORAGE-DISEASE; GLUTAMINE-SYNTHETASE; DIAGNOSTIC CATEGORY; GENETIC ALTERATIONS; ADENOMA; CARCINOMA	The distinction of hepatocellular adenoma from well-differentiated hepatocellular carcinoma (HCC) can be difficult in some cases, especially on biopsy specimens. These borderline cases often occur in men or older patients and may have -catenin activation or focal atypical morphologic features (such as small cell change, prominent pseudoacinar formation, cytologic atypia, focally thick plates, and/or focal reticulin loss) that are insufficient for an unequivocal diagnosis of HCC. The term atypical hepatocellular neoplasm has been advocated for these tumors, but a number of other terms, including atypical adenoma, hepatocellular neoplasm of uncertain malignant potential, and well-differentiated hepatocellular neoplasm with atypical or borderline features have also been proposed. This review proposes guidelines for designating tumors as atypical hepatocellular neoplasm and describes clinical, morphologic, immunohistochemical, molecular, and cytogenetic features that distinguish these tumors from typical hepatocellular adenoma and HCC.	[Choi, Won-Tak; Kakar, Sanjay] Univ Calif San Francisco, Dept Pathol, 505 Parnassus Ave,M552,POB 0102, San Francisco, CA 94143 USA	Choi, WT (reprint author), Univ Calif San Francisco, Dept Pathol, 505 Parnassus Ave,M552,POB 0102, San Francisco, CA 94143 USA.	Won-Tak.Choi@ucsf.edu					Agostini-Vulaj D, 2017, HUM PATHOL, V61, P105, DOI 10.1016/j.humpath.2016.12.001; Ally A, 2017, CELL, V169, P1327, DOI 10.1016/j.cell.2017.05.046; Audard V, 2007, J PATHOL, V212, P345, DOI 10.1002/path.2169; Austinat M, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-21; Balabaud C, 2015, HUM PATHOL, V46, P634, DOI 10.1016/j.humpath.2014.10.029; Bedossa P, 2014, HUM PATHOL, V45, P658, DOI 10.1016/j.humpath.2013.09.020; Berry RS, 2014, VIRCHOWS ARCH, V465, P241, DOI 10.1007/s00428-014-1620-8; Bioulac-Sage P, 2007, HEPATOLOGY, V46, P740, DOI 10.1002/hep.21743; Bioulac-Sage P, 2009, LIVER INT, V29, P459, DOI 10.1111/j.1478-3231.2008.01849.x; Bosman F. T., 2010, WHO CLASSIFICATION T, V3, P198; Burke ZD, 2006, BIOESSAYS, V28, P1072, DOI 10.1002/bies.20485; Cadoret A, 2002, ONCOGENE, V21, P8293, DOI 10.1038/sj.onc.1206118; Calderaro J, 2013, J HEPATOL, V58, P350, DOI 10.1016/j.jhep.2012.09.030; Chen YW, 2002, HEPATOLOGY, V36, P927, DOI 10.1053/jhep.2002.36126; Cho SJ, 2016, HUM PATHOL, V50, P135, DOI 10.1016/j.humpath.2015.12.002; Colombo M, 2016, J HEPATOL, V65, P386, DOI 10.1016/j.jhep.2016.04.001; Dal Bello B, 2010, CLIN CANCER RES, V16, P2157, DOI 10.1158/1078-0432.CCR-09-1978; Dhingra S, 2014, ARCH PATHOL LAB MED, V138, P1090, DOI 10.5858/arpa.2013-0183-RA; Di Tommaso L, 2007, HEPATOLOGY, V45, P725, DOI 10.1002/hep.21531; Di Tommaso L, 2009, J HEPATOL, V50, P746, DOI 10.1016/j.jhep.2008.11.014; Evason KJ, 2013, HUM PATHOL, V44, P750, DOI 10.1016/j.humpath.2012.07.019; Farges O, 2011, GUT, V60, P85, DOI 10.1136/gut.2010.222109; Hale G, 2016, MODERN PATHOL, V29, P1370, DOI 10.1038/modpathol.2016.122; Henriet E, 2017, HEPATOLOGY, V66, P2016, DOI 10.1002/hep.29336; Joseph NM, 2014, MODERN PATHOL, V27, P62, DOI 10.1038/modpathol.2013.114; Kakar S, 2014, MODERN PATHOL, V27, P1499, DOI 10.1038/modpathol.2014.50; Kakar S, 2014, HUM PATHOL, V45, P660, DOI 10.1016/j.humpath.2013.09.019; Kakar S, 2009, HISTOPATHOLOGY, V55, P197, DOI 10.1111/j.1365-2559.2009.03343.x; Kim YD, 2008, J GASTROEN HEPATOL, V23, P110, DOI 10.1111/j.1440-1746.2007.05250.x; Kishnani PS, 2009, HUM MOL GENET, V18, P4781, DOI 10.1093/hmg/ddp441; Lagana SM, 2013, APPL IMMUNOHISTO M M, V21, P170, DOI 10.1097/PAI.0b013e31825d527f; Moinzadeh P, 2005, BRIT J CANCER, V92, P935, DOI 10.1038/sj.bjc.6602448; Nault JC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3218; Nault JC, 2017, GASTROENTEROLOGY, V152, P880, DOI 10.1053/j.gastro.2016.11.042; Nguyen TB, 2016, MODERN PATHOL, V29, P283, DOI 10.1038/modpathol.2015.162; Paxian M, 2003, ANESTHESIOLOGY, V98, P1391, DOI 10.1097/00000542-200306000-00014; Pilati C, 2014, CANCER CELL, V25, P428, DOI 10.1016/j.ccr.2014.03.005; Pinyol R, 2014, J HEPATOL, V61, P685, DOI 10.1016/j.jhep.2014.05.028; Poon TCW, 2006, GASTROENTEROLOGY, V131, P1262, DOI 10.1053/j.gastro.2006.08.014; Prange W, 2003, J PATHOL, V201, P250, DOI 10.1002/path.1448; Rebouissou S, 2016, HEPATOLOGY, V64, P2047, DOI 10.1002/hep.28638; Rebouissou S, 2009, NATURE, V457, P200, DOI 10.1038/nature07475; Shafizadeh N, 2014, HUM PATHOL, V45, P976, DOI 10.1016/j.humpath.2013.12.011; Shafizadeh N, 2011, ADV ANAT PATHOL, V18, P438, DOI 10.1097/PAP.0b013e318234abb4; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Ueberham E, 2004, J HEPATOL, V41, P75, DOI 10.1016/j.jhep.2004.03.024; Wilkens L, 2001, J PATHOL, V193, P476, DOI 10.1002/path.825; Zucman-Rossi J, 2007, ONCOGENE, V26, P774, DOI 10.1038/sj.onc.1209824; Zucman-Rossi J, 2006, HEPATOLOGY, V43, P515, DOI 10.1002/hep.21068	49	1	1	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	JUL	2018	25	4					254	262		10.1097/PAP.0000000000000189			9	Pathology	Pathology	GJ4AY	WOS:000435290000004	29649004				2019-10-28	
J	Guo, ZY; Ge, MH; Chu, YH; Asioli, S; Lloyd, RV				Guo, Zhenying; Ge, Minghua; Chu, Ying-Hsia; Asioli, Sofia; Lloyd, Ricardo V.			Recent Advances in the Classification of Low-grade Papillary-like Thyroid Neoplasms and Aggressive Papillary Thyroid Carcinomas: Evolution of Diagnostic Criteria	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						papillary thyroid carcinoma; NIFTP; hyalinizing trabecular tumor; tall cell variant; hobnail variant; diffuse sclerosing variant; columnar cell variant	DIFFUSE SCLEROSING VARIANT; ENCAPSULATED FOLLICULAR VARIANT; HYALINIZING TRABECULAR TUMORS; TALL-CELL VARIANT; NEEDLE-ASPIRATION-CYTOLOGY; PROMINENT HOBNAIL FEATURES; BASEMENT-MEMBRANE MATERIAL; LYMPH-NODE METASTASIS; NUCLEAR FEATURES; PROGNOSTIC-SIGNIFICANCE	Papillary thyroid carcinomas account for approximate to 80% of well-differentiated thyroid tumors. During the past decade, several new variants of papillary-like thyroid neoplasms and papillary thyroid carcinomas have been recognized. Some of these neoplasms that were previously classified as malignant have been reclassified as low-grade neoplasms, as the diagnostic criteria have evolved. Similarly, some of the papillary thyroid carcinomas that were previously classified as conventional or classic papillary thyroid carcinomas have now been recognized as more aggressive variants of papillary thyroid carcinomas. Recognizing these differences becomes more important for the proper medical, surgical, and radiotherapeutic management of patients with these neoplasms	[Guo, Zhenying; Ge, Minghua] Zhejiang Canc Hosp, Dept Pathol, Hangzhou, Zhejiang, Peoples R China; [Guo, Zhenying; Ge, Minghua] Zhejiang Canc Hosp, Dept Head & Neck Surg, Hangzhou, Zhejiang, Peoples R China; [Chu, Ying-Hsia; Lloyd, Ricardo V.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; [Asioli, Sofia] Univ Bologna, Bellaria Hosp, Sect Anat Pathol M Malpighi, Dept Biomed & Neuromotor Sci, Bologna, Italy	Lloyd, RV (reprint author), Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA.	rvlloyd@wisc.edu	Chu, Ying-Hsia/J-4738-2019; Asioli, Sofia/K-1501-2016	Chu, Ying-Hsia/0000-0002-8289-7418; Asioli, Sofia/0000-0002-5035-2448	Zhejiang Provincial Natural Science Foundation of ChinaNatural Science Foundation of Zhejiang Province [LY16H160036]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81602348, 81672642]; University of Wisconsin Carbone Cancer Center Cancer Center Support Grant [P30 CA014520]	Supported by Zhejiang Provincial Natural Science Foundation of China (LY16H160036-Z.G.) and National Natural Science Foundation of China (No. 81602348-Z.G.) by National Natural Science Foundation of China (No. 81672642-M.G.) and by the University of Wisconsin Carbone Cancer Center Cancer Center Support Grant P30 CA014520 (R.V.L.).	Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Akaishi J, 2015, WORLD J SURG, V39, P1728, DOI 10.1007/s00268-015-3021-9; Akslen LA, 2000, HUM PATHOL, V31, P439, DOI 10.1053/1-ip.2000.6548; Ambrosi F, 2017, ENDOCR PATHOL, V28, P293, DOI 10.1007/s12022-017-9502-7; Asioli S, 2014, DIAGN CYTOPATHOL, V42, P78, DOI 10.1002/dc.23028; Asioli S, 2013, HUM PATHOL, V44, P320, DOI 10.1016/j.humpath.2012.06.003; Asioli S, 2010, AM J SURG PATHOL, V34, P44, DOI 10.1097/PAS.0b013e3181c46677; Axelsson TA, 2015, THYROID, V25, P216, DOI 10.1089/thy.2014.0075; Balachandar S, 2016, THYROID, V26, P219, DOI 10.1089/thy.2015.0287; Basolo F, 2002, AM J PATHOL, V160, P247, DOI 10.1016/S0002-9440(10)64368-4; Bizzarro T, 2016, CANCER CYTOPATHOL, V124, P699, DOI 10.1002/cncy.21777; Bongiovanni M, 2017, CANCER CYTOPATHOL, V125, P389, DOI 10.1002/cncy.21860; Borrelli N, 2017, MODERN PATHOL, V30, P39, DOI [10.1038/nnodpathol.2016.157, 10.1038/modpathol.2016.157]; Bychkov A, 2017, THYROID, V27, P983, DOI 10.1089/thy.2017.0079; Cameselle-Teijeiro JM, 2017, AM J SURG PATHOL, V41, P854, DOI 10.1097/PAS.0000000000000793; Canberk S, 2016, ACTA CYTOL, V60, P198, DOI 10.1159/000447990; Capella G, 1996, DIAGN MOL PATHOL, V5, P45, DOI 10.1097/00019606-199603000-00008; Carney JA, 2008, AM J SURG PATHOL, V32, P1877, DOI 10.1097/PAS.0b013e31817a8f1b; CARNEY JA, 1987, AM J SURG PATHOL, V11, P583, DOI 10.1097/00000478-198708000-00001; Chen JH, 2011, MODERN PATHOL, V24, P739, DOI 10.1038/modpathol.2011.2; Chereau N, 2016, J CLIN ENDOCR METAB, V101, P4603, DOI 10.1210/jc.2016-2341; Cheung CC, 2000, AM J SURG PATHOL, V24, P1622, DOI 10.1097/00000478-200012000-00005; Cho U, 2017, MODERN PATHOL, V30, P810, DOI 10.1038/modpathol.2017.9; Choi WJ, 2015, ACTA RADIOL, V56, P1113, DOI 10.1177/0284185114549225; Dettmer MS, 2015, ENDOCR-RELAT CANCER, V22, P419, DOI 10.1530/ERC-15-0057; Gaffney RL, 2003, AM J SURG PATHOL, V27, P494, DOI 10.1097/00000478-200304000-00009; GEOLLNER JR, 1989, AM J CLIN PATHOL, V91, P115, DOI 10.1093/ajcp/91.2.115; Ghossein RA, 2007, THYROID, V17, P655, DOI 10.1089/thy.2007.0061; Hak S, 2014, DIAGN CYTOPATHOL, V42, P11, DOI 10.1002/dc.23007; Hardin H, 2014, AM J PATHOL, V184, P2342, DOI 10.1016/j.ajpath.2014.04.011; Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020; HAWK WA, 1976, CLEVELAND CLIN Q, V43, P207, DOI 10.3949/ccjm.43.4.207; Higuchi M, 2017, CYTOPATHOLOGY, V28, P268, DOI 10.1111/cyt.12399; Vuong HG, 2017, EUR J ENDOCRINOL, V176, P433, DOI 10.1530/EJE-16-0863; JOHNSON TL, 1988, AM J SURG PATHOL, V12, P22, DOI 10.1097/00000478-198801000-00003; Joung JY, 2016, HISTOPATHOLOGY, V69, P45, DOI 10.1111/his.12902; Jung CK, 2014, J CLIN ENDOCR METAB, V99, pE276, DOI 10.1210/jc.2013-2503; Katoh R, 1999, MODERN PATHOL, V12, P1057; Kazaure HS, 2012, ANN SURG ONCOL, V19, P1874, DOI 10.1245/s10434-011-2129-x; Kim SK, 2016, THYROID, V26, P1077, DOI 10.1089/thy.2016.0113; Koo BS, 2014, ANN SURG ONCOL, V21, P2310, DOI 10.1245/s10434-014-3553-5; Koo JS, 2010, APMIS, V118, P744, DOI 10.1111/j.1600-0463.2010.02653.x; Koo JS, 2009, THYROID, V19, P1225, DOI 10.1089/thy.2009.0073; Lee S, 2011, THYROID, V21, P253, DOI 10.1089/thy.2010.0202; Lee SE, 2017, THYROID, V27, P802, DOI 10.1089/thy.2016.0547; Lee YS, 2015, INT J CLIN EXP PATHO, V8, P7988; Leonardo E, 2007, APPL IMMUNOHISTO M M, V15, P220, DOI 10.1097/01.pai.0000213122.66096.f0; Li MM, 1997, HUM PATHOL, V28, P1366, DOI 10.1016/S0046-8177(97)90225-2; Liu X, 2013, ENDO RELAT CANC, V160, P247; Lloyd RV, 2011, HEAD NECK PATHOL, V5, P51, DOI 10.1007/s12105-010-0236-9; Lloyd RV, 2017, WHO CLASSIFICATION T; Lubitz CC, 2014, THYROID, V24, P958, DOI 10.1089/thy.2013.0573; Malandrino P, 2016, THYROID, V26, P1285, DOI 10.1089/thy.2016.0168; McCluggage WG, 1996, HISTOPATHOLOGY, V28, P357, DOI 10.1046/j.1365-2559.1996.d01-432.x; Melo M, 2014, J CLIN ENDOCR METAB, V99, pE754, DOI 10.1210/jc.2013-3734; Michels JJ, 2007, HUM PATHOL, V38, P212, DOI 10.1016/j.humpath.2006.08.001; MOLBERG K, 1994, HUM PATHOL, V25, P192, DOI 10.1016/0046-8177(94)90277-1; Morandi L, 2017, ENDOCR-RELAT CANCER, V24, P107, DOI 10.1530/ERC-16-0546; Mostoufi-Moab S, 2018, THYROID, V28, P60, DOI 10.1089/thy.2017.0059; Nakamura N, 2005, LAB INVEST, V85, P1065, DOI 10.1038/labinvest.3700306; Nikiforov YE, 1997, CANCER RES, V57, P1690; Nikiforov YE, 2001, AM J SURG PATHOL, V25, P1478, DOI 10.1097/00000478-200112000-00002; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Ohashi R, 2017, HUM PATHOL, V67, P11, DOI 10.1016/j.humpath.2017.03.012; Ohashi R, 2017, HISTOPATHOLOGY, V70, P775, DOI 10.1111/his.13132; Papotti M, 2000, AM J SURG PATHOL, V24, P1615, DOI 10.1097/00000478-200012000-00004; Rosario PW, 2018, CLIN ENDOCRINOL, V88, P506, DOI 10.1111/cen.13523; Rosario PW, 2017, CLIN ENDOCRINOL, V87, P635, DOI 10.1111/cen.13317; Rosario PW, 2016, ENDOCR-RELAT CANCER, V23, P893, DOI 10.1530/ERC-16-0379; Rosario PW, 2014, CLIN ENDOCRINOL, V81, P630, DOI 10.1111/cen.12387; Rothenberg HJ, 1999, AM J SURG PATHOL, V23, P118, DOI 10.1097/00000478-199901000-00014; Saglietti C, 2017, J CLIN PATHOL, V70, P641, DOI 10.1136/jclinpath-2017-204360; Salvatore G, 2005, EUR J CANCER, V41, P816, DOI 10.1016/j.ejca.2005.01.004; Santoro M, 2000, BRIT J CANCER, V82, P315; Sheu SY, 2007, MODERN PATHOL, V20, P779, DOI 10.1038/modpathol.3800797; Shikama Y, 2003, VIRCHOWS ARCH, V443, P792, DOI 10.1007/s00428-003-0901-4; Silver CE, 2011, HEAD NECK-J SCI SPEC, V33, P1052, DOI 10.1002/hed.21494; Strickland KC, 2015, THYROID, V25, P987, DOI 10.1089/thy.2014.0612; Sujoy V, 2013, THYROID, V23, P714, DOI 10.1089/thy.2012.0455; Thompson LDR, 2005, ENDOCR PATHOL, V16, P331, DOI 10.1385/EP:16:4:331; Thompson LDR, 2016, MODERN PATHOL, V29, P698, DOI 10.1038/modpathol.2016.65; Verma R, 2016, DIAGN CYTOPATHOL, V44, P816, DOI 10.1002/dc.23517; Villar-Taibo R, 2017, ONCOL LETT, V13, P3501, DOI 10.3892/ol.2017.5948; Xu B, 2017, THYROID, V27, P512, DOI 10.1089/thy.2016.0649; Zhao LN, 2017, CANCER CYTOPATHOL, V125, P323, DOI 10.1002/cncy.21839	85	0	0	2	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	JUL	2018	25	4					263	272		10.1097/PAP.0000000000000198			10	Pathology	Pathology	GJ4AY	WOS:000435290000005	29762157				2019-10-28	
J	Lenggenhager, D; Weber, A				Lenggenhager, Daniela; Weber, Achim			An Update on the Clinicopathologic Features and Pathologic Diagnosis of Hepatitis E in Liver Specimens	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						liver; hepatitis E virus (HEV); histology; immunohistochemistry; PCR	E VIRUS-INFECTION; CLINICAL-FEATURES; VIRAL-HEPATITIS; NATIONAL-HEALTH; SEROPREVALENCE; GENOTYPE; IMMUNOHISTOCHEMISTRY; EPIDEMIOLOGY; CIRRHOSIS; HISTOLOGY	Infection with the hepatitis E virus (HEV) is globally seen a leading cause of hepatitis. Now increasingly recognized also in industrialized countries, hepatitis E constitutes a significant health problem worldwide. The patient's immune status determines the clinical course and histopathology of hepatitis E. In immunocompetent patients, hepatitis E usually follows an asymptomatic or subclinical course, but may also present with acute hepatitis. In contrast, immunocompromised patients may develop chronic hepatitis, and patients with preexisting liver diseases are at risk for liver decompensation with potentially fatal outcome. Whereas pathologists only occasionally encounter liver biopsies from immunocompetent individuals with hepatitis E, they are more likely exposed to biopsies from patients with preexisting liver disease or immunocompromised individuals. Histopathologic hallmarks of hepatitis E in immunocompetent patients comprise lobular disarray, lobular, and portal inflammation, as well as hepatocyte necrosis of varying extend and regeneration. Thus, it is similar to acute non-E viral hepatitis, yet further differential diagnoses include autoimmune hepatitis and drug-induced liver injury. Histopathologic findings of hepatitis E in preexisting liver disease are determined by the underlying pathology, but may be more severe. Histopathologic presentation of hepatitis E in immunocompromised patients is highly variable, ranging from minimal active hepatitis to chronic hepatitis with severe activity and progressive fibrosis. Taken together, the variability of the histologic features depending on the clinical context and the overlap with other liver diseases make the histopathologic diagnosis of hepatitis E challenging. Immunohistochemistry for HEV open reading frame 2 protein and molecular testing for HEV RNA are useful tissue-based ancillary tools.	Univ Zurich, Dept Pathol & Mol Pathol, Zurich, Switzerland; Univ Hosp Zurich, Zurich, Switzerland	Weber, A (reprint author), Univ Hosp Zurich, Dept Pathol & Mol Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.	achim.weber@usz.ch			center of clinic research (ZKF) innovation foundation	Supported by an institutional grant from the center of clinic research (ZKF) innovation foundation to A. W.	Acharya SK, 2007, J HEPATOL, V46, P387, DOI 10.1016/j.jhep.2006.09.016; Adlhoch C, 2016, J CLIN VIROL, V82, P9, DOI 10.1016/j.jcv.2016.06.010; Aggarwal R, 2011, HEPATOLOGY, V54, P2218, DOI 10.1002/hep.24674; Agrawal V, 2012, INDIAN J PATHOL MICR, V55, P22, DOI 10.4103/0377-4929.94849; Allweiss L, 2016, J HEPATOL, V64, P1033, DOI 10.1016/j.jhep.2016.01.011; Chijioke O, 2015, FRONT MED, V2, DOI 10.3389/fmed.2015.00020; Choi C, 2003, J HEPATOL, V38, P827, DOI 10.1016/S0168-8278(03)00115-6; Chris RB, 2016, J TRAVEL MED, V23, P1; Clemente-Casares P, 2016, BIOMED RES INT, DOI 10.1155/2016/9838041; Crossan CL, 2014, WORLD J HEPATOL, V6, P426, DOI 10.4254/wjh.v6.i6.426; Dalton HR, 2008, LANCET INFECT DIS, V8, P698, DOI 10.1016/S1473-3099(08)70255-X; Dalton HR, 2017, J HEPATOL, V67, P925, DOI 10.1016/j.jhep.2017.07.010; Dalton HR, 2016, TRANSFUS APHER SCI, V55, P271, DOI 10.1016/j.transci.2016.10.016; Dalton HR, 2016, DIGEST DIS, V34, P308, DOI 10.1159/000444468; Dalton HR, 2016, NAT REV NEUROL, V12, P77, DOI 10.1038/nrneurol.2015.234; Dalton HR, 2012, NAT REV GASTRO HEPAT, V9, P430, DOI 10.1038/nrgastro.2012.121; Dalton HR, 2009, NEW ENGL J MED, V361, P1025, DOI 10.1056/NEJMc0903778; Debing Y, 2016, J HEPATOL, V65, P200, DOI 10.1016/j.jhep.2016.02.045; Ditah I, 2014, HEPATOLOGY, V60, P815, DOI 10.1002/hep.27219; Drebber U, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00351; Feng ZD, 2014, ANNU REV VIROL, V1, P539, DOI 10.1146/annurev-virology-031413-085359; Friedman LS, 2016, NEW ENGL J MED, V375, P2082, DOI 10.1056/NEJMcpc1610099; Gerolami R, 2008, NEW ENGL J MED, V358, P859, DOI 10.1056/NEJMc0708687; Goyal R, 2012, ANTIVIR THER, V17, P1091, DOI 10.3851/IMP2317; Grodzki M, 2014, APPL ENVIRON MICROB, V80, P4269, DOI 10.1128/AEM.00978-14; GUPTA D N, 1957, Indian J Med Res, V45, P101; Gupta P, 2012, J VIRAL HEPATITIS, V19, pE177, DOI 10.1111/j.1365-2893.2011.01498.x; Gyarmati P, 2007, J VIROL METHODS, V146, P226, DOI 10.1016/j.jviromet.2007.07.014; Ha SK, 2004, J VIRAL HEPATITIS, V11, P263, DOI 10.1111/j.1365-2893.2004.00498.x; Haagsma EB, 2009, LIVER TRANSPLANT, V15, P1225, DOI [10.1002/It.21819, 10.1002/lt.21819]; Hartl J, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8080211; Hoofnagle JH, 2012, NEW ENGL J MED, V367, P1237, DOI 10.1056/NEJMra1204512; Huang SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013560; Inagaki Y, 2015, TOHOKU J EXP MED, V235, P275, DOI 10.1620/tjem.235.275; Kamar N, 2013, AM J TRANSPLANT, V13, P1935, DOI 10.1111/ajt.12253; Kamar N, 2008, NEW ENGL J MED, V358, P811, DOI 10.1056/NEJMoa0706992; Kamar N, 2012, LANCET, V379, P2477, DOI 10.1016/S0140-6736(11)61849-7; Kamar N, 2011, GASTROENTEROLOGY, V140, P1481, DOI 10.1053/j.gastro.2011.02.050; Kamar N, 2010, TRANSPLANTATION, V89, P353, DOI 10.1097/TP.0b013e3181c4096c; Khudyakov Y, 2011, VIRUS RES, V161, P84, DOI 10.1016/j.virusres.2011.06.006; KHUROO MS, 1981, AM J MED, V70, P252, DOI 10.1016/0002-9343(81)90758-0; KHUROO MS, 1980, AM J MED, V68, P818, DOI 10.1016/0002-9343(80)90200-4; Koning L, 2013, J HEART LUNG TRANSPL, V32, P78, DOI 10.1016/j.healun.2012.10.008; Kuniholm MH, 2015, HEPATOLOGY, V61, P1441, DOI 10.1002/hep.27286; Kuniholm MH, 2009, J INFECT DIS, V200, P48, DOI 10.1086/599319; LAU JYN, 1995, J HEPATOL, V22, P605, DOI 10.1016/0168-8278(95)80215-0; Lee GH, 2016, GASTROENTEROLOGY, V150, P355, DOI 10.1053/j.gastro.2015.10.048; Legrand-Abravanel F, 2009, EMERG INFECT DIS, V15, P110, DOI 10.3201/eid1501.080296; Legrand-Abravanel F, 2010, J INFECT DIS, V202, P835, DOI 10.1086/655899; Lenggenhager D, 2017, J HEPATOL, V67, P471, DOI 10.1016/j.jhep.2017.04.002; Lenggenhager D, 2017, GASTROENTEROL CLIN N, V46, P393, DOI 10.1016/j.gtc.2017.01.010; Lockwood GL, 2008, EUR J GASTROEN HEPAT, V20, P800, DOI 10.1097/MEG.0b013e3282f1cbff; Malcolm P, 2007, HISTOPATHOLOGY, V51, P190, DOI 10.1111/j.1365-2559.2007.02756.x; Mansuy JM, 2016, HEPATOLOGY, V63, P1145, DOI 10.1002/hep.28436; Meng XJ, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005695; Meng XJ, 2013, SEMIN LIVER DIS, V33, P41, DOI 10.1055/s-0033-1338113; Nimgaonkar I, 2018, NAT REV GASTRO HEPAT, V15, P96, DOI 10.1038/nrgastro.2017.150; Ollier L, 2009, ANN INTERN MED, V150, P430, DOI 10.7326/0003-4819-150-6-200903170-00026; Peron JM, 2007, J VIRAL HEPATITIS, V14, P298, DOI 10.1111/j.1365-2893.2007.00858.x; Peron JM, 2007, VIRCHOWS ARCH, V450, P405, DOI 10.1007/s00428-007-0382-y; Perrin HB, 2015, EMERG INFECT DIS, V21, P1928, DOI 10.3201/eid2111.141789; Pischke S, 2017, J HEPATOL, V66, P1082, DOI 10.1016/j.jhep.2016.11.016; Pischke S, 2010, LIVER TRANSPLANT, V16, P74, DOI 10.1002/lt.21958; Prost S, 2017, HISTOPATHOLOGY, V71, P580, DOI 10.1111/his.13266; Protzer U, 2015, MODERN PATHOL, V28, P523, DOI 10.1038/modpathol.2014.147; Purcell RH, 2008, J HEPATOL, V48, P494, DOI 10.1016/j.jhep.2007.12.008; Radha Krishna Y, 2009, LIVER INT, V29, P392, DOI 10.1111/j.1478-3231.2008.01887.x; Rasche A, 2016, EMERG INFECT DIS, V22, P1249, DOI 10.3201/eid2207.160168; Sayed IM, 2017, GUT, V66, P920, DOI 10.1136/gutjnl-2015-311109; Shrestha A, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0899-x; Siederdissen CHZ, 2014, HEPATOLOGY, V60, P1112, DOI 10.1002/hep.26987; Smith DB, 2014, J GEN VIROL, V95, P2223, DOI 10.1099/vir.0.068429-0; Teo CG, 2018, EPIDEMIOL INFECT, V146, P138, DOI 10.1017/S0950268817002837; van Eijk JJJ, 2017, NEUROLOGY, V89, P909, DOI [10.1212/WNL.0000000000004297, 10.1212/wnl.0000000000004297]; Woo PCY, 2014, EMERG INFECT DIS, V20, P1044, DOI 10.3201/eid2006.140140; Woolson KL, 2014, ALIMENT PHARM THER, V40, P1282, DOI 10.1111/apt.12986; Xu B, 2012, WORLD J GASTROENTERO, V18, P7279, DOI 10.3748/wjg.v18.i48.7279; Zaki ME, 2006, FEMS IMMUNOL MED MIC, V48, P16, DOI 10.1111/j.1574-695X.2006.00111.x	78	1	1	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	JUL	2018	25	4					273	281		10.1097/PAP.0000000000000195			9	Pathology	Pathology	GJ4AY	WOS:000435290000006	29697415	Green Accepted			2019-10-28	
J	Lau, SK; Koh, SS				Lau, Sean K.; Koh, Stephen S.			Cutaneous Smooth Muscle Tumors: A Review	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						smooth muscle hamartoma; pilar leiomyoma; genital leiomyoma; angioleiomyoma; leiomyosarcoma; smooth muscle; cutaneous; skin	RENAL-CELL CANCER; OF-THE-LITERATURE; UTERINE SYMPLASTIC LEIOMYOMA; ARRECTOR PILI HAMARTOMA; FUMARATE HYDRATASE FH; CLINICOPATHOLOGICAL ANALYSIS; DERMATOFIBROSARCOMA PROTUBERANS; HEREDITARY LEIOMYOMATOSIS; SUBCUTANEOUS LEIOMYOSARCOMAS; PLEOMORPHIC ANGIOLEIOMYOMA	Smooth muscle tumors occur infrequently in the skin. They consist of a diverse group of lesions representing hamartomas as well as benign and malignant neoplasms. They may arise from arrector pili muscle, specialized smooth muscle of the genitalia, or vascular smooth muscle. Although rare, accurate diagnosis and classification of cutaneous smooth muscle proliferations is important as they can exhibit a range of clinical behavior and may be associated with underlying syndromes. This review summarizes the clinicopathologic spectrum of smooth muscle tumors involving the skin.	[Lau, Sean K.; Koh, Stephen S.] Orange Cty Anaheim Med Ctr, Dept Pathol, Southern Calif Permanente Med Grp, 3440 E La Palma, Anaheim, CA 92806 USA	Lau, SK (reprint author), Orange Cty Anaheim Med Ctr, Dept Pathol, Southern Calif Permanente Med Grp, 3440 E La Palma, Anaheim, CA 92806 USA.	sean.k.lau@kp.org					Alam NA, 2005, BRIT J DERMATOL, V153, P11, DOI 10.1111/j.1365-2133.2005.06678.x; Alam NA, 2005, ARCH DERMATOL, V141, P199, DOI 10.1001/archderm.141.2.199; Aneiros-Fernandez J, 2016, EUR J DERMATOL, V26, P9, DOI 10.1684/ejd.2015.2681; ARCHER CB, 1988, BRIT J DERMATOL, V118, P255, DOI 10.1111/j.1365-2133.1988.tb01783.x; Baltz RG, 2014, J CUTAN PATHOL, V41, P680, DOI 10.1111/cup.12329; Banerjee SS, 1996, J CLIN PATHOL, V49, P950, DOI 10.1136/jcp.49.11.950; Bardella C, 2011, J PATHOL, V225, P4, DOI 10.1002/path.2932; Baugh W, 2000, J CUTAN PATHOL, V27, P526, DOI 10.1034/j.1600-0560.2000.027010526.x; Beer TW, 2005, AM J DERMATOPATH, V27, P418, DOI 10.1097/01.dad.0000178007.42139.c7; Bellezza G, 2004, INT J SURG PATHOL, V12, P39, DOI 10.1177/106689690401200106; Bernstein SC, 1996, DERMATOL SURG, V22, P631, DOI 10.1111/j.1524-4725.1996.tb00609.x; Berzal-Cantalejo F, 2006, J CUTAN PATHOL, V33, P29, DOI 10.1111/j.1600-0560.2006.00542.x; BRONSON DM, 1983, J AM ACAD DERMATOL, V8, P111, DOI 10.1016/S0190-9622(83)70015-0; Buelow B, 2016, AM J SURG PATHOL, V40, P982, DOI 10.1097/PAS.0000000000000626; Calonje E, 1996, J CUTAN PATHOL, V23, P30, DOI 10.1111/j.1600-0560.1996.tb00774.x; Carter CS, 2017, AM J SURG PATHOL, V41, P801, DOI 10.1097/PAS.0000000000000840; Christenson LJ, 2000, DERMATOL SURG, V26, P319, DOI 10.1046/j.1524-4725.2000.99250.x; Cook DL, 2013, J CUTAN PATHOL, V40, P564, DOI 10.1111/cup.12116; DAHL I, 1974, PATHOL EUR, V9, P307; DARLING TN, 1993, J AM ACAD DERMATOL, V28, P844, DOI 10.1016/0190-9622(93)70114-9; Deneve JL, 2013, CANCER CONTROL, V20, P307, DOI 10.1177/107327481302000408; Diaz-Cascajo C, 2000, AM J DERMATOPATH, V22, P251, DOI 10.1097/00000372-200006000-00008; Dotto JE, 2006, J CUTAN PATHOL, V33, P413, DOI 10.1111/j.0303-6987.2006.00477.x; DUHIG JT, 1959, ARCH PATHOL, V68, P424; ENGELKE H, 1979, ACTA DERM-VENEREOL, V59, P51; FARMAN AG, 1975, S AFR MED J, V49, P1333; Fauth CT, 2010, J CUTAN PATHOL, V37, P269, DOI 10.1111/j.1600-0560.2009.01405.x; FIELDS JP, 1981, CANCER, V47, P156, DOI 10.1002/1097-0142(19810101)47:1<156::AID-CNCR2820470127>3.0.CO;2-#; FISHER WC, 1963, ARCH DERMATOL, V88, P510, DOI 10.1001/archderm.1963.01590230018002; FISHMAN SJ, 1989, AM J DERMATOPATH, V11, P369, DOI 10.1097/00000372-198908000-00012; FITZPATRICK JE, 1990, J AM ACAD DERMATOL, V23, P1093, DOI 10.1016/0190-9622(90)70339-J; GLOVER MT, 1989, PEDIATR DERMATOL, V6, P329, DOI 10.1111/j.1525-1470.1989.tb00920.x; GOLDBLUM JR, 1995, ARCH PATHOL LAB MED, V119, P238; GOLDMAN MP, 1987, INT J DERMATOL, V26, P448, DOI 10.1111/j.1365-4362.1987.tb00589.x; Gru AA, 2013, SEMIN DIAGN PATHOL, V30, P4, DOI 10.1053/j.semdp.2012.01.001; Gualandri L, 2001, PEDIATR DERMATOL, V18, P17, DOI 10.1046/j.1525-1470.2001.018001017.x; GVOZDEN AB, 1987, PEDIATRICS, V79, P1021; HACHISUGA T, 1984, CANCER, V54, P126, DOI 10.1002/1097-0142(19840701)54:1<126::AID-CNCR2820540125>3.0.CO;2-F; Hall BJ, 2013, APPL IMMUNOHISTO M M, V21, P132, DOI 10.1097/PAI.0b013e31825f4af2; HANEKE E, 1979, J CUTAN PATHOL, V6, P53, DOI 10.1111/j.1600-0560.1979.tb00305.x; HEATLEY MK, 1989, ULSTER MED J, V58, P166; Heffernan MP, 1998, AM J DERMATOPATH, V20, P213, DOI 10.1097/00000372-199804000-00021; Hisaoka M, 2013, WHO CLASSIFICATION T, P120; Holst VA, 2002, J AM ACAD DERMATOL, V46, P477, DOI 10.1067/mjd.2002.121358; HSIAO GH, 1995, AM J DERMATOPATH, V17, P67, DOI 10.1097/00000372-199502000-00013; Idriss MH, 2013, J CUTAN PATHOL, V40, P557, DOI 10.1111/cup.12127; Jensen ML, 1996, J CUTAN PATHOL, V23, P458, DOI 10.1111/j.1600-0560.1996.tb01435.x; JOHNSON MD, 1989, ARCH DERMATOL, V125, P820, DOI 10.1001/archderm.125.6.820; Jones C, 2016, J CUTAN PATHOL, V43, P866, DOI 10.1111/cup.12764; Kacerovska D, 2008, J AM ACAD DERMATOL, V59, P1000, DOI 10.1016/j.jaad.2008.07.008; Kaddu S, 1997, AM J SURG PATHOL, V21, P979, DOI 10.1097/00000478-199709000-00001; Kawagishi N, 2000, AM J DERMATOPATH, V22, P268, DOI 10.1097/00000372-200006000-00012; Kraft S, 2011, AM J SURG PATHOL, V35, P599, DOI 10.1097/PAS.0b013e31820e6093; Llamas-Velasco M, 2016, AM J DERMATOPATH, V38, P887, DOI 10.1097/DAD.0000000000000580; LUNDGREN L, 1991, APMIS, V99, P820, DOI 10.1111/j.1699-0463.1991.tb01266.x; Luzar B, 2010, J CUTAN PATHOL, V37, P301, DOI 10.1111/j.1600-0560.2009.01425.x; Mahalingam M, 2001, AM J DERMATOPATH, V23, P299, DOI 10.1097/00000372-200108000-00004; Malhotra Purnima, 2010, Indian J Dermatol, V55, P337, DOI 10.4103/0019-5154.74535; Martinez JA, 1996, AM J DERMATOPATH, V18, P409, DOI 10.1097/00000372-199608000-00014; Massi D, 2010, HISTOPATHOLOGY, V56, P251, DOI 10.1111/j.1365-2559.2009.03471.x; Matoso A, 2014, AM J SURG PATHOL, V38, P1410, DOI 10.1097/PAS.0000000000000228; Matsuyama A, 2007, HUM PATHOL, V38, P645, DOI 10.1016/j.humpath.2006.10.012; Matthews JH, 2004, DERMATOL SURG, V30, P1249, DOI 10.1111/j.1524-4725.2004.30386.x; MIETTINEN M, 1985, ARCH DERMATOL, V121, P736, DOI 10.1001/archderm.121.6.736; MONTGOMERY H, 1959, ARCH DERMATOL, V79, P32, DOI 10.1001/archderm.1959.01560130034004; Morales-Callaghan A, 2005, J EUR ACAD DERMATOL, V19, P142, DOI 10.1111/j.1468-3083.2004.01109.x; Morgan MB, 2008, AM J DERMATOPATH, V30, P228, DOI 10.1097/DAD.0b013e31816de820; Morimitsu Y, 1998, HISTOPATHOLOGY, V32, P547, DOI 10.1046/j.1365-2559.1998.t01-1-00428.x; Morimoto A, 2014, CASE REP DERMATOL, V6, P16, DOI 10.1159/000358375; NEWMAN PL, 1991, HISTOPATHOLOGY, V18, P523, DOI 10.1111/j.1365-2559.1991.tb01479.x; Nielsen GP, 1996, AM J SURG PATHOL, V20, P779, DOI 10.1097/00000478-199607000-00001; Perez-Montiel MD, 2006, AM J DERMATOPATH, V28, P105, DOI 10.1097/01.dad.0000200009.02939.cc; Raj S, 1997, AM J DERMATOPATH, V19, P2, DOI 10.1097/00000372-199702000-00002; Rouhani P, 2008, CANCER-AM CANCER SOC, V113, P616, DOI 10.1002/cncr.23571; Sayeed S, 2018, AM J SURG PATHOL, V42, P84, DOI 10.1097/PAS.0000000000000920; SCHNUR RE, 1993, J AM ACAD DERMATOL, V28, P364, DOI 10.1016/0190-9622(93)70056-Y; SLIFMAN NR, 1985, ARCH DERMATOL, V121, P1034, DOI 10.1001/archderm.121.8.1034; SOURREIL P, 1969, Bulletin de la Societe Francaise de Dermatologie et de Syphiligraphie, V76, P602; Spencer JM, 1996, DERMATOL SURG, V22, P761, DOI 10.1111/j.1524-4725.1996.tb00726.x; Starling J, 2011, J AM ACAD DERMATOL, V64, P1119, DOI 10.1016/j.jaad.2010.11.051; Stokes JH, 1923, ARCH DERMATOL SYPH, V7, P479, DOI 10.1001/archderm.1923.02360100052007; STOUT AP, 1958, CANCER, V11, P844, DOI 10.1002/1097-0142(195807/08)11:4<844::AID-CNCR2820110425>3.0.CO;2-A; Suh Kee-Suk, 1998, Journal of Dermatology (Tokyo), V25, P121; SUSTER S, 1994, AM J SURG PATHOL, V18, P232, DOI 10.1097/00000478-199403000-00002; SUSTER S, 1988, AM J DERMATOPATH, V10, P234, DOI 10.1097/00000372-198806000-00008; SWANSON PE, 1988, J CUTAN PATHOL, V15, P129, DOI 10.1111/j.1600-0560.1988.tb00533.x; TAVASSOLI FA, 1979, OBSTET GYNECOL, V53, P213; THOMPSON JA, 1985, J AM ACAD DERMATOL, V13, P865, DOI 10.1016/S0190-9622(85)70230-7; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Toro JR, 2003, AM J HUM GENET, V73, P95, DOI 10.1086/376435; ul Bari Arfan, 2006, Indian J Dermatol Venereol Leprol, V72, P178; URBANEK RW, 1978, ARCH DERMATOL, V114, P104, DOI 10.1001/archderm.114.1.104; Usmani N, 2008, J CUTAN PATHOL, V35, P329, DOI 10.1111/j.1600-0560.2007.00803.x; Wang J, 2000, J MOL DIAGN, V2, P47, DOI 10.1016/S1525-1578(10)60614-9; Wang WL, 2012, CANCER-AM CANCER SOC, V118, P2900, DOI 10.1002/cncr.26590; Winchester DS, 2015, J AM ACAD DERMATOL, V72, P910, DOI 10.1016/j.jaad.2015.01.033; Winchester DS, 2014, J AM ACAD DERMATOL, V71, P919, DOI 10.1016/j.jaad.2014.07.020; WONG RC, 1985, CUTIS, V35, P369; Yancovitz Molly, 2009, Dermatol Online J, V15, P12; YOKOYAMA R, 1987, ACTA PATHOL JAPON, V37, P1415	100	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	JUL	2018	25	4					282	290		10.1097/PAP.0000000000000188			9	Pathology	Pathology	GJ4AY	WOS:000435290000007	29649005				2019-10-28	
J	Prayson, RA; Rowe, J				Prayson, Richard A.; Rowe, Jordi			The Five Es of Efficient Engagement Attaining Esprit de Corps	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Editorial Material						Physician burnout; Engagement; Leadership	PHYSICIAN WELLNESS; BURNOUT; WORK		[Prayson, Richard A.; Rowe, Jordi] Cleveland Clin, Cleveland, OH 44106 USA	Prayson, RA (reprint author), Cleveland Clin, Dept Anat Pathol, L25,9500 Euclid Ave, Cleveland, OH 44195 USA.	praysor@ccf.org					Bucklin BA, 2014, BMC MED EDUC, V14, DOI 10.1186/1472-6920-14-27; Lakier N, PHYS ENGAGEMENT CAN; Maslach C, 2001, ANNU REV PSYCHOL, V52, P397, DOI 10.1146/annurev.psych.52.1.397; Maslach C., 1996, MASLACH BURNOUT INVE; Medscape Lifestyle Report, 2016, BIAS BURN; Salyers MP, 2015, PSYCHIAT SERV, V66, P204, DOI 10.1176/appi.ps.201400138; Schrijver I, 2016, ARCH PATHOL LAB MED, V140, P976, DOI 10.5858/arpa.2015-0524-RA; Shanafelt TD, 2017, MAYO CLIN PROC, V92, P129, DOI 10.1016/j.mayocp.2016.10.004; Shanafelt TD, 2016, MAYO CLIN PROC, V91, P422, DOI 10.1016/j.mayocp.2016.02.001; Shanafelt TD, 2009, ARCH INTERN MED, V169, P990, DOI 10.1001/archinternmed.2009.70; Shanafelt TD, 2003, AM J MED, V114, P513, DOI 10.1016/S0002-9343(03)00117-7; Shanafelt TD, 2002, ANN INTERN MED, V136, P358, DOI 10.7326/0003-4819-136-5-200203050-00008; Wallace JE, 2009, LANCET, V374, P1714, DOI 10.1016/S0140-6736(09)61424-0; West CP, 2016, LANCET, V388, P2272, DOI 10.1016/S0140-6736(16)31279-X; Williams ES, 2010, HEALTH CARE MANAGE R, V35, P105, DOI 10.1097/01.HMR.0000304509.58297.6f	15	0	0	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JUL	2018	150	1					1	3		10.1093/ajcp/aqy035			3	Pathology	Pathology	GI0VP	WOS:000434088700001	29718091				2019-10-28	
J	Harrison, BT; Brock, JE				Harrison, Beth T.; Brock, Jane E.			Contemporary Evaluation of Breast Lymph Nodes in Anatomic Pathology	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Review						Sentinel lymph node; Immunohistochemistry; Breast carcinoma; Best practice; AMAROS; ACOSOG Z0011; IBCSG 23-01; Node mapping; OSNA; Internal mammary	NUCLEIC-ACID AMPLIFICATION; SURGICAL ADJUVANT BREAST; NO AXILLARY DISSECTION; INTERNAL MAMMARY CHAIN; ACOSOG Z1071 ALLIANCE; ISOLATED TUMOR-CELLS; GROUP Z0011 TRIAL; NEOADJUVANT CHEMOTHERAPY; SENTINEL-NODE; CANCER PATIENTS	Objectives: Management of the axilla in breast cancer patients has evolved considerably since the introduction of the sentinel lymph node (SLN) biopsy in the 1990s. Several new clinical and technological developments in the last decade warrant special consideration due to their impact on pathology practice. Methods: This review covers the SLN biopsy procedure, issues in the histopathologic and molecular diagnosis of the SLN, and most importantly, evidence from recent practice-changing clinical trials. Results: ACOSOG Z0011, IBCSG 23-01, and AMAROS trials have shown that early-stage breast cancer patients who have limited metastatic involvement of the SLNs do not benefit from completion axillary dissections. Conclusions: It is not necessary for pathologists to search for all small metastases to predict non-SLN involvement, regional recurrence, or death due to disease. Processing should be designed with the goal of detecting macrometastases. Multiple levels, routine immunohistochemistry, and molecular testing are not recommended.	[Harrison, Beth T.; Brock, Jane E.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St,Amory 3, Boston, MA 02115 USA	Harrison, BT (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St,Amory 3, Boston, MA 02115 USA.	bharrison3@bwh.harvard.edu					Bishop JA, 2016, ARCH PATHOL LAB MED, V140, P830, DOI 10.5858/arpa.2015-0296-OA; Boughey JC, 2016, ANN SURG, V263, P802, DOI 10.1097/SLA.0000000000001375; Boughey JC, 2014, LANCET ONCOL, V15, P1280, DOI 10.1016/S1470-2045(14)71018-6; Boughey JC, 2013, JAMA-J AM MED ASSOC, V310, P1455, DOI 10.1001/jama.2013.278932; Brady Elizabeth W, 2002, Breast J, V8, P97, DOI 10.1046/j.1524-4741.2002.08205.x; Caudle AS, 2011, ANN SURG ONCOL, V18, P2407, DOI 10.1245/s10434-011-1593-7; Chen SL, 2007, ANN SURG ONCOL, V14, P3378, DOI 10.1245/s10434-007-9513-6; Choi AH, 2015, JAMA SURG, V150, P1141, DOI 10.1001/jamasurg.2015.1687; Choi AH, 2014, AM SURGEON, V80, P932; Corben AD, 2010, AM J SURG PATHOL, V34, P1211, DOI 10.1097/PAS.0b013e3181e5e03e; Coutant C, 2009, J CLIN ONCOL, V27, P2800, DOI 10.1200/JCO.2008.19.7418; de Boer M, 2010, J NATL CANCER I, V102, P410, DOI 10.1093/jnci/djq008; de Boer M, 2009, NEW ENGL J MED, V361, P653, DOI 10.1056/NEJMoa0904832; Deambrogio C, 2014, J CLIN PATHOL, V67, P702, DOI 10.1136/jclinpath-2014-202384; Diego EJ, 2016, ANN SURG ONCOL, V23, P1549, DOI 10.1245/s10434-015-5052-8; Donker M, 2014, LANCET ONCOL, V15, P1303, DOI 10.1016/S1470-2045(14)70460-7; El-Rehim DMA, 2004, J PATHOL, V203, P661, DOI 10.1002/path.1559; Fitzgibbons PL, 2000, ARCH PATHOL LAB MED, V124, P966; Galimberti V, 2013, LANCET ONCOL, V14, P297, DOI 10.1016/S1470-2045(13)70035-4; GIULIANO AE, 1994, ANN SURG, V220, P391, DOI 10.1097/00000658-199409000-00015; Giuliano AE, 2016, ANN SURG, V264, P413, DOI 10.1097/SLA.0000000000001863; Giuliano AE, 2011, JAMA-J AM MED ASSOC, V306, P385, DOI 10.1001/jama.2011.1034; Giuliano AE, 2011, JAMA-J AM MED ASSOC, V305, P569, DOI 10.1001/jama.2011.90; Gooch J, 2014, ANN SURG ONCOL, V21, P2897, DOI 10.1245/s10434-014-3752-0; Goyal A, 2015, CLIN ONCOL-UK, V27, P692, DOI 10.1016/j.clon.2015.07.005; He PS, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2137-0; Hennessy BT, 2005, J CLIN ONCOL, V23, P9304, DOI 10.1200/JCO.2005.02.5023; HOLDSWORTH PJ, 1988, HISTOPATHOLOGY, V13, P226, DOI 10.1111/j.1365-2559.1988.tb02029.x; Jagsi R, 2014, J CLIN ONCOL, V32, P3600, DOI 10.1200/JCO.2014.56.5838; Jorns JM, 2016, AM J CLIN PATHOL, V146, P57, DOI 10.1093/ajcp/aqw078; Kenny TC, 2016, AM SURGEON, V82, P53; Kim T, 2006, CANCER-AM CANCER SOC, V106, P4, DOI 10.1002/cncr.21568; Kimbrough CW, 2015, SURGERY, V158, P494, DOI 10.1016/j.surg.2015.03.049; Klauber-DeMore N, 2006, ANN SURG ONCOL, V13, P685, DOI 10.1245/ASO.2006.03.010; Lester SC, 2009, ARCH PATHOL LAB MED, V133, P1515, DOI 10.1043/1543-2165-133.10.1515; Lucci A, 2001, J AM COLL SURGEONS, V192, P453, DOI 10.1016/S1072-7515(01)00798-0; Lyman GH, 2014, J CLIN ONCOL, V32, P1365, DOI 10.1200/JCO.2013.54.1177; Lyman GH, 2005, J CLIN ONCOL, V23, P7703, DOI 10.1200/JCO.2005.08.001; Mamounas EP, 2005, J CLIN ONCOL, V23, P2694, DOI 10.1200/JCO.2005.05.188; Manca G, 2014, Q J NUCL MED MOL IM, V58, P114; Mansel RE, 2006, J NATL CANCER I, V98, P599, DOI 10.1093/jnci/djj158; Nagi C, 2005, ARCH PATHOL LAB MED, V129, P1465; Orlandi A, 2015, CLIN ONCOL-UK, V27, P485, DOI 10.1016/j.clon.2015.04.002; Plecha D, 2015, ANN SURG ONCOL, V22, P4241, DOI 10.1245/s10434-015-4527-y; Provenzano E, 2015, MODERN PATHOL, V28, P1185, DOI 10.1038/modpathol.2015.74; Rastogi P, 2008, J CLIN ONCOL, V26, P778, DOI 10.1200/JCO.2007.15.0235; Reitsamer R, 2003, J SURG ONCOL, V84, P63, DOI 10.1002/jso.10294; RIDOLFI RL, 1977, CANCER-AM CANCER SOC, V39, P164, DOI 10.1002/1097-0142(197701)39:1<164::AID-CNCR2820390127>3.0.CO;2-T; Schwartz Gordon F, 2003, Breast J, V9, P374, DOI 10.1046/j.1524-4741.2003.09502.x; Silverberg SG, 2001, MODERN PATHOL, V14, P629; Subhedar P, 2015, ANN SURG ONCOL, V22, pS470, DOI 10.1245/s10434-015-4698-6; Tanis PJ, 2001, J AM COLL SURGEONS, V192, P399, DOI 10.1016/S1072-7515(00)00776-6; Tiernan JP, 2014, BRIT J SURG, V101, P298, DOI 10.1002/bjs.9386; Tsujimoto M, 2007, CLIN CANCER RES, V13, P4807, DOI 10.1158/1078-0432.CCR-06-2512; Van Rijk MC, 2006, J SURG ONCOL, V94, P281, DOI 10.1002/jso.20574; Weaver DL, 2011, NEW ENGL J MED, V364, P412, DOI 10.1056/NEJMoa1008108; Wei S, 2014, CLIN BREAST CANCER, V14, P280, DOI 10.1016/j.clbc.2013.12.009; Xu XW, 2000, ARCH PATHOL LAB MED, V124, P1310	58	3	3	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JUL	2018	150	1					4	17		10.1093/AJCP/AQY024			14	Pathology	Pathology	GI0VP	WOS:000434088700002	29746624				2019-10-28	
J	Klairmont, MM; Cheng, JJ; Martin, MG; Gradowski, JF				Klairmont, Matthew M.; Cheng, Jinjun; Martin, Mike G.; Gradowski, Joel F.			Recurrent Cytogenetic Abnormalities in Intravascular Large B-Cell Lymphoma	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Intravascular large B-cell lymphoma; Lymphoma; Cytogenetics; Karyotype; Recurrent cytogenetic abnormalities	MARGINAL ZONE LYMPHOMA; TUMOR-SUPPRESSOR GENE; ASIAN VARIANT; CHROMOSOMAL-ABERRATIONS; HEMOPHAGOCYTIC SYNDROME; T(1/14)(Q21,Q32) TRANSLOCATION; CLINICAL PRESENTATION; MULTIPLE-MYELOMA; NOTCH2; GAIN	Objectives: Data characterizing the cytogenetic landscape of intravascular large B-cell lymphoma (ILBCL) are limited. Here, we developed a comprehensive karyotypic data set to identify recurrent cytogenetic abnormalities in ILBCL. Methods: Cases of ILBCL with complete cytogenetic analysis were identified from an institutional database and the literature. The combined data were systematically reviewed for the presence of recurrent abnormalities. Results: Four new cases were identified and combined with 25 karyotypes previously published in the literature. Karyotypes were uniformly complex with a median of 10 aberrations. In total, 72.4% had abnormalities involving chromosome 1, with 31.0% involving rearrangements of 1p13 or 1q21; 58.6% had abnormalities involving chromosome 6, which in almost all cases involved 6q; 34.5% had abnormalities involving chromosome 14, with 27.6% involving rearrangements of 14q32; and 55.2% had abnormalities of chromosome 18, with 37.9% harboring trisomy 18. Conclusions: Recurrent cytogenetic abnormalities involving chromosomes 1, 6q, and 18 are present in greater than 50% of ILBCL.	[Klairmont, Matthew M.; Cheng, Jinjun; Gradowski, Joel F.] Univ Tennessee, Hlth Sci Ctr, Dept Pathol & Lab Med, Memphis, TN USA; [Martin, Mike G.] Univ Tennessee, Hlth Sci Ctr, West Canc Ctr, Dept Hematol Oncol, Memphis, TN USA	Klairmont, MM (reprint author), Dept Pathol & Lab Med, 930 Madison Ave,Suite 500, Memphis, TN 38163 USA.	mklairmo@uthsc.edu		Klairmont, Matthew/0000-0002-4463-0835			Arcaini L, 2015, HAEMATOLOGICA, V100, P246, DOI 10.3324/haematol.2014.116855; Bea S, 2005, BLOOD, V106, P3183, DOI 10.1182/blood-2005-04-1399; Berger F, 2000, BLOOD, V95, P1950, DOI 10.1182/blood.V95.6.1950; Bertram HC, 2001, AM J CLIN PATHOL, V116, P191; Bock F, 2016, BIOL BLOOD MARROW TR, V22, P2159, DOI 10.1016/j.bbmt.2016.09.003; Boi M, 2013, BLOOD, V122, P2683, DOI 10.1182/blood-2013-04-497933; Cao Y, 2016, ONCOTARGET, V7, P83294, DOI 10.18632/oncotarget.13065; Challa-Malladi M, 2011, CANCER CELL, V20, P728, DOI 10.1016/j.ccr.2011.11.006; Chen WY, 2001, ONCOGENE, V20, P7686, DOI 10.1038/sj.onc.1204989; Cigudosa JC, 1999, GENE CHROMOSOME CANC, V25, P123, DOI 10.1002/(SICI)1098-2264(199906)25:2<123::AID-GCC8>3.3.CO;2-W; DAVEY DD, 1990, ARCH PATHOL LAB MED, V114, P879; Deisch J, 2009, ARCH PATHOL LAB MED, V133, P1477, DOI 10.1043/1543-2165-133.9.1477; Dierlamm J, 1996, BLOOD, V87, P299; Dyomin VG, 2000, BLOOD, V95, P2666; Ferreri AJM, 2004, BRIT J HAEMATOL, V127, P173, DOI 10.1111/j.1365-2141.2004.05177.x; Fung KM, 2012, INT J CLIN EXP PATHO, V5, P448; Gilles F, 2000, BLOOD, V95, P2930, DOI 10.1182/blood.V95.9.2930.009k39_2930_2936; Grzasko N, 2012, LEUKEMIA LYMPHOMA, V53, P2500, DOI 10.3109/10428194.2012.684349; Hatzivassiliou G, 2001, IMMUNITY, V14, P277, DOI 10.1016/S1074-7613(01)00109-1; Ichikawa N, 2000, CANCER GENET CYTOGEN, V120, P83; Jardin Fabrice, 2005, Clin Lymphoma, V6, P46, DOI 10.3816/CLM.2005.n.027; Jerkeman M, 1999, EUR J HAEMATOL, V62, P184; Karube K, 2011, BLOOD, V118, P3195, DOI 10.1182/blood-2011-04-346890; Khoury H, 2003, MODERN PATHOL, V16, P716, DOI 10.1097/01.MP.0000077515.68734.85; Kiel MJ, 2012, J EXP MED, V209, P1553, DOI 10.1084/jem.20120910; Kim SY, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-76; Klein U, 2011, CANCER-AM CANCER SOC, V117, P2136, DOI 10.1002/cncr.25775; Kobayashi T, 2011, INTERNAL MED, V50, P2007, DOI 10.2169/internalmedicine.50.5706; Kucuk C, 2011, P NATL ACAD SCI USA, V108, P20119, DOI 10.1073/pnas.1115128108; LARSSON C, 1994, GENOMICS, V24, P253, DOI 10.1006/geno.1994.1613; Lee SY, 2009, CANCER SCI, V100, P920, DOI 10.1111/j.1349-7006.2009.01130.x; Mandelbaum J, 2010, CANCER CELL, V18, P568, DOI 10.1016/j.ccr.2010.10.030; Matsue K, 2011, ANN HEMATOL, V90, P417, DOI 10.1007/s00277-010-1101-3; Mock BA, 1996, GENOMICS, V37, P24, DOI 10.1006/geno.1996.0516; MOLINA A, 1990, CANCER, V66, P474, DOI 10.1002/1097-0142(19900801)66:3<474::AID-CNCR2820660313>3.0.CO;2-P; Murase T, 2000, BRIT J HAEMATOL, V111, P826; Murase T, 1999, LEUKEMIA LYMPHOMA, V33, P459, DOI 10.3109/10428199909058451; Murase T, 2007, BLOOD, V109, P478, DOI 10.1182/blood-2006-01-021253; Nakahara T, 1999, J NEUROL NEUROSUR PS, V67, P403, DOI 10.1136/jnnp.67.3.403; OFFIT K, 1991, BLOOD, V77, P1508; Parry M, 2015, CLIN CANCER RES, V21, P4174, DOI 10.1158/1078-0432.CCR-14-2759; Pasqualucci L, 2006, J EXP MED, V203, P311, DOI 10.1084/jem.20052204; Patel SS, 2014, LABMEDICINE, V45, P248, DOI 10.1309/LMSVEOKLN18M5XTV; Ponzoni M, 2007, J CLIN ONCOL, V25, P3168, DOI 10.1200/JCO.2006.08.2313; Rashid R, 2006, CANCER GENET CYTOGEN, V171, P101, DOI 10.1016/j.cancergencyto.2006.07.018; Rossi D, 2012, J EXP MED, V209, P1537, DOI 10.1084/jem.20120904; Shah V, 2018, LEUKEMIA, V32, P102, DOI 10.1038/leu.2017.179; Shimazaki C, 1999, BRIT J HAEMATOL, V104, P672, DOI 10.1111/j.1365-2141.1999.01239.x; Spina V, 2016, BLOOD, V128, P1362, DOI 10.1182/blood-2016-02-696757; Swerdlow SH, 2008, WHO CLASSIFICATION T; Tajima S, 2014, INT J CLIN EXP PATHO, V7, P8181; Thorns C, 2007, GENE CHROMOSOME CANC, V46, P37, DOI 10.1002/gcc.20386; Tsukadaira A, 2002, AM J CLIN ONCOL-CANC, V25, P178, DOI 10.1097/00000421-200204000-00015; Willis TG, 1998, BLOOD, V91, P1873, DOI 10.1182/blood.V91.6.1873.1873_1873_1881; WOTHERSPOON AC, 1995, BLOOD, V85, P2000, DOI 10.1182/blood.V85.8.2000.bloodjournal8582000; Xia Y, 2017, LEUKEMIA, V31, P625, DOI 10.1038/leu.2016.243; Yamamoto K, 2013, J CLIN EXP HEMATOP, V53, P161; Yoshioka T, 2005, GENE CHROMOSOME CANC, V42, P149, DOI 10.1002/gcc.20127; Zhou YP, 2007, HAEMATOL-HEMATOL J, V92, P921, DOI 10.3324/haematol.10191	59	1	1	1	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JUL	2018	150	1					18	26		10.1093/ajcp/aqy023			9	Pathology	Pathology	GI0VP	WOS:000434088700003	29767679				2019-10-28	
J	Hueth, KD; Jackson, BR; Schmidt, RL				Hueth, Kyle D.; Jackson, Brian R.; Schmidt, Robert L.			An Audit of Repeat Testing at an Academic Medical Center Consistency of Order Patterns With Recommendations and Potential Cost Savings	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Repeat testing; Laboratory test; Utilization; Cost saving; Health care cost; Health care utilization	CLINICAL-PRACTICE GUIDELINES; AMERICAN THYROID ASSOCIATION; HOSPITAL-ACQUIRED ANEMIA; LABORATORY-TEST REQUESTS; VITAMIN-D; CARDIOVASCULAR-DISEASE; CLOSTRIDIUM-DIFFICILE; TOTAL CHOLESTEROL; HEALTH; CARE	Objectives: To evaluate the prevalence of potentially unnecessary repeat testing (PURT) and the associated economic burden for an inpatient population at a large academic medical facility. Methods: We evaluated all inpatient test orders during 2016 for PURT by comparing the intertest times to published recommendations. Potential cost savings were estimated using the Centers for Medicare & Medicaid Services maximum allowable reimbursement rate. We evaluated result positivity as a determinant of PURT through logistic regression. Results: Of the evaluated 4,242 repeated target tests, 1,849 (44%) were identified as PURT, representing an estimated cost-savings opportunity of $37,376. Collectively, the association of result positivity and PURT was statistically significant (relative risk, 1.2; 95% confidence interval, 1.1-1.3; P<.001). Conclusions: PURT contributes to unnecessary health care costs. We found that a small percentage of providers account for the majority of PURT, and PURT is positively associated with result positivity.	[Hueth, Kyle D.; Jackson, Brian R.; Schmidt, Robert L.] Univ Utah, Dept Pathol, Hlth Sci Ctr, 15 N Med Dr East,Suite 1100, Salt Lake City, UT 84112 USA; [Jackson, Brian R.; Schmidt, Robert L.] ARCP Labs, Salt Lake City, UT USA	Schmidt, RL (reprint author), Univ Utah, Dept Pathol, Hlth Sci Ctr, 15 N Med Dr East,Suite 1100, Salt Lake City, UT 84112 USA.	Robert.Schmidt@hsc.utah.edu					[Anonymous], 2017, DIABETES CARE S1, V40, pS120, DOI DOI 10.2337/DC17-S017; Association for Clinical Biochemistry and Laboratory Medicine (ACB), 2013, NAT MIN RET INT PROJ; Bacon BR, 2011, HEPATOLOGY, V54, P328, DOI 10.1002/hep.24330; Bahn RS, 2011, ENDOCR PRACT, V17, P456, DOI 10.1089/thy.2010.0417; Balogh EP, 2015, IMPR DIAGN HLTH CAR, P472; Baricchi R, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-187; Chami N, 2017, CLIN BIOCHEM, V50, P822, DOI 10.1016/j.clinbiochem.2017.05.004; Cohen SH, 2010, INFECT CONT HOSP EP, V31, P431, DOI 10.1086/651706; Demir S, 2016, BIOCHEM MEDICA, V26, P77, DOI 10.11613/BM.2016.007; Eaton KP, 2017, JAMA INTERN MED, V177, P1833, DOI 10.1001/jamainternmed.2017.5152; Erlingsdottir H, 2015, SCAND J CLIN LAB INV, V75, P18, DOI 10.3109/00365513.2014.965734; Freedman Danielle B, 2015, EJIFCC, V26, P15; Garber JR, 2012, THYROID, V22, P1200, DOI 10.1089/thy.2012.0205; Georgiou A, 2015, STUD HEALTH TECHNOL, V216, P917, DOI 10.3233/978-1-61499-564-7-917; Goldzweig CL, 2015, ANN INTERN MED, V162, P557, DOI 10.7326/M14-2600; Handelsman Y, 2015, ENDOCR PRACT, V21, P1, DOI [10.4158/EP15672.GL, 10.4158/EP15672.GLSUPPL]; Hochreiter M, 2009, CRIT CARE, V13, DOI 10.1186/cc7903; Hutton HD, 2009, ANN CLIN BIOCHEM, V46, P155, DOI 10.1258/acb.2008.008126; Jellinger PS, 2017, ENDOCR PRACT, V23, P479, DOI 10.4158/EP171764.GL; KASSIRER JP, 1989, NEW ENGL J MED, V320, P1489, DOI 10.1056/NEJM198906013202211; Kawamoto K, 2015, J AM MED INFORM ASSN, V22, P223, DOI 10.1136/amiajnl-2013-002511; Koch CG, 2017, J PATIENT SAF, V13, P211, DOI 10.1097/PTS.0000000000000142; Koch CG, 2013, J HOSP MED, V8, P506, DOI 10.1002/jhm.2061; Krasowski MD, 2015, BMC MED INFORM DECIS, V15, DOI 10.1186/s12911-015-0137-7; Lanzoni M, 2017, J EVAL CLIN PRACT, V23, P654, DOI 10.1111/jep.12696; Laxmisan A, 2011, AM J MED, V124, P342, DOI 10.1016/j.amjmed.2010.10.019; Lin RJ, 2013, SOUTH MED J, V106, P316, DOI 10.1097/SMJ.0b013e318290f930; Lippi G, 2015, CLIN BIOCHEM, V48, P1174, DOI 10.1016/j.clinbiochem.2015.06.006; Luo RF, 2013, J CLIN MICROBIOL, V51, P3872, DOI 10.1128/JCM.01724-13; Makam AN, 2017, J HOSP MED, V12, P317, DOI 10.12788/jhm.2723; Mccoy RG, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h6138; Minerowicz C, 2015, AM J MANAG CARE, V21, P763; Miyakis S, 2006, POSTGRAD MED J, V82, P823, DOI 10.1136/pgmj.2006.049551; Morgen EK, 2015, AM J CLIN PATHOL, V144, P704, DOI 10.1309/AJCPYXDAUS2F8XJY; Moyer AM, 2016, CLIN CHEM, V62, P824, DOI 10.1373/clinchem.2015.250514; Pelloso M, 2016, J CLIN PATHOL, V69, P777, DOI 10.1136/jclinpath-2015-203447; Pietrangelo A, 2010, J HEPATOL, V53, P3, DOI 10.1016/j.jhep.2010.03.001; Procop GW, 2015, AM J CLIN PATHOL, V143, P623, DOI 10.1309/AJCPJOJ3HKEBD3TU; Procop GW, 2014, AM J CLIN PATHOL, V141, P718, DOI 10.1309/AJCPOWHOIZBZ3FRW; Seguela PE, 2011, CARDIOL YOUNG, V21, P392, DOI 10.1017/S104795111100014X; Smit I, 2015, ANN CLIN BIOCHEM, V52, P481, DOI 10.1177/0004563214567688; Souberbielle JC, 2010, AUTOIMMUN REV, V9, P709, DOI 10.1016/j.autrev.2010.06.009; Stone NJ, 2014, J AM COLL CARDIOL, V63, P2889, DOI 10.1016/j.jacc.2013.11.002; Thakkar RN, 2015, AM J CLIN PATHOL, V143, P393, DOI 10.1309/AJCPJS4EEM7UAUBV; Thomas RE, 2006, LANCET, V367, P1990, DOI 10.1016/S0140-6736(06)68888-0; Tosiri Pitima, 2010, J Med Assoc Thai, V93 Suppl 7, pS271; Trietsch J, 2017, BMC FAM PRACT, V18, DOI 10.1186/s12875-017-0605-5; van Walraven C, 1998, JAMA-J AM MED ASSOC, V280, P550, DOI 10.1001/jama.280.6.550; Vidyarthi AR, 2015, AM J MED QUAL, V30, P81, DOI 10.1177/1062860613517502; Waldron JL, 2014, J CLIN PATHOL, V67, P731, DOI 10.1136/jclinpath-2014-202256; WAUGH N, 2010, HEALTH TECHNOL ASSES, V14, P1; Welch HG, 2015, LESS MED MORE HLTH; Yarbrough PM, 2016, J HOSP MED, V11, P348, DOI 10.1002/jhm.2552	53	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JUL	2018	150	1					27	33		10.1093/AJCP/AQY020			7	Pathology	Pathology	GI0VP	WOS:000434088700004	29718090				2019-10-28	
J	Landmann, A; Farrugia, DJ; Zhu, L; Diego, EJ; Johnson, RR; Soran, A; Dabbs, DJ; Clark, BZ; Puhalla, SL; Jankowitz, RC; Brufsky, AM; Ahrendt, GM; McAuliffe, PF; Bhargava, R				Landmann, Alessandra; Farrugia, Daniel J.; Zhu, Li; Diego, Emilia J.; Johnson, Ronald R.; Soran, Atilla; Dabbs, David J.; Clark, Beth Z.; Puhalla, Shannon L.; Jankowitz, Rachel C.; Brufsky, Adam M.; Ahrendt, Gretchen M.; McAuliffe, Priscilla F.; Bhargava, Rohit			Low Estrogen Receptor ( ER)-Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy Is Response Similar to Typical ER-Positive or ER-Negative Disease?	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Low ER; Moderate ER; High ER; Neoadjuvant chemotherapy; Pathologic complete response; ER H-score; Immunohistochemistry	RECURRENCE-SCORE; ENDOCRINE THERAPY; GENE-EXPRESSION; TUMORS; WOMEN; IMMUNOHISTOCHEMISTRY; CARCINOMA; TAMOXIFEN; SURVIVAL; ASSAY	Objectives: Pathologic complete response (pCR) rate after neoadjuvant chemotherapy was compared between 141 estrogen receptor (ER)-negative (43%), 41 low ER+ (13%), 47 moderate ER+ (14%), and 98 high ER+ (30%) tumors. Methods: Human epidermal growth factor receptor 2-positive cases, cases without semiquantitative ER score, and patients treated with neoadjuvant endocrine therapy alone were excluded. Results: The pCR rate of low ER+ tumors was similar to the pCR rate of ER-tumors (37% and 26% for low ER and ER-respectively, P=.1722) but significantly different from the pCR rate of moderately ER+ (11%, P=.0049) and high ER+ tumors (4%, P<.0001). Patients with pCR had an excellent prognosis regardless of the ER status. In patients with residual disease (no pCR), the recurrence and death rate were higher in ER-and low ER+ cases compared with moderate and high ER+ cases. Conclusions: Low ER+ breast cancers are biologically similar to ER-tumors. Semiquantitative ER H-score is an important determinant of response to neoadjuvant chemotherapy.	[Landmann, Alessandra; Farrugia, Daniel J.; Diego, Emilia J.; Johnson, Ronald R.; Soran, Atilla; Ahrendt, Gretchen M.; McAuliffe, Priscilla F.] Univ Pittsburgh, Sch Med, Dept Surg, Div Surg Oncol, Pittsburgh, PA USA; [Dabbs, David J.; Clark, Beth Z.; Bhargava, Rohit] Univ Pittsburgh, Sch Med, Div Breast & Gynecol Pathol, Dept Pathol, Pittsburgh, PA USA; [Puhalla, Shannon L.; Jankowitz, Rachel C.; Brufsky, Adam M.] Univ Pittsburgh, Sch Med, Div Hematol Oncol, Dept Med, Pittsburgh, PA USA; [Zhu, Li] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA; [Landmann, Alessandra] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA; [Farrugia, Daniel J.] Centegra Hlth Syst, Centegra Comprehens Bre Program, Crystal Lake, IL USA; [Ahrendt, Gretchen M.] Univ Colorado, Denver, CO 80202 USA	Bhargava, R (reprint author), UPMC, Magee Womens Hosp, Dept Pathol, 300 Halket St, Pittsburgh, PA 15213 USA.	rbhargava@mail.magee.edu					ANTONIADES K, 1979, AM J CLIN PATHOL, V71, P497; Bhargava R, 2011, MODERN PATHOL, V24, P367, DOI 10.1038/modpathol.2010.209; Cuzick J, 2011, J CLIN ONCOL, V29, P4273, DOI 10.1200/JCO.2010.31.2835; Deyarmin B, 2013, ANN SURG ONCOL, V20, P87, DOI 10.1245/s10434-012-2588-8; Farrugia DJ, 2017, MODERN PATHOL, V30, P1078, DOI 10.1038/modpathol.2017.41; Flanagan MB, 2008, MODERN PATHOL, V21, P1255, DOI 10.1038/modpathol.2008.54; Fujii T, 2017, ANN ONCOL, V28, P2420, DOI 10.1093/annonc/mdx397; Gapstur SM, 1996, CANCER, V77, P1465, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1465::AID-CNCR7>3.3.CO;2-5; Gloyeske NC, 2014, AM J CLIN PATHOL, V141, P697, DOI 10.1309/AJCP34CYSATWFDPQ; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Iwamoto T, 2012, J CLIN ONCOL, V30, P729, DOI 10.1200/JCO.2011.36.2574; Johnston SJ, 2015, FUTURE ONCOL, V11, P1555, DOI 10.2217/fon.15.13; Klein ME, 2013, MODERN PATHOL, V26, P658, DOI 10.1038/modpathol.2013.36; MCCARTY KS, 1980, CANCER, V46, P2851, DOI 10.1002/1097-0142(19801215)46:12+<2851::AID-CNCR2820461424>3.0.CO;2-K; MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716; MCCARTY KS, 1983, ANN SURG, V197, P123, DOI 10.1097/00000658-198302000-00001; Morgan DAL, 2011, BREAST, V20, P215, DOI 10.1016/j.breast.2010.11.004; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Paik S, 2006, J CLIN ONCOL, V24, P3726, DOI 10.1200/JCO.2005.04.7985; Prabhu JS, 2014, J CANCER, V5, P156, DOI 10.7150/jca.7668; Provenzano E, 2015, MODERN PATHOL, V28, P1185, DOI 10.1038/modpathol.2015.74; Raghav KPS, 2012, CANCER-AM CANCER SOC, V118, P1498, DOI 10.1002/cncr.26431; Sheri A, 2017, BREAST CANCER RES TR, V164, P395, DOI 10.1007/s10549-017-4266-9; SILFVERSWARD C, 1980, CANCER, V45, P2001, DOI 10.1002/1097-0142(19800415)45:8<2001::AID-CNCR2820450803>3.0.CO;2-3	25	0	0	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JUL	2018	150	1					34	42		10.1093/AJCP/AQY028			9	Pathology	Pathology	GI0VP	WOS:000434088700005	29741562	Bronze			2019-10-28	
J	Douville, P; Theriault, S				Douville, Pierre; Theriault, Sebastien			Variability of High-Sensitivity Troponin T Concentrations in Emergency Settings Impact for the Diagnosis of Myocardial Infarction	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Myocardial infarction; Troponin; Acute coronary syndrome; Biological variation; Reference range	REFERENCE CHANGE VALUES; UPPER REFERENCE LIMITS; CARDIAC TROPONIN; BIOLOGICAL VARIATION; DEPARTMENT PATIENTS; GENERAL-POPULATION; 99TH PERCENTILE; CHEST-PAIN; RULE-OUT; ASSAY	Objectives: To assess biological variation of troponin T in emergency settings and establish limits for interpretation of serial results. Methods: We studied 6,557 consecutive patients with troponin measurements. A stable reference subset was selected to estimate biological variation and threshold limits. Results: The first troponin level was elevated in 32% of patients, and 2,490 had a second troponin level with a myocardial infarction (MI) prevalence of 16.2%. In the stable reference group with at least one abnormal value, the 99th percentile of the absolute delta between the first two samples was 16 ng/L. For MI diagnosis, the area under the receiver operating characteristic curve was 0.85 (confidence interval [CI], 0.83-0.87) for the first troponin level and 0.94 (CI, 0.93-0.95) for the absolute delta. Conclusions: An absolute delta of 16 ng/L has good specificity in the emergency setting. This threshold is valid for any sex, age, and sampling interval between 3 and 24 hours and is higher than published limits found in healthy outpatients.	[Douville, Pierre; Theriault, Sebastien] Univ Laval, IUCPQ, Dept Biol Med, Quebec City, PQ, Canada	Douville, P (reprint author), 11 Cote Palais, Quebec City, PQ G1R 2J6, Canada.	pierre.douville@fmed.ulaval.ca					Biener M, 2016, EUR HEART J-ACUTE CA, V5, P409, DOI 10.1177/2048872615610869; Biener Moritz, 2013, Int J Cardiol, V167, P1134, DOI 10.1016/j.ijcard.2012.09.122; Buccelletti F, 2012, INTERN EMERG MED, V7, P365, DOI 10.1007/s11739-012-0787-8; Chenevier-Gobeaux C, 2013, CLIN LAB, V59, P333, DOI 10.7754/Clin.Lab.2012.120230; de Lemos JA, 2010, JAMA-J AM MED ASSOC, V304, P2503, DOI 10.1001/jama.2010.1768; Eggers KM, 2013, CLIN CHEM, V59, P1068, DOI 10.1373/clinchem.2012.196634; Frankenstein L, 2011, CLIN CHEM, V57, P1068, DOI 10.1373/clinchem.2010.158964; Franzini M, 2015, CLIN CHIM ACTA, V438, P376, DOI 10.1016/j.cca.2014.09.010; Gore MO, 2014, J AM COLL CARDIOL, V63, P1441, DOI 10.1016/j.jacc.2013.12.032; Mansour M, 2013, CLIN CHIM ACTA, V421, P85, DOI 10.1016/j.cca.2013.02.013; McMullin N, 2011, AM J EMERG MED, V29, P162, DOI 10.1016/j.ajem.2009.08.016; Menacer S, 2013, CLIN CHIM ACTA, V417, P45, DOI 10.1016/j.cca.2012.11.031; Mueller M, 2012, CLIN CHEM, V58, P209, DOI 10.1373/clinchem.2011.171827; Nordenskjold AM, 2013, CLIN CHEM, V59, P401, DOI 10.1373/clinchem.2012.191700; Pretorius CJ, 2012, CLIN CHIM ACTA, V413, P1786, DOI 10.1016/j.cca.2012.07.001; Reichlin T, 2015, AM J MED, V128, P369, DOI 10.1016/j.amjmed.2014.10.032; Reichlin T, 2012, ARCH INTERN MED, V172, P1211, DOI 10.1001/archinternmed.2012.3698; Reichlin T, 2011, CIRCULATION, V124, P136, DOI 10.1161/CIRCULATIONAHA.111.023937; Roffi M, 2016, EUR HEART J, V37, P267, DOI 10.1093/eurheartj/ehv320; Sajeev JK, 2015, INT J CARDIOL, V184, P170, DOI 10.1016/j.ijcard.2015.01.074; Scharnhorst V, 2012, CLIN CHEM, V58, P1208, DOI 10.1373/clinchem.2011.179903; Simpson AJ, 2014, CLIN CHEM, V60, P848, DOI 10.1373/clinchem.2013.219410; Vasile VC, 2010, CLIN CHEM, V56, P1086, DOI 10.1373/clinchem.2009.140616	23	0	0	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JUL	2018	150	1					51	57		10.1093/AJCP/AQY025			7	Pathology	Pathology	GI0VP	WOS:000434088700007	29718099	Green Accepted, Bronze			2019-10-28	
J	Lin, F; Shi, JH; Wang, HLL; Ma, XJ; Monroe, R; Luo, YL; Che, ZM; Liu, HY				Lin, Fan; Shi, Jianhui; Wang, Hanlin L.; Ma, Xiao-Jun; Monroe, Robert; Luo, Yuling; Che, Zongming; Liu, Haiyan			Detection of Albumin Expression by RNA In Situ Hybridization Is a Sensitive and Specific Method for Identification of Hepatocellular Carcinomas and Intrahepatic Cholangiocarcinomas	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Albumin; RNA in situ hybridization; Hepatocellular carcinoma; Intrahepatic cholangiocarcinomas	TISSUE MICROARRAY ANALYSIS; USEFUL DIAGNOSTIC MARKER; HEPATIC STEM-CELLS; GLYPICAN-3 EXPRESSION; NEOPLASTIC TISSUES; HEP PAR-1; TUMORS; DIFFERENTIATION; ADENOCARCINOMAS; IMMUNOREACTIVITY	Objectives: Inconsistent data on detection of albumin expression by ribonucleic acid (RNA) in situ hybridization have been reported. We investigated the utility of RNAscope (Advanced Cell Diagnostics, Hayward, CA) in detection of albumin in hepatocellular carcinomas (HCCs), intrahepatic cholangiocarcinomas (ICCs), and carcinomas from various organs using manual and automated staining. Methods: RNAscope for albumin detection was performed on 482 cases on tissue microarray sections and on 22 cases of ICC, including 14 surgical resection and eight core biopsy specimens. Results: Thirty-six of 37 (97%) HCCs had detectable mRNA, whereas all non-HCC and non-ICC cases, except one lung adenocarcinoma, were negative for albumin. Fourteen of 22 ICCs (64%) were positive for albumin. Conclusions: RNAscope for albumin is highly sensitive and specific for identifying HCCs and is highly specific and moderately sensitive for detection of ICCs; however, rare carcinomas (non-HCC, non-ICC, and those with no hepatoid histomorphology) can also have aberrant expression of albumin.	[Lin, Fan; Shi, Jianhui; Che, Zongming; Liu, Haiyan] Geisinger Med Ctr, Danville, PA 17822 USA; [Wang, Hanlin L.] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA USA; [Ma, Xiao-Jun; Monroe, Robert; Luo, Yuling] Adv Cell Diagnost, Hayward, CA USA	Lin, F (reprint author), Geisinger Med Ctr, Dept Lab Med, MC 19-20,100 N Acad Ave, Danville, PA 17822 USA.	Flin1@geisinger.edu					Anatelli F, AM J CLIN PATHOL; Askan G, 2016, AM J CLIN PATHOL, V146, P163, DOI 10.1093/ajcp/aqw096; Avadhani V, 2017, MODERN PATHOL, V30, p413A; Avadhani V, 2017, MODERN PATHOL, V30, p159A; Baumhoer D, 2008, AM J CLIN PATHOL, V129, P899, DOI 10.1309/HCQWPWD50XHD2DW6; Cardinale V, 2010, WORLD J GASTRO ONCOL, V2, P407, DOI 10.4251/wjgo.v2.i11.407; Cardinale V, 2009, HEPATOLOGY, V50, p901A; Carter JM, 2015, AM J SURG PATHOL, V39, P75, DOI 10.1097/PAS.0000000000000290; Chu PGG, 2002, AM J SURG PATHOL, V26, P978, DOI 10.1097/01.PAS.0000020482.56467.09; Fan Z, 2003, MODERN PATHOL, V16, P137, DOI 10.1097/01.MP.0000052103.13730.20; Fasano M, 1998, MODERN PATHOL, V11, P934; Ferrone CR, 2016, ANN SURG ONCOL, V23, P290, DOI 10.1245/s10434-014-4247-8; Kakar S, 2003, AM J CLIN PATHOL, V119, P361, DOI 10.1309/8L872RPHEJRKF5JJ; Kandil D, 2007, CANCER CYTOPATHOL, V111, P316, DOI 10.1002/cncr.22954; Kuwahara R, 2008, HEPATOLOGY, V47, P1994, DOI 10.1002/hep.22218; Lehrke H, 2017, MODERN PATHOL, V30, p419A; Leong ASY, 1998, HISTOPATHOLOGY, V33, P318; Lugli A, 2004, AM J CLIN PATHOL, V122, P721, DOI 10.1309/KC09YTF2M4DLUY06; Maitra A, 2001, AM J CLIN PATHOL, V115, P689; Schmelzer E, 2007, J EXP MED, V204, P1973, DOI 10.1084/jem.20061603; Shafizadeh N, 2008, MODERN PATHOL, V21, P1011, DOI 10.1038/modpathol.2008.85; Shahid M, 2015, AM J SURG PATHOL, V39, P25, DOI 10.1097/PAS.0000000000000343; Shi JH, 2016, ARCH PATHOL LAB MED, V140, P332, DOI 10.5858/arpa.2014-0644-OA; Shirakawa H, 2009, INT J ONCOL, V34, P649, DOI 10.3892/ijo_00000190; Theise ND, 1999, HEPATOLOGY, V30, P1425, DOI 10.1002/hep.510300614; Timek DT, 2012, AM J CLIN PATHOL, V138, P203, DOI 10.1309/AJCPK1ZC9WNHCCMU; Wang F, 2012, J MOL DIAGN, V14, P22, DOI 10.1016/j.jmoldx.2011.08.002; Wang HL, 2008, ARCH PATHOL LAB MED, V132, P1723, DOI 10.1043/1543-2165-132.11.1723; Wang HW, 2014, METHODS MOL BIOL, V1211, P201, DOI 10.1007/978-1-4939-1459-3_16; Yan BC, 2010, AM J SURG PATHOL, V34, P1147, DOI 10.1097/PAS.0b013e3181e5dffa; Zynger DL, 2008, AM J CLIN PATHOL, V130, P224, DOI 10.1309/8DN7DQRDFB4QNH3N; Zynger DL, 2006, AM J SURG PATHOL, V30, P1570, DOI 10.1097/01.pas.0000213322.89670.48	32	1	1	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JUL	2018	150	1					58	64		10.1093/AJCP/AQY030			7	Pathology	Pathology	GI0VP	WOS:000434088700008	29746696				2019-10-28	
J	Abdulrahman, AA; Patel, KH; Yang, T; Koch, DD; Sivers, SM; Smith, GH; Jaye, DL				Abdulrahman, Ahmed A.; Patel, Kirtesh H.; Yang, Tong; Koch, David D.; Sivers, Sarah M.; Smith, Geoffrey H.; Jaye, David L.			Is a 500-Cell Count Necessary for Bone Marrow Differentials? A Proposed Analytical Method for Validating a Lower Cutoff	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Bone marrow aspirate; Differential cell counts; 300 vs 500 cutoffs; Method comparison analysis; Statistical and clinical significance	ASPIRATE; CRITERIA	Objectives: By convention, 500 cells are counted for bone marrow aspirate differentials. Evidence supporting such a cutoff is lacking. We hypothesized that 300-cell counts could be sufficient. Methods: Cell count results from 165 cases, for which values were recorded at 300 and 500 cells, were analyzed. We tested for statistical differences and changes in diagnostic classification between the two cutoffs. Results: Three hundred cell counts did not produce diagnostically different results, particularly for myeloblasts and plasma cells, where cell percentages are critical for disease classification. Method comparison analysis did not reach statistical significance for any cell type when comparing the two methods. Bias plots showed narrow, even spread about the mean bias. Contingency table analysis yielded no significant diagnostic discrepancies. Conclusions: Performing differential counts on 300 cells would produce clinically and statistically similar results to 500 cells. Reducing the cell number counted has potential cost/labor reductions without affecting quality of care.	[Abdulrahman, Ahmed A.; Patel, Kirtesh H.; Yang, Tong; Koch, David D.; Sivers, Sarah M.; Smith, Geoffrey H.; Jaye, David L.] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	Jaye, DL (reprint author), Emory Univ, Dept Pathol & Lab Med, Sch Med, 1364 Clifton Rd NE,Room F145C, Atlanta, GA 30322 USA.	dljaye@emory.edu		jaye, david/0000-0001-7977-6909			ALTMAN DG, 1983, J ROY STAT SOC D-STA, V32, P307, DOI 10.2307/2987937; Bain BJ, 1996, BRIT J HAEMATOL, V94, P206, DOI 10.1046/j.1365-2141.1996.d01-1786.x; Bain BJ, 2001, J CLIN PATHOL, V54, P657, DOI 10.1136/jcp.54.9.657; Bain BJ, 2011, DACIE LEWIS PRACTICA, P668; BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170; BLAND JM, 1986, LANCET, V1, P307; Choi JW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189259; Cornbleet PJ, 2002, CLIN LAB MED, V22, P101, DOI 10.1016/S0272-2712(03)00069-6; d'Onofrio G, 2015, CLIN LAB MED, V35, P25, DOI 10.1016/j.cll.2014.10.001; Glassy E. F., 1998, COLOR ATLAS HEMATOLO; Lee SH, 2008, INT J LAB HEMATOL, V30, P349, DOI 10.1111/j.1751-553X.2008.01100.x; Mori Y, 2004, CYTOM PART B-CLIN CY, V58B, P25, DOI 10.1002/cyto.b.10070; Rajkumar SV, 2014, LANCET ONCOL, V15, pE538, DOI 10.1016/S1470-2045(14)70442-5; ROSS DW, 1983, CYTOMETRY, V3, P287, DOI 10.1002/cyto.990030410; Ryan DH, 2015, WILLIAMS HEMATOLOGY, P27; Senent L, 2013, HAEMATOLOGICA, V98, P568, DOI 10.3324/haematol.2012.071449; Smock KJ, 2007, ARCH PATHOL LAB MED, V131, P951; Sundberg RD, 1950, B U MINNESOTA HOSP, V21, P471; Swerdlow SH, 2017, WHO CLASSIFICATION T; Thurman Alexander C, 2015, J Pathol Inform, V6, P2, DOI 10.4103/2153-3539.150252; van de Geijn GJ, 2011, CYTOM PART A, V79A, P694, DOI 10.1002/cyto.a.21105; Vollmer RT, 2009, AM J CLIN PATHOL, V131, P183, DOI 10.1309/AJCPBAYNCU35ZGZG	22	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JUL	2018	150	1					84	91		10.1093/AJCP/AQY034			8	Pathology	Pathology	GI0VP	WOS:000434088700011	29757362	Bronze			2019-10-28	
J	Conant, JL; Powers, J; Sharp, G				Conant, J. L.; Powers, J.; Sharp, G.			Lyme disease testing in a high-incidence state: clinician knowledge and patterns (vol 149, pg 234, 2018)	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Correction																Conant JL, 2018, AM J CLIN PATHOL, V149, P234, DOI [10.1093/ajcp/aqx153, 10.1093/AJCP/AQX153]	1	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JUL	2018	150	1					92	92		10.1093/ajcp/aqy059			1	Pathology	Pathology	GI0VP	WOS:000434088700012					2019-10-28	
J	Kuang, MY; Shen, XX; Yuan, CZ; Hu, HC; Zhang, Y; Pan, YJ; Cheng, C; Zheng, DF; Cheng, L; Zhao, Y; Tao, XT; Li, Y; Chen, HQ; Sun, YH				Kuang, Muyu; Shen, Xuxia; Yuan, Chongze; Hu, Haichuan; Zhang, Yang; Pan, Yunjian; Cheng, Chao; Zheng, Difan; Cheng, Lei; Zhao, Yue; Tao, Xiaoting; Li, Yuan; Chen, Haiquan; Sun, Yihua			Clinical Significance of Complex Glandular Patterns in Lung Adenocarcinoma Clinicopathologic and Molecular Study in a Large Series of Cases	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Complex glandular patterns; Cribriform; Fused gland; Lung adenocarcinoma	MINIMALLY INVASIVE ADENOCARCINOMA; 2011 IASLC/ATS/ERS CLASSIFICATION; CRIBRIFORM PATTERN; PULMONARY ADENOCARCINOMA; HISTOLOGICAL SUBTYPE; PATIENT PROGNOSIS; PROSTATE-CANCER; IN-SITU; ASSOCIATION; CARCINOMA	Objectives: To explore whether complex glandular patterns (CGPs) have a potential role in the clinical management of patients with lung adenocarcinoma. Methods: We included 356 patients with lung adenocarcinoma with available clinicopathologic information, gene mutations, and clinical outcomes for analysis. Results: We identified 54 (15.2%) CGP-predominant cases. The CGPs were associated with ALK rearrangement and HER2 mutation. Survival analysis showed that the clinical outcome of CGP-predominant patients was worse than that for acinar-predominant patients (overall survival [OS], 66.4 vs 90.3 months, P<.01; recurrence-free survival [RFS], 50.1 vs 73.1 months, P=.022) but was comparable with solid-predominant subtype tumors (OS, 66.4 vs 67.8 months, P=.558; RFS, 50.1 vs 41.3 months, P=.258). In particular, the coexistence of the cribriform and fused gland pattern was associated with the poorest survival, with a death risk increased by 2.25-fold (hazard ratio, 3.25; 95% confidence interval, 1.35-7.86, P=.009). Conclusions: Our results provide new insight into the potential role of CGPs in clinical management and will be beneficial for treatment decision making in patients with lung adenocarcinoma.	[Kuang, Muyu; Yuan, Chongze; Hu, Haichuan; Zhang, Yang; Pan, Yunjian; Cheng, Chao; Zheng, Difan; Zhao, Yue; Tao, Xiaoting; Chen, Haiquan; Sun, Yihua] Fudan Univ, Shanghai Canc Ctr, Dept Thorac Surg, Collaborat Innovat Ctr Canc Med, Shanghai, Peoples R China; [Shen, Xuxia; Li, Yuan] Fudan Univ, Shanghai Canc Ctr, Dept Pathol, Collaborat Innovat Ctr Canc Med, Shanghai, Peoples R China; [Cheng, Lei] Fudan Univ, Shanghai Canc Ctr, Canc Inst, Collaborat Innovat Ctr Canc Med, Shanghai, Peoples R China; [Kuang, Muyu; Shen, Xuxia; Yuan, Chongze; Hu, Haichuan; Zhang, Yang; Pan, Yunjian; Cheng, Chao; Zheng, Difan; Zhao, Yue; Tao, Xiaoting; Li, Yuan; Chen, Haiquan; Sun, Yihua] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China	Sun, YH (reprint author), Fudcoi Univ, Dept Thorac Surg, Shanghai Canc Ctr, 270 Dongan Rd, Shanghai 200030, Peoples R China.	sun_yihua76@hotmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81422029, 81572264, 81372525]; Chinese Minister of Science and Technology grant [2016YFA0501800]	This work was supported by the National Natural Science Foundation of China (No. 81422029, No. 81572264, and No. 81372525), Chinese Minister of Science and Technology grant (No. 2016YFA0501800).	Araki K, 2014, ANTICANCER RES, V34, P3153; Behera M, 2016, CLIN LUNG CANCER, V17, pE57, DOI 10.1016/j.cllc.2016.03.009; Detterbeck FC, 2016, J THORAC ONCOL, V11, P639, DOI 10.1016/j.jtho.2016.01.024; Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530; Iczkowski KA, 2011, AM J CLIN PATHOL, V136, P98, DOI 10.1309/AJCPZ7WBU9YXSJPE; Jokoji R, 2010, J CLIN PATHOL, V63, P1066, DOI 10.1136/jcp.2010.081166; Kadota K, 2014, MODERN PATHOL, V27, P690, DOI 10.1038/modpathol.2013.188; Kadota K, 2014, AM J SURG PATHOL, V38, P448, DOI 10.1097/PAS.0000000000000134; Kir G, 2014, PATHOL RES PRACT, V210, P640, DOI 10.1016/j.prp.2014.06.002; Kweldam CF, 2015, MODERN PATHOL, V28, P457, DOI 10.1038/modpathol.2014.116; Mackinnon AC, 2014, MODERN PATHOL, V27, P1063, DOI 10.1038/modpathol.2013.227; Maeshima AM, 2010, J THORAC ONCOL, V5, P333, DOI 10.1097/JTO.0b013e3181c8cb95; Makinen JM, 2015, LUNG CANCER, V90, P568, DOI 10.1016/j.lungcan.2015.10.014; Moreira AL, 2014, HUM PATHOL, V45, P213, DOI 10.1016/j.humpath.2013.10.011; Okada M, 2013, THORAC SURG CLIN, V23, P179, DOI 10.1016/j.thorsurg.2013.01.001; Petersen I, 2016, J CANCER RES CLIN, V142, P895, DOI 10.1007/s00432-015-2004-4; Pradhan D, 2015, PATHOL RES PRACT, V211, P712, DOI 10.1016/j.prp.2015.04.011; Sakurai H, 2014, EUR J CARDIO-THORAC, V45, P100, DOI 10.1093/ejcts/ezt284; Lino-Silva LS, 2015, INT J SURG PATHOL, V23, P13, DOI 10.1177/1066896914542125; Strand TE, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0335-8; Sun YH, 2010, J CLIN ONCOL, V28, P4616, DOI 10.1200/JCO.2010.29.6038; Travis WD, 2014, PATHOLOGE, V35, P188, DOI 10.1007/s00292-014-1974-3; Travis WD, 2015, WHO CLASSIFICATION T; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Urer HN, 2014, ANN THORAC CARDIOVAS, V20, P12, DOI 10.5761/atcs.oa.12.02073; Wang CL, 2014, INT J SURG PATHOL, V22, P149, DOI 10.1177/1066896913519165; Warth A, 2015, J THORAC ONCOL, V10, P638, DOI 10.1097/JTO.0000000000000490; Xu LR, 2013, AM J SURG PATHOL, V37, P1100, DOI 10.1097/PAS.0b013e31827fcf04; Yoshida A, 2011, AM J SURG PATHOL, V35, P1226, DOI 10.1097/PAS.0b013e3182233e06; Zhang Y, 2014, J THORAC ONCOL, V9, P1772, DOI 10.1097/JTO.0000000000000341	30	3	3	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JUL	2018	150	1					65	73		10.1093/AJCP/AQY032			9	Pathology	Pathology	GI0VP	WOS:000434088700009	29746612	Green Published, Other Gold			2019-10-28	
J	Li, H; Yang, LL; Xiao, Y; Deng, WW; Chen, L; Wu, L; Zhang, WF; Sun, ZJ				Li, Hao; Yang, Lei-Lei; Xiao, Yao; Deng, Wei-Wei; Chen, Lei; Wu, Lei; Zhang, Wen-Feng; Sun, Zhi-Jun			Overexpression of Golgi Phosphoprotein 2 Is Associated With Poor Prognosis in Oral Squamous Cell Carcinoma	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Cancer stem cell; Epithelial-mesenchymal transition; GOLPH2; Immune checkpoint; Oral squamous cell carcinoma	CANCER STEM-CELLS; EXPRESSION PROFILE; GOLPH2 EXPRESSION; HEAD; SURVIVAL; BLOCKADE; OCT4; SOX2; IDENTIFICATION; PROGRESSION	Objectives: The aims of this study were to investigate the relationship between Golgi phosphoprotein 2 (GOLPH2) and oral squamous cell carcinoma (OSCC) and explore the clinical significance of GOLPH2 in OSCC. Methods: Tissue microarrays from human OSCC samples were stained for GOLPH2 expression and clinicopathologic features. Kaplan-Meier analysis was used to compare the survival of patients with high GOLPH2 expression and patients with low GOLPH2 expression. Results: We found GOLPH2 is highly expressed in OSCC tissue, and the GOLPH2 expression in metastatic lymph nodes is higher than in tumor tissue. Our data indicate that patients with higher GOLPH2 expression have poor overall survival compared with those with lower GOLPH2 expression. This study demonstrated that GOLPH2 was associated with CD44, SOX2, Slug, B7-H3, B7-H4, TIM3, and VISTA. Conclusions: These findings suggest GOLPH2 is a potential marker for estimating the patient's prognosis and may be a target for molecular-targeted therapy against OSCC.	[Li, Hao; Yang, Lei-Lei; Xiao, Yao; Deng, Wei-Wei; Chen, Lei; Wu, Lei; Sun, Zhi-Jun] Wuhan Univ, Sch & Hosp Stomatol, State Key Lab Breeding Base Basic Sci Stomatol Hu, Minist Educ, Wuhan, Hubei, Peoples R China; [Li, Hao; Yang, Lei-Lei; Xiao, Yao; Deng, Wei-Wei; Chen, Lei; Wu, Lei; Sun, Zhi-Jun] Wuhan Univ, Sch & Hosp Stomatol, Minist Educ, Key Lab Oral Biomed, Wuhan, Hubei, Peoples R China; [Zhang, Wen-Feng; Sun, Zhi-Jun] Wuhan Univ, Sch & Hosp Stomatol, Dept Oral & Maxillofacial Head Neck Surg, Wuhan, Hubei, Peoples R China	Sun, ZJ (reprint author), Wuhan Univ, Sch & Hosp Stomatol, 237 Luoyu Rd, Wuhan 430079, Hubei, Peoples R China.	sunzj@whu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81472528, 81472529]; Fundamental Research Funds for the Central Universities of ChinaFundamental Research Funds for the Central Universities [2042017kf0171]	This work was supported by the National Natural Science Foundation of China (81472528, 81472529). Z.-J.S. was supported by the Fundamental Research Funds for the Central Universities of China (2042017kf0171) (Outstanding Young Scholars).	AHMED HOA, 2015, ORAL SURG ORAL MED O, V119, P459; Ali J, 2017, ORAL ONCOL, V70, P23, DOI 10.1016/j.oraloncology.2017.05.004; Brcic L, 2012, AM J CLIN PATHOL, V138, P712, DOI 10.1309/AJCP05TTWQTWNLTN; Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862; Byrne AM, 2015, BRIT J CANCER, V113, P1332, DOI 10.1038/bjc.2015.350; Camp ER, 2011, J SURG RES, V170, P56, DOI 10.1016/j.jss.2011.02.012; Chen YW, 2010, MOL CANCER THER, V9, P2879, DOI 10.1158/1535-7163.MCT-10-0504; Donizy P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101619; Faber A, 2011, ONCOL REP, V26, P321, DOI 10.3892/or.2011.1322; Ferris RL, 2015, J CLIN ONCOL, V33, P3293, DOI 10.1200/JCO.2015.61.1509; Fritzsche Florian Rudolf, 2008, BMC Urol, V8, P15, DOI 10.1186/1471-2490-8-15; Ginos MA, 2004, CANCER RES, V64, P55, DOI 10.1158/0008-5472.CAN-03-2144; Gupta S, 2009, INT J CANCER, V125, P2159, DOI 10.1002/ijc.24533; Ha NH, 2016, CYTOKINE, V86, P64, DOI 10.1016/j.cyto.2016.07.013; Huang CF, 2014, J ORAL PATHOL MED, V43, P492, DOI 10.1111/jop.12159; Inagi K, 2002, ACTA OTO-LARYNGOL, V122, P25, DOI 10.1080/000164802760057527; Isaji T, 2009, J BIOL CHEM, V284, P12207, DOI 10.1074/jbc.M807920200; Jin D, 2015, ONCOTARGET, V6, P33523, DOI 10.18632/oncotarget.5590; Kladney RD, 2000, GENE, V249, P53, DOI 10.1016/S0378-1119(00)00136-0; Kojima S, 2014, J HUM GENET, V59, P78, DOI 10.1038/jhg.2013.121; Kristiansen G, 2008, BRIT J CANCER, V99, P939, DOI 10.1038/sj.bjc.6604614; Li XX, 2012, INT J MOL SCI, V13, P7663, DOI 10.3390/ijms13067663; Liu GL, 2014, ONCOL REP, V32, P2077, DOI 10.3892/or.2014.3404; Liu JF, 2017, MOL ONCOL, V11, P235, DOI 10.1002/1878-0261.12029; Liu YM, 2016, ONCOTARGET, V7, P21404, DOI 10.18632/oncotarget.7271; Ma SR, 2015, ONCOTARGET, V6, P8807, DOI 10.18632/oncotarget.3556; Maccioni HJF, 2011, FEBS LETT, V585, P1691, DOI 10.1016/j.febslet.2011.03.030; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mao L, 2017, J CELL MOL MED, V21, P2199, DOI 10.1111/jcmm.13143; Millarte V, 2012, SCI WORLD J, DOI 10.1100/2012/498278; Mladinich M, 2016, STEM CELLS INT, DOI 10.1155/2016/5285892; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pu YF, 2014, ONCOL REP, V31, P2644, DOI 10.3892/or.2014.3124; Qiao B, 2014, INT J CLIN EXP PATHO, V7, P28; Riener MO, 2009, HEPATOLOGY, V49, P1602, DOI 10.1002/hep.22843; Rodrigo JP, 2002, AM J CLIN PATHOL, V118, P67; Schildberg FA, 2016, IMMUNITY, V44, P955, DOI 10.1016/j.immuni.2016.05.002; Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017; Shingaki S, 2003, AM J SURG, V185, P278, DOI 10.1016/S0002-9610(02)01378-8; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Sobin LH, 2002, TNM CLASSIFICATION M; Tang QF, 2013, ASIAN PAC J CANCER P, V14, P5747, DOI 10.7314/APJCP.2013.14.10.5747; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Toruner GA, 2004, CANCER GENET CYTOGEN, V154, P27, DOI 10.1016/j.cancergencyto.2004.01.026; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Wu L, 2017, CANCER IMMUNOL IMMUN, V66, P627, DOI 10.1007/s00262-017-1968-0; Wu L, 2016, CANCER IMMUNOL IMMUN, V65, P1035, DOI 10.1007/s00262-016-1867-9; Wu TF, 2017, EUR J PHARM SCI, V101, P243, DOI 10.1016/j.ejps.2017.02.020; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zhang JL, 2013, ORAL ONCOL, V49, P1043, DOI 10.1016/j.oraloncology.2013.08.003; Zhang W, 2018, J IMMUNOL, V200, P1480, DOI 10.4049/jimmunol.1700897; Zhang Y, 2017, BIOMARK MED, V11, P967, DOI 10.2217/bmm-2017-0199; Zhong LP, 2013, J CLIN ONCOL, V31, P744, DOI 10.1200/JCO.2012.43.8820	55	0	0	3	16	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JUL	2018	150	1					74	83		10.1093/AJCP/AQY029			10	Pathology	Pathology	GI0VP	WOS:000434088700010	29788173	Other Gold			2019-10-28	
J	Kubo, C; Nagata, S; Fukuda, T; Kano, R; Tanaka, T; Nakanishi, K; Ohsawa, M; Nakatsuka, S				Kubo, Chiaki; Nagata, Shigenori; Fukuda, Takeshi; Kano, Rieko; Tanaka, Takaaki; Nakanishi, Katsuyuki; Ohsawa, Masahiko; Nakatsuka, Shin-ichi			Late recurrence of pStage 1 low-grade serous ovarian tumor presenting as a symptomatic bone metastasis: a case report	DIAGNOSTIC PATHOLOGY			English	Article						Ovarian cancer; Serous borderline tumor; Atypical proliferative serous tumor; Low-grade serous carcinoma; Late recurrence; Bone metastasis; BRAF; KRAS	BORDERLINE TUMORS; CARCINOMA; MUTATIONS; BRAF; PERITONEUM; EXPRESSION; NEOPLASMS; PATTERNS; KRAS; PAX8	Background: Ovarian serous borderline tumor/atypical proliferative serous tumor (SBT/APST) is characterized by presenting at an early stage and much longer survival than high-grade serous carcinoma. Given that the prognosis of ovarian SBT/APST with no invasive features is excellent, remote relapse after surgery can pose a diagnostic pitfall. Bone metastasis as transformed low-grade carcinoma is an extremely rare initial presentation of recurrence in patients whose primary tumor was confined to the ovaries. Case presentation: A 55-year-old Japanese woman who had undergone surgery for a right ovarian tumor 13 years previously presented with right-lateral chest pain and neurologic abnormalities in the lower limbs. Computed tomography (CT) scan and magnetic resonance imaging revealed an irregular mass in the right arch of the 12th thoracic vertebra, extending through the intervertebral foramen and into surrounding soft tissue, the maximum diameter of the whole mass being 78 mm. Pathological examination of a CT-guided needle biopsy of the paraspinal lesion demonstrated papillary cell clusters with blunt nuclear atypia and psammomatous calcification that were positive for PAX8, estrogen receptor, and WT1, but negative for thyroglobulin on immunohistochemical testing, and of a P53 non-mutational pattern. On clinicopathologic review, the previous 13- x 11- x 9-cm ovarian tumor was an intracystic and exophytic papillary growth without surface involvement; it had ruptured intraoperatively. Microscopically there was serous epithelium with minimal cytologic atypia proliferating in hierarchical branches with no invasive foci or micropapillary components. The tumor was confined to the right ovary with no peritoneal implants. Neither primary nor metastatic tumor harbored KRAS/BRAF mutations according to polymerase chain reaction using formalin-fixed paraffin-embedded tissues. We concluded that, after a 13-year disease-free interval, the paraspinal lesion was bone metastasis of low-grade carcinoma originating from the ovarian SBT/APST. The patient received radiotherapy for the paraspinal lesion followed by administration of paclitaxel and carboplatin plus bevacizumab and remains alive 168 months after the initial surgery. Conclusions: Pathologists and radiologists should not exclude late recurrence of ovarian SBT/APST when bone metastases are suspected, even when neither peritoneal nor lymph node involvement are detected. Long-term surveillance of women with ovarian serous tumors with no invasive features is recommended.	[Kubo, Chiaki; Nagata, Shigenori; Kano, Rieko; Nakatsuka, Shin-ichi] Osaka Int Canc Inst Hosp, Dept Diagnost Pathol & Cytol, Chuo Ku, 3-1-69 Otemae, Osaka 5418567, Japan; [Fukuda, Takeshi] Osaka City Univ, Dept Obstet & Gynecol, Grad Sch Med, Osaka, Japan; [Tanaka, Takaaki] Osaka Int Canc Inst Hosp, Dept Orthoped Surg, Osaka, Japan; [Nakanishi, Katsuyuki] Osaka Int Canc Inst Hosp, Dept Diagnost & Intervent Radiol, Osaka, Japan; [Ohsawa, Masahiko] Osaka City Univ, Dept Diagnost Pathol, Grad Sch Med, Osaka, Japan	Nagata, S (reprint author), Osaka Int Canc Inst Hosp, Dept Diagnost Pathol & Cytol, Chuo Ku, 3-1-69 Otemae, Osaka 5418567, Japan.	nagata-si@mc.pref.osaka.jp					Ahn G, 2016, AM J SURG PATHOL, V40, P1165, DOI 10.1097/PAS.0000000000000693; Barcena C, 2011, ADV ANAT PATHOL, V18, P454, DOI 10.1097/PAP.0b013e318234aaed; Deavers MT, 2002, AM J SURG PATHOL, V26, P1129, DOI 10.1097/01.PAS.0000022581.14422.C1; Farley J, 2013, LANCET ONCOL, V14, P134, DOI 10.1016/S1470-2045(12)70572-7; Grisham RN, 2014, INT J GYNECOL CANCER, V24, P1010, DOI 10.1097/IGC.0000000000000190; Hannibal CG, 2017, GYNECOL ONCOL, V144, P174, DOI 10.1016/j.ygyno.2016.11.007; Jones S, 2012, J PATHOL, V226, P413, DOI 10.1002/path.3967; Longacre TA, 2005, AM J SURG PATHOL, V29, P707, DOI 10.1097/01.pas.0000164030.82810.db; Menczer J, 2015, ARCH GYNECOL OBSTET, V291, P1199, DOI 10.1007/s00404-014-3597-6; Nonaka D, 2008, MODERN PATHOL, V21, P192, DOI 10.1038/modpathol.3801002; Ozcan A, 2011, AM J SURG PATHOL, V35, P1837, DOI 10.1097/PAS.0b013e31822d787c; Recine MA, 2004, AM J SURG PATHOL, V28, P1646, DOI 10.1097/00000478-200412000-00015; Seidmam JD, 2014, WHO CLASSIFICATION T, P15; Seidman JD, 2000, HUM PATHOL, V31, P539, DOI 10.1053/hp.2000.8048; Sieben NLG, 2004, J PATHOL, V202, P336, DOI 10.1002/path.1521; Singer G, 2005, AM J SURG PATHOL, V29, P218, DOI 10.1097/01.pas.0000146025.91953.8d; Tsang YT, 2013, J PATHOL, V231, P449, DOI 10.1002/path.4252; Vang R, 2017, AM J SURG PATHOL, V41, P725, DOI 10.1097/PAS.0000000000000824; Wong KK, 2010, AM J PATHOL, V177, P1611, DOI 10.2353/ajpath.2010.100212; Xing DY, 2018, INT J GYNECOL PATHOL, V37, P52, DOI 10.1097/PGP.0000000000000389	20	0	0	1	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	JUN 30	2018	13								43	10.1186/s13000-018-0720-1			5	Pathology	Pathology	GL2XL	WOS:000436990100001	29960592	DOAJ Gold, Green Published			2019-10-28	
J	Conran, RM; Powell, SZE; Domen, RE; McCloskey, CB; Brissette, MD; Cohen, DA; Dixon, LR; George, MR; Gratzinger, DA; Post, MD; Roberts, CA; Rojiani, AM; Timmons, CF; Johnson, K; Hoffman, RD				Conran, Richard M.; Powell, Suzanne Zein-Eldin; Domen, Ronald E.; McCloskey, Cindy B.; Brissette, Mark D.; Cohen, David A.; Dixon, Lisa Ross; George, Melissa Robin; Gratzinger, Dita A.; Post, Miriam D.; Roberts, Cory A.; Rojiani, Amyn M.; Timmons, Charles Franklin, Jr.; Johnson, Kristen; Hoffman, Robert D.			Development of Professionalism in Graduate Medical Education: A Case-Based Educational Approach From the College of American Pathologists' Graduate Medical Education Committee	ACADEMIC PATHOLOGY			English	Article						case vignettes; hidden curriculum; medical education; professionalism; physician well-being	TEACHING PROFESSIONALISM; RESIDENT BURNOUT; BEHAVIOR	Professionalism and physician well-being are important topics in academic medicine. Lapses in professional judgment may lead to disciplinary action and put patient's health at risk. Within medical education, students and trainees are exposed to professionalism in the institution's formal curriculum and hidden curriculum. Development of professionalism starts early in medical school. Trainees entering graduate medical education already have developed professional behavior. As a learned behavior, development of professional behavior is modifiable. In addition to role modeling by faculty, other modalities are needed. Use of case vignettes based on real-life issues encountered in trainee and faculty behavior can serve as a basis for continued development of professionalism in trainees. Based on the experience of program directors and pathology educators, case vignettes were developed in the domains of service, research, and education and subdivided into the areas of duty, integrity, and respect. General and specific questions pertaining to each case were generated to reinforce model behavior and overcome professionalism issues encountered in the hidden curriculum. To address physician burnout, cases were generated to provide trainees with the skills to deal with burnout and promote well-being.	[Conran, Richard M.] Eastern Virginia Med Sch, Dept Pathol & Anat, Norfolk, VA 23501 USA; [Powell, Suzanne Zein-Eldin] Houston Methodist Hosp, Dept Pathol & Genom Med, Houston, TX USA; [Domen, Ronald E.; George, Melissa Robin] Penn State Hershey Med Ctr, Dept Pathol, Hershey, PA USA; [Domen, Ronald E.; George, Melissa Robin] Coll Med, Hershey, PA USA; [McCloskey, Cindy B.] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA; [Brissette, Mark D.] Joint Pathol Ctr, Silver Spring, MD USA; [Cohen, David A.] Emory Univ Hosp, Pathol & Lab Med, 1364 Clifton Rd NE, Atlanta, GA 30322 USA; [Dixon, Lisa Ross] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL USA; [Gratzinger, Dita A.] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; [Post, Miriam D.] Univ Colorado, Dept Pathol, Anschutz Med Campus, Aurora, CO USA; [Roberts, Cory A.] ProPath Associates, Dallas, TX USA; [Rojiani, Amyn M.] Augusta Univ, Med Coll Georgia, Dept Pathol, Augusta, GA USA; [Timmons, Charles Franklin, Jr.] Childrens Med Ctr Dallas, Dept Pathol, Dallas, TX USA; [Johnson, Kristen] Coll Amer Pathologists, Northfield, IL USA; [Hoffman, Robert D.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA	Conran, RM (reprint author), East Virginia Med Sch, Dept Pathol, 700 West Olney Rd,Lewis Hall Room 2164, Norfolk, VA 23507 USA.	conranrm@evms.edu					Accreditation Council on Graduate Medical Education, 2012, PROGR DIR GUID COMM; Accreditation Council on Graduate Medical Education, PATH MIL PROJ JOINT; Accreditation Council on Graduate Medical Education, 2013, ACGME I REQ 3 B 6 PR; ACGME Common Program Requirements, 2017, SECT 6 BACKGR INT; AMA Principles of Medical Ethics, 2017, AMA PRINCIPLES MED E; American Board of Internal Medicine Committee on Evaluation of Clinical Competence, 1995, PROJ PROF; American Board of Medical Specialties, BAS COR COMP; Baker Kathryn, 2016, AMA J Ethics, V18, P604, DOI 10.1001/journalofethics.2016.18.6.medu1-1606; Bernabeo EC, 2013, ADV HEALTH SCI EDUC, V18, P463, DOI 10.1007/s10459-012-9384-x; Brissette MD, 2017, ARCH PATHOL LAB MED, V141, P1394, DOI 10.5858/arpa.2016-0477-CP; Cull WL, 2017, ACAD MED, V92, P1595, DOI 10.1097/ACM.0000000000001721; Domen RE, 2002, HUM PATHOL, V33, P779, DOI 10.1053/hupa.2002.127446; Domen RE, 2015, ACAD PATHOL, V2, DOI 10.1177/2374289515592887; Domen RE, 2017, ARCH PATHOL LAB MED, V141, P215, DOI 10.5858/arpa.2016-0217-CP; Domen RE, 2014, AM J CLIN PATHOL, V141, P784, DOI 10.1309/AJCPSNPAP5R5NHUS; Goldie J, 2007, MED EDUC, V41, P610, DOI 10.1111/j.1365-2923.2007.02772.x; Gronowski AM, 2016, ACAD PATHOL, V3, DOI 10.1177/2374289516667509; Hafferty FW, 2013, PRACTICAL GUIDE MED, P52; Hafferty FW, 2000, ED PROFESSIONALISM C, P11; Hamstra SJ, MILESTONES ANN REPOR; Jha V, 2016, ACAD MED, V91, P1622, DOI 10.1097/ACM.0000000000001287; Kasten J, 2017, ACAD MED, V92, P904, DOI 10.1097/ACM.0000000000001765; Khan R, 2013, OPHTHALMOLOGY, V120, P874, DOI 10.1016/j.ophtha.2012.10.035; Kirch DG, 2015, JAMA-J AM MED ASSOC, V313, P1797, DOI 10.1001/jama.2015.4019; Kirk Lynne M, 2007, Proc (Bayl Univ Med Cent), V20, P13; Krisberg K, 2017, AAMC NEWS; Lehmann LS, 2018, ANN INTERN MED, V168, P506, DOI 10.7326/M17-2058; Lesser CS, 2010, JAMA-J AM MED ASSOC, V304, P2732, DOI 10.1001/jama.2010.1864; Liaison Committee on Medical Education, 2017, 35 LIAIS COMM MED ED; Mills AM, 2018, ARCH PATHOL LAB MED, V142, P12, DOI 10.5858/arpa.2017-0360-ED; Mulder H, 2019, MED TEACH, V41, P36, DOI 10.1080/0142159X.2018.1436760; Norcini J, 2017, PRACTICAL GUIDE MED, P252; O'Sullivan HM, 2017, PRACTICAL GUIDE MED, P203; Papadakis MA, 2005, NEW ENGL J MED, V353, P2673, DOI 10.1056/NEJMsa052596; Post MD, 2017, ARCH PATHOL LAB MED, V141, P193, DOI 10.5858/arpa.2015-0138-CP; Reamy BV, 2006, FAM MED, V38, P252; Rudolph Jenny W, 2007, Anesthesiol Clin, V25, P361, DOI 10.1016/j.anclin.2007.03.007; Thomas NK, 2004, JAMA-J AM MED ASSOC, V292, P2880, DOI 10.1001/jama.292.23.2880; Torre D, 2017, PRACTICAL GUIDE MED, P52; U. S. Department of Health and Human Services Office of Human Research Protections, 2016, THE BELM REP; Voo TC, 2017, PRACTICAL GUIDE MED, P195; Wagoner NE, 2000, ED PROFESSIONALISM C, P120	42	1	1	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	JUN 26	2018	5								UNSP 2374289518773493	10.1177/2374289518773493			12	Pathology	Pathology	GM4BI	WOS:000438057900001	30014035	DOAJ Gold, Green Published			2019-10-28	
J	Cotta, CV; Chute, DJ; Theil, KS				Cotta, Claudiu V.; Chute, Deborah J.; Theil, Karl S.			Quantification of the Effectiveness of a Residency Program Using the Resident In-Service Examination	ACADEMIC PATHOLOGY			English	Article						RISE Exam; residency; effectiveness; education; measurement		This study describes a quantitative tool in the assessment of residency programs, in which national ranking of residents after the resident in-service examination in postgraduate year 4 is compared to that in postgraduate year 1. The relationship between training and changes in ranking, resident in-service examination results before and after training in specific areas are also compared. To illustrate the use of this novel approach, data from a large residency program were analyzed. The 70 residents were ranked as a postgraduate year 1 group at the 50th national percentile. As postgraduate year 4 residents, they were ranked at the 59th percentile, a significant (P < .003) improvement. There was moderate correlation between performance in postgraduate year 1 and that in postgraduate year 4 (0.61); however, initial ranking was no indication of the final (R-2 = .34), with the exception of high performers. Training in specific areas improved ranking, demonstrating association between training and performance. In conclusion, the effectiveness of training provided by a residency program can be quantified using the resident in-service examination. This should provide a quantitative tool in the assessment of postgraduate programs.	[Cotta, Claudiu V.; Chute, Deborah J.; Theil, Karl S.] Cleveland Clin, RJ Tomsich Pathol & Lab Med Inst, 9500 Euclid Ave,L-30, Cleveland, OH 44122 USA	Cotta, CV (reprint author), Cleveland Clin, RJ Tomsich Pathol & Lab Med Inst, 9500 Euclid Ave,L-30, Cleveland, OH 44122 USA.	cottac@ccf.org						0	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	JUN 26	2018	5								UNSP 2374289518781575	10.1177/2374289518781575			5	Pathology	Pathology	GM4BN	WOS:000438058400001	30014036	DOAJ Gold, Green Published			2019-10-28	
J	Albawardi, A; Quddus, MR; Al Awar, S; Almarzooqi, S				Albawardi, Alia; Quddus, M. Ruhul; Al Awar, Shamsa; Almarzooqi, Saeeda			Frequency of rare and multi viral high-risk HPV types infection in cervical high grade squamous intraepithelial lesions in a non-native dominant middle eastern country: a polymerase chain reaction-based pilot study	DIAGNOSTIC PATHOLOGY			English	Article						Cervical cancer; HPV; Papillomaviridae; UAE	HUMAN-PAPILLOMAVIRUS GENOTYPES; WOMEN; PREVALENCE; CYTOLOGY; CANCER; CHINA; SMEAR; UAE	Background: The incidence of abnormal cervical smears in the United Arab Emirates (UAE) is 3.6%. Data regarding specific high-risk HPV (hrHPV) genotypes are insufficient. Identification of hrHPV subtypes is essential to allow formulating effective vaccination strategies. Methods: A total of 75 archival cervical cone biopsies with HSIL or higher lesions (2012-2016) were retrieved from a tertiary hospital, including HSIL (n = 70), adenocarcinoma in-situ (n = 1) and squamous cell carcinoma (n = 4). Five tissue sections (10-mu-thick each) were cut and DNA extracted using the QIAamp DNA FFPE Tissue Kit. GenomeMeTM's GeneNavTM HPV One qPCR Kit was used for specific detection of HPV 16 and 18; and non-16/18 samples were typed by GenomeMeTM's GeneNavTM HPV Genotyping qPCR Kit. Results: Median age was 34 years (range 19-58) with 70% UAE Nationals. hrHPV detected were 16, 18, 31, 33, 35, 39, 45, 51, 52, 58, 59, 66 & 68. hrHPV testing was negative in 12% of cases. Most common types were HPV 16 (49%), HPV 31 (20%) and HPV 18 (6.6%). hrHPV 16 and/or 18 represented 56% and rare subtypes 32%. Co-infection was present in 16%. Eight cases had two-viral subtype infections and 4 cases had 3 subtype infections. Multi-viral HPV infection was limited to hrHPV 16, 18, 31 & 33 subtypes. Conclusions: Infection by non HPV 16/18 is fairly common. A higher than expected incidence of rare subtype (20% hrHPV31) and multi-viral hrHPV (16%) were detected. This finding stresses the importance of this pilot study as currently only quadravalent vaccine is offered to control the HPV infection in the UAE population.	[Albawardi, Alia; Almarzooqi, Saeeda] UAE Univ, Coll Med & Hlth Sci, Pathol Dept, Al Ain, U Arab Emirates; [Quddus, M. Ruhul] Brown Univ, Dept Pathol, Women & Infants Hosp Alpert Med, Providence, RI 02905 USA; [Al Awar, Shamsa] UAE Univ, Coll Med & Hlth Sci, Obstet & Gynecol Dept, Al Ain, U Arab Emirates	Almarzooqi, S (reprint author), UAE Univ, Coll Med & Hlth Sci, Pathol Dept, Al Ain, U Arab Emirates.	saeeda.almazooqi@uaeu.ac.ae			College of Medicine and Health Sciences, United Arab Emirates University [NP16-32]	This work was supported by the College of Medicine and Health Sciences, United Arab Emirates University [grant# NP16-32, 2016].	Al Eyd Ghaith J, 2012, Sultan Qaboos Univ Med J, V12, P473; Al-Awadhi R, 2013, DIAGN CYTOPATHOL, V41, P107, DOI 10.1002/dc.21778; AlObaid A, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0643-8; [Anonymous], IARC MONOGRAPHS, V90-7; Aziz H, 2018, INT J INFECT DIS, V66, P83, DOI 10.1016/j.ijid.2017.11.009; Bedoya-Pilozo CH, 2018, REV ARGENT MICROBIOL, V50, P136, DOI 10.1016/j.ram.2017.06.004; Bruni L, 2010, J INFECT DIS, V202, P1789, DOI 10.1086/657321; Castellsague X, 2016, PAPILLOMAVIRUS RES, V2, P61, DOI 10.1016/j.pvr.2016.03.002; Castle PE, 2016, EPIDEMIOL INFECT, V144, P449, DOI 10.1017/S0950268815002198; Eghbali SS, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-194; Fakhreldin M, 2016, VACCINE, V34, P823, DOI 10.1016/j.vaccine.2015.12.011; Ghazal-Aswad S, 2006, ACTA CYTOL, V50, P41, DOI 10.1159/000325893; Ghazal-Aswad Saad, 2006, J Low Genit Tract Dis, V10, P151, DOI 10.1097/00128360-200607000-00006; Ginindza TG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170189; Gultekin M, 2018, INT J CANCER, V142, P1952, DOI 10.1002/ijc.31212; Hajjaj AA, 2006, SAUDI MED J, V27, P487; Health Authority of Abu Dhabi, CERV CANC PREV DAT; Health statistics, 2015, HLTH STAT 2015; Hui Y, 2015, HUM PATHOL, V46, P1376, DOI 10.1016/j.humpath.2015.05.022; International Agency of Research on Cancer GLOBOCAN, 2008, GLOBOCAN INC MORT DA; Khoo SP, 2018, SEX TRANSM INFECT, V94, P276, DOI 10.1136/sextrans-2017-053320; Krishnan K, 2016, DIAGN CYTOPATHOL, V44, P91, DOI 10.1002/dc.23391; Li KM, 2017, ONCOTARGET, V8, P28502, DOI 10.18632/oncotarget.16093; Maqsood F, 2011, ANN KING EDWARD MED, V17, P256; Mijit F, 2015, J MED VIROL, V87, P1960, DOI 10.1002/jmv.24240; Monsonego J, 2015, GYNECOL ONCOL, V137, P47, DOI 10.1016/j.ygyno.2015.01.551; Montealegre JR, 2018, GYNECOL ONCOL, V148, P357, DOI 10.1016/j.ygyno.2017.12.014; Quddus MR, 2017, MODERN PATHOL, V30, p305A; Quddus MR, 2014, HUM PATHOL, V45, P303, DOI 10.1016/j.humpath.2013.07.048; Senapati R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187844; Skinner SR, 2016, EXPERT REV VACCINES, V15, P367, DOI 10.1586/14760584.2016.1124763; Stoler M, 2014, WHO CLASSIFICATION T, P189; Tsakogiannis D, 2015, ARCH VIROL, V160, P207, DOI 10.1007/s00705-014-2261-6	33	0	0	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	JUN 26	2018	13								42	10.1186/s13000-018-0716-x			8	Pathology	Pathology	GL2XI	WOS:000436989800002	29945637	DOAJ Gold, Green Published			2019-10-28	
J	Shen, XX; Jin, Y; Shen, L; Sun, YH; Chen, HQ; Li, Y				Shen, Xuxia; Jin, Yan; Shen, Lei; Sun, Yihua; Chen, Haiquan; Li, Yuan			Thymoma and thymic carcinoma associated with multilocular thymic cyst: a clinicopathologic analysis of 18 cases	DIAGNOSTIC PATHOLOGY			English	Article						Multilocular thymic cyst; Thymoma; Thymic carcinoma		Background: Multilocular thymic cysts (MTCs) associated with thymomas or thymic carcinomas (TCs) are rare and may be misdiagnosed as other benign cystic lesions. Methods: We retrospectively analysed 18 cases of thymomas or TCs associated with MTCs, which were retrieved from 309 consecutive patients with thymomas or TCs in the Chinese population, emphasizing clinicopathologic characteristics, immunophenotypes and the prognostic impact. Results: A total of 14 tumours were described as cystic or solid-cystic masses, and the other 4 tumours were described as solid masses. Histologically, 2 atypical type A, 2 type AB, 1 type B1, 8 type B2, 1 type B3, 1 microscopic thymoma (type A), 2 squamous cell carcinomas (SCCs) and 1 lymphoepithelioma-like carcinoma (LELC) were classified. Prominent multilocular cystic areas with chronic inflammation were observed. The follow-up ranged from 2 to 79 months. Sixteen patients survived without any evidence of recurrence after complete resection. Conclusions: Our study suggests that thymomas or TCs associated with MTCs are rare in the Chinese population and have a better clinical behaviour than thymomas or TCs without MTCs. Our data also expand the histologic spectrum of thymomas or TCs accompanied by MTC. To our knowledge, this is the first report of atypical type A thymoma and LELC associated with MTCs.	[Shen, Xuxia; Jin, Yan; Shen, Lei; Li, Yuan] Fudan Univ, Shanghai Canc Ctr, Dept Pathol, 270 Dong An Rd, Shanghai 200032, Peoples R China; [Sun, Yihua; Chen, Haiquan] Fudan Univ, Shanghai Canc Ctr, Dept Thorac Surg, Shanghai, Peoples R China; [Shen, Xuxia; Jin, Yan; Shen, Lei; Sun, Yihua; Chen, Haiquan; Li, Yuan] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China	Li, Y (reprint author), Fudan Univ, Shanghai Canc Ctr, Dept Pathol, 270 Dong An Rd, Shanghai 200032, Peoples R China.; Li, Y (reprint author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China.	lumoxuan2009@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81472173]	This work was funded by the National Natural Science Foundation of China (81472173).	Choi YW, 2001, AM J ROENTGENOL, V177, P881, DOI 10.2214/ajr.177.4.1770881; Elouazzani Hafsa, 2011, J Med Case Rep, V5, P225, DOI 10.1186/1752-1947-5-225; Endo Katsuhiko, 2014, Kyobu Geka, V67, P595; Hattori H, 2003, HISTOPATHOLOGY, V43, P501, DOI 10.1046/j.1365-2559.2003.01697.x; INDEGLIA RA, 1967, ARCH SURG-CHICAGO, V94, P149; Kim NR, 2013, KOREAN J PATHOL, V47, P392, DOI 10.4132/KoreanJPathol.2013.47.4.392; Liang SB, 1996, PATHOL RES PRACT, V192, P1283, DOI 10.1016/S0344-0338(96)80170-1; Marx A, 2014, J THORAC ONCOL, V9, P596, DOI 10.1097/JTO.0000000000000154; MORAN CA, 1995, AM J SURG PATHOL, V19, P826, DOI 10.1097/00000478-199507000-00011; MullerHermelink HK, 1997, PATHOL RES PRACT, V193, P531; Nakamura S, 2012, AM J SURG PATHOL, V36, P1857, DOI 10.1097/PAS.0b013e31826320c4; Singhal M, 2012, J THORAC DIS, V4, P512, DOI 10.3978/j.issn.2072-1439.2012.03.05; SUSTER S, 1992, CANCER-AM CANCER SOC, V69, P92, DOI 10.1002/1097-0142(19920101)69:1<92::AID-CNCR2820690117>3.0.CO;2-#; SUSTER S, 1991, AM J SURG PATHOL, V15, P388, DOI 10.1097/00000478-199104000-00008; Travis WD, 2015, WHO CLASSIFICATION T, P183; Weissferdt A, 2011, AM J SURG PATHOL, V35, P1074, DOI 10.1097/PAS.0b013e31821c7402	16	1	1	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	JUN 26	2018	13								41	10.1186/s13000-018-0719-7			7	Pathology	Pathology	GL2XI	WOS:000436989800001	29945642	DOAJ Gold, Green Published			2019-10-28	
J	Zhang, XW; Wang, HM; Li, Q; Liu, YP; Zhao, PQ; Li, T				Zhang, Xiaowei; Wang, Haiming; Li, Qian; Liu, Yunpeng; Zhao, Peiqing; Li, Tao			RETRACTION: Differences in the expression profiles of claudin proteins in human nasopharyngeal carcinoma compared with non-neoplastic mucosa (Retraction of Vol 13, art no 11, 2018)	DIAGNOSTIC PATHOLOGY			English	Retraction									[Zhang, Xiaowei; Zhao, Peiqing; Li, Tao] Shandong Univ, Ctr Translat Med, Cent Hosp Zibo, Gongqingtuan Rd 54Hao, Zibo, Shandong, Peoples R China; [Zhang, Xiaowei; Li, Qian; Zhao, Peiqing; Li, Tao] Shandong Univ, Dept Spinal Surg, Cent Hosp Zibo, Gongqingtuan Rd 54Hao, Zibo, Shandong, Peoples R China; [Wang, Haiming] Binzhou Med Coll, Dept Gen Surg, Peoples Hosp Linzi Dist, Zibo, Shandong, Peoples R China; [Liu, Yunpeng] Jilin Univ, Dept Thorac Surg, Hosp 1, Changchun, Jilin, Peoples R China	Li, T (reprint author), Shandong Univ, Ctr Translat Med, Cent Hosp Zibo, Gongqingtuan Rd 54Hao, Zibo, Shandong, Peoples R China.; Li, T (reprint author), Shandong Univ, Dept Spinal Surg, Cent Hosp Zibo, Gongqingtuan Rd 54Hao, Zibo, Shandong, Peoples R China.	zbszxyylitao@126.com					Zhang XW, 2018, DIAGN PATHOL, V13, DOI 10.1186/s13000-018-0685-0	1	0	0	1	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	JUN 25	2018	13								40	10.1186/s13000-018-0718-8			1	Pathology	Pathology	GL2XG	WOS:000436989600001	29940962	DOAJ Gold, Green Published			2019-10-28	
J	Kim, T; Khader, SN; Goldstein, DY				Kim, Teresa; Khader, Samer N.; Goldstein, D. Yitzchak			Educational Case: Cervical Neoplasia: HPV and Its Link to Cancer	ACADEMIC PATHOLOGY			English	Article						pathology competencies; disease mechanisms; HPV; human papillomavirus; cervical cancer; neoplasia; disease screening; PAP smear	AMERICAN SOCIETY; GUIDELINES; COLPOSCOPY; PATHOLOGY	The following fictional case is intended as a learning tool within the Pathology Competencies for Medical Education (PCME), a set of national standards for teaching pathology. These are divided into three basic competencies: Disease Mechanisms and Processes, Organ System Pathology, and Diagnostic Medicine and Therapeutic Pathology. For additional information, and a full list of learning objectives for all three competencies, see http://journals.sagepub.com/doi/10.1177/2374289517715040.	[Kim, Teresa; Khader, Samer N.; Goldstein, D. Yitzchak] Albert Einstein Coll Med, 1935 Eastchester Rd,Apt 10D, Bronx, NY 10461 USA	Kim, T (reprint author), Albert Einstein Coll Med, 1935 Eastchester Rd,Apt 10D, Bronx, NY 10461 USA.	tkim2@mail.einstein.yu.edu		Goldstein, D. Yitzchak/0000-0001-6367-8335			Arvin A, 2007, HUMAN HERPESVIRUSES: BIOLOGY, THERAPY, AND IMMUNOPROPHYLAXIS, P700; Darragh TM, 2012, ARCH PATHOL LAB MED, V136, P1266, DOI 10.5858/arpa.LGT200570; Massad LS, 2013, J LOW GENIT TRACT DI, V17, pS1, DOI 10.1097/LGT.0b013e318287d329; Saslow D, 2012, CA-CANCER J CLIN, V62, P147, DOI 10.3322/caac.21139; Sellors JW, 2003, CAN MED ASSOC J, V168, P421; Wilbur CD, 2015, BETHESDA SYSTEM REPO; Wilson JMG, 1968, PRINCIPLES PRACTICE; Wright TC, 2011, BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT, SIXTH EDITION, P193, DOI 10.1007/978-1-4419-0489-8_5	8	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	JUN 17	2018	5								UNSP 2374289518770651	10.1177/2374289518770651			6	Pathology	Pathology	GK0VX	WOS:000435831200001	29978016	DOAJ Gold, Green Published			2019-10-28	
J	Lau, RP; Yee-Chang, M; Rapkiewicz, A				Lau, Ryan P.; Yee-Chang, Melissa; Rapkiewicz, Amy			Educational Case: Head and Neck Neoplasia: Salivary Gland Tumors	ACADEMIC PATHOLOGY			English	Article						pathology competencies; organ system pathology; head and neck neoplasia; salivary gland tumor; warthin tumor; pleomorphic adenoma; mucoepidermoid carcinoma		The following fictional case is intended as a learning tool within the Pathology Competencies for Medical Education (PCME), a set of national standards for teaching pathology. These are divided into three basic competencies: Disease Mechanisms and Processes, Organ System Pathology, and Diagnostic Medicine and Therapeutic Pathology. For additional information, and a full list of learning objectives for all three competencies, see http://journals.sagepub.com/doi/10.1177/2374289517715040.	[Lau, Ryan P.; Yee-Chang, Melissa; Rapkiewicz, Amy] NYU, Sch Med, 550 1st Ave, New York, NY 10016 USA	Lau, RP (reprint author), NYU, Sch Med, 550 1st Ave, New York, NY 10016 USA.	Ryan.Lau@nyumc.org					Barnes L, 2005, WORLD HLTH ORG CLASS; Cibas ES, 2014, CYTOLOGY DIAGNOSTIC; EVESON JW, 1985, J PATHOL, V146, P51, DOI 10.1002/path.1711460106; National Comprehensive Cancer Network, HEAD NECK CANC VERS; Vinay K, 2015, ROBBINS COTRAN PATHO	5	1	1	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	JUN 17	2018	5								UNSP 2374289518770655	10.1177/2374289518770655			5	Pathology	Pathology	GK0VP	WOS:000435830400001	29978017	DOAJ Gold, Green Published			2019-10-28	
J	Segura, S; Ramos-Rivera, G; Suhrland, M				Segura, Sheila; Ramos-Rivera, Gloria; Suhrland, Mark			Educational Case: Endocrine Neoplasm: Medullary Thyroid Carcinoma	ACADEMIC PATHOLOGY			English	Article						pathology competencies; organ system pathology; endocrine neoplasms; medullary thyroid carcinoma; cytologic diagnosis; molecular basis; clinical features; pathologic features	BETHESDA SYSTEM; CANCER; GUIDELINES; MANAGEMENT	Medullary thyroid cancer is a rare neuroendocrine tumor that arises the neural crest-derived parafollicular C cells and accounts for approximately 5% to 10% of thyroid cancers worldwide. These tumor can occur sporadically or as part of hereditary tumor syndromes, such as multiple endocrine neoplasia 2 and familial medullary thyroid cancer. The most common clinical presentation is a solitary thyroid nodule. The genetic defect in these disorders involves the RET proto-oncogene which is important for diagnosis of medullary thyroid cancer (including screening for hereditary medullary thyroid cancer) and for treatment guidance. This review summarizes the molecular basis and clinicopathologic features of medullary thyroid carcinoma.	[Segura, Sheila; Ramos-Rivera, Gloria; Suhrland, Mark] Montefiore Hosp & Med Ctr, 111 East 210th St, Bronx, NY 10467 USA	Segura, S (reprint author), Montefiore Hosp & Med Ctr, 111 East 210th St, Bronx, NY 10467 USA.	ssegura@montefiore.org					Ball DW, 2007, ENDOCRIN METAB CLIN, V36, P823, DOI 10.1016/j.ecl.2007.04.001; Ganeshan D, 2013, AM J ROENTGENOL, V201, pW867, DOI 10.2214/AJR.12.10370; Mondal SK, 2013, J CYTOL, V30, P94, DOI 10.4103/0970-9371.112650; Nose V, 2011, MODERN PATHOL, V24, pS19, DOI 10.1038/modpathol.2010.147; Renuka IV, 2012, INDIAN J OTOLARYNGOL, V64, P305, DOI 10.1007/s12070-011-0289-4; Roy M, 2013, ONCOLOGIST, V18, P1093, DOI 10.1634/theoncologist.2013-0053; Tuttle M, 2017, UP TO DATE      0927; Wells SA, 2015, THYROID, V25, P567, DOI 10.1089/thy.2014.0335	8	1	1	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	JUN 17	2018	5								UNSP 2374289518775722	10.1177/2374289518775722			5	Pathology	Pathology	GK0VU	WOS:000435830900001	29978018	DOAJ Gold, Green Published			2019-10-28	
J	Kishore, M; Gupta, P; Ahuja, A; Rao, ASN; Bhardwaj, M				Kishore, Manjari; Gupta, Prajwala; Ahuja, Arvind; Rao, A. S. N.; Bhardwaj, Minakshi			Large retroperitoneal soft tissue tumor: A cytopathological diagnosis	CYTOJOURNAL			English	Editorial Material							LIPOSARCOMA		[Kishore, Manjari; Gupta, Prajwala; Ahuja, Arvind; Bhardwaj, Minakshi] Post Grad Inst Med Educ & Res, Dept Pathol, New Delhi, India; [Rao, A. S. N.] Post Grad Inst Med Educ & Res, Dept Surg, New Delhi, India; [Rao, A. S. N.] Dr RML Hosp, New Delhi, India	Gupta, P (reprint author), Post Grad Inst Med Educ & Res, Dept Pathol, New Delhi, India.	drmanjarik@gmail.com; prajwala2000@yahoo.com; drarvindahuja@gmail.com; drasnrao@gmail.com; minakshi.bh@gmail.com					Ben Moualli S, 2002, ANN UROL, V36, P372, DOI 10.1016/S0003-4401(02)00131-6; Cormier JN, 2004, CA-CANCER J CLIN, V54, P94, DOI 10.3322/canjclin.54.2.94; Dodd LG, 2015, DIAGN CYTOPATHOL, V43, P138, DOI 10.1002/dc.23148; Fletcher CD, 2002, PATHOLOGY GENETICS T; FLETCHER CDM, 1992, AM J SURG PATHOL, V16, P213, DOI 10.1097/00000478-199203000-00001; Guillou L, 2010, VIRCHOWS ARCH, V456, P201, DOI 10.1007/s00428-009-0853-4; Nijhuis PHA, 2000, ANN SURG ONCOL, V7, P535, DOI 10.1007/s10434-000-0535-6; Shoji T, 2009, GEN THORAC CARDIOVAS, V57, P159, DOI [10.1007/s11748-008-0329-5, 10.1007/s11748-009-0440-2]; Suster S, 1997, AM J SURG PATHOL, V21, P195, DOI 10.1097/00000478-199702000-00009	9	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	JUN 14	2018	15								14	10.4103/cytojournal.cytojournal_22_17			4	Pathology	Pathology	GT3IL	WOS:000444395000001	30034504	DOAJ Gold, Green Published			2019-10-28	
J	Monappa, V; Reddy, SM; Kudva, R				Monappa, Vidya; Reddy, Saritha M.; Kudva, Ranjini			Hematolymphoid neoplasms in effusion cytology	CYTOJOURNAL			English	Article						Effusion cytology; leukemia; lymphocyte-rich effusion; lymphoma	MARGINAL ZONE LYMPHOMA; NON-HODGKINS-LYMPHOMA; PLEURAL EFFUSION; FLOW-CYTOMETRY; CELL LYMPHOMA; DIAGNOSIS; SPECIMENS	Background: Hematolymphoid neoplasms (HLNs) presenting as body cavity effusions are not a common finding. They may be the first manifestation of the disease. A diagnosis on effusion cytology may provide an early breakthrough for effective clinical management. Aims: Study the cytomorphology of HLNs in effusion cytology, determine common types, sites involved and uncover useful cytomorphologic clues to subclassify them. Materials and Methods: Twenty-four biopsy-proven HLN cases with malignant body cavity effusions and 8 cases suspicious for HLN on cytology but negative on biopsy are included in this study. Effusion cytology smears were reviewed for cytomorphological features: cellularity, cell size, nuclear features, accompanying cells, karyorrhexis, and mitoses. Results: Diffuse large B-cell lymphoma (37%) was the most common lymphoma type presenting as effusion followed by peripheral T-cell lymphoma (25%). Pleural effusion (75%) was most frequent presentation followed by peritoneal effusion (20.8%). Pericardial effusion was rare (4.1%). The common cytologic features of HLNs in effusions: high cellularity, lymphoid looking cells with nuclear enlargement, dyscohesive nature, and accompanying small lymphocytes. Mitosis and karyorrhexis were higher in high-grade HLNs when compared to low-grade HLNs. Myelomatous effusion showed plasmacytoid cells. Very large, blastoid looking cells with folded nuclei, high N: C ratio, and prominent nucleoli were seen in leukemic effusion. Conclusion: HLNs have characteristic cytomorphology and an attempt to subclassify them should be made on effusion cytology. Reactive lymphocyte-rich effusions cannot be distinguished from low-grade lymphomas based on cytomorphology alone. Ancillary tests such as immunocytochemistry, flow cytometry, and/or molecular techniques may prove more useful in this regard.	[Monappa, Vidya; Kudva, Ranjini] Manipal Acad Higher Educ, Kasturba Med Coll, Dept Pathol, Manipal, Karnataka, India; [Reddy, Saritha M.] St Johns Med Coll, Dept Pathol, Bengaluru, Karnataka, India	Monappa, V (reprint author), Manipal Acad Higher Educ, Kasturba Med Coll, Dept Pathol, Manipal, Karnataka, India.	vidsdr@yahoo.co.in; sarithareddy1104@gmail.com; ranjakudva@yahoo.com					Ameri MD, 2016, J GASTROINTEST ONCOL, V7, pS96, DOI 10.3978/j.issn.2078-6891.2015.054; Berkman N, 1996, LEUKEMIA LYMPHOMA, V20, P229, DOI 10.3109/10428199609051612; Cakir E, 2011, CYTOJOURNAL, V8, DOI 10.4103/1742-6413.83026; Ceran F, 2009, YONSEI MED J, V50, P862, DOI 10.3349/ymj.2009.50.6.862; Chen HJ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000800; Chen L, 2015, ACTA CYTOL, V59, P485, DOI 10.1159/000443760; Chen YB, 2007, ONCOLOGIST, V12, P569, DOI 10.1634/theoncologist.12-5-569; Crapanzano JP, 2003, CANCER CYTOPATHOL, V99, P301, DOI 10.1002/cncr.11509; Das DK, 2006, DIAGN CYTOPATHOL, V34, P335, DOI 10.1002/dc.20432; Das DK, 1999, ACTA CYTOL, V43, P498, DOI 10.1159/000331109; Elis A, 1998, CANCER, V83, P1607, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1607::AID-CNCR16>3.3.CO;2-X; MANOHARAN A, 1979, THORAX, V34, P29, DOI 10.1136/thx.34.1.29; Meykler S, 2016, CYTOPATHOLOGY, V27, P70, DOI 10.1111/cyt.12240; Palmer HE, 2000, DIAGN CYTOPATHOL, V22, P147, DOI 10.1002/(SICI)1097-0339(20000301)22:3<147::AID-DC3>3.3.CO;2-Y; Raina S, 2008, J Assoc Physicians India, V56, P914; Sanchez SR, 2007, CYTOPATHOLOGIC DIAGN, P171; Shidham VB, 2007, CYTOPATHOLOGIC DIAGN, P55; Siderits Richard, 2006, Cytojournal, V3, P13, DOI 10.1186/1742-6413-3-13; Vejabhuti C, 2007, CYTOPATHOLOGIC DIAGN, P195; Wakely PE, 2002, MODERN PATHOL, V15, P944, DOI 10.1097/01.MP.0000024287.19070.96; Yu GH, 2014, DIAGN CYTOPATHOL, V42, P664, DOI 10.1002/dc.23106	21	1	1	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	JUN 14	2018	15								15	10.4103/cytojournal.cytojournal_48_17			5	Pathology	Pathology	GT3IL	WOS:000444395000002	30034505	DOAJ Gold, Green Published			2019-10-28	
J	Burns, KH; Borowitz, MJ; Carroll, KC; Gocke, CD; Hooper, JE; Amukele, T; Tobian, AAR; Valentine, A; Kahl, R; Rodas-Eral, V; Boitnott, JK; Jackson, JB; Sanfilippo, F; Hruban, RH				Burns, Kathleen H.; Borowitz, Michael J.; Carroll, Karen C.; Gocke, Christopher D.; Hooper, Jody E.; Amukele, Timothy; Tobian, Aaron A. R.; Valentine, Allen; Kahl, Rob; Rodas-Eral, Vanessa; Boitnott, John K.; Jackson, J. Brooks; Sanfilippo, Fred; Hruban, Ralph H.			The Evolution of Earned, Transparent, and Quantifiable Faculty Salary Compensation: The Johns Hopkins Pathology Experience	ACADEMIC PATHOLOGY			English	Article						academic relative value unit (RVU); performance-based incentive compensation (PBIC); research RVU (rRVU); faculty salary; Bonus/Supplement/Incentive (BSI) component	PRODUCTIVITY; MISSION; SYSTEM; MODEL	Faculty value equitable and transparent policies for determining salaries and expect their compensation to compare favorably to the marketplace. Academic institutions use compensation to recruit and retain talented faculty as well as to reward accomplishment. Institutions are therefore working to decrease salary disparities that appear arbitrary or reflect long-standing biases and to identify metrics for merit-based remuneration. Ours is a large academic pathology department with 97 tenure-track faculty. Faculty salaries are comprised of 3 parts (A + B + C). Part A is determined by the type of appointment and years at rank; part B recognizes defined administrative, educational, or clinical roles; and part C is a bonus to reward and incentivize activities that forward the missions of the department and medical school. A policy for part C allocations was first codified and approved by department faculty in 1993. It rewarded performance using a semiquantitative scale, based on subjective evaluations of the department director (chair) in consultation with deputy directors (vice chairs) and division directors. Faculty could not directly calculate their part C, and distributions data were not widely disclosed. Over the last 2 years (2015-2017), we have implemented a more objective formula for quantifying an earned part C, which is primarily designed to recognize scholarship in the form of research productivity, educational excellence, and clinical quality improvement. Here, we share our experience with this approach, reviewing part C calculations as made for individual faculty members, providing a global view of the resulting allocations, and considering how the process and outcomes reflect our values.	[Burns, Kathleen H.; Borowitz, Michael J.; Carroll, Karen C.; Gocke, Christopher D.; Hooper, Jody E.; Amukele, Timothy; Tobian, Aaron A. R.; Valentine, Allen; Kahl, Rob; Rodas-Eral, Vanessa; Boitnott, John K.; Hruban, Ralph H.] Johns Hopkins Univ, Sch Med, Dept Pathol, Miller Res Bldg,Room 447, Baltimore, MD 21205 USA; [Jackson, J. Brooks] Roy J & Lucille A Carver Coll Med, Iowa City, IA USA; [Sanfilippo, Fred] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	Burns, KH (reprint author), Johns Hopkins Univ, Sch Med, Dept Pathol, Miller Res Bldg,Room 447, Baltimore, MD 21205 USA.; Hruban, RH (reprint author), Johns Hopkins Univ, Sch Med, Dept Pathol, Carnegie 415,600 North Wolfe St, Baltimore, MD 21231 USA.	kburns@jhmi.edu; rhruban@jhmi.edu		jackson, brooks/0000-0001-9458-135X; Burns, Kathleen/0000-0003-1620-3761			Akl EA, 2012, CAN MED ASSOC J, V184, pE602, DOI 10.1503/cmaj.111123; [Anonymous], 2009, J ONCOL PRACT, V5, P86, DOI 10.1200/JOP.0922502; [Anonymous], 2011, SILV BOOK PROF DEV G, V34; Biostatistics Center BSoPH, 2016 REP JOHNS HOPK; Carr PL, 2015, J WOMENS HEALTH, V24, P190, DOI 10.1089/jwh.2014.4848; Holmes EW, 2000, ACAD MED, V75, P303; Howell LP, 2016, ACAD PATHOL, V3, DOI 10.1177/2374289515628024; Jena AB, 2016, JAMA INTERN MED, V176, P1294, DOI 10.1001/jamainternmed.2016.3284; Leverence R, 2017, ACAD MED, V92, P1133, DOI 10.1097/ACM.0000000000001484; McArthur J, 2015, JOHNS HOPKINS MED SC; MCHUGH PR, 1994, ACAD MED, V69, P877, DOI 10.1097/00001888-199411000-00003; Mezrich Reuben, 2007, J Am Coll Radiol, V4, P471; Price EG, 2009, ACAD MED, V84, P95, DOI 10.1097/ACM.0b013e3181900f29; Rand C, 2014, FINAL REPORT ACTIONS; Reece EA, 2008, ACAD MED, V83, P76, DOI 10.1097/ACM.0b013e31815c6508; Reich DL, 2008, ANESTH ANALG, V107, P1981, DOI 10.1213/ane.0b013e31818ca31c; Sakai T, 2013, BRIT J ANAESTH, V111, P636, DOI 10.1093/bja/aet150; Scoggins CR, 2013, J AM COLL SURGEONS, V217, P46, DOI 10.1016/j.jamcollsurg.2013.01.066; Severance HW, 2016, ACAD MED, V91, P9	19	1	1	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	JUN 11	2018	5								UNSP 2374289518777463	10.1177/2374289518777463			12	Pathology	Pathology	GK0VG	WOS:000435829500001	29978019	DOAJ Gold, Green Published			2019-10-28	
J	McGary, CT				McGary, Carl T.			Educational Case: Medullary Thyroid Carcinoma	ACADEMIC PATHOLOGY			English	Article						pathology competencies; organ system pathology; cytology diagnostic certainty; endocrine; endocrine neoplasms; fine needle aspiration cytology; medullary thyroid carcinoma	SYSTEM	The following fictional case is intended as a learning tool within the Pathology Competencies for Medical Education (PCME), a set of national standards for teaching pathology. These are divided into three basic competencies: Disease Mechanisms and Processes, Organ System Pathology, and Diagnostic Medicine and Therapeutic Pathology. For additional information, and a full list of learning objectives for all three competencies, see http://journals.sagepub.com/doi/10.1177/2374289517715040.	[McGary, Carl T.] Univ Minnesota, Med Sch Duluth, Dept Biomed Sci, 1035 Univ Dr,SMED 227, Duluth, MN 55812 USA	McGary, CT (reprint author), Univ Minnesota, Med Sch Duluth, Dept Biomed Sci, 1035 Univ Dr,SMED 227, Duluth, MN 55812 USA.	cmcgary@d.umn.edu		McGary, Carl/0000-0003-4625-3030			ABT AB, 1995, ARCH PATHOL LAB MED, V119, P514; Barkan GA, 2016, ACTA CYTOL, V60, P185, DOI 10.1159/000446270; Bracamonte E, 2016, ACAD PATHOL, V3, DOI 10.1177/2374289516659079; Cibas ES, 2009, AM J CLIN PATHOL, V132, P658, DOI 10.1309/AJCPPHLWMI3JV4LA; Franc B, 2003, HUM PATHOL, V34, P1092, DOI 10.1016/S0046-8177(03)00403-9; Lloyd RV, 2017, WHO CLASSIFICATION T, P108; Maitra A, 2015, ROBBINS COTRAN PATHO, P1136; Maitra A, 2015, ROBBINS COTRAN PATHO, P1099	8	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	JUN 11	2018	5								UNSP 2374289518770173	10.1177/2374289518770173			5	Pathology	Pathology	GK0VM	WOS:000435830100001	29978015	DOAJ Gold, Green Published			2019-10-28	
J	Liu, CY; Huang, SH				Liu, Chih-Yi; Huang, Shih-Hung			EBV-associated lymphoepithelioma-like thyroid carcinoma with favorable outcome: case report with cytopathologic and histopathologic study	DIAGNOSTIC PATHOLOGY			English	Article						Thyroid; Cytology; Lymphoepithelioma-like carcinoma; Epstein-Barr virus; EBER ISH	EPSTEIN-BARR-VIRUS; THYMUS-LIKE DIFFERENTIATION; NEOPLASMS; SURVIVAL; GLAND; TUMOR	Background: Lymphoepithelioma-like carcinoma (LELC) is a rare entity among thyroid tumors. Based on the limited number of case reports that exist, the association of Epstein-Barr virus (EBV) with primary thyroid LELCs seems inconsistent. Case presentation: We present a confusing cytological case of lymphoepithelioma-like thyroid carcinoma with expression of EBV. The patient presented with a central neck mass and bilateral lymphadenopathy. Fine-needle aspiration cytology revealed three-dimensional and syncytial fragments of epithelioid cells accompanied by small lymphocytes. The surgical specimen of resected thyroid tumor disclosed typical histopathological features of LELC. Metastatic papillary carcinoma was also discovered in the metastatic lymph nodes. In situ hybridization for EBV-encoded RNA (EBER-ISH) was positive in the tumor cells. Negative immunoreactivity for TTF-1, Pax-8, and CD5 was observed. The patient is currently undergoing regular follow-up and is 1 year and 10 months postresection with no evidence of recurrence. Conclusions: Long-term survival is discussed in relation to this variant of thyroid carcinoma, which might differ in behavior from anaplastic carcinoma. Further investigation is required to elucidate the clinical significance of EBV expression and progression of this unique variant of thyroid carcinoma.	[Liu, Chih-Yi] Sijhih Cathay Gen Hosp, Div Pathol, 2,Lane 59,Jiancheng Rd, New Taipei 22174, Taiwan; [Huang, Shih-Hung] Cathay Gen Hosp, Dept Pathol, Taipei, Taiwan; [Liu, Chih-Yi] Fu Jen Catholic Univ, Coll Med, New Taipei, Taiwan	Liu, CY (reprint author), Sijhih Cathay Gen Hosp, Div Pathol, 2,Lane 59,Jiancheng Rd, New Taipei 22174, Taiwan.; Liu, CY (reprint author), Fu Jen Catholic Univ, Coll Med, New Taipei, Taiwan.	cyl1124@gmail.com		Liu, Chih Yi/0000-0002-3996-8452			Castro CY, 2001, HUM PATHOL, V32, P863, DOI 10.1053/hupa.2001.26457; Deyrup AT, 2008, HUM PATHOL, V39, P473, DOI 10.1016/j.humpath.2007.10.030; Dominguez-Malagon H, 2001, Ann Diagn Pathol, V5, P21, DOI 10.1053/adpa.2001.21480; Hirokawa M, 2016, ENDOCR J, V63, P441, DOI 10.1507/endocrj.EJ15-0705; Hirokawa M, 2012, DIAGN CYTOPATHOL, V40, pE16, DOI 10.1002/dc.21511; Kakudo K, 2013, HISTOL HISTOPATHOL, V28, P543, DOI 10.14670/HH-28.543; Lloyd RV, 2017, WHO CLASSIFICATION T; Nemolato S, 2008, WORLD J GASTROENTERO, V14, P4694, DOI 10.3748/wjg.14.4694; Ragazzi M, 2014, INT J ENDOCRINOL, DOI 10.1155/2014/790834; Rathore R, 2017, DIAGN CYTOPATHOL, V45, P239, DOI 10.1002/dc.23629; Shek TWH, 1996, HUM PATHOL, V27, P851, DOI 10.1016/S0046-8177(96)90461-X; Shimakage M, 2003, HUM PATHOL, V34, P1170, DOI 10.1053/S0046-8177(03)00467-2; Shinozaki-Ushiku A, 2015, INT J ONCOL, V46, P1421, DOI 10.3892/ijo.2015.2856; Wang YF, 2015, AM J CLIN PATHOL, V143, P223, DOI 10.1309/AJCPB7PS6QHWEFRK; Xu B, 2017, HUM PATHOL, V65, P133, DOI 10.1016/j.humpath.2017.05.013; Yang AW, 2017, BMC UROL, V17, DOI 10.1186/s12894-017-0224-4; Zhao W, 2014, INT J CLIN EXP PATHO, V7, P7951	17	0	0	0	1	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	JUN 9	2018	13								39	10.1186/s13000-018-0713-0			5	Pathology	Pathology	GJ0DT	WOS:000434918700002	29885658	DOAJ Gold, Green Published			2019-10-28	
J	Nielsen, LAG; Bangso, JA; Lindahl, KH; Dahlrot, RH; Hjelmborg, JV; Hansen, S; Kristensen, BW				Nielsen, Ljudmilla A. G.; Bangso, Julie A.; Lindahl, Kim H.; Dahlrot, Rikke H.; Hjelmborg, Jacob van B.; Hansen, Steinbjorn; Kristensen, Bjarne W.			Evaluation of the proliferation marker Ki-67 in gliomas: Interobserver variability and digital quantification	DIAGNOSTIC PATHOLOGY			English	Article						Glioblastoma; Astrocytoma; Digital analysis; Whole slides; Labelling index	ISOCITRATE DEHYDROGENASE 1; MIB-1 LABELING INDEX; PROGNOSTIC VALUE; HUMAN ASTROCYTOMAS; CLINICAL-VALUE; GRADE GLIOMAS; KI67 INDEX; TUMORS; MENINGIOMAS; EXPRESSION	Background: The Ki-67 Labelling Index (LI) is used as an ancillary tool in glioma diagnostics. Interobserver variability has been reported and no precise guidelines are available. Nor is it known whether novel digital approaches would be an advantage. Our aim was to evaluate the inter-and intraobserver variability of the Ki-67 LI between two pathologists and between pathologists and digital quantification both in whole tumour slides and in hot spots using narrow but diagnostically relevant intervals. Methods: In samples of 235 low and high grade gliomas, two pathologists (A and B) estimated the Ki-67 LI (5-10% intervals) for whole tumour slides and for hot spots. In 20 of the cases intraobserver variability was evaluated. For digital quantification (C) slides were scanned with subsequent systematic random sampling of viable tumour areas. A software classifier trained to identify positive and negative nuclei calculated the Ki-67 LI. The interobserver agreements were evaluated using kappa (K) statistics. Results: The observed proportions of agreement and. values for Ki-67 LI for whole tumour slides were: A/B: 46% (K = 0.32); A/C: 37% (K = 0.26); B/C: 37% (K = 0.26). For hot spots equivalent values were: A/B: 14% (K = 0.04); A/C: 18% (K = 0. 09); B/C: 31% (K = 0.21). Conclusions: Interobserver variability was pronounced between pathologists and for pathologists versus digital quantification when attempting to estimate a precise value of the Ki-67 LI. Ki-67 LI should therefore be used with caution and should not be over interpreted in the grading of gliomas. Digital quantification of Ki-67 LI in gliomas was feasible, but intra-and interlaboratory robustness need to be determined.	[Nielsen, Ljudmilla A. G.; Bangso, Julie A.; Lindahl, Kim H.; Kristensen, Bjarne W.] Odense Univ Hosp, Dept Pathol, JB Winslows Vej 15,Entrance 240, DK-5000 Odense C, Denmark; [Nielsen, Ljudmilla A. G.] Hosp Southern Jutland Sygehus Sonderjylland, Dept Pathol, Kresten Philipsens Vej 15, DK-6200 Aabenraa, Denmark; [Dahlrot, Rikke H.; Hansen, Steinbjorn] Odense Univ Hosp, Dept Oncol, Sdr Blvd 29, DK-5000 Odense C, Denmark; [Hjelmborg, Jacob van B.] Univ Southern Denmark, Dept Publ Hlth Epidemiol Biostat & Biodemog, JB Winslows Vej 9,Entrance B,1st, DK-5000 Odense C, Denmark; [Hansen, Steinbjorn; Kristensen, Bjarne W.] Univ Southern Denmark, Dept Clin Res, JB Winslows Vej 15,Entrance 240, DK-5000 Odense C, Denmark	Nielsen, LAG; Kristensen, BW (reprint author), Odense Univ Hosp, Dept Pathol, JB Winslows Vej 15,Entrance 240, DK-5000 Odense C, Denmark.; Nielsen, LAG (reprint author), Hosp Southern Jutland Sygehus Sonderjylland, Dept Pathol, Kresten Philipsens Vej 15, DK-6200 Aabenraa, Denmark.; Kristensen, BW (reprint author), Univ Southern Denmark, Dept Clin Res, JB Winslows Vej 15,Entrance 240, DK-5000 Odense C, Denmark.	Ljudmilla.Nielsen@rsyd.dk; bjarne.winther.kristensen@rsyd.dk		Hjelmborg, Jacob/0000-0001-9630-9149; Hansen, Steinbjorn/0000-0001-5651-6493	Odense University Hospital Research Funds	Odense University Hospital Research Funds.	Amin MR, 2000, NEUROL RES, V22, P495; Berghoff AS, 2013, CLIN NEUROPATHOL, V32, P148, DOI 10.5414/NP300646; Coleman KE, 2006, APPL IMMUNOHISTO M M, V14, P109, DOI 10.1097/01.pai.0000144557.31747.b9; Dahlrot RH, 2014, INT J CLIN EXP PATHO, V7, P3739; Dahlrot RH, 2013, J NEURO-ONCOL, V115, P453, DOI 10.1007/s11060-013-1246-8; Dahlrot RH, 2013, J NEURO-ONCOL, V114, P309, DOI 10.1007/s11060-013-1186-3; Dahlrot RH, 2013, INT J CLIN EXP PATHO, V6, P31; Fisher BJ, 2002, INT J RADIAT ONCOL, V52, P996, DOI 10.1016/S0360-3016(01)02720-1; Gamer M, 2012, IRR VARIOUS COEFFICI; Grala B, 2009, FOLIA HISTOCHEM CYTO, V47, P587, DOI 10.2478/v10042-008-0098-0; Grzybicki DM, 2001, CANCER, V92, P2720, DOI 10.1002/1097-0142(20011115)92:10<2720::AID-CNCR1626>3.0.CO;2-Z; Hsu CY, 2003, MODERN PATHOL, V16, P951, DOI 10.1097/01.MP.0000084631.64279.BC; Johannessen AL, 2006, PATHOL ONCOL RES, V12, P143, DOI 10.1007/BF02893360; Kirkwood B., 2003, ESSENTIAL MED STAT; Lopez XM, 2012, CYTOM PART A, V81A, P765, DOI 10.1002/cyto.a.22085; Louis DN, 2016, WHO CLASSIFICATION T; Mittler MA, 1996, J NEUROSURG, V85, P1091, DOI 10.3171/jns.1996.85.6.1091; Music D, 2016, J NEURO-ONCOL, V127, P381, DOI 10.1007/s11060-015-2050-4; Nielsen LAG, 2015, CLIN NEUROPATHOL, V34, P157; Petterson SA, 2015, J NEURO-ONCOL, V122, P517, DOI 10.1007/s11060-015-1723-3; Prayson RA, 2005, ADV ANAT PATHOL, V12, P144, DOI 10.1097/01.pap.0000163957.21409.52; Prayson Richard A, 2003, Ann Diagn Pathol, V7, P9, DOI 10.1053/adpa.2003.50001; Preusser M, 2008, HISTOPATHOLOGY, V53, P39, DOI 10.1111/j.1365-2559.2008.03065.x; Preusser M, 2012, HISTOPATHOLOGY, V60, P885, DOI 10.1111/j.1365-2559.2011.04134.x; R Core Team, 2013, R LANG ENV STAT COMP; R Studio Team, 2015, RSTUDIO INT DEV R; Rathi K R, 2007, Indian J Pathol Microbiol, V50, P754; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Swiderska Z, 2015, ANAL CELL PATHOL AMS, V2015, DOI DOI 10.1155/2015/49874626240787; Torp SH, 2002, CLIN NEUROPATHOL, V21, P252; Vankalakunti M, 2007, NEUROPATHOLOGY, V27, P407, DOI 10.1111/j.1440-1789.2007.00801.x	31	2	2	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	JUN 9	2018	13								38	10.1186/s13000-018-0711-2			8	Pathology	Pathology	GJ0DT	WOS:000434918700001	29885671	DOAJ Gold, Green Published			2019-10-28	
J	Javier, R; Shaikh, N; Lesniak, MS; Sonabend, A; Stupp, R; Behdad, A; Horbinski, C				Javier, Rodrigo; Shaikh, Nawal; Lesniak, Maciej S.; Sonabend, Adam; Stupp, Roger; Behdad, Amir; Horbinski, Craig			B cell-rich non-neoplastic sentinel lesion preceding primary central nervous system lymphoma	DIAGNOSTIC PATHOLOGY			English	Article						Primary CNS lymphoma; Diffuse large B cell lymphoma; Sentinel lesion	AUTOIMMUNE	Background: Primary central nervous system lymphoma (PCNSL) is an uncommon tumoi in the brain. Although most PCNSL are readily diagnosed as diffuse large B cell lymphoma (DLBCL) on the first biopsy, very rare cases have been described in which the first detected intracerebral lesions are non-neoplastic, and are composed mostly of perivascular T cells, not B cells. This phenomenon is known as "sentinel lesions".	[Javier, Rodrigo; Lesniak, Maciej S.; Sonabend, Adam; Stupp, Roger; Horbinski, Craig] Northwestern Univ, Feinberg Sch Med, Dept Neurol Surg, Tam 2-705,300 East Super St, Chicago, IL 60611 USA; [Shaikh, Nawal] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA; [Behdad, Amir; Horbinski, Craig] Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA	Horbinski, C (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Neurol Surg, Tam 2-705,300 East Super St, Chicago, IL 60611 USA.; Horbinski, C (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA.	caig.horbinski@northwester.edu	Stupp, Roger/L-3303-2019	Horbinski, Craig/0000-0001-8340-9992			Alderson L, 1996, J NEUROL NEUROSUR PS, V60, P102, DOI 10.1136/jnnp.60.1.102; Baecklund E, 2014, SEMIN CANCER BIOL, V24, P61, DOI 10.1016/j.semcancer.2013.12.001; Brunn A, 2013, ACTA NEUROPATHOL, V126, P603, DOI 10.1007/s00401-013-1169-7; Camdessanche JP, 2011, EUR J NEUROL, V18, P929, DOI 10.1111/j.1468-1331.2010.03180.x; Dalmau J, 2014, NEURO-ONCOLOGY, V16, P771, DOI 10.1093/neuonc/nou030; Giannini C, 2014, J NEUROPATH EXP NEUR, V73, P478, DOI 10.1097/NEN.0000000000000076; Husseini L, 2012, CAN J NEUROL SCI, V39, P6, DOI 10.1017/S0317167100012610; Jahnke K, 2006, ANN NEUROL, V59, P755, DOI 10.1002/ana.20804; Jahnke K, 2005, BRIT J HAEMATOL, V128, P616, DOI 10.1111/j.1365-2141.2004.05361.x; Kuhlmann T, 2001, J NEUROL NEUROSURG P, V70; Kvarta MD, 2016, BMC NEUROL, V16, DOI [10.1186/s12883-12016-10596-12881, DOI 10.1186/S12883-12016-10596-12881]; Li R, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab4176; Lu JQ, 2016, WORLD NEUROSURG, V88, DOI 10.1016/j.wneu.2015.11.099; Ng S, 2007, J CLIN NEUROSCI, V14, P1126, DOI 10.1016/j.jocn.2006.05.003; Olmes DG, 2014, BMJ CASE REP, V2014, DOI 10.1136/bcr-202014-206825; Ostrom QT, 2015, NEURO-ONCOLOGY, V17, P1, DOI 10.1093/neuonc/nov189; Papanicolau-Sengos A, 2012, INT J CLIN EXP PATHO, V5, P89; Park I, 2008, CLIN LYMPHOMA MYELOM, V8, P305, DOI 10.3816/CLM.2008.n.043; Phillips EH, 2014, CURR HEMATOL MALIG R, V9, P243, DOI 10.1007/s11899-014-0217-2; Roschewski M, 2012, CANCER J, V18, P469, DOI 10.1097/PPO.0b013e31826c5e19; Taieb G, 2014, J NEUROL SCI, V344, P224, DOI 10.1016/j.jns.2014.06.015; Yamamoto J, 2014, ONCOL LETT, V7, P1835, DOI 10.3892/ol.2014.2033	22	0	0	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	JUN 5	2018	13								37	10.1186/s13000-018-0717-9			6	Pathology	Pathology	GI2KV	WOS:000434200000001	29871654	DOAJ Gold, Green Published			2019-10-28	
J	Lorenz, RG; Karcher, DS; Gautreaux, MD; Limson, M; Zander, DS				Lorenz, Robin G.; Karcher, Donald S.; Gautreaux, Michael D.; Limson, Melvin; Zander, Dani S.			The Pathology Workforce and Clinical Licensure: The Role of the PhD Clinical Laboratorian in the United States	ACADEMIC PATHOLOGY			English	Article						laboratorian; pathology and laboratory medicine workforce; PhD clinical scientists; postdoctoral training	MEDICINE	There has been a recent recognition of the need to prepare PhD-trained scientists for increasingly diverse careers in academia, industry, and health care. The PhD Data Task Force was formed to better understand the current state of PhD scientists in the clinical laboratory workforce and collect up-to-date information on the training and certification of these laboratorians. In this report, we summarize the findings of the PhD Data Task Force and discuss the relevance of the data collected to the future supply of and demand for PhD clinical laboratory scientists. It is clear that there are multiple career opportunities for PhD scientists in academic medical centers, commercial clinical laboratories, biotechnology and pharmaceutical companies, and the federal government. Certified PhD scientists have and will continue to form an important resource for our technologically advancing field, bringing training in scientific methods, and technologies needed for modern laboratory medicine. The data gathered by the PhD Data Task Force will be of great interest to current and future PhD candidates and graduate PhD scientists as they make decisions regarding future career directions.	[Lorenz, Robin G.] Univ Alabama Birmingham, Dept Pathol, 1825 Univ Blvd,SHEL 121C, Birmingham, AL 35294 USA; [Karcher, Donald S.] George Washington Univ, Dept Pathol, Washington, DC USA; [Gautreaux, Michael D.] Wake Forest Sch Med, Dept Pathol, Winston Salem, NC USA; [Limson, Melvin] Assoc Pathol Chairs, Wilmington, DE USA; [Zander, Dani S.] Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH USA	Lorenz, RG (reprint author), Univ Alabama Birmingham, Dept Pathol, 1825 Univ Blvd,SHEL 121C, Birmingham, AL 35294 USA.	rlorenz@uabmc.edu	Zander, Dani/W-1692-2019	Zander, Dani/0000-0002-9243-8354; Lorenz, Robinna/0000-0002-2514-9819			AAMC, 2017, US MED SCH FAC; [Anonymous], 2012, NIH ADVISORY COMMITT; ASHI, DIR TRAIN REV CRED; Blick KE, 2016, J APPL LAB MED, P97; Garcia E, 2015, AM J CLIN PATHOL, V144, P432, DOI 10.1309/AJCPN7G0MXMSTXCD; Johnson RL, 2016, 12 ANN AAMC HLTH WOR; Robboy SJ, 2015, ARCH PATHOL LAB MED, V139, P1413, DOI 10.5858/arpa.2014-0559-OA; Robboy SJ, 2013, ARCH PATHOL LAB MED, V137, P1723, DOI 10.5858/arpa.2013-0200-OA; Scott MG, 2007, CLIN LAB MED, V27, P435, DOI 10.1016/j.cll.2007.03.013; Smith BR, 2008, CLIN CHIM ACTA, V393, P5, DOI 10.1016/j.cca.2008.03.019; Straseski Joely A, 2013, EJIFCC, V24, P21; Tebo AE, 2014, AM J CLIN PATHOL, V142, P437, DOI 10.1309/AJCPX25MFWNEYRIG	12	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	JUN 4	2018	5								UNSP 2374289518775948	10.1177/2374289518775948			8	Pathology	Pathology	GI4BJ	WOS:000434315600001	29888322	DOAJ Gold, Green Published			2019-10-28	
J	Gilgenkrantz, H; de l'Hortet, AC				Gilgenkrantz, Helene; de l'Hortet, Alexandra Collin			Understanding Liver Regeneration From Mechanisms to Regenerative Medicine	AMERICAN JOURNAL OF PATHOLOGY			English	Review							CELL-DERIVED HEPATOCYTES; HEPATIC PROGENITOR CELLS; SYNDROME TYPE-I; STEM-CELLS; PARTIAL-HEPATECTOMY; MOUSE-LIVER; STEM/PROGENITOR CELLS; MATURE HEPATOCYTES; DUCTULAR REACTION; HUMAN FIBROBLASTS	Liver regeneration is a complex and unique process. When two-thirds of a mouse liver is removed, the remaining liver recovers its initial weight in approximately 10 days. The understanding of the mechanisms responsible for liver regeneration may help patients needing large liver resections or transplantation and may be applied to the field of regenerative medicine. All differentiated hepatocytes are capable of self-renewal, but different subpopulations of hepatocytes seem to have distinct proliferative abilities. In the setting of chronic liver diseases, a ductular reaction ensues in which liver progenitor cells (LPCs) proliferate in the periportal region. Although these LPCs have the capacity to differentiate into hepatocytes and biliary cells in vitro, their ability to participate in liver regeneration is far from clear. Their expansion has even been associated with increased fibrosis and poorer prognosis in chronic liver diseases. Controversies also remain on their origin: lineage studies in experimental mouse models of chronic injury have recently suggested that these LPCs originate from hepatocyte dedifferentiation, whereas in other situations, they seem to come from cholangiocytes. This review summarizes data published in the past 5 years in the liver regeneration field, discusses the mechanisms leading to regeneration disruption in chronic liver disorders, and addresses the potential use of novel approaches for regenerative medicine.	[Gilgenkrantz, Helene] Univ Paris Diderot, Sorbonne Paris Cite, Ctr Res Inflammat, INSERM U1149, Paris, France; [de l'Hortet, Alexandra Collin] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA	Gilgenkrantz, H (reprint author), Ctr Recherhe Inflammat, Fac Med, 16 Rue Huchard, F-75018 Paris, France.	helene.gilgenkrantz@inserm.fr	Gilgenkrantz, Helene/G-5534-2017; Collin de l'Hortet, Alexandra/D-6025-2016	Collin de l'Hortet, Alexandra/0000-0002-9437-7030			Aravinthan A, 2013, J HEPATOL, V58, P549, DOI 10.1016/j.jhep.2012.10.031; Boulter L, 2012, NAT MED, V18, P572, DOI 10.1038/nm.2667; Cai X, 2012, HEPATOLOGY, V56, P1804, DOI 10.1002/hep.25874; Camp JG, 2017, NATURE, V546, P533, DOI 10.1038/nature22796; Carpentier A, 2014, J CLIN INVEST, V124, P4953, DOI 10.1172/JCI75456; Carpino G, 2015, J HEPATOL, V63, P1220, DOI 10.1016/j.jhep.2015.06.018; Chen Y, 2015, STEM CELL REP, V5, P22, DOI 10.1016/j.stemcr.2015.04.017; Choi TY, 2014, GASTROENTEROLOGY, V146, P776, DOI 10.1053/j.gastro.2013.10.019; Collin de l'Hortet A, 2016, AM J TRANSPLANT, V16, P1688, DOI 10.1111/ajt.13678; Collin de l'Hortet A, 2014, ENDOCRINOLOGY, V155, P2545, DOI 10.1210/en.2014-1010; Dagher I, 2006, TRANSPLANTATION, V82, P1067, DOI 10.1097/01.tp.0000236103.99456.8f; Darwish A, 2004, LIVER TRANSPLANT, V10, P1213, DOI 10.1002/lt.20228; Ding BS, 2010, NATURE, V468, P310, DOI 10.1038/nature09493; Dubuquoy L, 2015, GUT, V64, P1949, DOI 10.1136/gutjnl-2014-308410; Espanol-Suner R, 2012, GASTROENTEROLOGY, V143, P1564, DOI 10.1053/j.gastro.2012.08.024; Espejel S, 2010, J CLIN INVEST, V120, P3120, DOI 10.1172/JCI43267; Fan FQ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2304; Font-Burgada J, 2015, CELL, V162, P766, DOI 10.1016/j.cell.2015.07.026; Forbes SJ, 2016, NAT REV GASTRO HEPAT, V13, P473, DOI 10.1038/nrgastro.2016.97; Fox IJ, 1998, NEW ENGL J MED, V338, P1422, DOI 10.1056/NEJM199805143382004; Gandhi CR, 2015, GASTROENTEROLOGY, V148, P379, DOI 10.1053/j.gastro.2014.10.008; Gentric G, 2015, J CLIN INVEST, V125, P981, DOI 10.1172/JCI73957; Gilgenkrantz H, 2011, CLIN RES HEPATOL GAS, V35, P623, DOI 10.1016/j.clinre.2011.04.002; Gilgenkrantz H, 2015, GUT, V64, P1351, DOI 10.1136/gutjnl-2014-308746; Gomez D, 2007, BRIT J SURG, V94, P1395, DOI 10.1002/bjs.5820; Gouw ASH, 2011, HEPATOLOGY, V54, P1853, DOI 10.1002/hep.24613; Hannoun Z, 2016, J HEPATOL, V65, P182, DOI 10.1016/j.jhep.2016.02.025; He JB, 2014, GASTROENTEROLOGY, V146, P789, DOI 10.1053/j.gastro.2013.11.045; Huang PY, 2014, CELL STEM CELL, V14, P370, DOI 10.1016/j.stem.2014.01.003; Huang PY, 2011, NATURE, V475, P386, DOI 10.1038/nature10116; Huch M, 2015, CELL, V160, P299, DOI 10.1016/j.cell.2014.11.050; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Inaba Y, 2015, HEPATOLOGY, V61, P1343, DOI 10.1002/hep.27619; Itoh T, 2016, HEPATOLOGY, V64, P663, DOI 10.1002/hep.28661; Jin JL, 2015, HEPATOLOGY, V61, P315, DOI 10.1002/hep.27295; Jorns C, 2016, AM J TRANSPLANT, V16, P1021, DOI 10.1111/ajt.13487; Katsuda T, 2017, CELL STEM CELL, V20, P41, DOI 10.1016/j.stem.2016.10.007; Kaur S, 2015, AM J PATHOL, V185, P2342, DOI 10.1016/j.ajpath.2015.06.004; Kele PG, 2013, LIVER INT, V33, P469, DOI 10.1111/liv.12089; Konishi Takanori, 2017, Gene Expression, V17, P277, DOI 10.3727/105221617X15042750874156; Kuboki S, 2008, HEPATOLOGY, V48, P1213, DOI 10.1002/hep.22471; Kuramitsu K, 2013, AM J PATHOL, V183, P182, DOI 10.1016/j.ajpath.2013.03.018; Kwon H, 2016, HEPATOLOGY, V63, P1155, DOI 10.1002/hep.28289; Lanzoni G, 2016, HEPATOLOGY, V64, P277, DOI 10.1002/hep.28326; Leclercq IA, 2003, GASTROENTEROLOGY, V124, P1451, DOI 10.1016/S0016-5085(03)00270-1; Liu HX, 2015, J HEPATOL, V63, P1502, DOI 10.1016/j.jhep.2015.08.001; Lu WY, 2015, NAT CELL BIOL, V17, P971, DOI 10.1038/ncb3203; Lukacs-Kornek V, 2017, J HEPATOL, V66, P619, DOI 10.1016/j.jhep.2016.10.033; Malato Y, 2011, J CLIN INVEST, V121, P4850, DOI 10.1172/JCI59261; Michalopoulos GK, 2017, HEPATOLOGY, V65, P1384, DOI 10.1002/hep.28988; Miyajima A, 2014, CELL STEM CELL, V14, P561, DOI 10.1016/j.stem.2014.04.010; Miyaoka Y, 2012, CURR BIOL, V22, P1166, DOI 10.1016/j.cub.2012.05.016; Nejak-Bowen KN, 2011, SEMIN CANCER BIOL, V21, P44, DOI 10.1016/j.semcancer.2010.12.010; Ochoa B, 2010, HEPATOLOGY, V51, P1712, DOI 10.1002/hep.23525; Padrissa-Altes S, 2015, GUT, V64, P1444, DOI 10.1136/gutjnl-2014-307874; Paranjpe S, 2016, HEPATOLOGY, V64, P1711, DOI 10.1002/hep.28721; Patel SH, 2017, GASTROENTEROLOGY, V152, P533, DOI 10.1053/j.gastro.2016.10.047; Pean N, 2013, HEPATOLOGY, V58, P1451, DOI 10.1002/hep.26463; Planas-Paz L, 2016, NAT CELL BIOL, V18, P467, DOI 10.1038/ncb3337; Pu WJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13369; Puppi J, 2012, CELL TRANSPLANT, V21, P1, DOI 10.3727/096368911X566208; Raven A, 2017, NATURE, V547, P350, DOI 10.1038/nature23015; Reid LM, 2015, HEPATOLOGY, V62, P330, DOI 10.1002/hep.27917; Richardson MM, 2007, GASTROENTEROLOGY, V133, P80, DOI 10.1053/j.gastro.2007.05.012; Sancho-Bru P, 2012, HEPATOLOGY, V55, P1931, DOI 10.1002/hep.25614; Schaub JR, 2014, CELL REP, V8, P933, DOI 10.1016/j.celrep.2014.07.003; Shin S, 2015, GASTROENTEROLOGY, V148, P192, DOI 10.1053/j.gastro.2014.09.039; Soltys KA, 2010, J HEPATOL, V53, P769, DOI 10.1016/j.jhep.2010.05.010; Stevens KR, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah5505; Stueck AE, 2015, HEPATOLOGY, V61, P1696, DOI 10.1002/hep.27706; Swiderska-Syn M, 2016, HEPATOLOGY, V64, P232, DOI 10.1002/hep.28542; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tarlow BD, 2014, CELL STEM CELL, V15, P605, DOI 10.1016/j.stem.2014.09.008; Truant S, 2013, ANN SURG, V258, P696, DOI 10.1097/SLA.0b013e3182a61a22; Uriarte I, 2013, GUT, V62, P899, DOI 10.1136/gutjnl-2012-302945; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Wahlstrom A, 2016, CELL METAB, V24, P41, DOI 10.1016/j.cmet.2016.05.005; Wang B, 2015, NATURE, V524, P180, DOI 10.1038/nature14863; Williams MJ, 2014, GASTROENTEROLOGY, V146, P349, DOI 10.1053/j.gastro.2013.11.034; Xu Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1058; Yamanouchi K, 2009, HEPATOLOGY, V49, P258, DOI 10.1002/hep.22573; Yanger K, 2014, CELL STEM CELL, V15, P340, DOI 10.1016/j.stem.2014.06.003; Yimlamai D, 2014, CELL, V157, P1324, DOI 10.1016/j.cell.2014.03.060; Yu B, 2013, CELL STEM CELL, V13, P328, DOI 10.1016/j.stem.2013.06.017; Zhang LS, 2012, HEPATOLOGY, V56, P2336, DOI 10.1002/hep.25905; Zhu SY, 2014, NATURE, V508, P93, DOI 10.1038/nature13020	86	13	13	1	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUN	2018	188	6					1316	1327		10.1016/j.ajpath.2018.03.008			12	Pathology	Pathology	GH6BM	WOS:000433524800001	29673755	Bronze			2019-10-28	
J	van Hummel, A; Chan, G; van der Hoven, J; Morsch, M; Ippati, S; Suh, L; Bi, M; Asih, PR; Lee, WS; Butler, TA; Przybyla, M; Halliday, GM; Piguet, O; Kiernan, MC; Chung, RS; Ittner, LM; Ke, YD				van Hummel, Annika; Chan, Gabriella; van der Hoven, Julia; Morsch, Marco; Ippati, Stefania; Suh, Lisa; Bi, Mian; Asih, Prita R.; Lee, Wei S.; Butler, Troy A.; Przybyla, Magdalena; Halliday, Glenda M.; Piguet, Olivier; Kiernan, Matthew C.; Chung, Roger S.; Ittner, Lars M.; Ke, Yazi D.			Selective Spatiotemporal Vulnerability of Central Nervous System Neurons to Pathologic TAR DNA-Binding Protein 43 in Aged Transaenic Mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; FRONTOTEMPORAL LOBAR DEGENERATION; EXTENDS LIFE-SPAN; TRANSGENIC MICE; MOUSE MODEL; HEXANUCLEOTIDE REPEAT; GAIT ABNORMALITIES; TDP-43 MICE; DISEASE; ALS	Amyotrophic lateral sclerosis (ALS) is a rapidly progressing and fatal disease characterized by muscular atrophy because of loss of upper and lower motor neurons. Histopathologically, most patients with ALS have abnormal cytoplasmic accumulation and aggregation of the nuclear RNA-regulating protein TAR DNA-binding protein 43 (TDP-43). Pathogenic mutations in the TARDBP gene that encode TDP-43 have been identified in familial ALS. We have previously reported transgenic mice with neuronal expression of human TDP-43 carrying the pathogenic A315T mutation (iTDP-43(A315T) mice), presenting with early-onset motor deficits in adolescent animals. Here, we analyzed aged iTDP-43(A315T) mice, focusing on the spatiotemporal profile and progression of neurodegeneration in upper and Lower motor neurons. Magnetic resonance imaging and histologic analysis revealed a differential loss of upper motor neurons in a hierarchical order as iTDP-43(A315T) mice aged. Furthermore, we report progressive gait problems, profound motor deficits, and muscle atrophy in aged iTDP-43(A315T) mice. Despite these deficits and TDP-43 pathologic disorders in lower motor neurons, stereological analysis did not show cell loss in spinal cords. Taken together, neuronal populations in aging iTDP-43(A315T) mice show differential susceptibility to the expression of human TOP-43(A315T).	[van Hummel, Annika; Chan, Gabriella; Lee, Wei S.; Butler, Troy A.; Ke, Yazi D.] Univ New South Wales, Fac Med, Sch Med Sci, Dept Anat,Motor Neuron Dis Unit, Sydney, NSW, Australia; [van der Hoven, Julia; Ippati, Stefania; Suh, Lisa; Bi, Mian; Asih, Prita R.; Przybyla, Magdalena; Ittner, Lars M.] Univ New South Wales, Fac Med, Sch Med Sci, Dept Anat,Dementia Res Unit, Sydney, NSW, Australia; [Morsch, Marco; Chung, Roger S.] Macquarie Univ, Fac Med & Hlth Sci, Dept Biomed Sci, Sydney, NSW, Australia; [Halliday, Glenda M.; Piguet, Olivier; Kiernan, Matthew C.] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia; [Halliday, Glenda M.] Univ Sydney, Cent Clin Sch, Sydney, NSW, Australia; [Piguet, Olivier] Univ Sydney, Sch Psychol, Sydney, NSW, Australia; [Piguet, Olivier] ARC Ctr Excellence Cognit & Its Disorders, Sydney, NSW, Australia; [Ittner, Lars M.] Neurosci Res Australia, Sydney, NSW, Australia	Ke, YD (reprint author), Univ New South Wales, Motor Neuron Dis Unit, Room 232,Level 2,Wallace Wurth Bldg, Sydney, NSW 2052, Australia.	yazi.ke@unsw.edu.au	; Piguet, Olivier/C-9658-2011	Ittner, Lars/0000-0001-6738-3825; Morsch, Marco/0000-0001-9484-8050; Asih, Prita Riana/0000-0002-1973-9628; Piguet, Olivier/0000-0002-6696-1440; van Hummel, Annika/0000-0001-5192-6434; Chan, Gabriella/0000-0001-7526-4412; Chung, Roger/0000-0002-9286-947X; Ke, Yazi/0000-0002-1423-0451	Australian National Health & Medical Research Council (NHMRC)National Health and Medical Research Council of Australia [1037746, 1081916, 1132524, 1143848, 1095215, 1143978]; Australian Research CouncilAustralian Research Council [DP150104321, DP170100781, DP170100843]; Motor Neurone Disease Australia [GIA1824]; University of New South Wales; NHMRC R.D. Wright Biomedical Fellow grant [1123564]; NHMRC Senior Research Fellow grant [1103258]; NHMRC Principal Research Fellow grantNational Health and Medical Research Council of Australia [1136241]	Supported by Australian National Health & Medical Research Council (NHMRC) grants 1037746 (L.M.I., G.M.H., and M.C.K.), 1081916 (L.M.I.), 1132524 (L.M.I., G.M.H., M.C.K., and O.P.), 1143848 (Y.D.K.), 1095215 (R.S.C.), and 1143978 (Y.D.K.); Australian Research Council grants DP150104321 (Y.D.K.), DP170100781 (L.M.I.), and DP170100843 (L.M.I.); Motor Neurone Disease Australia grant GIA1824 (L.M.I.); the University of New South Wales; NHMRC R.D. Wright Biomedical Fellow grant 1123564 (Y.D.K.); NHMRC Senior Research Fellow grant 1103258 (O.P.); and NHMRC Principal Research Fellow grant 1136241 (L.M.I.).	Becker LA, 2017, NATURE, V544, P367, DOI 10.1038/nature22038; Broeck LV, 2014, TRENDS MOL MED, V20, P66, DOI 10.1016/j.molmed.2013.11.003; Buratti E, 2001, J BIOL CHEM, V276, P36337, DOI 10.1074/jbc.M104236200; Burrell JR, 2016, LANCET, V388, P919, DOI 10.1016/S0140-6736(16)00737-6; Cannon A, 2012, ACTA NEUROPATHOL, V123, P807, DOI 10.1007/s00401-012-0979-3; D'Alton S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086513; DeJesus-Hernandez M, 2011, NEURON, V72, P245, DOI 10.1016/j.neuron.2011.09.011; Delerue F, 2015, CLON TRANSGEN, V4, P135; Delerue F, 2014, TRANSGENIC RES, V23, P225, DOI 10.1007/s11248-013-9767-7; Ferfoglia RI, 2016, EUR NEUROL, V75, P109, DOI 10.1159/000444052; Fogarty MJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep37968; Handley EE, 2017, CEREB CORTEX, V27, P3630, DOI 10.1093/cercor/bhw185; Igaz LM, 2011, J CLIN INVEST, V121, P726, DOI 10.1172/JCI44867; Igaz LM, 2009, J BIOL CHEM, V284, P8516, DOI 10.1074/jbc.M809462200; Iguchi Y, 2016, BRAIN, V139, P3187, DOI 10.1093/brain/aww237; Ittner A, 2016, SCIENCE, V354, P904, DOI 10.1126/science.aah6205; Josephs KA, 2014, ACTA NEUROPATHOL, V127, P441, DOI 10.1007/s00401-013-1211-9; Kabashi E, 2008, NAT GENET, V40, P572, DOI 10.1038/ng.132; Ke YD, 2015, ACTA NEUROPATHOL, V130, P661, DOI 10.1007/s00401-015-1486-0; Mancuso R, 2011, BRAIN RES, V1406, P65, DOI 10.1016/j.brainres.2011.06.033; Moon Y, 2016, HUM MOVEMENT SCI, V47, P197, DOI 10.1016/j.humov.2016.03.010; Morsch M, 2012, EXP NEUROL, V237, P286, DOI 10.1016/j.expneurol.2012.06.034; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Ramirez-Jarquin UN, 2018, ACS CHEM NEUROSCI, V9, P211, DOI 10.1021/acschemneuro.7b00503; Perera ND, 2016, HUM MOL GENET, V25, P4080, DOI 10.1093/hmg/ddw247; Radovanovic S, 2014, AMYOTROPH LAT SCL FR, V15, P488, DOI 10.3109/21678421.2014.918148; Renton AE, 2011, NEURON, V72, P257, DOI 10.1016/j.neuron.2011.09.010; Roberson ED, 2012, ANN NEUROL, V72, P837, DOI 10.1002/ana.23722; Schludi MH, 2017, ACTA NEUROPATHOL, V134, P241, DOI 10.1007/s00401-017-1711-0; Spiller KJ, 2016, J NEUROSCI, V36, P7707, DOI 10.1523/JNEUROSCI.1457-16.2016; Ullmann JFP, 2013, NEUROIMAGE, V78, P196, DOI 10.1016/j.neuroimage.2013.04.008; Van Deerlin VM, 2008, LANCET NEUROL, V7, P409, DOI 10.1016/S1474-4422(08)70071-1; van Eersel J, 2015, NEUROPATH APPL NEURO, V41, P906, DOI 10.1111/nan.12233; van Hummel A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163236; Vergouts M, 2015, METAB BRAIN DIS, V30, P1369, DOI 10.1007/s11011-015-9706-9; Walker AK, 2015, HUM MOL GENET, V24, P7241, DOI 10.1093/hmg/ddv424; Walker AK, 2015, ACTA NEUROPATHOL, V130, P643, DOI 10.1007/s00401-015-1460-x; Wang WZ, 2016, NAT MED, V22, P869, DOI 10.1038/nm.4130; Wegorzewska I, 2009, P NATL ACAD SCI USA, V106, P18809, DOI 10.1073/pnas.0908767106; Wils H, 2010, P NATL ACAD SCI USA, V107, P3858, DOI 10.1073/pnas.0912417107; Winton MJ, 2008, J BIOL CHEM, V283, P13302, DOI 10.1074/jbc.M800342200; Xia Y, 2016, MED BIOL ENG COMPUT, V54, P1399, DOI 10.1007/s11517-015-1413-5; Xu YF, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-73	43	1	1	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUN	2018	188	6					1447	1456		10.1016/j.ajpath.2018.03.002			10	Pathology	Pathology	GH6BM	WOS:000433524800011	29577934				2019-10-28	
J	Agrawal, U; Kumari, N; Vasudeva, P; Mohanty, NK; Saxena, S				Agrawal, Usha; Kumari, Nitu; Vasudeva, Pawan; Mohanty, Nayan K.; Saxena, Sunita			Overexpression of COX2 indicates poor survival in urothelial bladder cancer	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						COX2; Urothelial bladder cancer	CYCLOOXYGENASE-2 COX-2; STROMA COMPARTMENTS; TUMOR; EXPRESSION; RECURRENCE; INFLAMMATION; PROGRESSION; INHIBITORS; NEOPLASM; CELLS	Background: COX2 is a cyclo-oxygenase enzyme expressed in the tumor cells, inflammatory cells, stromal and non-epithelial cells. The study was conducted to evaluate the expression of COX2 in Urothelial carcinoma and find the association with progression and recurrence. Methods: The expression of COX2 was evaluated by real-time PCR and immunohistochemistry. Results: Gene expression of COX2 was found to be upregulated > 28-fold in urothelial cancer compared to adjacent normal bladder mucosa. Inflammatory cell expression of COX2 was found in 92% cases whereas only 37% cases showed COX2 overexpression in tumor cells. Tumor cell COX2 overexpression was significantly associated with invasion and recurrence. Conclusion: COX2 expression is a marker of invasion, recurrence and poor survival and may have a role in predicting the cases which will benefit from additional treatment with COX2 inhibitors in urothelial carcinoma.	[Agrawal, Usha; Kumari, Nitu; Saxena, Sunita] Indian Council Med Res, Natl Inst Pathol, New Delhi 110029, India; [Agrawal, Usha] Symbiosis Int Univ, Fac Hlth & Biomed Sci, Pune 412115, Maharashtra, India; [Kumari, Nitu] BITS, Pilani, Rajasthan, India; [Vasudeva, Pawan] VMMC & Safdarjung Hosp, Dept Urol, New Delhi 110029, India; [Mohanty, Nayan K.] Saket City Hosp, Press Enclave Rd, New Delhi 110017, India	Saxena, S (reprint author), Indian Council Med Res, Natl Inst Pathol, New Delhi 110029, India.	uagrawal@instpath.gov.in; sunita_saxena@yahoo.com			Indian Council of Medical ResearchIndian Council of Medical Research [53/4/2008-BMS]	The authors would like to acknowledge the Indian Council of Medical Research (53/4/2008-BMS) for financial support.	Allaj V, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-8; Asting AG, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-238; Cohen BL, 2006, INT J CANCER, V119, P1082, DOI 10.1002/ijc.21749; Czachorowski MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045025; Ferrandina G, 2004, CLIN CANCER RES, V10, P3117, DOI 10.1158/1078-0432.CCR-1090-3; Ferrandina G, 2002, ANN ONCOL, V13, P1205, DOI 10.1093/annonc/mdf207; Ferrandina G, 2002, BRIT J CANCER, V87, P1145, DOI 10.1038/sj.bjc.6600578; Fiebich BL, 2000, J NEUROCHEM, V75, P2020, DOI 10.1046/j.1471-4159.2000.0752020.x; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; HENEY NM, 1992, UROL CLIN N AM, V19, P429; Hill R, 2012, MOL CANCER THER, V11, P2127, DOI 10.1158/1535-7163.MCT-12-0342; Jana D, 2014, INDIA J SURG ONCOL, V5, P59, DOI 10.1007/s13193-014-0290-y; Jimenez RE, 2000, AM J SURG PATHOL, V24, P980, DOI 10.1097/00000478-200007000-00009; Kim MJ, 2014, MOL CELLS, V37, P759, DOI 10.14348/molcells.2014.0232; Kurtova AV, 2015, NATURE, V517, P209, DOI 10.1038/nature14034; Kuwano T, 2004, FASEB J, V18, P300, DOI 10.1096/fj.03-0473com; Lebret T, 2000, J UROLOGY, V163, P63, DOI 10.1016/S0022-5347(05)67973-6; Maxwell JP, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0234-z; McDougal WS, 2011, DEVITA HELLMAN ROSEN, P1192; Michalowski J, 2002, J NATL CANCER I, V94, P248, DOI 10.1093/jnci/94.4.248; Okajima E, 2003, AKTUEL UROL, V34, P256; Pasin Erik, 2008, Rev Urol, V10, P31; Ploeg M, 2009, WORLD J UROL, V27, P289, DOI 10.1007/s00345-009-0383-3; Roelofs HMJ, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-1; Sauter G, 2004, WHO CLASSIFICATION T, P110; Singh B, 2005, INT J ONCOL, V26, P1393; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Tokgoz Husnu, 2007, Int. braz j urol., V33, P777, DOI 10.1590/S1677-55382007000600005; Tomozawa S, 2000, BRIT J CANCER, V83, P324, DOI 10.1054/bjoc.2000.1270; Vogel LK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105254; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Xu XC, 2002, ANTI-CANCER DRUG, V13, P127, DOI 10.1097/00001813-200202000-00003; Zhang XK, 2015, INT J CLIN EXP PATHO, V8, P5549; Zlotta AR, 2000, EUR UROL, V37, P470, DOI 10.1159/000020170	36	3	3	2	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						50	55		10.1016/j.anndiagpath.2018.01.008			6	Pathology	Pathology	GL1VO	WOS:000436900200009	29661728				2019-10-28	
J	Leo, C; Cotic, C; Pomp, V; Fink, D; Varga, Z				Leo, Cornelia; Cotic, Christine; Pomp, Victoria; Fink, Daniel; Varga, Zsuzsanna			Overexpression of Lox in triple-negative breast cancer	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Intrinsic subtypes; Breast cancer; Epithelial-mesenchymal transition	EPITHELIAL-MESENCHYMAL TRANSITION; LYSYL OXIDASE; STEM-CELLS; EXPRESSION; SNAIL; GENE; EMT	Background: Triple negative breast cancer (TNBC) accounts for approximately 15% of breast cancers. It is associated with a poor prognosis and typically earlier onset of metastasis in comparison with other breast cancer subtypes. Since TNBC lacks the expression of estrogen and progesterone receptors and Her2 status is also negative, there is currently no target that can be used for systemic therapy. Epithelial-mesenchymal transition (EMT) plays an important role in tumor progression and metastasis. In this study, we examined a subset of EMT markers consisting of Snail, Twist-1 and Lox in TNBC and non-TNBC breast cancer subtypes and analyzed their expression pattern in regard to subtype, clinico-pathological parameters and prognosis. Experimental design: We analyzed 659 breast cancer samples from two tissue microarrays. Breast cancer samples were categorized into two groups according to hormone receptor expression and Her2 status (n = 146 were triple negative, n = 513 were non triple-negative). Immunohistochemical expression of Snail, Twist-1 and Lox was semi-quantitatively analyzed using a three-tiered (weak-moderate-strong) scoring system. Results were statistically analyzed and correlated to clinico-pathological parameters and overall survival. Results: Strong overexpression of Lox was significantly higher in triple negative breast cancers when compared to non triple-negative breast cancers (p < 0.001). No difference was seen between the groups regarding Snail and Twist expression (p > 0.05). In addition, Lox expression was significantly stronger in poorly differentiated (G3) breast cancers (p < 0.001 for Lox). Conclusions: The EMT marker Lox has a differential expression pattern in breast cancer, being significantly overexpressed in triple negative breast cancers. We could not link this expression to prognosis, however, this marker might be explored in future studies as possible target for systemic therapy of TNBC.	[Leo, Cornelia] Kantonsspital Baden, Dept Gynecol, CH-5404 Baden, Switzerland; [Cotic, Christine; Fink, Daniel] Univ Hosp Zurich, Dept Gynecol, CH-8010 Zurich, Switzerland; [Pomp, Victoria; Varga, Zsuzsanna] Univ Hosp Zurich, Dept Pathol & Molecularpathol, CH-8010 Zurich, Switzerland	Leo, C (reprint author), Kantonsspital Baden, Dept Gynecol, CH-5404 Baden, Switzerland.	cornelia.leo@ksb.ch; christine.cotic@usz.ch; daniel.fink@usz.ch; zsuzsanna.varga@usz.ch			Julius-Miiller-Stiftung, Switzerland	Funding was received from the Julius-Miiller-Stiftung, Switzerland.	Alkatout I, 2013, EXP MOL PATHOL, V94, P168, DOI 10.1016/j.yexmp.2012.09.003; Bailey CK, 2012, J BIOL CHEM, V287, P19472, DOI 10.1074/jbc.M112.345728; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; El-Haibi CP, 2012, P NATL ACAD SCI USA, V109, P17460, DOI 10.1073/pnas.1206653109; Erler JT, 2006, CANCER RES, V66, P10238, DOI 10.1158/0008-5472.CAN-06-3197; Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Erler JT, 2005, BREAST CANC RES S2, V7; Granados-Principal S, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0527-x; Ito M, 2016, BREAST CANCER-TOKYO, V23, P437, DOI 10.1007/s12282-015-0583-1; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; Kallergi G, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2896; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Le QT, 2009, J CLIN ONCOL, V27, P4281, DOI 10.1200/JCO.2008.20.6003; Li LN, 2015, PHARMACOL THERAPEUT, V150, P33, DOI 10.1016/j.pharmthera.2015.01.004; Markiewicz A, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-226; McShane LM, 2005, NAT CLIN PRACT ONCOL, V2, P416, DOI 10.1038/ncponc0252; Mimeault M, 2014, CANCER EPIDEM BIOMAR, V23, P234, DOI 10.1158/1055-9965.EPI-13-0785; Pomp V, 2015, BREAST CANCER RES TR, V154, P45, DOI 10.1007/s10549-015-3598-6; Theurillat JP, 2007, NY BR 1 PROTEIN EXPR; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Wang YF, 2013, CURR CANCER DRUG TAR, V13, P963, DOI 10.2174/15680096113136660102; Wushou A, 2014, INT J MOL SCI, V15, P21621, DOI 10.3390/ijms151221621; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Zhang P, 2014, EUR J CLIN INVEST, V44, P1072, DOI 10.1111/eci.12343; Zhang YQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135851	27	4	4	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						98	102		10.1016/j.anndiagpath.2018.03.009			5	Pathology	Pathology	GL1VO	WOS:000436900200019	29661738				2019-10-28	
J	Tili, E; Mezache, L; Michaille, JJ; Amann, V; Williams, J; Vandiver, P; Quinonez, M; Fadda, P; Mikhail, A; Nuovo, G				Tili, Esmerina; Mezache, Louisa; Michaille, Jean-Jacques; Amann, Vicky; Williams, James; Vandiver, Paige; Quinonez, Maria; Fadda, Paolo; Mikhail, Adel; Nuovo, Gerard			microRNA 155 up regulation in the CNS is strongly correlated to Down's syndrome dementia	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Dementia; Down's syndrome; microRNA; Bcl2 family; Tau	ALZHEIMERS-DISEASE; MOUSE MODEL; EXPRESSION; CELLS; HIPPOCAMPUS; APOPTOSIS; PROLIFERATION; INHIBITION; CEREBELLUM; PROTECTS	This study examined the molecular correlates of Down's dementia. qRTPCR for chromosome 21 microRNAs was correlated with in situ hybridization, immunohistochemistry for microRNA targets, mRNAs located on chromosome 21, and neurofibrillary tangles in human and the Ts65 dn mouse Down's model. qRTPCR for the microRNAs on the triplicated chromosome showed miR-155 dominance in brain tissues (14.3 fold increase, human and 24.2 fold increase, mouse model) that co-expressed with hyperphosphorylated tau protein. miR-155 was not elevated in Alzheimer's disease or neonates with Downs' syndrome. Chromosome 21 genes APP/BA-42, DYRK1a and BACH1 were not correlated to pathologic changes in Down's dementia. Validated CNS targets of miR-155 that were present in controls and Alzheimer's disease but lacking in Down's dementia brains included BACH1, CoREST1, bcl6, BIM, bcl10, cyclin D, and SAPK4. It is concluded that Down's dementia strongly correlated with overexpression of chromosome 21 microRNA 155 with concomitant reduction of multiple CNS-functional targets. This study highlights the need for anatomic pathologists to determine the specific and diverse pathways cells may take to form neurofibrillary tangles in the different dementias.	[Tili, Esmerina] Ohio State Univ, Dept Anesthesiol, Wexner Med Ctr, Columbus, OH 43210 USA; [Tili, Esmerina; Michaille, Jean-Jacques] Ohio State Univ, Wexner Med Ctr, Dept Canc Biol & Genet, Columbus, OH 43210 USA; [Mezache, Louisa] Ohio State Univ, Wexner Med Ctr, Dept Neurosci, Columbus, OH 43210 USA; [Michaille, Jean-Jacques] Univ Bourgogne Franche Comte, Fac Gabriel, UB INSERM IFR 100, BioPerox IL, 6 Bd, F-21000 Dijon, France; [Amann, Vicky; Williams, James; Vandiver, Paige; Quinonez, Maria; Mikhail, Adel; Nuovo, Gerard] GNOME Diagnost, Powell, OH 43065 USA; [Fadda, Paolo; Nuovo, Gerard] OSU Comprehens Canc Ctr, Columbus, OH 43210 USA	Nuovo, G (reprint author), GNOME Diagnost, Powell, OH 43065 USA.	nuovo.1@osu.edu			Alzheimer's disease Drug Discovery Foundation [20160204]	Alzheimer's disease Drug Discovery Foundation #20160204.	Ahmed MM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119491; Ballard C, 2016, LANCET NEUROL, V15, P622, DOI 10.1016/S1474-4422(16)00063-6; Brian T, 2014, BLOOD, V124, P1671; Cataldo AM, 1996, J NEUROPATH EXP NEUR, V55, P704, DOI 10.1097/00005072-199606000-00004; Chawla G, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006247; Chen D, 2013, PLOS ONE, DOI [10.1371/journal.pone.0080625, DOI 10.1371/JOURNAL.PONE.0080625.]; COLE G, 1993, ACTA NEUROPATHOL, V85, P542; Dai Y, 2012, PLACENTA, V33, P824, DOI 10.1016/j.placenta.2012.07.012; Dupont T, 2016, ONCOTARGET, V7, P3510, DOI 10.18632/oncotarget.6513; Erturk B, 2016, BIOMED RES INT, DOI 10.1155/2016/5312674; Fang L, 2008, J VIROL, V82, P10436; Gong J, 2013, ONCOGENE, V32, P3071, DOI 10.1038/onc.2012.318; Iorio MV, 2012, CANCER J, V18, P215, DOI 10.1097/PPO.0b013e318250c001; Keck-Wherley J, 2011, DEV NEUROSCI-BASEL, V33, P451, DOI 10.1159/000330884; Kim JH, 2012, LEUKEMIA LYMPHOMA, V53, P1586, DOI 10.3109/10428194.2012.659736; Koval ED, 2013, HUM MOL GENET, V22, P4127, DOI 10.1093/hmg/ddt261; Kucherenko MM, 2012, EMBO J, V31, P4511, DOI 10.1038/emboj.2012.298; Lim JH, 2015, PLACENTA, V36, P322, DOI 10.1016/j.placenta.2014.12.020; Liu Q, 2015, J CELL BIOCHEM, V116, P1213, DOI 10.1002/jcb.25073; Liu YJ, 2015, J CELL BIOCHEM, V116, P2870, DOI 10.1002/jcb.25234; Lomoio S, 2009, BRAIN RES, V1297, P198, DOI 10.1016/j.brainres.2009.08.052; Monaghan CE, 2017, P NATL ACAD SCI USA, V114, pE406, DOI 10.1073/pnas.1620230114; Nazari-Jahantigh M, 2012, J CLIN INVEST, V122, P4190, DOI 10.1172/JCI61716; Ni JS, 2015, BRAIN BEHAV IMMUN, V49, P75, DOI 10.1016/j.bbi.2015.04.014; Nuovo G, 2017, ANN DIAGN PATHOL, V28, P24, DOI 10.1016/j.anndiagpath.2017.02.006; Nuovo GJ, 2012, MODERN PATHOL, V25, P1333, DOI 10.1038/modpathol.2012.95; REEVES RH, 1995, NAT GENET, V11, P177, DOI 10.1038/ng1095-177; Rueda N, 2011, INT J DEV NEUROSCI, V29, P711, DOI 10.1016/j.ijdevneu.2011.06.001; Ryoo SR, 2007, J BIOL CHEM, V282, P34850, DOI 10.1074/jbc.M707358200; Sacks CA, 2017, NEW ENGL J MED, V376, P1706, DOI 10.1056/NEJMp1701047; Satoh J, 2012, EXP NEUROL, V235, P436, DOI 10.1016/j.expneurol.2011.09.003; Shi XB, 2007, P NATL ACAD SCI USA, V104, P19983, DOI 10.1073/pnas.0706641104; Shim KS, 2003, J NEURAL TRANSMISSIO, V67; Shin JH, 2004, FREE RADICAL BIO MED, V37, P643, DOI 10.1016/j.freeradbiomed.2004.05.019; Soppa U, 2014, CELL CYCLE, V13, P2084, DOI 10.4161/cc.29104; Wulczyn FG, 2007, FASEB J, V21, P415, DOI 10.1096/fj.06-6130com; Xu Y, 2013, INT J MOL MED, V32, P1115, DOI 10.3892/ijmm.2013.1499	37	4	4	2	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						103	109		10.1016/j.anndiagpath.2018.03.006			7	Pathology	Pathology	GL1VO	WOS:000436900200020	29661714				2019-10-28	
J	Xue, T; Jiang, XN; Wang, WG; Zhou, XY; Li, XQ				Xue, Tian; Jiang, Xiang-Nan; Wang, Wei-Ge; Zhou, Xiao-Yan; Li, Xiao-Qiu			Interdigitating dendritic cell sarcoma: Clinicopathologic study of 8 cases with review of the literature	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Review						Interdigitating dendritic cell; Sarcoma; Clinicopathologic features	LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA; TUMOR; MELANOMA; REMISSION; LIVER	To investigate the clinicopathologic features and differential diagnoses of interdigitating dendritic cell sarcoma (IDCS), the clinical, morphological and immunohistochemical features of eight cases of IDCS were collected and analyzed. Three patients were males and five were females, the mean age and the median age were 56.5 years and 57 years respectively. Clinically, the majority of cases involved lymph nodes. Microscopically, neoplastic cells were spindle or ovoid, forming fascicles or whorls. Every case had active mitosis figures. Immunohistochemically, these neoplastic cells were consistently positive for 5100, but negative for CD21 and specific B-cell and T-cell associated antigens. Follow-up results were available in 7 cases, of which 5 cases of localized lesions survived, 2 cases died of organ involvement. Interdigitating dendritic cell sarcoma is an extremely rare neoplasm, with inferior prognosis and without standard treatment regimen. IDCS has similar but unique clinicopathologic features and the differential diagnoses include other histiocytic and dendritic cell neoplasms and malignant melanoma.	[Li, Xiao-Qiu] Fudan Univ, Shanghai Canc Ctr, Dept Pathol, 270 Dongan Rd, Shanghai 200032, Peoples R China; Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai, Peoples R China	Li, XQ (reprint author), Fudan Univ, Shanghai Canc Ctr, Dept Pathol, 270 Dongan Rd, Shanghai 200032, Peoples R China.	leexiaoqiu@hotmail.com					Barwell N, 2004, J CLIN PATHOL, V57, P87, DOI 10.1136/jcp.57.1.87; Cheuk W, 2001, AM J SURG PATHOL, V25, P721, DOI 10.1097/00000478-200106000-00003; De Pas T, 2008, CRIT REV ONCOL HEMAT, V65, P1, DOI 10.1016/j.critrevonc.2007.06.003; Di Liso E, 2015, CANCER BIOL THER, V16, P1128, DOI 10.1080/15384047.2015.1057359; Efune G, 2009, AM J OTOLARYNG, V30, P264, DOI 10.1016/j.amjoto.2008.05.002; Feldman AL, 2008, BLOOD, V111, P5433, DOI 10.1182/blood-2007-11-124792; FELTKAMP CA, 1981, VIRCHOWS ARCH A, V393, P183, DOI 10.1007/BF00431075; Fonseca R, 1998, AM J HEMATOL, V59, P161, DOI 10.1002/(SICI)1096-8652(199810)59:2<161::AID-AJH10>3.3.CO;2-I; Fraser CR, 2009, AM J CLIN PATHOL, V132, P928, DOI 10.1309/AJCPWQ0I0DGXBMHO; Helbig G, 2015, WSPOLCZESNA ONKOL, V19, P83, DOI 10.5114/wo.2014.43974; Hillen U, 2016, AM J SURG PATHOL, V40, P1721, DOI 10.1097/PAS.0000000000000746; HORSCHOWSKI N, 1993, PATHOL BIOL, V41, P255; Hutter G, 2015, NEUROSURGERY, V77, pE979, DOI 10.1227/NEU.0000000000000925; Kapucuoglu N, 2009, VIRCHOWS ARCH, V454, P333, DOI 10.1007/s00428-009-0729-7; Kawachi K, 2002, AM J SURG PATHOL, V26, P530, DOI 10.1097/00000478-200204000-00018; Kyogoku C, 2015, J CLIN EXP HEMATOP, V55, P33, DOI 10.3960/jslrt.55.33; Lupato V, 2016, HEAD NECK PATHOL, V10, P145, DOI 10.1007/s12105-015-0627-z; Magro CM, 2017, ANN DIAGN PATHOL, V30, P59, DOI 10.1016/j.anndiagpath.2017.02.008; O'Malley DP, 2015, ANN DIAGN PATHOL, V19, P113, DOI 10.1016/j.anndiagpath.2015.02.008; Parada D, 2012, PATHOL RES PRACT, V208, P368, DOI 10.1016/j.prp.2012.02.004; Perkins SM, 2013, AM J CLIN ONCOL-CANC, V36, P395, DOI 10.1097/COC.0b013e31824be22b; Pokuri VK, 2015, J NATL COMPR CANC NE, V13, P128, DOI 10.6004/jnccn.2015.0020; Radovic S, 2012, BOSNIAN J BASIC MED, V12, P203, DOI 10.17305/bjbms.2012.2485; Saygin C, 2013, CRIT REV ONCOL HEMAT, V88, P253, DOI 10.1016/j.critrevonc.2013.05.006; Shao HP, 2011, MODERN PATHOL, V24, P1421, DOI 10.1038/modpathol.2011.102; Shi F, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00719-2; Stowman AM, 2016, AM J SURG PATHOL, V40, P1270, DOI 10.1097/PAS.0000000000000678; Swerdlow SH, 2008, WHO CLASSIFICATION T; Wu Q, 2010, TRANSPL P, V42, P1963, DOI 10.1016/j.transproceed.2010.01.060; Yao ZG, 2016, PATHOLOGY, V48, P744, DOI 10.1016/j.pathol.2016.07.013; Zhang JX, 2014, ONCOL LETT, V7, P466, DOI 10.3892/ol.2013.1746; 徐位顿, 2002, [广东医学, Guangdong medical journal], V23, P682	32	1	3	4	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						155	160		10.1016/j.anndiagpath.2018.03.008			6	Pathology	Pathology	GL1VO	WOS:000436900200028	29660568	Other Gold			2019-10-28	
J	Chin, SF; Santonja, A; Grzelak, M; Ahn, S; Sammut, SJ; Clifford, H; Rueda, OM; Pugh, M; Goldgraben, MA; Bardwell, HA; Cho, EY; Provenzano, E; Rojo, F; Alba, E; Caldas, C				Chin, Suet-Feung; Santonja, Angela; Grzelak, Marta; Ahn, Soomin; Sammut, Stephen-John; Clifford, Harry; Rueda, Oscar M.; Pugh, Michelle; Goldgraben, Mae A.; Bardwell, Helen A.; Cho, Eun Yoon; Provenzano, Elena; Rojo, Federico; Alba, Emilio; Caldas, Carlos			Shallow whole genome sequencing for robust copy number profiling of formalin-fixed paraffin-embedded breast cancers	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Formalin-fixed paraffin-embedded (FFPE); Shallow whole genome sequencing (sWGS); Copy number (CN) and breast cancer	SOLID TUMORS; IDENTIFICATION; HYBRIDIZATION; SPECIMENS; TISSUES; SAMPLES; FRESH	Pathology archives with linked clinical data are an invaluable resource for translational research, with the limitation that most cancer samples are formalin-fixed paraffin-embedded (FFPE) tissues. Therefore, FFPE tissues are an important resource for genomic profiling studies but are under-utilised due to the low amount and quality of extracted nucleic acids. We profiled the copy number landscape of 356 breast cancer patients using DNA extracted FFPE tissues by shallow whole genome sequencing. We generated a total of 491 sequencing libraries from 2 kits and obtained data from 98.4% of libraries with 86.4% being of good quality. We generated libraries from as low as 3.8 ng of input DNA and found that the success was independent of input DNA amount and quality, processing site and age of the fixed tissues. Since copy number alterations (CNA) play a major role in breast cancer, it is imperative that we are able to use FFPE archives and we have shown in this study that sWGS is a robust method to do such profiling.	[Chin, Suet-Feung; Grzelak, Marta; Sammut, Stephen-John; Clifford, Harry; Rueda, Oscar M.; Bardwell, Helen A.; Caldas, Carlos] Univ Cambridge, Canc Res UK Cambridge Inst, Li Ka Shing Ctr, Robinson Way, Cambridge CB2 0RE, England; [Chin, Suet-Feung; Sammut, Stephen-John; Caldas, Carlos] Univ Cambridge, Dept Oncol, Cambridge CB2 2QQ, England; [Santonja, Angela; Alba, Emilio] Inst Invest Biomed Malaga IBIMA, Med Oncol Serv, Hosp Univ Reg & Virgen Victoria, Malaga, Spain; [Ahn, Soomin] Seoul Natl Univ, Dept Pathol, Bundang Hosp, 82,Gumi Ro 173 Beon Gil, Seongnam 13620, Gyeonggi, South Korea; [Pugh, Michelle] Inivata UK, Portway Bldg,Granta Pk, Cambridge CB21 6GS, England; [Goldgraben, Mae A.] Univ Cambridge, Dept Med Genet, Cambridge CB2 0QQ, England; [Cho, Eun Yoon] Sungkyunkwan Univ, Dept Pathol & Translat Genom, Samsung Med Ctr, Sch Med, 50 Irwon Dong, Seoul 135710, South Korea; [Provenzano, Elena; Caldas, Carlos] Cambridge Univ Hosp NHS Fdn Trust, Cambridge Breast Unit, Addenbrookes Hosp, NIHR Cambridge Biomed Res Ctr, Cambridge CB2 2QQ, England; [Chin, Suet-Feung; Sammut, Stephen-John; Rueda, Oscar M.; Provenzano, Elena; Caldas, Carlos] Canc Res UK Cambridge Canc Ctr, Cambridge CB2 0QQ, England; [Rojo, Federico] IIS FJD, Pathol Dept, Madrid, Spain; [Rojo, Federico; Alba, Emilio] GEICAM Spanish Breast Canc Res Grp, Madrid, Spain; [Santonja, Angela; Alba, Emilio] Univ Malaga, Lab Biol Mol Canc, Ctr Invest Med Sanit CIMES, Malaga, Spain; [Ahn, Soomin] Inivata, Li Ka Shing Ctr, Robinson Way, Cambridge CB2 0RE, England	Chin, SF; Caldas, C (reprint author), Univ Cambridge, Canc Res UK Cambridge Inst, Li Ka Shing Ctr, Robinson Way, Cambridge CB2 0RE, England.	suet-feung.chin@cruk.cam.ac.uk; carlos.caldas@cruk.cam.ac.uk	Caldas, Carlos/U-7250-2019; Alba, Emilio/S-1435-2019	Caldas, Carlos/0000-0003-3547-1489; Alba, Emilio/0000-0002-3364-2603; Grzelak, Marta/0000-0002-2653-2895; chin, suet-feung/0000-0001-5697-1082; Santonja, Angela/0000-0001-9367-7632; Rojo, Federico/0000-0001-9989-0290; Goldgraben, Mae/0000-0002-1111-2804	Cancer Research UKCancer Research UK [A16942]; National Institute for Health Research Cambridge Biomedical Research CentreNational Institute for Health Research (NIHR)	This sequencing project was funded by Cancer Research UK program grant A16942. We thank the Genomics, Histopathology, and Biorepository Core Facilities at the Cancer Research UK Cambridge Institute; the Addenbrooke's Human Research Tissue Bank (supported by the National Institute for Health Research Cambridge Biomedical Research Centre). We thank all the patients who donated tissue and the associated pseudo-anonymized clinical data for this project.	Ali HR, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0431-1; Astolfi A, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1982-6; Carrick DM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127353; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dang J, 2016, INT J ONCOL, V49, P1755, DOI 10.3892/ijo.2016.3654; De Paoli-Iseppi R, 2016, PATHOLOGY, V48, P261, DOI 10.1016/j.pathol.2016.01.001; Dumur CI, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0403-0; Fassunke J, 2015, INT J MOL MED, V36, P1233, DOI 10.3892/ijmm.2015.2339; Hadd AG, 2013, J MOL DIAGN, V15, P234, DOI 10.1016/j.jmoldx.2012.11.006; Holley T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050586; Hosein AN, 2013, LAB INVEST, V93, P701, DOI 10.1038/labinvest.2013.54; Hughesman CB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161274; Iddawela M, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3867-3; Janecka A, 2015, ANAL BIOCHEM, V476, P8, DOI 10.1016/j.ab.2015.01.019; Kader T, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0375-z; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Kerick M, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-68; Kinde I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041162; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Salawu A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050415; Scheinin I, 2014, GENOME RES, V24, P2022, DOI 10.1101/gr.175141.114; Singh RR, 2016, J MOL DIAGN, V18, P676, DOI 10.1016/j.jmoldx.2016.03.008; van Beers EH, 2006, BRIT J CANCER, V94, P333, DOI 10.1038/sj.bjc.6602889	25	4	4	1	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	JUN	2018	104	3					161	169		10.1016/j.yexmp.2018.03.006			9	Pathology	Pathology	GJ0AV	WOS:000434907600001	29608913	Green Published, Other Gold			2019-10-28	
J	Lusebrink, J; Pieper, M; Tillmann, RL; Brockmann, M; Schildgen, O; Schildgen, V				Luesebrink, Jessica; Pieper, Monika; Tillmann, Ramona-Liza; Brockmann, Michael; Schildgen, Oliver; Schildgen, Verena			Pre-clinical validation of a next generation sequencing testing panel	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						NGS; GeneReader; Actionable insights panel; Companion diagnostics	CELL LUNG-CANCER; EGFR; METAANALYSIS; MUTATION; SUPPORT; AZD9291; PIK3CA; KRAS; BRAF; NGS	Objective: Next Generation Sequencing (NGS) has become a useful tool for gene mutation testing which is required for targeted therapies. The aim of this study was to validate the GeneRead QIAact Actionable Insights Tumor Panel (Qiagen) on the GeneReader System in a diagnostic laboratory setting. Methods: The GeneRead QIAact Actionable Insights Tumor Panel allows the analysis of 773 variant positions in 12 genes (ALK, BRAF, EGFR, ERBB2, ERBB3, ESR1, KIT, KRAS, NRAS, PDGFRA, PIK3CA and RAF1). For the validation of the panel we used a commercial available multiplex reference standard carrying 11 mutations in defined positions, samples from interlaboratory tests, and FFPE tumor samples from patients which were tested previously for mutations in KRAS, NRAS, BRAF, EGFR, KIT, and/or PDGFRA with pyrosequencing. Results: Among the 122 tested samples, 121 samples (99.2%) were successfully sequenced. The sensitivity and specificity for detecting variants was 100% and results proved to be reproducible and precise. 119 (98.3%) results were concordant to the expected results. The differences between NGS and pyrosequencing observed in two samples were due to a wrong analysis by the pyrosequencing software which did not cover the present mutations. Conclusion: Overall, the GeneRead QIAact Actionable Insights Tumor Panel was specific and sensitive for mutation analysis for targeted therapies and can be incorporated into laboratory diagnostics' daily practice.	[Luesebrink, Jessica; Pieper, Monika; Tillmann, Ramona-Liza; Brockmann, Michael; Schildgen, Oliver; Schildgen, Verena] Klinikum Privaten Univ Witten Herdecke Sitz Koln, Kliniken Stadt Koln gGmbH, Inst Pathol, Ostmerheimer Str 200, D-51109 Cologne, Germany	Schildgen, V (reprint author), Klinikum Privaten Univ Witten Herdecke Sitz Koln, Kliniken Stadt Koln gGmbH, Inst Pathol, Ostmerheimer Str 200, D-51109 Cologne, Germany.	schildgenv@kliniken-koeln.de	Schildgen, Oliver/D-5327-2014	Schildgen, Oliver/0000-0003-4297-9627			Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337; Darwanto A, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3328-z; Dienstmann R, 2014, MOL ONCOL, V8, P859, DOI 10.1016/j.molonc.2014.03.021; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Koitzsch U, 2017, J CLIN PATHOL, V70, P725, DOI 10.1136/jclinpath-2017-204342; McCourt CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069604; Paleari L, 2016, CLIN ONCOL-UK, V28, P317, DOI 10.1016/j.clon.2015.11.008; Russo A, 2017, ONCOTARGET, V8, P8717, DOI 10.18632/oncotarget.14427; Scarpa A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080478; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Therkildsen C, 2014, ACTA ONCOL, V53, P852, DOI 10.3109/0284186X.2014.895036; Thress KS, 2015, LUNG CANCER, V90, P509, DOI 10.1016/j.lungcan.2015.10.004; Tuononen K, 2013, GENE CHROMOSOME CANC, V52, P503, DOI 10.1002/gcc.22047; Tuononen K, 2013, BIOMED RES INT, DOI 10.1155/2013/757490; Wang L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088291; Winterbottom F., 2016, UNLEASH POWER LIQUID, P1	16	2	2	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	JUN	2018	104	3					170	174		10.1016/j.yexmp.2018.04.001			5	Pathology	Pathology	GJ0AV	WOS:000434907600002	29641993				2019-10-28	
J	Eisinger, K; Rein-Fischboeck, L; Neumeier, M; Schmidhofer, S; Pohl, R; Haberl, EM; Liebisch, G; Kopp, A; Schmid, A; Krautbauer, S; Buechler, C				Eisinger, Kristina; Rein-Fischboeck, Lisa; Neumeier, Markus; Schmidhofer, Sandra; Pohl, Rebekka; Haberl, Elisabeth M.; Liebisch, Gerhard; Kopp, Andrea; Schmid, Andreas; Krautbauer, Sabrina; Buechler, Christa			Alpha-syntrophin deficient mice are protected from adipocyte hypertrophy and ectopic triglyceride deposition in obesity	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Insulin signaling; White adipose tissue; Fatty liver	ADIPOSE-TISSUE DYSFUNCTION; NITRIC-OXIDE SYNTHASE; FREE FATTY-ACIDS; NONALCOHOLIC STEATOHEPATITIS; INSULIN-RESISTANCE; LIPIDOMIC ANALYSIS; ATHEROGENIC DIET; OXIDATIVE STRESS; 3T3-L1 CELLS; NULL MICE	Alpha-syntrophin (SNTA) is a molecular adapter protein which is expressed in adipocytes. Knock-down of SNTA in 3T3-L1 preadipocytes increases cell proliferation, and differentiated adipocytes display small lipid droplets. These effects are both characteristics of healthy adipose tissue growth which is associated with metabolic improvements in obesity. To evaluate a role of SNTA in adipose tissue morphology and obesity associated metabolic dysfunction, SNTA deficient mice were fed a standard chow or a high fat diet. Mice deficient of SNTA had less fat mass and smaller adipocytes in obesity when compared to control animals. Accordingly, these animals did not develop liver steatosis and did not store excess triglycerides in skeletal muscle upon high fat diet feeding. SNTA-/-animals were protected from hyperinsulinemia and hepatic insulin resistance. Of note, body-weight, food uptake, and serum lipids were normal in the SNTA null mice. SNTA was induced in adipose tissues but not in the liver of diet induced obese and ob/ob mice. In human subcutaneous and visceral fat of seven patients SNTA was similarly expressed and was not associated with body mass index. Current data demonstrate beneficial effects of SNTA deficiency in obesity which is partly attributed to smaller adipocytes and reduced white adipose tissue mass. Higher SNTA protein in fat depots of obese mice may contribute to adipose tissue hypertrophy and ectopic lipid deposition which has to be confirmed in humans.	[Eisinger, Kristina; Rein-Fischboeck, Lisa; Neumeier, Markus; Schmidhofer, Sandra; Pohl, Rebekka; Haberl, Elisabeth M.; Kopp, Andrea; Schmid, Andreas; Krautbauer, Sabrina; Buechler, Christa] Univ Hosp Regensburg, Dept Internal Med 1, D-93042 Regensburg, Germany; [Liebisch, Gerhard] Univ Hosp Regensburg, Inst Clin Chem & Lab Med, Regensburg, Germany	Buechler, C (reprint author), Univ Hosp Regensburg, Dept Internal Med 1, D-93042 Regensburg, Germany.	christa.buechler@klinik.uni-regensburg.de	Liebisch, Gerhard/G-6130-2010	Liebisch, Gerhard/0000-0003-4886-0811	German Research FoundationGerman Research Foundation (DFG) [BU 1141/8-1, BU 1141/12-1]	The study was supported by grants from the German Research Foundation (BU 1141/8-1 and 12-1).	Adams ME, 2004, J NEUROSCI, V24, P10302, DOI 10.1523/JNEUROSCI.3408-04.2004; Altintas MM, 2011, J LIPID RES, V52, P480, DOI 10.1194/jlr.M011338; Barth S, 2010, J PATHOL, V221, P117, DOI 10.1002/path.2694; Bauer S, 2011, ENDOCRINOLOGY, V152, P26, DOI 10.1210/en.2010-1157; Bhat HF, 2013, CELL MOL LIFE SCI, V70, P2533, DOI 10.1007/s00018-012-1233-9; Boyle KE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106872; Buechler C, 2015, WORLD J DIABETES, V6, P548, DOI 10.4239/wjd.v6.i4.548; Buechler Christa, 2013, Inflammation & Allergy Drug Targets, V12, P391; Buechler C, 2012, CURR PHARM BIOTECHNO, V13, P319, DOI 10.2174/138920112799095365; Buechler C, 2011, WORLD J GASTROENTERO, V17, P2801, DOI 10.3748/wjg.v17.i23.2801; Buechler C, 2010, FEBS LETT, V584, P4280, DOI 10.1016/j.febslet.2010.09.035; Capurso C, 2012, VASC PHARMACOL, V57, P91, DOI 10.1016/j.vph.2012.05.003; Choi HJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056949; Christianson JL, 2008, J BIOL CHEM, V283, P2906, DOI 10.1074/jbc.M705656200; Di Naso F, 2015, OBESITY, V23, P120, DOI 10.1002/oby.20919; Ecker J, 2012, J CHROMATOGR B, V897, P98, DOI 10.1016/j.jchromb.2012.04.015; Eisinger K, 2016, EXP CELL RES, V345, P100, DOI 10.1016/j.yexcr.2016.05.020; Eisinger K, 2014, EXP MOL PATHOL, V97, P37, DOI 10.1016/j.yexmp.2014.05.002; Eisinger K, 2014, INT J MOL SCI, V15, P2991, DOI 10.3390/ijms15022991; Flowers JB, 2007, DIABETES, V56, P1228, DOI 10.2337/db06-1142; Flowers MT, 2012, J LIPID RES, V53, P1646, DOI 10.1194/jlr.M027508; Freitas P, 2013, PANMINERVA MED, V55, P253; Gerin I, 2005, J BIOL CHEM, V280, P23024, DOI 10.1074/jbc.M412564200; Gillum MP, 2011, DIABETES, V60, P3235, DOI 10.2337/db11-0616; Greenberg AS, 2011, J CLIN INVEST, V121, P2102, DOI 10.1172/JCI46069; Guilherme A, 2008, NAT REV MOL CELL BIO, V9, P367, DOI 10.1038/nrm2391; Hebel T, 2015, BBA-MOL CELL BIOL L, V1851, P527, DOI 10.1016/j.bbalip.2015.01.012; Hosaka Y, 2002, J CELL BIOL, V158, P1097, DOI 10.1083/jcb.200204076; Iacobini C, 2011, J HEPATOL, V54, P975, DOI 10.1016/j.jhep.2010.09.020; Ilan Y, 2016, AM J PHYSIOL-GASTR L, V310, pG1102, DOI 10.1152/ajpgi.00095.2016; Kameya S, 1999, J BIOL CHEM, V274, P2193, DOI 10.1074/jbc.274.4.2193; Khan T, 2009, MOL CELL BIOL, V29, P1575, DOI 10.1128/MCB.01300-08; Konige M, 2014, BBA-MOL BASIS DIS, V1842, P393, DOI 10.1016/j.bbadis.2013.05.007; Krause M, 2014, EUR J APPL PHYSIOL, V114, P251, DOI 10.1007/s00421-013-2769-6; Krautbauer S, 2014, CYTOKINE, V69, P263, DOI 10.1016/j.cyto.2014.06.016; Krautbauer S, 2013, EXP MOL PATHOL, V95, P199, DOI 10.1016/j.yexmp.2013.07.009; Liebisch G, 1999, J LIPID RES, V40, P1539; LONNQVIST F, 1995, NAT MED, V1, P950, DOI 10.1038/nm0995-950; Maeda Y, 1998, EMBO J, V17, P4920, DOI 10.1093/emboj/17.17.4920; Magdalon J, 2016, BBA-MOL CELL BIOL L, V1861, P430, DOI 10.1016/j.bbalip.2016.02.023; Moreno-Navarrete JM, 2013, DIABETOLOGIA, V56, P2524, DOI 10.1007/s00125-013-3015-9; Matsuzawa N, 2007, HEPATOLOGY, V46, P1392, DOI 10.1002/hep.21874; Morton NM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023944; Mulvey C, 2005, EUR J CELL BIOL, V84, P867, DOI 10.1016/j.ejcb.2005.06.007; Okumura A, 2008, FEBS J, V275, P22, DOI 10.1111/j.1742-4658.2007.06174.x; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; Putt KS, 2005, CHEMBIOCHEM, V6, P53, DOI 10.1002/cbic.200400330; Rasouli N, 2008, J CLIN ENDOCR METAB, V93, pS64, DOI 10.1210/jc.2008-1613; Rein-Fischboeck L, 2018, BBA-MOL CELL BIOL L, V1863, P526, DOI 10.1016/j.bbalip.2018.02.006; Rein-Fischboeck L, 2017, EXP MOL PATHOL, V103, P204, DOI 10.1016/j.yexmp.2017.09.005; Romacho T, 2014, ACTA PHYSIOL, V210, P733, DOI 10.1111/apha.12246; Roman AA, 2012, ENDOCRINE, V42, P243, DOI 10.1007/s12020-012-9698-8; Schattenberg JM, 2010, DIGEST DIS, V28, P247, DOI 10.1159/000282097; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Skopkova M, 2007, OBESITY, V15, P2396, DOI 10.1038/oby.2007.285; Sun K, 2013, CELL METAB, V18, P470, DOI 10.1016/j.cmet.2013.06.016; Sun K, 2011, J CLIN INVEST, V121, P2094, DOI 10.1172/JCI45887; Takeya R, 2008, EMBO J, V27, P618, DOI 10.1038/emboj.2008.7; Thompson K. J., 2017, LIVER INT, DOI 10. 1111\liv. 13639; Valerio A, 2006, J CLIN INVEST, V116, P2791, DOI 10.1172/JCI28570; Walker RW, 2014, OBESITY, V22, P1512, DOI 10.1002/oby.20730; Wang QA, 2013, NAT MED, V19, P1338, DOI 10.1038/nm.3324; Weigert J, 2008, FEBS LETT, V582, P2965, DOI 10.1016/j.febslet.2008.07.034; Yew NS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011239; Zabel BA, 2014, AM J CLIN EXP IMMUNO, V3, P1; Zeigerer A, 2015, CELL REP, V11, P884, DOI 10.1016/j.celrep.2015.04.018	67	2	2	2	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	JUN	2018	104	3					212	221		10.1016/j.yexmp.2018.04.003			10	Pathology	Pathology	GJ0AV	WOS:000434907600006	29702112				2019-10-28	
J	Yu, RL; Xuan, WJ; Zhou, L; Luo, Y; Liu, XY; Xiong, PW; Ren, XY				Yu, Runliu; Xuan, Wenjing; Zhou, Lei; Luo, Ying; Liu, Xinyang; Xiong, Peiwu; Ren, Xuyi			Detection of HER2 amplification in formalin-fixed paraffin-embedded breast carcinoma tissue with digital PCR using two TFF3 sequences as internal reference	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Droplet digital PCR; HER2 amplification; Breast cancer	COPY NUMBER; CANCER; TRASTUZUMAB	Purpose: Droplet digital PCR (ddPCR) is a highly accurate method to determine DNA concentration and detect copy number variations. We developed an approach to assess HER2 gene amplification status using ddPCR with two sequences of TFF3 as reference probes. Experimental design.: 76 templates of carcinoma DNA were prepared from formalin-fixed paraffin-embedded (FFPE) tissues. Digital PCR assay of the copy number of HER2 and TFF3 DNA was performed on the samples. The results were compared to prior fluorescent in-situ hybridation (FISH) assays performed on the same samples. Results: The ddPCR assay had high concordance with the conventionally used immunohistochemistry (IHC) and FISH methods. The ddPCR method returned fewer indeterminate results than IHC. Concordance between a ddPCR plus FISH method and IHC plus FISH can rise to 98.7% (75/76) after validation is carried out. Conclusion: It's potentially possible to improve the sensitivity and specifity of HER2 ddPCR assays using reference sequences not co-localized with HER2 on chromosome 17, and combining results from multiple sequences. Adopting an approach based on ddPCR HER2 assays plus FISH could lead to reduced costs, labour, and time consumption compared to current IHC plus FISH standard, while not losing precision.	[Yu, Runliu; Xuan, Wenjing; Zhou, Lei; Luo, Ying; Liu, Xinyang; Xiong, Peiwu; Ren, Xuyi] Hangzhou DA Med Lab, Res & Dev Ctr, Floor 8,Bldg A,859 Shi Xiang West Rd, Hangzhou 310030, Zhejiang, Peoples R China	Ren, XY (reprint author), Hangzhou DA Med Lab, Res & Dev Ctr, Floor 8,Bldg A,859 Shi Xiang West Rd, Hangzhou 310030, Zhejiang, Peoples R China.	Renxy@dazd.cn			National Key Research and Development Program of China [2017YFC-0908600]	This study was funded by the National Key Research and Development Program of China (Grant No. 2017YFC-0908600).	Bang YJ, 2010, LANCET, V376, P1302; Belgrader P, 2013, CLIN CHEM, V59, P991, DOI 10.1373/clinchem.2012.197855; Carrick DM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127353; Garcia-Murillas I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083409; Gevensleben H, 2013, CLIN CANCER RES, V19, P3276, DOI 10.1158/1078-0432.CCR-12-3768; Gravalos C, 2008, ANN ONCOL, V19, P1523, DOI 10.1093/annonc/mdn169; Heredia NJ, 2013, METHODS, V59, pS20, DOI 10.1016/j.ymeth.2012.09.012; Kinugasa H, 2015, BRIT J CANCER, V112, P1652, DOI 10.1038/bjc.2015.129; Matsusaka K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154430; Naoki T., 2016, ONCOTARGET, V7, P3453; Penault-Llorca F, 2009, AM J CLIN PATHOL, V132, P539, DOI 10.1309/AJCPV2I0HGPMGBSQ; Pinheiro LB, 2012, ANAL CHEM, V84, P1003, DOI 10.1021/ac202578x; Pohl G, 2004, EXPERT REV MOL DIAGN, V4, P41, DOI 10.1586/14737159.4.1.41; Shoda K., 2015, GASTRIC CANCER, V20, P126; Varga Z, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-615; Vogel C, 2001, EUR J CANCER, V37, pS25, DOI 10.1016/S0959-8049(00)00405-6; Wang HX, 2018, EUR J CANCER, V88, P92, DOI 10.1016/j.ejca.2017.10.032; Whale AS, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks203; Wolff AC, 2014, ARCH PATHOL LAB MED, V138, P241, DOI 10.5858/arpa.2013-0953-SA	19	0	0	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	JUN	2018	104	3					235	238		10.1016/j.yemp.2018.04.004			4	Pathology	Pathology	GJ0AV	WOS:000434907600009	29715436				2019-10-28	
J	Ferrara, G; Filosa, A; Mariani, MP; Fasanella, L				Ferrara, Gerardo; Filosa, Alessandra; Mariani, Maria Paola; Fasanella, Luigi			Occupational Argyria of the Nasal Mucosa	HEAD & NECK PATHOLOGY			English	Article						Nasal cavity; Argyria; Histopathology; Pigment	SILVER-NITRATE; ARGYROSIS; EXPOSURE	A biopsy specimen from the nasal mucosa of a 37-year-old man disclosed a subepithelial accumulation of black granules mainly running parallel to the surface in the absence of any inflammatory infiltrate. Since the mucosal pigment was negative with Perls' stain and resisted to melanin bleach, an exogenous pigmentation was suspected. The biopsy specimen had been taken because of a diffuse steel-blue pigmentation of the nasal mucosa, incidentally discovered during routine clinical examination. A diagnosis of occupational argyria of the nasal mucosa was finally made since the patient was a silver cleaner. Argyria is a rare cause of nasopharyngeal mucosal pigmentation; it is not a precancerous condition, but it can be mistaken for a melanosis or a melanocytic tumor both clinically and histopathologically. Clinicopathological correlation is mandatory, since the final diagnosis is based on a history of chronic silver exposure.	[Ferrara, Gerardo; Filosa, Alessandra; Mariani, Maria Paola] Macerata Gen Hosp, Anat Pathol Unit, Via Santa Lucia 2, I-62100 Macerata, Italy; [Fasanella, Luigi] Civitanova Marche Gen Hosp, Otorhyniloaryngol Unit, Civitanova Marche, Italy	Ferrara, G (reprint author), Macerata Gen Hosp, Anat Pathol Unit, Via Santa Lucia 2, I-62100 Macerata, Italy.	gerardo.ferrara@libero.it; alessandrafilosa@yahoo.it; paola.mariani@sanita.marche.it; luigi.fasanella@sanita.marche.it		Ferrara, Gerardo/0000-0003-0727-4015			Armitage SA, 1996, ANN OCCUP HYG, V40, P331, DOI 10.1016/0003-4878(95)00076-3; BLEEHEN SS, 1981, BRIT J DERMATOL, V104, P19, DOI 10.1111/j.1365-2133.1981.tb01706.x; Cho EA, 2008, J DERMATOL, V35, P759, DOI 10.1111/j.1346-8138.2008.00562.x; Humphreys SDM, 1998, ADVERSE DRUG REACT T, V17, P115; MATSUMURA T, 1992, Journal of Dermatology (Tokyo), V19, P87; PIFER JW, 1989, SCAND J WORK ENV HEA, V15, P210, DOI 10.5271/sjweh.1860; ROSENMAN KD, 1979, J OCCUP ENVIRON MED, V21, P430; SARSFIELD P, 1992, HISTOPATHOLOGY, V20, P73, DOI 10.1111/j.1365-2559.1992.tb00921.x; STAMMBERGER H, 1982, LARYNG RHINOL OTOL V, V61, P234, DOI 10.1055/s-2007-1008563; VIK H, 1985, LANCET, V1, P872; Williams N, 1999, OCCUP MED-OXFORD, V49, P397, DOI 10.1093/occmed/49.6.397	11	1	1	1	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	JUN	2018	12	2					252	254		10.1007/s12105-017-0842-x			3	Pathology	Pathology	GG0GC	WOS:000432355500014	28779465	Green Published			2019-10-28	
J	Sakata, J; Yamana, K; Yoshida, R; Matsuoka, Y; Kawahara, K; Arita, H; Nakashima, H; Nagata, M; Hirosue, A; Kawaguchi, S; Gohara, S; Nagao, Y; Hiraki, A; Shinohara, M; Toya, R; Murakami, R; Nakayama, H				Sakata, Junki; Yamana, Keisuke; Yoshida, Ryoji; Matsuoka, Yuichiro; Kawahara, Kenta; Arita, Hidetaka; Nakashima, Hikaru; Nagata, Masashi; Hirosue, Akiyuki; Kawaguchi, Sho; Gohara, Shunsuke; Nagao, Yuka; Hiraki, Akimitsu; Shinohara, Masanori; Toya, Ryo; Murakami, Ryuji; Nakayama, Hideki			Tumor budding as a novel predictor of occult metastasis in cT2N0 tongue squamous cell carcinoma	HUMAN PATHOLOGY			English	Article						Tumor budding; Depth of invasion; Tongue cancer; Occult metastasis; Elective neck dissection; Immunohistochemistry	LYMPH-NODE METASTASES; ORAL TONGUE; COLORECTAL-CANCER; PROGNOSTIC-FACTOR; NECK DISSECTION; METAANALYSIS; STATISTICS; EXPRESSION; SURVIVAL; MARKER	Occult neck metastasis is an important prognostic factor in patients with tongue squamous cell carcinoma (TSCC) who are deemed clinically negative for neck metastasis. The purpose of this study was to identify predictive factors for occult neck metastasis arising from TSCC and to determine patient prognosis. Ninety-seven patients with cT2N0 TSCC who underwent surgical resection of their primary lesion as initial therapy were enrolled in this retrospective study. Cutoff values for depth of invasion (>= 3.3 mm) and the tumor budding score (>= 4) were determined using receiver operator characteristic analyses. Univariate and multivariate analyses revealed that a tumor budding score >= 4 is a significant independent predictive factor for the occurrence of occult neck metastasis, which in turn is a significant independent prognostic factor. When evaluating tumor budding, we demonstrated greater interobserver and intraobserver agreement when using immunohistochemical staining for cytokeratin AE1/AE3 than with hematoxylin and eosin staining (HE). We conclude that the evaluation of tumor budding is effective for identifying populations at high risk of occult neck metastasis, which will enable the planning of appropriate therapeutic strategies for patients with cT2N0 TSCC. Furthermore, cytokeratin staining is recommended over HE staining for simpler and more accurate evaluation of tumor budding. (C) 2018 Elsevier Inc. All rights reserved.	[Sakata, Junki; Yamana, Keisuke; Yoshida, Ryoji; Matsuoka, Yuichiro; Kawahara, Kenta; Arita, Hidetaka; Nakashima, Hikaru; Nagata, Masashi; Hirosue, Akiyuki; Kawaguchi, Sho; Gohara, Shunsuke; Nagao, Yuka; Shinohara, Masanori; Nakayama, Hideki] Kumamoto Univ, Fac Life Sci, Dept Oral & Maxillofacial Surg, Kumamoto, Japan; [Hiraki, Akimitsu] Fukuoka Dent Coll, Dept Oral & Maxillofacial Surg, Sect Oral Oncol, Fukuoka, Japan; [Shinohara, Masanori] Itoh Dent Maxillofacial Hosp, Kumamoto, Japan; [Toya, Ryo] Kumamoto Univ Hosp, Dept Radiat Oncol, Kumamoto, Japan; [Murakami, Ryuji] Kumamoto Univ, Fac Life Sci, Dept Med Imaging, Kumamoto, Japan	Yoshida, R (reprint author), Kumamoto Univ, Fac Life Sci, Dept Oral & Maxillofacial Surg, Chuo Ku, Honjo 1-1-1, Kumamoto 8608556, Japan.	ryoshida1126@gmail.com		Sakata, Junki/0000-0002-5190-8663	Japanese Ministry of Education, Culture, Sport, Science and TechnologyMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [16K20591]	This study was supported by a grant from the Japanese Ministry of Education, Culture, Sport, Science and Technology, Grant-in-Aid for Young Scientists B (16K20591).	Almangush A, 2015, INT J ORAL MAX SURG, V44, P143, DOI 10.1016/j.ijom.2014.10.004; Almangush A, 2016, HISTOPATHOLOGY, V68, P173, DOI 10.1111/his.12781; Amin MB, 2017, AJCC CANC STAGING MA; Angadi PV, 2015, INT J SURG PATHOL, V23, P102, DOI 10.1177/1066896914565022; Barnes L., 2005, PATHOLOGY GENETICS H; D'Cruz AK, 2015, NEW ENGL J MED, V373, P521, DOI 10.1056/NEJMoa1506007; Edge SB, 2010, AJCC CANC STAGING MA; Fukumoto K, 2016, CANCER SCI, V107, P1338, DOI 10.1111/cas.12990; Ganly I, 2012, CANCER-AM CANCER SOC, V118, P101, DOI 10.1002/cncr.26229; Haddadin KJ, 1999, HEAD NECK-J SCI SPEC, V21, P517, DOI 10.1002/(SICI)1097-0347(199909)21:6<517::AID-HED4>3.0.CO;2-C; Hori Y, 2017, HEAD NECK PATHOL, V11, P477, DOI 10.1007/s12105-017-0814-1; Huang SH, 2009, CANCER-AM CANCER SOC, V115, P1489, DOI 10.1002/cncr.24161; Isayeva T, 2015, MODERN PATHOL, V28, P631, DOI 10.1038/modpathol.2014.149; Izumo T, 2012, JPN J CLIN ONCOL, V42, P1099, DOI 10.1093/jjco/hys141; Kai K, 2016, PATHOL INT, V66, P75, DOI 10.1111/pin.12374; Keski-Santti H, 2006, ORAL ONCOL, V42, P96, DOI 10.1016/j.oraloncology.2005.06.018; Kurokawa H, 2002, HEAD NECK-J SCI SPEC, V24, P731, DOI 10.1002/hed.10130; LANDIS JR, 1977, BIOMETRICS, V33, P363, DOI 10.2307/2529786; Luo WR, 2012, HISTOPATHOLOGY, V61, P1072, DOI 10.1111/j.1365-2559.2012.04350.x; Miyata H, 2009, CANCER, V115, P3324, DOI 10.1002/cncr.24390; National Comprehensive Cancer Network, 2017, NCCN CLIM PRACT GUID; O'Connor K, 2015, AM J SURG PATHOL, V39, P472, DOI 10.1097/PAS.0000000000000333; Okamoto M, 2002, J ORAL PATHOL MED, V31, P227, DOI 10.1034/j.1600-0714.2002.310406.x; Prall F, 2007, HISTOPATHOLOGY, V50, P151, DOI 10.1111/j.1365-2559.2006.02551.x; Rogers AC, 2016, BRIT J CANCER, V115, P831, DOI 10.1038/bjc.2016.274; Leao PLR, 2017, J ORAL PATHOL MED, V46, P949, DOI 10.1111/jop.12578; Sarioglu S, 2010, PATHOL RES PRACT, V206, P88, DOI 10.1016/j.prp.2009.09.006; Seki M, 2016, HEAD NECK-J SCI SPEC, V38, pE1582, DOI 10.1002/hed.24282; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sparano A, 2004, OTOLARYNG HEAD NECK, V131, P472, DOI 10.1016/j.otohns.2004.04.008; Taira T, 2012, LUNG CANCER, V76, P423, DOI 10.1016/j.lungcan.2011.11.010; Ueno H, 2004, ANN SURG, V240, P832, DOI 10.1097/01.sla.0000143243.81014.f2; Xie N, 2015, J ORAL PATHOL MED, V44, P266, DOI 10.1111/jop.12242; Yii NW, 1999, CLIN OTOLARYNGOL, V24, P75, DOI 10.1046/j.1365-2273.1999.00224.x; Yoshida R, 2013, LAB INVEST, V93, P1068, DOI 10.1038/labinvest.2013.95	35	6	6	1	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUN	2018	76						1	8		10.1016/j.humpath.2017.12.021			8	Pathology	Pathology	GK1ON	WOS:000435888200001	29307623				2019-10-28	
J	Gordetsky, JB; Schult, L; Porter, KK; Nix, JW; Thomas, JV; Pena, MDR; Rais-Bahrami, S				Gordetsky, Jennifer B.; Schult, Luciana; Porter, Kristin K.; Nix, Jeffrey W.; Thomas, John, V; Pena, Maria del Carmen Rodriguez; Rais-Bahrami, Soroush			Defining the optimal method for reporting prostate cancer grade and tumor extent on magnetic resonance/ultrasound fusion-targeted biopsies	HUMAN PATHOLOGY			English	Article						Prostate cancer; Cancer staging; Cancer grading; Radical prostatectomy; Multiparametric MR; Pathology	ISUP CONSENSUS CONFERENCE; INTERNATIONAL-SOCIETY; MRI; CARCINOMA; DIAGNOSIS; VOLUME	Magnetic resonance (MR)/ultrasound fusion-targeted biopsy (TB) routinely samples multiple cores from each MR lesion of interest. Pathologists can evaluate the extent of cancer involvement and grade using an individual core (IC) or aggregate (AG) method, which could potentially lead to differences in reporting. We reviewed patients who underwent TB followed by radical prostatectomy (RP). TB cores were evaluated for grade and tumor extent by 2 methods. In the IC method, the grade for each TB lesion was based on the core with the highest Gleason score. Tumor extent for each TB was based on the core with the highest percent of tumor involvement. In the AG method, the tumor from all cores within each TB lesion was aggregated to determine the final composite grade and percentage of tumor involvement. Each method was compared with MR lesional volume, MR lesional density (lesion volume/prostate volume), and RP. Fifty-five patients underwent TB followed by RP. Extent of tumor by the AG method showed a better correlation with target lesion volume (r = 0.27, P = .022) and lesional density (r = 0.32, P = .008) than did the IC method (r = 0.19 [P = .103] and r= 0.22 [P = .062]), respectively. Extent of tumor on TB was associated with extraprostatic extension on RP by the AG method (P = .04), but not by the IC method. This association was significantly higher in patients with a grade group (GG) of 3 or higher (P = .03). A change in cancer grade occurred in 3 patients when comparing methods (2 downgraded GG3 to GG2, 1 downgraded GG4 to GG3 by the AG method). For multiple cores obtained via TB, the AG method better correlates with target lesion volume, lesional density, and extraprostatic extension. (C) 2018 Elsevier Inc. All rights reserved.	[Gordetsky, Jennifer B.; Schult, Luciana; Pena, Maria del Carmen Rodriguez] Univ Alabama Birmingham, Dept Pathol, NP 3550,1802 6th Ave South, Birmingham, AL 35249 USA; [Gordetsky, Jennifer B.; Nix, Jeffrey W.; Rais-Bahrami, Soroush] Univ Alabama Birmingham, Dept Urol, Birmingham, AL 35249 USA; [Schult, Luciana] Inst Anat Patol, BR-13450 Piracicaba, Brazil; [Schult, Luciana] Inst Anat Patol, BR-13450 Santa Barbara Doeste, Brazil; [Porter, Kristin K.; Thomas, John, V; Rais-Bahrami, Soroush] Univ Alabama Birmingham, Dept Radiol, Birmingham, AL 35249 USA	Gordetsky, JB (reprint author), Univ Alabama Birmingham, Dept Pathol, NP 3550,1802 6th Ave South, Birmingham, AL 35249 USA.	jgordetsky@uabmc.edu					Borkowetz A, 2015, BJU INT, V116, P873, DOI 10.1111/bju.13023; Descazeaud A, 2005, EUR UROL, V48, P911, DOI 10.1016/j.eururo.2005.07.011; Engelhard K, 2014, SCAND J UROL, V48, P499, DOI 10.3109/21681805.2014.907338; Epstein JI, 2005, AM J SURG PATHOL, V29, P1228, DOI 10.1097/01.pas.0000173646.99337.b1; Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530; Gordetsky J, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0478-2; Gordetsky JB, 2017, AM J SURG PATHOL, V41, P101, DOI 10.1097/PAS.0000000000000723; Hamdy FC, 2016, NEW ENGL J MED, V375, P1415, DOI 10.1056/NEJMoa1606220; Hong CW, 2015, BJU INT, V115, P772, DOI 10.1111/bju.12871; Kunju LP, 2009, HUM PATHOL, V40, P558, DOI 10.1016/j.humpath.2008.07.020; Kunz GM, 2003, HUM PATHOL, V34, P911, DOI 10.1016/S0046-8177(03)00338-1; Lai WS, 2017, TRANSL ANDROL UROL, V6, P406, DOI 10.21037/tau.2017.03.50; Lai WS, 2017, CANCER-AM CANCER SOC, V123, P1941, DOI 10.1002/cncr.30548; Marin L, 2017, DIAGN INTERV IMAG, V98, P423, DOI 10.1016/j.diii.2017.02.004; Moch H, 2016, WHO CLASSIFICATION T; Mottet N, 2017, EUR UROL, V71, P618, DOI 10.1016/j.eururo.2016.08.003; Poulos CK, 2005, MODERN PATHOL, V18, P228, DOI 10.1038/modpathol.3800302; Puech P, 2013, RADIOLOGY, V268, P461, DOI 10.1148/radiol.13121501; Rais-Bahrami S, 2013, J UROLOGY, V190, P1721, DOI 10.1016/j.juro.2013.05.052; Rubin MA, 2004, AM J SURG PATHOL, V28, P946, DOI 10.1097/00000478-200407000-00016; Siddiqui MM, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw039; Siddiqui MM, 2015, JAMA-J AM MED ASSOC, V313, P390, DOI 10.1001/jama.2014.17942; Turkbey B, 2012, J UROLOGY, V188, P1157, DOI 10.1016/j.juro.2012.06.011	23	5	5	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUN	2018	76						68	75		10.1016/j.humpath.2018.03.005			8	Pathology	Pathology	GK1ON	WOS:000435888200009	29551676				2019-10-28	
J	Chen, X; Wang, YW; Zhu, WJ; Li, Y; Liu, L; Yin, G; Gao, P				Chen, Xu; Wang, Ya-Wen; Zhu, Wen-Jie; Li, Yan; Liu, Lin; Yin, Gang; Gao, Peng			A 4-microRNA signature predicts lymph node metastasis and prognosis in breast cancer	HUMAN PATHOLOGY			English	Article						Breast cancer; MiRNA signature; Metastasis; Prognosis; MiRNA profiles; MiRNA microarray	CELL-PROLIFERATION; HIGH EXPRESSION; MICRORNAS; MIR-489; MIR-214; BIOMARKERS; PATHWAY	Recent findings have reported that human microRNAs (miRNAs) could serve as prognostic biomarkers in various cancers. We aimed to identify miRNAs that were associated with lymph node metastasis (LNM) and prognosis in breast cancer patients. A miRNA microarray covering 2019 mature miRNAs was used to identify differentially expressed miRNAs in 9 patients with LNM and 3 patients without LNM. Thirty-five differentially expressed miRNAs were identified, of which 10 significantly were up-regulated, whereas the other 25 were down-regulated in tissues with LNM compared with those without LNM. Seven miRNAs were subjected to quantitative real-time polymerase chain PCR (qRT-PCR) reaction, and 4 miRNAs (miR-191-5p, miR-214-3p, miR-451a, and miR-489) were validated in a total of 159 patients including a training set (n = 64) and a validation set (n = 95). The 4 miRNAs were used to construct a miRNA signature by logistic regression. Risk scores derived from the 4-miRNA signature were calculated to stratify the patients into high- or low-risk groups. Patients with high-risk scores had poorer overall survival and disease-free survival than did those with low-risk scores. The miRNA signature was an independent prognostic factor. MiR-191-5p increased, whereas miR-214-3p, miR-451a, and miR-489 inhibited cell proliferation, migration, and invasion abilities. The 4-miRNA signature may be a reliable prognostic and predictive tool for metastasis and survival in breast cancer patients. (C) 2018 Elsevier Inc. All rights reserved.	[Chen, Xu; Wang, Ya-Wen; Zhu, Wen-Jie; Li, Yan; Liu, Lin; Gao, Peng] Shandong Univ, Qilu Hosp, Dept Pathol, 107 Wen Hua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Yin, Gang] Shandong Univ, Qilu Hosp, Dept Surg, 107 Wen Hua Xi Rd, Jinan 250012, Shandong, Peoples R China	Gao, P (reprint author), Shandong Univ, Qilu Hosp, Dept Pathol, 107 Wen Hua Xi Rd, Jinan 250012, Shandong, Peoples R China.; Yin, G (reprint author), Shandong Univ, Qilu Hosp, Dept Surg, 107 Wen Hua Xi Rd, Jinan 250012, Shandong, Peoples R China.	yg_2000@sina.com; gaopeng@sdu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81372856, 81672842]; Taishan Scholars Program of Shandong Province [ts201511096]	This study was supported by the National Natural Science Foundation of China (Grant Nos. 81372856 and 81672842) and the Taishan Scholars Program of Shandong Province (Grant No. ts201511096).	Bertoli G, 2015, THERANOSTICS, V5, P1122, DOI 10.7150/thno.11543; Chen X, 2016, J PATHOL, V239, P459, DOI 10.1002/path.4743; Derfoul A, 2011, CARCINOGENESIS, V32, P1607, DOI 10.1093/carcin/bgr184; Di Leva G, 2014, ANNU REV PATHOL-MECH, V9, P287, DOI 10.1146/annurev-pathol-012513-104715; Gao P, 2011, J HEPATOL, V54, P1177, DOI 10.1016/j.jhep.2010.09.023; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jiang L, 2014, FEBS LETT, V588, P2009, DOI 10.1016/j.febslet.2014.04.024; Kalniete D, 2015, HERED CANCER CLIN PR, V13, DOI 10.1186/s13053-015-0028-z; Lerebours F, 2013, INT J CANCER, V133, P1614, DOI 10.1002/ijc.28171; Lin XJ, 2015, LANCET ONCOL, V16, P804, DOI 10.1016/S1470-2045(15)00048-0; Liu B, 2016, ONCOL REP, V35, P3178, DOI 10.3892/or.2016.4749; Liu ZR, 2016, LIFE SCI, V149, P104, DOI 10.1016/j.lfs.2016.02.059; Liu ZR, 2015, BIOMED RES INT, DOI 10.1155/2015/207684; Mar-Aguilar F, 2013, ASIA-PAC J CLIN ONCO, V9, P53, DOI 10.1111/j.1743-7563.2012.01548.x; Nagpal N, 2015, SCI REP-UK, V5, DOI 10.1038/srep09650; Nagpal N, 2013, CARCINOGENESIS, V34, P1889, DOI 10.1093/carcin/bgt107; Patel Y, 2016, ONCOTARGET, V7, P18295, DOI 10.18632/oncotarget.7577; Saumet A, 2015, ADV EXP MED BIOL, V888, P5, DOI 10.1007/978-3-319-22671-2_2; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shi M, 2009, CANCER TREAT REV, V35, P328, DOI 10.1016/j.ctrv.2008.12.002; Sun EH, 2014, EUR REV MED PHARMACO, V18, P2783; Tang CG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182953; Wang YW, 2015, ONCOTARGET, V6, P10646, DOI 10.18632/oncotarget.3392; Wang YW, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0091307, 10.1371/journal.pone.0094548]; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Yu XF, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0480-4; Zhang JX, 2016, BIOCHEM BIOPH RES CO, V478, P337, DOI 10.1016/j.bbrc.2016.07.054	27	5	5	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUN	2018	76						122	132		10.1016/j.humpath.2018.03.010			11	Pathology	Pathology	GK1ON	WOS:000435888200016	29555574				2019-10-28	
J	Babarovic, E; Sladoljev, K; Perin, E; Klaric, M; Karnjus-Begonja, R; Sinozic, T; Dinter, M; Gacanin, LG; Eminovic, S				Babarovic, Emina; Sladoljev, Karla; Perin, Ena; Klaric, Marko; Karnjus-Begonja, Ruzica; Sinozic, Tamara; Dinter, Morana; Gacanin, Lana Glavan; Eminovic, Senija			Primary Carcinosarcoma of the Vagina Associated With Differentiated Squamous Intraepithelial Neoplasia in a Patient With Complete Uterine Prolapse: Case Report and Review of the Literature	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Review						vaginal malignancies; carcinosarcoma (CS); differentiated squamous intraepithelial neoplasia (DSIN); uterine prolapse; treatment	MIXED MULLERIAN TUMOR; PRIMARY-CARCINOMA; CELL-CARCINOMA; HUMAN-PAPILLOMAVIRUS; STAGE-I; HISTOGENESIS; RADIATION; CANCER	Vaginal carcinosarcomas (VCSs) are rare and clinically aggressive neoplasms. Primary vaginal malignancies are among the rarest malignant tumors, so clear management guidelines and optimal therapy, especially in the presence of significant pelvic organ prolapse, has not been determined. Here, we present a case of primary VCS closely associated with differentiated squamous intraepithelial neoplasia (DSIN), from which it appeared to have arisen in a postmenopausal patient with complete uterine prolapse. The unusual presentation of our case with DSIN in the adjacent vaginal epithelium with possible diagnostic pitfalls emphasizes the need for systemic presentation of these cases to help pathologists and clinicians know that such lesions can initially present in a patient with complete uterine prolapse. To our knowledge, this is the first case of vaginal DSIN described in the literature to date.	[Babarovic, Emina; Eminovic, Senija] Univ Rijeka, Sch Med, Dept Pathol, Brace Branchetta 20, HR-51000 Rijeka, Croatia; [Sladoljev, Karla; Perin, Ena] Univ Rijeka, Sch Med, Rijeka, Croatia; [Klaric, Marko; Gacanin, Lana Glavan] Rijeka Univ Hosp Ctr, Clin Dept Obstet & Gynecol, Rijeka, Croatia; [Karnjus-Begonja, Ruzica] Rijeka Univ Hosp Ctr, Clin Dept Radiotherapy & Oncol, Rijeka, Croatia; [Dinter, Morana] Rijeka Univ Hosp Ctr, Dept Cytol, Rijeka, Croatia	Babarovic, E (reprint author), Univ Rijeka, Sch Med, Dept Pathol, Brace Branchetta 20, HR-51000 Rijeka, Croatia.	esinozic@gmail.com					Ahuja A, 2011, PATHOL RES PRACT, V207, P253, DOI 10.1016/j.prp.2010.10.002; Ali MM, 1996, CANCER, V77, P1934, DOI 10.1002/(SICI)1097-0142(19960501)77:9<1934::AID-CNCR25>3.0.CO;2-#; Alonso I, 2012, GYNECOL ONCOL, V125, P194, DOI 10.1016/j.ygyno.2011.12.449; Arsenic R, 2013, VIRCHOWS ARCH, V462, P609, DOI 10.1007/s00428-013-1412-6; DAVIS PC, 1975, SOUTHERN MED J, V68, P1239, DOI 10.1097/00007611-197510000-00014; Ferguson SE, 2007, AM J SURG PATHOL, V31, P1653, DOI 10.1097/PAS.0b013e3181161ba3; Grayson W, 2001, AM J SURG PATHOL, V25, P338, DOI 10.1097/00000478-200103000-00008; Hegemann S, 2009, STRAHLENTHER ONKOL, V185, P184, DOI 10.1007/s00066-009-1930-y; Hellman K, 2006, INT J GYNECOL CANCER, V16, P1201, DOI 10.1111/j.1525-1438.2006.00520.x; Hellman K, 2014, BRIT J CANCER, V110, P1561, DOI 10.1038/bjc.2014.32; Jin Z, 2003, INT J GYNECOL PATHOL, V22, P368, DOI 10.1097/01.pgp.0000092134.88121.56; Ling B, 2008, GYNECOL ONCOL, V109, P92, DOI 10.1016/j.ygyno.2007.12.012; Neesham D, 1998, GYNECOL ONCOL, V70, P303, DOI 10.1006/gyno.1998.5054; Nomura H, 2015, INT J GYNECOL CANCER, V25, P320, DOI 10.1097/IGC.0000000000000351; PETERS WA, 1985, OBSTET GYNECOL, V65, P699; Platta CS, 2013, J CONTEMP BRACHYTHER, V5, P76, DOI 10.5114/jcb.2013.36177; RUBIN SC, 1985, GYNECOL ONCOL, V20, P346, DOI 10.1016/0090-8258(85)90216-1; RUTLEDGE F, 1967, AM J OBSTET GYNECOL, V97, P635, DOI 10.1016/0002-9378(67)90451-6; Schipf A, 2008, VIRCHOWS ARCH, V452, P259, DOI 10.1007/s00428-007-0557-6; Sebenik M, 2007, HUM PATHOL, V38, P1282, DOI 10.1016/j.humpath.2007.03.008; Shibata R, 2003, PATHOL INT, V53, P106, DOI 10.1046/j.1440-1827.2003.01442.x; Sotiropoulou Maria, 2005, Archives of Gynecology and Obstetrics, V271, P264; SREENAN JJ, 1995, AM J SURG PATHOL, V19, P666, DOI 10.1097/00000478-199506000-00007; STOCK RG, 1995, GYNECOL ONCOL, V56, P45, DOI 10.1006/gyno.1995.1008; Tjalma WAA, 2001, GYNECOL ONCOL, V81, P360, DOI 10.1006/gyno.2001.6171; van de Nieuwenhof HP, 2011, MODERN PATHOL, V24, P297, DOI 10.1038/modpathol.2010.192; Visvalingam Geetha, 2016, BMJ Case Rep, V2016, DOI 10.1136/bcr-2016-214856; Wasserman JK, 2016, HISTOPATHOLOGY, V68, P834, DOI 10.1111/his.12874	28	0	0	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	JUN	2018	26	4					370	376		10.1177/1066896917745592			7	Pathology; Surgery	Pathology; Surgery	GF9BK	WOS:000432270900016	29207889				2019-10-28	
J	Co, M; Chen, C; Tsang, JY; Tse, G; Kwong, A				Co, Michael; Chen, Clement; Tsang, Julia Y.; Tse, Gary; Kwong, Ava			Mammary phyllodes tumour: a 15-year multicentre clinical review	JOURNAL OF CLINICAL PATHOLOGY			English	Review						breast pathology; breast; surgical pathology	CYSTOSARCOMA-PHYLLODES; BREAST; PROGRESSION	Aims Phyllodes tumour (PT) is an uncommon fibroepithelial tumour of the breast. It has a spectrum of aggressiveness in biological behaviour with chance of local recurrence and, occasionally, metastasis. Methods A 15-year retrospective review from a multicentre database in Hong Kong was performed. Results Clinical and pathological records of 465 patients with 469 PTs between 1998 and 2014 were reviewed. Median age of occurrence was 44 years (range 12-86 years). 281 (59.9%) PTs were benign, 124 (26.4%) were borderline and 64 (13.6%) were malignant. About half of all PTs (239, 51.5%) were between 2 and 5 cm while another 186 (40.1%) were >5 cm in size. Most PT (84.6%) were radiologically benign. Breast-conserving surgery (BCS) was feasible in 384 (82%) patients, whereas 84 (18%) patients had mastectomy. Multivariate analysis found that positive surgical margin (P<0.001) and BCS (P<0.001) were the only significant risk factors for local recurrence, while large tumour size (P=0.008) and malignant PT histotype (P<0.001) were the only significant risk factors for metastasis. Long-term prognosis of benign and borderline PT was excellent. After median follow-up interval of 85 months (range 12-180 months), the disease-specific survival of benign, borderline and malignant PT were 99.6%, 100% and 90.6%, respectively. Conclusions Local recurrence of PTs occurs irrespective of the tumour grade. Surgical margin is the only amendable factor to reduce the chance of recurrence.	[Co, Michael; Chen, Clement; Kwong, Ava] Univ Hong Kong, Queen Mary Hosp, Div Breast Surg, Dept Surg, Hong Kong, Hong Kong, Peoples R China; [Tsang, Julia Y.; Tse, Gary] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China	Kwong, A (reprint author), Univ Hong Kong, Queen Mary Hosp, Div Breast Surg, Room K1401, Hong Kong, Hong Kong, Peoples R China.	avakwong@hku.h	Kwong, Ava/D-8005-2013	Kwong, Ava/0000-0002-6968-9489; CO, MICHAEL/0000-0002-1705-051X			BUCHBERGER W, 1991, AM J ROENTGENOL, V157, P715, DOI 10.2214/ajr.157.4.1654022; Co Michael, 2018, Cancer Treat Res Commun, V14, P17, DOI 10.1016/j.ctarc.2017.10.001; Co M, 2018, CLIN BREAST CANCER, V18, pE421, DOI 10.1016/j.clbc.2017.06.001; COHNCEDERMARK G, 1991, CANCER-AM CANCER SOC, V68, P2017, DOI 10.1002/1097-0142(19911101)68:9<2017::AID-CNCR2820680929>3.0.CO;2-V; Cserni G, 2006, PATHOL ONCOL RES, V12, P216, DOI 10.1007/BF02893415; Grabowski J, 2007, AM SURGEON, V73, P967; Kuijper A, 2002, J PATHOL, V197, P575, DOI 10.1002/path.1161; Lakhani SREI, 2012, WHO CLASSIFICATION T; LESTER J, 1954, CANCER-AM CANCER SOC, V7, P335, DOI 10.1002/1097-0142(195403)7:2<335::AID-CNCR2820070219>3.0.CO;2-J; MOFFAT CJC, 1995, HISTOPATHOLOGY, V27, P205, DOI 10.1111/j.1365-2559.1995.tb00212.x; NOGUCHI S, 1995, CANCER, V76, P1779, DOI 10.1002/1097-0142(19951115)76:10<1779::AID-CNCR2820761015>3.0.CO;2-0; NORRIS HJ, 1967, CANCER, V20, P2090, DOI 10.1002/1097-0142(196712)20:12<2090::AID-CNCR2820201206>3.0.CO;2-L; OBERMAN HA, 1965, CANCER, V18, P697, DOI 10.1002/1097-0142(196506)18:6<697::AID-CNCR2820180607>3.0.CO;2-L; REINFUSS M, 1993, EUR J CANCER, V29A, P1252, DOI 10.1016/0959-8049(93)90067-P; Reinfuss M, 1996, CANCER-AM CANCER SOC, V77, P910, DOI 10.1002/(SICI)1097-0142(19960301)77:5<910::AID-CNCR16>3.0.CO;2-6; SALVADORI B, 1989, CANCER, V63, P2532, DOI 10.1002/1097-0142(19890615)63:12<2532::AID-CNCR2820631229>3.0.CO;2-Q; Tan BY, 2016, HISTOPATHOLOGY, V68, P5, DOI 10.1111/his.12876; Tan PH, 2005, AM J CLIN PATHOL, V123, P529, DOI 10.1309/U6DVBFM81MLJC1FN; TREVES N, 1951, CANCER, V4, P1286, DOI 10.1002/1097-0142(195111)4:6<1286::AID-CNCR2820040614>3.0.CO;2-T; Warrier S, 2015, INT J SURG CASE REP, V11, P91, DOI 10.1016/j.ijscr.2015.02.009	20	6	6	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUN	2018	71	6					493	497		10.1136/jclinpath-2017-204827			5	Pathology	Pathology	GH2OI	WOS:000433240800003	29146885				2019-10-28	
J	Pinto, AM; Pereira, TA; Alves, V; Araujo, A; Lage, OM				Pinto, Ana Mafalda; Pereira, Tamegao Aires; Alves, Valquiria; Araujo, Antonio; Lage, Olga Maria			Incidence and serotype characterisation of Streptococcus agalactiae in a Portuguese hospital	JOURNAL OF CLINICAL PATHOLOGY			English	Article						streptococcus agalactiae; urogenital colonization; pregnancy; perinatal pathology; epidemiology	GROUP-B-STREPTOCOCCUS; MULTIPLEX PCR ASSAY; PREGNANT-WOMEN; ANTIMICROBIAL SUSCEPTIBILITY; CLINICAL-MANIFESTATIONS; ANTIGEN-DETECTION; WESTERN SWEDEN; COLONIZATION; INFECTIONS; DISEASE	Aims Streptococcus agalactiae, commonly known as group B Streptococcus (GBS), has been recognised as a worldwide causative pathogenic agent of neonatal sepsis, meningitis and pneumonia. To better understand the behaviour of S. agalactiae in pregnant women from a hospital from the North of Portugal, retrospective analyses were performed to describe epidemiological, clinical and microbiological characteristics of the isolates obtained. Methods Based on laboratorial records and the hospital's patient files, a 6-year retrospective study was performed to analyse S. agalactiae isolates from screened pregnant women between 35 and 37 weeks of gestation and hospitalised neonates from pregnant women between 24 and 41 weeks of gestation admitted in Hospital Pedro Hispano. Serotype characterisation was also performed in 67 GBS strains. Results In 6692 pregnant women between 35 and 37 weeks of gestation screened between 2011 and 2016, a total of 1377 S. agalactiae isolates (21%) were found. A high percentage (40%) of unknown colonisation status among hospitalised neonates from pregnant women between 24 and 41 weeks of gestations was also found. The incidence of neonatal sepsis was 8.7 (95% CI 7.0 to 10.8) cases per 1000 live births. Regarding serotype characterisation, serotype III (22.4%) was the most frequent, followed by serotype Ia (19.4%) and serotypes Ib and V (both with 17.9%). Conclusion High epidemiological values of GBS colonisation and incidence were found in this study. In Portugal studies on the epidemiology and behaviour of S. agalactiae remain limited, reinforcing the importance and need for S. agalactiae screening across the country.	[Pinto, Ana Mafalda; Lage, Olga Maria] Univ Porto, Dept Biol, Fac Sci, Porto, Portugal; [Pereira, Tamegao Aires] Hosp Pedro Hispano, Dept Women Children & Youth, Pediat & Neonatol Serv, Porto, Portugal; [Alves, Valquiria] Hosp Pedro Hispano, Dept MCDT, Clin Pathol Serv, Porto, Portugal; [Araujo, Antonio] Biogerm SA, Dept Microbiol, Maia, Australia; [Lage, Olga Maria] Univ Porto, CIMAR CIIMAR Interdisciplinary Ctr Marine & Envir, Porto, Portugal	Lage, OM (reprint author), Univ Porto, Fac Sci, P-4169007 Porto, Portugal.	olga.lage@fc.up.pt		Pinto, Ana/0000-0003-4271-9008	FCT - Foundation for Science and Technology [UID/Multi/04423/2013]; European Regional Development Fund (ERDF)European Union (EU)	This research was partially supported by the Strategic Funding UID/Multi/04423/2013 through national funds provided by FCT - Foundation for Science and Technology and European Regional Development Fund (ERDF), in the framework of the programme PT2020.	Afshar B, 2011, J CLIN MICROBIOL, V49, P1475, DOI 10.1128/JCM.02365-10; Aitmhand R, 2000, SCAND J INFECT DIS, V32, P339; Araujo M, 2010, THESIS; Areal A, 2008, ACTA OBSTET GINECOL, V2, P72; Areal A, 2010, ACTA PEDIAT PORT, V41, P16; Aryanna Kelly Pinheiro S., 2009, THESIS; Barcaite E, 2008, ACTA OBSTET GYN SCAN, V87, P260, DOI 10.1080/00016340801908759; Berg S, 2000, CLIN MICROBIOL INFEC, V6, P9, DOI 10.1046/j.1469-0691.2000.00007.x; Brigtsen AK, 2015, J MICROBIOL METH, V108, P31, DOI 10.1016/j.mimet.2014.11.001; Brimil N, 2006, INT J MED MICROBIOL, V296, P39, DOI 10.1016/j.ijmm.2005.11.001; Brown LD, 2001, STAT SCI, V16, P101; Castellano DS, 2010, BRAZ J MICROBIOL, V41, P1047, DOI 10.1590/S1517-838220100004000024; Chen VL, 2013, VACCINE, V31, pD13, DOI 10.1016/j.vaccine.2012.12.080; Cortese F, 2016, PEDIATR NEONATOL, V57, P265, DOI 10.1016/j.pedneo.2015.09.007; Dagnew AF, 2012, CLIN INFECT DIS, V55, P91, DOI 10.1093/cid/cis395; Dangor Z, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123014; Davies HD, 2001, PEDIATR INFECT DIS J, V20, P879, DOI 10.1097/00006454-200109000-00011; Dogan B, 2005, J CLIN MICROBIOL, V43, P5899, DOI 10.1128/JCM.43.12.5899-5906.2005; Faro Jonathan P, 2013, Infect Dis Obstet Gynecol, V2013, P367935, DOI 10.1155/2013/367935; Figueira-Coelho J, 2004, MICROB DRUG RESIST, V10, P31, DOI 10.1089/107662904323047772; Florindo C, 2014, EUROSURVEILLANCE, V19, P23, DOI 10.2807/1560-7917.ES2014.19.23.20825; Florindo C, 2010, CLIN MICROBIOL INFEC, V16, P1458, DOI [10.1111/j.1469-0691.2009.03106.x, 10.1111/j.1469-0691.2010.03106.x]; Gosiewski T, 2012, FOLIA MICROBIOL, V57, P163, DOI 10.1007/s12223-012-0108-7; Goudarzi Gholamreza, 2015, Glob J Health Sci, V7, P233, DOI 10.5539/gjhs.v7n6p233; Imperi M, 2010, J MICROBIOL METH, V80, P212, DOI 10.1016/j.mimet.2009.11.010; Joachim A, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-437; Konikkara KP, 2014, J CLIN DIAGN RES, V8, P47, DOI 10.7860/JCDR/2014/6675.4004; Kwatra G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098778; Lakshmi V, 2001, Indian J Med Microbiol, V19, P44; Lito D, 2013, ACTA MEDICA PORT, V26, P549; Madzivhandila M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017861; Martins ER, 2012, J CLIN MICROBIOL, V50, P1219, DOI 10.1128/JCM.05488-11; Martins ER, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00499; Neto MT, 2008, ARCH DIS CHILD-FETAL, V93, pF90, DOI 10.1136/adc.2007.127464; Nuccitelli Annalisa, 2015, Ther Adv Vaccines, V3, P76, DOI 10.1177/2051013615579869; Oviedo P, 2013, BRAZ J MICROBIOL, V44, P253, DOI 10.1590/S1517-83822013005000030; Parker JN, 2002, OFFICIAL PATIENTS SO; Persson E, 2004, CLIN MICROBIOL INFEC, V10, P791, DOI 10.1111/j.1469-0691.2004.00931.x; Picard FJ, 2004, EUR J CLIN MICROBIOL, V23, P665, DOI 10.1007/s10096-004-1183-8; Pinheiro S, 2016, ACTA FARMACEUTICA PO, V5, P75; Poyart C, 2007, J CLIN MICROBIOL, V45, P1985, DOI 10.1128/JCM.00159-07; Rallu F, 2006, J CLIN MICROBIOL, V44, P725, DOI 10.1128/JCM.44.3.725-728.2006; REGAN JA, 1991, OBSTET GYNECOL, V77, P604; Rivera L, 2015, BMC PEDIATR, V15, DOI 10.1186/s12887-015-0460-2; Rodrigues FB, 2009, THESIS; Shabayek S, 2014, EPIDEMIOL INFECT, V142, P208, DOI 10.1017/S0950268813000848; SUARA RO, 1994, J INFECT DIS, V170, P1316, DOI 10.1093/infdis/170.5.1316; Teatero S, 2014, J CLIN MICROBIOL, V52, P1441, DOI 10.1128/JCM.03554-13; Tsolia M, 2003, CLIN MICROBIOL INFEC, V9, P832, DOI 10.1046/j.1469-0691.2003.00662.x; Verani Jennifer R., 2010, Morbidity and Mortality Weekly Report, V59, P1; Xie Y, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0463-9; Yao KH, 2013, J CLIN MICROBIOL, V51, P503, DOI 10.1128/JCM.02417-12	52	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUN	2018	71	6					508	513		10.1136/jclinpath-2017-204646			6	Pathology	Pathology	GH2OI	WOS:000433240800006	29180508				2019-10-28	
J	Togashi, Y; Dobashi, A; Sakata, S; Sato, Y; Baba, S; Seto, A; Mitani, H; Kawabata, K; Takeuchi, K				Togashi, Yuki; Dobashi, Akito; Sakata, Seiji; Sato, Yukiko; Baba, Satoko; Seto, Akira; Mitani, Hiroki; Kawabata, Kazuyoshi; Takeuchi, Kengo			MYB and MYBL1 in adenoid cystic carcinoma: diversity in the mode of genomic rearrangement and transcripts	MODERN PATHOLOGY			English	Article							NFIB GENE FUSION; SALIVARY-GLAND; LUNG-CANCER; EXPRESSION; BREAST; HEAD; NECK	MYB-NFIB and MYBL1-NFIB have been reported in similar to 60% of adenoid cystic carcinoma cases, but driver alterations in the remaining similar to 40% of adenoid cystic carcinoma remain unclear. We examined 100 adenoid cystic carcinoma cases for MYB and MYBL1 locus rearrangements by fluorescence in situ hybridization (FISH) with originally designed probe sets using formalin-fixed paraffin-embedded materials. Approximately one-third of samples were also analyzed by fusion transcript-specific RT-PCR and capture RNA sequencing. In the 27 cases with frozen materials, MYB-NFIB and MYBL1-NFIB fusion transcripts were detected in 9 (33%) and 6 cases (22%) by RT-PCR, respectively. Meanwhile, high expression of MYB (18 cases, 67%) or MYBL1 (9 cases, 33%) was detected in all 27 cases in a mutually exclusive manner, regardless of its form (full-length, truncation, or fusion transcript). Interestingly, genomic rearrangements around the corresponding highly-expressed gene were observed in all 27 cases by FISH, suggesting a causative relationship between genomic rearrangements and gene expression. Among the 100 cases, including additional 73 cases, 97 harbored genomic rearrangements in the MYB (73 cases) or MYBL1 locus (24 cases) including 10 cases with atypical FISH patterns undetectable through ordinary split FISH approaches: breakpoints far distant from MYB (5 cases) and a small NFIB locus insertion into the MYB (3 cases) or MYBL1 locus (2 cases). In clinicopathological analyses, histological grade, primary tumor size, and lymph node metastasis were identified as prognostic factors, whereas MYB/MYBL1 rearrangements were not, but were associated with histological grade. In the present study, MYB or MYBL1 locus rearrangement was detected in nearly all adenoid cystic carcinoma cases, and therefore it would be a good diagnostic marker for adenoid cystic carcinoma. However, fusion transcript-specific RT-PCR for MYB-NFIB and MYBL1-NFIB and ordinary split FISH assays for MYB and MYBL1 were less sensitive, and thus detection methods should be judiciously designed because of the diversity of rearrangement modes in adenoid cystic carcinoma.	[Togashi, Yuki; Dobashi, Akito; Sakata, Seiji; Baba, Satoko; Takeuchi, Kengo] Japanese Fdn Canc Res, Inst Canc, Pathol Project Mol Targets, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan; [Togashi, Yuki; Sato, Yukiko; Takeuchi, Kengo] Japanese Fdn Canc Res, Inst Canc, Div Pathol, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan; [Togashi, Yuki; Takeuchi, Kengo] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept JFCR Canc Biol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan; [Seto, Akira; Mitani, Hiroki; Kawabata, Kazuyoshi] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Head & Neck Oncol, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan	Takeuchi, K (reprint author), Japanese Fdn Canc Res, Inst Canc, Pathol Project Mol Targets, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.; Takeuchi, K (reprint author), Japanese Fdn Canc Res, Inst Canc, Div Pathol, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.; Takeuchi, K (reprint author), Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept JFCR Canc Biol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	kentakeuchi-tky@umin.net	Takeuchi, Kengo/C-3614-2008	Takeuchi, Kengo/0000-0002-1599-5800; Sato, Yukiko/0000-0003-4277-0161	Japan Society for the Promotion of Science KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [16K21591]	We thank Mr. Motoyoshi Iwakoshi, Ms. Keiko Shiozawa, and Ms. Tomoyo Kakita for their technical assistance and Ms. Sayuri Sengoku for her management assistance in the research project. We also thank Dr. Hiroyuki Yonekawa, Dr. Hirofumi Fukushima, Dr. Toru Sasaki, Dr. Wataru Shinbashi, Dr. Kazutoshi Toda, Dr. Aya Ebina, and Dr. Hideki Tsuji for providing clinical specimens and Dr. Futoshi Akiyama and Dr. Yutaka Takazawa for giving advice on histological review. Computations were partially performed on the NIG supercomputer at ROIS National Institute of Genetics. This study was supported in part by the Japan Society for the Promotion of Science KAKENHI grant number 16K21591 (to Yuki Togashi).	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Antonescu CR, 2011, GENE CHROMOSOME CANC, V50, P559, DOI 10.1002/gcc.20881; Brayer KJ, 2016, CANCER DISCOV, V6, P176, DOI 10.1158/2159-8290.CD-15-0859; Brill LB, 2011, MODERN PATHOL, V24, P1169, DOI 10.1038/modpathol.2011.86; D'Alfonso TM, 2014, HUM PATHOL, V45, P2270, DOI 10.1016/j.humpath.2014.07.013; Daniel Nicorici MS, 2014, BIORXIV; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Drier Y, 2016, NAT GENET, V48, P265, DOI 10.1038/ng.3502; Fehr A, 2011, J PATHOL, V224, P322, DOI 10.1002/path.2909; Fujii K, 2017, HISTOPATHOLOGY, V71, P823, DOI 10.1111/his.13281; Geurts JMW, 1997, CANCER RES, V57, P13; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; Lloyd S, 2011, AM J CLIN ONCOL-CANC, V34, P76, DOI 10.1097/COC.0b013e3181d26d45; Martelotto LG, 2015, J PATHOL, V237, P179, DOI 10.1002/path.4573; Mitani Y, 2016, CLIN CANCER RES, V22, P725, DOI 10.1158/1078-0432.CCR-15-2867-T; Mitani Y, 2011, CLIN CANCER RES, V17, P7003, DOI 10.1158/1078-0432.CCR-11-1870; Mitani Y, 2010, CLIN CANCER RES, V16, P4722, DOI 10.1158/1078-0432.CCR-10-0463; NORDKVIST A, 1994, CANCER GENET CYTOGEN, V74, P77, DOI 10.1016/0165-4608(94)90001-9; North JP, 2015, AM J SURG PATHOL, V39, P1347, DOI 10.1097/PAS.0000000000000463; Persson M, 2012, GENE CHROMOSOME CANC, V51, P805, DOI 10.1002/gcc.21965; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; RC Team, 2016, R LANG ENV STAT COMP; Rettig EM, 2016, CANCER PREV RES, V9, P265, DOI 10.1158/1940-6207.CAPR-15-0316; Rettig EM, 2015, LARYNGOSCOPE, V125, pE292, DOI 10.1002/lary.25356; Schmieder R, 2011, BIOINFORMATICS, V27, P863, DOI 10.1093/bioinformatics/btr026; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Takeuchi K, 2009, CLIN CANCER RES, V15, P3143, DOI 10.1158/1078-0432.CCR-08-3248; Togashi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031323; von Holstein SL, 2013, OPHTHALMOLOGY, V120, P2130, DOI 10.1016/j.ophtha.2013.03.030; West RB, 2011, AM J SURG PATHOL, V35, P92, DOI 10.1097/PAS.0b013e3182002777; Wetterskog D, 2012, J PATHOL, V226, P84, DOI 10.1002/path.2974; Winnes M, 2007, GENE CHROMOSOME CANC, V46, P559, DOI 10.1002/gcc.20440; Wysocki PT, 2016, ONCOTARGET, V7, P66239, DOI 10.18632/oncotarget.11288; Zhang JH, 2013, NAT GENET, V45, P602, DOI 10.1038/ng.2611	35	5	5	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUN	2018	31	6					934	946		10.1038/s41379-018-0008-8			13	Pathology	Pathology	GJ1CH	WOS:000434991000009	29410490				2019-10-28	
J	Li, WD; Han, YW; Wang, CJ; Guo, XJ; Shen, BB; Liu, FF; Jiang, CY; Li, YQ; Yang, YL; Lang, RG; Fan, Y; Gu, F; Niu, Y; Zhang, XM; Zhang, LJ; Wen, HY; Fu, L				Li, Weidong; Han, Yunwei; Wang, Chijuan; Guo, Xiaojing; Shen, Beibei; Liu, Fangfang; Jiang, Chengying; Li, Yaqing; Yang, Yiling; Lang, Ronggang; Fan, Yu; Gu, Feng; Niu, Yun; Zhang, Xinmin; Zhang, Lanjing; Wen, Hannah Y.; Fu, Li			Precise pathologic diagnosis and individualized treatment improve the outcomes of invasive micropapillary carcinoma of the breast: a 12-year prospective clinical study	MODERN PATHOLOGY			English	Article							LYMPH-NODE METASTASIS; DUCTAL CARCINOMA; INCREASED EXPRESSION; FOLLOW-UP; FEATURES; UPDATE; CANCER	Invasive micropapillary carcinoma of the breast is a histologic subtype of breast cancer and associated with high incidence of lymphovascular invasion, lymph node metastasis and poor prognosis. The aim of this prospective study was to investigate the impact of precise pathologic diagnosis and individualized treatment on the outcomes of invasive micropapillary carcinoma of the breast. The study group included 2299 women with invasive micropapillary carcinoma diagnosed at Tianjin Medical University Cancer Institute and Hospital between January 2004 and December 2015. In the study group, specimens were examined with the method of whole-specimen orientation and serial sectioning, and patients received precise pathological diagnosis and individualized treatment. The control group of invasive micropapillary carcinoma consisted of 163 cases, identified through a retrospectively review of 9056 invasive carcinomas diagnosed at our institution between January 1989 and December 2003 using the standard pathology-evaluation method (i.e., not using the whole-specimen orientation and serial-sectioning method). The clinicopathological features, treatments and outcomes were compared between the two groups. The incidence of invasive micropapillary carcinoma in the study group was 6% (2299/39,714 cases), significantly higher than that of the control group (2%; 163/9056 cases). The 5-year disease-free survival in the study group was significantly higher than that in the control group (83.8 vs. 45.4%; p < 0.05). The 5-year overall survival was significantly increased from 57.4% in the control group to 90.9% in the study group (p < 0.05). In the multivariate analysis, lymphovascular invasion, estrogen receptor status and lymph node metastasis were independent prognostic factors. Although invasive micropapillary carcinoma of the breast is associated with poor prognosis, precise pathologic diagnosis and individualized treatment improved the disease-free survival and overall survival of invasive micropapillary carcinoma patients. Precise pathological diagnosis is the premises for individualized treatments and for improving the outcomes of patients with invasive micropapillary carcinoma of the breast.	[Li, Weidong; Han, Yunwei; Wang, Chijuan; Guo, Xiaojing; Shen, Beibei; Liu, Fangfang; Jiang, Chengying; Li, Yaqing; Yang, Yiling; Lang, Ronggang; Fan, Yu; Gu, Feng; Niu, Yun; Fu, Li] Tianjin Med Univ, Canc Inst & Hosp, Dept Breast Canc Pathol & Res Lab, Tianjin, Peoples R China; [Li, Weidong; Han, Yunwei; Wang, Chijuan; Guo, Xiaojing; Shen, Beibei; Liu, Fangfang; Jiang, Chengying; Li, Yaqing; Yang, Yiling; Lang, Ronggang; Fan, Yu; Gu, Feng; Niu, Yun; Fu, Li] Tianjin Med Univ, Minist Educ, Natl Clin Res Ctr Canc, Tianjin, Peoples R China; [Li, Weidong; Han, Yunwei; Wang, Chijuan; Guo, Xiaojing; Shen, Beibei; Liu, Fangfang; Jiang, Chengying; Li, Yaqing; Yang, Yiling; Lang, Ronggang; Fan, Yu; Gu, Feng; Niu, Yun; Fu, Li] Tianjin Med Univ, Minist Educ, Key Lab Breast Canc Prevent & Therapy, Tianjin, Peoples R China; [Li, Weidong; Han, Yunwei; Wang, Chijuan; Guo, Xiaojing; Shen, Beibei; Liu, Fangfang; Jiang, Chengying; Li, Yaqing; Yang, Yiling; Lang, Ronggang; Fan, Yu; Gu, Feng; Niu, Yun; Fu, Li] Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China; [Li, Weidong; Han, Yunwei; Wang, Chijuan; Guo, Xiaojing; Shen, Beibei; Liu, Fangfang; Jiang, Chengying; Li, Yaqing; Yang, Yiling; Lang, Ronggang; Fan, Yu; Gu, Feng; Niu, Yun; Fu, Li] State Key Lab Breast Canc Res, Tianjin, Peoples R China; [Li, Weidong; Han, Yunwei; Wang, Chijuan; Guo, Xiaojing; Shen, Beibei; Liu, Fangfang; Jiang, Chengying; Li, Yaqing; Yang, Yiling; Lang, Ronggang; Fan, Yu; Gu, Feng; Niu, Yun; Fu, Li] 2011 Collaborat Innovat Ctr Tianjin Med Epigenet, Tianjin, Peoples R China; [Zhang, Xinmin] Rowan Univ, Cooper Med Sch, Cooper Univ Hosp, Dept Pathol, One Cooper Plaza, Camden, NJ USA; [Zhang, Lanjing] Univ Med Ctr Princeton, Dept Pathol, Plainsboro, NJ USA; [Zhang, Lanjing] Rutgers State Univ, Dept Biol Sci, Newark, NJ USA; [Zhang, Lanjing] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA; [Zhang, Lanjing] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Biol Chem, Piscataway, NJ USA; [Wen, Hannah Y.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA	Fu, L (reprint author), Tianjin Med Univ, Canc Inst & Hosp, Dept Breast Canc Pathol & Res Lab, Tianjin, Peoples R China.; Fu, L (reprint author), Tianjin Med Univ, Minist Educ, Natl Clin Res Ctr Canc, Tianjin, Peoples R China.; Fu, L (reprint author), Tianjin Med Univ, Minist Educ, Key Lab Breast Canc Prevent & Therapy, Tianjin, Peoples R China.; Fu, L (reprint author), Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China.; Fu, L (reprint author), State Key Lab Breast Canc Res, Tianjin, Peoples R China.; Fu, L (reprint author), 2011 Collaborat Innovat Ctr Tianjin Med Epigenet, Tianjin, Peoples R China.; Wen, HY (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA.	weny@mskcc.org; fuli@tmu.edu.cn	Zhang, Lanjing/D-1544-2009	Zhang, Lanjing/0000-0001-5436-887X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [30470667, 30600225, 30930038]; Program for Chang Jiang Scholars and Innovative Research Team in University of Ministry of Education of China [IRT0743]; National Institutes of Health/National Cancer Institute Cancer Center Support Grant [P30CA008748]	This study was funded by National Natural Science Foundation of China (30470667, 30600225, 30930038), Program for Chang Jiang Scholars and Innovative Research Team in University of Ministry of Education of China (IRT0743). Hannah Y Wen was supported in part by a National Institutes of Health/National Cancer Institute Cancer Center Support Grant (P30CA008748).	Acs G, 2010, AM J SURG PATHOL, V34, P1637, DOI 10.1097/PAS.0b013e3181f5539c; AMIN MB, 1994, AM J SURG PATHOL, V18, P1224, DOI 10.1097/00000478-199412000-00005; Chen AC, 2014, BRIT J CANCER, V111, P619, DOI 10.1038/bjc.2014.301; Chen AC, 2013, CLIN BREAST CANCER, V13, P133, DOI 10.1016/j.clbc.2012.10.001; Chen L, 2008, INT J SURG PATHOL, V16, P155, DOI 10.1177/1066896907307047; Chen L, 2009, BREAST CANCER RES TR, V116, P471, DOI 10.1007/s10549-008-0147-6; Cui LF, 2008, HISTOPATHOLOGY, V53, P381, DOI 10.1111/j.1365-2559.2008.03128.x; FISHER ER, 1980, AM J CLIN PATHOL, V73, P313; Fu L, 1998, PATHOL INT, V48, P348, DOI 10.1111/j.1440-1827.1998.tb03917.x; Fu Li, 2004, Zhonghua Bing Li Xue Za Zhi, V33, P21; Guo XJ, 2008, MODERN PATHOL, V21, P1101, DOI 10.1038/modpathol.2008.72; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; Kuroda N, 2006, DIAGN CYTOPATHOL, V34, P224, DOI 10.1002/dc.20427; Lakhani S. R., 2012, WHO CLASSIFICATION T, P8; Li S, 2012, BREAST CANCER RES TR, V136, P77, DOI 10.1007/s10549-012-2166-6; Li WD, 2011, PATHOL RES PRACT, V207, P739, DOI 10.1016/j.prp.2011.09.009; Li WD, 2010, PATHOL RES PRACT, V206, P828, DOI 10.1016/j.prp.2010.09.008; Liu FF, 2009, HISTOPATHOLOGY, V54, P741, DOI 10.1111/j.1365-2559.2009.03289.x; Liu Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106564; Luna-More S, 2000, PATHOL RES PRACT, V196, P35, DOI 10.1016/S0344-0338(00)80019-9; Marchio C, 2008, J PATHOL, V215, P398, DOI 10.1002/path.2368; Marchio C, 2009, J PATHOL, V218, P301, DOI 10.1002/path.2572; Nassar H, 2001, MODERN PATHOL, V14, P836, DOI 10.1038/modpathol.3880399; Sakamoto K, 2005, HISTOPATHOLOGY, V47, P479, DOI 10.1111/j.1365-2559.2005.02241.x; Shi WB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101390; SIRIAUNKGUL S, 1993, MODERN PATHOL, V6, P660; Tavassoeli F.A., 2003, PATHOLOGY GENETICS T, P10; Wang XX, 2015, PATHOL ONCOL RES, V21, P1021, DOI 10.1007/s12253-015-9923-x; Wei J, 2010, INT J SURG PATHOL, V18, P193, DOI 10.1177/1066896908320832; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Yang YL, 2016, ARCH PATHOL LAB MED, V140, P799, DOI 10.5858/arpa.2016-0040-RA; Yu JI, 2015, CLIN BREAST CANCER, V15; Zekioglu O, 2004, HISTOPATHOLOGY, V44, P18, DOI 10.1111/j.1365-2559.2004.01757.x	33	0	2	1	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUN	2018	31	6					956	964		10.1038/s41379-018-0024-8			9	Pathology	Pathology	GJ1CH	WOS:000434991000011	29403084				2019-10-28	
J	Giardina, T; Robinson, C; Grieu-Iacopetta, F; Millward, M; Iacopetta, B; Spagnolo, D; Amanuel, B				Giardina, Tindaro; Robinson, Cleo; Grieu-Iacopetta, Fabienne; Millward, Michael; Iacopetta, Barry; Spagnolo, Dominic; Amanuel, Benhur			Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice	PATHOLOGY			English	Article						Next generation sequencing; somatic mutation; gene panels; molecular diagnostic testing laboratory	PRECISION MEDICINE; CANCER; VALIDATION; ASSAY; VARIANTS; ADENOCARCINOMA; MALIGNANCIES; DIAGNOSTICS; GUIDELINES; ONCOLOGY	The introduction of next generation sequencing (NGS) in the routine diagnostic setting is still in the development phase and has been limited by its complexity. Targeted NGS offers an attractive alternative to performing multiple single target assays and is very useful in meeting the increasing clinical demand for testing of multiple genetic aberrations in cancer specimens. To this end, we carried out a blinded validation study on 113 tumours in a diagnostic laboratory and compared mutation results from targeted NGS with those from Sanger sequencing, pyrosequencing, competitive allele specific TaqMan polymerase chain reaction (CAST PCR) and Cobas assays. DNA was extracted from formalin fixed, paraffin embedded (FFPE) tissue samples that included core biopsies, resections and cytology samples from three common and one rare cancer types [non-small cell lung cancer (NSCLC), colorectal cancer (CRC), malignant melanoma (MM) and gastrointestinal stromal tumour (GIST)]. Libraries were prepared using the TruSight Tumour 26 gene panel and NGS was carried out on the MiSeq instrument. Results from NGS were concordant with the mutational status determined by other platforms in 107 of the 113 cases tested (94.7%). The sequencing quality for NGS failed in four of the six false negative cases, while a further two samples gave false negative results because the c-KIT mutations were located outside the range of the NGS panel. One NSCLC sample contained an EGFR mutation previously detected by the Cobas assay. Reanalysis of the NGS data for this sample using a cut-off allele frequency of 1% revealed the mutation had an allele frequency of 2%, which was below the recommended software-determined threshold of 3%. NGS detected 113 additional mutations that were not previously known from analysis by the conventional methods. Twenty-six of these have known clinical importance, 37 have potential clinical significance, while 50 were novel mutations with unknown clinical significance. NGS detected variants using inputs of 10-20 ng of FFPE extracted DNA and from specimens with a tumour cell content less than 50%, for which when possible we recommend microdissection. We conclude that results from targeted NGS are highly concordant with those from other mutation testing platforms. Targeted NGS is suitable for a range of sample types received in the diagnostic pathology laboratory, including those with limited material or with low tumour cell content (TCC). This work has allowed us to determine the quality parameter settings required in order to obtain robust mutation data by NGS.	[Giardina, Tindaro; Robinson, Cleo; Grieu-Iacopetta, Fabienne; Spagnolo, Dominic; Amanuel, Benhur] QEII Med Ctr, PathWest Lab Med, Anat Pathol, Nedlands, WA, Australia; [Robinson, Cleo; Spagnolo, Dominic; Amanuel, Benhur] Univ Western Australia, Sch Pathol & Lab Med, Crawley, WA, Australia; [Robinson, Cleo; Millward, Michael] Univ Western Australia, Sch Med & Pharmacol, Crawley, WA, Australia; [Millward, Michael] Sir Charles Gairdner Hosp, Dept Med Oncol, Nedlands, WA, Australia; [Iacopetta, Barry] Univ Western Australia, Sch Biomed Sci, Crawley, WA, Australia	Amanuel, B (reprint author), QEII Med Ctr, PathWest Lab Med, Anat Pathol, Nedlands, WA, Australia.	benhur.amanuel@health.wa.gov.au					Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Ankala A, 2014, J MOL DIAGN, V16, P7, DOI 10.1016/j.jmoldx.2013.11.001; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Baudhuin LM, 2015, J MOL DIAGN, V17, P456, DOI 10.1016/j.jmoldx.2015.03.004; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Corless CL, 2016, J MOL DIAGN, V18, P813, DOI 10.1016/j.jmoldx.2016.08.002; Cottrell CE, 2014, J MOL DIAGN, V16, P89, DOI 10.1016/j.jmoldx.2013.10.002; Dong L, 2015, CURR GENOMICS, V16, P253, DOI 10.2174/1389202915666150511205313; Fisher KE, 2016, J MOL DIAGN, V18, P299, DOI 10.1016/j.jmoldx.2015.11.006; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Jennings LJ, 2017, J MOL DIAGN, V19, P341, DOI 10.1016/j.jmoldx.2017.01.011; Kluk MJ, 2016, J MOL DIAGN, V18, P507, DOI 10.1016/j.jmoldx.2016.02.003; Liu L, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/251364; Loman NJ, 2012, NAT BIOTECHNOL, V30, P434, DOI 10.1038/nbt.2198; Luthra R, 2015, CANCERS, V7, P2023, DOI 10.3390/cancers7040874; Matthijs G, 2016, EUR J HUM GENET, V24, P2, DOI 10.1038/ejhg.2015.226; Rafii A, 2014, HUM MOL GENET, V23, pR69, DOI 10.1093/hmg/ddu234; Rajeevan MS, 2017, J MOL DIAGN, V19, P226, DOI 10.1016/j.jmoldx.2017.01.001; Sukhai MA, 2016, GENET MED, V18, P128, DOI 10.1038/gim.2015.47; Wang SR, 2016, J MOL DIAGN, V18, P416, DOI 10.1016/j.jmoldx.2016.01.006; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764	21	5	5	1	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JUN	2018	50	4					389	401		10.1016/j.pathol.2018.01.005			13	Pathology	Pathology	GI6IW	WOS:000434474000005	29752127				2019-10-28	
J	Paton, DJW; Warburton, L; Chung, K; Meniawy, TM; Kumarasinghe, MP				Paton, David J. W.; Warburton, Lydia; Chung, Kim; Meniawy, Tarek M.; Kumarasinghe, M. Priyanthi			Ipilimumab- and nivolumab-associated enterocolitis with florid necrotising granulomatous inflammation: a novel manifestation of 'immunomodulatory' enterocolitis	PATHOLOGY			English	Letter							COLITIS; IMMUNOTHERAPY; MELANOMA		[Paton, David J. W.; Chung, Kim; Kumarasinghe, M. Priyanthi] QE2 Med Ctr, PathWest Lab Med, Perth, WA, Australia; [Warburton, Lydia; Meniawy, Tarek M.] Sir Charles Gairdner Hosp, Dept Med Oncol, Perth, WA, Australia; [Meniawy, Tarek M.] Univ Western Australia, Sch Med & Pharmacol, Nedlands, WA, Australia	Paton, DJW (reprint author), QE2 Med Ctr, PathWest Lab Med, Perth, WA, Australia.	david.paton@health.wa.gov.au		Meniawy, Tarek/0000-0002-1457-6137			Akel R, 2017, CASE REP ONCOL, V10, P456, DOI 10.1159/000475709; Bamias G, 2017, CANCER INVEST, V35, P443, DOI 10.1080/07357907.2017.1324032; Baroudjian B, 2016, MELANOMA RES, V26, P308, DOI 10.1097/CMR.0000000000000252; Beck KE, 2006, J CLIN ONCOL, V24, P2283, DOI 10.1200/JCO.2005.04.5716; Chen JH, 2017, AM J SURG PATHOL, V41, P643, DOI 10.1097/PAS.0000000000000829; De Felice KM, 2015, MELANOMA RES, V25, P321, DOI 10.1097/CMR.0000000000000165; Gonzalez RS, 2017, HISTOPATHOLOGY, V70, P223, DOI 10.1111/his.13068; Gupta A, 2015, ALIMENT PHARM THER, V42, P406, DOI 10.1111/apt.13281; Michot JM, 2016, EUR J CANCER, V54, P139, DOI 10.1016/j.ejca.2015.11.016; Mitchell KA, 2013, J CLIN GASTROENTEROL, V47, P781, DOI 10.1097/MCG.0b013e31828f1d51; Reuss JE, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0199-9; Zhang H, 2017, P NATL ACAD SCI USA, V114, pE970, DOI 10.1073/pnas.1616848114	12	0	0	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JUN	2018	50	4					466	469		10.1016/j.pathol.2017.11.094			5	Pathology	Pathology	GI6IW	WOS:000434474000019	29735170				2019-10-28	
J	Ellis, RJ; Small, DM; Ng, KL; Vesey, DA; Vitetta, L; Francis, RS; Gobe, GC; Morais, C				Ellis, Robert J.; Small, David M.; Ng, Keng Lim; Vesey, David A.; Vitetta, Luis; Francis, Ross S.; Gobe, Glenda C.; Morais, Christudas			Indoxyl Sulfate Induces Apoptosis and Hypertrophy in Human Kidney Proximal Tubular Cells	TOXICOLOGIC PATHOLOGY			English	Article						apoptosis/cell death; uremic toxins; nephrotoxin; mitochondria; kidney	MITOCHONDRIAL PERMEABILITY TRANSITION; BOUND UREMIC TOXINS; CHRONIC-RENAL-FAILURE; P-CRESYL SULFATE; NF-KAPPA-B; CYTOCHROME-C; PERITONEAL-DIALYSIS; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; GENE EXPRESSIONS	Indoxyl sulfate (IS) is a protein-bound uremic toxin that accumulates in patients with declining kidney function. Although generally thought of as a consequence of declining kidney function, emerging evidence demonstrates direct cytotoxic role of IS on endothelial cells and cardiomyocytes, largely through the expression of pro-inflammatory and pro-fibrotic factors. The direct toxicity of IS on human kidney proximal tubular epithelial cells (PTECs) remains a matter of debate. The current study explored the effect of IS on primary cultures of human PTECs and HK-2, an immortalized human PTEC line. Pathologically relevant concentrations of IS induced apoptosis and increased the expression of the proapoptotic molecule Bax in both cell types. IS impaired mitochondrial metabolic activity and induced cellular hypertrophy. Furthermore, statistically significant upregulation of pro-fibrotic (transforming growth factor-beta, fibronectin) and pro-inflammatory molecules (interleukin-6, interleukin-8, and tumor necrosis factor-alpha) in response to IS was observed. Albumin had no influence on the toxicity of IS. The results of this study suggest that IS directly induced a pro-inflammatory and pro-fibrotic phenotype in proximal tubular cells. In light of the associated apoptosis, hypertrophy, and metabolic dysfunction, this study demonstrates that IS may play a role in the progression of chronic kidney disease.	[Ellis, Robert J.; Small, David M.; Ng, Keng Lim; Vesey, David A.; Francis, Ross S.; Gobe, Glenda C.; Morais, Christudas] Univ Queensland, Translat Res Inst, Ctr Kidney Dis Res, Brisbane, Qld, Australia; [Ellis, Robert J.; Ng, Keng Lim] Princess Alexandra Hosp, Dept Urol, Brisbane, Qld, Australia; [Small, David M.] Cornell Univ, Dept Biomed Engn, Ithaca, NY USA; [Vesey, David A.; Francis, Ross S.] Princess Alexandra Hosp, Dept Nephrol, Brisbane, Qld, Australia; [Vitetta, Luis] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia; [Vitetta, Luis] Medlab Clin, Sydney, NSW, Australia	Gobe, GC (reprint author), Univ Queensland, Translat Res Inst, Ctr Kidney Dis Res, 37 Kent St, Woolloongabba, Qld 4102, Australia.	g.gobe@uq.edu.au	Ellis, Robert/C-7335-2016; Small, David M/E-6064-2019; Vitetta, Luis/F-4206-2010; Small, David M/S-1969-2019; Vesey, David A/C-2253-2011; Francis, Ross/A-7757-2011	Ellis, Robert/0000-0002-9755-9913; Small, David M/0000-0003-3034-4747; Vitetta, Luis/0000-0002-7490-9298; Small, David M/0000-0003-3034-4747; Vesey, David A/0000-0002-2856-6650; Francis, Ross/0000-0002-3995-7040	Australian Government Research Training Stipend	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Robert Ellis was supported by an Australian Government Research Training Stipend while undertaking a portion of this work.	Bammens B, 2003, KIDNEY INT, V64, P2238, DOI 10.1046/j.1523-1755.2003.00310.x; Benipal B, 2013, BIOCHEM PHARMACOL, V85, P1379, DOI 10.1016/j.bcp.2013.02.013; Benipal B, 2011, BIOCHEM PHARMACOL, V81, P295, DOI 10.1016/j.bcp.2010.10.010; Deguchi T, 2002, KIDNEY INT, V61, P1760, DOI 10.1046/j.1523-1755.2002.00318.x; Duranton F, 2012, J AM SOC NEPHROL, V23, P1258, DOI 10.1681/ASN.2011121175; Ellis Robert J, 2017, Asian Pac J Cancer Prev, V18, P3281; Ellis RJ, 2016, NEPHROLOGY, V21, P170, DOI 10.1111/nep.12580; Enoki Y, 2017, J CACHEXIA SARCOPENI, V8, P735, DOI 10.1002/jcsm.12202; Erkan E, 2007, J AM SOC NEPHROL, V18, P1199, DOI 10.1681/ASN.2006040407; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Gelasco AK, 2006, AM J PHYSIOL-RENAL, V290, pF1551, DOI 10.1152/ajprenal.00281.2004; Gobe Glenda, 2009, V466, P175, DOI 10.1007/978-1-59745-352-3_13; Hammarlund-Udenaes M, 2010, BASIC CLIN PHARMACOL, V106, P215, DOI 10.1111/j.1742-7843.2009.00517.x; HARRIS DCH, 1988, AM J PHYSIOL, V254, pF267; HWANG S, 1990, J AM SOC NEPHROL, V1, P822; Itoh Y, 2012, ANAL BIOANAL CHEM, V403, P1841, DOI 10.1007/s00216-012-5929-3; Johnson A, 2013, FASEB J, V27, P3893, DOI 10.1096/fj.12-214189; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kim SH, 2012, LAB INVEST, V92, P488, DOI 10.1038/labinvest.2011.194; Lee CT, 2010, PERITON DIALYSIS INT, V30, P456, DOI 10.3747/pdi.2009.00092; Lee Wen-Chin, 2015, ScientificWorldJournal, V2015, P620826, DOI 10.1155/2015/620826; Lesaffer G, 2000, NEPHROL DIAL TRANSPL, V15, P50, DOI 10.1093/ndt/15.1.50; Marchetti P, 1996, J IMMUNOL, V157, P4830; Mei SQ, 2017, SCI REP-UK, V7, DOI 10.1038/srep44892; Mene P, 1998, NEPHROL DIAL TRANSPL, V13, P1936, DOI 10.1093/ndt/13.8.1936; Meyer TW, 2007, NEW ENGL J MED, V357, P1316, DOI 10.1056/NEJMra071313; Miyazaki T, 1997, KIDNEY INT, V52, pS15; Miyazaki T, 1997, KIDNEY INT, pS211; Motojima M, 2003, KIDNEY INT, V63, P1671, DOI 10.1046/j.1523-1755.2003.00906.x; Mutsaers HAM, 2013, BBA-MOL BASIS DIS, V1832, P142, DOI 10.1016/j.bbadis.2012.09.006; NATH KA, 1990, AM J PHYSIOL, V258, pF1354; Nishikawa M, 2015, NEPHROL DIAL TRANSPL, V30, P934, DOI 10.1093/ndt/gfv103; NIWA T, 1994, J LAB CLIN MED, V124, P96; Ola MS, 2011, MOL CELL BIOCHEM, V351, P41, DOI 10.1007/s11010-010-0709-x; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Owada S, 2008, AM J NEPHROL, V28, P446, DOI 10.1159/000112823; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Rosse T, 1998, NATURE, V391, P496; Rossi M, 2014, ARCH MED RES, V45, P309, DOI 10.1016/j.arcmed.2014.04.002; SHAPIRO JI, 1994, KIDNEY INT, V45, pS100; Shimizu H, 2011, AM J PHYSIOL-CELL PH, V301, pC1201, DOI 10.1152/ajpcell.00471.2010; Shimizu H, 2010, AM J PHYSIOL-CELL PH, V299, pC1110, DOI 10.1152/ajpcell.00217.2010; Sun CY, 2013, NEPHROL DIAL TRANSPL, V28, P70, DOI 10.1093/ndt/gfs133; Sun CY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034026; Taki K, 2006, J RENAL NUTR, V16, P199, DOI 10.1053/j.jrn.2006.04.020; Tan X, 2017, HEMODIAL INT, V21, P161, DOI 10.1111/hdi.12483; Thakor P, 2017, J KIDNEY CANCER VHL, V4, P16, DOI 10.15586/jkcvhl.2017.64; Thomas GL, 1998, NEPHROL DIAL TRANSPL, V13, P2216, DOI 10.1093/ndt/13.9.2216; Ujhelyi L, 2006, KIDNEY INT, V69, P144, DOI 10.1038/sj.ki.5000007; Vanholder R, 2003, KIDNEY INT, V63, P1934, DOI 10.1046/j.1523-1755.2003.00924.x; Vanholder R, 1999, J AM SOC NEPHROL, V10, P1815; Vanholder R, 2014, J AM SOC NEPHROL, V25, P1897, DOI 10.1681/ASN.2013101062; Vesey David A., 2009, V466, P19, DOI 10.1007/978-1-59745-352-3_2; Wang HZ, 1996, J OCUL PHARMACOL TH, V12, P35, DOI 10.1089/jop.1996.12.35; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wu IW, 2011, NEPHROL DIAL TRANSPL, V26, P938, DOI 10.1093/ndt/gfq580; Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807; Yang B, 2001, J AM SOC NEPHROL, V12, P275; Yang K, 2015, J AM SOC NEPHROL, V26, P2434, DOI 10.1681/ASN.2014060543; YIN XM, 1994, COLD SPRING HARB SYM, V59, P387, DOI 10.1101/SQB.1994.059.01.043; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zhu YJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156729; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	64	4	4	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JUN	2018	46	4					449	459		10.1177/0192623318768171			11	Pathology; Toxicology	Pathology; Toxicology	GK3US	WOS:000436074500009	29683083	Bronze			2019-10-28	
J	Roma, AA; Fadare, O				Roma, Andres A.; Fadare, Oluwole			The pattern is the issue: recent advances in adenocarcinoma of the uterine cervix	VIRCHOWS ARCHIV			English	Review						Endocervical adenocarcinoma; Pattern; Risk stratification system; HPV; Cervix	INVASIVE ENDOCERVICAL ADENOCARCINOMA; CLINICAL-IMPLICATIONS; CLASSIFICATION-SYSTEM; GLANDULAR LESIONS; ADENOMA MALIGNUM; IN-SITU; CARCINOMA; MANAGEMENT; BENIGN; CANCER	In this article, we review a novel risk stratification system for endocervical adenocarcinoma, developed by an international consortium of pathologists after reviewing over 350 such tumors. Their analysis culminated in a three-tiered histopathologic system based on morphologic examination of the tumor, independent of clinical features and stage (depth of invasion). It resulted in better determination of patients' tumors and likelihood of lymph node metastasis as well as aggressive behavior. A non-destructive pattern (that in some cases was in the histologic differential diagnosis with adenocarcinoma in situ) had an indolent behavior and was labeled pattern A. The other two patterns had destructive invasion, one only focally (pattern B) while pattern C showed diffuse destructive invasion. This system can help select appropriate treatment modalities avoiding unnecessary complications. We comment on specifics of this system as well as issues in differentiation of the tumor patterns, its clinical utility and recent advances in the molecular arena.	[Roma, Andres A.; Fadare, Oluwole] Univ Calif San Diego, Dept Pathol, MC 8720,Room 2-129,200 West Arbor Dr, San Diego, CA 92103 USA	Roma, AA (reprint author), Univ Calif San Diego, Dept Pathol, MC 8720,Room 2-129,200 West Arbor Dr, San Diego, CA 92103 USA.	aroma@ucsd.edu					Alvarado-Cabrero I, 2017, INT J GYNECOL PATHOL, V36, P476, DOI 10.1097/PGP.0000000000000357; [Anonymous], 2017, NATL COMPREHENSIVE C; Bean SM, 2011, J LOW GENIT TRACT DI, V15, P146, DOI 10.1097/LGT.0b013e3181fb425d; Benedet JL, 2000, INT J GYNECOL OBSTET, V70, P209; BUSCEMA J, 1984, GYNECOL ONCOL, V17, P356, DOI 10.1016/0090-8258(84)90221-X; CREASMAN WT, 1985, AM J OBSTET GYNECOL, V153, P164, DOI 10.1016/0002-9378(85)90105-X; De Vivar AD, 2013, INT J GYNECOL PATHOL, V32, P592, DOI 10.1097/PGP.0b013e31829952c6; Diab Y, 2017, INT J GYNECOL CANCER, V27, P154, DOI 10.1097/IGC.0000000000000853; Douglas G, 2017, PATHOL RES PRACT, V213, P799, DOI 10.1016/j.prp.2017.03.008; Edge SB, 2010, AJCC CANC STAGING MA; Epstein JI, 2017, AM J SURG PATHOL, V41, pE1, DOI 10.1097/PAS.0000000000000820; Fujiwara H, 2014, INT J GYNECOL CANCER, V24, pS96, DOI 10.1097/IGC.0000000000000263; GILKS CB, 1989, AM J SURG PATHOL, V13, P717, DOI 10.1097/00000478-198909000-00001; Hodgson A, 2017, MODERN PATHOL, V30, P1633, DOI 10.1038/modpathol.2017.80; Ishii K, 1998, VIRCHOWS ARCH, V432, P315, DOI 10.1007/s004280050172; Kurman RJ, 2014, WHO CLASSIFICATION T, P170; Mikami Y, 2013, ADV ANAT PATHOL, V20, P227, DOI 10.1097/PAP.0b013e31829c2d66; Ostor AG, 2000, INT J GYNECOL PATHOL, V19, P29; Paquette C, 2015, AM J SURG PATHOL, V39, P93, DOI 10.1097/PAS.0000000000000316; Park KJ, 2018, PATHOLOGY, V50, P134, DOI 10.1016/j.pathol.2017.09.011; Parra-Herran C, 2016, MODERN PATHOL, V29, P879, DOI 10.1038/modpathol.2016.86; Pecorelli S, 2009, INT J GYNECOL OBSTET, V105, P103, DOI 10.1016/j.ijgo.2009.02.012; Poynor EA, 2006, GYNECOL ONCOL, V103, P960, DOI 10.1016/j.ygyno.2006.05.041; Reynolds EA, 2010, OBSTET GYNECOL, V116, P1150, DOI 10.1097/AOG.0b013e3181f74062; Roma AA, 2017, AM J SURG PATHOL, V41, P1205, DOI 10.1097/PAS.0000000000000822; Roma AA, 2016, GYNECOL ONCOL, V141, P36, DOI 10.1016/j.ygyno.2016.02.028; Roma AA, 2015, AM J SURG PATHOL, V39, P667, DOI 10.1097/PAS.0000000000000402; Rutgers JKL, 2016, MODERN PATHOL, V29, P1083, DOI 10.1038/modpathol.2016.94; SEVIN BU, 1992, CANCER, V70, P2121, DOI 10.1002/1097-0142(19921015)70:8<2121::AID-CNCR2820700819>3.0.CO;2-S; Togami S, 2012, GYNECOL OBSTET INVES, V73, P26, DOI 10.1159/000329319; Trope C, 2001, CME J GYNECOL ONCOL, V6, P240; Zaino RJ, 2002, INT J GYNECOL PATHOL, V21, P314, DOI 10.1097/01.PGP.0000035801.90350.90; Zaino RJ, 2000, MODERN PATHOL, V13, P261, DOI 10.1038/modpathol.3880047; Zhou C, 1998, AM J SURG PATHOL, V22, P113, DOI 10.1097/00000478-199801000-00015	34	1	1	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUN	2018	472	6					897	905		10.1007/s00428-018-2312-6			9	Pathology	Pathology	GJ5GU	WOS:000435410300003	29404709				2019-10-28	
J	Ip, PPC				Ip, Philip Pun-Ching			Benign endometrial proliferations mimicking malignancies: a review of problematic entities in small biopsy specimens	VIRCHOWS ARCHIV			English	Review						Endometrium; Papillary proliferation; Mucinous; Mucinous metaplasia; Arias-Stella reaction; Endometrial polyp; Endometrial hyperplasia; Mullerian adenosarcoma	ARIAS-STELLA REACTION; CLEAR-CELL CARCINOMA; MUCINOUS LESIONS; SYNCYTIAL CHANGE; POLYPS; METAPLASIA; ADENOCARCINOMA; HYPERPLASIA; FEATURES; EXPRESSION	Benign proliferations that mimic malignancies are commonly encountered during the course of assessment of small and fragmented endometrial samples. Although benign, endometrial epithelial metaplasias often coexist with premalignant or malignant lesions causing diagnostic confusion. The difficulty with mucinous metaplasia lies in its distinction from atypical mucinous glandular proliferations and mucinous carcinomas, which are associated with significant interobserver variability. Papillary proliferation of the endometrium is commonly associated with hormonal drugs and endometrial polyps and is characterised by papillae with fibrovascular cores covered by epithelial cells without cytologic atypia. They are classified into simple or complex papillary proliferations depending on the architectural complexity and extent of proliferation. Complex papillary proliferations are associated with a high risk of concurrent or subsequent hyperplasia with atypia/carcinoma. Papillary proliferations may have coexisting epithelial metaplasias and, most commonly, mucinous metaplasia and syncytial papillary change. Those with striking mucinous metaplasia overlap morphologically with papillary mucinous metaplasia. The latter has been proposed as a precursor of endometrial mucinous carcinoma. Misinterpreting the Arias-Stella reaction as a malignant or premalignant lesion is more likely to occur if the pathologist is unaware that the patient is pregnant or on hormonal drugs. Endometrial hyperplasia with secretory changes may occasionally be difficult to distinguish from the torturous and crowded glands of a late secretory endometrium. Endometrial polyps may have abnormal features that can be misinterpreted as endometrial hyperplasia or Mullerian adenosarcoma. Awareness of these benign endometrial proliferations and their common association with hormonal medication or altered endogenous hormonal levels will help prevent the over-diagnosis of premalignant and malignant lesions.	[Ip, Philip Pun-Ching] Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Block T,102 Pok Fu Lam Rd, Pok Fu Lam, Hong Kong, Peoples R China	Ip, PPC (reprint author), Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Block T,102 Pok Fu Lam Rd, Pok Fu Lam, Hong Kong, Peoples R China.	philipip@pathology.hku.hk		Ip, Philip Pun-Ching/0000-0002-0493-9838			Alomari A, 2014, MODERN PATHOL, V27, P675, DOI 10.1038/modpathol.2013.186; Arias-Stella J, 2002, ADV ANAT PATHOL, V9, P12, DOI 10.1097/00125480-200201000-00003; ARIASSTELLA J, 1972, HUM PATHOL, V3, P450, DOI 10.1016/S0046-8177(72)80003-0; BELL CD, 1987, HUM PATHOL, V18, P830; Clement PB, 2014, ATLAS GYNECOLOGIC SU, P148; DALCIN P, 1995, CANCER RES, V55, P1565; DEMOPOULOS RI, 1983, INT J GYNECOL PATHOL, V1, P383, DOI 10.1097/00004347-198301040-00008; Fadare O, 2016, HUM PATHOL, V54, P202, DOI 10.1016/j.humpath.2016.02.028; Fadare O, 2014, AM J SURG PATHOL, V38, P189, DOI 10.1097/PAS.0000000000000085; Fujiwara M, 2011, AM J SURG PATHOL, V35, P537, DOI 10.1097/PAS.0b013e31820f1cc2; Gurda GT, 2014, INT J GYNECOL PATHOL, V33, P114, DOI 10.1097/PGP.0000000000000092; Hattab EM, 1999, INT J GYNECOL PATHOL, V18, P332, DOI 10.1097/00004347-199910000-00007; He M, 2015, AM J CLIN PATHOL, V143, P778, DOI 10.1309/AJCP69RBNUHHOJRI; Heller D, 2016, INT J SURG PATHOL, V24, P320, DOI 10.1177/1066896916632589; HENDRICKSON MR, 1980, AM J SURG PATHOL, V4, P525, DOI 10.1097/00000478-198012000-00004; HOLMES EJ, 1973, ARCH PATHOL, V95, P302; Howitt BE, 2015, AM J SURG PATHOL, V39, P116, DOI 10.1097/PAS.0000000000000303; HUETTNER PC, 1994, INT J GYNECOL PATHOL, V13, P241, DOI 10.1097/00004347-199407000-00008; Ip PPC, 2013, AM J SURG PATHOL, V37, P167, DOI 10.1097/PAS.0b013e318272d428; Karim RZ, 2003, PATHOLOGY, V35, P522, DOI 10.1080/00313020310001619109; Kennedy MM, 1999, INT J GYNECOL PATHOL, V18, P130, DOI 10.1097/00004347-199904000-00006; Kim KR, 2004, AM J SURG PATHOL, V28, P1057, DOI 10.1097/01.pas.0000128659.73944.f3; Lehman MB, 2001, AM J SURG PATHOL, V25, P1347, DOI 10.1097/00000478-200111000-00001; Lim D, 2015, AM J SURG PATHOL, V39, P1061, DOI 10.1097/PAS.0000000000000436; LIPPER S, 1981, ARCH PATHOL LAB MED, V105, P116; MAZUR MT, 1983, AM J SURG PATHOL, V7, P415, DOI 10.1097/00000478-198307000-00004; MCCORMICK CJ, 1995, HISTOPATHOLOGY, V26, P575, DOI 10.1111/j.1365-2559.1995.tb00278.x; Mikami Y, 2009, HISTOPATHOLOGY, V54, P184, DOI 10.1111/j.1365-2559.2008.03202.x; Miliaras D., 1997, Journal of Obstetrics and Gynaecology (Abingdon), V17, P309; Murray SK, 2000, INT J SURG PATHOL, V8, P279, DOI 10.1177/106689690000800407; Nicolae A, 2011, INT J GYNECOL PATHOL, V30, P492, DOI 10.1097/PGP.0b013e318211d586; Nicolae A, 2011, J CLIN PATHOL, V64, P97, DOI 10.1136/jcp.2010.085555; Nucci MR, 1999, MODERN PATHOL, V12, P1137; Park CK, 2016, ONCOTARGET, V7, P39197, DOI 10.18632/oncotarget.10049; Rawish KR, 2017, HUM PATHOL, V63, P53, DOI 10.1016/j.humpath.2017.02.002; Rekhi B, 2015, DIAGN CYTOPATHOL, V43, P163, DOI 10.1002/dc.23170; Rosai J, 2015, INT J GYNECOL PATHOL, V34, P314, DOI 10.1097/PGP.0000000000000223; Seto MTY, 2016, EUR J OBSTET GYN R B, V203, P12, DOI 10.1016/j.ejogrb.2016.04.027; Shah SS, 2008, INT J GYNECOL PATHOL, V27, P534, DOI 10.1097/PGP.0b013e31817323b3; Tai LH, 2002, AM J SURG PATHOL, V26, P505, DOI 10.1097/00000478-200204000-00014; Tallini G, 2000, LAB INVEST, V80, P359, DOI 10.1038/labinvest.3780040; TOBON H, 1985, INT J GYNECOL PATHOL, V4, P328, DOI 10.1097/00004347-198512000-00005; Tresserra F, 2003, GYNECOL ONCOL, V88, P386, DOI 10.1016/S0090-8258(02)00140-3; Truskinovsky AM, 2014, INT J GYNECOL PATHOL, V33, P107, DOI 10.1097/PGP.0b013e3182a2945d; Vang R, 2004, INT J GYNECOL PATHOL, V23, P223, DOI 10.1097/01.pgp.0000130106.13533.38; Vang R, 2003, INT J SURG PATHOL, V11, P261, DOI 10.1177/106689690301100403; Wheeler DT, 2007, AM J SURG PATHOL, V31, P988, DOI 10.1097/PAS.0b013e31802d68ce; Yamani F, 2016, INT J SURG PATHOL, V24, P330, DOI 10.1177/1066896915626282; Yoo SH, 2012, MODERN PATHOL, V25, P1496, DOI 10.1038/modpathol.2012.113; Zaino RJ, 1998, AM J SURG PATHOL, V22, P1379, DOI 10.1097/00000478-199811000-00008; Zaino RJ, 2014, WHO CLASSIFICATION T, P125; ZAMAN SS, 1993, AM J CLIN PATHOL, V99, P741, DOI 10.1093/ajcp/99.6.741	52	1	1	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUN	2018	472	6					907	917		10.1007/s00428-018-2314-4			11	Pathology	Pathology	GJ5GU	WOS:000435410300004	29445890				2019-10-28	
J	Vento, SI; Jouhi, L; Mohamed, H; Haglund, C; Makitie, AA; Atula, T; Hagstrom, J; Makinen, LK				Vento, Seija I.; Jouhi, Lauri; Mohamed, Hesham; Haglund, Caj; Makitie, Antti A.; Atula, Timo; Hagstrom, Jaana; Makinen, Laura K.			MMP-7 expression may influence the rate of distant recurrences and disease-specific survival in HPV-positive oropharyngeal squamous cell carcinoma	VIRCHOWS ARCHIV			English	Article						Oropharyngeal cancer; Matrix metalloproteinase-7; MMP-7; HPV; Survival analysis	SQUAMOCOLUMNAR JUNCTION CELLS; HUMAN-PAPILLOMAVIRUS HPV; MATRIX METALLOPROTEINASES; TISSUE INHIBITORS; UNITED-STATES; NECK CANCERS; HEAD; POPULATION; MATRILYSIN; PROGNOSIS	The objective of this study was to determine if matrix metalloproteinase-7 (MMP-7) expression is related to human papilloma virus (HPV) status, clinical parameters, and outcome in oropharyngeal squamous cell carcinoma (OPSCC). Tumor tissue specimens from 201 OPSCC patients treated with curative intent were available for immunohistochemistry, and the samples were stained with monoclonal MMP-7 antibody. All the patients were followed up at least 3 years or until death. MMP-7 expression did not differ between HPV-positive and HPV-negative patients. MMP-7 was not prognostic among patients with HPV-negative OPSCC. In the HPV-positive subgroup, patients with moderate, high, or very high MMP-7 expression had significantly worse 5-year disease-specific survival (DSS) (56.6%) than patients with absent, or low MMP-7 expression (77.2%), and MMP-7 expression appeared as a prognostic factor in the multivariate analysis. In addition, among HPV-positive OPSCC with moderate, high, or very high MMP-7 expression, the 5-year distant recurrence-free survival was significantly lower (69.6%) than in those who had low or absent MMP-7 expression (97.5%). Our results suggest that among HPV-positive OPSCC patients, high MMP-7 expression is related to worse 5-year DSS and increased rate of distant recurrences.	[Vento, Seija I.; Jouhi, Lauri; Makitie, Antti A.; Atula, Timo; Makinen, Laura K.] Univ Helsinki, Dept Otorhinolalyngol Head & Neck Surg, POB 263, Hus Helsinki 00029, Finland; [Vento, Seija I.; Jouhi, Lauri; Makitie, Antti A.; Atula, Timo; Makinen, Laura K.] Helsinki Univ Hosp, POB 263, Hus Helsinki 00029, Finland; [Mohamed, Hesham; Hagstrom, Jaana] Univ Helsinki, Dept Pathol, Helsinki, Finland; [Mohamed, Hesham; Haglund, Caj; Hagstrom, Jaana] Helsinki Univ Hosp, Helsinki, Finland; [Haglund, Caj] Univ Helsinki, Dept Surg, Helsinki, Finland; [Haglund, Caj] Univ Helsinki, Res Programs Unit, Translat Canc Biol, Helsinki, Finland; [Makitie, Antti A.] Karolinska Inst, Div Ear Nose & Throat Dis, Dept Clin Sci Intervent & Technol, Karolinska Univ Hosp, S-17176 Stockholm, Sweden	Vento, SI (reprint author), Univ Helsinki, Dept Otorhinolalyngol Head & Neck Surg, POB 263, Hus Helsinki 00029, Finland.; Vento, SI (reprint author), Helsinki Univ Hosp, POB 263, Hus Helsinki 00029, Finland.	seija.vento@hus.fi	Atula, Timo/E-3880-2019; Hagstrom, Jaana/G-1468-2018; Haglund, Caj/N-1240-2019	Atula, Timo/0000-0002-6560-1128; Hagstrom, Jaana/0000-0001-6079-7881; 	Helsinki University Hospital Research Fund [TYH2017232]; Finska Lakaresallskapet	This study was funded by the Helsinki University Hospital Research Fund (Grant number of TYH2017232) and funding from the Finska Lakaresallskapet (AM).	Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Burduk PK, 2015, HEAD NECK-J SCI SPEC, V37, P418, DOI 10.1002/hed.23618; Chaturvedi AK, 2008, J CLIN ONCOL, V26, P612, DOI 10.1200/JCO.2007.14.1713; Chaturvedi AK, 2013, J CLIN ONCOL, V31, P4550, DOI 10.1200/JCO.2013.50.3870; Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596; Chuang HC, 2008, MODERN PATHOL, V21, P1444, DOI 10.1038/modpathol.2008.99; de Vicente JC, 2007, J ORAL PATHOL MED, V36, P415, DOI 10.1111/j.1600-0714.2007.00546.x; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Dunne AA, 2005, ANTICANCER RES, V25, P4129; Fung N, 2017, CANCER METAST REV, V36, P449, DOI 10.1007/s10555-017-9686-9; Gillison ML, 2008, JNCI-J NATL CANCER I, V100, P407, DOI 10.1093/jnci/djn025; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Herfs M, 2012, P NATL ACAD SCI USA, V109, P10516, DOI 10.1073/pnas.1202684109; Hua H, 2011, CELL MOL LIFE SCI, V68, P3853, DOI 10.1007/s00018-011-0763-x; Ii M, 2006, EXP BIOL MED, V231, P20; Iizuka S, 2014, CANCERS, V6, P396, DOI 10.3390/cancers6010396; Jouhi L, 2017, CANCER IMMUNOL IMMUN, V66, P1619, DOI 10.1007/s00262-017-2054-3; Lee SY, 2011, CLIN EXP OTORHINOLAR, V4, P88, DOI 10.3342/ceo.2011.4.2.88; Makinen LK, 2014, HEAD NECK-J SCI SPEC, V36, P1783, DOI 10.1002/hed.23539; Masaki T, 2001, BRIT J CANCER, V84, P1317, DOI 10.1054/bjoc.2001.1790; Mirghani H, 2015, INT J CANCER, V136, P1494, DOI 10.1002/ijc.28847; Morbini P, 2015, HISTOL HISTOPATHOL, V30, P833, DOI 10.14670/HH-11-590; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nasman A, 2009, INT J CANCER, V125, P362, DOI 10.1002/ijc.24339; Nichols AC, 2013, CURR ONCOL, V20, P212, DOI 10.3747/co.20.1375; O'Sullivan B, 2013, J CLIN ONCOL, V31, P543, DOI 10.1200/JCO.2012.44.0164; Ragin CCR, 2007, INT J CANCER, V121, P1813, DOI 10.1002/ijc.22851; Ramankulov A, 2008, CANCER SCI, V99, P1188, DOI 10.1111/j.1349-7006.2008.00802.x; Reimers N, 2007, INT J CANCER, V120, P1731, DOI 10.1002/ijc.22355; Rietbergen MM, 2014, J ORAL PATHOL MED, V43, P137, DOI 10.1111/jop.12123; Rietbergen MM, 2013, INT J CANCER, V132, P1565, DOI 10.1002/ijc.27821; Shiboski CH, 2005, CANCER-AM CANCER SOC, V103, P1843, DOI 10.1002/cncr.20998; Sorsa T, 2006, ANN MED, V38, P306, DOI 10.1080/07853890600800103; Sturgis EM, 2011, J NATL COMPR CANC NE, V9, P665, DOI 10.6004/jnccn.2011.0055; Wang WS, 2006, CARCINOGENESIS, V27, P1113, DOI 10.1093/carcin/bgi351; Weber A, 2007, HUM PATHOL, V38, P228, DOI 10.1016/j.humpath.2006.07.012; Yamamoto H, 2001, J CLIN ONCOL, V19, P1118, DOI 10.1200/JCO.2001.19.4.1118	37	1	1	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUN	2018	472	6					975	981		10.1007/s00428-018-2365-6			7	Pathology	Pathology	GJ5GU	WOS:000435410300011	29721609	Green Published			2019-10-28	
J	Bortesi, M; Martino, V; Marchetti, M; Cavazza, A; Gardini, G; Zanetti, E; Bassi, MC; Ghirotto, L; Costantini, M; Piana, S				Bortesi, M.; Martino, V.; Marchetti, M.; Cavazza, A.; Gardini, G.; Zanetti, E.; Bassi, M. C.; Ghirotto, L.; Costantini, M.; Piana, Simonetta			Pathologist's assistant (PathA) and his/her role in the surgical pathology department: a systematic review and a narrative synthesis	VIRCHOWS ARCHIV			English	Review						Pathologist's assistant; Extenders; Surgical pathology; Grossing; Anatomic pathology laboratory	LYMPH-NODE HARVEST; BIOMEDICAL SCIENTISTS; SPECIMENS; BENEFITS; QUALITY; PROGRAM; CANCER	In recent decades, various highly qualified individuals have increasingly performed tasks that have historically been handled by physicians with the aim of reducing their workload. Over time, however, these "physician assistants" or "physician extenders" have gained more and more responsibilities, showing that specific tasks can be performed equally skilfully by specialised health care professionals. The pathologist's assistant (PathA) is a highly qualified technician who works alongside the pathologist and is responsible for the grossing and autopsies. This profession was developed in the USA, with formal training programmes starting in 1970 when Dr. Kinney, director of the Department of Pathology of Duke University, Durham, NC, started the first dedicated course. Most institutes in the USA and Canada currently employ these technical personnel for grossing, and numerous papers published over the years demonstrate the quality of the assistance provided by the PathA, which is equal to or sometimes even better than the performance of pathologists. The PathA can be employed to carry out a wide range of tasks to assist the pathologist, such as grossing (the description and reduction of surgical specimens), judicial autopsies and administrative and supervisory practices within the laboratory or assistance in research, although the diagnosis is always the pathologist's responsibility. Since this role has already been consolidated in North America, part of the relevant literature is altogether out of date. However, the situation is different in Europe, where there is an increasing interest in PathA, mainly because of the benefits of their inclusion in anatomic pathology laboratories. In the UK, biomedical scientists (BMS, the British equivalent of PathA) are involved in many tasks both in surgical pathology and in cytopathology, which are generally performed by medically trained staff. Several papers have been recently published to highlight the role of BMS with the broader public. This report aimed to conduct a systematic review of all the articles published about the PathA/BMS and to perform a narrative synthesis. The results may contribute to the evidence for including the PAthA/BMS within a surgical pathology laboratory organisation.	[Bortesi, M.; Martino, V.; Marchetti, M.; Cavazza, A.; Gardini, G.; Zanetti, E.; Piana, Simonetta] Azienda USL, IRCCS Reggio Emilia, Arcispedale Santa Maria Nuova, Pathol Unit, Viale Risorgimento 80, I-40123 Reggio Emilia, Italy; [Bassi, M. C.] Azienda USL, Med Lib, IRCCS Reggio Emilia, Reggio Emilia, Italy; [Ghirotto, L.; Costantini, M.] Azienda USL, Sci Directorate, IRCCS Reggio Emilia, Reggio Emilia, Italy	Piana, S (reprint author), Azienda USL, IRCCS Reggio Emilia, Arcispedale Santa Maria Nuova, Pathol Unit, Viale Risorgimento 80, I-40123 Reggio Emilia, Italy.	Simonetta.Piana@ausl.re.it	Ghirotto, Luca/L-2191-2016; Cavazza, Alberto/K-2531-2018; Ghirotto, Luca/M-8650-2019	Ghirotto, Luca/0000-0001-7632-1271; Cavazza, Alberto/0000-0003-3590-319X; Ghirotto, Luca/0000-0001-7632-1271; Zanetti, Eleonora/0000-0002-3483-130X; PIANA, SIMONETTA/0000-0003-4875-6977			Allen DC, 2004, CURR DIAGN PATHOL, V10, P429, DOI 10.1016/j.cdip.2004.07.001; American Association of Pathologists' Assistant web site, 2017, WHAT IS PATH ASS; Breeze J, 2014, CYTOPATHOLOGY, V25, P316, DOI 10.1111/cyt.12106; Brown DC, 1999, CYTOPATHOLOGY, V10, P229, DOI 10.1046/j.1365-2303.1999.00202.x; Duthie FR, 2004, J CLIN PATHOL, V57, P27, DOI 10.1136/jcp.57.1.27; Enriquez R E, 1991, MLO Med Lab Obs, V23, P33; ENRIQUEZ RE, 1988, LAB MED, V19, P376, DOI 10.1093/labmed/19.6.376; Galvis CO, 2001, AM J CLIN PATHOL, V116, P816; Grealish M, 2017, J CLIN PATHOL, V70, P998, DOI 10.1136/jclinpath-2017-204731; Grzybicki DM, 1999, AM J CLIN PATHOL, V112, P619; Grzybicki DM, 2004, ARCH PATHOL LAB MED, V128, P165; Grzybicki DM, 2003, ARCH PATHOL LAB MED, V127, P666; Grzybicki DM, 2001, ARCH PATHOL LAB MED, V125, P905; James SL, 2016, DIAGN HISTOPATHOL, V22, P300, DOI [10.1016/j.mpdhp.2016.07.001, DOI 10.1016/J.MPDHP.2016.07.001]; Kelly LJ, 1979, LAB MED, V10, P367; KINNEY TD, 1974, HUM PATHOL, V5, P503, DOI 10.1016/S0046-8177(74)80001-8; Kuijpers CCHJ, 2013, J CLIN PATHOL, V66, P18, DOI 10.1136/jclinpath-2012-201089; Lee D, 2014, CAP ACP, V5, P128; Meeney A, 2013, EYE, V27, P272, DOI 10.1038/eye.2012.282; MERGNER WJ, 1981, HUM PATHOL, V12, P207, DOI 10.1016/S0046-8177(81)80120-7; Narine N, 2012, BRIT J BIOMED SCI, V69, P108, DOI 10.1080/09674845.2012.12069135; NERI RA, 1986, AM J CLIN PATHOL, V85, P87, DOI 10.1093/ajcp/85.1.87; Pope C., 2007, SYNTHESIZING QUALITA; Reese JA, 2009, J GASTROINTEST SURG, V13, P1459, DOI 10.1007/s11605-009-0820-z; Sanders SA, 2012, J CLIN PATHOL, V65, P517, DOI [10.1136/jcp.2009.069039, 10.1136/jclinpath-2011-200625]; Shaw A, 2008, TECH COLOPROCTOL, V12, P295, DOI 10.1007/s10151-008-0438-2; Simmons EJV, 2011, J CLIN PATHOL, V64, P363, DOI 10.1136/jcp.2011.088955; Vitale J, 2012, ARCH PATHOL LAB MED, V136, P1565, DOI 10.5858/arpa.2011-0629-OA; Vollmer RT, 1999, AM J CLIN PATHOL, V112, P597; Yesner R, 1973, PATHOLOGIST, V27, P387; Yousem SA, 2006, HUM PATHOL, V37, P253, DOI 10.1016/j.humpath.2005.11.003	31	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUN	2018	472	6					1041	1054		10.1007/s00428-018-2300-x			14	Pathology	Pathology	GJ5GU	WOS:000435410300018	29380127				2019-10-28	
J	Alison, MR				Alison, Malcolm R.			The many ways to mend your liver: A critical appraisal	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Review						axis inhibition protein 2; hepatic progenitor cells; hybrid hepatocytes; leucine-rich-repeat-containing G protein-coupled receptor 5; Mdm2; R-spondin-1; Sry [sex determining region Y] box 9; telomerase reverse transcriptase	HUMAN EPITHELIAL TISSUES; STEM-CELL NICHE; MOUSE-LIVER; HEPATOCYTE REGENERATION; PERIPORTAL HEPATOCYTES; MATURE HEPATOCYTES; PROGENITOR CELLS; INJURY; PROLIFERATION; HOMEOSTASIS	In the latter half of the 20th century, our understanding of mammalian liver regeneration was shaped by the manner of compensatory hyperplasia occurring after a partial rat liver resection. This response involves almost all hepatocytes and thus is unlikely to be the outcome of the multiple cycling of a small stem cell population. It was most intense in the outer third of lobule, the location closest to the afferent arterial blood supply. With the advent of heritable genetic labelling techniques, usually applied to mice, hitherto unrecognized hepatocytes with clonogenic potential have been discovered, contributing to homoeostatic renewal and/or regenerative responses after tissue loss. This review combines observations from cell lineage tracing studies with other data to summarize the Four proposed anatomical locations for hepatocyte stem cells: the periportal zone, the pericentral zone, a randomized distribution and finally within the intrahepatic biliary tree. As in other endodermal-derived tissues, it appears that there are both homoeostatic stem cells and regenerative stem cells, while some normally homoeostatic stem cells can become more active to boost regeneration.	[Alison, Malcolm R.] Barts & London Queen Marys Sch Med & Dent, Barts Canc Inst, Ctr Tumour Biol, London, England	Alison, MR (reprint author), Barts & London Queen Marys Sch Med & Dent, Barts Canc Inst, Ctr Tumour Biol, London, England.	m.alison@qmul.ac.uk	Alison, Malcolm/H-6961-2019	Alison, Malcolm/0000-0002-7348-3387			Alison Malcolm R, 2011, Hepatology, V53, P1393, DOI 10.1002/hep.24252; Aravinthan A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072904; Benhamouche S, 2006, DEV CELL, V10, P759, DOI 10.1016/j.devcel.2006.03.015; BRALET MP, 1994, AM J PATHOL, V144, P896; Carpentier R, 2011, GASTROENTEROLOGY, V141, P1432, DOI 10.1053/j.gastro.2011.06.049; FABRIKANT JI, 1967, JOHNS HOPKINS MED J, V120, P137; FABRIKANT JI, 1968, J CELL BIOL, V36, P551, DOI 10.1083/jcb.36.3.551; FABRIKANT JI, 1969, EXP CELL RES, V55, P277, DOI 10.1016/0014-4827(69)90493-5; Fellous TG, 2009, STEM CELLS, V27, P1410, DOI 10.1002/stem.67; Fellous TG, 2009, HEPATOLOGY, V49, P1655, DOI 10.1002/hep.22791; Font-Burgada J, 2015, CELL, V162, P766, DOI 10.1016/j.cell.2015.07.026; Furuyama K, 2011, NAT GENET, V43, P34, DOI 10.1038/ng.722; GRISHAM JW, 1962, CANCER RES, V22, P842; Grompe M, 2014, CELL STEM CELL, V15, P257, DOI 10.1016/j.stem.2014.08.004; Huch M, 2015, CELL, V160, P299, DOI 10.1016/j.cell.2014.11.050; Huch M, 2013, NATURE, V494, P247, DOI 10.1038/nature11826; Iannaccone S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031609; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; KUO FC, 1991, MOL CELL BIOL, V11, P6050, DOI 10.1128/MCB.11.12.6050; Kuwahara R, 2008, HEPATOLOGY, V47, P1994, DOI 10.1002/hep.22218; Lin SD, 2018, NATURE, V556, P244, DOI 10.1038/s41586-018-0004-7; Lin WR, 2010, HEPATOLOGY, V51, P1017, DOI 10.1002/hep.23483; Lin YT, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00675-5; Liu JL, 2017, HEPATOLOGY, V66, P2002, DOI 10.1002/hep.29340; Lu WY, 2015, NAT CELL BIOL, V17, P971, DOI 10.1038/ncb3203; Malato Y, 2011, J CLIN INVEST, V121, P4850, DOI 10.1172/JCI59261; Marshall A, 2005, GASTROENTEROLOGY, V128, P33, DOI 10.1053/j.gastro.2004.09.076; Monga SP, 2015, GASTROENTEROLOGY, V148, P1294, DOI 10.1053/j.gastro.2015.02.056; Paranjpe S, 2016, HEPATOLOGY, V64, P1711, DOI 10.1002/hep.28721; Planas-Paz L, 2016, NAT CELL BIOL, V18, P467, DOI 10.1038/ncb3337; Ponder KP, 1996, FASEB J, V10, P673; RABES HM, 1976, CELL TISSUE KINET, V9, P517; Raven A, 2017, NATURE, V547, P350, DOI 10.1038/nature23015; Schaub JR, 2014, CELL REP, V8, P933, DOI 10.1016/j.celrep.2014.07.003; SIGEL B, 1968, J CLIN INVEST, V47, P1231, DOI 10.1172/JCI105815; Stocker E, 1971, Beitr Pathol, V144, P400; Tarlow BD, 2014, CELL STEM CELL, V15, P605, DOI 10.1016/j.stem.2014.09.008; Tarlow BD, 2014, HEPATOLOGY, V60, P278, DOI 10.1002/hep.27084; Walther V, 2016, WIRES DEV BIOL, V5, P103, DOI 10.1002/wdev.203; Wang B, 2015, NATURE, V524, P180, DOI 10.1038/nature14863; Wang Y, 2017, J BIOL CHEM, V292, P8594, DOI 10.1074/jbc.M117.782029; Yanger K, 2014, CELL STEM CELL, V15, P340, DOI 10.1016/j.stem.2014.06.003; ZAJICEK G, 1985, LIVER, V5, P293	43	2	2	4	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	JUN	2018	99	3					106	112		10.1111/iep.12272			7	Pathology	Pathology	GR1WF	WOS:000442343900001	29882223	Green Published			2019-10-28	
J	Wang, Q; Gu, XF; Wang, JF				Wang Qiong; Gu Xiaofeng; Wang Junfang			Transforming growth factor-1 (TGF-1) induces mouse precartilaginous stem cell differentiation through TGFRII-CK1 epsilon--catenin signalling	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						beta -catenin; chondrogenesis; CK1 epsilon; differentiation; precartilaginous stem cells; signalling; TGF-beta 1	BETA-CATENIN; WNT; PATHWAY; NUCLEUS; KINASE; TARGET; ACTIVATION; INDUCTION; MEMBRANE; CANCER	Precartilaginous stem cells (PSCs) are adult stem cells which could self-renew or differentiate into chondrocytes to promote bone growth. In this study, we aimed to understand the role of transforming growth factor-1 (TGF-1) in precartilaginous stem cell (PSC) differentiation and to study the mechanisms that underlie this role. We purified PSCs from the neonatal murine perichondrial mesenchyme using immunomagnetic beads, and primary cultured them. Their phenotype was confirmed by the PSC marker fibroblast growth factor receptor-3 (FGFR-3) overexpression. TGF-1 was added to induce PSCs differentiation. TGF-1 increased mRNA expression of chondrogenesis-related genes (collagen type II, Sox 9 and aggrecan) in the cultured PSCs. This was abolished by TGF- receptor II (TGFRII) and Casein kinase 1 epsilon (CK1 epsilon) lentiviral shRNA depletion. Meanwhile, we found that TGF-1 induced CK1 epsilon activation, glycogen synthase kinase-3 (GSK3) phosphorylation and -catenin nuclear translocation in the mouse PSCs, which was almost completely blocked by TGFRII and CK1 epsilon shRNA knockdown. Based on these results, we suggest that TGF-1 induces CK1 epsilon activation to promote -catenin nuclear accumulation, which then regulates chondrogenesis-related gene transcription to eventually promote mouse PSC differentiation.	[Wang Qiong] Nanjing Med Univ, Wuxi Peoples Hosp, Dept Clin Lab, Wuxi, Peoples R China; [Gu Xiaofeng; Wang Junfang] Nanjing Med Univ, Wuxi Peoples Hosp, Dept Orthoped, Wuxi, Jiangsu, Peoples R China	Wang, JF (reprint author), Nanjing Med Univ, Wuxi Peoples Hosp, Dept Orthoped, Wuxi, Jiangsu, Peoples R China.	wjf801109@163.com			National Science Foundation of ChinaNational Natural Science Foundation of China [81101374]	The National Science Foundation of China, Grant/Award Number: 81101374	Ando W, 2007, BIOMATERIALS, V28, P5462, DOI 10.1016/j.biomaterials.2007.08.030; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Chen S, 2009, SPINE, V34, P1272, DOI 10.1097/BRS.0b013e3181a2b347; Fagotto F, 2013, EMBO REP, V14, P422, DOI 10.1038/embor.2013.45; Gadue P, 2006, P NATL ACAD SCI USA, V103, P16806, DOI 10.1073/pnas.0603916103; Guo X, 2008, J CELL BIOCHEM, V114, P2588; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Holland JD, 2013, CURR OPIN CELL BIOL, V25, P254, DOI 10.1016/j.ceb.2013.01.004; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Jian HY, 2006, GENE DEV, V20, P666, DOI 10.1101/gad.1388806; Kato M, 2009, NAT CELL BIOL, V11, P881, DOI 10.1038/ncb1897; Kim W, 2013, BIOCHEM J, V450, P9, DOI 10.1042/BJ20121284; King TD, 2012, J CELL BIOCHEM, V113, P13, DOI 10.1002/jcb.23350; Kuh SU, 2008, ACTA NEUROCHIR, V150, P1073, DOI 10.1007/s00701-008-0029-z; Lamouille S, 2007, J CELL BIOL, V178, P437, DOI 10.1083/jcb.200611146; Lee MK, 2007, EMBO J, V26, P3957, DOI 10.1038/sj.emboj.7601818; Mosimann C, 2009, NAT REV MOL CELL BIO, V10, P276, DOI 10.1038/nrm2654; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Piek E, 1999, FASEB J, V13, P2105; Robinson D, 1999, CLIN ORTHOP RELAT R, pS163; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Steck E, 2005, STEM CELLS, V23, P403, DOI 10.1634/stemcells.2004-0107; Tscheudschilsuren G, 2006, EXP CELL RES, V312, P63, DOI 10.1016/j.yexcr.2005.09.017; Watabe T, 2009, CELL RES, V19, P103, DOI 10.1038/cr.2008.323; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328	25	1	1	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	JUN	2018	99	3					113	120		10.1111/iep.12275			8	Pathology	Pathology	GR1WF	WOS:000442343900002		Green Published			2019-10-28	
J	Nesrine, Z; Haithem, H; Imen, B; Fadoua, N; Asma, O; Fadhel, NM; Ali, B				Nesrine, Zayani; Haithem, Hamdouni; Imen, Boumaiza; Fadoua, Neffati; Asma, Omezzine; Fadhel, Najjar Mohamed; Ali, Bouslama			Leptin and Leptin receptor polymorphisms, plasma Leptin levels and obesity in Tunisian volunteers	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						Leptin levels; LEP; LEPR; obesity; Tunisian volunteers	BODY-MASS INDEX; GENE POLYMORPHISMS; SERUM LEPTIN; INSULIN-RESISTANCE; METABOLIC SYNDROME; DIABETES-MELLITUS; ASSOCIATION; WEIGHT; RISK; OB	Adipose tissue is an important endocrine organ that secretes a number of adipokines, like Leptin (LEP). The aim this study was to investigate the prevalence of single nucleotide polymorphisms in LEP gene (LEP 3UTR A/C, -2548G/A) and LEPR (K109R and Q223R) and their association with Leptin level and obesity. We recruited 169 non-obese (body mass index [BMI]=24.51-3.69kg/m(2)) and 160 obese (BMI=36-4.78kg/m(2)) patients. Genotyping was performed using polymerase chain reaction-restriction fragment length polymorphism, BMI was calculated, and Leptin level was measured by ELISA. Statistical analyses were performed by spss19.0. According to LEP 3UTR A/C polymorphism, AC and CC genotype carriers had higher Leptin levels than AA genotype carriers, respectively, 31[0.05-148.8] (P=.008) vs 41[0.05-111.6] (P=.003). The K109R polymorphism was associated with obesity (P=.025) and seems to significantly decrease the LEP levels (P<.001). Concerning LEP G2548A polymorphism, our results showed that the OR of obesity associated with 2548 AA/GG was 1.87[1.106-2.78] P=.028 vs 1.41[1.035-1.85] P=.045 for 223AA/GG polymorphism. In our haplotype analysis, one haplotype seems to be the more protective and one other seems to be the highest risk to obesity. LEP 3UTR A/C and LEPR K109R polymorphisms were associated with Leptin level and obesity.	[Nesrine, Zayani; Haithem, Hamdouni; Imen, Boumaiza; Asma, Omezzine; Ali, Bouslama] Sahloul Univ Hosp, Biochem Dept, LR12SP11, Sousse, Tunisia; [Fadoua, Neffati; Fadhel, Najjar Mohamed] Monastirs Univ Hosp, Lab Biochem & Toxicol, Monastir, Tunisia	Nesrine, Z (reprint author), Sahloul Univ Hosp, Biochem Dept, LR12SP11, Sousse, Tunisia.	nesrina_1987@hotmail.com		Hamdouni, Haithem/0000-0001-5746-8075	Tunisian Ministry of Higher Education, Scientific Research and Technology; Tunisian Ministry of Health [LR12SP11]	Tunisian Ministry of Higher Education, Scientific Research and Technology; Tunisian Ministry of Health, Grant/Award Number: LR12SP11	Ahima RS, 2004, PHYSIOL BEHAV, V81, P223, DOI 10.1016/j.physbeh.2004.02.014; Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; Bell BB, 2016, CURR OBES REP, V5, P397, DOI 10.1007/s13679-016-0231-x; Bi S, 1997, J BIOL CHEM, V272, P30583, DOI 10.1074/jbc.272.48.30583; Boumaiza I, 2012, GENET TEST MOL BIOMA, V16, P726, DOI 10.1089/gtmb.2011.0324; Catli G, 2014, PEPTIDES, V56, P72, DOI 10.1016/j.peptides.2014.03.015; Chobanian AV, 2003, JAMA-J AM MED ASSOC, V289, P2560, DOI 10.1001/jama.289.19.2560; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Cnop M, 2002, DIABETES, V51, P1005, DOI 10.2337/diabetes.51.4.1005; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Constantin A, 2010, BIOCHEM BIOPH RES CO, V391, P282, DOI 10.1016/j.bbrc.2009.11.050; De Luis DA, 2009, MINERVA MED, V100, P229; Fan SH, 2014, J PHYSIOL ANTHROPOL, V33, DOI 10.1186/1880-6805-33-15; Fleisch AF, 2007, J CLIN ENDOCR METAB, V92, P948, DOI 10.1210/jc2006-1390; Fong TM, 1998, MOL PHARMACOL, V53, P234; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Furusawa T, 2010, HUM GENET, V127, P287, DOI 10.1007/s00439-009-0768-9; Gong DW, 1996, J BIOL CHEM, V271, P3971; Gotoda T, 1997, HUM MOL GENET, V6, P869, DOI 10.1093/hmg/6.6.869; Guizar-Mendoza JM, 2005, J HUM HYPERTENS, V19, P341, DOI 10.1038/sj.jhh.1001824; Jalilian Nasrin, 2016, Indian J Endocrinol Metab, V20, P324, DOI 10.4103/2230-8210.180005; Jurimae J, 2003, EUR J APPL PHYSIOL, V90, P533, DOI 10.1007/s00421-003-0879-2; Kalra SP, 2001, P NATL ACAD SCI USA, V98, P4279, DOI 10.1073/pnas.091101498; Karacabey K, 2009, J INT MED RES, V37, P1472, DOI 10.1177/147323000903700523; LEWONTIN RC, 1964, GENETICS, V49, P49; Lombard Z, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-000873; Lonnqvist F, 1999, J INTERN MED, V245, P643, DOI 10.1046/j.1365-2796.1999.00493.x; Madeira I, 2017, ARCH ENDOCRIN METAB, V61, P7, DOI 10.1590/2359-3997000000199; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Malinikovaa J, 2000, BIOMED PAPERS, V144, P51; Mammes O, 2000, ANN HUM GENET, V64, P391, DOI 10.1046/j.1469-1809.2000.6450391.x; Marginean CO, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003115; Masuo K, 2008, HYPERTENS RES, V31, P1093, DOI 10.1291/hypres.31.1093; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Mergen H, 2007, ENDOCR J, V54, P89, DOI 10.1507/endocrj.K06-023; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mishra PJ, 2008, CELL CYCLE, V7, P853, DOI 10.4161/cc.7.7.5666; Mishra PJ, 2007, P NATL ACAD SCI USA, V104, P13513, DOI 10.1073/pnas.0706217104; Mizuta E, 2008, HYPERTENS RES, V31, P1069, DOI 10.1291/hypres.31.1069; MOLL PP, 1991, AM J HUM GENET, V49, P1243; Montazerifar F, 2016, ARQ BRAS CARDIOL, V107, P348, DOI 10.5935/abc.20160134; Motawi T, 2015, ARCH MED SCI, V11, P937, DOI 10.5114/aoms.2015.54848; Nogueiras R, 2008, ANN NY ACAD SCI, V1126, P14, DOI 10.1196/annals.1433.054; Ogawa T, 2004, METABOLISM, V53, P879, DOI 10.1016/j.metabol.2004.02.009; Okada T, 2010, ACTA PAEDIATR, V99, P1213, DOI 10.1111/j.1651-2227.2010.01778.x; Okpechi IG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009086; Oksanen L, 1997, HUM GENET, V99, P559, DOI 10.1007/s004390050406; Okudan N, 2014, ARCH PHYSIOL BIOCHEM, V120, P136, DOI 10.3109/13813455.2014.946933; Paracchini V, 2005, AM J EPIDEMIOL, V162, P101, DOI 10.1093/aje/kwi174; Peelman F, 2006, J BIOL CHEM, V281, P15496, DOI 10.1074/jbc.M512622200; Quinton ND, 2001, HUM GENET, V108, P233, DOI 10.1007/s004390100468; Reinehr T, 2009, INT J PEDIATR OBES, V4, P215, DOI 10.3109/17477160902952464; Rey LK, 2011, MOL CELL PROBE, V25, P255, DOI 10.1016/j.mcp.2011.05.004; Riestra P, 2010, ACTA PAEDIATR, V99, P1527, DOI 10.1111/j.1651-2227.2010.01877.x; Rosmond R, 2000, J CLIN ENDOCR METAB, V85, P3126, DOI 10.1210/jc.85.9.3126; Rossetti L, 1997, J BIOL CHEM, V272, P27758, DOI 10.1074/jbc.272.44.27758; Sahin DS, 2013, CELL BIOCHEM BIOPHYS, V65, P243, DOI 10.1007/s12013-012-9427-1; Sari R, 2010, METAB SYNDR RELAT D, V8, P499, DOI 10.1089/met.2009.0127; Saukko M, 2010, METAB SYNDR RELAT D, V8, P425, DOI 10.1089/met.2010.0004; Steinberg GR, 2002, AM J PHYSIOL-ENDOC M, V283, pE187, DOI 10.1152/ajpendo.00542.2001; Tang NP, 2008, CLIN ENDOCRINOL, V68, P82, DOI 10.1111/j.1365-2265.2007.03003.x; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Wauters M, 2003, HORM METAB RES, V35, P92, DOI 10.1055/s-2003-39054; Wauters M, 2001, INT J OBESITY, V25, P714, DOI 10.1038/sj.ijo.0801609; Woo HY, 2006, CANCER LETT, V237, P137, DOI 10.1016/j.canlet.2005.05.041; World Health Organization, 1995, PHYS STAT US INT ANT; Yiannakouris N, 2001, J CLIN ENDOCR METAB, V86, P4434, DOI 10.1210/jc.86.9.4434; Yiannakouris Nikos, 2003, Hormones (Athens), V2, P229; Zabeau L, 2004, MOL ENDOCRINOL, V18, P150, DOI 10.1210/me.2003-0078; Zayani N, 2018, J CLIN LAB ANAL, V32, DOI 10.1002/jcla.22227; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	71	3	3	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	JUN	2018	99	3					121	130		10.1111/iep.12271			10	Pathology	Pathology	GR1WF	WOS:000442343900003	29893028	Green Published			2019-10-28	
J	Bojanac, AK; Rogosic, S; Sincic, N; Juric-Lekic, G; Vlahovic, M; Serman, L; Jezek, D; Bulic-Jakus, F				Bojanac, Ana Katusic; Rogosic, Srdjan; Sincic, Nino; Juric-Lekic, Gordana; Vlahovic, Maja; Serman, Ljiljana; Jezek, Davor; Bulic-Jakus, Floriana			Influence of hyperthermal regimes on experimental teratoma development invitro	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						anti-HSP; differentiation; embryo; growth; hyperthermia; teratoma	HEAT-SHOCK PROTEINS; RAT EGG-CYLINDERS; SERUM-FREE; EMBRYONIC-DEVELOPMENT; GENE-EXPRESSION; STEM-CELLS; DIFFERENTIATION; EXPOSURE; GROWTH; PROLIFERATION	We screened for the impact of hyperthermal regimes varying in the cumulative equivalent minutes at 43 degrees C (CEM43 degrees C) and media composition on tumour development using an original teratoma invitro model. Rat embryos (three germ layers) were microsurgically isolated and cultivated at the air-liquid interface. During a two week period, ectodermal, mesodermal and endodermal derivatives developed within trilaminar teratomas. Controls were grown at 37 degrees C. Overall growth was measured, and teratoma survival and differentiation were histologically assessed. Cell proliferation was stereologically quantified by the volume density of Proliferating Cell Nuclear Antigen. Hyperthermia of 42 degrees C, applied for 15minutes after plating (CEM43 degrees C 3.75minutes), diminished cell proliferation (P?.0001) and enhanced differentiation of both myotubes (P?.01) and cylindrical epithelium (P?.05). Hyperthermia of 43 degrees C applied each day for 30minutes during the first week (CEM43 degrees C 210minutes) impaired overall growth (P?.01) and diminished cell proliferation (P?.0001). Long-term hyperthermia of 40.5 degrees C applied for twoweeks (CEM43 degrees C 630minutes) significantly impaired survival (P?.005). Long-term hyperthermia of 40.5 degrees C applied from the second day when differentiation of tissues begins (CEM43 degrees C 585minutes) impaired survival (P?.0001), overall growth (P?.01) and cartilage differentiation (P?.05). No teratomas survived extreme regimes: 43 degrees C for 24hours (CEM43 degrees C 1440minutes), hyperthermia in the scant serum-free medium (CEM43 degrees C 630minutes) or treatment with an anti-HSP70 antibody before long-term hyperthermia 40.5 degrees C from the second day (CEM43 degrees C 585minutes). This invitro research provided novel insights into the impact of hyperthermia on the development of experimental teratomas from their undifferentiated sources and are thus of potential interest for future therapeutic strategies in corresponding invivo models.	[Bojanac, Ana Katusic; Rogosic, Srdjan; Sincic, Nino; Vlahovic, Maja; Serman, Ljiljana; Bulic-Jakus, Floriana] Univ Zagreb, Dept Med Biol, Sch Med, Zagreb, Croatia; [Bojanac, Ana Katusic; Sincic, Nino; Juric-Lekic, Gordana; Vlahovic, Maja; Serman, Ljiljana; Jezek, Davor; Bulic-Jakus, Floriana] Univ Zagreb, Ctr Excellence Reprod & Regenerat Med, Sch Med, Zagreb, Croatia; [Juric-Lekic, Gordana; Jezek, Davor] Univ Zagreb, Dept Histol & Embryol, Sch Med, Zagreb, Croatia	Bojanac, AK (reprint author), Univ Zagreb, Dept Med Biol, Sch Med, Zagreb, Croatia.; Bojanac, AK (reprint author), Univ Zagreb, Ctr Excellence Reprod & Regenerat Med, Sch Med, Zagreb, Croatia.	ana.katusic@mef.hr			EU Regional Development Fund [KK.01.1.1.01.0008]; Croatian Ministry of Science and EducationMinistry of Science, Education and Sports, Republic of Croatia [108-1080399-0335]; University of Zagreb Supportive Grant [1.2.1.17, 1101310, BM1.22]	EU Regional Development Fund, Grant/Award Number: KK.01.1.1.01.0008; Croatian Ministry of Science and Education, Grant/Award Number: 108-1080399-0335; University of Zagreb Supportive Grant, Grant/Award Number: 1.2.1.17, 1101310, BM1.22	Ades L, 2010, BLOOD, V115, P1690, DOI 10.1182/blood-2009-07-233387; Behrouzkia Zhaleh, 2016, Oman Med J, V31, P89, DOI 10.5001/omj.2016.19; Ben-David U, 2014, J MOL CELL BIOL, V6, P267, DOI 10.1093/jmcb/mju012; Bennett GD, 2010, BIRTH DEFECTS RES B, V89, P279, DOI 10.1002/bdrb.20254; Breen JG, 1999, REPROD TOXICOL, V13, P31, DOI 10.1016/S0890-6238(98)00056-2; BULIC-JAKUS F, 1990, International Journal of Developmental Biology, V34, P275; Bulic-Jakus F, 1999, ATLA-ALTERN LAB ANIM, V27, P925, DOI 10.1177/026119299902700601; Bulic-Jakus F, 2016, WIRES DEV BIOL, V5, P186, DOI 10.1002/wdev.219; Cho MJ, 2017, NANOMATERIALS-BASEL, V7, DOI 10.3390/nano7040072; COCKROFT DL, 1978, TERATOLOGY, V17, P277, DOI 10.1002/tera.1420170306; Crnek-Kunstelj V, 2001, LIBRI ONCOLOGICI, V29, P133; CUFF JM, 1993, TERATOLOGY, V48, P259, DOI 10.1002/tera.1420480309; Czeizel Andrew E., 2008, Congenital Anomalies, V48, P158, DOI 10.1111/j.1741-4520.2008.00202.x; Davidson Sean M, 2002, Prog Mol Subcell Biol, V28, P103; Dewey Retired WC, 1994, INT J HYPERTHER, V10, P457; Dewhirst MW, 2005, INT J HYPERTHER, V21, P779, DOI 10.1080/02656730500271668; EBERT PS, 1994, NEUROSURGERY, V34, P657, DOI 10.1227/00006123-199404000-00013; Edwards MJ, 2003, INT J HYPERTHER, V19, P295, DOI 10.1080/0265673021000039628; Fan GC, 2012, PROG MOL BIOL TRANSL, V111, P305, DOI 10.1016/B978-0-12-398459-3.00014-9; Garcia MB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044657; Gaspar N, 2010, MOL CANCER THER, V9, P1219, DOI 10.1158/1535-7163.MCT-09-0683; GERMAIN MA, 1985, TERATOLOGY, V31, P265, DOI 10.1002/tera.1420310212; Hendrickson ML, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018535; Hernandez-Vargas H, 2009, EPIGENOMICS-UK, V1, P261, DOI 10.2217/EPI.09.19; Horsman MR, 2007, CLIN ONCOL-UK, V19, P418, DOI 10.1016/j.clon.2007.03.015; Hunt CR, 2007, CANCER RES, V67, P3010, DOI 10.1158/0008-5472.CAN-06-4328; Hutson MR, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aal4055; Kamanga-Sollo E, 2011, J ANIM SCI, V89, P3473, DOI 10.2527/jas.2011-4123; Kanamori S, 1999, INT J HYPERTHER, V15, P267; KIMMEL CA, 1993, TERATOLOGY, V47, P229, DOI 10.1002/tera.1420470307; Kimmel GL, 2002, TOXICOL SCI, V69, P391, DOI 10.1093/toxsci/69.2.391; KIMMEL GL, 1993, TERATOLOGY, V47, P243, DOI 10.1002/tera.1420470308; Kuhl NM, 2000, CELL MOL LIFE SCI, V57, P450, DOI 10.1007/PL00000707; Lanneau D, 2007, PRION, V1, P53, DOI 10.4161/pri.1.1.4059; Lee J, 2009, BIRTH DEFECTS RES A, V85, P184, DOI 10.1002/bdra.20538; LIN PP, 1988, RADIAT RES, V113, P513, DOI 10.2307/3577247; MACKEY MA, 1988, CANCER RES, V48, P6478; Maglara AA, 2003, J PHYSIOL-LONDON, V548, P837, DOI 10.1113/jphysiol.2002.034520; Matwee C, 2001, MOL HUM REPROD, V7, P829, DOI 10.1093/molehr/7.9.829; Mendillo ML, 2012, CELL, V150, P549, DOI 10.1016/j.cell.2012.06.031; MIRKES PE, 1985, TERATOLOGY, V31, pA30; MIRKES PE, 1992, TERATOLOGY, V46, P301, DOI 10.1002/tera.1420460315; Mirkes PE, 1990, POSTIMPLANTATION MAM, P235; Morrissey JJ, 2009, J DRUG TARGET, V17, P719, DOI 10.3109/10611860903074968; Muneeb A, 2018, INT J HYPERTHER, V9, P1; Muzic V, 2013, CROAT MED J, V54, P489, DOI 10.3325/cmj.2013.54.489; Oei AL, 2017, INT J HYPERTHER, V33, P419, DOI 10.1080/02656736.2017.1279757; Olexikova L, 2010, ANIM REPROD SCI, V119, P130, DOI 10.1016/j.anireprosci.2009.12.008; Padmanabhan R, 2005, INT J HYPERTHER, V21, P29, DOI 10.1080/02656730410001716614; Quinn SD, 2015, INT J HYPERTHER, V31, P272, DOI 10.3109/02656736.2015.1010608; Ruell PA, 2004, MOL CELL BIOCHEM, V267, P187, DOI 10.1023/B:MCBI.0000049382.63841.e4; Salamanca HH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096330; Seifert G, 2016, RADIAT ONCOL, V11, DOI 10.1186/s13014-016-0639-1; Serman L, 2007, PLACENTA, V28, P803, DOI 10.1016/j.placenta.2007.04.001; Sharif-Khatibi L, 2007, INT J HYPERTHER, V23, P645, DOI 10.1080/02656730701769833; Shevtsov M, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00171; SKREB N, 1963, J EMBRYOL EXP MORPH, V11, P445; Skreb N, 1980, Results Probl Cell Differ, V11, P283; SKREB N, 1993, INT J DEV BIOL, V37, P151; SKREB N, 1987, DEV BIOL, V120, P584, DOI 10.1016/0012-1606(87)90261-2; Solter D, 2006, NAT REV GENET, V7, P319, DOI 10.1038/nrg1827; Song AS, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4027272; STEELE CE, 1974, J EMBRYOL EXP MORPH, V31, P707; Tonk ECM, 2013, REPROD TOXICOL, V41, P57, DOI 10.1016/j.reprotox.2013.06.069; van Rhoon GC, 2013, EUR RADIOL, V23, P2215, DOI 10.1007/s00330-013-2825-y; van Rhoon GC, 2016, INT J HYPERTHER, V32, P50, DOI 10.3109/02656736.2015.1114153; VELAZQUEZ JM, 1984, CELL, V36, P655, DOI 10.1016/0092-8674(84)90345-3; WALSH D, 1993, DEV GENET, V14, P127, DOI 10.1002/dvg.1020140207; WALSH DA, 1987, TERATOLOGY, V36, P181, DOI 10.1002/tera.1420360205; Wang L, 2014, TRANSPLANTATION, V97, P1225, DOI 10.1097/TP.0000000000000118; Wessalowski R, 2013, LANCET ONCOL, V14, P843, DOI 10.1016/S1470-2045(13)70271-7; Wu TC, 2006, CELL STRESS CHAPERON, V11, P1, DOI 10.1379/CSC-155R.1; Yamaguchi T, 2010, AM J PHYSIOL-CELL PH, V298, pC140, DOI 10.1152/ajpcell.00050.2009; Yarmolenko PS, 2011, INT J HYPERTHER, V27, P320, DOI 10.3109/02656736.2010.534527; Yoshida GJ, 2016, CANCER SCI, V107, P5, DOI 10.1111/cas.12817; Yun BG, 2005, EXP CELL RES, V307, P212, DOI 10.1016/j.yexcr.2005.03.003; Zorc M, 2003, CARDIOVASC PATHOL, V12, P36, DOI 10.1016/S1054-8807(02)00134-5	77	0	0	2	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	JUN	2018	99	3					131	144		10.1111/iep.12273			14	Pathology	Pathology	GR1WF	WOS:000442343900004	30066346	Other Gold, Green Accepted, Green Published			2019-10-28	
J	Pacagnelli, FL; Sabela, AKA; Okoshi, K; Mariano, TB; Campos, DH; Carvalho, RF; Cicogn, AC; Vanderlei, LC				Pacagnelli, F. L.; Sabela, Almeida A. K.; Okoshi, K.; Mariano, T. B.; Campos, D. H.; Carvalho, R. F.; Cicogn, A. C.; Vanderlei, L. C.			Preventive aerobic training exerts a cardioprotective effect on rats treated with monocrotaline (vol 97, pg 238, 2016)	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Correction														Sao Paulo Research Fondation (FAPESP) [2016/11344-0]	This study was supported by grant 2016/11344-0, Sao Paulo Research Fondation (FAPESP).	Pacagnelli FL, 2016, INT J EXP PATHOL, V97, P238, DOI 10.1111/iep.12166	1	0	0	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	JUN	2018	99	3					145	145		10.1111/iep.12274			1	Pathology	Pathology	GR1WF	WOS:000442343900005		Green Published			2019-10-28	
J	Liddell, C; Mittler, F; Morini, A; Boulagnon-Rombi, C				Liddell, Charly; Mittler, Faustine; Morini, Aurelien; Boulagnon-Rombi, Camille			The Annales de Pathologie are now on Facebook and Twitter!	ANNALES DE PATHOLOGIE			French	Editorial Material									[Liddell, Charly] Ctr Hosp, Dept Roche Yon, Paris, France; [Morini, Aurelien] Hop Europeen Georges Pompidou, Serv Anatomopathol, AP HP, Paris, France; [Boulagnon-Rombi, Camille] Ctr Hosp Univ Reims, Reims, France	Boulagnon-Rombi, C (reprint author), Ctr Hosp Univ Reims, Reims, France.	camille.boulagnon@gmail.com						0	1	1	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	JUN	2018	38	3					151	152		10.1016/j.annpat.2018.05.001			2	Pathology	Pathology	GO6EG	WOS:000440126300001	30047426				2019-10-28	
J	Lassalle, S; Caujolle, JP; Leger, F; Maschi, C; Gastaud, L; Nahon-Esteve, S; Thariat, J; Baillif, S; Hofman, P				Lassalle, Sandra; Caujolle, Jean-Pierre; Leger, Francois; Maschi, Celia; Gastaud, Lauris; Nahon-Esteve, Sacha; Thariat, Juliette; Baillif, Stephanie; Hofman, Paul			Focus on clinical and pathological management of conjunctival melanocytic tumors	ANNALES DE PATHOLOGIE			French	Review						Melanoma; Melanosis; Nevus; Conjonctive; Management; Pathology	PRIMARY ACQUIRED MELANOSIS; SYSTEMIC BRAF/MEK INHIBITORS; LYMPH-NODE BIOPSY; MALIGNANT-MELANOMA; NRAS MUTATIONS; HARBOR BRAF; FEATURES; LESIONS; NEVUS; PEMBROLIZUMAB	Conjunctival-pigmented tumors are rare, but they are one of the most commonly encountered by the pathologist working with the department of ophthalmology. Nevus and melanoma can be encountered and have some histological difference compared to their cutaneous counterpart. Primary acquired melanosis (PAM) is a conjunctival specific entity. This clinical term includes several histological lesions ranging from benignity to melanoma precursor lesion. Histologic examination determines the therapy and the risk of progression to melanoma. We present here a histopathological, clinical and therapeutic synthesis of conjunctival-pigmented lesions, emphasizing the importance of a good understanding between clinicians and pathologists. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Lassalle, Sandra; Hofman, Paul] CHU Nice, Hop Pasteur, Lab Pathol Clin & Expt, Pavillon J,30 Voie Romaine,CS 51069, F-06001 Nice 1, France; [Lassalle, Sandra; Hofman, Paul] IRCAN, UFR Med, Inserm, CNRS,UMR7284,U1081, 28 Ave Valombrose, F-06107 Nice 2, France; [Lassalle, Sandra; Hofman, Paul] FHU OncoAge Nice, 30 Ave Voie Romaine,CS 51069, F-06001 Nice 1, France; [Caujolle, Jean-Pierre; Maschi, Celia; Nahon-Esteve, Sacha; Baillif, Stephanie] CHU Nice, Hop Pasteur 2, Serv Ophtalmol, 30 Voie Romaine,CS 51069, F-06001 Nice 1, France; [Leger, Francois] CHU Bordeaux, Hop Pellegrin, Serv Pathol, F-33000 Bordeaux, France; [Gastaud, Lauris] Ctr Antoine Lacassagne, Dept Oncol Med, 33 Ave Valombrose, F-06189 Nice, France; [Thariat, Juliette] Ctr Antoine Lacassagne, Dept Radiotherapie, 33 Ave Valombrose, F-06189 Nice, France	Lassalle, S (reprint author), CHU Nice, Hop Pasteur, Lab Pathol Clin & Expt, Pavillon J,30 Voie Romaine,CS 51069, F-06001 Nice 1, France.; Lassalle, S (reprint author), IRCAN, UFR Med, Inserm, CNRS,UMR7284,U1081, 28 Ave Valombrose, F-06107 Nice 2, France.; Lassalle, S (reprint author), FHU OncoAge Nice, 30 Ave Voie Romaine,CS 51069, F-06001 Nice 1, France.	lassalle.s@chu-nice.fr	Hofman, Paul/P-7654-2018	Hofman, Paul/0000-0003-0431-9353; thariat, juliette/0000-0003-4755-496X			Anastassiou G, 2002, BRIT J OPHTHALMOL, V86, P163, DOI 10.1136/bjo.86.2.163; Brierley JD, 2017, AJCC CANC STAGING MA; Cao JF, 2017, ONCOTARGET, V8, P58021, DOI 10.18632/oncotarget.10770; Cao JF, 2017, ONCOTARGET, V8, P54722, DOI 10.18632/oncotarget.18039; Caujolle JP, 2009, J FR OPHTALMOL, V32, P707, DOI 10.1016/j.jfo.2009.10.016; Cohen VML, 2013, BRIT J OPHTHALMOL, V97, P1525, DOI 10.1136/bjophthalmol-2013-303671; Damato B, 2008, CLIN EXP OPHTHALMOL, V36, P786, DOI 10.1111/j.1442-9071.2008.01888.x; Esmaeli B, 2004, OPHTHALMOLOGY, V111, P2317, DOI 10.1016/j.ophtha.2004.09.011; Esmaeli Bita, 2012, Trans Am Ophthalmol Soc, V110, P64; Font RL, 2006, AFIP ATLAS TUMOR PAT, V4, P16; Ford J, 2017, OPHTHAL PLAST RECONS, V33, pE82, DOI 10.1097/IOP.0000000000000790; Gear J, 2004, INVEST OPHTH VIS SCI, V45, P2484, DOI 10.1167/iovs.04-0093; Glass LRD, 2017, OPHTHAL PLAST RECONS, V33, pE114, DOI 10.1097/IOP.0000000000000833; Griewank KG, 2013, CLIN CANCER RES, V19, P3143, DOI 10.1158/1078-0432.CCR-13-0163; Heegaard S, 2000, MELANOMA RES, V10, P350, DOI 10.1097/00008390-200008000-00006; Hosler GA, 2008, J CUTAN PATHOL, V35, P889, DOI 10.1111/j.1600-0560.2008.01041.x; Jakob JA, 2012, CANCER-AM CANCER SOC, V118, P4014, DOI 10.1002/cncr.26724; JAKOBIEC FA, 1989, OPHTHALMOLOGY, V96, P147; Jakobiec FA, 2010, ARCH OPHTHALMOL-CHIC, V128, P174, DOI 10.1001/archophthalmol.2009.394; Jakobiec FA, 2009, ARCH OPHTHALMOL-CHIC, V127, P970, DOI 10.1001/archophthalmol.2009.171; Kao A, 2016, CANCER CONTROL, V23, P117, DOI 10.1177/107327481602300205; Kenawy N, 2013, EYE, V27, P142, DOI 10.1038/eye.2012.254; Kini A, 2017, JAMA OPHTHALMOL, V135, P891, DOI 10.1001/jamaophthalmol.2017.2279; Larsen AC, 2016, ACTA OPHTHALMOL, V94, P463, DOI 10.1111/aos.13007; Larsen AC, 2016, ACTA OPHTHALMOL, V94, P1, DOI 10.1111/aos.13100; Larsen AC, 2015, JAMA OPHTHALMOL, V133, P1295, DOI 10.1001/jamaophthalmol.2015.3200; Maleka A, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2657-7; Mendoza Pia R, 2015, Int Ophthalmol Clin, V55, P123, DOI 10.1097/IIO.0000000000000051; Midena E, 2017, ASIA-PAC J OPHTHALMO, V6, P121, DOI 10.22608/APO.201751; Mor JM, 2017, OCUL ONCOL PATHOL, V3, P133, DOI 10.1159/000452473; Pahlitzsch M, 2014, J CLIN EXP OPHTHALMO, V5, P322; PARIDAENS ADA, 1994, BRIT J OPHTHALMOL, V78, P252, DOI 10.1136/bjo.78.4.252; Robert C, 2014, LANCET, V384, P1109, DOI 10.1016/S0140-6736(14)60958-2; Savar A, 2011, J CUTAN PATHOL, V38, P18, DOI 10.1111/j.1600-0560.2010.01625.x; Savar A, 2009, OPHTHALMOLOGY, V116, P2217, DOI 10.1016/j.ophtha.2009.04.012; SEREGARD S, 1995, OPHTHALMOLOGY, V102, P1524; Shields CL, 2017, ASIA-PAC J OPHTHALMO, V6, P109, DOI 10.22608/APO.201710; Shields CL, 2004, OPHTHALMOLOGY, V111, P1747, DOI 10.1016/j.ophtha.2004.02.013; Sugiura M, 2007, AM J SURG PATHOL, V31, P185, DOI 10.1097/01.pas.0000213339.32734.64; Thiagalingam S, 2008, AM J SURG PATHOL, V32, P399, DOI 10.1097/PAS.0b013e31815143f3; Thierauf J, 2015, MELANOMA RES, V25, P503, DOI 10.1097/CMR.0000000000000197; Tuomaala S, 2004, OPHTHALMOLOGY, V111, P816, DOI 10.1016/j.ophtha.2003.11.001; Tuomaala S, 2007, CURR EYE RES, V32, P939, DOI 10.1080/02713680701648019; Vora GK, 2017, SURV OPHTHALMOL, V62, P26, DOI 10.1016/j.survophthal.2016.06.001; Weber JL, 2013, CLIN CANCER RES, V19, P6329, DOI 10.1158/1078-0432.CCR-13-2007; Zembowicz A, 2010, ARCH PATHOL LAB MED, V134, P1785, DOI 10.1043/2009-0522-RAR.1	46	0	0	2	5	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	JUN	2018	38	3					153	163		10.1016/j.annpat.2018.03.006			11	Pathology	Pathology	GO6EG	WOS:000440126300002	29803361				2019-10-28	
J	Selves, J; Long-Mira, E; Mathieu, MC; Rochaix, P; Ilie, M				Selves, Janick; Long-Mira, Elodie; Mathieu, Marie-Christine; Rochaix, Philippe; Ilie, Marius			Carcinoma of unknown primary. Role of the pathologist in 2018: introduction	ANNALES DE PATHOLOGIE			French	Editorial Material							PRIMARY SITE; IMMUNOHISTOCHEMISTRY; CANCER; ORIGIN		[Selves, Janick; Rochaix, Philippe] Inst Univ Canc Oncopole, Dept Anat & Cytol Pathol, 1 Ave Irene Joliot Curie, F-31059 Toulouse 9, France; [Long-Mira, Elodie; Ilie, Marius] Univ Cote Azur, CHU Nice, Hop Pasteur, Lab Pathol Clin & Expt, 30 Voie Romaine, F-06000 Nice, France; [Mathieu, Marie-Christine] Inst Gustave Roussy, Dept Biol & Pathol Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, France	Ilie, M (reprint author), Univ Cote Azur, CHU Nice, Hop Pasteur, Lab Pathol Clin & Expt, 30 Voie Romaine, F-06000 Nice, France.	ilie.m@chu-nice.fr	; Rochaix, Philippe/O-4710-2014	Ilie, Marius/0000-0002-2014-1236; Rochaix, Philippe/0000-0001-6238-1599			Bahrami A, 2008, ARCH PATHOL LAB MED, V132, P326, DOI 10.1043/1543-2165(2008)132[326:UTTIBI]2.0.CO;2; Benderra MA, 2016, B CANCER, V103, P697, DOI 10.1016/j.bulcan.2016.05.003; Conner JR, 2015, ADV ANAT PATHOL, V22, P149, DOI 10.1097/PAP.0000000000000069; Hainsworth JD, 2013, J CLIN ONCOL, V31, P217, DOI 10.1200/JCO.2012.43.3755; Lesimple T, 2003, B CANCER, V90, P1071; Lin F, 2014, ARCH PATHOL LAB MED, V138, P1583, DOI 10.5858/arpa.2014-0061-RA; Pavlidis N, 2012, LANCET, V379, P1428, DOI 10.1016/S0140-6736(11)61178-1; Ross JS, 2015, JAMA ONCOL, V1, P40, DOI 10.1001/jamaoncol.2014.216; Voigt JJ, 2008, ONCOLOGIE, V10, P693, DOI 10.1007/s10269-008-0983-3	9	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	JUN	2018	38	3					164	167		10.1016/j.annpat.2018.04.009			4	Pathology	Pathology	GO6EG	WOS:000440126300003	29929740				2019-10-28	
J	[Anonymous]				[Anonymous]			Carcinoma of unknown primary. Role of the pathologist in 2018: Pre-test	ANNALES DE PATHOLOGIE			French	Editorial Material																	0	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	JUN	2018	38	3					168	169		10.1016/j.annpat.2018.04.010			2	Pathology	Pathology	GO6EG	WOS:000440126300004					2019-10-28	
J	Rochaix, P				Rochaix, Philippe			Carcinoma of unknown primary. Case no. 1	ANNALES DE PATHOLOGIE			French	Editorial Material									[Rochaix, Philippe] Inst Univ Canc Oncopole, Dept Anat & Cytol Pathol, 1 Ave Irene Joliot Curie, F-31059 Toulouse 9, France	Rochaix, P (reprint author), Inst Univ Canc Oncopole, Dept Anat & Cytol Pathol, 1 Ave Irene Joliot Curie, F-31059 Toulouse 9, France.		Rochaix, Philippe/O-4710-2014	Rochaix, Philippe/0000-0001-6238-1599			Antonescu CR, 2010, GENE CHROMOSOME CANC, V49, P1114, DOI 10.1002/gcc.20819; Fetsch JF, 2004, AM J SURG PATHOL, V28, P1360, DOI 10.1097/01.pas.0000135518.27224.3f; FLETCHER CDM, WHO CLASSIFICATION T; Kohashi K, 2010, MODERN PATHOL, V23, P981, DOI 10.1038/modpathol.2010.71	4	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	JUN	2018	38	3					170	173		10.1016/j.annpat.2018.04.011			4	Pathology	Pathology	GO6EG	WOS:000440126300005	29929742				2019-10-28	
J	Rochaix, P				Rochaix, Philippe			Carcinoma of unknown primary. Case no. 2	ANNALES DE PATHOLOGIE			French	Editorial Material							MESOTHELIOMA INTEREST GROUP; MALIGNANT MESOTHELIOMA; PATHOLOGICAL DIAGNOSIS; CONSENSUS STATEMENT; USEFUL MARKER; EXPRESSION; TISSUES; BREAST; GUIDELINES; GATA-3		[Rochaix, Philippe] Inst Univ Canc Oncopole, Dept Anat & Cytol Pathol, 1 Ave Irene Joliot Curie, F-31059 Toulouse 9, France	Rochaix, P (reprint author), Inst Univ Canc Oncopole, Dept Anat & Cytol Pathol, 1 Ave Irene Joliot Curie, F-31059 Toulouse 9, France.						Chu PG, 2002, HISTOPATHOLOGY, V40, P403, DOI 10.1046/j.1365-2559.2002.01387.x; Clark BZ, 2014, AM J CLIN PATHOL, V142, P64, DOI 10.1309/AJCP8H2VBDSCIOBF; Conner JR, 2015, ADV ANAT PATHOL, V22, P149, DOI 10.1097/PAP.0000000000000069; Davis DG, 2016, HUM PATHOL, V47, P26, DOI 10.1016/j.humpath.2015.09.015; Elias D., 1999, HEPATOGASTRO, V6, P429; Husain AN, 2013, ARCH PATHOL LAB MED, V137, P647, DOI 10.5858/arpa.2012-0214-OA; Husain AN, 2009, ARCH PATHOL LAB MED, V133, P1317, DOI 10.1043/1543-2165-133.8.1317; Liu HY, 2012, AM J CLIN PATHOL, V138, P57, DOI 10.1309/AJCP5UAFMSA9ZQBZ; Mery E, 2014, ANN PATHOL, V34, P26, DOI 10.1016/j.annpat.2014.01.004; Miettinen M, 2014, AM J SURG PATHOL, V38, P13, DOI 10.1097/PAS.0b013e3182a0218f; Nakatsuka S, 2006, MODERN PATHOL, V19, P804, DOI 10.1038/modpathol.3800588; Nonaka D, 2008, AM J SURG PATHOL, V32, P1566, DOI 10.1097/PAS.0b013e31816d71ad; Ozcan A, 2011, MODERN PATHOL, V24, P751, DOI 10.1038/modpathol.2011.3; Tacha D, 2011, APPL IMMUNOHISTO M M, V19, P293, DOI 10.1097/PAI.0b013e3182025f66	14	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	JUN	2018	38	3					174	178		10.1016/j.annpat.2018.04.012			5	Pathology	Pathology	GO6EG	WOS:000440126300006					2019-10-28	
J	Selves, J				Selves, Janick			Carcinoma of unknown primary. Case no. 3	ANNALES DE PATHOLOGIE			French	Editorial Material							COLORECTAL ADENOCARCINOMA; SATB2; BLADDER; CDX2		[Selves, Janick] Inst Univ Canc Oncopole, Dept Anat & Cytol Pathol, 1 Ave Irene Joliot Curie, F-31059 Toulouse 9, France	Selves, J (reprint author), Inst Univ Canc Oncopole, Dept Anat & Cytol Pathol, 1 Ave Irene Joliot Curie, F-31059 Toulouse 9, France.						Bayrak R, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-9; Dragomir A, 2014, AM J CLIN PATHOL, V141, P630, DOI 10.1309/AJCPWW2URZ9JKQJU; Fukuhara M, 2016, ARCH DERMATOL RES, V308, P449, DOI 10.1007/s00403-016-1655-6; Lin F, 2014, ARCH PATHOL LAB MED, V138, P1015, DOI 10.5858/arpa.2013-0452-OA; Lugli A, 2008, MODERN PATHOL, V21, P1403, DOI 10.1038/modpathol.2008.117; Olsen J, 2016, EXP MOL PATHOL, V100, P59, DOI 10.1016/j.yexmp.2015.11.009; Rao Q, 2013, MODERN PATHOL, V26, P725, DOI 10.1038/modpathol.2012.229; Roy S, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-151; Scoazec JY, 2012, ANN PATHOL, V32, pS32, DOI 10.1016/j.annpat.2012.08.003; Wang HLL, 2017, ARCH PATHOL LAB MED, V141, P1155, DOI 10.5858/arpa.2016-0489-RA	10	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	JUN	2018	38	3					179	181		10.1016/j.annpat.2018.04.013			3	Pathology	Pathology	GO6EG	WOS:000440126300007	29929741				2019-10-28	
J	Selves, J				Selves, Janick			Carcinoma of unknown primary. Case no. 4	ANNALES DE PATHOLOGIE			French	Editorial Material							PDGFRA; TUMORS; MUTATIONS; DIAGNOSIS; GISTS		[Selves, Janick] Inst Univ Canc Oncopole, Dept Anat & Cytol Pathol, 1 Ave Irene Joliot Curie, F-31059 Toulouse 9, France	Selves, J (reprint author), Inst Univ Canc Oncopole, Dept Anat & Cytol Pathol, 1 Ave Irene Joliot Curie, F-31059 Toulouse 9, France.						Capelli L, 2016, EJSO-EUR J SURG ONC, V42, P1206, DOI 10.1016/j.ejso.2016.05.022; Casali PG, 2014, ANN ONCOL, V25, P21, DOI 10.1093/annonc/mdu255; Choi WT, 2017, HUM PATHOL, V63, P1, DOI 10.1016/j.humpath.2016.12.025; Farag S, 2017, EUR J CANCER, V76, P76, DOI 10.1016/j.ejca.2017.02.007; Jin M, 2016, ENDOCR PATHOL, V27, P253, DOI 10.1007/s12022-016-9442-7; Lacobuzzo-Donahue C, 2010, SECONDARY TUMOURS LI, P251; Lasota J, 2004, LAB INVEST, V84, P874, DOI 10.1038/labinvest.3700122; Miettinen M, 2009, AM J SURG PATHOL, V33, P1401, DOI 10.1097/PAS.0b013e3181a90e1a; Rubin BP, 2015, SEMIN DIAGN PATHOL, V32, P392, DOI 10.1053/j.semdp.2015.02.017	9	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	JUN	2018	38	3					182	184		10.1016/j.annpat.2018.04.013			3	Pathology	Pathology	GO6EG	WOS:000440126300008	29929741				2019-10-28	
J	Long-Mira, E				Long-Mira, Elodie			Carcinoma of unknown primary. Case no. 5	ANNALES DE PATHOLOGIE			French	Editorial Material							PRIMARY SITE; IMMUNOHISTOCHEMISTRY; CANCER		[Long-Mira, Elodie] Univ Cote Azur, CHU Nice, Hop Pasteur, Lab Pathol Clin & Expt, 30 Voie Romaine, F-06000 Nice, France	Long-Mira, E (reprint author), Univ Cote Azur, CHU Nice, Hop Pasteur, Lab Pathol Clin & Expt, 30 Voie Romaine, F-06000 Nice, France.						Benderra MA, 2016, B CANCER, V103, P697, DOI 10.1016/j.bulcan.2016.05.003; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Evans AG, 2012, AM J SURG PATHOL, V36, P1222, DOI 10.1097/PAS.0b013e318258f03b; Kandalaft PL, 2016, ARCH PATHOL LAB MED, V140, P508, DOI 10.5858/arpa.2015-0173-CP; Lin F, 2015, ARCH PATHOL LAB MED, V139, P24, DOI 10.5858/arpa.2014-0072-RA; Lin F, 2014, ARCH PATHOL LAB MED, V138, P1583, DOI 10.5858/arpa.2014-0061-RA; Matsushima J, 2017, HUM PATHOL, V64, P179, DOI 10.1016/j.humpath.2017.04.006; Suryavanshi M, 2017, ADV ANAT PATHOL, V24, P151, DOI 10.1097/PAP.0000000000000150; Zhao L, 2013, AM J SURG PATHOL, V37, P1876, DOI 10.1097/PAS.0b013e31829e2525	9	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	JUN	2018	38	3					185	187		10.1016/j.annpat.2018.04.014			3	Pathology	Pathology	GO6EG	WOS:000440126300009	29929746				2019-10-28	
J	Long-Mira, E				Long-Mira, Elodie			Carcinoma of unknown primary. Case no. 6	ANNALES DE PATHOLOGIE			French	Editorial Material							ANDROGEN RECEPTOR EXPRESSION; PROSTATE; DIAGNOSIS; IMMUNOHISTOCHEMISTRY; CANCER		[Long-Mira, Elodie] Univ Cote Azur, CHU Nice, Hop Pasteur, Lab Pathol Clin & Expt, 30 Voie Romaine, F-06000 Nice, France	Long-Mira, E (reprint author), Univ Cote Azur, CHU Nice, Hop Pasteur, Lab Pathol Clin & Expt, 30 Voie Romaine, F-06000 Nice, France.						Carder PJ, 2005, J CLIN PATHOL, V58, P69, DOI 10.1136/jcp.2004.018291; Downes MR, 2013, J CLIN PATHOL, V66, P779, DOI 10.1136/jclinpath-2013-201586; Graddis TJ, 2011, INT J CLIN EXP PATHO, V4, P295; Johnsen JA, 1997, J UROLOGY, V157, P450, DOI 10.1016/S0022-5347(01)65167-X; Kandalaft PL, 2016, ARCH PATHOL LAB MED, V140, P508, DOI 10.5858/arpa.2015-0173-CP; Molinie V, 2008, PROG UROL, V18, pS47, DOI [10.1016/S1166-7087(08)74541-X, 10.1016/S1166-7087(08)70514-1]; Navaei AH, 2017, J CANCER, V8, P2604, DOI 10.7150/jca.16751; Queisser A, 2015, MODERN PATHOL, V28, P138, DOI 10.1038/modpathol.2014.77; Sheridan T, 2007, AM J SURG PATHOL, V31, P1351, DOI 10.1097/PAS.0b013e3180536678; Skinnider BF, 2005, SEMIN DIAGN PATHOL, V22, P51, DOI 10.1053/j.semdp.2005.11.004	10	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	JUN	2018	38	3					188	190		10.1016/j.annpat.2018.04.015			3	Pathology	Pathology	GO6EG	WOS:000440126300010	29929745				2019-10-28	
J	Ilie, M				Ilie, Marius			Carcinoma of unknown primary. Case no. 7	ANNALES DE PATHOLOGIE			French	Editorial Material							URACHAL CARCINOMA; URINARY-BLADDER; ADENOCARCINOMA; IMMUNOHISTOCHEMISTRY; DIAGNOSIS		[Ilie, Marius] Univ Cote Azur, CHU Nice, Hop Pasteur, Lab Pathol Clin & Expt, 30 Voie Romaine, F-06000 Nice, France	Ilie, M (reprint author), Univ Cote Azur, CHU Nice, Hop Pasteur, Lab Pathol Clin & Expt, 30 Voie Romaine, F-06000 Nice, France.	ilie.m@chu-nice.fr	Ilie, Marius/M-7964-2019	Ilie, Marius/0000-0002-2014-1236			Aly FZ, 2013, CYTOJOURNAL, V10, DOI 10.4103/1742-6413.106684; Amin MB, 2014, AM J SURG PATHOL, V38, pE20, DOI 10.1097/PAS.0000000000000240; Collazo-Lorduy A, 2016, EUR UROL, V70, P771, DOI 10.1016/j.eururo.2016.04.037; Ellis CL, 2013, AM J SURG PATHOL, V37, P1756, DOI 10.1097/PAS.0b013e31829cdba7; Gopalan A, 2009, AM J SURG PATHOL, V33, P659, DOI 10.1097/PAS.0b013e31819aa4ae; Lee S, 2017, J MED GENET, V54, P572, DOI 10.1136/jmedgenet-2016-104390; Lindner V, 2016, ANN PATHOL, V36, P398, DOI 10.1016/j.annpat.2016.09.006; Rao Q, 2013, MODERN PATHOL, V26, P725, DOI 10.1038/modpathol.2012.229; Szarvas T, 2016, UROL ONCOL-SEMIN ORI, V34, P388, DOI 10.1016/j.urolonc.2016.04.012; Thirunavukkarasu B, 2016, J CLIN DIAGN RES, V10, pED10, DOI 10.7860/JCDR/2016/16115.7586	10	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	JUN	2018	38	3					191	193		10.1016/j.annpat.2018.04.016			3	Pathology	Pathology	GO6EG	WOS:000440126300011	29929748				2019-10-28	
J	Mathieu, MC				Mathieu, Marie-Christine			Carcinoma of unknown primary. Case no. 8	ANNALES DE PATHOLOGIE			French	Editorial Material							EXPRESSION		[Mathieu, Marie-Christine] Inst Gustave Roussy, Dept Biol & Pathol Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, France	Mathieu, MC (reprint author), Inst Gustave Roussy, Dept Biol & Pathol Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, France.						Greco FA, 2010, ONCOLOGIST, V15, P500, DOI 10.1634/theoncologist.2009-0328; Hainsworth JD, 2013, J CLIN ONCOL, V31, P217, DOI 10.1200/JCO.2012.43.3755; Lau SK, 2004, AM J CLIN PATHOL, V122, P61, DOI 10.1309/9R6673QEC06D86Y4; Lok T, 2014, HUM PATHOL, V45, P394, DOI 10.1016/j.humpath.2013.10.004; Ma XJ, 2006, ARCH PATHOL LAB MED, V130, P465; Moran S, 2016, LANCET ONCOL, V17, P1386, DOI 10.1016/S1470-2045(16)30297-2; Ross JS, 2015, JAMA ONCOL, V1, P40, DOI 10.1001/jamaoncol.2014.216	7	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	JUN	2018	38	3					194	196		10.1016/j.annpat.2018.04.017			3	Pathology	Pathology	GO6EG	WOS:000440126300012	29929744				2019-10-28	
J	Ilie, M; Selves, J; Long-Mira, E; Mathieu, MC; Rochaix, P				Ilie, Marius; Selves, Janick; Long-Mira, Elodie; Mathieu, Marie-Christine; Rochaix, Philippe			Carcinoma of unknown primary. Role of the pathologist in 2018: Pre-test answers	ANNALES DE PATHOLOGIE			French	Editorial Material									[Ilie, Marius; Selves, Janick; Long-Mira, Elodie] Univ Cote Azur, CHU Nice, Hop Pasteur, Lab Pathol Clin & Expt, 30 Voie Romaine, F-06000 Nice, France; [Rochaix, Philippe] Inst Univ Canc Oncopole, Dept Anat & Cytol Pathol, 1 Ave Irene Joliot Curie, F-31059 Toulouse 9, France; [Mathieu, Marie-Christine] Inst Gustave Roussy, Dept Biol & Pathol Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, France	Ilie, M (reprint author), Univ Cote Azur, CHU Nice, Hop Pasteur, Lab Pathol Clin & Expt, 30 Voie Romaine, F-06000 Nice, France.							0	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	JUN	2018	38	3					197	197		10.1016/j.annpat.2018.04.018			1	Pathology	Pathology	GO6EG	WOS:000440126300013					2019-10-28	
J	Jean-Jacques, B; Michels, JJ; Veyssiere, A; Haidar, D				Jean-Jacques, Bastien; Michels, Jean-Jacques; Veyssiere, Alexis; Haidar, Dima			Microcystic adnexal carcinoma: A case report	ANNALES DE PATHOLOGIE			French	Article						Skin adhexal tumors; Microcystic adnexal carcinoma; Basal cell carcinoma; Desmoplastic trichoepithelioma; Syringomatous carcinoma		We report a case of microcystic adnexal carcinoma in a 80-year-old woman. This is a rare malignant adnexal cutaneous tumor with glandular and follicular differentiation, rare, often asymptomatic, with late diagnosis and slow growth, locally aggressive and rarely metastatic. The distinction with other benign and malignant skin tumors is difficult. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Jean-Jacques, Bastien; Michels, Jean-Jacques] CHU Caen, Serv Anat Pathol, Ave Cote Nacre, F-14033 Caen, France; [Veyssiere, Alexis] CHU Caen, Serv Chirurg Maxillofaciale, Ave Cote Nacre, F-14033 Caen, France; [Haidar, Dima] CHU Caen, Serv Dermatol, Ave Cote Nacre, F-14033 Caen, France	Jean-Jacques, B (reprint author), CHU Caen, Serv Anat Pathol, Ave Cote Nacre, F-14033 Caen, France.	bastienjj@gmail.com					Chen JX, 2016, ONCOL LETT, V11, P2471, DOI 10.3892/ol.2016.4242; Compton LA, 2015, DERMATOPATHOLOGY, V2, P15, DOI 10.1159/000377698; Frouin E, 2015, J EUR ACAD DERMATOL, V29, P1978, DOI 10.1111/jdv.13127; Frouin ED, 2013, B DIVISION FRANCAISE, P69; GOLDSTEIN DJ, 1982, CANCER, V50, P566, DOI 10.1002/1097-0142(19820801)50:3<566::AID-CNCR2820500330>3.0.CO;2-Q; Hamed NS, 2015, J DERMATOL DERMATOL, V19, P80, DOI 10.1016/j.jdds.2015.03.001; Inskip Mike, 2015, Dermatol Pract Concept, V5, P43, DOI 10.5826/dpc.0501a07; Jouary TD, 2013, B DIVISION FRANCAISE, P55; Castanon MCMN, 2015, AN BRAS DERMATOL, V90, P36, DOI 10.1590/abd1806-4841.20153445; El Ochi MR, 2015, PAN AFR MED J, V21, DOI [10.11604/pamj.2015.20.389.6202, 10.11604/pamj.2015.21.318.5657]; Sellheyer K, 2013, J CUTAN PATHOL, V40, P363, DOI 10.1111/cup.12085; Vidal CI, 2010, AM J DERMATOPATH, V32, P257, DOI 10.1097/DAD.0b013e3181b7fc76	12	0	0	0	1	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	JUN	2018	38	3					198	201		10.1016/j.annpat.2018.03.001			4	Pathology	Pathology	GO6EG	WOS:000440126300014	29622469				2019-10-28	
J	Kakudo, K; El-Naggar, AK; Hodak, SP; Khanafshar, E; Nikiforov, YE; Nose, V; Thompson, LDR				Kakudo, Kennichi; El-Naggar, Adel K.; Hodak, Steven P.; Khanafshar, Elham; Nikiforov, Yuri E.; Nose, Vania; Thompson, Lester D. R.			Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) in thyroid tumor classification	PATHOLOGY INTERNATIONAL			English	Editorial Material							NEEDLE-ASPIRATION-CYTOLOGY; BETHESDA SYSTEM; OBSERVER VARIATION; RAS MUTATIONS; CARCINOMA; VARIANT; IMPACT; CYTOPATHOLOGY; DIAGNOSIS; RISK		[Kakudo, Kennichi] Kindai Univ, Fac Med, Nara Hosp, Dept Pathol & Lab Med, Ikoma City, Nara, Japan; [El-Naggar, Adel K.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Hodak, Steven P.] NYU, Sch Med, Div Endocrinol & Metab, New York, NY USA; [Khanafshar, Elham] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Nikiforov, Yuri E.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA; [Nose, Vania] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Nose, Vania] Harvard Med Sch, Dept Pathol, Boston, MA USA; [Thompson, Lester D. R.] Southern Calif Permanente Med Grp, Woodland Hills, CA USA	Kakudo, K (reprint author), Kindai Univ, Fac Med, Nara Hosp, Dept Pathol & Lab Med, Ikoma City, Nara, Japan.						Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Ali S, 2017, CRITERIA EXPLANATORY; Baloch ZW, 2016, CANCER CYTOPATHOL, V124, P616, DOI 10.1002/cncy.21744; Bizzarro T, 2016, CANCER CYTOPATHOL, V124, P699, DOI 10.1002/cncy.21777; Bychkov A, 2018, ENDOCR PATHOL, V29, P276, DOI 10.1007/s12022-018-9519-6; Bychkov A, 2018, PATHOLOGY, V50, P411, DOI 10.1016/j.pathol.2017.11.088; Bychkov A, 2017, THYROID, V27, P983, DOI 10.1089/thy.2017.0079; Canberk S, 2016, ACTA CYTOL, V60, P198, DOI 10.1159/000447990; Carney JA, 2008, AM J SURG PATHOL, V32, P1877, DOI 10.1097/PAS.0b013e31817a8f1b; Cho U, 2017, MODERN PATHOL, V30, P810, DOI 10.1038/modpathol.2017.9; Conzo G, 2017, ENDOCRINE, V55, P530, DOI 10.1007/s12020-016-0953-2; DeLellis RA, 2004, WHO CLASSIFICATION T; Faquin WC, 2016, CANCER CYTOPATHOL, V124, P181, DOI 10.1002/cncy.21631; FUKUNAGA M, 1992, ACTA PATHOL JAPON, V42, P632; Ganly I, 2015, HUM PATHOL, V46, P657, DOI 10.1016/j.humpath.2015.01.010; Gupta N, 2013, J CLIN ENDOCR METAB, V98, pE914, DOI 10.1210/jc.2012-3396; Hahn SY, 2017, CLIN ENDOCRINOL, V86, P444, DOI 10.1111/cen.13263; Haugen BR, 2017, THYROID, V27, P481, DOI 10.1089/thy.2016.0628; Hirokawa M, 2002, AM J SURG PATHOL, V26, P1508, DOI 10.1097/00000478-200211000-00014; Hodak S, 2016, THYROID, V26, P869, DOI 10.1089/thy.2016.0205; Ibrahim AA, 2016, AM J CLIN PATHOL, V146, P373, DOI [10.1093/AJCP/AQW126, 10.1093/ajcp/aqw126]; Jung CK, 2017, J BASIC CLIN MED, V6, P22; Kakudo K, 2017, CYTOPATHOLOGY, V28, P455, DOI 10.1111/cyt.12491; Kakudo K, 2002, ENDOCR PATHOL, V13, P131, DOI 10.1385/EP:13:2:131; Kakudo K, 2017, J BASIC CLIN MED, V6, P3; Kakudo K, 2017, J BASIC CLIN MED, V6, P14; Kakudo K, 2018, GLAND SURG, V7, pS8, DOI 10.21037/gs.2017.08.02; Kakudo K, 2014, ENDOCR J, V61, P539, DOI 10.1507/endocrj.EJ13-0494; Kakudo K, 2012, PATHOL INT, V62, P155, DOI 10.1111/j.1440-1827.2011.02773.x; Kakudo K, 2012, ENDOCR J, V59, P1; Kim TH, 2018, HISTOPATHOLOGY, V72, P648, DOI 10.1111/his.13401; Krane JF, 2016, CANCER CYTOPATHOL, V124, P767, DOI 10.1002/cncy.21769; Lee SE, 2017, THYROID, V27, P802, DOI 10.1089/thy.2016.0547; Liu J, 2006, CANCER-AM CANCER SOC, V107, P1255, DOI 10.1002/cncr.22138; Liu Z, 2017, J BASIC CLIN MED, V6, P22, DOI DOI 10.3390/jcm6020022; Liu ZY, 2011, CANCER SCI, V102, P288, DOI 10.1111/j.1349-7006.2010.01769.x; Lloyd RV, 2018, HUM PATHOL, V74, P1, DOI 10.1016/j.humpath.2017.12.027; Lloyd RV, 2004, AM J SURG PATHOL, V28, P1336, DOI 10.1097/01.pas.0000135519.34847.f6; Lloyd RV, 2017, WHO CLASSIFICATION T; Maletta F, 2016, HUM PATHOL, V54, P134, DOI 10.1016/j.humpath.2016.03.014; Medici M, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0419-z; Ng D, 2017, J BASIC CLIN MED, V6, P51; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Ohori NP, 2017, CANCER CYTOPATHOL, V125, P692, DOI 10.1002/cncy.21892; Parente DN, 2018, WORLD J SURG, V42, P321, DOI 10.1007/s00268-017-4182-5; Paulson VA, 2017, THYROID, V27, P506, DOI 10.1089/thy.2016.0583; Piana S, 2010, AM J SURG PATHOL, V34, P868, DOI 10.1097/PAS.0b013e3181dbee07; Pusztaszeri M, 2016, ACTA CYTOL, V60, P399, DOI 10.1159/000451020; Pusztaszeri MP, 2017, J BASIC CLIN MED, V6, P29; Renshaw AA, 2002, AM J CLIN PATHOL, V117, P19; Rivera M, 2010, MODERN PATHOL, V23, P1191, DOI 10.1038/modpathol.2010.112; Rivera M, 2010, HUM PATHOL, V41, P172, DOI 10.1016/j.humpath.2009.08.011; Rosario PW, 2017, ENDOCR PATHOL, V28, P367, DOI 10.1007/s12022-017-9493-4; Rosario PW, 2016, ENDOCR-RELAT CANCER, V23, P893, DOI 10.1530/ERC-16-0379; Rossi ED., 2017, J BASIC CLIN MED, V6, P36; Saglietti C, 2017, J BASIC CLIN MED, V6, P57; Satoh S, 2017, J PATHOL TRANSL MED, V51, P548, DOI 10.4132/jptm.2017.09.29; Seethala RR, 2018, MODERN PATHOL, V31, P39, DOI 10.1038/modpathol.2017.130; Strickland KC, 2015, THYROID, V25, P987, DOI 10.1089/thy.2014.0612; Sugino K, 2015, J BASIC CLIN MED, V4, P92; The Japan Thyroid Association, 2013, GUID CLIN PRACT MAN; Thompson LDR, 2016, MODERN PATHOL, V29, P698, DOI 10.1038/modpathol.2016.65; Valderrabano P, 2016, AM THYR ASS ANN M, V26; Vivero M, 2013, THYROID, V23, P273, DOI 10.1089/thy.2012.0369; Widder S, 2008, SURGERY, V144, P80, DOI 10.1016/j.surg.2007.11.014; Williams ED, 2000, INT J SURG PATHOL, V8, P181, DOI 10.1177/106689690000800304; Xu B, 2017, THYROID, V27, P512, DOI 10.1089/thy.2016.0649; Yang GCH, 2017, DIAGN CYTOPATHOL, V45, P533, DOI 10.1002/dc.23709; Zhao LN, 2017, CANCER CYTOPATHOL, V125, P323, DOI 10.1002/cncy.21839	69	9	9	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUN	2018	68	6					327	333		10.1111/pin.12673			7	Pathology	Pathology	GI2VW	WOS:000434231000001	29675873				2019-10-28	
J	Yokozaki, H; Koma, Y; Shigeoka, M; Nishio, M				Yokozaki, Hiroshi; Koma, Yu-ichiro; Shigeoka, Manabu; Nishio, Mari			Cancer as a tissue: The significance of cancer-stromal interactions in the development, morphogenesis and progression of human upper digestive tract cancer	PATHOLOGY INTERNATIONAL			English	Review						cancer-associated fibroblast; esophageal cancer; stomach cancer; tumor-associated macrophage; tumor microenvironment	TUMOR-ASSOCIATED MACROPHAGES; SQUAMOUS-CELL CARCINOMA; EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN GASTRIC CARCINOMAS; HUMAN COLORECTAL-CANCER; TGF-BETA SUPERFAMILY; GROWTH-FACTOR; STEM-CELLS; DNA-DAMAGE; MYOFIBROBLASTS CONTRIBUTE	We review the significance of cancer-stromal interactions (CSIs) in the development, morphogenesis and progression of human gastric and esophageal cancer based on the data obtained from co-culture experiments. Orthotopic fibroblasts in the gastric cancer stroma not only promoted their growth by cancer cells but were also responsible for the mobility, morphogenesis and epithelial-to-mesenchymal transition (EMT) of the cancer cells through CSI. Bone marrow-derived mesenchymal stem cells could be part of the origin of cancer-associated fibroblasts (CAFs) of the gastric cancer providing an advantageous microenvironment for the restoration of cancer stem cells with the induction of the EMT. Tumor-associated macrophages (TAMs) may differentiate from bone marrow-derived monocytes/macrophages within the tumor microenvironment of esophageal cancer and participate in the growth and the progression of esophageal squamous cell carcinomas (ESCCs). Macrophages infiltrated into the intraepithelial neoplastic lesions of the esophagus may function as a biological promoter by promoting the growth and motility of squamous epithelia. Tumor cells build up cancer as a tissue by taking advantage of the existing network of growth factors, cytokines and chemokines through the interactions of TAMs, CAFs and cancer cells themselves.	[Yokozaki, Hiroshi; Koma, Yu-ichiro; Shigeoka, Manabu; Nishio, Mari] Kobe Univ, Grad Sch Med, Dept Pathol, Div Pathol,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan	Yokozaki, H (reprint author), Kobe Univ, Grad Sch Med, Dept Pathol, Div Pathol,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	hyoko@med.kobe-u.ac.jp	Nishio, Mari/C-9322-2016; Shigeoka, Manabu/O-6285-2019	Nishio, Mari/0000-0002-7413-0751; 	JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [05670175, 08670205, 09670186, 12670163, 14370070, 18659096, 20590341, 23590397, 26460418, JP17K08693, 26870364, JP16K21159, JP17K17247]; Ministry of Health, Labor and Welfare of JapanMinistry of Health, Labour and Welfare, Japan [14-7, 20-12]; Terry Fox Foundation for Cancer Research Fund	Hiroshi Yokozaki has been announced as the winner of the Japanese Society of Pathology; Japan Pathology Award in 2017. This review article was prepared based on the data presented at the 106th Annual Meeting of the Japanese Society of Pathology, Tokyo, 29 April 2017. We thank Emeritus Professor Eiichi Tahara and Professor Wataru Yasui (Hiroshima University), Emeritus Professor Hisao Ito (Tottori University) for their invaluable advice and continuous encouragement and Emeritus Professor Masahisa Kyogoku (Tohoku University) and Emeritus Professor Sakan Maeda (Kobe University) for their sincere support. We thank Dr. Shuho Semba (Kobe Ekisaikai Hospital), Prof. Akihiko Ito (Kindai University), and all former and present members of the Division of Pathology, Department of Pathology, Kobe University and Department of Molecular Pathology, Hiroshima University. We are also grateful to Prof. Tomoo Ito, Prof. Yoshihiro Kakeji, Prof. Takahide Komori, Prof. Masato Kasuga, Prof. Yoshikazu Kuroda, Dr. Noburo Aoyama, Prof. Yu-ichi Hori, Dr. Daisuke Kuroda, Dr. Takashi Kamigaki and Dr. Tetsu Nakamura (Kobe University), Prof. Atsushi Ochiai, Prof. Kazuyoshi Yanagihara, Dr. Masashi Fujii, Dr. Ken Hatogai, Dr. Hiroki Sasaki, Dr. Kazuhiko Aoyagi, Dr. Akiko Nagatsuma (National Cancer Center), Prof. Kose Hirakawa and Prof. Masakazu Yashiro (Osaka City University), Prof. Toshimitsu Suzuki and Prof. Hideki Chiba (Fukushima Medical University), Prof. Noriaki Sawada (Sapporo Medical University), Dr. Shihori Tanabe (National Institute of Health Sciences), Prof. Manabu Muto and Dr. Yusuke Amanuma (Kyoto University), Dr. Yu Usami (Osaka University) and all collaborators who kindly supported the research. The experimental work presented here was supported in part by JSPS KAKENHI Grant Number 05670175, 08670205, 09670186, 12670163, 14370070, 18659096, 20590341, 23590397, 26460418 and JP17K08693 to HY; 26870364 and JP16K21159 to YK; JP17K17247 to MS, Grants-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare of Japan (14-7 and 20-12 to HY) and grants for cancer research from the Terry Fox Foundation for Cancer Research Fund.	Allen SJ, 2007, ANNU REV IMMUNOL, V25, P787, DOI 10.1146/annurev.immunol.24.021605.090529; Amanuma Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep14142; Baek SJ, 2001, MOL PHARMACOL, V59, P901; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Balkwill FR, 2012, J CELL SCI, V125, P5591, DOI 10.1242/jcs.116392; Battistelli C, 2017, ONCOGENE, V36, P942, DOI 10.1038/onc.2016.260; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Boldrini L, 2005, LUNG CANCER, V50, P309, DOI 10.1016/j.lungcan.2005.07.002; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; Coleman SJ, 2014, EMBO MOL MED, V6, P467, DOI 10.1002/emmm.201302698; Corre J, 2012, CANCER RES, V72, P1395, DOI 10.1158/0008-5472.CAN-11-0188; Ditlevsen DK, 2008, J NEUROSCI RES, V86, P727, DOI 10.1002/jnr.21551; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Griner SE, 2013, BIOCHEM PHARMACOL, V85, P46, DOI 10.1016/j.bcp.2012.10.007; Hammes LS, 2007, GYNECOL ONCOL, V105, P157, DOI 10.1016/j.ygyno.2006.11.023; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hashimoto O, 2016, J PATHOL, V240, P211, DOI 10.1002/path.4769; Herrera M, 2013, CANCER SCI, V104, P437, DOI 10.1111/cas.12096; Hogger P, 1998, J IMMUNOL, V161, P1883; Hojo H, 1997, NIIGATA IGAKUKAI ZAS, V91, P737; Hosono M, 2017, ONCOTARGET, V8, P106071, DOI 10.18632/oncotarget.22526; Hromas R, 1997, BBA-GENE STRUCT EXPR, V1354, P40, DOI 10.1016/S0167-4781(97)00122-X; Huang SY, 2002, AM J PATHOL, V161, P125, DOI 10.1016/S0002-9440(10)64164-8; Ishii G, 2003, BIOCHEM BIOPH RES CO, V309, P232, DOI 10.1016/S0006-291X(03)01544-4; Ishii G, 2016, ADV DRUG DELIVER REV, V99, P186, DOI 10.1016/j.addr.2015.07.007; Ishii G, 2007, STEM CELLS, V25, P1469, DOI 10.1634/stemcells.2006-0449; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Kaneda MM, 2016, NATURE, V539, P437, DOI 10.1038/nature19834; Kanzawa M, 2013, PATHOBIOLOGY, V80, P235, DOI 10.1159/000346843; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kato H, 2004, CLIN CANCER RES, V10, P7318, DOI 10.1158/1078-0432.CCR-04-0485; Koma Y, 2017, BESSATSU BIO CLIN, V6, P123; Komohara Y, 2008, J PATHOL, V216, P15, DOI 10.1002/path.2370; Komohara Y, 2017, J PATHOL, V241, P313, DOI 10.1002/path.4824; Komohara Y, 2011, CANCER SCI, V102, P1424, DOI 10.1111/j.1349-7006.2011.01945.x; Kumagai Y, 2016, ESOPHAGUS-TOKYO, V13, P245, DOI 10.1007/s10388-015-0520-6; Lau LF, 2011, CELL MOL LIFE SCI, V68, P3149, DOI 10.1007/s00018-011-0778-3; Lee DH, 2003, CANCER RES, V63, P4648; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Masuda R, 2010, PATHOBIOLOGY, V77, P106, DOI 10.1159/000278293; Matsuda Y, 2007, CANCER SCI, V98, P1014, DOI 10.1111/j.1349-7006.2007.00490.x; Matsukawa Y, 2006, CANCER SCI, V97, P484, DOI 10.1111/j.1349-7006.2006.00203.x; Matsukawa Y, 2010, PATHOBIOLOGY, V77, P155, DOI 10.1159/000292649; Mishra PJ, 2008, CANCER RES, V68, P4331, DOI 10.1158/0008-5472.CAN-08-0943; Miskad UA, 2007, VIRCHOWS ARCH, V450, P303, DOI 10.1007/s00428-006-0361-8; Miskad UA, 2004, PATHOBIOLOGY, V71, P176, DOI 10.1159/000078671; Mizuuchi E, 2009, INT J CANCER, V124, P1802, DOI 10.1002/ijc.24111; Mori T, 2005, MOL CELL BIOL, V25, P5183, DOI 10.1128/MCB.25.12.5183-5195.2005; MOTOYAMA T, 1986, ACTA PATHOL JAPON, V36, P65; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Naito M, 2008, PATHOL INT, V58, P143, DOI 10.1111/j.1440-1827.2007.02203.x; Nakazawa K, 2003, CANCER RES, V63, P8848; NISHIHIRA T, 1993, J CANCER RES CLIN, V119, P441, DOI 10.1007/BF01215923; Nishimura K, 2012, PATHOBIOLOGY, V79, P290, DOI 10.1159/000337296; Nishio M, 2016, PATHOL INT, V66, P83, DOI 10.1111/pin.12381; OCHIAI A, 1985, JPN J CANCER RES, V76, P1064; Orimo A, 2007, CANCER BIOL THER, V6, P618, DOI 10.4161/cbt.6.4.4255; OSULLIVAN C, 1993, LANCET, V342, P148, DOI 10.1016/0140-6736(93)91348-P; Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760; PULFORD KAF, 1989, J CLIN PATHOL, V42, P414, DOI 10.1136/jcp.42.4.414; Quante M, 2011, CANCER CELL, V19, P257, DOI 10.1016/j.ccr.2011.01.020; Roth P, 2010, CLIN CANCER RES, V16, P3851, DOI 10.1158/1078-0432.CCR-10-0705; RUTISHAUSER U, 1976, P NATL ACAD SCI USA, V73, P577, DOI 10.1073/pnas.73.2.577; Sconocchia G, 2005, LEUKEMIA, V19, P69, DOI 10.1038/sj.leu.2403550; Semba S, 2009, BRIT J CANCER, V101, P1365, DOI 10.1038/sj.bjc.6605309; Shigeoka M, 2015, CANCER MED-US, V4, P437, DOI 10.1002/cam4.401; Shigeoka M, 2013, CANCER SCI, V104, P1112, DOI 10.1111/cas.12188; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Sica A, 2008, SEMIN CANCER BIOL, V18, P349, DOI 10.1016/j.semcancer.2008.03.004; STONER GD, 1991, CANCER RES, V51, P365; Sugimoto H, 2006, CANCER BIOL THER, V5, P1640, DOI 10.4161/cbt.5.12.3354; Takahashi K, 1996, PATHOL INT, V46, P473, DOI 10.1111/j.1440-1827.1996.tb03641.x; Takase N, 2016, CANCER LETT, V380, P47, DOI 10.1016/j.canlet.2016.06.009; Takeya M, 2016, PATHOL INT, V66, P491, DOI 10.1111/pin.12440; Tang XH, 2004, CLIN CANCER RES, V10, P301, DOI 10.1158/1078-0432.CCR-0999-3; Todorovic-Rakovic N, 2013, J INTERF CYTOK RES, V33, P563, DOI 10.1089/jir.2013.0023; Tomokiyo R, 2002, ATHEROSCLEROSIS, V161, P123, DOI 10.1016/S0021-9150(01)00624-4; TSUKADA T, 1987, AM J PATHOL, V127, P389; Ueda J, 2007, PATHOBIOLOGY, V74, P32, DOI 10.1159/000101049; Urakawa N, 2015, LAB INVEST, V95, P491, DOI 10.1038/labinvest.2015.36; Usami Y, 2008, J PATHOL, V215, P330, DOI 10.1002/path.2365; Usami Y, 2006, HUM PATHOL, V37, P569, DOI 10.1016/j.humpath.2005.12.018; Virchow R., 1863, KRANKHAFTEN GESCHWUL; Wang HH, 2007, CANCER RES, V67, P2922, DOI 10.1158/0008-5472.CAN-06-3598; WOLPE SD, 1988, J EXP MED, V167, P570, DOI 10.1084/jem.167.2.570; Wu Y, 2008, J IMMUNOL, V181, P6384, DOI 10.4049/jimmunol.181.9.6384; Xiao YC, 2015, CANCER LETT, V361, P22, DOI 10.1016/j.canlet.2015.02.021; YANAGIHARA K, 1991, CANCER RES, V51, P381; Yashiro M, 1996, BRIT J CANCER, V74, P1096, DOI 10.1038/bjc.1996.496; YokoyamaKobayashi M, 1997, J BIOCHEM-TOKYO, V122, P622; Yokozaki H, 2000, PATHOL INT, V50, P767, DOI 10.1046/j.1440-1827.2000.01117.x; YOKOZAKI H, 1993, INT J ONCOL, V3, P89; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3	102	4	4	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUN	2018	68	6					334	352		10.1111/pin.12674			19	Pathology	Pathology	GI2VW	WOS:000434231000002	29671926	Other Gold			2019-10-28	
J	Kataoka, T; Okudela, K; Matsumura, M; Mitsui, H; Suzuki, T; Koike, C; Sawazumi, T; Umeda, S; Tateishi, Y; Yamanaka, S; Ishikawa, Y; Arai, H; Tajiri, M; Ohashi, K				Kataoka, Toshiaki; Okudela, Koji; Matsumura, Mai; Mitsui, Hideaki; Suzuki, Takehisa; Koike, Chihiro; Sawazumi, Tomoe; Umeda, Shigeaki; Tateishi, Yoko; Yamanaka, Shoji; Ishikawa, Yoshihiro; Arai, Hiromasa; Tajiri, Michihiko; Ohashi, Kenichi			A molecular pathological study of four cases of ciliated muconodular papillary tumors of the lung	PATHOLOGY INTERNATIONAL			English	Article						ciliated muconodular papillary tumor; driver mutations; mucin proteins	MUTATIONS; BRAF	Ciliated muconodular papillary tumors (CMPTs) are a recently categorized benign or low-grade malignant neoplasm that develops in the peripheral lung. Only about 40 cases have been reported to date, and the clinicopathological characteristics have yet to be defined in detail. Here, we present four cases of CMPTs with a focus on their immunohistochemical profiles and driver gene mutations. These tumors were a papillary proliferation of a mixture of ciliated, mucous, and basal cells located in the peripheral lung. Ciliated, mucous and basal cells were positive for TTF-1 when using the clone SPT24, but negative for HNF-4. Basal cells were positive for p40. Mucous cells in some tumors were positive for MUC5AC and MUC6. The Ki-67 index was less than 5%, and strong expression of p53 was not detected. Three of the four tumors had a BRAF (V600E) driver mutation, an EGFR (del E746-T751/S752V) driver mutation, or driver mutations in both EGFR (E709G) and KRAS (G12V). These mutation types are rare for any histological type of lung cancer. The present results confirmed that CMPT is a neoplasm with immunohistochemical features and driver gene mutations that are distinct from those of common lung tumors.	[Kataoka, Toshiaki; Okudela, Koji; Matsumura, Mai; Mitsui, Hideaki; Suzuki, Takehisa; Koike, Chihiro; Sawazumi, Tomoe; Umeda, Shigeaki; Tateishi, Yoko; Yamanaka, Shoji; Ohashi, Kenichi] Yokohama City Univ, Grad Sch Med, Dept Pathol, Yokohama, Kanagawa, Japan; [Ishikawa, Yoshihiro] Yokohama City Univ, Grad Sch Med, Dept Surg, Yokohama, Kanagawa, Japan; [Arai, Hiromasa; Tajiri, Michihiko] Kanagawa Prefectural Cardiovasc & Resp Ctr Hosp, Div Gen Thorac Surg, Yokohama, Kanagawa, Japan	Okudela, K (reprint author), Yokohama City Univ, Grad Sch Med, Dept Pathol, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.	kojixok@yokohama-cu.ac.jp			Ministry of Education, Culture, Sports, and Science of Japan (Tokyo, Japan)Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT); Smoking Research Foundation (Tokyo, Japan)	This work was supported by the Ministry of Education, Culture, Sports, and Science of Japan (Tokyo, Japan), and by the Smoking Research Foundation (Tokyo, Japan). We thank Misaki Sugiyama and Emi Honda (Division of Pathology, Kanagawa Prefectural Cardiovascular and Respiratory Center Hospital, Kanagawa, Japan) for their assistance.	Harada T, 2008, RESP MED CME, V1, P176; Ishikawa M, 2016, J SURG CASE REP, V8, P1; Ishikawa Y., 2002, PATHOL CLIN MED, V20, P964; Jin Y, 2017, PATHOL INT, V67, P171, DOI 10.1111/pin.12512; Kamata T, 2016, J THORAC ONCOL, V11, P261, DOI 10.1016/j.jtho.2015.10.021; Kaneda T, 2014, LUNG CANCER, V86, P213, DOI 10.1016/j.lungcan.2014.09.014; Kojima Y, 2017, HISTOPATHOLOGY, V70, P568, DOI 10.1111/his.13103; Kris MG, 2014, JAMA-J AM MED ASSOC, V311, P1998, DOI 10.1001/jama.2014.3741; Liu LP, 2016, AM J SURG PATHOL, V40, P1631, DOI 10.1097/PAS.0000000000000707; Matsumura M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166795; Matsuoka Shunichiro, 2017, Asian Cardiovasc Thorac Ann, V25, P391, DOI 10.1177/0218492317713100; Miyake A, 2018, HISTOPATHOLOGY, V72, P609, DOI 10.1111/his.13397; Taguchi R, 2017, PATHOL INT, V67, P99, DOI 10.1111/pin.12504; Udo E, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0651-2	14	2	2	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUN	2018	68	6					353	358		10.1111/pin.12664			6	Pathology	Pathology	GI2VW	WOS:000434231000003	29624782				2019-10-28	
J	Amano, Y; Matsubara, D; Yoshimoto, T; Tamura, T; Nishino, H; Mori, Y; Niki, T				Amano, Yusuke; Matsubara, Daisuke; Yoshimoto, Taichiro; Tamura, Tomoko; Nishino, Hiroshi; Mori, Yoshiyuki; Niki, Toshiro			Expression of protein arginine methyltransferase-5 in oral squamous cell carcinoma and its significance in epithelial-to-mesenchymal transition	PATHOLOGY INTERNATIONAL			English	Article						cytokeratin; epithelial-to-mesenchymal transition; oral carcinoma; PRMT5	GENE-EXPRESSION; PRMT5; METHYLATION; INVASION; GROWTH; CANCER; ACTIVATION; PROGNOSIS; DISEASE; GRADE	Protein arginine methyltransferases (PRMT) 5, a member of type II arginine methyltransferases, catalyzes the symmetrical dimethylation of arginine residues on histone and non-histone substrates. Although the overexpression of PRMT5 has been reported in various cancers, its role in oral squamous cell carcinoma (OSCC) has not been elucidated. In the present study, we immunohistochemically examined the expression of PRMT5 in surgically resected oral epithelial dysplasia (OED, n=8), oral intraepithelial neoplasia (OIN)/carcinoma in situ (CIS) (n=11) and OSCC (n=52) with or without contiguous OED lesions. In the normal epithelium, PRMT5 was weakly expressed in the cytoplasm of basal layer cells. In OED, OIN/CIS, and OSCC, its expression consistently and uniformly increased in the cytoplasm of dysplastic and cancer cells. Moreover, nuclear and cytoplasmic localization was detected in the invasive front of cancer cells, particularly in cases showing poor differentiation or aggressive invasion patterns. The concomitant nuclear and cytoplasmic expression of PRMT5 correlated with the loss of E-cadherin and cytokeratin 17, and the upregulation of vimentin, features that are both indicative of epithelial-to-mesenchymal transition. PRMT5 may play a role from early oncogenesis through to the progression of OSCC, particularly in the aggressive mode of stromal invasion.	[Amano, Yusuke; Matsubara, Daisuke; Yoshimoto, Taichiro; Tamura, Tomoko; Niki, Toshiro] Jichi Med Univ, Dept Integrat Pathol, 1-3311 Yakushiji, Shimotsuke, Tochigi 3290498, Japan; [Nishino, Hiroshi] Jichi Med Univ, Dept Otolaryngol, Shimotsuke, Tochigi, Japan; [Mori, Yoshiyuki] Jichi Med Univ, Dept Dent Oral & Maxillofacial Surg, Shimotsuke, Tochigi, Japan	Niki, T (reprint author), Jichi Med Univ, Dept Integrat Pathol, 1-3311 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.	tniki@jichi.ac.jp	niki, toshiro/K-8917-2012		JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [17K17106]; JICHI MEDICAL UNIVERSITY YOUNG INVESTIGATOR AWARD	This work was supported in part by JSPS KAKENHI Grant Number 17K17106 (to YA) and JICHI MEDICAL UNIVERSITY YOUNG INVESTIGATOR AWARD (to YA).	Abe T, 2017, EXP MOL PATHOL, V102, P327, DOI 10.1016/j.yexmp.2017.02.018; Aggarwal P, 2010, CANCER CELL, V18, P329, DOI 10.1016/j.ccr.2010.08.012; Bao XX, 2013, J HISTOCHEM CYTOCHEM, V61, P206, DOI 10.1369/0022155413475452; Cho EC, 2012, EMBO J, V31, P1785, DOI 10.1038/emboj.2012.17; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gale N, 2005, WHO CLASSIFICATION T, P177; Genden EM, 2003, ORAL ONCOL, V39, P207, DOI 10.1016/S1368-8375(02)00049-0; Han XS, 2014, J NEURO-ONCOL, V118, P61, DOI 10.1007/s11060-014-1419-0; Hou ZY, 2008, MOL CELL BIOL, V28, P3198, DOI 10.1128/MCB.01435-07; Ibrahim R, 2014, HUM PATHOL, V45, P1397, DOI 10.1016/j.humpath.2014.02.013; IVANYI D, 1993, AM J VET RES, V54, P1095; Jansson M, 2008, NAT CELL BIOL, V10, P1431, DOI 10.1038/ncb1802; Kitamura R, 2012, J CANCER RES CLIN, V138, P1299, DOI 10.1007/s00432-012-1202-6; Kobayashi T, 2012, HISTOPATHOLOGY, V61, P910, DOI 10.1111/j.1365-2559.2012.04283.x; Kudo Y, 2004, CLIN CANCER RES, V10, P5455, DOI 10.1158/1078-0432.CCR-04-0372; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Li Y, 2015, CANCER DISCOV, V5, P288, DOI 10.1158/2159-8290.CD-14-0625; Mikami T, 2011, ORAL ONCOL, V47, P497, DOI 10.1016/j.oraloncology.2011.03.015; Nicholas C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074710; O'Sullivan Brian, 2003, Semin Surg Oncol, V21, P30, DOI 10.1002/ssu.10019; Pak MG, 2015, PATHOL INT, V65, P541, DOI 10.1111/pin.12338; Pal S, 2004, MOL CELL BIOL, V24, P9630, DOI 10.1128/MCB.24.21.9630-9645.2004; Pal S, 2007, EMBO J, V26, P3558, DOI 10.1038/sj.emboj.7601794; Richard S, 2005, BIOCHEM J, V388, P379, DOI 10.1042/BJ20040373; Saha K, 2015, J BIOL CHEM, V290, P13521, DOI 10.1074/jbc.M115.642868; Sasahira T, 2014, INT J CLIN ONCOL, V19, P431, DOI 10.1007/s10147-014-0684-4; Shilo K, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-201; Smith A, 2013, ORAL ONCOL, V49, P287, DOI 10.1016/j.oraloncology.2012.10.009; Stopa N, 2015, CELL MOL LIFE SCI, V72, P2041, DOI 10.1007/s00018-015-1847-9; Tanaka H, 2009, MOL CANCER RES, V7, P557, DOI 10.1158/1541-7786.MCR-08-0197; Wang C, 2011, J ORAL PATHOL MED, V40, P545, DOI 10.1111/j.1600-0714.2011.01041.x; YAMAMOTO E, 1983, CANCER, V51, P2175, DOI 10.1002/1097-0142(19830615)51:12<2175::AID-CNCR2820511205>3.0.CO;2-M; Yang H, 2016, ONCOTARGET, V7, P72131, DOI 10.18632/oncotarget.12351	33	4	4	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUN	2018	68	6					359	366		10.1111/pin.12666			8	Pathology	Pathology	GI2VW	WOS:000434231000004	29603824				2019-10-28	
J	Obata, Y; Yamashita, Y; Takahashi, K; Yasuda, K; Kato, T; Yasuda, M; Naiki-Ito, A; Takahashi, S; Nagasaka, T				Obata, Yoshie; Yamashita, Yoriko; Takahashi, Koji; Yasuda, Kouki; Kato, Tomomi; Yasuda, Masanori; Naiki-Ito, Aya; Takahashi, Satoru; Nagasaka, Tetsuro			MET amplification in endometrial cancers with clear-cell carcinoma components	PATHOLOGY INTERNATIONAL			English	Article						clear-cell carcinoma of the endometrium; copy number assay; fluorescence in situ hybridization; gene amplification; MET; real-time quantitative PCR	C-MET; GENE AMPLIFICATION; THERAPEUTIC INHIBITION; LUNG CANCERS; EXPRESSION; ADENOCARCINOMA; MUTATIONS; ARID1A; OVEREXPRESSION; PROGRESSION	Endometrial clear-cell carcinoma (ECC) is relatively rare. The expression of diagnostic markers in this disease is similar to that of clear-cell carcinoma, but the molecular carcinogenic events and therapeutic targets are mostly unknown. MET gene amplification has been reported in various cancers, including ovarian clear-cell carcinomas; however, the MET gene status has not previously been examined in ECC. We performed real-time quantitative PCR (QPCR) and fluorescence in situ hybridization (FISH) to analyze the MET gene statuses of 12 ECC cases. We found MET amplifications in two cases (2/12; 16.7%) by both methods. Of the 12 cases, 9 were pure clear-cell carcinomas, and 3 were mixed types that included mixes with endometrioid carcinomas in 2 cases, and the remaining case was a heterologous-type carcinosarcoma that primarily consisted of a clear-cell carcinoma component and a scarce chondrosarcoma component. Both of the MET amplification cases were mixed; one contained endometrioid features, and the other chondrosarcoma features. This is the first report to analyze the statuses of the MET gene in ECCs, and the two mixed cases exhibited amplifications that are shared with ovarian clear-cell carcinomas. Further studies with larger numbers of cases are necessary to reveal the relationship between ECC and MET amplification.	[Obata, Yoshie; Yamashita, Yoriko; Takahashi, Koji; Yasuda, Kouki; Naiki-Ito, Aya; Takahashi, Satoru] Nagoya City Univ, Grad Sch Med Sci, Dept Expt Pathol & Tumor Biol, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan; [Obata, Yoshie; Takahashi, Koji; Yasuda, Kouki; Nagasaka, Tetsuro] Nagoya Univ, Grad Sch Med, Dept Pathophysiol Lab Sci, Higashi Ku, 1-1-2 Daiko Minami, Nagoya, Aichi 4610047, Japan; [Kato, Tomomi; Yasuda, Masanori] Saitama Med Univ Int Med Ctr, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan	Yamashita, Y (reprint author), Nagoya City Univ, Grad Sch Med Sci, Dept Expt Pathol & Tumor Biol, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.	k46581a@nucc.cc.nagoya-u.ac.jp			Japan Society of the Promotion of Science, Tokyo, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science	The authors thank Ms. Junko Takekawa and Mr. Koji Kato for their excellent contributions in technical assistance. This study was supported by a Grant-in-Aid from the Japan Society of the Promotion of Science, Tokyo, Japan.	Arcila ME, 2011, CLIN CANCER RES, V17, P1169, DOI 10.1158/1078-0432.CCR-10-2277; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Brinton LA, 2013, GYNECOL ONCOL, V129, P277, DOI 10.1016/j.ygyno.2013.02.023; Cirisano FD, 1999, GYNECOL ONCOL, V74, P385, DOI 10.1006/gyno.1999.5505; Fadare O, 2014, AM J SURG PATHOL, V38, P189, DOI 10.1097/PAS.0000000000000085; Fadare O, 2013, MODERN PATHOL, V26, P1101, DOI 10.1038/modpathol.2013.35; Fadare O, 2013, AM J CANCER RES, V3, P70; Glasspool RM, 2013, CURR ONCOL REP, V15, P566, DOI 10.1007/s11912-013-0346-0; Hara T, 1998, LAB INVEST, V78, P1143; Hecht JL, 2006, J CLIN ONCOL, V24, P4783, DOI 10.1200/JCO.2006.06.7173; Hoang LN, 2015, HISTOPATHOLOGY, V66, P664, DOI 10.1111/his.12581; Hoang LN, 2014, HISTOPATHOLOGY, V64, P585, DOI 10.1111/his.12286; Janjigian YY, 2011, CANCER EPIDEM BIOMAR, V20, P1021, DOI 10.1158/1055-9965.EPI-10-1080; Jones NL, 2017, INT J CANCER, V140, P1396, DOI 10.1002/ijc.30537; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Kato N, 2009, HISTOL HISTOPATHOL, V24, P1479, DOI 10.14670/HH-24.1479; Kobel M, 2016, AM J SURG PATHOL, V40, P166, DOI 10.1097/PAS.0000000000000536; Kubo T, 2009, INT J CANCER, V124, P1778, DOI 10.1002/ijc.24150; Lennerz JK, 2011, J CLIN ONCOL, V29, P4803, DOI 10.1200/JCO.2011.35.4928; Ma PC, 2008, GENE CHROMOSOME CANC, V47, P1025, DOI 10.1002/gcc.20604; Ma PC, 2003, CANCER METAST REV, V22, P309, DOI 10.1023/A:1023768811842; Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6; Miller CT, 2006, ONCOGENE, V25, P409, DOI 10.1038/sj.onc.1209057; Murali R, 2014, LANCET ONCOL, V15, pE268, DOI 10.1016/S1470-2045(13)70591-6; Nakajima M, 1999, CANCER, V85, P1894; Okuda K, 2008, CANCER SCI, V99, P2280, DOI 10.1111/j.1349-7006.2008.00916.x; Olawaiye AB, 2009, GYNECOL ONCOL, V113, P277, DOI 10.1016/j.ygyno.2009.02.003; Onozato R, 2009, J THORAC ONCOL, V4, P5, DOI 10.1097/JTO.0b013e3181913e0e; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Sung PL, 2014, GYNECOL ONCOL, V133, P147, DOI 10.1016/j.ygyno.2014.02.016; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Umeki K, 1999, ONCOLOGY-BASEL, V56, P314, DOI 10.1159/000011985; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Yamamoto S, 2012, MODERN PATHOL, V25, P122, DOI 10.1038/modpathol.2011.143; Yamamoto S, 2011, MODERN PATHOL, V24, P1146, DOI 10.1038/modpathol.2011.70; Yamashita Y, 2015, MODERN PATHOL, V28, P111, DOI 10.1038/modpathol.2014.61; Yamashita Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057724	38	0	1	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUN	2018	68	6					367	373		10.1111/pin.12669			7	Pathology	Pathology	GI2VW	WOS:000434231000005	29633423				2019-10-28	
J	Ohara, Y; Kato, S; Yamashita, D; Satou, A; Shimoyama, Y; Hamaie, C; Sato, M; Ban, N; Yamamoto, K; Yamada, T; Kawai, H; Ohshima, K; Nakamura, S; Toyokuni, S				Ohara, Yuuki; Kato, Seiichi; Yamashita, Daisuke; Satou, Akira; Shimoyama, Yoshie; Hamaie, Chie; Sato, Motoki; Ban, Nobutaro; Yamamoto, Koji; Yamada, Takehiro; Kawai, Hisashi; Ohshima, Koichi; Nakamura, Shigeo; Toyokuni, Shinya			An autopsy case report: Differences in radiological images correlate with histology in Erdheim-Chester disease	PATHOLOGY INTERNATIONAL			English	Article						autopsy; bone scintigraphy; Erdheim-Chester disease; hexokinase II; non-Langerhans cell histiocytosis; oncogene-induced senescence; radio-histological correlation; F-18-fluorodeoxyglucose-positron emission tomography; computed tomography	ONCOGENE-INDUCED SENESCENCE; SECRETORY PHENOTYPE; EXPRESSION; CANCER; CONSENSUS; TUMOR	p16 activation caused by oncogenic mutations may represent oncogene-induced senescence (OIS), a protective mechanism against oncogenic events. However, OIS can contribute to tumor development via tissue remodeling in some tumors. Erdheim-Chester disease (ECD), a rare non-Langerhans cell histiocytosis, is one such tumor. Its clinical and histological features vary, making it difficult to diagnose. Herein, we describe an autopsy of an ECD patient. The patient underwent radiological examinations, including F-18-fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT), bone scintigraphy and CT. A biopsy from the lesion with the highest FDG accumulation confirmed the presence of foamy macrophages, a diagnostic clue for ECD. Based on this finding and the clinical features, ECD was diagnosed. However, the patient died from heart dysfunction. After the autopsy, each radiologically different site showed various histological findings regarding the morphology of macrophages, fibrosis, inflammation, and p16 expression. OIS-induced histological progression can cause certain changes observed in radiological images. In addition, in order to evaluate the increase in glucose metabolism, which can affect FDG accumulation, the expression of glucose transporter 1 and hexokinase II was also analyzed. Summarizing the radio-histological correlation can help further both the understanding and diagnosis of ECD.	[Ohara, Yuuki; Toyokuni, Shinya] Nagoya Univ, Grad Sch Med, Dept Pathol & Biol Responses, Nagoya, Aichi, Japan; [Kato, Seiichi; Yamashita, Daisuke; Nakamura, Shigeo] Nagoya Univ Hosp, Dept Pathol & Lab Med, Nagoya, Aichi, Japan; [Yamashita, Daisuke] Kobe City Hosp Org, Kobe City Med Ctr Gen Hosp, Dept Pathol, Kobe, Hyogo, Japan; [Satou, Akira] Aichi Med Univ Hosp, Dept Surg Pathol, Nagakute, Aichi, Japan; [Shimoyama, Yoshie] Nagoya Univ Hosp, Dept Pathol, Nagoya, Aichi, Japan; [Hamaie, Chie] Nagoya Univ, Grad Sch Med, Dept Gen Med Family & Community Med, Nagoya, Aichi, Japan; [Sato, Motoki] Nagoya Univ Hosp, Dept Gen Med, Nagoya, Aichi, Japan; [Ban, Nobutaro] Aichi Med Univ, Sch Med, Med Educ Ctr, Nagakute, Aichi, Japan; [Yamamoto, Koji] Nagoya Univ Hosp, Dept Transfus Med, Nagoya, Aichi, Japan; [Yamada, Takehiro; Kawai, Hisashi] Nagoya Univ, Grad Sch Med, Dept Radiol, Nagoya, Aichi, Japan; [Ohshima, Koichi] Kurume Univ, Sch Med, Dept Pathol, Kurume, Fukuoka, Japan	Ohara, Y (reprint author), Nagoya Univ, Grad Sch Med, Dept Pathol & Biol Responses, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	yuuki.oohara.1196@gmail.com	KATO, Seiichi/I-7298-2014; Nakamura, Shigeo/I-1571-2012; Toyokuni, Shinya/C-1358-2010; Ohara, Yuuki/V-3941-2019	Toyokuni, Shinya/0000-0002-5757-1109; Ohara, Yuuki/0000-0002-9171-4724	Takeda Science Foundation Fellowship	We thank Mr. Nobuaki Misawa (Nagoya University Graduate School of Medicine) for technical assistance. Yuuki Ohara was a recipient of Takeda Science Foundation Fellowship (April 2014-March 2018).	Aloj L, 1999, CANCER RES, V59, P4709; Branca M, 2004, INT J GYNECOL PATHOL, V23, P354, DOI 10.1097/01.pgp.0000139639.79105.40; Cangi MG, 2015, ANN RHEUM DIS, V74, P1596, DOI 10.1136/annrheumdis-2013-204924; Cavalli G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00281; Chilosi M, 2014, LEUKEMIA LYMPHOMA, V55, P2620, DOI 10.3109/10428194.2014.887713; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Di Mitri D, 2016, TRENDS CELL BIOL, V26, P215, DOI 10.1016/j.tcb.2015.10.005; Diamond EL, 2014, BLOOD, V124, P483, DOI 10.1182/blood-2014-03-561381; Emile JF, 2014, BLOOD, V124, P3016, DOI 10.1182/blood-2014-04-570937; Gianfreda D, 2015, BLOOD, V126, P1163, DOI 10.1182/blood-2015-01-620377; Johmura Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10574; Laberge RM, 2015, NAT CELL BIOL, V17, P1049, DOI 10.1038/ncb3195; Mazor RD, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-137; Mooi WJ, 2006, NEW ENGL J MED, V355, P1037, DOI 10.1056/NEJMra062285; Stoppacciaro A, 2006, ARTHRITIS RHEUM, V54, P4018, DOI 10.1002/art.22280; Thiele J, 2005, HAEMATOL-HEMATOL J, V90, P1128; VeyssierBelot C, 1996, MEDICINE, V75, P157, DOI 10.1097/00005792-199605000-00005; Wells JE, 2015, INT J CANCER, V137, P504, DOI 10.1002/ijc.28972; Yamada T, 2015, EIZOJOHO MED, V47, P620; Zhao SJ, 2005, J NUCL MED, V46, P675	20	0	0	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUN	2018	68	6					374	381		10.1111/pin.12663			8	Pathology	Pathology	GI2VW	WOS:000434231000006	29603831				2019-10-28	
J	Song, M; Kimura, H; Ogiyama, H; Nishigami, T				Song, Misa; Kimura, Hayato; Ogiyama, Hideharu; Nishigami, Takayuki			Eosinophilia in the muscle layer of the esophagus and the urinary bladder in a Multiple System Atrophy patient with dysphagia and dysuria	PATHOLOGY INTERNATIONAL			English	Article						dysphagia; dysuria; eosinophilia in visceral muscle; eosinophilic esophageal myositis; multiple system atrophy; neurodegenerative disorder	DYSFUNCTION; DISORDERS; ACHALASIA; DIAGNOSIS; CYSTITIS; CRITERIA	Multiple system atrophy (MSA) is a spinocerebellar degenerative disease characterized by cerebellar ataxia, parkinsonism, and autonomic failure. A 75-year-old woman who had suffered from dysphagia and dysuria under a diagnosis of probable MSA with predominant cerebellar ataxia underwent autopsy. Eosinophilia was seen extensively in the muscle layer of the esophagus and urinary bladder. Eosinophilic infiltration to the esophagus was localized in the smooth muscle layer and could be considered as eosinophilic esophageal myositis identified in patients with nutcracker esophagus and jackhammer esophagus. Dense eosinophilia was present within the smooth muscle layer of the urinary bladder along with muscle fiber degeneration. We suspected a neuropathic etiology associated with MSA as the cause of the histological changes in the esophagus and urinary bladder; however, the possibility that some other disease might also have been responsible for the eosinophilic infiltration of the muscle layer cannot be denied. To our knowledge, this is the first report showing localized eosinophilia in the muscle layers of the esophagus and urinary bladder in the same patient. Although localized eosinophilia in visceral muscle has not been understood well, our case suggests the possibility that it is a feature of functional motility disorders and may have a neuropathic etiology.	[Song, Misa; Kimura, Hayato] Itami City Hosp, Dept Diagnost Pathol, 1-100 Koyaike, Itami, Hyogo, Japan; [Ogiyama, Hideharu] Itami City Hosp, Gastrointestinal Med, Itami, Hyogo, Japan; [Nishigami, Takayuki] Steel Mem Hirohata Hosp, Dept Diagnost Pathol, Himeji, Hyogo, Japan	Song, M (reprint author), Itami City Hosp, Dept Diagnost Pathol, 1-100 Koyaike, Itami, Hyogo, Japan.	songmisams@yahoo.co.jp	Song, Misa/R-3197-2019				Awad RA, 2011, WORLD J GASTROENTERO, V17, P5035, DOI 10.3748/wjg.v17.i46.5035; Bredenoord AJ, 2012, NEUROGASTROENT MOTIL, V24, P57, DOI 10.1111/j.1365-2982.2011.01834.x; Furness JB., 2006, ENTERIC NERVOUS SYST, P32; Furuta GT, 2015, NEW ENGL J MED, V373, P1640, DOI 10.1056/NEJMra1502863; Gilman S, 2008, NEUROLOGY, V71, P670, DOI 10.1212/01.wnl.0000324625.00404.15; GOLDBLUM JR, 1994, AM J SURG PATHOL, V18, P327, DOI 10.1097/00000478-199404000-00001; Han SG, 2015, WORLD J GASTROENTERO, V21, P3139, DOI 10.3748/wjg.v21.i10.3139; Higo R, 2003, J NEUROL NEUROSUR PS, V74, P982, DOI 10.1136/jnnp.74.7.982; Hong YS, 2016, GUT LIVER, V10, P859, DOI 10.5009/gnl15388; Li G, 2015, INT J CLIN EXP MED, V8, P533; Nakajima N, 2017, NEUROGASTROENT MOTIL, V29, DOI 10.1111/nmo.12968; Pellegrini C, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0608-5; Roberts CGP, 2006, GUT, V55, P1697, DOI 10.1136/gut.2005.086074; Sakakibara R, 2000, J NEUROL NEUROSUR PS, V68, P65, DOI 10.1136/jnnp.68.1.65; Sato H, 2017, WORLD J GASTROENTERO, V23, P2414, DOI 10.3748/wjg.v23.i13.2414; Schroder Thomas, 2013, Acta Myol, V32, P148; Sodikoff JB, 2016, NEUROGASTROENT MOTIL, V28, P139, DOI 10.1111/nmo.12711; Tada M, 2007, ARCH NEUROL-CHICAGO, V64, P256, DOI 10.1001/archneur.64.2.256; Taniguchi H, 2015, DYSPHAGIA, V30, P669, DOI 10.1007/s00455-015-9641-2; van den Ouden D, 2000, EUR UROL, V37, P386, DOI 10.1159/000020183	20	0	0	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUN	2018	68	6					382	387		10.1111/pin.12668			6	Pathology	Pathology	GI2VW	WOS:000434231000007	29633461				2019-10-28	
J	Shioya, A; Saito, K; Kurose, N; Takase, Y; Kodama, K; Minato, H; Nojima, T; Yamada, S				Shioya, Akihiro; Saito, Katsuhiko; Kurose, Nozomu; Takase, Yasukazu; Kodama, Koichi; Minato, Hiroshi; Nojima, Takayuki; Yamada, Sohsuke			Primary enteric-type tubulovillous adenocarcinoma arising in the renal pelvis	PATHOLOGY INTERNATIONAL			English	Letter							CARCINOMA		[Shioya, Akihiro; Kurose, Nozomu; Minato, Hiroshi; Yamada, Sohsuke] Kanazawa Med Univ, Dept Pathol & Lab Med, Kanazawa, Ishikawa, Japan; [Shioya, Akihiro; Kurose, Nozomu; Yamada, Sohsuke] Kanazawa Med Univ Hosp, Dept Pathol, Kanazawa, Ishikawa, Japan; [Saito, Katsuhiko] Toyama City Hosp, Dept Diagnost Pathol, Toyama, Japan; [Takase, Yasukazu; Kodama, Koichi] Toyama City Hosp, Dept Urol, Toyama, Japan; [Minato, Hiroshi] Ishikawa Prefectural Cent Hosp, Dept Diagnost Pathol, Kanazawa, Ishikawa, Japan; [Nojima, Takayuki] Kanazawa Univ Hosp, Dept Orthopaed Surg, Kanazawa, Ishikawa, Japan	Yamada, S (reprint author), Kanazawa Med Univ, Dept Pathol & Lab Med, Kanazawa, Ishikawa, Japan.; Yamada, S (reprint author), Kanazawa Med Univ Hosp, Dept Pathol, Kanazawa, Ishikawa, Japan.						Han DS, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0739-7; HASEBE M, 1960, Yokohama Med Bull, V11, P491; Lai C, 2016, PATHOL RES PRACT, V212, P842, DOI 10.1016/j.prp.2016.06.006; Wang HLL, 2001, AM J SURG PATHOL, V25, P1380, DOI 10.1097/00000478-200111000-00005; Yonekawa M, 2000, ACTA CYTOL, V44, P442, DOI 10.1159/000328495	5	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUN	2018	68	6					388	390		10.1111/pin.12651			3	Pathology	Pathology	GI2VW	WOS:000434231000008	29446862				2019-10-28	
J	Inafuku, K; Tsuura, Y; Morohoshi, T; Ando, K; Masuda, H; Nabeshima, K; Masuda, M				Inafuku, Kenji; Tsuura, Yukio; Morohoshi, Takao; Ando, Kohei; Masuda, Haruhiko; Nabeshima, Kazuki; Masuda, Munetaka			A case of cytokeratin-negative sarcomatoid malignant pleural mesothelioma	PATHOLOGY INTERNATIONAL			English	Letter									[Inafuku, Kenji; Morohoshi, Takao; Ando, Kohei; Masuda, Haruhiko] Yokosuka Kyosai Hosp, Dept Gen Thorac Surg, Yokosuka, Kanagawa, Japan; [Tsuura, Yukio] Yokosuka Kyosai Hosp, Dept Diagnost Pathol, Yokosuka, Kanagawa, Japan; [Nabeshima, Kazuki] Fukuoka Univ Hosp & Sch Med, Dept Pathol, Fukuoka, Fukuoka, Japan; [Masuda, Munetaka] Yokohama City Univ, Grad Sch Med, Dept Surg, Yokohama, Kanagawa, Japan	Inafuku, K (reprint author), Yokosuka Kyosai Hosp, Dept Gen Thorac Surg, Yokosuka, Kanagawa, Japan.						Amatya VJ, 2017, MODERN PATHOL, V30, P1324; Berg KB, 2017, AM J SURG PATHOL, V41, P1221, DOI 10.1097/PAS.0000000000000825; Cigognetti M, 2015, MODERN PATHOL, V28, P1043, DOI 10.1038/modpathol.2015.65; Roggli V, 2015, WHO CLASSIFICATION T, P165; Tai HC, 2015, MODERN PATHOL, V28, P1324, DOI 10.1038/modpathol.2015.90	5	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUN	2018	68	6					391	393		10.1111/pin.12655			3	Pathology	Pathology	GI2VW	WOS:000434231000009	29488679				2019-10-28	
J	Hashimoto, H; Sasajima, Y; Miura, T; Ninomiya, H; Kusakabe, M; Tsunoda, H; Horiuchi, H				Hashimoto, Hirotsugu; Sasajima, Yuko; Miura, Tamaki; Ninomiya, Hironori; Kusakabe, Masashi; Tsunoda, Hajime; Horiuchi, Hajime			Uterine adenomatoid tumor containing epithelioid oxyphilic cells showing prominent down-expression of HBME1 and increased Ki-67 labeling index	PATHOLOGY INTERNATIONAL			English	Letter									[Hashimoto, Hirotsugu; Sasajima, Yuko; Miura, Tamaki; Horiuchi, Hajime] NTT Med Ctr Tokyo, Dept Diagnost Pathol, Tokyo, Japan; [Sasajima, Yuko] Teikyo Univ, Dept Diagnost Pathol, Tokyo, Japan; [Ninomiya, Hironori] Japanese Fdn Canc Res, Inst Canc, Div Pathol, Tokyo, Japan; [Kusakabe, Masashi] NTT Med Ctr Tokyo, Dept Radiol, Tokyo, Japan; [Tsunoda, Hajime] NTT Med Ctr Tokyo, Dept Obstet & Gynecol, Tokyo, Japan	Hashimoto, H (reprint author), NTT Med Ctr Tokyo, Dept Diagnost Pathol, Tokyo, Japan.						Cigognetti M, 2015, MODERN PATHOL, V28, P1043, DOI 10.1038/modpathol.2015.65; Irikoma M., 2001, Archives of Gynecology and Obstetrics, V265, P151, DOI 10.1007/s004040000156; Kawamura K, 2000, ACTA OBSTET GYN SCAN, V79, P798, DOI 10.1034/j.1600-0412.2000.079009798.x; QUIGLEY JC, 1981, AM J CLIN PATHOL, V76, P627; Wachter DL, 2011, VIRCHOWS ARCH, V458, P593, DOI 10.1007/s00428-011-1054-5	5	0	0	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUN	2018	68	6					394	396		10.1111/pin.12654			3	Pathology	Pathology	GI2VW	WOS:000434231000010	29465792				2019-10-28	
J	Thin, KZ; Liu, XF; Feng, XB; Raveendran, S; Tu, JC				Thin, Khaing Zar; Liu, Xuefang; Feng, Xiaobo; Raveendran, Sudheesh; Tu, Jian Cheng			LncRNA-DANCR: A valuable cancer related long non-coding RNA for human cancers	PATHOLOGY RESEARCH AND PRACTICE			English	Review						Long non-coding RNA-DANCR; Valuable biomarker	PROSTATE-CANCER; TUMOR PROGRESSION; DIFFERENTIATION; MYC; PROLIFERATION; EXPRESSION; BIOMARKER; CELLS; SOX4	Objectives: Long noncoding RNAs (IncRNA) are a type of noncoding RNA that comprise of longer than 200 nucleotides sequences. They can regulate chromosome structure, gene expression and play an essential role in the pathophysiology of human diseases, especially in tumorigenesis and progression. Nowadays, they are being targeted as potential biomarkers for various cancer types. And many research studies have proven that lncRNAs might bring a new era to cancer diagnosis and support treatment management. The purpose of this review was to inspect the molecular mechanism and clinical significance of long non-coding RNA-differentiation antagonizing nonprotein coding RNA(DANCR) in various types of human cancers. Materials and methods: In this review, we summarize and figure out recent research studies concerning the expression and biological mechanisms of IncRNA-DANCR in tumour development. The related studies were obtained through a systematic search of PubMed, Embase and Cochrane Library. Results: Long non-coding RNAs-DANCR is a valuable cancer-related lncRNA that its dysregulated expression was found in a variety of malignancies, including hepatocellular carcinoma, breast cancer, glioma, colorectal cancer, gastric cancer, and lung cancer. The aberrant expressions of DANCR have been shown to contribute to proliferation, migration and invasion of cancer cells. Conclusions: Long non-coding RNAs-DANCR likely serves as a useful disease biomarker or therapeutic cancer target.	[Thin, Khaing Zar; Liu, Xuefang; Tu, Jian Cheng] Wuhan Univ, Dept & Program Clin Lab Med, Ctr Gene Diag, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China; [Feng, Xiaobo] Wuhan Univ, Dept Pain Management, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China; [Raveendran, Sudheesh] Wuhan Univ, Dept Radiol & Nucl Med, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China	Tu, JC (reprint author), Wuhan Univ, Dept & Program Clin Lab Med, Ctr Gene Diag, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China.	scarletkhaingzar@gmail.com; 438160927@qq.com; jianchengtu@whu.edu.cn		ZARTHIN, KHAING/0000-0003-4029-9193	Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund [znpy2016046]; National Basic Research Program of China (973 Program)National Basic Research Program of China [2012CB720605]	This study was supported by Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund (Project znpy2016046) & National Basic Research Program of China (973 Program) (2012CB720605).	Bretones G, 2015, BBA-GENE REGUL MECH, V1849, P506, DOI 10.1016/j.bbagrm.2014.03.013; Bruix J, 2014, GUT, V63, P844, DOI 10.1136/gutjnl-2013-306627; Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028; Chen J, 2016, CLIN TRANSL ONCOL, V18, P65, DOI 10.1007/s12094-015-1337-4; Chen LL, 2016, CELL TISSUE RES, V364, P309, DOI 10.1007/s00441-015-2333-2; Das S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098965; de Groot JF, 2015, NEURO-ONCOLOGY, V21, P332, DOI DOI 10.1212/01.C0N.0000464173.58262.D9; Deng KY, 2014, TUMOR BIOL, V35, P9497, DOI 10.1007/s13277-014-2511-y; DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203; Duddempudi AT, 2014, CLIN GERIATR MED, V30, P149, DOI 10.1016/j.cger.2013.10.012; Fock KM, 2014, ALIMENT PHARM THER, V40, P250, DOI 10.1111/apt.12814; Hao YP, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317699798; Jia J, 2016, ONCOTARGET, V7, P37868, DOI 10.18632/oncotarget.9350; Jiang N, 2017, CANCER LETT, V405, P46, DOI 10.1016/j.canlet.2017.06.009; Johnsson P, 2014, BBA-GEN SUBJECTS, V1840, P1063, DOI 10.1016/j.bbagen.2013.10.035; Kuppers R, 2014, LANCET ONCOL, V15, pE435, DOI 10.1016/S1470-2045(14)70153-6; Liu Y, 2015, INT J CLIN EXP PATHO, V8, P11480; Lu QC, 2018, J CELL MOL MED, V22, P1527, DOI 10.1111/jcmm.13420; Lu YQ, 2018, CANCER RES, V78, P64, DOI 10.1158/0008-5472.CAN-17-0815; Ma X, 2016, ANTICANCER RES, V36, P6389, DOI 10.21873/anticanres.11236; Mao ZQ, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20171070; Nanavaty P, 2014, CANCER CONTROL, V21, P9, DOI 10.1177/107327481402100102; Pezaro C, 2014, INTERN MED J, V44, P433, DOI 10.1111/imj.12407; Picci P, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-6; Rashid F, 2016, GENOM PROTEOM BIOINF, V14, P73, DOI 10.1016/j.gpb.2016.03.005; Renganathan A, 2017, ADV EXP MED BIOL, V1008, P199, DOI 10.1007/978-981-10-5203-3_7; Salinas CA, 2014, NAT REV UROL, V11, P317, DOI 10.1038/nrurol.2014.91; Schreuders EH, 2015, GUT, V64, P1637, DOI 10.1136/gutjnl-2014-309086; Sha S, 2017, BIOL OPEN, V6, P1310, DOI 10.1242/bio.023135; Takenaka K, 2016, CANCER GENET-NY, V209, P445, DOI 10.1016/j.cancergen.2016.09.005; Tang ZY, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0406-8; Tong X, 2015, BIOSCI BIOTECH BIOCH, V79, P732, DOI 10.1080/09168451.2014.998617; Xiao ZG, 2018, ONCOL LETT, V15, P3395, DOI 10.3892/ol.2018.7758; Xu DW, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171664; Yuan S. X., 2016, HEPATOLOGY, V63; Zhang JL, 2018, INT J MOL MED, V41, P213, DOI 10.3892/ijmm.2017.3215; Zhang L, 2017, BIOSCI REP, V37; Zhang L, 2017, DNA CELL BIOL, V36, P136, DOI 10.1089/dna.2016.3544; Zhang L, 2015, J MOL HISTOL, V46, P467, DOI 10.1007/s10735-015-9638-z	39	14	14	0	8	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUN	2018	214	6					801	805		10.1016/j.prp.2018.04.003			5	Pathology	Pathology	GM6ZF	WOS:000438326800001	29728310				2019-10-28	
J	Liu, JM; Liu, BB; Guo, YY; Chen, ZJ; Sun, W; Gao, WY; Wu, HL; Wang, Y				Liu, Jianmin; Liu, Beibei; Guo, Yuanyuan; Chen, Zhijun; Sun, Wei; Gao, Wuyue; Wu, Hongliang; Wang, Yan			MiR-199a-3p acts as a tumor suppressor in clear cell renal cell carcinoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Clear cell renal cell carcinoma; miR-199a-3p; Cell growth and proliferation; Cell invasion and migration; Cell apoptosis	HEPATOCELLULAR-CARCINOMA; MAMMALIAN TARGET; CANCER CELLS; PROLIFERATION; MICRORNA-199A-3P; OSTEOSARCOMA; PROGRESSION; IDENTIFICATION; MANAGEMENT; MIGRATION	Objectives: To explore the biological function and mechanism of miR-199a-3p in clear cell renal cell carcinoma (CCRCC). Methods: We investigated the expression of miR-199a-3p in CCRCC through quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Over expression of miR-199a-3p was performed in CCRCC cell lines, and cell growth curve, colony formation capacity, cell invasion, wound healing and cell apoptosis assay were used for investigating the roles of miR-199a-3p in CCRCC. Results: The expression of miR-199a-3p in CCRCC tissues was significantly lower than that in pars-carcinoma tissues. Functional assay showed that over expression of miR-199a-3p influenced cell growth, colony formation, cell invasion, cell migration and cell apoptosis in CCRCC cell lines. Conclusions: Our work suggested that miR-199a-3p was related to cell growth, colony formation, cell invasion, cell migration and cell apoptosis, which might act as a tumor suppressor in CCRCC.	[Liu, Jianmin; Liu, Beibei; Guo, Yuanyuan; Chen, Zhijun; Sun, Wei; Gao, Wuyue; Wu, Hongliang; Wang, Yan] First Affiliated Hosp, Bengbu Med Coll, Dept Urol, 287 Changhuai Rd, Bengbu City 233000, Anhui, Peoples R China	Liu, JM (reprint author), First Affiliated Hosp, Bengbu Med Coll, Dept Urol, 287 Changhuai Rd, Bengbu City 233000, Anhui, Peoples R China.	liujianminah@163.com			The molecular mechanism study of microRNAs in the development of Clear cell renal cell carcinoma [KJ2017A244]	This work was funded by "The molecular mechanism study of microRNAs in the development of Clear cell renal cell carcinoma" (KJ2017A244).	Cheville JC, 2003, AM J SURG PATHOL, V27, P612, DOI 10.1097/00000478-200305000-00005; Chiong E, 2012, LANCET ONCOL, V13, pE482, DOI 10.1016/S1470-2045(12)70433-3; Deng YA, 2017, J OVARIAN RES, V10, DOI 10.1186/s13048-017-0333-4; Duan QL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031518; Duan ZF, 2011, MOL CANCER THER, V10, P1337, DOI 10.1158/1535-7163.MCT-11-0096; Escudier B, 2012, ANN ONCOL, V23, P65, DOI 10.1093/annonc/mds227; Fornari F, 2010, CANCER RES, V70, P5184, DOI 10.1158/0008-5472.CAN-10-0145; Frew IJ, 2015, ANNU REV PATHOL-MECH, V10, P263, DOI 10.1146/annurev-pathol-012414-040306; Gao Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep11365; Halverson SJ, 2013, J UROLOGY, V189, P441, DOI 10.1016/j.juro.2012.09.032; Han Y, 2014, BIOMED PHARMACOTHER, V68, P497, DOI 10.1016/j.biopha.2014.05.003; Henry JC, 2010, BIOCHEM BIOPH RES CO, V403, P120, DOI 10.1016/j.bbrc.2010.10.130; Hou J, 2011, CANCER CELL, V19, P232, DOI 10.1016/j.ccr.2011.01.001; Ichimi T, 2009, INT J CANCER, V125, P345, DOI 10.1002/ijc.24390; Kim S, 2008, J BIOL CHEM, V283, P18158, DOI 10.1074/jbc.M800186200; Kinose Y, 2015, ONCOTARGET, V6, P11342, DOI 10.18632/oncotarget.3604; Koshizuka K, 2017, CANCER SCI, V108, P1681, DOI 10.1111/cas.13298; Kuninty PR, 2016, ONCOTARGET, V7, P16396, DOI 10.18632/oncotarget.7651; Li K, 2017, ONCOTARGET, V8, P5048, DOI 10.18632/oncotarget.13790; Liu RF, 2016, ONCOTARGET, V7, P56628, DOI 10.18632/oncotarget.10652; Minna E, 2014, ONCOTARGET, V5, P2513, DOI 10.18632/oncotarget.1830; Morris MR, 2017, NAT REV NEPHROL, V13, P47, DOI 10.1038/nrneph.2016.168; Murakami Y, 2006, ONCOGENE, V25, P2537, DOI 10.1038/sj.onc.1209283; Murakami Y, 2009, J HEPATOL, V50, P453, DOI 10.1016/j.jhep.2008.06.010; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Qin J, 2017, ONCOTARGET, V8, P2745, DOI 10.18632/oncotarget.13740; Qu F, 2017, ONCOTARGET, V8, P52465, DOI 10.18632/oncotarget.17191; Qu Y, 2014, AM J PATHOL, V184, P1541, DOI [10.1016/j.ajpath.2014.01:017, 10.1016/j.ajpath.2014.01.017]; Ren KW, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929-016-0295-7; Riazalhosseini Y, 2016, NAT REV NEPHROL, V12, P655, DOI 10.1038/nrneph.2016.133; Russo A, 2016, SCI REP-UK, V6, DOI 10.1038/srep38369; Shatseva T, 2011, J CELL SCI, V124, P2826, DOI 10.1242/jcs.077529; Shen L, 2015, TUMOR BIOL, V36, P6929, DOI 10.1007/s13277-015-3409-z; Tian R, 2014, AM J CANCER RES, V4, P738; Wala SJ, 2015, MOL ONCOL, V9, P1667, DOI 10.1016/j.molonc.2015.04.007; Wang ZX, 2013, ONCOL LETT, V6, P789, DOI 10.3892/ol.2013.1448; Wu D, 2013, INT J GYNECOL CANCER, V23, P1191, DOI 10.1097/IGC.0b013e31829ea779; Zhang JD, 2017, FEBS LETT, V591, P145, DOI 10.1002/1873-3468.12521; Zhang LL, 2015, INT J NANOMED, V10, P2913, DOI 10.2147/IJN.S79143; Zhao RZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128771	40	2	2	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUN	2018	214	6					806	813		10.1016/j.prp.2018.05.005			8	Pathology	Pathology	GM6ZF	WOS:000438326800002	29773428				2019-10-28	
J	Byeon, H; Lee, SD; Hong, EK; Lee, DE; Kim, BH; Seo, Y; Joo, J; Han, SS; Kim, SH; Park, SJ				Byeon, Hyerim; Lee, Seung Duk; Hong, Eun-Kyung; Lee, Dong Eun; Kim, Bo Hyun; Seo, Yunsung; Joo, Jungnam; Han, Sung-Sik; Kim, Seong Hoon; Park, Sang-Jae			Long-term prognostic impact of osteopontin and Dickkopf-related protein 1 in patients with hepatocellular carcinoma after hepatectomy	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Hepatocellular carcinoma; Prognosis; Serum osteopontin; Serum dikkopf-related protein-1	POOR-PROGNOSIS; INTRAHEPATIC METASTASIS; EXPRESSION; RECURRENCE; RESECTION; SURVIVAL; FAMILY	Background. New biomarkers are essential for improving the prediction of the survival and prognosis of patients with hepatocellular carcinoma (HCC). Alpha-fetoprotein (AFP) is the most widely used biomarker, but the low sensitivity and specificity limit its clinical applications. The diagnostic and prognostic capabilities of osteopontin (OPN), dickkopf-related protein 1 (DKK1), and a combination of these biomarkers are being studied. Methods: From January 2006 to December 2008, patients undergoing hepatectomy for HCC were screened and their serum stored in tumor banks was analyzed. The serum was used to investigate OPN and DKK1 levels by enzyme-linked immunosorbent assay(ELISA). In the paraffin block, the status of OPN and DKK1 positivity was assessed using immunohistochemistry(IHC). Results: A total of 60 patients were enrolled. The optimal cut-off level for survival was identified as 3.0 ng/mL and 5.2 ng/mL of OPN and DKK1, respectively. In multivariate analysis, a high OPN level was the only significant prognostic factor for overall survival [hazard ratio3.79, p = .017]. Considering a combination of AFP (cut-off level, 200 ng/mL) and OPN/DKK1, the patients with high AFP and OPN/DKK1 levels showed significantly lower overall survivals than those with low AFP, high AFP, and low OPN/DKK1 levels (p = .0091 for the AFP and OPN group, p = .0344 for the AFP and DKK1 group). Comparison between IHC and ELISA results for OPN and DKK1 levels did not reveal any significant correlation. Conclusions: Serum OPN and DKK1 levels of HCC patients could be considered as novel biomarkers showing prognostic significance after hepatectomy based on long-term survival data.	[Byeon, Hyerim; Lee, Seung Duk; Hong, Eun-Kyung; Kim, Bo Hyun; Seo, Yunsung; Han, Sung-Sik; Kim, Seong Hoon; Park, Sang-Jae] Natl Canc Ctr, Ctr Liver Canc, Goyang Si, Gyeonggi Do, South Korea; [Lee, Dong Eun; Joo, Jungnam] Natl Canc Ctr, Biometr Res Branch, Goyang Si, Gyeonggi Do, South Korea	Lee, SD (reprint author), Natl Canc Ctr, Res Inst & Hosp, Ctr Liver Canc, 323 Ilsan Ro, Goyang Si 410769, Gyeonggi Do, South Korea.	lsd@ncc.re.kr			National Cancer Center, Republic of Korea [1610060-2, 1611820-1]	This study was supported by National Cancer Center, Republic of Korea (grant no. 1610060-2 and 1611820-1).	Agnholt J, 2007, SCAND J IMMUNOL, V65, P453, DOI 10.1111/j.1365-3083.2007.01908.x; Cheng JW, 2014, J CLIN GASTROENTEROL, V48, P806, DOI 10.1097/MCG.0000000000000018; Contal C, 1999, COMPUT STAT DATA AN, V30, P253, DOI 10.1016/S0167-9473(98)00096-6; Cui Bo-Kang, 2006, Ai Zheng, V25, P876; Denhardt DT, 2001, ANNU REV PHARMACOL, V41, P723, DOI 10.1146/annurev.pharmtox.41.1.723; Furger Kara A., 2001, Current Molecular Medicine (Hilversum), V1, P621, DOI 10.2174/1566524013363339; Ge TX, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0367-z; Genda T, 1999, HEPATOLOGY, V30, P1027, DOI 10.1002/hep.510300420; Glinka A, 1998, NATURE, V391, P357; Huang Y, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0966-8; Jang ES, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151069; Liver Leake I., 2014, NAT REV GASTRO HEPAT, V11, P3; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Maluccio M, 2012, CA-CANCER J CLIN, V62, P394, DOI 10.3322/caac.21161; Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054; Pan HW, 2003, CANCER-AM CANCER SOC, V98, P119, DOI 10.1002/cncr.11487; Park JG, 2015, CLIN MOL HEPATOL, V21, P287, DOI 10.3350/cmh.2015.21.3.287; Pote N, 2015, J HEPATOL, V62, P848, DOI 10.1016/j.jhep.2014.11.005; SENGER DR, 1979, CELL, V16, P885, DOI 10.1016/0092-8674(79)90103-X; Sieghart W, 2011, J HEPATOL, V54, P89, DOI 10.1016/j.jhep.2010.06.030; TAKETA K, 1990, HEPATOLOGY, V12, P1420, DOI 10.1002/hep.1840120625; Yu B, 2009, J HEPATOL, V50, P948, DOI 10.1016/j.jhep.2008.11.020; Yu MC, 2012, ANN SURG ONCOL, V19, pS455, DOI 10.1245/s10434-011-1946-2; YUKI K, 1990, CANCER, V66, P2174, DOI 10.1002/1097-0142(19901115)66:10<2174::AID-CNCR2820661022>3.0.CO;2-A; Zhang H, 2006, J CANCER RES CLIN, V132, P709, DOI 10.1007/s00432-006-0119-3; Zhu WW, 2014, ANN SURG ONCOL, V21, P1304, DOI 10.1245/s10434-013-3445-0	26	2	2	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUN	2018	214	6					814	820		10.1016/j.prp.2018.05.002			7	Pathology	Pathology	GM6ZF	WOS:000438326800003	29753515				2019-10-28	
J	Mohanty, SK; Sharma, S; Pradhan, D; Kandukuri, SR; Farahani, N; Barry, C; Wu, JM; Frishberg, D; Balzer, B				Mohanty, Sambit K.; Sharma, Shivani; Pradhan, Dinesh; Kandukuri, Shivani R.; Farahani, Navid; Barry, Catherine; Wu, Julie M.; Frishberg, David; Balzer, Bonnie			Microphthalmia-associated transcription factor (MiTF): Promiscuous staining patterns in fibrohistiocytic lesions is a potential pitfall	PATHOLOGY RESEARCH AND PRACTICE			English	Article						MITF; Melanoma; Benign fibrous histiocytoma; Atypical fibroxanthoma; Angiofibroma	MALIGNANT-MELANOMA; FACTOR EXPRESSION; DIAGNOSIS; GENE; MARKERS; UTILITY; TUMORS; LOCUS; SOX10	Microphthalmia-associated transcription factor (MiTF) is used as a marker of melanocytic differentiation. However, MiTF immunoexpression has also been observed in histiocytes, macrophages, smooth muscle cells and fibroblasts, which raise the concern of fibrohistiocytic (FH) lesions being misdiagnosed as melanoma based on MiTF immunoreactivity. MiTF has been known to be positive in FH tumors, but this is the first study evaluating ninety-three fibrohistiocytic neoplasms to understand and delineate the staining pattern of MiTF in these tumors. Ninety-three cases of FH, 30 cases of melanocytic lesions, and 20 miscellaneous cases were studied. The FH cases included benign fibrous histiocytoma (BFH, n = 29), angiofibroma (AF, n = 11), fibromatosis (FM, n = 14), keloid (KE, n = 10), atypical fibroxanthoma (AFX, n = 7), dermal scar (DS, n = 9), dermatofibrosarcoma protuberans (DFSP, n = 12), and pigmented DFSP (Bednar tumor, n = 1). Benign fibrous histiocytoma were subcategorized into dermatofibroma (n = 15) and epithelioid fibrous histiocytoma (n = 14). The melanocytic lesions included desmoplastic melanoma (DM, n = 8), melanoma in-situ (MIS, n = 5), re-excision-free of melanoma (RFM, n = 10), blue nevus (BN, n = 5), and spitz nevus (SN, n = 3). The miscellaneous category included osteosarcoma (OS, n = 3), pigmented basal cell carcinoma (PBCC, n = 5), spindle cell squamous cell carcinoma (SCA, n = 2), and giant cell tumor of tendon sheath (GCTTS, n = 10). All BFH, AF, AFX, KE, and DS cases showed a positive MiTF staining of variable extent and intensity. MiTF positivity was observed in 86% (n = 12) cases of FM and 17% (n = 2) cases of DFSP. Amongst the miscellaneous category, all cases of PBCC and GCTTS and 50% (n = 1) cases of SCA were immunoreactive for MiTF. All melanocytic lesions were positive for MiTF. None of the OS and pigmented DFSP showed positive labeling. Because of the promiscuity of MiTF labeling, awareness of its pattern in FH proliferations may avoid potential pitfalls in the diagnosis of spindle cell lesions.	[Mohanty, Sambit K.; Kandukuri, Shivani R.; Farahani, Navid; Barry, Catherine; Wu, Julie M.; Frishberg, David; Balzer, Bonnie] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA; [Sharma, Shivani] CORE Diagnost, Dept Pathol & Lab Med, Gurgaon, India; [Pradhan, Dinesh] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA	Balzer, B (reprint author), Cedars Sinai Med Ctr, Head & Neck Pathol & Bone & Soft Tissue Pathol, 8700 Beverly Blvd, Los Angeles, CA 90048 USA.	bonnie.balzer@cshs.org	Pradhan, Dinesh/I-7764-2013	Pradhan, Dinesh/0000-0001-8591-1601			Arnheiter H, 2010, PIGM CELL MELANOMA R, V23, P729, DOI 10.1111/j.1755-148X.2010.00759.x; Buonaccorsi JN, 2014, AM J DERMATOPATH, V36, P124, DOI 10.1097/DAD.0b013e318291485c; Busam KJ, 2001, AM J SURG PATHOL, V25, P197, DOI 10.1097/00000478-200102000-00007; Choy B, 2017, HISTOPATHOLOGY, V70, P734, DOI 10.1111/his.13139; Fuse N, 1996, BIOCHEM BIOPH RES CO, V219, P702, DOI 10.1006/bbrc.1996.0298; Gleason BC, 2007, AM J DERMATOPATH, V29, P22, DOI 10.1097/01.dad.0000249888.41884.6c; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; HUGHES MJ, 1993, J BIOL CHEM, V268, P20687; Hutchens KA, 2013, AM J SURG PATHOL, V37, P933, DOI 10.1097/PAS.0b013e3182815574; King R, 1999, AM J PATHOL, V155, P731, DOI 10.1016/S0002-9440(10)65172-3; Lu SY, 2014, EXP CELL RES, V328, P32, DOI 10.1016/j.yexcr.2014.08.018; Miettinen M, 2001, AM J SURG PATHOL, V25, P205, DOI 10.1097/00000478-200102000-00008; Perrino CM, 2015, CANCER CYTOPATHOL, V123, P394, DOI 10.1002/cncy.21531; Ramos RY, 2005, ARCH PATHOL LAB MED, V129, P360; Ramos-Herberth FI, 2010, J CUTAN PATHOL, V37, P944, DOI 10.1111/j.1600-0560.2010.01568.x; Seethala RR, 2004, MODERN PATHOL, V17, P1491, DOI 10.1038/modpathol.3800211; Shen J, 2014, EUR REV MED PHARMACO, V18, P798; Tallon B, 2014, AM J DERMATOPATH, V36, P888, DOI 10.1097/DAD.0000000000000054	18	1	1	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUN	2018	214	6					821	825		10.1016/j.prp.2018.05.001			5	Pathology	Pathology	GM6ZF	WOS:000438326800004	29773427				2019-10-28	
J	Tsikalakis, S; Chatziandreou, I; Michalopoulos, NV; Theodoropoulos, GE; Sakellariou, S; Korkolopoulou, P; Patsouris, E; Saetta, AA				Tsikalakis, Spyridon; Chatziandreou, Ilenia; Michalopoulos, Nikolaos, V; Theodoropoulos, Georgios E.; Sakellariou, Stratigoula; Korkolopoulou, Penelope; Patsouris, Efstratios; Saetta, Angelica A.			Comprehensive expression analysis of TNF-related apoptosis-inducing ligand and its receptors in colorectal cancer: Correlation with MAPK alterations and clinicopathological associations	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Apoptosis; mRNA expression; Real time RT-PCR; Colorectal cancer	TRAIL RECEPTORS; DEATH; METASTASIS; CARCINOMA; DCR2; RESISTANCE; INITIATION; MEMBRANE; CELLS; DR4	TNF-related, apoptosis-inducing ligand (TRAIL) apoptotic pathway constitutes a promising therapeutic target due to high selectivity and low toxicity of TRAIL targeting agents when administered in combination therapies. 106 colorectal cancers were examined for: relative mRNA expression of TRAIL pathway genes, decoy receptors TRAIL-R3 and TRAIL-R4 promoter methylation and the presence of KRAS, NRAS, BRAF mutations. Elevated mRNA levels were observed in 26%, 15%, 13%, 12% and 10% of the cases for TRAIL-R4, TRAIL-R3, TRAIL-R2, TRAIL-R1 and TRAIL genes respectively. Reduced mRNA levels were detected in 77%, 65%, 64%, 60% and 37% of the cases for TRAIL, TRAIL-R2, TRAIL-R3, TRAIL-R1 and TRAIL-R4 genes respectively. TRAIL-R3 and TRAIL-R4 promoter methylation was detected in 55% and 16% of the analysed samples respectively. TRAIL-R1, TRAIL-R2 elevated relative mRNA levels inversely correlated with tumor stage (p = .036, p = .048). Strong linear correlations of TRAIL receptors' mRNA levels were found: TRAIL-R1/TRAIL-R2 (R = 0.653, p <.001), TRAIL-R2/TRAIL-R3 (R = 0.573, p < .001). Finally, relative expression of TRAIL was correlated with KRAS, BRAF and NRAS mutation status, defining an inverse correlation between increased TRAIL expression and the absence of mutations in Mitogen-activated protein kinase (MAPK) pathway. In conclusion, simultaneous analysis of TRAIL pathway membrane components, pointed towards a significant deregulation of mRNA expression in colorectal tumours. Death receptor overexpression was an indicator of a less aggressive phenotype. The multiple expression patterns of TRAIL pathway components in colorectal tumours underscore the importance of patient selection in order to achieve maximum efficiency with TRAIL targeted therapy.	[Tsikalakis, Spyridon; Chatziandreou, Ilenia; Sakellariou, Stratigoula; Korkolopoulou, Penelope; Patsouris, Efstratios; Saetta, Angelica A.] Univ Athens, Dept Pathol 1, Sch Med, Milcras Asias 75, Athens, Goudi, Greece; [Michalopoulos, Nikolaos, V; Theodoropoulos, Georgios E.] Univ Athens, Dept Propaedeut Surg 1, Hippokrateion Hosp, Sch Med, Vas Sofias 114, Athens, Greece	Saetta, AA (reprint author), Univ Athens, Dept Pathol 1, Sch Med, Milcras Asias 75, Athens, Goudi, Greece.	asaetta@med.uoa.gr		Saetta, Angelica A./0000-0002-4862-3413			Amarante-Mendes GP, 2015, PHARMACOL THERAPEUT, V155, P117, DOI 10.1016/j.pharmthera.2015.09.001; Anees M, 2011, CANCER-AM CANCER SOC, V117, P1172, DOI 10.1002/cncr.25504; Aran D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01027-z; Aydin C, 2007, HUM GENE THER, V18, P39, DOI 10.1089/hum.2006.111; Baig S., 2016, POTENTIAL APOPTOTIC, P1, DOI [10.1038/cddis.2015.275, DOI 10.1038/CDDIS.2015.275]; Bavi P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-203; Bosch LJW, 2017, ONCOTARGET, V8, P63140, DOI 10.18632/oncotarget.18702; Buneker C, 2009, ONCOL REP, V21, P1289, DOI 10.3892/or_00000353; Chamuleau MED, 2011, LEUKEMIA RES, V35, P741, DOI 10.1016/j.leukres.2010.12.032; Chen JJ, 2013, ONCOTARGET, V4, P206, DOI 10.18632/oncotarget.813; Cheng Y., 2010, NIH PUBLIC ACCESS, V69, P327, DOI [10.1002/pros.20882, DOI 10.1002/PROS.20882]; Clancy L, 2005, P NATL ACAD SCI USA, V102, P18099, DOI 10.1073/pnas.0507329102; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Daniels RA, 2005, CELL RES, V15, P430, DOI 10.1038/sj.cr.7290311; Drosopoulos KG, 2005, J BIOL CHEM, V280, P22856, DOI 10.1074/jbc.M412483200; Ganten TM, 2009, J MOL MED, V87, P995, DOI 10.1007/s00109-009-0510-z; Gottwald L, 2013, ARCH GYNECOL OBSTET, V288, P889, DOI 10.1007/s00404-013-2840-x; Grosse-Wilde A, 2008, J CLIN INVEST, V118, P100, DOI 10.1172/JCI33061; Hervouet Eric, 2013, Cells, V2, P545, DOI 10.3390/cells2030545; Horak P, 2005, MOL CANCER RES, V3, P335, DOI 10.1158/1541-7786.MCR-04-0136; Hu JK, 2009, ONCOL REP, V21, P681, DOI 10.3892/or_00000271; Kheirelseid EAH, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-12; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Martinez-Lostao L, 2012, BIOCHEM PHARMACOL, V83, P1475, DOI 10.1016/j.bcp.2011.12.036; McLornan DP, 2010, CLIN CANCER RES, V16, P3442, DOI 10.1158/1078-0432.CCR-10-0052; Meng RD, 2000, MOL THER, V1, P130, DOI 10.1006/mthe.2000.0025; Merino D, 2006, MOL CELL BIOL, V26, P7046, DOI 10.1128/MCB.00520-06; Morizot A, 2011, CELL DEATH DIFFER, V18, P700, DOI 10.1038/cdd.2010.144; Oikonomou E, 2009, INT J CANCER, V125, P2127, DOI 10.1002/ijc.24613; Pal S, 2016, CANCER MICROENVIRON, V9, P77, DOI 10.1007/s12307-016-0184-3; Piras-Straub K, 2015, INT J CANCER, V136, pE154, DOI 10.1002/ijc.29139; Sakellariou S, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2213-5; Sanlioglu AD, 2007, J UROLOGY, V177, P359, DOI 10.1016/j.juro.2006.08.087; Sanz-pamplona R., 2014, MOL CANCER, P1; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Sheridan J.P., 2016, CONTROL TRAIL INDUCE, V277, P818; Shirley S, 2011, RECENT PAT ANTI-CANC, V6, P311, DOI 10.2174/157489211796957757; Stamatelli A, 2014, ARCH DERMATOL RES, V306, P561, DOI 10.1007/s00403-014-1454-x; Strater J, 2002, CLIN CANCER RES, V8, P3734; Stuckey DW, 2013, TRENDS MOL MED, V19, P685, DOI 10.1016/j.molmed.2013.08.007; Takeda K, 2007, ONCOGENE, V26, P3745, DOI 10.1038/sj.onc.1210374; Tarragona J, 2010, VIRCHOWS ARCH, V456, P39, DOI 10.1007/s00428-009-0855-2; Trivedi R, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00069; Tserga A, 2012, ONCOL REP, V27, P1630, DOI 10.3892/or.2011.1576; van Noesel MM, 2002, CANCER RES, V62, P2157; van Roosmalen IAM, 2014, BIOCHEM PHARMACOL, V91, P447, DOI 10.1016/j.bcp.2014.08.010; Venza M, 2013, BIOCHEM BIOPH RES CO, V441, P743, DOI 10.1016/j.bbrc.2013.10.114; von Karstedt S, 2017, NAT REV CANCER, V17, P352, DOI 10.1038/nrc.2017.28; von Karstedt S, 2015, CANCER CELL, V27, P561, DOI 10.1016/j.ccell.2015.02.014; Yoldas B, 2011, HEAD NECK-J SCI SPEC, V33, P1278, DOI 10.1002/hed.21598	50	1	1	2	2	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUN	2018	214	6					826	834		10.1016/j.prp.2018.04.019			9	Pathology	Pathology	GM6ZF	WOS:000438326800005	29731264				2019-10-28	
J	Saraggi, D; Galuppini, F; Fanelli, GN; Remo, A; Urso, EDL; Bao, RQ; Bacchin, D; Guzzardo, V; Luchini, C; Braconi, C; Farinati, F; Rugge, M; Fassan, M				Saraggi, Deborah; Galuppini, Francesca; Fanelli, Giuseppe N.; Remo, Andrea; Urso, Emanuele D. L.; Bao, Ricardo Q.; Bacchin, Deborah; Guzzardo, Vincenza; Luchini, Claudio; Braconi, Chiara; Farinati, Fabio; Rugge, Massimo; Fassan, Matteo			MiR-21 up-regulation in ampullary adenocarcinoma and its pre-invasive lesions	PATHOLOGY RESEARCH AND PRACTICE			English	Article						miR-21; Ampulla of vater; Biomarkers; Dysplasia	PANCREATIC ADENOCARCINOMA; MICRORNA PROFILES; PDCD4 EXPRESSION; VATER CARCINOMA; OVEREXPRESSION; DYSREGULATION; CANCERS; IMMUNOHISTOCHEMISTRY; CLASSIFICATION; DIAGNOSIS	Poor information is available on the molecular landscape characterizing the carcinogenetic process leading to ampullary carcinoma. MiR-21 is one of the most frequently up-regulated miRNAs in pancreatic adenocarcinoma, a tumor sharing similar molecular features with ampullary adenocarcinomas (AVCs), above all with the pancreatic-biliary type. We profiled, by in situ hybridization (ISH), miR-21 expression in a series of 26 AVCs, 50 ampullary dysplastic lesions (35 low-grade [LG-IEN] and 15 high-grade [HG-IEN]) and 10 normal duodenal mucosa samples. The same series was investigated by immunohistochemistry for beta-catenin, p53 and HER2 expression. HER2 gene amplification was evaluated by chromogenic in situ hybridization. To validate miR-21 ISH results we performed miR-21 qRT-PCR analysis in a series of 10 AVCs and their matched normal samples. All the normal control samples showed a negative or faint miR-21 expression, whereas a significant miR-21 up-regulation was observed during the carcinogenetic cascade (p < 0.001), with 21/26 (80.8%) of cancer samples showing a miR-21 overexpression. In comparison to control samples, a significant overexpression was found in samples of LG-IEN (p = .0003), HG-IEN (p = .0001), and AVCs (p < 0.0001). No significant difference in miR-21 overexpression was observed between LG-IEN, HG-IEN and AVCs. By qRT-PCR analysis, AVCs showed a 1.7 fold increase over the controls (p = .003). P53 was frequently dysregulated in both dysplastic and carcinoma samples (44 out of 76; 57.9%). A 20% (10/50) of dysplastic lesions and 11% (3/26) of carcinomas were characterized by a nuclear localization of beta-catenin. Only 2 AVCs (7.7%; both intestinal-type) showed a HER2 overexpression (both 2 +), which corresponded to a HER2 gene amplification at CISH analysis. This is the first study demonstrating a miRNA dysregulation in the whole spectrum of ampullary carcinogenesis. MiR-21 overexpression is an early molecular event during ampullary carcinogenesis and its levels increase with the neoplastic progression.	[Saraggi, Deborah; Galuppini, Francesca; Fanelli, Giuseppe N.; Bacchin, Deborah; Guzzardo, Vincenza; Rugge, Massimo; Fassan, Matteo] Univ Padua, Dept Med DIMED, Padua, PD, Italy; [Remo, Andrea] Mater Salutis Hosp ULSS9, Dept Pathol, I-37045 Legnago, VR, Italy; [Urso, Emanuele D. L.; Bao, Ricardo Q.; Farinati, Fabio] Univ Padua, Dept Surg Oncol & Gastroenterol DiSCOG, Padua, PD, Italy; [Luchini, Claudio] Univ & Hosp Trust Verona, ARC Net Res Ctr, Dept Diagnost & Publ Hlth, Verona, Italy; [Braconi, Chiara] Inst Canc Res, Div Canc Therapeut, London, England	Fassan, M (reprint author), Univ Padua, Surg Pathol & Cytopathol Unit, Dept Med DIMED, Via Gabelli 61, I-35121 Padua, Italy.	matteo.fassan@unipd.it	Luchini, Claudio/O-2187-2019; Luchini, Claudio/Q-4922-2016; Farinati, Fabio/A-8267-2012; remo, andrea/Q-7746-2016; Saraggi, Deborah/T-1957-2017	Luchini, Claudio/0000-0003-4901-4908; Luchini, Claudio/0000-0003-4901-4908; Farinati, Fabio/0000-0002-2944-1374; remo, andrea/0000-0002-2564-2988; braconi, chiara/0000-0003-4835-1259; Fanelli, Giuseppe Nicolo/0000-0001-7069-7980; Saraggi, Deborah/0000-0002-0942-2707	Italian Association for Cancer Research (AIRC Regional grant)Associazione Italiana per la Ricerca sul Cancro (AIRC) [6421]	This work was partly supported by a grant from the Italian Association for Cancer Research (AIRC Regional grant 2008 N. 6421).	Adsay V, 2012, AM J SURG PATHOL, V36, P1592, DOI 10.1097/PAS.0b013e31826399d8; Ang DC, 2014, AM J SURG PATHOL, V38, P1371, DOI 10.1097/PAS.0000000000000230; Baffa R, 2009, J PATHOL, V219, P214, DOI 10.1002/path.2586; Bloomston M, 2007, JAMA-J AM MED ASSOC, V297, P1901, DOI 10.1001/jama.297.17.1901; Bosman FT, 2010, WHO CLASSIFICATION T; Calatayud D, 2017, BIOMARK RES, V5, DOI 10.1186/s40364-017-0087-6; Cappellesso R, 2016, CANCER CYTOPATHOL, V124, P28, DOI 10.1002/cncy.21646; Cappellesso R, 2015, HUM PATHOL, V46, P665, DOI 10.1016/j.humpath.2015.02.007; Chang DK, 2013, J CLIN ONCOL, V31, P1348, DOI 10.1200/JCO.2012.46.8868; D'Angelo E, 2015, CURR DRUG TARGETS, V16, P383, DOI 10.2174/1389450116666141210091454; Fassan M, 2012, DIS ESOPHAGUS, V25, P263, DOI 10.1111/j.1442-2050.2011.01236.x; Fassan M, 2014, GASTRIC CANCER, V17, P442, DOI 10.1007/s10120-013-0315-1; Fassan M, 2012, HISTOPATHOLOGY, V61, P769, DOI 10.1111/j.1365-2559.2012.04272.x; Fassan M, 2011, WORLD J GASTROENTERO, V17, P5231, DOI 10.3748/wjg.v17.i48.5231; Fassan M, 2011, INT J CANCER, V129, P1661, DOI 10.1002/ijc.25823; Fassan M, 2011, VIRCHOWS ARCH, V458, P413, DOI 10.1007/s00428-011-1046-5; Fassan M, 2010, J CLIN PATHOL, V63, P692, DOI 10.1136/jcp.2010.078253; Frampton AE, 2014, GASTROENTEROLOGY, V146, P268, DOI 10.1053/j.gastro.2013.10.010; Garajova I, 2014, BIOMED RES INT, DOI 10.1155/2014/678401; Gingras MC, 2016, CELL REP, V14, P907, DOI 10.1016/j.celrep.2015.12.005; Giovannetti E, 2010, CANCER RES, V70, P4528, DOI 10.1158/0008-5472.CAN-09-4467; Grillo F, 2016, WORLD J GASTROENTERO, V22, P5879, DOI 10.3748/wjg.v22.i26.5879; Gyongyosi B, 2014, J HISTOCHEM CYTOCHEM, V62, P547, DOI 10.1369/0022155414537277; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hechtman JF, 2015, MODERN PATHOL, V28, P1123, DOI 10.1038/modpathol.2015.57; Hwang JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010630; Khan K, 2016, ONCOTARGET, V7, P12672, DOI 10.18632/oncotarget.7208; Ludwig K, 2013, VIRCHOWS ARCH, V462, P57, DOI 10.1007/s00428-012-1345-5; Luo GX, 2017, MOL MED REP, V15, P187, DOI 10.3892/mmr.2016.5971; Mafficini A, 2018, ANN SURG, V267, P149, DOI 10.1097/SLA.0000000000001999; Mian C, 2012, THYROID, V22, P890, DOI 10.1089/thy.2012.0045; Nagao Y, 2012, MODERN PATHOL, V25, P112, DOI 10.1038/modpathol.2011.142; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Park SH, 2000, WORLD J SURG, V24, P54, DOI 10.1007/s002689910011; Pennelli G, 2015, HUM PATHOL, V46, P50, DOI 10.1016/j.humpath.2014.09.006; Pennelli G, 2013, VIRCHOWS ARCH, V462, P95, DOI 10.1007/s00428-012-1352-6; Perilli L, 2014, ONCOTARGET, V5, P6611, DOI 10.18632/oncotarget.2245; Rashid A, 2002, CLIN CANCER RES, V8, P3156; Reid MD, 2016, MODERN PATHOL, V29, P1575, DOI 10.1038/modpathol.2016.124; Saraggi D, 2017, HISTOPATHOLOGY, V71, P470, DOI 10.1111/his.13254; Schueneman A, 2015, BRIT J CANCER, V113, P64, DOI 10.1038/bjc.2015.172; Schultz NA, 2012, MODERN PATHOL, V25, P1609, DOI 10.1038/modpathol.2012.122; Sessa F, 2007, VIRCHOWS ARCH, V451, P649, DOI 10.1007/s00428-007-0444-1; Simbolo M, 2014, ONCOTARGET, V5, P2839, DOI 10.18632/oncotarget.1943; Stell D, 2004, DIGEST SURG, V21, P434, DOI 10.1159/000083470; Wu D, 2015, ASIAN PAC J TROP MED, V8, P478, DOI [10.1016/S1995-7645(14)60364-3, 10.1016/j.apjtm.2015.05.003]; Yachida S, 2016, CANCER CELL, V29, P229, DOI 10.1016/j.ccell.2015.12.012	47	4	5	2	4	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUN	2018	214	6					835	839		10.1016/j.prp.2018.04.018			5	Pathology	Pathology	GM6ZF	WOS:000438326800006	29731265	Green Accepted			2019-10-28	
J	Isohookana, J; Haapasaari, KM; Soini, Y; Leppanen, J; Karihtala, P				Isohookana, Joel; Haapasaari, Kirsi-Maria; Soini, Ylermi; Leppanen, Joni; Karihtala, Peeter			Proteins of the retinoblastoma pathway, FEN1 and MGMT are novel potential prognostic biomarkers in pancreatic adenocarcinoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Cell cycle; DNA repair; Immunohistochemistry; Pancreatic cancer; Survival	BREAST-CANCER; EXPRESSION; SUPPRESSION; GENE; INHIBITION; GROWTH; CDK4/6; LUNG	Background We studied the expression of some major proteins involved in cell-cycle regulation and DNA repair, the roles of which are not well known in pancreatic ductal adenocarcinoma (PDAC), but which have a significant impact on carcinogenesis of many other cancers. Methods: We immunohistochemically assessed expression levels of the cell-cycle regulators Rb1, p16 and cyclindependent kinase 4 (CDK4), and the DNA repair enzymes O6-methylguanine-DNA-alkyltransferase (MGMT) and flap endonuclease-1 (FEN1) separately in malignant tissue and benign tissue from resection margins in 102 cases of PDAC. Nearly all (95.1%) patients had undergone pancreaticoduodenectomy. Results: The studied proteins showed wide but somewhat variable expression in both benign and malignant pancreatic tissues. Strong CDK4 expression in islets of Langerhans predicted poor relapse-free survival (RFS) (HR 2.874; 95% CI L261-6.550; p = .012) and within T3-4 tumors CDK4 expression in adenocarcinoma cells also predicted poor disease-free survival (DFS) (RR 2.148; 95% CI 1.081-4.272; p = .029). Strong MGMT expression was associated in N1 patients with weak local relapse-free survival (RFS), DFS and overall survival; all significantly in Cox regression analysis. FEN1 was also an independent predictor of decreased DFS (in the whole study population) and worse RFS (in the patients with T3-4 tumors). Conclusions: Major cell-cycle regulator also have predictive significance, but further studies are required to evaluate this.	[Isohookana, Joel; Karihtala, Peeter] Oulu Univ Hosp, Med Res Ctr Oulu, Dept Oncol & Radiotherapy, Oulu, Finland; [Isohookana, Joel; Haapasaari, Kirsi-Maria; Soini, Ylermi; Leppanen, Joni; Karihtala, Peeter] Univ Oulu, Oulu, Finland; [Haapasaari, Kirsi-Maria; Soini, Ylermi; Leppanen, Joni] Oulu Univ Hosp, Med Res Ctr Oulu, Dept Pathol, Oulu, Finland; [Soini, Ylermi] Univ Eastern Finland, Canc Ctr Eastern Finland, Dept Pathol & Forens Med, Kuopio, Finland; [Leppanen, Joni] Oulu Univ Hosp, Med Res Ctr Oulu, Dept Surg, Oulu, Finland	Karihtala, P (reprint author), Oulu Univ Hosp, Dept Oncol & Radiotherapy, POB 22, Oulu 90029, Finland.	peeter.karihtala@oulu.fi			Maud Kuistila Memorial Foundation; Mary and Georg C. Ehrnrooth Foundation; Finnish Anti-Tuberculosis Association; Ida Montin Foundation	We thank Riitta Vuento for technical expertise in preparation of the immunohistochemical stainings. This work was supported by grants from the Maud Kuistila Memorial Foundation, the Mary and Georg C. Ehrnrooth Foundation, the Finnish Anti-Tuberculosis Association and the Ida Montin Foundation. The funding sources did not have any involvement in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.	Abdel-Fatah TMA, 2014, MOL ONCOL, V8, P1326, DOI 10.1016/j.molonc.2014.04.009; Ali R, 2017, PATHOLOGY, V49, P156, DOI 10.1016/j.pathol.2016.11.002; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Bobustuc GC, 2015, PANCREAS, V44, P626, DOI 10.1097/MPA.0000000000000299; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Dong XQ, 2011, ONCOLOGIST, V16, P61, DOI 10.1634/theoncologist.2010-0127; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Gerson SL, 2004, NAT REV CANCER, V4, P296, DOI 10.1038/nrc1319; Guo ZG, 2012, MOL CELL, V47, P444, DOI 10.1016/j.molcel.2012.05.042; He LF, 2017, MOL ONCOL, V11, P1302, DOI 10.1002/1878-0261.12118; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Heilmann AM, 2014, CANCER RES, V74, P3947, DOI 10.1158/0008-5472.CAN-13-2923; Hiraoka N, 2015, BRIT J CANCER, V112, P1782, DOI 10.1038/bjc.2015.145; Lee JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008653; Li Q, 2017, ONCOL LETT, V14, P229, DOI 10.3892/ol.2017.6123; Liu LL, 2006, CLIN CANCER RES, V12, P328, DOI 10.1158/1078-0432.CCR-05-2543; Luo YL, 2013, HUM PATHOL, V44, P69, DOI 10.1016/j.humpath.2012.04.014; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Nikolova T, 2009, ANTICANCER RES, V29, P2453; Radulovich N, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-24; Rane SG, 1999, NAT GENET, V22, P44; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Soejima H, 2005, BIOCHEM CELL BIOL, V83, P429, DOI 10.1139/O05-140; Turner NC, 2017, LANCET, V389, P2403, DOI 10.1016/S0140-6736(16)32419-9; Vitellius C, 2017, CLIN DRUG INVEST, V37, P669, DOI 10.1007/s40261-017-0522-3; Witkiewicz AK, 2015, ONCOTARGET, V6, P15788, DOI 10.18632/oncotarget.3819; Wolff AC, 2016, NEW ENGL J MED, V375, P1993, DOI 10.1056/NEJMe1611926; Zhang L, 2016, TUMOR BIOL, V37, P11443, DOI 10.1007/s13277-016-5014-1	28	1	1	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUN	2018	214	6					840	847		10.1016/j.prp.2018.04.016			8	Pathology	Pathology	GM6ZF	WOS:000438326800007	29735403	Green Accepted			2019-10-28	
J	Sainio, M; Visakorpi, T; Tolonen, T; Ilvesaro, J; Bova, GS				Sainio, Miika; Visakorpi, Tapio; Tolonen, Teemu; Ilvesaro, Joanna; Bova, G. Steven			Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Neuroendocrine differentiation; hnmunohistochemistry; Castration-resistant prostate cancer; Androgen receptor; Chromogranin A; Synaptophysin	ANDROGEN-DEPRIVATION THERAPY; PROGNOSTIC-SIGNIFICANCE; CHROMOGRANIN-A; PROLIFERATION ACTIVITY; RECEPTOR; TISSUE; POSTMORTEM; CELLS; IMMUNOREACTIVITY; PROGRESSION	Neuroendocrine differentiation (NED) is a common phenomenon in prostate cancer, and it has been associated with poor prognosis in some studies of primary prostate cancer. Incidence and patterns of NED in metastatic prostate cancer sites have not been examined widely. In this study, we studied expression of three commonly used markers of NED (chromogranin A, neuron specific enolase and synaptophysin) in 89 metastases from 31 men that died of castration-resistant prostate cancer and underwent rapid autopsy, and in 89 hormone-naive primary tumors removed by radical prostatectomy. In addition, we examined NED association with androgen receptor, ERG and Ki-67 expression in metastatic tumor sites. Morphologically, 1 of 31 cases was classified as small cell carcinoma, and the remaining 30 were classified as usual prostate adenocarcinoma using a recently proposed classification of prostate cancers with NED. Metastases showed more expression of neuron specific enolase and synaptophysin compared to prostatectomies (6.3% of cells vs. 1.0%, p < 0.001 and 4.0% vs. 0.4%, p < 0.001, respectively). At least focal expression of one of the markers was seen in 78% of metastases. Strong expression was relatively uncommon, seen in 3/89 (chromogranin A), 8/89 (neuron specific enolase), and 5/89 (synaptophysin) metastases. Expression of chromogranin A and synaptophysin correlated with each other (r = 0.64, p < 0.001), but expression of neuron specific enolase did not correlate with the two other markers. Extent of NED varied significantly between different metastatic sites in individual patients. Absent androgen receptor expression was associated with strong expression of chromogranin A (p =.02) and neuron specific enolase (p =.02), but not with focal expression of any marker. No clear association was found between expression of NE markers and ERG or Ki-67. In conclusion, NED is a common and heterogeneous phenomenon in metastatic, castration-resistant prostate cancer. NED is more often present in castration-resistant prostate cancer compared to hormone-naive disease, and it is associated with androgen receptor negativity. More research is needed to understand significance of NED in the progression of prostate cancer.	[Sainio, Miika; Visakorpi, Tapio; Tolonen, Teemu; Bova, G. Steven] Univ Tampere, Prostate Canc Res Ctr, Fac Med & Life Sci, FI-33014 Tampere, Finland; [Sainio, Miika; Visakorpi, Tapio; Tolonen, Teemu; Bova, G. Steven] Univ Tampere, BioMediTech Inst, FI-33014 Tampere, Finland; [Tolonen, Teemu; Ilvesaro, Joanna] Tampere Univ Hosp, Fimlab Labs, Dept Pathol, Tampere, Finland	Bova, GS (reprint author), Univ Tampere, Prostate Canc Res Ctr, Fac Med & Life Sci, FI-33014 Tampere, Finland.; Bova, GS (reprint author), Univ Tampere, BioMediTech Inst, FI-33014 Tampere, Finland.	sainio.miika.s@student.uta.fi; tapio.visakorpi@uta.fi; teemu.tolonen@fimlab.fi; joanna.ilvesaro@fimlab.fi; g.steven.bova@uta.fi			Academy of FinlandAcademy of Finland; Cancer Society of Finland	Support from the Academy of Finland and Cancer Society of Finland is gratefully acknowledged.	APRIKIAN AG, 1994, J UROLOGY, V151, P914, DOI 10.1016/S0022-5347(17)35121-2; Ather M Hammad, 2008, BMC Urol, V8, P21, DOI 10.1186/1471-2490-8-21; Berruti A, 2010, PROSTATE, V70, P718, DOI 10.1002/pros.21104; Bluemn EG, 2017, CANCER CELL, V32, P474, DOI 10.1016/j.ccell.2017.09.003; Conteduca V, 2014, CRIT REV ONCOL HEMAT, V92, P11, DOI 10.1016/j.critrevonc.2014.05.008; Epstein JI, 2014, AM J SURG PATHOL, V38, P756, DOI 10.1097/PAS.0000000000000208; Espina V, 2009, PROTEOM CLIN APPL, V3, P874, DOI 10.1002/prca.200800001; Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI 10.1001/jamaoncol.2016.5688; Fodor M, 2002, J HISTOCHEM CYTOCHEM, V50, P641, DOI 10.1177/002215540205000505; Gundem G, 2015, NATURE, V520, P353, DOI 10.1038/nature14347; Hirano D, 2004, EUR UROL, V45, P586, DOI 10.1016/j.eururo.2003.11.032; Huang JT, 2006, PROSTATE, V66, P1399, DOI 10.1002/pros.20434; Komiya A, 2009, INT J UROL, V16, P37, DOI 10.1111/j.1442-2042.2008.02175.x; Krauss DJ, 2014, PROSTATE, V74, P520, DOI 10.1002/pros.22771; KRIJNEN JLM, 1993, HISTOCHEMISTRY, V100, P393, DOI 10.1007/BF00268938; Leinonen KA, 2013, CANCER EPIDEM BIOMAR, V22, P2333, DOI 10.1158/1055-9965.EPI-13-0333-T; Li Z, 2013, ASIAN J ANDROL, V15, P328, DOI 10.1038/aja.2013.7; Liu WN, 2009, NAT MED, V15, P559, DOI 10.1038/nm.1944; LIU XY, 1995, DEMENTIA, V6, P211, DOI 10.1159/000106949; May M, 2007, SCAND J UROL NEPHROL, V41, P375, DOI 10.1080/00365590701224445; Miettinen M, 2011, AM J SURG PATHOL, V35, P432, DOI 10.1097/PAS.0b013e318206b67b; Mounir Z, 2015, ONCOGENE, V34, P3815, DOI 10.1038/onc.2014.308; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Mucci NR, 2000, HUM PATHOL, V31, P406, DOI 10.1053/hp.2000.7295; NAKADA SY, 1993, CANCER RES, V53, P1967; Pascale M, 2016, RADIOL ONCOL, V50, P313, DOI 10.1515/raon-2016-0033; Pruneri G, 1998, PROSTATE, V34, P113, DOI 10.1002/(SICI)1097-0045(19980201)34:2<113::AID-PROS5>3.0.CO;2-L; Quek ML, 2006, UROLOGY, V67, P1247, DOI 10.1016/j.urology.2005.12.009; Roudier MP, 2003, HUM PATHOL, V34, P646, DOI 10.1016/S0046-8177(03)00190-4; Santer FR, 2015, SEMIN CANCER BIOL, V35, P133, DOI 10.1016/j.semcancer.2015.08.005; Segawa N, 2001, PATHOL INT, V51, P452, DOI 10.1046/j.1440-1827.2001.01226.x; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; St John Jason, 2012, J Cancer Sci Ther, V4, P94; Stan AD, 2006, BRAIN RES, V1123, P1, DOI 10.1016/j.brainres.2006.09.025; Surcel C. I., 2015, UROL ONCOL, V33, pe1, DOI DOI 10.1016/J.UR0L0NC.2014.08.007; Volante M, 2016, HUM PATHOL, V56, P81, DOI 10.1016/j.humpath.2016.06.004	37	3	4	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUN	2018	214	6					848	856		10.1016/j.prp.2018.04.015			9	Pathology	Pathology	GM6ZF	WOS:000438326800008	29728311				2019-10-28	
J	Gong, W; Cao, Y; Wang, YY; Yang, L; Su, WP; Qiu, FM; Datta, S; Rao, BQ; Xian, JF; Lin, MZ; Feng, YY; Zhang, X; Zhou, YF; Gao, XC; Lu, JC				Gong, Wei; Cao, Yi; Wang, Yuanyuan; Yang, Lei; Su, Wenpeng; Qiu, Fuman; Datta, Soham; Rao, Boqi; Xian, Jianfeng; Lin, Mingzhu; Feng, Yingyi; Zhang, Xin; Zhou, Yifeng; Gao, Xingcheng; Lu, Jiachun			Upregulation of LncRNA FEZF-AS1 is associated with advanced clinical stages and family history of cancer in patients with NSCLC	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Antisense RNA; FEZF-AS1; Non-small cell lung cancer; Clinical stages; FEZF1	LONG NONCODING RNAS; LUNG-CANCER; OVEREXPRESSION; PROGNOSIS; CHROMATIN; HALLMARKS; GENE	Antisense RNA (AS) is a type of long non-coding RNAs that functions as a post-transcriptional regulatory element on regulating parental coding gene expression via directly binding to complementary mRNA sequences. We aimed to investigate the effect of the AS to FEZF1 gene on non-small cell lung cancer (NSCLC) development. The expression level of lncRNA FEZF-AS1 and FEZF1 was determined by the quantitative Real-time PCR in 160 cases of NSCLC tissues and their adjacent non-tumour tissues. We found that IncRNA FEZF-AS1 was significantly up regulated in tumour tissues when compared to the adjacent non-cancerous tissues (P = 0.001), and it's high expression correlated with advanced stages (P = 0.002) and Tumour Family History (P = 0.029). Meanwhile, In 58 cases of NSCLC tissues the expression of IncRNA FEZF-AS1 was positively associated with that of FEZF/expression (r = 0.8810, p = 1.6575E-20). By GEPIA database analysis, we also found that the expression of IncRNA FEZF-AS1 and FEZF1 were significantly higher in tumour tissues than those of the adjacent non-cancerous tissues in 969 NSCLC patients (P < 0.05), and IncRNA FEZF-AS1 was positively correlated with FEZF1 (r = 0.90, P < 0.001). These results suggest that lncRNA FEZF-AS1 relate to the progression of lung cancer patients and it may be a potential target for cancer therapy.	[Gong, Wei; Cao, Yi; Wang, Yuanyuan; Yang, Lei; Su, Wenpeng; Qiu, Fuman; Datta, Soham; Rao, Boqi; Xian, Jianfeng; Lin, Mingzhu; Feng, Yingyi; Gao, Xingcheng; Lu, Jiachun] Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, 151 Yanjiangxi Rd, Guangzhou 510120, Guangdong, Peoples R China; [Yang, Lei; Zhang, Xin; Lu, Jiachun] Guangzhou Med Univ, Collaborat Innovat Ctr Environm Tox, Sch Publ Hlth, Inst Chem Carcinogenesis, 195 Dongfengxi Rd, Guangzhou 510182, Guangdong, Peoples R China; [Zhou, Yifeng] Soochow Univ, Med Coll, Dept Genet, 1 Shizi Rd, Suzhou 215123, Peoples R China; [Gao, Xingcheng] Guangzhou Med Univ, Affiliated Hosp 3, 63 Duobao Rd, Guangzhou 510120, Guangdong, Peoples R China	Gao, XC (reprint author), Guangzhou Med Univ, Affiliated Hosp 3, 63 Duobao Rd, Guangzhou 510120, Guangdong, Peoples R China.; Lu, JC (reprint author), Guangzhou Med Univ, Sch Publ Hlth, Collaborat Innovat Ctr Environm Tox, State Key Lab Resp Dis,Affiliated Hosp 1,Inst Che, 195 Dongfengxi Rd, Guangzhou 510182, Guangdong, Peoples R China.	gaoxingcheng@163.com; jcLu@gzhmu.edu.cn		/0000-0003-1121-7849	National Key RD Projects [2016YFC0903700]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81473040, 81673267, 81273149, 81402753, 81672303, 81602289]; Guangzhou Science and Technology Program Pearl River Nova projects [201710010049]; Guangdong education bureau Characteristic innovation project [2015KTSCX116]; Guangdong Provincial Major Projects Grants [2014KZDXM046, 1201541589]	This study was supported by the National Key R&D Projects (2016YFC0903700), the National Natural Science Foundation of China81473040, 81673267 (J. Lu), 81273149, 81402753, 81672303 (L. Yang), 81602289 (F. Qiu), and Guangzhou Science and Technology Program Pearl River Nova projects Grant 201710010049 (L. Yang). Guangdong education bureau Characteristic innovation project Grants 2015KTSCX116 (L. Yang) and Guangdong Provincial Major Projects Grants 2014KZDXM046, Yangcheng Scholar Grants 1201541589 (J. Lu). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; Cheng M, 2013, CARCINOGENESIS, V34, P2292, DOI 10.1093/carcin/bgt181; Edelman MJ, 2014, HUM PATHOL, V45, P1893, DOI 10.1016/j.humpath.2014.05.011; Filella X, 2013, TUMOR BIOL, V34, P1337, DOI 10.1007/s13277-013-0739-6; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Gibb EA, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-38; Godinho M, 2011, J CELL PHYSIOL, V226, P1741, DOI 10.1002/jcp.22503; Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang DS, 2013, HUM GENET, V132, P451, DOI 10.1007/s00439-013-1264-9; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115; Keller C, 2013, NAT STRUCT MOL BIOL, V20, P1340, DOI 10.1038/nsmb1113-1340; Kim K, 2013, ONCOGENE, V32, P1616, DOI 10.1038/onc.2012.193; Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021; Liu YW, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.150; Lv J, 2013, NUCLEIC ACIDS RES, V41, P10044, DOI 10.1093/nar/gkt818; Malek E, 2014, ONCOTARGET, V5, P8027, DOI 10.18632/oncotarget.2469; Mattick JS, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000459; Pan Z., 2017, MOLECULARCARCINOGENE, V57, P305; Pennisi E, 2013, SCIENCE, V340, P910; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Qi P, 2013, MODERN PATHOL, V26, P155, DOI 10.1038/modpathol.2012.160; Raungrut P, 2014, ASIAN PAC J CANCER P, V15, P3513, DOI 10.7314/APJCP.2014.15.8.3513; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Spizzo R, 2012, ONCOGENE, V31, P4577, DOI 10.1038/onc.2011.621; Sun RF, 2015, INT J CLIN EXP PATHO, V8, P2392; Yang BY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0722-8; Youlden DR, 2008, J THORAC ONCOL, V3, P819, DOI 10.1097/JTO.0b013e31818020eb	29	5	5	3	4	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUN	2018	214	6					857	861		10.1016/j.prp.2018.04.014			5	Pathology	Pathology	GM6ZF	WOS:000438326800009	29709443				2019-10-28	
J	Gu, LG; Ge, ZM; Wang, YM; Shen, MQ; Zhao, P				Gu, Liugen; Ge, Zhenming; Wang, Yamin; Shen, Meiqin; Zhao, Ping			Activating transcription factor 3 promotes intestinal epithelial cell apoptosis in Crohn's disease	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Activating transcription factor 3; Crohn's disease; Intestinal epithelial cell; Apoptosis; p53; Bax	INFLAMMATORY-BOWEL-DISEASE; ULCERATIVE-COLITIS; OXIDATIVE STRESS; CANCER CELLS; UP-REGULATION; FACTOR ATF3; P53; EXPRESSION; MUCOSA; TNF	Intestinal epithelial cell (IEC) apoptosis plays a vital role in the pathogenesis of Crohn's disease (CD), which is an inflammatory bowel disease (IBD). Activating transcription factor 3 (ATF3) modulates apoptosis under stress via regulating the p53 pathway. However, the expression and function of ATF3 in CD are unclear. In the present study, ATF3, p53, and p53 target gene Bax expression increased in CD patients; a mouse 2, 4, 6-trini-trobenzenesulfonic acid (TNBS)-induced CD model; and a TNF-alpha-treated HT29 cell colitis model. ATF3 knockdown effectively decreased TNF-alpha-induced p53 and Bax expression, as well as inhibited the apoptosis of HT29 cells. Additionally, ATF3 enhanced the stability and transcription activity of p53 via interacting with p53. In summary, these data indicated that ATF3 might promote IEC apoptosis in CD via up-regulating the stability and transcription activity of p53, implying a novel molecular target for CD therapy.	[Gu, Liugen; Ge, Zhenming; Wang, Yamin; Shen, Meiqin] Nantong Univ, Dept Gastroenterol, Affiliated Hosp 2, Nantong 226001, Jiangsu, Peoples R China; [Zhao, Ping] Nantong Univ, Dept Clin Lab, Affiliated Hosp 2, Nantong 226001, Jiangsu, Peoples R China	Gu, LG (reprint author), Nantong Univ, Dept Gastroenterol, Affiliated Hosp 2, Nantong 226001, Jiangsu, Peoples R China.	guliugen@ntu.edu.cn			Nantong Science and Technology Innovation Project [HS13947]	This work was partly supported by Nantong Science and Technology Innovation Project (Nos. HS13947).	Alkim C, 2009, DIGEST DIS SCI, V54, P1979, DOI 10.1007/s10620-008-0554-x; Allan AL, 2001, J BIOL CHEM, V276, P27272, DOI 10.1074/jbc.M103196200; Armstrong CM, 2017, DIGEST DIS SCI, V62, P1977, DOI 10.1007/s10620-017-4631-x; Bamias G, 2017, CURR OPIN GASTROEN, V33, P411, DOI 10.1097/MOG.0000000000000402; Berns M, 2016, EXPERT OPIN INV DRUG, V25, P129, DOI 10.1517/13543784.2016.1126247; Calton CM, 2013, CELL MICROBIOL, V15, P1837, DOI 10.1111/cmi.12153; Cao SS, 2016, INFLAMM BOWEL DIS, V22, P984, DOI 10.1097/MIB.0000000000000660; Chen BPC, 1996, MOL CELL BIOL, V16, P1157; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cui XP, 2016, EXP MOL PATHOL, V101, P1, DOI 10.1016/j.yexmp.2016.05.011; Nguyen CT, 2014, J INFECT DIS, V210, P1745, DOI 10.1093/infdis/jiu352; Garg SK, 2017, GASTROENTEROL CLIN N, V46, P515, DOI 10.1016/j.gtc.2017.05.006; Gilchrist M, 2006, NATURE, V441, P173, DOI 10.1038/nature04768; Gold ES, 2012, J EXP MED, V209, P807, DOI 10.1084/jem.20111202; Hai T, 2010, GENE EXPRESSION, V15, P1, DOI 10.3727/105221610X12819686555015; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hoetzenecker W, 2012, NAT MED, V18, P128, DOI 10.1038/nm.2557; Horvath B, 2015, GASTROENTEROL REP, V3, P344, DOI 10.1093/gastro/gov022; Jadhav Kavita, 2017, Liver Res, V1, P96, DOI 10.1016/j.livres.2017.08.001; Jensen AB, 2006, AM J GASTROENTEROL, V101, P1283, DOI 10.1111/j.1572-0241.2006.00520.x; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kiesslich R, 2012, GUT, V61, P1146, DOI 10.1136/gutjnl-2011-300695; Kim JY, 2017, J HEPATOL, V67, P349, DOI 10.1016/j.jhep.2017.03.023; KRISHNA M, 1995, MODERN PATHOL, V8, P654; Kruidenier L, 2002, ALIMENT PHARM THER, V16, P1997, DOI 10.1046/j.0269-2813.2002.01378.x; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Laass MW, 2014, AUTOIMMUN REV, V13, P467, DOI 10.1016/j.autrev.2014.01.029; Li XB, 2017, THORAC CANCER, V8, P181, DOI 10.1111/1759-7714.12421; Liu CC, 2016, BRAIN BEHAV IMMUN, V53, P96, DOI 10.1016/j.bbi.2015.11.004; Ma JY, 2016, J DIGEST DIS, V17, P155, DOI 10.1111/1751-2980.12324; Marini M, 2003, P NATL ACAD SCI USA, V100, P8366, DOI 10.1073/pnas.1432897100; Nathanson JW, 2008, DIGEST DIS SCI, V53, P474, DOI 10.1007/s10620-007-9886-1; Okamoto A, 2006, MOL CELL BIOL, V26, P1087, DOI 10.1128/MCB.26.3.1087-1097.2006; Park SH, 2014, J BIOL CHEM, V289, P27118, DOI 10.1074/jbc.M114.568717; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94; Pickert G, 2009, J EXP MED, V206, P1465, DOI 10.1084/jem.20082683; Popp V, 2017, GASTROENTEROLOGY, V152, P176, DOI 10.1053/j.gastro.2016.09.005; Qiu W, 2011, J CLIN INVEST, V121, P1722, DOI 10.1172/JCI42917; Raskov H, 2014, WORLD J GASTROENTERO, V20, P18151, DOI 10.3748/wjg.v20.i48.18151; Romero Mônica, 2008, Arq. Gastroenterol., V45, P295, DOI 10.1590/S0004-28032008000400007; Roulis M, 2011, P NATL ACAD SCI USA, V108, P5396, DOI 10.1073/pnas.1007811108; Souza HSP, 2005, INT J COLORECTAL DIS, V20, P277, DOI 10.1007/s00384-004-0639-8; Taketani K, 2012, ONCOGENE, V31, P2210, DOI 10.1038/onc.2011.397; Thompson MR, 2009, J MOL MED, V87, P1053, DOI 10.1007/s00109-009-0520-x; Thornborrow EC, 2002, ONCOGENE, V21, P990, DOI 10.1038/sj.onc.1205069; Vetuschi A, 2002, DIGEST DIS SCI, V47, P1447, DOI 10.1023/A:1015931128583; Wang XY, 2015, CANCER RES, V75, P5001, DOI 10.1158/0008-5472.CAN-15-0563; Weng SY, 2016, BMC GASTROENTEROL, V16, DOI 10.1186/s12876-016-0442-3; Whitmore MM, 2007, J IMMUNOL, V179, P3622, DOI 10.4049/jimmunol.179.6.3622; Xie JJ, 2014, ONCOTARGET, V5, P8569, DOI 10.18632/oncotarget.2322; Xu RJ, 2018, CELL DEATH DIFFER, V25, P841, DOI 10.1038/s41418-017-0018-y; Yan CH, 2005, EMBO J, V24, P2425, DOI 10.1038/sj.emboj.7600712; Yan CH, 2006, CELL CYCLE, V5, P926, DOI 10.4161/cc.5.9.2714; Yin X, 2010, J CELL SCI, V123, P3558, DOI 10.1242/jcs.064915; Young RS, 2017, INFLAMMATION, V40, P1726, DOI 10.1007/s10753-017-0614-5; Yu QF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059627; Yu TF, 2017, ONCOTARGET, V8, P98348, DOI 10.18632/oncotarget.21311; Zhao Q, 2016, NEUROSCI BULL, V32, P349, DOI 10.1007/s12264-016-0047-4; Zhou H, 2014, INT J CARDIOL, V174, P838, DOI 10.1016/j.ijcard.2014.04.160; Zhu H, 2012, EXP BIOL MED, V237, P474, DOI 10.1258/ebm.2011.011358	60	1	1	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUN	2018	214	6					862	870		10.1016/j.prp.2018.04.013			9	Pathology	Pathology	GM6ZF	WOS:000438326800010	29716766				2019-10-28	
J	Tang, LL; Lu, BJ				Tang, Lanlan; Lu, Bingjian			Intravenous leiomyomatosis of the uterus: A clinicopathologic analysis of 13 cases with an emphasis on histogenesis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						intravenous leiomyomatosis (IVL); Uterus; Prognosis; Histogenesis; Immunohistochemistry	BENIGN METASTASIZING LEIOMYOMA; SMOOTH-MUSCLE TUMORS; OF-THE-LITERATURE; INTRAVASCULAR-LEIOMYOMATOSIS; EXTENSION; UPDATE	The object of this study is to investigate the prognosis and potential histologic origin of uterine intravenous leiomyomatosis (IVL). We retrospectively analyzed the clinicopathologic and immunohistochemical features of 13 cases of IVL from a single institute. The patients underwent hysterectomy (3 with bilateral salpingo-oophorectomy, and 8 with excision of the broad ligaments and/or parametrium). They survived with no evidence of disease for 6-90 months. Intravascular worm-like plugs were macroscopically identified in the myometrium in 10 of 13 cases (76.9%). Six patients (46.1%) had extra-uterine involvement. Histopathologically, the intravascular tumor foci were covered with endothelium. We found the presence of congested vessels in the tumor and the surrounding myometrium in 9 of 13 cases (69.2%). The concurrent entities included seven uterine leiomyomas, one leiomyoma with adenomyosis, one adenomyosis, and one pulmonary benign metastasizing leiomyoma. Estrogen receptor and desmin were positive in IVL, and negative in the vascular wall. We conclude that IVL confined to the uterus may have a favorable prognosis, and we believe IVL is likely to originate from contiguous leiomyoma or myometrium.	[Tang, Lanlan; Lu, Bingjian] Zhejiang Univ, Affiliated Womens Hosp, Sch Med, Dept Surg Pathol, 1 Xueshi Rd, Hangzhou 310002, Zhejiang, Peoples R China; [Lu, Bingjian] Zhejiang Univ, Affiliated Womens Hosp, Ctr Uterine Canc Diag & Therapy Res Zhejiang Prov, Sch Med, 1 Xueshi Rd, Hangzhou 310002, Zhejiang, Peoples R China	Lu, BJ (reprint author), Zhejiang Univ, Affiliated Womens Hosp, Sch Med, Dept Surg Pathol, 1 Xueshi Rd, Hangzhou 310002, Zhejiang, Peoples R China.	5516046@zju.edu.cn; lbj@zju.edu.cn					Barjot P. J., 1998, Journal of Obstetrics and Gynaecology (Abingdon), V18, P492; Bodner-Adler B, 2009, ANTICANCER RES, V29, P495; Buza N, 2014, HUM PATHOL, V45, P1885, DOI 10.1016/j.humpath.2014.05.010; CANZONIERI V, 1994, VIRCHOWS ARCH, V425, P541; Carr RJ, 2015, INT J GYNECOL PATHOL, V34, P169, DOI 10.1097/PGP.0000000000000127; CLEMENT PB, 1988, AM J SURG PATHOL, V12, P932, DOI 10.1097/00000478-198812000-00004; Du J, 2011, HUM PATHOL, V42, P1240, DOI 10.1016/j.humpath.2010.10.015; Hirschowitz L, 2013, AM J SURG PATHOL, V37, P1395, DOI 10.1097/PAS.0b013e31828b2c99; Jimenez M, 1999, CARDIOVASC RES, V41, P737, DOI 10.1016/S0008-6363(98)00287-9; Kayser K, 2000, VIRCHOWS ARCH, V437, P284, DOI 10.1007/s004280000207; Kir G, 2004, EUR J GYNAECOL ONCOL, V25, P362; Kocica MJ, 2005, J THORAC CARDIOV SUR, V130, P1724, DOI 10.1016/j.jtcvs.2005.08.021; Lam PM, 2004, J VASC SURG, V39, P465, DOI 10.1016/j.jvs.2003.08.012; Lee HJ, 2008, INT J GYNECOL PATHOL, V27, P340, DOI [10.1097/PGP.0b0136181656dab, 10.1097/PGP.0b013e3181656dab]; Lo KWK, 2001, ARCH GYNECOL OBSTET, V264, P209, DOI 10.1007/s004040000115; Low HY, 2017, TAIWAN J OBSTET GYNE, V56, P362, DOI 10.1016/j.tjog.2017.04.017; Mahmoud MS, 2015, ARCH GYNECOL OBSTET, V291, P223, DOI 10.1007/s00404-014-3356-8; Masand RP, 2013, AM J SURG PATHOL, V37, P1635, DOI 10.1097/PAS.0000000000000083; Merchant S, 2002, AM J SURG PATHOL, V26, P232, DOI 10.1097/00000478-200202000-00010; MULVANY NJ, 1994, INT J GYNECOL PATHOL, V13, P1, DOI 10.1097/00004347-199401000-00001; Nam MS, 2003, GYNECOL ONCOL, V89, P175, DOI 10.1016/S0090-8258(02)00138-5; NOGALES FF, 1987, INT J GYNECOL PATHOL, V6, P331, DOI 10.1097/00004347-198712000-00005; NORRIS HJ, 1975, CANCER, V36, P2164, DOI 10.1002/cncr.2820360935; Ordulu Z, 2016, MODERN PATHOL, V29, P500, DOI 10.1038/modpathol.2016.36; Roth LM, 1999, AM J SURG PATHOL, V23, P1032, DOI 10.1097/00000478-199909000-00005; Sun Cong, 2010, Am J Surg, V200, pe41, DOI 10.1016/j.amjsurg.2009.09.027; Devesa VV, 2013, EUR J OBSTET GYN R B, V171, P209, DOI 10.1016/j.ejogrb.2013.09.031; Veras E, 2011, AM J SURG PATHOL, V35, P1626, DOI 10.1097/PAS.0b013e31822b44d2	28	3	4	1	6	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUN	2018	214	6					871	875		10.1016/j.prp.2018.04.011			5	Pathology	Pathology	GM6ZF	WOS:000438326800011	29699902				2019-10-28	
J	de Freitas, SAJ; Servato, JPS; de Sa, RT; Siqueira, CS; de Faria, PR; Loyola, AM; Cardoso, SV				Juvencio de Freitas Filho, Silas Antonio; Silva Servato, Joao Paulo; de Sa, Rodrigo Tavares; Siqueira, Carla Silva; de Faria, Paulo Rogerio; Loyola, Adriano Mota; Cardoso, Sergio Vitorino			Evaluation of specific modified histones in lip carcinogenesis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Actinic cheilitis; Squamous cell carcinoma; Lip cancer; Histone modifications; Epigenetics	SQUAMOUS-CELL CARCINOMA; ACTINIC CHEILITIS; LUNG-CANCER; H3; EXPRESSION; PROGNOSIS; ACETYLATION; TRIMETHYLATION; METHYLATION; CORRELATE	Objective: Histones regulate chromatin density and therefore influence gene expression and cellular proliferation. These properties are modified by methylation, acetylation and phosphorylation of histones. The aim of this study was to investigate the variation of specific modified histones in actinic cheilitis (AC) and squamous cell carcinoma of the lip (SCCL). Methods: Samples of non-neoplastic tissue of the lip (NNTL, n = 9), AC (n = 33), and SCCL (n = 27) were submitted to immunohistochemistry to detect the modified histones H3K36me3, H3K9ac, H4K12ac, and H3S10 ph. Results: Reactivity for all of the modified histones was significantly decreased from NNTL to AC, but not from AC to SCCL. Dysplasia in AC or histological grade in SCCL were not related to the reactivity of any modified his tones. Conclusions: Histone modifications are related to initial actinic damage, but not to malignant transformation in the lip.	[Juvencio de Freitas Filho, Silas Antonio; de Sa, Rodrigo Tavares; Loyola, Adriano Mota; Cardoso, Sergio Vitorino] Univ Fed Uberlandia, Sch Dent, Area Pathol, Uberlandia, MG, Brazil; [Silva Servato, Joao Paulo] Univ Uberaba UNIUBE, Sch Dent, Lab Biopathol, Uberaba, MG, Brazil; [Siqueira, Carla Silva] Univ Fed Goias, Jatai, GO, Brazil; [de Faria, Paulo Rogerio] Univ Fed Uberlandia, Biomed Sci Inst, Dept Morphol, Uberlandia, MG, Brazil	Cardoso, SV (reprint author), Univ Fed Uberlandia, Area Patol, Fac Odontol, Av Para 1720,Campus Umuarama, BR-38400902 Uberlandia, MG, Brazil.	sv.cardoso@ufu.br	de Freitas Filho, Silas Antonio Juvencio/T-2370-2019; de Faria, Paulo R/G-1431-2011; Cardoso, Sergio Vitorino/B-5804-2008	de Freitas Filho, Silas Antonio Juvencio/0000-0002-6478-7477; de Faria, Paulo R/0000-0003-2650-3960; Cardoso, Sergio Vitorino/0000-0003-1809-0617	Brazilian Governmental Agency FAPEMIG (Fundacao de Amparo a Pesquisa do Estado de Minas Gerais); Brazilian Governmental Agency CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior); Brazilian Governmental Agency CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico)	This work was supported by financial grants from the Brazilian Governmental Agencies FAPEMIG (Fundacao de Amparo a Pesquisa do Estado de Minas Gerais), CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior) and CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico). The authors thank Angela Maria Pereira and Lubia Cristina Fonseca for assisting in the immunohistochemistry technique.	Audia JE, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a019521; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Biswas S, 2017, PHARMACOL THERAPEUT, V173, P118, DOI 10.1016/j.pharmthera.2017.02.011; Carvalho S, 2014, ELIFE, V3, DOI 10.7554/eLife.02482; Chen YW, 2013, CANCER-AM CANCER SOC, V119, P4259, DOI 10.1002/cncr.28356; Chervona Y, 2012, AM J CANCER RES, V2, P589; Chrun ES, 2017, ORAL DIS, V23, P505, DOI 10.1111/odi.12641; Chrun ES, 2017, PATHOL RES PRACT, V213, P1329, DOI 10.1016/j.prp.2017.06.013; Colman H, 2006, AM J SURG PATHOL, V30, P657, DOI 10.1097/01.pas.0000202048.28203.25; da-Silva JP, 2012, PATHOL RES PRACT, V208, P598, DOI 10.1016/j.prp.2012.07.004; Daniel FI, 2016, J ORAL PATHOL MED, V45, P774, DOI 10.1111/jop.12453; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; Dougherty W, 2017, HEAD NECK-J SCI SPEC, V39, P1505, DOI 10.1002/hed.24817; El-Naggar AK, 2017, WHO CLASSIFICATION T; Ellinger J, 2010, INT J CANCER, V127, P2360, DOI 10.1002/ijc.25250; Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907; Garcia NG, 2016, CLIN ORAL INVEST, V20, P745, DOI 10.1007/s00784-015-1557-6; Ho TH, 2016, MODERN PATHOL, V29, P34, DOI 10.1038/modpathol.2015.123; de Oliveira DHIP, 2014, J ORAL PATHOL MED, V43, P357, DOI 10.1111/jop.12144; Katiyar SK, 2012, PHOTOCHEM PHOTOBIOL, V88, P1066, DOI 10.1111/j.1751-1097.2011.01020.x; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Liu L, 2017, BIOSCI TRENDS, V11, P214, DOI 10.5582/bst.2016.01228; McBrian MA, 2013, MOL CELL, V49, P310, DOI 10.1016/j.molcel.2012.10.025; Nakazawa T, 2012, HUM PATHOL, V43, P834, DOI 10.1016/j.humpath.2011.07.009; Noguchi A, 2013, OR SURG OR MED OR PA, V115, P385, DOI 10.1016/j.oooo.2012.12.013; Perez-Cadahia B, 2009, BIOCHEM CELL BIOL, V87, P695, DOI 10.1139/O09-053; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; Shield KD, 2017, CA-CANCER J CLIN, V67, P51, DOI 10.3322/caac.21384; Song JS, 2012, PATHOL INT, V62, P182, DOI 10.1111/j.1440-1827.2011.02776.x; Van Den Broeck A, 2008, CLIN CANCER RES, V14, P7237, DOI 10.1158/1078-0432.CCR-08-0869; Webber LP, 2017, HISTOPATHOLOGY, V71, P278, DOI 10.1111/his.13218; Yu YC, 2005, P NATL ACAD SCI USA, V102, P8650, DOI 10.1073/pnas.0501458102; Zhao JX, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317697546	33	1	1	1	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUN	2018	214	6					876	880		10.1016/j.prp.2018.04.004			5	Pathology	Pathology	GM6ZF	WOS:000438326800012	29699903				2019-10-28	
J	Kim, HS; Kwon, MJ; Song, JH; Kim, ES; Kim, HY; Min, KW				Kim, Hyun Sik; Kwon, Mi Jung; Song, Joon Ho; Kim, Eun Soo; Kim, Ho Young; Min, Kyueng-Whan			Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Diffuse glioma; TERT promoter mutation; MGMT promoter methylation; IDH mutation	O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; GRADE GLIOMAS; FREE SURVIVAL; TUMORS; CLASSIFICATION; GLIOBLASTOMA; CONTRIBUTE; SUBGROUPS; SUBSET; CELLS	IDH mutation and MGMT promoter methylation are reliable prognostic and predictive biomarkers in grade II-IV diffuse gliomas. Recurrent mutations in the promoter region of the telomerase reverse transcriptase (TERTp) gene have also been found in diffuse gliomas. However, the prognostic and predictive effects of TERTp mutation on IDH or MGMT status are largely unknown. IDH1/2 and TERTp mutations, as well as MGMT methylation statuses, were examined via peptide nucleic acid-mediated PCR clamping and MGMT methylation-specific PCR in 67 paraffinized tumor samples, respectively. TERM mutation was associated with older patients (>= 60 years) and frontally located gliomas. Old age, frontal location, and grade IV were found to be predictive factors of TERTp mutation. TERTp mutation resulted in poor prognosis in overall diffuse gliomas. TERTp mutation was not correlated with overall survival (OS) or progression-free survival (PFS) in the diffuse gliomas. However, TERTp mutations, in combination with MGMT methylation or IDH mutation, showed that there were statistical significant survival differences between MGMT-unmethylated/TERTp-mutated and MGMT-unmethylated/TERTp-wildtype subgroups in grade II gliomas. There was a statistical significant survival difference of OS between IDH-wildtype/TERTp-mutated and IDH-mutated/TERTp-mutated subgroups in grade III gliomas. No significant associations between survival and MGMT/TERTp or IDH/TERTp status were found in grade IV gliomas. In conclusion, the combination of TERTp with IDH or MGMT status may be a prognostic indicator depending on grades.	[Kim, Hyun Sik; Song, Joon Ho] Hallym Univ, Sacred Heart Hosp, Coll Med, Dept Neurosurg, Anyang, South Korea; [Kwon, Mi Jung] Hallym Univ, Sacred Heart Hosp, Coll Med, Dept Pathol, Anyang 431070, Gyeonggi Do, South Korea; [Kim, Eun Soo] Hallym Univ, Sacred Heart Hosp, Coll Med, Dept Radiol, Anyang, South Korea; [Kim, Ho Young] Hallym Univ, Sacred Heart Hosp, Coll Med, Dept Hematol Oncol, Anyang, South Korea; [Min, Kyueng-Whan] Hanyang Univ, Guri Hosp, Coll Med, Dept Pathol, Kyoungchun Ro 153, Guri Si 11923, Gyeonggi Do, South Korea; [Kwon, Mi Jung] Hallym Univ, Res Inst Complementary & Alternat Med, 40 Seokwoo Dong, Hwaseong 445170, Gyeonggi Do, South Korea	Kwon, MJ (reprint author), Hallym Univ, Sacred Heart Hosp, Coll Med, Dept Pathol, Anyang 431070, Gyeonggi Do, South Korea.	mulank99@hallym.or.kr	; Min, Kyueng-Whan/F-3981-2017	Kwon, Mi Jung/0000-0002-2441-0448; Min, Kyueng-Whan/0000-0002-4757-9211	Hallym University Research Fund [HURF-2017-38]; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [NRF-2016R1D1A1B03935447]	This research was supported by the Hallym University Research Fund (HURF-2017-38) and by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2016R1D1A1B03935447) to MJ Kwon.	Arita H, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0351-2; BURGER PC, 1985, CANCER, V56, P1106, DOI 10.1002/1097-0142(19850901)56:5<1106::AID-CNCR2820560525>3.0.CO;2-2; Cao Y, 2008, CANCER SCI, V99, P1092, DOI 10.1111/j.1349-7006.2008.00815.x; Chan AKY, 2015, MODERN PATHOL, V28, P177, DOI 10.1038/modpathol.2014.94; Eckel-Passow JE, 2015, NEW ENGL J MED, V372, P2499, DOI 10.1056/NEJMoa1407279; Everhard S, 2006, ANN NEUROL, V60, P740, DOI 10.1002/ana.21044; Fuller GN, 2007, WHO CLASSIFICATION T, P50; Gao K, 2016, ONCOTARGET, V7, P8712, DOI 10.18632/oncotarget.6007; Heuling ES, 2017, MOL CANCER RES, V15, P532, DOI 10.1158/1541-7786.MCR-16-0322; Vuong HG, 2017, CRIT REV ONCOL HEMAT, V120, P1, DOI 10.1016/j.critrevonc.2017.09.013; Killela PJ, 2013, P NATL ACAD SCI USA, V110, P6021, DOI 10.1073/pnas.1303607110; Komine C, 2003, BRAIN PATHOL, V13, P176; Kwon MJ, 2015, PANCREAS, V44, P484, DOI 10.1097/MPA.0000000000000280; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Myung JK, 2011, AM J SURG PATHOL, V35, P1794, DOI 10.1097/PAS.0b013e31823456e6; Park TJ, 2001, CANCER, V92, P2760, DOI 10.1002/1097-0142(20011201)92:11<2760::AID-CNCR10123>3.0.CO;2-8; Sun ZL, 2015, INT J CLIN EXP PATHO, V8, P11485; Yang P, 2016, NEURO-ONCOLOGY, V18, P1099, DOI 10.1093/neuonc/now021; Zhang ZY, 2015, ONCOTARGET, V6, P24871, DOI 10.18632/oncotarget.4549	19	1	1	4	8	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUN	2018	214	6					881	888		10.1016/j.prp.2018.04.002			8	Pathology	Pathology	GM6ZF	WOS:000438326800013	29650441	Other Gold			2019-10-28	
J	Fatehi, D; Soltani, A; Ghatrehsamani, M				Fatehi, Daryoush; Soltani, Amin; Ghatrehsamani, Mandi			SRT1720, a potential sensitizer for radiotherapy and cytotoxicity effects of NVB-BEZ235 in metastatic breast cancer cells	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Breast cancer; Chemo-radiotherapy; Cancer stem cells; IL-6; PI3K/AKT/mTOR; SIRT1	SIRT1; PATHWAY; MAINTENANCE; VIABILITY; PROTECTS; GROWTH; IL-6	Background: Chemo-radio therapy (CRT) resistance is a main barrier in treating the triple negative breast cancer (TNBC). The success of conventional treatment may be ameliorated by elevating the responsiveness of the cancer cells to CRT. NVP-BEZ235 as a PI3K/AKT/mTOR dual inhibitor has been shown promising results in treating breast cancer cells. However, potential radiation-sensitizing effect of NVP-BEZ235 in TNBC remained unclear. In addition, SIRT-1 activation state and environmental cytokine were identified as being responsible for cancer cells responses to CRT. Herein, we investigate the role of interleukin 6 (IL-6) as a tumor environmental cytokine and SIRT1 in the effectiveness of NVP-BEZ235 plus radiotherapy. Material and methods: TNBC cells were pre-treated with/without IL-6 and were exposed to single and combination of SRT1720 (SIRT1 activator)/EX-527 (SIRT1 inhibitor) and/or NVP-BEZ235 and/or gamma radiation. The effect of our treatments on cellular growth was determined by MIT and the cellular death and CSCs percentage were determined by Flow cytometry. Senescence detection kit was used to assay the effect of our treatments on cellular senescence induction. Results: Activation of SIRT1 via SRT1720 increased the efficacy of CRT in TNBC cells, especially when IL-6 exists in tumor microenvironment. Additionally, IL-6 pre-treatment followed by exposure to SRT1720 and NVP-BEZ235 significantly increased sensitivity of the cancer stem cells to radiation (p < 0.05). Conclusion: Our result shows that combination of NVP-BEZ235 and SRT1720 may effectively improve late stage breast cancer cells therapeutics approach. Activation of SIRT1 and STAT3 in resistance breast cancer cells improves the in-vitro therapeutic efficacy of CRT.	[Fatehi, Daryoush] Shahrekord Univ Med Sci, Fac Med, Dept Med Phys, Shahrekord, Iran; [Soltani, Amin; Ghatrehsamani, Mandi] Shahrekord Univ Med Sci, Cellular & Mol Res Ctr, POB 88155-571, Shahrekord, Iran	Ghatrehsamani, M (reprint author), Shahrekord Univ Med Sci, Cellular & Mol Res Ctr, POB 88155-571, Shahrekord, Iran.	ghatreh.m@SKUMS.ac.ir		Fatehi, Dr. Daryoush/0000-0002-8442-9810	Shahrekord university of medical science [2339]	This work was supported by the Shahrekord university of medical science [grant number 2339].	Bayou J., 2017, BREAST, V32, P37, DOI [10.1016/j.breast, DOI 10.1016/J.BREAST]; Bhat M, 2015, NAT REV DRUG DISCOV, V14, P261, DOI 10.1038/nrd4505; Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659; Chauhan D, 2011, BRIT J HAEMATOL, V155, P588, DOI 10.1111/j.1365-2141.2011.08888.x; D'Amico MA, 2016, J CELL PHYSIOL, V231, P576, DOI 10.1002/jcp.25101; Di Maggio FM, 2015, J INFLAMM-LOND, V12, DOI 10.1186/s12950-015-0058-3; Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106; Frojdo S, 2011, MOL CELL ENDOCRINOL, V335, P166, DOI 10.1016/j.mce.2011.01.008; Gang W., 2015, INT J NANOMED, V10, P5005, DOI [10.2147/IJN.S82282, DOI 10.2147/IJN.S82282]; German S, 2013, HERED CANCER CLIN PR, V11, DOI 10.1186/1897-4287-11-5; Gluz O, 2009, ANN ONCOL, V20, P1913, DOI 10.1093/annonc/mdp492; Gu W., 2016, INT J NANOMED, V11, P1947; Jin MS, 2016, TUMOR BIOL, V37, P4743, DOI 10.1007/s13277-015-4231-3; O'Toole A, 2014, BRIT J CANCER, V111, P927, DOI 10.1038/bjc.2014.367; Oh HM, 2012, J BIOL CHEM, V287, P30436, DOI 10.1074/jbc.M112.359661; Paplomata E, 2014, THER ADV MED ONCOL, V6, P154, DOI 10.1177/1758834014530023; Pinton G, 2016, ONCOTARGET, V7, P14366, DOI 10.18632/oncotarget.7321; Shiota M, 2010, CANCER SCI, V101, P1177, DOI 10.1111/j.1349-7006.2010.01503.x; Sonnemann J, 2016, J CANCER RES CLIN, V142, P17, DOI 10.1007/s00432-015-1994-2; Storozhuk Y, 2013, BRIT J CANCER, V108, P2021, DOI 10.1038/bjc.2013.187; Sun X.D., 2014, MATH PROBL ENG, V2014, P10, DOI DOI 10.7688/J.ISSN.1000-1646.2014.02.11; Torki S., 2017, BIOMED PHARMACOTHER; Yao HW, 2012, J CLIN INVEST, V122, P2032, DOI 10.1172/JCI60132; Yin YX, 2017, BIOMED PHARMACOTHER, V88, P449, DOI 10.1016/j.biopha.2017.01.087; Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104	25	2	2	1	5	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUN	2018	214	6					889	895		10.1016/j.prp.2018.04.001			7	Pathology	Pathology	GM6ZF	WOS:000438326800014	29653746				2019-10-28	
J	Zhang, TJ; Qian, Z; Wen, XM; Zhou, JD; Li, XX; Xu, ZJ; Ma, JC; Zhang, ZH; Lin, J; Qian, J				Zhang, Ting-juan; Qian, Zhen; Wen, Xiang-mei; Zhou, Jing-dong; Li, Xi-xi; Xu, Zi-jun; Ma, Ji-chun; Zhang, Zhi-hui; Lin, Jiang; Qian, Jun			Lower expression of bone marrow miR-122 is an independent risk factor for overall survival in cytogenetically normal acute myeloid leukemia	PATHOLOGY RESEARCH AND PRACTICE			English	Article						miR-122; Expression; Prognosis; AML	HEPATOCELLULAR-CARCINOMA; PLASMA MIR-122; MICRORNA-122; CANCER; OVEREXPRESSION; CELLS; PROGNOSIS	Background: The liver-enriched microRNA-122 (miR-122) plays a crucial role in pathogenesis of hepatocellular carcinoma (HCC) with prognostic value. Recently, miR-122 was also found to be related to many other cancers besides HCC. However, less study determined miR-122 expression and its clinical significance in acute myeloid leukemia (AML). Methods: Real-time quantitative PCR was performed to detect the level of bone marrow (BM) miR-122 in de novo AML patients. The clinical significance of miR-122 expression in AML was further investigated. Results: Among whole-cohort AML, lower expression of BM miR-122 was associated with male patients, higher hemoglobin and favorable-karyotypes (P = 0.038, 0.006, and 0.038, respectively). Among cytogenetically normal AML (CN-AML), lower expression of BM miR-122 was correlated with DNMT3A wild type (P = 0.043). Moreover, patients with lower expression of BM miR-122 presented lower complete remission (CR) rate and shorter overall survival (OS) than those with higher expression of BM miR-122 in CN-AML (P = 0.025 and 0.013, respectively). Cox regression analyses further confirmed the prognostic value of BM miR-122 expression in CN-AML (P = 0.024). In follow-up patients, BM miR-122 expression level in CR time was increased compared to diagnosis time, and was returned to primary level when in relapse time again (P = 0.062 and 0.049, respectively). Conclusions: Our findings indicated that lower expression of BM miR-122 acted as an independent risk factor for OS in CN-AML.	[Zhang, Ting-juan; Qian, Zhen; Zhou, Jing-dong; Li, Xi-xi; Zhang, Zhi-hui; Qian, Jun] Jiangsu Univ, Affiliated Peoples Hosp, Dept Hematol, 8 Dianli Rd, Zhenjiang 212002, Jiangsu, Peoples R China; [Wen, Xiang-mei; Xu, Zi-jun; Ma, Ji-chun; Lin, Jiang] Jiangsu Univ, Affiliated Peoples Hosp, Lab Ctr, 8 Dianli Rd, Zhenjiang 212002, Jiangsu, Peoples R China; [Zhang, Ting-juan; Qian, Zhen; Wen, Xiang-mei; Zhou, Jing-dong; Li, Xi-xi; Xu, Zi-jun; Ma, Ji-chun; Zhang, Zhi-hui; Lin, Jiang; Qian, Jun] Key Lab Precis Diag & Treatment Zhenjiang City, Zhenjiang, Jiangsu, Peoples R China	Qian, J (reprint author), Jiangsu Univ, Affiliated Peoples Hosp, Dept Hematol, 8 Dianli Rd, Zhenjiang 212002, Jiangsu, Peoples R China.; Lin, J (reprint author), Jiangsu Univ, Affiliated Peoples Hosp, Lab Ctr, 8 Dianli Rd, Zhenjiang 212002, Jiangsu, Peoples R China.	linjiangmail@sina.com; QianJun@jskfhn.org.cn		Zhang, Zhi-hui/0000-0001-9612-5446	National Natural Science foundation of ChinaNational Natural Science Foundation of China [81270630]; Medical Innovation Team of Jiangsu Province [CXTDB2017002]; 333 Project of Jiangsu ProvinceNatural Science Foundation of Jiangsu Province [BRA2016131]; Six Talent Peaks Project in Jiangsu Province [2015-WSN-115]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2016M601748]; Postgraduate Research & Practice Innovation Program of Jiangsu Province [KYCX17_1821]; Medical Science and Technology Development Fund of Jiangsu University [JLY20160011]; Social Development Foundation of Zhenjiang [SH2016045, SH2016046]; Key Medical Talent Program of Zhenjiang City	This work was supported by National Natural Science foundation of China (81270630), Medical Innovation Team of Jiangsu Province (CXTDB2017002), 333 Project of Jiangsu Province (BRA2016131), Six Talent Peaks Project in Jiangsu Province (2015-WSN-115), China Postdoctoral Science Foundation funded project (2016M601748), Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX17_1821), 2016 Medical Science and Technology Development Fund of Jiangsu University (JLY20160011), Social Development Foundation of Zhenjiang (SH2016045, SH2016046), Key Medical Talent Program of Zhenjiang City.	Chen QJ, 2014, ONCOL REP, V31, P1863, DOI 10.3892/or.2014.3004; Chen YJ, 2013, BIOCHEM PHARMACOL, V86, P620, DOI 10.1016/j.bcp.2013.06.009; Dohner H, 2015, NEW ENGL J MED, V373, P1136, DOI 10.1056/NEJMra1406184; Dohner H, 2010, BLOOD, V115, P453, DOI 10.1182/blood-2009-07-235358; Filipowicz W, 2011, PROG DRUG RES, V67, P221, DOI 10.1007/978-3-7643-8989-5_11; Grimwade D, 2010, BLOOD, V116, P354, DOI 10.1182/blood-2009-11-254441; He JX, 2014, CELL BIOCHEM BIOPHYS, V70, P1343, DOI 10.1007/s12013-014-0062-x; Maierthaler M, 2017, INT J CANCER, V140, P176, DOI 10.1002/ijc.30433; Metzeler KH, 2009, J CLIN ONCOL, V27, P5031, DOI 10.1200/JCO.2008.20.5328; Mrozek K, 2007, BLOOD, V109, P431, DOI 10.1182/blood-2006-06-001149; Niederwieser C, 2015, LEUKEMIA, V29, P567, DOI 10.1038/leu.2014.267; Peng Y, 2014, MOLECULES, V19, P11586, DOI 10.3390/molecules190811586; Wu W, 2007, INT J CANCER, V120, P953, DOI 10.1002/ijc.22454; Xie XH, 2015, MOL MED REP, V12, P1375, DOI 10.3892/mmr.2015.3554; Xu YM, 2016, CANCER LETT, V371, P171, DOI 10.1016/j.canlet.2015.11.034; Yang J, 2017, PATHOL RES PRACT, V213, P1166, DOI 10.1016/j.prp.2017.06.017; Zhang R, 2009, J GENET GENOMICS, V36, P1, DOI 10.1016/S1673-8527(09)60001-1; Zhang TJ, 2018, J CELL PHYSIOL, V233, P3274, DOI 10.1002/jcp.26171; Zhou JD, 2017, J CELL MOL MED, V21, P1468, DOI 10.1111/jcmm.13073; Zhou JD, 2016, LEUKEMIA LYMPHOMA, V57, P828, DOI 10.3109/10428194.2015.1088648	20	2	2	0	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUN	2018	214	6					896	901		10.1016/j.prp.2018.03.027			6	Pathology	Pathology	GM6ZF	WOS:000438326800015	29627222				2019-10-28	
J	Chen, JH				Chen, Jey-Hsin			Histopathology of locally advanced colorectal carcinoma, with emphasis on tumor invasion of adherent peritoneal membranes	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Colorectal carcinoma; Peritoneum; Elastic lamina; Adhesions; Keratin	STAGE-II; COLON-CANCER; RECOMMENDATIONS; ADHESIONS	Locally advanced colorectal carcinomas are characterized by neoplastic cells that invade beyond the colon and directly into surrounding organs and structures that include the retroperitoneum and abdominopelvic sidewall. These aggressive tumors are prognostically adverse and are categorized with highest possible tumor stage in current cancer staging systems. Recognizing colorectal carcinoma with extensive locoregional invasion is typically straightforward, but some cases can be diagnostically challenging. These include tumors with limited invasion of extracolonic tissue such as the subserosa in which there are no cells or structures that are histologically or architecturally distinct from the colonic primary. Tumor-associated injury of the colonic peritoneum often precedes invasion by the neoplastic cells and can cause the peritoneal membrane of the colon to adhere and subsequently fuse to the peritoneal membrane of a neighboring organ or structure, thereby creating a trans peritoneal bridge through which a tumor can directly invade the adherent extracolonic tissue. Hence, locally advanced colorectal carcinoma can be narrowly defined by neoplastic cells that completely invade through the fused peritoneal membrane and into the subserosa of the adherent extracolonic tissue. The evaluation of tumor invasion of the fused peritoneal membrane, which is enhanced by the combined use of an elastic stain and an immunostain for pan-keratin, is essential for the proper staging of locally advanced colorectal carcinoma and its clinical management.	[Chen, Jey-Hsin] CellNetix Pathol & Labs, 1124 Columbia St,Suite 200, Seattle, WA 98104 USA; [Chen, Jey-Hsin] Swedish Med Ctr, Seattle, WA USA; [Chen, Jey-Hsin] Providence Hlth & Serv, Renton, WA USA	Chen, JH (reprint author), CellNetix Pathol & Labs, 1124 Columbia St,Suite 200, Seattle, WA 98104 USA.	jchen@cellnetix.com		Chen, Jey-Hsin/0000-0003-1678-0091			[Anonymous], 2015, CURR PROB SURG, V52, P271, DOI 10.1067/j.cpsurg.2015.05.001; Arung W, 2011, WORLD J GASTROENTERO, V17, P4545, DOI 10.3748/wjg.v17.i41.4545; Benson AB, 2004, J CLIN ONCOL, V22, P3408, DOI 10.1200/JCO.2004.05.063; BLENKINSOPP WK, 1981, J CLIN PATHOL, V34, P509, DOI 10.1136/jcp.34.5.509; Brierley JD, 2017, TNM CLASSIFICATION M, P73; Chen JH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173833; Grin A, 2013, HUM PATHOL, V44, P2696, DOI 10.1016/j.humpath.2013.07.013; Gunderson LL, 2010, J CLIN ONCOL, V28, P264, DOI 10.1200/JCO.2009.24.0952; HUBBARD TB, 1967, ANN SURG, V165, P908, DOI 10.1097/00000658-196706000-00006; Jass JR, 2007, VIRCHOWS ARCH, V450, P1, DOI 10.1007/s00428-006-0302-6; Jessup J. M., 2016, AJCC CANC STAGING MA; Kojima M, 2010, AM J SURG PATHOL, V34, P1351, DOI 10.1097/PAS.0b013e3181ecfe98; Liang WY, 2013, AM J SURG PATHOL, V37, P1565, DOI 10.1097/PAS.0b013e31828ea2de; Marshall John L, 2007, Gastrointest Cancer Res, V1, P146; Snaebjornsson P, 2014, INT J CANCER, V135, P467, DOI 10.1002/ijc.28676; Stewart Colin J R, 2011, Cancers (Basel), V3, P164, DOI 10.3390/cancers3010164; Swamy R, 2010, J CLIN PATHOL, V63, P110, DOI 10.1136/jcp.2009.069658; Woodburne RT, 1994, ESSENTIALS HUMAN ANA	18	0	1	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUN	2018	214	6					902	906		10.1016/j.prp.2018.03.024			5	Pathology	Pathology	GM6ZF	WOS:000438326800016	29631918				2019-10-28	
J	Montezuma, MAP; Fonseca, FP; Benites, BM; Soares, CD; do Amaral-Silva, GK; de Almeida, OP; Soares, FA; Pagano, RL; Fregnani, ER				Petroni Montezuma, Marco Aurelio; Fonseca, Felipe Paiva; Benites, Bernar Monteiro; Soares, Ciro Dantas; do Amaral-Silva, Gleyson Kleber; de Almeida, Oslei Paes; Soares, Fernando Augusto; Pagano, Rosana Lima; Fregnani, Eduardo Rodrigues			COX-2 as a determinant of lower disease-free survival for patients affected by ameloblastoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Ameloblastoma; Odontogenic tumors; COX-2; Cyclooxigenase-2; CD34	ENDOTHELIAL GROWTH-FACTOR; CYCLOOXYGENASE-2 EXPRESSION; TUMOR ANGIOGENESIS; PROGNOSTIC-SIGNIFICANCE; TISSUE MICROARRAY; VEGF EXPRESSION; NECK-CANCER; PATHWAY; PROLIFERATION; MARKERS	Ameloblastoma is a locally aggressive neoplasm with a poorly understood pathogenesis. Therefore, the aim of this study is to investigate whether COX-2 expression is associated with ameloblastoma microvascular density (MVD) and with tumor aggressiveness. Sixty-three cases of primary ameloblastomas arranged in tissue micro array were submitted to immunohistochemistry against cyclooxigenase-2 (COX-2) and CD34. Clinicopathological parameters regarding sex, age, tumour size, tumour duration, tumour location, treatment, recurrences, radiographic features, vestibular/lingual and basal cortical disruption and follow-up data were obtained from patients' medical record s and correlated with the proteins expression. The results on BRAF-V600E expression were obtained from our previous study and correlated with COX-2 and CD34 expressions. Log-rank univariate analysis and multivariate Cox regression model were done to investigate the prognostic potential of the molecular markers. Twenty-eight cases (44.4%) exhibited cytoplasmic positivity for COX-2, predominantly in the columnar peripheral cells, with a mean MVD of 2.2 vessels/mm(2). COX-2 was significantly associated with recurrences (p < 0.001) and BRAF-V600E expression (p < 0.001), whereas lower MVD was associated with the use of conservative therapy (p = 0.004). Using univariate and multivariate analyses, COX-2 was significantly associated with a lower 5-year disease-free survival (DFS) rate (p < 0.001 and p = 0.012, respectively), but not with a higher MVD (p = 0.68). In conclusion, COX-2 expression in ameloblastomas is not associated with MVD, but it is significantly associated with recurrences and with a lower DFS.	[Petroni Montezuma, Marco Aurelio; Benites, Bernar Monteiro; Fregnani, Eduardo Rodrigues] Sirio Libanes Hosp, Oral Med Dept, Dona Adma Jafet St 115, BR-01308050 Sao Paulo, SP, Brazil; [Fonseca, Felipe Paiva] Univ Fed Minas Gerais, Sch Dent, Dept Oral Surg & Pathol, Av Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil; [Soares, Ciro Dantas; do Amaral-Silva, Gleyson Kleber; de Almeida, Oslei Paes] Univ Estadual Campinas, Piracicaba Dent Sch, Dept Oral Diag, Av Limeira 901, BR-13414903 Sao Paulo, Brazil; [Soares, Fernando Augusto] AC Camargo Canc Ctr, Dept Pathol, Prof Antonio Prudente St 211, BR-01509010 Sao Paulo, Brazil; [Pagano, Rosana Lima] Sirio Libanes Hosp, Lab Mol Biol, Dona Adma Jafet St 115, BR-01308050 Sao Paulo, SP, Brazil	Fregnani, ER (reprint author), Sirio Libanes Hosp, Oral Med Dept, Dona Adma Jafet St 115, BR-01308050 Sao Paulo, SP, Brazil.	eduardofregnani@me.com	, Ap/AAB-2985-2019; Pagano, Rosana Lima/I-1088-2013; Soares, Ciro/D-4401-2015; Fregnani, Eduardo/I-4453-2013; Fonseca, Felipe/C-4158-2012	, Ap/0000-0002-5351-6575; Soares, Ciro/0000-0002-6861-6640; Fregnani, Eduardo/0000-0001-5196-7631; Fonseca, Felipe/0000-0002-6657-4547; do Amaral Silva, Gleyson Kleber/0000-0002-6644-3264			Abdullah Murdani, 2013, Acta Med Indones, V45, P187; Adisa AO, 2017, J CLIN DIAGN RES, V11, pZC33, DOI 10.7860/JCDR/2017/28067.10568; Alsaegh MA, 2017, EXP THER MED, V13, P247, DOI 10.3892/etm.2016.3939; Pontes HAB, 2013, ANN DIAGN PATHOL, V17, P45, DOI 10.1016/j.anndiagpath.2012.04.008; Campillo A, 2014, EUR J GASTROEN HEPAT, V26, P871, DOI 10.1097/MEG.0000000000000131; Cecim RL, 2014, J ORAL PATHOL MED, V43, P143, DOI 10.1111/jop.12103; Chen WL, 2009, J CRANIOFAC SURG, V20, P171, DOI 10.1097/SCS.0b013e31818435cd; Cheng ASL, 2004, INT J ONCOL, V24, P853; Chiang SL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06673-3; Czachorowski MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045025; Davies G, 2003, CLIN CANCER RES, V9, P2651; DOAMARALSILVA GK, 2017, OR SURG OR MED OR PA, V124, P286, DOI DOI 10.1016/J.OOOO.2017.05.511; Edwards J, 2004, EUR J CANCER, V40, P50, DOI 10.1016/j.ejca.2003.08.010; Fonseca FP, 2016, OR SURG OR MED OR PA, V121, pE154, DOI 10.1016/j.oooo.2015.09.021; Fonseca FP, 2014, OR SURG OR MED OR PA, V117, P81, DOI 10.1016/j.oooo.2013.08.029; Fosslien E, 2001, ANN CLIN LAB SCI, V31, P325; Fregnani ER, 2017, HISTOPATHOLOGY, V70, P473, DOI 10.1111/his.13095; Gadbail AR, 2013, HEAD NECK-J SCI SPEC, V35, P329, DOI 10.1002/hed.22960; Gallo O, 2001, NEOPLASIA, V3, P53, DOI 10.1038/sj.neo.7900127; Gao SH, 2017, MOL MED REP, V15, P3755, DOI 10.3892/mmr.2017.6447; Half E, 2002, CANCER RES, V62, P1676; Hu H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00288-4; Hu ZX, 2017, ONCOTARGETS THER, V10, P2893, DOI 10.2147/OTT.S134599; Huang ML, 2013, INT J CANCER, V132, P363, DOI 10.1002/ijc.27686; Ilhan N, 2016, ANTICANCER RES, V36, P3953; Jiang H, 2013, CLIN CHIM ACTA, V419, P26, DOI 10.1016/j.cca.2013.01.012; Kumamoto H, 2002, J ORAL PATHOL MED, V31, P28, DOI 10.1046/j.0904-2512.2001.10061.x; Liu XH, 2000, J UROLOGY, V164, P820, DOI 10.1016/S0022-5347(05)67321-1; Liu Y, 2018, MOL CELL BIOCH; Mendes RA, 2011, J ORAL PATHOL MED, V40, P497, DOI 10.1111/j.1600-0714.2010.00997.x; Mendes RA, 2011, ORAL SURG ORAL MED O, V111, P333, DOI 10.1016/j.tripleo.2010.10.004; Mendes RA, 2009, ORAL ONCOL, V45, pE124, DOI 10.1016/j.oraloncology.2009.03.016; Milman T, 2016, HEAD NECK PATHOL, V10, P513, DOI 10.1007/s12105-016-0734-5; Neves-Silva R, 2016, J ORAL PATHOL MED, V45, P704, DOI 10.1111/jop.12428; Oksuz E, 2016, J NEURO-ONCOL, V126, P271, DOI 10.1007/s11060-015-1976-x; Pang LY, 2016, STEM CELLS INT, DOI 10.1155/2016/2048731; Pastuszak-Lewandoska D., PLOS ONE, V19; Pereira Treville, 2016, J Oral Maxillofac Pathol, V20, P51, DOI 10.4103/0973-029X.180929; Sackett MK, 2008, CLIN CANCER RES, V14, P67, DOI 10.1158/1078-0432.CCR-07-2028; Sanchez-Romero C, 2017, J ORAL PATHOL MED, V46, P618, DOI 10.1111/jop.12524; Sano Y, 2018, OTOLARYNGOL HEAD NEC, V1; Seyedmajidi Maryam, 2015, Dent Res J (Isfahan), V12, P278; Siar CH, 2015, J ORAL PATHOL MED, V44, P378, DOI 10.1111/jop.12247; Soares CD, 2017, MELANOMA RES, V27, P448, DOI 10.1097/CMR.0000000000000368; Sweeney RT, 2014, NAT GENET, V46, P722, DOI 10.1038/ng.2986; Wang J, 2013, MOL CLIN ONCOL, V1, P982, DOI 10.3892/mco.2013.169; Yang B, 2016, ONCOTARGET, V7, P47265, DOI 10.18632/oncotarget.10059	47	3	3	0	2	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUN	2018	214	6					907	913		10.1016/j.prp.2018.03.014			7	Pathology	Pathology	GM6ZF	WOS:000438326800017	29559247				2019-10-28	
J	Wang, DH; Marshall, D; Veldtman, G; Gupta, A; Trout, AT; Villafane, J; Bove, K				Wang, Dehua; Marshall, Darren; Veldtman, Gruschen; Gupta, Anita; Trout, Andrew T.; Villafane, Juan; Bove, Kevin			Intrahepatic cholangiocarcinoma after Fontan procedure in an adult with visceral heterotaxy	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Cholangiocarcinoma; Fontan palliation; Heterotaxy; Cholangiociliopathy; Atypical ductular proliferation; MYST3 mutation	HEPATOCELLULAR-CARCINOMA; BILE-DUCT; LIVER; OPERATION; PATHOLOGY; CIRRHOSIS; FEATURES	Hepatic dysfunction, including development of hepatocellular carcinoma and other liver lesions has been increasingly reported following Fontan procedure for congenital heart disease. We report a unique case of intrahepatic cholangiocarcinoma 28 years after a Fontan procedure in a 31year old female with heterotaxy syndrome. The subcapsular mass-forming tumor was composed of poorly differentiated tumor cells arranged in small vague glandular or slit-lumen nests, and focally fused or anastomosing large trabecular patterns within the prominent fibrotic stroma. The tumor cells with immunoreactivity to CK7, CK19, Cam5.2, COX2, EMA, BCL-2, MOC-31 and AE1/AE3, supported a diagnosis of intrahepatic cholangiocarcinoma. Focal atypical ductular proliferation within the background liver may represent a precursor lesion to this tumor. Dysmorphic cilia observed by electron microscopy examination in the background liver may suggest cholangiociliopathy in heterotaxy. MYST3 mutation at Q1388H detected in intrahepatic cholangiocarcinoma is reported for the first time.	[Wang, Dehua; Gupta, Anita; Bove, Kevin] Cincinnati Childrens Hosp Med Ctr, Div Pathol & Lab Med, Cincinnati, OH 45229 USA; [Marshall, Darren; Veldtman, Gruschen] Cincinnati Childrens Hosp Med Ctr, Cincinnati Adult Congenital Heart Dis Program, Cincinnati, OH 45229 USA; [Trout, Andrew T.] Cincinnati Childrens Hosp Med Ctr, Dept Radiol, Cincinnati, OH 45229 USA; [Villafane, Juan] Univ Kentucky, Dept Pediat, Louisville, KY 40202 USA	Wang, DH (reprint author), Cincinnati Childrens Hosp Med Ctr, Div Pathol & Lab Med, Cincinnati, OH 45229 USA.	Dehua.wang@cchmc.org		Villafane, Juan/0000-0003-2901-8338			Aishima S, 2015, J HEPATO-BIL-PAN SCI, V22, P94, DOI 10.1002/jhbp.154; Asrani SK, 2013, NEW ENGL J MED, V368, P1756, DOI 10.1056/NEJMc1214222; Baumhoer D, 2008, AM J CLIN PATHOL, V129, P899, DOI 10.1309/HCQWPWD50XHD2DW6; Chen J, 2016, CURR PROTEIN PEPT SC, V17, P411, DOI 10.2174/1389203717666160122120008; Eipel C, 2010, WORLD J GASTROENTERO, V16, P6046, DOI 10.3748/wjg.v16.i48.6046; Gewillig M, 2005, HEART, V91, P839, DOI 10.1136/hrt.2004.051789; Ghaferi AA, 2005, J THORAC CARDIOV SUR, V129, P1348, DOI 10.1016/j.jtcvs.2004.10.005; Jitta DJ, 2016, INT J CARDIOL, V206, P21, DOI 10.1016/j.ijcard.2015.12.033; Kan Zuxing, 2008, Semin Intervent Radiol, V25, P77, DOI 10.1055/s-2008-1076685; Lee KB, 2016, CLIN MOL HEPATOL, V22, P400, DOI 10.3350/cmh.2016.0105; Liau JY, 2014, MODERN PATHOL, V27, P1163, DOI 10.1038/modpathol.2013.241; Mansini A. P., 2017, BIOCH BIOPHYS ACTA; Martinez-Quintana E, 2017, REV ESP ENFERM DIG, V109, P373; Nakanuma Y, 2008, HEPATOL RES, V38, P325, DOI 10.1111/j.1872-034X.2007.00312.x; Nakanuma Y, 2010, WORLD J HEPATOL, V2, P419, DOI 10.4254/wjh.v2.i12.419; ORGAN BC, 1991, ARCH SURG-CHICAGO, V126, P1150; Pundi K, 2016, AM J CARDIOL, V117, P456, DOI 10.1016/j.amjcard.2015.11.014; Rychik J, 2012, PEDIATR CARDIOL, V33, P1001, DOI 10.1007/s00246-012-0315-7; Shapiro AJ, 2015, CARDIOL YOUNG, V25, P752, DOI 10.1017/S1047951114000912; Xu J, 2012, LIVER INT, V32, P1156, DOI 10.1111/j.1478-3231.2012.02783.x	20	3	3	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUN	2018	214	6					914	918		10.1016/j.prp.2018.03.016			5	Pathology	Pathology	GM6ZF	WOS:000438326800018	29559246				2019-10-28	
J	Li, WJ; Cooley, LD; August, K				Li, Weijie; Cooley, Linda D.; August, Keith			Juvenile myelomonocytic leukemia with t(3;5)(q25;q35), Auer rods and marked myelodysplasia	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Juvenile myelomonocytic leukemia; t(3;5); Auer rods; Myelodysplasia; 19q LOH	ACUTE MYELOID-LEUKEMIA; MUTATIONS; FUSION; GENE	Juvenile myelomonocytic leukemia (JMML) is a rare aggressive childhood leukemia characterized by an excess proliferation of cells of granulocytic and monocytic lineages. The WHO classifies JMML with the myelodysplastic/myeloproliferative neoplasms. Myelodysplasia in JMML is usually minimal to mild. Auer rods have never been reported in JMML. We present a 2-year-old boy with splenomegaly, leukocytosis, thrombocytopenia, anemia, and excess myeloblasts with easily seen Auer rods, and marked dysgranulopoiesis and dyserythropoiesis. Conventional cytogenetic analysis showed a sole abnormality of t(3;5)(q25;q35). Microarray analysis showed a terminal 21 Mb region of copy-neutral loss of heterozygosity on 19q. Disease-related somatic NRAS mutation was detected. This case represents an unusual JMML with Auer rods and marked myelodysplasia. These unusual histopathologic features may be related to the t(3;5)(q25;q35). A t(3;5) with variable breakpoints has been reported in a small proportion of acute myeloid leukemias and myelodysplastic syndromes. To our knowledge, this is the first JMML case reported with this translocation.	[Li, Weijie; Cooley, Linda D.] Univ Missouri Kansas City, Sch Med, Childrens Mercy Hosp, Dept Pathol & Lab Med, Kansas City, MO USA; [August, Keith] Univ Missouri Kansas City, Sch Med, Childrens Mercy Hosp, Div Hematol Oncol, Kansas City, MO USA	Li, WJ (reprint author), 2401 Gillham Rd, Kansas City, MO 64108 USA.	wli@cmh.edu	August, Keith/L-2805-2019; COOLEY, LINDA/R-6086-2019	Li, Weijie/0000-0003-4922-5473			Arber DA, 2003, HUM PATHOL, V34, P809, DOI 10.1016/S0046-8177(03)00251-X; Aypar U, 2014, J MOL DIAGN, V16, P527, DOI 10.1016/j.jmoldx.2014.05.004; Berger R, 2006, LEUKEMIA, V20, P319, DOI 10.1038/sj.leu.2404063; Chang TY, 2014, BLOOD, V124, P2487, DOI 10.1182/blood-2014-03-300319; Dumezy F, 2013, HAEMATOLOGICA, V98, pE52, DOI 10.3324/haematol.2012.082149; Grimwade D, 2010, BLOOD, V116, P354, DOI 10.1182/blood-2009-11-254441; Lim G, 2010, CANCER GENET CYTOGEN, V199, P101, DOI 10.1016/j.cancergencyto.2010.02.009; Locatelli F, 2015, BLOOD, V125, P1083, DOI 10.1182/blood-2014-08-550483; Niemeyer CM, 2010, NAT GENET, V42, P794, DOI 10.1038/ng.641; Swerdlow SH, 2008, WHO CLASSIFICATION T; Swerdlow SH, 2017, WHO CLASSIFICATION T; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Wouters BJ, 2007, LEUKEMIA, V21, P2382, DOI 10.1038/sj.leu.2404795; YonedaKato N, 1996, ONCOGENE, V12, P265; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	15	0	0	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUN	2018	214	6					919	923		10.1016/j.prp.2017.11.024			5	Pathology	Pathology	GM6ZF	WOS:000438326800019	29496305				2019-10-28	
J	Machado, I; Yoshida, A; Morales, MGN; Abrahao-Machado, LF; Navarro, S; Cruz, J; Lavernia, J; Parafioriti, A; Picci, P; Llombart-Bosch, A				Machado, Isidro; Yoshida, Akihiko; Nieto Morales, Maria Gema; Abrahao-Machado, Lucas Faria; Navarro, Samuel; Cruz, Julia; Lavernia, Javier; Parafioriti, Antonina; Picci, Piero; Llombart-Bosch, Antonio			Review with novel markers facilitates precise categorization of 41 cases of diagnostically challenging, "undifferentiated small round cell tumors". A clinicopathologic, immunophenotypic and molecular analysis	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Review						Undifferentiated small round cell tumors; Ewing sarcoma; Histopathology; Immunohistochemistry; Fish; Molecular biology	EWING-LIKE-SARCOMA; CIC-FOXO4 GENE FUSION; IMMUNOHISTOCHEMICAL MARKER; BCOR; EXPRESSION; CHILDREN; VARIANT; REARRANGEMENTS; DIVERSITY; FEATURES	Background: Despite extensive immunohistochemical (IHC) and molecular studies combined with morphologic findings, a group of round/ovoid cell tumors histologically similar to Ewing sarcomas (ES) but lacking EWSR1-rearrangements may remain unclassifiable. Design: We retrospectively analyzed 41 Ewing-like tumors (formalin-fixed, paraffin-embedded) previously determined as negative or non-informative for EWSR1-rearrangements by FISH and/or RT-PCR. A new histopathology revision and additional IHC and molecular analyses were carried out in order to investigate whether additional IHC and/or molecular testing in combination with the morphological findings may help in reaching a definitive diagnosis. Results: Almost all the tumors (n = 40) involved soft tissue and/or bone and half the patients died of disease. In the archival cases all diagnoses were Ewing sarcoma (ES), Ewing-like sarcoma (ELS), myoepithelial tumor and undifferentiated sarcoma (US). In the new review all the tumors were re-classified as, ES (n = 16), Ewing-like tumor with EWSR1 rearrangement and amplification and possible EWSR1-NFATC2 gene fusion (n = 1), CIC-rearranged sarcomas or undifferentiated sarcoma, most consistent with C/C-rearranged sarcoma (n = 7), sarcoma with BCOR-alteration or undifferentiated sarcoma, consistent with BCOR-associated sarcoma (n = 3), neuroblastoma (n = 2), unclassifiable neoplasm with neuroblastic differentiation (n = 1), malignant rhabdoid tumor (n = 2), lymphoblastic lymphoma (n = 1), clear cell sarcoma of the gastrointestinal tract (n = 1), small cell carcinoma (n = 1), sclerosing rhabdomyosarcoma (n = 1), desmoplastic small round cell tumor (n = 1), malignant peripheral sheath nerve tumor (n = 1), poorly-differentiated synovial sarcoma (n = 1), Possible gastrointestinal stromal tumor/GIST with predominant round cells (n = 1) and possible SMARCA4-deficient-sarcoma (n = 1). NKX2.2, ETV4 and BCOR immunoreactivity was observed in all ES, CIC-rearranged sarcomas and sarcomas with BCOR alteration, respectively. CIC-rearrangement by FISH was observed in many of the CIC-rearranged sarcomas. Conclusion: Our analysis of 41 Ewing-like tumors confirms that there may be a significant pathological and IHC overlap among Ewing-like tumors, with prognostic and therapeutic impacts. Additional IHC (NKX2.2, ETV4 and BCOR) and molecular studies including FUS, CIC or BCOR analysis may support the final diagnosis when FISH or RT-PCR fail to detect EWSR1-rearrangements. Any molecular findings should always be interpreted in relation to the specific clinical and pathological context.	[Machado, Isidro; Cruz, Julia] Inst Valenciano Oncol, Dept Pathol, C Gregorio Gea 31, Valencia, Spain; [Yoshida, Akihiko] Natl Canc Ctr, Dept Pathol, Tokyo, Japan; [Yoshida, Akihiko] Natl Canc Ctr, Clin Labs, Tokyo, Japan; [Nieto Morales, Maria Gema] Univ Valencia, Dept Pathol, Mol Biol Lab, Valencia, Spain; [Abrahao-Machado, Lucas Faria] Hosp Canc Barretos, Dept Patol & Diagnost Mol, Sao Paulo, Brazil; [Navarro, Samuel; Llombart-Bosch, Antonio] Univ Valencia, Dept Pathol, Valencia, Spain; [Lavernia, Javier] Inst Valenciano Oncol, Med Oncol, Valencia, Spain; [Parafioriti, Antonina] ASST Ctr Specialist Ortoped Traumatol Gaetano PIN, Dept Pathol, Milan, Italy; [Picci, Piero] Rizzoli Orthoped Inst, Lab Expt Pathol, Bologna, Italy	Machado, I (reprint author), Inst Valenciano Oncol, Dept Pathol, C Gregorio Gea 31, Valencia, Spain.	isidro.machado@uv.es		Parafioriti, Antonina/0000-0002-4091-1541	JSPSMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [15K19065]	The authors thank David Harrison for the English review and editing of the manuscript. The authors also thanks Laura Martinez, Sachiko Miura, Toshiko Sakaguchi, Chizu Kina, and Susumu Wakai for their technical assistance. The study was supported in part by JSPS Grant-in-Aid for Young Scientists (15K19065, AY)".	Antonescu CR, 2017, AM J SURG PATHOL, V41, P941, DOI 10.1097/PAS.0000000000000846; Bovee JVMG, 2010, VIRCHOWS ARCH, V456, P193, DOI 10.1007/s00428-009-0828-5; Charville GW, 2017, MODERN PATHOL, DOI [10.1038/modpathol.2017.49, DOI 10.1038/MODPATHOL.2017.49.]; Chiang S, 2017, MODERN PATHOL, V30, P1251, DOI 10.1038/modpathol.2017.42; Cohen-Gogo S, 2014, PEDIATR BLOOD CANCER, V61, P2191, DOI 10.1002/pbc.25210; de Alava Enrique, 2017, Surg Pathol Clin, V10, P575, DOI 10.1016/j.path.2017.04.001; Fisher C, 2014, HISTOPATHOLOGY, V64, P134, DOI 10.1111/his.12269; Folpe AL, 2005, AM J SURG PATHOL, V29, P1025; Folpe AL, 2000, AM J SURG PATHOL, V24, P1657, DOI 10.1097/00000478-200012000-00010; Godkhindi VM, 2016, J CLIN DIAGN RES, V10, pED1, DOI 10.7860/JCDR/2016/20237.9080; Hung YP, 2017, HISTOPATHOLOGY, V71, P786, DOI 10.1111/his.13288; Ito J, 2016, HUM PATHOL, V47, P32, DOI 10.1016/j.humpath.2015.09.010; Kao YC, 2017, GENE CHROMOSOME CANC, V56, P296, DOI 10.1002/gcc.22435; Kao YC, 2016, AM J SURG PATHOL, V40, P1670, DOI 10.1097/PAS.0000000000000697; Kao YC, 2016, AM J SURG PATHOL, V40, P1009, DOI 10.1097/PAS.0000000000000629; Kinkor Zdenek, 2014, Cesk Patol, V50, P87; Kreiger PA, 2009, MODERN PATHOL, V22, P142, DOI 10.1038/modpathol.2008.185; Le Loarer Francois, 2017, Surg Pathol Clin, V10, P587, DOI 10.1016/j.path.2017.04.002; Ludwig K, 2017, PEDIATR DEVEL PATHOL, V20, P321, DOI 10.1177/1093526617698263; Machado I, 2016, ANN DIAGN PATHOL, V22, P25, DOI 10.1016/j.anndiagpath.2016.03.002; Magro G, 2017, HUM PATHOL, V60, P58, DOI 10.1016/j.humpath.2016.07.038; Marzano Ettore, 2009, HPB Surg, V2009, P628206, DOI 10.1155/2009/628206; McCuiston A, 2017, HEAD NECK PATHOL, DOI [10.1007/s12105-017-0830-1, DOI 10.1007/S12105-017-0830-1.]; Peters TL, 2015, MODERN PATHOL, V28, P575, DOI 10.1038/modpathol.2014.139; Puls F, 2014, AM J SURG PATHOL, V38, P1307, DOI 10.1097/PAS.0000000000000223; Rooper LM, 2017, APPL IMMUNOHISTO M M, DOI [10.1097/PAI, DOI 10.1097/PAI.]; Sadri N, 2014, VIRCHOWS ARCH, V465, P233, DOI 10.1007/s00428-014-1613-7; Shibayama T, 2015, PATHOL INT, V65, P410, DOI 10.1111/pin.12319; Siegele B, 2017, AM J SURG PATHOL, V41, P423, DOI 10.1097/PAS.0000000000000772; Solomon DA, 2014, AM J SURG PATHOL, V38, P1724, DOI 10.1097/PAS.0000000000000335; Sugita S, 2014, AM J SURG PATHOL, V38, P1571, DOI 10.1097/PAS.0000000000000286; Szuhai K, 2009, CLIN CANCER RES, V15, P2259, DOI 10.1158/1078-0432.CCR-08-2184; Wang WL, 2017, VIRCHOWS ARCH, V470, P371, DOI 10.1007/s00428-017-2080-8; Wang X J, 2017, Zhonghua Bing Li Xue Za Zhi, V46, P102, DOI 10.3760/cma.j.issn.0529-5807.2017.02.008; Yang M, 2014, INT J CLIN EXP PATHO, V7, P2411; Yoshida A, 2017, HISTOPATHOLOGY, V71, P461, DOI 10.1111/his.13252; Yoshida A, 2016, AM J SURG PATHOL, V40, P313, DOI 10.1097/PAS.0000000000000570; Yoshida A, 2012, AM J SURG PATHOL, V36, P993, DOI 10.1097/PAS.0b013e31824ee43c	38	7	9	3	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						1	12		10.1016/j.anndiagpath.2017.11.011			12	Pathology	Pathology	GL1VO	WOS:000436900200001	29661713				2019-10-28	
J	de Souza, MF; Araujo, ALCD; da Silva, MT; Athanazio, DA				de Souza, Maiara Ferreira; Cardoso de Azevedo Araujo, Andre Luis; da Silva, Mariana Trindade; Athanazio, Daniel Abensur			The Gleason pattern 4 in radical prostatectomy specimens in current practice - Quantification, morphology and concordance with biopsy	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Prostatic neoplasms; Pathology; Biopsy; Large-core Needle	ISUP CONSENSUS-CONFERENCE; 2014 INTERNATIONAL SOCIETY; GRADE TUMOR VOLUME; PROSTATIC-CARCINOMA; BIOCHEMICAL RECURRENCE; CRIBRIFORM PATTERN; CANCER; SCORE; PERCENTAGE; SYSTEM	Purpose: The upgrading of a prostate acinar adenocarcinoma grade group 1 (GG1) between needle biopsy and prostatectomy is common. The extent of high-grade tumor and cribriform morphology are currently suggested as prognostic factors. Methods: We reviewed 159 prostatectomy specimens from a private laboratory and an academic/public institution in Salvador, Bahia. Results: Tumors signed as GG1 at biopsy were upgraded in 59% of all cases. These tumors showed a low frequency of non-focal extraprostatic extension (one case, 3%), extensive positive surgical margins (two cases, 6%) and seminal vesicle invasion (one case, 3%). Among GG2 and GG3 tumors at prostatectomy, the percentage of Gleason pattern 4 (Gp4) involving the gland at <= 1%, 2-5% and > 5% was associated with extensive extraprostatic extension (9%, 8% and 42%, respectively) and seminal vesicle invasion (1%, 10% and 31%, respectively). The volume of Gp4 of <= 1 ml, > 1 to 2 ml and > 2 ml was associated with extensive extraprostatic extension (8%, 26% and 38%, respectively), seminal vesicle invasion (2%, 21% and 33%, respectively) and nonfocal positive surgical margins (12%, 26% and 29%, respectively). Some GG2 tumors (similar to 20%) indeed showed at least one measurement of Gp4 higher than one quarter of GG3 carcinomas. Cribriform morphology showed no significant associations for other adverse pathologic prognostic factors. Conclusion: Upgrading from GG1 to GG2 is associated with a very low frequency of morphologic features associated with poor prognosis. Routine quantification of Gp4 is feasible in radical prostatectomy products and seems to better stratify tumors regarding the association with other morphologic parameters of prognostic importance.	[de Souza, Maiara Ferreira; Cardoso de Azevedo Araujo, Andre Luis; da Silva, Mariana Trindade; Athanazio, Daniel Abensur] Univ Fed Bahia, Fac Med, Dept Pathol, Largo Terreiro Jesus S-N, BR-40025010 Salvador, BA, Brazil; [de Souza, Maiara Ferreira; Athanazio, Daniel Abensur] Hosp Univ Prof Edgard Santos, Rua Augusto Viana Sn, BR-40110060 Salvador, BA, Brazil	Athanazio, DA (reprint author), Univ Fed Bahia, Fac Med Bahia, Dept Patol & Med Legal, Praca 15 Novembro S-N, BR-40025010 Salvador, BA, Brazil.	daa@ufba.br					Albertsen PC, 2005, JAMA-J AM MED ASSOC, V293, P2095, DOI 10.1001/jama.293.17.2095; Arias-Stella JA, 2015, AM J SURG PATHOL, V39, P1213, DOI 10.1097/PAS.0000000000000499; Athanazio D, 2017, HISTOPATHOLOGY, V70, P1098, DOI 10.1111/his.13179; Billis Athanase, 2004, International Urology and Nephrology, V36, P363, DOI 10.1007/s11255-004-0922-1; Cheng L, 2007, CANCER, V110, P1967, DOI 10.1002/cncr.23004; Chun FKH, 2007, EUR J CANCER, V43, P536, DOI 10.1016/j.ejca.2006.10.018; Danneman D, 2017, BJU INT, V119, P50, DOI 10.1111/bju.13458; Deng FM, 2016, EUR UROL, V70, P248, DOI 10.1016/j.eururo.2015.10.026; Dong F, 2013, AM J SURG PATHOL, V37, P1855, DOI 10.1097/PAS.0b013e3182a02169; Epstein JI, 2005, AM J SURG PATHOL, V29, P1228, DOI 10.1097/01.pas.0000173646.99337.b1; Epstein JI, 2017, AM J SURG PATHOL, V41, pE1, DOI 10.1097/PAS.0000000000000820; Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530; Epstein JI, 2012, EUR UROL, V61, P1019, DOI 10.1016/j.eururo.2012.01.050; Fadul LC, 2016, PATHOL RES PRACT, V212, P217, DOI 10.1016/j.prp.2015.12.014; Athanazio PRF, 2014, PATHOL RES PRACT, V210, P312, DOI 10.1016/j.prp.2014.02.002; Gordetsky J, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0478-2; Hansen J, 2014, BJU INT, V113, P399, DOI 10.1111/bju.12424; Humphrey PA, 2016, WHO CLASSIFICATION T, P138; Keefe DT, 2015, VIRCHOWS ARCH, V467, P437, DOI 10.1007/s00428-015-1809-5; Kweldam CF, 2017, MODERN PATHOL, V30, P1126, DOI 10.1038/modpathol.2017.29; Kweldam CF, 2015, MODERN PATHOL, V28, P457, DOI 10.1038/modpathol.2014.116; Kwon O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109031; Qian JQ, 1997, MODERN PATHOL, V10, P1113; Samaratunga H, 2015, PATHOLOGY, V47, P515, DOI 10.1097/PAT.0000000000000315	24	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						13	17		10.1016/j.anndiagpath.2017.12.005			5	Pathology	Pathology	GL1VO	WOS:000436900200002	29661718				2019-10-28	
J	Syring, I; Weiten, R; Muller, T; Schmidt, D; Steiner, S; Muller, SC; Kristiansen, G; Ellinger, J				Syring, Isabella; Weiten, Richard; Mueller, Tim; Schmidt, Doris; Steiner, Susanne; Mueller, Stefan C.; Kristiansen, Glen; Ellinger, Joerg			The knockdown of the mediator complex subunit MED30 suppresses the proliferation and migration of renal cell carcinoma cells	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Mediator complex subunit MED30; Renal cell carcinoma; Proliferation; Migration	PROSTATE-CANCER; ERG REARRANGEMENT; TRANSCRIPTIONAL REGULATION; VHL GENE; THERAPIES; FREQUENCY; MED15	Background: The mediator complex consists of 33 subunits and plays a central role in transcription. Studies have already described the involvement of individual subunits, especially in carcinogenesis. With regard to the subunit MED30, this has, so far, only been confirmed in gastric and breast carcinoma. The role of MED30 in urological tumours is unknown. Materials and methods: First, a database analysis using cBioPortal was performed for the mRNA expression and survival analysis of MED30 in clear cell renal cell carcinoma (ccRCC) and papillary RCC (pRCC). The immunohistochemical analysis (IHC) against MED30 was performed on tissue microarrays (TMA), with benign, ccRCC, pRCC samples, and ccRCC-metastases. Intensity evaluation was performed using the IRS (Immunoreactive Score). The ccRCC cell lines ACHN and A-498 were used for the functional investigation of proliferation, migration, and invasion after the knockdown of MED30 by siRNA. Results: In a database analysis by cBioPortal, it was shown that mRNA overexpression of MED30 in the pRCC was significantly associated with a poorer overall survival and progression-free survival. In the IHC, pRCC showed the highest level of MED30 expression, unfortunately without significant results in the survival analysis. The knockdown of MED30 resulted in a significant decrease in proliferation, migration, and invasion in ccRCC. Conclusion: In summary, MED30 seems to be involved in the progression of the RCC.	[Syring, Isabella; Weiten, Richard; Schmidt, Doris; Mueller, Stefan C.; Ellinger, Joerg] Univ Hosp Bonn, Clin Urol & Paediat Urol, Sigmund Freud Str 25, D-53127 Bonn, Germany; [Mueller, Tim; Steiner, Susanne; Kristiansen, Glen] Univ Hosp Bonn, Inst Pathol, Sigmund Freud Str 25, D-53127 Bonn, Germany	Syring, I (reprint author), Univ Hosp Bonn, Clin Urol & Paediat Urol, Sigmund Freud Str 25, D-53127 Bonn, Germany.	isabella.syring@ukbonn.de; s4riweit@uni-bonn.de; tim.mueller@ukbonn.de; doris.schmidt@ukbonn.de; susanne.steiner@ukbonn.de; stefan.mueller@ukbonn.de; glen.kristiansen@ukbonn.de; joerg.ellinger@ukb.uni-bonn.de			Ferdinand Eisenberger-Fellowship of the German Society of Urology (DGU) [SYI1/FE-13]; Maria von Linden-Program of the University of Bonn	The study was supported by the Ferdinand Eisenberger-Fellowship of the German Society of Urology (DGU) (SYI1/FE-13), and the Maria von Linden-Program of the University of Bonn for IS.	Ansari SA, 2013, CELL MOL LIFE SCI, V70, P2743, DOI 10.1007/s00018-013-1265-9; Arai E, 2014, INT J CANCER, V135, P1330, DOI 10.1002/ijc.28768; Boube M, 2002, CELL, V110, P143, DOI 10.1016/S0092-8674(02)00830-9; Bragelmann J, 2017, CLIN CANCER RES, V23, P1829, DOI 10.1158/1078-0432.CCR-16-0094; Braun M, 2011, HISTOPATHOLOGY, V58, P1028, DOI 10.1111/j.1365-2559.2011.03862.x; Casamassimi A, 2007, BIOCHIMIE, V89, P1439, DOI 10.1016/j.biochi.2007.08.002; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cowey CL, 2009, CURR ONCOL REP, V11, P94, DOI 10.1007/s11912-009-0015-5; Dabestani S, 2016, CURR OPIN UROL, V26, P566, DOI 10.1097/MOU.0000000000000330; Duran I, 2017, TARGET ONCOL, V12, P19, DOI 10.1007/s11523-016-0463-4; Gao J., 2013, SCI SIGNAL, V6, P269, DOI DOI 10.1126/SCISIGNAL.2004088; Hasegawa N, 2012, MOL CELL BIOL, V32, P1483, DOI 10.1128/MCB.05245-11; Klumper N, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0398-6; Kondo K, 2002, GENE CHROMOSOME CANC, V34, P58, DOI 10.1002/gcc.10054; Lee YJ, 2015, PLOS ONE, V10; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Napoli C, 2012, BIOCHIMIE, V94, P579, DOI 10.1016/j.biochi.2011.09.016; Offermann A, 2017, ONCOTARGET, V8, P7964, DOI 10.18632/oncotarget.13860; REMMELE W, 1987, PATHOLOGE, V8, P138; Robert Koch Institut, 2015, ZENTR KREBSR GES BUN; Scheble VJ, 2010, MODERN PATHOL, V23, P1061, DOI 10.1038/modpathol.2010.87; Scheble VJ, 2010, HISTOPATHOLOGY, V56, P937, DOI 10.1111/j.1365-2559.2010.03564.x; Shaikhibrahim Z, 2014, INT J CANCER, V135, P19, DOI 10.1002/ijc.28647; Stadler WM, 2011, J CLIN ONCOL, V29, P3443, DOI 10.1200/JCO.2010.34.4028; Syring I, 2016, ONCOTARGET, V7, P23043, DOI 10.18632/oncotarget.8469; Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136; Zhao H, 2016, CELL, V11, P1	27	1	1	1	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						18	26		10.1016/j.anndiagpath.2017.12.008			9	Pathology	Pathology	GL1VO	WOS:000436900200003	29661722				2019-10-28	
J	Guarch, R; Lawrie, CH; Larrinaga, G; Angulo, JC; Pulido, R; Lopez, JI				Guarch, Rosa; Lawrie, Charles H.; Larrinaga, Gorka; Angulo, Javier C.; Pulido, Rafael; Lopez, Jose, I			High levels of intratumor heterogeneity characterize the expression of epithelial-mesenchymal transition markers in high-grade clear cell renal cell carcinoma	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Clear cell renal cell carcinoma; Intratumor heterogeneity; Immunohistochemistry; Epithelial-mesenchymal transition; Multi-site tumor sampling	INTERNATIONAL-SOCIETY; CANCER MEDICINE; EVOLUTION	Immunohistochemistry is a basic routine in establishing the diagnosis of many tumors. However, immunomarkers are often irregularly distributed across different regions of the same tumor, alternating positive and negative areas without any apparent 'cause. Full identification of this type of intratumor heterogeneity is crucial for patients since the expression of many markers is linked to the prognosis and/or treatment of some tumors. We have quantified this variability testing 406 tumor samples from eight clear cell renal cell carcinomas using four epithelial-mesenchymal transition markers (vimentin, ZEB 1, beta-catenin, and E-cadherin) and two different sampling protocols. Routine sampling included an amount of 59 samples (average, 7.3 samples/case) and multisite tumor sampling did a total of 347 samples (average, 43.3 samples/case). High variability of immunostaining was detected with E-cadherin and ZEB-1 in all high-grade cases. Irregular patterns of expression were detected in all tumors including all histologically homogeneous low-grade tumors. Multisite tumor sampling protocol detected a significant decreased number of E-cadherin, beta-catenin and ZEB-1 positive samples in high-grade tumors. We conclude that high levels of intratumor heterogeneity characterize the immunohistochemical expression of epithelial-mesenchymal transition markers in high-grade clear cell renal cell carcinomas. Multisite tumor sampling protocol outperforms routine sampling in detecting immunohistochemical intratumor heterogeneity.	[Guarch, Rosa] Complejo Hosp B Navarra, Dept Pathol, Navarra, Spain; [Lawrie, Charles H.] Biodonostia Res Inst, Oncohematol Unit, Donostia San Sebastian, Spain; [Lawrie, Charles H.; Larrinaga, Gorka] Univ Basque Country, UPV EHU, Dept Physiol, Leioa, Spain; [Lawrie, Charles H.] Univ Oxford, Nuffield Dept Clin Lab Sci, Oxford, England; [Lawrie, Charles H.; Pulido, Rafael] IKERBASQUE, Basque Fdn Sci, Bilbao, Spain; [Larrinaga, Gorka] Univ Basque Country, UPV EHU, Dept Nursing 1, Leioa, Spain; [Larrinaga, Gorka; Pulido, Rafael; Lopez, Jose, I] Biocruces Res Inst, Biomarkers Canc Unit, Baracaldo, Spain; [Angulo, Javier C.] Getafe Univ Hosp, Dept Urol, Madrid, Spain; [Angulo, Javier C.] Laureate Univ, Univ Europea Madrid, Fac Ciencias Biomed, Dept Clin, Madrid, Spain; [Pulido, Rafael] Univ Basque Country, UPV EHU, Dept Cellular Biol & Histol, Leioa, Spain; [Lopez, Jose, I] Univ Basque Country, UPV EHU, Cruces Univ Hosp, Dept Pathol, Baracaldo, Spain	Lopez, JI (reprint author), Hosp Univ Cruces, Dept Pathol, Plaza Cruces S-N, Baracaldo 48903, Bizkaia, Spain.	joseignacio.lopez@osakidetza.eus	Lopez, Jose Ignacio/L-3884-2019	Lopez, Jose Ignacio/0000-0003-0842-5348; Angulo, Javier/0000-0002-1735-8792	Ministerio de Economia y Competitividad (MINECO), Spain [SAF 2016-79847-R]	This work is supported by the grant SAF 2016-79847-R from Ministerio de Economia y Competitividad (MINECO), Spain.	Audenet F, 2012, BJU INT, V109, P1864, DOI 10.1111/j.1464-410X.2011.10661.x; Cai JQ, 2013, EXP THER MED, V6, P1489, DOI 10.3892/etm.2013.1345; Cortes JM, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00025; Delahunt B, 2013, AM J SURG PATHOL, V37, P1490, DOI 10.1097/PAS.0b013e318299f0fb; Fang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062558; Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891; Guarch Rosa, 2016, F1000Res, V5, P2020; Harada K, 2012, BJU INT, V110, pE1131, DOI 10.1111/j.1464-410X.2012.11297.x; Iacovelli R, 2015, EXPERT OPIN EMERG DR, V20, P379, DOI 10.1517/14728214.2015.1047761; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Lipinski KA, 2016, TRENDS CANCER, V2, P49, DOI 10.1016/j.trecan.2015.11.003; Lopez JI, 2012, BJU INT, DOI 10.1002/BJUIw-2012-091-web; Lopez JI, 2017, HUM PATHOL, V64, P1, DOI 10.1016/j.humpath.2017.02.010; Lopez Jose I, 2016, F1000Res, V5, P385, DOI 10.12688/f1000research.8196.1; Lopez JI, 2013, APMIS, V121, P1187, DOI 10.1111/apm.12073; Marcucci F, 2016, NAT REV DRUG DISCOV, V15, P311, DOI 10.1038/nrd.2015.13; Nassar A, 2010, APPL IMMUNOHISTO M M, V18, P433, DOI 10.1097/PAI.0b013e3181dddb20; Ohba K, 2014, INT J CLIN EXP PATHO, V7, P3158; Palsdottir HB, 2012, J UROLOGY, V187, P48, DOI 10.1016/j.juro.2011.09.025; Rasti A, 2018, CLIN EXP MED, V18, P177, DOI 10.1007/s10238-017-0481-2; Renovanz M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00142; Ricketts CJ, 2014, NAT GENET, V46, P214, DOI 10.1038/ng.2904; Sahai E, 2017, NAT REV CLIN ONCOL, V14, P709, DOI 10.1038/nrclinonc.2017.121; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Soultati A, 2015, CURR OPIN UROL, V25, P358, DOI 10.1097/MOU.0000000000000204; Trpkov K, 2013, AM J SURG PATHOL, V37, P1505, DOI 10.1097/PAS.0b013e31829a85d0; Venkatesan Subramanian, 2016, Am Soc Clin Oncol Educ Book, V35, pe141, DOI 10.14694/EDBK_158930; Verbiest A, 2017, CLIN GENITOURIN CANC, DOI 10.1016/j.dgc.2017.10.017; Zaldumbide L, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2237-x; Zaldumbide L, 2015, VIRCHOWS ARCH, V466, P61, DOI 10.1007/s00428-014-1673-8	30	3	3	2	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						27	30		10.1016/j.anndiagpath.2018.01.001			4	Pathology	Pathology	GL1VO	WOS:000436900200004	29661723				2019-10-28	
J	Mostafa, ME; Abdelkader, A; Kuroda, N; Perez-Montiel, D; Banerjee, A; Hes, O; Iczkowski, KA				Mostafa, Mohamed E.; Abdelkader, Amrou; Kuroda, Naoto; Perez-Montiel, Delia; Banerjee, Anjishnu; Hes, Ondrej; Iczkowski, Kenneth A.			Variation in nuclear size and PD-L2 positivity correlate with aggressive chromophobe renal cell carcinoma	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article; Proceedings Paper	107th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP)	MAR 17-23, 2018	Vancouver, CANADA	US & Canadian Acad Pathol		Renal cell carcinoma; Chromophobe; Nuclear size variation; PD-12; Prognosis	COMPARATIVE GENOMIC HYBRIDIZATION; PROGNOSTIC-SIGNIFICANCE; HISTOLOGIC SUBTYPES; GRADING SYSTEM; FEATURES; CLASSIFICATION; MULTICENTER; PARAMETERS; EXPERIENCE; SURVIVAL	Chromophobe renal cell carcinoma (CRCC) is not amenable to International Society for Urologic Pathology endorsed nucleolar grading. Novel grading approaches were proposed, but the rarity of adverse pathology hampers their discriminatory value. We investigate simple linear micrometer measurements and a proposed immunostain in CRCCs. 32 patients' CRCCs were studied: 12 adverse cases (stage pT3, recurrence, or metastasis), 15 controls (stage <= pT2, no recurrence or metastasis after > 3 years), and 8 metastases (3 were paired with primary adverse cases). The ratio of greatest dimensions of largest and smallest nuclei, in each of 5 "worst" high power fields, excluding those with degenerative features, was designated variation in nuclear size (VNS). Percent multinucleate cells (PMC) were also counted. Mouse anti PD-L2 monoclonal antibody immunostaining was performed. Mean VNS measured in adverse primary and control primary tumors were 3.7 +/- 0.5 and 2.4 +/- 0.4 respectively (P < .001), and 3.4 +/- 0.4 for metastases (P < .001). Optimal VNS cut-off was 2.5, with sensitivity and specificity 0.85 and 0.81, respectively. PMCs were 6.0 +/- 3.0 for adverse group, 5.7 +/- 2.7 for controls, and 4.1 +/- 1.6 for metastases (P = NS). PD-L2 could not discriminate adverse versus good primary tumors (chi(2)1.6, P = .2), but was higher in metastases (chi(2) 6.9, P < .01), or metastases plus adverse primary tumors (chi(2) 4.8, P = .03), compared to good-pathology primary tumors. In conclusion, VNS is an easily obtained measurement that can predict adverse behavior of chromophdbe RCC, and may impart value for needle biopsy reporting and the choice of active surveillance. PD-L2 was elevated in metastases but was less useful for primary tumors.	[Mostafa, Mohamed E.; Abdelkader, Amrou; Iczkowski, Kenneth A.] Med Coll Wisconsin, Dept Pathol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA; [Kuroda, Naoto] Kochi Red Cross Hosp, Dept Diagnost Pathol, Kochi, Kochi, Japan; [Perez-Montiel, Delia] Inst Nacl Cancerol, Dept Pathol, Mexico City, DF, Mexico; [Banerjee, Anjishnu] Med Coll Wisconsin, Dept Biostat, Milwaukee, WI 53226 USA; [Hes, Ondrej] Charles Univ Prague, Fac Med Plzen, Dept Pathol, Plzen, Czech Republic	Iczkowski, KA (reprint author), Med Coll Wisconsin, Dept Pathol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	kaiczkowski@mcw.edu		Abdelkader, Amrou/0000-0003-1886-1784			Amin MB, 2002, AM J SURG PATHOL, V26, P281, DOI 10.1097/00000478-200203000-00001; [Anonymous], 2013, ACTAS UROL ESP, V37, P338; Beck SDW, 2004, ANN SURG ONCOL, V11, P71, DOI 10.1245/ASO.2004.06.016; Brunelli M, 2015, MODERN PATHOL, V18, P161; Brunelli M, 2007, MODERN PATHOL, V20, P303, DOI 10.1038/modpathol.3800739; Cheville JC, 2003, AM J SURG PATHOL, V27, P612, DOI 10.1097/00000478-200305000-00005; Cheville JC, 2004, AM J SURG PATHOL, V28, P435, DOI 10.1097/00000478-200404000-00002; Cheville JC, 2012, AM J SURG PATHOL, V36, P851, DOI 10.1097/PAS.0b013e3182496895; CROTTY TB, 1995, J UROLOGY, V154, P964, DOI 10.1016/S0022-5347(01)66944-1; de Peralta-Venturina M, 2001, AM J SURG PATHOL, V25, P275, DOI 10.1097/00000478-200103000-00001; Delahunt B, 2007, AM J SURG PATHOL, V31, P957, DOI 10.1097/01.pas.0000249446.28713.53; Delahunt B, 2013, AM J SURG PATHOL, V37, P1490, DOI 10.1097/PAS.0b013e318299f0fb; Erlmeier F, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-0926-1; Erlmeier F, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0833-x; FUHRMAN SA, 1982, AM J SURG PATHOL, V6, P655, DOI 10.1097/00000478-198210000-00007; Gudbjartsson T, 2005, EUR UROL, V48, P593, DOI 10.1016/j.eururo.2005.04.016; Lee WK, 2010, INT J UROL, V17, P898, DOI 10.1111/j.1442-2042.2010.02630.x; Ljungberg B, 1999, EUR UROL, V36, P565, DOI 10.1159/000020049; Lohse CM, 2002, AM J CLIN PATHOL, V118, P877, DOI 10.1092/5PWP08HKHX0LY56L; Miller BL, 2017, UROLOGY, DOI [10.1016/j.urology.2017.09.016, DOI 10.1016/J.UROLOGY.2017.09.016.]; Moch H, 2000, CANCER, V89, P604, DOI 10.1002/1097-0142(20000801)89:3<604::AID-CNCR16>3.3.CO;2-H; Onishi T, 2002, BJU INT, V90, P529, DOI 10.1046/j.1464-410X.2002.02977.x; Paner GP, 2010, AM J SURG PATHOL, V34, P1233, DOI 10.1097/PAS.0b013e3181e96f2a; Patard JJ, 2005, J CLIN ONCOL, V23, P2763, DOI 10.1200/JCO.2005.07.055; Peckova K, 2015, ANN DIAGN PATHOL, V19, P261, DOI 10.1016/j.anndiagpath.2015.05.001; Ren Y, 2015, AM J TRANSL RES, V7, P2482; RO JY, 1987, CANCER, V59, P516, DOI 10.1002/1097-0142(19870201)59:3<516::AID-CNCR2820590327>3.0.CO;2-W; Sperga M, 2013, VIRCHOWS ARCH, V463, P563, DOI 10.1007/s00428-013-1457-6; THOENES W, 1985, VIRCHOWS ARCH B, V48, P207, DOI 10.1007/BF02890129; Weinzierl EP, 2014, KOREAN J UROL, V55, P39; Yusenko MV, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-152	31	0	0	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						31	35		10.1016/j.anndiagpath.2018.01.002			5	Pathology	Pathology	GL1VO	WOS:000436900200005	29661724				2019-10-28	
J	Nuovo, GJ; de Andrade, CV; Thirukkumaran, C; Nicol, AF				Nuovo, Gerard J.; de Andrade, Cecilia Vianna; Thirukkumaran, Chandini; Nicol, Alcina F.			Importin-beta and exportin-5 are indicators of acute viral infection: Correlation of their detection with commercially available detection kits	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Virus; Importin; Exportin; Background; Horseradish Peroxidase	NUCLEAR-PORE COMPLEX; MESSENGER-RNA; TRANSPORT; TRAFFICKING; ACTIVATION; APOPTOSIS; PATHWAY; TARGET; CANCER; RABIES	This work focused on immunohistochemistry markers of acute viral infections. Viral infected cells were detected by in situ based methods (reovirus, rabies virus) or cytologic changes (human papillomavirus, molloscum contagiosum virus, herpes simplex virus). Two proteins involved in nuclear trafficking, importin-beta and exportin-5, were detected in the infected cells for each virus and not in the control tissues. A wide variety of other proteins, including caspase-3, and bcl-2 family members (bcl2, bcIX, MCL1, BAK, BAX, BIM, BAD) showed wide variations in expression among the different viral infections. Specificity of the importin-beta and exportin-5 signals varied greatly with different commercially available peroxidase conjugates. It is concluded that immunohistochemistry detection of importin-beta and exportin-5 may be useful markers of acute viral infection, which suggests that increased nuclear trafficking may be an important concomitant of viral proliferation.	[Nuovo, Gerard J.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Nuovo, Gerard J.] Phylogeny Med Lab, Powell, OH USA; [de Andrade, Cecilia Vianna] Fiocruz MS, IFF, Fundacao Oswaldo Cruz, Inst Nacl Saude Mulher Crianca & Adolescente Fern, Rio De Janeiro, Brazil; [Thirukkumaran, Chandini] Univ Calgary, Tom Baker Canc Ctr, 1331,29th St NW, Calgary, AB, Canada; [Nicol, Alcina F.] IOC, Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, Brazil; [Nicol, Alcina F.] IOC, Lab Interdisciplinary Med Res LIPMED, Rio De Janeiro, Brazil	Nuovo, GJ (reprint author), Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.	nuovo.1@osu.edu			Alzheimer's disease Drug Discovery Foundation [20160204]	Alzheimer's disease Drug Discovery Foundation #20160204.	Chen JL, 2013, HEPATOLOGY, V57, P470, DOI 10.1002/hep.26064; Chung KM, 2000, J VIROL, V74, P5233, DOI 10.1128/JVI.74.11.5233-5241.2000; Faria PA, 2005, MOL CELL, V17, P93, DOI 10.1016/j.molcel.2004.11.023; Fraser JE, 2014, J INFECT DIS, V210, P1780, DOI 10.1093/infdis/jiu319; Gustin KE, 2001, EMBO J, V20, P240, DOI 10.1093/emboj/20.1.240; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Kamada S, 2005, J BIOL CHEM, V280, P857, DOI 10.1074/jbc.C400538200; Malik P, 2012, J BIOL CHEM, V287, P12277, DOI 10.1074/jbc.M111.331777; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; Mezache L, 2017, APPL IMMUNOHISTO M M, V25, P100, DOI 10.1097/PAI.0000000000000298; Nuovo G, 2006, ARCH PATHOL LAB MED, V130, P979; Nuovo G, 2016, ANN DIAGN PATHOL, V25, P54, DOI 10.1016/j.anndiagpath.2016.09.010; Nuovo GJ, 2012, MODERN PATHOL, V25, P1333, DOI 10.1038/modpathol.2012.95; Nuovo GJ, 2005, MODERN PATHOL, V18, P62, DOI 10.1038/modpathol.3800274; Nuovo GJ, 1995, J HISTOTECHNOL, V18, P295; Nuovo GJ, 1953, ANN DIAG PATHOL; Pumroy RA, 2015, BIOCHEM J, V466, P13, DOI 10.1042/BJ20141186; Rowe CL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150477; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Shigeyasu K, 2017, CLIN CANCER RES, V23, P1312, DOI 10.1158/1078-0432.CCR-16-1023; Suja MS, 2009, CLIN NEUROPATHOL, V28, P113; Thirukkumaran C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168233; Xu W, 2014, CELL HOST MICROBE, V16, P187, DOI 10.1016/j.chom.2014.07.008; Yasuhara N, 1997, GENES CELLS, V2, P55, DOI 10.1046/j.1365-2443.1997.1010302.x; Yuan J, 2010, CELL, V140, P384, DOI 10.1016/j.cell.2009.12.032	26	5	5	2	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						36	41		10.1016/j.anndiagpath.2018.01.003			6	Pathology	Pathology	GL1VO	WOS:000436900200006	29661725				2019-10-28	
J	Berry, D; Mahadevan, M; Wick, MR				Berry, Debra; Mahadevan, Mani; Wick, Mark R.			Detection of synchronous primary lung adenocarcinomas with genomic sequencing	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Lung cancer; Gene sequencing; Synchronous; Adenocarcinoma	GENE-MUTATIONS; CANCERS; HEAD	In the setting of synchronous pulmonary carcinomas, distinguishing between a monoclonal process with intrapulmonary metastasis and two independent tumors has significant therapeutic and prognostic implications. We describe two cases in which molecular profiling was used to characterize synchronous, primary pulmonary tumors and guide clinical management. In both cases, the patients underwent surgical resection without adjuvant chemotherapy or radiation and remain free of disease.	[Berry, Debra; Mahadevan, Mani; Wick, Mark R.] Univ Virginia Hlth Syst, Dept Pathol, POB 800214,1215 Lee St, Charlottesville, VA 22908 USA	Berry, D (reprint author), Univ Virginia Hlth Syst, Dept Pathol, POB 800214,1215 Lee St, Charlottesville, VA 22908 USA.	db5kf@hscmail.mcc.virginia.edu; msm8r@virginia.edu; mrw9c@hscmail.mcc.virginia.edu		Wick, Mark/0000-0002-6803-144X			Arai J, 2012, LUNG CANCER, V77, P281, DOI 10.1016/j.lungcan.2012.04.003; CHUNG KY, 1993, CANCER RES, V53, P1676; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gazdar AF, 2009, J NATL CANCER I, V101, P541, DOI 10.1093/jnci/djp059; Geurts TW, 2005, CLIN CANCER RES, V11, P6608, DOI 10.1158/1078-0432.CCR-05-0257; Horn L, 2014, HARRISONS PRINCIPLES; Okudela K, 2010, PATHOL INT, V60, P651, DOI 10.1111/j.1440-1827.2010.02580.x; Vega FJ, 1997, BRIT J CANCER, V76, P44, DOI 10.1038/bjc.1997.334; Wang XY, 2009, JNCI-J NATL CANCER I, V101, P560, DOI 10.1093/jnci/djp054; Warth A, 2012, EUR RESPIR J, V39, P1437, DOI 10.1183/09031936.00105911	10	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						42	44		10.1016/j.anndiagpath.2018.01.007			3	Pathology	Pathology	GL1VO	WOS:000436900200007	29661726				2019-10-28	
J	Karaarslan, S; Sen, N				Karaarslan, Serap; Sen, Nazime			Investigation of the relationship of Epstein-Barr virus with in situ hybridization in renal-cell carcinomas	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article							SYSTEMIC-LUPUS-ERYTHEMATOSUS; GASTRIC ADENOCARCINOMA; BREAST-CANCER; LYMPHOMA; INFECTION; NEPHRITIS; DISEASE		[Karaarslan, Serap] Private Buca Med Ctr, Pathol Dept, Izmir, Turkey; [Sen, Nazime] Private Tinaztepe Hosp, Microbiol Dept, Izmir, Turkey	Karaarslan, S (reprint author), TAPDI Buca Med Ctr, Dept Pathol, Kosuyolu Cad 506 Sk 2, TR-35100 Izmir, Turkey.	serapkaraarslan@gmail.com					Bematsky S, 2009, BEST PRACT RES CLIN, V23, P539; Bergstrom A, 2001, BRIT J CANCER, V85, P984, DOI 10.1038/sj.bjc.6692040; Bernatsky S, 2012, CURR OPIN RHEUMATOL, V24, P177, DOI 10.1097/BOR.0b013e32834ff258; Chan ACL, 1999, HISTOPATHOLOGY, V34, P16; Cohen JI, 2000, NEW ENGL J MED, V343, P481, DOI 10.1056/NEJM200008173430707; de Aquino PF, 2012, GENET MOL RES, V11, P4442, DOI 10.4238/2012.October.15.3; Delahunt B, 2015, SEMIN DIAGN PATHOL, V32, P90, DOI 10.1053/j.semdp.2015.02.002; Dobrowolski Z, 2002, EUR UROL, V42, P475, DOI 10.1016/S0302-2838(02)00400-1; EPSTEIN MA, 1964, LANCET, V1, P702; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hunt JD, 2005, INT J CANCER, V114, P101, DOI 10.1002/ijc.20618; Huo Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031656; Kang MJ, 2013, TRANSL ONCOL, V6, P282, DOI 10.1593/tlo.13256; Kishi N, 2013, CEN CASE REP, V2, P190, DOI 10.1007/s13730-013-0062-5; LABRECQUE LG, 1995, CANCER RES, V55, P39; Lin MH, 2003, LUPUS, V12, P486, DOI 10.1191/0961203303lu414cr; Lofstrom B, 2007, ANN RHEUM DIS, V66, P1627, DOI 10.1136/ard.2006.067108; Mansur A, 2011, NEPHRON CLIN PRACT, V119, pC293, DOI 10.1159/000329671; Mohammadizadeh F, 2014, ADV BIOMED RES, V3; Moore LE, 2005, CANCER INVEST, V23, P240, DOI 10.1081/CNV-200055962; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; NIEDOBITEK G, 1991, J PATHOL, V165, P17, DOI 10.1002/path.1711650105; PITTALUGA S, 1993, AM J SURG PATHOL, V17, P678, DOI 10.1097/00000478-199307000-00004; Salehipoor M, 2012, SAUDI J KIDNEY DIS T, V23, P53; SHIBATA D, 1992, AM J PATHOL, V140, P769; Shimakage M, 2007, ONCOL REP, V18, P41; Sokoloff MH, 1996, CA-CANCER J CLIN, V46, P284, DOI 10.3322/canjclin.46.5.284; Toussirot E, 2008, BEST PRACT RES CL RH, V22, P883, DOI 10.1016/j.berh.2008.09.007; WEISS LM, 1989, NEW ENGL J MED, V320, P502, DOI 10.1056/NEJM198902233200806; Wong KW, 2015, ONLINE BMJ CASE REP; Yahia ZA, 2014, INFECT AGENTS CANCER, V9, DOI 10.1186/1750-9378-9-9	31	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						45	49		10.1016/j.anndiagpath.2018.01.009			5	Pathology	Pathology	GL1VO	WOS:000436900200008	29661727				2019-10-28	
J	Bekers, EM; Eijkelenboom, A; Grunberg, K; Roverts, RC; de Rooy, JWJ; van der Geest, ICM; van Gorp, JM; Creytens, D; Flucke, U				Bekers, Elise M.; Eijkelenboom, Astrid; Grunberg, Katrien; Roverts, Rona C.; de Rooy, Jacky W. J.; van der Geest, Ingrid C. M.; van Gorp, Joost M.; Creytens, David; Flucke, Uta			Myositis ossificans - Another condition with USP6 rearrangement, providing evidence of a relationship with nodular fasciitis and aneurysmal bone cyst	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						USP6 rearrangement; Myositis ossificans; Soft tissue tumors	ONCOGENE	Myositis ossificans is defined as a self-limiting pseudotumor composed of reactive hypercellular fibrous tissue and bone. USP6 rearrangements have been identified as a consistent genetic driving event in aneurysmal bone cyst and nodular fasciitis. It is therefore an integral part of the diagnostic workup when dealing with (myo)fibroblastic lesions of soft tissue and bone. Two cases of myositis ossificans with USP6 rearrangement were published so far. We determine herein the incidence of USP6 rearrangement in myositis ossificans using USP6 fluorescence in situ hybridization analysis (FISH). Of the 11 cases included, seven patients were female and four were male. Age ranged from 6 to 56 years (mean 27 years). Lesions were located in the thigh (n = 5), knee (n = 1), lower leg (n = 1), lower arm (n = 1), perineum (n = 1), gluteal (n = 1) and thoracic wall (n = 1). All assessable cases except one (8/9) showed rearrangement of USP6 providing evidence that myositis ossificans is genetically related to nodular fasciitis and aneurysmal bone cyst.	[Bekers, Elise M.; Eijkelenboom, Astrid; Grunberg, Katrien; Roverts, Rona C.; Flucke, Uta] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, POB 9101, NL-6500 HB Nijmegen, Netherlands; [Bekers, Elise M.] Jeroen Bosch Hosp, Dept Pathol Pathol DNA, Den Bosch, Netherlands; [de Rooy, Jacky W. J.] Radboud Univ Nijmegen, Med Ctr, Dept Radiol & Nucl Med, Nijmegen, Netherlands; [van der Geest, Ingrid C. M.] Radboud Univ Nijmegen, Med Ctr, Dept Orthoped, Nijmegen, Netherlands; [van Gorp, Joost M.] Diakonessenhuis Utrecht, Dept Pathol Pathol DNA, Utrecht, Netherlands; [Creytens, David] Ghent Univ Hosp, Dept Pathol, Ghent, Belgium	Flucke, U (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Pathol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	uta.flucke@radboudumc.nl	Grunberg, Katrien/M-9715-2015	Grunberg, Katrien/0000-0003-1164-4365			Agaram NP, 2014, HUM PATHOL, V45, P1147, DOI 10.1016/j.humpath.2014.01.020; Amary MF, 2013, VIRCHOWS ARCH, V463, P97, DOI 10.1007/s00428-013-1418-0; Carter JM, 2016, MODERN PATHOL, V29, P865, DOI 10.1038/modpathol.2016.83; Erickson-Johnson MR, 2011, LAB INVEST, V91, P1427, DOI 10.1038/labinvest.2011.118; Guseva NV, 2017, GENE CHROMOSOME CANC, V56, P266, DOI 10.1002/gcc.22432; Lazar A., 2013, WHO CLASSIFICATION T, P46; Li HR, 2017, HUM PATHOL; Li LS, 2018, MOL CELL BIOL, V38, DOI 10.1128/MCB.00320-17; Madan B, 2016, P NATL ACAD SCI USA, V113, pE2945, DOI 10.1073/pnas.1605691113; Nielsen GP, 2013, WHO CLASSIFICATION T, P348; Oliveira AM, 2004, CANCER RES, V64, P1920, DOI 10.1158/0008-5472.CAN-03-2827; Oliveira AM, 2014, HUM PATHOL, V45, P1, DOI 10.1016/j.humpath.2013.03.005; Patel NR, 2017, MODERN PATHOL, V30, P1577, DOI 10.1038/modpathol.2017.78; Quick L, 2016, CANCER RES, V76, P5337, DOI 10.1158/0008-5472.CAN-15-2391; Rosenberg AE, 2013, WHO CLASSIFICATION T, P50; Rosenberg AE, 2008, ARCH PATHOL LAB MED, V132, P579, DOI 10.1043/1543-2165(2008)132[579:POST]2.0.CO;2; Sukov WR, 2008, SKELETAL RADIOL, V37, P321, DOI 10.1007/s00256-007-0442-z; Taylor WJ, 1903, ANN SURG, V37, P825	18	10	10	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						56	59		10.1016/j.anndiagpath.2018.01.006			4	Pathology	Pathology	GL1VO	WOS:000436900200010	29661729	Other Gold, Green Published			2019-10-28	
J	Cao, C; Feng, J; Gu, HT; Tang, HL; Xu, LJ; Dong, HJ; Dong, BX; Shu, MM; Bai, QX; Liang, R; Zhang, T; Yang, L; Wang, Z; Chen, XQ; Gao, GX				Cao, Chun; Feng, Juan; Gu, Hongtao; Tang, Hailong; Xu, Li; Dong, Hongjuan; Dong, Baoxia; Shu, Mimi; Bai, Qingxian; Liang, Rong; Zhang, Tao; Yang, Lan; Wang, Zhe; Chen, Xiequn; Gao, Guangxun			Distribution of lymphoid neoplasms in Northwest China: Analysis of 3244 cases according to WHO classification in a single institution	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Lymphoid neoplasms; Distribution; Northwest China; WHO classification	HEALTH-ORGANIZATION CLASSIFICATION; NON-HODGKINS-LYMPHOMA; MALIGNANT-LYMPHOMA; CANCER STATISTICS; CELL LYMPHOMA; UNITED-STATES; SUBTYPE; EPIDEMIOLOGY; REGISTRY; NHL	To explore the distribution of lymphoid neoplasms in Northwest China, the clinical and pathological data of lymphoma patients from 2006 to 2014 were analyzed according to the WHO classification in Xijing Hospital. Of the 3244 cases, mature B-cell neoplasms occupied 60.7%, while mature T/NK-cell neoplasms and Hodgkin's lymphomas (HL) occupied 26.2% and 8.1%, respectively. The most common subtype of lymphoma was diffuse large B-cell lymphoma (35.0%), followed by extranodal NK/T-cell lymphoma, nasal type (ENKTCL) (12.9%) and marginal zone B-cell lymphoma (7.8%). Mixed cellularity (34.0%) was the most common subtype of HL. The especially high proportion of ENKTCL was the most outstanding feature of our study in comparison to previous reports. The mean age of all lymphoid neoplasms cases was 51 years and most subtypes showed male predominance, with an average male-female ratio of 1.6. Extranodal lymphomas took up about 60% of all cases and gastrointestinal tract was the most frequently involved site. In conclusion, the distribution of lymphoid neoplasms of Northwest China showed some features similar to previous reports of China and other countries, but some subtypes presented distinct features.	[Cao, Chun; Feng, Juan; Gu, Hongtao; Tang, Hailong; Xu, Li; Dong, Hongjuan; Dong, Baoxia; Shu, Mimi; Bai, Qingxian; Liang, Rong; Zhang, Tao; Yang, Lan; Chen, Xiequn; Gao, Guangxun] Fourth Mil Med Univ, Xijing Hosp, Peoples Liberat Army Ctr Hematol Disorders, Dept Hematol, Xian 710032, Shaanxi, Peoples R China; [Wang, Zhe] Fourth Mil Med Univ, Xijing Hosp, Dept Pathol, Xian 710032, Shaanxi, Peoples R China	Wang, Z (reprint author), Xijing Hosp, Dept Pathol, 17 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.; Chen, XQ; Gao, GX (reprint author), Xijing Hosp, Dept Hematol, 17 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.	zhwang@fmmu.edu.cn; xiequnchen@fmmu.edu.cn; gaoguangxun@fmmu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [30900639]; Shaanxi Province Natural Science Foundation of ChinaNational Natural Science Foundation of China [2014JM2-816]	This work was supported by the National Natural Science Foundation of China [grant numbers 30900639] and Shaanxi Province Natural Science Foundation of China [grant numbers 2014JM2-816].	AI-Hamadani M, 2015, AM J HEMATOL, V90, P790; Anderson JR, 1998, ANN ONCOL, V9, P717, DOI 10.1023/A:1008265532487; [Anonymous], 2008, IARC SCI PUBL, VIX, P1, DOI DOI 10.1007/978-3-642-85851-2; Aoki R, 2008, PATHOL INT, V58, P174, DOI 10.1111/j.1440-1827.2007.02207.x; Armstrong AA, 1998, LEUKEMIA, V12, P1272, DOI 10.1038/sj.leu.2401097; Bray F, 2015, INT J CANCER, V137, P2060, DOI 10.1002/ijc.29670; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chen WL, 2010, ANN HEMATOL, V89, P553, DOI 10.1007/s00277-009-0870-z; Daniel Carreon J, 2008, CANCER CAUSE CONTROL, V19, P1171, DOI 10.1007/s10552-008-9184-z; Gross SA, 2008, INT J HEMATOL, V88, P165, DOI 10.1007/s12185-008-0132-1; HARRIS NL, 1994, BLOOD, V84, P1361; Jaffe ES, 2001, PATHOLOGY GENETICS T; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]; Krol ADG, 2003, ANN ONCOL, V14, P131, DOI 10.1093/annonc/mdg004; Luminari S, 2007, HEMATOL ONCOL, V25, P189, DOI 10.1002/hon.826; Morton LM, 2007, BLOOD, V110, P695, DOI 10.1182/blood-2006-11-051672; Morton LM, 2006, BLOOD, V107, P265, DOI 10.1182/blood-2005-06-2508; Muller AMS, 2005, ANN HEMATOL, V84, P1, DOI 10.1007/s00277-004-0939-7; Naresh KN, 2000, ANN ONCOL, V11, P63, DOI 10.1023/A:1008325827059; Sant M, 2010, BLOOD, V116, P3724, DOI 10.1182/blood-2010-05-282632; Sukpanichnant S, 2004, HUM PATHOL, V35, P224, DOI 10.1016/j.humpath.2003.10.007; Sun J, 2012, AM J CLIN PATHOL, V138, P429, DOI 10.1309/AJCP7YLTQPUSDQ5C; Swerdlow SH, 2008, WHO CLASSIFICATION T; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Thieblemont C, 2007, J CLIN ONCOL, V25, P1916, DOI 10.1200/JCO.2006.10.5957; Vose JM, 2008, J CLIN ONCOL, V26, P4124, DOI 10.1200/JCO.2008.16.4558; Xu JX, 2007, INT J CANCER, V120, P406, DOI 10.1002/ijc.22313; Yang QP, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-77; Yoon SO, 2010, AM J HEMATOL, V85, P760, DOI 10.1002/ajh.21824	29	0	0	2	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						60	65		10.1016/j.anndiagpath.2017.05.005			6	Pathology	Pathology	GL1VO	WOS:000436900200011	29661730				2019-10-28	
J	Pereira, JD; Nobrega, FJD; Vasconcelos, RG; Camara, ACDM; de Souza, LB; Queiroz, LMG				Pereira, Joabe dos Santos; de Oliveira Nobrega, Fernando Jose; Vasconcelos, Rodrigo Gadelha; de Souza Martins Camara, Adriana Costa; de Souza, Lelia Batista; Guedes Queiroz, Lelia Maria			Myofibroblasts and mast cells: influences on biological behavior of odontogenic lesions	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Myofibroblasts; Mast cells; Dentigerous cyst; Odontogenic keratocysts; Ameloblastomas	STROMAL FIBROBLASTS; DENTIGEROUS CYSTS; DIFFERENTIATION; EXPRESSION; CARCINOMA; CANCER; TUMORS; ANGIOGENESIS; CONTRACTION; FIBROSIS	Odontogenic lesions differ in their rate of recurrence and aggressiveness. This study aimed to evaluate the presence of myofibroblasts and mast cells in odontogenic lesions. Sample consisted of 20 cases each of dentigerous cysts, odontogenic keratocysts, and solid ameloblastomas. Histologic sections were submitted to immunohistochemistry using anti-alpha-smooth muscle actin and anti-tryptase antibodies. Myofibroblasts and mast cells were counted at x400 magnification in 5 and 10 fields, respectively. Myofibroblasts were more frequent in ameloblastomas (24.41), followed by odontogenic keratocysts (16.21) and dentigerous cysts (11.85; P = .002). Granulated and degranulated mast cells were more frequent in dentigerous cysts (7.88 and 8.96, respectively), followed by odontogenic keratocysts (6.53 and 7.08) and ameloblastomas (5.21 and 1.88). The difference was only significant for degranulated mast cells (P < .05). Analysis of the correlation between myofibroblasts and mast cells (granulated and degranulated) revealed a moderate positive correlation only in ameloblastomas (R = 0.621, P = .003). Probably, myofibroblasts are related to the biological behavior of the odontogenic lesions studied, particularly their aggressiveness. On the other hand, mast cells seem to be associated with inflammatory processes, which are more frequent in cystic lesions than in benign neoplasms. In addition, mast cells may induce the differentiation of fibroblasts into myofibroblasts, thus increasing the number of the latter. (C) 2016 Elsevier Inc. All rights reserved.	[Pereira, Joabe dos Santos; de Oliveira Nobrega, Fernando Jose; Vasconcelos, Rodrigo Gadelha; de Souza Martins Camara, Adriana Costa; de Souza, Lelia Batista; Guedes Queiroz, Lelia Maria] Univ Fed Rio Grande do Norte, Dept Dent, Postgra Program Oral Pathol, Av Senador Salgado Filho 1787, BR-59056000 Natal, RN, Brazil	Queiroz, LMG (reprint author), Univ Fed Rio Grande do Norte, Dept Dent, Postgra Program Oral Pathol, Av Senador Salgado Filho 1787, BR-59056000 Natal, RN, Brazil.	lmgqueiroz@hotmail.com					Alaeddini M, 2009, ORAL DIS, V15, P422, DOI 10.1111/j.1601-0825.2009.01566.x; Angadi PV, 2011, J ORAL PATHOL MED, V40, P208, DOI 10.1111/j.1600-0714.2010.00995.x; Avelar Rafael L, 2009, J Oral Sci, V51, P581; Barnes L., 2009, SURG PATHOLOGY HEAD; Barnes L., 2005, PATHOLOGY GENETICS H; Bello IO, 2009, ORAL ONCOL, V45, P760, DOI 10.1016/j.oraloncology.2008.11.011; Brown JM, 2008, CLIN EXP ALLERGY, V38, P4, DOI 10.1111/j.1365-2222.2007.02886.x; Brown RA, 2002, EXP CELL RES, V274, P310, DOI 10.1006/excr.2002.5471; Pereira FDC, 2012, TUMOR BIOL, V33, P455, DOI 10.1007/s13277-011-0274-2; Caughey GH, 2007, IMMUNOL REV, V217, P141, DOI 10.1111/j.1600-065X.2007.00509.x; Chiappetta N, 2006, SEMIN ARTHRITIS RHEU, V36, P32, DOI 10.1016/j.semarthrit.2006.03.004; Darby IA, 2007, INT REV CYTOL, V257, P143, DOI 10.1016/S0074-7696(07)57004-X; de Andrade Santos P. P., 2011, ORAL SURG ORAL MED O, V112, P476; Santos PPD, 2011, ARCH ORAL BIOL, V56, P231, DOI 10.1016/j.archoralbio.2010.09.020; de Oliveira MDC, 2004, J ORAL PATHOL MED, V33, P354, DOI 10.1111/j.1600-0714.2004.00212.x; Desmouliere A, 2005, WOUND REPAIR REGEN, V13, P7, DOI 10.1111/j.1067-1927.2005.130102.x; Desmouliere A, 2004, INT J DEV BIOL, V48, P509, DOI 10.1387/ijdb.041802ad; Diaz-Fernandez Jose Maria, 2005, Med Oral Patol Oral Cir Bucal, V10 Suppl 1, pE57; Drazic R, 2010, J ORAL PATHOL MED, V39, P257, DOI 10.1111/j.1600-0714.2009.00870.x; Etemad-Moghadam S, 2009, J ORAL PATHOL MED, V38, P639, DOI 10.1111/j.1600-0714.2009.00768.x; Evans RA, 2003, EXP CELL RES, V282, P90, DOI 10.1016/S0014-4827(02)00015-0; Figueroa A, 2010, OTOLARYNG HEAD NECK, V142, P179, DOI 10.1016/j.otohns.2009.10.008; Fregnani ER, 2009, PATHOL ONCOL RES, V15, P231, DOI 10.1007/s12253-008-9110-4; Freitas VS, 2009, ORAL SURG ORAL MED O, V108, P417, DOI 10.1016/j.tripleo.2009.03.035; Gailit J, 2001, J INVEST DERMATOL, V117, P1113, DOI 10.1046/j.1523-1747.2001.15211.x; Garbuzenko E, 2002, CLIN EXP ALLERGY, V32, P237, DOI 10.1046/j.1365-2222.2002.01293.x; Gnepp Douglas R, 2009, DIAGNOSTIC SURG PATH; Guidolin D, 2009, CANCER LETT, V273, P80, DOI 10.1016/j.canlet.2008.07.032; Guo XY, 2008, J BIOL CHEM, V283, P19864, DOI 10.1074/jbc.M800798200; Janssens AS, 2005, J CLIN PATHOL, V58, P285, DOI 10.1136/jcp.2004.017210; Manfredi M, 2004, INT J ORAL MAXILLOF, V33; Mangia A, 2011, HISTOPATHOLOGY, V58, P1096, DOI 10.1111/j.1365-2559.2011.03842.x; Martinez-Mata G, 2008, ORAL ONCOL, V44, P601, DOI 10.1016/j.oraloncology.2007.08.009; Mendenhall WM, 2007, AM J CLIN ONCOL-CANC, V30, P645, DOI 10.1097/COC.0b013e3181573e59; Mohamed A, 2010, INT J ORAL MAX SURG, V39, P843, DOI 10.1016/j.ijom.2010.06.014; Mohtasham N, 2010, ACTA ODONTOL SCAND, V68, P300, DOI 10.3109/00016357.2010.494622; Neville B. W., 2009, ORAL MAXILLOFACIAL P; Nielsen BS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002959; Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112; Powell DW, 2005, AM J PHYSIOL-GASTR L, V289, pG2, DOI 10.1152/ajpgi.00075.2005; Roy Swati, 2013, J Oral Maxillofac Pathol, V17, P207, DOI 10.4103/0973-029X.119789; Netto JDS, 2012, J ORAL PATHOL MED, V41, P630, DOI 10.1111/j.1600-0714.2012.01126.x; Shruthi DK, 2014, U RES J DENT, V4, P115; Tawfik MA, 2010, ORAL SURG ORAL MED O, V109, pE67, DOI 10.1016/j.tripleo.2009.09.003; Thode C, 2011, J ORAL PATHOL MED, V40, P201, DOI 10.1111/j.1600-0714.2010.00999.x; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Vaughan MB, 2000, EXP CELL RES, V257, P180, DOI 10.1006/excr.2000.4869; Vered M, 2005, ORAL ONCOL, V41, P1028, DOI 10.1016/j.oraloncology.2005.06.011; De Castro ICV, 2014, LASER MED SCI, V29, P1405, DOI 10.1007/s10103-014-1537-0; Nonaka CFW, 2012, ARCH ORAL BIOL, V57, P230, DOI 10.1016/j.archoralbio.2011.08.002; Yamashita M, 2012, BREAST CANCER-TOKYO, V19, P170, DOI 10.1007/s12282-010-0234-5	51	1	1	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						66	71		10.1016/j.anndiagpath.2014.09.003			6	Pathology	Pathology	GL1VO	WOS:000436900200012	29661731				2019-10-28	
J	Niranjan, KC; Sarathy, NA; Alrani, D				Niranjan, Kochli Channappa; Sarathy, Niharika Abhay; Alrani, Devendra			MCM-2 expression differentiates potentially malignant verrucous lesions from oral carcinomas	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Mcm-2; Hyperplasia; Dysplasia; Carcinoma; Proliferation	SQUAMOUS-CELL CARCINOMAS; KI67; PROLIFERATION; PROGNOSIS; GEMININ; CANCER; MUCOSA; KI-67; P53	Background: Mcm-2 is a biomarker belonging to Mcm family of proteins which has rarely been used in oral potentially malignant and malignant lesions of the verrucous type. The objective of this study is to assess the expression of Mcm-2 in Normal Oral Mucosa (NM), Verrucous Hyperplasia (VH), Verrucous Carcinoma (VC) and Oral Squamous Cell Carcinoma (OSCC) and compare it with the clinicopathological characteristics. Methodology: A total of 70 formalin fixed paraffin embedded tissue samples (10 cases of Normal Mucosa NM-Group A, 10 cases of Verrucous Hyperplasia- VH without Dysplasia- Group B, 10 cases of Verrucous Hyperplasia-VH with Dysplasia- Group C, 20 cases of Verrucous Carcinoma VC-Group D, 20 cases of Oral Squamous Cell Carcinoma OSCC- Group E) were subjected to immunohistochemistry with Mcm-2 antibody. Statistical analysis was carried out with various tests like ANOVA, Tukey HSD, Chi-Square and Shapiro-Wilk test by using the SPSS software. Results: There was a significant difference in Mcm-2 expression with quantitative analysis among all the groups (p < 0.05). There was a significant progressive increase in nuclear Labelling Indices (nLI) from NM (49.08%), VC (60.45%), VH with Dysplasia (64.10%), and OSCC (89.22%). Conclusion: The findings suggest that Mcm-2 may be a sensitive proliferation marker in oral potentially malignant and malignant lesions which may be useful for differentiating between VH with/ without dysplasia, VC and OSCC.	[Niranjan, Kochli Channappa; Sarathy, Niharika Abhay; Alrani, Devendra] SDM Coll Dent Sci & Hosp, Dept Oral & Maxillofacial Pathol, Dharwad 580009, Karnataka, India	Niranjan, KC (reprint author), SDM Coll Dent Sci & Hosp, Dept Oral & Maxillofacial Pathol, Dharwad 580009, Karnataka, India.	niranjankc@sdmcds.edu					Bankfalvi A, 2000, J ORAL PATHOL MED, V29, P291, DOI 10.1034/j.1600-0714.2000.290701.x; Banoczy J, 1972, J Oral Pathol, V1, P265, DOI 10.1111/j.1600-0714.1972.tb01665.x; Chatrath P, 2003, BRIT J CANCER, V89, P1048, DOI 10.1038/sj.bjc.6601234; GimenezConti IB, 1996, CANCER-AM CANCER SOC, V78, P17, DOI 10.1002/(SICI)1097-0142(19960701)78:1<17::AID-CNCR4>3.0.CO;2-E; Gouvea AF, 2010, J ORAL PATHOL MED, V39, P447, DOI 10.1111/j.1600-0714.2010.00889.x; Habiba U, 2014, ONCOL REP, V31, P1547, DOI 10.3892/or.2014.3017; Kodani I, 2003, J ORAL PATHOL MED, V32, P468, DOI 10.1034/j.1600-0714.2003.00116.x; Labib K, 2001, MOL BIOL CELL, V12, P3658, DOI 10.1091/mbc.12.11.3658; Santoro A, 2011, J SKIN CANCER, DOI 10.1155/2011/370605; SHALASH HN, 2012, AUST J BASIC APPL SC, V6, P445; SHEAR M, 1980, CANCER, V46, P1855, DOI 10.1002/1097-0142(19801015)46:8<1855::AID-CNCR2820460825>3.0.CO;2-#; Thomas GJ, 2009, DIAGN HISTOPATHOL, V15, P279; Torres-Rendon A, 2009, BRIT J CANCER, V100, P1128, DOI 10.1038/sj.bjc.6604967; Vargas PA, 2008, J ORAL PATHOL MED, V37, P309, DOI 10.1111/j.1600-0714.2007.00631.x; Yang C, 2012, ONCOL REP, V27, P135, DOI 10.3892/or.2011.1473; Zargaran M, 2012, ASIAN PAC J CANCER P, V13, P5811, DOI 10.7314/APJCP.2012.13.11.5811	16	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						72	76		10.1016/j.anndiagpath.2018.03.001			5	Pathology	Pathology	GL1VO	WOS:000436900200013	29661732				2019-10-28	
J	Verzura, M; Batagelj, E; Bagnes, C; Martin, C; Enrico, D; Richardet, E; De la Iglesia, P				Verzura, Maria; Batagelj, Emilio; Bagnes, Claudia; Martin, Claudio; Enrico, Diego; Richardet, Eduardo; De la Iglesia, Paola			Analysis of EML4-ALK rearrangement in non-small cell lung cancer in Argentina	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Non-small cell lung cancer; ALK rearrangement; FISH; Biopsy; Argentina	FUSION GENE; ADENOCARCINOMA; CLASSIFICATION; POPULATION; CRIZOTINIB; FEATURES	Introduction: Identification of EML4-ALK rearrangement by FISH test has become standard in advanced NSCLC patients. There is limited information about the prevalence and clinical characteristics of ALK translocation in Latin America. The aim of our study was to evaluate this lung cancer subtype features in Argentinian patients and the factibility of FISH test with different methods used for obtaining tissue samples. Methods: Between August 2014 and February 2017, 183 non-squamous NSCLC patients were prospectively enrolled from five Argentinian institutions. Different techniques and procedures were used to obtained tissue samples material. ALK determination was performed by FISH and immunohistochemistry (IHC). Correlation with clinico-pathological information and different biopsy procedures was assessed. Results: From 183 non-squamous NSCLC samples, 131 could perform FISH test, finding 123 (93.9%) negative and 8 (6.1%) positive patients. Fifty-one samples were not evaluable by FISH, 35 because of technical problems and 16 due to not/weak signal. The difficulties in obtaining adequate FISH tests were observed significantly more frequently for fine-needle aspiration (FNA) and core-needle biopsy than for excisional and incisional biopsy (p = 0.009). Regarding the procedures, surgery was the most efficient, obtaining only 12.7% (10/79) of not evaluable samples for FISH, while CT guided biopsy and transbronchial biopsy (TBB) failed in 43.8% (21/48) and 41.3% (19/46) of patients respectively (p < 0.001). We observed a significant association between ALK translocation and never smoking habit (p = 0.004). Conclusion: Our ALK rearrangements frequency (6.1%) was similar to the reports worldwide. One of the major determinants for the ALK FISH test success is the quality of the tissue sample obtained.	[Verzura, Maria; Batagelj, Emilio; Bagnes, Claudia; Martin, Claudio; Enrico, Diego; Richardet, Eduardo; De la Iglesia, Paola] AAOC, Av Federico Lacroze 2252 2 A C1426CPU, Buenos Aires, DF, Argentina	Enrico, D (reprint author), AAOC, Av Federico Lacroze 2252 2 A C1426CPU, Buenos Aires, DF, Argentina.	diego-enrico@hotmail.com			Pfizer Oncology; Argentine Association of Clinical Oncology (AAOC)	This study was supported by Pfizer Oncology and the Argentine Association of Clinical Oncology (AAOC).	Camidge DR, 2012, LANCET ONCOL, V13, P1011, DOI 10.1016/S1470-2045(12)70344-3; Cruz-Rico G, 2017, AM J CLIN ONCOL-CANC, V40, P631, DOI 10.1097/COC.0000000000000213; de Melo AC, 2015, ONCOLOGY-BASEL, V89, P175, DOI 10.1159/000376552; Ferlay J., 2015, INT J CANC, V136; Lopes LF, 2012, CLINICS, V67, P845, DOI 10.6061/clinics/2012(07)23; Martelli MP, 2009, AM J PATHOL, V174, P661, DOI 10.2353/ajpath.2009.080755; Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584; Paik JH, 2012, LUNG CANCER, V76, P403, DOI 10.1016/j.lungcan.2011.11.008; Rodig SJ, 2009, CLIN CANCER RES, V15, P5216, DOI 10.1158/1078-0432.CCR-09-0802; Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886; Shaw AT, 2009, J CLIN ONCOL, V27, P4247, DOI 10.1200/JCO.2009.22.6993; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Soda M, 2012, CLIN CANCER RES, V18, P5682, DOI 10.1158/1078-0432.CCR-11-2947; Sowley DT, 2016, J THORAC ONCOL, V11, pS222; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Wong DWS, 2009, CANCER-AM CANCER SOC, V115, P1723, DOI 10.1002/cncr.24181; Woo CG, 2017, ANN ONCOL, V28, P791, DOI 10.1093/annonc/mdw693	18	3	3	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						77	81		10.1016/j.anndiagpath.2018.02.009			5	Pathology	Pathology	GL1VO	WOS:000436900200014	29661733				2019-10-28	
J	Prayson, RA				Prayson, Richard A.			Pathology resident perspectives about early autopsy experiences	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Autopsy; Resident Training; Reflection; Humanism	MEDICAL-STUDENTS	The performance of autopsies remains an integral part of residency training in Anatomic Pathology. A number of medical schools no longer require an autopsy experience; therefore, a subset of pathology residents has never seen an autopsy performed prior to commencement of residency training. Although much as been written regarding student's perspectives on their medical school anatomy experiences, practically nothing has been written about resident perspectives on the autopsy experience. Surveys were sent to all Pathology resident trainees (n = 27) in a training program exploring resident perspectives on their early autopsy experiences. Of the 13 residents who completed the survey, ten indicated a discomfort level of 3 or 4 (Likert scale of 1-5 with 1 = no discomfort and 5 = very uncomfortable) associated with their first autopsy; the most commonly cited reasons included discomfort with odors/body fluids (n = 6), fear of making a mistake (n = 5), and uncertainty about what to do (n = 4). Six residents felt it would be worthwhile to engage in a discussion around the first autopsy experience to help process it. In summary, a subset of residents experience discomfort around their first autopsy experience. Sensitivity to and acknowledgement of this discomfort and an opportunity to vet feelings and concerns should be considered as part of Pathology residency education.	[Prayson, Richard A.] Cleveland Clin, Dept Anat Pathol, L25,9500 Euclid Ave, Cleveland, OH 44195 USA	Prayson, RA (reprint author), Cleveland Clin, Dept Anat Pathol, L25,9500 Euclid Ave, Cleveland, OH 44195 USA.	praysor@ccf.org					Bertman SL, 1989, CLIN ANAT, V2, P103, DOI DOI 10.1002/CA.980020207; Black-Schaffer WS, 2016, ACAD PATHOL, V3, DOI 10.1177/2374289516665393; Coulehan JL, 1995, TEACH LEARN MED, V7, P61; HAFFERTY FW, 1988, J HEALTH SOC BEHAV, V29, P344, DOI 10.2307/2136868; Martyn H, 2013, ANAT SCI EDUC, V6, P410, DOI 10.1002/ase.1372; PENNEY JC, 1985, J MED EDUC, V60, P58; Prayson RA, 2018, AM J CLIN PATHOL, V149, P96, DOI [10.1093/AJCP/AQX140, 10.1093/ajcp/aqx140]; Prayson RA, 2014, ANAT SCI EDUC, V7, P417, DOI 10.1002/ase.1437; Tschernig T, 2000, ANAT REC, V261, P11	9	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						82	84		10.1016/j.anndiagpath.2018.03.004			3	Pathology	Pathology	GL1VO	WOS:000436900200015	29661734				2019-10-28	
J	Mostafa, M; Abbott, D; Parsons, LN				Mostafa, Mohamed; Abbott, Daniel; Parsons, Lauren N.			Fine needle aspiration of alveolar soft part sarcoma in a child: Cytomorphological clues for the surgical pathologist	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article							TFE3 GENE FUSIONS; 17Q25; INVOLVEMENT; CYTOLOGY; UPDATE; ORIGIN; CELL	Alveolar soft part sarcoma (ASPS) is a rare soft tissue neoplasm generally affecting adolescents and young adults. Its unique histologic and ultrastructural features have been well-described; however, the cytopathological features of ASPS are less well-characterized, and recognition of this entity's features on cytologic preparations can ensure that the specimen adequacy and appropriate/rapid tissue allocation for additional testing. Herein we report a FNA case of ASPS with emphasis on cytomorphologic characteristics.	[Mostafa, Mohamed; Abbott, Daniel; Parsons, Lauren N.] Med Coll Wisconsin, Dept Pathol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA; [Parsons, Lauren N.] Childrens Hosp Wisconsin, Div Pediat Pathol, 9000 W Wisconsin Ave MS 701, Milwaukee, WI 53226 USA	Parsons, LN (reprint author), Childrens Hosp Wisconsin, Div Pediat Pathol, 9000 W Wisconsin Ave MS 701, Milwaukee, WI 53226 USA.	lparsons@mcw.edu					Argani P, 2005, CLIN LAB MED, V25, P363, DOI 10.1016/j.cll.2005.01.008; Argani P, 2003, AM J SURG PATHOL, V27, P750, DOI 10.1097/00000478-200306000-00005; Argani P, 2010, AM J SURG PATHOL, V34, P1395, DOI 10.1097/PAS.0b013e3181f17ac0; CHRISTOPHERSON WM, 1952, CANCER, V5, P100, DOI 10.1002/1097-0142(195201)5:1<100::AID-CNCR2820050112>3.0.CO;2-K; CULLINANE C, 1992, CANCER, V70, P2444, DOI 10.1002/1097-0142(19921115)70:10<2444::AID-CNCR2820701010>3.0.CO;2-6; Fanburg-Smith JC, 2004, HISTOPATHOLOGY, V45, P526, DOI 10.1111/j.1365-2559.2004.01966.x; Ferrari A, 2011, PEDIATR BLOOD CANCER, V57, P943, DOI 10.1002/pbc.23252; Folpe AL, 2006, J CLIN PATHOL, V59, P1127, DOI 10.1136/jcp.2005.031120; Heimann P, 1998, GENE CHROMOSOME CANC, V23, P194, DOI 10.1002/(SICI)1098-2264(199810)23:2<194::AID-GCC14>3.3.CO;2-O; KAMEI T, 1985, J JPN SOC CLIN CYTOL, V24, P523; Ladanyi M, 2001, ONCOGENE, V20, P48, DOI 10.1038/sj.onc.1204074; LIEBERMAN PH, 1989, CANCER-AM CANCER SOC, V63, P1, DOI 10.1002/1097-0142(19890101)63:1<1::AID-CNCR2820630102>3.0.CO;2-E; MCDONALD EC, 1981, ARCH PATHOL LAB MED, V105, P263; Ordonez NG, 1999, ADV ANAT PATHOL, V6, P125, DOI 10.1097/00125480-199905000-00001; Policarpio-Nicolas ML, 2008, DIAGN CYTOPATHOL, V36, P89, DOI 10.1002/dc.20647; SCIOT R, 1993, HISTOPATHOLOGY, V23, P439, DOI 10.1111/j.1365-2559.1993.tb00492.x; SHABB N, 1991, DIAGN CYTOPATHOL, V7, P293, DOI 10.1002/dc.2840070317; Tsuji K, 2012, HUM PATHOL, V43, P356, DOI 10.1016/j.humpath.2011.05.004; VANECHTEN J, 1995, CANCER GENET CYTOGEN, V82, P57, DOI 10.1016/0165-4608(94)00291-I; Wakely P Jr, 2000, Ann Diagn Pathol, V4, P316, DOI 10.1053/adpa.2000.17891; Wakely PE, 2009, CANCER CYTOPATHOL, V117, P500, DOI 10.1002/cncy.20054; Williams A, 2011, VIRCHOWS ARCH, V458, P291, DOI 10.1007/s00428-010-1039-9; Zeppa P, 1999, DIAGN CYTOPATHOL, V21, P405, DOI 10.1002/(SICI)1097-0339(199912)21:6<405::AID-DC8>3.3.CO;2-8	23	1	1	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						85	88		10.1016/j.anndiagpath.2018.02.004			4	Pathology	Pathology	GL1VO	WOS:000436900200016	29661735				2019-10-28	
J	Lopez, JI; Pulido, R; Lawrie, CH; Angulo, JC				Lopez, Jose, I; Pulido, Rafael; Lawrie, Charles H.; Angulo, Javier C.			Loss of PD-L1 (SP-142) expression characterizes renal vein tumor thrombus microenvironment in clear cell renal cell carcinoma	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Clear cell renal cell carcinoma; Intratumor heterogeneity; Tumor thrombus; Immunotherapy; PD-L1; Tumor sampling	CANCER-SPECIFIC SURVIVAL; INTRATUMOR HETEROGENEITY; TISSUE FACTOR; CONSISTENCY; IMPACT; SUBTYPE	Immunotherapy is a promising tool in the treatment of patients with advancer renal cancer, in particular the blockage of immune checkpoint inhibitors. Clear cell renal cell carcinoma is an example of heterogeneous neoplasm and this particular characteristic is responsible of many therapeutic failures so far. Since variations in the local microenvironment across a tumor may conditionate the effect of this new therapy, a deeper knowledge of this issue seems advisable for any treatment success. We have analyzed the PD-L1 (SP142) expression in three different areas in the tumor and in two areas in the renal vein/caval thrombi in 39 advanced clear cell renal cell carcinomas to determine the extent and potential clinical significance of this regional variability. A statistically significant decrease in PD-L1 expression has been detected between the main tumor and its thrombus faction (p < 0.0001). Also, we have observed a high variability in the PD-L1 positivity across the three different areas of the main tumor tested, with only three cases being uniformly positive in all tested areas. In conclusion, PD-L1 expression display a highly variable distribution in clear cell renal cell carcinomas and this particularity should be kept in mind when selecting the tumor samples to be tested for immunotherapy.	[Lopez, Jose, I] Cruces Univ Hosp, Dept Pathol, Plaza Cruces S-N, Baracaldo 48903, Bizkaia, Spain; [Lopez, Jose, I; Pulido, Rafael] Biocruces Res Inst, Biomarkers Canc Unit, Baracaldo, Spain; [Lopez, Jose, I] Univ Basque Country, Dept Med Surg Specialties, UPV EHU, Leioa, Spain; [Pulido, Rafael; Lawrie, Charles H.] IKERBASQUE, Basque Fdn Sci, Bilbao, Spain; [Lawrie, Charles H.] Biodonostia Res Inst, Mol Oncol, Donostia San Sebastian, Spain; [Lawrie, Charles H.] Univ Basque Country, Dept Physiol, UPV EHU, Leioa, Spain; [Lawrie, Charles H.] Univ Oxford, Radcliffe Dept Med, Oxford, England; [Angulo, Javier C.] Univ Hosp Getafe, Serv Urol, Madrid, Spain; [Angulo, Javier C.] Laureate Univ, European Univ Madrid, Clin Dept, Madrid, Spain	Lopez, JI (reprint author), Cruces Univ Hosp, Dept Pathol, Plaza Cruces S-N, Baracaldo 48903, Bizkaia, Spain.	joseignacio.lopez@osakidetza.eus	Lopez, Jose Ignacio/L-3884-2019	Lopez, Jose Ignacio/0000-0003-0842-5348; Angulo, Javier/0000-0002-1735-8792	Ministerio de Economia y Competitividad (MINECO), Spain [SAF-2016-79847-R]	This work has been partially supported by the grant SAF-2016-79847-R of Ministerio de Economia y Competitividad (MINECO), Spain.	Alaghehbandan R, 2017, ANN DIAGN PATHOL, V29, P17, DOI 10.1016/j.anndiagpath.2017.04.007; Antonelli A, 2015, INT J UROL, V22, P534, DOI 10.1111/iju.12738; Atkins MB, 2017, ANN ONCOL, V28, P1484, DOI 10.1093/annonc/mdx151; Bedke J, 2018, CURR OPIN UROL, V28, P8, DOI 10.1097/MOU.0000000000000466; Bertini R, 2011, EUR UROL, V60, P358, DOI 10.1016/j.eururo.2011.05.029; Callea M, 2015, CANCER IMMUNOL RES, V3, P1158, DOI 10.1158/2326-6066.CIR-15-0043; Chang K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02005-7; De Cicco M, 2004, CRIT REV ONCOL HEMAT, V50, P187, DOI 10.1016/j.critrevonc.2003.10.003; Erlmeier F, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0833-x; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gonzalez J, 2018, EXPERT REV ANTICANC, DOI [10.1080/14737140.2018.1431530, DOI 10.1080/14737140.2018.1431530.]; Guarch R, 2018, ANN DIAGN PATHOL, V34, P27, DOI 10.1016/j.anndiagpath.2018.01.001; Gulati S, 2014, EUR UROL, V66, P936, DOI 10.1016/j.eururo.2014.06.053; Jefferson E., 2011, FDA APPROVES NEW TRE; John A, 2018, CLIN GENITOURIN CANC, V16, pE29, DOI 10.1016/j.clgc.2017.07.013; Kammerer-Jacquet SF, 2017, INT J CANCER, V140, P142, DOI 10.1002/ijc.30429; Khagi Y, 2017, CANCER METAST REV, V36, P179, DOI 10.1007/s10555-016-9652-y; Kim KH, 2012, BJU INT, V110, pE673, DOI 10.1111/j.1464-410X.2012.11498.x; Kondo T, 2013, INT J UROL, V20, P1072, DOI 10.1111/iju.12123; Lopez JI, 2017, HUM PATHOL, V64, P1, DOI 10.1016/j.humpath.2017.02.010; Lopez Jose I, 2016, F1000Res, V5, P385, DOI 10.12688/f1000research.8196.1; Lopez JI, 2016, APMIS, V124, P153, DOI 10.1111/apm.12500; Lopez JI, 2013, PATHOL RES PRACT, V209, P137, DOI 10.1016/j.prp.2013.01.007; Mager R, 2016, J SURG ONCOL, V114, P764, DOI 10.1002/jso.24395; Matsushita H, 2016, CANCER IMMUNOL RES, V4, P463, DOI 10.1158/2326-6066.CIR-15-0225; McDermott DF, 2016, J CLIN ONCOL, V34, P833, DOI 10.1200/JCO.2015.63.7421; Milsom C, 2007, THROMB RES, V120, pS82, DOI 10.1016/S0049-3848(07)70135-4; Milsom C, 2007, PATHOPHYSIOL HAEMO T, V36, P160, DOI 10.1159/000175154; Motoshima T, 2017, BMC UROL, V17, DOI 10.1186/s12894-016-0195-x; Palsdottir HB, 2012, J UROLOGY, V187, P48, DOI 10.1016/j.juro.2011.09.025; Reese AC, 2013, UROL ONCOL-SEMIN ORI, V31, P1305, DOI 10.1016/j.urolonc.2011.12.006; Rong Y, 2005, CANCER RES, V65, P1406, DOI 10.1158/0008-5472.CAN-04-3376; Ruf M, 2016, INT J CANCER, V139, P396, DOI 10.1002/ijc.30077; Sansregret L, 2018, NAT REV CLIN ONCOL, DOI 10.1038/nrclinonc.2017.198; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Taube JM, 2018, MODERN PATHOL, V31, P214, DOI 10.1038/modpathol.2017.156; Tilki D, 2014, EUR UROL, V66, P577, DOI 10.1016/j.eururo.2013.06.048; Verbiest A, 2017, CLIN GENITOURIN CANC, DOI [10.1016/j.clgc.2017.10, DOI 10.1016/J.CLGC.2017.10.]; Wang Z, 2018, CLIN EXP MED, DOI [10.1007/s10238-018-0488-3, DOI 10.1007/S10238-018-0488-3.]; Weiss VL, 2014, BJU INT, V113, P209, DOI 10.1111/bju.12322; Whitson JM, 2011, BJU INT, V107, P729, DOI 10.1111/j.1464-410X.2010.09593.x	41	5	5	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						89	93		10.1016/j.anndiagpath.2018.03.007			5	Pathology	Pathology	GL1VO	WOS:000436900200017	29661736				2019-10-28	
J	East, EG; Gabbeart, M; Roberts, E; Zhao, LL; Jorns, JM				East, Ellen G.; Gabbeart, Matthew; Roberts, Emily; Zhao, Lili; Jorns, Julie M.			A rapid triage protocol to optimize cold ischemic time for breast resection specimens	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Breast; Carcinoma; Cold ischemia; Cold ischemic time	INTRAOPERATIVE MARGIN ASSESSMENT; FROZEN-SECTION ANALYSIS; IN-SITU HYBRIDIZATION; FORMALIN FIXATION; CONSERVING SURGERY; CLINICAL ONCOLOGY/COLLEGE; PROGESTERONE-RECEPTORS; ESTROGEN-RECEPTOR; AMERICAN SOCIETY; HER2 EXPRESSION	Prolonged time from specimen excision to adequate formalin exposure, or cold ischemic time (CIT), negatively impacts estrogen receptor (ER), progesterone receptor (PR) and HER-2 biomarker studies routinely performed on breast specimens. Current guidelines recommend CIT of <= 1 h. Since formalin penetrates resections slowly, optimal fixation requires incision. We evaluated the efficacy of a rapid triage protocol developed to optimize CIT. We identified 2821 specimens: 650 (23.0%) excisional biopsies (EB), 1051 (37.3%) lumpectomies, and 1120 (39.7%) mastectomies. CIT was available for 2362 (83.7%), with 1845 (78.1%) <= 1 h and 2323 (98.3%) <= 4 h. IHC was performed in 533/2821 (18.9%) and was associated with lumpectomy and mastectomy procedures when compared to EB. However, IHC was also performed on 11.1% (72/650) of EB specimens despite EB being significantly less likely to have CIT recorded (468/650; 72% for EB vs. 1894/2171; 87.2% for lumpectomies/ mastectomies). Our study highlights the need for rapid triage of breast resections with known or suspected malignant diagnoses and outlines our procedure for optimizing CIT. Additionally, we advocate treating ALL breast resections as having the potential of being malignant and requiring biomarker studies for which optimal CIT is of great importance.	[East, Ellen G.; Gabbeart, Matthew] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Roberts, Emily; Zhao, Lili] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA; [Jorns, Julie M.] Med Coll Wisconsin, Dept Pathol, 9200 W Wisconsin Ave,Lab Bldg,Lower Level,L53, Milwaukee, WI 53226 USA	Jorns, JM (reprint author), Med Coll Wisconsin, Dept Pathol, 9200 W Wisconsin Ave,Lab Bldg,Lower Level,L53, Milwaukee, WI 53226 USA.	jjorns@mcw.edu		Roberts, Emily/0000-0002-5838-9691			Balch GC, 2005, AM SURGEON, V71, P22; Cabioglu N, 2007, ANN SURG ONCOL, V14, P1458, DOI 10.1245/s10434-006-9236-0; Chagpar A, 2003, AM J SURG, V186, P371, DOI 10.1016/S0002-9610(03)00264-2; De Cecco L, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-409; Gwin J, 2005, AM SURGEON, V71, P27; Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, pE48, DOI 10.1043/1543-2165-134.7.e48; Hatzis C, 2011, J NATL CANCER I, V103, P1871, DOI 10.1093/jnci/djr438; Kalkman S, 2014, AM J CLIN PATHOL, V142, P16, DOI 10.1309/AJCP96YDQSTYBXWU; Khoury T, 2014, APPL IMMUNOHISTO M M, V22, P688, DOI 10.1097/PAI.0000000000000018; Khoury T, 2012, APPL IMMUNOHISTO M M, V20, P531, DOI 10.1097/PAI.0b013e318248bf6d; Khoury T, 2009, MODERN PATHOL, V22, P1457, DOI 10.1038/modpathol.2009.117; Li XX, 2013, MODERN PATHOL, V26, P71, DOI 10.1038/modpathol.2012.135; Masood S, 2005, CLIN LAB MED, V25, P809, DOI 10.1016/j.cll.2005.08.012; Olson TP, 2007, ANN SURG ONCOL, V14, P2953, DOI 10.1245/s10434-007-9437-1; OSBORNE CK, 1980, CANCER-AM CANCER SOC, V46, P2884, DOI 10.1002/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U; Portier BP, 2013, MODERN PATHOL, V26, P1, DOI 10.1038/modpathol.2012.123; Sabel MS, 2012, AM J SURG, V204, P66, DOI 10.1016/j.amjsurg.2011.07.016; Schnitt SJ, 2001, MODERN PATHOL, V14, P213, DOI 10.1038/modpathol.3880288; Weber S, 1997, CANCER J SCI AM, V3, P273; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Yildiz-Aktas IZ, 2012, MODERN PATHOL, V25, P1098, DOI 10.1038/modpathol.2012.59	21	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						94	97		10.1016/j.anndiagpath.2018.02.010			4	Pathology	Pathology	GL1VO	WOS:000436900200018	29661737				2019-10-28	
J	Ren, HY; Guo, YH; Yang, LM; Dai, TJ; Lin, MZ; Yu, L; Zhu, QG; Meng, JR				Ren, Hong-Yue; Guo, Yi-He; Yang, Li-Min; Dai, Tai-Jian; Lin, Ming-Zhu; Yu, Le; Zhu, Qi-Gan; Meng, Jia-Rong			Expression and clinical significance of retinoid X receptor alpha in esophageal carcinoma	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						RXR alpha; Esophageal carcinoma; Biomarker; Expression; Prognosis	RXR-ALPHA; CANCER STATISTICS; BREAST-CANCER; GAMMA	Purpose: Esophageal carcinoma (EC) is one of the most aggressive type cancers and dysregulation of retinoid X receptor alpha (RXR alpha) involves various tumors. However, the relationship of RXR alpha with the clinicopathological factors of EC, particularly prognostic characteristics, remains unclear. This present study was to evaluate the effect of RXR alpha expression in the development of EC. Methods: The mRNA and protein expression level of RXR alpha in EC and normal esophageal tissues using reverse transcription-polymerase chain reaction (RT-PCR) and Western blot, respectively. The subcellular localization was detected by immunohistochemistry (IHC) analysis. The clinicopathological parameters were included age, sex, tumor size, differentiation, TNM stages and lymph node metastasis. Kaplan-Meier method and Cox's regression analyses were performed to evaluate the prognosis of 60 patients with EC. Results: RXR alpha was elevated in EC tissues comparing with normal esophageal tissues at both mRNA and protein levels. The overexpression level of RXR alpha was closely associated to the tumor differentiation, TNM stage and lymph node metastasis of patients with EC. In addition, EC patients with RXR alpha high expression had significantly lower disease-free survival (DFS) and overall survival (OS). Multivariate analysis showed RXR expression as an independent predictor for the DFS and OS rate of patients with EC. Conclusions: Our results showed that overexpression of RXR alpha was correlated with unfavorable prognosis, suggesting that RXR alpha may serve as a potential targeted therapeutic marker in the treatment of EC.	[Ren, Hong-Yue; Guo, Yi-He; Yang, Li-Min; Dai, Tai-Jian; Lin, Ming-Zhu; Yu, Le; Zhu, Qi-Gan; Meng, Jia-Rong] Xiamen Univ, Affiliated Southeast Hosp, Dept Pathol, Zhangzhou 363000, Fujian, Peoples R China	Meng, JR (reprint author), Xiamen Univ, Affiliated Southeast Hosp, Dept Pathol, Zhangzhou 363000, Fujian, Peoples R China.	mengjiarong175@163.com			Natural Science Foundation of Zhangzhou, Fujian, China [ZZ2017J36]; Youth Nursery Foundation of the Affiliated Southeast Hospital of Xiamen University, Zhangzhou, Fujian, China [16Y019]	This work was supported by the Natural Science Foundation of Zhangzhou, Fujian, China (grant no. ZZ2017J36) and the Youth Nursery Foundation of the Affiliated Southeast Hospital of Xiamen University, Zhangzhou, Fujian, China (grant no. 16Y019).	Buentig N, 2004, CANCER BIOTHER RADIO, V19, P331, DOI 10.1089/1084978041425007; Chen L, 2017, NAT COMMUN, V8, P160; Ditsch N, 2012, IN VIVO, V26, P87; Evans RM, 2014, CELL, V157, P255, DOI 10.1016/j.cell.2014.03.012; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Friedrich M, 2002, HISTOCHEM J, V34, P35, DOI 10.1023/A:1021343825552; Giaginis C, 2009, MED SCI MONITOR, V15, pBR148; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Huang GL, 2015, CANCER SCI, V106, P1515, DOI 10.1111/cas.12802; Lefebvre P, 2010, TRENDS ENDOCRIN MET, V21, P676, DOI 10.1016/j.tem.2010.06.009; Martens JHA, 2010, CANCER CELL, V17, P173, DOI 10.1016/j.ccr.2009.12.042; Picard E, 1999, J NATL CANCER I, V91, P1059, DOI 10.1093/jnci/91.12.1059; Rubenstein JH, 2015, GASTROENTEROLOGY, V149, P302, DOI 10.1053/j.gastro.2015.04.053; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Su Y, 2017, CURR TOP MED CHEM, V17, P663, DOI 10.2174/1568026616666160617092241; Takiyama Y, 2004, J CLIN ENDOCR METAB, V89, P5851, DOI 10.1210/jc.2003-032036; Tanaka T, 2004, MOL CELL BIOL, V24, P3972, DOI 10.1128/MCB.24.9.3972-3982.2004; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wu Y, 2004, EXP MOL PATHOL, V76, P24, DOI 10.1016/j.yexmp.2003.10.009; Zhang XK, 2015, ACTA PHARMACOL SIN, V36, P102, DOI 10.1038/aps.2014.109; Zhong C, 2003, CANCER BIOL THER, V2, P179, DOI 10.4161/cbt.2.2.281; Zhou H, 2010, CANCER CELL, V17, P560, DOI 10.1016/j.ccr.2010.04.023	22	0	0	2	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						110	115		10.1016/j.anndiagpath.2018.03.003			6	Pathology	Pathology	GL1VO	WOS:000436900200021	29661715				2019-10-28	
J	Magro, CM; Olson, LC				Magro, Cynthia M.; Olson, Luke C.			Small cell lymphocytic variant of marginal zone lymphoma: A distinct form of marginal zone lymphoma derived from naive B cells as a cutaneous counterpart to the naive marginal zone lymphoma of splenic origin	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Primary cutaneous marginal zone lymphoma; Naive small cell lymphocytic marginal zone lymphoma of the skin	MUTATION ANALYSIS; SURFACE IGM; LEUKEMIA; IMMUNOGLOBULIN; GENES; EXPRESSION; APOPTOSIS; FEATURES; SUBSETS; SALT		[Magro, Cynthia M.; Olson, Luke C.] Weill Cornell Med, New York Presbyterian Hosp, Dept Pathol & Lab Med, New York, NY USA	Magro, CM (reprint author), Weill Cornell Med, New York Presbyterian Hosp, Dept Pathol & Lab Med, New York, NY USA.; Magro, CM (reprint author), Cornell Univ, Weill Cornell Med Coll, Div Dermatopathol, 1300 York Ave,Room F309-B, New York, NY 10065 USA.	cym2003@med.cornell.edu					Assem Magda, 2009, J Egypt Natl Canc Inst, V21, P287; Bahler DW, 2002, AM J PATHOL, V161, P81, DOI 10.1016/S0002-9440(10)64159-4; Bailey EM, 1996, AM J SURG PATHOL, V20, P1011, DOI 10.1097/00000478-199608000-00010; Breza TS, 2006, J CUTAN PATHOL, V33, P522, DOI 10.1111/j.1600-0560.2006.00475.x; Camacho FI, 2001, AM J SURG PATHOL, V25, P1268, DOI 10.1097/00000478-200110000-00007; Coscia M, 2011, LEUKEMIA, V25, P828, DOI 10.1038/leu.2011.12; Damle RN, 2004, BLOOD, V103, P375, DOI 10.1182/blood-2003-04-1345; Dunn-Walters DK, 1998, HUM PATHOL, V29, P585, DOI 10.1016/S0046-8177(98)80007-5; Edinger JT, 2010, AM J SURG PATHOL, V34, P1830, DOI 10.1097/PAS.0b013e3181f72835; Ensafi AA, 2016, BIOSENS BIOELECTRON, V77, P409, DOI 10.1016/j.bios.2015.09.063; Evans PAS, 2007, LEUKEMIA, V21, P207, DOI 10.1038/sj.leu.2404479; Ferrara G, 2011, J CUTAN PATHOL, V38, P342, DOI 10.1111/j.1600-0560.2010.01659.x; Fuhler M, 2010, HAUTARZT, V61, P145, DOI 10.1007/s00105-009-1766-5; Hamblin TJ, 1999, BLOOD, V94, P1848; Lanham S, 2003, BLOOD, V101, P1087, DOI 10.1182/blood-2002-06-1822; Magro CM, 2016, AM J DERMATOPATH, V38, P105, DOI 10.1097/DAD.0000000000000401; Magro CM, 2013, AM J DERMATOPATH, V35, P319, DOI 10.1097/DAD.0b013e318267495f; Miranda RN, 1999, HUM PATHOL, V30, P306, DOI 10.1016/S0046-8177(99)90010-2; Patten PEM, 2012, BLOOD, V120, P4802, DOI 10.1182/blood-2012-08-449744; Roisman A, 2015, TUMOR BIOL, V36, P4433, DOI 10.1007/s13277-015-3083-1; SLATER DN, 1994, BRIT J DERMATOL, V131, P557; Sroa N, 2006, J CUTAN PATHOL, V33, P1, DOI 10.1111/j.1600-0560.2006.00506.x; Tierens A, 1998, BLOOD, V91, P2381, DOI 10.1182/blood.V91.7.2381.2381_2381_2386; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; Zupo S, 2000, BLOOD, V95, P1199, DOI 10.1182/blood.V95.4.1199.004k21_1199_1206	25	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						116	121		10.1016/j.anndiagpath.2018.02.006			6	Pathology	Pathology	GL1VO	WOS:000436900200022	29661716				2019-10-28	
J	Talu, CK; Leblebici, C; Ozturk, TK; Hacihasanoglu, E; Koca, SB; Gucin, Z				Talu, Canan Kelten; Leblebici, Cem; Ozturk, Tulin Kilicaslan; Hacihasanoglu, Ezgi; Koca, Sevim Baykal; Gucin, Zuhal			Primary breast carcinomas with neuroendocrine features: Clinicopathological features and analysis of tumor growth patterns in 36 cases	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Breast; Neuroendocrine carcinoma	ENDOCRINE DIFFERENTIATION; PROGNOSTIC-SIGNIFICANCE; MAMMARY CARCINOMAS; CANCER; CELLS; EXPRESSION; NEOPLASMS; DISTINCT; ORIGIN; TISSUE	Primary breast carcinoma with neuroendocrine features (NEBC) is an uncommon tumor. In the classification of WHO 2012, these tumors were categorized as: 1- neuroendocrine tumor, well-differentiated; 2- neuroendocrine carcinoma, poorly differentiated/small cell carcinoma; and 3- invasive breast carcinoma with neuroendocrine differentiation. In this study, we reviewed NEBC except poorly differentiated/small cell carcinoma variant in order to define the morphological growth patterns and cytonuclear details of these tumors. All breast surgical excision materials between 2007 and 2016 were re-evaluated in terms of neuroendocrine differentiation. Thirty-six cases showing positive staining for synaptophysin and/or chromogranin A in >= 50% of tumor cells were included in the study. All cases were female with a mean age of 67.4. Mean tumor diameter was 26 mm. Multifocality was noted in 5 cases. Grossly, they were mostly infiltrative mass lesions. T stages, identified in 34 cases, were as follows: 13 cases with pTl; 19 pT2 and 2 pT3. We described schematically 4 types of patterns depending on predominant growth pattern, except one case: 1) Large-sized solid cohesive groups (6 cases), 2) Small- to medium-sized solid cohesive groups with trabeculae/ribbons and glandular structures (6 cases), 3) Mixed growth patterns (20 cases), 4) Invasive tumor with prominent extracellular and/or intracellular mucin (3 cases). The tumor cells were mostly polygonal-oval with eosinophilic/eosinophilic-granular cytoplasm. The nuclei of tumor cells were mostly round to oval with evenly distributed chromatin. Only 5 cases showed high grade nuclear and histological features. Molecular subtypes of the cases were as follows: 33 luminal A, 2 luminal B, and 1 triple negative. NEBC should come to mind when a tumor display one of the morphological patterns described above, composed of monotonous cells with mild to moderate nuclear pleomorphism and abundant eosinophilic/eosinophilic granular or clear cytoplasm, especially in elderly patients.	[Talu, Canan Kelten; Leblebici, Cem; Hacihasanoglu, Ezgi; Koca, Sevim Baykal] Univ Hlth Sci, Dept Pathol, Istanbul SUAM, Istanbul, Turkey; [Ozturk, Tulin Kilicaslan] Istanbul Univ, Cerrahpasa Fac Med, Dept Pathol, Istanbul, Turkey; [Gucin, Zuhal] Besmialem Univ, Fac Med, Dept Pathol, Istanbul, Turkey	Talu, CK (reprint author), Univ Hlth Sci, Dept Pathol, Istanbul SUAM, Istanbul, Turkey.	esracanankelten.talu@sbu.edu.tr; ezgihaci@yahoo.com					Adams RW, 2014, BREAST, V23, P120, DOI 10.1016/j.breast.2013.11.005; Alkaied H, 2012, MED ONCOL, V29, P2613, DOI 10.1007/s12032-012-0222-z; Asch-Kendrick R, 2016, HUM PATHOL, V48, P37, DOI 10.1016/j.humpath.2015.09.035; Bogina G, 2016, HISTOPATHOLOGY, V68, P422, DOI 10.1111/his.12766; BUSSOLATI G, 1985, AM J PATHOL, V120, P186; Chia SY, 2010, BREAST, V19, P355, DOI 10.1016/j.breast.2010.02.007; CUBILLA AL, 1977, AM J SURG PATHOL, V1, P283, DOI 10.1097/00000478-197712000-00001; Davis DG, 2016, HUM PATHOL, V47, P26, DOI 10.1016/j.humpath.2015.09.015; FEYRTER F, 1963, Frankf Z Pathol, V73, P24; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; Inno A, 2016, ONCOLOGIST, V21, P28, DOI 10.1634/theoncologist.2015-0309; Kawasaki T, 2012, J CLIN PATHOL, V65, P699, DOI 10.1136/jclinpath-2012-200765; Kimura N, 2002, ENDOCR PATHOL, V13, P117, DOI 10.1385/EP:13:2:117; Koo J, 2012, MODERN PATHOL, V25, P893, DOI 10.1038/modpathol.2012.34; Lai JP, 2015, ENDOCR PATHOL, V26, P54, DOI 10.1007/s12022-014-9346-3; Lakhani SREI, 2012, WHO CLASSIFICATION T; Lavigne M, 2018, MODERN PATHOL, V31, P68, DOI 10.1038/modpathol.2017.107; Lin XQ, 2007, APPL IMMUNOHISTO M M, V15, P407, DOI 10.1097/01.pai.0000210416.53493.0f; Lopez-Bonet E, 2008, ONCOL REP, V20, P1369, DOI 10.3892/or_00000154; Makretsov N, 2003, HUM PATHOL, V34, P1001, DOI 10.1053/S0046-8177(03)00411-8; MALUF HM, 1994, VIRCHOWS ARCH, V425, P449; MALUF HM, 1995, AM J SURG PATHOL, V19, P1237, DOI 10.1097/00000478-199511000-00003; Miremadi A, 2002, HISTOPATHOLOGY, V40, P215, DOI 10.1046/j.1365-2559.2002.01336.x; Mohanty SK, 2016, MODERN PATHOL, V29, P788, DOI 10.1038/modpathol.2016.69; NESLAND JM, 1987, HISTOL HISTOPATHOL, V2, P73; PAPOTTI M, 1989, SEMIN DIAGN PATHOL, V6, P174; Park YM, 2014, AM J ROENTGENOL, V203, pW221, DOI 10.2214/AJR.13.10749; PARTANEN S, 1981, VIRCHOWS ARCH A, V391, P45, DOI 10.1007/BF00589794; Righi L, 2010, SEMIN DIAGN PATHOL, V27, P69, DOI 10.1053/j.semdp.2009.12.003; Rosen LE, 2017, ARCH PATHOL LAB MED, V141, P1577, DOI 10.5858/arpa.2016-0364-RS; Rovera Francesca, 2013, Int J Surg, V11 Suppl 1, pS79, DOI 10.1016/S1743-9191(13)60023-0; Rovera Francesca, 2008, Int J Surg, V6 Suppl 1, pS113, DOI 10.1016/j.ijsu.2008.12.007; Sapino A, 2000, SEMIN DIAGN PATHOL, V17, P127; Tang F, 2011, HISTOPATHOLOGY, V59, P106, DOI 10.1111/j.1365-2559.2011.03880.x; Tavassoli FA, 2003, PATHOLOGY GENETICS T; Tian Z, 2011, HUM PATHOL, V42, P1169, DOI 10.1016/j.humpath.2010.11.014; Tse GM, 2009, HISTOPATHOLOGY, V55, P441, DOI 10.1111/j.1365-2559.2009.03400.x; van Krimpen C, 2004, BREAST, V13, P329, DOI 10.1016/j.breast.2003.11.008; Wang J, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-147; Wei B, 2010, CANCER-AM CANCER SOC, V116, P4463, DOI 10.1002/cncr.25352; Weigelt B, 2008, J PATHOL, V216, P141, DOI 10.1002/path.2407; Weigelt B, 2009, MODERN PATHOL, V22, P1401, DOI 10.1038/modpathol.2009.112; Wolff AC, 2014, ARCH PATHOL LAB MED, V138, P241, DOI 10.5858/arpa.2013-0953-SA; Zekioglu O, 2003, BREAST, V12, P251, DOI 10.1016/S0960-9776(03)00059-6	44	1	1	2	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						122	130		10.1016/j.anndiagpath.2018.03.010			9	Pathology	Pathology	GL1VO	WOS:000436900200023	29661717				2019-10-28	
J	Lee, H; Sheuka, N; El-kadi, O; Murray, BP; Fisher, HA; Kallakury, BVS; Lee, EC; Boguniewicz, A; Jennings, TA				Lee, Hwajeong; Sheuka, Natallia; El-kadi, Osama; Murray, Brian P.; Fisher, Hugh A.; Kallakury, Bhaskar V. S.; Lee, Edward C.; Boguniewicz, Ann; Jennings, Timothy A.			Rectal ulcer and pseudomalignant epithelial changes after prostate seed brachytherapy: A rare complication with a diagnostic pitfall	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Brachytherapy; Radiation atypia; Rectal ulcer; Pseudomalignant gland; Pitfall	RADIATION-THERAPY; STRANDED SEEDS; CANCER; LOOSE; ADENOCARCINOMA; CARCINOMA; MIGRATION; BIOPSIES; RADIOTHERAPY; DOSIMETRY	Background: Implant brachytherapy (IBT) is a well-recognized treatment modality for early stage prostate cancer. Rectal ulcer and rectourethral fistula complicating IBT may cause an alteration of the normal anatomic landmarks. In this context, pseudomalignant radiation-induced changes within prostatic epithelium may be misinterpreted as a primary rectal malignancy. Such challenging and misleading findings have not been described, and may not be recognized as such. Materials and methods: We present the clinical and pathologic aspects of two patients who underwent IBT for low stage prostate cancer that was complicated by deep rectal ulcer. Both patients underwent extensive palliative surgical resection for disease control. Results: The histologic changes in both cases were noteworthy for extensive necrosis and inflammation of the prostate, associated with loss of recto-prostatic anatomical landmarks. Prostate glands showed striking radiation-induced atypia and pseudomalignant epithelial changes extending to the rectal ulcer bed, with no residual viable tumor. The first patient had undergone a biopsy of the rectal ulcer bed that was misinterpreted as a rectal adenocarcinoma prior to surgery. The similarity between atypical glands of the biopsy and the benign prostatic tissue with radiation-induced atypia in resection specimen confirmed their benign nature. Conclusions: Deep rectal ulcer complicating IBT may lead to distortion of the normal recto-prostatic anatomical landmarks, resulting in detection of pseudo-malignant prostatic glands at the ulcer base. Such findings may be mistaken for a primary rectal malignancy in limited biopsy material if not familiar to the pathologist.	[Lee, Hwajeong; Sheuka, Natallia; El-kadi, Osama; Kallakury, Bhaskar V. S.; Boguniewicz, Ann; Jennings, Timothy A.] Albany Med Coll, Anat Pathol, Albany, NY 12208 USA; [Murray, Brian P.] St Peters Hlth Partner Med Associates, Urol, Albany, NY USA; [Fisher, Hugh A.] Albany Med Coll, Urol, Albany, NY 12208 USA; [Kallakury, Bhaskar V. S.] Georgetown Univ, Pathol, Washington, DC USA; [Lee, Edward C.] Albany Med Coll, Gen Surg, Albany, NY 12208 USA	Jennings, TA (reprint author), 47 New Scotland Ave MC81, Albany, NY 12208 USA.	leeh5@amc.edu; sheukan@amc.educ; fisherH@amc.edu; kallakub@gunet.georgetown.edu; leeE@amc.edu; Bogunia@amc.edu; JenninT@amc.edu					BOCKING A, 1987, DIAGN CYTOPATHOL, V3, P108, DOI 10.1002/dc.2840030204; BRAWER MK, 1989, CANCER, V63, P454, DOI 10.1002/1097-0142(19890201)63:3<454::AID-CNCR2820630311>3.0.CO;2-E; Buergy D, 2018, HEALTH QUAL LIFE OUT, V16, DOI 10.1186/s12955-018-0844-8; Chen WC, 2012, BRACHYTHERAPY, V11, P354, DOI 10.1016/j.brachy.2011.12.003; Cheng L, 1999, AM J SURG PATHOL, V23, P1173, DOI 10.1097/00000478-199910000-00002; Crook J, 2000, INT J RADIAT ONCOL, V48, P355, DOI 10.1016/S0360-3016(00)00637-4; Crook JM, 1997, CANCER, V79, P81, DOI 10.1002/(SICI)1097-0142(19970101)79:1<81::AID-CNCR12>3.3.CO;2-I; Eshleman JS, 2004, INT J RADIAT ONCOL, V59, P419, DOI 10.1016/j.ijrobp.2003.10.050; Gelblum DY, 2000, INT J RADIAT ONCOL, V48, P119, DOI 10.1016/S0360-3016(00)00632-5; GRIGNON DJ, 1995, CANCER, V75, P1837, DOI 10.1002/1097-0142(19950401)75:7+<1837::AID-CNCR2820751613>3.0.CO;2-S; Hathout L, 2011, AM J CLIN ONCOL-CANC, V34, P449, DOI 10.1097/COC.0b013e3181ec63c5; Herbert C, 2011, BRACHYTHERAPY, V10, P442, DOI 10.1016/j.brachy.2011.01.011; Hinnen KA, 2010, RADIOTHER ONCOL, V96, P30, DOI 10.1016/j.radonc.2010.02.012; Hu K, 1998, INT J RADIAT ONCOL, V41, P263, DOI 10.1016/S0360-3016(98)00080-7; Humphrey PA, 2007, J CLIN PATHOL, V60, P35, DOI 10.1136/jcp.2005.036442; Kang SK, 2002, INT J RADIAT ONCOL, V53, P99, DOI 10.1016/S0360-3016(01)02811-5; Leong N, 2016, J UROLOGY, V195, P1811, DOI 10.1016/j.juro.2015.12.095; Lesperance RN, 2008, AM J SURG, V195, P616, DOI 10.1016/j.amjsurg.2007.12.037; Magi-Galluzzi C, 2003, AM J SURG PATHOL, V27, P206, DOI 10.1097/00000478-200302000-00009; Moerland MA, 2009, RADIOTHER ONCOL, V91, P202, DOI 10.1016/j.radonc.2008.09.013; Moreira SG, 2004, BJU INT, V93, P31, DOI 10.1046/j.1464-410X.2004.04550.x; Phan J, 2009, CANCER-AM CANCER SOC, V115, P1827, DOI 10.1002/cncr.24223; Sanda MG, 2008, NEW ENGL J MED, V358, P1250, DOI 10.1056/NEJMoa074311; Shah SA, 2004, DIS COLON RECTUM, V47, P1487, DOI 10.1007/s10350-004-0603-2; Sugawara A, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-130; Tapen EM, 1998, INT J RADIAT ONCOL, V42, P1063, DOI 10.1016/S0360-3016(98)00353-8; Tian W, 2017, HISTOPATHOLOGY, V71, P150, DOI 10.1111/his.13214; WALLNER K, 1995, INT J RADIAT ONCOL, V32, P465, DOI 10.1016/0360-3016(94)00599-G	28	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						131	134		10.1016/j.anndiagpath.2018.03.011			4	Pathology	Pathology	GL1VO	WOS:000436900200024	29661719				2019-10-28	
J	Guleria, P; Husain, N; Shukla, S; Kumar, S; Parshad, R; Jain, D				Guleria, Prerna; Husain, Nuzhat; Shukla, Saumya; Kumar, Sunil; Parshad, Rajinder; Jain, Deepali			PD-L1 immuno-expression assay in thymomas: Study of 84 cases and review of literature	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Review						Thymoma; PD-L1 expression; Immunohistochemistry; Immunotherapy; SP263	LIGAND 1 EXPRESSION; ANTI-PD-L1 ANTIBODY; MYASTHENIA-GRAVIS; TOXICITIES; MPDL3280A; MELANOMA; THERAPY; PATIENT	Background and aims: Programmed death ligand 1 (PD-L1), an immune check point inhibitor, is known to be expressed in several malignancies and is being considered as a prognostic factor and a potential immunotherapeutic target. The aim of this study was to characterize PD-L1 expression in thymomas and to determine correlation with clinicopathological features and previously published studies in the literature. Methods: Tissue microarrays were prepared from selected blocks of thymomas and immunohistochemistry (IHC) for PD-L1 was performed. Cases were considered as PD-L1 positive or negative depending on whether the percentage of stained thymic epithelial cells were < 25 or > 25%. Results were compared clinically and with previously published studies using Google and Pubmed search engines. Results: Of 84 cases of thymoma, 69 (82.1%) revealed PD-Ll positivity in > 25% cells. 94.23% of type B thy mama subtypes (B1/B2/B3) were PD-L1 positive (P < 0.001). There was no correlation of PD-L1 with age, gender, myasthenia gravis, the tumor size or stage of disease. Nine studies were available in the literature; most of which showed PD-L1 expression in higher stage and B subtype however percentage positivity varied from 53.7% to over 90%. Conclusions: PD-L1 expression is frequent in type B (B1/B2/B3) thymomas. It can be easily evaluated by IHC even on small biopsies in unresectable cases, thereby enabling improved clinical evaluation as well as prognostic stratification of patients. It will serve as a potential indicator for benefit from anti-PD-L1 antibody immunotherapy in thymomas.	[Guleria, Prerna; Jain, Deepali] All India Inst Med Sci, Dept Pathol, New Delhi 110029, India; [Kumar, Sunil] All India Inst Med Sci, Dept Surg Oncol, New Delhi 110029, India; [Parshad, Rajinder] All India Inst Med Sci, Dept Surg, New Delhi 110029, India; [Husain, Nuzhat; Shukla, Saumya] Dr Ram Manohar Lohia Inst Med Sci, Dept Pathol, Lucknow, Uttar Pradesh, India	Jain, D (reprint author), All India Inst Med Sci, Dept Pathol, New Delhi 110029, India.	deepalijain76@gmail.com		Guleria, Prerna/0000-0001-9608-7152; Kumar, Sunil/0000-0002-9942-3403			Arbour KC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182665; Berardi R, 2015, WORLD J CLIN ONCOL, V6, P96, DOI 10.5306/wjco.v6.i5.96; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Brown JA, 2003, J IMMUNOL, V170, P1257, DOI 10.4049/jimmunol.170.3.1257; Chen QJ, 2018, CEREB CORTEX, V28, P2162, DOI 10.1093/cercor/bhx120; Cooper Dana S, 2017, J Neuromuscul Dis, V4, P169, DOI 10.3233/JND-170219; Dacic S, 2015, IASLC ATLAS PD L1 IM, P73; Davies M, 2014, CANCER MANAG RES, V6, P63, DOI 10.2147/CMAR.S57550; Detterbeck F, 2011, J THORAC ONCOL, V6, pS1698, DOI 10.1097/JTO.0b013e31821e7b12; du Vignaux CM, 2017, CURR TREAT OPTION ON, V18, DOI 10.1007/s11864-017-0495-8; Enkner F, 2017, PATHOL ONCOL RES, V23, P551, DOI 10.1007/s12253-016-0144-8; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Javelin Simoneaux R, 2017, ONCOL TIMES, V39, P17; Katsuya Y, 2016, LUNG CANCER, V99, P4, DOI 10.1016/j.lungcan.2016.05.007; Kitazono S, 2015, CLIN LUNG CANCER, V16, P385, DOI 10.1016/j.cllc.2015.03.008; Lau KHV, 2016, MUSCLE NERVE, V54, P157, DOI 10.1002/mus.25141; Lipson EJ, 2013, CLIN CANCER RES, V19, P462, DOI 10.1158/1078-0432.CCR-12-2625; Maeda O, 2016, NAGOYA J MED SCI, V78, P119; Makarious D, 2017, EUR J CANCER, V82, P128, DOI 10.1016/j.ejca.2017.05.041; Marchevsky AM, 2017, HUM PATHOL, V60, P16, DOI 10.1016/j.humpath.2016.09.023; Moreno BH, 2015, BRIT J CANCER, V112, P1421, DOI 10.1038/bjc.2015.124; Muenst S, 2014, BREAST CANCER RES TR, V146, P15, DOI 10.1007/s10549-014-2988-5; Naidoo J, 2015, ANN ONCOL, V26, P2375, DOI 10.1093/annonc/mdv383; Padda SK, 2015, J THORAC ONCOL, V10, P500, DOI 10.1097/JTO.0000000000000429; Patel SP, 2015, MOL CANCER THER, V14, P847, DOI 10.1158/1535-7163.MCT-14-0983; Philips GK, 2015, INT IMMUNOL, V27, P39, DOI 10.1093/intimm/dxu095; Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Roden AC, 2016, J THORAC DIS, V8, P1859, DOI 10.21037/jtd.2016.05.66; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Smith J, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0494-2; Tiseo M, 2017, LUNG CANCER, V104, P24, DOI 10.1016/j.lungcan.2016.12.005; Travis WD, 2015, WHO CLASSIFICATION T; Vallonthaiel AG, 2017, ANN DIAGN PATHOL, V31, P56, DOI 10.1016/j.anndiagpath.2017.07.001; Wang X, 2016, ONCOTARGETS THER, V9, P5023, DOI 10.2147/OTT.S105862; Weber JS, 2015, J CLIN ONCOL, V33, P2092, DOI 10.1200/JCO.2014.60.0379; Weissferdt A, 2017, MODERN PATHOL, V30, P826, DOI 10.1038/modpathol.2017.6; Yokoyama S, 2016, ANN THORAC SURG, V101, P1361, DOI 10.1016/j.athoracsur.2015.10.044; Zimmer L, 2016, EUR J CANCER, V60, P210, DOI 10.1016/j.ejca.2016.02.024	39	1	1	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						135	141		10.1016/j.anndiagpath.2018.03.012			7	Pathology	Pathology	GL1VO	WOS:000436900200025	29661720				2019-10-28	
J	Ronchi, A; Cozzolino, I; Marino, FZ; Accardo, M; Montella, M; Panarese, I; Roccuzzo, G; Toni, G; Franco, R; De Chiara, A				Ronchi, Andrea; Cozzolino, Immacolata; Marino, Federica Zito; Accardo, Marina; Montella, Marco; Panarese, Iacopo; Roccuzzo, Giuseppe; Toni, Giorgio; Franco, Renato; De Chiara, Annarosaria			Extrapleural solitary fibrous tumor: A distinct entity from pleural solitary fibrous tumor. An update on clinical, molecular and diagnostic features	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Review						Extrapleural Solitary Fibrous Tumor; Hemangiopericytoma; Soft Tissue Neoplasm; STAT6; NAB2; Dedifferentiation	OF-THE-LITERATURE; SOFT-TISSUE TUMORS; FINE-NEEDLE-ASPIRATION; LIPOMATOUS HEMANGIOPERICYTOMA; CLINICOPATHOLOGICAL FEATURES; PATHOLOGICAL CORRELATION; PROGNOSTIC-SIGNIFICANCE; DIFFERENTIAL-DIAGNOSIS; RADIATION-THERAPY; NAB2-STAT6 FUSION	Solitary fibrous tumor (SFT) is a mesenchymal neoplasm that was originally described to be localized in the pleura, but thereafter, this has been reported in several anatomic sites. Although the etiology of the neoplasm remains largely unknown, the pathogenesis seems to be related to an NAB2-STAT6 fusion gene due to paracentric inversion on chromosome 12q13. The diagnosis of extrapleural SFT is challenging, owing to its rarity, and requires an integrated approach that includes specific clinical, histological, immunohistochemical, and even molecular findings. Histologically, extrapleural SFT shares morphological features same as those of the pleural SFT because it is characterized by a patternless distribution of both oval- and spindle-shaped cells in a variable collagen stroma. In addition, morphological variants of mixoid, fat-forming, and giant cell-rich tumors are described. A correct diagnosis is mandatory for a proper therapy and management of the patients with extra pleural SFT, as extrapleural SFT is usually more aggressive than pleural form, particularly cases occurring in the mediastinum, retroperitoneum, pelvis, and meninges. Although SFT is usually considered as a clinically indolent neoplasm, the prognosis is substantially unpredictable and only partially related to morphological features. In this context, cellularity, neoplastic borders, cellular atypias, and mitotic activity can show a wide range of variability. We review extrapleural SFT by discussing diagnostic clues, differential diagnosis, recent molecular findings, and prognostic factors.	[Ronchi, Andrea; Cozzolino, Immacolata; Marino, Federica Zito; Accardo, Marina; Montella, Marco; Panarese, Iacopo; Roccuzzo, Giuseppe; Toni, Giorgio; Franco, Renato] Univ Campania Luigi Vanvitelli, Dept Mental & Phys Hlth & Prevent Med, Pathol Unit, Via Luciano Armanni 20, I-80100 Naples, Italy; [De Chiara, Annarosaria] Ist Nazl Tumori IRCCS Fdn Pascale, Pathol Unit, Dept Support Oncol Paths, Diagnost Area, Via Mariano Sernmola 52, I-80131 Naples, Italy	Franco, R (reprint author), Univ Campania Luigi Vanvitelli, Dept Mental & Phys Hlth & Prevent Med, Pathol Unit, Via Luciano Armanni 20, I-80100 Naples, Italy.	renato.franco@unicampania.it					Akaike K, 2015, HUM PATHOL, V46, P347, DOI 10.1016/j.humpath.2014.11.018; Alawi F, 2001, AM J SURG PATHOL, V25, P900, DOI 10.1097/00000478-200107000-00008; Alobid I, 2005, OTOLARYNG HEAD NECK, V133, P163, DOI 10.1016/j.otohns.2004.09.058; Barazani Y, 2012, CAN UROL ASS J, V6, pE131; Barresi V, 2016, J NEUROSCI RES, V94, P1604, DOI 10.1002/jnr.23801; Barthelmess S, 2014, AM J PATHOL, V184, P1209, DOI 10.1016/j.ajpath.2013.12.016; Bauer JL, 2012, HEAD NECK PATHOL, V6, P21, DOI 10.1007/s12105-011-0305-8; Bertucci F, 2013, GENE CHROMOSOME CANC, V52, P156, DOI 10.1002/gcc.22015; Bishop AJ, 2018, AM J CLIN ONCOL-CANC, V41, P81, DOI 10.1097/COC.0000000000000218; Bledrzycki OJ, 2007, INT J GYNECOL PATHOL, V26, P259, DOI 10.1097/01.pgp.0000250144.59839.a8; Bouvier C, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-10; Bouvier C, 2012, BRAIN PATHOL, V22, P511, DOI 10.1111/j.1750-3639.2011.00552.x; Cardillo G, 2009, ANN THORAC SURG, V88, P1632, DOI 10.1016/j.athoracsur.2009.07.026; Carter JM, 2014, MODERN PATHOL, V27, P294, DOI 10.1038/modpathol.2013.139; Chang SK, 2008, KOREAN J RADIOL, V9, P568, DOI 10.3348/kjr.2008.9.6.568; Chmielecki J, 2013, NAT GENET, V45, P131, DOI 10.1038/ng.2522; CLAGETT OT, 1952, J THORAC SURG, V24, P213; Clayton AC, 2001, DIAGN CYTOPATHOL, V25, P172, DOI 10.1002/dc.2032; Cranshaw IM, 2009, EJSO-EUR J SURG ONC, V35, P994, DOI 10.1016/j.ejso.2009.02.015; DalCin P, 1996, CANCER GENET CYTOGEN, V86, P58, DOI 10.1016/0165-4608(95)00179-4; Davies PE, 2002, CLIN EXP OPHTHALMOL, V30, P281, DOI 10.1046/j.1442-9071.2002.00542.x; Demicco EG, 2015, HUM PATHOL, V46, P1015, DOI 10.1016/j.humpath.2015.03.014; Demicco EG, 2015, AM J CLIN PATHOL, V143, P672, DOI 10.1309/AJCPN25NJTOUNPNF; Demicco EG, 2012, MODERN PATHOL, V25, P1298, DOI 10.1038/modpathol.2012.83; Dobashi Y, 2009, MODERN PATHOL, V22, P1328, DOI 10.1038/modpathol.2009.104; Domanski HA, 2003, DIAGN CYTOPATHOL, V29, P287, DOI 10.1002/dc.10371; Dotto JE, 2006, ARCH PATHOL LAB MED, V130, P213; Doyle LA, 2014, MODERN PATHOL, V27, P1231, DOI 10.1038/modpathol.2013.247; Doyle LA, 2014, MODERN PATHOL, V27, P390, DOI 10.1038/modpathol.2013.164; Dungarwalla MM, 2017, J LARYNGOL OTOL, V131, P838, DOI 10.1017/S0022215117001396; Endo M, 2013, CLIN CANCER RES, V19, P450, DOI 10.1158/1078-0432.CCR-12-1067; Erdag G, 2007, J CUTAN PATHOL, V34, P844, DOI 10.1111/j.1600-0560.2006.00728.x; Fan CY, 2006, OTOLARYNG HEAD NECK, V134, P880, DOI 10.1016/j.otohns.2005.07.021; Feng LH, 2015, PATHOL RES PRACT, V211, P911, DOI 10.1016/j.prp.2015.09.004; Fine SW, 2006, ARCH PATHOL LAB MED, V130, P857; Fletcher C, 2013, WHO CLASSIFICATION T; Fukasawa Y, 1998, PATHOL INT, V48, P47, DOI 10.1111/j.1440-1827.1998.tb03827.x; Fukunaga M, 1997, MODERN PATHOL, V10, P443; Gold JS, 2002, CANCER, V94, P1057, DOI 10.1002/cncr.10328; Goldblum JR, 2013, ENZINGER WEISSS SOFT; Guillou L, 2000, AM J SURG PATHOL, V24, P971, DOI 10.1097/00000478-200007000-00008; Guillou L, 2000, HUM PATHOL, V31, P1108, DOI 10.1053/hupa.2000.9777; Guner G, 2016, HUM PATHOL, V54, P184, DOI 10.1016/j.humpath.2016.03.011; Hajdu M, 2010, J PATHOL, V221, P300, DOI 10.1002/path.2715; Hansel Donna E, 2008, Surg Pathol Clin, V1, P105, DOI 10.1016/j.path.2008.07.003; Havlik DM, 2000, ARCH PATHOL LAB MED, V124, P756; HENSEY OJ, 1975, IRISH MED J, V68, P37; Herawi M, 2007, AM J SURG PATHOL, V31, P870, DOI 10.1097/01.pas.0000213416.23256.71; Horton ES, 2007, CANCER GENET CYTOGEN, V172, P77, DOI 10.1016/j.cancergencyto.2006.07.015; Insabato L, 2009, INT J SURG PATHOL, V17, P250, DOI 10.1177/1066896909333779; Jelinic P, 2007, J PATHOL, V211, P261, DOI 10.1002/path.2116; Jing HB, 2011, WORLD J GASTROENTERO, V17, P4835, DOI 10.3748/wjg.v17.i43.4835; Kawamura S, 2007, PATHOL INT, V57, P213, DOI 10.1111/j.1440-1827.2007.02083.x; Khairwa A, 2015, CYTOPATHOLOGY, V26, P391, DOI 10.1111/cyt.12218; Khater N, 2013, UROL INT, V91, P373, DOI 10.1159/000354394; Kim JM, 2017, PATHOL RES PRACT, V213, P619, DOI 10.1016/j.prp.2017.04.026; Krishnamurthy P, 2016, IMMUNE NETW, V16, P201, DOI 10.4110/in.2016.16.4.201; Lecoutere E, 2015, VIRCHOWS ARCH, V467, P119, DOI 10.1007/s00428-015-1768-x; Lee JY, 2015, AM J DERMATOPATH, V37, P570, DOI 10.1097/DAD.0000000000000154; Li XM, 2014, WORLD J GASTROENTERO, V20, P5066, DOI 10.3748/wjg.v20.i17.5066; Liu YQ, 2013, J CANCER RES THER, V9, P724, DOI 10.4103/0973-1482.126469; Louis DN, 2016, WHO CLASSIFICATION T; Miettinen M, 2017, MODERN SOFT TISSUE P; Miettinen M, 2014, HISTOPATHOLOGY, V64, P101, DOI 10.1111/his.12298; Mohajeri A, 2013, GENE CHROMOSOME CANC, V52, P873, DOI 10.1002/gcc.22083; MORAN CA, 1992, SEMIN DIAGN PATHOL, V9, P169; Morimitsu Y, 2000, APMIS, V108, P617, DOI 10.1034/j.1600-0463.2000.d01-105.x; Moser T, 2005, AM J ROENTGENOL, V184, P1578, DOI 10.2214/ajr.184.5.01841578; Mosquera JM, 2009, AM J SURG PATHOL, V33, P1314, DOI 10.1097/PAS.0b013e3181a6cd33; Nielsen GP, 1997, MODERN PATHOL, V10, P1028; Nishida K, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-014-0422-4; Oike N, 2017, WORLD J SURG ONCOL, V15, DOI 10.1186/s12957-017-1161-0; Ouladan S, 2015, INT J ONCOL, V46, P2595, DOI 10.3892/ijo.2015.2975; Papathanassiou ZG, 2013, CLIN SARCOMA RES, V3, DOI 10.1186/2045-3329-3-1; Papi G, 2007, THYROID, V17, P119, DOI 10.1089/thy.2005.0202; Pasquali S, 2016, EJSO-EUR J SURG ONC, V42, P1064, DOI 10.1016/j.ejso.2016.01.023; Placide N, 2012, INT J SURG PATHOL, V20, P101, DOI 10.1177/1066896911413577; Prevot S, 1996, MODERN PATHOL, V9, P1170; Rajeev R, 2015, CLIN SARCOMA RES, V5, DOI 10.1186/s13569-015-0034-y; Rao N, 2013, AM J SURG PATHOL, V37, P155, DOI 10.1097/PAS.0b013e31826a92f5; Robinson DR, 2013, NAT GENET, V45, P180, DOI 10.1038/ng.2509; Rodriguez I, 2001, AM J SURG PATHOL, V25, P1424, DOI 10.1097/00000478-200111000-00011; Ronchi A, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0640-5; Schweizer L, 2013, ACTA NEUROPATHOL, V125, P651, DOI 10.1007/s00401-013-1117-6; Setsu N, 2012, CANCER-AM CANCER SOC, V118, P1637, DOI 10.1002/cncr.26448; Sheng WQ, 2001, J PATHOL, V194, P88, DOI 10.1002/path.839; Shim YS, 2008, KOREAN J RADIOL, V9, P286, DOI 10.3348/kjr.2008.9.3.286; Shin JH, 2001, AM J NEURORADIOL, V22, P1890; Sigel J E, 2000, Ann Diagn Pathol, V4, P240, DOI 10.1053/adpa.2000.8129; Smith SC, 2017, AM J SURG PATHOL, V41, P1642, DOI 10.1097/PAS.0000000000000940; Song MJ, 2017, APPL IMMUNOHISTO M M, V25, P712, DOI [10.1097/PAI.0000000000000364, 10.1097/PAI.0000000000000365]; Steigen SE, 2009, MODERN PATHOL, V22, P914, DOI 10.1038/modpathol.2009.48; Stout AP, 1942, ANN SURG, V116, P26, DOI 10.1097/00000658-194207000-00004; Suster S, 1998, AM J SURG PATHOL, V22, P863, DOI 10.1097/00000478-199807000-00008; SUSTER S, 1995, AM J SURG PATHOL, V19, P1257, DOI 10.1097/00000478-199511000-00005; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Tallini G, 2002, J PATHOL, V196, P194, DOI 10.1002/path.1023; Tanaka K, 2018, INT OPHTHALMOL, V38, P345, DOI 10.1007/s10792-016-0421-2; Tanaka M, 2006, MED SCI MONITOR, V12, pCS95; Thway K, 2016, INT J SURG PATHOL, V24, P281, DOI 10.1177/1066896915627485; Thway K, 2015, HISTOPATHOLOGY, V67, P755, DOI 10.1111/his.12771; Thway K, 2013, ANN DIAGN PATHOL, V17, P457, DOI 10.1016/j.anndiagpath.2012.08.006; Tomita Y, 2006, CLIN CANCER RES, V12, P3070, DOI 10.1158/1078-0432.CCR-05-1732; TOS APD, 1995, AM J SURG PATHOL, V19, P1286; van Houdt WJ, 2013, ANN SURG ONCOL, V20, P4090, DOI 10.1245/s10434-013-3242-9; Vivero M, 2014, HISTOPATHOLOGY, V65, P71, DOI 10.1111/his.12377; Wan S, 2010, J INT MED RES, V38, P694, DOI 10.1177/147323001003800234; Wang J, 2001, AM J SURG PATHOL, V25, P1194, DOI 10.1097/00000478-200109000-00011; Wat SYJ, 2008, CLIN IMAG, V32, P152, DOI 10.1016/j.clinimag.2007.07.003; Yamada Y, 2014, CANCER-AM CANCER SOC, V120, P864, DOI 10.1002/cncr.28506; Zafar H, 2003, MED ONCOL, V20, P403, DOI 10.1385/MO:20:4:403; Zhang HK, 2016, ONCOL LETT, V12, P4027, DOI 10.3892/ol.2016.5155	112	13	15	3	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						142	150		10.1016/j.anndiagpath.2018.01.004			9	Pathology	Pathology	GL1VO	WOS:000436900200026	29660566				2019-10-28	
J	Mauzo, SH; Milton, DR; Prieto, VG; Torres-Cabala, CA; Wang, WL; Chakravarti, N; Nagarajan, P; Tetzlaff, MT; Curry, JL; Ivan, D; Brown, RE; Aung, PP				Mauzo, Shakuntala H.; Milton, Denai R.; Prieto, Victor G.; Torres-Cabala, Carlos A.; Wang, Wei-Lien; Chakravarti, Nitin; Nagarajan, Priyadharsini; Tetzlaff, Michael T.; Curry, Jonathan L.; Ivan, Doina; Brown, Robert E.; Aung, Phyu P.			Summary of expression of SPARC protein in cutaneous vascular neoplasms and mimickers	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						SPARC expression; Immunohistochemical study; AFX; Kaposi Sarcoma; Melanoma; Cutaneous angiosarcoma	NAB-PACLITAXEL; EXTRACELLULAR-MATRIX; CYSTEINE SPARC; OSTEONECTIN; BONE; RICH; ANGIOSARCOMA; METHYLATION; PROGRESSION; MECHANISMS	Background: Serum protein acidic and rich in cysteine (SPARC) is a matricellular glycoprotein, which regulates cell proliferation and facilitates intracellular transport of albumin bound particles including chemotherapeutic agents such as Nab-paclitaxel/ABI-007. Therefore the presence of SPARC may achieve higher intra-tumoral drug concentration with lower dosage and thus reduce systemic side-effects. Several trials of ABI-007, in melanoma, show promising clinical activity. Design: Fifty-four cases of dermal based neoplasms were retrieved including 24 angiosarcomas (AS), 10 hemangiomas, 9 nodular melanomas, 4 Kaposi sarcomas (KS), 3 leiomyosarcomas (LMS), 3 atypical fibroxanthomas (AFX) and 1 spindle cell squamous cell carcinoma (SSCC). SPARC immunohistochemistry (IHC) was performed with a mouse monoclonal antibody. Results: SPARC expression was detected in a majority of AS (17/24), melanomas (8/9), AFX (3/3), LMS (3/3) and KS (4/4) with some expression in hemangiomas (3/10), while being negative in SSCC (0/1); and was significantly associated with tumor group (p = 0.017). Although a significant difference in overall survival was observed between SPARC expression groups (positive vs. negative) for all patients, there was no significant difference noted among angiosarcoma patients. Conclusion: We have confirmed the presence of SPARC expression in melanoma, KS, LMS and AS and also detected it for the first time in AFX. Since paclitaxel has shown some effectiveness in AS, melanoma and KS, ABI-007 could also be beneficial in these patients.	[Mauzo, Shakuntala H.; Prieto, Victor G.; Torres-Cabala, Carlos A.; Wang, Wei-Lien; Chakravarti, Nitin; Nagarajan, Priyadharsini; Tetzlaff, Michael T.; Curry, Jonathan L.; Ivan, Doina; Aung, Phyu P.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Milton, Denai R.] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Brown, Robert E.] Univ Texas Houston, Hlth Sci Ctr, Dept Pathol, Houston, TX USA	Aung, PP (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.	paung@mdanderson.org	Chakravarti, Nitin/O-8232-2019	Chakravarti, Nitin/0000-0002-6619-953X; Nagarajan, Priyadharsini/0000-0002-5346-2669			Al Salihi S, 2016, ANN CLIN LAB SCI, V46, P537; Al-Batran SE, 2014, ONCOL RES TREAT, V37, P128, DOI 10.1159/000358890; Alonso SR, 2007, CANCER RES, V67, P3450, DOI 10.1158/0008-5472.CAN-06-3481; BELLAHCENE A, 1995, AM J PATHOL, V146, P95; Byeon S, 2016, CLIN SARCOMA RES, V6, DOI 10.1186/s13569-016-0048-0; Cancer. gov. FDA Nanoparticle Paclitaxel, FDA NAN PACL; Davis EJ, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2694-2; FDA. Taxol Injection, TAX INJ; Fenouille N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040378; Han W, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145803; Hara N, 2016, DRUG DISCOV THER, V10, P114, DOI 10.5582/ddt.2016.01005; IRUELAARISPE ML, 1991, ARTERIOSCLER THROMB, V11, P805, DOI 10.1161/01.ATV.11.4.805; Ledda F, 1997, J INVEST DERMATOL, V108, P210, DOI 10.1111/1523-1747.ep12334263; Leon-Ferre RA, 2015, EXPERT REV ANTICANC, V15, P1371, DOI 10.1586/14737140.2015.1110024; Mauzo SH, 2015, ANN CLIN LAB SCI, V45, P360; Morgan SS, 2014, CLIN SARCOMA RES, V4, DOI 10.1186/2045-3329-4-2; PORTER PL, 1995, J HISTOCHEM CYTOCHEM, V43, P791, DOI 10.1177/43.8.7622842; Puolakkainen PA, 2004, MOL CANCER RES, V2, P215; Rempel SA, 1998, J NEUROPATH EXP NEUR, V57, P1112, DOI 10.1097/00005072-199812000-00002; Sato N, 2003, ONCOGENE, V22, P5021, DOI 10.1038/sj.onc.1206807; SCHULZ A, 1988, AM J PATHOL, V132, P233; Socha MJ, 2009, NEOPLASIA, V11, P126, DOI 10.1593/neo.81146; Spitler LE, 2015, AM J CLIN ONCOL-CANC, V38, P61, DOI 10.1097/COC.0b013e318287bbae; Tai IT, 2005, J CLIN INVEST, V115, P1492, DOI 10.1172/JCI23002; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; Wang WL, 2015, AM J DERMATOPATH, V37, P455, DOI 10.1097/DAD.0000000000000237; Watkins G, 2005, PROSTAG LEUKOTR ESS, V72, P267, DOI 10.1016/j.plefa.2004.12.003; WEWER UM, 1988, AM J PATHOL, V132, P345; Wiernik P H, 1993, J Natl Cancer Inst Monogr, P185; Yang EN, 2007, INT J CANCER, V121, P567, DOI 10.1002/ijc.22706; Yardley DA, 2013, J CONTROL RELEASE, V170, P365, DOI 10.1016/j.jconrel.2013.05.041; Yiu GK, 2001, AM J PATHOL, V159, P609, DOI 10.1016/S0002-9440(10)61732-4; Zhu AJ, 2016, ONCOTARGET, V7, P76628, DOI 10.18632/oncotarget.10532	33	1	1	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						151	154		10.1016/j.anndiagpath.2018.03.005			4	Pathology	Pathology	GL1VO	WOS:000436900200027	29660567				2019-10-28	
J	Zheng, YZ; Liang, L				Zheng, Ying-Ze; Liang, Lei			High expression of PXDN is associated with poor prognosis and promotes proliferation, invasion as well as migration in ovarian cancer	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Ovarian cancer; Peroxidasin; PI3K/Akt pathway; Proliferation	SIGNALING PATHWAY; PEROXIDASIN; MATRIX	Background: Peroxidasin (PXDN) is an extracellular matrix protein with peroxidase activity. PXDN has been reported to participate in the processes of epithelial mesenchymal transition. However, the roles of PXDN in progression of cancers are still rare. Methods: Expression profiles of PXDN in ovarian cancer (OC) tissues were obtained from GEO and TCGA database. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed to measure the expression of PXDN in OC cells. Kaplan-Meier method was used to analyze the overall survival of OC patients. Furthermore, effects of PXDN knockdown on the proliferation, invasion as well as migration of HEY cells were examined by Cell Counting kit-8 (CCK-8), wound healing and transwell assay. Additionally, western blot assay was conducted to detect the levels of several key proteins in PI3K/Akt pathway. Results: PXDN was highly expressed in OC tissues and cells. OC Patients with high PXDN expression showed poorer overall survival rate compared to the OC patients with low PXDN expression. The results of the present study demonstrated that knockdown of PXDN significantly suppressed the proliferation, invasion and migration of HEY cells. In addition, after silencing PXDN in HEY cells, the expression levels of the key protein phosphorylation in PI3K/Akt pathway were obviously decreased, including p-PI3K and p-Akt, that resulting in the inhibition of PI3K/Akt pathway activation. Conclusion: PXDN might play a promoter role in the proliferation, invasion and migration of OC cells through regulating the activation of PI3K/Akt pathway. Therefore, PXDN might be regarded as a potential target for OC therapy.	[Zheng, Ying-Ze; Liang, Lei] Daqing Peoples Hosp, Dept Obstet, 213 Construct Rd, Daqing 163000, Heilongjiang, Peoples R China	Liang, L (reprint author), Daqing Peoples Hosp, Dept Obstet, 213 Construct Rd, Daqing 163000, Heilongjiang, Peoples R China.	Lianglei-dq@163.com					Barnett P, 2011, BIOCHEM BIOPH RES CO, V404, P34, DOI 10.1016/j.bbrc.2010.11.044; Bartholomeusz C, 2012, EXPERT OPIN THER TAR, V16, P121, DOI 10.1517/14728222.2011.644788; Castronovo V, 2006, MOL CELL PROTEOMICS, V5, P2083, DOI 10.1074/mcp.M600164-MCP200; Chen QY, 2015, CELL PHYSIOL BIOCHEM, V36, P956, DOI 10.1159/000430270; Emdad L, 2007, PHARMACOL THERAPEUT, V114, P155, DOI 10.1016/j.pharmthera.2007.01.010; Holmila R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174265; Jayachandran A, 2016, ONCOTARGET, V7, P41186, DOI 10.18632/oncotarget.9227; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115; Li HX, 2014, ARCH GYNECOL OBSTET, V290, P1067, DOI 10.1007/s00404-014-3377-3; Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836; Mirzaei H, 2016, J CANCER RES THER, V12, P498, DOI 10.4103/0973-1482.153661; Mitchell MS, 2000, CANCER RES, V60, P6448; NELSON RE, 1994, EMBO J, V13, P3438, DOI 10.1002/j.1460-2075.1994.tb06649.x; Perren TJ, 2011, NEW ENGL J MED, V365, P2484, DOI 10.1056/NEJMoa1103799; Peterfi Z, 2014, TRENDS BIOCHEM SCI, V39, P305, DOI 10.1016/j.tibs.2014.05.005; Peterfi Z, 2009, AM J PATHOL, V175, P725, DOI 10.2353/ajpath.2009.080693; Shapira I, 2014, BRIT J CANCER, V110, P976, DOI 10.1038/bjc.2013.795; Sitole BN, 2018, GENE, V646, P195, DOI 10.1016/j.gene.2018.01.011; Tauber S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-200; Wang D, 2012, J BIOSCIENCES, V37, P91, DOI 10.1007/s12038-011-9172-4; Woods K., 2013, CANC RES, V73; Yan XH, 2014, HUM MOL GENET, V23, P5597, DOI 10.1093/hmg/ddu274; Young CD, 2015, MOL CELL PROTEOMICS, V14, P1959, DOI 10.1074/mcp.M115.049783	23	1	1	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						161	165		10.1016/j.anndiagpath.2018.03.002			5	Pathology	Pathology	GL1VO	WOS:000436900200029	29661721				2019-10-28	
J	Mantsopoulos, K; Goncalvesa, M; Koch, M; Iro, H; Agaimy, A				Mantsopoulos, Konstantinos; Goncalvesa, Miguel; Koch, Michael; Iro, Heinrich; Agaimy, Abbas			Submandibular gland pleomorphic adenoma: Histopathological capsular characteristics and correlation with the surgical outcome	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Pleomorphic adenoma; Submandibular gland; Submandibulectomy; Pseudopodium; Satellite tumor; Recurrence	MAJOR SALIVARY-GLANDS; PAROTID-GLAND; TUMORS; SURGERY; MANAGEMENT; BENIGN; EXPERIENCE	Pleomorphic adenoma (PA) of the submandibular gland is known to have a very low recurrence rate. The aim of this study was to investigate the histopathological and capsular characteristics of submandibular gland PA, looking for any differences between submandibular PA and the reported data for PA of the parotid gland as possible explanation for its low recurrence rate. We reviewed 72 submandibular gland PM resected at our center between 2000 and 2016. Patient age ranged from 14 to 77 years (mean, 47.2). At least follow (range, 12 to 170 months; mean, 82), none of the 72 patients developed a local recurrence. Histologically, all of the tumors were encased by a complete and intact anatomical capsule (100%). Pseudopodia were detected in 11 (15.3%) and satellite nodules in 3 (4.2%) cases. The histological subtype (according to Seifert et al.) was classic (mixed) in 39 (54.2%), stroma-rich/myxoid in 18/72 (25%) and cellular in 15 (20.8%) cases. A complete rim of healthy pericapsular tissue encasing the tumor and its capsule was observed in only 23/72 (31.9%) cases. In conclusion, submandibular PAs are characterized by consistent presence of an intact anatomical capsule, infrequent occurrence of pseudopodia, a remarkably infrequent occurrence lower frequency of secondary satellite tumor nodules and a comparatively lower proportion of the fragile risky myxoid subtype. Despite the fact that surgery of the submandibular gland can frequently lead to focal capsular exposure, the aforementioned capsular characteristics of submandibular gland PA are probably responsible for the excellent oncologic results.	[Mantsopoulos, Konstantinos; Goncalvesa, Miguel; Koch, Michael; Iro, Heinrich] Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Otorhinolaryngol Head & Neck Surg, Waldstr 1, D-91054 Erlangen, Germany; [Agaimy, Abbas] Friedrich Alexander Univ Erlangen Nurnberg FAU, Inst Pathol, Erlangen, Germany	Mantsopoulos, K (reprint author), Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Otorhinolaryngol Head & Neck Surg, Waldstr 1, D-91054 Erlangen, Germany.	konstantinos.mantsopoulos@uk-erlangen.de	Mantsopoulos, Konstantinos/I-1097-2019	Mantsopoulos, Konstantinos/0000-0002-4948-8882			Beahm DD, 2009, INT J SURG, V7, P503, DOI 10.1016/j.ijsu.2009.09.006; CHIDZONGA MM, 1995, ORAL SURG ORAL MED O, V79, P747, DOI 10.1016/S1079-2104(05)80310-5; DONOVAN DT, 1984, LARYNGOSCOPE, V94, P324; Dulguerov P, 2017, FRONT SURG, V4, DOI 10.3389/fsurg.2017.00026; ENEROTH CM, 1965, ANN OTO RHINOL LARYN, V74, P944, DOI 10.1177/000348946507400403; EVESON JW, 1985, J PATHOL, V146, P51, DOI 10.1002/path.1711460106; Alves CAF, 2007, HEAD NECK PATHOL, V1, P178, DOI 10.1007/s12105-007-0037-y; Ge N, 2016, INT J ORAL MAX SURG, V45, P750, DOI 10.1016/j.ijom.2015.12.013; LASKAWI R, 1995, J ORAL MAXIL SURG, V53, P506, DOI 10.1016/0278-2391(95)90057-8; Mantsopoulos K, 2017, LARYNSCOPE INVESTIG, V2, P369, DOI 10.1002/lio2.113; Mantsopoulos K, 2015, LARYNGOSCOPE, V125, P122, DOI 10.1002/lary.24837; Molina EJ, 2008, J PEDIATR SURG, V43, P1224, DOI 10.1016/j.jpedsurg.2008.01.056; Park GC, 2012, J SURG ONCOL, V106, P942, DOI 10.1002/jso.23202; PATEY DH, 1958, BRIT J SURG, V45, P477, DOI 10.1002/bjs.18004519314; Preuss SF, 2007, J ORAL MAXIL SURG, V65, P953, DOI 10.1016/j.joms.2006.02.036; Roh JL, 2008, BRIT J SURG, V95, P1252, DOI 10.1002/bjs.6306; SEIFERT G, 1976, HNO, V24, P415; SPIRO RH, 1986, HEAD NECK SURG, V8, P177, DOI 10.1002/hed.2890080309; Stennert E, 2001, LARYNGOSCOPE, V111, P2195, DOI 10.1097/00005537-200112000-00024; Webb AJ, 2001, CLIN OTOLARYNGOL, V26, P134, DOI 10.1046/j.1365-2273.2001.00440.x; Witt RL, 2002, LARYNGOSCOPE, V112, P2141, DOI 10.1097/00005537-200212000-00004; Witt RL, 2015, LARYNGOSCOPE, V125, P888, DOI 10.1002/lary.24964; Wittekindt C, 2007, HEAD NECK-J SCI SPEC, V29, P822, DOI 10.1002/hed; Zbaren P, 2007, HEAD NECK-J SCI SPEC, V29, P751, DOI 10.1002/hed.20569	24	3	4	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						166	169		10.1016/j.anndiagpath.2018.04.002			4	Pathology	Pathology	GL1VO	WOS:000436900200030	29689463				2019-10-28	
J	Khan, F; Ricks-Santi, LJ; Zafar, R; Kanaan, Y; Naab, T				Khan, Farhan; Ricks-Santi, Luisel J.; Zafar, Rabia; Kanaan, Yasmine; Naab, Tammey			Expression of p27 and c-Myc by immunohistochemistry in breast ductal cancers in African American women	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						p27; c-Myc; Cyclin and; cyclin dependent kinase; Axin I tumor suppressor gene; Triple negative breast cancer; African American	SUBTYPES; TARGET	Objectives: Proteins p27 and c-Myc are both key players in the cell cycle. While p27, a tumor suppressor, inhibits progression from G1 to S phase, c-Myc, a proto-oncogene, plays a key role in cell cycle regulation and apoptosis. The objective of our study was to determine the association between expression of c-Myc and the loss of p27 by immunohistochemistry (IHC) in the four major subtypes of breast cancer (BC) (Luminal A, Luminal B, HER2, and Triple Negative) and with other clinicopathological factors in a population of 202 African-American (AA) women. Materials and methods: Tissue microarrays (TMAs) were constructed from FFPE tumor blocks from primary ductal breast carcinomas in 202 AA women. Five micrometer sections were stained with a mouse monoclonal antibody against p27 and a rabbit monoclonal antibody against c-Myc. The sections were evaluated for intensity of nuclear reactivity (1-3) and percentage of reactive cells; an H-score was derived from the product of these measurements. Results: Loss of p27 expression and c-Myc overexpression showed statistical significance with ER negative (p < 0.0001), PR negative (p < 0.0001), triple negative (TN) (p < 0.0001), grade 3 (p = 0.038), and overall survival (p = 0.047). There was no statistical significant association between c-Myc expression/p27 loss and luminal A/B and Her2 overexpressing subtypes. Conclusion: In our study, a statistically significant association between c-Myc expression and p27 loss and the triple negative breast cancers (TNBC) was found in AA women. A recent study found that constitutive c-Myc expression is associated with inactivation of the axin 1 tumor suppressor gene. p27 inhibits cyclin dependent kinase2/cyclin A/E complex formation. Axin 1 and CDK inhibitors may represent possible therapeutic targets for TNBC.	[Khan, Farhan; Zafar, Rabia; Naab, Tammey] Howard Univ, Coll Med, Dept Pathol, 2041 Georgia Ave NW, Washington, DC 20060 USA; [Kanaan, Yasmine] Howard Univ, Coll Med, Dept Microbiol, Washington, DC 20060 USA; [Ricks-Santi, Luisel J.] Hampton Univ, Dept Biol Sci, Hampton, VA 23668 USA	Khan, F (reprint author), Howard Univ, Coll Med, Dept Pathol, 2041 Georgia Ave NW, Washington, DC 20060 USA.	farhan.khan@wustl.edu			National Center for Research Resources (NCRR), National Institutes of Health, through the Clinical and Translational Science Awards Program (CTSA), a trademark of DHHS, part of the Roadmap Initiative, "Re-Engineering the Clinical Research Enterprise" [UL1RR031975]; RCMI Program at Howard University, Division of Research Infrastructure, National Center for Research Resources, NIH [G12 RR003048]; Howard University Cancer Center/Johns Hopkins Cancer Center Partnership, National Cancer Institute, NIH [U54 CA091431]	This project has been funded in whole or in part with Federal funds (UL1RR031975) from the National Center for Research Resources (NCRR), National Institutes of Health, through the Clinical and Translational Science Awards Program (CTSA), a trademark of DHHS, part of the Roadmap Initiative, "Re-Engineering the Clinical Research Enterprise," (G12 RR003048) from the RCMI Program at Howard University, Division of Research Infrastructure, National Center for Research Resources, NIH and (U54 CA091431) the Howard University Cancer Center/Johns Hopkins Cancer Center Partnership, National Cancer Institute, NIH.	American Cancer Society, 2009, CANC FACTS FIG AFR A; Arnold HK, 2009, EMBO J, V28, P500, DOI 10.1038/emboj.2008.279; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Charafe-Jauffret E, 2005, INT J ONCOL, V27, P1307; Dang CV, 1999, MOL CELL BIOL, V19, P1; DeSantis CE, 2015, BREAST CANC STAT, DOI DOI 10.3322/CAAC.21320/EPDF.; Horiuchi D, 2012, J EXP MED, DOI [10.1084/jem.20111512., DOI 10.1084/JEM.20111512.]; Nakayama K, 2001, BIOCHEM BIOPH RES CO, V282, P853, DOI 10.1006/bbrc.2001.4627; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tsihlias J, 1999, ANNU REV MED, V50, P401; Vita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015; Xu Jinhua, 2010, Genes Cancer, V1, P629, DOI 10.1177/1947601910378691; Zhang XL, 2012, P NATL ACAD SCI USA, V109, P2790, DOI 10.1073/pnas.1100764108	16	1	1	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	JUN	2018	34						170	174		10.1016/j.anndiagpath.2018.03.013			5	Pathology	Pathology	GL1VO	WOS:000436900200031	29715580	Green Accepted			2019-10-28	
J	Laxl, SF				Laxl, Sigurd F.			Miniseries of reviews: gynecological pathology	VIRCHOWS ARCHIV			English	Article							MOLECULAR-BASED CLASSIFICATION; ENDOMETRIAL CARCINOMA; CANCER		[Laxl, Sigurd F.] Hosp Graz Sud West, Dept Pathol, Gostingerstr 22, AT-8020 Graz, Austria	Laxl, SF (reprint author), Hosp Graz Sud West, Dept Pathol, Gostingerstr 22, AT-8020 Graz, Austria.	sigurd.lax@medunigraz.at					BOKHMAN JV, 1983, GYNECOL ONCOL, V15, P10, DOI 10.1016/0090-8258(83)90111-7; De Vivar AD, 2013, INT J GYNECOL PATHOL, V32, P592, DOI 10.1097/PGP.0b013e31829952c6; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Lax S F, 1997, Verh Dtsch Ges Pathol, V81, P228; Lax SF, 2004, VIRCHOWS ARCH, V444, P213, DOI 10.1007/s00428-003-0947-3; Nucci MR, 1999, MODERN PATHOL, V12, P1137; Roma AA, 2016, GYNECOL ONCOL, V141, P36, DOI 10.1016/j.ygyno.2016.02.028; Talhouk A, 2015, BRIT J CANCER, V113, P299, DOI 10.1038/bjc.2015.190; Travis WD, 2013, J CLIN ONCOL, V31, P992, DOI 10.1200/JCO.2012.46.9270; Vuong D, 2014, VIRCHOWS ARCH, V465, P1, DOI 10.1007/s00428-014-1593-7	10	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUN	2018	472	6					883	884		10.1007/s00428-018-2385-2			2	Pathology	Pathology	GJ5GU	WOS:000435410300001	29862419	Bronze			2019-10-28	
J	Goebel, EA; Vidal, A; Matias-Guiu, X; Gilks, CB				Goebel, Emily A.; Vidal, August; Matias-Guiu, Xavier; Gilks, C. Blake			The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future	VIRCHOWS ARCHIV			English	Review						Endometrial carcinoma; Classification of endometrial carcinoma; Immunohistochemistry; Molecular diagnostics	CLEAR-CELL-CARCINOMA; SEROUS CARCINOMA; UNDIFFERENTIATED CARCINOMA; PROTEIN EXPRESSION; CANCER; ADENOCARCINOMA; MUTATION; REPRODUCIBILITY; FEATURES; P53	Uterine cancer was first subclassified based on anatomic site, separating those tumours arising from the endometrium from cervical cancers. There was then further subclassification of endometrial cancers based on cell type, and this correlated with the Type I and Type II categories identified through the epidemiological studies of Bokhman, with endometrioid carcinoma corresponding (approximately) to Type I and serous carcinoma to Type II. These histotypes are not clearly separable in practice, however, with considerable interobserver variability in histotype diagnosis, especially for high-grade tumours. There followed studies of immunomarkers and then mutational studies of single genes, in attempts to improve subclassification. While these have revealed significant differences in protein expression and mutation profiles between endometrioid and serous carcinomas, there is also considerable overlap, so that there remain challenges in subclassification of endometrial carcinoma. Gene panel testing, using next-generation sequencing, was applied to endometrial cancers and highlighted that there are tumours that show genetic alterations intermediate between classic Type I/endometrioid and Type II/serous carcinomas. The Cancer Genome Atlas studies of endometrioid and serous carcinoma offered revolutionary insight into the subclassification of endometrial carcinoma, i.e. that there are four distinct categories of endometrial carcinoma, rather than two, based on genomic architecture. In this review, we provide an overview of immunohistochemical and molecular markers in endometrial carcinoma and comment on the important future directions in endometrial carcinoma subclassification arising from The Cancer Genome Atlas results.	[Goebel, Emily A.] Western Univ, Dept Pathol & Lab Med, London, ON, Canada; [Goebel, Emily A.] London Hlth Sci Ctr, London, ON, Canada; [Vidal, August] Hosp Univ Bellvitge, IDIBELL, CIBERONC, Barcelona, Spain; [Matias-Guiu, Xavier] Hosp Univ Amau Vilanova Lleida, Dept Pathol, Barcelona, Spain; [Matias-Guiu, Xavier] Hosp Univ Bellvitge, IRBLleida, IDIBELL, CIBERONC, Barcelona, Spain; [Gilks, C. Blake] Vancouver Gen Hosp, Dept Anat Pathol, Vancouver, BC, Canada	Gilks, CB (reprint author), Vancouver Gen Hosp, Dept Anat Pathol, Vancouver, BC, Canada.	Blake.Gilks@vch.ca	matias-guiu, xavier/C-3039-2009; Vidal, August/N-4662-2016	matias-guiu, xavier/0000-0002-7201-6605; Vidal, August/0000-0001-5727-2099			Al-Maghrabi JA, 2016, APPL IMMUNOHISTO M M, V1, P632, DOI [10.1097/PAI, DOI 10.1097/PAI]; Alkushi A, 2007, MODERN PATHOL, V20, P1156, DOI 10.1038/modpathol.3800950; Alkushi A, 2010, INT J GYNECOL PATHOL, V29, P343, DOI 10.1097/PGP.0b013e3181cd6552; Bakhsh S, 2016, HISTOPATHOLOGY, V68, P916, DOI 10.1111/his.12878; BOKHMAN JV, 1983, GYNECOL ONCOL, V15, P10, DOI 10.1016/0090-8258(83)90111-7; Boruta DM, 2004, CANCER-AM CANCER SOC, V101, P2214, DOI 10.1002/cncr.20645; Cancer Genome Atlas Research Network T, 2013, INTEGRATED GENOMIC C, DOI [10.1038/nature12113, DOI 10.1038/NATURE12113]; Chekmareva M, 2008, INT J GYNECOL PATHOL, V27, P547, DOI 10.1097/PGP.0b013e318177eadc; CHRISTOPHERSON W M, 1982, Cancer, V49, P1511, DOI 10.1002/1097-0142(19820415)49:8<1511::AID-CNCR2820490802>3.0.CO;2-6; Church DN, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju402; Coenegrachts L, 2015, VIRCHOWS ARCH, V466, P415, DOI 10.1007/s00428-015-1728-5; Djordjeyic B, 2012, MODERN PATHOL, V25, P699, DOI 10.1038/modpathol.2011.208; Fadare O, 2014, AM J SURG PATHOL, V38, P189, DOI 10.1097/PAS.0000000000000085; Garg K, 2009, J CLIN PATHOL, V62, P679, DOI 10.1136/jcp.2009.064949; Garg K, 2010, MODERN PATHOL, V23, P80, DOI 10.1038/modpathol.2009.153; Gatius S, 2016, MODERN PATHOL, V29, pS45, DOI 10.1038/modpathol.2015.141; Gilks CB, 2013, AM J SURG PATHOL, V37, P874, DOI 10.1097/PAS.0b013e31827f576a; Goto T, 2012, EUR J GYNAECOL ONCOL, V33, P579; Guan B, 2011, AM J SURG PATHOL, V35, P625, DOI 10.1097/PAS.0b013e318212782a; Hamilton CA, 2006, BRIT J CANCER, V94, P642, DOI 10.1038/sj.bjc.6603012; Han GM, 2013, MODERN PATHOL, V26, P1594, DOI 10.1038/modpathol.2013.102; HENDRICKSON M, 1982, AM J SURG PATHOL, V6, P93, DOI 10.1097/00000478-198203000-00002; Hoang LN, 2017, AM J SURG PATHOL, V41, P245, DOI 10.1097/PAS.0000000000000764; Hoang LN, 2016, HISTOPATHOLOGY, V69, P560, DOI 10.1111/his.12989; Hoang LN, 2015, HISTOPATHOLOGY, V66, P664, DOI 10.1111/his.12581; Hoang LN, 2014, HISTOPATHOLOGY, V64, P585, DOI 10.1111/his.12286; Hoang LN, 2013, AM J SURG PATHOL, V37, P1421, DOI 10.1097/PAS.0b013e31828c63ed; Kapucuoglu N, 2008, INT J GYNECOL CANCER, V18, P790, DOI 10.1111/j.1525-1438.2007.01067.x; Karamanou M, 2015, J BUON, V20, P1645; Karnezis AN, 2016, MODERN PATHOL, V29, P302, DOI 10.1038/modpathol.2015.155; Kobel M, 2016, J PATHOL CLIN RES, V2, P247, DOI 10.1002/cjp2.53; Kobel M, 2016, AM J SURG PATHOL, V40, P166, DOI 10.1097/PAS.0000000000000536; Kumar M, 2015, MOL ASPECTS MED, V45, P55, DOI 10.1016/j.mam.2015.06.009; KURMAN RJ, 1976, CANCER-AM CANCER SOC, V37, P872, DOI 10.1002/1097-0142(197602)37:2<872::AID-CNCR2820370236>3.0.CO;2-L; Kurman RJ, 2014, WHO CLASSIFICATION T; Lax SF, 2000, CANCER-AM CANCER SOC, V88, P814, DOI 10.1002/(SICI)1097-0142(20000215)88:4<814::AID-CNCR12>3.3.CO;2-L; Lax SF, 1998, HUM PATHOL, V29, P924, DOI 10.1016/S0046-8177(98)90197-6; Lee S, 2016, INT CONF UBIQ ROBOT, P35, DOI 10.1109/URAI.2016.7734015; Li ZB, 2016, APPL IMMUNOHISTO M M, V24, P562, DOI 10.1097/PAI.0000000000000232; Lomo L, 2008, MODERN PATHOL, V21, P937, DOI 10.1038/modpathol.2008.97; Mackenzie R, 2015, AM J SURG PATHOL, V39, P1548, DOI 10.1097/PAS.0000000000000476; Maiques O, 2014, HUM PATHOL, V45, P522, DOI 10.1016/j.humpath.2013.10.018; McCluggage WG, 2003, INT J GYNECOL PATHOL, V22, P231, DOI 10.1097/01.PGP.0000055172.04957.2F; McConechy MK, 2015, GYNECOL ONCOL, V137, P306, DOI 10.1016/j.ygyno.2015.01.541; McConechy MK, 2016, CLIN CANCER RES, V22, P2865, DOI 10.1158/1078-0432.CCR-15-2233; McConechy MK, 2012, J PATHOL, V228, P20, DOI 10.1002/path.4056; McConechy MK, 2011, J PATHOL, V223, P567, DOI 10.1002/path.2848; McGunigal M, 2017, INT J GYNECOL CANCER, V27, P85, DOI 10.1097/IGC.0000000000000844; Mittal K, 2008, ARCH PATHOL LAB MED, V132, P402, DOI 10.1043/1543-2165(2008)132[402:AOITGP]2.0.CO;2; Moreno-Bueno G, 2003, CANCER RES, V63, P5697; Mota A, 2017, MODERN PATHOL, V30, P134, DOI 10.1038/modpathol.2016.143; Nastic D, 2017, INT J GYNECOL PATHOL, V36, P339, DOI 10.1097/PGP.0000000000000334; Nicolini A, 2018, SEMIN CANCER BIOL, V52, P56, DOI 10.1016/j.semcancer.2017.08.010; Oda K, 2005, CANCER RES, V65, P10669, DOI 10.1158/0008-5472.CAN-05-2620; Piulats JM, 2017, GYNECOL ONCOL, V145, P200, DOI 10.1016/j.ygyno.2016.12.015; Piulats JM, 2016, CLIN CANCER RES, V22, P5623, DOI 10.1158/1078-0432.CCR-16-1820; Ramalingam P, 2017, HISTOPATHOLOGY, V70, P359, DOI 10.1111/his.13091; Ramalingam P, 2016, INT J GYNECOL PATHOL, V35, P410, DOI 10.1097/PGP.0000000000000248; Rudd ML, 2011, CLIN CANCER RES, V17, P1331, DOI 10.1158/1078-0432.CCR-10-0540; Santacana M, 2014, HUM PATHOL, V45, P2394, DOI 10.1016/j.humpath.2014.06.031; Sato Y, 1985, Nihon Sanka Fujinka Gakkai Zasshi, V37, P1015; Schultheis AM, 2016, INT J GYNECOL PATHOL, V35, P289, DOI 10.1097/PGP.0000000000000243; Shikama A, 2016, GYNECOL ONCOL, V140, P226, DOI 10.1016/j.ygyno.2015.11.032; Singh N, 2017, HISTOPATHOLOGY, V70, P56, DOI 10.1111/his.13080; Soslow RA, 2007, AM J SURG PATHOL, V31, P979, DOI 10.1097/PAS.0b013e31802ee494; Soslow RA, 2010, SEMIN DIAGN PATHOL, V27, P261, DOI 10.1053/j.semdp.2010.09.003; Stelloo E, 2016, CLIN CANCER RES, V22, P4215, DOI 10.1158/1078-0432.CCR-15-2878; Stewart CJR, 2015, PATHOLOGY, V47, P439, DOI 10.1097/PAT.0000000000000270; Talhouk A, 2015, BRIT J CANCER, V113, P299, DOI 10.1038/bjc.2015.190; Talhouk A, 2017, CANCER-AM CANCER SOC, V123, P802, DOI 10.1002/cncr.30496; Talhouk A, 2016, GYNECOL ONCOL, V143, P46, DOI 10.1016/j.ygyno.2016.07.090; Thomas S, 2016, ARCH PATHOL LAB MED, V140, P836, DOI 10.5858/arpa.2015-0220-OA; Voss MA, 2012, GYNECOL ONCOL, V124, P15, DOI 10.1016/j.ygyno.2011.07.030; Wei JJ, 2013, ARCH PATHOL LAB MED, V137, P1574, DOI 10.5858/arpa.2012-0445-OA; Yeramian A, 2013, ONCOGENE, V32, P403, DOI 10.1038/onc.2012.76; Yoon G, 2017, ONCOTARGET, V8, P4826, DOI 10.18632/oncotarget.13594	76	4	4	2	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUN	2018	472	6					885	896		10.1007/s00428-017-2279-8			12	Pathology	Pathology	GJ5GU	WOS:000435410300002	29234950				2019-10-28	
J	Cibula, D; Potter, R; Planchamp, F; Avall-Lundqvist, E; Fischerova, D; Haie-Meder, C; Kohler, C; Landoni, F; Lax, S; Lindegaard, JC; Mahantshetty, U; Mathevet, P; McCluggage, WG; McCormack, M; Naik, R; Nout, R; Pignata, S; Ponce, J; Querleu, D; Raspagliesi, F; Rodolakis, A; Tamussino, K; Wimberger, P; Raspollini, MR				Cibula, David; Poetter, Richard; Planchamp, Francois; Avall-Lundqvist, Elisabeth; Fischerova, Daniela; Haie-Meder, Christine; Koehler, Christhardt; Landoni, Fabio; Lax, Sigurd; Lindegaard, Jacob Christian; Mahantshetty, Umesh; Mathevet, Patrice; McCluggage, W. Glenn; McCormack, Mary; Naik, Raj; Nout, Remi; Pignata, Sandro; Ponce, Jordi; Querleu, Denis; Raspagliesi, Francesco; Rodolakis, Alexandros; Tamussino, Karl; Wimberger, Pauline; Raspollini, Maria Rosaria			The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer	VIRCHOWS ARCHIV			English	Article						Cervical cancer; Guidelines; Management; Staging; Follow-up		The European Society of Gynecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) jointly develop clinically relevant and evidence-based guidelines in order to improve the quality of care for women with cervical cancer across Europe and worldwide. The ESGO/ESTRO/ESP nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of cervical cancer (23 experts across Europe). To ensure that the guidelines are evidence based, the current literature identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 159 international reviewers, selected through ESGO/ESTRO/ESP and including patient representatives. The guidelines cover comprehensively staging, management, and follow-up for patients with cervical cancer. Management includes fertility sparing treatment; stage T1a, T1b1/T2a1, clinically occult cervical cancer diagnosed after simple hysterectomy; early and locally advanced cervical cancer; primary distant metastatic disease; cervical cancer in pregnancy; and recurrent disease. Principles of radiotherapy and pathological evaluation are defined.	[Cibula, David; Fischerova, Daniela] Charles Univ Prague, Fac Med 1, Gynecol Oncol Ctr, Dept Obstet & Gynecol, Katerinska 32, Prague 12108, Czech Republic; [Cibula, David; Fischerova, Daniela] Gen Univ Hosp, Katerinska 32, Prague 12108, Czech Republic; [Poetter, Richard] Med Univ Vienna, Dept Radiotherapy, Vienna, Austria; [Planchamp, Francois; Querleu, Denis] Inst Bergoni, Bordeaux, France; [Avall-Lundqvist, Elisabeth] Linkoping Univ, Linkoping, Sweden; [Haie-Meder, Christine] Inst Gustave Roussy, Dept Radiotherapy, Villejuif, France; [Koehler, Christhardt] Asklepios Hambourg Altona & Univ Cologne, Fac Med, Dept Gynecol, Hamburg, Germany; [Landoni, Fabio] Univ Milano Bicocca, Monza, Italy; [Lax, Sigurd] Gen Hosp Graz Sued West, Graz, Austria; [Lindegaard, Jacob Christian] Aarhus Univ, Dept Oncol, Aarhus, Denmark; [Mahantshetty, Umesh] Tata Mem Hosp, Dept Radiat Oncol, Mumbai, Maharashtra, India; [Mathevet, Patrice] Lausanne Univ, Lausanne, Switzerland; [McCluggage, W. Glenn] Belfast Hlth & Social Care Tmst, Dept Pathol, Belfast, Antrim, North Ireland; [McCormack, Mary] Univ Coll London Hosp, London, England; [Naik, Raj] Queen Elizabeth Hosp, Gateshead, England; [Nout, Remi] Leiden Univ, Dept Radiat Oncol, Leiden, Netherlands; [Pignata, Sandro] IRCCS, Ist Nazl Studio & Curd Tumori Fdn G Pascale, Naples, Italy; [Ponce, Jordi] Univ Hosp Bellvitge IDIBELL, Barcelona, Spain; [Raspagliesi, Francesco] Fdn IRCCS Ist Nazl Tumori, Milan, Italy; [Rodolakis, Alexandros] Univ Athens, Athens, Greece; [Tamussino, Karl] Med Univ Graz, Graz, Austria; [Wimberger, Pauline] Dresden Univ, TU Dresden, Dresden, Germany; [Raspollini, Maria Rosaria] Univ Hosp, Florence, Italy	Cibula, D (reprint author), Charles Univ Prague, Fac Med 1, Gynecol Oncol Ctr, Dept Obstet & Gynecol, Katerinska 32, Prague 12108, Czech Republic.; Cibula, D (reprint author), Gen Univ Hosp, Katerinska 32, Prague 12108, Czech Republic.	dc@davidcibula.cz			Institut National du Cancer (France)Institut National du Cancer (INCA) France	The authors thank the Guidelines, Recommendations and Quality Assurance Committee of ESGO. The authors also thank the 159 international reviewers for their participation (Supplementary Material 3). Lastly, the authors also wish to express gratitude to the Institut National du Cancer (France) for providing major funding for this work.		0	11	11	1	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUN	2018	472	6					919	936		10.1007/s00428-018-2362-9			18	Pathology	Pathology	GJ5GU	WOS:000435410300005	29725757				2019-10-28	
J	Cibula, D; Potter, R; Planchamp, F; Avall-Lundqvist, E; Fischerova, D; Haie-Meder, C; Kohler, C; Landoni, F; Lax, S; Lindegaard, JC; Mahantshetty, U; Mathevet, P; McCluggage, WG; McCormack, M; Naik, R; Nout, R; Pignata, S; Ponce, J; Querleu, D; Raspagliesi, F; Rodolakis, A; Tamussino, K; Wimberger, P; Raspollini, MR				Cibula, David; Poetter, Richard; Planchamp, Francois; Avall-Lundqvist, Elisabeth; Fischerova, Daniela; Haie-Meder, Christine; Koehler, Christhardt; Landoni, Fabio; Lax, Sigurd; Lindegaard, Jacob Christian; Mahantshetty, Umesh; Mathevet, Patrice; McCluggage, W. Glenn; McCormack, Mary; Naik, Raj; Nout, Remi; Pignata, Sandro; Ponce, Jordi; Querleu, Denis; Raspagliesi, Francesco; Rodolakis, Alexandros; Tamussino, Karl; Wimberger, Pauline; Raspollini, Maria Rosaria			The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer (vol 28, pg 641, 2018)	VIRCHOWS ARCHIV			English	Correction									[Cibula, David; Fischerova, Daniela] Charles Univ Prague, Gynecol Oncol Ctr, Dept Obstet & Gynecol, Fac Med 1, Katerinska 32, Prague 12108, Czech Republic; [Cibula, David; Fischerova, Daniela] Gen Univ Hosp, Katerinska 32, Prague 12108, Czech Republic; [Poetter, Richard] Med Univ Vienna, Dept Radiotherapy, Vienna, Austria; [Planchamp, Francois; Querleu, Denis] Inst Bergoni, Bordeaux, France; [Avall-Lundqvist, Elisabeth] Linkoping Univ, Linkoping, Sweden; [Haie-Meder, Christine] Inst Gustave Roussy, Dept Radiotherapy, Villejuif, France; [Koehler, Christhardt] Asklepios Hambourg Altona & Univ Cologne, Fac Med, Dept Gynecol, Hamburg, Germany; [Landoni, Fabio] Univ Milano Bicocca, Monza, Italy; [Lax, Sigurd] Gen Hosp Graz Sued West, Graz, Austria; [Lindegaard, Jacob Christian] Aarhus Univ, Dept Oncol, Aarhus, Denmark; [Mahantshetty, Umesh] Tata Mem Hosp, Dept Radiat Oncol, Mumbai, Maharashtra, India; [Mathevet, Patrice] Lausanne Univ, Lausanne, Switzerland; [McCluggage, W. Glenn] Belfast Hlth & Social Care Trust, Dept Pathol, Belfast, Antrim, North Ireland; [McCormack, Mary] Univ Coll London Hosp, London, England; [Naik, Raj] Queen Elizabeth Hosp, Gateshead, England; [Nout, Remi] Leiden Univ, Dept Radiat Oncol, Leiden, Netherlands; [Pignata, Sandro] IRCCS, Ist Nazl Studio & Cura Tumori Fdn G Pascale, Naples, Italy; [Ponce, Jordi] Univ Hosp Bellvitge IDIBELL, Barcelona, Spain; [Raspagliesi, Francesco] Fdn IRCCS Ist Nazl Tumori, Milan, Italy; [Rodolakis, Alexandros] Univ Athens, Athens, Greece; [Tamussino, Karl] Med Univ Graz, Graz, Austria; [Wimberger, Pauline] Dresden Univ, TU Dresden, Dresden, Germany; [Raspollini, Maria Rosaria] Univ Hosp, Florence, Italy	Cibula, D (reprint author), Charles Univ Prague, Gynecol Oncol Ctr, Dept Obstet & Gynecol, Fac Med 1, Katerinska 32, Prague 12108, Czech Republic.; Cibula, D (reprint author), Gen Univ Hosp, Katerinska 32, Prague 12108, Czech Republic.	dc@davidcibula.cz		pignata, sandro/0000-0002-8836-2633			Cibula D, 2018, VIRCHOWS ARCH, V472, P919, DOI 10.1007/s00428-018-2362-9	1	0	0	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUN	2018	472	6					937	938		10.1007/s00428-018-2380-7			2	Pathology	Pathology	GJ5GU	WOS:000435410300006	29789924				2019-10-28	
J	Luchini, C; Veronese, N; Nottegar, A; Cheng, M; Kaneko, T; Pilati, C; Tabbo, F; Stubbs, B; Pea, A; Bagante, F; Demurtas, J; Fassan, M; Infante, M; Cheng, L; Scarpa, A				Luchini, Claudio; Veronese, Nicola; Nottegar, Alessia; Cheng, Monica; Kaneko, Takuma; Pilati, Camilla; Tabbo, Fabrizio; Stubbs, Brendon; Pea, Antonio; Bagante, Fabio; Demurtas, Jacopo; Fassan, Matteo; Infante, Maurizio; Cheng, Liang; Scarpa, Aldo			Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis	VIRCHOWS ARCHIV			English	Article						Lung cancer; NSCLC; Prognosis; Extranodal; Extracapsular; Metastasis	MEDIASTINAL LYMPH-NODES; EXTRACAPSULAR EXTENSION; CARCINOMA; HETEROGENEITY; INVOLVEMENT; RECURRENCE; SURVIVAL; HEAD; BIAS	Extranodal extension (ENE) of nodal metastasis is defined as the extension of metastatic cells through the nodal capsule into the perinodal tissue. This morphological parameter, recently proposed as an important prognostic factor in different types of malignancy, has not been included in the TNM staging system for non-small cell lung cancer (NSCLC). In this systematic review with meta-analysis, we weighted the prognostic role of ENE in patients with lymph node-positive NSCLC. Two independent authors searched SCOPUS and PubMed through 28 February 2017. Prospective and retrospective studies on NSCLC, comparing patients with presence of ENE (ENE+) ENE+) vs. only intranodal extension (ENE-) and including data regarding prognosis, were considered as eligible. Data were summarized using risk ratios (RR) for the number of deaths/recurrences, and hazard ratios (HR) with 95% confidence intervals (CI) for time-dependent risk related to ENE+, adjusted for potential confounders. We identified 13 studies, including 1709 patients (573 ENE+ and 1136 ENE-) with a median follow-up of 60 months. ENE was associated with a significantly increased risk of mortality of all causes (RR = 1.39, 95% CI: 1.18-1.65, P < 0.0001, I (2) = 70%; HR = 1.30, 95% CI: 1.01-1.67, P = 0.04, I (2) = 0%) and of disease recurrence (RR = 1.32, 95% CI: 1.04-1.68, P = 0.02, I (2) = 42%; HR = 1.93, 95% CI: 1.53-2.44, P < 0.0001, I (2) = 0%). We conclude that in NSCLC, requirements for assessment of ENE should be included in gross sampling and ENE status should be included in the pathology report. Inclusion of ENE status in oncology staging systems will allow further assessment of its role as prognostic parameter.	[Luchini, Claudio; Scarpa, Aldo] Univ & Hosp Trust Verona, Dept Diagnost & Publ Hlth, Piazzale Scuro 10, I-37134 Verona, Italy; [Luchini, Claudio; Fassan, Matteo; Scarpa, Aldo] Univ & Hosp Trust Verona, ARC Net Res Ctr, Verona, Italy; [Veronese, Nicola] CNR, Aging Branch, Neurosci Inst, Padua, Italy; [Veronese, Nicola] Inst Clin Res & Educ Med IREM, Padua, Italy; [Nottegar, Alessia] San Bortolo Hosp, Dept Surg, Vicenza, Italy; [Cheng, Monica; Cheng, Liang] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA; [Kaneko, Takuma] Tohoku Univ, Sch Med, Dept Mol Pathol, Sendai, Miyagi, Japan; [Pilati, Camilla] Univ Paris 05, Personalized Med, Pharmacogen, Therapeut Optimizat, Paris, France; [Tabbo, Fabrizio] Univ Turin, Dept Oncol, Turin, Italy; [Stubbs, Brendon] Kings Coll London, Hlth Serv & Populat Res Dept, De Crespigny Pk, London SE5 8AF, England; [Pea, Antonio; Bagante, Fabio] Univ & Hosp Trust Verona, Dept Surg, Verona, Italy; [Demurtas, Jacopo] LHT South East Tuscany, Primary Care Dept, Grosseto, Italy; [Infante, Maurizio] Borgo Trento City Hosp, Thorac Surg Unit, Verona, Italy	Luchini, C (reprint author), Univ & Hosp Trust Verona, Dept Diagnost & Publ Hlth, Piazzale Scuro 10, I-37134 Verona, Italy.; Luchini, C (reprint author), Univ & Hosp Trust Verona, ARC Net Res Ctr, Verona, Italy.	claudio.luchini@katamail.com	Luchini, Claudio/O-2187-2019; Luchini, Claudio/Q-4922-2016; INFANTE, Maurizio Valentino/AAC-1834-2019; Demurtas, Jacopo/AAA-8814-2019; Stubbs, Brendon/X-1904-2018	Luchini, Claudio/0000-0003-4901-4908; Luchini, Claudio/0000-0003-4901-4908; INFANTE, Maurizio Valentino/0000-0002-0920-4443; Demurtas, Jacopo/0000-0003-3001-8546; Stubbs, Brendon/0000-0001-7387-3791; Bagante, Fabio/0000-0002-5386-0958; Pea, Antonio/0000-0002-0509-6756	Cassini Project, a scientific project of French Embassy in Italy; Associazione Italiana per la Ricerca sul CancroAssociazione Italiana per la Ricerca sul Cancro (AIRC) [12182]	This work is supported by Cassini Project, a scientific project of French Embassy in Italy to support the collaboration among Italian and French researchers (coordinator: Dr. C. Luchini). Prof. Scarpa is supported by Associazione Italiana per la Ricerca sul Cancro (12182). The financial sources have not influenced in any step this manuscript and its content.	Ahn TS, 2015, ANN SURG ONCOL, V22, P3745, DOI 10.1245/s10434-014-4359-1; Amin MB, 2017, AJCC CANC STAGING MA, DOI [10.1007/978-3-319-40618-3, DOI 10.1007/978-3-319-40618-3]; Bergh NP, 1965, ACTA CHIR SCAND    S, V347, P1; BOLLEN ECM, 1994, SCAND J THORAC CARD, V28, P97, DOI 10.3109/14017439409099112; Borghetti P, 2016, RADIOL MED, V121, P696, DOI 10.1007/s11547-016-0648-z; Cetinkaya E, 2017, ENDOSC ULTRASOUND, V6, P162, DOI 10.4103/eus.eus_3_17; Depypere LP, 2017, ANN SURG; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Edge SB, 2010, AJCC CANC STAGING MA; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Feigenberg SJ, 2007, J THORAC ONCOL, V2, P287, DOI 10.1097/01.JTO.0000263710.54073.b3; Han H, 2017, J THORAC DIS, V9, P2102, DOI 10.21037/jtd.2017.06.04; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; ISHIDA T, 1990, J SURG ONCOL, V43, P161, DOI 10.1002/jso.2930430308; LARSSON S, 1976, SCAND J THORAC CARD, P5; Lee YC, 2007, CHEST, V131, P993, DOI 10.1378/chest.06-1810; Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700; Lilo MT, 2017, CANCER CYTOPATHOL, V125, P717, DOI 10.1002/cncy.21886; Liu WS, 2015, INT J CLIN EXP PATHO, V8, P11268; Luchini C, 2016, ANN ONCOL, V27, P1647, DOI 10.1093/annonc/mdw173; Luchini C, 2016, ANN ONCOL, V27, P955, DOI 10.1093/annonc/mdw034; Luchini C, 2016, J CLIN PATHOL; Luchini C, 2017, J THORAC DIS, V9, P3609, DOI 10.21037/jtd.2017.09.36; Luchini C, 2017, WORLD J META-ANAL, V5, P80, DOI 10.13105/wjma.v5.i4.80; Luchini C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02577-4; Luchini C, 2017, ORAL ONCOL, V66, pE1, DOI 10.1016/j.oraloncology.2016.12.032; Luchini C, 2016, SURG ONCOL, V25, P60, DOI 10.1016/j.suronc.2015.09.005; Luchini C, 2016, EUR J GASTROEN HEPAT, V28, P205, DOI 10.1097/MEG.0000000000000520; Macis Giuseppe, 2000, Rays (Rome), V25, P447; Mermod M, 2016, ORAL ONCOL, V62, P60, DOI 10.1016/j.oraloncology.2016.10.003; Moretti L, 2009, ONCOLOGIST, V14, P1106, DOI 10.1634/theoncologist.2009-0130; Nakagawa Tatsuo, 2007, Interact Cardiovasc Thorac Surg, V6, P474, DOI 10.1510/icvts.2007.154641; Nottegar A, 2016, EJSO-EUR J SURG ONC, V42, P919, DOI 10.1016/j.ejso.2016.02.259; Rami-Porta R, 2017, CA-CANCER J CLIN, V67, P138, DOI 10.3322/caac.21390; Sergeant G, 2009, ANN SURG ONCOL, V16, P3070, DOI 10.1245/s10434-009-0627-x; Shin S, 2013, ANN THORAC SURG, V96, P969, DOI 10.1016/j.athoracsur.2013.04.070; Smith RA, 2017, CA-CANCER J CLIN, V67, P100, DOI 10.3322/caac.21392; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; SUEMASU K, 1982, JPN J CLIN ONCOL, V12, P207; Tamura M, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-1048-5; Torre Lindsey A, 2016, Adv Exp Med Biol, V893, P1, DOI 10.1007/978-3-319-24223-1_1; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Travis WD, 2015, WHO CLASSIFICATION T; Vansteenkiste JF, 1997, ANN THORAC SURG, V63, P1441, DOI 10.1016/S0003-4975(97)00314-7; vanVelzen E, 1996, CHEST, V110, P1469, DOI 10.1378/chest.110.6.1469; Veronese N, 2016, ANN ONCOL, V27, P42, DOI 10.1093/annonc/mdv494; Veronese N, 2016, J GASTROINTEST SURG, V20, P1692, DOI 10.1007/s11605-016-3199-7; Veronese N, 2015, J SURG ONCOL, V112, P828, DOI 10.1002/jso.24070; Wells GA, NEWCASTLE OTTAWA SCA; Wind J, 2007, EJSO-EUR J SURG ONC, V33, P401, DOI 10.1016/j.ejso.2006.11.001; Xu HR, 2008, PAEDIATR PERINAT EP, V22, P18, DOI 10.1111/j.1365-3016.2007.00908.x	52	3	3	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUN	2018	472	6					939	947		10.1007/s00428-018-2309-1			9	Pathology	Pathology	GJ5GU	WOS:000435410300007	29392400				2019-10-28	
J	Zombori, T; Nyari, T; Tiszlavicz, L; Palfoldi, R; Csada, E; Geczi, T; Ottlakan, A; Pecsy, B; Cserni, G; Furak, J				Zombori, Tamas; Nyari, Tibor; Tiszlavicz, Laszl; Palfoldi, Regina; Csada, Edit; Geczi, Tibor; Ottlakan, Aurl; Pecsy, Balazs; Cserni, Gabor; Furak, Jozsef			The more the micropapillary pattern in stage I lung adenocarcinoma, the worse the prognosis-a retrospective study on digitalized slides	VIRCHOWS ARCHIV			English	Article						Lung adenocarcinoma; Growth pattern; Predominant; Second predominant component; Survival	SIGNIFICANTLY POOR-PROGNOSIS; DISTINCT PATHOLOGICAL MARKER; IASLC/ATS/ERS CLASSIFICATION; HISTOLOGIC SUBTYPE; PULMONARY ADENOCARCINOMAS; IMPACT; EGFR; INVASION; INTEROBSERVER; ASSOCIATION	Although the majority of lung adenocarcinomas show mixed pattern, only the predominant component is taken into account according to the novel classification. We evaluated the proportion of different patterns and their impact on overall survival (OS) and disease-free survival (DFS). Patterns were recorded according to predominance and their proportions were rated and calculated by objective area measuring on digitalized, annotated slides of resected stage I lung adenocarcinomas. Spearman's rank correlation, Kaplan-Meier models and the log rank test were used for statistical evaluation. Two hundred forty-three stage I adenocarcinoma were included. Lepidic pattern is more frequent in tumours without recurrence (20 vs. 8%), and lepidic predominant tumours have favourable prognosis (OS 90.5%, DFS 89.4%), but proportions above 25% are not associated with improving outcome. Solid and micropapillary patterns are more frequent in patients with recurrence (48 vs. 5% and 13 vs. 4%) and predominance of each one is associated with unfavourable prognosis (OS 64.1%, DFS 56.3% and OS 28.1%, DFS 28.1%, respectively). Above 25%, a growing proportion of solid or micropapillary pattern is not associated with worsening prognosis. In contrast, tumours having micropapillary pattern as secondly predominant form a different intermediate group (OS 51.1%, DFS 57.8%). Our study was based on measured area of each growth pattern on all available slides digitalized. This is the most precise way of determining the size of each component from the material available. We propose using predominant and secondly predominant patterns for prognostic purposes, particularly in tumours having solid or micropapillary patterns.	[Zombori, Tamas; Tiszlavicz, Laszl; Cserni, Gabor] Univ Szeged, Dept Pathol, Fac Med, Allomas U 1, H-6725 Szeged, Hungary; [Nyari, Tibor] Univ Szeged, Dept Med Phys & Informat, Koranyi Fasor 9, H-6720 Szeged, Hungary; [Palfoldi, Regina; Csada, Edit] Hosp Chest Dis, Csongrad Cty, Alkotmany U 36, H-6772 Deszk, Hungary; [Geczi, Tibor; Ottlakan, Aurl; Pecsy, Balazs; Furak, Jozsef] Univ Szeged, Dept Surg, Semmelweis U 8, H-6720 Szeged, Hungary; [Cserni, Gabor] Bacs Kiskun Cty Teaching Hosp, Dept Pathol, Nyiri Ut 38, H-6000 Kecskemet, Hungary	Zombori, T (reprint author), Univ Szeged, Dept Pathol, Fac Med, Allomas U 1, H-6725 Szeged, Hungary.	zomtam@gmail.com		Zombori, Tamas/0000-0002-0654-563X; Cserni, Gabor/0000-0003-1344-7744	National Research, Development and Innovation Office [GINOP-2.3.2-15-2016-00020]	This study was partially funded by the National Research, Development and Innovation Office grant GINOP-2.3.2-15-2016-00020.	Amin MB, 2017, AJCC CANC STAGING MA; Cai YR, 2016, SCI REP-UK, V6, DOI 10.1038/srep23755; Campos-Parra AD, 2014, EUR RESPIR J, V43, P1439, DOI 10.1183/09031936.00138813; Cha MJ, 2014, J THORAC CARDIOV SUR, V147, P921, DOI 10.1016/j.jtcvs.2013.09.045; Girard N, 2012, EUR RESPIR J, V39, P366, DOI 10.1183/09031936.00010111; Jiang Wei, 2015, Zhonghua Wai Ke Za Zhi, V53, P737; Kamiya K, 2008, MODERN PATHOL, V21, P992, DOI 10.1038/modpathol.2008.79; Koga K, 2013, LUNG CANCER, V82, P413, DOI 10.1016/j.lungcan.2013.09.005; Lee MC, 2014, LUNG CANCER MANAG, V3, P245, DOI 10.2217/LMT.14.15; Makimoto Y, 2005, HISTOPATHOLOGY, V46, P677, DOI 10.1111/j.1365-2559.2005.02126.x; Makinen JM, 2015, LUNG CANCER, V90, P568, DOI 10.1016/j.lungcan.2015.10.014; Matsuoka Y, 2016, ANTICANCER RES, V36, P4923, DOI 10.21873/anticanres.11058; Miyoshi T, 2003, AM J SURG PATHOL, V27, P101, DOI 10.1097/00000478-200301000-00011; Nagano T, 2010, LUNG CANCER, V69, P315, DOI 10.1016/j.lungcan.2009.11.016; Nitadori J, 2013, JNCI-J NATL CANCER I, V105, P1212, DOI 10.1093/jnci/djt166; Pelosi G, 2016, VIRCHOWS ARCH, V468, P651, DOI 10.1007/s00428-016-1931-z; Roh MS, 2004, HISTOPATHOLOGY, V45, P580, DOI 10.1111/j.1365-2559.2004.01953.x; Sanchez-Mora N, 2008, HUM PATHOL, V39, P324, DOI 10.1016/j.humpath.2007.05.029; Sumiyoshi S, 2014, LUNG CANCER, V84, P281, DOI 10.1016/j.lungcan.2014.03.013; Sumiyoshi S, 2013, LUNG CANCER, V81, P53, DOI 10.1016/j.lungcan.2013.04.003; Thunnissen E, 2012, MODERN PATHOL, V25, P1574, DOI 10.1038/modpathol.2012.106; Travis WD, 2015, WHO CLASSIFICATION T; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Tsubokawa N, 2016, EUR J CARDIO-THORAC, V49, P293, DOI 10.1093/ejcts/ezv058; Ujiie H, 2015, J CLIN ONCOL, V33, P2877, DOI 10.1200/JCO.2015.60.9818; Warth A, 2012, EUR RESPIR J, V40, P1221, DOI 10.1183/09031936.00219211; Yanagawa N, 2016, J THORAC ONCOL, V11, P1976, DOI 10.1016/j.jtho.2016.06.014; Yatabe Y, 2005, AM J SURG PATHOL, V29, P633, DOI 10.1097/01.pas.0000157935.28066.35; Yeh YC, 2012, J CLIN PATHOL, V65, P910, DOI 10.1136/jclinpath-2012-200882; Yoshida A, 2011, AM J SURG PATHOL, V35, P1226, DOI 10.1097/PAS.0b013e3182233e06; Yoshizawa A, 2013, J THORAC ONCOL, V8, P52, DOI 10.1097/JTO.0b013e3182769aa8; Zhang HB, 2016, ONCOTARGETS THER, V9, P2337, DOI 10.2147/OTT.S100965; Zhang J, 2011, HISTOPATHOLOGY, V59, P1204, DOI 10.1111/j.1365-2559.2011.04050.x; Zhao ZR, 2015, LUNG CANCER, V90, P604, DOI 10.1016/j.lungcan.2015.10.026; Zombori T, 2018, J CLIN PATHOL, V71, P135, DOI 10.1136/jclinpath-2016-204302	35	2	3	2	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUN	2018	472	6					949	958		10.1007/s00428-018-2337-x			10	Pathology	Pathology	GJ5GU	WOS:000435410300008	29611055	Green Accepted			2019-10-28	
J	Wang, YJ; Liu, HJ; Hou, YY; Zhou, XY; Liang, L; Zhang, ZH; Shi, HY; Xu, SP; Hu, PZ; Zheng, ZY; Liu, R; Tang, TD; Ye, F; Liang, ZY; Bu, H				Wang, Yajian; Liu, Haijing; Hou, Yingyong; Zhou, Xiaoyan; Liang, Li; Zhang, Zhihong; Shi, Huaiyin; Xu, Sanpeng; Hu, Peizhen; Zheng, Zuyu; Liu, Rui; Tang, Tingdong; Ye, Feng; Liang, Zhiyong; Bu, Hong			Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients	VIRCHOWS ARCHIV			English	Article						Next-generation sequencing (NGS); Molecular test validation; Colorectal cancer (CRC); Actionable variants	GENE-MUTATIONS; INTRATUMOR HETEROGENEITY; MOLECULAR DIAGNOSTICS; KRAS MUTATIONS; BRAF; DNA; ADENOCARCINOMA; ONCOLOGY; SYSTEM; NRAS	Next-generation sequencing (NGS) has become a promising approach for tumor somatic mutation detection. However, stringent validation is required for its application on clinical specimens, especially for low-quality formalin-fixed paraffin-embedded (FFPE) tissues. Here, we validated the performance of an amplicon-based targeted NGS assay, OncoAim (TM) DNA panel, on both commercial reference FFPE samples and clinical FFPE samples of Chinese colorectal cancer (CRC) patients. Then we profiled the mutation spectrum of 648 Chinese CRC patients in a multicenter study to explore its clinical utility. This NGS assay achieved 100% test specificity and 95-100% test sensitivity for variants with mutant allele frequency (MAF) ae<yen> 5% when median read depth ae<yen> 500x. The orthogonal methods including amplification refractory mutation system (ARMS)-PCR and Sanger sequencing validated that NGS generated three false negatives (FNs) but no false positives (FPs) among 516 clinical samples for KRAS aberration detection. Genomic profiling of Chinese CRC patients with this assay revealed that 63.3% of the tumors harbored clinically actionable alterations. Besides the commonly mutated genes including TP53 (52.82%), KRAS (46.68%), APC (24.09%), PIK3CA (18.94%), SMAD4 (9.47%), BRAF (6.15%), FBXW7 (5.32%), and NRAS (4.15%), other less frequently mutated genes were also identified. Statistically significant association of specific mutated genes with certain clinicopathological features was detected, e.g., both BRAF and PIK3CA were more prevalent in right-side CRC (p < 0.001 and p = 0.002, respectively). We concluded this targeted NGS assay is qualified for clinical practice, and our findings could help the diagnosis and prognosis of Chinese CRC patients.	[Wang, Yajian; Bu, Hong] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu 610041, Sichuan, Peoples R China; [Wang, Yajian; Ye, Feng; Bu, Hong] Sichuan Univ, West China Hosp, Pathol Lab, Chengdu 610041, Sichuan, Peoples R China; [Liu, Haijing] Peking Univ Third Hosp, Dept Pathol, Beijing 100000, Peoples R China; [Hou, Yingyong] Fudan Univ, Zhongshan Hosp, Dept Pathol, Shanghai 200032, Peoples R China; [Zhou, Xiaoyan] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Liang, Li] Southern Med Univ, Huayin Lab, Guangzhou 510515, Guangdong, Peoples R China; [Zhang, Zhihong] Nanjing Med Univ, Affiliated Hosp 1, Dept Pathol, Nanjing 210000, Jiangsu, Peoples R China; [Shi, Huaiyin] Chinese Peoples Liberat Army Gen Hosp, Dept Pathol, Beijing 100000, Peoples R China; [Shi, Huaiyin] Chinese PLA Med Sch, Beijing 100000, Peoples R China; [Xu, Sanpeng] Huazhong Univ Sci & Technol, Inst Pathol, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China; [Hu, Peizhen] Fourth Mil Med Univ, Xijing Hosp, Dept Pathol, Xian 710032, Shaanxi, Peoples R China; [Zheng, Zuyu; Liu, Rui; Tang, Tingdong] Singlera Genom Inc, Shanghai 201318, Peoples R China; [Ye, Feng; Bu, Hong] Sichuan Univ, West China Hosp, Key Lab Transplant Engn & Immunol, Minist Hlth, Chengdu 610041, Sichuan, Peoples R China; [Liang, Zhiyong] Chinese Acad Med Sci, Dept Pathol, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China; [Liang, Zhiyong] Peking Union Med Coll, Beijing 100730, Peoples R China	Ye, F (reprint author), Sichuan Univ, West China Hosp, Pathol Lab, Chengdu 610041, Sichuan, Peoples R China.; Ye, F (reprint author), Sichuan Univ, West China Hosp, Key Lab Transplant Engn & Immunol, Minist Hlth, Chengdu 610041, Sichuan, Peoples R China.	fengye@scu.edu.cn			National Key Research and Development Plan of Precision Medical research in China [2016YFC0906000]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81401990]; Key Research and Development Project of Department of Science and Technology in Sichuan Province [2017SZ0005]	This work was supported by the funding from the National Key Research and Development Plan of Precision Medical research in China (2016YFC0906000), National Natural Science Foundation of China (81401990), and Key Research and Development Project of Department of Science and Technology in Sichuan Province (2017SZ0005).	Al-Shamsi HO, 2016, J GASTROINTEST ONCOL, V7, P882, DOI 10.21037/jgo.2016.11.02; Chen QF, 2007, J MOL DIAGN, V9, P272, DOI 10.2353/jmoldx.2007.060133; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Deans ZC, 2017, VIRCHOWS ARCH, V470, P5, DOI 10.1007/s00428-016-2025-7; Do HD, 2015, CLIN CHEM, V61, P64, DOI 10.1373/clinchem.2014.223040; Eifert C, 2017, PERS MED, V14, P309, DOI 10.2217/pme-2017-0011; Fontanges Q, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122117; Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696; Hirsch B, 2018, VIRCHOWS ARCH, V472, P557, DOI 10.1007/s00428-017-2288-7; Huang TG, 2013, BIOMARK RES, V1, DOI 10.1186/2050-7771-1-3; Jauhri M, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317692265; Kamps R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020308; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kaul KL, 2017, VIRCHOWS ARCH, V471, P141, DOI 10.1007/s00428-017-2141-z; Korphaisarn K, 2017, ONCOTARGET, V8, P39268, DOI 10.18632/oncotarget.16848; Lan YT, 2015, J SURG ONCOL, V111, P905, DOI 10.1002/jso.23895; Langley RE, 2013, NAT REV CLIN ONCOL, V10, P8, DOI 10.1038/nrclinonc.2012.216; Larki P, 2017, CELL J, V19, P113, DOI 10.22074/cellj.2017.5123; Liang M, 2016, INT J ONCOL, V49, P2088, DOI 10.3892/ijo.2016.3707; Ling YYJ, 2012, ZHONGHUA BING LI XUE, V41, P4; Lopez JI, 2017, PATHOLOGICA, V109, P110; Ludyga N, 2012, VIRCHOWS ARCH, V460, P131, DOI 10.1007/s00428-011-1184-9; Marmol I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010197; Mendelsohn J, 2013, J CLIN ONCOL, V31, P1904, DOI 10.1200/JCO.2012.45.3605; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Ogasawara N, 2011, JPN J CLIN ONCOL, V41, P52, DOI 10.1093/jjco/hyq151; Robbe P, 2018, GENET MED, DOI [10.1038/gim.2017, DOI 10.1038/GIM.2017]; Ryu D, 2016, HUM GENET, V135, P635, DOI 10.1007/s00439-016-1670-x; Shen YC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081628; Singh RR, 2013, J MOL DIAGN, V15, P607, DOI 10.1016/j.jmoldx.2013.05.003; Srinivasan M, 2002, AM J PATHOL, V161, P1961, DOI 10.1016/S0002-9440(10)64472-0; Tafe LJ, 2017, VIRCHOWS ARCH, V471, P155, DOI 10.1007/s00428-017-2101-7; Tsiatis AC, 2010, J MOL DIAGN, V12, P425, DOI 10.2353/jmoldx.2010.090188; Vagaja NN, 2015, J CLIN PATHOL, V68, P657, DOI 10.1136/jclinpath-2015-202969; Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235; Vendrell JA, 2017, ONCOTARGET, V8, P40345, DOI 10.18632/oncotarget.15875; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wong SQ, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-23; Ye JX, 2015, WORLD J GASTROENTERO, V21, P1595, DOI 10.3748/wjg.v21.i5.1595; Zhang J, 2015, SIGNAL PROCESS, V110, P5, DOI 10.1016/j.sigpro.2014.08.001; Zhang LX, 2014, ONCOLOGIST, V19, P336, DOI 10.1634/theoncologist.2013-0180	41	4	4	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUN	2018	472	6					959	968		10.1007/s00428-018-2359-4			10	Pathology	Pathology	GJ5GU	WOS:000435410300009	29705968				2019-10-28	
J	Kulac, I; Arslankoz, S; Netto, GJ; Baydar, DE				Kulac, Ibrahim; Arslankoz, Sehbal; Netto, George J.; Baydar, Dilek Ertoy			Reduced immunohistochemical PTEN staining is associated with higher progression rate and recurrence episodes in non-invasive low-grade papillary urothelial carcinoma of the bladder	VIRCHOWS ARCHIV			English	Article						Bladder; Urothelial carcinoma; Bladder cancer; Non-invasive; PTEN	PROSTATE-CANCER; URINARY-BLADDER; ENDOMETRIAL CARCINOMA; TUMOR RECURRENCE; VOIDED URINE; EXPRESSION; STAGE; MUTATION; INDICATOR; MARKER	Non-invasive low-grade papillary urothelial carcinoma (NILGPUC) of the bladder is regarded as a relatively indolent disease. However, its propensity for frequent recurrences constitutes a major clinical problem. Additionally, there is a progression risk of 10-15% to either a higher grade and/or a higher stage disease in these tumors. The molecular factors that will predict recurrence and progression in low-grade pTa bladder carcinoma have not yet been elucidated. Herein, we investigated the association of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) alterations with recurrence and progression in NILGPUC using immunohistochemistry. Eighty-one cases of bladder cancer initially diagnosed as NILGPUC in a single institution with follow-up were encountered after searching medical records. Tissue microarrays (TMA) that contained both tumor and non-neoplastic mucosa from each case were constructed using paraffin blocks of transurethral resections. Sections from TMA blocks were stained immunohistochemically for PTEN protein and were evaluable in 76 cases. Any absence of staining was recorded and correlated with clinical findings. Ten patients (13.2%) showed progression and 41 (53.9%) showed recurrence. Reduced PTEN expression was observed in 29 cases (38.1%). Cases with reduced PTEN had higher progression rate compared to cases with intact PTEN (p = 0.026). Tumor relapse was more frequent in cases with reduced PTEN (65.5 vs 46.8%), but this difference was not statistically significant (p = 0.112). On the other hand, decreased PTEN expression was associated with higher number of recurrence episodes (p = 0.002). PTEN seems to have a link with the disease course in NILGPUC of the bladder.	[Kulac, Ibrahim; Arslankoz, Sehbal; Baydar, Dilek Ertoy] Hacettepe Univ, Dept Pathol, Sch Med, Ankara, Turkey; [Kulac, Ibrahim] Mardin State Hosp, Dept Pathol, Mardin, Turkey; [Netto, George J.] Univ Alabama Birmingham, Dept Pathol, Sch Med, Birmingham, AL USA	Baydar, DE (reprint author), Hacettepe Univ, Dept Pathol, Sch Med, Ankara, Turkey.	dilekertoy@yahoo.com	Kulac, Ibrahim/U-9563-2018	Kulac, Ibrahim/0000-0003-2003-7567	Scientific Research Unit of Hacettepe UniversityHacettepe University [012 D06 101 014]	This research was supported by a grant from the Scientific Research Unit of Hacettepe University (grant no. 012 D06 101 014).	Aveyard JS, 1999, BRIT J CANCER, V80, P904, DOI 10.1038/sj.bjc.6690439; Babjuk M, 2017, EUR UROL, V71, P447, DOI 10.1016/j.eururo.2016.05.041; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Cheng L, 2009, FUTURE ONCOL, V5, P843, DOI 10.2217/FON.09.50; Djordjeyic B, 2012, MODERN PATHOL, V25, P699, DOI 10.1038/modpathol.2011.208; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037; Holmang S, 1999, J UROLOGY, V162, P702, DOI 10.1097/00005392-199909010-00019; Holmang S, 2001, J UROLOGY, V165, P1124, DOI 10.1016/S0022-5347(05)66443-9; Kobayashi H, 2014, BMC UROL, V14, DOI 10.1186/1471-2490-14-5; Liu SH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123617; Lotan TL, 2015, MODERN PATHOL, V28, P128, DOI 10.1038/modpathol.2014.85; Lotan TL, 2011, CLIN CANCER RES, V17, P6563, DOI 10.1158/1078-0432.CCR-11-1244; McMenamin ME, 1999, CANCER RES, V59, P4291; Miyake M, 2010, CANCER SCI, V101, P250, DOI 10.1111/j.1349-7006.2009.01334.x; Miyamoto H, 2010, ARCH PATHOL LAB MED, V134, P1160, DOI 10.1043/2009-0403-OA.1; Netto GJ, 2012, NAT REV UROL, V9, P41, DOI 10.1038/nrurol.2011.193; Picanco-Albuquerque CG, 2016, VIRCHOWS ARCH, V468, P607, DOI 10.1007/s00428-016-1904-2; Pich A, 2002, CANCER, V95, P784, DOI 10.1002/cncr.10733; Platt FM, 2009, CLIN CANCER RES, V15, P6008, DOI 10.1158/1078-0432.CCR-09-0898; Puzio-Kuter AM, 2009, GENE DEV, V23, P675, DOI 10.1101/gad.1772909; Schmitz M, 2007, INT J CANCER, V120, P1284, DOI 10.1002/ijc.22359; Schultz L, 2010, CANCER-AM CANCER SOC, V116, P5517, DOI 10.1002/cncr.25502; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Sun CH, 2011, HISTOPATHOLOGY, V58, P1054, DOI 10.1111/j.1365-2559.2011.03856.x; Sylvester RJ, 2006, EUR UROL, V49, P466, DOI 10.1016/j.eururo.2005.12.031; van Rhijn BWG, 2010, EUR UROL, V58, P433, DOI 10.1016/j.eururo.2010.05.043; Vollmer RT, 2016, AM J CLIN PATHOL, V146, P215, DOI [10.1093/AJCP/AQW103, 10.1093/ajcp/aqw103]; Wang DS, 2000, INT J CANCER, V88, P620, DOI 10.1002/1097-0215(20001115)88:4<620::AID-IJC16>3.0.CO;2-Z; Zuiverloon TCM, 2010, CLIN CANCER RES, V16, P3011, DOI 10.1158/1078-0432.CCR-09-3013	31	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUN	2018	472	6					969	974		10.1007/s00428-018-2302-8			6	Pathology	Pathology	GJ5GU	WOS:000435410300010	29368083				2019-10-28	
J	Matsuo, FS; Andrade, MF; Loyola, AM; da Silva, SJ; Silva, MJB; Cardoso, S; de Faria, PR				Matsuo, Flavia Sayuri; Andrade, Marilia Ferreira; Loyola, Adriano Mota; da Silva, Sindeval Jose; Barbosa Silva, Marcelo Jose; Cardoso, Sergio Vitorino; de Faria, Paulo Rogerio			Pathologic significance of AKT, mTOR, and GSK3 beta proteins in oral squamous cell carcinoma-affected patients	VIRCHOWS ARCHIV			English	Article						Oral squamous cell carcinoma; Cervical lymph node metastasis; AKT; mTOR; Glycogen synthase kinase-3 beta; prognosis	HUMAN CANCER; NECK-CANCER; PATHWAY; HEAD; KINASE; PIK3CA; TUMORIGENESIS; EXPRESSION; SITE; PROGRESSION	Phosphatidylinositol-3-kinases are kinases that lead to AKT phosphorylation and thus mTOR and GSK3 beta activation. These proteins are linked to tumorigenesis, but their roles in driving cervical lymph node (CLN) metastasis of oral squamous cell carcinoma (OSCC) cells are unknown. This study aimed to investigate the role of AKT, mTOR, and GSK3 beta proteins in the occurrence of CLN metastasis in OSCC patients. Ninety and 18 paraffin-embedded OSCC and oral mucosa samples were included, respectively. We divided our OSCC patients into non-metastasizing (PNM) and metastasizing (PM) groups, and the expression of total AKT, pAKT1(Thr308), pAKT(Ser473), GSK3 beta, pGSK3 beta(Ser9), and pmTOR(Ser2448) was analyzed by immunohistochemistry. The mean expression of GSK3 beta, pGSK3 beta(Ser9), total AKT, and pmTOR(2448) was always higher in the OSCC tissues than that in the controls. A positive correlation was also found among these proteins. Total AKT, pmTOR(Ser2448), and pGSK3 beta(Ser9) expression was significantly higher in the PNM and PM groups than that in the control group. However, only GSK3 beta expression was significantly higher in the PM group compared with the PNM group. High expression levels of GSK3 beta and pGSK3 beta(Ser9) were significantly associated with CLN metastasis, but only GSK3 beta remained an independent predictor of CLN metastasis. pGSK3 beta(Ser9) and CLN metastasis were associated with a poor prognosis, but only the latter remained an independent prognostic parameter. Kaplan-Meier survival curves showed that pGSK3 beta(Ser9) and CLN metastasis were significantly related to reduced survival rates. These results suggest that AKT and mTOR proteins are involved in OSCC biology and that GSK3 beta itself may drive CLN metastatic spread of OSCC cells.	[Matsuo, Flavia Sayuri] Univ Sao Paulo, Sch Med, Dept Cell & Mol Biol & Pathogen Bioagents, 1900 Bandeirantes Ave, Sao Paulo, Brazil; [Andrade, Marilia Ferreira; Barbosa Silva, Marcelo Jose] Univ Fed Uberlandia, Inst Biomed Sci, Dept Immunol, 1720 Para Ave,Block 4C, BR-38400902 Uberlandia, MG, Brazil; [Loyola, Adriano Mota; Cardoso, Sergio Vitorino] Univ Fed Uberlandia, Sch Dent, Dept Oral Pathol, 1720 Para Ave,Block 4L, BR-38400902 Uberlandia, MG, Brazil; [da Silva, Sindeval Jose] Univ Fed Uberlandia, Sch Med, Dept Surg, 1720 Para Ave, BR-38400902 Uberlandia, MG, Brazil; [de Faria, Paulo Rogerio] Univ Fed Uberlandia, Inst Biomed Sci, Dept Morphol, 1720 Para Ave,Block 2B, BR-38400902 Uberlandia, MG, Brazil; [de Faria, Paulo Rogerio] Univ Fed Uberlandia, Inst Cincias Biomed, Lab Histol, Ave Amazonas S-N,Bloco 2B,Sala 2B-254, BR-38405320 Uberlandia, MG, Brazil	de Faria, PR (reprint author), Univ Fed Uberlandia, Inst Biomed Sci, Dept Morphol, 1720 Para Ave,Block 2B, BR-38400902 Uberlandia, MG, Brazil.; de Faria, PR (reprint author), Univ Fed Uberlandia, Inst Cincias Biomed, Lab Histol, Ave Amazonas S-N,Bloco 2B,Sala 2B-254, BR-38405320 Uberlandia, MG, Brazil.	paulo.faria@ufu.br	Silva, Marcelo JB/J-4298-2012; de Faria, Paulo R/G-1431-2011	Silva, Marcelo JB/0000-0002-5807-4286; de Faria, Paulo R/0000-0003-2650-3960	Fundacao deAmparo a Pesquisa do Estado de Minas GeraisMinas Gerais State Research Foundation (FAPEMIG) [APQ-01746-13]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, BrazilNational Council for Scientific and Technological Development (CNPq) [471130/2013-13]	This study was supported by the Fundacao deAmparo a Pesquisa do Estado de Minas Gerais (grant number APQ-01746-13) e o Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (grant number 471130/2013-13), Brazil.	Acosta-Jaquez HA, 2009, MOL CELL BIOL, V29, P4308, DOI 10.1128/MCB.01665-08; Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Baltzis D, 2007, J BIOL CHEM, V282, P31675, DOI 10.1074/jbc.M704491200; Biazevic Maria Gabriela Haye, 2006, Cad. Saúde Pública, V22, P2105, DOI 10.1590/S0102-311X2006001000016; Broek RV, 2015, ORAL DIS, V21, P815, DOI 10.1111/odi.12206; Cardesa A, 2005, WHO CLASSIFICATION T, P118; Clark C, 2010, LARYNGOSCOPE, V120, P1159, DOI 10.1002/lary.20917; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cooper JS, 2009, HEAD NECK-J SCI SPEC, V31, P748, DOI 10.1002/hed.21022; Cortesina G, 2006, Acta Otorhinolaryngol Ital, V26, P317; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Du L, 2012, J ONCOL, DOI 10.1155/2012/450179; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Farago M, 2005, CANCER RES, V65, P5792, DOI 10.1158/0008-5472.CAN-05-1021; Fenic I, 2007, ONCOL REP, V18, P253; Gao SG, 2017, MOL CARCINOGEN, V56, P2301, DOI 10.1002/mc.22685; Genden EM, 2010, EUR ARCH OTO-RHINO-L, V267, P1001, DOI 10.1007/s00405-010-1206-2; Giudice FS, 2013, J CARCINOG MUTAGEN, DOI [10.4172/2157-2518.s5-003, DOI 10.4172/2157-2518.S5-003]; Hedberg ML, 2016, J CLIN INVEST, V126, P1606, DOI 10.1172/JCI86862; Iamaroon A, 2009, ORAL ONCOL, V45, pE175, DOI 10.1016/j.oraloncology.2009.06.003; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kozaki KI, 2006, CANCER SCI, V97, P1351, DOI 10.1111/j.1349-7006.2006.00343.x; LEEMANS CR, 1994, CANCER-AM CANCER SOC, V73, P187, DOI 10.1002/1097-0142(19940101)73:1<187::AID-CNCR2820730132>3.0.CO;2-J; Lim J, 2005, J CLIN PATHOL, V58, P1199, DOI 10.1136/jcp.2004.024786; Massarelli E, 2005, CANCER-AM CANCER SOC, V104, P2430, DOI 10.1002/cncr.21476; McCubrey JA, 2014, ONCOTARGET, V5, P2881, DOI 10.18632/oncotarget.2037; Mendonca DF, 2012, INT J CLIN EXP PATHO, V5, P547; Mishra R, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0300-x; Mishra R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-144; Moral M, 2008, HISTOL HISTOPATHOL, V23, P1269, DOI 10.14670/HH-23.1269; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Prasad CP, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-325; Qiu WL, 2006, CLIN CANCER RES, V12, P1441, DOI 10.1158/1078-0432.CCR-05-2173; Simard EP, 2014, ORAL ONCOL, V50, P387, DOI 10.1016/j.oraloncology.2014.01.016; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang J, 2009, J HISTOCHEM CYTOCHEM, V57, P363, DOI 10.1369/jhc.2008.953091; Wong KK, 2010, CURR OPIN GENET DEV, V20, P87, DOI 10.1016/j.gde.2009.11.002; Wu HT, 2009, J ORAL PATHOL MED, V38, P206, DOI 10.1111/j.1600-0714.2008.00659.x; Zheng HC, 2010, HUM PATHOL, V41, P1255, DOI 10.1016/j.humpath.2010.02.003; Zheng ST, 2016, HUM PATHOL, V53, P121, DOI 10.1016/j.humpath.2015.11.013	42	3	4	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUN	2018	472	6					983	997		10.1007/s00428-018-2318-0			15	Pathology	Pathology	GJ5GU	WOS:000435410300012	29713826				2019-10-28	
J	Cavalcante, RB; Nonaka, CFW; Santos, HBD; Rabenhorst, SHB; Pinto, LP; de Souza, LB				Cavalcante, Roberta Barroso; Weege Nonaka, Cassiano Francisco; de Pontes Santos, Hellen Bandeira; Barem Rabenhorst, Silvia Helena; Pinto, Leao Pereira; de Souza, Lelia Batista			Assessment of CTNNB1 gene mutations and beta-catenin immunoexpression in salivary gland pleomorphic adenomas and adenoid cystic carcinomas	VIRCHOWS ARCHIV			English	Article						beta-Catenin; Salivary gland neoplasm; Mutation; Immunohistochemistry; Pleomorphic adenoma; Adenoid cystic carcinoma	BASAL-CELL ADENOCARCINOMA; CYCLIN D1; PROGNOSTIC-SIGNIFICANCE; SIGNALING PATHWAY; EXPRESSION; CANCER; MYB; RECEPTOR; COMPLEX; TUMORS	beta-Catenin exerts multiple functions in several neoplasms, playing a major role in cell signaling and tumor progression. This study analyzed possible CTNNB1 mutations in salivary gland pleomorphic adenomas (PAs) and adenoid cystic carcinomas (ACCs), and determined possible differences in beta-catenin immunoexpression in relation to these mutations, as well as histopathological aspects of these tumors. Twenty-four PAs (15 cell-rich and 9 cell-poor tumors) and 24 ACCs (10 tubular, 8 cribriform, and 6 solid tumors) were selected for the analysis of beta-catenin distribution and cellular localization. Furthermore, beta-catenin expression was evaluated using the H-score scoring system. Mutations in CTNNB1 exon 3 were investigated by the single-strand conformational polymorphism test. Diffuse beta-catenin expression was more frequently observed in ACCs compared to PAs (P = 0.008). No significant difference in beta-catenin cellular localization was observed between these tumors (P = 0.098). Comparisons between PA and ACC cases revealed a higher median H-score in the latter (P = 0.036). Cell-rich PAs exhibited a trend for higher H-score than cell-poor tumors (P = 0.060), whereas lower H-scores were observed in cribriform ACCs when compared to tubular and solid ACCs (P = 0.042). Mutations in CTNNB1 were observed in 6 PAs and 7 ACCs, with no significant difference in H-scores for beta-catenin according to mutation status (P = 0.135). beta-Catenin is important in the pathogenesis of salivary gland PAs and ACCs. In addition, CTNNB1 exon 3 mutations do not seem to significantly influence beta-catenin cytoplasmic/membranous expression or nuclear translocation in these tumors.	[Cavalcante, Roberta Barroso] Univ Fortaleza, Dept Oral Pathol, Fortaleza, Ceara, Brazil; [Weege Nonaka, Cassiano Francisco] State Univ Paraiba, Dept Dent, Campina Grande, PB, Brazil; [de Pontes Santos, Hellen Bandeira; Pinto, Leao Pereira; de Souza, Lelia Batista] Univ Fed Rio Grande do Norte, Dept Oral Pathol, Natal, RN, Brazil; [Barem Rabenhorst, Silvia Helena] Univ Fed Ceara, Dept Pathol & Forens Med, Mol Genet Lab, Fortaleza, Ceara, Brazil	de Souza, LB (reprint author), Univ Fed Rio Grande do Norte, Dept Oral Pathol, Natal, RN, Brazil.	hellenbps@hotmail.com; leliabsouza@gmail.com	Santos, Hellen HPBS/C-4565-2019; Nonaka, Cassiano FW/F-7158-2012	Santos, Hellen HPBS/0000-0002-6596-5220; Nonaka, Cassiano FW/0000-0003-2380-109X	National Council for Scientific and Technological Development (CNPq)National Council for Scientific and Technological Development (CNPq) [479935/04-1]	This study was supported by grant number 479935/04-1 from the National Council for Scientific and Technological Development (CNPq).	Bankfalvi A, 2002, J ORAL PATHOL MED, V31, P450, DOI 10.1034/j.1600-0714.2002.00147.x; Cavalcante RB, 2017, ARCH ORAL BIOL, V73, P48, DOI 10.1016/j.archoralbio.2016.09.005; Chandrashekar C, 2011, INT J SURG PATHOL, V19, P433, DOI 10.1177/1066896909346366; Neves EH, 2012, PATHOBIOLOGY, V79, P323, DOI 10.1159/000338436; Daa T, 2004, MODERN PATHOL, V17, P1475, DOI 10.1038/modpathol.3800209; de Ridder M, 2015, CANCER EPIDEMIOL, V39, P14, DOI 10.1016/j.canep.2014.10.007; Ellis GL, 2008, AFIP ATLAS TUMOR PAT; Ferrazzo KL, 2009, J ORAL PATHOL MED, V38, P701, DOI 10.1111/j.1600-0714.2009.00776.x; Fonseca I, 2008, HISTOPATHOLOGY, V52, P244, DOI 10.1111/j.1365-2559.2007.02878.x; Furuse C, 2006, INT J SURG PATHOL, V14, P212, DOI 10.1177/1066896906290652; Garcia-Rostan G, 2001, AM J PATHOL, V158, P987, DOI 10.1016/S0002-9440(10)64045-X; Genelhu MCLS, 2007, APPL IMMUNOHISTO M M, V15, P273, DOI 10.1097/01.pai.0000213123.04215.95; Gonzalez-Moles MA, 2014, ORAL ONCOL, V50, P818, DOI 10.1016/j.oraloncology.2014.06.005; Hakata Y, 2010, EXP THER MED, V1, P437, DOI 10.3892/etm_00000068; Jamieson C, 2014, SEMIN CANCER BIOL, V27, P20, DOI 10.1016/j.semcancer.2014.04.012; Jo VY, 2016, AM J SURG PATHOL, V40, P1143, DOI 10.1097/PAS.0000000000000669; Kawahara A, 2011, J ORAL PATHOL MED, V40, P460, DOI 10.1111/j.1600-0714.2011.01010.x; Lee YH, 2018, J FORMOS MED ASSOC, V117, P894, DOI 10.1016/j.jfma.2017.11.011; Liu YX, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju245; Masuda T, 2017, J BIOCHEM, V161, P9, DOI 10.1093/jb/mvw072; MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716; Namboodiripad P C Anila, 2014, J Oral Biol Craniofac Res, V4, P127, DOI 10.1016/j.jobcr.2014.05.003; Pai SG, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0471-6; Psyrri A, 2014, ORAL ONCOL, V50, P298, DOI 10.1016/j.oraloncology.2014.01.005; Rooney SL, 2017, J ORAL PATHOL MED, V46, P798, DOI 10.1111/jop.12617; Schneider S, 2016, EUR ARCH OTO-RHINO-L, V273, P1283, DOI 10.1007/s00405-015-3609-6; Shiratsuchi H, 2007, HEAD NECK-J SCI SPEC, V29, P577, DOI 10.1002/hed.20583; Soares AB, 2009, J ORAL PATHOL MED, V38, P623, DOI 10.1111/j.1600-0714.2009.00794.x; Takahara M, 2004, HUM PATHOL, V35, P86, DOI 10.1016/S0046-8177(03)00517-3; Tornesello ML, 2013, GENOMICS, V102, P74, DOI 10.1016/j.ygeno.2013.04.001; Wang RN, 2015, BIO-MED MATER ENG, V26, pS2145, DOI 10.3233/BME-151520; Wang XD, 2015, BRIT J ORAL MAX SURG, V53, P132, DOI 10.1016/j.bjoms.2014.10.008; West RB, 2011, AM J SURG PATHOL, V35, P92, DOI 10.1097/PAS.0b013e3182002777; Wilson TC, 2016, HEAD NECK PATHOL, V10, P494, DOI 10.1007/s12105-016-0730-9; Xu B, 2017, AM J SURG PATHOL, V41, P1422, DOI 10.1097/PAS.0000000000000918; Zhang Q, 2016, AM J TRANSL RES, V8, P4490; Zhou CX, 2006, ONCOL REP, V16, P505	37	0	0	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUN	2018	472	6					999	1005		10.1007/s00428-018-2335-z			7	Pathology	Pathology	GJ5GU	WOS:000435410300013	29577164				2019-10-28	
J	Zombori, T; Cserni, G				Zombori, Tamas; Cserni, Gabor			Elastic stains in the evaluation of DCIS with comedo necrosis in breast cancers	VIRCHOWS ARCHIV			English	Article						Breast cancer; Comedo necrosis; Ductal carcinoma in situ; Elastic stain; Neoductgenesis	CASTING-TYPE CALCIFICATIONS; PROGNOSTIC-FACTOR; DUCTAL CARCINOMA; WOMEN; SITU	As concerns the microscopic morphology of ductal carcinoma in situ (DCIS), neoplastic cells are surrounded by both a myoepithelial cell layer and a basement membrane as expected from the outer structure of ducts and lobules. However, in some cases, it is impossible to state whether the structures involved by the disease are ducts or lobules. Altogether 1220 anatomic structures involved by DCIS displaying comedo necrosis from 27 slides of 21 patients (seen on both haematoxylin and eosin-stained and orcein-stained slides) were identified as representing ducts, likely ducts, unclassifiable structures, likely acini or acini on the basis of their distribution and resemblance to normal anatomic structures. All structures were then rated as having a circumferential elastic layer (as normal ducts), a partial elastic layer around more or less than half of the periphery or having no peripheral elastic layer at all (as normal acini). Structures classified as ducts or likely ducts were likely to have an elastic coating, whereas acini and likely acini had no such coating. Unclassifiable structures were generally devoid of an elastic layer. Structures (and cases) that were likely to represent neoductgenesis as proposed by Zhou et al. (Int J Breast Cancer 2014;2014:581706) were generally unclassifiable and devoid of outer elastic layer. Many duct-like structures in DCIS with comedo necrosis are devoid of elastic layer typical of normal ducts, suggesting that these structures are abnormal despite conservation of the myoepithelium and the basement membrane.	[Zombori, Tamas; Cserni, Gabor] Univ Szeged, Dept Pathol, Albert Szent Gyorgyi Med Ctr, Allomas U 1, H-6720 Szeged, Hungary; [Cserni, Gabor] Bacs Kiskun Cty Teaching Hosp, Dept Pathol, Nyiri Ut 38, H-6000 Kecskemet, Hungary	Cserni, G (reprint author), Univ Szeged, Dept Pathol, Albert Szent Gyorgyi Med Ctr, Allomas U 1, H-6720 Szeged, Hungary.; Cserni, G (reprint author), Bacs Kiskun Cty Teaching Hosp, Dept Pathol, Nyiri Ut 38, H-6000 Kecskemet, Hungary.	cserni@freemail.hu		Zombori, Tamas/0000-0002-0654-563X; Cserni, Gabor/0000-0003-1344-7744	National Research, Development and Innovation Office [GINOP-2.3.2-15-2016-00020]	This study was partially funded by the National Research, Development and Innovation Office grant GINOP-2.3.2-15-2016-00020.	Azzopardi JG, 1979, PROBLEMS BREAST PATH, P57; Bennett RL, 2011, BREAST, V20, P525, DOI 10.1016/j.breast.2011.05.008; FECHNER RE, 1971, CANCER, V28, P274, DOI 10.1002/1097-0142(197108)28:2<274::AID-CNCR2820280203>3.0.CO;2-3; Hilson JB, 2009, AM J SURG PATHOL, V33, P227, DOI 10.1097/PAS.0b013e318180431d; James JJ, 2003, CLIN RADIOL, V58, P54, DOI 10.1053/crad.2002.1110; KERNER H, 1986, HISTOPATHOLOGY, V10, P621, DOI 10.1111/j.1365-2559.1986.tb02515.x; Kovari B, 2015, PATHOBIOLOGY, V82, P166, DOI 10.1159/000375127; Mansson E, 2009, J SURG ONCOL, V100, P670, DOI 10.1002/jso.21405; Oakes SR, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1411; Palka I, 2007, ACTA ONCOL, V46, P1178, DOI 10.1080/02841860701373611; Tabar L, 2004, CANCER-AM CANCER SOC, V101, P1745, DOI 10.1002/cncr.20582; Tabar L, 2000, LANCET, V355, P429; Tabar L, 2007, CASTING TYPE CALCIFI; Tot T, 2005, VIRCHOWS ARCH, V447, P1, DOI 10.1007/s00428-005-1274-7; TOT T, 2005, SEMIN BREAST DIS, V8, P144; Tot T, 2014, PRACTICAL BREAST PAT, P1; Wells CAAI, 2006, EUROPEAN GUIDELINES, P219; Zhou WJ, 2014, INT J BREAST CANCER, DOI 10.1155/2014/581706; Zhou WJ, 2017, INT J BREAST CANCER, DOI 10.1155/2017/4351319; Zunzunegui RG, 2003, ARCH SURG-CHICAGO, V138, P537, DOI 10.1001/archsurg.138.5.537	20	0	0	1	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUN	2018	472	6					1007	1014		10.1007/s00428-017-2259-z			8	Pathology	Pathology	GJ5GU	WOS:000435410300014	29101458	Green Published			2019-10-28	
J	Righi, A; Sbaraglia, M; Gambarotti, M; Cocchi, S; Drago, G; Casadei, R; Picci, P; Vanel, D; Dei Tos, A				Righi, A.; Sbaraglia, M.; Gambarotti, M.; Cocchi, S.; Drago, G.; Casadei, R.; Picci, P.; Vanel, D.; Dei Tos, A. P.			Extra-axial chordoma: a clinicopathologic analysis of six cases	VIRCHOWS ARCHIV			English	Article						Extra-axial chordoma; Brachyury; Bone; Soft tissue; Prognosis	EXTRASKELETAL MYXOID CHONDROSARCOMA; MYOEPITHELIAL TUMORS; SOFT-TISSUE; BRACHYURY EXPRESSION; PARACHORDOMA; RARE; TIBIA; BONE	Extra-axial chordoma is an exceedingly rare tumor, with only 28 cases reported in the literature to date. Axial and extra-axial chordoma exhibits complete morphologic and immunophenotypic (expression of brachyury) overlap. However, in consideration of the non-canonical presentation, extra-axial chordoma is under-recognized and often misdiagnosed, most often as extraskeletal myxoid chondrosarcoma or myoepithelioma. To increase our understanding of the clinicopathologic features of extra-axial chordoma, six cases have been retrieved from the files of the Istituto Ortopedico Rizzoli and of the General Hospital of Treviso. The clinicoradiologic, morphologic, and molecular features have been analyzed, and the follow-up was updated. Our series included four female and two male patients; their ages ranged from 20 to 67 years (mean 45.8 years). All patients presented with a single mass localized in four cases in the soft tissue (posterior arm, left leg, dorsal aspect of the foot, and popliteal fossa), and in two cases in the bone (radius and second metacarpal bone). Grossly, the neoplasm was lobulated, with a fleshy cut surface and a diameter ranging between 0.8 and 8 cm (mean 3.4 cm). Morphologically, all six cases showed an epithelioid cell proliferation organized in nests and cords demarcated by fibrous septa and set in an abundant extracellular myxoid matrix. Neoplastic cells featured hyperchromatic nuclei and abundant vacuolated cytoplasm. Immunohistochemically, all six cases were strongly positive for EMA, cytokeratin AE1/AE3, S100, and brachyury. INI1 nuclear expression was retained. Smooth muscle actin, calponin, p63, and GFAP were all negative. Fluorescent in situ hybridization (FISH) analysis did not reveal rearrangements involving NR4A3, FUS, and EWSR1 genes. At follow-up (mean 55 months), all patients were alive without disease after local surgical treatment. One patient underwent thigh amputation following multiple local recurrences and inguinal node metastases treated with marginal resection. In conclusion, primary extra-axial chordoma is an extremely rare neoplasm with distinct morphological and immunohistochemical features. Immunomorphology and molecular analysis allow distinction from both extraskeletal myxoid chondrosarcoma and myoepithelioma. Complete surgical resection appears to be curative.	[Righi, A.; Gambarotti, M.; Cocchi, S.; Picci, P.; Vanel, D.; Dei Tos, A. P.] IRCCS Ist Ortoped Rizzoli, Dept Pathol, Bologna, Italy; [Sbaraglia, M.; Dei Tos, A. P.] Treviso Gen Hosp, Dept Pathol & Mol Genet, Treviso, Italy; [Sbaraglia, M.; Dei Tos, A. P.] Univ Padua, Sch Med, Dept Med, Padua, Italy; [Drago, G.; Casadei, R.] Ist Ortoped Rizzoli, Dept Orthopaed Oncol, Bologna, Italy	Righi, A (reprint author), IRCCS Ist Ortoped Rizzoli, Dept Pathol, Bologna, Italy.	alberto.righi@ior.it	COCCHI, STEFANIA/D-1725-2019; Righi, Alberto/J-6028-2016; Gambarotti, Marco/C-6878-2019	COCCHI, STEFANIA/0000-0001-6853-4621; Righi, Alberto/0000-0002-1074-0155; Gambarotti, Marco/0000-0002-8080-4484; DEI TOS, ANGELO/0000-0002-1228-8940			Benini S, 2014, J MOL DIAGN, V16, P314, DOI 10.1016/j.jmoldx.2013.12.002; Bitzer A, 2017, J HAND SURG-AM, V42, DOI 10.1016/j.jhsa.2017.05.033; DABSKA M, 1977, CANCER, V40, P1586, DOI 10.1002/1097-0142(197710)40:4<1586::AID-CNCR2820400431>3.0.CO;2-C; Finos L, 2017, PATHOL RES PRACT, V213, P461, DOI 10.1016/j.prp.2017.02.008; Fisher C, 2000, ADV ANAT PATHOL, V7, P141, DOI 10.1097/00125480-200007030-00002; Flanagan A, 2013, WHO CLASSIFICATION T, P326; Fletcher CDM, 2013, WHO CLASSIFICATION T, P208; Flucke U, 2011, MODERN PATHOL, V24, P1444, DOI 10.1038/modpathol.2011.108; Folpe AL, 1999, AM J SURG PATHOL, V23, P1059, DOI 10.1097/00000478-199909000-00008; Huang SC, 2015, GENE CHROMOSOME CANC, V54, P267, DOI 10.1002/gcc.22240; Jo VY, 2013, AM J SURG PATHOL, V37, P710, DOI 10.1097/PAS.0b013e3182772bba; Koh JS, 2000, PATHOL RES PRACT, V196, P269, DOI 10.1016/S0344-0338(00)80077-1; Kurzawa P, 2018, HISTOPATHOLOGY, V72, P883, DOI 10.1111/his.13440; Lauer SR, 2013, AM J SURG PATHOL, V37, P719, DOI 10.1097/PAS.0b013e31827813e7; Miettinen M, 2015, AM J SURG PATHOL, V39, P1305, DOI 10.1097/PAS.0000000000000462; Mobley BC, 2010, ACTA NEUROPATHOL, V120, P745, DOI 10.1007/s00401-010-0767-x; Nielsen GP, 2001, AM J SURG PATHOL, V25, P263, DOI 10.1097/00000478-200102000-00016; Rekhi B, 2016, APMIS, V124, P238, DOI 10.1111/apm.12468; Rekhi B, 2012, VIRCHOWS ARCH, V461, P687, DOI 10.1007/s00428-012-1335-7; Righi A, 2015, AM J SURG PATHOL, V39, P691, DOI 10.1097/PAS.0000000000000412; Suzuki H, 2011, PATHOL RES PRACT, V207, P327, DOI 10.1016/j.prp.2011.02.001; Tirabosco R, 2008, AM J SURG PATHOL, V32, P572, DOI 10.1097/PAS.0b013e31815b693a; Tirabosco R, 2012, HISTOPATHOLOGY, V61, P1245, DOI 10.1111/j.1365-2559.2012.04346.x; Yamaguchi Takehiko, 2017, Surg Pathol Clin, V10, P637, DOI 10.1016/j.path.2017.04.008	24	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUN	2018	472	6					1015	1020		10.1007/s00428-018-2334-0			6	Pathology	Pathology	GJ5GU	WOS:000435410300015	29560513				2019-10-28	
J	Ohtani, H; Terashima, T; Sato, E				Ohtani, Haruo; Terashima, Toru; Sato, Eiichi			Immune cell expression of TGF beta 1 in cancer with lymphoid stroma: dendritic cell and regulatory T cell contact	VIRCHOWS ARCHIV			English	Article						TGF beta; Lymphocyte-rich gastric cancer; Dendritic cell; Regulatory T cell; Tertiary lymphoid tissue	TGF-BETA; GASTRIC-CARCINOMA; TUMOR-IMMUNITY; SURVIVAL; PROTEIN	Although cancer tissue generally shows limited immune responses, some cancers abound with lymphocytes, which generally show favorable prognosis. These cancers, despite their rarity, are important in analyzing immune responses in cancer tissue. Transforming growth factor beta 1 (TFG beta 1) is a multifunctional cytokine, generally having an immunosuppressive function. The present study analyzes the in situ TGF beta 1 expression in 23 cases of lymphocyte-rich gastric carcinomas (Ly-rich GCs) using immunohistochemistry and in situ hybridization. Immunohistochemistry revealed that latency-associated peptide (LAP) of TGF beta 1 was localized in mainly immune cells in all cases, which was more abundant than in control GCs. Expression of LAP by cancer cells was only focal. In situ hybridization also confirmed abundant TGF beta 1 mRNA expression in the lymphoid stroma. Double immunofluorescent microscopy identified LAP(+) cells as macrophages, dendritic cells, and part of T cells. Close cell-to-cell contact was observed between LAP(+) dendritic-shaped cells and FoxP3(+) regulatory T cells (T-reg cells). Mature dendritic cells in Ly-rich GCs expressed LAP more frequently than those in the secondary lymphoid organs. Our data revealed abundant expression of TGF beta 1 in immune cells with contact to T-reg cells in lymphoid stroma, which is consistent with the notion that TGF beta 1 is one of the immunosuppressive factors in cancer stroma.	[Ohtani, Haruo] Mito Saiseikai Gen Hosp, Dept Pathol, 3-3-10 Futabadai, Mito, Ibaraki 3114198, Japan; [Ohtani, Haruo] Natl Hosp Org, Dept Pathol, Mito Med Ctr, Ibaraki, Japan; [Terashima, Toru] Natl Hosp Org, Dept Surg, Mito Med Ctr, Ibaraki, Japan; [Sato, Eiichi] Tokyo Med Univ, Inst Med Sci, Dept Pathol, Med Res Ctr,Shijuku Ku, Tokyo, Japan	Ohtani, H (reprint author), Mito Saiseikai Gen Hosp, Dept Pathol, 3-3-10 Futabadai, Mito, Ibaraki 3114198, Japan.; Ohtani, H (reprint author), Natl Hosp Org, Dept Pathol, Mito Med Ctr, Ibaraki, Japan.	311serenity@gmail.com			National Hospital Organization Collaborative Clinical Research Grant, Japan; Ministry of Education, Culture, Sports, Science and Technology, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); Project for Development of Innovative Research on Cancer Therapeutics, the Japan Agency for Medical Research and Development (AMED)Japan Agency for Medical Research and Development (AMED)	This study was supported by the National Hospital Organization Collaborative Clinical Research Grant, Japan, "Nanotechnology Network Project" from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and Project for Development of Innovative Research on Cancer Therapeutics, the Japan Agency for Medical Research and Development (AMED).	Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Bonertz A, 2009, J CLIN INVEST, V119, P3311, DOI 10.1172/JCI39608; Chen WJ, 2016, NAT REV IMMUNOL, V16, P723, DOI 10.1038/nri.2016.112; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Dieu-Nosjean MC, 2014, TRENDS IMMUNOL, V35, P571, DOI 10.1016/j.it.2014.09.006; Dumitriu IE, 2009, J IMMUNOL, V182, P2795, DOI 10.4049/jimmunol.0712671; Flavell RA, 2010, NAT REV IMMUNOL, V10, P554, DOI 10.1038/nri2808; Gigante M, 2012, CURR PHARM DESIGN, V18, P4126, DOI 10.2174/138161212802430378; Guilliams M, 2014, NAT REV IMMUNOL, V14, P571, DOI 10.1038/nri3712; Kinugasa S, 1998, ONCOLOGY-BASEL, V55, P582, DOI 10.1159/000011916; Kobayashi A, 2008, MUCOSAL IMMUNOL, V1, P412, DOI 10.1038/mi.2008.33; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; Mizoi T, 1993, CANCER RES, V53, P1; Ohtani H, 2009, J PATHOL, V217, P21, DOI 10.1002/path.2448; Ohtani H, 2015, PATHOL INT, V65, P644, DOI 10.1111/pin.12355; Ohtani H, 2010, VIRCHOWS ARCH, V456, P615, DOI 10.1007/s00428-010-0921-9; Ravi R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02696-6; Saiki Y, 1996, LAB INVEST, V75, P67; Saito T, 2016, NAT MED, V22, P679, DOI 10.1038/nm.4086; Sobin LH, 2009, UICC TNM CLASSIFICAT; Speiser DE, 2016, NAT REV IMMUNOL, V16, P500, DOI 10.1038/nri.2016.80; Tanchot C, 2013, CANCER MICROENVIRON, V6, P147, DOI 10.1007/s12307-012-0122-y; Terabe M, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1308616; Tian M, 2009, FUTURE ONCOL, V5, P259, DOI 10.2217/14796694.5.2.259; Tu E, 2014, CYTOKINE GROWTH F R, V25, P423, DOI 10.1016/j.cytogfr.2014.07.014; Vagenas K, 2007, J SURG RES, V139, P182, DOI 10.1016/j.jss.2006.10.005; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280	27	1	1	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUN	2018	472	6					1021	1028		10.1007/s00428-018-2336-y			8	Pathology	Pathology	GJ5GU	WOS:000435410300016	29594353	Green Published, Other Gold			2019-10-28	
J	Musalkova, D; Sticova, E; Reboun, M; Sokolova, J; Krijt, J; Honzikova, J; Gurka, J; Neroldova, M; Honzik, T; Zeman, J; Jirsa, M; Dvorakova, L; Hrebicek, M				Musalkova, Dita; Sticova, Eva; Reboun, Martin; Sokolova, Jitka; Krijt, Jakub; Honzikova, Jitka; Gurka, Jiri; Neroldova, Magdalena; Honzik, Tomas; Zeman, Jiri; Jirsa, Milan; Dvorakova, Lenka; Hrebicek, Martin			Variable X-chromosome inactivation and enlargement of pericentral glutamine synthetase zones in the liver of heterozygous females with OTC deficiency	VIRCHOWS ARCHIV			English	Article						Ornithine transcarbamylase; X chromosome inactivation; Glycogen storage; Liver; Liver zonation; Glutamine synthetase	ORNITHINE TRANSCARBAMYLASE DEFICIENCY; UREA CYCLE; PHOSPHATE SYNTHETASE; GENE; DISEASE; TRANSPLANTATION; EXPRESSION; DISORDERS; MUTATIONS; ZONATION	Ornithine transcarbamylase (OTC) deficiency is an X-linked disorder that causes recurrent and life-threatening episodes of hyperammonemia. The clinical picture in heterozygous females is highly diverse and derives from the genotype and the degree of inactivation of the mutated X chromosome in hepatocytes. Here, we describe molecular genetic, biochemical, and histopathological findings in the livers explanted from two female patients with late-onset OTC deficiency. Analysis of X-inactivation ratios by DNA methylation-based assays showed remarkable intra-organ variation ranging from 46:54 to 82:18 (average 70:30, n = 37), in favor of the active X chromosome carrying the mutation c.583G > C (p.G195R), in the first patient and from 75:25 to 90:10 (average 82:18, n = 20) in favor of the active X chromosome carrying the splicing mutation c.663+1G > A in the second patient. The X-inactivation ratios in liver samples correlated highly with the proportions of OTC-positive hepatocytes calculated from high-resolution image analyses of the immunohistochemically detected OTC in frozen sections that was performed on total area > 5 cm(2). X-inactivation ratios in blood in both female patients corresponded to the lower limit of the liver values. Our data indicate that the proportion of about 20-30% of hepatocytes expressing the functional OTC protein is not sufficient to maintain metabolic stability. X-inactivation ratios assessed in liver biopsies taken from heterozygous females with X-linked disorders should not be considered representative of the whole liver.	[Musalkova, Dita; Reboun, Martin; Sokolova, Jitka; Krijt, Jakub; Honzikova, Jitka; Gurka, Jiri; Dvorakova, Lenka; Hrebicek, Martin] Charles Univ Prague, Res Unit Rare Dis, Dept Pediat & Adolescent Med, Fac Med 1, Ke Karlovu 2, Prague 12808 2, Czech Republic; [Musalkova, Dita; Reboun, Martin; Sokolova, Jitka; Krijt, Jakub; Honzikova, Jitka; Gurka, Jiri; Honzik, Tomas; Zeman, Jiri; Dvorakova, Lenka; Hrebicek, Martin] Gen Univ Hosp Prague, Ke Karlovu 2, Prague 12808 2, Czech Republic; [Sticova, Eva] Inst Clin & Expt Med IKEM, Dept Clin & Transplant Pathol, Prague, Czech Republic; [Gurka, Jiri] Charles Univ Prague, Inst Histol & Embryol, Fac Med 1, Prague, Czech Republic; [Neroldova, Magdalena; Jirsa, Milan] Inst Clin & Expt Med IKEM, Lab Expt Hepatol, Prague, Czech Republic; [Honzik, Tomas; Zeman, Jiri] Charles Univ Prague, Dept Pediat & Adolescent Med, Fac Med 1, Prague, Czech Republic	Musalkova, D; Hrebicek, M (reprint author), Charles Univ Prague, Res Unit Rare Dis, Dept Pediat & Adolescent Med, Fac Med 1, Ke Karlovu 2, Prague 12808 2, Czech Republic.; Musalkova, D; Hrebicek, M (reprint author), Gen Univ Hosp Prague, Ke Karlovu 2, Prague 12808 2, Czech Republic.	dita.musalkova@lf1.cuni.cz; martin.hrebicek@lf1.cuni.cz	Zeman, Jiri/K-2691-2017; Musalkova, Dita/F-4909-2017; Jirsa, Milan/C-9340-2017; Neroldova, Magdalena/M-2298-2017; Sokolova, Jitka/H-9924-2015; Krijt, Jakub/F-4861-2017	Zeman, Jiri/0000-0002-2678-7919; Musalkova, Dita/0000-0003-4795-3960; Jirsa, Milan/0000-0001-7300-6735; Neroldova, Magdalena/0000-0002-3792-9564; Sokolova, Jitka/0000-0002-0453-3336; Krijt, Jakub/0000-0002-1738-654X; Sticova, Eva/0000-0003-2486-6266	Grant Agency of Charles University in Prague [42314, 580716]; project SVV [SVV 260367]; project UWE [204011/2012]; project Progres [Q26]; project MH CZ-DRO VFN [64165]	This study was supported by the projects GA UK No. 42314 and No. 580716 from the Grant Agency of Charles University in Prague, and also by projects SVV 260367, UWE 204011/2012, Progres Q26, and MH CZ-DRO VFN 64165.	ALLEN RC, 1992, AM J HUM GENET, V51, P1229; Badizadegan K, 1997, HEPATOLOGY, V26, P365, DOI 10.1002/hep.510260217; Burrage L, 2016, ASHG 2016 M 2016 OCT; Carpentieri D, 2015, MOLEC GENET METAB RE, V2, P47, DOI 10.1016/j.ymgmr.2014.12.005; Cavicchi C, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023-014-0105-9; Choi JH, 2015, J HUM GENET, V60, P501, DOI 10.1038/jhg.2015.54; de Hoon B, 2015, J MED GENET, V52, P784, DOI 10.1136/jmedgenet-2015-103194; Gebhardt R, 2014, WORLD J GASTROENTERO, V20, P8491, DOI 10.3748/wjg.v20.i26.8491; Hallows WC, 2011, MOL CELL, V41, P139, DOI 10.1016/j.molcel.2011.01.002; Halpern KB, 2017, NATURE, V542, P352, DOI 10.1038/nature21065; HERS H G, 1964, Adv Metab Disord, V13, P1; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kim Gu-Hwan, 2006, Hum Mutat, V27, P1159, DOI 10.1002/humu.9465; Kogo T, 1998, J HUM GENET, V43, P54, DOI 10.1007/s100380050037; Li H, 2011, BIOINFORMATICS, V27, P2987, DOI 10.1093/bioinformatics/btr509; Lichter-Konecki U, 2016, GENEREVIEWS, P1993; Matsuda I, 1997, AM J MED GENET, V71, P378, DOI 10.1002/(SICI)1096-8628(19970905)71:4<378::AID-AJMG2>3.3.CO;2-9; Miles L, 2005, J PEDIATR GASTR NUTR, V40, P471, DOI 10.1097/01.MPG.0000157200.33486.CE; Musalkova D, 2015, BLOOD CELL MOL DIS, V54, P210, DOI 10.1016/j.bcmd.2014.10.001; Nakagawa T, 2009, CELL, V137, P560, DOI 10.1016/j.cell.2009.02.026; Oldfors CH, 2015, NEUROMUSCULAR DISORD, V25, P493, DOI 10.1016/j.nmd.2015.03.005; Rahayatri TH, 2017, PEDIATR TRANSPLANT, V21, DOI 10.1111/petr.12848; Shiojiri N, 1997, AM J PATHOL, V151, P413; Storkanova G, 2013, CLIN GENET, V84, P552, DOI 10.1111/cge.12085; Torre C, 2010, PROG MOL BIOL TRANSL, V97, P127, DOI 10.1016/B978-0-12-385233-5.00005-2; TUCHMAN M, 1989, PEDIATR RES, V26, P77, DOI 10.1203/00006450-198907000-00021; TUCHMAN M, 1994, HUM MUTAT, V4, P57, DOI 10.1002/humu.1380040109; Wakiya T, 2012, PEDIATR TRANSPLANT, V16, pE196, DOI 10.1111/j.1399-3046.2012.01716.x; Wakiya T, 2012, MOL GENET METAB, V105, P404, DOI 10.1016/j.ymgme.2011.12.019; Wu H, 2014, NEURON, V81, P103, DOI 10.1016/j.neuron.2013.10.051; Yaplito-Lee J, 2013, MOL GENET METAB, V108, P161, DOI 10.1016/j.ymgme.2013.01.006; Yorifuji T, 1998, CLIN GENET, V54, P349, DOI 10.1034/j.1399-0004.1998.5440415.x; Yu W, 2009, J BIOL CHEM, V284, P13669, DOI 10.1074/jbc.M901921200	33	0	0	3	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUN	2018	472	6					1029	1039		10.1007/s00428-018-2345-x			11	Pathology	Pathology	GJ5GU	WOS:000435410300017	29623395				2019-10-28	
J	Bartels, S; Adisa, A; Aladelusi, T; Lemound, J; Stucki-Koch, A; Hussein, S; Kreipe, H; Hartmann, C; Lehmann, U; Hussein, K				Bartels, Stephan; Adisa, Akinyele; Aladelusi, Timothy; Lemound, Juliana; Stucki-Koch, Angelika; Hussein, Sami; Kreipe, Hans; Hartmann, Christian; Lehmann, Ulrich; Hussein, Kais			Molecular defects in BRAF wild-type ameloblastomas and craniopharyngiomas-differences in mutation profiles in epithelial-derived oropharyngeal neoplasms	VIRCHOWS ARCHIV			English	Article						BRAF; CTNNB1, FGFR; Ameloblastoma; Ameloblastic carcinoma; Craniopharyngioma	TARGETS; PATHWAY; RARE	The aim of this study was to evaluate the mutation profile of BRAF wild-type craniopharyngiomas and ameloblastomas. Pre-screening by immunohistochemistry and pyrosequencing for identifying BRAF wild-type tumors was performed on archived specimens of ameloblastic tumors (n = 20) and craniopharyngiomas (n = 62). Subsequently, 19 BRAF wild-type tumors (nine ameloblastic tumors and ten craniopharyngiomas) were analyzed further using next-generation sequencing (NGS) targeting hot spot mutations of 22 cancer-related genes. Thereby, we found craniopharyngiomas mainly CTNNB1 mutated (8/10), including two FGFR3/CTNNB1-double mutated tumors. Ameloblastic tumors were often FGFR2 mutated (4/9; including one FGFR2/TP53/PTEN-triple mutated case) and rarely CTNNB1/TP53-double mutated (1/9) and KRAS-mutated (1/9). In the remaining samples, no mutation could be detected in the 22 genes under investigation. In conclusion, mutation profiles of BRAF wild-type craniopharyngiomas and ameloblastomas share mutations of FGFR genes and have additional mutations with potential for targeted therapy.	[Bartels, Stephan; Stucki-Koch, Angelika; Kreipe, Hans; Hartmann, Christian; Lehmann, Ulrich; Hussein, Kais] Hannover Med Sch, Inst Pathol, Carl Neuberg Str 1, D-30625 Hannover, Germany; [Adisa, Akinyele] Univ Ibadan, Dept Oral Pathol, Univ Coll Hosp lbadan, Ibadan, Nigeria; [Aladelusi, Timothy] Univ Ibadan, Oral & Maxillofacial Surg Dept, Univ Coll Hosp lbadan, Ibadan, Nigeria; [Lemound, Juliana] Hannover Med Sch, Dept Craniomaxillofacial Surg, Hannover, Germany; [Hussein, Sami] Al Makassed Hosp, Al Quds Sch Med, Dept Neurosurg, Jerusalem, Israel; [Hartmann, Christian] Hannover Med Sch, Dept Neuropathol, Hannover, Germany	Hussein, K (reprint author), Hannover Med Sch, Inst Pathol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	hussein.kais@mh-hannover.de	Hartmann, Christian/D-1882-2010	Bartels, Stephan/0000-0002-8903-2345	"Niedersachsische Krebsgesellschaft, e.V." (Hannover, DE)	This study was funded by "Niedersachsische Krebsgesellschaft, e.V." (Hannover, DE).	Bartels S, 2016, ONCOTARGET, V7, P30084, DOI 10.18632/oncotarget.8310; Bartels S, 2015, METHODS MOL BIOL, V1315, P103, DOI 10.1007/978-1-4939-2715-9_8; Brastianos PK, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv310; Brastianos PK, 2014, NAT GENET, V46, P161, DOI 10.1038/ng.2868; Brown NA, 2014, CLIN CANCER RES, V20, P5517, DOI 10.1158/1078-0432.CCR-14-1069; Diniz MG, 2017, J ORAL PATHOL MED, V46, P371, DOI 10.1111/jop.12505; Gomes CC, 2014, J PATHOL, V232, P488, DOI 10.1002/path.4331; Gomes DC, 2015, EUR J ENDOCRINOL, V172, P603, DOI 10.1530/EJE-14-0934; Gump JM, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-015-0211-5; Heikinheimo K, 2015, J DENT RES, V94, P237, DOI 10.1177/0022034514560373; Hussain I, 2013, J NEUROSURG, V119, P106, DOI 10.3171/2013.3.JNS122214; Katoh M, 2016, INT J MOL MED, V38, P3, DOI 10.3892/ijmm.2016.2620; Kaye Frederic J, 2015, J Natl Cancer Inst, V107, P378, DOI 10.1093/jnci/dju378; Kurppa KJ, 2014, J PATHOL, V232, P492, DOI 10.1002/path.4317; Lemound J, 2016, J ORAL PATHOL MED, V45, P655, DOI 10.1111/jop.12429; Li J, 2014, ONCOL LETT, V8, P914, DOI 10.3892/ol.2014.2230; Negoto Tetsuya, 2015, Surg Neurol Int, V6, P50, DOI 10.4103/2152-7806.154274; Oikonomou E, 2014, ONCOTARGET, V5, P11752, DOI 10.18632/oncotarget.2555; Pakneshan S, 2013, PATHOLOGY, V45, P346, DOI 10.1097/PAT.0b013e328360b61d; Schiebler TH, 1995, ANATOMIE; Sekine S, 2004, HISTOPATHOLOGY, V45, P573, DOI 10.1111/j.1365-2559.2004.02029.x; Sekine S, 2003, AM J PATHOL, V163, P1707, DOI 10.1016/S0002-9440(10)63528-6; Tan S, 2016, OR SURG OR MED OR PA, V122, pE5, DOI 10.1016/j.oooo.2015.12.016	23	0	1	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUN	2018	472	6					1055	1059		10.1007/s00428-018-2323-3			5	Pathology	Pathology	GJ5GU	WOS:000435410300019	29546640				2019-10-28	
J	Elmore, SA				Elmore, Susan A.			Preprints: What Role Do These Have in Communicating Scientific Results?	TOXICOLOGIC PATHOLOGY			English	Editorial Material									[Elmore, Susan A.] NIEHS, Natl Toxicol Program, 111 TW Alexander Dr, Res Triangle Pk, NC 27707 USA	Elmore, SA (reprint author), NIEHS, Natl Toxicol Program, 111 TW Alexander Dr, Res Triangle Pk, NC 27707 USA.	elmore@niehs.nih.gov			Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [Z99 ES999999]		Berg JM, 2016, SCIENCE, V352, P899, DOI 10.1126/science.aaf9133; Bourne PE, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005473; Powell K, 2016, NATURE, V530, P148, DOI 10.1038/530148a	3	0	0	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JUN	2018	46	4					364	365		10.1177/0192623318767322			2	Pathology; Toxicology	Pathology; Toxicology	GK3US	WOS:000436074500001	29628000	Green Accepted			2019-10-28	
J	Gad, SC; Schuh, JCL				Gad, Shayne C.; Schuh, JoAnn C. L.			Toxicologic Pathology Forum Opinion Paper: Considerations for Toxicologic Pathologists Evaluating the Safety of Biomaterials and Finished Medical Devices	TOXICOLOGIC PATHOLOGY			English	Article						safety assessment; toxicologic pathology; medical devices; histopathology	FOREIGN-BODY REACTION	Safety ("biocompatibility") assessment of medical devices has evolved along a different path than that of drugs, being historically governed more by the considerations and needs of engineers rather than chemists and biologists. As a result, the involvement of veterinary pathologists has been much more limited-almost entirely to evaluating tissue responses in tissues in direct contact with implanted devices. As devices have become more complex in composition, structure, placement, and use, concerns as to adverse systemic responses in patients have called for more comprehensive and thoughtful evaluations of effects throughout the body. Further complexities arise from the increasing marriage of devices and drug/biologic therapeutics to achieve either better dose control and, specifically, in delivery to target organs/tissues or better tolerance of the body to medical devices (i.e., minimization of the foreign body response). The challenge to pathologists is to integrate in new technologies (such as in vivo imaging and immunology) and ways of viewing interactions with patient bodies. To fail to do so will allow the methods and standards for medical device safety evaluation to be based on chemical analysis and then the limited details inherent in literature-based risk assessments.	[Gad, Shayne C.] Gad Consulting Serv, 4008 Barrett Dr, Raleigh, NC 27609 USA; [Schuh, JoAnn C. L.] PLLC, Bainbridge Isl, WA USA	Gad, SC (reprint author), Gad Consulting Serv, 4008 Barrett Dr, Raleigh, NC 27609 USA.	scgad@ix.netcom.com		Schuh, JoAnn C. L./0000-0002-2399-8518			Alves A, 2012, WOODH PUBL SER BIOM, V50, P457; Anderson JM, 2008, SEMIN IMMUNOL, V20, P86, DOI 10.1016/j.smim.2007.11.004; Badylak S, 2015, HOST RESPONSE BIOMAT; Boutrand J.-P., 2012, BIOCOMPATIBILITY PER; Diller R. B., 2015, MOL HISTOPATHOLOGY T, P153; Funk K. A., TOXICOLOGIC PATHOLOG; Gad SC, 2016, BIOMATERIALS MED DEV; Goad M., 2013, HASCHEK ROUSSEAUXS H, P459; Goud NS, 2017, COMPREHENSIVE GUIDE TO TOXICOLOGY IN NONCLINICAL DRUG DEVELOPMENT, 2ND EDITION, P825, DOI 10.1016/B978-0-12-803620-4.00031-1; Greaves P, 2013, J TOXICOL PATHOL, V26, p1S, DOI 10.1293/tox.26.1S; HUTT PB, 1989, FOOD DRUG LAW J, V44, P99; International Organization for Standardization, 2016, 1099362016 ISO; Klopfleisch R, 2017, J BIOMED MATER RES A, V105, P927, DOI 10.1002/jbm.a.35958; Nikula KJ, 2016, TOXICOL PATHOL, V44, P9, DOI 10.1177/0192623315617035; Ratner BD, 2013, BIOMATERIALS SCI INT; Rentsch Claudia, 2014, Biomatter, V4, DOI 10.4161/biom.27993; Schwartz RS, 2004, CIRCULATION, V110, P2498, DOI 10.1161/01.CIR.0000145164.85178.2E; Swanson E, 2017, PLAST RECONSTR SURG, V139, p558E, DOI 10.1097/PRS.0000000000002966; The Organisation for Economic Co operation and Development (OECD), 2015, GEN QUEST ANSW OECD; United States Food & Drug Administration, 2014, IS PROD MED DEV; US Food and Drug Administration, 2016, 109931 ISO US FOOD D; US Food and Drug Administration, 2016, TITL 21 FOOD DRUG 58; US Food and Drug Administration, 2017, BREAST IMPL ASS AN L	23	4	4	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JUN	2018	46	4					366	371		10.1177/0192623318768719			6	Pathology; Toxicology	Pathology; Toxicology	GK3US	WOS:000436074500002	29683082	Bronze			2019-10-28	
J	Bolon, B; Krinke, G; Butt, MT; Rao, DB; Pardo, ID; Jortner, BS; Garman, RH; Jensen, K; Andrews-Jones, L; Morrison, JP; Sharma, AK; Thibodeau, MS				Bolon, Brad; Krinke, Georg; Butt, Mark T.; Rao, Deepa B.; Pardo, Ingrid D.; Jortner, Bernard S.; Garman, Robert H.; Jensen, Karl; Andrews-Jones, Lydia; Morrison, James P.; Sharma, Alok K.; Thibodeau, Michael S.			STP Position Paper: Recommended Best Practices for Sampling, Processing, and Analysis of the Peripheral Nervous System (Nerves and Somatic and Autonomic Ganglia) during Nonclinical Toxicity Studies	TOXICOLOGIC PATHOLOGY			English	Article						peripheral nervous system; neuropathology; neurotoxicity; best practices; nerve; ganglia; tissue sampling; tissue processing	DORSAL-ROOT GANGLION; FIBER-TYPE COMPOSITION; SPINAL-CORD; TECHNICAL GUIDE; INJURY; NEUROPATHY; NEURONS; REGENERATION; PERMEABILITY; INNERVATION	Peripheral nervous system (PNS) toxicity is surveyed inconsistently in nonclinical general toxicity studies. These Society of Toxicologic Pathology "best practice" recommendations are designed to ensure consistent, efficient, and effective sampling, processing, and evaluation of PNS tissues for four different situations encountered during nonclinical general toxicity (screening) and dedicated neurotoxicity studies. For toxicity studies where neurotoxicity is unknown or not anticipated (situation 1), PNS evaluation may be limited to one sensorimotor spinal nerve. If somatic PNS neurotoxicity is suspected (situation 2), analysis minimally should include three spinal nerves, multiple dorsal root ganglia, and a trigeminal ganglion. If autonomic PNS neuropathy is suspected (situation 3), parasympathetic and sympathetic ganglia should be assessed. For dedicated neurotoxicity studies where a neurotoxic effect is expected (situation 4), PNS sampling follows the strategy for situations 2 and/or 3, as dictated by functional or other compound/target-specific data. For all situations, bilateral sampling with unilateral processing is acceptable. For situations 1-3, PNS is processed conventionally (immersion in buffered formalin, paraffin embedding, and hematoxylin and eosin staining). For situation 4 (and situations 2 and 3 if resources and timing permit), perfusion fixation with methanol-free fixative is recommended. Where PNS neurotoxicity is suspected or likely, at least one (situations 2 and 3) or two (situation 4) nerve cross sections should be postfixed with glutaraldehyde and osmium before hard plastic resin embedding; soft plastic embedding is not a suitable substitute for hard plastic. Special methods may be used if warranted to further characterize PNS findings. Initial PNS analysis should be informed, not masked ("blinded"). Institutions may adapt these recommendations to fit their specific programmatic requirements but may need to explain in project documentation the rationale for their chosen PNS sampling, processing, and evaluation strategy.	[Bolon, Brad] GEMpath Inc, 1100 East 17th Ave,Unit M202, Longmont, CO 80504 USA; [Krinke, Georg] AnaPath GmbH, Oberbuchsiten, Switzerland; [Butt, Mark T.] Tox Path Specialists LLC, Frederick, MD USA; [Rao, Deepa B.] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA; [Pardo, Ingrid D.] Pfizer, Groton, CT USA; [Jortner, Bernard S.] Virginia Polytech Inst & State Univ, Blacksburg, VA 24061 USA; [Garman, Robert H.] Consultants Vet Pathol Inc, Murrysville, PA USA; [Jensen, Karl] US EPA, Res Triangle Pk, NC 27711 USA; [Andrews-Jones, Lydia] Allergan Pharmaceut Inc, Irvine, CA USA; [Morrison, James P.] Charles River Labs Inc, Shrewsbury, MA USA; [Sharma, Alok K.] Covance Labs Inc, Madison, WI USA; [Thibodeau, Michael S.] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA	Bolon, B (reprint author), GEMpath Inc, 1100 East 17th Ave,Unit M202, Longmont, CO 80504 USA.	bradgempath@aol.com					Abram SE, 2006, ANESTHESIOLOGY, V105, P146, DOI 10.1097/00000542-200607000-00024; ARMSTRONG RB, 1984, AM J ANAT, V171, P259, DOI 10.1002/aja.1001710303; Azhary H, 2010, AM FAM PHYSICIAN, V81, P887; BAILEY CS, 1988, AM J VET RES, V49, P115; Baumel J. J., 1975, SISSON GROSSMANS ANA, V2, P2038; BHATHAL PS, 1974, J PATHOL, V112, P19, DOI 10.1002/path.1711120105; Ton BHT, 2013, ACTA HISTOCHEM, V115, P840, DOI 10.1016/j.acthis.2013.04.007; Bilbao JM, 2015, BIOPSY DIAGNOSIS PER; Bolon B, 2006, TOXICOL PATHOL, V34, P296, DOI 10.1080/01926230600713269; Bolon B., 2014, ENCY NEUROLOGICAL SC, V2, P312; Bolon B, 2013, HASCHEK AND ROUSSEAUX'S HANDBOOK OF TOXICOLOGIC PATHOLOGY, VOL 1-3, 3RD EDITION, P2005, DOI 10.1016/B978-0-12-415759-0.00052-2; Bolon B, 2017, TOXICOL PATHOL, V45, P580, DOI 10.1177/0192623317720120; Bolon B, 2013, TOXICOL PATHOL, V41, P1028, DOI 10.1177/0192623312474865; Bolon B, 2011, FUNDAMENTAL NEUROPATHOLOGY FOR PATHOLOGISTS AND TOXICOLOGISTS: PRINCIPLES AND TECHNIQUES, P89; Bolon B, 2011, TOXICOL PATHOL, V39, P92, DOI 10.1177/0192623310385145; Bolon B, 2008, TOXICOL PATHOL, V36, P871, DOI 10.1177/0192623308322313; BRAUND KG, 1980, VET PATHOL, V17, P422, DOI 10.1177/030098588001700404; Butt AM, 2004, EYE, V18, P1110, DOI 10.1038/sj.eye.6701595; Butt M, 2014, TOXICOL SCI, V142, P463, DOI 10.1093/toxsci/kfu192; Carrier CA, 2014, J MED PRIMATOL, V43, P52, DOI 10.1111/jmp.12087; Cerri PS, 2003, MICRON, V34, P365, DOI 10.1016/S0968-4328(03)00098-2; Clarkson C, 2015, CARNIVORE DISSECTION; Crissman JW, 2004, TOXICOL PATHOL, V32, P126, DOI 10.1080/01926230490268756; Dellman H.-D., 1975, SISSON GROSSMANS ANA, V2, P1360; DIEMER NH, 1982, CRC CR REV TOXICOL, V10, P215, DOI 10.3109/10408448209037456; DYCK PJ, 2005, PERIPHERAL NEUROPATH, P733; Dykstra M. J., 1992, BIOL ELECT MICROSCOP; Espinosa-Medina I, 2016, SCIENCE, V354, P893, DOI 10.1126/science.aah5454; Fix AS, 2000, TOXICOL PATHOL, V28, P122, DOI 10.1177/019262330002800115; Fletcher T. F., 1993, Miller's anatomy of the dog., P800; Fletcher T. F., 2010, CANINE AUTONOMIC NER; Francis GJ, 2011, J NEUROPATH EXP NEUR, V70, P323, DOI 10.1097/NEN.0b013e318215669a; FRIEDE RL, 1982, BRAIN RES, V235, P335, DOI 10.1016/0006-8993(82)91012-5; Furness JB, 2006, ENTERIC NERVOUS SYST; Garman RH, 2016, TOXICOL PATHOL, V44, P14, DOI 10.1177/0192623315596858; Garman RH, 2011, FUNDAMENTAL NEUROPATHOLOGY FOR PATHOLOGISTS AND TOXICOLOGISTS: PRINCIPLES AND TECHNIQUES, P191; Garman RH, 2011, TOXICOL PATHOL, V39, P22, DOI 10.1177/0192623310389621; Ghoshal N. G., 1975, SISSON GROSSMANS ANA, V2, P1383; Ghoshal N. G., 1975, SISSON GROSSMANS ANA, V2, P1699; Gosselin SJ, 2011, TOXICOL PATHOL, V39, P422, DOI 10.1177/0192623310395331; GREENE EC, 1935, ANATOMY RAT; Gropp KE, 2017, TOXICOL PATHOL, V45, P939, DOI 10.1177/0192623317735794; Hancock S. K., 2005, CURR PROTOC TOXICOL; Hyman BT, 1998, J NEUROPATH EXP NEUR, V57, P305, DOI 10.1097/00005072-199804000-00001; Jimenez-Andrade JM, 2006, NEUROSCI LETT, V405, P62, DOI 10.1016/j.neulet.2006.06.043; JORTNER BS, 1989, NEUROTOXICOLOGY, V10, P717; Jortner BS, 2000, TOXICOL PATHOL, V28, P54, DOI 10.1177/019262330002800108; JUNGHERR EL, 1969, AVIAN DIS, P1; Kammoun M, 2014, EUR J HISTOCHEM, V58, P163, DOI 10.4081/ejh.2014.2254; Kaufman MH, 1999, ANATOMICAL BASIS MOU; Kiernan J. A., 2008, HISTOLOGICAL HISTOCH; Kiernan J. A., 2000, MICROSC TODAY, V08, P8, DOI DOI 10.1017/S1551929500057060; Kremzier J. E., 1984, MUSCLE PATHOLOGY, P31; KRINKE G, 1978, ACTA NEUROPATHOL, V43, P213; KRINKE G, 1979, AGENTS ACTIONS, V9, P227, DOI 10.1007/BF02024740; Krinke GJ, 2011, FUNDAMENTAL NEUROPATHOLOGY FOR PATHOLOGISTS AND TOXICOLOGISTS: PRINCIPLES AND TECHNIQUES, P365; Krinke GJ, 2000, TOXICOL PATHOL, V28, P113, DOI 10.1177/019262330002800114; Krinke GJ, 2001, EXP TOXICOL PATHOL, V53, P365, DOI 10.1078/0940-2993-00202; Krinke GJ, 1997, EXP TOXICOL PATHOL, V49, P451, DOI 10.1016/S0940-2993(97)80133-9; Kristiansen SLB, 2012, APMIS, V120, P327, DOI 10.1111/j.1600-0463.2012.02889.x; LAMOTTE CC, 1991, J COMP NEUROL, V311, P546, DOI 10.1002/cne.903110409; Lauria G, 2005, EUR J NEUROL, V12, P747, DOI 10.1111/j.1468-1331.2005.01260.x; Lauria G, 2005, J PERIPHER NERV SYST, V10, P202, DOI 10.1111/j.1085-9489.2005.0010210.x; Lee M, 2017, AM J TRANSL RES, V9, P926; Magette E., 2012, RAT DISSECTION MUS 2; Mangus LM, 2016, TOXICOL PATHOL, V44, P904, DOI 10.1177/0192623316650286; Marmiroli P, 2009, CLIN NEUROPATHOL, V28, P263, DOI 10.2379/NP300136; Martyn C, 1997, J NEUROL NEUROSUR PS, V62, P310, DOI 10.1136/jnnp.62.4.310; Mathias CJ, 2003, J NEUROL NEUROSUR PS, V74, pIII31, DOI 10.1136/jnnp.74.suppl_3.iii31; Miller KE, 2002, BRAIN RES, V945, P202, DOI 10.1016/S0006-8993(02)02802-0; Morfini GA, 2012, BASIC NEUROCHEMISTRY: PRINCIPLES OF MOLECULAR, CELLULAR, AND MEDICAL NEUROBIOLOGY, 8THEDITION, P146; Morton D, 2010, TOXICOL PATHOL, V38, P1118, DOI 10.1177/0192623310383991; Mueller M, 2000, AM J PATHOL, V157, P1829, DOI 10.1016/S0002-9440(10)64822-5; Muller KA, 2008, DIABETES, V57, P1693, DOI 10.2337/db08-0022; Muratori L, 2012, MICROSURG, V32, P383, DOI 10.1002/micr.21969; Myers MI, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-012-0323-2; OECD, 2007, TEST NO 426 DEV NEUR; OECD, 1997, TEST NO 424 NEUR STU; Oliveira ALR, 1997, NEUROREPORT, V8, P2837; OLSSON Y, 1990, CRIT REV NEUROBIOL, V5, P265; Palazzi X, 2011, BEAGLE BRAIN STEREOT; Pardo ID, 2012, TOXICOL PATHOL, V40, P624, DOI 10.1177/0192623311436180; Patro N, 2010, INDIAN J EXP BIOL, V48, P110; PAXINOS G, 2000, RHESUS MONKEY BRAIN; Paxinos G, 2007, RAT BRAIN STEREOTAXI; Paxinos G., 2001, MOUSE BRAIN STEREOTA; PENTTILA A, 1974, J CELL BIOL, V63, P197, DOI 10.1083/jcb.63.1.197; Peters A, 1991, FINE STRUCTURE NERVO; PEYRONNARD JM, 1986, BRAIN RES, V364, P137, DOI 10.1016/0006-8993(86)90994-7; Raimondo S, 2009, INT REV NEUROBIOL, V87, P81, DOI 10.1016/S0074-7742(09)87005-0; Rao DB, 2011, TOXICOL PATHOL, V39, P463, DOI 10.1177/0192623311401044; Rigaud M, 2008, PAIN, V136, P188, DOI 10.1016/j.pain.2008.01.016; Ronchi G, 2014, J PERIPHER NERV SYST, V19, P224, DOI 10.1111/jns.12090; SADUN AA, 1983, J NEUROPATH EXP NEUR, V42, P200, DOI 10.1097/00005072-198303000-00009; Salvo H, 2011, FUNDAMENTAL NEUROPATHOLOGY FOR PATHOLOGISTS AND TOXICOLOGISTS: PRINCIPLES AND TECHNIQUES, P519; Sant'Anna MB, 2016, SCI REP-UK, V6, DOI 10.1038/srep26955; Sapunar Damir, 2012, J Pain Res, V5, P31, DOI 10.2147/JPR.S26603; Schaeffer V, 2010, GLIA, V58, P169, DOI 10.1002/glia.20910; Schafer KA, 2018, TOXICOL PATHOL, V46, P256, DOI 10.1177/0192623318761348; Schaumburg HH, 2010, J PERIPHER NERV SYST, V15, P128, DOI 10.1111/j.1529-8027.2010.00262.x; Schiaffino S, 2011, PHYSIOL REV, V91, P1447, DOI 10.1152/physrev.00031.2010; Schmeichel AM, 2003, DIABETES, V52, P165, DOI 10.2337/diabetes.52.1.165; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Sengul G, 2012, MOUSE NERVOUS SYSTEM, P424, DOI 10.1016/B978-0-12-369497-3.10013-5; SHARP JW, 1990, ANAT HISTOL EMBRYOL, V19, P359, DOI 10.1111/j.1439-0264.1990.tb00911.x; Shirai N, 2016, TOXICOL PATHOL, V44, P1160, DOI 10.1177/0192623316673921; SPENCER PS, 1977, J NEUROPATH EXP NEUR, V36, P300, DOI 10.1097/00005072-197703000-00006; Staron RS, 1999, HISTOCHEM CELL BIOL, V111, P117, DOI 10.1007/s004180050341; STRICH SJ, 1968, J NEUROL NEUROSUR PS, V31, P110, DOI 10.1136/jnnp.31.2.110; Turnquist JE, 2012, AM COLL LAB, P87, DOI 10.1016/B978-0-12-381365-7.00004-2; U.S EPA, 1998, HLTH EFF TEST GUID O; Ulrich-Lai YM, 2009, NAT REV NEUROSCI, V10, P397, DOI 10.1038/nrn2647; US National Toxicology Program, 2011, PATHOLOGY; Vleggeert-Lankamp CLAM, 2007, J NEUROSURG, V107, P1168, DOI 10.3171/JNS-07/12/1168; Watson C, 2015, NEUROSCI RES, V93, P164, DOI 10.1016/j.neures.2014.12.012; Young J T, 1981, Fundam Appl Toxicol, V1, P309, DOI 10.1016/S0272-0590(81)80037-1	117	8	8	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JUN	2018	46	4					372	402		10.1177/0192623318772484			31	Pathology; Toxicology	Pathology; Toxicology	GK3US	WOS:000436074500003	29787347	Bronze			2019-10-28	
J	Shrader, SM; Greentree, WF				Shrader, Stephanie M.; Greentree, William F.			Gottingen Minipigs in Ocular Research	TOXICOLOGIC PATHOLOGY			English	Review						minipig; preclinical safety assessment/risk management; ocular; toxicity; drug development	SWINE; MODEL	Since their development in the 1960s, Gottingen minipigs have become a popular nonrodent animal model in biomedical research, especially for ocular studies, because of their ease of handling, size, well-monitored genetics, and ocular anatomy that is similar to humans. The purpose of this mini-review is to introduce the reader to the various ways in which this animal model is currently being utilized in ocular research and to provide an overview of the diagnostic modalities that aid in this research. To date, the Gottingen minipig has been used for a variety of ocular research endeavors, including studies evaluating the safety and efficacy of ocular therapeutics, glaucoma etiopathogenesis and treatment, novel biomaterials, surgical procedures, and implantable materials/devices. In addition to histopathologic evaluation of enucleated globes, the majority of these studies make use of advanced in vivo diagnostic techniques, including electroretinography, optical coherence tomography, fundoscopic imaging, and fluorescein angiography.	[Shrader, Stephanie M.; Greentree, William F.] Charles River Labs, 640 North Elizabeth St, Spencerville, OH 45887 USA	Shrader, SM (reprint author), Charles River Labs, 640 North Elizabeth St, Spencerville, OH 45887 USA.	stephanie.shrader@crl.com					Berman E. R., 1991, BIOCH EYE, P292; Chen SC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143511; de Castro JPF, 2014, INVEST OPHTH VIS SCI, V55, P2460, DOI 10.1167/iovs.13-13724; Ehall H, 2012, MINIPIG IN BIOMEDICAL RESEARCH, P293; Forster R., 2013, SOC TOX SAN ANT TEX; Galdos M, 2012, VET OPHTHALMOL, V15, P36, DOI 10.1111/j.1463-5224.2011.00937.x; Laube T, 2012, GRAEF ARCH CLIN EXP, V250, P51, DOI 10.1007/s00417-011-1756-z; MCMENAMIN PG, 1991, J ANAT, V178, P65; Merindano M. D., 2002, EUR J ANAT, V6, P133; Nielsen LS, 2005, SCAND J LAB ANIM SCI, V32, P9; Noulas AV, 2004, BIOMED CHROMATOGR, V18, P457, DOI 10.1002/bmc.336; QUIGLEY HA, 1990, ARCH OPHTHALMOL-CHIC, V108, P51, DOI 10.1001/archopht.1990.01070030057028; Shikari H., 2016, J CLIN OPHTHALMOL RE, V4, P51; Simianer H, 2010, J PHARMACOL TOX MET, V62, P221, DOI 10.1016/j.vascn.2010.05.004; Stricker-Krongrad A, 2016, TOXICOL PATHOL, V44, P612, DOI 10.1177/0192623316641784; Swindle MM, 2012, VET PATHOL, V49, P344, DOI 10.1177/0300985811402846; Swindle MM, 2007, SWINE LAB SURG ANEST; Vezina M., 2013, ASSESSING OCULAR TOX, P9	18	1	1	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JUN	2018	46	4					403	407		10.1177/0192623318770379			5	Pathology; Toxicology	Pathology; Toxicology	GK3US	WOS:000436074500004	29683084	Bronze			2019-10-28	
J	Gropp, KE; Carlson, CS; Evans, MG; Bagi, CM; Reagan, WJ; Hurst, SI; Shelton, DL; Zorbas, MA				Gropp, Kathryn E.; Carlson, Cathy S.; Evans, Mark G.; Bagi, Cedo M.; Reagan, William J.; Hurst, Susan I.; Shelton, David L.; Zorbas, Mark A.			Effects of Monoclonal Antibodies against Nerve Growth Factor on Healthy Bone and Joint Tissues in Mice, Rats, and Monkeys: Histopathologic, Biomarker, and Microcomputed Tomographic Assessments	TOXICOLOGIC PATHOLOGY			English	Article						osteoarthritis; tanezumab; nerve growth factor; bone safety; joint safety	PHASE-III TRIAL; LOW-BACK-PAIN; DOUBLE-BLIND; CYNOMOLGUS MACAQUES; OSTEOARTHRITIS PAIN; HIP OSTEOARTHRITIS; TANEZUMAB; EFFICACY; SAFETY; MODEL	Tanezumab, an anti-nerve growth factor (NGF) antibody, is in development for management of chronic pain. During clinical trials of anti-NGF antibodies, some patients reported unexpected adverse events requiring total joint replacements, resulting in a partial clinical hold on all NGF inhibitors. Three nonclinical toxicology studies were conducted to evaluate the effects of tanezumab or the murine precursor muMab911 on selected bone and joint endpoints and biomarkers in cynomolgus monkeys, Sprague-Dawley rats, and C57BL/6 mice. Joint and bone endpoints included histology, immunohistochemistry, microcomputed tomography (mCT) imaging, and serum biomarkers of bone physiology. Responses of bone endpoints to tanezumab were evaluated in monkeys at 4 to 30 mg/kg/week for 26 weeks and in rats at 0.2 to 10 mg/kg twice weekly for 28 days. The effects of muMab911 at 10 mg/kg/week for 12 weeks on selected bone endpoints were determined in mice. Tanezumab and muMab911 had no adverse effects on any bone or joint parameter. There were no test article-related effects on bone or joint histology, immunohistochemistry, or structure. Reversible, higher osteocalcin concentrations occurred only in the rat study. No deleterious effects were observed in joints or bones in monkeys, rats, or mice administered high doses of tanezumab or muMab911.	[Gropp, Kathryn E.; Bagi, Cedo M.; Reagan, William J.] Pfizer Inc, Drug Safety Res & Dev, MS8274-1213,Eastern Point Rd, Groton, CT 06340 USA; [Carlson, Cathy S.] Univ Minnesota, Coll Vet Med, Dept Vet Populat Med, St Paul, MN 55108 USA; [Evans, Mark G.; Zorbas, Mark A.] Pfizer Inc, Drug Safety Res & Dev, San Diego, CA USA; [Hurst, Susan I.] Pfizer Inc, Dept Biomed Design, Groton, CT 06340 USA; [Shelton, David L.] Pfizer Inc, San Francisco, CA USA	Gropp, KE (reprint author), Pfizer Inc, Drug Safety Res & Dev, MS8274-1213,Eastern Point Rd, Groton, CT 06340 USA.	kathryn.gropp@pfizer.com			Eli Lilly Co.Eli Lilly; PfizerPfizer	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Medical writing support was provided by Joseph Oleynek at Engage Scientific Solutions and was funded by Eli Lilly & Co. and Pfizer. These studies were funded by Pfizer.	Abdiche YN, 2008, PROTEIN SCI, V17, P1326, DOI 10.1110/ps.035402.108; Apfel SC, 2000, JAMA-J AM MED ASSOC, V284, P2215, DOI 10.1001/jama.284.17.2215; Apfel SC, 2002, INT REV NEUROBIOL, V50, P393; Bagi C. M., 2012, OSTEOCALCIN; Bagi CM, 2011, COMPARATIVE MED, V61, P76; Balanescu AR, 2014, ANN RHEUM DIS, V73, P1665, DOI 10.1136/annrheumdis-2012-203164; Brommage R., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P307; Brown MT, 2013, ARTHRITIS RHEUM-US, V65, P1795, DOI 10.1002/art.37950; Brown MT, 2012, J PAIN, V13, P790, DOI 10.1016/j.jpain.2012.05.006; CARLSON CS, 1994, J ORTHOP RES, V12, P331, DOI 10.1002/jor.1100120305; Carlson CS, 1996, J BONE MINER RES, V11, P1209; David V, 2006, AM J PHYSIOL-ENDOC M, V290, pE440, DOI 10.1152/ajpendo.00293.2004; Denk F, 2017, ANNU REV NEUROSCI, V40, P307, DOI 10.1146/annurev-neuro-072116-031121; Dyck PJ, 1997, NEUROLOGY, V48, P501, DOI 10.1212/WNL.48.2.501; Ekman EF, 2014, J RHEUMATOL, V41, P2249, DOI 10.3899/jrheum.131294; FDA ( Food and Drug Administration ), 2012, BACKGR PACK ADD; FDA (Food and Drug Administration), 2016, M ARTHR ADV COMM ACC; FROST HM, 1992, BONE MINER, V18, P227, DOI 10.1016/0169-6009(92)90809-R; Hale LV, 2007, BONE, V40, P1103, DOI 10.1016/j.bone.2006.11.027; Ham KD, 2002, ARTHRITIS RHEUM-US, V46, P1956, DOI 10.1002/art.10406; Hochberg MC, 2016, ARTHRITIS RHEUMATOL, V68, P382, DOI 10.1002/art.39492; Ivaska KK, 2004, J BIOL CHEM, V279, P18361, DOI 10.1074/jbc.M314324200; Jerome CP, 2001, BONE, V29, P1, DOI 10.1016/S8756-3282(01)00477-X; Katz N, 2011, PAIN, V152, P2248, DOI 10.1016/j.pain.2011.05.003; Kivitz AJ, 2013, PAIN, V154, P1009, DOI 10.1016/j.pain.2013.03.006; Koewler NJ, 2007, J BONE MINER RES, V22, P1732, DOI 10.1359/JBMR.070711; LaBranche TP, 2017, ANN RHEUM DIS, V76, P295, DOI 10.1136/annrheumdis-2015-208913; Lane NE, 2010, NEW ENGL J MED, V363, P1521, DOI 10.1056/NEJMoa0901510; Mantyh PW, 2011, ANESTHESIOLOGY, V115, P189, DOI 10.1097/ALN.0b013e31821b1ac5; MILLER SC, 1991, BONE, V12, P439, DOI 10.1016/8756-3282(91)90033-F; National Research Council, 1996, GUID CAR US LAB AN; Palazzi X, 2016, TOXICOL PATHOL, V44, P810, DOI 10.1177/0192623316642527; Pfizer, 2012, TAN ARTHR ADV COMM B; RADIN EL, 1991, SEMIN ARTHRITIS RHEU, V21, P12, DOI 10.1016/0049-0172(91)90036-Y; Rissanen JP, 2008, CALCIFIED TISSUE INT, V82, P155, DOI 10.1007/s00223-007-9101-6; Rosen HN, 2000, CALCIFIED TISSUE INT, V66, P100, DOI 10.1007/PL00005830; Sabsovich I, 2008, PAIN, V138, P47, DOI 10.1016/j.pain.2007.11.004; Schnitzer TJ, 2015, ANN RHEUM DIS, V74, P1202, DOI 10.1136/annrheumdis-2013-204905; Sevcik MA, 2005, PAIN, V115, P128, DOI 10.1016/j.pain.2005.02.022; Shelton DL, 2005, PAIN, V116, P8, DOI 10.1016/j.pain.2005.03.039; Spierings ELH, 2013, PAIN, V154, P1603, DOI 10.1016/j.pain.2013.04.035; STENSTROM A, 1977, CALC TISS RES, V23, P161, DOI 10.1007/BF02012782; Tomlinson RE, 2017, P NATL ACAD SCI USA, V114, pE3632, DOI 10.1073/pnas.1701054114; Tomlinson RE, 2016, CELL REP, V16, P2723, DOI 10.1016/j.celrep.2016.08.002; WRONSKI TJ, 1988, CALCIFIED TISSUE INT, V43, P179, DOI 10.1007/BF02571317; Zorbas M, 2011, REGUL TOXICOL PHARM, V59, P334, DOI 10.1016/j.yrtph.2010.11.005	46	0	0	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JUN	2018	46	4					408	420		10.1177/0192623318772501			13	Pathology; Toxicology	Pathology; Toxicology	GK3US	WOS:000436074500005	29768985	Bronze			2019-10-28	
J	Jackson-Humbles, DN; Seely, JC; Herbert, RA; Malarkey, DE; McIntyre, BS; Foster, PM; Dixon, D				Jackson-Humbles, Daven N.; Seely, John Curtis; Herbert, Ronald A.; Malarkey, David E.; McIntyre, Barry S.; Foster, Paul M.; Dixon, Darlene			Uterine Paramesonephric Cysts in Sprague-Dawley Rats from National Toxicology Program Studies	TOXICOLOGIC PATHOLOGY			English	Article						Mullerian duct; Wolffian duct; paramesonephric; mesonephric; uterine cyst; PAX8; GATA3	FEMALE REPRODUCTIVE-TRACT; SEROSAL INCLUSION CYSTS; MESONEPHRIC LESIONS; GENITAL-TRACT; EXPRESSION; GATA3; MICE; DIETHYLSTILBESTROL; BENIGN; TUMORS	Congenital uterine wall cysts arising from paramesonephric (Mullerian) and mesonephric (Wolffian) ducts are typically incidental findings in most species. We used immunohistochemistry to characterize and determine the origin of uterine cysts in Sprague-Dawley (SD) rats from multigeneration studies conducted by the National Toxicology Program. Subserosal uterine cysts were observed in 20 of the 2,400 SD rats evaluated in five studies, and 10 cysts were characterized for this study. Single cysts were unilocular, fluid-filled, and occurred throughout the uterus. Microscopically, all cysts had a well-developed smooth muscle wall, lined by flattened to cuboidal, sometimes ciliated, epithelium that stained intensely positive for cytokeratin 18 and paired box protein 8 (PAX8). Most cyst epithelia displayed weak to moderate positivity for progesterone receptor (PR) and/or estrogen receptor alpha (ER-alpha), as well as were negative for GATA binding protein 3 (GATA3). Cyst lumens contained basophilic flocculent material. The cysts appeared to be developmental anomalies arising from paramesonephric tissue based on positive PAX8 and ER-alpha and/or PR staining. Additionally, 70% of the cysts lacked GATA3 expression. Taken together, the subserosal uterine cysts observed in adult rats in these studies most likely arose from the paramesonephric duct.	[Jackson-Humbles, Daven N.; Herbert, Ronald A.; Malarkey, David E.; McIntyre, Barry S.; Foster, Paul M.; Dixon, Darlene] NIEHS, Div Natl Toxicol Program, 111 TW Alexander Dr, Res Triangle Pk, NC 27707 USA; [Seely, John Curtis] Expt Pathol Labs Inc, Res Triangle Pk, NC USA	Dixon, D (reprint author), NIEHS, Div Natl Toxicol Program, 111 TW Alexander Dr, Res Triangle Pk, NC 27707 USA.	dixon@niehs.nih.gov	Jackson-Humbles, Daven/G-5717-2017	Jackson-Humbles, Daven/0000-0002-1550-0863	Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [ZIA ES021196-23]		Arnold S, 1996, J SMALL ANIM PRACT, V37, P235, DOI 10.1111/j.1748-5827.1996.tb01777.x; Bartel C, 2011, REPROD DOMEST ANIM, V46, P950, DOI 10.1111/j.1439-0531.2011.01764.x; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; Devouassoux-Shisheboran M, 1999, HUM PATHOL, V30, P856, DOI 10.1016/S0046-8177(99)90148-X; Dixon D, 2000, ENVIRON HEALTH PERSP, V108, P795, DOI 10.2307/3454309; Dixon D., 2018, BOORMANS PATHOLOGY R, P537; Dixon D, 2014, J TOXICOL PATHOL, V27, p1S, DOI 10.1293/tox.27.1S; Eilber KS, 2003, J UROLOGY, V170, P717, DOI 10.1097/01.ju.0000062543.99821.a2; GELBERG HB, 1986, VET PATHOL, V23, P770, DOI 10.1177/030098588602300617; Godfrey DR, 1998, VET REC, V142, P673, DOI 10.1136/vr.142.24.673; Goldman J. M., 2011, REPROD TOXICOL, P36; Goyal A, 2014, INT J GYNECOL PATHOL, V33, P613, DOI 10.1097/PGP.0000000000000102; Greaves P, 2012, HISTOPATHOLOGY OF PRECLINICAL TOXICITY STUDIES: INTERPRETATION AND RELEVANCE IN DRUG SAFETY EVALUATION, 4TH EDITION, P667, DOI 10.1016/B978-0-444-53856-7.00012-9; Grote D, 2006, DEVELOPMENT, V133, P53, DOI 10.1242/dev.02184; HANEY AF, 1986, AM J PATHOL, V124, P405; Heidarpour Mitra, 2014, Adv Biomed Res, V3, P96, DOI 10.4103/2277-9175.129366; Howitt BE, 2018, PATHOLOGY, V50, P141, DOI 10.1016/j.pathol.2017.11.084; Howitt BE, 2015, AM J SURG PATHOL, V39, P1411, DOI 10.1097/PAS.0000000000000471; Jacob M., 2012, THE HUMAN EMBRYO, DOI [10. 5772/34351, DOI 10.5772/34351]; Kobayashi A, 2003, NAT REV GENET, V4, P969, DOI 10.1038/nrg1225; Laury AR, 2011, AM J SURG PATHOL, V35, P816, DOI 10.1097/PAS.0b013e318216c112; Liang L, 2016, ARCH PATHOL LAB MED, V140, P148, DOI 10.5858/arpa.2015-0081-OA; Matalliotakis IM, 2003, OBSTET GYN CLIN N AM, V30, P65; McEntee K., 1990, REPROD PATHOLOGY DOM, P142; McEntee K, 1990, REPROD PATHOLOGY DOM, P118; Miettinen M, 2014, AM J SURG PATHOL, V38, P13, DOI 10.1097/PAS.0b013e3182a0218f; Mittag J, 2007, ENDOCRINOLOGY, V148, P719, DOI 10.1210/en.2006-1054; Mullen RD, 2014, SEX DEV, V8, P281, DOI 10.1159/000364935; Mutter GL, 2007, INT J GYNECOL PATHOL, V26, P103, DOI 10.1097/PGP.0b013e31802e4696; NERI A, 1966, GYNAECOLOGIA, V162, P225, DOI 10.1159/000303028; Newbold RR, 2009, ENVIRON HEALTH PERSP, V117, P879, DOI 10.1289/ehp.0800045; NEWBOLD RR, 1987, TERATOGEN CARCIN MUT, V7, P377, DOI 10.1002/tcm.1770070405; NEWBOLD RR, 1982, CANCER RES, V42, P2003; NRC [National Research Council], 2011, GUIDE CARE USE LAB A, P4; NTP, 2011, SPEC COND STUD EV RE; Ozcan A, 2011, MODERN PATHOL, V24, P751, DOI 10.1038/modpathol.2011.3; Parrott E, 2001, AM J PATHOL, V159, P623, DOI 10.1016/S0002-9440(10)61733-6; Protopapas A, 2008, GYNECOL OBSTET INVES, V65, P275, DOI 10.1159/000113871; Roma AA, 2015, INT J GYNECOL PATHOL, V34, P480, DOI 10.1097/PGP.0000000000000167; Roos AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084660; SHERRICK JC, 1962, OBSTET GYNECOL, V19, P486; Silver SA, 2001, AM J SURG PATHOL, V25, P379, DOI 10.1097/00000478-200103000-00013; Tong GX, 2011, DIAGN CYTOPATHOL, V39, P567, DOI 10.1002/dc.21426; Wang H, 2000, BIOL REPROD, V63, P1331, DOI 10.1095/biolreprod63.5.1331; Wu HX, 2014, INT J CLIN EXP PATHO, V7, P7012; Yucer N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05519-2; Zhao F, 2017, SCIENCE, V357, P717, DOI 10.1126/science.aai9136	47	0	0	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JUN	2018	46	4					421	430		10.1177/0192623318772487			10	Pathology; Toxicology	Pathology; Toxicology	GK3US	WOS:000436074500006	29706125	Green Accepted			2019-10-28	
J	Bahamonde, J; Brenseke, B; Chan, MY; Kent, RD; Vikesland, PJ; Prater, MR				Bahamonde, Javiera; Brenseke, Bonnie; Chan, Matthew Y.; Kent, Ronald D.; Vikesland, Peter J.; Prater, M. Renee			Gold Nanoparticle Toxicity in Mice and Rats: Species Differences	TOXICOLOGIC PATHOLOGY			English	Article						nanotoxicity; gold nanoparticles; mouse; rat; granulomas; interleukin-18	ENGINEERED NANOMATERIALS; COLLOIDAL GOLD; BIODISTRIBUTION; CYTOTOXICITY; SURFACE; CONFORMATION; LIVER	Nanotoxicity studies are greatly needed to advance nanomedical technologies into clinical practice. We assessed the toxic effects of a single intravenous exposure to commercially available gold nanoparticles (GNPs) in mice and rats. Fifteen-nm GNPs were purchased and independently characterized. Animals were exposed to either 1,000 mg GNPs/kg body weight (GNP group) or phosphate-buffered saline. Subsets of animals were euthanized and samples collected at 1, 7, 14, 21, and 28 days postexposure. Independent characterization demonstrated that the physicochemical properties of the purchased GNPs were in good agreement with the information provided by the supplier. Mice exposed to GNPs developed granulomas in the liver and transiently increased serum levels of the pro-inflammatory cytokine interleukin-18. No such alterations were found in rats. While there was no fatality in mice post-GNP exposure, a number of the rats died within hours of GNP administration. Differences in GNP biodistribution and excretion were also detected between the two species, with rats having a higher relative accumulation of GNPs in spleen and greater fecal excretion. In conclusion, GNPs have the ability to incite a robust macrophage response in mice, and there are important species-specific differences in their biodistribution, excretion, and potential for toxicity.	[Bahamonde, Javiera; Brenseke, Bonnie; Prater, M. Renee] Virginia Tech, Dept Biomed Sci & Pathobiol, Blacksburg, VA USA; [Bahamonde, Javiera] Univ Austral Chile, Fac Ciencias Vet, Inst Farmacol & Morfofisiol, Valdivia, Chile; [Brenseke, Bonnie] Campbell Univ, Sch Osteopath Med, Dept Pathol, Lillington, NC USA; [Chan, Matthew Y.; Kent, Ronald D.; Vikesland, Peter J.] Virginia Tech, Charles E Via Jr Dept Civil & Environm Engn, Blacksburg, VA USA; [Chan, Matthew Y.; Vikesland, Peter J.] Virginia Tech, Inst Crit Technol & Appl Sci, Blacksburg, VA USA; [Prater, M. Renee] Edward Via Coll Osteopath Med, Dept Biomed Sci, 2265 Kraft Dr, Blacksburg, VA 24060 USA	Prater, MR (reprint author), Edward Via Coll Osteopath Med, Dept Biomed Sci, 2265 Kraft Dr, Blacksburg, VA 24060 USA.	rprater@vcom.vt.edu	Bahamonde, Javiera/P-1572-2019; Bahamonde, Javiera/E-4358-2018; Vikesland, Peter/B-3960-2013	Bahamonde, Javiera/0000-0003-4987-5740; Vikesland, Peter/0000-0003-2654-5132; Chan, Matthew/0000-0003-0801-8101	Institute of Critical Technology and Applied Science (ICTAS) at Virginia Tech; Edward Via College of Osteopathic Medicine	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Institute of Critical Technology and Applied Science (ICTAS) at Virginia Tech and the Edward Via College of Osteopathic Medicine.	Balasubramanian SK, 2010, BIOMATERIALS, V31, P2034, DOI 10.1016/j.biomaterials.2009.11.079; Bednarski M, 2015, PHARMACOL REP, V67, P405, DOI 10.1016/j.pharep.2014.10.019; Breton MF, 2013, J PHYS CHEM LETT, V4, P2202, DOI 10.1021/jz400938q; Cardoso E, 2014, MUTAT RES-FUND MOL M, V766, P25, DOI 10.1016/j.mrfmmm.2014.05.009; Chen H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058208; Cho EC, 2009, NANO LETT, V9, P1080, DOI 10.1021/nl803487r; Cho WS, 2010, TOXICOL APPL PHARM, V245, P116, DOI 10.1016/j.taap.2010.02.013; Cho WS, 2009, TOXICOL APPL PHARM, V236, P16, DOI 10.1016/j.taap.2008.12.023; Chrissopoulou K, 2011, MACROMOLECULES, V44, P9710, DOI 10.1021/ma201711r; De Jong WH, 2008, BIOMATERIALS, V29, P1912, DOI 10.1016/j.biomaterials.2007.12.037; Donaldson K, 2006, NANOMEDICINE-UK, V1, P229, DOI 10.2217/17435889.1.2.229; Dragoni S, 2012, TOXICOL SCI, V128, P186, DOI 10.1093/toxsci/kfs150; Du LB, 2012, TALANTA, V101, P11, DOI 10.1016/j.talanta.2012.08.044; Dykman LA, 2011, ACTA NATURAE, V3, P34, DOI 10.32607/20758251-2011-3-2-34-56; EATON DL, 2008, CASARETT DOULLS TOXI, P11; Fischer HC, 2007, CURR OPIN BIOTECH, V18, P565, DOI 10.1016/j.copbio.2007.11.008; Gracie JA, 2003, J LEUKOCYTE BIOL, V73, P213, DOI 10.1189/jlb.0602313; Hainfeld JF, 2006, BRIT J RADIOL, V79, P248, DOI 10.1259/bjr/13169882; Hainfeld JF, 2004, PHYS MED BIOL, V49, pN309, DOI 10.1088/0031-9155/49/18/N03; Hirn S, 2011, EUR J PHARM BIOPHARM, V77, P407, DOI 10.1016/j.ejpb.2010.12.029; Hwang JH, 2012, TOXICOLOGY, V294, P27, DOI 10.1016/j.tox.2012.01.013; Khan HA, 2013, BIOMED RES INT, DOI 10.1155/2013/590730; Khlebtsov N, 2011, CHEM SOC REV, V40, P1647, DOI 10.1039/c0cs00018c; Kumar A, 2013, BIOTECHNOL ADV, V31, P593, DOI 10.1016/j.biotechadv.2012.10.002; Kumar A, 2011, J NANOMATER, DOI 10.1155/2011/202187; Leroy P, 2011, NITRIC OXIDE-BIOL CH, V25, P54, DOI 10.1016/j.niox.2011.04.012; Levin CS, 2006, ANAL CHEM, V78, P3277, DOI 10.1021/ac060041z; Li CH, 2015, TOXICOL SCI, V148, P192, DOI 10.1093/toxsci/kfv176; Li JJ, 2010, BIOMATERIALS, V31, P5996, DOI 10.1016/j.biomaterials.2010.04.014; Maojo V, 2012, INT J NANOMED, V7, P3867, DOI 10.2147/IJN.S24582; MAXFIELD J, 1975, POLYMER, V16, P505, DOI 10.1016/0032-3861(75)90008-7; Maynard AD, 2011, TOXICOL SCI, V120, pS109, DOI 10.1093/toxsci/kfq372; Morais T, 2012, EUR J PHARM BIOPHARM, V80, P185, DOI 10.1016/j.ejpb.2011.09.005; Nanoprobes, 2011, AUROVIST 15 PROD INF; Naz F, 2016, J DRUG TARGET, V24, P720, DOI 10.3109/1061186X.2016.1144758; Nystrom AM, 2012, J CONTROL RELEASE, V161, P403, DOI 10.1016/j.jconrel.2012.01.027; Oberdorster G, 2005, ENVIRON HEALTH PERSP, V113, P823, DOI 10.1289/ehp.7339; Oberdorster G, 2007, NANOTOXICOLOGY, V1, P2, DOI 10.1080/17435390701314761; Oostingh GJ, 2011, PART FIBRE TOXICOL, V8, DOI 10.1186/1743-8977-8-8; Paciotti GF, 2004, DRUG DELIV, V11, P169, DOI 10.1080/10717540490433895; Pan Y, 2012, METHOD ENZYMOL, V509, P225, DOI 10.1016/B978-0-12-391858-1.00012-5; Park H, 2010, ENVIRON TOXICOL CHEM, V29, P715, DOI 10.1002/etc.72; Resnik DB, 2007, CONTEMP CLIN TRIALS, V28, P433, DOI 10.1016/j.cct.2006.11.001; Sadauskas E, 2009, NANOMED-NANOTECHNOL, V5, P162, DOI 10.1016/j.nano.2008.11.002; Siddiqi NJ, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-123; Sonavane G, 2008, COLLOID SURFACE B, V66, P274, DOI 10.1016/j.colsurfb.2008.07.004; Sperling RA, 2008, CHEM SOC REV, V37, P1896, DOI 10.1039/b712170a; Thakor AS, 2011, NANO LETT, V11, P4029, DOI 10.1021/nl202559p; TURKEVICH J, 1951, DISCUSS FARADAY SOC, P55, DOI 10.1039/df9511100055; US Department of Health and Human Services, 2010, GUID IND M3 R2 NONCL; Wang XF, 2012, CHINESE J CHEM, V30, P1931, DOI 10.1002/cjoc.201200662; Yokel R, 2013, WIRES NANOMED NANOBI, V5, P346, DOI 10.1002/wnan.1202	52	4	4	4	17	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JUN	2018	46	4					431	443		10.1177/0192623318770608			13	Pathology; Toxicology	Pathology; Toxicology	GK3US	WOS:000436074500007	29742986	Bronze			2019-10-28	
J	Boyle, MH; Paranjpe, MG; Creasy, DM				Boyle, Molly H.; Paranjpe, Madhav G.; Creasy, Dianne M.			High Background Incidence of Spontaneous Subcapsular Adrenal Gland Hyperplasia of Tg.rasH2 Mice Used in 26-week Carcinogenicity Studies	TOXICOLOGIC PATHOLOGY			English	Article						preclinical safety-assessment/risk management; transgenic animals; adrenal gland; subcapsular hyperplasia; Tg.rasH2 mouse; endocrine system; historical control data	CELL HYPERPLASIA; MAST-CELLS; LESIONS	The Tg.rasH2 model was accepted by regulatory agencies worldwide for 26-week carcinogenicity assays as an alternative to the standard 2-year assays in conventional mice in 2003. Several references documenting spontaneous nonneoplastic findings and incidences of spontaneous tumors in the Tg.rasH2 mice have been published. The purpose of this publication is to add adrenal gland subcapsular hyperplasia to the database pertaining to spontaneous lesions noted in Tg.rasH2 mice, review physiology related to this finding, and discuss its significance. The incidence of spontaneous subcapsular adrenal gland hyperplasia was determined in control Tg.rasH2 mice from nine 26-week carcinogenicity studies carried out within the last 5 years at two contract research organizations. Incidence of this finding ranged from 56% to 79% in males and 88% to 100% in females, with an incidence average of 62% in males and 93% in females. Adrenal gland subcapsular hyperplasia is a common finding in male and female Tg.rasH2 mice that did not progress to neoplasia in Tg.rasH2 mice. In general, it tends to be more frequent and severe in females in comparison to males.	[Boyle, Molly H.] Envigo Safety Assessment, 100 Mettlers Rd, Somerset, NJ 08873 USA; [Paranjpe, Madhav G.] BioReliance, Rockville, MD USA; [Creasy, Dianne M.] Dianne Creasy Consulting, Diss IP22 2JJ, Norfolk, England	Boyle, MH (reprint author), Envigo Safety Assessment, 100 Mettlers Rd, Somerset, NJ 08873 USA.	mollyhopevet@gmail.com					Aiba M, 2011, J HISTOCHEM CYTOCHEM, V59, P557, DOI 10.1369/0022155411404071; [Anonymous], 1986, 303 NTP USDHHS NAT I; [Anonymous], 1986, 289 NTP USDHHS NAT I; [Anonymous], 1989, 341 NTP USDHHS NAT I; Bielohuby M, 2007, AM J PHYSIOL-ENDOC M, V293, pE139, DOI 10.1152/ajpendo.00705.2006; Capen C. C., 2001, INT CLASSIFICATION R, P300; CHVEDOFF M, 1980, FOOD COSMET TOXICOL, V18, P517, DOI 10.1016/0015-6264(80)90167-4; Duparc C, 2015, J CLIN ENDOCR METAB, V100, pE550, DOI 10.1210/jc.2014-3660; Frith C H, 1994, IARC Sci Publ, P595; Frith CH, 1996, ENDOCRINE SYSTEM, P386; Goodman DG, 1996, MONOGRAPHS PATHOLOGY, P464; Greaves P, 2012, HISTOPATHOLOGY OF PRECLINICAL TOXICITY STUDIES: INTERPRETATION AND RELEVANCE IN DRUG SAFETY EVALUATION, 4TH EDITION, P725, DOI 10.1016/B978-0-444-53856-7.00013-0; Hoenerhoff M. J., 2014, NATL TOXICOLOGIC PRO; Kim JS, 1997, EXP ANIM TOKYO, V46, P103, DOI 10.1538/expanim.46.103; Kim JS, 2000, TOXICOL PATHOL, V28, P297, DOI 10.1177/019262330002800209; Mann PC, 2013, HASCHEK AND ROUSSEAUX'S HANDBOOK OF TOXICOLOGIC PATHOLOGY, VOL 1-3, 3RD EDITION, P551, DOI 10.1016/B978-0-12-415759-0.00017-0; Nyska A, 1999, PATHOLOGY MOUSE, P509; Paranjpe MG, 2013, TOXICOL PATHOL, V41, P1137, DOI 10.1177/0192623313478207; Rosol TJ, 2001, TOXICOL PATHOL, V29, P41, DOI 10.1080/019262301301418847; Sass B., 1996, ENDOCRINE SYSTEM, P381; Taylor I., 2011, BACKGROUND LESIONS L, P45; Yarrington JT, 1996, PATHOBIOLOGY AGING M, P125; Yates R, 2013, CURR TOP DEV BIOL, V106, P239, DOI 10.1016/B978-0-12-416021-7.00007-9; YOSHIDA A, 1986, JPN J VET SCI, V48, P719	24	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JUN	2018	46	4					444	448		10.1177/0192623318770965			5	Pathology; Toxicology	Pathology; Toxicology	GK3US	WOS:000436074500008	29695215				2019-10-28	
J	Bhaskaran, M; Cornwell, PD; Sorden, SD; Elwell, MR; Russell, NR; Pritt, ML; Vahle, JL				Bhaskaran, Manoj; Cornwell, Paul D.; Sorden, Steven D.; Elwell, Michael R.; Russell, Natalie R.; Pritt, Michael L.; Vahle, John L.			Pancreatic Effects of a Bruton's Tyrosine Kinase Small-molecule Inhibitor in Rats Are Strain-dependent	TOXICOLOGIC PATHOLOGY			English	Article						pancreatic islets; Bruton's tyrosine kinase (BTK); endocrine-exocrine interface; exocrine acinar cell atrophy; lobular atrophy; islet/peri-islet hemorrhage and fibrosis; rat strains	SPRAGUE-DAWLEY RATS; ENDOCRINE PANCREAS; ISLET CHANGES; B-CELL; BTK; AGAMMAGLOBULINEMIA; ARTHRITIS; TOXICITY; FIBROSIS; LESIONS	Inhibitors of Bruton's tyrosine kinase (BTK) are under development as potential therapies for various autoimmune diseases. In repeat-dose toxicity studies, small-molecule BTK inhibitors (BTKi) have been reported to cause a constellation of histologic effects at the pancreatic endocrine-exocrine interface in male rats; however, similar findings were not reported in other species. Since the BTKi-induced pancreatic effect is morphologically similar to well-documented spontaneous changes (predominantly characterized by insular/peri-insular hemorrhage, pigment deposition, chronic inflammation, and fibrosis) that are known to vary by rat strain, we investigated potential strain-dependent differences in the pancreatic effects of a small-molecule BTKi, LY3337641. Following 13 weeks of LY3337641 treatment, Crl:CD(SD) rats were most sensitive, Crl:WI(Han) rats were of intermediate sensitivity, and Hsd:SD rats were least sensitive. These strain differences appear to be related to differences in rate of weight gain across strains and sexes; however, a definitive mechanism was not determined. This study demonstrated that BTKi-induced pancreatic effects were highly dependent on rat strain and correlated with differences in the incidence and severity of the spontaneous background change. When considered with the lack of pancreas effects in nonrat species, these changes in rats are unlikely predictive of similar changes in humans administered a BTK inhibitor.	[Bhaskaran, Manoj; Cornwell, Paul D.; Russell, Natalie R.; Pritt, Michael L.; Vahle, John L.] Eli Lilly & Co, Indianapolis, IN 46285 USA; [Sorden, Steven D.] Covance Labs Inc, Madison, WI USA; [Elwell, Michael R.] Covance Labs Inc, Chantilly, VA USA	Bhaskaran, M (reprint author), Lilly Corp Ctr, 355 East Merrill St, Indianapolis, IN 46285 USA.	bhaskaran_manoj@lilly.com		Vahle, John/0000-0001-7964-9133			AHUJA SK, 1987, DIABETES RES CLIN EX, V6, P137; Brenneman KA, 2014, TOXICOL PATHOL, V42, P229, DOI 10.1177/0192623313508851; Chadwick KD, 2014, DIABETES, V63, P1303, DOI 10.2337/db13-1268; Chakravarty SD, 2013, CLIN IMMUNOL, V148, P66, DOI 10.1016/j.clim.2013.04.007; Conley ME, 2009, ANNU REV IMMUNOL, V27, P199, DOI 10.1146/annurev.immunol.021908.132649; Di Paolo JA, 2011, NAT CHEM BIOL, V7, P41, DOI 10.1038/NCHEMBIO.481; DILLBERGER JE, 1994, TOXICOL PATHOL, V22, P48, DOI 10.1177/019262339402200107; DUMM CLAG, 1990, PANCREAS, V5, P533, DOI 10.1097/00006676-199009000-00007; Erickson Rebecca I, 2017, J Pharmacol Exp Ther, V360, P226; Greaves P, 2012, HISTOPATHOLOGY OF PRECLINICAL TOXICITY STUDIES: INTERPRETATION AND RELEVANCE IN DRUG SAFETY EVALUATION, 4TH EDITION, P725, DOI 10.1016/B978-0-444-53856-7.00013-0; HAJDU A, 1967, DIABETES, V16, P108, DOI 10.2337/diab.16.2.108; Hendriks RW, 2011, NAT CHEM BIOL, V7, P4, DOI 10.1038/nchembio.502; Imaoka M, 2007, TOXICOL PATHOL, V35, P388, DOI 10.1080/01926230701230304; Imaoka M, 2013, J TOXICOL PATHOL, V26, P1, DOI 10.1293/tox.26.1; Imaoka M, 2009, TOXICOL PATHOL, V37, P218, DOI 10.1177/0192623308329283; Jones HB, 2010, INT J EXP PATHOL, V91, P288, DOI 10.1111/j.1365-2613.2010.00713.x; Katsuda Y, 2014, EXP ANIM TOKYO, V63, P121, DOI 10.1538/expanim.63.121; Lacraz G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006963; Mann PC, 2012, TOXICOL PATHOL, V40, P7, DOI 10.1177/0192623312438738; Masuyama T, 2004, BIOCHEM BIOPH RES CO, V314, P870, DOI 10.1016/j.bbrc.2003.12.180; Monticello TM, 2017, TOXICOL APPL PHARM, V334, P100, DOI 10.1016/j.taap.2017.09.006; MORI Y, 1990, PANCREAS, V5, P452, DOI 10.1097/00006676-199007000-00013; Olson H, 2000, REGUL TOXICOL PHARM, V32, P56, DOI 10.1006/rtph.2000.1399; REAVEN EP, 1981, J CLIN INVEST, V68, P75, DOI 10.1172/JCI110256; Schwartzberg PL, 2005, NAT REV IMMUNOL, V5, P284, DOI 10.1038/nri1591; SHINO A, 1973, DIABETOLOGIA, V9, P413, DOI 10.1007/BF01239438; SMITH CIE, 1994, J IMMUNOL, V152, P557; Tamaki C, 2013, J TOXICOL SCI, V38, P581, DOI 10.2131/jts.38.581; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0	29	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JUN	2018	46	4					460	472		10.1177/0192623318770163			13	Pathology; Toxicology	Pathology; Toxicology	GK3US	WOS:000436074500010	29699458				2019-10-28	
J	Pan, CC; Tsuzuki, T; Morii, E; Fushimi, H; Chen, PCH; Epstein, JI				Pan, Chin-Chen; Tsuzuki, Toyonori; Morii, Eiichi; Fushimi, Hiroaki; Chen, Paul Chih-Hsueh; Epstein, Jonathan, I			Whole-exome sequencing demonstrates recurrent somatic copy number alterations and sporadic mutations in specialized stromal tumors of the prostate	HUMAN PATHOLOGY			English	Article						Prostatic stromal tumor of uncertain malignant potential; Stromal sarcoma; Whole-exome sequencing; Fluorescence in situ hybridization; Somatic copy number alteration	COMPARATIVE GENOMIC HYBRIDIZATION; PHYLLODES TUMOR; HUMAN CANCERS; LANDSCAPE; DISCOVERY; HYPERPLASIA; PROGRESSION; LESIONS; GENES; END	In a previous array comparative genomic hybridization study, we detected common deletions of chromosomes 13 and 14 in prostatic stromal sarcoma and stromal tumor of uncertain malignant potential (STUMP). In this study, we performed whole-exome sequencing (WES) and fluorescence in situ hybridization to explore somatic mutations in 1 low-grade stromal sarcoma, 1 high-grade stromal sarcoma, and 12 STUMPs including 5 cases of degenerative atypia type, 1 myxoid type, 1 phyllodes type, and 5 cases of recently described round cell type. WES was successful on 13 cases that revealed frequent somatic copy number alterations including losses of chromosomes 13 (11 cases), 14 (11 cases), and 1p (9 cases), and partial or complete loss of chromosome 10 (7 cases). Fluorescence in situ hybridization was done on 9 cases and showed compatible chromosome 13 copy numbers with the WES results. STUMPs and the low-grade stromal sarcoma carried moderate tumor mutation burdens that ranged from 1.23 to 7.24 mutations per megabase, while the high-grade stromal sarcoma harbored a significantly higher mutation burden (11.55 mutations per megabase). Sporadic somatic mutations were observed, but no recurrent driver mutations could be discerned. In conjunction with prior array comparative genomic hybridization, we have demonstrated the consistent gene dosage profiles that support the clonal nature and the concept of specialized stromal tumors of the prostate as a distinctive tumor entity. (C) 2017 Elsevier Inc. All rights reserved.	[Pan, Chin-Chen; Chen, Paul Chih-Hsueh] Taipei Vet Gen Hosp, Dept Pathol, 201,Shi Pai Rd,Sec 2, Taipei 11217, Taiwan; [Pan, Chin-Chen; Chen, Paul Chih-Hsueh] Natl Yang Ming Univ, Taipei 11217, Taiwan; [Tsuzuki, Toyonori] Aichi Med Univ, Sch Med, Dept Surg Pathol, Nagoya, Aichi 4801195, Japan; [Morii, Eiichi] Osaka Univ, Dept Pathol, Osaka 5650871, Japan; [Fushimi, Hiroaki] Osaka Gen Med Ctr, Dept Pathol, Osaka 5588558, Japan; [Epstein, Jonathan, I] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Epstein, Jonathan, I] James Buchanan Brady Urol Inst, Dept Pathol, Baltimore, MD 21205 USA; [Epstein, Jonathan, I] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA	Pan, CC (reprint author), Taipei Vet Gen Hosp, Dept Pathol, 201,Shi Pai Rd,Sec 2, Taipei 11217, Taiwan.; Epstein, JI (reprint author), Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.; Epstein, JI (reprint author), James Buchanan Brady Urol Inst, Dept Pathol, Baltimore, MD 21205 USA.; Epstein, JI (reprint author), Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA.	ccpan@vghtpe.gov.tw; jepstein@jhmi.edu			Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan [104-2320-B-075-005, 103-2320-B-075-003]; Taipei Veterans General Hospital, Taipei TaiwanTaipei Veterans General Hospital [V103C-021]	This work was supported by grants from the Ministry of Science and Technology, Taiwan (104-2320-B-075-005, 103-2320-B-075-003) and Taipei Veterans General Hospital, Taipei Taiwan (V103C-021).	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Aron M, 2015, AM J SURG PATHOL, V39, P873, DOI 10.1097/PAS.0000000000000446; ATTAH EB, 1977, AM J CLIN PATHOL, V67, P324; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bostwick DG, 2004, J UROLOGY, V172, P894, DOI 10.1097/01.ju.0000134580.71261.57; Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2; D'Aurizio R, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw695; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Gaudin PB, 1998, AM J SURG PATHOL, V22, P148, DOI 10.1097/00000478-199802000-00002; Govind SK, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-78; Hansel DE, 2007, MODERN PATHOL, V20, P148, DOI 10.1038/modpathol.3800676; Herawi M, 2006, AM J SURG PATHOL, V30, P694, DOI 10.1097/00000478-200606000-00004; Hiltemann S, 2015, GENOME RES, V25, P1382, DOI 10.1101/gr.183053.114; Kamnasaran D, 2002, J MED GENET, V39, P81, DOI 10.1136/jmg.39.2.81; KEVWITCH MK, 1993, J UROLOGY, V149, P860, DOI 10.1016/S0022-5347(17)36234-1; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Kumar A, 2011, P NATL ACAD SCI USA, V108, P17087, DOI 10.1073/pnas.1108745108; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Li J, 2012, BIOINFORMATICS, V28, P1307, DOI 10.1093/bioinformatics/bts146; Ma ZY, 2008, INT J CANCER, V123, P2574, DOI 10.1002/ijc.23578; Pan CC, 2013, MODERN PATHOL, V26, P1536, DOI 10.1038/modpathol.2013.99; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Sadimin ET, 2016, HUM PATHOL, V52, P68, DOI 10.1016/j.humpath.2016.01.002; Sauder KJ, 2005, J UROLOGY, V174, P2373, DOI 10.1097/01.ju.0000187571.38284.c2; Struski S, 2002, CANCER GENET CYTOGEN, V135, P63, DOI 10.1016/S0165-4608(01)00624-0; Tan J, 2015, NAT GENET, V47, P1341, DOI 10.1038/ng.3409; Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808; Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI 10.1002/0471250953.bi1110s43; Wang JH, 2004, CLIN CANCER RES, V10, P6169, DOI 10.1158/1078-0432.CCR-04-0408; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Xu B, 2010, PROSTATE CANCER P D, V13, P270, DOI 10.1038/pcan.2010.6; Yang LX, 2016, AM J HUM GENET, V98, P843, DOI 10.1016/j.ajhg.2016.03.017; Zeitouni B, 2010, BIOINFORMATICS, V26, P1895, DOI 10.1093/bioinformatics/btq293	35	0	0	1	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUN	2018	76						9	16		10.1016/j.humpath.2017.12.004			8	Pathology	Pathology	GK1ON	WOS:000435888200002	29258903				2019-10-28	
J	Zhang, Q; Kanis, MJ; Ubago, J; Liu, DC; Scholtens, DM; Strohl, AE; Lurain, JR; Shahabi, S; Kong, BH; Wei, JJ				Zhang, Qing; Kanis, Margaux Jenna; Ubago, Julianne; Liu, Dachao; Scholtens, Denise M.; Strohl, Anna E.; Lurain, John R.; Shahabi, Shohreh; Kong, Beihua; Wei, Jian-Jun			The selected biomarker analysis in 5 types of uterine smooth muscle tumors	HUMAN PATHOLOGY			English	Article						Uterine smooth muscle tumor; Leiomyosarcoma; Immunohistochemistry; Clinical correlation; Biomarker; Atypical smooth muscle tumor	PROGESTERONE-RECEPTOR EXPRESSION; FUMARATE HYDRATASE MUTATION; ATYPICAL LEIOMYOMA; LEIOMYOSARCOMA; ESTROGEN; UTERUS; KI-67; P53; MANAGEMENT; MARKERS	Uterine smooth muscle tumors (USMTs) consist of a group of histologically heterogeneous and clinically diverse diseases ranging from malignant leiomyosarcoma (LMS) to benign leiomyoma (ULM). The genetic alterations in LMS are complex, with some genetic alterations present in both LMS and other atypical histologic variants of USMT. In this study, we reviewed 119 USMTs with a diagnosis of LMS, smooth muscle tumor of uncertain malignant potential, atypical leiomyomas/leiomyoma with bizarre nuclei, and cellular leiomyoma, as well as 46 ULMs and 60 myometrial controls. We selected 17 biomarkers highly relevant to LMS in 4 tumorigenic pathways including steroid hormone receptors (estrogen receptor [ER] and progesterone receptor [PR]), cell cycle/tumor suppressor genes, AKT pathway markers, and associated oncogenes. ER and PR expression was significantly lower in LMS than smooth muscle tumor of uncertain malignant potential, atypical leiomyomas/leiomyoma with bizarre nuclei, cellular leiomyoma, and ULM (P < .01). Sixty-five percent of LMSs showed complete loss of ER, and 75% of LMSs showed complete loss of PR. All cell cycle genes were differentially expressed in different types of tumor, but significant overlap was noted. More than 75% of LMSs had Ki-67 index greater than 33%, and only 5% in all other types of USMT. Expression of the selected oncogenes varied widely among different types of USMT. PR positivity and p53 had a borderline association with progression-free survival (P = .055 for PR and P = .0847 for p53). Furthermore, high PR expression was significantly associated with a longer overall survival (P = .0163, hazard ratio 0.198). Cell proliferative indices (Ki-67) and sex steroid hormone receptors were the most valuable markers in differentiating LMS from other USMT variants. (C) 2017 Published by Elsevier Inc.	[Zhang, Qing; Ubago, Julianne; Wei, Jian-Jun] Northwestern Univ, Dept Pathol, Feinberg Sch Med, 251 E Huron St,Room 7-334, Chicago, IL 60611 USA; [Zhang, Qing; Kong, Beihua] Shandong Univ, Qilu Hosp, Dept Obstet & Gynecol, Jinan 250012, Shandong, Peoples R China; [Kanis, Margaux Jenna; Strohl, Anna E.; Lurain, John R.; Shahabi, Shohreh; Wei, Jian-Jun] Northwestern Univ, Feinberg Sch Med, Dept Gynecol & Obstet, Chicago, IL 60611 USA; [Liu, Dachao; Scholtens, Denise M.] Feinberg Sch Med, Dept Prevent Med, Chicago, IL USA	Wei, JJ (reprint author), Northwestern Univ, Dept Pathol, Feinberg Sch Med, 251 E Huron St,Room 7-334, Chicago, IL 60611 USA.	jianjun-wei@northwestern.edu		Wei, JianJun/0000-0003-0281-2793	Edna Foundation of Hope New Jersey, U.S.A.; National Institutes of Health, National Institute of Child Health and Human Development, Bethesda, MD, U.S.A. [P01HD057877]	This study is supported in part by funding from the Edna Foundation of Hope New Jersey, U.S.A. and P01HD057877 (National Institutes of Health, National Institute of Child Health and Human Development, Bethesda, MD, U.S.A.).	Akhan SE, 2005, GYNECOL ONCOL, V99, P36, DOI 10.1016/j.ygyno.2005.05.019; BELL SW, 1994, AM J SURG PATHOL, V18, P535, DOI 10.1097/00000478-199406000-00001; Bertsch E, 2014, MODERN PATHOL, V27, P1144, DOI 10.1038/modpathol.2013.243; Brisken C, 2013, NAT REV CANCER, V13, P385, DOI 10.1038/nrc3518; Chen LW, 2008, INT J GYNECOL PATHOL, V27, P326, DOI 10.1097/PGP.0b013e31815ea7f5; Davidson B, 2016, AM J CLIN PATHOL, V145, P449, DOI 10.1093/ajcp/aqw030; Gannon BR, 2008, INT J GYNECOL PATHOL, V27, P68, DOI 10.1097/pgp.0b013e3180ca954f; Giuntoli RL, 2003, GYNECOL ONCOL, V89, P460, DOI 10.1016/S0090-8258(03)00137-9; Gockley AA, 2014, INT J GYNECOL CANCER, V24, P1538, DOI 10.1097/IGC.0000000000000290; Hewedi IH, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-1; Ito M, 2011, CLIN CANCER RES, V17, P416, DOI 10.1158/1078-0432.CCR-10-2050; Kefeli M, 2009, INT J GYNECOL PATHOL, V28, P328, DOI 10.1097/PGP.0b013e318195da9f; Kobayashi H, 2013, MOL CLIN ONCOL, V1, P599, DOI 10.3892/mco.2013.124; Layfield LJ, 2000, ARCH PATHOL LAB MED, V124, P221; Lee PJ, 2017, EXP MOL PATHOL, V102, P156, DOI 10.1016/j.yexmp.2017.01.012; LEIBSOHN S, 1990, AM J OBSTET GYNECOL, V162, P968, DOI 10.1016/0002-9378(90)91298-Q; Leitao MM, 2012, GYNECOL ONCOL, V124, P558, DOI 10.1016/j.ygyno.2011.11.009; Lu BJ, 2017, HUM PATHOL, V59, P139, DOI 10.1016/j.humpath.2016.09.014; Mehine M, 2016, P NATL ACAD SCI USA, V113, P1315, DOI 10.1073/pnas.1518752113; Mills AM, 2013, AM J SURG PATHOL, V37, P634, DOI 10.1097/PAS.0b013e318287779c; Mittal K, 2001, HUM PATHOL, V32, P984, DOI 10.1053/hupa.2001.27113; O'Cearbhaill R, 2010, GYNECOL ONCOL, V116, P424, DOI 10.1016/j.ygyno.2009.10.064; Raspollini MR, 2004, GYNECOL ONCOL, V93, P718, DOI 10.1016/j.ygyno.2004.03.017; Raspollini MR, 2003, J CHEMOTHERAPY, V15, P596, DOI 10.1179/joc.2003.15.6.596; Rice KE, 2012, J MIDWIFERY WOM HEAL, V57, P241, DOI 10.1111/j.1542-2011.2012.00176.x; Salawu A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050415; Skubitz KM, 2003, CANCER, V98, P1029, DOI 10.1002/cncr.11586; Wei JJ, 2016, INT J GYNECOL PATHOL, V35, P531, DOI 10.1097/PGP.0000000000000276; Wheeler KC, 2016, FERTIL STERIL, V105, P144, DOI 10.1016/j.fertnstert.2015.09.034; Zhang Q, 2014, CANCER-AM CANCER SOC, V120, P3165, DOI 10.1002/cncr.28900	30	0	0	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUN	2018	76						17	27		10.1016/j.humpath.2017.12.005			11	Pathology	Pathology	GK1ON	WOS:000435888200003	29258902	Green Accepted			2019-10-28	
J	Tabata, Y; Nakanishi, Y; Hatanaka, KC; Hatanaka, Y; Tsuchikawa, T; Okamura, K; Noji, T; Shichinohe, T; Matsuno, Y; Hirano, S				Tabata, Yukiko; Nakanishi, Yoshitsugu; Hatanaka, Kanako C.; Hatanaka, Yutaka; Tsuchikawa, Takahiro; Okamura, Keisuke; Noji, Takehiro; Shichinohe, Toshiaki; Matsuno, Yoshihiro; Hirano, Satoshi			DJ-1 is a useful biomarker for invasive extrahepatic cholangiocarcinoma	HUMAN PATHOLOGY			English	Article						DJ-1; Extrahepatic cholangiocarcinoma; Prognosis; Biomarker; Immunohistochemical staining; ELISA	PROTEIN; PROTEOMICS; CARCINOMA	We have previously reported that DJ-1 protein is up-regulated in cholangiocarcinoma compared with non-neoplastic epithelium of the bile duct in a study using liquid-chromatography mass spectrometry-based proteomics. The aim of this study was to clarify whether DJ-1 expression offers a biomarker for patients with invasive extrahepatic cholangiocarcinoma (EHCC) who undergo surgical resection with curative intent. Positive immunohistochemical (IHC) staining of DJ-1 was significantly more frequent in the cytoplasm of 96 invasive EHCCs (n = 28, 29.2%) than in that of 66 non-neoplastic epithelial lesions adjacent to invasive EHCC (n = 7, 10.6%; P = .006). No significant difference in clinicopathological features was evident between invasive EHCC patients with negative (n = 68) and positive (n = 28) NC staining. However, negative IHC staining for DJ-1 in cytoplasm was selected as an independent risk factor for adverse prognosis on multivariate analysis (P = .004, hazard ratio 2.13, 95% confidence interval 1.28-3.57). Serum levels of DJ-1 in 16 invasive EHCC patients with metastasis were compared with 12 invasive EHCC patients without metastasis. Serum levels of DJ-1 tended to be higher in 16 patients with metastasis (median, 40.9 ng/ml) than in 12 patients without (27.6 ng/ml, P = .137). In addition, patients with high serum levels (>= 40 ng/ml) of DJ-1 tended to have metastasis more frequently than those without (P = .054, Fisher's exact test). We concluded that IHC staining pattern and serum level of DJ-1 in patients with invasive EHCC might be predictive of prognosis and metastasis, respectively. (C) 2018 Elsevier Inc. All rights reserved.	[Tabata, Yukiko; Nakanishi, Yoshitsugu; Tsuchikawa, Takahiro; Okamura, Keisuke; Noji, Takehiro; Shichinohe, Toshiaki; Hirano, Satoshi] Hokkaido Univ, Fac Med, Dept Gastroenterol Surg 2, Sapporo, Hokkaido 0608638, Japan; [Tabata, Yukiko; Hatanaka, Kanako C.; Hatanaka, Yutaka; Matsuno, Yoshihiro] Hokkaido Univ Hosp, Dept Surg Pathol, Sapporo, Hokkaido 0608648, Japan	Nakanishi, Y (reprint author), Hokkaido Univ, Fac Med, Dept Gastroenterol Surg 2, Kita Ku, North 15,West 7, Sapporo, Hokkaido 0608638, Japan.	y.nakanishi@mac.com					Ariga H., 2013, OXID MED CELL LONGEV, V2013; BACUS S, 1988, AM J CLIN PATHOL, V90, P233, DOI 10.1093/ajcp/90.3.233; Biosa A, 2017, NEUROBIOL DIS, V108, P65, DOI 10.1016/j.nbd.2017.08.005; Cao J, 2015, BIOCHEM PHARMACOL, V93, P241, DOI 10.1016/j.bcp.2014.11.012; Chen LL, 2015, J CANCER RES CLIN, V141, P315, DOI 10.1007/s00432-014-1804-2; Chen Y, 2012, J CANCER RES CLIN, V138, P1463, DOI 10.1007/s00432-012-1205-3; Di Cello A, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705746; Kawase H, 2009, J PROTEOME RES, V8, P4092, DOI 10.1021/pr900468k; Kawate T, 2015, CANCER SCI, V106, P938, DOI 10.1111/cas.12673; Kiriyama M, 2015, BRIT J SURG, V102, P399, DOI 10.1002/bjs.9752; Le Naour F, 2001, CLIN CANCER RES, V7, P3328; Nagino M, 2013, ANN SURG, V258, P129, DOI 10.1097/SLA.0b013e3182708b57; Oda M, 2012, CANCER SCI, V103, P1172, DOI 10.1111/j.1349-7006.2012.02267.x; Tian M, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-241; Tsuchiya B, 2012, HISTOPATHOLOGY, V61, P69, DOI 10.1111/j.1365-2559.2012.04202.x; Wang MC, 2015, J THORAC ONCOL, V10, P286, DOI 10.1097/JTO.0000000000000396	16	0	0	1	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUN	2018	76						28	36		10.1016/j.humpath.2018.02.010			9	Pathology	Pathology	GK1ON	WOS:000435888200004	29447925				2019-10-28	
J	Ding, Q; Li, Z; Liu, B; Ling, LP; Tian, XG; Zhang, CQ				Ding, Qian; Li, Zhen; Liu, Bin; Ling, Liping; Tian, Xiangguo; Zhang, Chunqing			Propranolol prevents liver cirrhosis by inhibiting hepatic stellate cell activation mediated by the PDGFR/Akt pathway	HUMAN PATHOLOGY			English	Article						Liver cirrhosis; Propranolol; Hepatic stellate cell; Platelet-derived growth factor receptor; Akt	GROWTH-FACTOR RECEPTOR; PORTAL-HYPERTENSION; ENDOTHELIAL-CELLS; SIGNALING PATHWAY; FIBROSIS; ANGIOGENESIS; PROLIFERATION; MIGRATION; HEMANGIOMAS; CARVEDILOL	Propranolol is known to reduce portal pressure by decreasing blood flow to the splanchnic circulation and the liver. However, it is unknown if propranolol improves fibrogenesis and sinusoidal remodeling in the cirrhotic liver. The aim of this study was to investigate the therapeutic effects of propranolol on carbon tetrachloride (CCl4)-induced liver fibrosis in a mouse model and the intrinsic mechanisms underlying those effects. In this study, a hepatic cirrhosis mouse model was induced by CCl4 administration for 6 weeks. Propranolol was simultaneously administered orally in the experimental group. Liver tissue and blood samples were collected for histological and molecular analyses. LX-2 cells induced by platelet-derived growth factor-BB (PDGF-BB) were used to evaluate the anti-fibrogenic effect of propranolol in vitro. The results showed that treatment of mice with CCl4 induced hepatic fibrosis, as evidenced by inflammatory cell infiltration, collagen deposition and abnormal vascular formation in the liver tissue. All these changes were significantly attenuated by propranolol treatment. Furthermore, we also found that propranolol inhibited PDGF-BB-induced hepatic stellate cell migration, fibrogenesis, and PDGFR/Akt phosphorylation. Taken together, propranolol might prevent CCl4-induced liver injury and fibrosis at least partially through inhibiting the PDGF-BB-induced PDGFR/Akt pathway. The anti-fibrogenic effect of propranolol may support its status as a first-line treatment in patients with chronic liver disease. (C) 2018 Elsevier Inc. All rights reserved.	[Ding, Qian; Li, Zhen; Ling, Liping; Tian, Xiangguo; Zhang, Chunqing] Shandong Univ, Dept Gastroenterol, Shandong Prov Hosp, 9677 Jingshi Rd, Jinan 250021, Shandong, Peoples R China; [Li, Zhen; Ling, Liping] Shandong Prov Engn & Technol Res Ctr Liver Dis Pr, Jinan, Shandong, Peoples R China; [Liu, Bin] Kyoto Univ, Dept Neurosurg, Grad Sch Med, Kyoto 6068507, Japan	Zhang, CQ (reprint author), Shandong Univ, Dept Gastroenterol, Shandong Prov Hosp, 9677 Jingshi Rd, Jinan 250021, Shandong, Peoples R China.	zhangchunqing_sdu@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81370590, 81770606]	This work was supported by National Natural Science Foundation of China, NO.81370590 and National Natural Science Foundation of China, NO.81770606.	Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Brito-Azevedo A, 2016, GUT, V65, P1391, DOI 10.1136/gutjnl-2016-311696; CALLENSELAMRANI F, 1989, J HYPERTENS, V7, P947, DOI 10.1097/00004872-198912000-00004; Chen H, 2012, CELL BIOL INT, V36, P237, DOI 10.1042/CBI20110162; de Franchis R, 2015, J HEPATOL, V63, P743, DOI 10.1016/j.jhep.2015.05.022; DeLeve LD, 2015, HEPATOLOGY, V61, P1740, DOI 10.1002/hep.27376; Ding Q, 2015, WORLD J GASTROENTERO, V21, P9566, DOI 10.3748/wjg.v21.i32.9566; Fernandez M, 2004, GASTROENTEROLOGY, V126, P886, DOI 10.1053/j.gastro.2003.12.012; Fernandez M, 2009, J HEPATOL, V50, P604, DOI 10.1016/j.jhep.2008.12.011; Filippi L, 2015, MED RES REV, V35, P619, DOI 10.1002/med.21336; Friedman SL, 2010, NAT REV GASTRO HEPAT, V7, P425, DOI 10.1038/nrgastro.2010.97; Garcia-Tsao G, 2017, HEPATOLOGY, V65, P310, DOI 10.1002/hep.28906; Garcia-Tsao G, 2010, NEW ENGL J MED, V362, P823, DOI 10.1056/NEJMra0901512; Ikeda K, 1999, HEPATOLOGY, V29, P1760, DOI 10.1002/hep.510290640; Kikuchi A, 2017, AM J PATHOL, V187, P2273, DOI 10.1016/j.ajpath.2017.06.009; Kocabayoglu P, 2015, J HEPATOL, V63, P141, DOI 10.1016/j.jhep.2015.01.036; Kuo JJ, 2012, PLANTA MED, V78, P341, DOI 10.1055/s-0031-1280472; Lai WK, 2005, J HEPATOL, V42, P7, DOI 10.1016/j.jhep.2004.11.008; Lamy S, 2010, VASC PHARMACOL, V53, P200, DOI 10.1016/j.vph.2010.08.002; Leaute-Labreze C, 2008, NEW ENGL J MED, V358, P2649, DOI 10.1056/NEJMc0708819; Melton AC, 2007, HEPATOLOGY, V45, P1446, DOI 10.1002/hep.21606; Mende S, 2013, DIGEST DIS SCI, V58, P1271, DOI 10.1007/s10620-012-2499-3; Oben JA, 2004, GUT, V53, P438, DOI 10.1136/gut.2003.026658; Pacca SRMC, 2002, J CARDIOVASC PHARM, V39, P201, DOI 10.1097/00005344-200202000-00006; Pan WK, 2015, PEDIATR BLOOD CANCER, V62, P1414, DOI 10.1002/pbc.25453; Park J, 2006, J HEART LUNG TRANSPL, V25, P683, DOI 10.1016/j.healun.2006.01.008; Pinzani M, 2001, SEMIN LIVER DIS, V21, P397, DOI 10.1055/s-2001-17554; Sakata R, 2004, J HEPATOL, V40, P52, DOI 10.1016/S0168-8278(03)00477-X; Sancho-Bru P, 2006, AM J PHYSIOL-GASTR L, V291, pG877, DOI 10.1152/ajpgi.00537.2005; Strack I, 2011, LAB INVEST, V91, P252, DOI 10.1038/labinvest.2010.162; Thabut D, 2010, J HEPATOL, V53, P976, DOI 10.1016/j.jhep.2010.07.004; Trudel D, 2014, MODERN PATHOL, V27, P1394, DOI 10.1038/modpathol.2014.32; Wang RS, 2015, J BIOL CHEM, V290, P30684, DOI 10.1074/jbc.M115.671735; Yano N, 2007, AM J PHYSIOL-HEART C, V293, pH385, DOI 10.1152/ajpheart.01318.2006; Zhang L, 2014, INT J CLIN EXP PATHO, V7, P48	35	4	4	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUN	2018	76						37	46		10.1016/j.humpath.2018.02.018			10	Pathology	Pathology	GK1ON	WOS:000435888200005	29514109				2019-10-28	
J	Gallan, AJ; Chon, WJ; Josephson, MA; Cunningham, PN; Henriksen, KJ; Chang, A				Gallan, Alexander J.; Chon, Woojin James; Josephson, Michelle A.; Cunningham, Patrick N.; Henriksen, Kammi J.; Chang, Anthony			Bowman capsulitis predicts poor kidney allograft outcome in T cell-mediated rejection	HUMAN PATHOLOGY			English	Article						Allograft outcomes; Banff classification; Bowman capsule; Capsulitis; Kidney biopsy; T cell-mediated rejection	CLASSIFICATION	Acute T cell-mediated rejection (TCMR) is an important cause of renal allograft loss. The Banff classification for tubulointerstitial (type I) rejection is based on the extent of both interstitial inflammation and tubulitis. Lymphocytes may also be present between parietal epithelial cells and Bowman capsules in this setting, which we have termed "capsulitis." We conducted this study to determine the clinical significance of capsulitis. We identified 42 patients from the pathology archives at The University of Chicago with isolated Banff type I TCMR from 2010 to 2015. Patient demographic data, Banff classification, and graft outcome measurements were compared between capsulitis and noncapsulitis groups using Mann-Whitney U test. Capsulitis was present in 26 (62%) and was more frequently seen in Banff IB than in IA TCMR (88% versus 44%, P = .01). Patients with capsulitis had a higher serum creatinine at biopsy (4.6 versus 2.9 mg/dL, P = .04) and were more likely to progress to dialysis (42% versus 13%, P = .06), with fewer recovering their baseline serum creatinine (12% versus 38%, P = .08). Patients with both Banff IA TCMR and capsulitis have clinical outcomes similar to or possibly worse than Banff IB TCMR compared with those with Banff IA and an absence of capsulitis. Capsulitis is an important pathologic parameter in the evaluation of kidney transplant biopsies with potential diagnostic, prognostic, and therapeutic implications in the setting of TCMR. (C) 2018 Elsevier Inc. All rights reserved.	[Gallan, Alexander J.; Henriksen, Kammi J.; Chang, Anthony] Univ Chicago, Dept Pathol, 5841 S Maryland Ave,MC 6101,Room S-615, Chicago, IL 60637 USA; [Chon, Woojin James] Univ Missouri, Dept Med, Kansas City, MO 64108 USA; [Josephson, Michelle A.; Cunningham, Patrick N.] Univ Chicago, Dept Med, Sect Nephrol, Chicago, IL 60637 USA	Gallan, AJ (reprint author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave,MC 6101,Room S-615, Chicago, IL 60637 USA.	alexandergallan@gmail.com	; Chon, W. James/K-9860-2013	Chang, Anthony/0000-0002-6877-5510; Chon, W. James/0000-0002-3167-8549			BROCKMEYER C, 1993, TRANSPLANTATION, V55, P610; FAULL RJ, 1989, TRANSPLANTATION, V48, P226, DOI 10.1097/00007890-198908000-00009; FUGGLE SV, 1983, TRANSPLANTATION, V35, P385, DOI 10.1097/00007890-198304000-00024; Hart A, 2017, AM J TRANSPLANT, V17, DOI 10.1111/ajt.14124; Mateu LMP, 2004, NEPHROL DIAL TRANSPL, V19, P38, DOI 10.1093/ndt/gfh1013; Minervini MI, 2000, AM J SURG PATHOL, V24, P553, DOI 10.1097/00000478-200004000-00009; Mueller A, 2000, TRANSPLANTATION, V69, P1123, DOI 10.1097/00007890-200003270-00017; Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523-1755.1999.00299.x; Randhawa P, 2015, CURR OPIN ORGAN TRAN, V20, P325, DOI 10.1097/MOT.0000000000000189; REITAMO S, 1980, HISTOPATHOLOGY, V4, P517, DOI 10.1111/j.1365-2559.1980.tb02946.x; Shankland SJ, 2014, NAT REV NEPHROL, V10, P158, DOI 10.1038/nrneph.2014.1; Wu KY, 2014, TRANSPLANTATION, V97, P1146, DOI 10.1097/01.TP.0000441094.32217.05	12	0	0	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUN	2018	76						47	51		10.1016/j.humpath.2018.02.016			5	Pathology	Pathology	GK1ON	WOS:000435888200006	29501487				2019-10-28	
J	Manley, PN; Abu-Abed, S; Kirsch, R; Hawrysh, A; Perrier, N; Feilotter, H; Pollett, A; Riddell, RH; Hookey, L; Walia, JS				Manley, Paul N.; Abu-Abed, Suzy; Kirsch, Richard; Hawrysh, Andrea; Perrier, Nicole; Feilotter, Harriet; Pollett, Aaron; Riddell, Robert H.; Hookey, Lawrence; Walia, Jagdeep S.			Familial PDGFRA-mutation syndrome: somatic and gastrointestinal phenotype	HUMAN PATHOLOGY			English	Article						Inflammatory fibroid polyp; GIST; PDGFRA; Telocyte; Dysmophology	ALPHA; TELOCYTE; TUMORS; TRACT	Germline activating platelet-derived growth factor receptor alpha (PDGFRA) mutations have been described in four families. All the index patients have presented with multiple mesenchymal tumors of the gastrointestinal tract. We identified a fifth family with four first-degree relatives that harbor a PDGFRA exon 18 (D846V) germline mutation. The affected kindred have a unique phenotype including coarse facies and skin, broad hands and feet, and previously undescribed premature tooth loss. While the index patient presented with multiple small bowel inflammatory fibroid polyps (IFPs) and has a gastric gastrointestinal stromal tumor (GIST), no tumors have yet been identified in other family members. We describe the pathology, genetics, the incomplete penetrance and variable expressivity of the familial PDGFRA-mutation syndrome referencing the mouse knock-in Pdgfra model. We speculate on the role of the telocyte, a recently described CD34, PDGFRA+ stromal cell, in the development of inflammatory fibroid polyps and the somatic phenotype. (C) 2018 Elsevier Inc. All rights reserved.	[Manley, Paul N.; Walia, Jagdeep S.] Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada; [Manley, Paul N.; Walia, Jagdeep S.] Kingston Gen Hosp, Kingston, ON K7L 3N6, Canada; [Abu-Abed, Suzy; Feilotter, Harriet] Royal Columbian Hosp, Dept Pathol, New Westminster, BC V3L 3W7, Canada; [Kirsch, Richard; Pollett, Aaron; Riddell, Robert H.] Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada; [Hawrysh, Andrea; Perrier, Nicole; Walia, Jagdeep S.] Kingston Gen Hosp, Dept Pediat, Div Med Genet, Kingston, ON K7L 2V7, Canada; [Hookey, Lawrence] Kingston Gen Hosp, Dept Med, Div Gastroenterol, Kingston, ON K7L 2V7, Canada	Manley, PN; Walia, JS (reprint author), Queens Univ, Dept Pathol & Mol Med, Richardson Lab, Kingston, ON K7L 3N6, Canada.	manleyp@queensu.ca; waliaj@kgh.kari.net					Carney JA, 2008, AM J SURG PATHOL, V32, P1412, DOI 10.1097/PAS.0b013e31816250ce; Chompret A, 2004, GASTROENTEROLOGY, V126, P318, DOI 10.1053/j.gastro.2003.10.079; De Raedt T, 2006, GASTROENTEROLOGY, V131, P1907, DOI 10.1053/j.gastro.2006.07.002; Hoch RV, 2003, DEVELOPMENT, V130, P4769, DOI 10.1242/dev.00721; Ibba-Manneschi L, 2016, SEMIN CELL DEV BIOL, V55, P62, DOI 10.1016/j.semcdb.2016.01.022; Karlsson L, 2000, DEVELOPMENT, V127, P3457; Kirsch R., 2014, GASTROINTESTINAL PAT, P333; Liu TC, 2013, AM J SURG PATHOL, V37, P586, DOI 10.1097/PAS.0b013e31827ae11e; Mirancea N, 2016, ROM J MORPHOL EMBRYO, V57, P7; Olson LE, 2009, DEV CELL, V16, P303, DOI 10.1016/j.devcel.2008.12.003; Pasini B, 2007, J CLIN ENDOCR METAB, V92, P3728, DOI 10.1210/jc.2007-0894; Ricci R, 2015, MODERN PATHOL, V28, P954, DOI 10.1038/modpathol.2015.56; Vannucchi MG, 2013, J CELL MOL MED, V17, P1099, DOI 10.1111/jcmm.12134	13	3	3	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUN	2018	76						52	57		10.1016/j.humpath.2018.02.014			6	Pathology	Pathology	GK1ON	WOS:000435888200007	29486293				2019-10-28	
J	Ding, QS; Zhang, L; Wang, BC; Zeng, Z; Zou, XQ; Cao, PB; Zhou, GM; Tang, M; Wu, L; Wu, LL; Yu, HG; Guo, Y; Zhou, FX				Ding, Qian-shan; Zhang, Li; Wang, Bi-cheng; Zeng, Zhi; Zou, Xian-qiong; Cao, Peng-bo; Zhou, Guang-ming; Tang, Meng; Wu, Lu; Wu, Lian-lian; Yu, Hong-gang; Guo, Yong; Zhou, Fu-xiang			Aberrant high expression level of MORC2 is a common character in multiple cancer	HUMAN PATHOLOGY			English	Article						MORC2; Cancers; Pathology; Prognosis; Oncogene	PROTEIN MORC2; FAMILY; LIPOGENESIS; ARGBP2	Microrchidia 2 (MORC2) plays important roles in DNA damage repair and lipogenesis, but the clinical and functional role of MORC2 in cancer remains largely unexplored. In this study, we showed that MORC2 was widely expressed in human tissues while significantly up-regulated in most cancer types using immunohistochemical staining and analysis of messenger RNA expression profile of more than 2000 human tissue samples from 15 different organs (lung, prostate, liver, breast, brain, stomach, colon/rectum, pancreas, ovary, endometrium, skin, nasopharynx, kidney, esophagus, and bladder). We also found that the MORC2 expression level in high-grade cancer tissues was much more elevated and associated with unfavorable pathological characteristics, poor overall survival, and disease-free survival in several kinds of cancers such as non-small cell lung cancer and breast cancer. Gene set enrichment analysis was used to predict the genes modulated by MORC2, and the results showed that dysregulation of MORC2 in tumor may take part in the cell cycle regulation and genomic instability. We observed that MORC2 knockdown would arrest the cell cycle progress, and the genome of tumors with high MORC2 expression contained more point mutations and gene copy number variation, which validates our gene set enrichment analysis results. The results also showed that MORC2 knockdown would significantly inhibit the proliferation, colony forming, migration, and invasion in multiple cancer cell lines. Taken together, these results highlight the importance of MORC2 in tumorigenesis and cancer progression, and it may act as a potential diagnostic marker and therapeutic target for these diseases. (C) 2018 Elsevier Inc. All rights reserved.	[Ding, Qian-shan; Tang, Meng; Zhou, Fu-xiang] Wuhan Univ, Zhongnan Hosp, Hubei Key Lab Tumor Biol Behav, Hubei Clin Canc Study Ctr,Dept Radiat & Med Oncol, Donghu Rd 115, Wuhan 430071, Hubei, Peoples R China; [Ding, Qian-shan; Wu, Lu; Wu, Lian-lian; Yu, Hong-gang] Wuhan Univ, Renmin Hosp, Inst Gastroenterol & Hepatol, Dept Gastroenterol, Wuhan 430060, Hubei, Peoples R China; [Zhang, Li] Chinese Univ Hong Kong, Prince Wales Hosp, State Key Lab Oncol South China, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; [Wang, Bi-cheng] Wuhan Univ, Zhongnan Hosp, Dept Pathol, Wuhan 430071, Hubei, Peoples R China; [Zeng, Zhi] Wuhan Univ, Renmin Hosp, Dept Pathol, Wuhan 430060, Hubei, Peoples R China; [Zou, Xian-qiong; Guo, Yong] Guilin Med Univ, Coll Biotechnol, Guilin 541100, Peoples R China; [Cao, Peng-bo; Zhou, Guang-ming] Beijing Proteome Res Ctr, Beijing Inst Radiat Med, State Key Lab Prote, Beijing 100850, Peoples R China	Zhou, FX (reprint author), Wuhan Univ, Zhongnan Hosp, Hubei Key Lab Tumor Biol Behav, Hubei Clin Canc Study Ctr,Dept Radiat & Med Oncol, Donghu Rd 115, Wuhan 430071, Hubei, Peoples R China.; Guo, Y (reprint author), Guilin Med Univ, Coll Biotechnol, North 2nd Huancheng Rd 109, Guilin 541004, Peoples R China.	guoyong74@163.com; 592071015@qq.com			Natural Science Foundation of ChinaNational Natural Science Foundation of China [81172129, 81472798, 81703030]	The study was supported by the Natural Science Foundation of China (No. 81172129, No. 81472798, and No. 81703030).	Calvisi DF, 2011, GASTROENTEROLOGY, V140, P1071, DOI 10.1053/j.gastro.2010.12.006; Chen LH, 2011, PLOS ONE; Douse CH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03045-x; Eswaran J, 2012, CLIN CANCER RES, V18, P3743, DOI 10.1158/1078-0432.CCR-11-1952; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hong GJ, 2017, J CELL PHYSIOL, V232, P928, DOI 10.1002/jcp.25665; King H, 2014, INT REV CEL MOL BIO, V309, P347, DOI 10.1016/B978-0-12-800255-1.00007-7; Li DQ, 2013, EPIGENETICS-US, V8, P685, DOI 10.4161/epi.24976; Li DQ, 2012, CELL REP, V2, P1657, DOI 10.1016/j.celrep.2012.11.018; Liao XH, 2017, ONCOTARGET, V8, P97941, DOI 10.18632/oncotarget.18556; Lin RT, 2013, MOL CELL, V51, P506, DOI 10.1016/j.molcel.2013.07.002; Moissiard G, 2012, SCIENCE, V336, P1448, DOI 10.1126/science.1221472; Mounier C, 2014, INT J ONCOL, V45, P485, DOI 10.3892/ijo.2014.2441; Sanchez-Solana B, 2014, BBA-MOL CELL RES, V1843, P316, DOI 10.1016/j.bbamcr.2013.11.012; Schottmann G, 2016, BRAIN, V139, DOI 10.1093/brain/aww252; Shao YG, 2010, NUCLEIC ACIDS RES, V38, P2813, DOI 10.1093/nar/gkq006; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tchasovnikarova IA, 2017, NAT GENET, V49, P1035, DOI 10.1038/ng.3878; Tong YX, 2018, BBA-MOL BASIS DIS, V1864, P1104, DOI 10.1016/j.bbadis.2018.01.011; Tong YX, 2015, BIOCHEM BIOPH RES CO, V467, P821, DOI 10.1016/j.bbrc.2015.10.059; Wang GL, 2010, ANAT REC, V293, P1002, DOI 10.1002/ar.21119; Wang GL, 2015, ONCOTARGET, V6, P9877, DOI 10.18632/oncotarget.3185; Weir B, 2004, CANCER CELL, V6, P433, DOI 10.1016/j.ccr.2004.11.004; Zhang Q, 2015, ONCOTARGET, V6, P16461, DOI 10.18632/oncotarget.3889	24	6	7	1	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUN	2018	76						58	67		10.1016/j.humpath.2018.03.011			10	Pathology	Pathology	GK1ON	WOS:000435888200008	29555576				2019-10-28	
J	Bai, CG; Liu, XH; Xu, JJ; Qiu, C; Wang, RQ; Zheng, JM				Bai, Chenguang; Liu, Xiaohong; Xu, Jingjing; Qiu, Cen; Wang, Runqiu; Zheng, Jianming			Expression profiles of stemness genes in gastrointestinal stromal tumor	HUMAN PATHOLOGY			English	Article						Gastrointestinal stromal tumor; Stemness genes; BMI1; Proliferation; Progression	GASTRIC-CANCER; CELLS; BMI-1; PROLIFERATION; DYSREGULATION; PATTERNS; MARKER; NESTIN; TRACT; RAB18	Gastrointestinal stromal tumor (GIST) is believed to originate from intestinal cells of Cajal or their stem cell precursors, and expresses sternness-related markers, such as CD117, CD34, DOG1 and nestin. To further characterize phenotypic features of GISTs, we examined expression profiles of a panel of sternness genes in GISTs, by analyzing existing gene expression profiling datasets. Our results showed that mRNA levels of B-lymphoma moloney murine leukaemia virus insertion region-1 (BMI1), kruppel-like factor 4 (KLF4), sal-like protein 4 (SALL4) and telomerase reverse transcriptase (TERT) were significantly unregulated in GISTs. Subsequently, protein expression of BMI1 and TERT was identified in GIST specimens by immunohistochemistry. Especially, we found that high expression of nuclear BMI1 was associated with large tumor size (P = .0239), high mitotic count (P < .01), high Ki-67 index (P = .0357), advanced National Institute of Health (NIH) criteria (P = .0025) and advanced World Health Organization (WHO) classification (P < .01) in GISTs. Functional and pathway enrichment analysis showed that most of BMI1's coexpressed genes were involved in tumor growth-related process, such as regulation of cell cycle and proliferation. Furthermore, we confirmed RAS oncogene family (RAB18) and limb development membrane protein 1 (LMBR1) genes as novel targets for BMI1 in GIST cells. These results provide valuable information for the expression profiles of sternness genes in GISTs, and identified nuclear BMI1 as an important marker of GIST cell proliferation and progression. (C) 2018 Elsevier Inc. All rights reserved.	[Bai, Chenguang; Liu, Xiaohong; Xu, Jingjing; Qiu, Cen; Wang, Runqiu; Zheng, Jianming] Second Mil Med Univ, Changhai Hosp, Dept Pathol, 168 Changhai Rd, Shanghai 200433, Peoples R China	Zheng, JM (reprint author), Second Mil Med Univ, Changhai Hosp, Dept Pathol, 168 Changhai Rd, Shanghai 200433, Peoples R China.	zhengjianm1005@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81472276]; Shanghai Municipal Commission of Health and Family planning, Key Developing Disciplines [2015ZB0202]	The work was supported by research grants from the National Natural Science Foundation of China (Grants 81472276) and Shanghai Municipal Commission of Health and Family planning, Key Developing Disciplines (No. 2015ZB0202).	Ardeleanu C, 2009, APPL IMMUNOHISTO M M, V17, P413, DOI 10.1097/PAI.0b013e31819e4dc5; Arne G, 2011, INT J CANCER, V129, P1149, DOI 10.1002/ijc.25755; Bi DB, 2015, COMPUT BIOL CHEM, V56, P71, DOI 10.1016/j.compbiolchem.2015.04.001; Chen JW, 2012, GENE CHROMOSOME CANC, V51, P186, DOI 10.1002/gcc.20942; Cho JY, 2011, CLIN CANCER RES, V17, P1850, DOI 10.1158/1078-0432.CCR-10-2180; Choi KD, 2009, STEM CELLS, V27, P559, DOI 10.1634/stemcells.2008-0922; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; Horikoshi T, 2003, J BONE MINER METAB, V21, P1, DOI 10.1007/s007740300000; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Li DW, 2010, J CANCER RES CLIN, V136, P997, DOI 10.1007/s00432-009-0745-7; Linn SC, 2003, AM J PATHOL, V163, P2383, DOI 10.1016/S0002-9440(10)63593-6; Liu JC, 2016, GENE, V592, P308, DOI 10.1016/j.gene.2016.07.034; MAZUR MT, 1983, AM J SURG PATHOL, V7, P507, DOI 10.1097/00000478-198309000-00001; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Park D, 2010, STEM CELLS, V28, P2162, DOI 10.1002/stem.541; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Reinisch C, 2006, HISTOL HISTOPATHOL, V21, P1143, DOI 10.14670/HH-21.1143; Sarlomo-Rikala M, 1998, MODERN PATHOL, V11, P728; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Segal NH, 2003, AM J PATHOL, V163, P691, DOI 10.1016/S0002-9440(10)63696-6; Siddique HR, 2012, STEM CELLS, V30, P372, DOI 10.1002/stem.1035; Song LB, 2006, CANCER RES, V66, P6225, DOI 10.1158/0008-5472.CAN-06-0094; Subramanian S, 2005, J PATHOL, V206, P433, DOI 10.1002/path.1792; Teshima K, 2014, ONCOGENE, V33, P2191, DOI 10.1038/onc.2013.177; Tsujimura T, 2001, AM J PATHOL, V158, P817, DOI 10.1016/S0002-9440(10)64029-1; van Leenders GJLH, 2007, EUR UROL, V52, P455, DOI 10.1016/j.eururo.2006.11.020; VANDERIJN M, 1994, HUM PATHOL, V25, P766, DOI 10.1016/0046-8177(94)90245-3; Wang JL, 2017, PATHOL RES PRACT, V213, P1542, DOI 10.1016/j.prp.2017.09.013; Wang MC, 2016, ONCOTARGET, V7, P9587, DOI 10.18632/oncotarget.7078; You XN, 2013, CARCINOGENESIS, V34, P1644, DOI 10.1093/carcin/bgt089; Zhong K, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-703	31	0	0	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUN	2018	76						76	84		10.1016/j.humpath.2018.02.015			9	Pathology	Pathology	GK1ON	WOS:000435888200010	29486292				2019-10-28	
J	Tejerina, EE; Padilla, R; Abril, E; Frutos-Vivar, F; Ballen, A; Rodriguez-Barbero, JM; Lorente, JA; Esteban, A				Tejerina, Eva E.; Padilla, Rebeca; Abril, Elena; Frutos-Vivar, Fernando; Ballen, Aida; Maria Rodriguez-Barbero, Jose; Angel Lorente, Jose; Esteban, Andres			Autopsy-detected diagnostic errors over time in the intensive care unit	HUMAN PATHOLOGY			English	Article						Autopsy diagnosis; Premortem diagnosis; Diagnostic discrepancies; Intensive care; Quality assurance	POST-MORTEM FINDINGS; CLINICAL DIAGNOSES; MALIGNANT NEOPLASMS; POSTMORTEM FINDINGS; DISCREPANCIES; PREMORTEM	We evaluate the evolution over time of discrepancies between clinical diagnoses and postmortem findings in critically ill patients and assess the factors associated with these discrepancies. We conducted a prospective study of all consecutive patients who underwent autopsy in a medical-surgical intensive care unit (ICU) between January 2008 and December 2015. Among 7655 patients admitted to our ICU, 671 (8.8%) died. Clinical autopsy was performed in 215 (32%) patients. Major missed diagnoses were noted in 38 patients (17.7%). Eighteen patients (8.4%) had class I discrepancies, and 20 patients (9.3%) had class II discrepancies. The most frequently missed diagnoses were invasive aspergillosis, intestinal ischemia, myocardial infarction, cancer, and intra-abdominal abscesses. We did not find a statistically significant correlation between any premortem factor, including age, sex, severity of illness, length of hospital stay before ICU admission, length of ICU stay before death, duration of mechanical ventilation, or admitting unit, and the level of agreement between clinical and pathological diagnosis. In the last decades, the discrepancies between clinical and autopsy diagnoses persisted despite advances in medical skills and technology. Specific clinical entities such as invasive aspergillosis, mesenteric ischemia, myocardial infarction, intra-abdominal abscesses, and neoplastic diseases remain a diagnostic challenge in critically ill patients. Clinical level of diagnostic certainty does not increase with specific premortem characteristics. (C) 2018 Elsevier Inc. All rights reserved.	[Tejerina, Eva E.; Padilla, Rebeca; Abril, Elena; Frutos-Vivar, Fernando; Angel Lorente, Jose; Esteban, Andres] Hosp Univ Getafe, Intens Care Unit, Madrid 28905, Spain; [Tejerina, Eva E.; Frutos-Vivar, Fernando; Angel Lorente, Jose; Esteban, Andres] Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid 28905, Spain; [Ballen, Aida; Maria Rodriguez-Barbero, Jose] Hosp Univ Getafe, Dept Pathol, Madrid 28905, Spain	Tejerina, EE (reprint author), Hosp Univ Getafe, Intens Care Unit, Carretera Toledo,Km 12-5, Getafe 28905, Spain.	evateje@gmail.com			Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain	Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.	Aalten CM, 2006, NETH J MED, V64, P186; Avgerinos DV, 2001, APMIS, V109, P774, DOI 10.1034/j.1600-0463.2001.d01-145.x; Baddley JW, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-29; BATTLE RM, 1987, JAMA-J AM MED ASSOC, V258, P339, DOI 10.1001/jama.258.3.339; Burton EC, 1998, JAMA-J AM MED ASSOC, V280, P1245, DOI 10.1001/jama.280.14.1245; Combes A, 2004, ARCH INTERN MED, V164, P389, DOI 10.1001/archinte.164.4.389; De Vlieger GYA, 2010, CRIT CARE, V14, DOI 10.1186/cc8925; Dimopoulos G, 2004, INTENS CARE MED, V30, P2080, DOI 10.1007/s00134-004-2448-5; Dimopoulos G, 2003, J CHEMOTHERAPY, V15, P71, DOI 10.1179/joc.2003.15.1.71; Fares AF, 2011, ARQ BRAS CARDIOL, V97, P449, DOI 10.1590/S0066-782X2011005000111; FERNANDEZSEGOVIANO P, 1988, CRIT CARE MED, V16, P683, DOI 10.1097/00003246-198807000-00007; Gibson TN, 2004, J CLIN PATHOL, V57, P980, DOI 10.1136/jcp.2004.016246; GOLDMAN L, 1983, NEW ENGL J MED, V308, P1000, DOI 10.1056/NEJM198304283081704; Hartemink KJ, 2003, INTENS CARE MED, V29, P2068, DOI 10.1007/s00134-003-1778-z; Kotovicz F, 2008, CLINICS, V63, P581, DOI 10.1590/S1807-59322008000500003; Lionakis MS, 2003, LANCET, V362, P1828, DOI 10.1016/S0140-6736(03)14904-5; Mahler HT, 1978, WHO INT CLASSIFICATI; MANZINI VD, 1995, HUM PATHOL, V26, P280, DOI 10.1016/0046-8177(95)90058-6; Maris C, 2007, VIRCHOWS ARCH, V450, P329, DOI 10.1007/s00428-006-0364-5; Mort TC, 1999, CRIT CARE MED, V27, P299, DOI 10.1097/00003246-199902000-00035; MOSQUERA DA, 1993, ANN ROY COLL SURG, V75, P115; Roosen J, 2000, MAYO CLIN PROC, V75, P562, DOI 10.4065/75.6.562; SARODE VR, 1993, HUM PATHOL, V24, P194, DOI 10.1016/0046-8177(93)90300-6; Schwanda-Burger S, 2012, MODERN PATHOL, V25, P777, DOI 10.1038/modpathol.2011.199; Shojania KG, 2003, JAMA-J AM MED ASSOC, V289, P2849, DOI 10.1001/jama.289.21.2849; Sondereger-Iselli K, 2003, LANCET, V355, P2027; Taccone FS, 2015, CRIT CARE, V19, DOI 10.1186/s13054-014-0722-7; Tai DYH, 2001, CHEST, V119, P530, DOI 10.1378/chest.119.2.530; Tavora F, 2008, AM J CLIN PATHOL, V129, P102, DOI 10.1309/9M7DFE62RTDKHH4D; Tejerina E, 2012, CRIT CARE MED, V40, P842, DOI 10.1097/CCM.0b013e318236f64f; Thurnheer R, 2009, EUR J INTERN MED, V20, P784, DOI 10.1016/j.ejim.2009.08.005; Torgersen C, 2009, ANESTH ANALG, V108, P1841, DOI 10.1213/ane.0b013e318195e11d; Twigg SJ, 2001, INTENS CARE MED, V27, P706, DOI 10.1007/s001340100903; VERESS B, 1994, HUM PATHOL, V25, P140, DOI 10.1016/0046-8177(94)90269-0; Winters B, 2012, BMJ QUAL SAF, V21, P894, DOI 10.1136/bmjqs-2012-000803	35	2	2	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUN	2018	76						85	90		10.1016/j.humpath.2018.02.025			6	Pathology	Pathology	GK1ON	WOS:000435888200011	29530753				2019-10-28	
J	Matoso, A; Khandakar, B; Yuan, SY; Wu, T; Wang, LJ; Lombardo, KA; Mangray, S; Mannan, AASR; Yakirevich, E				Matoso, Andres; Khandakar, Binny; Yuan, Songyang; Wu, Tony; Wang, Li J.; Lombardo, Kara A.; Mangray, Shamlal; Mannan, Abul Ala Syed Rifat; Yakirevich, Evgeny			Spectrum of findings in orchiectomy specimens of persons undergoing gender confirmation surgery	HUMAN PATHOLOGY			English	Article						Transgender; Transsexual; Testes histopathology; Leydig cells; Orchiectomy; Cytomegaly	SEX REASSIGNMENT SURGERY; TO-FEMALE TRANSSEXUALS; IN-UTERO EXPOSURE; TESTICULAR DYSGENESIS; PENILE SKIN; VAGINOPLASTY; ADOLESCENTS; DYSPHORIA; PHTHALATE; BIOPSIES	Gender confirmation surgery is increasingly common in persons with gender dysphoria. We describe changes seen in gonads from individuals seeking male-to-female physical adaptation. We studied 99 orchiectomies from 50 persons. The average age was 33 years (range, 21-63 years). Eighty-six (86.8%) of 99 testes were normal in size with an average size of 3.87 cm (range, 3.0-5.5 cm). Thirteen (13.1%) of 99 testes were hypotrophic and measured up to 2.5 cm. Seminiferous tubules were reduced in diameter compared with controls (0.137 mm versus 0.237 mm; P < .001) and showed peritubular fibrosis in 41 (82%) of 50 persons. In 40 (80%) of 50 persons, there was maturation arrest at the spermatogonia level. In 10 (20%) of 50 persons, the seminiferous tubules showed focal spermatids/spermatozoa up to 7 per 10 tubules mixed with partial maturation arrest at primary spermatocytes. Twenty-six (26%) of 99 testes showed seminiferous tubules with rare cells with large nuclei (3 x size of Sertoli cells nuclei) and degenerative chromatin (cytomegaly). Leydig cells were absent in 50 (50%), markedly reduced in 30 (30%), and similar to controls (mean, 33/high-power field) in 20 (20%). A subset (20/99; 20%) of testes had epithelial hyperplasia of the proximal epididymis with stratification and micropapillae. There was no germ cell tumor, sex cord stromal tumors, or germ cell neoplasia in situ. In summary, the histologic changes include (1) decreased diameter of seminiferous tubules and expansion of the interstitium, (2) marked hypoplasia of germ cells, (3) rare cytomegaly, (4) hypoplasia or absence of Leydig cells, and (5) epididymal hyperplasia. (C) 2018 Elsevier Inc. All rights reserved.	[Matoso, Andres] Johns Hopkins Med Inst, Dept Pathol Urol & Oncol, Baltimore, MD 21231 USA; [Khandakar, Binny; Yuan, Songyang; Mannan, Abul Ala Syed Rifat] Mt Sinai Beth Israel Med Ctr, Dept Pathol, New York, NY 10029 USA; [Wu, Tony] Rhode Isl Hosp, Dept Med, Providence, RI 02903 USA; [Wu, Tony] Brown Univ, Providence, RI 02912 USA; [Wang, Li J.; Lombardo, Kara A.; Mangray, Shamlal; Yakirevich, Evgeny] Rhode Isl Hosp, Dept Pathol & Lab Med, Providence, RI 02903 USA	Matoso, A (reprint author), Johns Hopkins Univ Hosp, Weinberg 2242,401 N,Broadway, Baltimore, MD 21231 USA.	amatoso1@jhmi.edu			Department of Pathology of Lifespan Academic Medical Center; Laboratory Medicine of Lifespan Academic Medical Center; Department of Pathology of Johns Hopkins University	This study was supported by the Department of Pathology and Laboratory Medicine of Lifespan Academic Medical Center and the Department of Pathology of Johns Hopkins University.	Dekker JJML, 2007, ANN PLAS SURG, V59, P546, DOI 10.1097/01.sap.0000258953.00234.50; Fisher JS, 2003, HUM REPROD, V18, P1383, DOI 10.1093/humrep/deg273; Flores A, 2016, MANY ADULTS IDENTIFY; Gates Gary J., 2011, MANY PEOPLE ARE LESB; Hage JJ, 1996, PLAST RECONSTR SURG, V97, P1226, DOI 10.1097/00006534-199605000-00018; HANDELSMAN DJ, 1985, J ANDROL, V6, P144; Hembree WC, 2009, J CLIN ENDOCR METAB, V94, P3132, DOI 10.1210/jc.2009-0345; Jones A, 2009, ENDOCRINOLOGY, V150, P385, DOI 10.1210/en.2008-0674; Kanhai RCJ, 2000, AM J SURG PATHOL, V24, P74, DOI 10.1097/00000478-200001000-00009; Lakis NS, 2017, APPL IMMUNOHISTOCHEM; Liu KJ, 2005, BIOL REPROD, V73, P180, DOI 10.1095/biolreprod.104.039404; MEYER R, 1980, PLAST RECONSTR SURG, V66, P401, DOI 10.1097/00006534-198066030-00015; Nistal M, 2007, AM J SURG PATHOL, V31, P1269, DOI 10.1097/PAS.0b013e318030979a; Nistal M, 2015, PEDIATR DEVEL PATHOL, V18, P173, DOI 10.2350/12-09-1255-PB.1; Papadopulos NA, 2017, J SEX MED, V14, P721, DOI 10.1016/j.jsxm.2017.01.022; PEROVIC S, 1993, PLAST RECONSTR SURG, V91, P703, DOI 10.1097/00006534-199304000-00021; Perovic S, 1995, Acta Chir Iugosl, V42-43, P143; Perovic SV, 2000, BJU INT, V86, P843, DOI 10.1046/j.1464-410x.2000.00934.x; Ponte R, 2018, J REPROD IMMUNOL, V125, P16, DOI 10.1016/j.jri.2017.10.043; SAPINO A, 1987, VIRCHOWS ARCH A, V411, P409, DOI 10.1007/BF00735221; Schneider F, 2015, J SEX MED, V12, P2190, DOI 10.1111/jsm.13022; Smith KP, 2014, PHARMACOTHERAPY, V34, P1282, DOI 10.1002/phar.1487; Smith YLS, 2001, J AM ACAD CHILD PSY, V40, P472, DOI 10.1097/00004583-200104000-00017; Tornello SL, 2017, LGBT HEALTH, V4, P115, DOI 10.1089/lgbt.2016.0153; van Zuuren EJ, 2016, BRIT J DERMATOL, V175, P45, DOI 10.1111/bjd.14486; Yakirevich E, 2003, APPL IMMUNOHISTO M M, V11, P37, DOI 10.1097/00022744-200303000-00007	26	5	5	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUN	2018	76						91	99		10.1016/j.humpath.2018.03.007			9	Pathology	Pathology	GK1ON	WOS:000435888200012	29555572				2019-10-28	
J	Pu, XH; Ye, Q; Yang, J; Wu, HY; Ding, XW; Shi, J; Mao, L; Fan, XS; Chen, J; Qiu, YD; Huang, Q				Pu, Xiao-Hong; Ye, Qing; Yang, Jun; Wu, Hong-Yan; Ding, Xi-Wei; Shi, Jiong; Mao, Liang; Fan, Xiang-Shan; Chen, Jun; Qiu, Yu-Dong; Huang, Qin			Low-level clonal FGFR2 amplification defines a unique molecular subtype of intrahepatic cholangiocarcinoma in a Chinese population	HUMAN PATHOLOGY			English	Article						FGFR2; Low-level clonal amplification; Intrahepatic cholangiocarcinoma	GROWTH-FACTOR; CANCER; MUTATIONS; THERAPY; FUSIONS; GENE	Intrahepatic cholangiocarcinoma (ICC) is a subtype of primary liver cancer rarely curable by surgery that is increasing rapidly in incidence. Chromosomal translocations and amplifications of the fibroblast growth factor receptor 2 (FGFR2) locus are present in several kinds of tumors including ICC, but their incidence has not been assessed in Chinese patients. Using break-apart probes and by determining the ratios of FGFR2/chromosome enumeration probe (CEP) 10 double-color probes, we evaluated 122 ICCs for the presence of FGFR2 translocations and amplifications, respectively, by fluorescence in situ hybridization. We further determined FGFR2 protein expression by immunohistochemistry and analyzed the clinicopathologic records of the patients. Eight tumors (6.6%) had FGFR2 translocations, whereas 15 (12.3%) had low-level FGFR2 amplification. Interestingly, the tumors that showed both translocation and lowlevel amplification frequently were of the mass-forming type. Compared with the ICCs with normal FGFR2s, tumors with amplifications secreted less mucus (P = .017) and typically were accompanied by hepatitis B virus infection (P = .004). Tumors with low-level amplification generally were of lower stage (P = .013) and associated with better overall survival (P = .017). As tumors with FGFR2 amplification exhibit different biology from lesions with a normal gene, low-level amplification of FGFR2 may play an important role in tumor progression and may be a marker for targeted therapy. (C) 2018 Elsevier Inc. All rights reserved.	[Pu, Xiao-Hong; Ye, Qing; Yang, Jun; Wu, Hong-Yan; Shi, Jiong; Fan, Xiang-Shan; Huang, Qin] Nanjing Univ, Dept Pathol, Affiliated Hosp, Med Sch,Nanjing Drum Tower Hosp, Nanjing 210008, Jiangsu, Peoples R China; [Ding, Xi-Wei] Nanjing Univ, Dept Gastroenterol, Affiliated Hosp, Med Sch,Nanjing Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China; [Mao, Liang; Chen, Jun; Qiu, Yu-Dong] Nanjing Univ, Dept Hepatopancreatobiliary Surg, Affiliated Hosp, Med Sch,Nanjing Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China; [Huang, Qin] Vet Affairs Boston Healthcare Syst, Dept Pathol & Lab Med, West Roxbury, MA 02132 USA; [Huang, Qin] Harvard Med Sch, West Roxbury, MA 02132 USA	Chen, J (reprint author), Nanjing Drum Tower Hosp, Dept Pathol, 321 Zhong Shan Rd, Nanjing 210008, Jiangsu, Peoples R China.; Qiu, YD (reprint author), Nanjing Drum Tower Hosp, Dept Hepatopancreatobiliary Surg, Nanjing, Jiangsu, Peoples R China.	ichenjun@qq.com			Six Talent Peaks Project in Jiangsu Province [WSW-073, 2015-WSN-080]; Health Young Talent Training Project in Nanjing [QRX-17055]; Innovation Capability Development Project of Jiangsu Province [BM2015004]; Nanjing Health and Family Planning Commission Medical Science Technology Innovation Platform Project [ZDX16006]; National Human Genetic Resources Sharing Service Platform [2005DKA21300]; Key Research and Development Programs Social Development Project of Science and Technology Commission Foundation of Jiangsu Province [BE2016604]	Six Talent Peaks Project in Jiangsu Province (WSW-073), Health Young Talent Training Project in Nanjing (QRX-17055), Innovation Capability Development Project of Jiangsu Province (BM2015004), Nanjing Health and Family Planning Commission Medical Science Technology Innovation Platform Project (ZDX16006), National Human Genetic Resources Sharing Service Platform (2005DKA21300), Key Research and Development Programs Social Development Project of Science and Technology Commission Foundation of Jiangsu Province (BE2016604), and Six Talent Peaks Project in Jiangsu Province (2015-WSN-080).	Arai Y, 2014, HEPATOLOGY, V59, P1427, DOI 10.1002/hep.26890; BATTS KP, 1995, AM J SURG PATHOL, V19, P1409, DOI 10.1097/00000478-199512000-00007; Boberg KM, 2000, J HEPATOL, V32, P374, DOI 10.1016/S0168-8278(00)80386-4; Borad MJ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004135; Borger DR, 2012, ONCOLOGIST, V17, P72, DOI 10.1634/theoncologist.2011-0386; Bosman FT, 2010, WHO CLASSIFICATION T; Cereda S, 2012, WORLD J GASTROENTERO, V18, P2591, DOI [10.3748/wjg.v18.i21.2591, 10.3748/wjg.v18.21.2591]; Chen J, 2017, HUM PATHOL, V64, P118, DOI 10.1016/j.humpath.2017.01.016; Dieci MV, 2013, CANCER DISCOV, V3, P264, DOI 10.1158/2159-8290.CD-12-0362; Druker BJ, 2008, BLOOD, V112, P4808, DOI 10.1182/blood-2008-07-077958; Edge SB, 2010, AJCC CANC STAGING MA, P247; Gatius S, 2011, MODERN PATHOL, V24, P1500, DOI 10.1038/modpathol.2011.110; Graham RP, 2014, HUM PATHOL, V45, P1630, DOI 10.1016/j.humpath.2014.03.014; Imai K, 2010, HEPATO-GASTROENTEROL, V57, P1333; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; Korc M, 2009, CURR CANCER DRUG TAR, V9, P639, DOI 10.2174/156800909789057006; McLean L, 2006, LIVER INT, V26, P1047, DOI 10.1111/j.1478-3231.2006.01350.x; Murase H, 2014, MOL CLIN ONCOL, V2, P509, DOI 10.3892/mco.2014.293; Nagatsuma AK, 2015, GASTRIC CANCER, V18, P227, DOI 10.1007/s10120-014-0360-4; Nakamura H, 2015, NAT GENET, V47, P1003, DOI 10.1038/ng.3375; Nakeeb Attila, 2005, HPB (Oxford), V7, P278, DOI 10.1080/13651820500373028; Ornitz DM, 2001, GENOME BIOL, V2; Pearson A, 2016, CANCER DISCOV, V6, P838, DOI 10.1158/2159-8290.CD-15-1246; Ross JS, 2014, ONCOLOGIST, V19, P235, DOI 10.1634/theoncologist.2013-0352; Sandhu DS, 2014, HEPATOLOGY, V59, P1166, DOI 10.1002/hep.26679; Schneider CP, 2008, J THORAC ONCOL, V3, P1446, DOI 10.1097/JTO.0b013e31818ddcaa; Tabernero J, 2015, J CLIN ONCOL, V33, P3401, DOI 10.1200/JCO.2014.60.7341; Tannapfel A, 2000, DIGEST DIS SCI, V45, P317, DOI 10.1023/A:1005412626515; Toyokawa T, 2009, ONCOL REP, V21, P875, DOI 10.3892/or_00000297; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Tyson GL, 2011, HEPATOLOGY, V54, P173, DOI 10.1002/hep.24351; Valle J, 2010, NEW ENGL J MED, V362, P1273, DOI 10.1056/NEJMoa0908721; Wang YZ, 2013, J CLIN ONCOL, V31, P1188, DOI 10.1200/JCO.2012.41.5984; Wu YM, 2013, CANCER DISCOV, V3, P636, DOI 10.1158/2159-8290.CD-13-0050; Zhao WM, 2010, CLIN CANCER RES, V16, P5750, DOI 10.1158/1078-0432.CCR-10-0531	35	0	0	1	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUN	2018	76						100	109		10.1016/j.humpath.2017.12.028			10	Pathology	Pathology	GK1ON	WOS:000435888200013	29514108				2019-10-28	
J	Tanaka, J; Su, P; Luedke, C; Jug, R; Yang, LH; Deak, K; Rapisardo, S; Zhang, Y; Delos Angeles, M; Xie, Y; Wang, ED				Tanaka, John; Su, Pu; Luedke, Catherine; Jug, Rachel; Yang, Lian-He; Deak, Kristen; Rapisardo, Sarah; Zhang, Yang; Delos Angeles, Marc; Xie, Yi; Wang, Endi			Composite lymphoma of follicular B-cell and peripheral T-cell types with distinct zone distribution in a 75-year-old male patient: a case study	HUMAN PATHOLOGY			English	Article						Composite lymphoma; Follicular lymphoma; T-cell lymphoma; B-cell lymphoma; Zone distribution; In situ	CLINICOPATHOLOGICAL ANALYSIS	Composite lymphoma of T-/B-cell type is rare, and follicular lymphoma composite with peripheral T-cell lymphoma (PTCL) has not previously been reported. We report such a case with both neoplastic components displaying a unique zone of distribution. A 75-year-old male patient presented with generalized lymphadenopathy. Sections of axillary lymph node demonstrated potentially 2 clonal processes, PTCL with aberrant CD20 expression and follicular lymphoma. Interestingly, the 2 neoplastic components were confined to their respective classic distribution zones, with PTCL occupying the interfollicular areas and follicular lymphoma residing in follicles. Both populations were detected by flow cytometry, but their immunophenotypes were insufficient to define clonality. Nonetheless, biclonality was demonstrated by lymphoid receptor gene rearrangement analyses. Molecular cytogenetics showed IGH/BCL2 fusion in the follicular lymphoma and amplification of IGH gene or trisomy/tetrasomy 14 in the PTCL. The current case underscores the complexity of composite lymphoma and advocates a multimodal approach to establishing the diagnosis. (C) 2017 Elsevier Inc. All rights reserved.	[Tanaka, John; Su, Pu; Luedke, Catherine; Jug, Rachel; Yang, Lian-He; Deak, Kristen; Rapisardo, Sarah; Zhang, Yang; Xie, Yi; Wang, Endi] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27710 USA; [Delos Angeles, Marc] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA	Wang, ED (reprint author), Duke Hosp South, Dept Pathol, DUMC Box 3712,M-345 Davison Bldg Green Zone, Durham, NC 27710 USA.	endi.wang@duke.edu					Amato T, 2016, AM J CLIN PATHOL, V145, P116, DOI [10.1093/AJCP/AQV011, 10.1093/ajcp/aqv011]; Balague O, 2007, AM J SURG PATHOL, V31, P1310, DOI 10.1097/PAS.0b013e3180339f18; Carbone A, 2011, AM J HEMATOL, V86, pE66, DOI 10.1002/ajh.22169; Carlotti E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134833; Cong PJ, 2002, BLOOD, V99, P3376, DOI 10.1182/blood.V99.9.3376; Copur MS, 2004, LEUKEMIA LYMPHOMA, V45, P1071, DOI 10.1080/1042819032000159870; Demurtas A, 2011, AM J CLIN PATHOL, V135, P541, DOI 10.1309/AJCPQKE25ADCFZWN; Dogan A, 2017, WHO CLASSIFICATION T, P407; Hu SM, 2012, HUM PATHOL, V43, P1789, DOI 10.1016/j.humpath.2012.05.002; KIM H, 1977, CANCER, V40, P959, DOI 10.1002/1097-0142(197709)40:3<959::AID-CNCR2820400302>3.0.CO;2-3; Mokhtar Nadia M, 2007, J Egypt Natl Canc Inst, V19, P171; Papalas John A, 2011, Am J Dermatopathol, V33, P719, DOI 10.1097/DAD.0b013e3181fe363b; Papathomas TG, 2012, HUM PATHOL, V43, P467, DOI 10.1016/j.humpath.2011.08.024; Rahemtullah A, 2008, AM J SURG PATHOL, V32, P1593, DOI 10.1097/PAS.0b013e31817d7452; Suefuji N, 2012, PATHOL INT, V62, P690, DOI 10.1111/j.1440-1827.2012.02858.x; Wang ED, 2014, HUM PATHOL, V45, P768, DOI 10.1016/j.humpath.2013.11.008; Whitling NA, 2013, HUM PATHOL, V44, P670, DOI 10.1016/j.humpath.2012.09.014; Zettl A, 2002, AM J CLIN PATHOL, V117, P368	18	0	0	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUN	2018	76						110	116		10.1016/j.humpath.2017.11.017			7	Pathology	Pathology	GK1ON	WOS:000435888200014	29217426				2019-10-28	
J	Li, HR; Tai, CF; Huang, HY; Jin, YT; Chen, YT; Yang, SF				Li, Hung-Ru; Tai, Chih-Feng; Huang, Hsuan-Ying; Jin, Ying-Tai; Chen, Yi-Ting; Yang, Sheau-Fang			USP6 gene rearrangement differentiates primary paranasal sinus solid aneurysmal bone cyst from A other giant cell-rich lesions: report of a rare case	HUMAN PATHOLOGY			English	Article						Solid aneurysmal bone cyst; Giant cell reparative granuloma; Giant cell tumor of bone; Paranasal sinus; USP6 gene rearrangement	VARIANT; 17P13	Aneurysmal bone cysts (ABCs) mostly occur in the metaphysis of long bones. Primary paranasal ABCs are extremely rare, and most reported cases reveal typical histopathological features including cystic space with fibrous septa and hemorrhage. Solid-variant ABCs or solid ABCs lacking cyst formation may be histologically indistinguishable from giant cell reparative granulomas, giant cell tumor of bone, and brown tumor. Here we report the case of a 24-year-old woman with a paranasal mass diagnosed as USP6-rearranged solid ABC, mimicking giant cell reparative granuloma, giant cell tumor of bone, and brown tumor. For paranasal sinus bone or soft tissue tumors containing numerous giant cells, molecular analysis including the USP6 gene may serve as a useful diagnostic tool to distinguish solid ABCs from other giant cell-rich lesions. (C) 2017 Elsevier Inc. All rights reserved.	[Li, Hung-Ru; Chen, Yi-Ting; Yang, Sheau-Fang] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Pathol, 100,Tzyou 1st Rd, Kaohsiung 807, Taiwan; [Li, Hung-Ru; Chen, Yi-Ting; Yang, Sheau-Fang] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung, Taiwan; [Tai, Chih-Feng] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Otorhinolaryngol, Kaohsiung, Taiwan; [Huang, Hsuan-Ying] Kaohsiung Chang Gung Mem Hosp, Dept Pathol, Kaohsiung, Taiwan; [Huang, Hsuan-Ying] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan; [Jin, Ying-Tai] Taiwan Adventist Hosp, Dept Pathol, Taipei, Taiwan	Yang, SF (reprint author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Pathol, 100,Tzyou 1st Rd, Kaohsiung 807, Taiwan.	sfyang1225@gmail.com		Chen, yiting/0000-0002-0817-1539; Yang, Sheau-Fang/0000-0002-1773-3716			Agaram NP, 2014, HUM PATHOL, V45, P1147, DOI 10.1016/j.humpath.2014.01.020; Amary F, 2017, AM J SURG PATHOL, V41, P1059, DOI 10.1097/PAS.0000000000000859; Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814; BERTONI F, 1993, CANCER, V71, P729, DOI 10.1002/1097-0142(19930201)71:3<729::AID-CNCR2820710313>3.0.CO;2-0; Bozbuga M, 2009, TURK NEUROSURG, V19, P172; Carter JM, 2016, MODERN PATHOL, V29, P865, DOI 10.1038/modpathol.2016.83; Dal Cin P, 2000, GENE CHROMOSOME CANC, V28, P233, DOI 10.1002/(SICI)1098-2264(200006)28:2<233::AID-GCC13>3.3.CO;2-8; DEDIOS AMV, 1992, CANCER, V69, P2921, DOI 10.1002/1097-0142(19920615)69:12<2921::AID-CNCR2820691210>3.0.CO;2-E; Hashemi Seyyed Mostafa, 2015, Iran J Otorhinolaryngol, V27, P395; Janjua N, 2014, BMJ CASE REP; Lange T, 2013, EUR SPINE J, V22, P1417, DOI 10.1007/s00586-013-2715-7; Mankin HJ, 2005, J CLIN ONCOL, V23, P6756, DOI 10.1200/JCO.2005.15.255; ODA Y, 1992, CANCER, V70, P2642, DOI 10.1002/1097-0142(19921201)70:11<2642::AID-CNCR2820701113>3.0.CO;2-#; Oliveira AM, 2005, ONCOGENE, V24, P3419, DOI 10.1038/sj.onc.1208506; Oliveira AM, 2004, AM J PATHOL, V165, P1773, DOI 10.1016/S0002-9440(10)63432-3; Panoutsakopoulos G, 1999, GENE CHROMOSOME CANC, V26, P265, DOI 10.1002/(SICI)1098-2264(199911)26:3<265::AID-GCC12>3.0.CO;2-#; SANERKIN NG, 1983, CANCER, V51, P2278, DOI 10.1002/1097-0142(19830615)51:12<2278::AID-CNCR2820511219>3.0.CO;2-Y; Shin C, 2016, HISTOPATHOLOGY, V69, P784, DOI 10.1111/his.13011; Winnepenninckx W, 2001, VIRCHOWS ARCH, V439, P636, DOI 10.1007/s004280100449	19	3	3	1	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUN	2018	76						117	121		10.1016/j.humpath.2017.11.018			5	Pathology	Pathology	GK1ON	WOS:000435888200015	29217425				2019-10-28	
J	Hui, P; Gysler, SM; Uduman, M; Togun, TA; Prado, DE; Brambs, CE; Nallur, S; Schwartz, PE; Rutherford, TJ; Santin, AD; Weidhaas, JB; Ratner, ES				Hui, Pei; Gysler, Stefan M.; Uduman, Mohamed; Togun, Taiwo A.; Prado, Daniel E.; Brambs, Christine E.; Nallur, Sunitha; Schwartz, Peter E.; Rutherford, Thomas J.; Santin, Alessandro D.; Weidhaas, Joanne B.; Ratner, Elena S.			MicroRNA signatures discriminate between uterine and ovarian serous carcinomas	HUMAN PATHOLOGY			English	Article						MicroRNAs; Uterine serous carcinoma; Ovarian serous carcinoma; Differential diagnosis; Synchronous serous carcinoma	CHRONIC LYMPHOCYTIC-LEUKEMIA; SYNCHRONOUS PRIMARY CANCERS; BREAST-CANCER; MICROSATELLITE INSTABILITY; DIFFERENTIAL-DIAGNOSIS; EXPRESSION PROFILES; ENDOMETRIAL; GENE; HETEROZYGOSITY; METASTASIS	Synchronous endometrial and ovarian malignancies occur in 5% of women presenting with endometrial cancer and 10% of patients presenting with ovarian malignancy. When a high-grade serous carcinoma concurrently involves both ovary and endometrium, pathological determination of whether they are synchronous primaries or metastatic tumors from one primary site can be challenging. MicroRNAs (miRNA) are 22-nucleotide noncoding RNAs that are aberrantly expressed in cancer cells and may inherit their cellular lineage characteristics. We explored possible differential miRNA signatures that may separate high-grade ovarian serous carcinoma from primary endometrial serous carcinoma. Forty-seven samples of histologically pure high-grade serous carcinoma of both uterine (16 case) and ovarian primaries (31 cases) were included. Expression of 384 mature miRNAs was analyzed using ABI TaqMan Low-Density Arrays technology. A random forest model was used to identify miRNAs that together could differentiate between uterine and ovarian serous carcinomas. Among 150 miRNAs detectable at various levels in the study cases, a panel of 11-miRNA signatures was identified to significantly discriminate between ovarian and uterine serous carcinoma (P < .05). A nested cross-validated convergent forest plot using 6 of the 11 miRNA signature was eventually established to classify the tumors with 91.5% accuracy. In conclusion, we have characterized a miRNA signature panel in this exploratory study that shows significant discriminatory power in separating primary ovarian high-grade serous carcinoma from its endometrial counterpart. (C) 2018 Elsevier Inc. All rights reserved.	[Hui, Pei] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; [Gysler, Stefan M.; Brambs, Christine E.; Schwartz, Peter E.; Rutherford, Thomas J.; Santin, Alessandro D.; Ratner, Elena S.] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, Div Gynecol Oncol, New Haven, CT 06520 USA; [Uduman, Mohamed; Togun, Taiwo A.] Yale Univ, Interdept Program Computat Biol & Bioinformat, New Haven, CT 06511 USA; [Prado, Daniel E.; Nallur, Sunitha] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06511 USA; [Prado, Daniel E.] Open Univ, Fac Sci, Milton Keynes MK7 6AA, Bucks, England; [Weidhaas, Joanne B.] Univ Calif Los Angeles, Div Mol & Cellular Oncol, Dept Radiat Oncol, Los Angeles, CA 90095 USA	Hui, P (reprint author), Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA.	pei.hui@yale.edu			program of Discovery to Cure, Yale School of Medicine	This work is supported by the program of Discovery to Cure, Yale School of Medicine.	Banno K, 2014, BIOMED RES INT, DOI 10.1155/2014/232817; BenBaruch G, 1996, GYNECOL ONCOL, V60, P393, DOI 10.1006/gyno.1996.0060; Bienkowska JR, 2009, GENOMICS, V94, P423, DOI 10.1016/j.ygeno.2009.08.008; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Chen CY, 2011, J CELL MOL MED, V15, P14, DOI 10.1111/j.1582-4934.2010.01219.x; Chen J, 2012, J SURG ONCOL, V106, P260, DOI 10.1002/jso.22153; Chiang YC, 2008, INT J GYNECOL CANCER, V18, P159, DOI 10.1111/j.1525-1438.2007.00975.x; Clement PB, 2014, ATLAS GYNECOLOGIC SU; Diaz-Uriarte R, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-3; Donnem T, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-6; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Fujita M, 1996, AM J CLIN PATHOL, V105, P350; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Habbe N, 2009, CANCER BIOL THER, V8, P340, DOI 10.4161/cbt.8.4.7338; Hamilton CA, 2006, BRIT J CANCER, V94, P642, DOI 10.1038/sj.bjc.6603012; Hui P, 2005, MODERN PATHOL, V18, P75, DOI 10.1038/modpathol.3800271; Hurst DR, 2009, CANCER RES, V69, P1279, DOI 10.1158/0008-5472.CAN-08-3559; Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936; Jiang FZ, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-425; Jurcevic S, 2014, CANCER CELL INT, V14, DOI 10.1186/s12935-014-0088-6; Kaneki E, 2004, HUM PATHOL, V35, P1484, DOI 10.1016/j.humpath.2004.08.011; Kelemen LE, 2017, CANCER CAUSE CONTROL, V28, P447, DOI 10.1007/s10552-017-0855-5; Kulbe H, 2012, CANCER RES, V72, P66, DOI 10.1158/0008-5472.CAN-11-2178; Li Y, 2010, CANCER RES, V70, P7894, DOI 10.1158/0008-5472.CAN-10-1675; Lin WM, 1998, CLIN CANCER RES, V4, P2577; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Calle ML, 2011, HUM HERED, V72, P121, DOI 10.1159/000330778; Ma XD, 2011, J MOL CELL BIOL, V3, P159, DOI 10.1093/jmcb/mjr007; Moreno-Bueno G, 2001, DIAGN MOL PATHOL, V10, P116, DOI 10.1097/00019606-200106000-00008; Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436; Pekarsky Y, 2006, CANCER RES, V66, P11590, DOI 10.1158/0008-5472.CAN-06-3613; PRAT J, 1991, CANCER-AM CANCER SOC, V68, P2455, DOI 10.1002/1097-0142(19911201)68:11<2455::AID-CNCR2820681122>3.0.CO;2-Q; R Foundation, LANG ENV STAT COMP V; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Ratner ES, 2010, GYNECOL ONCOL, V118, P251, DOI 10.1016/j.ygyno.2010.05.010; Rosenfeld N, 2008, NAT BIOTECHNOL, V26, P462, DOI 10.1038/nbt1392; Schotte D, 2009, LEUKEMIA, V23, P313, DOI 10.1038/leu.2008.286; SHENSON DL, 1995, CANCER-AM CANCER SOC, V76, P650, DOI 10.1002/1097-0142(19950815)76:4<650::AID-CNCR2820760417>3.0.CO;2-1; Smyth G., 2005, LIMMA LINEAR MODELS; Smyth GK, 2004, STAT APPL GENET MOL, V3, P1, DOI DOI 10.2202/1544-6115.1027; Soliman PT, 2004, GYNECOL ONCOL, V94, P456, DOI 10.1016/j.ygyno.2004.05.006; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; ULBRIGHT TM, 1985, HUM PATHOL, V16, P28, DOI 10.1016/S0046-8177(85)80210-0; Zaino R, 2001, GYNECOL ONCOL, V83, P355, DOI 10.1006/gyno.2001.6400; Zhang YX, 2013, INT J GYNECOL PATHOL, V32, P476, DOI 10.1097/PGP.0b013e31826ddc4e	46	2	2	1	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUN	2018	76						133	140		10.1016/j.humpath.2018.02.019			8	Pathology	Pathology	GK1ON	WOS:000435888200017	29518404				2019-10-28	
J	Chen, ZX; Luo, SJ; Chen, YL; Xie, XM; Du, ZB; Jiang, L				Chen, Zhixiong; Luo, Shengjun; Chen, Yanlin; Xie, Xuemei; Du, Zhongbo; Jiang, Li			High expression of NPRL2 is linked to poor prognosis in patients with prostate cancer	HUMAN PATHOLOGY			English	Article						Prostate cancer; NPRL2; Prognosis; Progression; Biomarker	TUMOR-SUPPRESSOR; CELLS; ENZALUTAMIDE; PROGRESSION; RESISTANCE; AUTOPHAGY; COMPLEX; PROTEIN; 3P21.3; MTORC1	As a tumor suppressor candidate gene, NPRL2 has anticancer effects against several cancers, but its potential role in prostate cancer (PCa) has not been reported. The present study aimed to explore the expression of NPRL2 in PCa and its potential clinical significance. Our results showed that expression of NPRL2 in PCa tissues was significantly higher than that in non-PCa tissues (P < .001). High NPRL2 expression in PCa tissue was significantly correlated with a high Gleason grade group (P < .001), high pT stage (P < .001), and lymph node metastasis (P = .003). The overall survival of PCa patients with negative to weak NPRL2 expression was significantly higher than that of patients with moderate to strong positive NPRL2 expression. Furthermore, in vitro, we found that the up-regulated NPRL2 level in LNCaP and PC3 cells, and forced reexpression of NPRL2 significant promoted the growth of those cells and vice versa. Contrary to existing reports, our results interestingly showed, for the first time, that the expression level of NPRL2 was significantly up-regulated in PCa and its high expression was correlated with poor prognosis, suggesting its pivotal role in the progression of PCa. NPRL2 may serve as a potential prognostic biomarker for PCa patients. (C) 2018 Elsevier Inc. All rights reserved.	[Chen, Zhixiong; Luo, Shengjun; Du, Zhongbo; Jiang, Li] Chongqing Med Univ, Dept Urol, Affiliated Hosp 1, Chongqing 400010, Peoples R China; [Chen, Yanlin] Chongqing Med Univ, Dept Pathol, Affiliated Hosp 1, Chongqing 400010, Peoples R China; [Xie, Xuemei] Chongqing Med Univ, Mol & Pathol Diag Ctr, Chongqing 400016, Peoples R China	Jiang, L (reprint author), Chongqing Med Univ, Dept Urol, Affiliated Hosp 1, Chongqing 400010, Peoples R China.	czxcqmu@126.com; 276552842@qq.com; 501522391@qq.com; 285222906@qq.com; 112751265@qq.com; jiangli0529@163.com			research grant from Chongqing Municipal Health and Family Planning Commission [2016MSXM182]	Our research was supported by the research grant from the Chongqing Municipal Health and Family Planning Commission (No. 2016MSXM182).	Aus G, 2005, EUR UROL, V48, P546, DOI 10.1016/j.eururo.2005.06.001; Bar-Peled L, 2013, SCIENCE, V340, P1100, DOI 10.1126/science.1232044; Dutchak PA, 2015, CELL REP, V12, P371, DOI 10.1016/j.celrep.2015.06.042; Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gao YZ, 2012, CANCER BIOMARK, V12, P31, DOI 10.3233/CBM-120290; Huang LL, 2016, HUM PATHOL, V47, P109, DOI 10.1016/j.humpath.2015.08.021; Huang N, 2016, MOL CARCINOGEN, V55, P1613, DOI 10.1002/mc.22413; James ND, 2017, NEW ENGL J MED, V377, P338, DOI 10.1056/NEJMoa1702900; Jayachandran G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011994; Kira S, 2014, AUTOPHAGY, V10, P1565, DOI 10.4161/auto.29397; Kregel S, 2016, ONCOTARGET, V7, P26259, DOI 10.18632/oncotarget.8456; Kurata A, 2008, CANCER SCI, V99, P1827, DOI 10.1111/j.1349-7006.2008.00874.x; Kwak SS, 2016, CELL SIGNAL, V28, P32, DOI 10.1016/j.cellsig.2015.11.008; Lerman MI, 2000, CANCER RES, V60, P6116; Li F, 2004, CANCER RES, V64, P6438, DOI 10.1158/0008-5472.CAN-03-3869; Liu AY, 2014, CANCER BIOL THER, V15, P489, DOI 10.4161/cbt.28016; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; Nagamatsu H, 2015, PROSTATE, V75, P1092, DOI 10.1002/pros.22994; Neklesa TK, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000515; Nguyen HG, 2014, ONCOGENE, V33, P4521, DOI 10.1038/onc.2014.25; Pang C, 2016, JPN J CLIN ONCOL, V46, P497, DOI 10.1093/jjco/hyw034; Peng Y, 2015, CANCER RES, V75, P378, DOI 10.1158/0008-5472.CAN-14-2315; Robinson D, 2015, CELL, V162, P454, DOI 10.1016/j.cell.2015.06.053; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Shao Q, 2012, CANCER LETT, V315, P170, DOI 10.1016/j.canlet.2011.09.035; Shtivelman E, 2014, ONCOTARGET, V5, P7217, DOI 10.18632/oncotarget.2406; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Tang YY, 2014, PATHOL ONCOL RES, V20, P829, DOI 10.1007/s12253-014-9761-2; Ueda K, 2006, CANCER RES, V66, P9682, DOI 10.1158/0008-5472.CAN-06-1483; Wei Y, 2014, CELL DEATH DIFFER, V21, P1460, DOI 10.1038/cdd.2014.63; Wilt TJ, 2017, NEW ENGL J MED, V377, P132, DOI 10.1056/NEJMoa1615869; Ye Dingwei, 2015, Zhonghua Wai Ke Za Zhi, V53, P249; Zeng Y, 2016, BIOL CHEM, V397, P1163, DOI 10.1515/hsz-2016-0143	34	1	2	1	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUN	2018	76						141	148		10.1016/j.humpath.2018.02.011			8	Pathology	Pathology	GK1ON	WOS:000435888200018	29458069				2019-10-28	
J	Saluja, K; Thomas, J; Zhang, SL; Sturgis, EM; Jain, KS; Prieto, VG; El-Naggar, AK; Bell, D				Saluja, Karan; Thomas, Jaiyeola; Zhang, Songlin; Sturgis, Erich M.; Jain, Kunal S.; Prieto, Victor G.; El-Naggar, Adel K.; Bell, Diana			Malignant perivascular epithelioid cell tumor of the oropharynx with strong TFE3 expression mimicking alveolar soft part sarcoma: a case report and review of the literature	HUMAN PATHOLOGY			English	Review						Perivascular epithelioid cell tumor; PEComa; Malignant; Oropharynx; TFE3; Head and neck	NASAL CAVITY; PECOMA; CARCINOMA; NEOPLASM; FEATURES; TISSUE	Perivascular epithelioid cell tumors (PEComas) in the head and neck region are rare, with 26 cases described in literature. These distinct mesenchymal tumors nomially express both myoid and melanocytic markers. We here report an interesting and challenging case of malignant PEComa that showed transcription factor E3 (TFE3) protein expression and rearrangement, paucity of muscle and melanocytic marker expression, and morphologically mimicked alveolar soft part sarcoma. Awareness of this morphologic pitfall and recognition of TFE3 gene rearranged PEComa, as a distinct subtype of PEComa, is essential to avoid misdiagnosis. (C) 2017 Elsevier Inc. All rights reserved.	[Saluja, Karan; Thomas, Jaiyeola; Zhang, Songlin] Univ Texas Hlth Sci Ctr Houston, Dept Pathol & Lab Med, 6341 Fannin St, Houston, TX 77030 USA; [Sturgis, Erich M.] MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; [Jain, Kunal S.] Univ Texas Hlth Sci Ctr Houston, Dept Otorhinolaryngol Head & Neck Surg, Houston, TX 77030 USA; [Prieto, Victor G.; El-Naggar, Adel K.; Bell, Diana] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Div Pathol & Lab Med, Houston, TX 77030 USA	Saluja, K (reprint author), Univ Texas Hlth Sci Ctr Houston, Dept Pathol & Lab Med, 6341 Fannin St, Houston, TX 77030 USA.	karan.saluja@uth.tmc.edu					Argani P, 2010, AM J SURG PATHOL, V34, P1395, DOI 10.1097/PAS.0b013e3181f17ac0; Argani P, 2009, AM J SURG PATHOL, V33, P609, DOI 10.1097/PAS.0b013e31818fbdff; Bandhlish A, 2011, HEAD NECK PATHOL, V5, P233, DOI 10.1007/s12105-011-0268-9; Banerjee SS, 2001, INT J SURG PATHOL, V9, P309, DOI 10.1177/106689690100900410; Bocciolini C, 2013, ANN OTO RHINOL LARYN, V122, P725, DOI 10.1177/000348941312201110; BONETTI F, 1992, AM J SURG PATHOL, V16, P307, DOI 10.1097/00000478-199203000-00013; Calder KB, 2008, J CUTAN PATHOL, V35, P499, DOI 10.1111/j.1600-0560.2007.00842.x; Dickson MA, 2013, INT J CANCER, V132, P1711, DOI 10.1002/ijc.27800; Fletcher CDM, 2002, MODERN PATHOL, V15, P324, DOI 10.1038/modpathol.3880526; Folpe AL, 2005, AM J SURG PATHOL, V29, P1558, DOI 10.1097/01.pas.0000173232.22117.37; Folpe AL, 2010, HUM PATHOL, V41, P1, DOI 10.1016/j.humpath.2009.05.011; Furusato E, 2010, HUM PATHOL, V41, P768, DOI 10.1016/j.humpath.2009.12.006; Gana S, 2012, ACTA OTORHINOLARYNGO, V32, P198; Ghazali N, 2010, ORAL SURG ORAL MED O, V110, pE26, DOI 10.1016/j.tripleo.2009.10.053; Goodman AL, 2017, MODERN PATHOL, V30, p325A; Guthoff R, 2008, ARCH OPHTHALMOL-CHIC, V126, P1009, DOI 10.1001/archopht.126.7.1009; Huai-yin S, 2009, PATHOL RES PRACT, V205, P595, DOI 10.1016/j.prp.2009.02.003; Iyengar P, 2005, PEDIATR DEVEL PATHOL, V8, P98, DOI 10.1007/s10024-004-5055-0; Koutlas IG, 2005, ARCH PATHOL LAB MED, V129, P690; Kuroda N, 2009, PATHOL INT, V59, P769, DOI 10.1111/j.1440-1827.2009.02443.x; Lehman NL, 2004, AM J SURG PATHOL, V28, P1230, DOI 10.1097/01.pas.0000128668.34934.81; Lubo I, 2016, CASE REP PATHOL, DOI 10.1155/2016/1936421; Panelos J, 2009, OTOLARYNG HEAD NECK, V141, P543, DOI 10.1016/j.otohns.2009.03.009; Rao Q, 2015, AM J SURG PATHOL, V39, P1181, DOI 10.1097/PAS.0000000000000502; Rao Q, 2013, AM J SURG PATHOL, V37, P804, DOI 10.1097/PAS.0b013e31827e17cb; Zamboni G, 1996, AM J SURG PATHOL, V20, P722, DOI 10.1097/00000478-199606000-00010	26	0	1	1	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUN	2018	76						149	155		10.1016/j.humpath.2017.11.016			7	Pathology	Pathology	GK1ON	WOS:000435888200019	29208563				2019-10-28	
J	Aida, J; Ishizaki, T; Arai, T; Takubo, K				Aida, Junko; Ishizaki, Tatsuro; Arai, Tomio; Takubo, Kaiyo		Japan Res Soc Early Esophageal Can	Prognostication of superficial Barrett's carcinoma: a Japanese multicenter study	HUMAN PATHOLOGY			English	Article						Superficial Barrett's carcinoma; Risk factor; Lymph node metastasis; Prognostication; Endoscopic resection; Surgical resection	SQUAMOUS-CELL CARCINOMA; LYMPH-NODE METASTASIS; ENDOSCOPIC RESECTION; EARLY ADENOCARCINOMA; ESOPHAGEAL CANCER; INVASION; RISK; NEOPLASIA; DIAGNOSIS; JUNCTION	Endoscopic resection (ER) has become the standard therapy for superficial Barrett's carcinoma (BC) in Japan and other countries. Patients undergoing ER sometimes require additional treatment because of recurrence of lymph node metastasis (LNM). We attempted to clarify the histopathologic risk factors for LNM, and the difference between these risk factors for Japanese patients and the conventional risk factors documented for Western patients. This multi-center study included 12 leading institutions belonging to the Japan Research Society for Early Esophageal Cancer and Chromoendoscopy, and was based on a questionnaire designed to gather data on the features of superficial BC cases, except for high-grade intraepithelial neoplasia, treated at those institutions. These features were assessed using the standardized pathologic approach employed in Japan, whereby surgically and endoscopically resected specimens are cut into parallel slices 4-5 mm and 2 mm thick, respectively. Seventy-four surgically resected (SR) and 201 ER specimens were analyzed separately. Significant risk factors for LNM were almost the same as conventional risk factors, such as tumor size (cut-off value; 17.5 mm) and depth, vessel infiltration, presence of poorly differentiated components, and the depth (cut-off value; 990 mu m) and width (cut-off value; 4300 mu m) of the submucosal component, in addition to growth pattern (a protruding or flat elevated pattern) and the presence of infiltrative growth. Histopathologic examination revealed that BC cases without invasion to the deep muscularis mucosae (DMM) had almost no risk of LNM. Detailed histopathologic evaluation of thin-slice preparations of ER specimens is considered highly important for prognostication. (C) 2018 Elsevier Inc. All rights reserved.	[Aida, Junko; Arai, Tomio; Takubo, Kaiyo] Tokyo Metropolitan Inst Gerontol, Res Team Geriatr Pathol, Tokyo 1730015, Japan; [Aida, Junko; Arai, Tomio; Takubo, Kaiyo] Res Soc Early Esophageal Canc & Chromoendoscopy, Tokyo 1138510, Japan; [Aida, Junko; Arai, Tomio; Takubo, Kaiyo] Tokyo Metropolitan Geriatr Hosp, Dept Pathol, Tokyo, Japan; [Ishizaki, Tatsuro] Tokyo Metropolitan Inst Gerontol, Human Care Res Team, Tokyo, Japan	Aida, J (reprint author), Tokyo Metropolitan Inst Gerontol, Res Team Geriatr Pathol, Itabashi Ku, 35-2 Sakae Cho, Tokyo 1730015, Japan.	aidajs@centm.center.tmig.or.jp; tatsuro@tmig.or.jp; arai@tmig.or.jp; takubo@tmig.or.jp	Aida, Junko/Q-5697-2019	Aida, Junko/0000-0003-4923-5540	Tokyo Metropolitan Institute of Gerontology	This study was supported by Tokyo Metropolitan Institute of Gerontology. The authors and our institution did not receive payment or services from a third party for any aspect of the submitted work. This manuscript represents no conflicts of interest, none of the content has been published previously, and the manuscript is not under consideration by any other journal.	Amano T, 2007, PATHOL INT, V57, P759, DOI 10.1111/j.1440-1827.2007.02171.x; [Anonymous], 2000, REP STUD COMM, P24; Ell C, 2007, GASTROINTEST ENDOSC, V65, P3, DOI 10.1016/j.gie.2006.04.033; Fitzgerald RC, 2014, GUT, V63, P7, DOI 10.1136/gutjnl-2013-305372; Herrero LA, 2010, ENDOSCOPY, V42, P1030, DOI 10.1055/s-0030-1255858; Hongo M, 2009, J GASTROEN HEPATOL, V24, P729, DOI 10.1111/j.1440-1746.2009.05824.x; Japan Esophageal Society, 2008, JAP CLASS ES CANC; Japanese Gastric Canc Assoc, 2011, GASTRIC CANCER, V14, P101, DOI 10.1007/s10120-011-0041-5; Japanese Society for Cancer of the Colon and Rectum, 2009, JAP CLASS COL CARC; Kaneshiro DK, 2011, AM J SURG PATHOL, V35, P697, DOI 10.1097/PAS.0b013e3182159c4b; Kashimura H, 1999, GASTRIC CANCER, V2, P33; Landau MS, 2014, MODERN PATHOL, V27, P1578, DOI 10.1038/modpathol.2014.66; Leers JM, 2011, ANN SURG, V253, P271, DOI 10.1097/SLA.0b013e3181fbad42; Li ZG, 2015, J DIGEST DIS, V16, P197, DOI 10.1111/1751-2980.12230; Liu W, 2009, AM J GASTROENTEROL, V104, P816, DOI 10.1038/ajg.2009.85; Manner H, 2008, AM J GASTROENTEROL, V103, P2589, DOI 10.1111/j.1572-0241.2008.02083.x; Martinek JFP, 2013, GASTROENT HEPATOL, V67, P479; Nentwich MF, 2014, J GASTROINTEST SURG, V18, P242, DOI 10.1007/s11605-013-2367-2; Oyama Tsuneo, 2002, Stomach and Intestine (Tokyo), V37, P71; Pech O, 2007, ENDOSCOPY, V39, P588, DOI 10.1055/s-2007-966363; Pechz O, 2008, GUT, V57, P1200, DOI 10.1136/gut.2007.142539; Perry C, 2015, DIS ESOPHAGUS, V28, P262, DOI 10.1111/dote.12190; Raja S, 2011, J THORAC CARDIOV SUR, V142, P1403, DOI 10.1016/j.jtcvs.2011.09.027; Satodate H, 2003, GASTROINTEST ENDOSC, V58, P288, DOI 10.1067/mge.2003.361; Sobin LH, 2009, TNM CLASSIFICATION M; Society JE, 2017, ESOPHAGUS, V14, P1, DOI DOI 10.1007/S10388-016-0551-7; Society JE, 2017, ESOPHAGUS, V14, P37; Takubo K, 2007, HISTOPATHOLOGY, V51, P733, DOI 10.1111/j.1365-2559.2007.02766.x; Takubo K., 2017, PATHOLOGY ESOPHAGUS; Tomita N, 2008, PATHOL INT, V58, P282, DOI 10.1111/j.1440-1827.2008.02224.x; Vieth M, 2005, ENDOSCOPY, V37, P1254, DOI 10.1055/s-2005-870457; Vieth M, 2004, DIGEST DIS, V22, P196, DOI 10.1159/000080319; Westerterp M, 2005, VIRCHOWS ARCH, V446, P497, DOI 10.1007/s00428-005-1243-1; Zemler B, 2010, VIRCHOWS ARCH, V456, P609, DOI 10.1007/s00428-010-0925-5	34	0	0	1	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUN	2018	76						156	166		10.1016/j.humpath.2018.03.001			11	Pathology	Pathology	GK1ON	WOS:000435888200020	29534888				2019-10-28	
J	Creytens, D; Van Bockstal, M; Ferdinande, L; Van Dorpe, J				Creytens, David; Van Bockstal, Mieke; Ferdinande, Liesbeth; Van Dorpe, Jo			Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in schwannomas: the chosen clone matters	HUMAN PATHOLOGY			English	Letter							TTF-1 EXPRESSION; BREAST-CARCINOMA; ADENOCARCINOMA		[Creytens, David] Ghent Univ Hosp, Dept Pathol, B-9000 Ghent, Belgium; Univ Ghent, CRIG, B-9000 Ghent, Belgium	Creytens, D (reprint author), Ghent Univ Hosp, Dept Pathol, B-9000 Ghent, Belgium.	david.creytens@uzgent.be	Van Bockstal, Mieke/H-8111-2019	Van Bockstal, Mieke/0000-0003-4498-928X			Bisceglia M, 2011, AM J SURG PATHOL, V35, P1087, DOI 10.1097/PAS.0b013e31821c2d47; Comperat E, 2005, MODERN PATHOL, V18, P1371, DOI 10.1038/modpathol.3800422; Conner JR, 2015, ADV ANAT PATHOL, V22, P149, DOI 10.1097/PAP.0000000000000069; Galloway M, 2007, VIRCHOWS ARCH, V451, P109, DOI 10.1007/s00428-007-0432-5; Kristensen MH, 2011, APPL IMMUNOHISTO M M, V19, P437, DOI 10.1097/PAI.0b013e31820e6baf; Ni YB, 2014, HISTOPATHOLOGY, V64, P504, DOI 10.1111/his.12287; Penman D, 2006, J CLIN PATHOL, V59, P663, DOI 10.1136/jcp.2005.030064; Wang DZ, 2018, HUM PATHOL, V71, P84, DOI 10.1016/j.humpath.2017.10.025; Zhang PJ, 2009, INT J GYNECOL PATHOL, V28, P10, DOI 10.1097/PGP.0b013e3181804bc6	9	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUN	2018	76						167	168		10.1016/j.humpath.2018.02.026			2	Pathology	Pathology	GK1ON	WOS:000435888200021	29634981				2019-10-28	
J	Wang, DZ; Yao, L; Tang, XB				Wang, Dai-Zhong; Yao, Li; Tang, Xian-Bin			Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in schwannomas: the chosen clone matters-reply	HUMAN PATHOLOGY			English	Letter									[Wang, Dai-Zhong; Yao, Li; Tang, Xian-Bin] Hubei Univ Med, Taihe Hosp, Dept Pathol, Shiyan 442000, Hubei, Peoples R China	Wang, DZ (reprint author), Hubei Univ Med, Taihe Hosp, Dept Pathol, Shiyan 442000, Hubei, Peoples R China.	taiheblk@126.com					Comperat E, 2005, MODERN PATHOL, V18, P1371, DOI 10.1038/modpathol.3800422; Kashima K, 2014, APPL IMMUNOHISTO M M, V22, P119, DOI 10.1097/PAI.0b013e31828acad2; Kristensen MH, 2011, APPL IMMUNOHISTO M M, V19, P437, DOI 10.1097/PAI.0b013e31820e6baf; Maki T, 2017, INT J ONCOL, V50, P129, DOI 10.3892/ijo.2016.3786; Ordonez NG, 2012, APPL IMMUNOHISTO M M, V20, P429, DOI 10.1097/PAI.0b013e31825439bc; Wang DZ, 2018, HUM PATHOL, V71, P84, DOI 10.1016/j.humpath.2017.10.025	6	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUN	2018	76						168	169		10.1016/j.humpath.2018.02.028			2	Pathology	Pathology	GK1ON	WOS:000435888200022	29634979				2019-10-28	
J	Westenend, PJ; Dinjens, WN				Westenend, Pieter J.; Dinjens, Winand N.			Somatic polymerase epsilon mutations as another route leading to loss of DNA MMR protein expression in endometrial carcinoma	HUMAN PATHOLOGY			English	Letter							LYNCH SYNDROME; CANCER; DEFICIENCY		[Westenend, Pieter J.] PAL Dordrecht, NL-3318 AL Dordrecht, Netherlands; [Dinjens, Winand N.] Erasmus MC, Josephine Nefkens Inst, Pathol Dept, NL-3000 DR Rotterdam, Netherlands	Westenend, PJ (reprint author), PAL Dordrecht, NL-3318 AL Dordrecht, Netherlands.	pwestenend@kpnmail.nl		Westenend, Pieter/0000-0002-5509-920X			Buchanan DD, 2018, GENET MED, V20, P890, DOI 10.1038/gim.2017.185; Castellucci E, 2017, ONCOLOGIST, V22, P497, DOI 10.1634/theoncologist.2017-0034; Church DN, 2013, HUM MOL GENET, V22, P2820, DOI 10.1093/hmg/ddt131; Dillon JL, 2017, HUM PATHOL, V70, P121, DOI 10.1016/j.humpath.2017.10.022; Leenen CHM, 2012, GYNECOL ONCOL, V125, P414, DOI 10.1016/j.ygyno.2012.01.049; Shia J, 2013, MODERN PATHOL, V26, P131, DOI 10.1038/modpathol.2012.138; van Lier MGF, 2012, J PATHOL, V226, P764, DOI 10.1002/path.3963	7	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUN	2018	76						169	169		10.1016/j.humpath.2018.01.028			1	Pathology	Pathology	GK1ON	WOS:000435888200023	29634980				2019-10-28	
J	Tafe, LJ				Tafe, Laura J.			Somatic polymerase epsilon mutations as another route leading to loss of DNA MMR protein expression in endometrial carcinoma-reply	HUMAN PATHOLOGY			English	Letter							MISMATCH REPAIR; CANCERS		[Tafe, Laura J.] Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA; [Tafe, Laura J.] Geisel Sch Med Dartmouth, Lebanon, NH 03756 USA	Tafe, LJ (reprint author), Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA.; Tafe, LJ (reprint author), Geisel Sch Med Dartmouth, Lebanon, NH 03756 USA.	laura.j.tafe@hitchcock.org					Espinosa I, 2017, AM J SURG PATHOL, V41, P1121, DOI 10.1097/PAS.0000000000000873; Haraldsdottir S, 2014, GASTROENTEROLOGY, V147, P1308, DOI 10.1053/j.gastro.2014.08.041; Howitt BE, 2015, JAMA ONCOL, V1, P1319, DOI 10.1001/jamaoncol.2015.2151; Jansen AML, 2016, EUR J HUM GENET, V24, P1089, DOI 10.1038/ejhg.2015.252; Talhouk A, 2017, CANCER-AM CANCER SOC, V123, P802, DOI 10.1002/cncr.30496	5	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUN	2018	76						170	170		10.1016/j.humpath.2018.01.029			1	Pathology	Pathology	GK1ON	WOS:000435888200024	29630911				2019-10-28	
J	Bryant, JL; Guda, PR; Asemu, G; Subedi, R; Ray, S; Khalid, OS; Shukla, V; Patel, D; Davis, H; Nimmagadda, VKC; Makar, TK				Bryant, Joseph L.; Guda, Poornachander R.; Asemu, Girma; Subedi, Rogin; Ray, Sugata; Khalid, Omar S.; Shukla, Vivek; Patel, Dhruvil; Davis, Harry; Nimmagadda, Vamshi K. C.; Makar, Tapas K.			Glomerular mitochondrial changes in HIV associated renal injury	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						HIVAN; Mitochondrial dynamics; Mitochondrial homeostasis; Mitophagy; Apoptosis	ENDOPLASMIC-RETICULUM STRESS; HUMAN-IMMUNODEFICIENCY-VIRUS; ACUTE KIDNEY INJURY; NF-KAPPA-B; OXIDATIVE STRESS; CYTOCHROME-C; SEGMENTAL GLOMERULOSCLEROSIS; PODOCYTE DEPLETION; CELL INJURY; APOPTOSIS	HIV-associated nephropathy (HIVAN) is an AIDs-related disease of the kidney. HIVAN is characterized by severe proteinuria, podocyte hyperplasia, collapse, glomerular, and tubulointerstitial damage. HIV-1 transgenic (Tg26) mouse is the most popular model to study the HIV manifestations that develop similar renal presentations as HIVAN. Viral proteins, including Tat, Nef, and Vpr play a significant role in renal cell damage. It has been shown that mitochondrial changes are involved in several kidney diseases, and therefore, mitochondrial dysfunction may be implicated in the pathology of HIVAN. In the present study, we investigated the changes of mitochondrial homeostasis, biogenesis, dynamics, mitophagy, and examined the role of reactive oxygen species (ROS) generation and apoptosis in the Tg26 mouse model. The Tg26 mice showed significant impairment of kidney function, which was accompanied by increased blood urea nitrogen (BUN), creatinine and protein urea level. In addition, histological, western blot and PCR analysis of the Tg26 mice kidneys showed a downregulation of NAMPT, SIRT1, and SIRT3 expressions levels. Furthermore, the kidney of the Tg26 mice showed a down regulation of PGC1 alpha, MFN2, and PARKIN, which are coupled with decrease of mitochondrial biogenesis, imbalance of mitochondrial dynamics, and downregulation of mitophagy, respectively. Furthermore, our results indicate that mitochondria] dysfunction were associated with ER stress, ROS generation and apoptosis. These results strongly suggest that the impaired mitochondrial morphology, homeostasis, and function associated with HIVAN. These findings indicated that a new insight on pathological mechanism associated with mitochondrial changes in HIVAN and a potential therapeutic target.	[Guda, Poornachander R.; Subedi, Rogin; Ray, Sugata; Khalid, Omar S.; Shukla, Vivek; Patel, Dhruvil; Nimmagadda, Vamshi K. C.; Makar, Tapas K.] Univ Maryland, Dept Neurol, 655 West Baltimore St, Baltimore, MD 21201 USA; [Bryant, Joseph L.; Asemu, Girma; Davis, Harry] Univ Maryland, Inst Human Virol, Baltimore, MD 21201 USA	Makar, TK (reprint author), Univ Maryland, Dept Neurol, 655 West Baltimore St, Baltimore, MD 21201 USA.	Tmakar@som.umaryland.edu			Departmental grant, Institute of Virology, Baltimore, MD	This work was supported by Departmental grant, Institute of Virology, Baltimore, MD.	Adih William K, 2011, J Int Assoc Physicians AIDS Care (Chic), V10, P5, DOI 10.1177/1545109710384505; Ansari A, 2017, AGING CELL, V16, P4, DOI 10.1111/acel.12538; Barisoni L, 2000, KIDNEY INT, V58, P137, DOI 10.1046/j.1523-1755.2000.00149.x; BAYER E, 1981, EUR J BIOCHEM, V120, P155, DOI 10.1111/j.1432-1033.1981.tb05683.x; Bayomy NA, 2017, ANAT REC, V300, P1137, DOI 10.1002/ar.23525; Brooks C, 2009, J CLIN INVEST, V119, P1275, DOI 10.1172/JCI37829; Burlaka I, 2016, KIDNEY INT, V90, P135, DOI 10.1016/j.kint.2016.03.026; BURNS EM, 1979, J GERONTOL, V34, P642, DOI 10.1093/geronj/34.5.642; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Cardozo AK, 2005, DIABETES, V54, P452, DOI 10.2337/diabetes.54.2.452; CARLOS TM, 1994, BLOOD, V84, P2068; Che RC, 2014, AM J PHYSIOL-RENAL, V306, pF367, DOI 10.1152/ajprenal.00571.2013; Chen XL, 2004, CURR PHARM DESIGN, V10, P879, DOI 10.2174/1381612043452901; Chen Y, 2011, CIRC RES, V109, P1327, DOI 10.1161/CIRCRESAHA.111.258723; Choi AI, 2007, J AM SOC NEPHROL, V18, P2968, DOI 10.1681/ASN.2007040402; Cigremis Y, 2015, CAN J PHYSIOL PHARM, V93, P727, DOI 10.1139/cjpp-2014-0420; Csordas G, 2006, J CELL BIOL, V174, P915, DOI 10.1083/jcb.200604016; Daehn I, 2014, J CLIN INVEST, V124, P1608, DOI 10.1172/JCI71195; DAGATI V, 1989, KIDNEY INT, V35, P1358, DOI 10.1038/ki.1989.135; de Cavanagh EMV, 2007, AM J NEPHROL, V27, P545, DOI 10.1159/000107757; Deniaud A, 2008, ONCOGENE, V27, P285, DOI 10.1038/sj.onc.1210638; DROGE W, 1993, PHARMACOLOGY, V46, P61, DOI 10.1159/000139029; Funk JA, 2012, AM J PHYSIOL-RENAL, V302, pF853, DOI 10.1152/ajprenal.00035.2011; Galehdar Z, 2010, J NEUROSCI, V30, P16938, DOI 10.1523/JNEUROSCI.1598-10.2010; Gucer S, 2005, PEDIATR DEVEL PATHOL, V8, P710, DOI 10.1007/s10024-005-0058-z; Gunst J, 2013, CRIT CARE MED, V41, P182, DOI 10.1097/CCM.0b013e3182676657; Handy DE, 2012, ANTIOXID REDOX SIGN, V16, P1323, DOI 10.1089/ars.2011.4123; Hanson J, 2010, J CLIN INVEST, V120, P2910, DOI 10.1172/JCI42273; Higgins GC, 2014, BRIT J PHARMACOL, V171, P1917, DOI 10.1111/bph.12503; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Husain M, 2009, J BIOL CHEM, V284, P16648, DOI 10.1074/jbc.M109.008482; Inagi R, 2010, CURR OPIN PHARMACOL, V10, P156, DOI 10.1016/j.coph.2009.11.006; Jin SM, 2012, J CELL SCI, V125, P795, DOI 10.1242/jcs.093849; Kim I, 2007, ARCH BIOCHEM BIOPHYS, V462, P245, DOI 10.1016/j.abb.2007.03.034; Kim YH, 2001, KIDNEY INT, V60, P957, DOI 10.1046/j.1523-1755.2001.060003957.x; Kong XX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011707; KOPP JB, 1992, P NATL ACAD SCI USA, V89, P1577, DOI 10.1073/pnas.89.5.1577; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kwon HS, 2008, CELL HOST MICROBE, V3, P158, DOI 10.1016/j.chom.2008.02.002; Lee S, 2006, NEPHROL DIAL TRANSPL, V21, P2085, DOI 10.1093/ndt/gfl209; Li W, 2016, BIOCHEM BIOPH RES CO, V478, P612, DOI 10.1016/j.bbrc.2016.07.115; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lombard DB, 2007, MOL CELL BIOL, V27, P8807, DOI 10.1128/MCB.01636-07; MANDAL AK, 1982, AM J KIDNEY DIS, V2, P363, DOI 10.1016/S0272-6386(82)80096-6; MANNY J, 1980, ISRAEL J MED SCI, V16, P153; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Mundel P, 1997, J CELL BIOL, V139, P193, DOI 10.1083/jcb.139.1.193; Negi G, 2011, J PINEAL RES, V50, P124, DOI 10.1111/j.1600-079X.2010.00821.x; Nemoto S, 2005, J BIOL CHEM, V280, P16456, DOI 10.1074/jbc.M501485200; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Nimmagadda VK, 2013, J IMMUNOL, V190, P4595, DOI 10.4049/jimmunol.1202584; Pagans S, 2005, PLOS BIOL, V3, P210, DOI 10.1371/journal.pbio.0030041; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rai P, 2015, CELL SIGNAL, V27, P460, DOI 10.1016/j.cellsig.2014.12.011; Rosenberg AZ, 2015, NAT REV NEPHROL, V11, P150, DOI 10.1038/nrneph.2015.9; Rubattu S, 2015, INT J MOL SCI, V16, P823, DOI 10.3390/ijms16010823; Salhan D, 2012, AM J PHYSIOL-RENAL, V303, pF503, DOI 10.1152/ajprenal.00170.2012; Santos NAG, 2007, ARCH TOXICOL, V81, P495, DOI 10.1007/s00204-006-0173-2; Shi YH, 2012, P NATL ACAD SCI USA, V109, P16510, DOI 10.1073/pnas.1119738109; Shokeir AA, 2015, PHYSIOL RES, V64, P313; Smith JA, 2015, J PHARMACOL EXP THER, V352, P346, DOI 10.1124/jpet.114.221085; SOHAL RS, 1991, MECH AGEING DEV, V57, P187, DOI 10.1016/0047-6374(91)90034-W; SONNERBORG A, 1988, SCAND J INFECT DIS, V20, P287, DOI 10.3109/00365548809032453; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; Stephensen CB, 2005, JAIDS-J ACQ IMM DEF, V38, P180, DOI 10.1097/00126334-200502010-00009; Surh YJ, 2008, GENES NUTR, V2, P313, DOI 10.1007/s12263-007-0063-0; Tran M, 2011, J CLIN INVEST, V121, P4003, DOI 10.1172/JCI58662; Wang G, 2014, CELL, V158, P1324, DOI 10.1016/j.cell.2014.07.040; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Xiao X, 2014, AM J PHYSIOL-RENAL, V306, pF1318, DOI 10.1152/ajprenal.00036.2014; Yin W, 2008, STROKE, V39, P3057, DOI 10.1161/STROKEAHA.108.520114; Yoon Y, 2003, MOL CELL BIOL, V23, P5409, DOI 10.1128/MCB.23.15.5409-5420.2003; Zhan M, 2015, J AM SOC NEPHROL, V26, P1304, DOI 10.1681/ASN.2014050457; Zhang HS, 2010, J CELL BIOCHEM, V110, P1464, DOI 10.1002/jcb.22704; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982; Zuo YQ, 2006, J AM SOC NEPHROL, V17, P2832, DOI 10.1681/ASN.2005080878	76	2	2	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	JUN	2018	104	3					175	189		10.1016/j.yexmp.2018.03.004			15	Pathology	Pathology	GJ0AV	WOS:000434907600003	29608912				2019-10-28	
J	Raposo, TP; Comes, MS; Idowu, A; Agit, B; Hassall, J; Fadhil, W; Nica, R; Ecker, R; Yao, T; Ilyas, M				Raposo, Teresa P.; Sueca Comes, Mireia; Idowu, Adeyemi; Agit, Bora; Hassall, James; Fadhil, Wakkas; Nica, Robert; Ecker, Rupert; Yao, Takashi; Ilyas, Mohammad			CD10 inhibits cell motility but expression is associated with advanced stage disease in colorectal cancer	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						CD10; NEP; CALLA; Colorectal cancer; Epithelial-mesenchymal transition; Metastasis	LIVER METASTASIS; NEUTRAL ENDOPEPTIDASE; TUMOR-DEVELOPMENT; CARCINOMA; DIFFERENTIATION; PROGRESSION; TRANSITION; PROGNOSIS; PATTERNS; ADHESION	Introduction: CD10 is a cell membrane-bound endopeptidase which is expressed in normal small bowel but not in normal colon. It is aberrantly expressed in a small proportion of colorectal cancers (CRC) and this has been associated with liver metastasis and poor prognosis. We sought to investigate the mechanism of CD10 activity and its association with clinicopathological features. Material and methods: CD10 was stably knocked down by lentiviral shRNA transduction in the CRC cell lines SW480 and SW620 which are derived from a primary tumour and its corresponding metastasis respectively. Expression of epithelial mesenchymal transition (EMT) markers was tested as well as the effect of knockdown on cell viability, migration and invasion assays. In addition, immunohistochemical expression of CD10 in primary colorectal tumours (N = 84) in a tissue microarray was digitally quantified and analysed for associations with clinicopathological variables. Results: Knockdown of CD10 did not alter cell viability in SW480, but migration and invasion levels increased (P < 0.001 for each) and this was associated with a cadherin switch. In SW620, CD10 knockdown caused a reduction in cell viability after 72 h (P = 0.0018) but it had no effect on cell migration and invasion. Expression of epithelial CD10 in primary tumours was associated with presence of lymph node invasion (P = 0.001) and advanced Duke's stage (P = 0.001). Conclusions: Our results suggest that the function of CD10 may change during tumour evolution. It may inhibit cell motility in early-stage disease whilst promoting cell viability in late-stage disease. It has a complex role and further studies are needed to elucidate the suitability of CD10 as a prognostic marker or therapeutic target.	[Raposo, Teresa P.; Idowu, Adeyemi; Agit, Bora; Hassall, James; Fadhil, Wakkas; Ilyas, Mohammad] Univ Nottingham, Div Canc & Stem Cells, Sch Med, Nottingham, England; [Raposo, Teresa P.; Hassall, James; Fadhil, Wakkas; Ilyas, Mohammad] Nottingham Mol Pathol Node, Nottingham, England; [Sueca Comes, Mireia] Univ Rovira & Virgili, Biochem & Mol Biol, Tarragona, Spain; [Nica, Robert; Ecker, Rupert] Tissue Gnost GmbH, Vienna, Austria; [Yao, Takashi] Juntendo Univ, Dept Human Pathol, Sch Med, Tokyo, Japan	Raposo, TP (reprint author), Univ Nottingham, Canc Biol Unit, Div Canc & Stem Cells, Queens Med Ctr, West Block,D Floor,Derby Rd, Nottingham NG7 2UH, England.	msztp2@nottingham.ac.uk		Raposo, Teresa/0000-0003-4033-8498	EC Marie Curie Actions, AIDPATH projectEuropean Union (EU) [612471]; Pathological Society of Great Britain and Ireland; Ministry of Education, Science, Sports and Culture, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [17K08704]	The authors acknowledge financial support from the EC Marie Curie Actions, AIDPATH project (Contract No.612471). Support was also provided by an International Collaborator Award from the Pathological Society of Great Britain and Ireland. Takashi Yao received financial support from Grant-in-Aid for General Scientific Research from the Ministry of Education, Science, Sports and Culture (#17K08704), Japan.	Albasri A, 2014, ANTICANCER RES, V34, P3969; Chu YS, 2006, J BIOL CHEM, V281, P2901, DOI 10.1074/jbc.M506185200; Fleischmann A, 2008, CLIN CANCER RES, V14, P7838, DOI 10.1158/1078-0432.CCR-08-1432; Fujimoto Y, 2005, DIS COLON RECTUM, V48, P1883, DOI 10.1007/s10350-005-0141-6; Fujita S, 2010, INT J COLORECTAL DIS, V25, P681, DOI 10.1007/s00384-010-0913-x; Grigore AD, 2016, J CLIN MED, V5, P51, DOI 10.3390/jcm5050051; Huang RYJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.442; Ibrahim WS, 2011, INDIAN J PATHOL MICR, V54, P741, DOI 10.4103/0377-4929.91511; Iwase A, 2014, REPROD SCI, V21, P82, DOI 10.1177/1933719113488449; Iwase T, 2005, PATHOL RES PRACT, V201, P83, DOI 10.1016/j.prp.2004.09.016; Jana SH, 2014, INDIAN J PATHOL MICR, V57, P530, DOI 10.4103/0377-4929.142639; Jang TJ, 2013, KOREAN J PATHOL, V47, P340, DOI 10.4132/KoreanJPathol.2013.47.4.340; Jiang W, 2015, SCI REP-UK, V5, DOI 10.1038/srep13875; Katano T, 2017, CLIN COLORECTAL CANC, V16, P141, DOI 10.1016/j.clcc.2016.09.009; Kuniyasu H, 2010, GUT, V59, P348, DOI 10.1136/gut.2009.178376; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lloyd JM, 2011, MODERN PATHOL, V24, P1627, DOI 10.1038/modpathol.2011.122; Lu TX, 2016, SCI REP-UK, V6, DOI 10.1038/srep20465; Maeda M, 2005, J CELL SCI, V118, P873, DOI 10.1242/jcs.01634; Maguer-Satta V, 2011, STEM CELLS, V29, P389, DOI 10.1002/stem.592; Mizerska-Kowalska M, 2016, TUMOR BIOL, V37, P13355, DOI 10.1007/s13277-016-5248-y; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Ogawa H, 2002, HUM PATHOL, V33, P806, DOI 10.1053/hupa.2002.125773; Ohji Y, 2007, ONCOL REP, V17, P525; Pei Y, 2006, NAT METHODS, V3, P670, DOI 10.1038/NMETH911; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Puri V, 2016, J CANCER RES THER, V12, P667, DOI 10.4103/0973-1482.177215; Sasaki T, 2014, J SURG RES, V192, P390, DOI 10.1016/j.jss.2014.05.071; Sato Y, 1996, J GASTROENTEROL, V31, P12, DOI 10.1007/BF01211181; Tariq Muhammad Usman, 2015, Asian Pac J Cancer Prev, V16, P3147; Terauchi M, 2005, ONCOLOGY-BASEL, V69, P52, DOI 10.1159/000087476; Wang Z, 2017, CANCER RES, V77, P2413, DOI 10.1158/0008-5472.CAN-16-3229; Yao T, 2002, PATHOLOGY, V34, P556, DOI 10.1080/0031302021000035965; Zheng R, 2006, ONCOGENE, V25, P5942, DOI 10.1038/sj.onc.1209586	34	1	1	1	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	JUN	2018	104	3					190	198		10.1016/j.yexmp.2018.04.002			9	Pathology	Pathology	GJ0AV	WOS:000434907600004	29653092	Green Accepted			2019-10-28	
J	Petrovic, D; Seke, M; Borovic, ML; Jovic, D; Borisev, I; Srdjenovic, B; Rakocevic, Z; Pavlovic, V; Djordjevic, A				Petrovic, Danijela; Seke, Mariana; Borovic, Milica Labudovic; Jovic, Danica; Borisev, Ivana; Srdjenovic, Branislava; Rakocevic, Zlatko; Pavlovic, Vladimir; Djordjevic, Aleksandar			Hepatoprotective effect of fullerenol/doxorubicin nanocomposite in acute treatment of healthy rats	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Fullerenol/doxorubicin nanocomposite; Drug delivery; AFM; qRT-PCR; Ultrastructural analysis	FULLERENOL C-60(OH)(24); OXIDATIVE STRESS; POLYHYDROXYLATED FULLERENE; DOXORUBICIN; LIVER; HEPATOTOXICITY; NANOPARTICLES; GLUTATHIONE; INHIBITION; TOXICITY	In our recent studies we have designed fullerenol/doxorubicin nanocomposite (FNP/DOX) as the new drug nanocarrier. This research has demonstrated that this novel nanocomposite has had better implications on the liver tissue in vivo (Wistar rats treated intraperitoneally), than treatment based only on DOX. FNP/DOX has been characterised by DLS, TEM and AFM measurements which have shown that DOX loaded onto FNP did not influence fullerenol nanoparticle's size. FNP/DOX affected oxidative status in blood causing a significant decrease of catalase and SOD activity in comparison to DOX, implicating the reduction in oxidative stress. qRT-PCR results on the mRNA level of antioxidative enzymes (catalase and MnSOD) revealed that the effect of oxidative stress is significantly reduced by the treatment with FNP/DOX (p<.05). The ultrastructural analysis of the liver tissue has revealed that FNP/DOX nanocomposite generated considerably less damage in the liver tissue, than DOX applied at the same dose. Hence, our results have indicated that FNP, within FNP/DOX nanocomposite, exhibits protective effects to the liver tissue of the healthy rats.	[Petrovic, Danijela] Univ Novi Sad, Dept Nat Sci & Management Educ, Fac Educ Sombor, Novi Sad, Serbia; [Seke, Mariana; Rakocevic, Zlatko] Univ Belgrade, Inst Nucl Sci Vinca, Belgrade, Serbia; [Borovic, Milica Labudovic] Univ Belgrade, Inst Histol & Embryol Aleksandar Dj Kostic, Fac Med, Belgrade, Serbia; [Jovic, Danica; Borisev, Ivana; Djordjevic, Aleksandar] Univ Novi Sad, Dept Chem Biochem & Environm Protect, Fac Sci, Novi Sad, Serbia; [Srdjenovic, Branislava] Univ Novi Sad, Dept Pharm, Fac Med, Novi Sad, Serbia; [Pavlovic, Vladimir] Serbian Acad Arts & Sci, Inst Tech Sci, Belgrade, Serbia	Petrovic, D (reprint author), Univ Novi Sad, Dept Nat Sci & Management Educ, Fac Educ Sombor, Novi Sad, Serbia.; Seke, M (reprint author), Univ Belgrade, Inst Nucl Sci Vinca, Belgrade, Serbia.	danijela.petrovic@pef.uns.ac.rs; marianaseke@yahoo.com	Pavlovic, Vladimir/E-5202-2016	Pavlovic, Vladimir/0000-0002-1138-0331; Srdjenovic Conic, Branislava/0000-0003-3344-9229; , Aleksandar/0000-0003-4120-7318; Seke, Mariana/0000-0001-8024-2832; Jovic, Danica/0000-0003-4240-3732	Ministry of Education, Science and Technological Development, Republic of Serbia [III 45005]	This work has received a financial support from the Ministry of Education, Science and Technological Development, Republic of Serbia, Grant No. III 45005. We thank Professor Vladimir Srdic (Faculty of Technology, University of Novi Sad, Serbia) for DLS measurements, Professor Stefan Grimm (Applied Physical Chemistry, Nanomaterials for Optoelectronics Group, University of Heidelberg, Germany) for Raman spectroscopy measurement and Mr. Vladimir Majski (Faculti of Education in Sombor, University of Novi Sad, Serbia), for technical support.	Alshabanah OA, 2010, OXID MED CELL LONGEV, V3, P428, DOI 10.4161/oxim.3.6.14416; BALLET F, 1987, CANCER CHEMOTH PHARM, V19, P240; Beutler E., 1975, RED CELL METABOLISM; Blanco JG, 2008, CANCER-AM CANCER SOC, V112, P2789, DOI 10.1002/cncr.23534; BLUM J, 1985, ARCH BIOCHEM BIOPHYS, V240, P500, DOI 10.1016/0003-9861(85)90056-6; BOUCEK RJ, 1987, PEDIATR RES, V21, pA187, DOI 10.1203/00006450-198704010-00127; Brisebois PP, 2012, EUR BIOPHYS J BIOPHY, V41, P535, DOI 10.1007/s00249-012-0809-5; DAEMEN T, 1995, INT J CANCER, V61, P716, DOI 10.1002/ijc.2910610520; Djordjevic A, 2011, DIG J NANOMATER BIOS, V6, P99; Djordjevic A, 1998, FULLERENE SCI TECHN, V6, P689, DOI 10.1080/10641229809350229; Dobrovolskaia MA, 2008, MOL PHARMACEUT, V5, P487, DOI 10.1021/mp800032f; El-Sayyad HI, 2009, INT J BIOL SCI, V5, P466; Forrest RA, 2012, BIOCHEM PHARMACOL, V83, P1602, DOI 10.1016/j.bcp.2012.02.026; Goto S, 1999, FREE RADICAL RES, V31, P549, DOI 10.1080/10715769900301121; Govindan PN, 2012, J PHYS CHEM B, V116, P10676, DOI 10.1021/jp3046577; Grebowski J, 2013, BIOMED RES INT, DOI 10.1155/2013/751913; Icevic ID, 2011, HEM IND, V65, P329, DOI 10.2298/HEMIND101231006I; Injac R, 2008, BIOMATERIALS, V29, P3451, DOI 10.1016/j.biomaterials.2008.04.048; Injac R, 2009, PHARMACOL REP, V61, P335, DOI 10.1016/S1734-1140(09)70041-6; Injac R, 2009, BIOMATERIALS, V30, P1184, DOI 10.1016/j.biomaterials.2008.10.060; Jacevic V, 2017, EXP MOL PATHOL, V102, P360, DOI 10.1016/j.yexmp.2017.03.005; Ji ZQ, 2006, J NANOPART RES, V8, P53, DOI 10.1007/s11051-005-9001-5; Johnson-Lyles DN, 2010, TOXICOL APPL PHARM, V248, P249, DOI 10.1016/j.taap.2010.08.008; Jovic DS, 2016, RSC ADV, V6, P38563, DOI 10.1039/c6ra03879d; Kahl R, 2004, DRUG METAB REV, V36, P747, DOI 10.1081/DMR-200033488; Kalender Y, 2005, TOXICOLOGY, V209, P39, DOI 10.1016/j.tox.2004.12.003; Kassner N, 2008, DRUG METAB DISPOS, V36, P2113, DOI 10.1124/dmd.108.022251; Le Couteur DG, 2001, HEPATOLOGY, V33, P537, DOI 10.1053/jhep.2001.22754; LEBEDEV AV, 1982, J MOL CELL CARDIOL, V14, P99, DOI 10.1016/0022-2828(82)90136-5; Li S, 2015, INT J MOL SCI, V16, P26087, DOI 10.3390/ijms161125942; Li Y, 2016, RSC ADV, V6, P31122, DOI 10.1039/c5ra25750f; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ma H, 2015, AN BRAS DERMATOL, V90, P209, DOI 10.1590/abd1806-4841.20153708; Mirkov SM, 2004, NITRIC OXIDE-BIOL CH, V11, P201, DOI 10.1016/j.niox.2004.08.003; Mokni M, 2015, PAK J PHARM SCI, V28, P1971; Monti M, 2013, PHARMACOL RES, V76, P171, DOI 10.1016/j.phrs.2013.08.003; Pedrycz A., 2003, ANN U M CURIESKLOD D, V59, P319; Pieniazek A, 2013, ADV MED SCI-POLAND, V58, P104, DOI 10.2478/v10039-012-0063-1; Radomski A, 2005, BRIT J PHARMACOL, V146, P882, DOI 10.1038/sj.bjp.0706386; Ratnikova TA, 2011, ACS NANO, V5, P6306, DOI 10.1021/nn201331n; Rochette L, 2015, TRENDS PHARMACOL SCI, V36, P326, DOI 10.1016/j.tips.2015.03.005; Rokitskaya TI, 2016, BBA-BIOMEMBRANES, V1858, P1165, DOI 10.1016/j.bbamem.2016.02.009; Seke M, 2016, NANOTECHNOLOGY, V27, DOI 10.1088/0957-4484/27/48/485101; SHEN H, 1993, ARCH BIOCHEM BIOPHYS, V300, P137, DOI 10.1006/abbi.1993.1019; Singal AK, 2011, LIVER INT, V31, P1432, DOI 10.1111/j.1478-3231.2011.02604.x; Slavic M, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-013-1650-1; SOKOLOV VS, 1981, BIOFIZIKA+, V26, P147; Srdjenovic B, 2010, TOXICOL MECH METHOD, V20, P298, DOI 10.3109/15376516.2010.485622; Ueng TH, 1997, TOXICOL LETT, V93, P29, DOI 10.1016/S0378-4274(97)00071-4; Wang N, 2011, FOOD CHEM TOXICOL, V49, P2975, DOI 10.1016/j.fct.2011.06.080; Wen J, 2002, J BIOL CHEM, V277, P38954, DOI 10.1074/jbc.M203842200; Wided K., 2014, PAK J PHARM SCI; Yang LY, 2016, J HAZARD MATER, V301, P119, DOI 10.1016/j.jhazmat.2015.08.046; Zhang YN, 2016, J CONTROL RELEASE, V240, P332, DOI 10.1016/j.jconrel.2016.01.020	54	2	2	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	JUN	2018	104	3					199	211		10.1016/j.yexmp.2018.04.005			13	Pathology	Pathology	GJ0AV	WOS:000434907600005	29727604				2019-10-28	
J	Su, HY; Yang, Y				Su, Hongyan; Yang, Yi			The roles of CyPA and CD147 in cardiac remodelling	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Review						Cyclophilin A (CyPA); CD147 (EMMPRIN); Cardiac remodelling	CORONARY-ARTERY-DISEASE; ACUTE MYOCARDIAL-INFARCTION; METALLOPROTEINASE INDUCER EMMPRIN; MYOCYTE MITOTIC DIVISION; SMOOTH-MUSCLE-CELLS; ANGIOTENSIN-II; CYCLOPHILIN-A; PRESSURE-OVERLOAD; HEART-FAILURE; EXTRACELLULAR CYCLOPHILIN	Cyclophilin A (CyPA), an abundantly expressed protein belonging to the immunophilin family, is involved in a variety of physiological and pathological activities together with its extracellular receptor, CD147. Many studies have provided compelling evidence supporting critical roles of CyPA in immune and infectious diseases and malignant tumours. Recent studies have revealed that both CyPA and CD147 strongly promote cardiovascular inflammation, myocardial ischaemia-reperfusion injury, and myocardial remodelling processes. Here, we review the potential roles of CyPA and CD147 in cardiac remodelling and their implications for the development of novel pharmacological therapies for heart failure.	[Su, Hongyan] Shandong Prov Chest Hosp, Dept Cardiol, 46 Lishan Rd, Jinan, Shandong, Peoples R China; [Yang, Yi] Shandong Univ, Key Lab Cardiovasc Remodelling & Funct Res, Chinese Minist Educ, Qilu Hosp, Jinan, Shandong, Peoples R China; [Yang, Yi] Shandong Univ, Chinese Minist Hlth, State & Shandong Prov Joint Key Lab Translat Card, Qilu Hosp, Jinan, Shandong, Peoples R China	Su, HY (reprint author), Shandong Prov Chest Hosp, Dept Cardiol, 46 Lishan Rd, Jinan, Shandong, Peoples R China.	bupeili@sdu.edu.cn			Medical and Health Science and Technology Development Project of Shandong Province in China [2017WS295]	This work was supported by the Medical and Health Science and Technology Development Project of Shandong Province in China (No. 2017WS295).	Agrawal SM, 2011, BBA-MOL BASIS DIS, V1812, P213, DOI 10.1016/j.bbadis.2010.07.018; Akki A, 2009, J MOL CELL CARDIOL, V47, P15, DOI 10.1016/j.yjmcc.2009.04.004; ANVERSA P, 1991, CIRC RES, V69, P1159, DOI 10.1161/01.RES.69.4.1159; ANVERSA P, 1991, LAB INVEST, V64, P441; CAPASSO JM, 1993, J CELL PHYSIOL, V155, P635, DOI 10.1002/jcp.1041550320; Chevalier F, 2012, PROTEOMICS, V12, P1756, DOI 10.1002/pmic.201100319; Cohn JN, 2000, J AM COLL CARDIOL, V35, P569, DOI 10.1016/S0735-1097(99)00630-0; Coppinger JA, 2004, BLOOD, V103, P2096, DOI 10.1182/blood-2003-08-2804; Crosnier C, 2011, NATURE, V480, P534, DOI 10.1038/nature10606; Cuadrado I, 2016, THERANOSTICS, V6, P545, DOI 10.7150/thno.13352; Doti N, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.518; Doti N, 2017, NEURAL REGEN RES, V12, P1428, DOI 10.4103/1673-5374.215248; Farina B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01337-8; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; GALAT A, 1995, PROG BIOPHYS MOL BIO, V63, P67, DOI 10.1016/0079-6107(94)00009-X; Gong KZ, 2011, J HYPERTENS, V29, P1810, DOI 10.1097/HJH.0b013e32834a4d03; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; Hattori F, 2012, J MOL CELL CARDIOL, V53, P1, DOI 10.1016/j.yjmcc.2012.04.006; Haug C, 2004, ARTERIOSCL THROM VAS, V24, P1823, DOI 10.1161/01.ATV.0000142806.59283.11; Heinzmann D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124606; Huang CH, 2015, INT J BIOL SCI, V11, P38, DOI 10.7150/ijbs.10271; Kajstura J, 1998, P NATL ACAD SCI USA, V95, P8801, DOI 10.1073/pnas.95.15.8801; Kim H, 2005, CLIN IMMUNOL, V116, P217, DOI 10.1016/j.clim.2005.05.004; Kim SH, 2004, AM J PATHOL, V164, P1567, DOI 10.1016/S0002-9440(10)63715-7; Leri A, 2002, J CARD FAIL, V8, pS518, DOI 10.1054/jcaf.2002.129269; Lizarbe TR, 2009, AM J PATHOL, V175, P1421, DOI 10.2353/ajpath.2009.080845; Lyon RC, 2015, CIRC RES, V116, P1462, DOI 10.1161/CIRCRESAHA.116.304937; Mehta PK, 2007, AM J PHYSIOL-CELL PH, V292, pC82, DOI 10.1152/ajpcell.00287.2006; Muramatsu T, 2003, HISTOL HISTOPATHOL, V18, P981, DOI 10.14670/HH-18.981; Nakamura K, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-191; Nigro P, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.410; Nigro P, 2011, J EXP MED, V208, P53, DOI 10.1084/jem.20101174; Ohtsuki T, 2017, ARTERIOSCL THROM VAS, V37, P685, DOI 10.1161/ATVBAHA.116.308986; OLIVETTI G, 1994, J AM COLL CARDIOL, V24, P140, DOI 10.1016/0735-1097(94)90554-1; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Ramachandran S, 2012, PROTEOMICS, V12, P2808, DOI 10.1002/pmic.201100586; Sano M, 2007, NATURE, V446, P444, DOI 10.1038/nature05602; Satoh K, 2014, CIRC RES, V115, P738, DOI 10.1161/CIRCRESAHA.115.304563; Satoh K, 2013, CIRC J, V77, P447, DOI 10.1253/circj.CJ-12-0805; Satoh K, 2011, ARTERIOSCL THROM VAS, V31, P1116, DOI 10.1161/ATVBAHA.110.214601; Satoh K, 2010, CIRC J, V74, P2249, DOI 10.1253/circj.CJ-10-0904; Schmidt R, 2006, CIRCULATION, V113, P834, DOI 10.1161/CIRCULATIONAHA.105.568162; Schmidt R, 2008, CIRC RES, V102, P302, DOI 10.1161/CIRCRESAHA.107.157990; Seizer P, 2016, PLATELETS, V27, P155, DOI 10.3109/09537104.2015.1051466; Seizer P, 2015, ARTERIOSCL THROM VAS, V35, P655, DOI 10.1161/ATVBAHA.114.305112; Seizer P, 2013, INT J CARDIOL, V163, P299, DOI 10.1016/j.ijcard.2011.06.049; Seizer P, 2012, J MOL CELL CARDIOL, V53, P6, DOI 10.1016/j.yjmcc.2012.03.004; Seizer P, 2011, ARTERIOSCL THROM VAS, V31, P1377, DOI 10.1161/ATVBAHA.111.225771; Seizer P, 2010, ATHEROSCLEROSIS, V209, P51, DOI 10.1016/j.atherosclerosis.2009.08.029; Seko Y, 2004, BIOCHEM BIOPH RES CO, V317, P162, DOI 10.1016/j.bbrc.2004.03.021; Setoguchi M, 1999, LAB INVEST, V79, P1545; SHERRY B, 1992, P NATL ACAD SCI USA, V89, P3511, DOI 10.1073/pnas.89.8.3511; Shimizu I, 2010, J CLIN INVEST, V120, P1506, DOI 10.1172/JCI40096; Spinale FG, 2000, CIRCULATION, V102, P1944, DOI 10.1161/01.CIR.102.16.1944; Spisni E, 2009, NEUROTOXICOLOGY, V30, P605, DOI 10.1016/j.neuro.2009.03.005; Sturhan H, 2015, THROMB RES, V135, P1160, DOI 10.1016/j.thromres.2015.03.022; Su HY, 2016, MOL CELL BIOCHEM, V422, P85, DOI 10.1007/s11010-016-2808-9; Suzuki J, 2006, CIRC RES, V98, P811, DOI 10.1161/01.RES.0000216405.85080.a6; Suzuki K, 2016, ARTERIOSCL THROM VAS, V36, P636, DOI 10.1161/ATVBAHA.115.306686; TAN LB, 1991, CIRC RES, V69, P1185, DOI 10.1161/01.RES.69.5.1185; Tang W, 2004, MOL BIOL CELL, V15, P4043, DOI 10.1091/mbc.E04-05-0402; Urban ML, 2015, NEW ENGL J MED, V373, P95, DOI 10.1056/NEJMc1504848; Vigliano CA, 2011, J AM COLL CARDIOL, V57, P1523, DOI 10.1016/j.jacc.2010.09.080; VILLARREAL FJ, 1993, CIRCULATION, V88, P2849, DOI 10.1161/01.CIR.88.6.2849; Wang CH, 2011, J CELL MOL MED, V15, P850, DOI 10.1111/j.1582-4934.2010.01084.x; WEBER KT, 1990, CIRCULATION, V82, P1387, DOI 10.1161/01.CIR.82.4.1387; Wei YA, 2010, ATHEROSCLEROSIS, V213, P415, DOI 10.1016/j.atherosclerosis.2010.09.033; Weidle Ulrich H., 2010, Cancer Genomics & Proteomics, V7, P157; Yan JC, 2012, CLIN CHIM ACTA, V413, P691, DOI 10.1016/j.cca.2011.12.009	69	0	0	4	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	JUN	2018	104	3					222	226		10.1016/j.yexmp.2018.05.001			5	Pathology	Pathology	GJ0AV	WOS:000434907600007	29772453				2019-10-28	
J	Hermes-Uliana, C; Frez, FCV; Sehaber, CC; Ramalho, FV; de Souza, FP; Cecchini, R; Guarnier, FA; Zanoni, JN				Hermes-Uliana, Catchia; Vieira Frez, Flavia Cristina; Sehaber, Camila Caviquioli; Ramalho, Francielle Veiga; de Souza Neto, Fernando Pinheiro; Cecchini, Rubens; Guarnier, Flavia Alessandra; Zanoni, Jacqueline Nelisis			Supplementation with L-glutathione improves oxidative status and reduces protein nitration in myenteric neurons in the jejunum in diabetic Rattus norvegicus	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Antioxidants; Diabetes mellitus type 1; Oxidative stress; Nitrotyrosine; Enteric nervous system; Nitric oxide	ANTIOXIDANT ENZYME-ACTIVITIES; NITRIC-OXIDE; LIPID-PEROXIDATION; SUPEROXIDE-DISMUTASE; ORAL GLUTATHIONE; L-ARGININE; STRESS; RATS; PEROXYNITRITE; PATHOGENESIS	Diabetes mellitus is a syndrome with multiple etiologies, characterized by chronic hyperglycemia that increases the production of reactive oxygen species and decreases antioxidant defenses. The present study evaluated oxidative stress parameters and protein nitration in myenteric neurons in the jejunum in diabetic rats supplemented with L-glutathione. Rats (90 days of age) were distributed into four groups (n = 6/group): normoglycemic (N), normoglycemic supplemented with L-glutathione (NGT), diabetic (D), and diabetic supplemented with L-glutathione (DGT). At 210 days of age, the animals were sacrificed, and the jejunum was collected, washed, and subjected to various procedures: tert-butyl hydroperoxide chemiluminescence (CL), determination of total antioxidant capacity (TAC), determination of catalase activity, quantification of nitric oxide (NO), and double-labeling of HuC/D-immunoreactive myenteric neurons and nitrotyrosine (3-NT). Diabetes increased oxidative stress in the jejunum in the D group, reflected by increases in lipid peroxidation, TAC, catalase activity, and NO. The D group exhibited an increase in the percentage of myenteric neurons that were double-labeled with 3-NT. Supplementation with L-glutathione did not cause differences in the average CL curves between the D and DGT groups, but reductions of TAC and catalase activity were observed. Supplementation with L-glutathione promoted a reduction of neurons that contained 3-NT in the DGT group. Diabetes mellitus promoted oxidative stress in the jejunum, and supplementation with L-glutathione improved oxidative status by preventing protein nitration in myenteric neurons in diabetic animals that received supplementation.	[Hermes-Uliana, Catchia] Univ Fed Mato Grosso do Sul, BR-79613000 Tres Lagoas, MS, Brazil; [Vieira Frez, Flavia Cristina; Sehaber, Camila Caviquioli; Ramalho, Francielle Veiga; Zanoni, Jacqueline Nelisis] Univ Estadual Maringa, Dept Ciencias Morfol, BR-08020900 Maringa, PR, Brazil; [de Souza Neto, Fernando Pinheiro; Cecchini, Rubens; Guarnier, Flavia Alessandra] Univ Estadual Londrina, Dept Ciencias Patol, BR-86051980 Londrina, PR, Brazil	Hermes-Uliana, C (reprint author), Univ Fed Mato Grosso Sul UNID II, Ave Ranulpho Marques Leal,3484 Cx,Postal 210, BR-79613000 Tres Lagoras, MS, Brazil.	catchiahermes@gmail.com		Guarnier, Flavia/0000-0001-9302-878X	Fundacao Araucaria - PRFundacao Araucaria [521/2010]	This work was supported by Fundacao Araucaria - PR (521/2010).	AEBI H, 1984, METHOD ENZYMOL, V105, P121; Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS62, DOI [10.2337/dc11-S062, 10.2337/dc10-S062, 10.2337/dc10-s062]; AW TY, 1991, CHEM-BIOL INTERACT, V80, P89, DOI 10.1016/0009-2797(91)90033-4; Barbosa DS, 2003, NUTRITION, V19, P837, DOI 10.1016/S0899-9007(03)00162-X; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Bergmeyer H. U., 1974, METHODS ENZYMATIC AN, V12; Bhor VM, 2004, INT J BIOCHEM CELL B, V36, P89, DOI 10.1016/S1357-2725(03)00142-0; Caballero F, 2000, CHEM-BIOL INTERACT, V126, P215, DOI 10.1016/S0009-2797(00)00168-X; Ceriello A, 2001, DIABETOLOGIA, V44, P834; Chandrasekharan B, 2011, NEUROGASTROENT MOTIL, V23, DOI 10.1111/j.1365-2982.2010.01611.x; Chirino Yolanda I., 2004, BMC Pharmacology, V4, P20, DOI 10.1186/1471-2210-4-20; Conget I, 2002, REV ESP CARDIOL, V55, P528, DOI 10.1016/S0300-8932(02)76646-3; Damasceno DC, 2004, PHYTOMEDICINE, V11, P196, DOI 10.1078/0944-7113-00348; De Angelis KLD, 2000, BRAZ J MED BIOL RES, V33, P1363, DOI 10.1590/S0100-879X2000001100016; Dias Alexandre Simões, 2004, Arq. Gastroenterol., V41, P108, DOI 10.1590/S0004-28032004000200008; Ferrer-Sueta G, 2009, ACS CHEM BIOL, V4, P161, DOI 10.1021/cb800279q; FLECHA BG, 1991, FREE RADICAL BIO MED, V10, P93; Forman HJ, 2009, MOL ASPECTS MED, V30, P1, DOI 10.1016/j.mam.2008.08.006; Furness JB, 2012, NAT REV GASTRO HEPAT, V9, P286, DOI 10.1038/nrgastro.2012.32; Guo W, 2003, AM J PHYSIOL-HEART C, V285, pH1396, DOI 10.1152/ajpheart.00096.2003; Halliwell B, 2007, FREE RADICAL BIO MED, V4, P187; Halliwell B., 1999, FREE RADICAL BIO MED, P1; Hermes-Uliana C, 2014, DIGEST DIS SCI, V59, P937, DOI 10.1007/s10620-013-2993-2; Jarvinen MK, 1999, ANAT EMBRYOL, V199, P99, DOI 10.1007/s004290050213; Johansen JS, 2005, CARDIOVASC DIABETOL, V4, DOI 10.1186/1475-2840-4-5; JONES DP, 1995, FUND APPL TOXICOL, V26, P1, DOI 10.1006/faat.1995.1069; Kakkar R, 1996, CLIN SCI, V91, P441, DOI 10.1042/cs0910441; KAKKAR R, 1995, MOL CELL BIOCHEM, V151, P113, DOI 10.1007/BF01322333; Kalkan IH, 2013, PAK J MED SCI, V29, P938, DOI 10.12669/pjms.294.2859; Kedziora-Kornatowska K, 2002, CLIN CHIM ACTA, V322, P105, DOI 10.1016/S0009-8981(02)00167-5; KIKUCHI K, 1993, ANAL CHEM, V65, P1794, DOI 10.1021/ac00061a025; Kochar NI, 2009, PHARMACOL REP, V61, P665, DOI 10.1016/S1734-1140(09)70118-5; Kosenko EA, 1999, VOP MED KHIM, V45, P304; Liu F., 2014, BIOL TRACE ELEM RES, V11, P1; LOVEN D, 1986, DIABETES, V35, P503, DOI 10.2337/diabetes.35.5.503; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Melo P. S., 2007, METROCAMP PESQUISA, V1, P37; Melo SS, 2000, ACTA DIABETOL, V37, P33, DOI 10.1007/s005920070033; MILLER GL, 1959, ANAL CHEM, V31, P964, DOI 10.1021/ac60149a611; Mohan IK, 1998, FREE RADICAL BIO MED, V25, P757, DOI 10.1016/S0891-5849(98)00129-4; Obrosova IG, 2000, EUR J PHARMACOL, V398, P139, DOI 10.1016/S0014-2999(00)00286-7; Oliveira FJD, 2000, J PARASITOL, V86, P1067, DOI 10.1645/0022-3395(2000)086[1067:OSOLIH]2.0.CO;2; Palace VP, 1999, FREE RADICAL BIO MED, V26, P1501, DOI 10.1016/S0891-5849(99)00013-1; Pandey A, 2011, J PHARM BIOALLIED SC, V3, P504, DOI 10.4103/0975-7406.90103; Reis JS, 2008, ARQ BRAS ENDOCRINOL, V52, P1096, DOI 10.1590/S0004-27302008000700005; Repetto M, 1996, CLIN CHIM ACTA, V255, P107, DOI 10.1016/0009-8981(96)06394-2; Rivera LR, 2011, CELL TISSUE RES, V344, P111, DOI 10.1007/s00441-010-1126-x; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Shishehbor MH, 2003, JAMA-J AM MED ASSOC, V289, P1675, DOI 10.1001/jama.289.13.1675; Sindhu RK, 2004, CLIN EXP HYPERTENS, V26, P43, DOI 10.1081/CEH-120027330; Stavniichuk R, 2014, DIABETES-METAB RES, V30, P669, DOI 10.1002/dmrr.2549; Takaku M, 2006, FEMINA, V34, P763; Terra VA, 2012, FREE RADICAL RES, V46, P872, DOI 10.3109/10715762.2012.686036; Ueno Y, 2002, J NUTR, V132, P897; Van Nassauw L, 2001, CELL TISSUE RES, V303, P329, DOI 10.1007/s004410000338; VANDAM PS, 1995, DIABETES METAB REV, V11, P181, DOI 10.1002/dmr.5610110303; VIARO F., 2000, ARQUIVOS BRASILEIROS, V74, P365; Vincent AM, 2004, ENDOCR REV, V25, P612, DOI 10.1210/er.2003-0019; Whiting DR, 2011, DIABETES RES CLIN PR, V94, P311, DOI 10.1016/j.diabres.2011.10.029; Yadav P, 1996, CURR SCI INDIA, V71, P404; Ye G, 2004, DIABETES, V53, P1336, DOI 10.2337/diabetes.53.5.1336; Zanoni JN, 2003, AUTON NEUROSCI-BASIC, V104, P32, DOI 10.1016/S1566-0702(02)00266-7	63	0	0	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	JUN	2018	104	3					227	234		10.1016/j.yexmp.2018.05.002			8	Pathology	Pathology	GJ0AV	WOS:000434907600008	29758186				2019-10-28	
J	Bryant, JL; Guda, PR; Ray, S; Asemu, G; Sagi, AR; Mubariz, F; Arvas, MI; Khalid, OS; Shukla, V; Nimmagadda, VKC; Makar, TK				Bryant, Joseph L.; Guda, Poornachander R.; Ray, Sugata; Asemu, Girma; Sagi, Avinash R.; Mubariz, Fahad; Arvas, Muhammed I.; Khalid, Omar S.; Shukla, Vivek; Nimmagadda, Vamshi K. C.; Makar, Tapas K.			Renal aquaporin-4 associated pathology in TG-26 mice	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Aquaporin-4; Kidney pathology; HIVAN; TG-26 mice	ENDOPLASMIC-RETICULUM STRESS; HIV-ASSOCIATED NEPHROPATHY; UNFOLDED PROTEIN RESPONSE; PROXIMAL TUBULE CELLS; DIABETIC-NEPHROPATHY; OXIDATIVE STRESS; ER STRESS; REPERFUSION INJURY; GENE-EXPRESSION; KIDNEY	Human immunodeficiency virus-associated nephropathy (HIVAN) is a leading cause of end-stage renal disease in HIV patients, which is characterized by glomerulosclerosis and renal tubular dysfunction. Aquaporin-4 (AQP-4) is a membrane bound water channel protein that plays a distinct role in water reabsorption from renal tubular fluid. It has been proven that failure of AQP-4 insertion into the renal tubular membrane leads to renal dysfunction. However, the role of AQP-4 in HIVAN is unclear. We hypothesize that impaired water reabsorption leads to renal injury in HIVAN, where AQP-4 plays a crucial role. Renal function is assessed by urinary protein and serum blood urea nitrogen (BUN). Kidneys from HIV Transgenic (TG26) mice (HIVAN animal model) were compared to wild type mice by immunostaining, immunoblotting and quantitative RT-PCR. TG26 mice had increased proteinuria and BUN. We found decreased AQP-4 levels in the renal medulla, increased endothelin-1, endothelin receptor A and reduced Sirtuinl (SIRT-1) levels in TG26 mice. Also, oxidative and endoplasmic reticulum stress was enhanced in kidneys of TG26 mice. We provide the first evidence that AQP-4 is inhibited due to induction of HIV associated stress in the kidneys of TG26 mice which limits water reabsorption in the kidney which may be one of the cause associated with HIVAN, impairing kidney physiology. AQP-4 dysregulation in TG26 mice suggests that similar changes may occur in HIVAN patients. This work may identify new therapeutic targets to be evaluated in HIVAN.	[Guda, Poornachander R.; Ray, Sugata; Sagi, Avinash R.; Mubariz, Fahad; Arvas, Muhammed I.; Khalid, Omar S.; Shukla, Vivek; Nimmagadda, Vamshi K. C.; Makar, Tapas K.] Univ Maryland, Dept Neurol, Baltimore, MD 21201 USA; [Nimmagadda, Vamshi K. C.; Makar, Tapas K.] VA Med Ctr, Baltimore, MD USA; [Bryant, Joseph L.; Asemu, Girma] Univ Maryland, Inst Human Virol, Baltimore, MD USA	Makar, TK (reprint author), Univ Maryland, Dept Neurol, Baltimore, MD 21201 USA.	tmakar@som.umaiyland.edu					Adih William K, 2011, J Int Assoc Physicians AIDS Care (Chic), V10, P5, DOI 10.1177/1545109710384505; AGRE P, 1987, J BIOL CHEM, V262, P17497; AGRE P, 1993, AM J PHYSIOL, V265, pF463; Almaghrabi OA, 2015, SAUDI J BIOL SCI, V22, P227, DOI 10.1016/j.sjbs.2014.12.008; Anelli T, 2008, EMBO J, V27, P315, DOI 10.1038/sj.emboj.7601974; Arany I, 2008, J BIOL CHEM, V283, P6110, DOI 10.1074/jbc.M708799200; Bahrehmand F, 2015, LUPUS, V24, P597, DOI 10.1177/0961203314559085; Barton M, 2011, CONTRIB NEPHROL, V172, P255, DOI 10.1159/000328859; Bedford JJ, 2003, J AM SOC NEPHROL, V14, P2581, DOI 10.1097/01.ASN.0000089566.28106.F6; Bienert GP, 2007, J BIOL CHEM, V282, P1183, DOI 10.1074/jbc.M603761200; Biswas C, 2014, J BIOL CHEM, V289, P26882, DOI 10.1074/jbc.M114.567685; Bruggeman LA, 2000, J AM SOC NEPHROL, V11, P2079; Cai Q, 2010, AM J PHYSIOL-RENAL, V299, pF712, DOI 10.1152/ajprenal.00690.2009; Canaud G, 2014, J AM SOC NEPHROL, V25, P407, DOI 10.1681/ASN.2013050564; Chen P, 2011, J AM SOC NEPHROL, V22, P496, DOI 10.1681/ASN.2010040379; Cheng YS, 2013, EUR J PHARMACOL, V721, P249, DOI 10.1016/j.ejphar.2013.09.028; Choi AI, 2007, J AM SOC NEPHROL, V18, P2968, DOI 10.1681/ASN.2007040402; Cong XD, 2012, J PHARM PHARMACOL, V64, P1138, DOI 10.1111/j.2042-7158.2012.01507.x; Cong XD, 2012, INFLAMMATION, V35, P1031, DOI 10.1007/s10753-011-9407-4; DAGATI V, 1989, KIDNEY INT, V35, P1358, DOI 10.1038/ki.1989.135; Dassanayake R. S., 2014, I INORG BIOCH C, V142C, P54; De Giusti VC, 2008, LIFE SCI, V83, P264, DOI 10.1016/j.lfs.2008.06.008; Deng W, 2010, CARDIOVASC RES, V88, P93, DOI 10.1093/cvr/cvq125; DICKIE P, 1991, VIROLOGY, V185, P109, DOI 10.1016/0042-6822(91)90759-5; Freeman BA, 2008, J BIOL CHEM, V283, P15515, DOI 10.1074/jbc.R800004200; Gao R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098909; Ge YQ, 2005, AM J PHYSIOL-RENAL, V288, pF912, DOI 10.1152/ajprenal.00432.2004; Groenendyk J, 2010, CIRC RES, V107, P1185, DOI 10.1161/CIRCRESAHA.110.227033; Hasegawa K, 2013, NAT MED, V19, P1496, DOI 10.1038/nm.3363; Hoffmann EK, 2009, PHYSIOL REV, V89, P193, DOI 10.1152/physrev.00037.2007; Huber TB, 2006, J CLIN INVEST, V116, P1337, DOI 10.1172/JCI27400; Ikeda M, 2002, J BIOL CHEM, V277, P39873, DOI 10.1074/jbc.M207008200; Jung YJ, 2012, BIOCHEM BIOPH RES CO, V419, P206, DOI 10.1016/j.bbrc.2012.01.148; Karet FE, 2011, NEPHRON PHYSIOL, V118, pP28, DOI 10.1159/000320885; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Kitada M, 2013, CLIN SCI, V124, P153, DOI 10.1042/CS20120190; KITAMURA K, 1989, BIOCHEM BIOPH RES CO, V161, P348, DOI 10.1016/0006-291X(89)91603-3; Knepper MA, 1996, KIDNEY INT, V49, P1712, DOI 10.1038/ki.1996.253; Kohan DE, 2013, AM J PHYSIOL-REG I, V305, pR659, DOI 10.1152/ajpregu.00345.2013; Kong LL, 2015, MOL MED, V21, DOI 10.2119/molmed.2014.00211; KOPP JB, 1992, P NATL ACAD SCI USA, V89, P1577, DOI 10.1073/pnas.89.5.1577; KORBMACHER C, 1993, AM J PHYSIOL, V265, pC349; Leonard MO, 2006, FASEB J, V20, P2624, DOI 10.1096/fj.05-5097fje; Liu GG, 2008, BIOCHEM BIOPH RES CO, V370, P651, DOI 10.1016/j.bbrc.2008.04.031; Liu HS, 2005, REPROD BIOL ENDOCRIN, V3, DOI 10.1186/1477-7827-3-18; Lorz C, 2004, J AM SOC NEPHROL, V15, P380, DOI 10.1097/01.ASN.0000111289.91206.B0; Mann JFE, 2010, J AM SOC NEPHROL, V21, P527, DOI 10.1681/ASN.2009060593; Marciniak SJ, 2006, PHYSIOL REV, V86, P1133, DOI 10.1152/physrev.00015.2006; Marras D, 2002, NAT MED, V8, P522, DOI 10.1038/nm0502-522; Mortuza R, 2015, J CELL MOL MED, V19, P1857, DOI 10.1111/jcmm.12557; Nielsen S, 2002, PHYSIOL REV, V82, P205, DOI 10.1152/physrev.00024.2001; Noda Y, 2010, NAT REV NEPHROL, V6, P168, DOI 10.1038/nrneph.2009.231; Paneni F, 2014, ATHEROSCLEROSIS, V236, P426, DOI 10.1016/j.atherosclerosis.2014.07.027; Parreira KS, 2009, PFLUG ARCH EUR J PHY, V458, P745, DOI 10.1007/s00424-009-0667-x; Pinzone MR, 2013, CURR DRUG TARGETS, V14, P648, DOI 10.2174/1389450111314060005; Rai P, 2015, CELL SIGNAL, V27, P460, DOI 10.1016/j.cellsig.2014.12.011; Ray PE, 1998, KIDNEY INT, V53, P1217, DOI 10.1046/j.1523-1755.1998.00900.x; Ross MJ, 2006, J AM SOC NEPHROL, V17, P996, DOI 10.1681/ASN.2005070692; Sakamaki Y, 2010, NEPHRON EXP NEPHROL, V115, pE22, DOI 10.1159/000312883; Salhan D, 2012, AM J PHYSIOL-RENAL, V303, pF503, DOI 10.1152/ajprenal.00170.2012; Salhan D, 2012, AM J PHYSIOL-RENAL, V302, pF129, DOI 10.1152/ajprenal.00024.2011; Saparov SM, 2007, J BIOL CHEM, V282, P5296, DOI 10.1074/jbc.M609343200; Schaldecker T, 2013, J CLIN INVEST, V123, P5298, DOI 10.1172/JCI71165; Schrier RW, 2006, J AM SOC NEPHROL, V17, P1820, DOI 10.1681/ASN.2006030240; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Selik RM, 2002, J ACQ IMMUN DEF SYND, V29, P378; Shah ZA, 2007, NEUROSCIENCE, V147, P53, DOI 10.1016/j.neuroscience.2007.02.066; Shichiri M, 2000, ARTERIOSCL THROM VAS, V20, P989, DOI 10.1161/01.ATV.20.4.989; Singh P, 2012, VIROLOGY, V434, P68, DOI 10.1016/j.virol.2012.09.009; Susztak K, 2006, DIABETES, V55, P225, DOI 10.2337/diabetes.55.01.06.db05-0894; Susztak K, 2005, PLOS MED, V2, P152, DOI 10.1371/journal.pmed.0020045; Taghvaei M, 2015, J FOOD SCI TECH MYS, V52, P1272, DOI 10.1007/s13197-013-1080-1; Tanji N, 2006, HISTOL HISTOPATHOL, V21, P393, DOI 10.14670/HH-21.393; Terris J, 1995, AM J PHYSIOL-RENAL, V269, pF775; Verkman Alan S, 2009, Handb Exp Pharmacol, P359, DOI 10.1007/978-3-540-79885-9_18; Wu J, 2014, TOXICOLOGY, V318, P22, DOI 10.1016/j.tox.2014.01.008; Yamamoto H, 2007, MOL ENDOCRINOL, V21, P1745, DOI 10.1210/me.2007-0079; Yamamoto T, 1998, KIDNEY INT, V54, P1041, DOI 10.1046/j.1523-1755.1998.00123.x; Yuan H, 2015, ANTIOXID REDOX SIGN, V22, P1308, DOI 10.1089/ars.2014.6004; Zelenina M, 2005, PEDIATR RES, V57, p47R, DOI 10.1203/01.PDR.0000159572.79074.0B; Zeng QH, 2008, J PHARMACOL EXP THER, V326, P732, DOI 10.1124/jpet.108.140301; Zhang GL, 2012, ACTA PHARMACOL SIN, V33, P470, DOI 10.1038/aps.2011.175; Zhao ZQ, 2006, CARDIOVASC RES, V70, P200, DOI 10.1016/j.cardiores.2006.01.024	85	4	4	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	JUN	2018	104	3					239	249		10.1016/j.yexmp.2018.03.005			11	Pathology	Pathology	GJ0AV	WOS:000434907600010	29608911	Other Gold			2019-10-28	
J	Tan, SS; Yeo, XY; Liang, ZC; Sethi, SK; Tay, SSW				Tan, Shaun S.; Yeo, Xin Yi; Liang, Zhen Chang; Sethi, Sunil K.; Tay, Samuel S. W.			Stromal vascular fraction promotes fibroblast migration and cellular viability in a hyperglycemic microenvironment through up-regulation of wound healing cytokines	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Fibroblasts; Cell migration; Wound healing; Tissue engineering; Stem cells	STEM-CELLS; ASSISTED LIPOTRANSFER; GROWTH-FACTOR; ADIPOSE; MOUSE	Diabetic wounds have impaired healing and a propensity for further morbidity, which may result in amputations. Stromal vascular fraction (SW) is an autologous source of heterogeneous cell population obtained from adipose tissue, which is rich in stem cells and presents little immunogenicity to the host. In this study, we hypothesized that murine fibroblasts subjected to hyperglycemic conditions co-treated with SW exhibit greater functional activity through the colorimetric MTT assay and a cell-monolayer in-vitro scratch assay. We sought to establish the underlying mechanism of action via the utility of an ELISA chemiluminescence array on the supernatant medium of the cells. Our results demonstrate that the mean percentage gap closure at 24 h in the hyperglycemia + SW group was significantly greater at 41.1% 1.6% compared to the hyperglycemia alone group 16.6% +/- 1.5% (post-hoc Bonferroni test p < 0.001, n = 3) although there was no difference between the SW and normoglycemia group. Further, this SW group exhibited a significantly greater 2.4 fold increase in fibroblastic cell viability as compared to the hyperglycemia alone group (p = 0.001, n = 3). The supernatant medium of the cells upon testing with ELISA indicated that early phase wound healing cytokines including platelet-derived growth factor (p = 0.012, n = 3), interleukin-1 (p = 0.003, n = 3), basic fibroblast growth factor (p = 0.003, n = 3) and interleukin-10 (p = 0.009, n = 3) were expressed in significantly greater relative luminescent units in SW as compared to hyperglycemia alone groups (Student t-test). Taken together and for the first time, our study shows that SW is a promising therapeutic agent for up-regulating fibroblastic activity in a hyperglycemic microenvironment, and this result can be explained in part by the stimulation of wound-healing cytokines.	[Tan, Shaun S.; Sethi, Sunil K.] Natl Univ Singapore Hosp, Dept Lab Med, 1E Kent Ridge Rd, Singapore 119228, Singapore; [Tan, Shaun S.; Yeo, Xin Yi; Liang, Zhen Chang; Tay, Samuel S. W.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore, Singapore	Tan, SS (reprint author), Natl Univ Singapore Hosp, Dept Lab Med, 1E Kent Ridge Rd, Singapore 119228, Singapore.	shaun.tan@mohh.com.sg			Exxonmobil NUS	We would like to express our gratitude to the Exxonmobil NUS Research Fellowship for funding this study.	Akita S, 2013, ADV WOUND CARE, V2, P44, DOI 10.1089/wound.2011.0324; Aziz Z, 2011, DIABET FOOT ANKLE, V2, DOI 10.3402/dfa.v2i0.7463; Balaji S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124302; Barrientos S, 2008, WOUND REPAIR REGEN, V16, P585, DOI 10.1111/j.1524-475X.2008.00410.x; Chung MT, 2013, STEM CELL TRANSL MED, V2, P808, DOI 10.5966/sctm.2012-0183; Doi K, 2013, J TISSUE ENG REGEN M, V7, P864, DOI 10.1002/term.1478; Forouhi Nita Gandhi, 2014, Medicine (Abingdon), V42, P698; Freedberg IM, 2001, J INVEST DERMATOL, V116, P633, DOI 10.1046/j.1523-1747.2001.01327.x; Galiano RD, 2004, AM J PATHOL, V164, P1935, DOI 10.1016/S0002-9440(10)63754-6; Hantash BM, 2008, FRONT BIOSCI-LANDMRK, V13, P51, DOI 10.2741/2559; Kim EK, 2011, PLAST RECONSTR SURG, V128, P387, DOI 10.1097/PRS.0b013e31821e6de2; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Minteer DM, 2015, CLIN PLAST SURG, V42, P169, DOI 10.1016/j.cps.2014.12.007; SAUDER DN, 1990, LYMPHOKINE RES, V9, P465; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Stillaert F, 2007, TISSUE ENG, V13, P2291, DOI 10.1089/ten.2006.0382; Wetzler C, 2000, J INVEST DERMATOL, V115, P245, DOI 10.1046/j.1523-1747.2000.00029.x; Yoshimura K, 2008, DERMATOL SURG, V34, P1178, DOI 10.1111/j.1524-4725.2008.34256.x; Yoshimura K, 2008, AESTHET PLAST SURG, V32, P48, DOI 10.1007/s00266-007-9019-4	19	5	5	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	JUN	2018	104	3					250	255		10.1016/j.yexmp.2018.03.007			6	Pathology	Pathology	GJ0AV	WOS:000434907600011	29621477				2019-10-28	
J	Panarelli, NC; Yantiss, RK				Panarelli, Nicole C.; Yantiss, Rhonda K.			Inflammatory and infectious manifestations of immunodeficiency in the gastrointestinal tract	MODERN PATHOLOGY			English	Review							VERSUS-HOST-DISEASE; COMMON VARIABLE IMMUNODEFICIENCY; CORD COLITIS SYNDROME; CHRONIC GRANULOMATOUS-DISEASE; STEM-CELL TRANSPLANTATION; MYCOBACTERIUM-AVIUM COMPLEX; X-LINKED AGAMMAGLOBULINEMIA; PARAFFIN-EMBEDDED TISSUE; HERPES-SIMPLEX-VIRUS; INTESTINAL TUBERCULOSIS	Immune compromise may result from genetic abnormalities, HIV/AIDS, or consequences of therapy for neoplastic and autoimmune diseases. Many immunocompromised patients develop severe gastrointestinal symptoms, particularly diarrhea, accompanied by non-specific or mild endoscopic abnormalities; mucosal biopsy with pathologic interpretation has a major role in the diagnosis and management of these patients. Immunocompromised individuals are at risk for all the diseases that affect those with a healthy immune system, but they are also prone to other illnesses that rarely affect immunocompetent patients. This review discusses the gastrointestinal manifestations of primary and acquired immunodeficiency, chemotherapy-related injury, and infections that show a predilection for immunocompromised patients. Key histologic features and relevant differential diagnoses are emphasized.	[Panarelli, Nicole C.] Albert Einstein Coll Med, Bronx, NY 10467 USA; [Yantiss, Rhonda K.] Weill Cornell Med, New York, NY 10065 USA	Yantiss, RK (reprint author), Weill Cornell Med, New York, NY 10065 USA.	npanarel@montefiore.org					Abraham J, 2014, TRANSPLANTATION, V97, P965, DOI 10.1097/01.TP.0000438209.50089.60; Agarwal S, 2009, J ALLERGY CLIN IMMUN, V124, P658, DOI 10.1016/j.jaci.2009.06.018; Aghamohammadi A, 2009, J CLIN IMMUNOL, V29, P130, DOI 10.1007/s10875-008-9229-9; Alimchandani M, 2013, AM J SURG PATHOL, V37, P1365, DOI 10.1097/PAS.0b013e318297427d; Almadi MA, 2009, AM J GASTROENTEROL, V104, P1003, DOI 10.1038/ajg.2008.162; Amarapurkar D N, 2004, J Assoc Physicians India, V52, P863; Assi MA, 2007, MEDICINE, V86, P162, DOI 10.1097/md.0b013e3180679130; Barton SH, 2008, GASTROENTEROL CLIN N, V37, P411, DOI 10.1016/j.gtc.2008.02.001; BATMAN PA, 1989, J CLIN PATHOL, V42, P275, DOI 10.1136/jcp.42.3.275; Batman PA, 2014, J CLIN PATHOL, V67, P14, DOI 10.1136/jclinpath-2012-201289; Bhatt AS, 2013, NEW ENGL J MED, V369, P517, DOI 10.1056/NEJMoa1211115; Biagi F, 2012, AM J CLIN PATHOL, V138, P185, DOI 10.1309/AJCPEIILH2C0WFYE; Bonilla FA, 2016, J ALLER CL IMM-PRACT, V4, P38, DOI 10.1016/j.jaip.2015.07.025; Cama VA, 2015, CLIN LAB MED, V35, P423, DOI 10.1016/j.cll.2015.02.010; Cannon MJ, 2010, REV MED VIROL, V20, P202, DOI 10.1002/rmv.655; Cello JP, 2009, GASTROENTEROLOGY, V136, P1952, DOI 10.1053/j.gastro.2008.12.073; Chandrakasan S, 2017, PEDIATR CLIN N AM, V64, P139, DOI 10.1016/j.pcl.2016.08.010; Chen YM, 2014, J MICROBIOL IMMUNOL, V47, P345, DOI 10.1016/j.jmii.2013.01.011; CHETTY R, 1994, J CLIN PATHOL, V47, P968, DOI 10.1136/jcp.47.11.968; Colombo AL, 2011, MED MYCOL, V49, P785, DOI 10.3109/13693786.2011.577821; Conley ME, 1999, CLIN IMMUNOL, V93, P190, DOI 10.1006/clim.1999.4799; Cruz-Correa M, 2002, ENDOSCOPY, V34, P808, DOI 10.1055/s-2002-34257; Daniels JA, 2007, AM J SURG PATHOL, V31, P1800, DOI 10.1097/PAS.0b013e3180cab60c; DENG ZL, 1985, AM J CLIN PATHOL, V84, P323, DOI 10.1093/ajcp/84.3.323; DENG ZL, 1988, REV INFECT DIS, V10, P640; Dolmans RAV, 2017, CLIN MICROBIOL REV, V30, P529, DOI 10.1128/CMR.00033-16; Donoghue HD, 2009, CURR OPIN INFECT DIS, V22, P490, DOI 10.1097/QCO.0b013e3283306712; EPSTEIN RJ, 1980, GASTROENTEROLOGY, V78, P764; Field AS, 2015, CLIN LAB MED, V35, P445, DOI 10.1016/j.cll.2015.02.011; FOX JP, 1969, AM J EPIDEMIOL, V89, P25, DOI 10.1093/oxfordjournals.aje.a120913; GENTA RM, 1992, CLIN MICROBIOL REV, V5, P345; Girardin Marc, 2010, Clin Gastroenterol Hepatol, V8, pe28, DOI 10.1016/j.cgh.2009.09.036; GOODELL SE, 1983, NEW ENGL J MED, V308, P868, DOI 10.1056/NEJM198304143081503; Gorkiewicz G, 2013, NEW ENGL J MED, V369, P1866, DOI 10.1056/NEJMc1311318; Gupta S, 2008, INDIAN J MED MICROBI, V26, P172; Harris JR, 2011, CLIN INFECT DIS, V53, P1188, DOI 10.1093/cid/cir723; Heimall J, 2017, BIOL BLOOD MARROW TR, V23, P379, DOI 10.1016/j.bbmt.2016.12.619; Hermsen JL, 2008, J SURG RES, V148, P67, DOI 10.1016/j.jss.2008.02.027; Herrera AF, 2011, NEW ENGL J MED, V365, P815, DOI 10.1056/NEJMoa1104959; Holtan SG, 2014, BLOOD, V124, P363, DOI 10.1182/blood-2014-01-514786; HORSBURGH CR, 1991, NEW ENGL J MED, V324, P1332, DOI 10.1056/NEJM199105093241906; Horwath MC, 2015, FUTURE MICROBIOL, V10, P967, DOI [10.2217/FMB.15.25, 10.2217/fmb.15.25]; Juric-Sekhar G, 2017, HUM PATHOL, V60, P11, DOI 10.1016/j.humpath.2016.09.009; Kamar N, 2004, TRANSPL INT, V17, P463, DOI 10.1007/s00147-004-0745-0; Kazan E, 2011, CLIN MICROBIOL INFEC, V17, P588, DOI 10.1111/j.1469-0691.2010.03310.x; Keates J, 2001, GASTROINTEST ENDOSC, V53, P355, DOI 10.1067/mge.2001.112040; Kirsch R, 2006, J CLIN PATHOL, V59, P840, DOI 10.1136/jcp.2005.032383; Kisacik B, 2016, J RHEUMATOL, V43, P524, DOI 10.3899/jrheum.150177; Kishimoto K, 2008, WORLD J GASTROENTERO, V14, P1768, DOI 10.3748/wjg.14.1768; KLATT EC, 1987, HUM PATHOL, V18, P709, DOI 10.1016/S0046-8177(87)80242-3; Ko CI, 1999, GASTROINTEST ENDOSC, V50, P111, DOI 10.1016/S0016-5107(99)70359-7; Kreft A, 2015, VIRCHOWS ARCH, V467, P255, DOI 10.1007/s00428-015-1803-y; Krones E, 2012, GASTROENTEROL CLIN N, V41, P677, DOI 10.1016/j.gtc.2012.06.009; Lai KK, 2016, AM J SURG PATHOL, V40, P1070, DOI 10.1097/PAS.0000000000000660; Lai KK, 2014, SEMIN DIAGN PATHOL, V31, P176, DOI 10.1053/j.semdp.2014.02.004; LAMPERT IA, 1985, HISTOPATHOLOGY, V9, P875, DOI 10.1111/j.1365-2559.1985.tb02872.x; Lamps LW, 2014, ADV ANAT PATHOL, V21, P217, DOI 10.1097/PAP.0000000000000016; Lamps LW, 2001, AM J SURG PATHOL, V25, P508, DOI 10.1097/00000478-200104000-00011; LEDERMAN HM, 1985, MEDICINE, V64, P145, DOI 10.1097/00005792-198505000-00001; Lee SJ, 2008, HEMATOL-AM SOC HEMAT, V1, P134, DOI DOI 10.1182/ASHEDUCATI0N-2008.1.134; Leen AM, 2005, BRIT J HAEMATOL, V128, P135, DOI 10.1111/j.1365-2141.2004.05218.x; LERNER KG, 1974, TRANSPLANT P, V6, P367; Levenhagen MA, 2014, ACTA TROP, V135, P33, DOI 10.1016/j.actatropica.2014.03.015; Levine JE, 2013, BLOOD, V122, P1505, DOI 10.1182/blood-2013-02-485813; Machado NO, 2010, N AM J MED SCI, V2, P293; Malamut G, 2010, AM J GASTROENTEROL, V105, P2262, DOI 10.1038/ajg.2010.214; Marciano BE, 2004, PEDIATRICS, V114, P462, DOI 10.1542/peds.114.2.462; Marks DJB, 2009, AM J GASTROENTEROL, V104, P117, DOI 10.1038/ajg.2008.72; Mccoy MH, 2014, HUM PATHOL, V45, P48, DOI 10.1016/j.humpath.2013.07.040; McCurdy JD, 2015, INFLAMM BOWEL DIS, V21, P2833, DOI 10.1097/MIB.0000000000000556; MILDER JE, 1981, GASTROENTEROLOGY, V80, P1481; Mills AM, 2013, AM J SURG PATHOL, V37, P995, DOI 10.1097/PAS.0b013e31827fcc33; Minematsu H, 2011, DIGESTION, V83, P210, DOI 10.1159/000321812; Molaei M, 2009, INDIAN J PATHOL MICR, V52, P530, DOI 10.4103/0377-4929.56152; Mortaz E, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00365; Mustafa T, 2006, MODERN PATHOL, V19, P1606, DOI 10.1038/modpathol.3800697; Myerson D, 2017, BIOL BLOOD MARROW TR, V23, P1573, DOI 10.1016/j.bbmt.2017.05.017; Narkhede M, 2017, AM J HEMATOL, V92, P683, DOI 10.1002/ajh.24749; Nikkels AF, 1996, J CLIN PATHOL, V49, P243, DOI 10.1136/jcp.49.3.243; Obayashi N, 2016, J PEDIATR GASTR NUTR, V62, P56, DOI 10.1097/MPG.0000000000000905; Oberhuber G, 1997, SCAND J GASTROENTERO, V32, P48, DOI 10.3109/00365529709025062; Oberhuber G, 2016, AM J SURG PATHOL, V40, P1280, DOI 10.1097/PAS.0000000000000665; Pallav K, 2016, J GASTROEN HEPATOL, V31, P133, DOI 10.1111/jgh.13176; Panarelli NC, 2017, AM J SURG PATHOL, V41, P570, DOI 10.1097/PAS.0000000000000817; Patterson TF, 2000, MEDICINE, V79, P250, DOI 10.1097/00005792-200007000-00006; Patuzzo G, 2016, AUTOIMMUN REV, V15, P877, DOI 10.1016/j.autrev.2016.07.011; Petrikkos G, 2012, CLIN INFECT DIS, V54, pS23, DOI 10.1093/cid/cir866; Robertson S, 2015, MODERN PATHOL, V28, p187A; Ross WA, 2005, CURR OPIN GASTROEN, V21, P64; Runde V, 2001, BONE MARROW TRANSPL, V28, P51, DOI 10.1038/sj.bmt.1703083; Ryan U, 2016, WATER RES, V105, P305, DOI 10.1016/j.watres.2016.09.013; Sachak T, 2015, AM J SURG PATHOL, V39, P1635, DOI 10.1097/PAS.0000000000000517; Shah R, 2015, ACG CASE REP J, V2, P165, DOI 10.14309/crj.2015.42; Shimoji S, 2013, BONE MARROW TRANSPL, V48, P1249, DOI 10.1038/bmt.2013.44; Shulman HM, 2015, BIOL BLOOD MARROW TR, V21, P589, DOI 10.1016/j.bbmt.2014.12.031; Singh SP, 1998, AM J SURG PATHOL, V22, P93, DOI 10.1097/00000478-199801000-00012; Solomon IH, 2017, AM J CLIN PATHOL, V147, P96, DOI [10.1093/AJCP/AQW198, 10.1093/ajcp/aqw198]; Star KV, 2013, AM J SURG PATHOL, V37, P1319, DOI 10.1097/PAS.0b013e31829ab1ef; Sun HY, 2005, GASTROINTEST ENDOSC, V61, P775, DOI 10.1016/S0016-5107(04)02786-5; Thompson BF, 2004, GASTROINTEST ENDOSC, V59, P906, DOI 10.1016/S0016-5107(04)00337-2; Washington K, 1996, AM J SURG PATHOL, V20, P1240, DOI 10.1097/00000478-199610000-00010; WASHINGTON K, 1991, MODERN PATHOL, V4, P707; Weidner AS, 2016, AM J CLIN PATHOL, V146, P627, DOI [10.1093/AJCP/AQW179, 10.1093/ajcp/aqw179]; Welch DC, 2006, AM J SURG PATHOL, V30, P444, DOI 10.1097/00000478-200604000-00003; Woods GL, 1996, CLIN MICROBIOL REV, V9, P382, DOI 10.1128/CMR.9.3.382; Workowski Kimberly A., 2010, Morbidity and Mortality Weekly Report, V59, P1; Yan L, 2013, MICROBIOL RES, V168, P389, DOI 10.1016/j.micres.2013.02.008; Yan Z, 2014, INT J SURG PATHOL, V22, P492, DOI 10.1177/1066896914537681; Yeh SP, 2004, AM J CLIN PATHOL, V122, P919, DOI 10.1309/23DAL9F6P74XWJHL	109	2	2	1	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUN	2018	31	6					844	861		10.1038/s41379-018-0015-9			18	Pathology	Pathology	GJ1CH	WOS:000434991000001	29403083				2019-10-28	
J	Berg, KB; Schaeffer, DF				Berg, Kyra B.; Schaeffer, David F.			Tumor budding as a standardized parameter in gastrointestinal carcinomas: more than just the colon	MODERN PATHOLOGY			English	Review							LYMPH-NODE METASTASIS; SQUAMOUS-CELL CARCINOMA; EPITHELIAL-MESENCHYMAL-TRANSITION; PANCREATIC DUCTAL ADENOCARCINOMA; INDEPENDENT PROGNOSTIC-FACTOR; INVASIVE COLORECTAL-CARCINOMA; SUBMUCOSAL INVASION; GASTRIC ADENOCARCINOMA; RECTAL-CANCER; RISK-FACTORS	Tumor budding, defined as single cells or clusters of less than five cells, is thought to be a histomorphologic marker of an aggressive tumor behavior mimicking the embryologic epithelial-mesenchymal transition, and has been well established in the past two decades as a poor prognostic factor in colorectal carcinoma. Slow uptake in routine reporting of this important pathologic prognostic feature was in part due to differing methods of assessment of budding reported in the literature, but has recently been clarified at a consensus conference on tumor budding in colorectal carcinoma. Tumor budding is also increasingly being reported as a useful pathologic prognostic feature in other gastrointestinal carcinomas, including esophageal squamous cell carcinoma and adenocarcinoma, gastric intestinal-type adenocarcinoma, pancreatic ductal adenocarcinoma, and ampullary adenocarcinoma. In this review, we will summarize the studies on tumor budding in gastrointestinal carcinomas, with a focus on the methods of assessment used and the potential clinical applications of the findings.	[Berg, Kyra B.; Schaeffer, David F.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada; [Schaeffer, David F.] Vancouver Gen Hosp, Div Anat Pathol, Vancouver, BC, Canada	Berg, KB (reprint author), Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada.	kyraberg@alumni.ubc.ca					Betge J, 2012, ANN SURG ONCOL, V19, P3706, DOI 10.1245/s10434-012-2426-z; Bosch SL, 2013, ENDOSCOPY, V45, P827, DOI 10.1055/s-0033-1344238; Boxberg M, 2017, HISTOPATHOLOGY, V70, P1125, DOI 10.1111/his.13173; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Che KY, 2017, ONCOTARGETS THER, V10, P1039, DOI 10.2147/OTT.S127762; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; De Smedt L, 2016, BRIT J CANCER, V116, P58; Edge S.B., 2010, AJCC CANC STAGING MA, P143; Giger OT, 2012, MODERN PATHOL, V25, P1048, DOI 10.1038/modpathol.2012.56; Gulluoglu M, 2015, INT J SURG PATHOL, V23, P349, DOI 10.1177/1066896915581200; HASE K, 1993, DIS COLON RECTUM, V36, P627, DOI 10.1007/BF02238588; Imai T, 1954, FUKUOKA IGAKU ZASSHI, V45, P72; Jesinghaus M, 2017, AM J SURG PATHOL, V41, P1112, DOI 10.1097/PAS.0000000000000865; Karamitopoulou E, 2013, EUR J CANCER, V49, P1032, DOI 10.1016/j.ejca.2012.10.022; Karamitopoulou E, 2017, MODERN PATHOL, V30, P1116, DOI 10.1038/modpathol.2017.35; Kawachi H, 2015, MODERN PATHOL, V28, P872, DOI 10.1038/modpathol.2015.36; Kitajima K, 2004, J GASTROENTEROL, V39, P534, DOI 10.1007/s00535-004-1339-4; Koelzer VH, 2016, HUM PATHOL, V47, P4, DOI 10.1016/j.humpath.2015.08.007; Kohler I, 2015, J GASTROEN HEPATOL, V30, P78, DOI 10.1111/jgh.12752; Koike M, 2008, ANN SURG ONCOL, V15, P1977, DOI 10.1245/s10434-008-9901-6; Lai YH, 2014, COLORECTAL DIS, V16, P259, DOI 10.1111/codi.12454; Lugli A, 2017, MODERN PATHOL, V30, P1299, DOI 10.1038/modpathol.2017.46; Miyata H, 2009, CANCER, V115, P3324, DOI 10.1002/cncr.24390; Nakamura T, 2005, HEPATO-GASTROENTEROL, V52, P1432; Nakanishi Y, 2011, WORLD J SURG, V35, P349, DOI 10.1007/s00268-010-0880-y; Nascimbeni R, 2002, DIS COLON RECTUM, V45, P200, DOI 10.1007/s10350-004-6147-7; NIVATVONGS S, 1991, DIS COLON RECTUM, V34, P323, DOI 10.1007/BF02050592; O'Connor K, 2015, AM J SURG PATHOL, V39, P472, DOI 10.1097/PAS.0000000000000333; Ohike N, 2010, AM J SURG PATHOL, V34, P1417, DOI 10.1097/PAS.0b013e3181f0b05a; Olsen S, 2017, HUM PATHOL, V68, P26, DOI 10.1016/j.humpath.2017.03.021; Pai RK, 2017, MODERN PATHOL, V30, P113, DOI 10.1038/modpathol.2016.166; Petrelli F, 2015, J Gastrointest Cancer, V46, P212, DOI 10.1007/s12029-015-9716-1; Puppa G, 2012, HISTOPATHOLOGY, V61, P562, DOI 10.1111/j.1365-2559.2012.04270.x; Rogers AC, 2014, MODERN PATHOL, V27, P156, DOI 10.1038/modpathol.2013.124; Roh MS, 2004, DIS ESOPHAGUS, V17, P333, DOI 10.1111/j.1442-2050.2004.00436.x; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Smyth EC, 2016, ANN ONCOL, V27, pv38, DOI 10.1093/annonc/mdw350; Teramoto H, 2013, J SURG ONCOL, V108, P42, DOI 10.1002/jso.23341; Thies S, 2016, HUM PATHOL, V52, P1, DOI 10.1016/j.humpath.2016.01.016; Toh EW, 2015, DIS COLON RECTUM, V58, P393, DOI 10.1097/DCR.0000000000000315; Tsuruta O, 2000, Diagn Ther Endosc, V6, P101, DOI 10.1155/DTE.6.101; Ueno H, 2004, GASTROENTEROLOGY, V127, P385, DOI 10.1053/S0016-5085(04)00717-6; Ueno H, 2002, HISTOPATHOLOGY, V40, P127, DOI 10.1046/j.1365-2559.2002.01324.x; Wang HS, 2005, DIS COLON RECTUM, V48, P1182, DOI 10.1007/s10350-004-0935-y; Wang LM, 2009, AM J SURG PATHOL, V33, P134, DOI 10.1097/PAS.0b013e318184cd55; Wartenberg M, 2015, ONCOTARGET, V6, P4190, DOI 10.18632/oncotarget.2775; Watanabe T, 2017, INT J CLIN ONCOL; Weichert W, 2016, EUR RESPIR J, V47, P938, DOI 10.1183/13993003.00937-2015; Yamada N, 2017, HUM PATHOL, V60, P151, DOI 10.1016/j.humpath.2016.10.007; Zlobec I, 2013, BRIT J CANCER, V110, P1008; Zlobec I, 2010, WORLD J GASTROENTERO, V16, P4823, DOI 10.3748/wjg.v16.i38.4823	51	4	5	2	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUN	2018	31	6					862	872		10.1038/s41379-018-0028-4			11	Pathology	Pathology	GJ1CH	WOS:000434991000002	29403085				2019-10-28	
J	Margolskee, E; Mikita, G; Rea, B; Bagg, A; Zuo, Z; Sun, Y; Goswami, M; Wang, SA; Oak, J; Arber, DA; Allen, MB; George, TI; Rogers, HJ; Hsi, E; Hasserjian, RP; Orazi, A				Margolskee, Elizabeth; Mikita, Geoff; Rea, Bryan; Bagg, Adam; Zuo, Zhuang; Sun, Yi; Goswami, Maitrayee; Wang, Sa A.; Oak, Jean; Arber, Daniel A.; Allen, M. Brandon; George, Tracy I.; Rogers, Heesun J.; Hsi, Eric; Hasserjian, Robert P.; Orazi, Attilio			A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria	MODERN PATHOLOGY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; MYELODYSPLASTIC SYNDROMES; EXCESS BLASTS; CELL LINEAGES; CLASSIFICATION; INVOLVEMENT; NEOPLASMS	The 2016 WHO update changed the diagnostic criteria for myeloid neoplasms with erythroid predominance, limiting the diagnosis of acute myeloid leukemia to cases with >= 20% blasts in the bone marrow or peripheral blood. Although acute myeloid leukemia with >= 50% erythroid cells has historically been presumed to represent acute myeloid leukemia with myelodysplasia-related changes, this hypothesis has never been systematically examined. We sought to investigate the clinicopathologic, cytogenetic, and molecular features of acute myeloid leukemia with erythroid predominance to subclassify cases as defined by the 2016 WHO. We retrospectively identified patients with >= 50% erythroid precursors and either >= 20% bone marrow blasts or >= 20% peripheral blood blasts at the time of initial diagnosis at seven major academic centers. Laboratory and clinical data were obtained. Patients were then reclassified according to 2016 WHO guidelines. A matched control group was also obtained. We identified 146 patients with acute myeloid leukemia with erythroid predominance (62% M, average age: 62 y, range: 5-93 y). Of these, 91 were acute myeloid leukemia with myelodysplasia-related changes, 20 (14%) were therapy-related myeloid neoplasm, 23 (16%) acute myeloid leukemia, not otherwise specified, and ten acute myeloid leukemia with recurrent cytogenetic/molecular abnormalities. The bone marrow blast count ranged from 9-41%. There was no difference in survival for patients with erythroid predominance compared to patients with acute myeloid leukemia without erythroid proliferations. In a multivariable analysis, cytogenetic risk was the only significant predictor of survival. We find a significantly lower rate of FLT3 and RAS pathway alterations in acute myeloid leukemia with erythroid predominance compared to controls. Our study is one of the first to apply the 2016 WHO guidelines for classification of acute myeloid leukemia. We find acute myeloid leukemia with erythroid predominance is a heterogeneous group and that erythroid richness has no impact on overall survival.	[Margolskee, Elizabeth; Mikita, Geoff; Orazi, Attilio] New York Presbyterian Hosp, Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY 10032 USA; [Rea, Bryan; Bagg, Adam] Hosp Univ Penn, Dept Pathol & Lab Med, 3400 Spruce St, Philadelphia, PA 19104 USA; [Zuo, Zhuang; Sun, Yi; Goswami, Maitrayee; Wang, Sa A.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Oak, Jean; Arber, Daniel A.] Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA; [Allen, M. Brandon; George, Tracy I.] Univ New Mexico, Dept Pathol, Hlth Sci Ctr, Albuquerque, NM 87131 USA; [Rogers, Heesun J.; Hsi, Eric] Cleveland Clin, Dept Pathol & Lab Med, Cleveland, OH 44106 USA; [Hasserjian, Robert P.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA	Margolskee, E (reprint author), New York Presbyterian Hosp, Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY 10032 USA.	emm9030@med.cornell.edu	Bagg, Adam/R-8450-2019	Margolskee, Elizabeth/0000-0001-8597-0636			Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Bacher U, 2011, HAEMATOL-HEMATOL J, V96, P1284, DOI 10.3324/haematol.2011.043687; Calvo X, 2016, MODERN PATHOL, V29, P1541, DOI 10.1038/modpathol.2016.146; Cervera N, 2016, LEUKEMIA, V30, P966, DOI 10.1038/leu.2015.198; Chang H, 2005, CANCER GENET CYTOGEN, V158, P43, DOI 10.1016/j.cancergencyto.2004.08.018; DAMESHEK W, 1969, BLOOD-J HEMATOL, V34, P567, DOI 10.1182/blood.V34.5.567.567; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Grimwade D, 2010, BLOOD, V116, P354, DOI 10.1182/blood-2009-11-254441; Grossmann V, 2013, LEUKEMIA, V27, P1940, DOI 10.1038/leu.2013.144; Haferlach T, 1998, BRIT J HAEMATOL, V103, P93, DOI 10.1046/j.1365-2141.1998.00959.x; Hasserjian RP, 2010, BLOOD, V115, P1985, DOI 10.1182/blood-2009-09-243964; KNUUTILA S, 1994, GENE CHROMOSOME CANC, V10, P95, DOI 10.1002/gcc.2870100204; vanLom K, 1997, LEUKEMIA, V11, P202, DOI 10.1038/sj.leu.2400544; Wang SA, 2016, MODERN PATHOL, V29, P1221, DOI 10.1038/modpathol.2016.118; Zuo Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041485	15	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUN	2018	31	6					873	880		10.1038/s41379-018-0001-2			8	Pathology	Pathology	GJ1CH	WOS:000434991000003	29403082				2019-10-28	
J	Gao, Q; Yellapantula, V; Fenelus, M; Pichardo, J; Wang, L; Landgren, O; Dogan, A; Roshal, M				Gao, Qi; Yellapantula, Venkata; Fenelus, Maly; Pichardo, Janine; Wang, Lu; Landgren, Ola; Dogan, Ahmet; Roshal, Mikhail			Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms	MODERN PATHOLOGY			English	Article							MINIMAL RESIDUAL DISEASE; MULTIPARAMETER FLOW-CYTOMETRY; MULTIPLE-MYELOMA; TRANSENDOTHELIAL MIGRATION; MIC2 EXPRESSION; MRD DETECTION; CRITERIA; IMPACT	CD99(MIC2) is a widely expressed cell surface glycoprotein and functions as a tumor suppressor involved in downregulation of SRC family of tyrosine kinase. CD99 expression is tightly regulated through B-cell development. The principal aims of this study were to investigate the clinical utility of CD99 expression (i) in distinguishing normal plasma cells from primary plasma cell neoplasms; (ii) in detection of minimal residual disease in primary plasma cell neoplasms; and (iii) in distinguishing plasma cell component of B-cell lymphomas from primary plasma cell neoplasms. We analyzed expression of CD99 by flow cytometry and immunohistochemistry in lymph nodes, peripheral blood, and bone marrow samples. CD99 showed stage-specific expression with highest expression seen in precursor B and plasma cells. In contrast to the uniform bright expression on normal plasma cells, CD99 expression on neoplastic plasma cells was lost in 39 out of 56 (69.6%) cases. Furthermore, 8 out of 56 samples (14%) showed visibly (>10-fold) reduced CD99 expression. Overall, CD99 expression was informative (absent or visibly dimmer than normal) in 84% of primary plasma cell neoplasm. In the context of minimal residual disease detection, CD99 showed superior utility in separating normal and abnormal plasma cells over currently established antigens CD117, CD81, and CD27 by principal component analysis. Preservation of CD99 expression was strongly associated with cyclin D1 translocation in myeloma (p < 0.05). B-cell lymphomas with plasma cell component could be distinguished from myeloma by CD99 expression. In summary, we established that tumor suppressor CD99 is markedly downregulated in multiple myeloma. The loss is highly specific for identification of abnormal cells in primary plasma cell neoplasms, and can be exploited for diagnostic purposes. The role of CD99 in myeloma pathogenesis requires further investigation.	[Gao, Qi; Pichardo, Janine; Dogan, Ahmet; Roshal, Mikhail] Mem Sloan Kettering Canc Ctr, Hematopathol Serv, 1275 York Ave, New York, NY 10021 USA; [Yellapantula, Venkata] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, 1275 York Ave, New York, NY 10021 USA; [Fenelus, Maly] Mem Sloan Kettering Canc Ctr, Dept Lab Med, 1275 York Ave, New York, NY 10021 USA; [Wang, Lu] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Landgren, Ola] Mem Sloan Kettering Canc Ctr, Myeloma Serv, 1275 York Ave, New York, NY 10021 USA	Dogan, A; Roshal, M (reprint author), Mem Sloan Kettering Canc Ctr, Hematopathol Serv, 1275 York Ave, New York, NY 10021 USA.	dogana@mskcc.org; roshalm@mskcc.org	Wang, Lu/N-8128-2018	Wang, Lu/0000-0002-0073-0666; Fenelus, Maly/0000-0003-1959-4489	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA008748]		Chanan-Khan AA, 2010, J CLIN ONCOL, V28, P2612, DOI 10.1200/JCO.2009.25.4250; Chung SS, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaj2025; Coluccia AML, 2008, BLOOD, V112, P1346, DOI 10.1182/blood-2007-10-116590; de Tute RM, 2016, HAEMATOLOGICA, V101, pE69, DOI 10.3324/haematol.2015.128215; Dworzak MN, 1999, BRIT J HAEMATOL, V105, P690, DOI 10.1046/j.1365-2141.1999.01426.x; Dworzak MN, 1998, EXP HEMATOL, V26, P305; DWORZAK MN, 1994, BLOOD, V83, P415, DOI 10.1182/blood.V83.2.415.bloodjournal832415; Flores-Montero J, 2017, LEUKEMIA, V31, P2094, DOI 10.1038/leu.2017.29; Flores-Montero J, 2016, CYTOM PART B-CLIN CY, V90, P61, DOI 10.1002/cyto.b.21265; Fonseca R, 2002, BLOOD, V99, P3735, DOI 10.1182/blood.V99.10.3735; Gil M, 2015, IMMUNOL LETT, V168, P329, DOI 10.1016/j.imlet.2015.10.015; Hahn JH, 1997, J IMMUNOL, V159, P2250; Imbert AM, 2006, BLOOD, V108, P2578, DOI 10.1182/blood-2005-12-010827; Kumar S, 2016, LANCET ONCOL, V17, pE328, DOI 10.1016/S1470-2045(16)30206-6; Landgren O, 2016, BONE MARROW TRANSPL, V51, P1565, DOI 10.1038/bmt.2016.222; Landgren O, 2014, AM J HEMATOL, V89, P1159, DOI 10.1002/ajh.23831; Lonial S, 2014, BLOOD, V124, P722; Lou O, 2007, J IMMUNOL, V178, P1136, DOI 10.4049/jimmunol.178.2.1136; Mailankody S, 2015, NAT REV CLIN ONCOL, V12, P286, DOI 10.1038/nrclinonc.2014.239; Manara MC, 2006, MOL BIOL CELL, V17, P1910, DOI 10.1091/mbc.E05-10-0971; Martinez-Lopez J, 2014, BLOOD, V123, P3073, DOI 10.1182/blood-2014-01-550020; Paiva B, 2015, BLOOD, V125, P3059, DOI 10.1182/blood-2014-11-568907; Park CK, 1999, J KOREAN MED SCI, V14, P600, DOI 10.3346/jkms.1999.14.6.600; Rawstron AC, 2016, CYTOM PART B-CLIN CY, V90, P21, DOI 10.1002/cyto.b.21272; Rawstron AC, 2015, BLOOD, V125, P1932, DOI 10.1182/blood-2014-07-590166; Rawstron AC, 2013, J CLIN ONCOL, V31, P2540, DOI 10.1200/JCO.2012.46.2119; Rosado FG, 2015, BRIT J HAEMATOL, V169, P368, DOI 10.1111/bjh.13303; Roshal M, 2017, BLOOD ADV, V1, P728, DOI 10.1182/bloodadvances.2016003715; Royston DJ, 2016, AM J CLIN PATHOL, V146, P41, DOI 10.1093/ajcp/aqw052; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Shin Su-Jin, 2014, Korean J Pathol, V48, P209, DOI 10.4132/KoreanJPathol.2014.48.3.209; Sohn HW, 2001, J IMMUNOL, V166, P787, DOI 10.4049/jimmunol.166.2.787; Sullivan DP, 2013, AM J PATHOL, V182, P1031, DOI 10.1016/j.ajpath.2012.11.037; Szalat R, 2015, CURR OPIN GENET DEV, V30, P56, DOI 10.1016/j.gde.2015.03.008; Watson RL, 2015, J EXP MED, V212, P1021, DOI 10.1084/jem.20150354; Zucchini C, 2014, ONCOGENE, V33, P1912, DOI 10.1038/onc.2013.152	36	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUN	2018	31	6					881	889		10.1038/s41379-018-0011-0			9	Pathology	Pathology	GJ1CH	WOS:000434991000004	29403080	Green Accepted			2019-10-28	
J	Iguchi, T; Takaori, K; Mii, A; Sato, Y; Suzuki, Y; Yoshifuji, H; Seno, H; Ogawa, O; Omori, K; Bessho, K; Kondo, S; Yoshizaki, T; Nakashima, H; Saito, T; Mimori, T; Haga, H; Kawano, M; Yanagita, M				Iguchi, Taku; Takaori, Koji; Mii, Akiko; Sato, Yuki; Suzuki, Yasunori; Yoshifuji, Hajime; Seno, Hiroshi; Ogawa, Osamu; Omori, Koichi; Bessho, Kazuhisa; Kondo, Satoru; Yoshizaki, Tomokazu; Nakashima, Hitoshi; Saito, Takao; Mimori, Tsuneyo; Haga, Hironori; Kawano, Mitsuhiro; Yanagita, Motoko			Glucocorticoid receptor expression in resident and hematopoietic cells in IgG4-related disease	MODERN PATHOLOGY			English	Article							REGULATORY IMMUNE-REACTIONS; KIDNEY-DISEASE; TUBULOINTERSTITIAL NEPHRITIS; DIAGNOSTIC-CRITERIA; DYSFUNCTION; MECHANISMS; STATEMENT; FIBROSIS; THERAPY; TH2	Immunoglobulin G4-related disease is a rare immune-mediated disease characterized by the infiltration of IgG4-positive plasma cells and unique storiform fibrosis of multiple organs. The majority of IgG4-related disease patients respond to glucocorticoids, yet the precise mechanism of their action remains unclear. Pathological sections of the submaxillary gland, kidney, and retroperitoneum from 20 patients in total diagnosed with IgG4-related disease were analyzed for glucocorticoid receptor expression and the cell types expressing glucocorticoid receptor. Strong and abundant expression of glucocorticoid receptor was observed in the submaxillary gland, kidney, and retroperitoneum of IgG4-related disease patients, while glucocorticoid receptor was rarely or only faintly observed in the submaxillary gland of patients with Sjogren's syndrome, radicular cysts and sialolithiasis or in the healthy kidney. Glucocorticoid receptor was mainly expressed in fibro/myofibroblasts, CD4-positive T cells and IgG4-positive plasma cells in the submandibular glands and kidneys of IgG4-related disease patients. The abundant expression of glucocorticoid receptor in various types of cells, including resident fibro/myofibroblasts in IgG4-related disease patients might provide clues to the mechanism of steroid responsiveness in IgG4-related disease patients.	[Iguchi, Taku; Sato, Yuki] Kyoto Univ, Grad Sch Med, Med Innovat Ctr, TMK Project, Kyoto, Kyoto, Japan; [Iguchi, Taku] Mitsubishi Tanabe Pharma Corp, Sohyaku Innovat Res Div, Res Unit Innovat Med Sci, Toda, Saitama, Japan; [Takaori, Koji; Mii, Akiko; Sato, Yuki; Yanagita, Motoko] Kyoto Univ, Grad Sch Med, Dept Nephrol, Kyoto, Kyoto, Japan; [Suzuki, Yasunori; Kawano, Mitsuhiro] Kanazawa Univ, Grad Sch Med, Dept Internal Med, Div Rheumatol, Kanazawa, Ishikawa, Japan; [Yoshifuji, Hajime; Mimori, Tsuneyo] Kyoto Univ, Grad Sch Med, Dept Rheumatol & Clin Immunol, Kyoto, Kyoto, Japan; [Seno, Hiroshi] Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Kyoto, Kyoto, Japan; [Ogawa, Osamu] Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto, Kyoto, Japan; [Omori, Koichi] Kyoto Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Kyoto, Kyoto, Japan; [Bessho, Kazuhisa] Kyoto Univ, Grad Sch Med, Dept Oral & Maxillofacial Surg, Kyoto, Kyoto, Japan; [Kondo, Satoru; Yoshizaki, Tomokazu] Kanazawa Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Kanazawa, Ishikawa, Japan; [Nakashima, Hitoshi] Fukuoka Univ, Fac Med, Dept Internal Med, Div Nephrol & Rheumatol, Fukuoka, Fukuoka, Japan; [Saito, Takao] Sanko Clin, Fukuoka, Fukuoka, Japan; [Haga, Hironori] Kyoto Univ Hosp, Dept Diagnost Pathol, Kyoto, Kyoto, Japan; [Takaori, Koji] Japanese Red Cross Otsu Hosp, Dept Nephrol, Otsu, Shiga, Japan; [Mii, Akiko] Nippon Med Sch, Dept Internal Med, Div Nephrol, Tokyo, Japan	Yanagita, M (reprint author), Kyoto Univ, Grad Sch Med, Dept Nephrol, Kyoto, Kyoto, Japan.	motoy@kuhp.kyoto-u.ac.jp		Seno, Hiroshi/0000-0002-8509-8128	Funding Program for Next-Generation World-leading Researchers, "Project for Elucidating and Controlling Mechanisms of Aging and Longevity" from Japan Agency for Medical Research and development, AMEDJapan Agency for Medical Research and Development (AMED); Japan Society for the Promotion of Science (JSPS), CREST from the Japan Science and Technology Agency [26293202, 17H04187]; TMK Project, Mitsubishi Tanabe Pharma Corporation	We appreciate valuable discussion with Professor Jurgen Floege and Professor Pierre Ronco during the preparation of the manuscript. This study was performed as one of the collaborative projects of the IgG4-RKD Working Group within the Japanese Society of Nephrology. We thank Ms. Tomita and Ms. Ozone for their excellent technical assistance. This study was supported by the Funding Program for Next-Generation World-leading Researchers, "Project for Elucidating and Controlling Mechanisms of Aging and Longevity" from Japan Agency for Medical Research and development, AMED, Grant-in-Aids for Scientific Research B (26293202, 17H04187) from the Japan Society for the Promotion of Science (JSPS), CREST from the Japan Science and Technology Agency, and partly by grants from the TMK Project, Mitsubishi Tanabe Pharma Corporation.	Alexander MP, 2013, KIDNEY INT, V83, P455, DOI 10.1038/ki.2012.382; Asada N, 2011, J CLIN INVEST, V121, P3981, DOI 10.1172/JCI57301; Bazso A, 2015, AUTOIMMUN REV, V14, P349, DOI 10.1016/j.autrev.2014.12.007; Cortazar FB, 2015, NAT REV NEPHROL, V11, P599, DOI 10.1038/nrneph.2015.95; Deshpande V, 2012, MODERN PATHOL, V25, P1181, DOI 10.1038/modpathol.2012.72; GLADMAN DD, 1991, J RHEUMATOL, V18, P681; Kamisawa T, 2009, GUT, V58, P1504, DOI 10.1136/gut.2008.172908; Kamisawa T, 2010, J GASTROENTEROL, V45, P471, DOI 10.1007/s00535-010-0221-9; Kawano M, 2011, CLIN EXP NEPHROL, V15, P615, DOI 10.1007/s10157-011-0521-2; Khosroshahi A, 2015, ARTHRITIS RHEUMATOL, V67, P1688, DOI 10.1002/art.39132; Kuppe C, 2017, J AM SOC NEPHROL, V28, P1408, DOI 10.1681/ASN.2016010060; Li X, 2010, J RHEUMATOL, V37, P316, DOI 10.3899/jrheum.090191; Maehara T, 2012, ANN RHEUM DIS, V71, P2011, DOI 10.1136/annrheumdis-2012-201477; Mahajan VS, 2014, ANNU REV PATHOL-MECH, V9, P315, DOI 10.1146/annurev-pathol-012513-104708; Nakashima H, 2010, CLIN NEPHROL, V73, P385; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Saeki T, 2016, CLIN EXP NEPHROL, V20, P87, DOI 10.1007/s10157-015-1140-0; Saeki T, 2013, KIDNEY INT, V84, P826, DOI 10.1038/ki.2013.191; Saeki T, 2010, KIDNEY INT, V78, P1016, DOI 10.1038/ki.2010.271; SINICROPE FA, 1995, CANCER RES, V55, P237; Souma T, 2013, J AM SOC NEPHROL, V24, P1599, DOI 10.1681/ASN.2013010030; Stone JH, 2012, NEW ENGL J MED, V366, P539, DOI 10.1056/NEJMra1104650; Tanaka A, 2012, ARTHRITIS RHEUM-US, V64, P254, DOI 10.1002/art.33320; TANAKA H, 1992, J RHEUMATOL, V19, P878; Umehara H, 2012, MOD RHEUMATOL, V22, P21, DOI 10.1007/s10165-011-0571-z; Umehara H, 2012, MOD RHEUMATOL, V22, P1, DOI 10.1007/s10165-011-0508-6; van Everdingen AA, 2002, CLIN EXP RHEUMATOL, V20, P463; Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412; Zen Y, 2007, HEPATOLOGY, V45, P1538, DOI 10.1002/hep.21697	29	3	4	3	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUN	2018	31	6					890	899		10.1038/s41379-018-0036-4			10	Pathology	Pathology	GJ1CH	WOS:000434991000005	29434340				2019-10-28	
J	Mete, O; Cintosun, A; Pressman, I; Asa, SL				Mete, Ozgur; Cintosun, Amber; Pressman, Irwin; Asa, Sylvia L.			Epidemiology and biomarker profile of pituitary adenohypophysial tumors	MODERN PATHOLOGY			English	Article							MULTIPLE ENDOCRINE NEOPLASIA; SILENT CORTICOTROPH ADENOMAS; CYCLE INHIBITOR P27(KIP1); NULL-CELL ADENOMAS; GRANULATION PATTERN; SOMATOTROPH ADENOMAS; EXPRESSION; HORMONE; RESPONSIVENESS; PATHOGENESIS	Recent studies have reported the prevalence of pituitary tumors to be similar to 1/1000 population. Many are prolactin-producing tumors that are managed medically, however, the epidemiology of surgically resected pituitary adenohypophysial neuroendocrine tumors has not been reported in a large series with detailed characterization. We reviewed 1055 adenohypophysial tumors from 1169 transsphenoidal resections from the pathology files of University Health Network, Toronto, 2001-2016. Tumors were characterized by immunohistochemical localization of transcription factors (Pit-1, ERa, SF-1, Tpit), hormones (adrenocorticotropin, growth hormone, prolactin, ss-thyrotropin, ss-folliculotropin, ss-luteotropin, a-subunit), and other biomarkers (keratins, Ki67, p27, FGFR4). Electron microscopy was used only for unusual lesions. In this cohort, 51.3% of patients were female; the average age was 51 years. Gonadotroph tumors represented 42.5%. Pit-1-lineage-tumors represented 29.9%; these were subclassified as growth-hormone-predominant (somatotroph/mammosomatotroph/mixed; 53%), prolactin-predominant (lactotroph/acidophil-stem-cell; 28%), thyrotrophs (2%), plurihormonal (14%), and not-otherwise-specified (3%). Corticotroph tumors represented 17.1%. Only 4.5% were null cell tumors and 0.5% were unusual plurihormonal tumors. In 5.5% the tumor was not characterized for technical reasons (sample size, fixation, necrosis or other artifact). All corticotroph and plurihormonal tumors were positive for keratins; others tumors showed variable negativity with highest rates in gonadotroph (37.1%) and null cell tumors (28.2%). Tumors with a Ki67 >= 3% comprised 60% of this cohort. Global loss of p27 was most frequent in corticotroph neoplasms, specifically those associated with elevated glucocorticoid levels. Corticotroph and lactotroph tumors were more common among females; gonadotroph tumors were more common among males. Younger patients had mainly corticotroph and Pit-1-lineage neoplasms, whereas older patients harbored mainly gonadotroph tumors. This represents one of the largest surgical series of morphologically characterized pituitary tumors reported to date and the first to include the routine use of transcription factors for tumor classification. The data provide the basis for clinicopathologic correlations that are helpful for prognostic and predictive patient management.	[Mete, Ozgur; Cintosun, Amber; Asa, Sylvia L.] Univ Hlth Network, Dept Pathol, Lab Med Program, Toronto, ON M5G 2M9, Canada; [Mete, Ozgur; Cintosun, Amber; Asa, Sylvia L.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada; [Pressman, Irwin] Carlton Univ, Sch Math & Stat, Ottawa, ON, Canada	Asa, SL (reprint author), Univ Hlth Network, Dept Pathol, Lab Med Program, Toronto, ON M5G 2M9, Canada.; Asa, SL (reprint author), Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada.	sylvia.asa@uhn.ca		Asa, Sylvia/0000-0001-8418-5054			Agustsson TT, 2015, EUR J ENDOCRINOL, V173, P655, DOI 10.1530/EJE-15-0189; Alahmadi H, 2012, ACTA NEUROCHIR, V154, P1493, DOI 10.1007/s00701-012-1378-1; Asa SL, 2017, ENDOCR-RELAT CANCER, V24, pC5, DOI 10.1530/ERC-17-0004; Asa SL, 1996, J CLIN ENDOCR METAB, V81, P2165, DOI 10.1210/jc.81.6.2165; Asa SL, 1998, ENDOCR REV, V19, P798, DOI 10.1210/er.19.6.798; ASA SL, 1986, J CLIN ENDOCR METAB, V62, P1011, DOI 10.1210/jcem-62-5-1011; Asa SL, 2016, ENDOCR PATHOL, P315; Asa SL, 2011, AFIP ATLAS TUMOR P 4, P55; Asa SL, 1998, TUMORS PITUITARY GLA, P47; Asa SL, 2017, ENDOCR-RELAT CANCER, V24, pC1, DOI 10.1530/ERC-16-0496; Asa SL, 2016, EXPERT REV ENDOCRINO, V11, P149, DOI 10.1586/17446651.2016.1153422; Asa SL, 2009, ANNU REV PATHOL-MECH, V4, P97, DOI 10.1146/annurev.pathol.4.110807.092259; Bakir B, 2016, ENDOCR PATHOL, P109; Bamberger CM, 1999, EUR J ENDOCRINOL, V140, P250, DOI 10.1530/eje.0.1400250; Bhayana S, 2005, J CLIN ENDOCR METAB, V90, P6290, DOI 10.1210/jc.2005-0998; Brzana J, 2013, PITUITARY, V16, P490, DOI 10.1007/s11102-012-0445-1; Dahia PLM, 1998, ONCOGENE, V16, P69, DOI 10.1038/sj.onc.1201516; Daly AF, 2006, J CLIN ENDOCR METAB, V91, P4769, DOI 10.1210/jc.2006-1668; Ezzat S, 2004, CANCER, V101, P613, DOI 10.1002/cncr.20412; Ezzat S, 1995, EUR J ENDOCRINOL, V133, P686, DOI 10.1530/eje.0.1330686; Fernandez A, 2010, CLIN ENDOCRINOL, V72, P377, DOI 10.1111/j.1365-2265.2009.03667.x; Fontana E, 2009, Rev Med Suisse, V5, P2172; Fougner SL, 2012, CLIN ENDOCRINOL, V76, P96, DOI 10.1111/j.1365-2265.2011.04163.x; Georgitsi M, 2007, J CLIN ENDOCR METAB, V92, P3321, DOI 10.1210/jc.2006-2843; Georgitsi M, 2010, BEST PRACT RES CL EN, V24, P425, DOI 10.1016/j.beem.2010.01.001; GOLD EB, 1981, EPIDEMIOL REV, V3, P163, DOI 10.1093/oxfordjournals.epirev.a036232; Hagiwara A, 2003, RADIOLOGY, V228, P533, DOI 10.1148/radiol.2282020695; Heck A, 2012, CLIN ENDOCRINOL, V77, P72, DOI 10.1111/j.1365-2265.2011.04286.x; Hyrcza MD, 2017, AM J SURG PATHOL, V41, P525, DOI 10.1097/PAS.0000000000000784; Kato M, 2012, ENDOCR J, V59, P221, DOI 10.1507/endocrj.EJ11-0177; Kiseljak-Vassiliades K, 2015, ENDOCRINE, V49, P231, DOI 10.1007/s12020-014-0383-y; Korbonits M, 2002, J CLIN ENDOCR METAB, V87, P2635, DOI 10.1210/jc.87.6.2635; KOVACS K, 1978, AM J MED, V64, P492, DOI 10.1016/0002-9343(78)90236-X; KOVACS K, 1980, VIRCHOWS ARCH A, V387, P165, DOI 10.1007/BF00430697; Kovacs K, 1990, ENDOCR PATHOL, P17; Larkin S, 2013, EUR J ENDOCRINOL, V168, P491, DOI 10.1530/EJE-12-0864; Lidhar K, 1999, J CLIN ENDOCR METAB, V84, P3823, DOI 10.1210/jc.84.10.3823; Liu W, 2002, BRAIN PATHOL, V12, P412; Lloyd RV, 2004, WHO CLASSIFICATION T, P10; Lopez JA, 2004, HUM PATHOL, V35, P1137, DOI 10.1016/j.humpath.2004.04.016; Mete O, 2017, ENDOCR PATHOL, V28, P228, DOI 10.1007/s12022-017-9498-z; Mete O, 2016, MODERN PATHOL, V29, P131, DOI 10.1038/modpathol.2015.151; Mete O, 2013, ENDOCR PATHOL, V24, P191, DOI 10.1007/s12022-013-9270-y; Mete O, 2012, BRAIN PATHOL, V22, P443, DOI 10.1111/j.1750-3639.2012.00599.x; Nakano-Tateno T, 2014, MOL ENDOCRINOL, V28, P525, DOI 10.1210/me.2013-1412; Nishioka H, 2015, ENDOCR PATHOL, V26, P349, DOI 10.1007/s12022-015-9398-z; Nose V, 2011, ARCH PATHOL LAB MED, V135, P640, DOI 10.1043/2010-0470-SAR1.1; Obari A, 2008, ENDOCR PATHOL, V19, P82, DOI 10.1007/s12022-008-9029-z; Osamura RY, 2017, WHO CLASSIFICATION T, V10, P14; Potorac I, 2016, ENDOCR-RELAT CANCER, V23, P871, DOI 10.1530/ERC-16-0356; Qian ZR, 2004, J CLIN ENDOCR METAB, V89, P1904, DOI 10.1210/jc.2003-031489; Scheithauer B W, 1984, Pathol Annu, V19 Pt 1, P317; Scheithauer BW, 2000, NEUROSURGERY, V47, P723, DOI 10.1097/00006123-200009000-00039; STEFANEANU L, 1991, VIRCHOWS ARCH A, V419, P107, DOI 10.1007/BF01600224; Tateno T, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002400; Thakker RV, 2014, MOL CELL ENDOCRINOL, V386, P2, DOI 10.1016/j.mce.2013.08.002; Tjornstrand A, 2014, EUR J ENDOCRINOL, V171, P519, DOI 10.1530/EJE-14-0144; YAMADA S, 1988, VIRCHOWS ARCH A, V413, P333, DOI 10.1007/BF00783026	58	12	12	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUN	2018	31	6					900	909		10.1038/s41379-018-0016-8			10	Pathology	Pathology	GJ1CH	WOS:000434991000006	29434339				2019-10-28	
J	Wirsing, AM; Ervik, IK; Seppola, M; Uhlin-Hansen, L; Steigen, SE; Hadler-Olsen, E				Wirsing, Anna Maria; Ervik, Ida Korsnes; Seppola, Marit; Uhlin-Hansen, Lars; Steigen, Sonja Eriksson; Hadler-Olsen, Elin			Presence of high-endothelial venules correlates with a favorable immune microenvironment in oral squamous cell carcinoma	MODERN PATHOLOGY			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; HPV-ASSOCIATED HEAD; REGULATORY T-CELLS; DENDRITIC CELLS; NECK-CANCER; PROGNOSTIC-FACTORS; OVARIAN-CANCER; BREAST-CANCER; LYMPH-NODE; MACROPHAGES	Oral squamous cell carcinomas are associated with a poor prognosis, which may be partly due to functional impairment of the immune response. Lymphocyte recruitment to the tumor site is facilitated by high-endothelial venules, whereas expression of programmed-death ligand 1 (PD-L1) can impair T-cell function. Thus, we hypothesize that these factors are important in shaping the immune response in oral squamous cell carcinoma. In the present study, we characterized the immune infiltrate in formalin-fixed, paraffin-embedded tumor samples from 75 oral squamous cell carcinoma patients. We used immunohistochemistry to determine the distribution of immune cell subsets, high-endothelial venules, and PD-L1, as well as quantitative real-time polymerase chain reaction to assess the expression of inflammatory cytokines and chemokines associated with lymphocyte trafficking. Finally, we calculated correlations between the presence of immune cell subsets, the gene expression patterns, high-endothelial venules, PD-L1, and the clinicopathological parameters, including patient survival. The presence of high-endothelial venules correlated with increased number of CD3+ T cells and CD20+ B cells, higher levels of the chemokines CXCL12 and CCL21, and lower levels of CCL20, irrespective of the tumors' T stage. In univariate analysis, high levels of CD20+ B cells and CD68+ macrophages, positive high-endothelial venule status, and low T and N stages predicted longer patient survival. However, only the presence of high-endothelial venules and a low T stage were independent positive prognosticators. This indicates that high-endothelial venules are important mediators and a convenient marker of an antitumor immune response in oral squamous cell carcinoma. Our findings suggest that these vessels are a potential immunomodulatory target in this type of cancer. PD-L1 staining in tumor cells correlated with lower T stage, increased infiltration of CD4+ cells, and higher expression of several inflammation-related cytokines. Thus, oral squamous cell carcinomas rich in CD4+ cells may preferentially respond to PD-1/PD-L1 blockade therapy.	[Wirsing, Anna Maria; Ervik, Ida Korsnes; Seppola, Marit; Uhlin-Hansen, Lars; Steigen, Sonja Eriksson; Hadler-Olsen, Elin] Univ Tromso, Fac Hlth Sci, Dept Med Biol, N-9037 Tromso, Norway; [Uhlin-Hansen, Lars; Steigen, Sonja Eriksson; Hadler-Olsen, Elin] Univ Hosp North Norway, Dept Clin Pathol, N-9038 Tromso, Norway	Hadler-Olsen, E (reprint author), Univ Tromso, Fac Hlth Sci, Dept Med Biol, N-9037 Tromso, Norway.; Hadler-Olsen, E (reprint author), Univ Hosp North Norway, Dept Clin Pathol, N-9038 Tromso, Norway.	elin.hadler-olsen@uit.no			North Norwegian Health Authorities	The study was supported by grants from The North Norwegian Health Authorities. The authors thank the technical staff at the Department of Clinical Pathology, University Hospital of North Norway, Bente Mortensen, Mehrdad Rakaee Khanehkenari, and Kjersti Julin at the Department of Medical Biology, University of Tromso-The Arctic University of Norway (UiT) for excellent technical help. We are also grateful for statistical advice from Professor Tom Wilsgard at the Department of Community Medicine, UiT.	Al-Hajeili M, 2017, ONCOLOGY-NY, V31, P301; Altman DG, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-51; Annertz K, 2012, ACTA OTO-LARYNGOL, V132, P552, DOI 10.3109/00016489.2011.649146; Badoual C, 2013, CANCER RES, V73, P128, DOI 10.1158/0008-5472.CAN-12-2606; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Chen KJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024671; Clemente CG, 1996, CANCER, V77, P1303, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.3.CO;2-0; Fleming ID, 1997, AJCC CANC STAG MAN, P24; Frick VO, 2016, WORLD J GASTROENTERO, V22, P833, DOI 10.3748/wjg.v22.i2.833; Fujii N, 2012, J ORAL PATHOL MED, V41, P444, DOI 10.1111/j.1600-0714.2012.01127.x; Gajewski TF, 2015, SEMIN ONCOL, V42, P663, DOI 10.1053/j.seminoncol.2015.05.011; Gasparoto TH, 2010, CANCER IMMUNOL IMMUN, V59, P819, DOI 10.1007/s00262-009-0803-7; Hayasaka H, 2010, CANCER SCI, V101, P2302, DOI 10.1111/j.1349-7006.2010.01687.x; Hoffmann TK, 2002, CLIN CANCER RES, V8, P2553; Holdenrieder S, 2016, J CLIN LAB INVEST S, V245, pS40; Hong AM, 2016, ONCOTARGET, V7, P77010, DOI 10.18632/oncotarget.12776; Hsu MC, 2010, MODERN PATHOL, V23, P1393, DOI 10.1038/modpathol.2010.130; Ibrahim R, 2015, SEMIN ONCOL, V42, P474, DOI 10.1053/j.seminoncol.2015.02.007; Iwaia Y, 2002, IMMUNOL LETT, V83, P215, DOI 10.1016/S0165-2478(02)00088-3; Jordanova ES, 2008, CLIN CANCER RES, V14, P2028, DOI 10.1158/1078-0432.CCR-07-4554; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Krisl JC, 2017, AM J TRANSPLANT, V17, P1974, DOI 10.1111/ajt.14238; Lee JJ, 2017, J IMMUNOL, V199, P467, DOI 10.4049/jimmunol.1601815; Lee SY, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-206; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Liu JY, 2015, BRIT J CANCER, V113, P747, DOI 10.1038/bjc.2015.290; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lyford-Pike S, 2013, CANCER RES, V73, P1733, DOI 10.1158/0008-5472.CAN-12-2384; Mandal R, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.89829; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Marcus A, 2014, ADV IMMUNOL, V122, P91, DOI 10.1016/B978-0-12-800267-4.00003-1; Marcus B, 2004, CANCER-AM CANCER SOC, V101, P2779, DOI 10.1002/cncr.20701; Marrogi AJ, 1997, INT J CANCER, V74, P492, DOI 10.1002/(SICI)1097-0215(19971021)74:5<492::AID-IJC3>3.0.CO;2-Z; Marsland BJ, 2005, IMMUNITY, V22, P493, DOI 10.1016/j.immuni.2005.02.010; Martinet L, 2012, ONCOIMMUNOLOGY, V1, P829, DOI 10.4161/onci.20492; Martinet L, 2012, ONCOIMMUNOLOGY, V1, P789, DOI 10.4161/onci.19787; Martinet L, 2011, CANCER RES, V71, P5678, DOI 10.1158/0008-5472.CAN-11-0431; Miyasaka M, 2004, NAT REV IMMUNOL, V4, P360, DOI 10.1038/nri1354; Moussion C, 2011, NATURE, V479, P542, DOI 10.1038/nature10540; Nelson BH, 2010, J IMMUNOL, V185, P4977, DOI 10.4049/jimmunol.1001323; Ni YH, 2015, TUMOR BIOL, V36, P5291, DOI 10.1007/s13277-015-3189-5; Pablos JL, 1999, AM J PATHOL, V155, P1577, DOI 10.1016/S0002-9440(10)65474-0; Pattyn F, 2003, NUCLEIC ACIDS RES, V31, P122, DOI 10.1093/nar/gkg011; Phillips R, 2002, EUR J IMMUNOL, V32, P837, DOI 10.1002/1521-4141(200203)32:3<837::AID-IMMU837>3.0.CO;2-Q; Pretscher D, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-292; Qian CN, 2006, CANCER RES, V66, P10365, DOI 10.1158/0008-5472.CAN-06-2977; Reichert TE, 2002, CLIN CANCER RES, V8, P3137; Rikardsen OG, 2014, BMC ORAL HEALTH, V14, DOI 10.1186/1472-6831-14-103; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Shi F, 2011, INT J CANCER, V128, P887, DOI 10.1002/ijc.25397; Soland TM, 2013, HISTOPATHOLOGY, V63, P297, DOI 10.1111/his.12184; Spranger S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006504; Swann JB, 2007, J CLIN INVEST, V117, P1137, DOI 10.1172/JCI31405; Tong CCL, 2012, IMMUNOL RES, V54, P266, DOI 10.1007/s12026-012-8306-6; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; van Herpen CML, 2008, INT J CANCER, V123, P2354, DOI 10.1002/ijc.23756; van Zante A, 2003, BIOCHEM SOC T, V31, P313, DOI 10.1042/BST0310313; Watanabe Y, 2010, ORAL SURG ORAL MED O, V109, P744, DOI 10.1016/j.tripleo.2009.12.015; Wirsing AM, 2016, TUMOR BIOL, V37, P2449, DOI 10.1007/s13277-015-4036-4; Wirsing AM, 2014, BMC CLIN PATHOL, V14, DOI 10.1186/1472-6890-14-38; Woo SR, 2015, TRENDS IMMUNOL, V36, P250, DOI 10.1016/j.it.2015.02.003; Zandberg DP, 2014, ORAL ONCOL, V50, P627, DOI 10.1016/j.oraloncology.2014.04.003; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177	64	4	4	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUN	2018	31	6					910	922		10.1038/s41379-018-0019-5			13	Pathology	Pathology	GJ1CH	WOS:000434991000007	29416107				2019-10-28	
J	Takamatsu, M; Sato, Y; Muto, M; Nagano, H; Ninomiya, H; Sakakibara, R; Baba, S; Sakata, S; Takeuchi, K; Okumura, S; Ishikawa, Y				Takamatsu, Manabu; Sato, Yukiko; Muto, Mariko; Nagano, Hiroko; Ninomiya, Hironori; Sakakibara, Rie; Baba, Satoko; Sakata, Seiji; Takeuchi, Kengo; Okumura, Sakae; Ishikawa, Yuichi			Hyalinizing clear cell carcinoma of the bronchial glands: presentation of three cases and pathological comparisons with salivary gland counterparts and bronchial mucoepidermoid carcinomas	MODERN PATHOLOGY			English	Article							ADENOID CYSTIC CARCINOMA; OF-THE-LITERATURE; LUNG; METASTASES; FUSION; CAVITY; TUMORS	Hyalinizing clear cell carcinoma of the bronchial glands is a very rare tumor. Since only five reports describing six tumors have been published to date, only a little is known about specific histologic findings and clinical features. Because of its rarity, hyalinizing clear cell carcinoma has not been described in the latest WHO classification of pulmonary tumors yet. Here we present three cases of bronchial hyalinizing clear cell carcinomas, confirmed by both fluorescence in situ hybridization (FISH) and RT-PCR, focusing on histologic and immunohistochemical characteristics in a comparison with three cases of salivary gland origin. In addition, we compared immunohistochemical features with bronchial mucoepidermoid carcinoma, a lesion that needs to be taken into account in differential diagnosis of hyalinizing clear cell carcinoma. All our bronchial hyalinizing clear cell carcinoma cases were surgically resected. Histologically, tumor cells showed clear to eosinophilic cytoplasm with hyalinizing stroma in various proportions, resembling those of salivary gland origin. Immunohistochemically, tumor cells were positive for CK7, CK5/6, p40, p63, and ATF1, while they were negative for TTF1, Napsin A, HMB45, and SOX10. The CK5/6 staining pattern varied in mucoepidermoid carcinomas, while that of hyalinizing clear cell carcinoma was uniformly positive. FISH revealed EWSR1-ATF1 fusion, and RT-PCR with sequencing confirmed specificity of the chimeric gene for hyalinizing clear cell carcinoma. Clinically, bronchial hyalinizing clear cell carcinoma was characterized by occurrence in the fourth to sixth decades, no link with smoking history, and a predilection for the right lung, in line with previous reports. In summary, our study confirmed that the bronchial hyalinizing clear cell carcinoma is a histologically and genetically identical tumor to that of salivary gland origin, and that gene rearrangement analysis can play a critical role in distinction from mucoepidermoid carcinoma.	[Takamatsu, Manabu; Sato, Yukiko; Muto, Mariko; Nagano, Hiroko; Ninomiya, Hironori; Sakakibara, Rie; Takeuchi, Kengo; Ishikawa, Yuichi] Japanese Fdn Canc Res, Canc Inst Hosp, Inst Canc, Div Pathol, Tokyo 1358550, Japan; [Takamatsu, Manabu; Sato, Yukiko; Muto, Mariko; Nagano, Hiroko; Ninomiya, Hironori; Sakakibara, Rie; Takeuchi, Kengo; Ishikawa, Yuichi] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Pathol, Tokyo 1358550, Japan; [Baba, Satoko; Sakata, Seiji; Takeuchi, Kengo] Japanese Fdn Canc Res, Inst Canc, Pathol Project Mol Targets, Tokyo 1358550, Japan; [Okumura, Sakae] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Thorac Surg, Tokyo 1358550, Japan	Ishikawa, Y (reprint author), Japanese Fdn Canc Res, Canc Inst Hosp, Inst Canc, Div Pathol, Tokyo 1358550, Japan.; Ishikawa, Y (reprint author), Japanese Fdn Canc Res, Canc Inst Hosp, Dept Pathol, Tokyo 1358550, Japan.	ishikawa@jfcr.or.jp					Antonescu CR, 2011, GENE CHROMOSOME CANC, V50, P559, DOI 10.1002/gcc.20881; AUCLAIR PL, 1992, CANCER, V69, P2021, DOI 10.1002/1097-0142(19920415)69:8<2021::AID-CNCR2820690803>3.0.CO;2-7; Azukari K, 1996, INTERNAL MED, V35, P407, DOI 10.2169/internalmedicine.35.407; Carretta Angelo, 2004, Interact Cardiovasc Thorac Surg, V3, P663, DOI 10.1016/j.icvts.2004.07.017; Ereno C, 2000, HISTOPATHOLOGY, V37, P89, DOI 10.1046/j.1365-2559.2000.00955-6.x; Falk N, 2016, ADV ANAT PATHOL, V23, P13, DOI 10.1097/PAP.0000000000000099; Garcia JJ, 2015, HUM PATHOL, V46, P471, DOI 10.1016/j.humpath.2014.11.010; Hijjawi SB, 2012, OR SURG OR MED OR PA, V114, pE32, DOI 10.1016/j.oooo.2012.02.003; Jeffus SK, 2017, AM J CLIN PATHOL, V148, P73, DOI [10.1093/AJCP/AQX048, 10.1093/ajcp/aqx048]; Langner C, 2003, J HISTOCHEM CYTOCHEM, V51, P1097, DOI 10.1177/002215540305100813; MECKSTROTH CV, 1961, DIS CHEST, V40, P652; MILCHGRUB S, 1994, AM J SURG PATHOL, V18, P74, DOI 10.1097/00000478-199401000-00007; Newman WC, 2016, WORLD NEUROSURG, V90, DOI 10.1016/j.wneu.2016.02.001; Nolan LP, 2001, INT J GYNECOL PATHOL, V20, P155, DOI 10.1097/00004347-200104000-00007; NOMORI H, 1988, J THORAC CARDIOV SUR, V96, P271; Rinaldo A, 1999, ORL J OTO-RHINO-LARY, V61, P48, DOI 10.1159/000027639; Roden AC, 2014, MODERN PATHOL, V27, P1479, DOI 10.1038/modpathol.2014.72; Shah AA, 2015, HISTOPATHOLOGY, V67, P274, DOI 10.1111/his.12636; Shahi M, 2017, HEAD NECK PATHOL, V11, P575, DOI 10.1007/s12105-017-0820-3; Shanks JH, 1998, HISTOPATHOLOGY, V33, P90, DOI 10.1046/j.1365-2559.1998.0415f.x; Su HK, 2015, HEAD NECK-J SCI SPEC, V37, pE19, DOI 10.1002/hed.23764; Travis WD, 2015, WORLD HLTH ORG CLASS; Wang H, 2016, PATHOLOGY, V48, P518, DOI 10.1016/j.pathol.2016.04.011; Yang SD, 2008, ORAL SURG ORAL MED O, V106, P712, DOI 10.1016/j.tripleo.2008.04.016; Zhao W, 2014, INT J CLIN EXP MED, V7, P5469; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	26	1	1	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUN	2018	31	6					923	933		10.1038/s41379-018-0025-7			11	Pathology	Pathology	GJ1CH	WOS:000434991000008	29434341				2019-10-28	
J	Lee, WC; Diao, LX; Wang, J; Zhang, JH; Roarty, EB; Varghese, S; Chow, CW; Fujimoto, J; Behrens, C; Cascone, T; Peng, WY; Kalhor, N; Moran, CA; Weissferdt, A; Johnson, FM; William, WN; Swisher, SG; Lee, JJ; Hong, WK; Heymach, JV; Wistuba, II; Futreal, PA; Zhang, JJ				Lee, Won-Chul; Diao, Lixia; Wang, Jing; Zhang, Jianhua; Roarty, Emily B.; Varghese, Susan; Chow, Chi-Wan; Fujimoto, Junya; Behrens, Carmen; Cascone, Tina; Peng, Weiyi; Kalhor, Neda; Moran, Cesar A.; Weissferdt, Annikka; Johnson, Faye M.; William, William N., Jr.; Swisher, Stephen G.; Lee, J. Jack; Hong, Waun Ki; Heymach, John V.; Wistuba, Ignacio I.; Futreal, P. Andrew; Zhang, Jianjun			Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer	MODERN PATHOLOGY			English	Article							SQUAMOUS-CELL CARCINOMA; INTRATUMOR HETEROGENEITY; MESENCHYMAL TRANSITION; PD-L1 EXPRESSION; BREAST-CANCER; EVOLUTION; RESISTANCE; SENSITIVITY; BLOCKADE; ANTIBODY	Intra-tumor heterogeneity may be present at all molecular levels. Genomic intra-tumor heterogeneity at the exome level has been reported in many cancer types, but comprehensive gene expression intra-tumor heterogeneity has not been well studied. Here, we delineated the gene expression intra-tumor heterogeneity by exploring gene expression profiles of 35 tumor regions from 10 non-small cell lung cancer tumors (three or four regions/tumor), including adenocarcinoma, squamous cell carcinoma, large-cell carcinoma, and pleomorphic carcinoma of the lung. Using Affymetrix Gene 1.0 ST arrays, we generated the gene expression data for every sample. Inter-tumor heterogeneity was generally higher than intra-tumor heterogeneity, but some tumors showed a substantial level of intra-tumor heterogeneity. The analysis of various clinically relevant gene expression signatures including molecular subtype, epithelial-to-mesenchymal transition, and anti-PD-1 resistance signatures also revealed heterogeneity between different regions of the same tumor. The gene expression intra-tumor heterogeneity we observed was associated with heterogeneous tumor microenvironments represented by stromal and immune cells infiltrated. Our data suggest that RNA-based prognostic or predictive molecular tests should be carefully conducted in consideration of the gene expression intra-tumor heterogeneity.	[Lee, Won-Chul; Zhang, Jianhua; Futreal, P. Andrew; Zhang, Jianjun] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Lee, Won-Chul; Roarty, Emily B.; Varghese, Susan; Behrens, Carmen; Cascone, Tina; Johnson, Faye M.; William, William N., Jr.; Hong, Waun Ki; Heymach, John V.; Wistuba, Ignacio I.; Zhang, Jianjun] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Diao, Lixia; Wang, Jing] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Chow, Chi-Wan; Fujimoto, Junya; Wistuba, Ignacio I.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Peng, Weiyi] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA; [Kalhor, Neda; Moran, Cesar A.; Weissferdt, Annikka] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Swisher, Stephen G.] Univ Texas MD Anderson Canc Ctr, Dept Thorac Surg, Houston, TX 77030 USA; [Lee, J. Jack] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	Futreal, PA; Zhang, JJ (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA.; Wistuba, II; Zhang, JJ (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA.; Wistuba, II (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA.	iiwistuba@mdanderson.org; afutreal@mdanderson.org; jzhang20@mdanderson.org	Lee, Won-Chul/D-5789-2012	Lee, Won-Chul/0000-0001-8052-2420	MD Anderson Lung cancer Moon Shot Program; MD Anderson Physician Scientist Program; Conquer Cancer Foundation Young Investigator Award; Khalifa Scholar Award; Cancer Prevention and Research Institute of Texas [R120501]; Cancer Prevention and Research Institute of Texas Multi-Investigator Research Award [RP160668]; University of Texas (UT) Systems Stars Award [PS100149]; Welch Foundation Robert A. Welch Distinguished University Chair Award [G-0040]; Department of Defense PROSPECT grantUnited States Department of Defense [W81XWH-07-1-0306]; UT Lung Specialized Programs of Research Excellence grant [P50CA70907]; T.J. Martell Foundation	This work was supported by MD Anderson Lung cancer Moon Shot Program, MD Anderson Physician Scientist Program, Conquer Cancer Foundation Young Investigator Award, Khalifa Scholar Award, the Cancer Prevention and Research Institute of Texas (R120501), the Cancer Prevention and Research Institute of Texas Multi-Investigator Research Award grant (RP160668), the University of Texas (UT) Systems Stars Award (PS100149), the Welch Foundation Robert A. Welch Distinguished University Chair Award (G-0040), Department of Defense PROSPECT grant (W81XWH-07-1-0306), the UT Lung Specialized Programs of Research Excellence grant (P50CA70907), and T.J. Martell Foundation.	Boutros PC, 2009, P NATL ACAD SCI USA, V106, P2824, DOI 10.1073/pnas.0809444106; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Chen LM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6241; Chung GG, 2007, LAB INVEST, V87, P662, DOI 10.1038/labinvest.3700543; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; de Bruin EC, 2014, SCIENCE, V346, P251, DOI 10.1126/science.1253462; Frederick BA, 2007, MOL CANCER THER, V6, P1683, DOI 10.1158/1535-7163.MCT-07-0138; Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Gyanchandani R, 2016, CLIN CANCER RES, V22, P5362, DOI 10.1158/1078-0432.CCR-15-2889; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Kratz JR, 2012, LANCET, V379, P823, DOI 10.1016/S0140-6736(11)61941-7; Kuner Ruprecht, 2013, Microarrays (Basel), V2, P318, DOI 10.3390/microarrays2040318; Matsubara D, 2014, PATHOL INT, V64, P560, DOI 10.1111/pin.12214; McGranahan N, 2015, CANCER CELL, V27, P15, DOI 10.1016/j.ccell.2014.12.001; Nitsche K, 2012, J CANCER RES CLIN, V138, P415, DOI 10.1007/s00432-011-1108-8; Papadimitrakopoulou V, 2016, J CLIN ONCOL, V34, P3638, DOI 10.1200/JCO.2015.66.0084; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Patel SP, 2015, MOL CANCER THER, V14, P847, DOI 10.1158/1535-7163.MCT-14-0983; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PERTSCHUK LP, 1999, BREAST J, V5, P369, DOI DOI 10.1046/J.1524-4741.1999.97088.X; Ringner M, 2016, CLIN CANCER RES, V22, P218, DOI 10.1158/1078-0432.CCR-15-0529; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thomson S, 2005, CANCER RES, V65, P9455, DOI 10.1158/0008-5472.CAN-05-1058; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wilkerson MD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036530; Wilkerson MD, 2010, CLIN CANCER RES, V16, P4864, DOI 10.1158/1078-0432.CCR-10-0199; Yang JY, 2012, CELL BIOCHEM BIOPHYS, V62, P221, DOI 10.1007/s12013-011-9286-1; Yauch RL, 2005, CLIN CANCER RES, V11, P8686, DOI 10.1158/1078-0432.CCR-05-1492; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Zhang JJ, 2014, SCIENCE, V346, P256, DOI 10.1126/science.1256930; Zhu CQ, 2010, J CLIN ONCOL, V28, P4417, DOI 10.1200/JCO.2009.26.4325	38	7	7	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUN	2018	31	6					947	955		10.1038/s41379-018-0029-3			9	Pathology	Pathology	GJ1CH	WOS:000434991000010	29410488				2019-10-28	
J	Zen, Y; Yeh, MM				Zen, Yoh; Yeh, Matthew M.			Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury	MODERN PATHOLOGY			English	Article							CELL LUNG-CANCER; NIVOLUMAB; IPILIMUMAB; MELANOMA; ANTIBODIES; EXPRESSION; ZONATION; CTLA-4	The adverse effects of immune checkpoint inhibitors in various organs may be attributed to immune-mediated processes triggered by disrupted self-tolerance; however, it remains unclear whether they are similar or dissimilar to classic organ-specific autoimmune diseases. The present study aimed to compare clinicopathologic features between checkpoint inhibitor-induced liver injury and acutely presenting autoimmune hepatitis or idiosyncratic drug-induced liver injury. Seven patients treated with nivolumab (n = 5) or ipilimumab (n = 2) presented with liver dysfunction a median of 41 days (range 21-120) after the initiation of immunotherapy. All patients had elevated liver enzymes, whereas hyper-bilirubinemia was less common. None of the patients had antinuclear antibodies or IgG elevations. Stopping the immunotherapy and additional immunosuppression with corticosteroids normalized or decreased liver enzymes in all patients treated. Histologically, all biopsies showed predominantly lobular hepatitis with milder portal inflammation. Centrilobular confluent necrosis and plasmacytosis were observed in a single case, and were markedly less common and milder than those in autoimmune hepatitis (p = 0.017 and p < 0.001, respectively). Bile duct injury, micro-abscesses, and extramedullary hematopoiesis were also found in one case each. Immunostaining revealed the presence of large numbers of CD3+ and CD8+ lymphocytes, whereas CD20+ B cells and CD4+ T cells were fewer in checkpoint inhibitor-induced liver injury than in autoimmune hepatitis or drug-induced liver injury. In conclusion, liver injury caused by cancer immunotherapy shares some features with injury of autoimmune hepatitis; however, there are obvious differences between the two conditions. Checkpoint inhibitor-induced liver injury may represent an immune-mediated, less zone-selective hepatocyte necrosis not requiring the strong activation of helper T cells and immunoglobulin production.	[Zen, Yoh] Kobe Univ, Grad Sch Med, Dept Diagnost Pathol, Kobe, Hyogo, Japan; [Yeh, Matthew M.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA	Zen, Y (reprint author), Kobe Univ, Grad Sch Med, Dept Diagnost Pathol, Kobe, Hyogo, Japan.	yohzen@med.kobe-u.ac.jp					Abdel-Wahab N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160221; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Everett J, 2017, AM J SURG PATHOL, V41, P134, DOI 10.1097/PAS.0000000000000759; Fong L, 2008, J CLIN ONCOL, V26, P5275, DOI 10.1200/JCO.2008.17.8954; Francisco LM, 2009, J EXP MED, V206, P3015, DOI 10.1084/jem.20090847; Gelsomino F, 2018, INVEST NEW DRUG, V36, P144, DOI 10.1007/s10637-017-0484-6; Hennes EM, 2008, HEPATOLOGY, V48, P169, DOI 10.1002/hep.22322; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Huffman BM, 2018, AM J CLIN ONCOL-CANC, V41, P760, DOI 10.1097/COC.0000000000000374; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; Johncilla M, 2015, AM J SURG PATHOL, V39, P1075, DOI 10.1097/PAS.0000000000000453; Kawakami H, 2017, INVEST NEW DRUG, V35, P529, DOI 10.1007/s10637-017-0453-0; Kim KW, 2013, INVEST NEW DRUG, V31, P1071, DOI 10.1007/s10637-013-9939-6; Kleiner DE, 2012, DIGEST DIS SCI, V57, P2233, DOI 10.1007/s10620-012-2140-5; Lindros KO, 1997, GEN PHARMACOL, V28, P191, DOI 10.1016/S0306-3623(96)00183-8; Melero I, 2007, NAT REV CANCER, V7, P95, DOI 10.1038/nrc2051; Melosky B, 2016, J CLIN ONCOL, V34, P1676, DOI 10.1200/JCO.2015.63.8049; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Motzer RJ, 2015, J CLIN ONCOL, V33, P1430, DOI 10.1200/JCO.2014.59.0703; O'Day SJ, 2007, CANCER-AM CANCER SOC, V110, P2614, DOI 10.1002/cncr.23086; Oinonen T, 1998, BIOCHEM J, V329, P17, DOI 10.1042/bj3290017; Peggs KS, 2009, J EXP MED, V206, P1717, DOI 10.1084/jem.20082492; Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358; Quezada SA, 2010, J EXP MED, V207, P637, DOI 10.1084/jem.20091918; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Simonelli M, 2016, IMMUNOTHERAPY-UK, V8, P1363, DOI 10.2217/imt-2016-0057; Weber JS, 2012, J CLIN ONCOL, V30, P2691, DOI 10.1200/JCO.2012.41.6750; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369	29	26	27	2	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUN	2018	31	6					965	973		10.1038/s41379-018-0013-y			9	Pathology	Pathology	GJ1CH	WOS:000434991000012	29403081				2019-10-28	
J	Muller, M; Guillaud-Bataille, M; Salleron, J; Genestie, C; Deveaux, S; Slama, A; de Paillerets, BB; Richard, S; Benusiglio, PR; Ferlicot, S				Muller, Marie; Guillaud-Bataille, Marine; Salleron, Julia; Genestie, Catherine; Deveaux, Sophie; Slama, Abdelhamid; de Paillerets, Brigitte Bressac; Richard, Stephane; Benusiglio, Patrick R.; Ferlicot, Sophie			Pattern multiplicity and fumarate hydratase (FH)/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration	MODERN PATHOLOGY			English	Article							CANCER HLRCC; UTERINE LEIOMYOMATOSIS; IMMUNOHISTOCHEMISTRY; MUTATIONS; CLASSIFICATION; SUCCINATION; SPECTRUM; AID	Hereditary leiomyomatosis and renal cell carcinoma syndrome is characterized by an increased risk of agressive renal cell carcinoma, often of type 2 papillary histology, and is caused by FH germline mutations. A prominent eosinophilic macronucleolus with a perinucleolar clear halo is distinctive of hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cell carcinoma according to the 2012 ISUP and 2016 WHO kidney tumor classification. From an immunohistochemistry perspective, tumors are often FH-negative and S-(2-succino)-cysteine (2SC) positive. We performed a pathology review of 24 renal tumors in 23 FH mutation carriers, and compared them to 12 type 2 papillary renal cell carcinomas from FH wild-type patients. Prominent eosinophilic nucleoli with perinucleolar halos were present in almost all FH-deficient renal cell carcinomas (23/24). Unexpectedly, they were also present in 58% of type 2 papillary renal cell carcinomas from wild-type patients. Renal cell carcinoma in mutation carriers displayed a complex architecture with multiple patterns, typically papillary, tubulopapillary, and tubulocystic, but also sarcomatoid and rhabdoid. Such pattern diversity was not seen in non-carriers. FH/2SC immunohistochemistry was informative as all hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas were either FH- or 2SC+. For FH and 2SC immunohistochemistries taken separately, sensitivity of negative anti-FH immunohistochemistry was 87.5% and specificity was 100%. For positive anti-2SC immunohistochemistry, sensitivity, and specificity were 91.7% and 91.7%, respectively. All FH wild-type renal cell carcinoma were FH-positive, and all but one were 2SC-negative. In conclusion, multiplicity of architectural patterns, rhabdoid/sarcomatoid components and combined FH/2SC staining, but not prominent eosinophilic nucleoli with perinucleolar halos, differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma from type 2 papillary renal cell carcinoma with efficient FH gene. Our findings are crucial in identifying who should be referred to Cancer Genetics clinics for genetic counseling and testing.	[Muller, Marie; Deveaux, Sophie; Richard, Stephane; Ferlicot, Sophie] Hop Bicetre, Reseau Natl Canc Rares Adulte PREDIR AP HP Labell, Inst Natl Canc INCa, F-94275 Le Kremlin Bicetre, France; [Muller, Marie] Inst Cancerol Lorraine Alexis Vautrin, Dept Med Oncol, F-54519 Vandoeuvre Les Nancy, France; [Guillaud-Bataille, Marine; de Paillerets, Brigitte Bressac] Univ Paris Saclay, Serv Genet, Dept Biopathol, Gustave Roussy, F-94805 Villejuif, France; [Salleron, Julia] Inst Cancerol Lorraine Alexis Vautrin, Unite Biostat, F-54519 Vandoeuvre Les Nancy, France; [Genestie, Catherine] Univ Paris Saclay, Serv Anat Pathol, Dept Biopathol, Gustave Roussy, F-94805 Villejuif, France; [Slama, Abdelhamid] Hop Bicetre, AP HP, Serv Biol Mol, F-94275 Le Kremlin Bicetre, France; [Richard, Stephane] PSL Res Univ, Ecole Prat Hautes Etudes, F-75014 Paris, France; [Richard, Stephane] Univ Paris Saclay, Lab Genet Oncol, Gustave Roussy, EPHE,INSERM,U1186, F-94805 Villejuif, France; [Richard, Stephane; Ferlicot, Sophie] Univ Paris Sud, Le Kremlin Bicetre, France; [Benusiglio, Patrick R.] Groupement Hosp La Pitie Salpetriere, AP HP, Dept Genet, Unite Fonct Oncogenet, Paris, France; [Ferlicot, Sophie] Hop Univ Paris Sud, AP HP, Serv Anat Pathol, Le Kremlin Bicetre, France	Muller, M (reprint author), Hop Bicetre, Reseau Natl Canc Rares Adulte PREDIR AP HP Labell, Inst Natl Canc INCa, F-94275 Le Kremlin Bicetre, France.; Muller, M (reprint author), Inst Cancerol Lorraine Alexis Vautrin, Dept Med Oncol, F-54519 Vandoeuvre Les Nancy, France.	mariemuller.onco@gmail.com	de Paillerets, Brigitte Bressac-/D-8954-2018; Benusiglio, Patrick R./H-8661-2019	de Paillerets, Brigitte Bressac-/0000-0003-0245-8608; Benusiglio, Patrick R./0000-0003-1003-1997; Muller, Marie/0000-0001-6412-932X	French National Cancer Institute (INCa)Institut National du Cancer (INCA) France; French Department of Health; French league against Cancer (Comites du Cher et de l'Indre)	The PREDIR Centre is supported by the French National Cancer Institute (INCa) and the French Department of Health. The Laboratoire de Genetique Oncologique EPHE is supported by grants from the French league against Cancer (Comites du Cher et de l'Indre).	Alam NA, 2003, HUM MOL GENET, V12, P1241, DOI 10.1093/hmg/ddg148; Bardella C, 2011, J PATHOL, V225, P4, DOI 10.1002/path.2932; Bavle Radhika M, 2014, J Oral Maxillofac Pathol, V18, P152, DOI 10.4103/0973-029X.140716; Buelow B, 2016, AM J SURG PATHOL, V40, P982, DOI 10.1097/PAS.0000000000000626; Chen YB, 2014, AM J SURG PATHOL, V38, P627, DOI 10.1097/PAS.0000000000000163; Frizzell N, 2011, FREE RADICAL RES, V45, P101, DOI 10.3109/10715762.2010.524643; Gardie B, 2011, J MED GENET, V48, P226, DOI 10.1136/jmg.2010.085068; Grubb RL, 2007, J UROLOGY, V177, P2074, DOI 10.1016/j.juro.2007.01.155; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Joseph NM, 2015, AM J SURG PATHOL, V39, P1529, DOI 10.1097/PAS.0000000000000520; Launonen V, 2001, P NATL ACAD SCI USA, V98, P3387, DOI 10.1073/pnas.051633798; Llamas-Velasco M, 2014, J CUTAN PATHOL, V41, P859, DOI 10.1111/cup.12396; Menko FH, 2014, FAM CANCER, V13, P637, DOI 10.1007/s10689-014-9735-2; Merino MJ, 2007, AM J SURG PATHOL, V31, P1578, DOI 10.1097/PAS.0b013e31804375b8; Moch H, 2016, EUR UROL, V70, P93, DOI 10.1016/j.eururo.2016.02.029; Muller M, 2017, CLIN GENET, V92, P606, DOI 10.1111/cge.13014; Ristau BT, 2015, CASE REP UROL, V2015, P1; Sciacovelli M, 2016, NATURE, V537, P544, DOI 10.1038/nature19353; Smith SC, 2016, AM J SURG PATHOL, V40, P1457, DOI 10.1097/PAS.0000000000000719; Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Trpkov K, 2016, AM J SURG PATHOL, V40, P865, DOI 10.1097/PAS.0000000000000617	22	7	7	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUN	2018	31	6					974	983		10.1038/s41379-018-0017-7			10	Pathology	Pathology	GJ1CH	WOS:000434991000013	29410489				2019-10-28	
J	Priore, SF; Schwartz, LE; Epstein, JI				Priore, Salvatore F.; Schwartz, Lauren E.; Epstein, Jonathan I.			An expanded immunohistochemical profile of osteoclast-rich undifferentiated carcinoma of the urinary tract	MODERN PATHOLOGY			English	Article							GIANT-CELL TUMOR; RENAL PELVIS; UROTHELIAL CARCINOMA; UROPLAKIN-III; BLADDER; BONE; THROMBOMODULIN; PANCREAS; BENIGN; MARKER	Osteoclast-rich undifferentiated carcinoma of the urinary tract (ORUCUT) is a rare tumor composed of ovoid to spindle-shaped mononuclear cells with intermixed or focally clustered osteoclast-like giant cells. Previous studies have demonstrated that the mononuclear cells are neoplastic cells, while the giant cells are reactive cells of histiocytic lineage. The association between these tumors and classic urothelial carcinomas suggest that the mononuclear cells are derived from urothelial cells; however, no studies have been conducted to assess the immunohistochemical profile of ORUCUT with more specific urothelial markers. This study identified 21 cases of ORUCUT and performed immunohistochemistry for GATA3, uroplakin II, and thrombomodulin along with pancytokeratin (AE1/3) on all cases. Mononuclear cells stained positive in 20 cases (95%) for GATA3 and 19 cases (90%) for thrombomodulin. None of the mononuclear cells were positive for uroplakin II and only three cases showed focal positivity for AE1/3. The osteoclast-like giant cells were negative for GATA3, uroplakin II, thrombomodulin, and AE1/3, providing additional support to a reactive origin for these cells. Additionally, 15 cases (71%) were associated with either in situ or invasive urothelial carcinoma. This study provides an expanded immunohistochemical profile for ORUCUT and more definitively supports a urothelial origin for this tumor.	[Priore, Salvatore F.; Schwartz, Lauren E.] Univ Penn, Dept Pathol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Epstein, Jonathan I.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; [Epstein, Jonathan I.] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA; [Epstein, Jonathan I.] Johns Hopkins Med Inst, Dept Urol, Baltimore, MD 21205 USA	Epstein, JI (reprint author), Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA.; Epstein, JI (reprint author), Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA.; Epstein, JI (reprint author), Johns Hopkins Med Inst, Dept Urol, Baltimore, MD 21205 USA.	jepstein@jhmi.edu					Akhtar M., 1999, J UROL PATHOL, V11, P181; AMIR G, 1990, HISTOPATHOLOGY, V17, P413, DOI 10.1111/j.1365-2559.1990.tb00761.x; Balke M, 2008, J CANCER RES CLIN, V134, P969, DOI 10.1007/s00432-008-0370-x; Baydar D, 2006, MODERN PATHOL, V19, P161, DOI 10.1038/modpathol.3800521; Behzatoglu K, 2009, DIAGN PATHOL, V4, DOI 10.1186/1746-1596-4-48; BERENDT RC, 1987, ARCH PATHOL LAB MED, V111, P43; BORGGRECH A, 1987, HISTOPATHOLOGY, V11, P415, DOI 10.1111/j.1365-2559.1987.tb02646.x; Castelino-Prabhu S, 2010, DIAGN CYTOPATHOL, V38, P364, DOI 10.1002/dc.21218; DORNEY P, 1967, BRIT HEART J, V29, P276; EUSEBI V, 1984, AM J CLIN PATHOL, V81, P666, DOI 10.1093/ajcp/81.5.666; Fadare O, 2003, AM J SURG PATHOL, V27, P854, DOI 10.1097/00000478-200306000-00021; Heller KN, 1998, UROLOGY, V51, P495, DOI 10.1016/S0090-4295(97)00649-3; Higgins JPT, 2007, AM J SURG PATHOL, V31, P673, DOI 10.1097/01.pas.0000213438.01278.5f; Hoang LL, 2014, ARCH PATHOL LAB MED, V138, P943, DOI 10.5858/arpa.2013-0221-OA; HOLTZ F, 1972, CANCER, V29, P294, DOI 10.1002/1097-0142(197202)29:2<294::AID-CNCR2820290205>3.0.CO;2-V; HUTTER RVP, 1962, CANCER, V15, P653, DOI 10.1002/1097-0142(196207/08)15:4<653::AID-CNCR2820150402>3.0.CO;2-M; Kanthan Rani, 2004, BMC Urol, V4, P7, DOI 10.1186/1471-2490-4-7; Kawano H, 2011, PATHOL RES PRACT, V207, P722, DOI 10.1016/j.prp.2011.09.003; KENNEY RM, 1984, AM J SURG PATHOL, V8, P139, DOI 10.1097/00000478-198402000-00008; KIMURA K, 1983, VIRCHOWS ARCH A, V398, P357, DOI 10.1007/BF00583591; KITAZAWA M, 1985, J UROLOGY, V133, P472, DOI 10.1016/S0022-5347(17)49029-X; KURODA M, 1994, PATHOL INT, V44, P158, DOI 10.1111/j.1440-1827.1994.tb01701.x; Li W, 2014, AM J CLIN PATHOL, V142, P864, DOI 10.1309/AJCP1J0JPJBPSUXF; LIDGI S, 1989, J UROLOGY, V142, P120, DOI 10.1016/S0022-5347(17)38680-9; MAHESWARAN P, 1990, HISTOPATHOLOGY, V16, P604, DOI 10.1111/j.1365-2559.1990.tb01168.x; McCash SI, 2010, APMIS, V118, P407, DOI 10.1111/j.1600-0463.2010.02608.x; Miettinen M, 2014, AM J SURG PATHOL, V38, P13, DOI 10.1097/PAS.0b013e3182a0218f; Molinie V, 1997, ARCH PATHOL LAB MED, V121, P162; MUNOZ PA, 1980, CANCER-AM CANCER SOC, V46, P771, DOI 10.1002/1097-0142(19800815)46:4<771::AID-CNCR2820460422>3.0.CO;2-L; O'Connor RC, 2002, J UROLOGY, V167, P1784, DOI 10.1016/S0022-5347(05)65203-2; Ordonez NG, 1998, AM J CLIN PATHOL, V110, P385, DOI 10.1093/ajcp/110.3.385; Parker DC, 2003, AM J SURG PATHOL, V27, P1, DOI 10.1097/00000478-200301000-00001; Reid MD, 2017, CANCER CYTOPATHOL, V125, P563, DOI 10.1002/cncy.21859; SILVERBERG SG, 1973, CANCER-AM CANCER SOC, V31, P621, DOI 10.1002/1097-0142(197303)31:3<621::AID-CNCR2820310319>3.0.CO;2-N; TUBBS WS, 1992, AM J ROENTGENOL, V158, P331, DOI 10.2214/ajr.158.2.1729794; Wieneke JA, 2001, MODERN PATHOL, V14, P1209, DOI 10.1038/modpathol.3880462; Wu PJ, 2009, J CHIN MED ASSOC, V72, P495, DOI 10.1016/S1726-4901(09)70415-0; Zanella M., 2000, J UROL PATHOL, V12, P13; ZUKERBERG LR, 1990, HISTOPATHOLOGY, V17, P407, DOI 10.1111/j.1365-2559.1990.tb00760.x	39	2	2	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUN	2018	31	6					984	988		10.1038/s41379-018-0012-z			5	Pathology	Pathology	GJ1CH	WOS:000434991000014	29410491				2019-10-28	
J	Johncilla, M; Stachler, M; Misdraji, J; Lisovsky, M; Yozu, M; Lindeman, N; Lauwers, GY; Odze, RD; Srivastava, A				Johncilla, Melanie; Stachler, Matthew; Misdraji, Joseph; Lisovsky, Mikhail; Yozu, Masato; Lindeman, Neal; Lauwers, Gregory Y.; Odze, Robert D.; Srivastava, Amitabh			Mutational landscape of goblet cell carcinoids and adenocarcinoma ex goblet cell carcinoids of the appendix is distinct from typical carcinoids and colorectal adenocarcinomas	MODERN PATHOLOGY			English	Article							GENOMIC ALTERATIONS; CANCER; TUMORS; ARID1A; FEATURES	There is limited data on the spectrum of molecular alterations in goblet cell carcinoids and adenocarcinoma ex goblet cell carcinoids of the appendix. We used next generation sequencing to determine mutations of potential pathogenetic and therapeutic significance in this rare group of tumors. Adequate DNA was successfully extracted in 34/46 cases and the final group included 18 goblet cell carcinoids and 16 adenocarcinoma ex goblet cell carcinoids. Illumina TruSeq (TM) was used for sequencing exons of a custom 282 gene panel using an Illumina HiSeq 2000. All cases had a minimum coverage depth of at least 50 reads. After filtering through the Exome Sequencing Project, the number of mutations per case ranged from 0-9 (mean: 3). The mutational burden in adenocarcinoma ex goblet cell carcinoids was significantly higher than goblet cell carcinoids (mean 5 vs. 3; p < 0.05) but the spectrum of alterations overlapped between the two groups. The most frequent mutations included ARID1A (4/34), ARID2 (4/34), CDH1 (4/34), RHPN2 (4/34), and MLL2 (3/34). Some mutations typically seen in conventional colorectal adenocarcinomas were also identified but with much lower frequency (APC : 4/34; KRAS : 2/34). MLL2 and KRAS mutations were only seen in adenocarcinoma ex goblet cell carcinoids and TP53 mutations were limited to poorly differentiated adenocarcinoma ex goblet cell carcinoids (2/34). Copy number changes could be evaluated in 15/34 cases and showed low copy number gains in CDKN1B (6/15) and NFKBIA (6/15), among others. The overlapping molecular alterations suggest that goblet cell carcinoids and adenocarcinoma ex goblet cell carcinoids are best considered two grades of differentiation of the same tumor rather than two distinct histological types. Mutations in TP53, CDH1 and MLL2 mutations were predominantly present in the adenocarcinoma ex goblet cell carcinoid group consistent with transformation to a higher grade lesion. The unique mutational profile also offers an explanation for the poor chemosensitivity in these tumors and highlights the need for developing new targeted therapies.	[Johncilla, Melanie; Stachler, Matthew; Lindeman, Neal; Odze, Robert D.; Srivastava, Amitabh] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Johncilla, Melanie; Stachler, Matthew; Lindeman, Neal; Odze, Robert D.; Srivastava, Amitabh] Harvard Med Sch, Boston, MA 02215 USA; [Misdraji, Joseph; Yozu, Masato; Lauwers, Gregory Y.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Lisovsky, Mikhail] Dartmouth Hitchcock Med Ctr, Dept Pathol, Lebanon, NH 03766 USA	Srivastava, A (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.; Srivastava, A (reprint author), Harvard Med Sch, Boston, MA 02215 USA.	asrivastava@bwh.harvard.edu					Alakus H, 2014, GENOME MED, V6, DOI 10.1186/gm559; Ali SM, 2015, ONCOLOGIST, V20, P499, DOI 10.1634/theoncologist.2014-0378; Bitler BG, 2015, EXPERT OPIN THER TAR, V19, P1419, DOI 10.1517/14728222.2015.1062879; Cajuso T, 2014, INT J CANCER, V135, P611, DOI 10.1002/ijc.28705; Dossus L, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0546-7; Drage MG, 2017, ARCH PATHOL LAB MED, V141, P970, DOI 10.5858/arpa.2016-0318-OA; Ford DJ, 2015, CANCER GENET-NY, V208, P178, DOI 10.1016/j.cancergen.2015.01.005; GAGNE F, 1969, Annales d'Anatomie Pathologique, V14, P393; Kovac M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7336; Lamarca A, 2016, NEUROENDOCRINOLOGY, V103, P500, DOI 10.1159/000440725; McConnell YJ, 2014, ANN SURG ONCOL, V21, P1975, DOI 10.1245/s10434-013-3469-5; Modlin IM, 2006, ANN SURG, V244, P52, DOI 10.1097/01.sla.0000217617.06782.d5; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Olsen IH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117627; Pape UF, 2012, NEUROENDOCRINOLOGY, V95, P135, DOI 10.1159/000335629; Ramnani DM, 1999, CANCER, V86, P14, DOI 10.1002/(SICI)1097-0142(19990701)86:1<14::AID-CNCR4>3.0.CO;2-X; Roy P, 2010, WORLD J GASTRO ONCOL, V2, P251, DOI 10.4251/wjgo.v2.i6.251; Shain AH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055119; Stancu M, 2003, MODERN PATHOL, V16, P1189, DOI 10.1097/01.MP.0000097362.10330.B1; SUBBUSWAMY SG, 1974, CANCER-AM CANCER SOC, V34, P338, DOI 10.1002/1097-0142(197408)34:2<338::AID-CNCR2820340218>3.0.CO;2-W; Taggart MW, 2015, ARCH PATHOL LAB MED, V139, P782, DOI 10.5858/arpa.2013-0047-OA; Tang LH, 2008, AM J SURG PATHOL, V32, P1429, DOI 10.1097/PAS.0b013e31817f1816; Wagle N, 2012, CANCER DISCOV, V2, P82, DOI 10.1158/2159-8290.CD-11-0184; Wang K, 2011, NAT GENET, V43, P1219, DOI 10.1038/ng.982; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Zucman-Rossi J, 2015, GASTROENTEROLOGY, V149, P1226, DOI 10.1053/j.gastro.2015.05.061	26	6	6	1	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUN	2018	31	6					989	996		10.1038/s41379-018-0003-0			8	Pathology	Pathology	GJ1CH	WOS:000434991000015	29422640				2019-10-28	
J	Baldauf, MC; Gerke, JS; Orth, MF; Dallmayer, M; Baumhoer, D; de Alava, E; Hartmann, W; Kirchner, T; Gruenewald, TGP				Baldauf, Michaela C.; Gerke, Julia S.; Orth, Martin F.; Dallmayer, Marlene; Baumhoer, Daniel; de Alava, Enrique; Hartmann, Wolfgang; Kirchner, Thomas; Gruenewald, Thomas G. P.			Are EWSR1-NFATc2-positive sarcomas really Ewing sarcomas?	MODERN PATHOLOGY			English	Letter							PAX7 EXPRESSION; GENE; SUSCEPTIBILITY; EWSR1-FLI1; EWS-FLI1; EGR2		[Baldauf, Michaela C.; Gerke, Julia S.; Orth, Martin F.; Dallmayer, Marlene; Gruenewald, Thomas G. P.] Ludwig Maximilians Univ Munchen, Fac Med, Inst Pathol, Max Eder Res Grp Pediat Sarcoma Biol, Munich, Germany; [Baumhoer, Daniel] Univ Basel, Univ Basel Hosp, Inst Pathol, Bone Tumour Reference Ctr, Basel, Switzerland; [de Alava, Enrique] Univ Seville, CIBERONC, Hosp Univ Virgen del Rocio, Inst Biomed Seville IBiS,CSIC, Seville, Spain; [Hartmann, Wolfgang] Westfalian Wilhelms Univ, Univ Hosp Munster, Gerhard Domagk Inst Pathol, Munster, Germany; [Kirchner, Thomas; Gruenewald, Thomas G. P.] Ludwig Maximilians Univ Munchen, Inst Pathol, Fac Med, Munich, Germany; [Kirchner, Thomas; Gruenewald, Thomas G. P.] German Canc Consortium DKTK, Heidelberg, Germany; [Kirchner, Thomas; Gruenewald, Thomas G. P.] German Canc Res Ctr, Heidelberg, Germany	Gruenewald, TGP (reprint author), Ludwig Maximilians Univ Munchen, Fac Med, Inst Pathol, Max Eder Res Grp Pediat Sarcoma Biol, Munich, Germany.; Gruenewald, TGP (reprint author), Ludwig Maximilians Univ Munchen, Inst Pathol, Fac Med, Munich, Germany.; Gruenewald, TGP (reprint author), German Canc Consortium DKTK, Heidelberg, Germany.; Gruenewald, TGP (reprint author), German Canc Res Ctr, Heidelberg, Germany.	thomas.gruenewald@med.uni-muenchen.de	; Hartmann, Wolfgang/G-1893-2017	de Alava, Enrique/0000-0001-8400-046X; Hartmann, Wolfgang/0000-0002-7609-5021			Baldauf MC, 2018, ONCOTARGET, V9, P1587, DOI 10.18632/oncotarget.20098; Beck R, 2012, CANCER GENET-NY, V205, P304, DOI 10.1016/j.cancergen.2012.04.004; Charville GW, 2017, MODERN PATHOL, V30, P1312, DOI 10.1038/modpathol.2017.49; Charville GW, 2016, AM J SURG PATHOL, V40, P1305, DOI 10.1097/PAS.0000000000000717; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; Grunewald TGP, 2015, NAT GENET, V47, P1073, DOI 10.1038/ng.3363; Kovar H, 2016, ONCOTARGET, V7, P8613, DOI 10.18632/oncotarget.6937; Monument MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104378; Postel-Vinay S, 2012, NAT GENET, V44, P323, DOI 10.1038/ng.1085; Riggi N, 2014, CANCER CELL, V26, P668, DOI 10.1016/j.ccell.2014.10.004; Shibuya R, 2014, VIRCHOWS ARCH, V465, P599, DOI 10.1007/s00428-014-1627-1; Szuhai K, 2009, CLIN CANCER RES, V15, P2259, DOI 10.1158/1078-0432.CCR-08-2184; Tomazou EM, 2015, CELL REP, V10, P1082, DOI 10.1016/j.celrep.2015.01.042; van der Maaten L, 2008, J MACH LEARN RES, V9, P2579; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612	15	7	8	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUN	2018	31	6					997	999		10.1038/s41379-018-0009-7			3	Pathology	Pathology	GJ1CH	WOS:000434991000016	29895896	Bronze			2019-10-28	
J	Yanagita, K; Nagashio, R; Jiang, SX; Kuchitsu, Y; Hachimura, K; Ichinoe, M; Igawa, S; Fukuda, E; Goshima, N; Satoh, Y; Murakumo, Y; Saegusa, M; Sato, Y				Yanagita, Kengo; Nagashio, Ryo; Jiang, Shi-Xu; Kuchitsu, Yuki; Hachimura, Kazuo; Ichinoe, Masaaki; Igawa, Satoshi; Fukuda, Eriko; Goshima, Naoki; Satoh, Yukitoshi; Murakumo, Yoshiki; Saegusa, Makoto; Sato, Yuichi			Cytoskeleton-Associated Protein 4 Is a Novel Serodiagnostic Marker for Lung Cancer	AMERICAN JOURNAL OF PATHOLOGY			English	Article							ANTIPROLIFERATIVE FACTOR; EXPRESSION; RECEPTOR	Our aim was to develop a serodiagnostic marker for lung cancer. Monoclonal antibodies were generated, and one antibody designated as KU-Lu-1, recognizing cytoskeleton-associated protein 4 (CKAP4), was studied further. To evaluate the utility of KU-Lu-1 antibody as a serodiagnostic marker for lung cancer, reverse-phase protein array analysis was performed with sera of 271 lung cancer patients and 100 healthy controls. CKAP4 was detected in lung cancer cells and tissues, and its secretion into the culture supernatant was also confirmed. The serum CKAP4 levels of lung cancer patients were significantly higher than those of healthy controls (P < 0.0001), and the area under the curve of receiver-operating characteristic curve analysis was 0.890, with 81.1% sensitivity and 86.0% specificity. Furthermore, the serum CKAP4 levels were also higher in patients with stage I adenocarcinoma or squamous cell carcinoma than in healthy controls (P < 0.0001). Serum CKAP4 levels may differentiate lung cancer patients from healthy controls, and they may be detected early even in stage I non-small cell lung cancer. Serum CKAP4 levels were also significantly higher in lung cancer patients than in healthy controls in the validation set (P < 0.0001). The present results provide evidence that CKAP4 may be a novel early serodiagnostic marker for lung cancer.	[Yanagita, Kengo; Nagashio, Ryo; Hachimura, Kazuo; Sato, Yuichi] Kitasato Univ, Sch Allied Hlth Sci, Dept Mol Diagnost, Sagamihara, Kanagawa, Japan; [Nagashio, Ryo; Kuchitsu, Yuki; Sato, Yuichi] Kitasato Univ, Dept Appl Tumor Pathol, Grad Sch Med Sci, Sagamihara, Kanagawa, Japan; [Jiang, Shi-Xu; Ichinoe, Masaaki; Murakumo, Yoshiki; Saegusa, Makoto] Kitasato Univ, Sch Med, Dept Pathol, Sagamihara, Kanagawa, Japan; [Igawa, Satoshi] Kitasato Univ, Sch Med, Dept Resp Med, Sagamihara, Kanagawa, Japan; [Satoh, Yukitoshi] Kitasato Univ, Sch Med, Dept Thorac & Cardiovasc Surg, Sagamihara, Kanagawa, Japan; [Fukuda, Eriko; Goshima, Naoki] Natl Inst Adv Ind Sci & Technol, Div Quantitat Prote Team, Mol Profiling Res Ctr Drug Discovery, Tokyo, Japan	Nagashio, R (reprint author), Kitasato Univ, Sch Allied Hlth Sci, Dept Mol Diagnost, Minami Ku, 1-15-1 Kitasato, Sagamihara, Kanagawa 2520373, Japan.	nagashio@kitasato-u.ac.jp	Fukuda, Eriko/M-2854-2018; 直樹, 五島/M-8363-2018	Fukuda, Eriko/0000-0003-3086-3707; Nagashio, Ryo/0000-0002-9925-9316	Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science; JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [17K08729, 15K21359]; Japan Agency for Medical Research and Development, AMED, Medical Research and Development Programs Focused on Technology Transfers: Development of Advanced Measurement and Analysis SystemsJapan Agency for Medical Research and Development (AMED) [16hm0102029h0002]	Supported in part by a Japan Society for the Promotion of Science grant-in-aid for scientific research (C), JSPS KAKENHI grants 17K08729 and 15K21359, and a Japan Agency for Medical Research and Development, AMED, Medical Research and Development Programs Focused on Technology Transfers: Development of Advanced Measurement and Analysis Systems (16hm0102029h0002).	Beckler MD, 2013, MOL CELL PROTEOMICS, V12, P343, DOI 10.1074/mcp.M112.022806; Conrads TP, 2006, J BIOL CHEM, V281, P37836, DOI 10.1074/jbc.M604581200; Franco OE, 2010, SEMIN CELL DEV BIOL, V21, P33, DOI 10.1016/j.semcdb.2009.10.010; Gonzales PA, 2009, J AM SOC NEPHROL, V20, P363, DOI 10.1681/ASN.2008040406; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jiang SX, 2004, MODERN PATHOL, V17, P222, DOI 10.1038/modpathol.3800038; Kazi AS, 2010, AM J PHYSIOL-LUNG C, V299, pL794, DOI 10.1152/ajplung.00372.2009; Kimura H, 2016, J CLIN INVEST, V126, P2689, DOI 10.1172/JCI84658; Kobayashi M, 2015, LUNG CANCER, V90, P342, DOI 10.1016/j.lungcan.2015.08.015; Liang B, 2013, J PROTEOMICS, V80, P171, DOI 10.1016/j.jprot.2012.12.029; Matika CA, 2012, MOL BIOL CELL, V23, P1976, DOI 10.1091/mbc.E11-08-0714; Nagashio R, 2010, LUNG CANCER, V69, P54, DOI 10.1016/j.lungcan.2009.09.015; Patel JL, 2010, CLIN BIOCHEM, V43, P1449, DOI 10.1016/j.clinbiochem.2010.09.014; Planey SL, 2009, MOL BIOL CELL, V20, P1454, DOI 10.1091/mbc.E08-08-0849; Razzaq TM, 2003, J BIOL CHEM, V278, P42679, DOI 10.1074/jbc.M305695200	15	7	7	2	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUN	2018	188	6					1328	1333		10.1016/j.ajpath.2018.03.007			6	Pathology	Pathology	GH6BM	WOS:000433524800002	29751934				2019-10-28	
J	Shannon, ML; Fame, RM; Chau, KF; Dani, N; Calicchio, ML; Geleoc, GS; Lidov, HGW; Alexandrescu, S; Lehtinen, MK				Shannon, Morgan L.; Fame, Ryann M.; Chau, Kevin F.; Dani, Neil; Calicchio, Monica L.; Geleoc, Gwenaelle S.; Lidov, Hart G. W.; Alexandrescu, Sanda; Lehtinen, Maria K.			Mice Expressing Myc in Neural Precursors Develop Choroid Plexus and Ciliary Body Tumors	AMERICAN JOURNAL OF PATHOLOGY			English	Article							LI-FRAUMENI SYNDROME; PROTEIN-SYNTHESIS; NERVOUS-SYSTEM; C-MYC; RIBOSOME BIOGENESIS; ROOF PLATE; CANCER; CELLS; GENE; MEDULLOEPITHELIOMA	Choroid plexus tumors and ciliary body medulloepithelioma are predominantly pediatric neoplasms. Progress in understanding the pathogenesis of these tumors has been hindered by their rarity and lack of models that faithfully recapitulate the disease. Here, we find that endogenous Myc proto-oncogene protein is down-regulated in the forebrain neuroepithelium, whose neural plate border domains give rise to the anterior choroid plexus and ciliary body. To uncover the consequences of persistent Myc expression, MYC expression was forced in multipotent neural precursors (nestin-Cre:Myc), which produced fully penetrant models of choroid plexus carcinoma and ciliary body medulloepithelioma. Nestin-mediated MYC expression in the epithelial cells of choroid plexus leads to the regionalized formation of choroid plexus carcinoma in the posterior domain of the lateral ventricle choroid plexus and the fourth ventricle choroid plexus that is accompanied by loss of multiple cilia, up-regulation of protein biosynthetic machinery, and hydrocephalus. Parallel MYC expression in the ciliary body leads also to up-regulation of protein biosynthetic machinery. Additionally, Myc expression in human choroid plexus tumors increases with aggressiveness of disease. Collectively, our findings expose a select vulnerability of the neuroepithelial lineage to postnatal tumorigenesis and provide a new mouse model for investigating the pathogenesis of these rare pediatric neoplasms.	[Shannon, Morgan L.; Fame, Ryann M.; Chau, Kevin F.; Dani, Neil; Calicchio, Monica L.; Lidov, Hart G. W.; Alexandrescu, Sanda; Lehtinen, Maria K.] Boston Childrens Hosp, Dept Pathol, 300 Longwood Ave, Boston, MA 02115 USA; [Geleoc, Gwenaelle S.] Boston Childrens Hosp, Dept Otolaryngol, Boston, MA 02115 USA; [Geleoc, Gwenaelle S.] Boston Childrens Hosp, FM Kirby Ctr Neurobiol, Boston, MA 02115 USA; [Chau, Kevin F.; Lehtinen, Maria K.] Harvard Med Sch, Program Biol & Biomed Sci, Boston, MA USA	Lehtinen, MK (reprint author), Boston Childrens Hosp, Dept Pathol, 300 Longwood Ave, Boston, MA 02115 USA.	maria.lehtinen@childrens.harvard.edu		Fame, Ryann/0000-0002-8244-2624; Shannon, Morgan/0000-0003-4941-7643	National Science Foundation Graduate Research FellowshipNational Science Foundation (NSF); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HL110852, R01 NS088566]; William Randolph Hearst Fund; Pediatric Hydrocephalus Foundation; New York Stem Cell Foundation; Boston Children's Hospital Intellectual and Developmental Disabilities Research Center [BCH IDDRC 1U54HD090255]	Supported by a National Science Foundation Graduate Research Fellowship (K.F.C.); NIH grant T32 HL110852 (K.F.C. and R.M.F.); the William Randolph Hearst Fund (N.D.); the Pediatric Hydrocephalus Foundation, NIH grant R01 NS088566, and the New York Stem Cell Foundation (M.K.L.); and Boston Children's Hospital Intellectual and Developmental Disabilities Research Center (BCH IDDRC 1U54HD090255). M.K.L. is a New York Stem Cell Foundation-Robertson Investigator.	Abedalthagafi MS, 2016, J PATHOL, V238, P584, DOI 10.1002/path.4682; Al-Salam S, 2008, NEUROPATHOLOGY, V28, P551, DOI 10.1111/j.1440-1789.2008.00886.x; Archer TC, 2017, NEUROTHERAPEUTICS, V14, P265, DOI 10.1007/s13311-017-0526-y; Awatramani R, 2003, NAT GENET, V35, P70, DOI 10.1038/ng1228; Baker NE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058266; Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; Calado DP, 2012, NAT IMMUNOL, V13, P1092, DOI 10.1038/ni.2418; Chau KF, 2018, ELIFE, V7, DOI 10.7554/eLife.36998; Currle DS, 2005, DEVELOPMENT, V132, P3549, DOI 10.1242/dev.01915; Dang L, 2006, ONCOGENE, V25, P487, DOI 10.1038/sj.onc.1209074; Dudley RWR, 2015, J NEURO-ONCOL, V121, P201, DOI 10.1007/s11060-014-1628-6; Gozali AE, 2012, PEDIATR BLOOD CANCER, V58, P905, DOI 10.1002/pbc.23349; HIRVONEN H, 1990, ONCOGENE, V5, P1787; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Hunecke D, 2012, J PATHOL, V228, P520, DOI 10.1002/path.4059; Hunter NL, 2007, DEVELOPMENT, V134, P3449, DOI 10.1242/dev.003095; Jeibmann A, 2006, J NEUROPATH EXP NEUR, V65, P1069, DOI 10.1097/01.jnen.0000240464.26005.90; Kaliki S, 2013, OPHTHALMOLOGY, V120, P2552, DOI 10.1016/j.ophtha.2013.05.015; Kidder BL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003932; Li L, 2016, NAT CELL BIOL, V18, P418, DOI 10.1038/ncb3327; Louis DN, 2016, WHO CLASSIFICATION T, P124; Lun MP, 2015, NAT REV NEUROSCI, V16, P445, DOI 10.1038/nrn3921; Lun MP, 2015, J NEUROSCI, V35, P4903, DOI 10.1523/JNEUROSCI.3081-14.2015; Mai PL, 2016, CANCER-AM CANCER SOC, V122, P3673, DOI 10.1002/cncr.30248; Matsushima D, 2011, DEVELOPMENT, V138, P443, DOI 10.1242/dev.055178; Mishra A, 2012, J PEDIATR NEUROSCI, V7, P71, DOI 10.4103/1817-1745.97633; Momota H, 2008, ONCOGENE, V27, P4392, DOI 10.1038/onc.2008.81; Northcott PA, 2017, NATURE, V547, P311, DOI 10.1038/nature22973; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Pourdehnada M, 2013, P NATL ACAD SCI USA, V110, P11988, DOI 10.1073/pnas.1310230110; RUPPERT C, 1986, EMBO J, V5, P1897, DOI 10.1002/j.1460-2075.1986.tb04442.x; Safaee M, 2013, NEURO-ONCOLOGY, V15, P255, DOI 10.1093/neuonc/nos289; Sanchez CG, 2016, CELL STEM CELL, V18, P276, DOI 10.1016/j.stem.2015.11.004; Santagata S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007932; Schittenhelm J, 2012, AM J CLIN PATHOL, V138, P85, DOI 10.1309/AJCPPRKNNL09JTLP; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; STEUHL KP, 1993, OPHTHALMOLOGY, V100, P208; Streit A, 2004, DEV BIOL, V276, P1, DOI 10.1016/j.ydbio.2004.08.037; Swartling FJ, 2012, CANCER CELL, V21, P601, DOI 10.1016/j.ccr.2012.04.012; Tabori U, 2010, J CLIN ONCOL, V28, P1995, DOI 10.1200/JCO.2009.26.8169; Tong YA, 2015, CANCER CELL, V27, P712, DOI 10.1016/j.ccell.2015.04.005; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Valdez JM, 2017, BRIT J HAEMATOL, V176, P539, DOI 10.1111/bjh.14461; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Wang XY, 2015, FEBS LETT, V589, P3989, DOI 10.1016/j.febslet.2015.11.012	45	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUN	2018	188	6					1334	1344		10.1016/j.ajpath.2018.02.009			9	Pathology	Pathology	GH6BM	WOS:000433524800003	29545198	Green Published, Bronze			2019-10-28	
J	Juiz, NA; Torrejon, I; Burgos, M; Torres, AMF; Duffy, T; Cayo, NM; Tabasco, A; Salvo, M; Longhi, SA; Schijman, AG				Juiz, Natalia A.; Torrejon, Irma; Burgos, Marianela; Torres, Ana M. F.; Duffy, Tomas; Cayo, Neilly M.; Tabasco, Anahi; Salvo, Miriam; Longhi, Silvia A.; Schijman, Alejandro G.			Alterations in Placental Gene Expression of Pregnant Women with Chronic Chagas Disease	AMERICAN JOURNAL OF PATHOLOGY			English	Article							TRYPANOSOMA-CRUZI INFECTION; CONGENITAL TRANSMISSION; MATERNAL INFECTIONS; PREECLAMPSIA; KISSPEPTIN; MOTHERS; SUSCEPTIBILITY; ASSOCIATION; DIAGNOSIS; CHILDREN	Trypanosoma cruzi infection in women of reproductive age is associated with congenital transmission and adverse pregnancy outcomes. The placenta is a key barrier to infection. Gene expression profiles of term placental environment from T. cruzi-seropositive (SP) and -seronegative (SN) mothers were characterized by RNA-Seq. Nine pools of placental RNA paired samples were used: three from SN and six from SP tissues. Each pool consisted of female/male newborns and vaginal/cesarean delivery binomials. No newborn was congenitally infected. T. cruzi satellite DNA quantitative PCR in placental tissues and maternal and neonatal blood, and parasite 18S quantitative RT-PCR from placental RNA were negative, except in three SP women's bloodstream. To identify pathways associated with maternal T. cruzi infection, a gene-set association analysis was implemented: SP placental samples showed over-expression of inflammatory response and lymphocytic activation, whereas numerous biosynthetic processes were down-regulated. About 42 genes showed a significant fold-change between SP and SN groups. KISS1 and CGB5 were down-regulated, whereas KIF12, HLA-G, PRG2, TAC3, FN1, and ATXN3L were up-regulated. Several expressed genes in SP placentas encode proteins associated with preeclampsia and miscarriage. This first transcriptomics study in human term placental environment shows a placental response that may affect the fetus while protecting it from parasite infection; this host response could be responsible for the low rate of congenital transmission in chronic Chagas disease.	[Juiz, Natalia A.; Tabasco, Anahi; Longhi, Silvia A.; Schijman, Alejandro G.] INGEBI CONICET, Genet Engn & Mol Biol Res Inst Dr Hector Torres, Mol Biol Chagas Dis Lab, Buenos Aires, DF, Argentina; [Torrejon, Irma; Torres, Ana M. F.; Cayo, Neilly M.] Natl Univ Jujuy, Height Biol Inst, San Salvador De Jujuy, Argentina; [Burgos, Marianela; Salvo, Miriam] Prof Alejandro Posadas Natl Hosp, Maternal & Child Dept, Obstet Serv, Buenos Aires, DF, Argentina; [Duffy, Tomas] Univ Southern Calif, Scripps Res Inst, San Diego, CA USA	Juiz, NA; Schijman, AG (reprint author), Inst Invest Ingn Genet & Biol Mol Dr Hector Torre, 2490 Vuelta Obligado,C1428ADN, Buenos Aires, DF, Argentina.	njuiz@dna.uba.ar; schijman@dna.uba.ar	Duffy, Tomas/S-6045-2017		Argentinean Ministry of Science and Technology [PICT 2014-1188, PICT 2015-0074]; European Union's Research and Innovation funding program grant [ERANET-LAC HD 328]	Supported by the Argentinean Ministry of Science and Technology grants PICT 2014-1188 and PICT 2015-0074, and the European Union's Research and Innovation funding program grant ERANET-LAC HD 328 (A.G.S).	Albu A R, 2014, J Med Life, V7, P165; Alvarado-Esquivel C, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-167; Juiz NA, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005436; Armstrong RA, 2009, PRENATAL DIAG, V29, P982, DOI 10.1002/pd.2328; Bisio M, 2011, T ROY SOC TROP MED H, V105, P543, DOI 10.1016/j.trstmh.2011.07.003; Bua J, 2012, T ROY SOC TROP MED H, V106, P623, DOI 10.1016/j.trstmh.2012.03.015; Burgos JM, 2009, DIAGN MICR INFEC DIS, V65, P58, DOI 10.1016/j.diagmicrobio.2009.04.010; Carlier Y, 2015, ACTA TROP, V151, P103, DOI 10.1016/j.actatropica.2015.07.016; Cuna WR, 2009, J PARASITOL, V95, P891, DOI 10.1645/GE-1927.1; Dauby N, 2012, LANCET INFECT DIS, V12, P330, DOI 10.1016/S1473-3099(11)70341-3; Dobin A, 2015, CURR PROTOC BIOINFOR, V51; Duaso J, 2012, J TROP MED, DOI 10.1155/2012/758357; Duffy T, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002000; Fretes RE, 2012, J TROP MED, V2012; Gamboa-Leon R, 2014, AM J TROP MED HYG, V91, P348, DOI 10.4269/ajtmh.13-0527; Gueneuc A, 2017, MALARIA J, V16, DOI 10.1186/s12936-016-1664-0; Hermann E, 2006, PEDIATR RES, V60, P38, DOI 10.1203/01.pdr.0000220335.05588.ea; Jayasena CN, 2014, J CLIN ENDOCR METAB, V99, pE2652, DOI 10.1210/jc.2014-1953; Jin XH, 2017, BBA-PROTEINS PROTEOM, V1865, P1207, DOI 10.1016/j.bbapap.2017.07.003; Juiz NA, 2016, J INFECT DIS, V213, P1299, DOI 10.1093/infdis/jiv561; Liempi A, 2016, MICROB PATHOGENESIS, V99, P123, DOI 10.1016/j.micpath.2016.08.022; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Messenger LA, 2017, CLIN INFECT DIS, V65, P268, DOI 10.1093/cid/cix277; NAKHLE MC, 1989, REV INST MED TROP SP, V31, P384, DOI 10.1590/S0036-46651989000600004; Negrette OS, 2005, PEDIATRICS, V115, pE668, DOI 10.1542/peds.2004-1732; Oride A, 2015, REPROD BIOL ENDOCRIN, V13, DOI 10.1186/s12958-015-0083-3; Page NM, 2000, NATURE, V405, P797; Paredes V, 2017, GYNECOL ENDOCRINOL, V33, P79, DOI 10.1080/09513590.2016.1241228; Park DW, 2012, AM J REPROD IMMUNOL, V67, P132, DOI 10.1111/j.1600-0897.2011.01073.x; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rustveld LO, 2008, MATERN CHILD HLTH J, V12, P223, DOI 10.1007/s10995-007-0224-1; Sadissou I, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-312; Shiadeh MN, 2017, INFECTION, V45, P589, DOI 10.1007/s15010-017-1031-2; Sood R, 2006, P NATL ACAD SCI USA, V103, P5478, DOI 10.1073/pnas.0508035103; Soydinc HE, 2013, CLIN TER, V164, pE199, DOI 10.7417/CT.2013.1568; Torrico F, 2004, AM J TROP MED HYG, V70, P201, DOI 10.4269/ajtmh.2004.70.201; Weyer K, 2011, BIOL REPROD, V84, P1077, DOI 10.1095/biolreprod.110.090209; WHO/Department of control of neglected tropical diseases, 2017, INT NEGL TROP DIS GL; Wu PS, 2017, CIRC-CARDIOVASC QUAL, V10, DOI 10.1161/CIRCOUTCOMES.116.003497; Xiong Q, 2014, SCI REP-UK, V4, DOI 10.1038/srep06347	40	4	4	2	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUN	2018	188	6					1345	1353		10.1016/j.ajpath.2018.02.011			9	Pathology	Pathology	GH6BM	WOS:000433524800004	29545200	Bronze			2019-10-28	
J	Tawiah, A; Cornick, S; Moreau, F; Gorman, H; Kumar, M; Tiwari, S; Chadee, K				Tawiah, Adelaide; Cornick, Steve; Moreau, France; Gorman, Hayley; Kumar, Manish; Tiwari, Sameer; Chadee, Kris			High MUC2 Mucin Expression and Misfolding Induce Cellular Stress, Reactive Oxygen Production, and Apoptosis in Goblet Cells	AMERICAN JOURNAL OF PATHOLOGY			English	Article							ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; INFLAMMATORY-BOWEL-DISEASE; OXIDATIVE STRESS; ENTAMOEBA-HISTOLYTICA; INTESTINAL INFLAMMATION; EPITHELIAL-CELLS; ER STRESS; MICE; CANCER	MUC2 mucin is a large glycoprotein produced by goblet cells that forms the protective mucus blanket overlying the intestinal epithelium as the first line of innate host defense. High MUC2 production in inflammatory bowel disease and infectious colitis depletes goblet cells and the mucus layer by an unknown mechanism. Herein, we analyzed the effect of high MUC2 biosynthesis on endoplasmic reticulum (ER) stress and apoptosis in goblet cells using a high MUC2-producing human goblet cell line (HT29-H) and an HT29-H clone (HT29-L) silenced for MUC2 expression by lentivirus-mediated shRNA. Goblet cell ER stress and apoptosis were quantified during early onset of dextran sulfate sodiuminduced colitis in C57BL/6 and Mathl(M1GFP) mice. Compared with HT29-L and MUC2 nonproducing Caco-2 cells, high MUC2-producing HT29-H cells had significantly increased ER stress and apoptosis after treatment with ER stress-inducing agents. Apoptosis was driven by increased misfolded MUC2 that triggered elevated levels of reactive oxygen species. Correcting MUC2 folding and inhibiting reactive oxygen species alleviated ER stress and rescued cells from apoptosis. During early-onset colitis, mucus hypersecretion caused severe ER stress and apoptosis of goblet cells that preceded absorptive epithelial cell damage. Thus, in gastrointestinal inflammation, high MUC2 biosynthesis and goblet cell apoptosis lead to a dysfunctional epithelial barrier. Enhancing MUC2 folding may help alleviate goblet cell depletion and maintain mucosal integrity.	[Tawiah, Adelaide; Cornick, Steve; Moreau, France; Gorman, Hayley; Kumar, Manish; Tiwari, Sameer; Chadee, Kris] Univ Calgary, Hlth Sci Ctr, Fac Med,Snyder Inst Chron Dis, Dept Microbiol Immunol & Infect Dis,Gastrointesti, Calgary, AB, Canada	Chadee, K (reprint author), Univ Calgary, Hlth Sci Ctr, Dept Microbiol Immunol & Infect Dis, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	kchadee@ucalgary.ca			Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [KC MOP 142776]; Crohn's and Colitis Canada; Eleanor Mackie Doctoral Scholarship in Women's Health	Supported by Canadian Institutes of Health Research grant KC MOP 142776, Crohn's and Colitis Canada (K.C.), and the Eleanor Mackie Doctoral Scholarship in Women's Health (A.T.).	Akiba Y, 2000, AM J PHYSIOL-GASTR L, V279, pG437; Ambort D, 2012, P NATL ACAD SCI USA, V109, P5645, DOI 10.1073/pnas.1120269109; AUGERON C, 1984, CANCER RES, V44, P3961; Backstrom M, 2013, MOL BIOTECHNOL, V54, P250, DOI 10.1007/s12033-012-9562-3; Belley A, 1996, GASTROENTEROLOGY, V111, P1484, DOI 10.1016/S0016-5085(96)70009-4; Boltin D, 2013, J CLIN GASTROENTEROL, V47, P106, DOI 10.1097/MCG.0b013e3182688e73; Cao SS, 2013, GASTROENTEROLOGY, V144, P989, DOI 10.1053/j.gastro.2013.01.023; CHADEE K, 1987, J CLIN INVEST, V80, P1245, DOI 10.1172/JCI113199; Cobo ER, 2015, MUCOSAL IMMUNOL, V8, P1360, DOI 10.1038/mi.2015.27; Cone RA, 2009, ADV DRUG DELIVER REV, V61, P75, DOI 10.1016/j.addr.2008.09.008; Corfield AP, 2001, FRONT BIOSCI-LANDMRK, V6, pD1321, DOI 10.2741/Corfield; Das I, 2013, J EXP MED, V210, P1201, DOI 10.1084/jem.20121268; DEVINE PL, 1993, BRIT J CANCER, V67, P1182, DOI 10.1038/bjc.1993.223; Dharmani P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025058; Ding W, 2012, BIOCHEM BIOPH RES CO, V418, P451, DOI 10.1016/j.bbrc.2012.01.037; Gaudier E, 2004, AM J PHYSIOL-GASTR L, V287, pG1168, DOI 10.1152/ajpgi.00219.2004; Godl K, 2002, J BIOL CHEM, V277, P47248, DOI 10.1074/jbc.M208483200; Gum JR, 1999, AM J PHYSIOL-GASTR L, V276, pG666; Hamouda HE, 2011, WORLD J GASTROENTERO, V17, P2417, DOI 10.3748/wjg.v17.i19.2417; Hasnain SZ, 2013, GASTROENTEROLOGY, V144, P357, DOI 10.1053/j.gastro.2012.10.043; Haynes CM, 2004, MOL CELL, V15, P767, DOI 10.1016/j.molcel.2004.08.025; Heazlewood CK, 2008, PLOS MED, V5, P440, DOI 10.1371/journal.pmed.0050054; Higa A, 2012, CELL SIGNAL, V24, P1548, DOI 10.1016/j.cellsig.2012.03.011; Higa A, 2011, J BIOL CHEM, V286, P44855, DOI 10.1074/jbc.M111.275529; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Hu S, 2007, GASTROENTEROLOGY, V133, P1893, DOI 10.1053/j.gastro.2007.09.026; Jager R, 2012, BIOL CELL, V104, P259, DOI 10.1111/boc.201100055; Johansson MEV, 2013, DIGEST DIS, V31, P305, DOI 10.1159/000354683; Johansson MEV, 2008, P NATL ACAD SCI USA, V105, P15064, DOI 10.1073/pnas.0803124105; Karp SM, 2006, DM-DIS MON, V52, P199, DOI 10.1016/j.disamonth.2006.05.005; Kim Young S, 2010, Curr Gastroenterol Rep, V12, P319, DOI 10.1007/s11894-010-0131-2; Kurihara Y, 2012, J BIOL CHEM, V287, P3265, DOI 10.1074/jbc.M111.280156; Malhotra JD, 2007, ANTIOXID REDOX SIGN, V9, P2277, DOI 10.1089/ars.2007.1782; McCracken VJ, 2001, CELL MICROBIOL, V3, P1, DOI 10.1046/j.1462-5822.2001.00090.x; McGuckin MA, 2010, AM J PHYSIOL-GASTR L, V298, pG820, DOI 10.1152/ajpgi.00063.2010; Moncada DM, 2006, GASTROENTEROLOGY, V130, P721, DOI 10.1053/j.gastro.2005.11.012; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; O'Connell J, 2000, J CELL PHYSIOL, V185, P331, DOI 10.1002/1097-4652(200012)185:3<331::AID-JCP3>3.0.CO;2-V; Park SW, 2009, P NATL ACAD SCI USA, V106, P6950, DOI 10.1073/pnas.0808722106; Quan ZW, 2010, CANCER LETT, V295, P252, DOI 10.1016/j.canlet.2010.03.008; Radermacher KA, 2013, ANTIOXID REDOX SIGN, V18, P1418, DOI 10.1089/ars.2012.4797; Shkoda A, 2007, GASTROENTEROLOGY, V132, P190, DOI 10.1053/j.gastro.2006.10.030; Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779; Van der Sluis M, 2006, GASTROENTEROLOGY, V131, P117, DOI 10.1053/j.gastro.2006.04.020; van Es JH, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1017; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; Vereecke L, 2011, TRENDS MOL MED, V17, P584, DOI 10.1016/j.molmed.2011.05.011; Wei XC, 2012, CELL HOST MICROBE, V11, P140, DOI 10.1016/j.chom.2011.12.006	49	9	10	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUN	2018	188	6					1354	1373		10.1016/j.ajpath.2018.02.007			20	Pathology	Pathology	GH6BM	WOS:000433524800005	29545196				2019-10-28	
J	He, SY; Xue, MM; Liu, CP; Xie, F; Bai, L				He, Shuying; Xue, Minmin; Liu, Cuiping; Xie, Fang; Bai, Lan			Parathyroid HormoneLike Hormone Induces Epithelial-to-Mesenchymal Transition of Intestinal Epithelial Cells by Activating the Runt-Related Transcription Factor 2	AMERICAN JOURNAL OF PATHOLOGY			English	Article							GROWTH-FACTOR-BETA; MESSENGER-RNA EXPRESSION; CROHNS-DISEASE; SIGNALING PATHWAY; FIBROBLASTS DERIVE; INSULIN-SECRETION; PROTEIN INTERACTS; HEPATIC-FIBROSIS; RECEPTOR; PTHRP	Epithelial-to-mesenchymal transition (EMT) is a key contributor to fibroblast activation in fibrosis of multiple organs, including the intestine. Parathyroid hormonelike hormone (PTHLH) is an important factor in renal fibrosis and regulates several processes, including EMT. Herein, we investigated the role of PTHLH-induced EMT in intestinal fibrosis associated with Crohn disease. The expression levels of the EMT-related proteins, PTHLH, and parathyroid hormone receptor 1 (PTH1R) in intestinal tissues were determined by immunohistochemistry, and our results revealed that PTHLH and PTH1R were significantly elevated and associated with EMT marker expression. Moreover, neutralizing PTH1R and antagonizing PTHLH bioactivity prevented transforming growth factor-beta 1induced EMT. PTH1R can propagate the protein kinase A (PKA) signaland activate downstream nucleartranscription factors, including runt-related transcription factor 2 (Runx2). In addition, lentiviralvector-PTHLHtreated mice were highly sensitive to 2,4,6-trinitrobenzene sulfonic acid, and analysis of the PTHLH-PTH1R axis revealed the involvement of PKA-Runx2 in PTHLH-induced EMT. Our results indicate that PTHLH triggered EMT in intestinal epithelial cells through the PKA-Runx2 pathway, which might serve as a therapeutic target for intestinal fibrosis in Crohn disease.	[He, Shuying; Xie, Fang; Bai, Lan] Southern Med Univ, Guangdong Prov Key Lab Gastroenterol, Nanfang Hosp, Dept Gastroenterol, Guangzhou, Guangdong, Peoples R China; [Liu, Cuiping] Southern Med Univ, Zhujiang Hosp, Dept Crit Care Med, Guangzhou, Guangdong, Peoples R China; [Xue, Minmin] Chinese Peoples Liberat Army 254 Hosp, Dept Gastroenterol, Tianjin, Peoples R China	Bai, L (reprint author), Nanfang Hosp, Dept Gastroenterol, 1838 N Guangzhou Ave, Guangzhou 510515, Guangdong, Peoples R China.	hsy212@smu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81470790]; Natural Science Foundation of Guangdong ProvinceNational Natural Science Foundation of Guangdong Province [2015A030313295]; Guangzhou Pilot Project of Clinical and Translational Research Center [7415696196402]	Supported by National Natural Science Foundation of China grant 81470790 (L.B.), Natural Science Foundation of Guangdong Province grant 2015A030313295 (L.B.), and the Guangzhou Pilot Project of Clinical and Translational Research Center (number 7415696196402).	Ahn BY, 2016, ONCOGENE, V35, P1411, DOI 10.1038/onc.2015.199; Ardura JA, 2010, J AM SOC NEPHROL, V21, P237, DOI 10.1681/ASN.2009050462; Ardura JA, 2008, AM J PHYSIOL-RENAL, V295, pF415, DOI 10.1152/ajprenal.00018.2008; Ardura JA, 2013, KIDNEY INT, V83, P825, DOI 10.1038/ki.2012.476; Bataille F, 2008, INFLAMM BOWEL DIS, V14, P1514, DOI 10.1002/ibd.20590; Baumgart DC, 2012, LANCET, V380, P1590, DOI 10.1016/S0140-6736(12)60026-9; Bernstein CN, 2012, GUT, V61, P622, DOI 10.1136/gutjnl-2011-301397; Bhatia V, 2016, PANCREAS, V45, P659, DOI 10.1097/MPA.0000000000000522; Bhatia V, 2014, AM J PHYSIOL-GASTR L, V307, pG533, DOI 10.1152/ajpgi.00428.2013; Bhatia V, 2012, REGUL PEPTIDES, V175, P49, DOI 10.1016/j.regpep.2012.01.006; Chang CW, 2015, INTEST RES, V13, P19, DOI 10.5217/ir.2015.13.1.19; Cheloha RW, 2015, NAT REV ENDOCRINOL, V11, P712, DOI 10.1038/nrendo.2015.139; Cunningham MF, 2010, AM J PHYSIOL-GASTR L, V299, pG457, DOI 10.1152/ajpgi.00351.2009; Doerks T, 2002, GENOME RES, V12, P47, DOI 10.1101/gr.203201; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Falzon M, 2015, CANCERS, V7, P1091, DOI 10.3390/cancers7020826; Flier SN, 2010, J BIOL CHEM, V285, P20202, DOI 10.1074/jbc.M110.102012; Henquin JC, 2014, ENDOCRINOLOGY, V155, P3274, DOI 10.1210/en.2014-1247; Holvoet T, 2017, GASTROENTEROLOGY, V153, P1054, DOI 10.1053/j.gastro.2017.06.013; Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518; Kakonen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim KK, 2006, P NATL ACAD SCI USA, V103, P13180, DOI 10.1073/pnas.0605669103; KIRIYAMA T, 1993, MOL CELL ENDOCRINOL, V92, P55, DOI 10.1016/0303-7207(93)90074-T; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Krishnan V, 2003, MOL ENDOCRINOL, V17, P423, DOI 10.1210/me.2002-0225; Lawrance IC, 2003, GASTROENTEROLOGY, V125, P1750, DOI 10.1053/j.gastro.2003.08.027; Lezcano V, 2013, BBA-MOL CELL RES, V1833, P2834, DOI 10.1016/j.bbamcr.2013.06.029; Li C, 2014, INFLAMM BOWEL DIS, V20, P1250, DOI 10.1097/MIB.0000000000000043; Liang FF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076517; Liu XJ, 2006, LIVER INT, V26, P8, DOI 10.1111/j.1478-3231.2005.01192.x; MARTIN TJ, 1991, CRIT REV BIOCHEM MOL, V26, P377, DOI 10.3109/10409239109114073; Maycas M, 2015, J BONE MINER RES, V30, P1231, DOI 10.1002/jbmr.2439; McCauley LK, 2012, J BONE MINER RES, V27, P1231, DOI 10.1002/jbmr.1617; McCormick BA, 2008, GASTROENTEROLOGY, V134, P872, DOI 10.1053/j.gastro.2008.01.019; Medina C, 2011, J PATHOL, V224, P461, DOI 10.1002/path.2870; MERRYMAN JI, 1994, ENDOCRINOLOGY, V134, P2424, DOI 10.1210/en.134.6.2424; Nenquin M, 2016, DIABETES OBES METAB, V18, P698, DOI 10.1111/dom.12607; Ortega A, 2006, J AM SOC NEPHROL, V17, P1594, DOI 10.1681/ASN.2005070690; Rieder F, 2007, GUT, V56, P130, DOI 10.1136/gut.2006.090456; Rieder F, 2013, GUT, V62, P1072, DOI 10.1136/gutjnl-2012-304353; Rieder F, 2011, AM J PATHOL, V179, P2660, DOI 10.1016/j.ajpath.2011.07.042; Saini V, 2013, J BIOL CHEM, V288, P20122, DOI 10.1074/jbc.M112.441360; Scharl M, 2015, CLIN TRANSL MED, V4, DOI 10.1186/s40169-015-0046-5; Scharl M, 2013, GUT, V62, P63, DOI 10.1136/gutjnl-2011-300498; Sellers RS, 2004, PROSTATE, V58, P366, DOI 10.1002/pros.20029; Shishikura K, 2016, BRIT J PHARMACOL, V173, P319, DOI 10.1111/bph.13373; Southby J, 1996, ENDOCRINOLOGY, V137, P1349, DOI 10.1210/en.137.4.1349; Videla S, 2006, J PHARMACOL EXP THER, V316, P940, DOI 10.1124/jpet.105.090837; Wang BL, 2006, J ENDOCRINOL INVEST, V29, P101, DOI 10.1007/BF03344081; Weng L, 2015, CELL PHYSIOL BIOCHEM, V36, P1911, DOI 10.1159/000430160; Wirtz S, 2017, NAT PROTOC, V12, P1295, DOI 10.1038/nprot.2017.044; Wysolmerski JJ, 2012, J CLIN ENDOCR METAB, V97, P2947, DOI 10.1210/jc.2012-2142; Xu XP, 2017, ANTIOXID REDOX SIGN, V27, P37, DOI 10.1089/ars.2015.6611; Yata Y, 2002, HEPATOLOGY, V35, P1022, DOI 10.1053/jhep.2002.32673; Ye YM, 2001, ENDOCRINOLOGY, V142, P1906, DOI 10.1210/en.142.5.1906; Zeisberg EM, 2007, NAT MED, V13, P952, DOI 10.1038/nm1613; Zeisberg M, 2004, J MOL MED, V82, P175, DOI 10.1007/s00109-003-0517-9; Zeisberg M, 2007, J BIOL CHEM, V282, P23337, DOI 10.1074/jbc.M700194200	60	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUN	2018	188	6					1374	1388		10.1016/j.ajpath.2018.03.003			15	Pathology	Pathology	GH6BM	WOS:000433524800006	29577935				2019-10-28	
J	Russell, JO; Ko, S; Saggi, HS; Singh, S; Poddar, M; Shin, DH; Monga, SP				Russell, Jacquelyn O.; Ko, Sungjin; Saggi, Harvinder S.; Singh, Sucha; Poddar, Minakshi; Shin, Donghun; Monga, Satdarshan P.			Bromodomain and Extraterminal (BET) Proteins Regulate Hepatocyte Proliferation in Hepatocvte-Driven Liver Regeneration	AMERICAN JOURNAL OF PATHOLOGY			English	Article							FACTOR-KAPPA-B; HUMAN HEPATOCELLULAR-CARCINOMA; CELL-CYCLE PROGRESSION; SUPER-ENHANCERS; STEM-CELLS; SELECTIVE-INHIBITION; CANCER-CELLS; CATENIN; EXPRESSION; ZEBRAFISH	Bromodomain and extraterminal (BET) proteins recruit key components of basic transcriptional machinery to promote gene expression. Aberrant expression and mutations in BET genes have been identified in many malignancies. Small molecule inhibitors of BET proteins such as JQ1 have shown efficacy in preclinical cancer models, including affecting growth of hepatocellular carcinoma. BET proteins also regulate cell proliferation in nontumor settings. We recently showed that BET proteins regulate cholangiocyte-driven liver regeneration. Here, we studied the role of BET proteins in hepatocyte-driven liver regeneration in partial hepatectomy (PHx) and acetaminophen-induced liver injury models in mice and zebrafish. JQ1 was injected 2 or 16 hours after PHx in mice to determine effect on hepatic injury, regeneration, and signaling. Mice treated with JQ1 after PHx displayed increased liver injury and a near-complete inhibition of hepatocyte proliferation. Levels of Ccndl mRNA and Cyclin D1 protein were reduced in animals injected with JQ1 16 hours after PHx and were even further reduced in animals injected with JQ1 2 hours after PHx. JQ1-treated zebrafish larvae after acetaminophen-induced injury also displayed notably impaired hepatocyte proliferation. In both models, Wnt signaling was prominently suppressed by JQ1. Our results show that BET proteins regulate hepatocyte proliferation-driven liver regeneration, and Wnt signaling is particularly sensitive to BET protein inhibition.	[Russell, Jacquelyn O.; Saggi, Harvinder S.; Singh, Sucha; Poddar, Minakshi; Monga, Satdarshan P.] Univ Pittsburgh, Med Ctr, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; [Russell, Jacquelyn O.; Ko, Sungjin; Saggi, Harvinder S.; Singh, Sucha; Poddar, Minakshi; Shin, Donghun; Monga, Satdarshan P.] Univ Pittsburgh, Med Ctr, Sch Med, Dept Dev Biol, Pittsburgh, PA 15261 USA; [Ko, Sungjin; Shin, Donghun] Univ Pittsburgh, Med Ctr, Sch Med, Pittsburgh Liver Res Ctr, Pittsburgh, PA 15261 USA	Monga, SP (reprint author), Univ Pittsburgh, Pittsburgh Liver Res Ctr, Sch Med, 200 Lothrop St S-422 BST, Pittsburgh, PA 15261 USA.; Shin, DH (reprint author), Dept Dev Biol, 3501 5th Ave 5063, Pittsburgh, PA 15260 USA.	donghuns@pitt.edu; smonga@pitt.edu		Shin, Donghun/0000-0002-7975-9014; Monga, Satdarshan/0000-0002-8437-3378	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01DK62277, 1R01DK100287, R01CA204586, DK101426, T32EB0010216, 1F31DK115017-01]; Endowed Chair for Experimental Pathology	Supported by NIH grants 1R01DK62277 (S.P.M.), 1R01DK100287 (S.P.M.), R01CA204586 (S.P.M.), DK101426 (D.S.), T32EB0010216 (J.O.R.) and 1F31DK115017-01 (J.O.R.), and Endowed Chair for Experimental Pathology (S.P.M.).	ALBRECHT JH, 1995, BIOCHEM BIOPH RES CO, V209, P648, DOI 10.1006/bbrc.1995.1548; Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; Anand P, 2013, CELL, V154, P569, DOI 10.1016/j.cell.2013.07.013; Apte U, 2009, AM J PATHOL, V175, P1056, DOI 10.2353/ajpath.2009.080976; Choi TY, 2015, JOVE-J VIS EXP, DOI 10.3791/52785; Choi TY, 2014, GASTROENTEROLOGY, V146, P776, DOI 10.1053/j.gastro.2013.10.019; Chu J, 2009, HEPATOLOGY, V50, P1656, DOI 10.1002/hep.23157; Committee for the Update of the Guide for the Care and Use of Laboratory Animal, 2011, GUID CAR US LAB AN; Cox AG, 2014, CELL REP, V6, P56, DOI 10.1016/j.celrep.2013.12.007; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; de Groh ED, 2010, J AM SOC NEPHROL, V21, P794, DOI 10.1681/ASN.2009080851; Delgado E, 2015, J HEPATOL, V62, P380, DOI 10.1016/j.jhep.2014.10.021; Delgado I, 2011, AM J PHYSIOL-GASTR L, V301, pG20, DOI 10.1152/ajpgi.00481.2010; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Ding N, 2015, P NATL ACAD SCI USA, V112, P15713, DOI 10.1073/pnas.1522163112; Du Q, 2009, CANCER RES, V69, P3764, DOI 10.1158/0008-5472.CAN-09-0014; Duncan AW, 2009, GASTROENTEROLOGY, V137, P466, DOI 10.1053/j.gastro.2009.05.044; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; FITZGERALD MJ, 1995, CELL GROWTH DIFFER, V6, P417; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; He JH, 2013, J PHARMACOL TOX MET, V67, P25, DOI 10.1016/j.vascn.2012.10.003; Hnisz D, 2015, MOL CELL, V58, P362, DOI 10.1016/j.molcel.2015.02.014; Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053; Hong SH, 2016, ONCOTARGET, V7, P32628, DOI 10.18632/oncotarget.8701; Jaeschke H, 2014, J CLIN TRANSL HEPATO, V2, P153, DOI 10.14218/JCTH.2014.00014; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; Kennedy AL, 2015, ONCOTARGET, V6, P30178, DOI 10.18632/oncotarget.4903; Ko S, 2016, J HEPATOL, V64, P316, DOI 10.1016/j.jhep.2015.10.017; Kochanek Kenneth D, 2016, Natl Vital Stat Rep, V65, P1; Li GQ, 2016, ONCOTARGET, V7, P2462, DOI 10.18632/oncotarget.6275; Lockwood WW, 2012, P NATL ACAD SCI USA, V109, P19408, DOI 10.1073/pnas.1216363109; Lorent K, 2010, DEV DYNAM, V239, P855, DOI 10.1002/dvdy.22220; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Luedde T, 2014, GASTROENTEROLOGY, V147, P765, DOI 10.1053/j.gastro.2014.07.018; McCloy RA, 2014, CELL CYCLE, V13, P1400, DOI 10.4161/cc.28401; Michalopoulos GK, 2015, GASTROENTEROLOGY, V149, P876, DOI 10.1053/j.gastro.2015.08.004; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Mittal S, 2013, J CLIN GASTROENTEROL, V47, pS2, DOI 10.1097/MCG.0b013e3182872f29; Nejak-Bowen KN, 2009, J BIOL CHEM, V284, P28115, DOI 10.1074/jbc.M109.047258; Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589; Ninov N, 2012, DEVELOPMENT, V139, P1557, DOI 10.1242/dev.076000; Njei B, 2015, HEPATOLOGY, V61, P191, DOI 10.1002/hep.27388; North TE, 2010, P NATL ACAD SCI USA, V107, P17315, DOI 10.1073/pnas.1008209107; Nourjah P, 2006, PHARMACOEPIDEM DR S, V15, P398, DOI 10.1002/pds.1191; Nunez KG, 2017, OCHSNER J, V17, P56; Ovejero C, 2004, HEPATOLOGY, V40, P167, DOI 10.1002/hep.20286; Parker SCJ, 2013, P NATL ACAD SCI USA, V110, P17921, DOI 10.1073/pnas.1317023110; Pellicoro A, 2014, NAT REV IMMUNOL, V14, P181, DOI 10.1038/nri3623; Rickheim DG, 2002, HEPATOLOGY, V36, P30, DOI 10.1053/jhep.2002.33996; Shi JW, 2014, MOL CELL, V54, P728, DOI 10.1016/j.molcel.2014.05.016; Shimizu N, 2012, DEV BIOL, V370, P71, DOI 10.1016/j.ydbio.2012.07.016; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sugiyama M, 2009, P NATL ACAD SCI USA, V106, P20812, DOI 10.1073/pnas.0906464106; Tan XP, 2006, GASTROENTEROLOGY, V131, P1561, DOI 10.1053/j.gastro.2006.08.042; Tao JY, 2017, HEPATOLOGY, V65, P1581, DOI 10.1002/hep.28975; Tao JY, 2016, HEPATOLOGY, V64, P1587, DOI 10.1002/hep.28601; Tao JY, 2014, GASTROENTEROLOGY, V147, P690, DOI 10.1053/j.gastro.2014.05.004; Taub R, 2004, NAT REV MOL CELL BIO, V5, P836, DOI 10.1038/nrm1489; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thorgeirsson SS, 1996, FASEB J, V10, P1249; Timmers C, 2007, MOL CELL BIOL, V27, P65, DOI 10.1128/MCB.02147-06; Togel L, 2016, MOL CANCER THER, V15, P1217, DOI 10.1158/1535-7163.MCT-15-0724; Wang YH, 2015, ONCOL LETT, V10, P2227, DOI 10.3892/ol.2015.3570; Weglarz TC, 2000, P NATL ACAD SCI USA, V97, P12595, DOI 10.1073/pnas.220430497; Westerfield M., 2007, ZEBRAFISH BOOK; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Xu YL, 2014, TRENDS CELL BIOL, V24, P615, DOI 10.1016/j.tcb.2014.09.005; Yang J, 2014, HEPATOLOGY, V60, P964, DOI 10.1002/hep.27082; Ye HG, 1999, MOL CELL BIOL, V19, P8570; Zhang PF, 2015, INT J IMMUNOPATH PH, V28, P36, DOI 10.1177/0394632015572070; Zhang WS, 2012, J BIOL CHEM, V287, P43137, DOI 10.1074/jbc.M112.413047	74	2	2	1	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUN	2018	188	6					1389	1405		10.1016/j.ajpath.2018.02.006			17	Pathology	Pathology	GH6BM	WOS:000433524800007	29545201	Bronze, Green Published			2019-10-28	
J	Borude, P; Bhushan, B; Gunewardena, S; Akakpo, J; Jaeschke, H; Apte, U				Borude, Prachi; Bhushan, Bharat; Gunewardena, Sumedha; Akakpo, Jephte; Jaeschke, Hartmut; Apte, Udayan			Pleiotropic Role of p53 in Injury and Liver Regeneration after Acetaminophen Overdose	AMERICAN JOURNAL OF PATHOLOGY			English	Article							INDUCED HEPATOTOXICITY; DIRECT ACTIVATION; MICE; AUTOPHAGY; CELL; MECHANISMS; FAILURE; EXPRESSION; REGULATOR; APOPTOSIS	p53 is the major cellular gatekeeper involved in proliferation, cell death, migration, and homeostasis. The role of p53 in pathogenesis of drug-induced liver injury is unknown. We investigated the role of p53 in liver injury and regeneration after acetaminophen (APAP) overdose, the most common cause of acute liver failure in the Western world. Eight-week-old male wild-type (WT) and p53 knockout (p53K0) mice were treated with 300 mg/kg APAP, and the dynamics of liver injury and regeneration were studied over a time course of 0 to 96 hours. Deletion of p53 resulted in a threefold higher liver injury than in WT mice. Interestingly, despite higher liver injury, p53K0 mice recovered similarly as the WT mice because of faster liver regeneration. Deletion of p53 did not affect APAP bioactivation and initiation of injury. Microarray analysis revealed that p53K0 mice had disrupted metabolic homeostasis and induced inflammatory and proliferative signaling. p53K0 mice showed prolonged steatosis correlating with prolonged liver injury. Initiation of liver regeneration in p53K0 mice was delayed, but once initiated, cell cycle was significantly faster than WT mice because of sustained AKT, extracellular signalregulated kinase, and mammalian target of rapamycin signaling. These studies show that p53 plays a pleotropic role after APAP overdose, where it prevents progression of liver injury by maintaining metabolic homeostasis and also regulates initiation of liver regeneration through proliferative signaling.	[Borude, Prachi; Bhushan, Bharat; Akakpo, Jephte; Jaeschke, Hartmut; Apte, Udayan] Univ Kansas, Med Ctr, Dept Pharmacol Toxicol & Therapeut, Kansas City, KS 66160 USA; [Gunewardena, Sumedha] Univ Kansas, Med Ctr, Dept Biostat, Kansas City, KS 66160 USA	Apte, U (reprint author), Univ Kansas, Med Ctr, Dept Pharmacol, 3901 Rainbow Blvd,MS1018, Kansas City, KS 66160 USA.; Apte, U (reprint author), Univ Kansas, Med Ctr, Dept Toxicol & Therapeut, 3901 Rainbow Blvd,MS1018, Kansas City, KS 66160 USA.	uapte@kumc.edu			NIH Centers of Biomedical Research Excellence grant [P20 RR021940-03]; National Institute of Environmental Health Sciences Toxicology Training grant [T32ES007079-34]; National Institute of Diabetes and Digestive and Kidney DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK98414]	Supported by NIH Centers of Biomedical Research Excellence grant P20 RR021940-03, National Institute of Environmental Health Sciences Toxicology Training grant T32ES007079-34, and National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK98414 (U.A.).	Aloni-Grinstein R, 2014, FEBS LETT, V588, P2580, DOI 10.1016/j.febslet.2014.02.011; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Bernal W, 2013, NEW ENGL J MED, V369, P2525, DOI 10.1056/NEJMra1208937; Bhushan B, 2014, AM J PATHOL, V184, P3013, DOI 10.1016/j.ajpath.2014.07.019; Bhushan B, 2013, AM J PATHOL, V183, P1518, DOI 10.1016/j.ajpath.2013.07.012; Borude P, 2012, HEPATOLOGY, V56, P2344, DOI 10.1002/hep.25918; Bourdi M, 2002, HEPATOLOGY, V35, P289, DOI 10.1053/jhep.2002.30956; Broz DK, 2013, AUTOPHAGY, V9, P1440, DOI 10.4161/auto.25833; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Feng ZH, 2007, CANCER RES, V67, P3043, DOI 10.1158/0008-5472.CAN-06-4149; Fromenty B, 2013, J HEPATOL, V58, P824, DOI 10.1016/j.jhep.2012.12.018; Huo YZ, 2017, FREE RADICAL BIO MED, V106, P111, DOI 10.1016/j.freeradbiomed.2017.02.028; Jaeschke H, 2006, TOXICOL SCI, V89, P31, DOI 10.1093/toxsci/kfi336; Jaeschke H, 2012, LIVER INT, V32, P8, DOI 10.1111/j.1478-3231.2011.02501.x; Jin JL, 2015, HEPATOLOGY, V61, P315, DOI 10.1002/hep.27295; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Kruiswijk F, 2015, NAT REV MOL CELL BIO, V16, P393, DOI 10.1038/nrm4007; Kurinna S, 2013, HEPATOLOGY, V57, P2004, DOI 10.1002/hep.26233; Kurinna S, 2010, HEPATOLOGY, V52, P1023, DOI 10.1002/hep.23746; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Larson AM, 2005, HEPATOLOGY, V42, P1364, DOI 10.1002/hep.20948; Lu SC, 2000, CURR TOP CELL REGUL, V36, P95; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Martina JA, 2012, AUTOPHAGY, V8, P903, DOI 10.4161/auto.19653; McGill MR, 2013, TOXICOL APPL PHARM, V269, P240, DOI 10.1016/j.taap.2013.03.026; McGill MR, 2012, J CLIN INVEST, V122, P1574, DOI 10.1172/JCI59755; Mehendale HM, 2005, TOXICOL PATHOL, V33, P41, DOI 10.1080/01926230590881808; Menendez D, 2013, CURR OPIN ONCOL, V25, P85, DOI 10.1097/CCO.0b013e32835b6386; Michaut A, 2014, LIVER INT, V34, pE171, DOI 10.1111/liv.12514; Muller PAJ, 2011, J CELL BIOL, V192, P209, DOI 10.1083/jcb.201009059; Ni HM, 2016, J HEPATOL, V65, P354, DOI 10.1016/j.jhep.2016.04.025; Park JY, 2009, CIRC RES, V105, P705, DOI 10.1161/CIRCRESAHA.109.205310; Parrales A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122074; Reid AB, 2005, J PHARMACOL EXP THER, V312, P509, DOI 10.1124/jpet.104.075945; Rooney JP, 2015, METHODS MOL BIOL, V1241, P23, DOI 10.1007/978-1-4939-1875-1_3; Schmidt LE, 2005, HEPATOLOGY, V41, P26, DOI 10.1002/hep.20511; Schnackenberg LK, 2009, TOXICOL APPL PHARM, V235, P25, DOI 10.1016/j.taap.2008.11.015; Shehab N, 2016, JAMA-J AM MED ASSOC, V316, P2115, DOI 10.1001/jama.2016.16201; Stamper BD, 2015, GENE REGUL SYST BIO, V9, P1, DOI 10.4137/GRSB.S25388; Stepniak E, 2006, GENE DEV, V20, P2306, DOI 10.1101/gad.390506; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Walesky C, 2013, HEPATOLOGY, V57, P2480, DOI 10.1002/hep.26251; Williams CD, 2010, TOXICOL APPL PHARM, V247, P169, DOI 10.1016/j.taap.2010.07.004; Woolbright BL, 2017, J HEPATOL, V66, P836, DOI 10.1016/j.jhep.2016.11.017; Zhang LL, 2015, HEPATOLOGY, V61, P2030, DOI 10.1002/hep.27755	45	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUN	2018	188	6					1406	1418		10.1016/j.ajpath.2018.03.006			13	Pathology	Pathology	GH6BM	WOS:000433524800008	29654721	Green Published			2019-10-28	
J	Mauldin, EA; Crumrine, D; Casal, ML; Jeong, S; Opalka, L; Vavrova, K; Uchida, Y; Park, K; Craiglow, B; Choate, KA; Shin, KO; Lee, YM; Grove, GL; Wakefield, JS; Khnykin, D; Elias, PM				Mauldin, Elizabeth A.; Crumrine, Debra; Casal, Margret L.; Jeong, Sekyoo; Opalka, Lukas; Vavrova, Katerina; Uchida, Yoshikazu; Park, Kyungho; Craiglow, Brittany; Choate, Keith A.; Shin, Kyong-Oh; Lee, Yong-Moon; Grove, Gary L.; Wakefield, Joan S.; Khnykin, Denis; Elias, Peter M.			Cellular and Metabolic Basis for the Ichthyotic Phenotype in NIPAL4 (Ichthyin)Deficient Canines	AMERICAN JOURNAL OF PATHOLOGY			English	Article							RECESSIVE CONGENITAL ICHTHYOSIS; SJOGREN-LARSSON SYNDROME; LIPID ENVELOPE CLE; PERMEABILITY BARRIER ABNORMALITY; OMEGA-O-ACYLCERAMIDES; ESSENTIAL FATTY-ACID; STRATUM-CORNEUM; EPIDERMAL STRUCTURE; EPITHELIAL-CELLS; GAUCHER-DISEASE	Mutations in several Lipid synthetic enzymes that block fatty acid and ceramide production produce autosomal recessive congenital ichthyoses (ARCIs) and associated abnormalities in permeability barrier homeostasis. However, the basis for the phenotype in patients with NIPAL4 (ichthyin) mutations (among the most prevalent ARCIs) remains unknown. Barrier function was abnormal in an index patient and in canines with homozygous NIPAL4 mutations, attributable to extensive membrane stripping, likely from detergent effects of nonesterified free fatty acid. Cytotoxicity compromised not only lamellar body secretion but also formation of the corneocyte lipid envelope (CLE) and attenuation of the cornified envelope (CE), consistent with a previously unrecognized, scaffold function of the CLE. Together, these abnormalities result in failure to form normal lamellar bilayers, accounting for the permeability barrier abnormality and clinical phenotype in NIPA-like domaincontaining 4 (NIPAL4) deficiency. Thus, NIPAL4 deficiency represents another lipid synthetic ARCI that converges on the CLE (and CE), compromising their putative scaffold function. However, the clinical phenotype only partially improved after normalization of CLE and CE structure with topical w-O-acylceramide because of ongoing accumulation of toxic metabolites, further evidence that proximal, cytotoxic metabolites contribute to disease pathogenesis.	[Mauldin, Elizabeth A.; Casal, Margret L.] Univ Penn, Sch Vet Med, Dept Dermatopathol, Philadelphia, PA 19104 USA; [Crumrine, Debra; Uchida, Yoshikazu; Park, Kyungho; Wakefield, Joan S.; Elias, Peter M.] Vet Affairs Med Ctr, Dermatol Serv, 4150 Clement St,MS 190, San Francisco, CA 94121 USA; [Crumrine, Debra; Uchida, Yoshikazu; Park, Kyungho; Wakefield, Joan S.; Elias, Peter M.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [Jeong, Sekyoo; Vavrova, Katerina] Seowon Univ, Dept BioCosmet, Cheongju, South Korea; [Opalka, Lukas; Vavrova, Katerina; Craiglow, Brittany; Choate, Keith A.] Charles Univ Prague, Dept Pharm, Hradec Kralove, Czech Republic; [Craiglow, Brittany; Choate, Keith A.] Yale Univ, Dept Dermatol Genet & Pathol, New Haven, CT USA; [Shin, Kyong-Oh; Lee, Yong-Moon] Chungbuk Natl Univ, Coll Pharm, Cheongju, South Korea; [Grove, Gary L.] cyberDERM, Dept Res & Dev, Media, PA USA; [Khnykin, Denis] Oslo Univ Hosp, Dept Pathol, Oslo, Norway	Elias, PM (reprint author), Vet Affairs Med Ctr, Dermatol Serv, 4150 Clement St,MS 190, San Francisco, CA 94121 USA.	peter.elias@ucsf.edu	Vavrova, Katerina/A-2895-2008	Vavrova, Katerina/0000-0002-8502-4372	NIH National Institute of Arthritis, Musculoskeletal, and Skin [AR061106]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P40 OD010939, AR068392]; Commonwealth of Pennsylvania; GACR Czech Science FoundationGrant Agency of the Czech Republic [16-25687J]; Veterans Affairs Medical Center, San Francisco, CA	Supported by the NIH National Institute of Arthritis, Musculoskeletal, and Skin grant AR061106, administered by the Northern California Institute for Research and Education, with additional resources provided by the Veterans Affairs Medical Center, San Francisco, CA, NIH grants P40 OD010939 and AR068392, the Commonwealth of Pennsylvania, and GACR Czech Science Foundation grant 16-25687J.	Akiyama M, 2017, J DERMATOL SCI, V88, P3, DOI 10.1016/j.jdermsci.2017.06.002; Akiyama M, 2011, NAGOYA J MED SCI, V73, P79; Behne M, 2000, J INVEST DERMATOL, V114, P185, DOI 10.1046/j.1523-1747.2000.00846.x; Brash AR, 2007, FEBS J, V274, P3494, DOI 10.1111/j.1742-4658.2007.05909.x; Casal ML, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170708; Chan A, 2011, MOL GENET METAB, V104, P631, DOI 10.1016/j.ymgme.2011.09.008; Choate KA, 2015, J CLIN INVEST, V125, P1703, DOI 10.1172/JCI64415; Choate KA, 2010, SCIENCE, V330, P94, DOI 10.1126/science.1192280; Dahlqvist J, 2007, J MED GENET, V44, P615, DOI 10.1136/jmg.2007.050542; Dahlqvist J, 2012, ARCH DERMATOL RES, V304, P377, DOI 10.1007/s00403-012-1207-7; Eckl KM, 2013, J INVEST DERMATOL, V133, P2202, DOI 10.1038/jid.2013.153; Elias PM, 2014, BBA-MOL CELL BIOL L, V1841, P353, DOI 10.1016/j.bbalip.2013.11.009; Elias PM, 2014, BBA-MOL CELL BIOL L, V1841, P314, DOI 10.1016/j.bbalip.2013.09.011; Elias PM, 2012, CLIN DERMATOL, V30, P311, DOI 10.1016/j.clindermatol.2011.08.017; Elias PM, 2002, EXP DERMATOL, V11, P248, DOI 10.1034/j.1600-0625.2001.110308.x; Elias PM, 2010, ICHTHYOSES CLIN BIOC; Fischer J, 2009, J INVEST DERMATOL, V129, P1319, DOI 10.1038/jid.2009.57; Glaesser D, 1996, EUR J CELL BIOL, V71, P286; Goytain A, 2008, AM J PHYSIOL-CELL PH, V295, pC944, DOI 10.1152/ajpcell.00091.2008; Grond S, 2017, J INVEST DERMATOL, V137, P403, DOI 10.1016/j.jid.2016.09.025; Grond S, 2017, J INVEST DERMATOL, V137, P394, DOI 10.1016/j.jid.2016.08.036; Gruber R, 2011, AM J PATHOL, V178, P2252, DOI 10.1016/j.ajpath.2011.01.053; Hachem JP, 2006, J INVEST DERMATOL, V126, P1609, DOI 10.1038/sj.jid.5700288; Hellstrom Pigg M, 2016, ACTA DERM-VENEREOL, V96, P932, DOI 10.2340/00015555-2418; Herrmann T, 2003, J CELL BIOL, V161, P1105, DOI 10.1083/jcb.200207080; Hirabayashi T, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14609; Holleran WM, 2006, CLIN GENET, V69, P355, DOI 10.1111/j.1399-0004.2006.00589.x; HOLLERAN WM, 1991, J CLIN INVEST, V88, P1338, DOI 10.1172/JCI115439; HOU SYE, 1991, J INVEST DERMATOL, V96, P215, DOI 10.1111/1523-1747.ep12461361; ITO M, 1991, ARCH DERMATOL RES, V283, P141, DOI 10.1007/BF00372053; Iwig M, 2004, EXP EYE RES, V79, P689, DOI 10.1016/j.exer.2004.07.009; Jennemann R, 2012, HUM MOL GENET, V21, P586, DOI 10.1093/hmg/ddr494; Khnykin D, 2012, J AM ACAD DERMATOL, V66, P606, DOI 10.1016/j.jaad.2011.04.014; Kihara A, 2016, PROG LIPID RES, V63, P50, DOI 10.1016/j.plipres.2016.04.001; Krieg P, 2013, J INVEST DERMATOL, V133, P172, DOI 10.1038/jid.2012.250; Kusakabe M, 2017, ACTA DERM-VENEREOL, V97, P397, DOI 10.2340/00015555-2550; Lefevre C, 2004, HUM MOL GENET, V13, P2473, DOI 10.1093/hmg/ddh263; Li H, 2013, J DERMATOL SCI, V69, P195, DOI 10.1016/j.jdermsci.2012.11.593; Lieberthal W, 1997, J LAB CLIN MED, V129, P260, DOI 10.1016/S0022-2143(97)90148-7; Lin MH, 2015, J INVEST DERMATOL, V135, P462, DOI 10.1038/jid.2014.378; Lin MH, 2014, BBA-MOL CELL BIOL L, V1841, P362, DOI 10.1016/j.bbalip.2013.09.016; Lin TK, 2012, J INVEST DERMATOL, V132, P2430, DOI 10.1038/jid.2012.173; MATSUOKA LY, 1982, AM J DERMATOPATH, V4, P295, DOI 10.1097/00000372-198208000-00002; Mauldin EA, 2015, VET PATHOL, V52, P654, DOI 10.1177/0300985814551425; Menon GK, 2014, ARCH DERMATOL RES, V306, P731, DOI 10.1007/s00403-014-1478-2; MENON GK, 1992, BRIT J DERMATOL, V126, P337, DOI 10.1111/j.1365-2133.1992.tb00675.x; MENON GK, 1991, ARCH DERMATOL, V127, P57, DOI 10.1001/archderm.127.1.57; MENON GK, 1992, CELL TISSUE RES, V270, P503, DOI 10.1007/BF00645052; MENON GK, 1986, J INVEST DERMATOL, V86, P591, DOI 10.1111/1523-1747.ep12355263; Moulson CL, 2007, J BIOL CHEM, V282, P15912, DOI 10.1074/jbc.M701779200; National Research Council, 2011, GUIDE CARE USE LAB A; Ohno Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14610; Oji V, 2010, J AM ACAD DERMATOL, V63, P607, DOI 10.1016/j.jaad.2009.11.020; Opalka L, 2015, ORG LETT, V17, P5456, DOI 10.1021/acs.orglett.5b02816; PAIGE DG, 1994, BRIT J DERMATOL, V131, P23, DOI 10.1111/j.1365-2133.1994.tb08452.x; Paller AS, 2011, J INVEST DERMATOL, V131, P2242, DOI 10.1038/jid.2011.189; PALMQUIST DL, 1986, J DAIRY SCI, V69, P1020, DOI 10.3168/jds.S0022-0302(86)80497-0; Rizzo WB, 2010, ARCH DERMATOL RES, V302, P443, DOI 10.1007/s00403-009-1022-y; Sandhoff R, 2010, FEBS LETT, V584, P1907, DOI 10.1016/j.febslet.2009.12.032; Schmuth M, 2005, J INVEST DERMATOL, V125, P1174, DOI 10.1111/j.0022-202X.2005.23934.x; Schmuth M, 2004, J INVEST DERMATOL, V122, P909, DOI 10.1111/j.0022-202X.2004.22431.x; Schmuth M, 2001, J INVEST DERMATOL, V117, P837, DOI 10.1046/j.0022-202x.2001.01471.x; Schmuth M, 2008, J LIPID RES, V49, P499, DOI 10.1194/jlr.R800001-JLR200; Sugiura K, 2015, J DERMATOL SCI, V79, P4, DOI 10.1016/j.jdermsci.2015.04.009; Uchida Y, 2008, J DERMATOL SCI, V51, P77, DOI 10.1016/j.jdermsci.2008.01.002; Uchida Y, 2010, J INVEST DERMATOL, V130, P2497, DOI 10.1038/jid.2010.145; Vasireddy V, 2007, HUM MOL GENET, V16, P471, DOI 10.1093/hmg/ddl480; Wajid M, 2010, DERMATOLOGY, V220, P8, DOI 10.1159/000265757; WERTZ PW, 1989, J INVEST DERMATOL, V93, P169, DOI 10.1111/1523-1747.ep12277394; WILLIAMS ML, 1993, ARCH DERMATOL, V129, P626, DOI 10.1001/archderm.129.5.626; Zhang L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161465; Zheng YX, 2011, J BIOL CHEM, V286, P24046, DOI 10.1074/jbc.M111.251496	72	2	2	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUN	2018	188	6					1419	1429		10.1016/j.ajpath.2018.02.008			11	Pathology	Pathology	GH6BM	WOS:000433524800009	29548991	Bronze, Green Published			2019-10-28	
J	Yu, JG; Zanotti, S; Schilling, L; Schoenherr, C; Economides, AN; Sanjay, A; Canalis, E				Yu, Jungeun; Zanotti, Stefano; Schilling, Lauren; Schoenherr, Chris; Economides, Aris N.; Sanjay, Archana; Canalis, Ernesto			Induction of the Hajdu-Cheney Syndrome Mutation in CD19 B Cells in Mice Alters B-Cell Allocation but Not Skeletal Homeostasis	AMERICAN JOURNAL OF PATHOLOGY			English	Article							SPLENIC MARGINAL ZONE; TRANSCRIPTION COMPLEXES; NOTCH2 MUTATION; B1B CELLS; BONE LOSS; IN-VIVO; OSTEOPOROSIS; LYMPHOCYTES; ACTIVATION; GENERATION	Mice harboring Notch2 mutations replicating Hajdu-Cheney syndrome (Notch2(tm1.1ECan)) have osteopenia and exhibit an increase in splenic marginal zone B cells with a decrease in follicular B cells. Whether the altered B-cell allocation is responsible for the osteopenia of Notch2(tm1.1ECan) mutants is unknown. To determine the effect of NOTCH2 activation in B cells on splenic B-cell allocation and skeletal phenotype, a conditional-by-inversion (COIN) Hajdu-Cheney syndrome allele of Notch2 (Notch2([Delta PEST]COIN)) was used. Cre recombination generates a permanent Notch2(Delta PEST) allele expressing a transcript for which sequences coding for the proline, glutamic acid, serine, and threonine-rich (PEST) domain are replaced by a stop codon. CD19-Cre drivers were backcrossed into Notch2([Delta PEST]COIN/[Delta PEST]COIN) to generate CD19-specific Notch2(Delta PEST/Delta PEST) mutants and control Notch2([Delta PEST]COIN/[Delta PEST]COIN) littermates. There was an increase in marginal zone B cells and a decrease in follicular B cells in the spleen of CD19(Cre/WT); Notch2(Delta PEST/Delta PEST) mice, recapitulating the splenic phenotype of Notch2(tm1.1ECan) mice. The effect was reproduced when the N0TCH1 intracellular domain was induced in CD19-expressing cells (CD19(Cre/WT);Rosa(Notch1/WT) mice). However, neither CD19(Cre/WT);Notch2(Delta PEST/Delta PEST) nor CD19(Cre/WT);Rosa(Notch1/WT) mice had a skeletal phenotype. Moreover, splenectomies in Notch2(tm1.1ECan) mice did not reverse their osteopenic phenotype. In conclusion, Notch2 activation in CD19-expressing cells determines B-cell allocation in the spleen but has no skeletal consequences.	[Yu, Jungeun; Zanotti, Stefano; Sanjay, Archana; Canalis, Ernesto] UConn Hlth, Dept Orthopaed Surg, 263 Farmington Ave, Farmington, CT 06030 USA; [Zanotti, Stefano; Canalis, Ernesto] UConn Hlth, Dept Med, Farmington, CT 06030 USA; [Yu, Jungeun; Zanotti, Stefano; Schilling, Lauren; Sanjay, Archana; Canalis, Ernesto] UConn Hlth, UConn Musculoskeletal Inst, Farmington, CT 06030 USA; [Schoenherr, Chris; Economides, Aris N.] Regeneron Pharmaceut, Genome Engn Technol, Tarrytown, NY USA	Sanjay, A; Canalis, E (reprint author), UConn Hlth, Dept Orthopaed Surg, 263 Farmington Ave, Farmington, CT 06030 USA.	asanjay@uchc.edu; canalis@uchc.edu			National Institute of Diabetes and Digestive and Kidney DiseaseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK045227]; National Institute of Arthritis and Musculoskeletal and Skin DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [AR063049, AR068160]	Supported by National Institute of Diabetes and Digestive and Kidney Disease grant DK045227 (E.C.) and National Institute of Arthritis and Musculoskeletal and Skin Diseases grants AR063049 (E.C.) and AR068160 (E.C.).	Adami G, 2016, BONE, V92, P150, DOI 10.1016/j.bone.2016.08.025; AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141; Canalis E, 2017, ENDOCRINOLOGY, V158, P730, DOI 10.1210/en.2016-1787; Canalis E, 2016, CURR OSTEOPOROS REP, V14, P126, DOI 10.1007/s11914-016-0311-6; Canalis E, 2016, J BIOL CHEM, V191, P1538, DOI 10.1074/jbc.M115.685453; Canalis E, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023-014-0200-y; Canalis E, 2013, ENDOCRINOLOGY, V154, P623, DOI 10.1210/en.2012-1732; Descatoire M, 2014, J EXP MED, V211, P986, DOI 10.1084/jem.20132203; Economides AN, 2013, P NATL ACAD SCI USA, V110, pE3179, DOI 10.1073/pnas.1217812110; Fukushima H, 2017, MOL CELL, V68, P645, DOI 10.1016/j.molcel.2017.10.018; Gibb DR, 2010, J EXP MED, V207, P623, DOI 10.1084/jem.20091990; Gibson DG, 2009, NAT METHODS, V6, P343, DOI [10.1038/nmeth.1318, 10.1038/NMETH.1318]; Glatt V, 2007, J BONE MINER RES, V22, P1197, DOI 10.1359/JBMR.070507; Gray MJ, 2012, EUR J HUM GENET, V20, P122, DOI 10.1038/ejhg.2011.125; Hampel F, 2011, BLOOD, V118, P6321, DOI 10.1182/blood-2010-12-325944; Horowitz MC, 2010, BONE, V47, P472, DOI 10.1016/j.bone.2010.06.011; Isidor B, 2011, NAT GENET, V43, P306, DOI 10.1038/ng.778; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Kouadjo KE, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-127; Kovall RA, 2008, ONCOGENE, V27, P5099, DOI 10.1038/onc.2008.223; Lee SY, 2009, CANCER SCI, V100, P920, DOI 10.1111/j.1349-7006.2009.01130.x; Li Y, 2007, BLOOD, V109, P3839, DOI 10.1182/blood-2006-07-037994; Li Yan, 2014, Open Bone J, V6, P8; Liu ZY, 2015, DEVELOPMENT, V142, P2452, DOI 10.1242/dev.125492; Majewski J, 2011, HUM MUTAT, V32, P1114, DOI 10.1002/humu.21546; Manilay JO, 2014, TRENDS MOL MED, V20, P405, DOI 10.1016/j.molmed.2014.03.003; Meednu N, 2016, ARTHRITIS RHEUMATOL, V68, P805, DOI 10.1002/art.39489; Murtaugh LC, 2003, P NATL ACAD SCI USA, V100, P14920, DOI 10.1073/pnas.2436557100; Nam Y, 2006, CELL, V124, P973, DOI 10.1016/j.cell.2005.12.037; Nazarenko I, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e37; Nazarenko I, 2002, NUCLEIC ACIDS RES, V30, P2089, DOI 10.1093/nar/30.9.2089; NYE JS, 1994, DEVELOPMENT, V120, P2421; Onal M, 2012, J BIOL CHEM, V287, P29851, DOI 10.1074/jbc.M112.377945; Pear WS, 2004, CURR OPIN HEMATOL, V11, P426, DOI 10.1097/01.moh.0000143965.90813.70; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Rickert RC, 1997, NUCLEIC ACIDS RES, V25, P1317, DOI 10.1093/nar/25.6.1317; Rossi D, 2012, J EXP MED, V209, P1537, DOI 10.1084/jem.20120904; Saito T, 2003, IMMUNITY, V18, P675, DOI 10.1016/S1074-7613(03)00111-0; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schwenk F, 1997, J IMMUNOL METHODS, V207, P203, DOI 10.1016/S0022-1759(97)00116-6; Shirayoshi Y, 1997, GENES CELLS, V2, P213, DOI 10.1046/j.1365-2443.1997.d01-310.x; Simpson MA, 2011, NAT GENET, V43, P303, DOI 10.1038/ng.779; Six EM, 2004, J BIOL CHEM, V279, P55818, DOI 10.1074/jbc.M408022200; Tang SHE, 2002, GENESIS, V32, P199, DOI 10.1002/gene.10030; Tanigakik K, 2002, NAT IMMUNOL, V3, P443, DOI 10.1038/ni793; Vollersen N, 2018, J BONE MINER RES, V33, P70, DOI 10.1002/jbmr.3283; Wilson JJ, 2006, CELL, V124, P985, DOI 10.1016/j.cell.2006.01.035; Witt CM, 2003, MOL CELL BIOL, V23, P8637, DOI 10.1128/MCB.23.23.8637-8650.2003; Witt CM, 2003, J IMMUNOL, V171, P2783, DOI 10.4049/jimmunol.171.6.2783; Yu JG, 2018, AM J PATHOL, V188, P149, DOI 10.1016/j.ajpath.2017.09.010; Yuan ZY, 2012, J BIOL CHEM, V287, P34904, DOI 10.1074/jbc.M112.403287; Zanotti S, 2017, J BIOL CHEM, V292, P12232, DOI 10.1074/jbc.M117.786129; Zanotti S, 2016, ENDOCR REV, V37, P223, DOI 10.1210/er.2016-1002; Zanotti S, 2010, MOL CELL BIOL, V30, P886, DOI 10.1128/MCB.01285-09; Zhao W, 2013, OSTEOPOROSIS INT, V24, P2275, DOI 10.1007/s00198-013-2298-5; Zouali M, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00063	57	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUN	2018	188	6					1430	1446		10.1016/j.ajpath.2018.02.010			17	Pathology	Pathology	GH6BM	WOS:000433524800010	29545197	Green Published			2019-10-28	
J	Li, N; Yang, YM; Liang, CL; Qiu, Q; Pan, C; Li, MY; Yang, SY; Chen, LJ; Zh, XJ; Hu, YG				Li, Ning; Yang, Yeming; Liang, Cailing; Qiu, Qiang; Pan, Cong; Li, Mengyuan; Yang, Shengyong; Chen, Lijuan; Zh, Xianjun; Hu, Yiguo			Tmem30a Plays Critical Roles in Ensuring the Survival of Hematopoietic Cells and Leukemia Cells in Mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							P-TYPE ATPASE; HUMAN INTERACTOME; ATP8A2 GENE; PROTEIN; PHOSPHATIDYLSERINE; ATP11C; EXPRESSION; MOUSE; TRANSLOCASE; DISRUPTION	The fundamental structure of eukaryotic cell plasma membrane is the phospholipid bilayer, which contains four major phospholipids. These phospholipids are asymmetrically distributed between the outer and inner leaflets. P4-ATPase flippase complexes play essential roles in ensuring this asymmetry. We found that conditional deletion of Tmem30a, the beta subunit of P4-ATPase flippase complex, caused pancytopenia in mice. Tmem30a deficiency resulted in depletion of lineage-committed blood cells in the peripheral blood, spleen, and bone marrow. Ablation of Tmem30a also caused the depletion of hematopoietic stem cells (HSCs). HSC RNA sequencing results revealed that multiple biological processes and signal pathways were involved in the event, including mammalian target of rapamycin signaling, genes for HSC sternness, and genes responding to interferons. Our results also revealed that targeting Tmem30a signaling had therapeutic utility in BCR/ABL1-induced chronic myeloid leukemia.	[Li, Ning; Liang, Cailing; Qiu, Qiang; Pan, Cong; Li, Mengyuan; Yang, Shengyong; Chen, Lijuan; Hu, Yiguo] Sichuan Univ, West China Hosp, Dept Thyroid Surg, Chengdu, Sichuan, Peoples R China; [Li, Ning; Liang, Cailing; Qiu, Qiang; Pan, Cong; Li, Mengyuan; Hu, Yiguo] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China; [Li, Ning; Liang, Cailing; Qiu, Qiang; Pan, Cong; Li, Mengyuan; Hu, Yiguo] Sichuan Univ, West China Hosp, Collaborat Innovat Ctr Biotherapy, Chengdu, Sichuan, Peoples R China; [Yang, Yeming; Zh, Xianjun] Univ Elect Sci & Technol China, Sichuan Prov Key Lab Human Dis Gene Study, Sichuan Prov Peoples Hosp, Chengdu, Sichuan, Peoples R China; [Zh, Xianjun] Sichuan Acad Med Sci, Dept Lab Med, Chengdu, Sichuan, Peoples R China; [Zh, Xianjun] Sichuan Prov Peoples Hosp, Chengdu, Sichuan, Peoples R China; [Zh, Xianjun] Chinese Acad Sci, Sichuan Translat Med Res Hosp, Chengdu Inst Biol, Chengdu, Sichuan, Peoples R China	Zh, XJ (reprint author), Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Chengdu 610072, Sichuan, Peoples R China.; Hu, YG (reprint author), 17 Third Part Ren Min Nan Rd, Chengdu 610041, Sichuan, Peoples R China.	xjzhu@uestc.edu.cn; huyiguo@scu.edu.cn		Zhu, Xianjun/0000-0002-2531-7552	Natural Science Foundation of ChinaNational Natural Science Foundation of China [81541092, 21561142003, 81770950, 81470668]; National Key Basic Research Program of ChinaNational Basic Research Program of China [2015CB554100]; Department of Science and Technology of Sichuan Province [2016TD0009, 2017TJPT0010]	Supported by Natural Science Foundation of China grants 81541092 (Y.H.), 21561142003 (X.Z.), 81770950 (X.Z.), and 81470668 (X.Z.); National Key Basic Research Program of China grant 2015CB554100 (X.Z.); and Department of Science and Technology of Sichuan Province grants 2016TD0009 and 2017TJPT0010 (X.J.Z.).	Andersen JB, 2007, ONCOGENE, V26, P3081, DOI 10.1038/sj.onc.1210111; Baldridge RD, 2012, P NATL ACAD SCI USA, V109, pE290, DOI 10.1073/pnas.1115725109; Brown AL, 2006, J LEUKOCYTE BIOL, V80, P433, DOI 10.1189/jlb.0206112; Cacciagli P, 2010, EUR J HUM GENET, V18, P1360, DOI 10.1038/ejhg.2010.126; Chen CY, 1999, J CELL BIOL, V147, P1223, DOI 10.1083/jcb.147.6.1223; Chen J, 2017, J BIOL CHEM, V292, P2315, DOI 10.1074/jbc.M116.767608; Christian SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044267; Chyla BJ, 2008, MOL CELL BIOL, V28, P6234, DOI 10.1128/MCB.00404-08; Coleman JA, 2009, J BIOL CHEM, V284, P32670, DOI 10.1074/jbc.M109.047415; Cooper GM, 2000, STRUCTURE PLASMA MEM; Couzinet A, 2008, P NATL ACAD SCI USA, V105, P2556, DOI 10.1073/pnas.0712295105; Darland-Ransom M, 2008, SCIENCE, V320, P528, DOI 10.1126/science.1155847; Doulatov S, 2012, CELL STEM CELL, V10, P120, DOI 10.1016/j.stem.2012.01.006; Guo FK, 2013, HAEMATOLOGICA, V98, P1353, DOI 10.3324/haematol.2012.080424; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; Hu Y, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.53; Hu Y, 2009, LEUKEMIA, V23, P109, DOI 10.1038/leu.2008.262; Huttlin EL, 2017, NATURE, V545, P505, DOI 10.1038/nature22366; Huttlin EL, 2015, CELL, V162, P425, DOI 10.1016/j.cell.2015.06.043; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Jaatinen T, 2006, STEM CELLS, V24, P631, DOI 10.1634/stemcells.2005-0185; Jaworski E, 2014, J BIOL CHEM, V289, P22284, DOI 10.1074/jbc.M114.549659; JORDAN VC, 1993, BRIT J PHARMACOL, V110, P507, DOI 10.1111/j.1476-5381.1993.tb13840.x; Kato U, 2013, J BIOL CHEM, V288, P4922, DOI 10.1074/jbc.M112.402701; Lee SB, 1997, VIROLOGY, V231, P81, DOI 10.1006/viro.1997.8494; Levano K, 2012, J NEUROCHEM, V120, P302, DOI 10.1111/j.1471-4159.2011.07543.x; Leventis PA, 2010, ANNU REV BIOPHYS, V39, P407, DOI 10.1146/annurev.biophys.093008.131234; Lin RJ, 2016, CHINESE MED J-PEKING, V129, P326, DOI 10.4103/0366-6999.174503; Liu LM, 2017, AM J PATHOL, V187, P2775, DOI 10.1016/j.ajpath.2017.08.011; Lopez-Marques RL, 2014, PFLUG ARCH EUR J PHY, V466, P1227, DOI 10.1007/s00424-013-1363-4; Martin-Hernandez E, 2016, NEUROGENETICS, V17, P259, DOI 10.1007/s10048-016-0496-y; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Onat OE, 2013, EUR J HUM GENET, V21, P281, DOI 10.1038/ejhg.2012.170; Rossetti S, 2010, J CELL MOL MED, V14, P1358, DOI 10.1111/j.1582-4934.2009.00982.x; Siggs OM, 2011, P NATL ACAD SCI USA, V108, P7890, DOI 10.1073/pnas.1104631108; Siggs OM, 2011, NAT IMMUNOL, V12, P434, DOI 10.1038/ni.2012; Stawowczyk M, 2011, J BIOL CHEM, V286, P7257, DOI 10.1074/jbc.M110.207068; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thomas E, 2012, GASTROENTEROLOGY, V142, P978, DOI 10.1053/j.gastro.2011.12.055; Wang L, 2004, DEV BIOL, V267, P203, DOI 10.1016/j.ydbio.2003.11.004; Xu H, 2014, J PATHOL, V234, P386, DOI 10.1002/path.4404; Yabas M, 2014, J BIOL CHEM, V289, P19531, DOI 10.1074/jbc.C114.570267; Yabas M, 2011, NAT IMMUNOL, V12, P441, DOI 10.1038/ni.2011; Zhang L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09506-5; Zhou XM, 2009, P NATL ACAD SCI USA, V106, P16586, DOI 10.1073/pnas.0904293106	45	5	5	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUN	2018	188	6					1457	1468		10.1016/j.ajpath.2018.02.015			12	Pathology	Pathology	GH6BM	WOS:000433524800012	29574182	Bronze			2019-10-28	
J	Xue, YH; Mars, WM; Bowen, W; Singhi, AD; Stoops, J; Michalopoulos, GK				Xue, Yuhua; Mars, Wendy M.; Bowen, William; Singhi, Aatur D.; Stoops, John; Michalopoulos, George K.			Hepatitis C Virus Mimics Effects of Glypican-3 on CD81 and Promotes Development of Hepatocellular Carcinomas via Activation of Hippo Pathway in Hepatocytes	AMERICAN JOURNAL OF PATHOLOGY			English	Article							3 TRANSGENIC MICE; LIVER-REGENERATION; THERAPEUTIC TARGET; DYSPLASTIC NODULES; CANCER DEVELOPMENT; IN-VITRO; PROLIFERATION; GROWTH; SUPPRESSION; ANEUPLOIDY	Glypican (GPC)-3 is overexpressed in hepatocellular carcinomas (HCCs). GPC3 binds to CD81. Forced expression of CD81 in a GPC3-expressing HCC cell line caused activation of Hippo, a decrease in ezrin phosphorylation, and a decrease in yes-associated protein (YAP). CD81 is also associated with hepatitis C virus (HCV) entry into hepatocytes. Activation of CD81 by agonistic antibody causes activation of tyrosine-protein kinase SYK (SYK) and phosphorylation of ezrin, a regulator of the Hippo pathway. In cultures of normal hepatocytes, CD81 agonistic antibody led to enhanced phosphorylation of ezrin and an increase in nuclear YAP. HCV E2 protein mimicked GPC3 and led to enhanced Hippo activity and decreased YAP in cultured normal human hepatocytes. HCC tissue microarray revealed a lack of expression of CD81 in most HCCs, rendering them insusceptible to HCV infection. Activation of CD81 by agonistic antibody suppressed the Hippo pathway and increased nuclear YAP. HCV mimicked GPC3, causing Hippo activation and a decrease in YAP. HCV is thus likely to enhance hepatic neoplasia by acting as a promoter of growth of early CD81-negative neoplastic hepatocytes, which are resistant to HCV infection, and thus have a proliferative advantage to clonally expand as they participate in compensatory regeneration for the required maintenance of 100% of liver weight (hepatostat).	[Xue, Yuhua; Mars, Wendy M.; Bowen, William; Singhi, Aatur D.; Stoops, John; Michalopoulos, George K.] Univ Pittsburgh, Dept Pathol, 200 Lothrop St,BST 5410, Pittsburgh, PA 15261 USA	Michalopoulos, GK (reprint author), Univ Pittsburgh, Dept Pathol, 200 Lothrop St,BST 5410, Pittsburgh, PA 15261 USA.	michalopoulosgk@upmc.edu			NIH/NIDDKUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P01 DK096690]; Cleveland Foundation; Menten Endowment Foundation of the University of Pittsburgh	Supported by NIH/NIDDK Program Project grant P01 DK096690 (P.I. David Perlmutter) (G.K.M.), the Cleveland Foundation, and the Menten Endowment Foundation of the University of Pittsburgh.	Altekruse SF, 2009, J CLIN ONCOL, V27, P1485, DOI 10.1200/JCO.2008.20.7753; Andersson TB, 2012, EXPERT OPIN DRUG MET, V8, P909, DOI 10.1517/17425255.2012.685159; Angus L, 2012, ONCOGENE, V31, P238, DOI 10.1038/onc.2011.224; [Anonymous], 2011, GUIDE CARE USE LAB A; ANTI M, 1994, CANCER, V73, P281, DOI 10.1002/1097-0142(19940115)73:2<281::AID-CNCR2820730208>3.0.CO;2-6; Bhave VS, 2013, AM J PATHOL, V183, P153, DOI 10.1016/j.ajpath.2013.03.013; Bhave VS, 2011, HEPATOLOGY, V54, P1360, DOI 10.1002/hep.24507; Bouchard MJ, 2011, CANCER LETT, V305, P123, DOI 10.1016/j.canlet.2010.11.014; Bukong TN, 2013, HEPATOLOGY, V58, P1569, DOI 10.1002/hep.26500; Capurro M, 2003, GASTROENTEROLOGY, V125, P89, DOI 10.1016/S0016-5085(03)00689-9; Capurro MI, 2008, DEV CELL, V14, P700, DOI 10.1016/j.devcel.2008.03.006; Coffey GP, 2009, J CELL SCI, V122, P3137, DOI 10.1242/jcs.045658; De Cat B, 2001, SEMIN CELL DEV BIOL, V12, P117, DOI 10.1006/scdb.2000.0240; Duncan AW, 2012, J CLIN INVEST, V122, P3307, DOI 10.1172/JCI64026; Duncan AW, 2012, GASTROENTEROLOGY, V142, P25, DOI 10.1053/j.gastro.2011.10.029; FARBER E, 1976, CANCER RES, V36, P3879; Filmus J, 2013, FEBS J, V280, P2471, DOI 10.1111/febs.12126; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Gao W, 2014, HEPATOLOGY, V60, P576, DOI 10.1002/hep.26996; Huang SF, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-306; Ioannidou A, 2016, FRONT GENET, V7, DOI 10.3382/fgene.2016.00187; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Kim H, 2003, AM J RESP CELL MOL, V29, P694, DOI 10.1165/rcmb.2003-0061OC; Koral K, 2015, HEPATOLOGY, V61, P537, DOI 10.1002/hep.27444; Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377; Libbrecht L, 2006, AM J SURG PATHOL, V30, P1405, DOI 10.1097/01.pas.0000213323.97294.9a; Lin CW, 2011, HEPATOLOGY, V54, P620, DOI 10.1002/hep.24417; Liu B, 2010, HEPATOLOGY, V52, P1060, DOI 10.1002/hep.23794; Liu BW, 2009, AM J PATHOL, V175, P717, DOI 10.2353/ajpath.2009.081129; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Michalopoulos GK, 2017, HEPATOLOGY, V65, P1384, DOI 10.1002/hep.28988; Michalopoulos GK, 2013, COMPR PHYSIOL, V3, P485, DOI 10.1002/cphy.c120014; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; NOVICKI DL, 1983, IN VITRO CELL DEV B, V19, P191; Perra A, 2014, J HEPATOL, V61, P1088, DOI 10.1016/j.jhep.2014.06.033; Rullier A, 2001, MODERN PATHOL, V14, P496, DOI 10.1038/modpathol.3880338; Shimomura T, 2014, BIOCHEM BIOPH RES CO, V443, P917, DOI 10.1016/j.bbrc.2013.12.100; Sun CK, 2011, NEOPLASIA, V13, P735, DOI 10.1593/neo.11664; Wang SK, 2014, ADV ANAT PATHOL, V21, P450, DOI 10.1097/PAP.0000000000000043; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhang YY, 2010, J VIROL, V84, P3396, DOI 10.1128/JVI.02391-09	41	2	2	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUN	2018	188	6					1469	1477		10.1016/j.ajpath.2018.02.013			9	Pathology	Pathology	GH6BM	WOS:000433524800013	29577937	Green Published			2019-10-28	
J	Haffner, MC; Guner, G; Taheri, D; Netto, GJ; Palsgrove, DN; Zheng, QZ; Guedes, LB; Kim, K; Tsai, H; Esopi, DM; Lotan, TL; Sharma, R; Meeker, AK; Chinnaiyan, AM; Nelson, WG; Yegnasubramania, S; Luo, J; Mehra, R; Antonarakis, ES; Drake, CG; de Marzo, AM				Haffner, Michael C.; Guner, Gunes; Taheri, Diana; Netto, George J.; Palsgrove, Doreen N.; Zheng, Qizhi; Guedes, Liana Benevides; Kim, Kunhwa; Tsai, Harrison; Esopi, David M.; Lotan, Tamara L.; Sharma, Rajni; Meeker, Alan K.; Chinnaiyan, Arul M.; Nelson, William G.; Yegnasubramania, Srinivasan; Luo, Jun; Mehra, Rohit; Antonarakis, Emmanuel S.; Drake, Charles G.; de Marzo, Angelo M.			Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer	AMERICAN JOURNAL OF PATHOLOGY			English	Article							CELL LUNG-CANCER; ADAPTIVE IMMUNE RESISTANCE; PD-L1 EXPRESSION; MUTATIONAL LANDSCAPE; BLOCKADE; IMMUNOTHERAPY; ABIRATERONE; ANTIBODY; ENZALUTAMIDE; GENOMICS	Antibodies targeting the programmed cell death protein 1/programmed death-ligand 1 (PD-L1) interaction have shown clinical activity in multiple cancer types. PD-L1 protein expression is a clinically validated predictive biomarker of response for such therapies. Prior studies evaluating the expression of PD-L1 in primary prostate cancers have reported highly variable rates of PD-L1 positivity. In addition, limited data exist on PD-L1 expression in metastatic castrate-resistant prostate cancer (mCRPC). Here, we determined PD-L1 protein expression by immunohistochemistry using a validated PD-L1specific antibody (SP263) in a large and representative cohort of primary prostate cancers and prostate cancer metastases. The study included 539 primary prostate cancers comprising 508 acinar adenocarcinomas, 24 prostatic duct adenocarcinomas, 7 small-cell carcinomas, and a total of 57 cases of mCRPC. PD-L1 positivity was low in primary acinar adenocarcinoma, with only 7.7% of cases showing detectable PD-L1 staining. Increased levels of PD-L1 expression were noted in 42.9% of small-cell carcinomas. In mCRPC, 31.6% of cases showed PD-L1specific immunoreactivity. In conclusion, in this comprehensive evaluation of PD-L1 expression in prostate cancer, PD-L1 expression is rare in primary prostate cancers, but increased rates of PD-L1 positivity were observed in mCRPC. These results will be important for the future clinical development of programmed cell death protein 1/PD-L1targeting therapies in prostate cancer.	[Haffner, Michael C.; Netto, George J.; Kim, Kunhwa; Esopi, David M.; Lotan, Tamara L.; Meeker, Alan K.; Nelson, William G.; Yegnasubramania, Srinivasan; Luo, Jun; Antonarakis, Emmanuel S.; Drake, Charles G.; de Marzo, Angelo M.] Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; [Haffner, Michael C.; Guner, Gunes; Taheri, Diana; Netto, George J.; Palsgrove, Doreen N.; Zheng, Qizhi; Guedes, Liana Benevides; Lotan, Tamara L.; Sharma, Rajni; Meeker, Alan K.; Nelson, William G.; Yegnasubramania, Srinivasan; Luo, Jun; de Marzo, Angelo M.] Johns Hopkins Sch Med, Dept Pathol, Baltimore, MD USA; [Netto, George J.; Meeker, Alan K.; Nelson, William G.; Luo, Jun; Antonarakis, Emmanuel S.; de Marzo, Angelo M.] Johns Hopkins Sch Med, Brady Urol Inst, Baltimore, MD USA; [Tsai, Harrison] Brigham & Women Hosp, Dept Pathol, Boston, MA USA; [Chinnaiyan, Arul M.] Univ Michigan Hlth Syst, Michigan Ctr Translat Pathol, Ann Arbor, MI USA; [Chinnaiyan, Arul M.; Mehra, Rohit] Univ Michigan Hlth Syst, Dept Pathol, Ann Arbor, MI USA; [Taheri, Diana] Isfahan Univ Med Sci, Isfahan Kidney Dis Res Ctr, Dept Pathol, Esfahan, Iran; [Drake, Charles G.] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Med Ctr, New York, NY USA	de Marzo, AM (reprint author), Johns Hopkins Univ, 1550 Orleans St,David H Koch Canc Res Bldg, Baltimore, MD 21128 USA.; Drake, CG (reprint author), Columbia Univ, Med Ctr, 177 Ft Washington Ave,Ste 6GN-435, New York, NY 10032 USA.	cgd2139@cumc.columbia.edu; ademarz@jhmi.edu		Guner, Gunes/0000-0002-7338-1524	National Cancer Institute/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P50CA058236, U01 CA196390, CCSG P30CA006973]; US Department of Defense Prostate Cancer Research Program (PCRP)United States Department of Defense [W81XWH-14-2-0182]; Prostate Cancer Biorepository Network; Prostate Cancer Foundation Challenge Award; Commonwealth Foundation	Supported in part by National Cancer Institute/NIH grants P50CA058236 (W.G.N., S.Y., A.M.D.M.), U01 CA196390 (S.Y., A.M.D.M.), CCSG P30CA006973 (T.L.L., A.K.M., W.G.N., S.Y., E.S.A., A.M.D.M.), US Department of Defense Prostate Cancer Research Program (PCRP) W81XWH-14-2-0182, The Prostate Cancer Biorepository Network (A.M.D.M.), a Prostate Cancer Foundation Challenge Award (S.Y., C.G.D.), and the Commonwealth Foundation (S.Y.).	Aggen DH, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0299-1; Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Baas W, 2017, CLIN GENITOURIN CANC, V15, P577, DOI 10.1016/j.clgc.2017.04.002; Bishop JL, 2015, ONCOTARGET, V6, P234, DOI 10.18632/oncotarget.2703; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Calagua C, 2017, CLIN CANCER RES, V23, P6812, DOI 10.1158/1078-0432.CCR-17-0807; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Faith DA, 2004, PROSTATE, V61, P215, DOI 10.1002/pros.20095; Gannon PO, 2009, J IMMUNOL METHODS, V348, P9, DOI 10.1016/j.jim.2009.06.004; Gaule P, 2017, JAMA ONCOL, V3, P256, DOI 10.1001/jamaoncol.2016.3015; Gevensleben H, 2016, CLIN CANCER RES, V22, P1969, DOI 10.1158/1078-0432.CCR-15-2042; Graff JN, 2016, ONCOTARGET, V7, P52810, DOI 10.18632/oncotarget.10547; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guedes LB, 2017, CLIN CANCER RES, V23, P6863, DOI 10.1158/1078-0432.CCR-17-0955; Haffner MC, 2010, NAT GENET, V42, P668, DOI 10.1038/ng.613; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Kantoff PW, 2010, J CLIN ONCOL, V28, P1099, DOI 10.1200/JCO.2009.25.0597; Kataoka K, 2016, NATURE, V534, P402, DOI 10.1038/nature18294; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Martin AM, 2015, PROSTATE CANCER P D, V18, P325, DOI 10.1038/pcan.2015.39; Maughan BL, 2016, CANCER CHEMOTH PHARM, V78, P1297, DOI 10.1007/s00280-016-3191-7; McLaughlin J, 2016, JAMA ONCOL, V2, P46, DOI 10.1001/jamaoncol.2015.3638; Ness N, 2017, ONCOTARGET, V8, P26789, DOI 10.18632/oncotarget.15817; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Reinhold WC, 2012, CANCER RES, V72, P3499, DOI 10.1158/0008-5472.CAN-12-1370; Ribas A, 2016, J EXP MED, V213, P2835, DOI 10.1084/jem.20161462; Ribas A, 2015, CANCER DISCOV, V5, P915, DOI 10.1158/2159-8290.CD-15-0563; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Schweizer MT, 2016, ONCOTARGET, V7, P82504, DOI 10.18632/oncotarget.12697; Schweizer MT, 2014, CANCER METAST REV, V33, P641, DOI 10.1007/s10555-013-9479-8; Schweizer MT, 2012, THER ADV UROL, V4, P167, DOI 10.1177/1756287212452196; Sunshine J, 2015, CURR OPIN PHARMACOL, V23, P32, DOI 10.1016/j.coph.2015.05.011; Sunshine JC, 2017, CLIN CANCER RES, V23, P4938, DOI 10.1158/1078-0432.CCR-16-1821; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tsai HK, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3729-z; Udager AM, 2014, PROSTATE, V74, P1199, DOI 10.1002/pros.22836; Zhu YZ, 2018, EUR UROL, V73, P727, DOI 10.1016/j.eururo.2017.08.009	43	24	24	1	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUN	2018	188	6					1478	1485		10.1016/j.ajpath.2018.02.014			8	Pathology	Pathology	GH6BM	WOS:000433524800014	29577933	Green Published			2019-10-28	
J	Madsen, M; Hansen, PR; Nielsen, LB; Cardoso, RM; van Eck, M; Pedersen, TX				Madsen, Marie; Hansen, Peter R.; Nielsen, Lars B.; Cardoso, Renata M.; van Eck, Miranda; Pedersen, Tanja X.			Imiquimod-Induced Psoriasis-Like Skin Lesions Do Not Accelerate Atherosclerosis in Low-Density Lipoprotein ReceptorDeficient Mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							VASCULAR INFLAMMATION; P-GLYCOPROTEIN; MOUSE MODEL; DIGOXIN; RISK; HYPERCHOLESTEROLEMIA; DIFFERENTIATION; MECHANISMS	Psoriasis is a chronic inflammatory skin disorder associated with several comorbidities, including atherosclerosis. Disease mechanisms that may affect both psoriasis and atherosclerosis include activation of T helper 1 and T helper 17 cells. Imiquimod application is an established mouse model of psoriasis-like skin inflammation. The cardiac glycoside digoxin inhibits the master transcription factor of T helper 17 differentiation, retinoid acid receptorrelated orphan nuclear receptor gamma t, and attenuates IL-17dependent pathologies in mice. We investigated whether cyclic imiquimod-induced psoriasis-like skin inflammation affects atherosclerosis in low-density lipoprotein receptordeficient mice and whether digoxin modifies either disease. Topical imiquimod application increased ear thickness, keratinocyte proliferation, and accumulation of CD3(+) T cells in the skin of low-density lipoprotein receptordeficient mice. Also, imiquimod affected the mice systemically with induction of splenomegaly as well as increased plasma levels of IL-17A and serum amyloid A. Overall, imiquimod reduced atherosclerosis in the aortic arch en face, but it did not affect atherosclerosis in the aortic root. Digoxin significantly reduced the imiquimod-induced ear thickening, had divergent effects on imiquimod-induced systemic inflammation, and did not affect atherosclerosis. In conclusion, cyclic imiquimod applications can be used for long-term induction of psoriasis-like skin lesions, but they attenuate atherosclerosis in low-density lipoproteindeficient mice. In this model, digoxin reduces skin inflammation, but it has no effect on atherosclerosis.	[Madsen, Marie; Hansen, Peter R.; Nielsen, Lars B.; Pedersen, Tanja X.] Univ Copenhagen, Dept Biomed Sci, Copenhagen N, Denmark; [Hansen, Peter R.] Herlev Gentofte Univ Hosp, Dept Cardiol, Hellerup, Denmark; [Nielsen, Lars B.] Copenhagen Univ Hosp, Rigshosp, Dept Clin Biochem, Copenhagen O, Denmark; [Cardoso, Renata M.; van Eck, Miranda] Leiden Univ, Leiden Acad Ctr Drug Res, Cluster BioTherapeut, Leiden, Netherlands; [Nielsen, Lars B.] Aarhus Univ, Fac Hlth Sci, Aarhus C, Denmark; [Pedersen, Tanja X.] Gubra, In Vivo Pharmacol, Horsholm Kongevej 11B, DK-2970 Horsholm, Denmark	Pedersen, TX (reprint author), Gubra, In Vivo Pharmacol, Horsholm Kongevej 11B, DK-2970 Horsholm, Denmark.	txp@gubra.dk		Hansen, Peter Riis/0000-0002-9056-535X; Martins Cardoso, Renata/0000-0002-0435-2113; Madsen, Marie/0000-0001-6579-9376	LEO foundation, Lautrupsgade 7 [DK-2100]	Supported by an unrestricted grant from the LEO foundation, Lautrupsgade 7, DK-2100 (P.R.H.)	Ahlehoff O, 2012, EUR HEART J, V33, P2054, DOI 10.1093/eurheartj/ehr285; Armstrong AW, 2011, EXP DERMATOL, V20, P544, DOI 10.1111/j.1600-0625.2011.01308.x; Armstrong EJ, 2016, AM J CARDIOL, V118, P603, DOI 10.1016/j.amjcard.2016.05.060; Bosteen MH, 2017, ATHEROSCLEROSIS, V265, P93, DOI 10.1016/j.atherosclerosis.2017.08.005; Eichhorn EJ, 2002, PROG CARDIOVASC DIS, V44, P251, DOI 10.1053/pcad.2002.31591; Flutter B, 2013, EUR J IMMUNOL, V43, P3138, DOI 10.1002/eji.201343801; Gelfand JM, 2006, JAMA-J AM MED ASSOC, V296, P1735, DOI 10.1001/jama.296.14.1735; Golden JB, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0738-z; GRIFFITHS NM, 1984, BIOCHEM PHARMACOL, V33, P3041, DOI 10.1016/0006-2952(84)90606-3; Grine L, 2016, SCI REP-UK, V6, DOI 10.1038/srep20134; Hawkes JE, 2017, J INVEST DERMATOL, V137, P546, DOI 10.1016/j.jid.2016.10.024; Huh JR, 2011, NATURE, V472, P486, DOI 10.1038/nature09978; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Karbach S, 2014, ARTERIOSCL THROM VAS, V34, P2658, DOI 10.1161/ATVBAHA.114.304108; Kim J, 2017, ANNU REV MED, V68, P255, DOI 10.1146/annurev-med-042915-103905; Ko KWS, 2009, BIOCHEM BIOPH RES CO, V384, P93, DOI 10.1016/j.bbrc.2009.04.083; Kong LL, 2015, SCI REP-UK, V5, DOI 10.1038/srep11747; Lee J, 2015, INT IMMUNOPHARMACOL, V26, P103, DOI 10.1016/j.intimp.2015.03.017; Libby P, 2012, ARTERIOSCL THROM VAS, V32, P2045, DOI 10.1161/ATVBAHA.108.179705; Madsen M, 2017, ANN DERMATOL; Madsen M, 2016, BMC DERMATOL, V16, DOI 10.1186/s12895-016-0046-1; Petersen TK, 2006, BASIC CLIN PHARMACOL, V99, P104, DOI 10.1111/j.1742-7843.2006.pto_298.x; Pincus M, 2016, AUST PRESCR, V39, P18, DOI 10.18773/austprescr.2016.006; Plikus MV, 2008, J INVEST DERMATOL, V128, P1071, DOI 10.1038/sj.jid.5701180; Salagianni M, 2012, CIRCULATION, V126, P952, DOI 10.1161/CIRCULATIONAHA.111.067678; SCHINKEL AH, 1995, J CLIN INVEST, V96, P1698, DOI 10.1172/JCI118214; Shi HR, 2016, BRIT J PHARMACOL, V173, P1517, DOI 10.1111/bph.13453; Stern RS, 2011, J INVEST DERMATOL, V131, P1159, DOI 10.1038/jid.2010.399; Swindell WR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0415-3; Taleb S, 2014, ARTERIOSCLER THROMB, V35, P1; Terhorst D, 2015, J IMMUNOL, V195, P4953, DOI 10.4049/jimmunol.1500551; van der Fits L, 2009, J IMMUNOL, V182, P5836, DOI 10.4049/jimmunol.0802999; Wakkee M, 2010, J INVEST DERMATOL, V130, P962, DOI 10.1038/jid.2009.321; Wang YM, 2012, J INVEST DERMATOL, V132, P2067, DOI 10.1038/jid.2012.112; Wei ZJ, 2014, ARTERIOSCL THROM VAS, V34, P2429, DOI 10.1161/ATVBAHA.114.304435; Xie XR, 2017, J DERMATOL SCI, V88, P20, DOI 10.1016/j.jdermsci.2017.05.003; Yokogawa M, 2014, ARTHRITIS RHEUMATOL, V66, P694, DOI 10.1002/art.38298; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zhu S, 2012, CLIN SCI, V122, P487, DOI 10.1042/CS20110496	40	3	3	1	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUN	2018	188	6					1486	1496		10.1016/j.ajpath.2018.02.005			11	Pathology	Pathology	GH6BM	WOS:000433524800015	29545199				2019-10-28	
J	Ueshima, C; Kataoka, TR; Hirata, M; Sugimoto, A; Iemura, Y; Minamiguchi, S; Nomura, T; Haga, H				Ueshima, Chiyuki; Kataoka, Tatsuki R.; Hirata, Masahiro; Sugimoto, Akihiko; Iemura, Yoshiki; Minamiguchi, Sachiko; Nomura, Takashi; Haga, Hironori			Possible Involvement of Human Mast Cells in the Establishment of Pregnancy via Killer Cell Ig-Like Receptor 2DL4	AMERICAN JOURNAL OF PATHOLOGY			English	Article							FC-EPSILON-RI; ASSISTED REPRODUCTION; TROPHOBLAST CELLS; HLA-G; EXPRESSION; PREECLAMPSIA; DEXAMETHASONE; INVASION; ANTIGEN; PATHOGENESIS	The involvement of mast cells in the establishment of pregnancy is unclear. Herein, we found that human mast cells are present in the decidual tissues of parous women and expressed a human-specific protein killer cell Ig-like receptor (KIR) 2DL4, a receptor for human leukocyte antigen G expressed on human trophoblasts. In contrast, decreased numbers of decidual mast cells and reduced KIR2DL4 expression were observed in these cells of infertile women who had undergone long-term corticosteroid treatment. Co-culture of the human mast cell line, LAD2, and human trophoblast cell line, HTR-8/SVneo, accelerated the migration and tube formation of HTR-8/SVneo cells in a KIR2DL4-dependent manner. These observations suggest the possible involvement of human mast cells in the establishment of pregnancy via KIR2DL4 and that long-term corticosteroid treatment may cause infertility by influencing the phenotypes of decidual mast cells.	[Ueshima, Chiyuki; Kataoka, Tatsuki R.; Hirata, Masahiro; Sugimoto, Akihiko; Iemura, Yoshiki; Minamiguchi, Sachiko; Haga, Hironori] Kyoto Univ Hosp, Dept Diagnost Pathol, Kyoto, Japan; [Nomura, Takashi] Kyoto Univ Hosp, Dept Dermatol, Kyoto, Japan	Kataoka, TR (reprint author), Kyoto Univ Hosp, Dept Diagnost Pathol, Sakyo Ku, 54 Syogoinkawahara Cho, Kyoto 6068507, Japan.	trkata@kuhp.kyoto-u.ac.jp			FUSO Pharmaceutical Industries, LTD. (Japan); JSPSMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [15K08362, 16K19080]	Supported by a FUSO Pharmaceutical Industries, LTD. (Japan) grant (T.R.K.) and JSPS KAKENHI grants 15K08362 (T.R.K.) and 16K19080 (C.U.).	Allen RE, 2014, EUR J OBSTET GYN R B, V182, P194, DOI 10.1016/j.ejogrb.2014.09.027; Arck PC, 2013, NAT MED, V19, P548, DOI 10.1038/nm.3160; Chen HF, 2004, HUM REPROD, V19, P1647, DOI 10.1093/humrep/deh193; Clark DA, 2014, J REPROD IMMUNOL, V103, P1, DOI 10.1016/j.jri.2014.02.006; Da Silva CA, 2002, BRIT J PHARMACOL, V135, P1634, DOI 10.1038/sj.bjp.0704617; Eller K, 2011, J IMMUNOL, V186, P83, DOI 10.4049/jimmunol.1001183; Faure M, 2002, J IMMUNOL, V168, P6208, DOI 10.4049/jimmunol.168.12.6208; Figueiredo AS, 2016, IMMUNOLOGY, V148, P13, DOI 10.1111/imm.12595; Gilfillan AM, 2011, ADV EXP MED BIOL, V716, P2, DOI 10.1007/978-1-4419-9533-9_1; GRAHAM CH, 1993, EXP CELL RES, V206, P204, DOI 10.1006/excr.1993.1139; Guo WW, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00741; HORIE K, 1993, HUM REPROD, V8, P1955, DOI 10.1093/oxfordjournals.humrep.a137967; Huang QT, 2015, CELL PHYSIOL BIOCHEM, V35, P1654, DOI 10.1159/000373979; Jeong HJ, 2003, ENDOCRINOLOGY, V144, P4080, DOI 10.1210/en.2003-0115; Kataoka TR, 2010, J IMMUNOL, V184, P2468, DOI 10.4049/jimmunol.0902450; KING SJ, 1985, P NATL ACAD SCI USA, V82, P1214, DOI 10.1073/pnas.82.4.1214; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; Klitkou L, 2015, HUM IMMUNOL, V76, P254, DOI 10.1016/j.humimm.2015.01.013; KOVATS S, 1990, SCIENCE, V248, P220, DOI 10.1126/science.2326636; Li PF, 2013, CLIN SCI, V124, P27, DOI 10.1042/CS20120121; Mamas L, 2009, CURR OPIN OBSTET GYN, V21, P306, DOI 10.1097/GCO.0b013e32832e0785; Menzies FM, 2012, IMMUNOL CELL BIOL, V90, P321, DOI 10.1038/icb.2011.40; Meyer N, 2017, SCI REP-UK, V7, DOI 10.1038/srep45106; Poehlmann TG, 2005, PLACENTA, V26, pS37, DOI 10.1016/j.placenta.2005.01.007; Rajagopalan S, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00258; Rajalingam Raja, 2012, Methods Mol Biol, V882, P391, DOI 10.1007/978-1-61779-842-9_23; Robertson SA, 2016, HUM REPROD, V31, P2164, DOI 10.1093/humrep/dew186; SAUNDERS PR, 1992, AGENTS ACTIONS, V36, P4, DOI 10.1007/BF01991220; Seval Y, 2004, ACTA HISTOCHEM, V106, P353, DOI 10.1016/j.acthis.2004.07.005; Smith SJ, 2002, CLIN EXP ALLERGY, V32, P906, DOI 10.1046/j.1365-2745.2002.01418.x; Staun-Ram E, 2005, REPROD BIOL ENDOCRIN, V3, DOI 10.1186/1477-7827-3-56; Ueshima C, 2015, CANCER IMMUNOL RES, V3, P871, DOI 10.1158/2326-6066.CIR-14-0199; Woidacki K, 2015, SCI REP-UK, V5, DOI 10.1038/srep13938; Woidacki K, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00029; Woldacki K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.214; Yan WH, 2007, AM J REPROD IMMUNOL, V57, P233, DOI 10.1111/j.1600-0897.2007.00469.x; Zhao Y, 2012, FERTIL STERIL, V98, P917, DOI 10.1016/j.fertnstert.2012.06.038	37	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUN	2018	188	6					1497	1508		10.1016/j.ajpath.2018.02.012			12	Pathology	Pathology	GH6BM	WOS:000433524800016	29577936				2019-10-28	
J	Flotte, TJ; Bell, DA				Flotte, Thomas James; Bell, Debra Ann			Anatomical pathology is at a crossroads	PATHOLOGY			English	Editorial Material									[Flotte, Thomas James; Bell, Debra Ann] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA	Flotte, TJ (reprint author), Mayo Clin, Hilton 11-04,200 First St SW, Rochester, MN 55021 USA.	flotte.thomas@mayo.edu		Flotte, Thomas/0000-0001-5691-8249			LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539; United States Food & Drug Administration, 2017, FDA ALL MARK 1 WHOL	2	3	3	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JUN	2018	50	4					373	374		10.1016/j.pathol.2018.01.003			2	Pathology	Pathology	GI6IW	WOS:000434474000001	29665965				2019-10-28	
J	Glassy, EF				Glassy, Eric F.			Digital pathology: quo vadis?	PATHOLOGY			English	Editorial Material									[Glassy, Eric F.] Affiliated Pathologists Med Grp, 2374 E Pacifica Pl, Rancho Dominguez, CA 90220 USA	Glassy, EF (reprint author), Affiliated Pathologists Med Grp, 2374 E Pacifica Pl, Rancho Dominguez, CA 90220 USA.	efglassymd@affiliatedpath.com					Acs B, 2018, JAMA ONCOL, V4, P403, DOI 10.1001/jamaoncol.2017.5449; Baraniuk C., 2015, CYBORG CHESS PLAYERS; Crenner CW, 1998, ANN INTERN MED, V128, P488, DOI 10.7326/0003-4819-128-6-199803150-00010; Flotte TJ, 2018, PATHOLOGY, V50, P373, DOI 10.1016/j.pathol.2018.01.003; Goacher E, 2017, ARCH PATHOL LAB MED, V141, P151, DOI 10.5858/arpa.2016-0025-RA; United States Food & Drug Administration, 2017, FDA ALL MARK 1 WHOL	6	1	1	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JUN	2018	50	4					375	376		10.1016/j.pathol.2018.03.001			2	Pathology	Pathology	GI6IW	WOS:000434474000002	29625709				2019-10-28	
J	Buglyo, G; Beyer, D; Biro, S; Olah, E				Buglyo, Gergely; Beyer, Daniel; Biro, Sandor; Olah, Eva			The Wilms' tumour 1 gene as a factor in non-syndromic hypospadias: evidence and controversy	PATHOLOGY			English	Review						Hypospadias; WT1 gene; rs2234583; WTIP gene; WTAP gene	CANDIDATE GENES; GENITAL TUBERCLE; WT1; SUPPRESSOR; PROTEIN; MUTATIONS; TRANSLATION; DISEASE; MALFORMATION; ACTIVATION	Hypospadias is one of the most frequent congenital anomalies of the male external genitalia. Its pathogenesis is due to largely unknown or poorly understood genetic factors and is further complicated by environmental-intrauterine-risk factors. One of the genes currently in focus by molecular biologists and clinicians studying syndromic forms of hypospadias is the Wilms' tumour 1 (WT1) gene. There is controversy over whether WT1 defects are also responsible for isolated hypospadias. In this review, we briefly cover the role of WT1 as a transcription factor and discuss proposed pathogenic pathways leading to hypospadias, outlining possible directions for research. We assess available evidence on the gene's mutations and polymorphisms recently suggested in the background of the disease, and examine the putative role of WT1-associated proteins. We also review relevant aspects of genome-wide association studies carried out so far, and raise some points to consider in future efforts.	[Buglyo, Gergely; Beyer, Daniel; Biro, Sandor] Univ Debrecen, Dept Human Genet, Debrecen, Hungary; [Olah, Eva] Univ Debrecen, Dept Pediat, Debrecen, Hungary	Buglyo, G (reprint author), Univ Debrecen, 98 Nagyerdei Korut, H-4032 Debrecen, Hungary.	gbuglyo@hotmail.com	Buglyo, Gergely/J-3537-2019	Buglyo, Gergely/0000-0001-5994-2658			Aho M, 2000, ENVIRON HEALTH PERSP, V108, P463, DOI 10.2307/3454389; Akpa MM, 2016, J BIOL CHEM, V291, P3785, DOI 10.1074/jbc.M115.678029; Allali S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024117; Bandiera R, 2015, MOL CELL ENDOCRINOL, V408, P145, DOI 10.1016/j.mce.2015.01.009; Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; Bergman JEH, 2015, WORLD J UROL, V33, P2159, DOI 10.1007/s00345-015-1507-6; Bor YC, 2006, GENE DEV, V20, P1597, DOI 10.1101/gad.1402306; Bradford ST, 2009, HUM MOL GENET, V18, P3429, DOI 10.1093/hmg/ddp283; Buglyo Gergely, 2017, Curr Urol, V10, P136, DOI 10.1159/000447167; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Canto P, 2004, J CLIN ENDOCR METAB, V89, P4480, DOI 10.1210/jc.2004-0863; Carmichael SL, 2013, J UROLOGY, V190, P1884, DOI 10.1016/j.juro.2013.05.061; Chiu HS, 2010, DEV BIOL, V344, P1071, DOI 10.1016/j.ydbio.2010.05.495; Essafi A, 2011, DEV CELL, V21, P559, DOI 10.1016/j.devcel.2011.07.014; Gana S, 2012, EUR J HUM GENET, V20, P852, DOI 10.1038/ejhg.2012.19; Geller F, 2014, NAT GENET, V46, P957, DOI 10.1038/ng.3063; Hohenstein P, 2006, HUM MOL GENET, V15, pR196, DOI 10.1093/hmg/ddl196; Huang B, 1999, AM J MED GENET, V87, P349, DOI 10.1002/(SICI)1096-8628(19991203)87:4<349::AID-AJMG13>3.0.CO;2-N; Jameson SA, 2012, DEV BIOL, V370, P24, DOI 10.1016/j.ydbio.2012.06.009; Kalfa N, 2009, INT J ANDROL, V32, P187, DOI 10.1111/j.1365-2605.2008.00899.x; Kohler B, 2011, J CLIN ENDOCR METAB, V96, pE1131, DOI 10.1210/jc.2010-2804; Kohler B, 2007, J MOL ENDOCRINOL, V38, P547, DOI 10.1677/JME-06-0020; Kohler B, 2004, EUR J ENDOCRINOL, V150, P825, DOI 10.1530/eje.0.1500825; Kohler B, 2001, J PEDIATR-US, V138, P421, DOI 10.1067/mpd.2001.112512; Laity JH, 2000, P NATL ACAD SCI USA, V97, P11932, DOI 10.1073/pnas.97.22.11932; Lee KY, 2017, CARCINOGENESIS, V38, P1228, DOI 10.1093/carcin/bgx108; Lim HN, 2001, MOL CELL ENDOCRINOL, V185, P43, DOI 10.1016/S0303-7207(01)00631-1; LITTLE MH, 1993, HUM MOL GENET, V2, P259, DOI 10.1093/hmg/2.3.259; Little NA, 2000, HUM MOL GENET, V9, P2231, DOI 10.1093/oxfordjournals.hmg.a018914; Lund L, 2009, EUR UROL, V55, P1022, DOI 10.1016/j.eururo.2009.01.005; Miller-Hodges E, 2012, J PATHOL, V226, P229, DOI 10.1002/path.2977; Miyagawa S, 2009, MOL ENDOCRINOL, V23, P871, DOI 10.1210/me.2008-0478; Morrison AA, 2008, BBA-REV CANCER, V1785, P55, DOI 10.1016/j.bbcan.2007.10.002; Nordenskjold A, 1999, UROL RES, V27, P49, DOI 10.1007/s002400050088; Paulozzi LJ, 1999, ENVIRON HEALTH PERSP, V107, P297, DOI 10.2307/3434597; Porter MP, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1552; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; Schnack TH, 2008, AM J EPIDEMIOL, V167, P251, DOI 10.1093/aje/kwm317; Singh JC, 2008, INDIAN J UROL, V24, P249, DOI 10.4103/0970-1591.40623; Smigielski EM, 2000, NUCLEIC ACIDS RES, V28, P352, DOI 10.1093/nar/28.1.352; Springer A, 2016, J PEDIAT UROL, V12, DOI DOI 10.1016/J.JPUR0L.2015.12.002; Srichai MB, 2004, J BIOL CHEM, V279, P14398, DOI 10.1074/jbc.M314155200; Sun G, 2009, UROLOGY, V73, P1241, DOI 10.1016/j.urology.2008.12.081; Utsch B, 2003, SCAND J UROL NEPHROL, V37, P498, DOI 10.1080/00365590310014517; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068; van der Zanden LFM, 2012, HUM REPROD UPDATE, V18, P260, DOI 10.1093/humupd/dms002; Wagner KD, 2003, J CELL SCI, V116, P1653, DOI 10.1242/jcs.00405; Wang YP, 2004, EUR J HUM GENET, V12, P706, DOI 10.1038/sj.ejhg.5201232; Wilhelm D, 2002, GENE DEV, V16, P1839, DOI 10.1101/gad.220102; Yang L, 2007, LEUKEMIA, V21, P868, DOI 10.1038/sj.leu.2404624	51	1	1	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JUN	2018	50	4					377	381		10.1016/j.pathol.2017.12.341			5	Pathology	Pathology	GI6IW	WOS:000434474000003	29743143				2019-10-28	
J	Lindh, C; Delahunt, B; Egevad, L				Lindh, Claes; Delahunt, Brett; Egevad, Lars			Macroscopic features of prostate cancer	PATHOLOGY			English	Article						Prostatectomy; pathology; prostate cancer; macroscopic; adenocarcinoma	SPECIMENS	This study investigates the macroscopic features of prostate cancers in unfixed prostatic tissue. For the study 514 radical prostatectomy specimens received at the Karolinska University Hospital were examined. The glands were bisected horizontally prior to fixation. Features on the cut surface of the prostate that were considered conclusive or suspicious for cancer were seen in 52% and 24% of specimens, respectively. In microscopic sections from these areas substantial cancers (>= 2 mm) were found in 94% and 69%, of glands, respectively. When no cancer was seen grossly, substantial cancers were still identified histologically in 56% of cases on the cut surface of the prostate. Of substantial tumours 58% had distinct gross findings and 20% were considered to be suspicious for cancer on macroscopic examination. It was noted that gross assessment of the tumour diameter usually underestimated the microscopic extent of the tumour (p < 0.001). Of tumours that could be identified conclusively, 30% were tan, 30% white, 16% yellow and 24% orange. Transition zone tumours were most often orange (61%) while peripheral zone tumours were usually tan or white (35% and 33%). All macroscopically identifiable cancers were poorly circumscribed. Among substantial cancers, transition zone tumours were less frequently visualised than peripheral zone tumours (33% and 13%, respectively; p < 0.001). Findings conclusive for cancer macroscopically usually predict microscopic cancer, but substantial cancers may be present even if no cancer is seen grossly. Transition zone tumours are more difficult than peripheral zone tumours to visualise macroscopically.	[Lindh, Claes; Egevad, Lars] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden; [Delahunt, Brett] Univ Otago, Dept Pathol & Mol Med, Wellington Sch Med & Hlth Sci, Wellington, New Zealand	Egevad, L (reprint author), Karolinska Inst, Dept Oncol Pathol, Karolinska Univ Hosp, Radiumhemmet P1 02, S-17176 Stockholm, Sweden.	lars.egevad@ki.se			Swedish Cancer Foundation [CAN 2014/624]; Stockholm Cancer Society [144043]	This study was funded by grants from The Swedish Cancer Foundation (grant no. CAN 2014/624) and The Stockholm Cancer Society (grant no. 144043). The authors state that there are no conflicts of interest to disclose.	Egevad L, 1998, J UROL PATHOL, V9, P17; Fitzmaurice C, 2015, JAMA ONCOL, V1, P505, DOI 10.1001/jamaoncol.2015.0735; HALL GS, 1992, AM J SURG PATHOL, V16, P315, DOI 10.1097/00000478-199204000-00001; Humphrey P, 2003, PROSTATE PATHOLOGY; Lindh C, 2018, HISTOPATHOLOGY, V72, P481, DOI 10.1111/his.13386; MCNEAL JE, 1988, AM J SURG PATHOL, V12, P897, DOI 10.1097/00000478-198812000-00001; Moch H, 2016, WHO CLASSIFICATION T; Renshaw AA, 1998, AM J CLIN PATHOL, V110, P38; Riddick AC, 2003, BJU INT, V91, P23; Riddick ACP, 2003, BJU INT, V91, P315, DOI 10.1046/j.1464-4096.2003.03041.x; Samaratunga H, 2011, MODERN PATHOL, V24, P6, DOI 10.1038/modpathol.2010.178	11	0	0	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JUN	2018	50	4					382	388		10.1016/j.pathol.2018.01.002			7	Pathology	Pathology	GI6IW	WOS:000434474000004	29709289				2019-10-28	
J	Nielsen, PS; Riber-Hansen, R; Steiniche, T				Nielsen, Patricia Switten; Riber-Hansen, Rikke; Steiniche, Torben			Immunohistochemical CD271 expression correlates with melanoma progress in a case-control study	PATHOLOGY			English	Article						Cancer stem cells; CD271; CD166; CD20; immunohistochemistry; Ki-67; melanoma; metastasis; naevus	CANCER STEM-CELLS; AUTOMATED QUANTIFICATION; MALIGNANT-MELANOMA; INDEXES; HETEROGENEITY; MARKERS; LESIONS; SOX10	Putative cancer stem cell (CSC) markers have arisen from melanoma mouse and in vitro models, but their expression in paraffin embedded patient samples relative to clinical outcome remains largely unexplored. Rather than cells of the tumour bulk, conceivably, CSC drive tumour progression. Accordingly, complete eradication may prevent melanoma relapse. Because elevated tumour-cell proliferation is an established indicator of aggressive disease, this study aimed to investigate the correlation between melanoma recurrence and proliferation of putative CSC that express CD271, CD166, or CD20. Additionally, the expression of these markers was studied in naevi, melanomas, and their recurrence. In melanoma patients, 30 with relapse (cases) and 30 without (controls) were matched for tumour thickness, ulceration, Clark level, subtype, site, gender, and age. One paraffin-embedded section of the patients' primary melanoma (n = 60), relapse (n = 21), and naevus (n = 17) were immunohistochemically double-stained for Ki-67/MART1 and single-stained for CD271, CD166, and CD20. Their whole slide images were aligned as virtual quadruple stains. Image analysis established proliferation indices of each putative stem cell marker and the tumour bulk in addition to the markers' percentage level in tumour areas and the epidermis. In cases vs controls, median dermal proliferation indices (no./mm(2)) were 211 vs 103 (p = 0.04) for CD271, 512 vs 227 (p = 0.3) for CD166, 184 vs 97 (p = 0.3) for CD20, and 95 vs 103 (p = 0.6) for the tumour bulk. Of additional interest, epidermal CD271(+) keratinocytes totalled 8.8% in naevi and 0.98% inmelanomas (p = 0.0007). Even though differences between naevi and melanomas also were observed for CD166 in both the epidermis (p = 0.002) and dermis (p = 0.006), they were visually less apparent. CD20(+) MART1+ cells were absent in half of the melanomas, and all naevi and relapses. In conclusion, high levels of CD271(+) Ki-67(+) MART1(+) cells were linked to melanoma relapse as opposed to common Ki-67 indices in this particular case-control study. With further investigation, such cells could be potential targets of therapy. Especially, loss of epidermal CD271+ keratinocytes seemed necessary for melanoma development; hence, identification may serve as a diagnostic tool with additional research.	[Nielsen, Patricia Switten; Riber-Hansen, Rikke; Steiniche, Torben] Aarhus Univ Hosp, Dept Pathol, Palle Juul Jensens Blvd 99, DK-8200 Aarhus N, Denmark	Nielsen, PS (reprint author), Aarhus Univ Hosp, Dept Pathol, Palle Juul Jensens Blvd 99, DK-8200 Aarhus N, Denmark.	swittenp@gmail.com	Nielsen, Patricia Switten/I-1497-2019	Nielsen, Patricia Switten/0000-0002-7859-6321	Knud og Edith Eriksens Mindefond; Direktor Emil C. Hertz og Hustru Inger Hertz' Fond; Kraeftfonden; Aase og Einar Danielsens Fond; Ulla og Mogens Folmer Andersens Fond; Kong Christian den Tiendes Fond; Harboefonden; Tomrermester Jorgen Holm og Hustru Elisa F. Hansens Mindelegat; Agnes og Poul Friis Fond	The study was funded by Knud og Edith Eriksens Mindefond, Direktor Emil C. Hertz og Hustru Inger Hertz' Fond, Kraeftfonden, Aase og Einar Danielsens Fond, Ulla og Mogens Folmer Andersens Fond, Kong Christian den Tiendes Fond, Harboefonden, Tomrermester Jorgen Holm og Hustru Elisa F. Hansens Mindelegat and Agnes og Poul Friis Fond. The authors state that there are no conflicts of interest to disclose.	Akamatsu H, 2016, J DERMATOL, V43, P311, DOI 10.1111/1346-8138.13048; Al Dhaybi R, 2010, MODERN PATHOL, V23, P376, DOI 10.1038/modpathol.2009.163; Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799; Beretti F, 2015, BRIT J DERMATOL, V172, P662, DOI 10.1111/bjd.13301; Berset M, 2001, INT J CANCER, V95, P73, DOI 10.1002/1097-0215(20010120)95:1<73::AID-IJC1013>3.3.CO;2-J; Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Cheli Y, 2014, ONCOTARGET, V5, P5272, DOI 10.18632/oncotarget.1967; Civenni G, 2011, CANCER RES, V71, P3098, DOI 10.1158/0008-5472.CAN-10-3997; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Donizy P, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0331-z; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Fukunaga-Kalabis M, 2011, J INVEST DERMATOL, V131, P1600, DOI 10.1038/jid.2011.159; Gambichler T, 2016, CLIN EXP DERMATOL, V41, P709, DOI 10.1111/ced.12928; Gershenwald JE, 2017, CA-CANCER J CLIN, V67, P472, DOI 10.3322/caac.21409; Girouard SD, 2011, LAB INVEST, V91, P647, DOI 10.1038/labinvest.2011.50; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hemmings C, 2010, PATHOLOGY, V42, P105, DOI 10.3109/00313020903488773; Hirobe T, 2014, DERMATOL SIN, V32, P200, DOI 10.1016/j.dsi.2014.05.002; Innominato PF, 2001, J PATHOL, V194, P95, DOI 10.1002/path.861; Klein WM, 2007, MODERN PATHOL, V20, P102, DOI 10.1038/modpathol.3800720; Knoblich JA, 2008, CELL, V132, P583, DOI 10.1016/j.cell.2008.02.007; Larkin J, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Lee N, 2014, LAB INVEST, V94, P13, DOI 10.1038/labinvest.2013.116; Mohamed A, 2014, APPL IMMUNOHISTO M M, V22, P142, DOI 10.1097/PAI.0b013e3182910a3d; Moore N, 2011, J ONCOL, DOI 10.1155/2011/396076; Nielsen PS, 2013, MODERN PATHOL, V26, P404, DOI 10.1038/modpathol.2012.188; Nielsen PS, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0484-4; Nielsen PS, 2014, HUM PATHOL, V45, P1153, DOI 10.1016/j.humpath.2014.01.009; Nielsen PS, 2012, ARCH PATHOL LAB MED, V136, P627, DOI 10.5858/arpa.2011-0360-OA; Pallini R, 2008, CLIN CANCER RES, V14, P8205, DOI 10.1158/1078-0432.CCR-08-0644; Pinc A, 2012, MOL THER, V20, P1056, DOI 10.1038/mt.2012.27; Pincelli C, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00022; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Quintana E, 2010, CANCER CELL, V18, P510, DOI 10.1016/j.ccr.2010.10.012; Sabatino M, 2009, CANCER LETT, V279, P119, DOI 10.1016/j.canlet.2008.10.039; Schatton T, 2008, PIGM CELL MELANOMA R, V21, P39, DOI 10.1111/j.1755-148X.2007.00427.x; Schmidt P, 2011, P NATL ACAD SCI USA, V108, P2474, DOI 10.1073/pnas.1009069108; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017; Shanesmith RP, 2011, AM J DERMATOPATH, V33, P663, DOI 10.1097/DAD.0b013e318214ae8a; Sharma BK, 2010, J SURG RES, V163, pE11, DOI 10.1016/j.jss.2010.03.043; Truzzi F, 2015, J INVEST DERMATOL, V135, P786, DOI 10.1038/jid.2014.454; van Kempen LCLT, 2000, AM J PATHOL, V156, P769, DOI 10.1016/S0002-9440(10)64943-7	43	0	0	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JUN	2018	50	4					402	410		10.1016/j.pathol.2017.12.340			9	Pathology	Pathology	GI6IW	WOS:000434474000006	29678478				2019-10-28	
J	Bychkov, A; Keelawat, S; Agarwal, S; Jain, D; Jung, CK; Hong, S; Lai, CR; Satoh, S; Kakudo, K				Bychkov, Andrey; Keelawat, Somboon; Agarwal, Shipra; Jain, Deepali; Jung, Chan Kwon; Hong, SoonWon; Lai, Chiung-Ru; Satoh, Shinya; Kakudo, Kennichi			Impact of non-invasive follicular thyroid neoplasm with papillary-like nuclear features on the Bethesda system for reporting thyroid cytopathology: a multi-institutional study in five Asian countries	PATHOLOGY			English	Article						Non-invasive follicular thyroid neoplasm with papillary-like nuclear features; NIFTP; the Bethesda system for reporting thyroid cytopathology; fine-needle aspiration (FNA); risk of malignancy (ROM); thyroid nodules; Asia; papillary thyroid carcinoma; follicular variant of papillary thyroid carcinoma	NEEDLE-ASPIRATION-CYTOLOGY; VARIANT; CARCINOMA; MALIGNANCY; NODULES; PERFORMANCE; PREVALENCE; MUTATION; LESIONS; CANCER	Several Western studies showed that the recent introduction of non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) significantly decreased risk of malignancy for cytological diagnostic categories. We aimed to determine the impact of NIFTP on risk of malignancy within a cohort of thyroid nodules from Asian countries, and to compare distribution of diagnostic categories between NIFTP and invasive encapsulated follicular variant of papillary thyroid carcinoma (eFV-PTC). Consecutive thyroid fine-needle aspirates from six institutions were retrospectively analysed. Histopathology slides with a diagnosis of eFV-PTC were reviewed and reclassified into invasive eFV-PTC and NIFTP. The risk of malignancy was calculated with and without NIFTP. Of 11,372 thyroid nodules, 2044 had available surgical follow-up. NIFTP was diagnosed in 59 cases, which constituted 2.9% of all excised nodules, and 5.3% of malignant nodules. Preoperative cytological diagnoses for NIFTP were non-diagnostic (10.2%), benign (18.6%), atypia of undetermined significance/follicular lesion of undetermined significance (22.0%), follicular neoplasm/suspicious for follicular neoplasm (FN/SFN) (32.2%), suspicious for malignancy (SM) (11.9%), and malignant (5.1%). The only category which showed a relative reduction in risk of malignancy after reclassification of more than 20%, was FN/SFN (24.4%). There was a significantly higher prevalence of benign cytology in NIFTP (p = 0.04) and SM/malignant in invasive eFV-PTC (p = 0.05). A majority of NIFTP cases were classified in indeterminate categories, which decreased the corresponding risk of malignancy. However, the magnitude of NIFTP impact was much lower than in the Western reports. Asian countries may not experience significant effects of NIFTP reclassification on the practice of thyroid cytopathology.	[Bychkov, Andrey; Keelawat, Somboon] Chulalongkorn Univ, Dept Pathol, Fac Med, Bangkok, Thailand; [Agarwal, Shipra; Jain, Deepali] All India Inst Med Sci, Dept Pathol, New Delhi, India; [Jung, Chan Kwon] Catholic Univ Korea, Dept Hosp Pathol, Coll Med, Seoul, South Korea; [Hong, SoonWon] Yonsei Univ, Dept Pathol, Coll Med, Seoul, South Korea; [Lai, Chiung-Ru] Taipei Vet Gen Hosp, Dept Pathol, Taipei, Taiwan; [Satoh, Shinya] Yamashita Thyroid Hosp, Dept Endocrine Surg, Fukuoka, Japan; [Kakudo, Kennichi] Kindai Univ, Nara Hosp, Dept Pathol, Fac Med, Nara, Japan	Jung, CK (reprint author), Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Hosp Pathol, 222 Banpo Daero, Seoul 06591, South Korea.	ckjung@catholic.ac.kr	Jung, Chan Kwon/C-7578-2014; Bychkov, Andrey/N-1884-2019	Jung, Chan Kwon/0000-0001-6843-3708; Bychkov, Andrey/0000-0002-4203-5696	Rachadapisek Sompot Fund for Postdoctoral Fellowship, Chulalongkorn University, Bangkok, Thailand; Basic Science Research Program through the National Research Foundation of Korea - Ministry of Science, ICT and Future Planning [NRF-2017R1D1A1B03029597]; Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea [HI16C2013]	This study was supported by the Rachadapisek Sompot Fund for Postdoctoral Fellowship, Chulalongkorn University, Bangkok, Thailand to AB; a grant (NRF-2017R1D1A1B03029597) of Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT and Future Planning; and a grant (HI16C2013) of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea. The authors state that there are no conflicts of interest to disclose.	Bongiovanni M, 2012, ACTA CYTOL, V56, P333, DOI 10.1159/000339959; Bychkov A, 2017, THYROID, V27, P983, DOI 10.1089/thy.2017.0079; Bychkov A, 2017, MALAYS J PATHOL, V39, P95; Canberk S, 2016, ACTA CYTOL, V60, P198, DOI 10.1159/000447990; Cho U, 2017, MODERN PATHOL, V30, P810, DOI 10.1038/modpathol.2017.9; Cibas ES, 2009, AM J CLIN PATHOL, V132, P658, DOI 10.1309/AJCPPHLWMI3JV4LA; Faquin WC, 2016, CANCER CYTOPATHOL, V124, P181, DOI 10.1002/cncy.21631; Ferlay J, 2013, GLOBOCAN 2012 V 1 0; Golding A, 2017, INT J SURG ONCOL, DOI 10.1155/2017/4689465; Hang JF, 2017, CANCER CYTOPATHOL, V125, P683, DOI 10.1002/cncy.21879; Haugen BR, 2017, THYROID, V27, P481, DOI 10.1089/thy.2016.0628; Hirokawa M, 2002, AM J SURG PATHOL, V26, P1508, DOI 10.1097/00000478-200211000-00014; Howitt BE, 2015, AM J CLIN PATHOL, V144, P850, DOI 10.1309/AJCPEIE12POICULI; Ibrahim AA, 2016, AM J CLIN PATHOL, V146, P373, DOI [10.1093/AJCP/AQW126, 10.1093/ajcp/aqw126]; Jung CK, 2017, J BASIC CLIN MED, V6, P26; Layfield LJ, 2017, ACTA CYTOL, V61, P187, DOI 10.1159/000469654; Lee SE, 2017, THYROID, V27, P802, DOI 10.1089/thy.2016.0547; Limlunjakorn Phanop, 2017, Journal of the Medical Association of Thailand, V100, P783; LiVolsi VA, 2017, DIAGN CYTOPATHOL, V45, P479, DOI 10.1002/dc.23732; Maletta F, 2016, HUM PATHOL, V54, P134, DOI 10.1016/j.humpath.2016.03.014; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Parente DN, 2018, WORLD J SURG, V42, P321, DOI 10.1007/s00268-017-4182-5; Poller DN, 2017, J BASIC CLIN MED, V6, P63; Pusztaszeri M, 2016, ACTA CYTOL, V60, P399, DOI 10.1159/000451020; Rosario PW, 2016, ENDOCR-RELAT CANCER, V23, P893, DOI 10.1530/ERC-16-0379; Saglietti C, 2017, J BASIC CLIN MED, V6, P57; Sheffield BS, 2014, EXPERT REV ENDOCRINO, V9, P97, DOI 10.1586/17446651.2014.887435; Song YS, 2015, ENDOCRINOL METAB, V30, P252, DOI 10.3803/EnM.2015.30.3.252; Straccia P, 2015, CANCER CYTOPATHOL, V123, P713, DOI 10.1002/cncy.21605; Strickland KC, 2015, THYROID, V25, P987, DOI 10.1089/thy.2014.0612; Valderrabano P, 2017, ENDOCR-RELAT CANCER, V24, P127, DOI 10.1530/ERC-16-0512; Zhao LN, 2017, CANCER CYTOPATHOL, V125, P323, DOI 10.1002/cncy.21839	32	11	11	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JUN	2018	50	4					411	417		10.1016/j.pathol.2017.11.088			7	Pathology	Pathology	GI6IW	WOS:000434474000007	29631726	Other Gold			2019-10-28	
J	Katona, K; Farkas, N; Kneif, M; Suto, G; Berki, T; Balatonyi, B; Tornoczky, T				Katona, Krisztian; Farkas, Nelli; Kneif, Maria; Suto, Gabor; Berki, Timea; Balatonyi, Balazs; Tornoczky, Tamas			Image analysis of fibrosis in labial salivary glands of patients with systemic autoimmune diseases. Close correlation of lobular fibrosis to seropositive rheumatoid arthritis and increased anti-CCP and RF titres in the serum	PATHOLOGY			English	Article						Labial salivary gland; image analysis; fibrosis; systemic autoimmune disease; rheumatoid arthritis; RF; CCP	SJOGRENS-SYNDROME; CLASSIFICATION CRITERIA; AMERICAN-COLLEGE; RHEUMATOLOGY/EUROPEAN LEAGUE; FATTY INFILTRATION; XEROSTOMIA; AUTOANTIBODIES; ANTIBODIES; BIOPSIES; AGE	Lobular fibrosis in labial salivary glands of patients with systemic autoimmune disease is a rarely examined and rather neglected histological change. Its significance and disease association is poorly understood. Our aim was to explore the clinical correlations of fibrosis in labial salivary gland samples using objective methods and laboratory parameters. Labial salivary gland samples from more than 300 patients over a 3-year period were selected from the archives of the pathology department, histologically examined, digitised, image analysed and statistically evaluated to identify the presence and intensity of lobular fibrosis, its relation to age, clinical diagnoses of systemic autoimmune disease and the presence of rheumatoid factor (RF), anti-cyclic citrullinated peptide (CCP), antinuclear antibodies (ANAs), and anti-dsDNA serum markers. Significant correlation was found between lobular fibrosis and the presence of autoimmune disease (p = 0.023), mainly seropositive rheumatoid arthritis (p < 0.001). Also significant association was found between the fibrosis and the presence of serum anti-CCP (p < 0.001) and IgA/IgG/IgM-RF (p < 0.001, p < 0.001 and p = 0.008, respectively). Significant association was explored between the anti-dsDNA positivity and the negative histology groups (p = 0.033) and between the ANA positivity and the inflammation only group (p = 0.021). The results suggest that lobular fibrosis tends to associate to certain systemic autoimmune diseases, mainly seropositive rheumatoid arthritis, and seems to be rare in labial salivary gland biopsies of autoimmune diseases characterised by presence of anti-dsDNA. The close correlation of ANA positivity and the inflammation only histology was not surprising, since the majority of patients (62%) have Sjogren's syndrome, known for its inflammatory infiltrate. These findings emphasise that evaluation of lobular fibrosis and inflammation in histological samples of labial salivary gland biopsies are equally important.	[Katona, Krisztian; Kneif, Maria; Balatonyi, Balazs; Tornoczky, Tamas] Pecs Univ, Dept Pathol, Sch Med, Oral Pathol Unit, Pecs, Hungary; [Katona, Krisztian; Farkas, Nelli; Kneif, Maria; Suto, Gabor; Berki, Timea; Balatonyi, Balazs; Tornoczky, Tamas] Pecs Univ, Ctr Clin, Pecs, Hungary; [Katona, Krisztian] Pecs Univ, Dept Dent Oral & Maxillofacial Surg, Sch Med, Pecs, Hungary; [Farkas, Nelli] Inst Bioanal, Sch Med, Pecs, Hungary; [Suto, Gabor] Pecs Univ, Dept Rheumatol & Immunol, Sch Med, Pecs, Hungary; [Berki, Timea] Pecs Univ, Dept Immunol & Biotechnol, Sch Med, Pecs, Hungary	Katona, K (reprint author), Szigeti St 12, H-7643 Pecs, Baranya, Hungary.	krisztian13katona@gmail.com			 [EFOP-3.6.1-16-2016-00004]	The presented scientific contribution is dedicated to the 650th anniversary of the foundation of the University of Pecs, Hungary. Krisztian Katona would like to acknowledge the EFOP-3.6.1-16-2016-00004 project and the Romhanyi Gyorgy College for Advanced Studies.	Aletaha D, 2010, ARTHRITIS RHEUM-US, V62, P2569, DOI 10.1002/art.27584; Chisholm D M, 1969, Proc Int Acad Oral Pathol, P44; CHISHOLM DM, 1968, J CLIN PATHOL, V21, P656, DOI 10.1136/jcp.21.5.656; Conigliaro P, 2016, AUTOIMMUN REV, V15, P673, DOI 10.1016/j.autrev.2016.03.003; Conrad K, 2010, AUTOIMMUN REV, V9, P431, DOI 10.1016/j.autrev.2009.11.017; Daha NA, 2011, NAT REV RHEUMATOL, V7, P203, DOI 10.1038/nrrheum.2011.28; Dasgupta B, 2012, ARTHRITIS RHEUM-US, V64, P943, DOI 10.1002/art.34356; DEWILDE PCM, 1986, J CLIN PATHOL, V39, P406, DOI 10.1136/jcp.39.4.406; DRUMMOND JR, 1984, ARCH ORAL BIOL, V29, P151, DOI 10.1016/0003-9969(84)90120-1; Fischer A, 2012, RESP MED, V106, P1040, DOI 10.1016/j.rmed.2012.03.006; Fragoulis GE, 2016, J AUTOIMMUN, V73, P85, DOI 10.1016/j.jaut.2016.06.008; FRIEDMAN H, 1979, ORAL SURG ORAL MED O, V47, P256, DOI 10.1016/0030-4220(79)90150-6; GREENSPAN JS, 1974, ORAL SURG ORAL MED O, V37, P217, DOI 10.1016/0030-4220(74)90417-4; Han B, 2014, AM J HUM GENET, V94, P522, DOI 10.1016/j.ajhg.2014.02.013; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; Katona K, 2017, AUTOIMMUNITY, V50, P199, DOI 10.1080/08916934.2017.1316381; Katona K, 2017, J ORAL PATHOL MED, V46, P537, DOI 10.1111/jop.12512; Korkmaz C, 2006, CLIN BIOCHEM, V39, P961, DOI 10.1016/j.clinbiochem.2006.06.004; Krutsay M., 1999, PATHOLOGIAI TECHIKA, P517; Llamas-Gutierrez FJ, 2014, INT J RHEUM DIS, V17, P898, DOI 10.1111/1756-185X.12502; MARKKANEN S O, 1989, Applied Pathology, V7, P233; Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125; Porter SR, 2004, ORAL SURG ORAL MED O, V97, P28, DOI 10.1016/j.tripleo.2003.07.010; Seegobin SD, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4439; SEGERBERGKONTTINEN M, 1988, SCAND J RHEUMATOL, V17, P379, DOI 10.3109/03009748809105274; Skopouli FN, 1998, CLIN EXP RHEUMATOL, V16, P63; Sorensen CE, 2014, EXP GERONTOL, V57, P211, DOI 10.1016/j.exger.2014.06.004; Sutton B, 2000, IMMUNOL TODAY, V21, P177, DOI 10.1016/S0167-5699(00)01589-9; TARPLEY TM, 1974, ORAL SURG ORAL MED O, V37, P64, DOI 10.1016/0030-4220(74)90160-1; Ubara Y, 1999, AM J KIDNEY DIS, V33; van den Hoogen F, 2013, ARTHRITIS RHEUM-US, V65, P2737, DOI 10.1002/art.38098; van der Helm-van Mil AHM, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2384; Vered M, 2000, EXP GERONTOL, V35, P1075, DOI 10.1016/S0531-5565(00)00129-7; Vitali C, 2002, ANN RHEUM DIS, V61, P554, DOI 10.1136/ard.61.6.554; Wick G, 2013, ANNU REV IMMUNOL, V31, P107, DOI 10.1146/annurev-immunol-032712-095937; Wick G, 2010, TRENDS IMMUNOL, V31, P110, DOI 10.1016/j.it.2009.12.001; Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807; Zalewska A, 2013, OR SURG OR MED OR PA, V115, P483, DOI 10.1016/j.oooo.2012.10.013	38	0	0	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JUN	2018	50	4					418	425		10.1016/j.pathol.2017.12.339			8	Pathology	Pathology	GI6IW	WOS:000434474000008	29735168				2019-10-28	
J	Favaloro, EJ; McCaughan, G; Mohammed, S; Lau, KKE; Gemmell, R; Cavanaugh, L; Donikian, D; Kondo, M; Brighton, T; Pasalic, L				Favaloro, Emmanuel J.; McCaughan, Georgia; Mohammed, Soma; Lau, Kun Kan Edwin; Gemmell, Rosalie; Cavanaugh, Lauren; Donikian, Dea; Kondo, Mayuko; Brighton, Timothy; Pasalic, Leonardo			HIT or miss? A comprehensive contemporary investigation of laboratory tests for heparin induced thrombocytopenia	PATHOLOGY			English	Article						Heparin induced thrombocytopenia; HIT; diagnosis; laboratory testing; clinical identification	MULTIPLE ELECTRODE AGGREGOMETRY; LATERAL FLOW IMMUNOASSAY; IMPEDANCE AGGREGOMETRY; ACUSTAR HIT; DIAGNOSIS; ANTIBODIES; ASSAYS	Heparin induced thrombocytopenia (HIT) is a rare but potentially fatal complication of heparin therapy, which in a proportion of patients causes platelet activation and thrombosis. Initial clinical assessment of the likelihood of HIT is facilitated by laboratory testing to confirm or exclude HIT. This prospective investigation was performed over an 18-month period, and has involved testing of over 300 test samples from over 100 consecutive patients. Clinical assessment by 4T score was supplemented by laboratory tests that comprised both immunological [lateral flow ('STiC'), chemiluminescence (AcuStar; HIT-IgG(PF4-H)), ELISA (Asserachrom HPIA IgG)] and functional assays [SRA, platelet aggregation using whole blood ('Multiplate') and platelet rich plasma ('LTA')]. We observed both false positive and false negative test findings with most assays. Overall, the whole blood aggregation method provided a reasonable alternative to SRA for identifying functional HIT. STiC, AcuStar and ELISA procedures were fairly comparable in terms of screening for HIT, although STiC and AcuStar both yielded false negatives, albeit also resulting in fewer false positives than ELISA. The 4T score had less utility in our patient cohort than we were expecting, although there was an association with the likelihood of HIT. Nevertheless, we accept that our observations are based on limited test numbers. In conclusion, no single approach (clinical or laboratory) was associated with optimal sensitivity or specificity of HIT exclusion or identification, and thus, a combination of clinical evaluation and laboratory testing will best ensure the accuracy of diagnosis.	[Favaloro, Emmanuel J.; McCaughan, Georgia; Mohammed, Soma; Lau, Kun Kan Edwin; Pasalic, Leonardo] Westmead Hosp, Dept Haematol, ICPMR, Westmead, NSW 2145, Australia; [Favaloro, Emmanuel J.; McCaughan, Georgia; Mohammed, Soma; Lau, Kun Kan Edwin; Gemmell, Rosalie; Cavanaugh, Lauren; Donikian, Dea; Kondo, Mayuko; Brighton, Timothy; Pasalic, Leonardo] NSW Hlth Pathol, Newcastle, NSW, Australia; [Favaloro, Emmanuel J.; Pasalic, Leonardo] Sydney Ctr Thrombosis & Haemostasis, Westmead, NSW, Australia; [McCaughan, Georgia] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia; [Gemmell, Rosalie; Cavanaugh, Lauren] St George Hosp, Kogarah, NSW, Australia; [Donikian, Dea; Kondo, Mayuko; Brighton, Timothy] Prince Wales Hosp, Randwick, NSW, Australia	Favaloro, EJ (reprint author), Westmead Hosp, Dept Haematol, ICPMR, Westmead, NSW 2145, Australia.	Emmanuel.Favaloro@health.nsw.gov.au	Favaloro, Emmanuel J./J-7689-2019				Althaus K, 2013, THROMB RES, V131, pE85, DOI 10.1016/j.thromres.2013.01.005; Berroeta C, 2016, SEMIN THROMB HEMOST, V42, P69, DOI 10.1055/s-0035-1564840; Cuker A, 2014, SEMIN THROMB HEMOST, V40, P106, DOI 10.1055/s-0033-1363461; Cuker A, 2012, BLOOD, V120, P4160, DOI 10.1182/blood-2012-07-443051; De Cooman L, 2016, BRIT J HAEMATOL, V172, P464, DOI 10.1111/bjh.13488; FAVALORO EJ, 1992, PATHOLOGY, V24, P177, DOI 10.3109/00313029209063169; Favaloro EJ, 2017, PATHOLOGY, V49, P346, DOI 10.1016/j.pathol.2017.02.005; Favaloro EJ, 2015, SEMIN THROMB HEMOST, V41, P208, DOI 10.1055/s-0035-1546827; Greinacher A, 2015, NEW ENGL J MED, V373, P252, DOI 10.1056/NEJMcp1411910; Lau Kun Kan Edwin, 2017, Methods Mol Biol, V1646, P227, DOI 10.1007/978-1-4939-7196-1_19; Legnani C, 2010, THROMB HAEMOSTASIS, V104, P402, DOI 10.1160/TH10-01-0002; Leroux D, 2014, BRIT J HAEMATOL, V166, P774, DOI 10.1111/bjh.12939; McKenzie SE, 2014, CURR OPIN HEMATOL, V21, P380, DOI 10.1097/MOH.0000000000000066; Minet V, 2014, THROMB RES, V133, P1074, DOI 10.1016/j.thromres.2014.01.014; Minet V, 2013, THROMB RES, V132, P352, DOI 10.1016/j.thromres.2013.06.004; Morel-Kopp MC, 2016, J THROMB HAEMOST, V14, P2548, DOI 10.1111/jth.13516; Morel-Kopp MC, 2012, THROMB HAEMOSTASIS, V107, P575, DOI 10.1160/TH11-09-0631; Pouplard C, 2005, BRIT J HAEMATOL, V128, P837, DOI 10.1111/j.1365-2141.2005.05381.x; Pouplard C, 2016, BRIT J HAEMATOL, V172, P466, DOI 10.1111/bjh.13490; SHERIDAN D, 1986, BLOOD, V67, P27; Slavik L, 2014, CLIN LAB, V60, P1319, DOI 10.7754/Clin.Lab.2013.130740; Streiff MB, 2016, J THROMB THROMBOLYS, V41, P32, DOI 10.1007/s11239-015-1317-0; Van Hoecke F, 2012, INT J LAB HEMATOL, V34, P410, DOI 10.1111/j.1751-553X.2012.01413.x; Vianello F, 2015, CLIN CHEM LAB MED, V53, P257, DOI 10.1515/cclm-2014-0809; Warkentin TE, 2015, AM J HEMATOL, V90, P564, DOI 10.1002/ajh.24006; Warkentin TE, 2009, BLOOD, V113, P4963, DOI 10.1182/blood-2008-10-186064	26	6	7	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JUN	2018	50	4					426	436		10.1016/j.pathol.2017.11.089			11	Pathology	Pathology	GI6IW	WOS:000434474000009	29678479				2019-10-28	
J	Hughes, C; Ashhurst-Smith, C; Ferguson, JK				Hughes, C.; Ashhurst-Smith, C.; Ferguson, J. K.			Gram negative anaerobe susceptibility testing in clinical isolates using Sensititre and Etest methods	PATHOLOGY			English	Article						Anaerobe; Sensititre; Etest	BACTEROIDES-FRAGILIS GROUP; AGAR DILUTION METHOD; ANTIMICROBIAL SUSCEPTIBILITY; ANTIBIOTIC SUSCEPTIBILITY; MALDI-TOF; MULTICENTER SURVEY; BACTERIA; RESISTANCE; IDENTIFICATION; MICRODILUTION	Gram negative anaerobic organisms are important pathogens in a range of clinical infections, and susceptibility testing is not commonly performed in the microbiology laboratory. We performed anaerobic susceptibility testing on 70 clinically relevant Gram negative anaerobes isolated from routine cultures in a busy diagnostic laboratory which were identified by MALDI-TOF mass spectrometry (MALDI-TOF MS). The susceptibility testing was performed by two methods: Sensititre trays (ThermoFisher Scientific) against 15 different antibiotics, and Etests (bioMerieux) against five clinically relevant antibiotics (metronidazole, piperacillin-tazobactam, amoxicillin-clavulanate, meropenem and clindamycin). We found that all isolates were susceptible to metronidazole, and overall susceptibility to commonly used antibiotics such as piperacillin-tazobactam and amoxicillin-clavulanate was high (93-100% and 89-100%, respectively). Two isolates of Bacteroides fragilis were resistant to both broad spectrum beta-lactams and carbapenems. Comparing the two methods, using Sensititre broth microdilution as gold standard, there was high categorical agreement (92-100%). Antibiograms provide useful information for clinicians when choosing antimicrobials for infections caused by anaerobic organisms. This study has shown that in our area, use of metronidazole as a broad spectrum anti-anaerobic agent remains appropriate. Anaerobic susceptibility testing is also important to perform in individual clinical isolates, especially from sterile sites or in pure culture. The emergence of broad spectrum beta-lactam and carbapenem resistance in clinical isolates of Bacteroides fragilis is of concern and will require further monitoring. The Etest method was considered superior to Sensititre trays given that the higher inoculum used may allow demonstration of heteroresistance, anaerobiasis can be maintained during setup, lower failure rates, and the ability to select only the antibiotics required.	[Hughes, C.; Ashhurst-Smith, C.; Ferguson, J. K.] Pathol North Hunter Lab, Newcastle, NSW, Australia; [Ferguson, J. K.] Univ Newcastle, Newcastle, NSW, Australia	Hughes, C (reprint author), Monash Med Ctr Clayton, Monash Infect Dis, 246 Clayton Rd, Clayton, Vic 3168, Australia.	carly_m_hughes@yahoo.com.au					APPELBAUM PC, 1994, DIAGN MICR INFEC DIS, V18, P25, DOI 10.1016/0732-8893(94)90130-9; BANDOH K, 1992, J ANTIBIOT, V45, P542, DOI 10.7164/antibiotics.45.542; Barba MJ, 2014, ANAEROBE, V30, P126, DOI 10.1016/j.anaerobe.2014.09.008; Brook I, 2013, CLIN MICROBIOL REV, V26, P526, DOI 10.1128/CMR.00086-12; CHEN SCA, 1992, J ANTIMICROB CHEMOTH, V30, P811, DOI 10.1093/jac/30.6.811; CLSI, 2012, M11A8 CLSI, V32; COLLIGNON PJ, 1988, PATHOLOGY, V20, P48, DOI 10.3109/00313028809085196; COUROUX PR, 1993, AM J CLIN PATHOL, V100, P301, DOI 10.1093/ajcp/100.3.301; DOWZICKY MJ, 1994, J CLIN MICROBIOL, V32, P2204; Dubreuil L, 1999, J CLIN MICROBIOL, V37, P1824; DUERDEN BI, 1995, CLIN INFECT DIS, V20, pS180, DOI 10.1093/clinids/20.Supplement_2.S180; Fille M, 2006, CURR MICROBIOL, V52, P153, DOI 10.1007/s00284-005-0249-x; Goldstein EJC, 2008, ANAEROBE, V14, P68, DOI 10.1016/j.anaerobe.2008.01.001; Greenwood D, 1996, J ANTIMICROB CHEMOTH, V38, P17, DOI 10.1093/jac/38.1.17; Handal N, 2015, APMIS, V123, P749, DOI 10.1111/apm.12410; HEIZMANN W, 1988, EUR J CLIN MICROBIOL, V7, P758, DOI 10.1007/BF01975043; La Scola B, 2011, ANAEROBE, V17, P106, DOI 10.1016/j.anaerobe.2011.05.010; Liu CY, 2008, ANTIMICROB AGENTS CH, V52, P3161, DOI 10.1128/AAC.00355-08; Lubbe MM, 1999, EUR J CLIN MICROBIOL, V18, P46, DOI 10.1007/s100960050225; Marchand-Austin A, 2014, ANAEROBE, V28, P120, DOI 10.1016/j.anaerobe.2014.05.015; Nagy E, 2011, CLIN MICROBIOL INFEC, V17, P371, DOI 10.1111/j.1469-0691.2010.03256.x; Nguyen MH, 2000, CLIN INFECT DIS, V30, P870, DOI 10.1086/313805; OLSSONLILJEQUIST B, 1994, CLIN INFECT DIS, V18, pS293, DOI 10.1093/clinids/18.Supplement_4.S293; Roberts SA, 2006, J ANTIMICROB CHEMOTH, V57, P992, DOI 10.1093/jac/dk1052; ROSENBLATT JE, 1995, DIAGN MICR INFEC DIS, V22, P279, DOI 10.1016/0732-8893(95)00049-G; Salonen JH, 1998, CLIN INFECT DIS, V26, P1413, DOI 10.1086/516355; Seifert H, 2010, J ANTIMICROB CHEMOTH, V65, P2405, DOI 10.1093/jac/dkq321; Snydman DR, 2011, ANAEROBE, V17, P147, DOI 10.1016/j.anaerobe.2011.05.014; Veloo ACM, 2015, ANAEROBE, V31, P19, DOI 10.1016/j.anaerobe.2014.08.011; Wexler HM, 1998, YONSEI MED J, V39, P495, DOI 10.3349/ymj.1998.39.6.495; WUST J, 1992, EUR J CLIN MICROBIOL, V11, P1169; Wybo I, 2014, J ANTIMICROB CHEMOTH, V69, P155, DOI 10.1093/jac/dkt344	32	1	1	1	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JUN	2018	50	4					437	441		10.1016/j.pathol.2017.10.020			5	Pathology	Pathology	GI6IW	WOS:000434474000010	29678480				2019-10-28	
J	Le, L; Molehin, AJ; Nash, S; Sennoune, SR; Ahmad, G; Torben, W; Zhang, W; Siddiqui, AA				Le, Loc; Molehin, Adebayo J.; Nash, Stewart; Sennoune, Souad R.; Ahmad, Gul; Torben, Workineh; Zhang, Weidong; Siddiqui, Afzal A.			Schistosoma egg-induced liver pathology resolution by Sm-p80-based schistosomiasis vaccine in baboons	PATHOLOGY			English	Article						Schistosomiasis; Sm-p80 vaccine; Anti-pathology; Schistosoma mansoni	NONHUMAN PRIMATE MODEL; DNA VACCINE; MANSONI INFECTION; PROPHYLACTIC EFFICACY; IMMUNOPATHOGENESIS; FORMULATION; PROTECTION; JAPONICUM	Schistosomiasis remains a serious chronic debilitating hepato-intestinal disease. Current control measures based on mass drug administration are inadequate due to sustained re-infection rates, low treatment coverage and emergence of drug resistance. Hence, there is an urgent need for a schistosomiasis vaccine for disease control. In this study, we assessed the anti-pathology efficacy of Schistosoma mansoni large subunit of calpain (Sm-p80)-based vaccine against schistosomiasis caused by infections with Schistosoma mansoni in baboons. We also evaluated the disease transmission-blocking potential of Sm-p80 vaccine. Immunisations with Sm-p80-based vaccine resulted in significant reduction of hepatic egg load in vaccinated baboons (67.7% reduction, p = 0.0032) when compared to the control animals, indicative of reduction in pathology. There was also a significant reduction in sizes of egg-induced granulomas in baboons immunised with Sm-p80 vaccine compared to their control counterparts. Egg hatching rate analysis revealed an overall 85.6% reduction (p = 0.0018) in vaccinated animals compared to the controls, highlighting the potential role of Sm-p80 vaccine in disease transmission. The findings on antipathology efficacy and transmission-blocking potential presented in this study have formed the basis for a large-scale double-blinded baboon experiment that is currently underway.	[Le, Loc; Molehin, Adebayo J.; Nash, Stewart; Sennoune, Souad R.; Zhang, Weidong; Siddiqui, Afzal A.] Texas Tech Univ, Hlth Sci Ctr, Sch Med, Ctr Trop Med & Infect Dis, Lubbock, TX 79430 USA; [Le, Loc; Molehin, Adebayo J.; Nash, Stewart; Sennoune, Souad R.; Zhang, Weidong; Siddiqui, Afzal A.] Texas Tech Univ, Hlth Sci Ctr, Dept Internal Med, Lubbock, TX 79430 USA; [Le, Loc] Biomed Res Inst, Rockville, MD 20852 USA; [Ahmad, Gul] Peru State Coll, Dept Nat Sci, Sch Arts & Sci, Peru, NE USA; [Torben, Workineh] Tulane Natl Primate Res Ctr, Covington, LA USA	Siddiqui, AA (reprint author), Texas Tech Univ, Hlth Sci Ctr, Sch Med, 3601 4th St, Lubbock, TX 79430 USA.	Afzal.Siddiqui@ttuhsc.edu		Le, Loc/0000-0002-3177-8662	Bill and Melinda Gates FoundationGates Foundation [OPP1097535]; NIAID/NIH SBIR [R43/R44 AI103983]; NIH-NIAIDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [HHSN2722010000051]	This work was supported in part by grants from the Bill and Melinda Gates Foundation grant (OPP1097535) and from the NIAID/NIH SBIR (R43/R44 AI103983). The snails were supplied through a NIH-NIAID contract (HHSN2722010000051) to Biomedical Research Institute. The authors state that there are no conflicts of interest to disclose.	Ahmad G, 2009, PARASITE IMMUNOL, V31, P156, DOI 10.1111/j.1365-3024.2008.01091.x; Ahmad G, 2011, J INFECT DIS, V204, P1437, DOI 10.1093/infdis/jir545; Ahmad G, 2010, INT J INFECT DIS, V14, pE781, DOI 10.1016/j.ijid.2010.02.2266; Ahmad G, 2009, PARASITOL RES, V105, P1767, DOI 10.1007/s00436-009-1646-z; Ahmad G, 2009, VACCINE, V27, P2830, DOI 10.1016/j.vaccine.2009.02.096; Boissier J, 2015, LANCET INFECT DIS, V15, P757, DOI 10.1016/S1473-3099(15)00084-5; Burke ML, 2009, PARASITE IMMUNOL, V31, P163, DOI 10.1111/j.1365-3024.2009.01098.x; Cao Y, 2016, BIOMED RES INT, V2016; Chitsulo L, 2004, NAT REV MICROBIOL, V2, P12, DOI 10.1038/nrmicro801; Colley DG, 2014, PARASITE IMMUNOL, V36, P347, DOI 10.1111/pim.12087; Colley DG, 2014, LANCET, V383, P2253, DOI 10.1016/S0140-6736(13)61949-2; Da'Dara AA, 2008, VACCINE, V26, P3617, DOI 10.1016/j.vaccine.2008.04.080; Elbaz T, 2013, J ADV RES, V4, P445, DOI 10.1016/j.jare.2012.12.001; Frey A, 1998, J IMMUNOL METHODS, V221, P35, DOI 10.1016/S0022-1759(98)00170-7; Gryseels B, 2006, LANCET, V368, P1106, DOI 10.1016/S0140-6736(06)69440-3; Hams E, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00089; Karmakar S, 2014, J INFECT DIS, V209, P1929, DOI 10.1093/infdis/jiu031; Le L, 2014, PARASITOL RES, V113, P1195, DOI 10.1007/s00436-014-3757-4; Tang LF, 2007, CELL MOL IMMUNOL, V4, P153; Mo AX, 2014, AM J TROP MED HYG, V90, P54, DOI 10.4269/ajtmh.13-0467; Molehin AJ, 2017, PARASITOL RES, V116, P3175, DOI 10.1007/s00436-017-5634-4; Molehin AJ, 2016, EXPERT REV VACCINES, V15, P619, DOI 10.1586/14760584.2016.1131127; Nascimento M, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004282; Olveda DU, 2014, INT J INFECT DIS, V28, P193, DOI 10.1016/j.ijid.2014.07.009; Pearce EJ, 2015, CELL MICROBIOL, V17, P796, DOI 10.1111/cmi.12444; Prichard RK, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001549; Romeih MH, 2008, ACTA BIOCH BIOPH SIN, V40, P327, DOI 10.1111/j.1745-7270.2008.00404.x; Ross AGP, 2002, NEW ENGL J MED, V346, P1212, DOI 10.1056/NEJMra012396; Siddiqui AA, 2017, TRENDS PARASITOL, V33, P194, DOI 10.1016/j.pt.2016.10.010; Tucker Matthew S, 2013, Curr Protoc Immunol, V103, DOI 10.1002/0471142735.im1901s103; von LICHTENBERG, 1962, Am J Pathol, V41, P711; Wynn TA, 2004, IMMUNOL REV, V201, P156, DOI 10.1111/j.0105-2896.2004.00176.x; Yepes E, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003893; Zhang WD, 2010, J INFECT DIS, V201, P1105, DOI 10.1086/651147	34	0	0	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JUN	2018	50	4					442	449		10.1016/j.pathol.2018.01.004			8	Pathology	Pathology	GI6IW	WOS:000434474000011	29739616				2019-10-28	
J	Thapa, K; Ellem, JA; Basile, K; Carter, I; Olma, T; Chen, SCA; Dwyer, DE; Kok, J				Thapa, Kiran; Ellem, Justin A.; Basile, Kerri; Carter, Ian; Olma, Tom; Chen, Sharon C-A.; Dwyer, Dominic E.; Kok, Jen			Simultaneous co-detection of wild-type and vaccine strain measles virus using the BD MAX system	PATHOLOGY			English	Article						Measles; genotype; wild-type; vaccine	PCR; DIAGNOSIS; TRANSMISSION; INFECTION; INFLUENZA; GENOTYPE; ASSAY; D8	Despite the reported elimination of measles virus in Australia, importation of cases from endemic countries continues to lead to secondary local transmission and outbreaks. Rapid laboratory confirmation of measles is paramount for individual patient management and outbreak responses. Further, it is important to rapidly distinguish infection from wild-type virus or vaccine strains to guide public health responses. We developed a high throughput, TaqMan-based multiplex reverse-transcription-polymerase chain reaction (PCR) assay using the BD MAX platform (Becton Dickinson) that simultaneously detects measles virus and differentiates between wild-type and vaccine strains without the need for sequencing.	[Thapa, Kiran; Ellem, Justin A.; Basile, Kerri; Carter, Ian; Olma, Tom; Chen, Sharon C-A.; Dwyer, Dominic E.; Kok, Jen] New South Wales Hlth Pathol, Ctr Infect Dis & Microbiol Lab Serv, Inst Clin Pathol & Med Res, Westmead, NSW, Australia; [Thapa, Kiran; Ellem, Justin A.; Basile, Kerri; Carter, Ian; Olma, Tom; Chen, Sharon C-A.; Dwyer, Dominic E.; Kok, Jen] Westmead Hosp, Westmead, NSW, Australia; [Chen, Sharon C-A.; Dwyer, Dominic E.; Kok, Jen] Univ Sydney, Marie Bashir Inst Infect Dis & Biosecur, Sydney, NSW, Australia	Basile, K (reprint author), Westmead Hosp, Ctr Infect Dis & Microbiol Lab Serv, Inst Clin Pathol & Med Res, NSW Hlth Pathol, Westmead, NSW 2145, Australia.	kerri.basile@health.nsw.gov.au					Bonner AB, 2003, PEDIATRICS, V112, P363, DOI 10.1542/peds.112.2.363; Chua KYL, 2015, J CLIN VIROL, V70, P46, DOI 10.1016/j.jcv.2015.07.004; CSL Limited/Merck, 2014, M M R 2 VACC PROD IN; Flego KL, 2013, COMMUN DIS INTELL, V37, pE240; Gardy JL, 2015, J INFECT DIS, V212, P1574, DOI 10.1093/infdis/jiv271; Hacker JK, 2017, J CLIN MICROBIOL, V55, P686, DOI [10.1128/JCM.01879-16, 10.1128/JCM.02329-16]; Helfand RF, 1997, J INFECT DIS, V175, P195, DOI 10.1093/infdis/175.1.195; Hubschen JM, 2008, J VIROL METHODS, V149, P246, DOI 10.1016/j.jviromet.2008.01.032; Hummel KB, 2006, J VIROL METHODS, V132, P166, DOI 10.1016/j.jviromet.2005.10.006; Keighley CL, 2015, CURR OPIN INFECT DIS, V28, P139, DOI 10.1097/QCO.0000000000000145; Najjar Z, 2014, WEST PAC SURVEILL RE, V5, DOI [10.5365/WPSAR.2013.4.4.002, 10.5365/wpsar.2013.4.4.002]; Ndegwa LK, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2131-9; NSW Health, 2017, MEASL OURBR APR 2017; Roy F, 2017, J CLIN MICROBIOL, V55, P735, DOI 10.1128/JCM.01879-16; SCHWARZ AJF, 1962, AM J DIS CHILD, V103, P386, DOI 10.1001/archpedi.1962.02080020398042; Sheppeard Vicky, 2009, N S W Public Health Bull, V20, P81, DOI 10.1071/NB08014; Weston KM, 2006, COMMUN DIS INTELL, V30, P358; World Health Organization, 2014, 4 W PAC COUNTR AR AR	18	1	1	1	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JUN	2018	50	4					450	454		10.1016/j.pathol.2017.11.093			5	Pathology	Pathology	GI6IW	WOS:000434474000012	29752126				2019-10-28	
J	Jiang, JX; Kakar, F; Wing, H; Bhattacharyya, A; Berglund, LJ				Jiang, Jocelyn X.; Kakar, Fakhria; Wing, Hong; Bhattacharyya, Abir; Berglund, Lucinda J.			The case of the interfering IgM	PATHOLOGY			English	Letter							RHEUMATOID-FACTOR		[Jiang, Jocelyn X.; Kakar, Fakhria; Wing, Hong; Berglund, Lucinda J.] Westmead Hosp, ICPMR, NSW Hlth Pathol, Dept Immunopathol, Westmead, NSW, Australia; [Jiang, Jocelyn X.; Berglund, Lucinda J.] Univ Sydney, Sydney, NSW, Australia; [Bhattacharyya, Abir] Westmead Hosp, Dept Haematol, Westmead, NSW, Australia	Jiang, JX (reprint author), Westmead Hosp, ICPMR, NSW Hlth Pathol, Dept Immunopathol, Westmead, NSW, Australia.; Jiang, JX (reprint author), Univ Sydney, Sydney, NSW, Australia.	joce.jiang@gmail.com	Berglund, Lucinda/S-7921-2019				BANFI G, 1990, CLIN LAB HAEMATOL, V12, P112; Churchman SM, 2012, CLIN EXP RHEUMATOL, V30, P534; Hunter ZR, 2010, HAEMATOL-HEMATOL J, V95, P470, DOI [10.3324/haemato1.2009.010348, 10.3324/haematol.2009.010348]; King RI, 2010, PATHOLOGY, V42, P397, DOI 10.3109/00313025.2010.493868; MULLER W, 1985, J IMMUNOL METHODS, V80, P77, DOI 10.1016/0022-1759(85)90166-8; ROBERT F, 1993, AM J MED SCI, V306, P359, DOI 10.1097/00000441-199312000-00001; SORENSEN S, 1988, CLIN CHIM ACTA, V173, P217, DOI 10.1016/0009-8981(88)90259-8; Todd DJ, 2011, ARTHRITIS RHEUM-US, V63, P894, DOI 10.1002/art.30213; WALDMANN TA, 1971, J CLIN INVEST, V50, P951, DOI 10.1172/JCI106567; Zola H, 1995, DIAGNOSTIC IMMUNOPAT, P16	10	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JUN	2018	50	4					455	457		10.1016/j.pathol.2017.10.021			3	Pathology	Pathology	GI6IW	WOS:000434474000013	29681414				2019-10-28	
J	Williams, VK				Williams, Vaughan K.			A simple kaolin clotting time confirm ratio for the presence of a lupus anticoagulant	PATHOLOGY			English	Letter							VIPER VENOM TIME; TESTS		[Williams, Vaughan K.] SA Pathol Womens & Childrens Hosp, Haematol Dept, Adelaide, SA, Australia	Williams, VK (reprint author), SA Pathol Womens & Childrens Hosp, Haematol Dept, Adelaide, SA, Australia.	vaughan.williams@sa.gov.au					Aryurachai K, 2014, J HEMATOL TRANSFUS M, V24, P379; CLSI, 2014, H60A CLSI; Derksen RHWM, 2004, THROMB RES, V114, P521, DOI 10.1016/j.thromres.2004.06.009; EXNER T, 1985, THROMB HAEMOSTASIS, V53, P15; EXNER T, 1978, BRIT J HAEMATOL, V40, P143, DOI 10.1111/j.1365-2141.1978.tb03648.x; GALLI M, 1995, BLOOD, V86, P617, DOI 10.1182/blood.V86.2.617.bloodjournal862617; LO SCL, 1989, AM J HEMATOL, V30, P213, DOI 10.1002/ajh.2830300405; Martin BA, 1996, BLOOD COAGUL FIBRIN, V7, P31, DOI 10.1097/00001721-199601000-00004; Pengo V, 2009, J THROMB HAEMOST, V7, P1737, DOI 10.1111/j.1538-7836.2009.03555.x; ROSNER E, 1987, THROMB HAEMOSTASIS, V57, P144; TRIPLETT DA, 1983, AM J CLIN PATHOL, V79, P678, DOI 10.1093/ajcp/79.6.678	11	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JUN	2018	50	4					457	459		10.1016/j.pathol.2017.10.022			4	Pathology	Pathology	GI6IW	WOS:000434474000014	29743144				2019-10-28	
J	Favaloro, EJ; McVicker, W; Mohammed, S; Hamdam, S				Favaloro, Emmanuel J.; McVicker, Wendy; Mohammed, Soma; Hamdam, Sayed			Mathematical rounding as a post-analytical issue in pathology reporting: generation of bias in INR resulting	PATHOLOGY			English	Letter							INTERNATIONAL NORMALIZED RATIO; ANTICOAGULATION; THERAPY		[Favaloro, Emmanuel J.; McVicker, Wendy; Mohammed, Soma] Westmead Hosp, Dept Haematol, Inst Clin Pathol & Med Res, NSW Hlth Pathol, Westmead, NSW, Australia; [Favaloro, Emmanuel J.] Sydney Ctr Thrombosis & Haemostasis, Westmead, NSW, Australia; [Hamdam, Sayed] Blacktown Hosp, NSW Hlth Pathol, Blacktown, NSW, Australia	Favaloro, EJ (reprint author), Westmead Hosp, Dept Haematol, Inst Clin Pathol & Med Res, NSW Hlth Pathol, Westmead, NSW, Australia.; Favaloro, EJ (reprint author), Sydney Ctr Thrombosis & Haemostasis, Westmead, NSW, Australia.	emmanuel.favaloro@health.nsw.gov.au	Favaloro, Emmanuel J./J-7689-2019		NSW Health Pathology	This research was supported in-kind by NSW Health Pathology. The views expressed herein are those of the authors and are not necessarily those of NSW Health Pathology. The authors state that there are no conflicts of interest to disclose.	Blennerhassett R, 2017, SEMIN THROMB HEMOST, V43, P706, DOI 10.1055/s-0037-1602667; Bonar R, 2017, THROMB RES, V150, P22, DOI 10.1016/j.thromres.2016.12.007; Bonar R, 2015, SEMIN THROMB HEMOST, V41, P279, DOI 10.1055/s-0035-1549091; Favaloro EJ, 2017, PATHOLOGY, V49, P639, DOI 10.1016/j.pathol.2017.04.011; Favaloro Emmanuel J, 2017, Methods Mol Biol, V1646, P59, DOI 10.1007/978-1-4939-7196-1_4; Favaloro EJ, 2016, AM J CLIN PATHOL, V145, P191, DOI 10.1093/ajcp/aqv022; Moffat KA, 2017, SEMIN THROMB HEMOST, V43, P245, DOI 10.1055/s-0036-1587690; Olson JD, 2007, ARCH PATHOL LAB MED, V131, P1641	8	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JUN	2018	50	4					459	461		10.1016/j.pathol.2017.11.090			4	Pathology	Pathology	GI6IW	WOS:000434474000015	29731140				2019-10-28	
J	Koerbin, G; Sikaris, K; Jones, GRD; Tate, JR; Intervals, AHCCR				Koerbin, G.; Sikaris, K.; Jones, G. R. D.; Tate, J. R.; Intervals, A. A. C. B. Harmonisation Comm Common Reference			Urea: another analyte recommended for harmonised reference intervals	PATHOLOGY			English	Letter									[Koerbin, G.] NSW Hlth Pathol, Sydney, NSW, Australia; [Koerbin, G.] Univ Canberra, Canberra, ACT, Australia; [Sikaris, K.] Melbourne Pathol, Collingwood, Vic, Australia; [Jones, G. R. D.] St Vincents Hosp, SydPath, Dept Chem Pathol, Sydney, NSW, Australia; [Jones, G. R. D.] Univ NSW, Sydney, NSW, Australia; [Tate, J. R.] Royal Brisbane & Womens Hosp, Pathol Queensland, Dept Chem Pathol, Herston, Qld, Australia	Koerbin, G (reprint author), NSW Hlth Pathol, Sydney, NSW, Australia.; Koerbin, G (reprint author), Univ Canberra, Canberra, ACT, Australia.	gus.koerbin@health.nsw.gov.au					Jones Graham, 2008, Clin Biochem Rev, V29 Suppl 1, pS93; Koerbin G, 2015, PATHOLOGY, V47, P138, DOI 10.1097/PAT.0000000000000227; Koerbin Gus, 2014, Clin Biochem Rev, V35, P203; Koerbin G, 2014, CLIN CHIM ACTA, V432, P99, DOI 10.1016/j.cca.2013.10.021; Ozarda Y, 2014, CLIN CHEM LAB MED, V52, P1823, DOI 10.1515/cclm-2014-0228; Rustad P, 2004, SCAND J CLIN LAB INV, V64, P271, DOI 10.1080/00365510410006324	6	0	0	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JUN	2018	50	4					461	462		10.1016/j.pathol.2017.10.025			3	Pathology	Pathology	GI6IW	WOS:000434474000016	29773325				2019-10-28	
J	Choudhury, S				Choudhury, Saugata			Routine susceptibility testing for Candida albicans isolated from blood stream	PATHOLOGY			English	Letter							INFECTIOUS-DISEASES SOCIETY; ANTIFUNGAL SUSCEPTIBILITY; MANAGEMENT; AMERICA; UPDATE		[Choudhury, Saugata] Tan Tock Seng Hosp, Dept Lab Med, Singapore, Singapore	Choudhury, S (reprint author), Tan Tock Seng Hosp, Dept Lab Med, Singapore, Singapore.	drsaugata@yahoo.com					Clinical and Laboratory Standards Institute (CLSI), 2012, M27ES4 CLSI; Pappas PG, 2016, CLIN INFECT DIS, V62, pE1, DOI 10.1093/cid/civ933; Pappas PG, 2009, CLIN INFECT DIS, V48, P503, DOI 10.1086/596757; Pfaller MA, 2007, CLIN MICROBIOL REV, V20, P133, DOI 10.1128/CMR.00029-06; Posteraro B, 2015, ANTIMICROB AGENTS CH, V59, P3944, DOI 10.1128/AAC.00285-15; Stevenson LG, 2010, J CLIN MICROBIOL, V48, P3482, DOI 10.1128/JCM.00687-09; Tan TY, 2016, MED MYCOL, V54, P471, DOI 10.1093/mmy/myv114	7	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JUN	2018	50	4					462	464		10.1016/j.pathol.2017.10.019			4	Pathology	Pathology	GI6IW	WOS:000434474000017	29551390				2019-10-28	
J	Tedjaseputra, A; Kumar, B; de Silva, S; Opat, S				Tedjaseputra, Aditya; Kumar, Beena; de Silva, Sabine; Opat, Stephen			Concurrent Mycobacterium tuberculosis infection and nodal marginal zone lymphoma	PATHOLOGY			English	Letter							GENE		[Tedjaseputra, Aditya; Opat, Stephen] Monash Hlth, Dept Clin Haematol, Clayton, Vic, Australia; [Kumar, Beena] Monash Hlth, Dept Pathol, Clayton, Vic, Australia; [de Silva, Sabine] Monash Hlth, Dept Infect Dis, Clayton, Vic, Australia	Tedjaseputra, A (reprint author), Monash Hlth, Dept Clin Haematol, Clayton, Vic, Australia.	aditya.tedjaseputra@monashhealth.org					Chan CH, 2001, BLOOD, V97, P1023, DOI 10.1182/blood.V97.4.1023; Dheda K, 2016, LANCET, V387, P1211, DOI 10.1016/S0140-6736(15)00151-8; Flynn JL, 2003, CURR OPIN IMMUNOL, V15, P450, DOI 10.1016/S0952-7915(03)00075-X; Kim KW, 2001, LEUKEMIA LYMPHOMA, V42, P1151, DOI 10.3109/10428190109097739; Maglione PJ, 2009, EUR J IMMUNOL, V39, P676, DOI 10.1002/eji.200839148; Marasca R, 2001, AM J PATHOL, V159, P253, DOI 10.1016/S0002-9440(10)61691-4; Shomer NH, 2003, INFECT IMMUN, V71, P3572, DOI 10.1128/IAI.71.6.3572-3577.2003; Spina V, 2016, BLOOD, V128, P1362, DOI 10.1182/blood-2016-02-696757; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Thieblemont C, 2014, SEMIN CANCER BIOL, V24, P33, DOI 10.1016/j.semcancer.2013.11.005; van den Brand M, 2013, HAEMATOLOGICA, V98, P1003, DOI 10.3324/haematol.2012.083386; Zuckerman E, 1997, ANN INTERN MED, V127, P423, DOI 10.7326/0003-4819-127-6-199709150-00002	12	0	0	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JUN	2018	50	4					464	466		10.1016/j.pathol.2017.10.023			4	Pathology	Pathology	GI6IW	WOS:000434474000018	29731142				2019-10-28	
J	Wilkinson, L; Coucher, J; Murphy, M; Joubert, W; Cooper, C				Wilkinson, Lisa; Coucher, John; Murphy, Michelle; Joubert, Warren; Cooper, Caroline			CIC-rearranged sarcoma of the pleura: an unreported primary site, expanding the anatomical distribution of an emerging entity	PATHOLOGY			English	Letter							ROUND-CELL SARCOMA; SOFT-TISSUE; EWING SARCOMAS; FUSION; TUMORS; FEATURES; BONE		[Wilkinson, Lisa; Cooper, Caroline] Princess Alexandra Hosp, Pathol Queensland, Brisbane, Qld, Australia; [Wilkinson, Lisa; Cooper, Caroline] Univ Queensland, Sch Med, Brisbane, Qld, Australia; [Coucher, John] Princess Alexandra Hosp, Dept Radiol, Brisbane, Qld, Australia; [Murphy, Michelle] Princess Alexandra Hosp, Dept Resp & Sleep Med, Brisbane, Qld, Australia; [Joubert, Warren] Princess Alexandra Hosp, Dept Med Oncol, Brisbane, Qld, Australia	Wilkinson, L (reprint author), Princess Alexandra Hosp, Pathol Queensland, Brisbane, Qld, Australia.; Wilkinson, L (reprint author), Univ Queensland, Sch Med, Brisbane, Qld, Australia.	lisamwilkinson@hotmail.com					Chebib I, 2016, CANCER CYTOPATHOL, V124, P350, DOI 10.1002/cncy.21685; Choi EYK, 2013, AM J SURG PATHOL, V37, P1379, DOI 10.1097/PAS.0b013e318297a57d; Fletcher C, 2013, WHO CLASSIFICATION T; Gambarotti M, 2016, HISTOPATHOLOGY, V69, P624, DOI 10.1111/his.12985; Haidar A, 2015, AM J CASE REP, V16, P87, DOI 10.12659/AJCR.892551; Kawamura-Saito M, 2006, HUM MOL GENET, V15, P2125, DOI 10.1093/hmg/ddl136; Kosemehmetoglu K, 2009, MODERN PATHOL, V22, P872, DOI 10.1038/modpathol.2009.47; Le Guellec S, 2016, MODERN PATHOL, V29, P1523, DOI 10.1038/modpathol.2016.155; Specht K, 2014, GENE CHROMOSOME CANC, V53, P622, DOI 10.1002/gcc.22172; Yoshida A, 2016, AM J SURG PATHOL, V40, P313, DOI 10.1097/PAS.0000000000000570	10	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JUN	2018	50	4					469	472		10.1016/j.pathol.2017.11.092			5	Pathology	Pathology	GI6IW	WOS:000434474000020	29743145				2019-10-28	
J	Fuchs, TL; Sioson, L; Sheen, A; Clarkson, A; Gill, AJ				Fuchs, Talia L.; Sioson, Loretta; Sheen, Amy; Clarkson, Adele; Gill, Anthony J.			Immunohistochemical expression of somatostatin receptors SSTR2A and SSTR5 in 299 pituitary adenomas	PATHOLOGY			English	Letter							MONOCLONAL-ANTIBODIES		[Fuchs, Talia L.; Sioson, Loretta; Sheen, Amy; Clarkson, Adele; Gill, Anthony J.] Royal North Shore Hosp, Kolling Inst Med Res, Canc Diag & Pathol Grp, St Leonards, NSW, Australia; [Fuchs, Talia L.; Clarkson, Adele; Gill, Anthony J.] Royal North Shore Hosp, Dept Anat Pathol, NSW Hlth Pathol, St Leonards, NSW, Australia; [Gill, Anthony J.] Univ Sydney, Sydney, NSW, Australia	Gill, AJ (reprint author), Royal North Shore Hosp, Kolling Inst Med Res, Canc Diag & Pathol Grp, St Leonards, NSW, Australia.; Gill, AJ (reprint author), Royal North Shore Hosp, Dept Anat Pathol, NSW Hlth Pathol, St Leonards, NSW, Australia.	affgill@med.usyd.edu.au	Fuchs, Talia/N-7416-2019; Gill, Anthony J./M-5015-2019	Fuchs, Talia/0000-0002-9166-6822; 	Sydney Vital, Translational Cancer Research Centre, through a Cancer Institute NSW competitive grant	This project was supported by the Sydney Vital, Translational Cancer Research Centre, through a Cancer Institute NSW competitive grant. The views expressed herein are those of the authors and are not necessarily those of the Cancer Institute NSW (CINSW). The authors state that there are no conflicts of interest to disclose.	Casar-Borota O, 2013, J CLIN ENDOCR METAB, V98, pE1730, DOI 10.1210/jc.2013-2145; Chinezu L, 2014, HUM PATHOL, V45, P71, DOI 10.1016/j.humpath.2013.08.007; Colao A, 2012, NEW ENGL J MED, V366, P914, DOI 10.1056/NEJMoa1105743; Elston MS, 2015, HUM PATHOL, V46, P390, DOI 10.1016/j.humpath.2014.11.012; Farzin M, 2014, PATHOLOGY, V46, P79, DOI 10.1097/PAT.0000000000000033; Fougner SL, 2012, CLIN ENDOCRINOL, V76, P96, DOI 10.1111/j.1365-2265.2011.04163.x; Gill AJ, 2014, AM J SURG PATHOL, V38, P560, DOI 10.1097/PAS.0000000000000149; Korner M, 2012, AM J SURG PATHOL, V36, P242, DOI 10.1097/PAS.0b013e31823d07f3; Lupp A, 2011, NEUROENDOCRINOLOGY, V94, P255, DOI 10.1159/000329876; Mehta S, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001281; Pawlikowski M, 2003, ENDOCR PATHOL, V14, P231	11	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JUN	2018	50	4					472	474		10.1016/j.pathol.2017.10.024			4	Pathology	Pathology	GI6IW	WOS:000434474000021	29731144				2019-10-28	
J	Siref, A; Patel, V; Reith, JD; Balzer, BL; Shon, W				Siref, Andrew; Patel, Vatsal; Reith, John D.; Balzer, Bonnie L.; Shon, Wonwoo			Evaluation of p16 protein expression and CDKN2A deletion in conventional and fibrosarcomatous dermatofibrosarcoma protuberans	PATHOLOGY			English	Letter									[Siref, Andrew; Balzer, Bonnie L.; Shon, Wonwoo] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA; [Patel, Vatsal; Reith, John D.] Univ Florida, Coll Med, Gainesville, FL USA; [Patel, Vatsal; Reith, John D.] Cleveland Clin, Dept Pathol, Cleveland, OH 44106 USA	Shon, W (reprint author), Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA.	wonwoo.shon@cshs.org					Eilers G, 2015, MOL CANCER THER, V14, P1346, DOI 10.1158/1535-7163.MCT-14-0793; Stacchiotti S, 2016, MOL CANCER RES, V14, P820, DOI 10.1158/1541-7786.MCR-16-0068	2	0	0	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JUN	2018	50	4					474	475		10.1016/j.pathol.2017.11.096			3	Pathology	Pathology	GI6IW	WOS:000434474000022	29743142				2019-10-28	
J	Van Haverbeke, C; Ferdinande, L; Verbeke, S; Van Dorpe, J; Creytens, D				Van Haverbeke, Carole; Ferdinande, Liesbeth; Verbeke, Sofie; Van Dorpe, Jo; Creytens, David			Malignant peripheral nerve sheath tumour with heterologous liposarcomatous differentiation: case report and review of the literature	PATHOLOGY			English	Letter							DISTINGUISHES SYNOVIAL SARCOMA; HISTOLOGIC MIMICS; MARKER; IMMUNOHISTOCHEMISTRY; EXPRESSION		[Van Haverbeke, Carole; Ferdinande, Liesbeth; Verbeke, Sofie; Van Dorpe, Jo; Creytens, David] Univ Ghent, Dept Pathol, Ghent, Belgium; [Van Haverbeke, Carole; Ferdinande, Liesbeth; Verbeke, Sofie; Van Dorpe, Jo; Creytens, David] Ghent Univ Hosp, Ghent, Belgium; [Ferdinande, Liesbeth; Verbeke, Sofie; Van Dorpe, Jo; Creytens, David] Univ Ghent, Canc Res Inst Ghent, CRIG, Ghent, Belgium	Creytens, D (reprint author), Univ Ghent, Dept Pathol, Ghent, Belgium.; Creytens, D (reprint author), Ghent Univ Hosp, Ghent, Belgium.; Creytens, D (reprint author), Univ Ghent, Canc Res Inst Ghent, CRIG, Ghent, Belgium.	david.creytens@uzgent.be					Arnold MA, 2013, HUM PATHOL, V44, P881, DOI 10.1016/j.humpath.2012.08.014; Cleven AHG, 2016, MODERN PATHOL, V29, P582, DOI 10.1038/modpathol.2016.45; Doyle LA, 2014, MODERN PATHOL, V27, P390, DOI 10.1038/modpathol.2013.164; Doyle LA, 2011, AM J SURG PATHOL, V35, P733, DOI 10.1097/PAS.0b013e318210c268; Fadare O, 2011, ADV ANAT PATHOL, V18, P60, DOI 10.1097/PAP.0b013e3182026be7; Guo AT, 2012, J CANCER, V3, P303, DOI 10.7150/jca.4179; Le Guellec S, 2016, AM J SURG PATHOL, V40, P896, DOI 10.1097/PAS.0000000000000655; Lyle PL, 2016, HISTOPATHOLOGY, V68, P1040, DOI 10.1111/his.12898; Poo WC, 2011, AM J CLIN PATHOL, V135, P839, DOI 10.1309/AJCP45SSNAOPXYXU; Prieto-Granada CN, 2016, AM J SURG PATHOL, V40, P479, DOI 10.1097/PAS.0000000000000564; Schaefer IM, 2016, MODERN PATHOL, V29, P4, DOI 10.1038/modpathol.2015.134; Tirabosco R, 2010, PATHOL RES PRACT, V206, P138, DOI 10.1016/j.prp.2009.04.005	12	0	0	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JUN	2018	50	4					475	478		10.1016/j.pathol.2017.12.343			5	Pathology	Pathology	GI6IW	WOS:000434474000023	29731141				2019-10-28	
J	Karpathiou, G; Kassir, R; Berremila, SA; Camy, F; Peoc'h, M				Karpathiou, Georgia; Kassir, Radwan; Berremila, Sid Ali; Camy, Florian; Peoc'h, Michel			Liver ectopic pregnancy complicating a focal nodular hyperplasia	PATHOLOGY			English	Letter									[Karpathiou, Georgia; Berremila, Sid Ali; Camy, Florian; Peoc'h, Michel] Univ Hosp St Etienne, North Hosp, Dept Pathol, St Etienne, France; [Kassir, Radwan] Univ Hosp Felix Guyon, Dept Bariatr Surg, La Reunion, France	Karpathiou, G (reprint author), Univ Hosp St Etienne, North Hosp, Dept Pathol, St Etienne, France.	gakarpath@yahoo.gr	Karpathiou, Georgia/J-5312-2019	Karpathiou, Georgia/0000-0003-0864-935X; KASSIR, Radwan/0000-0002-3987-5272			Bosman FT, 2010, WHO CLASSIFICATION T; Brouard KJ, 2015, OBSTET GYNECOL, V126, P207, DOI 10.1097/AOG.0000000000000703; Guo B, 2016, J GASTROEN HEPATOL, V31, P1514, DOI 10.1111/jgh.13396; Hao JW, 2016, CLIN NUCL MED, V41, P697, DOI 10.1097/RLU.0000000000001307; Kriebs JM, 2006, J MIDWIFERY WOM HEAL, V51, P431, DOI 10.1016/j.jmwh.2006.07.008; Pisarska MD, 1998, LANCET, V351, P1115, DOI 10.1016/S0140-6736(97)11476-3	6	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JUN	2018	50	4					478	479		10.1016/j.pathol.2017.11.091			3	Pathology	Pathology	GI6IW	WOS:000434474000024	29731143				2019-10-28	
J	Khanna, G; Ghosh, S; Barwad, A; Yadav, R; Das, P				Khanna, Gaurav; Ghosh, Shouriyo; Barwad, Adarsh; Yadav, Rajni; Das, Prasenjit			Mucosal Schwann cell hamartoma of gall bladder: a novel observation	PATHOLOGY			English	Letter							GALLBLADDER		[Khanna, Gaurav; Ghosh, Shouriyo; Barwad, Adarsh; Yadav, Rajni; Das, Prasenjit] All India Inst Med Sci, Dept Pathol, New Delhi, India	Das, P (reprint author), All India Inst Med Sci, Dept Pathol, New Delhi, India.	prasenaiims@gmail.com					Acebo Elvira, 1998, General and Diagnostic Pathology, V143, P337; Bae MN, 2013, ANN COLOPROCTOL, V29, P130, DOI 10.3393/ac.2013.29.3.130; EGGLESTON JF, 1982, AM J GASTROENTEROL, V77, P335; Gibson JA, 2009, AM J SURG PATHOL, V33, P781, DOI 10.1097/PAS.0b013e31818dd6ca; Kizil C, 2015, EMBO REP, V16, P416, DOI 10.15252/embr.201439702; Liu LN, 2014, WORLD J GASTROENTERO, V20, P6685, DOI 10.3748/wjg.v20.i21.6685; Namikawa Tsutomu, 2016, Surg Technol Int, V30, P89; Odze RD, 2009, SURG PATHOLOGY GI TR, P520; Rehman A, 2015, AM J CLIN PATHOL, V144, pA335, DOI 10.1093/ajcp/144.suppl2.335; SARLOMORIKALA M, 1995, HISTOPATHOLOGY, V27, P355, DOI 10.1111/j.1365-2559.1995.tb01526.x; van Deen Welmoed K, 2013, Gastroenterol Hepatol (N Y), V9, P185; Vandana U. G., 2011, Al Ameen Journal of Medical Sciences, V4, P295	12	0	0	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JUN	2018	50	4					480	482		10.1016/j.pathol.2017.11.095			3	Pathology	Pathology	GI6IW	WOS:000434474000025	29739615				2019-10-28	
J	Ng, J; Harvey, NT; von Nida, J; Wood, BA				Ng, Jeremy; Harvey, Nathan Tobias; von Nida, Jamie; Wood, Benjamin Andrew			Subungual acantholytic dyskeratotic acanthoma: an unusual cause of longitudinal erythronychia	PATHOLOGY			English	Letter							WARTY DYSKERATOMA; DISEASE; FEATURES; NAIL		[Ng, Jeremy; von Nida, Jamie] Sir Charles Gairdner Hosp, Dept Dermatol, Perth, WA, Australia; [Harvey, Nathan Tobias; Wood, Benjamin Andrew] PathWest, Dept Anat Pathol, QEII Med Ctr, Perth, WA, Australia; [Harvey, Nathan Tobias; Wood, Benjamin Andrew] Univ Western Australia, Sch Med, Fac Hlth & Med Sci, Perth, WA, Australia	Wood, BA (reprint author), PathWest, Dept Anat Pathol, QEII Med Ctr, Perth, WA, Australia.; Wood, BA (reprint author), Univ Western Australia, Sch Med, Fac Hlth & Med Sci, Perth, WA, Australia.	benjamin.wood@health.wa.gov.au		Harvey, Nathan/0000-0001-5253-976X			ACKERMAN AB, 1972, ARCH DERMATOL, V106, P702, DOI 10.1001/archderm.106.5.702; Baran R, 1997, DERMATOLOGY, V195, P278, DOI 10.1159/000245962; BURGE SM, 1992, BRIT J DERMATOL, V126, P275, DOI 10.1111/j.1365-2133.1992.tb00658.x; Davis MDP, 1999, MAYO CLIN PROC, V74, P229, DOI 10.4065/74.3.229; Engineer L, 2000, J AM ACAD DERMATOL, V43, P529, DOI 10.1067/mjd.2000.106236; Ionokami M, 1990, SKIN RES, V32, P507; Kaddu S, 2002, J AM ACAD DERMATOL, V47, P423, DOI 10.1067/mjd.2002.122756; Ko CJ, 2008, J CUTAN PATHOL, V35, P298, DOI 10.1111/j.1600-0560.2007.00799.x; Omulecki A, 2007, J CUTAN PATHOL, V34, P494, DOI 10.1111/j.1600-0560.2006.00642.x; Sakuntabhai A, 1999, NAT GENET, V21, P271; Sass U, 2009, J CUTAN PATHOL, V36, P1308, DOI 10.1111/j.1600-0560.2009.01276.x; ZAIAS N, 1973, ARCH DERMATOL, V107, P193, DOI 10.1001/archderm.107.2.193	12	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JUN	2018	50	4					482	484		10.1016/j.pathol.2017.12.342			4	Pathology	Pathology	GI6IW	WOS:000434474000026	29735169				2019-10-28	
J	Islam, A				Islam, Anwarul			Bone marrow solid core biopsy needle: a critical assessment of the utility, benefits and limitations of the instruments employed in current day haematology and oncology	JOURNAL OF CLINICAL PATHOLOGY			English	Review						bone marrow trephines; bone marrow; diagnostics	DIAGNOSIS; LEUKEMIA; LYMPHOMA; DISEASES; DEVICE	The optimal clinical evaluation of the bone marrow requires an examination of air-dried and well-stained films of the aspirated tissue along with a histopathological evaluation of adequately processed and properly stained core biopsy specimens. A bone marrow evaluation can be essential in establishing a diagnosis, determining the efficacy of treatment in haematological disorders and to monitor haematological status of patients following bone marrow/stem cell transplantation. It is also an essential component of the staging process for newly diagnosed malignancies. Currently available bone marrow aspiration needles are quite satisfactory and if properly used provide good-quality specimens for morphological evaluation. However, if a bone marrow core biopsy is concerned, several needles are currently in use but not all of them provide good-quality biopsy specimens for histological evaluation or are user friendly. We have compared the recently introduced Moeller Medical single use bone marrow core biopsy needle with the Jamshidi needle with marrow acquisition cradle (CareFusion), J-needle (Cardinal Health) and OnControl device (Vidacare). It is concluded that the Moeller Medical needle system has definite advantages over others and is recommended for routine use.	[Islam, Anwarul] Buffalo Gen Hosp, Div Hematol & Oncol, Dept Med, Buffalo, NY 14203 USA	Islam, A (reprint author), Buffalo Gen Hosp, Div Hematol & Oncol, Dept Med, Buffalo, NY 14203 USA.	aislam@acsu.buffalo.edu					Arinkin MJ, 1929, FOLIA HAEMATOL LEIPZ, V38, P233; BRUNNING RD, 1975, ANN INTERN MED, V82, P365, DOI 10.7326/0003-4819-82-3-365; BURKE JS, 1978, AM J CLIN PATHOL, V70, P876; BURKHARDT R, 1966, KLIN WOCHENSCHR, V44, P326, DOI 10.1007/BF01752281; ELLMAN L, 1976, AM J MED, V60, P1, DOI 10.1016/0002-9343(76)90527-1; FALCON MG, 2012, BLOOD, V120; GHEDINI G, 1908, CLIN MED ITAL, V47, P724; Goldenberg AS, 2001, AM J HEMATOL, V68, P189, DOI 10.1002/ajh.1177; GRUBER HE, 1981, SEMIN HEMATOL, V18, P258; Health Care Utilization Project, 2017, HCUP NAT INP SAMPL N; ISLAM A, 1980, BRIT J HAEMATOL, V45, P535, DOI 10.1111/j.1365-2141.1980.tb07175.x; ISLAM A, 1988, HISTOPATHOLOGY, V12, P641, DOI 10.1111/j.1365-2559.1988.tb01988.x; ISLAM A, 1982, J CLIN PATHOL, V35, P359, DOI 10.1136/jcp.35.3.359; Islam A, 1988, HEMATOLOGY REV COMMU, V2, P187; Islam A., 2013, MANUAL BONE MARROW E; Jacobs P., 1995, HEMATOL REV, V9, P163; JAMSHIDI K, 1971, SCAND J HAEMATOL, V8, P69; JAMSHIDI K, 1971, J LAB CLIN MED, V77, P335; LANDYS K, 1975, SCAND J HAEMATOL, V15, P104; MCFARLAND W, 1958, JAMA-J AM MED ASSOC, V166, P1464, DOI 10.1001/jama.1958.62990120004011a; Miller LJ, 2011, HEMATOL REP, V3, P22, DOI 10.4081/hr.2011.e8; NOTTER B, 1953, SCHWEIZ MED WSCHR, V83, P1263; SACKER LS, 1954, LANCET, V1, P347; Snowden JA, 2017, J CLIN PATHOL, V70, P461, DOI 10.1136/jclinpath-2016-204029; Swords RT, 2010, J CLIN PATHOL, V63, P562, DOI 10.1136/jcp.2009.072843; WESTERMAN MP, 1981, SEMIN HEMATOL, V18, P293; Worldwide Medical Technologies inventor, COR LOC TM BON MARR	27	3	3	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUN	2018	71	6					475	482		10.1136/jclinpath-2017-204865			8	Pathology	Pathology	GH2OI	WOS:000433240800001	29217729				2019-10-28	
J	McCarthy, AJ; Chetty, R				McCarthy, Aoife J.; Chetty, Runjan			Tumours composed of fat are no longer a simple diagnosis: an overview of fatty tumours with a spindle cell component	JOURNAL OF CLINICAL PATHOLOGY			English	Review						Spindle cell fatty tumours; atypical lipomatous tumour; atypical spindle cell lipomatous tumour; cellular angiofibroma; liposarcoma; mammary-type myofibroblastoma; spindle cell lipoma	WELL-DIFFERENTIATED LIPOSARCOMA; MAMMARY-TYPE MYOFIBROBLASTOMA; SOLITARY FIBROUS TUMOR; SOFT-TISSUE TUMORS; METAPLASTIC BONE-FORMATION; MENINGOTHELIAL-LIKE WHORLS; ATYPICAL LIPOMATOUS TUMOR; DESMOID-TYPE FIBROMATOSIS; IN-SITU HYBRIDIZATION; DEDIFFERENTIATED LIPOSARCOMA	This is a review of the morphological spectrum of fatty tumours containing a component of spindle cells, highlighting the immunohistochemical and cytogenetic workup that is now mandatory for accurate diagnosis, with the goal of providing a practical approach for practising surgical pathologists. There have been significant advances in recent years in classifying and understanding the pathogenesis of fatty tumours with spindle cells, based on the correlation of histological, immunohistochemical and cytogenetic/molecular findings. In spite of this, morphological diagnosis and accurate classification of fatty tumours with spindle cells can be challenging to diagnostic pathologists. A group of three lesions: spindle cell lipoma, mammary-type myofibroblastoma and cellular angiofibroma share morphological features and are united by retinoblastoma protein (pRb) loss. Closely allied to these lesions, especially spindle cell lipoma is the newly designated atypical spindle cell lipomatous tumour, which shares morphological, immunohistochemical and cytogenetic features with the trio of tumours lacking nuclear pRb. All of these lesions lack MDM2 and CDK4 amplification as well and separation is based on clinical features, principally location. Atypical lipomatous tumour or well-differentiated liposarcoma shows retention of pRb but overexpression and amplification of MDM2. Fatty tumours with spindle cells need to be extensively sampled, with careful attention paid to cellular atypia and location, and they need to have immunohistochemical workup with pRb, MDM2, desmin, CD34 and p16. In addition, cytogenetic analysis for MDM2 and CDK4 amplification has become crucial for the proper identification of these lesions.	[McCarthy, Aoife J.; Chetty, Runjan] Univ Toronto, Dept Pathol, Lab Med Program, Univ Hlth Network, Toronto, ON, Canada	Chetty, R (reprint author), Toronto Gen Hosp, Dept Pathol, Lab Med Program, Univ Hlth Network, Toronto, ON M5G 2C4, Canada.	runjan.chetty@gmail.com		Chetty, Runjan/0000-0002-2124-515X			Abeshouse A, 2017, CELL, V171, P950, DOI DOI 10.1016/J.CELL.2017.10.014; Adsay NV, 2002, MODERN PATHOL, V15, P492, DOI 10.1038/modpathol.3880553; Aleixo PB, 2009, J CLIN PATHOL, V62, P1127, DOI 10.1136/jcp.2009.070201; Argani P, 1997, AM J SURG PATHOL, V21, P884, DOI 10.1097/00000478-199708000-00002; AZUMI N, 1987, AM J SURG PATHOL, V11, P161, DOI 10.1097/00000478-198703000-00001; Binh MBN, 2007, AM J SURG PATHOL, V31, P1557, DOI 10.1097/PAS.0b013e31804b4109; Binh MBN, 2005, AM J SURG PATHOL, V29, P1340, DOI 10.1097/01.pas.0000170343.09562.39; Boland JM, 2012, AM J SURG PATHOL, V36, P1395, DOI 10.1097/PAS.0b013e3182562bc1; Boland JM, 2010, AM J SURG PATHOL, V34, P837, DOI 10.1097/PAS.0b013e3181dbf2f7; Brennan MF, 2014, ANN SURG, V260, P416, DOI 10.1097/SLA.0000000000000869; Chen BJ, 2012, AM J SURG PATHOL, V36, P1119, DOI 10.1097/PAS.0b013e31825d532d; Chen E, 2010, AM J SURG PATHOL, V34, P707, DOI 10.1097/PAS.0b013e3181d74bdb; Clark MA, 2005, NEW ENGL J MED, V353, P701, DOI 10.1056/NEJMra041866; Clay MR, 2015, AM J SURG PATHOL, V39, P1433, DOI 10.1097/PAS.0000000000000468; Coindre JM, 2003, MODERN PATHOL, V16, P256, DOI 10.1097/01.MP.0000056983.78547.77; Creytens D, 2014, VIRCHOWS ARCH, V465, P97, DOI 10.1007/s00428-014-1568-8; Dei Tos Angelo P., 1994, American Journal of Surgical Pathology, V18, P913, DOI 10.1097/00000478-199409000-00006; Deyrup AT, 2013, AM J SURG PATHOL, V37, P1373, DOI 10.1097/PAS.0b013e31829562ed; Doyle LA, 2014, CANCER-AM CANCER SOC, V120, P1763, DOI 10.1002/cncr.28657; Doyle LA, 2014, MODERN PATHOL, V27, P390, DOI 10.1038/modpathol.2013.164; DUCATMAN BS, 1986, CANCER-AM CANCER SOC, V57, P2006, DOI 10.1002/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6; Elgar F, 1997, MODERN PATHOL, V10, P113; EVANS HL, 1994, AM J SURG PATHOL, V18, P1150, DOI 10.1097/00000478-199411000-00009; Eversole LR, 2009, HEAD NECK PATHOL, V3, P136, DOI 10.1007/s12105-009-0112-7; Fanburg-Smith JC, 1998, HISTOPATHOLOGY, V33, P414, DOI 10.1046/j.1365-2559.1998.00536.x; Fernanda M, 2007, AM J SURG PATHOL, V31, P1299; FLETCHER CDM, 1987, HISTOPATHOLOGY, V11, P803, DOI 10.1111/j.1365-2559.1987.tb01884.x; Fletcher CDM, 2006, HISTOPATHOLOGY, V48, P3, DOI 10.1111/j.1365-2559.2005.02284.x; FLETCHER CDM, 1992, AM J SURG PATHOL, V16, P373, DOI 10.1097/00000478-199204000-00006; Flucke U, 2011, MODERN PATHOL, V24, P82, DOI 10.1038/modpathol.2010.170; French CA, 2000, AM J DERMATOPATH, V22, P496, DOI 10.1097/00000372-200012000-00003; Fritchie KJ, 2012, AM J CLIN PATHOL, V137, P963, DOI 10.1309/AJCPQEG6YNN6CNAL; Fukunaga M, 2001, PATHOL INT, V51, P392, DOI 10.1046/j.1440-1827.2001.01208.x; Gronchi A, 2009, J CLIN ONCOL, V27, P24, DOI 10.1200/JCO.2008.17.8871; Guillou L, 2000, HUM PATHOL, V31, P1108, DOI 10.1053/hupa.2000.9777; Hasegawa T, 2000, HUM PATHOL, V31, P717, DOI 10.1053/hupa.2000.8222; He M, 2009, APPL IMMUNOHISTO M M, V17, P51, DOI 10.1097/PAI.0b013e3181719223; Henricks WH, 1997, AM J SURG PATHOL, V21, P271, DOI 10.1097/00000478-199703000-00002; Howitt BE, 2016, AM J SURG PATHOL, V40, P361, DOI 10.1097/PAS.0000000000000540; Huang K, 2014, AM J SURG, V207, P847, DOI 10.1016/j.amjsurg.2013.08.007; Iwasa Y, 2004, AM J SURG PATHOL, V28, P1426, DOI 10.1097/01.pas.0000138002.46650.95; Kandil DH, 2009, J CLIN PATHOL, V62, P945, DOI 10.1136/jcp.2009.067124; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Kraus MD, 1997, AM J SURG PATHOL, V21, P518, DOI 10.1097/00000478-199705000-00003; Laurino L, 2001, SEMIN DIAGN PATHOL, V18, P258, DOI 10.1053/sdia.2001.28254; Louis-Brennetot C, 2011, GENE CHROMOSOME CANC, V50, P896, DOI 10.1002/gcc.20909; LUCAS DR, 1994, AM J CLIN PATHOL, V102, P677, DOI 10.1093/ajcp/102.5.677; Maggiam F, 2007, HISTOPATHOLOGY, V51, P410, DOI 10.1111/j.1365-2559.2007.02775.x; Magro G, 2008, ARCH PATHOL LAB MED, V132, P1813, DOI 10.1043/1543-2165-132.11.1813; Magro G, 2013, HUM PATHOL, V44, P1941, DOI 10.1016/j.humpath.2013.01.018; Magro G, 2009, AM J SURG PATHOL, V33, P1085, DOI 10.1097/PAS.0b013e31819e642a; MANDAHL N, 1994, J CANCER RES CLIN, V120, P707, DOI 10.1007/BF01194267; Marino-Enriquez A, 2017, AM J SURG PATHOL, V41, P234, DOI 10.1097/PAS.0000000000000770; Marino-Enriquez A, 2010, AM J SURG PATHOL, V34, P1122, DOI 10.1097/PAS.0b013e3181e5dc49; McCluggage WG, 2004, HISTOPATHOLOGY, V45, P360, DOI 10.1111/j.1365-2559.2004.01923.x; MCCORMICK D, 1994, AM J SURG PATHOL, V18, P1213, DOI 10.1097/00000478-199412000-00004; McMenamin ME, 2000, INT J SURG PATHOL, V8, P99, DOI 10.1177/106689690000800204; McMenamin ME, 2001, AM J SURG PATHOL, V25, P1022, DOI 10.1097/00000478-200108000-00006; Mentzel T, 2010, MODERN PATHOL, V23, P729, DOI 10.1038/modpathol.2010.66; Mertens F, 2010, VIRCHOWS ARCH, V456, P129, DOI 10.1007/s00428-009-0736-8; Michal M, 2017, HUM PATHOL, V65, P140, DOI 10.1016/j.humpath.2017.05.006; Montgomery E, 2003, AM J SURG PATHOL, V27, P40, DOI 10.1097/00000478-200301000-00005; Nascimento AG, 2001, SEMIN DIAGN PATHOL, V18, P263, DOI 10.1053/sdia.2001.27842; Nascimento AG, 1998, AM J SURG PATHOL, V22, P945, DOI 10.1097/00000478-199808000-00004; Neuhaus SJ, 2005, BRIT J SURG, V92, P246, DOI 10.1002/bjs.4802; Nucci MR, 2000, HISTOPATHOLOGY, V36, P97; Robinson DR, 2013, NAT GENET, V45, P180, DOI 10.1038/ng.2509; Rosai J, 1996, AM J SURG PATHOL, V20, P1182, DOI 10.1097/00000478-199610000-00002; Sioletic S, 2013, HISTOPATHOLOGY, V62, P287, DOI 10.1111/j.1365-2559.2012.04348.x; Sirvent N, 2007, AM J SURG PATHOL, V31, P1476, DOI 10.1097/PAS.0b013e3180581fff; Thway K, 2016, ADV ANAT PATHOL, V23, P30, DOI 10.1097/PAP.0000000000000101; Thway K, 2012, AM J SURG PATHOL, V36, P462, DOI 10.1097/PAS.0b013e3182417330; Thway K, 2011, AM J SURG PATHOL, V35, P356, DOI 10.1097/PAS.0b013e31820832c1; Tos APD, 2000, J PATHOL, V190, P531; Val-Bernal JF, 2007, APMIS, V115, P254, DOI 10.1111/j.1600-0463.2007.apm_572.x; Weaver J, 2008, MODERN PATHOL, V21, P943, DOI 10.1038/modpathol.2008.84; Weaver J, 2010, MODERN PATHOL, V23, P1301, DOI 10.1038/modpathol.2010.106; WEISS SW, 1992, AM J SURG PATHOL, V16, P1051, DOI 10.1097/00000478-199211000-00003; Yang HY, 2017, ARCH PATHOL LAB MED, V141, P1092, DOI 10.5858/arpa.2016-0598-RA	79	7	7	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUN	2018	71	6					483	492		10.1136/jclinpath-2017-204975			10	Pathology	Pathology	GH2OI	WOS:000433240800002	29358476	Bronze, Green Published			2019-10-28	
J	Chen, YW; Zhang, LH; Hong, LQ; Luo, X; Chen, JP; Tang, LM; Chen, JH; Liu, X; Chen, ZJ				Chen, Yiwen; Zhang, Lahong; Hong, Liquan; Luo, Xian; Chen, Juping; Tang, Leiming; Chen, Jiahuan; Liu, Xia; Chen, Zhaojun			Rapid diagnosis of pulmonary tuberculosis and detection of drug resistance by combined simultaneous amplification testing and reverse dot blot	JOURNAL OF CLINICAL PATHOLOGY			English	Article						mycobacterium tuberculosis; SAT; RDB; rapid diagnosis; drug-resistance	MONITORING THERAPEUTIC-EFFICACY; MYCOBACTERIUM-TUBERCULOSIS; ETHAMBUTOL RESISTANCE; ASSAY; SPECIMENS; COMPLEX; SPUTUM; IDENTIFICATION; RNA	Aims Making a correct and rapid diagnosis is essential for managing pulmonary tuberculosis (PTB), particularly multidrug-resistant tuberculosis. We aimed to evaluate the efficacy of the combination of simultaneous amplification testing (SAT) and reverse dot blot (RDB) for the rapid detection of Mycobacterium tuberculosis (MTB) and drug-resistant mutants in respiratory samples. Methods 225 suspected PTB and 32 non-TB pulmonary disease samples were collected. All sputum samples were sent for acid-fast bacilli smear, SAT, culture and drug susceptibility testing (DST) by the BACTEC(TM) MGIT(TM) 960 system. 53 PTB samples were tested by both RDB and DNA sequencing to identify drug resistance genes and mutated sites. Results The SAT positive rate (64.9%) was higher than the culture positive rate (55.1%), with a coincidence rate of 83.7%. The sensitivity and specificity of SAT for diagnosing PTB were 66.7% and 100%, respectively, while those for culture were 53.9% and 84.2%, respectively. RDB has high sensitivity and specificity in identifying drug resistance genes and mutated sites. The results of RDB correlated well with those of DST and DNA sequencing, with coincidence rates of 92.5% and 98.1%, respectively. Conclusions The combination of SAT and RDB is promising for rapidly detecting PTB and monitoring drug resistance in clinical laboratories.	[Chen, Yiwen] Hangzhou Normal Univ, Affiliated Hosp, Clin Coll, Hangzhou, Zhejiang, Peoples R China; [Zhang, Lahong; Hong, Liquan; Luo, Xian; Liu, Xia; Chen, Zhaojun] Hangzhou Normal Univ, Clin Lab Dept, Affiliated Hosp, Hangzhou 310015, Zhejiang, Peoples R China; [Chen, Juping; Tang, Leiming; Chen, Jiahuan] Hangzhou Normal Univ, Affiliated Hosp, TB Lab Dept, Hangzhou, Zhejiang, Peoples R China	Chen, ZJ (reprint author), Hangzhou Normal Univ, Clin Lab Dept, Affiliated Hosp, Hangzhou 310015, Zhejiang, Peoples R China.	hzczj2006@163.com			Hangzhou Science and Technology Development Plans [20140633B11]; Zhejiang Medical and Health Technology Program [2014ZDA018]	This work was supported by Hangzhou Science and Technology Development Plans (20140633B11) and Zhejiang Medical and Health Technology Program (2014ZDA018).	Chen GF, 2015, ENVIRON SCI POLLUT R, V22, P10516, DOI 10.1007/s11356-015-4141-3; Chinese Antituberculosis Association, 1995, CHIN LAB SCI PROC DI, P9; Cruciani M, 2004, J CLIN MICROBIOL, V42, P2321, DOI 10.1128/JCM.42.5.2321-2325.2004; Cui ZL, 2012, J CLIN MICROBIOL, V50, P646, DOI 10.1128/JCM.05853-11; Dheda K, 2017, CLIN MICROBIOL INFEC, V23, P131, DOI 10.1016/j.cmi.2016.10.008; Fan L, 2014, CHINESE MED J-PEKING, V127, P1863, DOI 10.3760/cma.j.issn.0366-6999.20133010; Gandhi NR, 2010, LANCET, V375, P1830, DOI 10.1016/S0140-6736(10)60410-2; Greco S, 2006, THORAX, V61, P783, DOI 10.1136/thx.2005.054908; Guerra RL, 2008, J CLIN MICROBIOL, V46, P314, DOI 10.1128/JCM.01313-07; Jiang LJ, 2012, J MICROBIOL BIOTECHN, V22, P1301, DOI 10.4014/jmb.1202.02032; Johnson R, 2006, INT J TUBERC LUNG D, V10, P68; JONAS V, 1993, J CLIN MICROBIOL, V31, P2410; Ling feng C, 2016, LAB MED, V31, P163; Mdivani N, 2009, CLIN CHEM, V55, P1694, DOI 10.1373/clinchem.2009.124396; Mokrousov I, 2004, J MICROBIOL METH, V57, P323, DOI 10.1016/j.mimet.2004.02.006; Morlock GP, 2003, ANTIMICROB AGENTS CH, V47, P3799, DOI 10.1128/AAC.47.12.3799-3805.2003; Ramaswamy S., 1998, Tubercle and Lung Disease, V79, P3, DOI 10.1054/tuld.1998.0002; Ramaswamy SV, 2000, ANTIMICROB AGENTS CH, V44, P326, DOI 10.1128/AAC.44.2.326-336.2000; Reischl U, 1998, J CLIN MICROBIOL, V36, P2853; Schon T, 2017, CLIN MICROBIOL INFEC, V23, P154, DOI 10.1016/j.cmi.2016.10.022; Sethi SK, 2013, J CLIN LAB ANAL, V27, P272, DOI 10.1002/jcla.21596; Slayden RA, 2000, MICROBES INFECT, V2, P659, DOI 10.1016/S1286-4579(00)00359-2; Speers David J, 2006, Clin Biochem Rev, V27, P39; Spinato J, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0786-4; TELENTI A, 1993, LANCET, V341, P647, DOI 10.1016/0140-6736(93)90417-F; Van Rie A, 2001, J CLIN MICROBIOL, V39, P636, DOI 10.1128/JCM.39.2.636-641.2001; WHO, 2016, GLOB TUB REP 2016; *WHO, 2009, WHOHTMTB2009422; World Health Organization, 2010, WHOHTMTB2009420; World Health Organization, 2016, WHOHTMTB20164; Wu Xue-Qiong, 2006, Acta Genetica Sinica, V33, P655, DOI 10.1016/S0379-4172(06)60096-6; Wu XQ, 2009, MOL BIOTECHNOL, V41, P1, DOI 10.1007/s12033-008-9085-0; Yan LP, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002597	33	0	0	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUN	2018	71	6					498	503		10.1136/jclinpath-2017-204714			6	Pathology	Pathology	GH2OI	WOS:000433240800004	29138284	Other Gold, Green Published			2019-10-28	
J	Chandan, VS; Shah, SS; Mounajjed, T; Torbenson, MS; Wu, TT				Chandan, Vishal S.; Shah, Sejal S.; Mounajjed, Taofic; Torbenson, Michael S.; Wu, Tsung-Teh			Copper deposition in focal nodular hyperplasia and inflammatory hepatocellular adenoma	JOURNAL OF CLINICAL PATHOLOGY			English	Article						liver; staining; histopathology	BINDING PROTEIN; SUBTYPE CLASSIFICATION; GLUTAMINE-SYNTHETASE; NEEDLE-BIOPSY; LIVER; DIAGNOSIS; MANAGEMENT; CARCINOMA; LESIONS; CELLS	Aims To examine copper deposition in focal nodular hyperplasia (FNH) and inflammatory hepatocellular adenoma (IHA) and to determine if it can play a role in their differentiation. Methods 28 FNHs and 19 IHAs from surgical resections showing typical morphological and immunohistochemical features were stained with rhodanine to evaluate for copper deposition. Histological features such as nodularity, fibrous bands, ductular proliferation, steatosis, ballooned hepatocytes and lymphocytic inflammation were also scored. Results Copper deposition was detected in 96% (27/28) of FNHs and 37% (7/19) of IHAs, P<0.001. In all cases, copper was seen within the hepatocytes only around the pseudo-portal tracts or areas of fibrosis. Copper deposition in IHA was significantly associated with presence of lymphocytic inflammation (P=0.04) but not associated with features like nodularity, fibrous bands, ductular proliferation, ballooned hepatocytes and steatosis (P>0.05, for all). In FNH, the presence and degree of copper deposition was not significantly associated with any histological features (P>0.05, for all). Conclusions Copper deposition occurs more frequently in FNH (96%) than IHA (37%), P<0.001. However, the presence of copper alone cannot be used as a feature to differentiate between FNH and IHA.	[Chandan, Vishal S.; Shah, Sejal S.; Mounajjed, Taofic; Torbenson, Michael S.; Wu, Tsung-Teh] Mayo Clin, Dept Anat Pathol, 200 First St SW, Rochester, MN 55902 USA	Chandan, VS (reprint author), Mayo Clin, Dept Anat Pathol, 200 First St SW, Rochester, MN 55902 USA.	chandan.vishal@mayo.edu					Bioulac-Sage P, 2007, J HEPATOL, V46, P521, DOI 10.1016/j.jhep.2006.12.007; Bioulac-Sage P, 2005, GASTROENTEROLOGY, V128, P1211, DOI 10.1053/j.gastro.2005.02.004; Bioulac-Sage P, 2007, HEPATOLOGY, V46, P740, DOI 10.1002/hep.21743; Bioulac-Sage P, 2007, WORLD J GASTROENTERO, V13, P2649, DOI 10.3748/wjg.v13.i19.2649; Bioulac-Sage P, 2010, DIGEST SURG, V27, P39, DOI 10.1159/000268406; Bioulac-Sage P, 2009, HEPATOLOGY, V50, P481, DOI 10.1002/hep.22995; Bosman F. T., 2010, WHO CLASSIFICATION T, V3, P198; GUARASCIO P, 1983, J CLIN PATHOL, V36, P18, DOI 10.1136/jcp.36.1.18; GUIGUI B, 1988, CANCER, V61, P1155, DOI 10.1002/1097-0142(19880315)61:6<1155::AID-CNCR2820610616>3.0.CO;2-6; HARATAKE J, 1986, ARCH PATHOL LAB MED, V110, P192; Joseph NM, 2014, MODERN PATHOL, V27, P62, DOI 10.1038/modpathol.2013.114; LEFKOWITCH JH, 1983, CANCER, V51, P97, DOI 10.1002/1097-0142(19830101)51:1<97::AID-CNCR2820510120>3.0.CO;2-1; Lepreux S, 2003, VIRCHOWS ARCH, V442, P226, DOI 10.1007/s00428-003-0762-x; Makhtouf HR, 2005, HUM PATHOL, V36, P1210, DOI 10.1016/j.humpath.2005.08.014; Marrero JA, 2014, AM J GASTROENTEROL, V109, P1328, DOI 10.1038/ajg.2014.213; Mounajjed T, 2013, AM J CLIN PATHOL, V139, P79, DOI 10.1309/AJCPDZR4OHDQNG3L; Nguyen BN, 1999, AM J SURG PATHOL, V23, P1441, DOI 10.1097/00000478-199912000-00001; Paradis V, 2004, GASTROENTEROLOGY, V126, P1323, DOI 10.1053/j.gastro.2004.02.005; Paradis V, 1997, HEPATOLOGY, V26, P891; Sato Y, 2009, HUM PATHOL, V40, P181, DOI 10.1016/j.humpath.2008.04.024; STERNLIEB I, 1980, GASTROENTEROLOGY, V78, P1615; SUMITHRAN E, 1985, HUM PATHOL, V16, P677, DOI 10.1016/S0046-8177(85)80151-9; Tsai JH, 2012, PATHOLOGY, V44, P605, DOI 10.1097/PAT.0b013e32835817c6; VECCHIO FM, 1986, DIGESTION, V35, P109, DOI 10.1159/000199354; WANLESS IR, 1989, MODERN PATHOL, V2, P456; WANLESS IR, 1985, HEPATOLOGY, V5, P1194, DOI 10.1002/hep.1840050622; Zucman-Rossi J, 2006, HEPATOLOGY, V43, P515, DOI 10.1002/hep.21068	27	0	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUN	2018	71	6					504	507		10.1136/jclinpath-2017-204820			4	Pathology	Pathology	GH2OI	WOS:000433240800005	29127141				2019-10-28	
J	Kuo, MC; Lin, TH; Sun, CF; Lin, TL; Wu, JH; Wang, PN; Huang, YJ; Chang, H; Huang, TY; Shih, LY				Kuo, Ming-Chung; Lin, Tung-Huei; Sun, Chien-Feng; Lin, Tung-Liang; Wu, Jin-Hou; Wang, Po-Nan; Huang, Ying-Jung; Chang, Hung; Huang, Ting-Yu; Shih, Lee-Yung			The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis	JOURNAL OF CLINICAL PATHOLOGY			English	Article						molecular genetics; leukaemia; myelofibrosis	BONE-MARROW FIBROSIS; ERYTHROID COLONY FORMATION; POLYCYTHEMIA-VERA; MYELOPROLIFERATIVE NEOPLASMS; ESSENTIAL THROMBOCYTHEMIA; CALRETICULIN MUTATIONS; CALR MUTATIONS; JAK2 V617F; PRV-1 OVEREXPRESSION; EUROPEAN CONSENSUS	Aims We investigated the clinical and prognostic relevance of the mutational status of driver genes with allele burden and endogenous erythroid colony (EEC) growth in 203 Taiwanese patients with primary myelofibrosis (PMF). Methods Pyrosequencing was used to detect JAK2(V617F) mutational status and measure allele burden, while MPL (exon 10) mutations were analysed by PCR assay and then by direct sequencing. CALR exon 9 mutations were first screened for length changes by GeneScan followed by sequencing. The allele burden of the mutated CALR gene was measured by pyrosequencing. The EEC assay was conducted using a serum-free culture system. Results The frequencies of the three driver mutations and triple-negative status were similarly distributed between pre-PMF and overt PMF patients, except that pre-PMF patients had a higher incidence of CALR type 2/type-2 like mutations and a lower JAK2(V617F) allele burden. EEC growth and CALR mutations conferred favourable overall survival (OS). A lower JAK2(V617F) allele burden and grade 3 bone marrow fibrosis were associated with shorter OS and decreased leukaemia-free survival (LFS). Type 2/type 2-like CAL mutations were associated with better LFS compared with type1/type 1-like mutations. Patients with triple-negative mutation status had significantly worse OS and LFS. The allele burden of CALR mutations remained unchanged, while some JAK2(V617F) mutations showed clonal expansion in patients during secondary acute myeloid leukaemia transformation. Conclusions Our study showed that EEC growth, a higher JAK2(V617F) allele burden and CALR mutations, especially type 2, were independent predictors for better outcomes in PMF. The allele burden of CALR mutations remained stable, but the allele burden of JAK2(V617F)mutations was variable during leukaemia transformation.	[Kuo, Ming-Chung; Lin, Tung-Huei; Lin, Tung-Liang; Wu, Jin-Hou; Wang, Po-Nan; Huang, Ying-Jung; Chang, Hung; Huang, Ting-Yu; Shih, Lee-Yung] Chang Gung Mem Hosp Linkou, Div Hematol Oncol, Taoyuan 333, Taiwan; [Kuo, Ming-Chung; Chang, Hung; Shih, Lee-Yung] Chang Gung Univ, Coll Med, Taoyuan, Taiwan; [Sun, Chien-Feng] Chang Gung Mem Hosp Linkou, Dept Pathol, Taoyuan, Taiwan	Shih, LY (reprint author), Chang Gung Mem Hosp Linkou, Div Hematol Oncol, Taoyuan 333, Taiwan.	sly7012@adm.cgmh.org.tw			Chang Gung Memorial Hospital, TaiwanChang Gung Memorial Hospital [CMRPG3D1533]; Ministry of Health and Welfare, Taiwan [DOH102-TD-C-111-006, MOHW105-TDU-B-212-134005]	This study was supported in part by grants from Chang Gung Memorial Hospital, Taiwan (CMRPG3D1533) and the Ministry of Health and Welfare, Taiwan (DOH102-TD-C-111-006 and MOHW105-TDU-B-212-134005).	Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Barosi G, 2007, BLOOD, V110, P4030, DOI 10.1182/blood-2007-07-099184; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Beer PA, 2008, BLOOD, V112, P141, DOI 10.1182/blood-2008-01-131664; Bellosillo B, 2006, LEUKEMIA, V20, P736, DOI 10.1038/sj.leu.2404123; Cabagnols X, 2015, LEUKEMIA, V29, P249, DOI 10.1038/leu.2014.270; Campbell PJ, 2006, BLOOD, V107, P2098, DOI 10.1182/blood-2005-08-3395; Cervantes F, 2009, BLOOD, V113, P2895, DOI 10.1182/blood-2008-07-170449; Chachoua I, 2016, BLOOD, V127, P1325, DOI 10.1182/blood-2015-11-681932; Gianelli U, 2012, MODERN PATHOL, V25, P1193, DOI 10.1038/modpathol.2012.87; Goerttler PS, 2005, BLOOD, V106, P2862, DOI 10.1182/blood-2005-04-1515; Guglielmelli P, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.90; Guglielmelli P, 2017, BLOOD, V129, P3227, DOI 10.1182/blood-2017-01-761999; Guglielmelli P, 2016, AM J HEMATOL, V91, P918, DOI 10.1002/ajh.24442; Guglielmelli P, 2009, BLOOD, V114, P1477, DOI 10.1182/blood-2009-04-216044; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Kim BH, 2015, J KOREAN MED SCI, V30, P882, DOI 10.3346/jkms.2015.30.7.882; Kim SY, 2015, AM J CLIN PATHOL, V143, P635, DOI 10.1309/AJCPUAAC16LIWZMM; Klampfl T, 2013, NEW ENGL J MED, V369, P2379, DOI 10.1056/NEJMoa1311347; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; LACOMBE C, 1980, BRIT J HAEMATOL, V44, P189, DOI 10.1111/j.1365-2141.1980.tb01201.x; LEMOINE F, 1986, BLOOD, V68, P996; Li B, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.116; Li B, 2014, HAEMATOLOGICA, V99, P1697, DOI 10.3324/haematol.2014.109249; Li N, 2015, LEUKEMIA RES, V39, P510, DOI 10.1016/j.leukres.2015.02.006; Marty C, 2016, BLOOD, V127, P1317, DOI 10.1182/blood-2015-11-679571; Nangalia J, 2013, NEW ENGL J MED, V369, P2391, DOI 10.1056/NEJMoa1312542; Pardanani AD, 2006, BLOOD, V108, P3472, DOI 10.1182/blood-2006-04-018879; Pietra D, 2016, LEUKEMIA, V30, P431, DOI 10.1038/leu.2015.277; Pikman Y, 2006, PLOS MED, V3, P1140, DOI 10.1371/journal.pmed.0030270; PRCHAL JF, 1974, NEW ENGL J MED, V290, P1382; Rumi E, 2014, BLOOD, V124, P1062, DOI 10.1182/blood-2014-05-578435; Shih LY, 2013, LEUKEMIA RES, V37, P43, DOI 10.1016/j.leukres.2012.09.012; SHIH LY, 1994, BLOOD, V83, P744; Shirane S, 2015, HAEMATOLOGICA, V100, pE46, DOI 10.3324/haematol.2014.115113; Swerdlow S. H., 2008, WHO CLASSIFICATION T, P439; Tefferi A, 2008, LEUKEMIA, V22, P756, DOI 10.1038/sj.leu.2405097; Tefferi A, 2005, BRIT J HAEMATOL, V131, P320, DOI 10.1111/j.1365-2141.2005.05776.x; Tefferi A, 2014, LEUKEMIA, V28, P1568, DOI 10.1038/leu.2014.83; Tefferi A, 2014, LEUKEMIA, V28, P1472, DOI 10.1038/leu.2014.3; Tefferi A, 2010, LEUKEMIA, V24, P1128, DOI 10.1038/leu.2010.69; Tefferi A, 2014, BLOOD, V124, P2507, DOI 10.1182/blood-2014-05-579136; Tefferi A, 2014, BLOOD, V124, P2465, DOI 10.1182/blood-2014-07-588426; Thiele J, 2005, HAEMATOL-HEMATOL J, V90, P1128; Wu ZY, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0048-6; Xu Z F, 2016, Zhonghua Xue Ye Xue Za Zhi, V37, P576, DOI 10.3760/cma.j.issn.0253-2727.2016.07.007; Xu ZF, 2012, BLOOD, V119, P2469, DOI 10.1182/blood-2011-11-389866; ZANJANI ED, 1977, J CLIN INVEST, V59, P841, DOI 10.1172/JCI108706; Zhao RX, 2005, J BIOL CHEM, V280, P22788, DOI 10.1074/jbc.C500138200	49	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUN	2018	71	6					514	521		10.1136/jclinpath-2017-204829			8	Pathology	Pathology	GH2OI	WOS:000433240800007	29203554				2019-10-28	
J	Ng, CWS; Kosmo, B; Lee, PL; Lee, CK; Guo, JX; Chen, ZJ; Chiu, L; Lee, HK; Ho, S; Zhou, JB; Lin, MX; Tan, KML; Ban, KHK; Tan, TW; Chng, WJ; Yan, B				Ng, Christopher Wai Siong; Kosmo, Bustamin; Lee, Peak-Ling; Lee, Chun Kiat; Guo, Jingxue; Chen, Zhaojin; Chiu, Lily; Lee, Hong Kai; Ho, Sherry; Zhou, Jianbiao; Lin, Mingxuan; Tan, Karen M. L.; Ban, Kenneth H. K.; Tan, Tin Wee; Chng, Wee Joo; Yan, Benedict			CEBPA mutational analysis in acute myeloid leukaemia by a laboratory-developed next-generation sequencing assay	JOURNAL OF CLINICAL PATHOLOGY			English	Article						leukaemia; haemato-oncology; molecular pathology	VALIDATION; AML	Aim The presence of biallelic CEBPA mutations is a favourable prognostic feature in acute myeloid leukaemia (AML). CEBPA mutations are currently identified through conventional capillary sequencing (CCS). With the increasing adoption of next-generation sequencing (NGS) platforms, challenges with regard to amplification efficiency of CEBPA due to the high GC content may be encountered, potentially resulting in suboptimal coverage. Here, the performance of an amplicon-based NGS method using a laboratory-developed CEBPA-specific Nextera XT (CEBNX) was evaluated. Methods Mutational analyses of the CEBPA gene of 137 AML bone marrow or peripheral blood retrospective specimens were performed by the amplification of the CEBPA gene using the Expand Long Range dNTPack and the amplicons processed by CCS and NGS. CEBPA-specific libraries were then constructed using the Nextera XT V.2 kit. All FASTQ files were then processed with the MiSeq Reporter V.2.6.2.3 using the PCR Amplicon workflow via the customised CEBPA-specific manifest file. The variant calling format files were analysed using the Illumina Variant Studio V.2.2. Results A coverage per base of 3631X to 28184X was achieved. 22 samples (16.1%) were found to contain CEBPA mutations, with variant allele frequencies (VAF) ranging from 3.8% to 58.2%. Taking CCS as the gold standard', sensitivity and specificity of 97% and 97% was achieved. For the transactivation domain 2 polymorphism (c.584_589dupACCCGC/p.His195_Pro196dup), the CEBNX achieved 100% sensitivity and 100% specificity relative to CCS. Conclusions Our laboratory-developed CEBNX workflow shows high coverage and thus overcomes the challenges associated with amplification efficiency and low coverage of CEBPA. Therefore, our assay is suitable for deployment in the clinical laboratory.	[Ng, Christopher Wai Siong; Kosmo, Bustamin; Lee, Peak-Ling; Lee, Chun Kiat; Chiu, Lily; Lee, Hong Kai; Ho, Sherry; Lin, Mingxuan; Tan, Karen M. L.; Yan, Benedict] Natl Univ Hlth Syst, Mol Diag Ctr, Dept Lab Med, Singapore 119074, Singapore; [Guo, Jingxue; Ban, Kenneth H. K.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore, Singapore; [Chen, Zhaojin] Natl Univ Hlth Syst, Invest Med Unit, Singapore, Singapore; [Zhou, Jianbiao; Chng, Wee Joo] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore; [Zhou, Jianbiao; Chng, Wee Joo] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore; [Tan, Tin Wee] Natl Supercomp Ctr Singapore, Singapore, Singapore; [Chng, Wee Joo] Natl Univ Hlth Syst, Natl Univ Canc Inst, Dept Haematol Oncol, Singapore, Singapore; [Yan, Benedict] Natl Univ Hlth Syst, Translat Ctr Dev & Res, Singapore, Singapore	Ng, CWS; Yan, B (reprint author), Natl Univ Hlth Syst, Mol Diag Ctr, Dept Lab Med, Singapore 119074, Singapore.	christopher.ws.ng@gmail.com; tranceblues@gmail.com		Tan, Karen/0000-0002-7768-037X	Centre for Personalized and Precision Health (CPPH) of National University Hospital (NUH), Singapore	This study was funded by Centre for Personalized and Precision Health (CPPH) of National University Hospital (NUH), Singapore (CPPH/FY2016/ProjectBudget/003).	ALTMAN DG, 1994, BRIT MED J, V308, P1552, DOI 10.1136/bmj.308.6943.1552; [Anonymous], 2014, HEMATOPATHOLOGY M MM; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Barjesteh van Waalwijk van Doorn-Khosrovani Sahar, 2003, Hematol J, V4, P31; Biggio V, 2008, LEUKEMIA, V22, P655, DOI 10.1038/sj.leu.2404926; Der A, 2014, FASTQ DATA HIGH CONF; Dohner H, 2015, NEW ENGL J MED, V373, P1136, DOI 10.1056/NEJMra1406184; Dufour A, 2010, J CLIN ONCOL, V28, P570, DOI 10.1200/JCO.2008.21.6010; Fasan A, 2014, LEUKEMIA, V28, P794, DOI 10.1038/leu.2013.273; Frey B, 1995, BIOCHEMICA, V2, P7; Frohling S, 2004, J CLIN ONCOL, V22, P624, DOI 10.1200/JCO.2004.06.060; Monaghan KG, 2012, MOL METHODS CLIN GEN; Renneville A, 2009, BLOOD, V113, P5090, DOI 10.1182/blood-2008-12-194704; Singh RR, 2013, J MOL DIAGN, V15, P607, DOI 10.1016/j.jmoldx.2013.05.003; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Thomas M, 2017, ARCH PATHOL LAB MED, V141, P759, DOI 10.5858/arpa.2016-0547-RA; Yan B, 2016, J CLIN PATHOL, V69, P801, DOI 10.1136/jclinpath-2015-203580	17	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUN	2018	71	6					522	531		10.1136/jclinpath-2017-204825			10	Pathology	Pathology	GH2OI	WOS:000433240800008	29180507				2019-10-28	
J	Hinnouho, GM; Barffour, MA; Wessells, KR; Brown, KH; Kounnavong, S; Chanhthavong, B; Ratsavong, K; Kewcharoenwong, C; Hess, SY				Hinnouho, Guy-Marino; Barffour, Maxwell A.; Wessells, K. Ryan; Brown, Kenneth H.; Kounnavong, Sengchanh; Chanhthavong, Bigphone; Ratsavong, Kethmany; Kewcharoenwong, Chidchamai; Hess, Sonja Y.			Comparison of haemoglobin assessments by HemoCue and two automated haematology analysers in young Laotian children	JOURNAL OF CLINICAL PATHOLOGY			English	Article						paediatric haematology; diagnosis; epidemiology; evaluating instrument	MIDDLE-INCOME COUNTRIES; BLOOD-DONORS; CAPILLARY BLOOD; CORRELATION-COEFFICIENT; ANEMIA; RELIABILITY; SYSTEM; WOMEN; PREVALENCE; ACCURACY	Background Haemoglobin (Hb) assessment by Hemocue is used widely for anaemia screening in both adults and children. However, few studies have compared the diagnostic accuracy of Hemocue with an automated haematology analyser in young children. Aim To compare Hb concentrations by Hemocue Hb301 and two automated haematology analysers in young children in rural communities of Lao PDR. Methods Capillary blood was collected from 6-month-old to 23-month-old children (n=1487) for determination of Hb concentration by Hemocue Hb301. On the same day, venous blood was collected for complete blood count using one of two haematology analysers (XT-1800i, Sysmex, and BC-3000Plus, Mindray Medical International). In a subsample of children (n=129), venous Hb was also measured by HemoCue Hb301. Agreement between the two methods was estimated using Bland-Altman plots. Results Mean capillary Hb by Hemocue was significantly higher than mean venous Hb by haematology analysers combined (108.410.3g/L vs 102.3 +/- 13.1g/L; P<0.001), resulting in a significantly lower anaemia prevalence (Hb <110g/L) by Hemocue (53.7% vs 73.9%; P<0.001). The Bland-Altman assessment of agreement showed a bias of 6.1g/L and limits of agreement were -11.5g/L to 23.7g/L. Mean venous Hb concentration by Hemocue Hb301 (113.6 +/- 14.0g/L) was significantly higher than mean capillary Hb concentration by Hemocue Hb301 (110.0 +/- 10.7; P=0.03g/L), which in turn was significantly higher than mean venous Hb concentration by the Mindray BC-3000Plus (102.3 +/- 17.4g/L). Conclusion Capillary and venous Hb concentrations assessed by Hemocue Hb301 showed poor agreement compared with venous Hb by automated haematology analysers, resulting in significantly different anaemia prevalences.	[Hinnouho, Guy-Marino; Barffour, Maxwell A.; Wessells, K. Ryan; Brown, Kenneth H.; Hess, Sonja Y.] Univ Calif Davis, Dept Nutr, Program Int & Community Nutr, One Shields Ave, Davis, CA 95616 USA; [Brown, Kenneth H.] Bill & Melinda Gates Fdn, Nutr & Global Dev, Seattle, WA USA; [Kounnavong, Sengchanh; Chanhthavong, Bigphone; Ratsavong, Kethmany] Natl Inst Publ Hlth, Viangchan, Laos; [Kewcharoenwong, Chidchamai] Khon Kaen Univ, Fac Associated Med Sci, Ctr Res & Dev Med Diagnost Labs, Khon Kaen, Thailand	Hinnouho, GM (reprint author), Univ Calif Davis, Dept Nutr, Program Int & Community Nutr, One Shields Ave, Davis, CA 95616 USA.	gmhinnouho@ucdavis.edu			Mathile Institute for the Advancement of Human Nutrition; Bill & Melinda Gates FoundationGates Foundation; Nutrition International	Funding for this research was provided by the Mathile Institute for the Advancement of Human Nutrition, Nutrition International (formerly known as the Micronutrient Initiative) and the Bill & Melinda Gates Foundation.	Adam I, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-30; Balarajan Y, 2011, LANCET, V378, P2123, DOI 10.1016/S0140-6736(10)62304-5; Black RE, 2013, LANCET, V382, P427, DOI 10.1016/S0140-6736(13)60937-X; BLAND JM, 1986, LANCET, V1, P307; BOULTON FE, 1994, TRANSFUSION MED, V4, P221, DOI 10.1111/j.1365-3148.1994.tb00275.x; Bridges N, 1987, AM CLIN PROD REV, V6, P22; Brooker S, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000291; CHEN PP, 1992, ANAESTH INTENS CARE, V20, P497, DOI 10.1177/0310057X9202000419; COHEN AR, 1988, AM J CLIN PATHOL, V90, P302, DOI 10.1093/ajcp/90.3.302; De Rosa SC, 2001, CLIN LAB MED, V21, P697; Desai M, 2007, LANCET INFECT DIS, V7, P93, DOI 10.1016/S1473-3099(07)70021-X; GORE CJ, 1992, EUR J APPL PHYSIOL O, V65, P302, DOI 10.1007/BF00868132; Gwetu T P, 2015, SAMJ, S. Afr. med. j., V105, P596, DOI [10.7196/SAMJNEW.7919, 10.7196/SAMJnew.7919]; Haider BA, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3443; Karakochuk CD, 2017, CLIN CHEM LAB MED, V55, pE247, DOI 10.1515/cclm-2017-0118; Karakochuk CD, 2015, CLIN CHIM ACTA, V441, P148, DOI 10.1016/j.cca.2014.12.021; KUPKE IR, 1981, CLIN CHIM ACTA, V112, P177, DOI 10.1016/0009-8981(81)90376-4; Lamhaut L, 2011, ANESTHESIOLOGY, V115, P548, DOI 10.1097/ALN.0b013e3182270c22; Lau AY, 2008, LAB CHIP, V8, P1116, DOI 10.1039/b803598a; LIN LI, 1989, BIOMETRICS, V45, P255, DOI 10.2307/2532051; Lu MJ, 2016, INT J BIOSTAT, V12, DOI 10.1515/ijb-2015-0039; Rudolf-Oliveira RCM, 2013, TRANSFUS APHER SCI, V49, P578, DOI 10.1016/j.transci.2013.09.004; MILLS A F, 1989, Archives of Disease in Childhood, V64, P1468; Mimoz O, 2011, MINERVA ANESTESIOL, V77, P979; Morris SS, 1999, AM J CLIN NUTR, V69, P1243; Mukaka MM, 2012, MALAWI MED J, V24, P69; Neufeld L, 2002, SALUD PUBLICA MEXICO, V44, P219, DOI 10.1590/s0036-36342002000300005; Nkrumah B, 2011, BMC CLIN PATHOL, V11, DOI 10.1186/1472-6890-11-5; Paiva AD, 2004, REV SAUDE PUBL, V38, P585, DOI 10.1590/s0034-89102004000400017; Patel AJ, 2013, VOX SANG, V104, P317, DOI 10.1111/vox.12006; Ranganathan H, 2006, IEEE T INF TECHNOL B, V10, P657, DOI 10.1109/TITB.2006.874195; Rappaport AI, 2017, J CLIN PATHOL, V70, P615, DOI 10.1136/jclinpath-2017-204351; Rippmann CE, 1997, J CLIN MONITOR, V13, P373, DOI 10.1023/A:1007451611748; Sanchis-Gomar F, 2013, JALA-J LAB AUTOM, V18, P198, DOI 10.1177/2211068212457560; Sari M, 2001, B WORLD HEALTH ORGAN, V79, P506; SHARMAN A, 2000, ANEMIA TESTING POPUL; Stevens GA, 2013, LANCET GLOB HEALTH, V1, pE16, DOI 10.1016/S2214-109X(13)70001-9; STOTT GJ, 1995, B WORLD HEALTH ORGAN, V73, P369; Tong E, 2010, VOX SANG, V98, P547, DOI 10.1111/j.1423-0410.2009.01285.x; VANASSENDELFT OW, 1990, CLIN LAB HAEMATOL, V12, P31; VONSCHENCK H, 1986, CLIN CHEM, V32, P526; World Health Organization, 2011, HAEM CONC DIAGN AN A; World Health Organization, 2001, IR DEF AN ASS PREV C	43	4	4	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUN	2018	71	6					532	538		10.1136/jclinpath-2017-204786			7	Pathology	Pathology	GH2OI	WOS:000433240800009	29197856	Green Published			2019-10-28	
J	Hex, C; Smeets, M; Penders, J; Van Hoof, V; Verbakel, J; Buntinx, F; Vaes, B				Hex, Chiel; Smeets, Miek; Penders, Joris; Van Hoof, Viviane; Verbakel, Jan; Buntinx, Frank; Vaes, Bert			Accuracy, user-friendliness and usefulness of the Cobas h232 point-of-care test for NT-proBNP in primary care	JOURNAL OF CLINICAL PATHOLOGY			English	Article						cardiovascular; poc testing; diagnosis; heart	PRIMARY-HEALTH-CARE; HEART-FAILURE; NATRIURETIC PEPTIDE; DIAGNOSTIC-ACCURACY; POPULATION; BNP	Aims N-terminal pro-B-type natriuretic peptide (NT-proBNP) has been shown to be useful for ruling out heart failure in primary care. In this study, we examined the accuracy of the Cobas h232 point-of-care (POC) instrument in primary care compared with an in-hospital measurement. Furthermore, we investigated the user-friendliness and usefulness of the POC device. Methods Five general practitioner (GP) groups were asked to evaluate adult patients who were suspected of having heart failure and to test NT-proBNP with the Cobas h232. The samples were subsequently delivered to and analysed at a central hospital laboratory by the Cobas e602 using conventional transport and storage. Difference between the paired measurements was analysed using a percentage difference plot, and correlation was assessed using Passing-Bablok linear regression analysis. User-friendliness and usefulness were assessed using semistructured questionnaires. Results Nineteen GPs studied 94 patients. Passing-Bablok analysis showed a slope of 1.05 (95% CI 1.00 to 1.11) (R-2=0.97). The percentage difference plot showed a mean difference of 15.7% (95% CI -46.0% to -77.4%). User-friendliness and usefulness had median scores of 4 or 5 on a five-point Likert scale. Eighteen out of 19 GPs confirmed that the device influenced their clinical practice. During the study, GPs' confidence in using NT-proBNP increased significantly from a mean score of 4.4 (95% CI 3.2 to 5.6) to 7.6 out of 10 (95% CI 7.1 to 8.2). Conclusions The Cobas h232 NT-proBNP POC test proved to be an accurate, user-friendly and useful test in primary care. Nearly all participating GPs were convinced that the test could benefit clinical decision making.	[Hex, Chiel; Smeets, Miek; Buntinx, Frank; Vaes, Bert] Katholieke Univ Leuven, Dept Publ Hlth & Primary Care, B-3000 Leuven, Belgium; [Penders, Joris] ZOL Genk Hosp, Dept Clin Biol, Genk, Belgium; [Van Hoof, Viviane] Antwerp Univ Hosp, Dept Clin Chem, Edegem, Belgium; [Verbakel, Jan] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford, England	Vaes, B (reprint author), Katholieke Univ Leuven, Dept Publ Hlth & Primary Care, B-3000 Leuven, Belgium.	bert.vaes@kuleuven.be	Verbakel, Jan/E-6758-2015; Bert, Vaes/I-6850-2019	Verbakel, Jan/0000-0002-7166-7211; Bert, Vaes/0000-0001-5244-1930; Penders, Joris/0000-0003-1877-6125			Alehagen U, 2008, EUR J HEART FAIL, V10, P260, DOI 10.1016/j.ejheart.2008.01.005; [Anonymous], 2016, Drug Ther Bull, V54, P117, DOI 10.1136/dtb.2016.10.0432; [Anonymous], 2002, FDA APPROVAL K022516; Camacho Ryan ORB, 2016, MONITORING POINT CAR; Collinson Paul O, 2006, Congest Heart Fail, V12, P103, DOI 10.1111/j.1527-5299.2006.04885.x; Fonseca C, 2004, EUR J HEART FAIL, V6, P795, DOI 10.1016/j.ejheart.2004.08.002; Fuat A, 2006, BRIT J GEN PRACT, V56, P327; Gils C, 2015, SCAND J CLIN LAB INV, V75, P602, DOI 10.3109/00365513.2015.1066846; Goode KM, 2008, INT J CARDIOL, V130, P426, DOI 10.1016/j.ijcard.2007.08.131; Hardy V, 2016, BMC FAM PRACT, V17, DOI 10.1186/s12875-016-0549-1; Hellinckx H, 2012, COST EFFECTIVENESS B; Howick J, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005611; Huddy JR, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009959; Jacobsen CE, 2013, REPORT EVALUATION SK; Larsson A, 2015, UPSALA J MED SCI, V120, P1, DOI 10.3109/03009734.2015.1006347; Mosterd A, 1999, EUR HEART J, V20, P447, DOI 10.1053/euhj.1998.1239; Mosterd A, 2007, HEART, V93, P1137, DOI 10.1136/hrt.2003.025270; NICE, 2014, PNEUM DIAGN MAN COMM, V191; Olofsson M, 2007, CARDIOLOGY, V107, P226, DOI 10.1159/000095422; Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128; Shephard Mark D S, 2006, Clin Biochem Rev, V27, P161; Shephard Mark D S, 2005, Rural Remote Health, V5, P371; Siebert U, 2006, AM J CARDIOL, V98, P800, DOI 10.1016/j.amjcard.2006.06.005; Tomonaga Y, 2011, BMC FAM PRACT, V12, DOI 10.1186/1471-2296-12-12; Twomey PJ, 2006, ANN CLIN BIOCHEM, V43, P124, DOI 10.1258/000456306776021616; Van Brabandt H, 2005, HET GEBRUIK NATRIURE; Verbakel JY, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0679-2; Weber M, 2006, HEART, V92, P843, DOI 10.1136/hrt.2005.071233; Zaphiriou A, 2005, EUR J HEART FAIL, V7, P537, DOI 10.1016/j.ejheart.2005.01.022	29	0	0	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUN	2018	71	6					539	545		10.1136/jclinpath-2017-204746			7	Pathology	Pathology	GH2OI	WOS:000433240800010	29263170				2019-10-28	
J	Yu, BH; Tang, SX; Xu, XL; Cheng, YF; Bi, R; Shui, RH; Tu, XY; Lu, HF; Zhou, XY; Yang, WT				Yu, Bao-Hua; Tang, Shao-Xian; Xu, Xiao-Li; Cheng, Yu-Fan; Bi, Rui; Shui, Ruo-Hong; Tu, Xiao-Yu; Lu, Hong-Fen; Zhou, Xiao-Yan; Yang, Wen-Tao			Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions	JOURNAL OF CLINICAL PATHOLOGY			English	Article						breast pathology; histopathology; immunohistochemistry	IN-SITU; CANCER; UPDATE	Aims To fully elucidate the clinicopathological features of breast carcinoma in sclerosing adenosis (SA-BC). Methods Clinical and histological characteristics of 206 SA-BCs from 180 patients were retrospectively evaluated. Immunohistochemical phenotype was examined. The clinicopathological relevance of the topographical pattern of SA-BCs was analysed. Results Overall, up to 46 patients (25.6%) had contralateral cancer, either SA associated or not. Of 99 cases who underwent core needle biopsy (CNB), 36 were underestimated as adenosis or atypical ductal hyperplasia at CNB, 5 invasive cases were misinterpreted as in situ carcinomas, whereas 4 ductal carcinoma in situ (DCIS) cases were overdiagnosed as invasive carcinoma. Microscopically, 163 tumours were in situ, including 136 DCIS, 19 lobular carcinomas in situ (LCIS) and 8 mixed DCIS/LCIS; of these carcinomas in situ (CIS), 37 had microinvasion. The DCIS group exhibited low, intermediate and high grades in 53.7%, 34.6% and 11.8% of cases, respectively, mostly with solid (43.4%) or cribriform (41.9%) pattern. Forty out of 43 invasive cases were invasive ductal carcinoma (IDC), mostly DCIS predominant. Immunophenotypically, luminal A phenotype was identified in 55.1%, 63.2% and 45.0% of DCIS, LCIS and IDC cases, respectively. Topographical type A group (carcinoma being entirely confined to SA, n=176) was characterised by smaller size, less invasiveness, lower grade and more frequency of luminal A immunophenotype compared with type B group ( 50% but not all of the carcinomatous lesion being located in SA, n=30) (all P<0.05). Conclusions CIS, especially non-high-grade DCIS, represents the most common variant of SA-BC, and luminal A is the most predominant immunophenotype. CNB assessment might be challenging in some SA-BCs. The topographical pattern has great clinicopathological relevance. Careful evaluation of the contralateral breast and long-term follow-up for patients with SA-BC is necessary given its high prevalence of bilaterality.	[Yu, Bao-Hua; Tang, Shao-Xian; Xu, Xiao-Li; Cheng, Yu-Fan; Bi, Rui; Shui, Ruo-Hong; Tu, Xiao-Yu; Lu, Hong-Fen; Zhou, Xiao-Yan; Yang, Wen-Tao] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Yu, Bao-Hua; Tang, Shao-Xian; Xu, Xiao-Li; Cheng, Yu-Fan; Bi, Rui; Shui, Ruo-Hong; Tu, Xiao-Yu; Lu, Hong-Fen; Zhou, Xiao-Yan; Yang, Wen-Tao] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China	Yang, WT (reprint author), Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.	yangwt2000@163.com			Science and Technology Commission of Shanghai MunicipalityScience & Technology Commission of Shanghai Municipality (STCSM) [15495810300]	This study was funded by Science and Technology Commission of Shanghai Municipality (15495810300).	Chen JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095185; Doyle EM, 2007, HISTOPATHOLOGY, V50, P607, DOI 10.1111/j.1365-2559.2007.02660.x; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; Gunhan-Bilgen I, 2002, EUR J RADIOL, V44, P232, DOI 10.1016/S0720-048X(02)00020-7; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; Hannemann J, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1613; Hicks DG, 2012, DIAGNOSTIC PATHOLOGY, P32; Jung WH, 2000, YONSEI MED J, V41, P293, DOI 10.3349/ymj.2000.41.2.293; Liu CJ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000402; Mardekian SK, 2016, HUM PATHOL, V49, P114, DOI 10.1016/j.humpath.2015.11.003; Moritani S, 2011, HISTOPATHOLOGY, V58, P835, DOI 10.1111/j.1365-2559.2011.03792.x; Muggerud AA, 2010, MOL ONCOL, V4, P357, DOI 10.1016/j.molonc.2010.06.007; OBERMAN HA, 1991, MODERN PATHOL, V4, P31; Ogura K, 2014, BREAST CANCER-TOKYO, V21, P732, DOI 10.1007/s12282-013-0450-x; Oiwa M, 2015, VIRCHOWS ARCH, V467, P71, DOI 10.1007/s00428-015-1769-9; Ross DS, 2013, ADV ANAT PATHOL, V20, P205, DOI 10.1097/PAP.0b013e3182976ed5; Simpson JF, 2012, WHO CLASSIFICATION T, P112; Tang P, 2016, ARCH PATHOL LAB MED, V140, P806, DOI 10.5858/arpa.2015-0133-RA; Visscher DW, 2014, BREAST CANCER RES TR, V144, P205, DOI 10.1007/s10549-014-2862-5; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Yoshida A, 2012, CLIN BREAST CANCER, V12, P398, DOI 10.1016/j.clbc.2012.08.002; Zhou WJ, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-512	22	0	1	2	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUN	2018	71	6					546	553		10.1136/jclinpath-2017-204751			8	Pathology	Pathology	GH2OI	WOS:000433240800011	29436376				2019-10-28	
J	Newby, RS; Dryden, M; Allan, RN; Salib, RJ				Newby, Rachel S.; Dryden, Matthew; Allan, Raymond N.; Salib, Rami J.			Antimicrobial activity of a novel bioengineered honey against non-typeable Haemophilus influenzae biofilms: an in vitro study	JOURNAL OF CLINICAL PATHOLOGY			English	Article						haemophilus spp; antimicrobial resistance; bacteriology; infection control	STREPTOCOCCUS-PNEUMONIAE; HYDROGEN-PEROXIDE; ENGINEERED HONEY; REACTIVE OXYGEN	The opportunistic pathogen non-typeable Haemophilus influenzae (NTHi) plays an important role in many chronic respiratory diseases including otitis media, chronic rhinosinusitis, cystic fibrosis and chronic obstructive pulmonary disease. Biofilm formation has been implicated in NTHi colonisation, persistence of infection and recalcitrance towards antimicrobials. There is therefore a pressing need for the development of novel treatment strategies that are effective against NTHi biofilm-associated diseases. SurgihoneyRO is a honey-based product that has been bioengineered to enable the slow release of H2O2, a reactive oxygen species to which H. influenzae is susceptible. Treatment of established NTHi biofilms with SurgihoneyRO significantly reduced biofilm viability through enhanced H2O2 production and was shown to be more effective than the conventional antibiotic co-amoxiclav.	[Newby, Rachel S.; Allan, Raymond N.] Univ Southampton, Clin & Expt Sci, Fac Med, Southampton, Hants, England; [Newby, Rachel S.; Allan, Raymond N.] Univ Southampton, Inst Life Sci, Southampton, Hants, England; [Dryden, Matthew] Hampshire Hosp NHS Fdn Trust, Winchester, Hants, England; [Dryden, Matthew; Salib, Rami J.] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England; [Allan, Raymond N.] Univ Hosp Southampton NHS Fdn Trust, Southampton NIHR Wellcome Trust Clin Res Facil, Southampton, Hants, England; [Salib, Rami J.] Univ Hosp Southampton NHS Fdn Trust, Southampton NIHR Resp Biomed Res Unit, Southampton, Hants, England	Salib, RJ (reprint author), Acad Unit Clin & Expt Sci, Fac Med, Southampton SO16 6YD, Hants, England.	R.J.Salib@soton.ac.uk	Allan, Raymond/K-2494-2017	Allan, Raymond/0000-0001-7764-4849; Salib, Rami/0000-0002-6753-7844			Allan RN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107015; Allegrucci M, 2006, J BACTERIOL, V188, P2325, DOI 10.1128/JB.188.7.2325-2335.2006; Cooke Jonathan, 2015, BMC Res Notes, V8, P20, DOI 10.1186/s13104-014-0960-4; Cope EK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028523; Dryden MS, 2017, J GLOB ANTIMICROB RE, V8, P186, DOI 10.1016/j.jgar.2016.12.006; Halstead FD, 2017, J WOUND CARE, V26, P442, DOI 10.12968/jowc.2017.26.8.442; Halstead FD, 2016, J WOUND CARE, V25, P93, DOI 10.12968/jowc.2016.25.2.93; Koo H, 2017, NAT REV MICROBIOL, V15, P740, DOI 10.1038/nrmicro.2017.99; Pericone CD, 2000, INFECT IMMUN, V68, P3990, DOI 10.1128/IAI.68.7.3990-3997.2000; Regev-Yochay G, 2006, J BACTERIOL, V188, P4996, DOI 10.1128/JB.00317-06; Stover CK, 2000, NATURE, V406, P959; Swords WE, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00097	12	2	2	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUN	2018	71	6					554	558		10.1136/jclinpath-2017-204901			5	Pathology	Pathology	GH2OI	WOS:000433240800012	29449345				2019-10-28	
J	Howie, HL; Wang, XH; Kapp, L; Lebedev, JN; Zimring, JC				Howie, Heather L.; Wang, Xiaohong; Kapp, Linda; Lebedev, Jenna N.; Zimring, James C.			Identification of IgG3-specific epitope that remedies problem in diagnostic IgG subclass determination due to human genetic variation	JOURNAL OF CLINICAL PATHOLOGY			English	Article						immunoglobulin; immunohistochemistry; antigenic epitopes	IMMUNOGLOBULIN G3; ALLOTYPES	There are four subtypes of human IgG with different effector functions. Quantifying the relative amount of each IgG subtype is important for laboratory diagnosis in multiple settings. However, in an evolving landscape of the appreciation of human variability and the need for precision/personalised laboratory diagnosis, it has also been shown that there are numerous natural variants of IgG subtypes, with at least 29 having been described. It has recently been reported that commercially available polyclonal antisera to IgG3 cross react with variants of other IgG subtypes, while available monoclonal anti-IgG3 have a blind-spot for the IgG3-04 variant. Herein, we report that IgG3-04 contains an epitope in common with all known IgG3 variants and absent in other subtypes. A novel monoclonal anti-IgG3 is described that is specific to IgG3 but without any blind-spots for known IgG3 variants, providing a remedy to the problem of genetic variability of IgG3.	[Howie, Heather L.; Wang, Xiaohong; Kapp, Linda; Lebedev, Jenna N.; Zimring, James C.] Bloodworks NW Res Inst, 1551 Eastlake Ave E, Seattle, WA 98102 USA; [Zimring, James C.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; [Zimring, James C.] Univ Washington, Div Hematol, Dept Internal Med, Seattle, WA 98195 USA	Zimring, JC (reprint author), Bloodworks NW Res Inst, 1551 Eastlake Ave E, Seattle, WA 98102 USA.	jzimring@bloodworksnw.org					Beck LH, 2015, KIDNEY INT, V87, P494, DOI 10.1038/ki.2014.367; Cao RY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064024; Cavacini LA, 2003, AIDS RES HUM RETROV, V19, P785, DOI 10.1089/088922203769232584; Chapuy-Regaud S, 2005, CLIN EXP IMMUNOL, V139, P542, DOI 10.1111/j.1365-2249.2004.02708.x; Dugoujon JM, 2004, AM J PHYS ANTHROPOL, V125, P175, DOI 10.1002/ajpa.10405; Einarsdottir H, 2014, TRANSFUSION, V54, P665, DOI 10.1111/trf.12334; Einarsdottir HK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108319; Howie HL, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94532; Howie HL, 2016, TRANSFUSION, V56, P2953, DOI 10.1111/trf.13812; Huijbers MG, 2015, EUR J NEUROL, V22, P1151, DOI 10.1111/ene.12758; MATHIESEN T, 1988, Clinical and Experimental Immunology, V72, P211; MICHAELSEN TE, 1987, CLIN EXP IMMUNOL, V67, P637; Outschoorn IM, 2011, AUTOIMMUNITY, V44, P195, DOI 10.3109/08916934.2010.515275; Parker AR, 2017, LAB MED, V48, P314, DOI 10.1093/labmed/lmx058; Recke A, 2010, J AUTOIMMUN, V34, P435, DOI 10.1016/j.jaut.2009.11.003; Scharf O, 2001, J VIROL, V75, P6558, DOI 10.1128/JVI.75.14.6558-6565.2001; Stiehm RE, 2007, ADV EXP MED BIOL, V601, P15; Tay MZ, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005817; Valenzuela NM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00433; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Zhao Y, 2009, ENCY MOL MECH DIS, P1913	21	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUN	2018	71	6					559	561		10.1136/jclinpath-2018-205001			3	Pathology	Pathology	GH2OI	WOS:000433240800013	29550761				2019-10-28	
J	Starling, C; Bhathal, PS; Quaglia, A				Starling, Chris; Bhathal, Prithi S.; Quaglia, Alberto			Do orcein-positive copper-binding protein deposits and cytokeratin 7 co-localise in periportal hepatocytes in chronic cholestasis?	JOURNAL OF CLINICAL PATHOLOGY			English	Letter						liver disease; biliary; liver			[Starling, Chris] Kings Coll Hosp NHS Fdn Trust, London, England; [Bhathal, Prithi S.] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia; [Quaglia, Alberto] Kings Coll Hosp London, Inst Liver Studies, London SE5 9RS, England	Quaglia, A (reprint author), Kings Coll Hosp London, Inst Liver Studies, London SE5 9RS, England.	alberto.quaglia@nhs.net					[Anonymous], 2015, SCHEUERS LIVER BIOPS; [Anonymous], 2017, MACSWEENS PATHOLOGY; Quaglia A, 2017, HISTOPATHOLOGY, V71, P1006, DOI 10.1111/his.13314	3	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUN	2018	71	6					563	564		10.1136/jclinpath-2018-205139			2	Pathology	Pathology	GH2OI	WOS:000433240800014	29559520				2019-10-28	
J	Ravella, L; Barritault, M; Bringuier, PP; Chalabreysse, L; Thivolet-Bejui, F; Maury, JM; Duruisseaux, M; Brevet, M				Ravella, Lucie; Barritault, Marc; Bringuier, Pierre-Paul; Chalabreysse, Lara; Thivolet-Bejui, Francoise; Maury, Jean-Michel; Duruisseaux, Michael; Brevet, Marie			Multiple lung carcinoma: Primary or intrapulmonary metastasis?	ANNALES DE PATHOLOGIE			French	Article						Multiple; Lung; Carcinoma; Primary; Metastasis	ADENOCARCINOMAS; TUMORS	Multiple lung carcinomas are 5 to 11,5% of lung carcinomas. The distinction between primary lung carcinomas from carcinomas with intrapulmonary metastasis is essential for optimal patient management. The histopathological analysis is very useful but it has to be completed by genotypic assessment using molecular biology (NGS). Molecular biology can also identify genetic alterations with therapeutic implications. We present the case of a patient with a history of surgery for multiple lung carcinomas diagnosed from 2013 to 2017. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Ravella, Lucie; Barritault, Marc; Bringuier, Pierre-Paul; Chalabreysse, Lara; Thivolet-Bejui, Francoise; Brevet, Marie] CHU Lyon, Multisites Hosp Civils Lyon, Serv Pathol, Site Est,59 Blvd Pinel, F-69677 Bron, France; [Ravella, Lucie; Barritault, Marc; Bringuier, Pierre-Paul; Chalabreysse, Lara; Thivolet-Bejui, Francoise; Maury, Jean-Michel; Duruisseaux, Michael; Brevet, Marie] Univ Lyon 1, F-69100 Villeurbanne, France; [Maury, Jean-Michel] CHU Lyon, Hosp Civils Lyon, Serv Chirurg Thorac, 59 Blvd Pinel, F-69677 Bron, France; [Duruisseaux, Michael] CHU Lyon, Hosp Civils Lyon, Serv Oncol Thorac, 59 Blvd Pinel, F-69677 Bron, France	Ravella, L (reprint author), Ctr Hosp Lyon Est, 59 Blvd Pinel, F-69677 Bron, France.	lucieravella@gmail.com	; Duruisseaux, Michael/D-8371-2017	BREVET, Marie/0000-0003-2275-691X; Duruisseaux, Michael/0000-0003-1495-0966; maury, jean-michel/0000-0002-3494-3678			Girard N, 2009, AM J SURG PATHOL, V33, P1752, DOI 10.1097/PAS.0b013e3181b8cf03; Girard N, 2009, CLIN CANCER RES, V15, P5184, DOI 10.1158/1078-0432.CCR-09-0594; MARTINI N, 1975, J THORAC CARDIOV SUR, V70, P606; Nicholson AG, 2018, J THORAC ONCOL, V13, P205, DOI 10.1016/j.jtho.2017.10.019; Saab J, 2017, TRANSL ONCOL, V10, P442, DOI 10.1016/j.tranon.2017.02.009; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Zhang JJ, 2014, SCIENCE, V346, P256, DOI 10.1126/science.1256930	7	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	JUN	2018	38	3					202	205		10.1016/j.annpat.2018.02.001			4	Pathology	Pathology	GO6EG	WOS:000440126300015	29555057				2019-10-28	
J	Himchak, E; Marks, E; Shi, Y; Wang, YH				Himchak, Evan; Marks, Etan; Shi, Yang; Wang, Yanhua			Did I Miss It? Discovering Hidden Coexisting Hematological Neoplasms: A Single Institutional Review of 100 Collision Tumors	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Review						collision tumor; carcinoma; sarcoma; lymphoma; leukemia	CELL LYMPHOMA; CARCINOMA; LEUKEMIA; ADENOCARCINOMA; MALIGNANCY; CANCERS; PATIENT; DISEASE; COLON	A collision tumor is defined as two histologically distinct tumor types identified at the same anatomic site. Hematolymphoid proliferative disorders (HLPDs), which coincide with non-hematological neoplasms, can mimic an immune response and can easily be overlooked as an immune reaction to a solid organ neoplasm, especially when low grade. In order to avoid a delay in the diagnosis of a HLPD during the workup for a non-hematological neoplasm, we identified a cohort of 100 cases with a HLPD diagnosis during the initial workup and treatment of a non-hematological neoplasm, or vice versa. Among the 100 collision tumors, the most common non-hematological neoplasms associated with a HLPD were from the colon (17%), breast (15%), and prostate (12%). The most commonly identified HLPDs were chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; 18%), diffuse large B-cell lymphoma (17%), follicular lymphoma (14%), marginal zone lymphoma (10%), acute myeloid leukemia (8%), and classical Hodgkin lymphoma (5%). Interestingly, in this cohort 5% of the low-grade HLPDs, all of them CLL/SLL, were missed at initial sign-out and subsequently required an addendum report. The other 95% of cases were reviewed or signed out by a hematopathologist before the report was finalized for the non-hematological neoplasm. In summary, high-grade hematological malignancies are less likely to be missed; however, low-grade coexisting HLPDs can be overlooked as a reactive immune response to a solid organ neoplasm. Therefore, it is important to keep in mind the existence of collision low-grade HLPDs before assuming the lymphoid infiltrates as an immunological response.	[Himchak, Evan; Marks, Etan; Shi, Yang; Wang, Yanhua] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA	Wang, YH (reprint author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Pathol, 111 E 210th St, Bronx, NY 10467 USA.	ywang@Montefiore.org	Marks, Etan/M-5056-2019	Marks, Etan/0000-0002-4601-0285; Wang, Yanhua/0000-0002-7946-2843			Barroeta JE, 2007, DIAGN CYTOPATHOL, V35, P293, DOI 10.1002/dc.20616; Boissiere-Michot F, 2016, VIRCHOWS ARCH, V469, P135, DOI 10.1007/s00428-016-1958-1; Bosman FT, 2010, WHO CLASSIFICATION T; CORNES JS, 1960, J CLIN PATHOL, V13, P483, DOI 10.1136/jcp.13.6.483; Di Napoli A, 2015, INT J SURG PATHOL, V23, P419, DOI 10.1177/1066896915582263; Dong C, 2001, BRIT J CANCER, V85, P997, DOI 10.1054/bjoc.2001.1998; Kus T, 2016, ONCOL LETT, V11, P2801, DOI 10.3892/ol.2016.4310; Lin HH, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-147; Mashiah A, 2008, ACTA HAEMATOL-BASEL, V119, P142, DOI 10.1159/000125551; McKenna DB, 2000, BRIT J DERMATOL, V143, P171, DOI 10.1046/j.1365-2133.2000.03610.x; MOERTEL CG, 1957, BLOOD, V12, P788, DOI 10.1182/blood.V12.9.788.788; Pandey U, 2003, J CLIN PATHOL, V56, P970, DOI 10.1136/jcp.56.12.970; Quigley DA, 2015, MOL ONCOL, V9, P2054, DOI 10.1016/j.molonc.2015.10.003; Radman I, 2005, DIAGN CYTOPATHOL, V32, P97, DOI 10.1002/dc.20176; Schwock J., 2012, PATHOLOG RES INT, V2012; Swerdlow SH, 2017, WHO CLASSIFICATION T; Tseng CE, 2013, WORLD J GASTROENTERO, V19, P1850, DOI 10.3748/wjg.v19.i11.1850; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; WHIPHAM T, 1878, T PATHOL SOC LOND, V29, P313	19	1	1	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	JUN	2018	26	4					296	305		10.1177/1066896917752862			10	Pathology; Surgery	Pathology; Surgery	GF9BK	WOS:000432270900001	29320898				2019-10-28	
J	Bassiouny, D; Ismiil, N; Dube, V; Han, GM; Cesari, M; Lu, FI; Slodkowska, E; Parra-Herran, C; Chiu, HF; Naeim, M; Li, N; Khalifa, M; Nofech-Mozes, S				Bassiouny, Dina; Ismiil, Nadia; Dube, Valerie; Han, Guangming; Cesari, Matthew; Lu, Fang-I; Slodkowska, Elzbieta; Parra-Herran, Carlos; Chiu, Hak Fai; Naeim, Magda; Li, Nim; Khalifa, Mahmoud; Nofech-Mozes, Sharon			Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						ovarian cancer; mucinous; immunohistochemistry; SATB2; HER2; PAX8; napsin A; HNFlb	LYMPH-NODE METASTASIS; CLEAR-CELL CARCINOMA; DIFFERENTIAL-DIAGNOSIS; ENDOMETRIOID CARCINOMA; TUMOR-SUPPRESSOR; SATB2 EXPRESSION; LYNCH SYNDROME; BREAST-CANCER; ARID1A; ADENOCARCINOMA	The distinction of primary mucinous ovarian carcinoma (PMOC) from other primaries or secondaries is essential for selecting therapeutic options and prognostication. We aimed to characterize the immunohistochemical profile of 36 PMOCs using an extended immunohistochemical panel, with clinicopathologic features and outcome. PAX8 was negative in 30 (83.3%), and SATB2 was negative in 32/35. HNF1B, AMACR, and napsin-A were detected in 33 (91.7%), 35 (97.2%), and 0 (0%), respectively. MMR proteins and ARID1A were retained in 100%; PTEN was lost in 4 (11.1%). P53 was aberrant in 10 (27.8%); none overexpressed p16. HER2 was positive in 6/35 (17.1%). Most PMOCs had a favorable outcome. However, recurrence is usually fatal. The typical tumor profile was CK7+, CK20+/-, CDX2+/-, PAX8-, ER-, PgR-, and SATB2-. HER2 positivity suggests a possible target for therapy in advanced disease.	[Bassiouny, Dina; Ismiil, Nadia; Dube, Valerie; Han, Guangming; Cesari, Matthew; Lu, Fang-I; Slodkowska, Elzbieta; Parra-Herran, Carlos; Chiu, Hak Fai; Naeim, Magda; Li, Nim; Khalifa, Mahmoud; Nofech-Mozes, Sharon] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [Bassiouny, Dina; Ismiil, Nadia; Dube, Valerie; Han, Guangming; Cesari, Matthew; Lu, Fang-I; Slodkowska, Elzbieta; Parra-Herran, Carlos; Khalifa, Mahmoud; Nofech-Mozes, Sharon] Univ Toronto, Toronto, ON, Canada; [Bassiouny, Dina] Mansoura Univ, Mansoura, Egypt	Nofech-Mozes, S (reprint author), Sunnybrook Hlth Sci Ctr, Dept Pathol, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	Sharon.nofech-mozes@Sunnybrook.ca		Bassiouny, Dina/0000-0003-1446-2348; Parra-Herran, Carlos/0000-0003-1420-7291	Ontario Institute for Cancer Research through the Government of Ontario	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was conducted with the support of the Ontario Institute for Cancer Research through funding provided by the Government of Ontario.	Anglesio MS, 2013, J PATHOL, V229, P111, DOI 10.1002/path.4088; Cao DF, 2005, INT J GYNECOL PATHOL, V24, P67, DOI 10.1097/01.pgp.0000139648.17750.35; Carleton C, 2016, AM J SURG PATHOL, V40, P636, DOI 10.1097/PAS.0000000000000578; Cathro HP, 2002, AM J CLIN PATHOL, V117, P944, DOI 10.1309/2T1Y-7BB7-DAPE-PQ6L; Chao WR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142135; Chu PG, 2005, AM J SURG PATHOL, V29, P359, DOI 10.1097/01.pas.0000149708.12335.6a; Djordjeyic B, 2012, MODERN PATHOL, V25, P699, DOI 10.1038/modpathol.2011.208; Domanska K, 2007, INT J GYNECOL CANCER, V17, P789, DOI 10.1111/j.1525-1438.2007.00875.x; Elebro J, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0289-8; Guan B, 2011, CANCER RES, V71, P6718, DOI 10.1158/0008-5472.CAN-11-1562; Guan B, 2011, AM J SURG PATHOL, V35, P625, DOI 10.1097/PAS.0b013e318212782a; Huang J, 2012, NAT GENET, V44, P1117, DOI 10.1038/ng.2391; Human Protein Atlas SATB2, SATB2; Jones S, 2012, HUM MUTAT, V33, P100, DOI 10.1002/humu.21633; Kalloger SE, 2011, MODERN PATHOL, V24, P512, DOI 10.1038/modpathol.2010.215; Katagiri A, 2012, MODERN PATHOL, V25, P282, DOI 10.1038/modpathol.2011.161; Kikkawa F, 2006, GYNECOL ONCOL, V103, P171, DOI 10.1016/j.ygyno.2006.02.015; Kobel M, 2016, J PATHOL CLIN RES, V2, P247, DOI 10.1002/cjp2.53; Kobel M, 2016, INT J GYNECOL PATHOL, V35, P430, DOI 10.1097/PGP.0000000000000274; Kobel M, 2010, INT J GYNECOL PATHOL, V29, P203, DOI 10.1097/PGP.0b013e3181c042b6; Kolasa IK, 2006, GYNECOL ONCOL, V103, P692, DOI 10.1016/j.ygyno.2006.05.007; Kunz PL, 2012, APPL IMMUNOHISTO M M, V20, P13, DOI 10.1097/PAI.0b013e31821c821c; Kurose K, 2001, AM J PATHOL, V158, P2097, DOI 10.1016/S0002-9440(10)64681-0; Laury AR, 2011, AM J SURG PATHOL, V35, P816, DOI 10.1097/PAS.0b013e318216c112; Lu FI, 2012, INT J GYNECOL PATHOL, V31, P524, DOI 10.1097/PGP.0b013e31824fe2aa; Maeda D, 2013, ADV ANAT PATHOL, V20, P45, DOI 10.1097/PAP.0b013e31827bc24d; Maeda D, 2010, INT J MOL SCI, V11, P5121, DOI 10.3390/ijms11125120; Magnusson K, 2011, AM J SURG PATHOL, V35, P937, DOI 10.1097/PAS.0b013e31821c3dae; Mamo A, 2012, ONCOGENE, V31, P2090, DOI 10.1038/onc.2011.386; Massad LS, 2016, GYNECOL OBSTET INVES, V81, P411, DOI 10.1159/000441791; McAlpine JN, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-433; Moh M, 2016, AM J SURG PATHOL, V40, P419, DOI 10.1097/PAS.0000000000000553; Nafisi H, 2015, INT J GYNECOL PATHOL, V34, P424, DOI 10.1097/PGP.0000000000000179; Montiel DP, 2015, ANN DIAGN PATHOL, V19, P249, DOI 10.1016/j.anndiagpath.2015.05.004; Powless CA, 2011, GYNECOL ONCOL, V122, P536, DOI 10.1016/j.ygyno.2011.05.001; Rambau P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030515; Rambau PF, 2016, HISTOPATHOLOGY, V69, P288, DOI 10.1111/his.12934; RUTGERS JL, 1988, CANCER-AM CANCER SOC, V61, P340, DOI 10.1002/1097-0142(19880115)61:2<340::AID-CNCR2820610225>3.0.CO;2-U; Samartzis EP, 2012, MODERN PATHOL, V25, P885, DOI 10.1038/modpathol.2011.217; Schmeler KM, 2010, OBSTET GYNECOL, V116, P269, DOI 10.1097/AOG.0b013e3181e7961d; Silverberg SG, 2000, INT J GYNECOL PATHOL, V19, P7, DOI 10.1097/00004347-200001000-00003; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Strickland S, 2016, HISTOPATHOLOGY, V68, P977, DOI 10.1111/his.12899; Strickland S, 2016, INT J GYNECOL PATHOL, V35, P191, DOI 10.1097/PGP.0000000000000238; Tabrizi AD, 2010, INT J GYNECOL PATHOL, V29, P99, DOI 10.1097/PGP.0b013e3181bbbcc1; UEDA G, 1993, GYNECOL ONCOL, V51, P219, DOI 10.1006/gyno.1993.1276; Vang R, 2006, MODERN PATHOL, V19, P1421, DOI 10.1038/modpathol.3800698; Vierkoetter KR, 2014, GYNECOL ONCOL, V135, P81, DOI 10.1016/j.ygyno.2014.07.100; Watson P, 2001, GYNECOL ONCOL, V82, P223, DOI 10.1006/gyno.2001.6279; Werling RW, 2003, AM J SURG PATHOL, V27, P303, DOI 10.1097/00000478-200303000-00003; Wilsker D, 2005, GENOMICS, V86, P242, DOI 10.1016/j.ygeno.2005.03.013; Yamamoto S, 2012, MODERN PATHOL, V25, P615, DOI 10.1038/modpathol.2011.189; Yan XJ, 2006, GYNECOL ONCOL, V102, P348, DOI 10.1016/j.ygyno.2005.12.033; Zaino RJ, 2011, CANCER-AM CANCER SOC, V117, P554, DOI 10.1002/cncr.25460; Zhai QH, 2008, INT J CLIN EXP PATHO, V1, P502	55	2	2	1	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	JUN	2018	26	4					306	317		10.1177/1066896917752861			12	Pathology; Surgery	Pathology; Surgery	GF9BK	WOS:000432270900002	29338553				2019-10-28	
J	Ekinci, O; Ogut, B; Celik, B; Dursun, A				Ekinci, Ozgur; Ogut, Betul; Celik, Bulent; Dursun, Ayse			Compared With Elastin Stains, h-Caldesmon and Desmin Offer Superior Detection of Vessel Invasion in Gastric, Pancreatic, and Colorectal Adenocarcinomas	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						vessel invasion; h-caldesmon; elastin; gastric cancer; colorectal cancer; pancreatic cancer	LYMPHOVASCULAR INVASION; MONOCLONAL-ANTIBODY; VASCULAR INVASION; VENOUS INVASION; BREAST-CANCER; CARCINOMA; MARKERS; D2-40; BLOOD; RELEVANCE	Background. The presence of vessel invasion is considered indicative of a poor prognosis in many malignant tumors. We aimed to compare the sensitivity of elastin stains (van Gieson's and orcein methods) with 2 smooth muscle markers (h-caldesmon and desmin) in gastric, pancreatic, and colorectal adenocarcinoma specimens. Materials and Methods. We used 27 (29.3%) gastric, 35 (38.0%) pancreatic, and 30 (32.6%) colorectal resection specimens. We applied a provisional classification of vessel invasion patterns: type A, a focus with a nearby artery unaccompanied by a vein; type T, a focus at the invasive front without an unaccompanied artery; and type X, foci that only appeared by any of the 4 stains used. Results. There were 369 foci. The smooth muscle markers were more sensitive than the elastin stains, and h-caldesmon more sensitive than desmin, in all types. Among the 139 type A foci, 33 (23.7%) were positive by desmin and h-caldesmon, whereas the elastin stains were not (P = .001). h-Caldesmon was the only positive marker in 11 (7.9%; P = .011). Among the 78 type T foci, 21 (26.9%) were positive by desmin and h-caldesmon, when both elastin stains were negative (P = .000). In 16 (20.5%) foci, h-caldesmon was the only positive marker (P = .002). Among 152 type X foci, 91 (59.9%) were positive by all markers, 26 (17.1%) by both desmin and h-caldesmon, and 9 (5.9%) by only the 2 elastin stains (P = .001). Conclusion. We recommend these stains for suspect foci in gastric, pancreatic, and colorectal adenocarcinoma specimens. They might highlight both predictable and unpredictable foci.	[Ekinci, Ozgur; Ogut, Betul; Celik, Bulent; Dursun, Ayse] Gazi Univ, Ankara, Turkey	Ekinci, O (reprint author), Gazi Univ, Sch Med, Dept Med Pathol, TR-06500 Ankara, Turkey.	ozzyekinci@hotmail.com	Celik, Bulent/A-7793-2017; Ekinci, Ozgur/I-2727-2018	Celik, Bulent/0000-0002-0481-4808; Ekinci, Ozgur/0000-0003-0364-1316			Afonso J, 2009, HISTOPATHOLOGY, V55, P514, DOI 10.1111/j.1365-2559.2009.03425.x; Arkill KP, 2010, J ANAT, V216, P547, DOI 10.1111/j.1469-7580.2010.01215.x; Arnaout-Alkarain A, 2007, MODERN PATHOL, V20, P183, DOI 10.1038/modpathol.3800728; Barresi V, 2012, AM J SURG PATHOL, V36, P66, DOI 10.1097/PAS.0b013e31822d3008; Bridenbaugh Eric A, 2003, Lymphat Res Biol, V1, P147, DOI 10.1089/153968503321642633; Compton CC, 2003, MODERN PATHOL, V16, P376, DOI 10.1097/01.MP.0000062859.46942.93; Dawson H, 2015, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00354; Gresta LT, 2013, WORLD J GASTROENTERO, V19, P3761, DOI 10.3748/wjg.v19.i24.3761; Grin A, 2013, HUM PATHOL, V44, P2696, DOI 10.1016/j.humpath.2013.07.013; Imamura Y, 2012, J SURG ONCOL, V105, P277, DOI 10.1002/jso.22079; Kim JH, 2010, J SURG RES, V162, P177, DOI 10.1016/j.jss.2009.07.015; King JE, 2006, HISTOPATHOLOGY, V48, P223, DOI 10.1111/j.1365-2559.2005.02331.x; Klimstra DS, 2012, HISTOLOGY PATHOLOGIS, P790; Messenger DE, 2012, HUM PATHOL, V43, P965, DOI 10.1016/j.humpath.2011.11.015; Mohammed RAA, 2007, AM J SURG PATHOL, V31, P1825, DOI 10.1097/PAS.0b013e31806841f6; Muthuchamy M, 2008, ANN NY ACAD SCI, V1131, P89, DOI 10.1196/annals.1413.008; Perry C, 2015, DIS ESOPHAGUS, V28, P262, DOI 10.1111/dote.12190; Poggi P, 1995, LYMPHOLOGY, V28, P189; Roberts JA, 2014, INT J CLIN EXP PATHO, V7, P792; Rose AE, 2011, AM J SURG PATHOL, V35, P1441, DOI 10.1097/PAS.0b013e31822573f5; Sacchi G., 1999, Journal of Submicroscopic Cytology and Pathology, V31, P515; Stewart CJR, 2012, PATHOLOGY, V44, P48, DOI 10.1097/PAT.0b013e32834e426d; Van den Eynden GG, 2006, BRIT J CANCER, V94, P1643, DOI 10.1038/sj.bjc.6603152; von der Weid PY, 2004, INT J BIOCHEM CELL B, V36, P1147, DOI 10.1016/j.biocel.2003.12.008; Yonemura Y, 2006, HUM PATHOL, V37, P1193, DOI 10.1016/j.humpath.2006.04.014; Zawieja David C., 2009, Lymphatic Research and Biology, V7, P87, DOI 10.1089/lrb.2009.0007	26	0	0	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	JUN	2018	26	4					318	326		10.1177/1066896917752442			9	Pathology; Surgery	Pathology; Surgery	GF9BK	WOS:000432270900003	29325463				2019-10-28	
J	Cox, HY; Cracchiolo, B; Galan, M; Heller, D				Cox, Hecca Y.; Cracchiolo, Bernadette; Galan, Mark; Heller, Debra			Pitfalls of Frozen Section in Gynecological Pathology: A Case of Endometrial Tumor With Sex Cord-Like Elements	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						endometrium; endometrial stromal sarcoma; sex cord-like elements; frozen section; pathology	HYBRIDIZATION; RECURRENCE	Endometrial stromal tumor with sex cord-like elements (ESTSCLE) is a rare entity that shares similar histological features with uterine tumors resembling ovarian sex cord tumors (UTROSCT). Differentiating the 2 entities involves ample sampling of the tissue to distinguish the percentage of sex cord components within the tissue, genetic studies, and immunohistochemical staining. Frozen section provides limited information for exclusion of either tumor; and the tumor is rare enough that the diagnosis may not be considered with the limited sampling; therefore, deferral of diagnosis to permanent sections may be appropriate.	[Cox, Hecca Y.; Cracchiolo, Bernadette; Galan, Mark; Heller, Debra] Rutgers New Jersey Med Sch, Newark, NJ USA	Cox, HY (reprint author), Rutgers New Jersey Med Sch, Dept Pathol, UH E161,185 South Orange Ave, Newark, NJ 07103 USA.	hc712@njms.rutgers.edu		Cox, Hecca/0000-0003-3324-4522			Blake EA, 2014, EUR J OBSTET GYN R B, V181, P163, DOI 10.1016/j.ejogrb.2014.07.050; CLEMENT PB, 1976, AM J CLIN PATHOL, V66, P512; Flicker K, 2015, EXP MOL PATHOL, V98, P367, DOI 10.1016/j.yexmp.2015.03.009; Hodge JC, 2016, J MOL DIAGN, V18, P516, DOI 10.1016/j.jmoldx.2016.02.001; Leiser AL, 2004, GYNECOL ONCOL, V94, P567, DOI 10.1016/j.ygyno.2004.03.025; McCluggage WG, 1999, HISTOPATHOLOGY, V34, P374; Schraag SM, 2017, GYNECOL ONCOL REP, V19, P53, DOI 10.1016/j.gore.2017.01.004	7	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	JUN	2018	26	4					327	329		10.1177/1066896917749041			3	Pathology; Surgery	Pathology; Surgery	GF9BK	WOS:000432270900004	29488417				2019-10-28	
J	Sweeney, J; Skovgard, M; Hoda, S				Sweeney, Jacob; Skovgard, Matthew; Hoda, Syed			Iatrogenic Breast Infarct Following Coronary Artery Bypass Graft Surgery With Harvesting of Left Internal Mammary Artery	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article									[Sweeney, Jacob; Skovgard, Matthew; Hoda, Syed] Weill Cornell, 525 East 68th St,Starr 1031c, New York, NY 10065 USA	Hoda, S (reprint author), Weill Cornell, 525 East 68th St,Starr 1031c, New York, NY 10065 USA.	sahoda@med.cornell.edu					Bintoudi A, 2011, BREAST J, V17, P83, DOI 10.1111/j.1524-4741.2010.01016.x; Cathenis K, 2011, ANN THORAC SURG, V91, P1603, DOI 10.1016/j.athoracsur.2010.10.088; Gonyon DL, 2005, ANN PLAS SURG, V54, P88, DOI 10.1097/01.sap.0000141597.38288.3c; Hoda SA., 2014, ROSENS BREAST PATHOL, P39; Otsuka F, 2013, ANN CARDIOTHORAC SUR, V2, P519, DOI 10.3978/j.issn.2225-319X.2013.07.06; Rashid A, 2004, BRIT J PLAST SURG, V57, P366, DOI 10.1016/j.bjps.2004.01.006; Rosato F, 2006, BREAST J, V12, P485, DOI 10.1111/j.1075-122X.2006.00308.x; Walker ME, 2014, EUR J PLAST SURG, V37, P109, DOI 10.1007/s00238-013-0885-5; Wong MS, 2008, ANN PLAS SURG, V61, P368, DOI 10.1097/SAP.0b013e3181640851	9	0	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	JUN	2018	26	4					330	331		10.1177/1066896917735896			2	Pathology; Surgery	Pathology; Surgery	GF9BK	WOS:000432270900005	29022414				2019-10-28	
J	Rakheja, D; Seaward, JR; Timmons, CF				Rakheja, Dinesh; Seaward, James R.; Timmons, Charles F.			Low-Grade Fibromyxoid Sarcoma With Striking Zonation	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article							GENE		[Rakheja, Dinesh; Seaward, James R.; Timmons, Charles F.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA; [Rakheja, Dinesh; Seaward, James R.; Timmons, Charles F.] Childrens Hlth, Dallas, TX USA	Rakheja, D (reprint author), Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	dinesh.rakheja@utsouthwestern.edu		Rakheja, Dinesh/0000-0001-6888-7902			Evans HL, 2011, AM J SURG PATHOL, V35, P1450, DOI 10.1097/PAS.0b013e31822b3687; EVANS HL, 1987, AM J CLIN PATHOL, V88, P615, DOI 10.1093/ajcp/88.5.615; EVANS HL, 1993, AM J SURG PATHOL, V17, P595, DOI 10.1097/00000478-199306000-00007; Lau PPL, 2013, AM J SURG PATHOL, V37, P734, DOI 10.1097/PAS.0b013e31827560f8; Mertens F, 2005, LAB INVEST, V85, P408, DOI 10.1038/labinvest.3700230; Mohamed M, 2017, ANN DIAGN PATHOL, V28, P60, DOI 10.1016/j.anndiagpath.2017.04.001; Panagopoulos L, 2004, GENE CHROMOSOME CANC, V40, P218, DOI 10.1002/gcc.20037	7	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	JUN	2018	26	4					332	333		10.1177/1066896917742724			2	Pathology; Surgery	Pathology; Surgery	GF9BK	WOS:000432270900006	29212404				2019-10-28	
J	Zanelli, M; Mengoli, MC; Puma, F; Spaggiari, L; Lococo, F; De Marco, L; Ascani, S				Zanelli, Magda; Mengoli, Maria Cecilia; Puma, Francesco; Spaggiari, Lucia; Lococo, Filippo; De Marco, Loredana; Ascani, Stefano			Diffuse Alveolar-Septal Amyloidosis Associated With Multiple Myeloma	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article									[Zanelli, Magda; Mengoli, Maria Cecilia; Spaggiari, Lucia; Lococo, Filippo; De Marco, Loredana] Arcispedale Santa Maria Nuova IRCCS Reggio Emilia, Reggio Emilia, Italy; [Puma, Francesco; Ascani, Stefano] Univ Perugia, Perugia, Italy	Mengoli, MC (reprint author), Arcispedale Santa Maria Nuova IRCCS Reggio Emilia, Pathol Unit, Viale Risorgimento 80, I-42100 Reggio Emilia, Italy.	cecilia.mengoli@gmail.com		Mengoli, Maria Cecilia/0000-0002-1437-8747; zanelli, Magda/0000-0002-8733-9933			de Almeida RR, 2015, LUNG, V193, P875, DOI 10.1007/s00408-015-9791-x; Khoor A, 2017, ARCH PATHOL LAB MED, V141, P247, DOI 10.5858/arpa.2016-0102-RA; Nomenclature of amyloid and amyloidosis, 1993, B WORLD HEALTH ORGAN, V71, P105	3	0	0	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	JUN	2018	26	4					334	335		10.1177/1066896917742200			2	Pathology; Surgery	Pathology; Surgery	GF9BK	WOS:000432270900007	29183204				2019-10-28	
J	Wang, RQ; Nie, L				Wang, Renqing; Nie, Ling			Mixed Type A Thymoma and Micronodular Thymoma With Lymphoid Stroma	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article							HYPERPLASIA		[Wang, Renqing; Nie, Ling] Nanjing Univ, Affiliated Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China	Nie, L (reprint author), Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Pathol, Nanjing 210008, Jiangsu, Peoples R China.	nielingnjuer@126.com					Cha YJ, 2015, J PATHOL TRANSL MED, V49, P75, DOI 10.4132/jptm.2014.10.27; de Montpreville VT, 2002, ANN PATHOL, V22, P177; Ishikawa Y, 2015, HISTOPATHOLOGY, V66, P300, DOI 10.1111/his.12428; Mende S, 2004, VIRCHOWS ARCH, V444, P397, DOI 10.1007/s00428-003-0961-5; Mneimneh WS, 2015, MODERN PATHOL, V28, P1415, DOI 10.1038/modpathol.2015.104; Strobel P, 2005, J PATHOL, V207, P72, DOI 10.1002/path.1808; Suster S, 1999, AM J SURG PATHOL, V23, P955, DOI 10.1097/00000478-199908000-00014	7	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	JUN	2018	26	4					336	337		10.1177/1066896917742723			2	Pathology; Surgery	Pathology; Surgery	GF9BK	WOS:000432270900008	29161955				2019-10-28	
J	Shivane, A; Pearce, A; Khatib, N; Smith, MEF				Shivane, Aditya; Pearce, Amy; Khatib, Nadia; Smith, Mark E. F.			EBV+ HHV-8+Multicentric Castleman Disease With Plasmablastic Aggregates in an HIV plus Man: An Evolving Clinicopathologic Entity	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						multicentric Castleman disease; plasmablastic aggregates; HIV; HHV-8; EBV	SARCOMA-ASSOCIATED HERPESVIRUS; LYMPHOPROLIFERATIVE DISORDERS; LYMPHOMA; SPECTRUM	We report a case of EBV+ and HHV-8+ multicentric Castleman disease with plasmablastic aggregates in an HIV-positive individual. A 41-year-old man presented in early 2015 with fevers, sweats, weight loss, intractable itching, and on subsequent testing was found to be HIV positive. Investigations showed cervical lymphadenopathy and splenomegaly. He was treated for HIV and his symptoms resolved. His symptoms recurred in January 2016, and a provisional diagnosis of multicentric Castleman disease was entertained. The HHV-8 (human herpesvirus-8) and EBV (Epstein-Barr virus) viral load was elevated. A left supraclavicular lymph node core biopsy was performed, which showed features of multicentric Castleman disease with plasmablastic aggregates that are EBV (EBER) and HHV-8 positive. He responded well to rituximab treatment and remains well with no symptoms at recent follow-up.	[Shivane, Aditya; Smith, Mark E. F.] Derriford Hosp, Plymouth, Devon, England; [Pearce, Amy] Royal Cornwall Hosp, Truro, England; [Khatib, Nadia] Torbay Hosp, Torquay, England	Shivane, A (reprint author), Derriford Hosp, Dept Cellular & Anat Pathol, Level 4,Derriford Rd, Plymouth PL6 8DH, Devon, England.	aditya.shivane@nhs.net					Cesarman E, 1997, SEMIN DIAGN PATHOL, V14, P54; Du MQ, 2001, BLOOD, V97, P2130, DOI 10.1182/blood.V97.7.2130; Du MQ, 2002, BLOOD, V100, P3415, DOI 10.1182/blood-2002-02-0487; Dupin N, 2000, BLOOD, V95, P1406, DOI 10.1182/blood.V95.4.1406.004k26_1406_1412; Md AC, 2017, AM J CLIN PATHOL, V147, P171, DOI 10.1093/ajcp/aqw218; Seliem RM, 2007, AM J SURG PATHOL, V31, P1439, DOI 10.1097/PAS.0b013e31804d43d8	6	2	2	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	JUN	2018	26	4					338	341		10.1177/1066896917745584			4	Pathology; Surgery	Pathology; Surgery	GF9BK	WOS:000432270900009	29198143				2019-10-28	
J	Nguyen, S; Perron, M; Nadeau, S; Odashiro, AN; Corriveau, MN				Nguyen, Sally; Perron, Marjorie; Nadeau, Sylvie; Odashiro, Alexandre Nakao; Corriveau, Marie-Noelle			Epithelial Myoepithelial Carcinoma of the Nasal Cavity: Clinical, Histopathological, and Immunohistochemical Distinction of a Case Report	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						epithelial myoepithelial carcinoma; oncocytoma; salivary gland tumors; nasal cavity; immunohistochemistry	SALIVARY-GLANDS	Background. Epithelial myoepithelial carcinomas (EMCs) are rare low-grade salivary gland tumors. Here, we report the case of a 75-year-old man presenting with an oncocytic variant of EMC of the nasal cavity, initially diagnosed as an oncocytoma. Methods. Our patient underwent functional sinus surgery in 2012. On pathology, an oncocytic neoplasm was found in the right nasal cavity, characterized by fragments of uniform bland oncocytic cells with bilayered arrangement of nuclei. Immunohistochemical stains demonstrated biphasic cells: luminal epithelial and basal cell-type myoepithelial cells. The tumor was best diagnosed as an oncocytoma. In 2015, the patient presented with a recurrent right inferior turbinate lesion, compatible with oncocytic EMC. Results. The patient underwent oncological surgery and received adjuvant radiotherapy. He had no disease recurrence. Conclusion. Different variants of EMCs exist, such as oncocytic EMC. EMCs should be treated aggressively because they can be locally invasive, recur, and give rise to distant metastases.	[Nguyen, Sally; Perron, Marjorie; Nadeau, Sylvie; Odashiro, Alexandre Nakao; Corriveau, Marie-Noelle] Laval Univ, Quebec City, PQ, Canada; [Nadeau, Sylvie; Odashiro, Alexandre Nakao; Corriveau, Marie-Noelle] CHU Quebec, Quebec City, PQ, Canada	Nguyen, S (reprint author), Univ Laval, Fac Med, Dept Ophthalmol & Otolaryngol Head & Neck Surg, 1050 Ave Med,Local 4889, Quebec City, PQ G1V 0A6, Canada.	sally.nguyen.1@ulaval.ca					Arora S. K., 2013, ISRN PEDIAT, V2013, P1; CHO KJ, 1995, AM J CLIN PATHOL, V103, P432; DONATH K, 1972, VIRCHOWS ARCH A, V356, P16, DOI 10.1007/BF00543554; Flam JO, 2015, ALLERGY RHINOL, V6, pE133, DOI 10.2500/ar.2015.6.0127; Guan M, 2014, ONCOL LETT, V7, P1978, DOI 10.3892/ol.2014.2024; Harada H, 1996, J LARYNGOL OTOL, V110, P397, DOI 10.1017/S0022215100133754; Imate Y, 2000, ORL-J OTO-RHIN-LARYN, V62, P282, DOI 10.1159/000027761; Jin XL, 1999, PATHOLOGY, V31, P148, DOI 10.1080/003130299105340; Kim SH, 2015, ONCOL LETT, V10, P927, DOI 10.3892/ol.2015.3314; Kong SK, 2008, OTOLARYNG HEAD NECK, V139, P598, DOI 10.1016/j.otohns.2008.04.024; Konoglou M, 2014, J THORAC DIS, V6, pS194, DOI 10.3978/j.issn.2072-1439.2013.11.17; Lee HM, 2000, EUR ARCH OTO-RHINO-L, V257, P376, DOI 10.1007/s004050000250; Lee Jae-Wook, 2012, Korean J Audiol, V16, P148, DOI 10.7874/kja.2012.16.3.148; M'sakni I, 2007, Ann Otolaryngol Chir Cervicofac, V124, P228, DOI 10.1016/j.aorl.2007.04.006; Morresi-Hauf AT, 2013, PATHOLOGE, V34, P56, DOI 10.1007/s00292-012-1610-z; Park JO, 2011, J LARYNGOL OTOL, V125, P1286, DOI 10.1017/S0022215111002222; Patra SK, 2012, LARYNGOSCOPE, V122, P1579, DOI 10.1002/lary.23310; Seethala RR, 2013, HEAD NECK PATHOL, V7, pS77, DOI 10.1007/s12105-013-0461-0; SEIFERT G, 1992, CANCER-AM CANCER SOC, V70, P379, DOI 10.1002/1097-0142(19920715)70:2<379::AID-CNCR2820700202>3.0.CO;2-C; SIMPSON RHW, 1991, J CLIN PATHOL, V44, P419, DOI 10.1136/jcp.44.5.419; Singh G, 2012, ANN DIAGN PATHOL, V16, P292, DOI 10.1016/j.anndiagpath.2011.02.004; Turner JH, 2012, HEAD NECK-J SCI SPEC, V34, P877, DOI 10.1002/hed.21830; Yamanegi K, 2008, AURIS NASUS LARYNX, V35, P408, DOI 10.1016/j.anl.2007.10.001; Ye Zhiteng, 2012, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V26, P1092; 정호진, 2013, [Journal of The Korean Radiological Society, 대한영상의학회지], V69, P265, DOI 10.3348/jksr.2013.69.4.265	25	1	1	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	JUN	2018	26	4					342	346		10.1177/1066896917747732			5	Pathology; Surgery	Pathology; Surgery	GF9BK	WOS:000432270900010	29237344				2019-10-28	
J	Sun, BL; Jain, R; Patel, C; Bhattacharyya, AK				Sun, Belinda L.; Jain, Richa; Patel, Charmi; Bhattacharyya, Achyut K.			Graft-Versus-Host Disease With Early Cytomegalovirus Infection in Gastrointestinal Tract Biopsies	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						gastrointestinal biopsy; graft-versus-host disease; cytomegalovirus infection	ACUTE GVHD; TRANSPLANTATION; PATHOLOGY; CRITERIA; RISK	Gastrointestinal (GI) graft-versus-host disease (GVHD) and cytomegalovirus (CMV) infection often simulate each other. However, distinction between GVHD and CMV infection is critical in the management of immunosuppression for transplant recipients. This study retrospectively reviewed 16 patients diagnosed with GVHD from 2010 to 2016 and found 4 cases (25%) coinfected with CMV. Two cases were initially diagnosed as GVHD only but found to have CMV infection by serological testing within 3 days after immunosuppression treatment for GVHD. The remarkable histological feature of CMV infection appeared to be significant acute inflammation in addition to apoptotic epithelial injuries, and particularly in an early stage of CMV replication, acute inflammation is possibly the only detectable feature of CMV infection.	[Sun, Belinda L.; Jain, Richa; Patel, Charmi; Bhattacharyya, Achyut K.] Banner Univ, Med Ctr Tucson, Tucson, AZ USA	Sun, BL (reprint author), Banner Univ, Med Ctr Tucson, Dept Pathol, 1501 N Campbell Ave,POB 245108, Tucson, AZ 85724 USA.	bsun@email.arizona.edu					BARNES DWH, 1955, RADIOBIOLOGY S, P134; Cantoni N, 2010, BIOL BLOOD MARROW TR, V16, P1309, DOI 10.1016/j.bbmt.2010.03.020; Cho BS, 2013, ANN HEMATOL, V92, P497, DOI 10.1007/s00277-012-1632-x; Jagasia M, 2012, BLOOD, V119, P296, DOI 10.1182/blood-2011-06-364265; Lee SE, 2013, BONE MARROW TRANSPL, V48, P587, DOI 10.1038/bmt.2012.187; Ponec RJ, 1999, GASTROINTEST ENDOSC, V49, P612, DOI 10.1016/S0016-5107(99)70390-1; Sale G, 2004, THOMAS HEMATOPOIETIC, P286; Shidham VB, 2003, BMC GASTROENTEROL, V3, DOI 10.1186/1471-230X-3-5; Shulman HM, 2015, BIOL BLOOD MARROW TR, V21, P589, DOI 10.1016/j.bbmt.2014.12.031; SNOVER DC, 1985, TRANSPLANTATION, V39, P669; Star KV, 2013, AM J SURG PATHOL, V37, P1319, DOI 10.1097/PAS.0b013e31829ab1ef; Washington K, 1997, AM J SURG PATHOL, V21, P1037, DOI 10.1097/00000478-199709000-00008; Washington K, 2009, HUM PATHOL, V40, P909, DOI 10.1016/j.humpath.2009.04.001	13	0	0	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	JUN	2018	26	4					347	352		10.1177/1066896917746745			6	Pathology; Surgery	Pathology; Surgery	GF9BK	WOS:000432270900011	29207904				2019-10-28	
J	Elfituri, O; Sonawane, S; Xu, HL; Warso, MA; Wiley, E				Elfituri, Osama; Sonawane, Snehal; Xu, Haoliang; Warso, Michael A.; Wiley, Elizabeth			A Recurrence of Bilateral Diffuse Sclerosing Lobular Hyperplasia of Breast: A Case Report	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						breast; sclerosing lobular hyperplasia; fibroadenoma		Mammary sclerosing lobular hyperplasia is an uncommon benign fibroproliferative lesion of adolescent and young women, often of African American heritage with an incidence of similar to 3%. Patients generally complain of a palpable, painless, or slightly tender and well-defined lump in breast. Very rarely, this lesion may be bilateral and diffuse. The definitive diagnosis of sclerosing lobular hyperplasia requires histopathologic evaluation. Here, we describe a case of diffuse sclerosing lobular hyperplasia in a 29-year-old African American woman that required bilateral mastectomy and recurred bilaterally requiring second resections. This appears to be the first report of this phenomenon.	[Elfituri, Osama; Sonawane, Snehal; Xu, Haoliang; Warso, Michael A.; Wiley, Elizabeth] Univ Illinois, Coll Med Chicago, Chicago, IL USA	Elfituri, O (reprint author), 840 S Wood St,Suite 130 CSN, Chicago, IL 60612 USA.	oelfitur@uic.edu					Jain M, 2001, ACTA CYTOL, V45, P765, DOI 10.1159/000328301; Kapur Payal, 2006, Cytojournal, V3, P8, DOI 10.1186/1742-6413-3-8; KOVI J, 1984, HUM PATHOL, V15, P336, DOI 10.1016/S0046-8177(84)80031-3; Lamichaney R, 2014, J CLIN DIAGN RES, V8, P125, DOI 10.7860/JCDR/2014/6891.4132; Lyle WG, 2000, ANN PLAS SURG, V45, P454; Manucha V, 2005, ARCH PATHOL LAB MED, V129, P1345; POULTON TB, 1995, AM J ROENTGENOL, V165, P291, DOI 10.2214/ajr.165.2.7618542; Rosen P. P., 2001, ROSENS BREAST PATHOL	8	1	1	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	JUN	2018	26	4					353	355		10.1177/1066896917746744			3	Pathology; Surgery	Pathology; Surgery	GF9BK	WOS:000432270900012	29228880				2019-10-28	
J	Richards, SM; Pine-Twaddell, ED; Ioffe, OB; Bellavance, EC				Richards, Stephanie M.; Pine-Twaddell, Elyse D.; Ioffe, Olga B.; Bellavance, Emily C.			A Case of Benign Phyllodes Tumor in a Transgender Woman Receiving Cross-Sex Hormones	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						benign phyllodes tumor; transgender	BREAST; FIBROADENOMA	Phyllodes tumor is a relatively uncommon fibroepithelial neoplasm of the breast characterized by proliferation of both stromal and epithelial elements. Benign phyllodes tumors are distinguished from fibroadenomas by their prominent leaf-like architecture and exaggerated intracanalicular stromal growth pattern. Typically, these lesions affect older natal females; however, we present what we believe is the first reported case of benign phyllodes tumor in a hormonally treated transgender woman.	[Richards, Stephanie M.; Ioffe, Olga B.; Bellavance, Emily C.] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA; [Pine-Twaddell, Elyse D.] Chase Brexton Hlth Serv, Baltimore, MD USA	Richards, SM (reprint author), Univ Maryland, Med Ctr, Dept Pathol, 22 South Greene St,Room NBW43, Baltimore, MD 21201 USA.	srichards@umm.edu					Abe M, 2011, BREAST CANCER-TOKYO, V18, P268, DOI 10.1007/s12282-009-0185-x; Bernardes J R M Jr, 2003, Breast J, V9, P302, DOI 10.1046/j.1524-4741.2003.09410.x; BERNSTEIN L, 1993, CANCER-AM CANCER SOC, V71, P3020, DOI 10.1002/1097-0142(19930515)71:10<3020::AID-CNCR2820711022>3.0.CO;2-G; Bowman E, 2012, BREAST J, V18, P242, DOI 10.1111/j.1524-4741.2012.01230.x; Brogi E, 2014, ROSENS BREAST PATHOL, P213; Kanhai RCJ, 1999, HISTOPATHOLOGY, V35, P183, DOI 10.1046/j.1365-2559.1999.0744c.x; Kanhai RCJ, 2000, AM J SURG PATHOL, V24, P74, DOI 10.1097/00000478-200001000-00009; Krishnamurthy S, 2000, CANCER CYTOPATHOL, V90, P342, DOI 10.1002/1097-0142(20001225)90:6<342::AID-CNCR4>3.3.CO;2-9; Lakhani SREI, 2012, WHO CLASSIFICATION T; Lee JW, 2007, BREAST J, V13, P312, DOI 10.1111/j.1524-4741.2007.00431.x; Lemmo GianFranco, 2003, Eur J Surg Suppl, P69; Maycock LB, 2014, J MIDWIFERY WOM HEAL, V59, P74, DOI 10.1111/jmwh.12066; Murray MP, 2014, ROSENS BREAST PATHOL, P957; Phillips J, 2014, AM J ROENTGENOL, V202, P1149, DOI 10.2214/AJR.13.10810; Sapino A, 2006, MODERN PATHOL, V19, P599, DOI 10.1038/modpathol.3800574; Tan BY, 2016, HISTOPATHOLOGY, V68, P5, DOI 10.1111/his.12876; Wierckx K, 2014, J SEX MED, V11, P1240, DOI 10.1111/jsm.12487; Yang XF, 2014, ARCH PATHOL LAB MED, V138, P25, DOI 10.5858/arpa.2012-0443-RA	18	0	0	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	JUN	2018	26	4					356	359		10.1177/1066896917743011			4	Pathology; Surgery	Pathology; Surgery	GF9BK	WOS:000432270900013	29169272				2019-10-28	
J	Jenkins, TM; Morrissette, JJD; Kucharczuk, JC; Deshpande, CG				Jenkins, Taylor M.; Morrissette, Jennifer J. D.; Kucharczuk, John C.; Deshpande, Charuhas G.			ROS1 Rearrangement in a Case of Classic Biphasic Pulmonary Blastoma	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						ROS1; pulmonary blastoma; non-small cell lung carcinoma; NSCLC; tyrosine kinase inhibitor; biphasic	GENE	Classic biphasic pulmonary blastoma (CBPB) is a rare and aggressive type of non-small cell lung carcinoma (NSCLC) presenting in adults in the fourth to fifth decade. The prognosis is poor and after surgical resection, therapeutic options are often limited. ROSl is a proto-oncogene receptor tyrosine kinase that has been identified in some types of NSCLC. We report a case of a 36-year-old woman with CBPB, which was subsequently found to have a ROSl rearrangement. This is the first reported case of a ROSl-rearranged CBPB. This finding has therapeutic implications as these tumors have the potential to be treated with receptor tyrosine kinase inhibitors.	[Jenkins, Taylor M.; Morrissette, Jennifer J. D.; Kucharczuk, John C.; Deshpande, Charuhas G.] Hosp Univ Penn, 3400 Spruce St,6 Founders Bldg, Philadelphia, PA 19104 USA	Jenkins, TM (reprint author), Hosp Univ Penn, 3400 Spruce St,6 Founders Bldg, Philadelphia, PA 19104 USA.	taylor.jenkins@uphs.upenn.edu					Amaravadi RK, 2015, CLIN CANCER RES, V21, P5215, DOI 10.1158/1078-0432.CCR-15-0469; BARNARD WG, 1952, THORAX, V7, P299, DOI 10.1136/thx.7.4.299; Bodner SM, 1996, HUM PATHOL, V27, P1117, DOI 10.1016/S0046-8177(96)90302-0; Bosch-Barrera J, 2015, ANTICANCER RES, V35, P4871; Daber R, 2013, CANCER GENET-NY, V206, P441, DOI 10.1016/j.cancergen.2013.11.005; Gallo K, 2015, ANTICANCER RES, V35, P6325; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Larsen H, 1996, CANCER TREAT REV, V22, P145, DOI 10.1016/S0305-7372(96)90000-6; Liman ST, 2006, RESP MED, V100, P1174, DOI 10.1016/j.rmed.2005.10.026; Magistrelli P, 2014, WORLD J CLIN ONCOL, V5, P1113, DOI 10.5306/wjco.v5.i5.1113; Nakatani Y, 2004, AM J SURG PATHOL, V28, P921, DOI 10.1097/00000478-200407000-00012; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Shaw AT, 2014, NEW ENGL J MED, V371, P1963, DOI 10.1056/NEJMoa1406766; Smyth Robert J, 2014, BMC Res Notes, V7, P294, DOI 10.1186/1756-0500-7-294; Speicher MR, 1996, NAT GENET, V12, P368, DOI 10.1038/ng0496-368; Van Loo S, 2011, LUNG CANCER, V73, P127, DOI 10.1016/j.lungcan.2011.03.018; Weissferdt A, 2011, ADV ANAT PATHOL, V18, P179, DOI 10.1097/PAP.0b013e318216980c; Zhao YY, 2016, ONCOTARGETS THER, V9, P6915, DOI 10.2147/OTT.S117097	18	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	JUN	2018	26	4					360	363		10.1177/1066896917749928			4	Pathology; Surgery	Pathology; Surgery	GF9BK	WOS:000432270900014	29295663				2019-10-28	
J	Shelekhova, KV; Egorenkov, VV; Kheinstein, VA; Konstantinova, AM; Iyevleva, A; Imyanitov, EN; Matsko, MV; Matsko, DE				Shelekhova, Ksenya V.; Egorenkov, Vitaly V.; Kheinstein, Valery A.; Konstantinova, Anastasia M.; Iyevleva, Aglaya; Imyanitov, Evgeny N.; Matsko, Marina V.; Matsko, Dmitry E.			Myxopapillary Ependymoma of Lumbar Soft Tissue: A Case Report With Gene Expression Evaluation	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						myxopapillary ependymoma; lumbar; soft tissue; ectopic; extraspinal; gene expression	TUMORS; TEMOZOLOMIDE; GLIOMAS	Primary extraspinal myxopapillary ependymoma (MPE) is an exceptionally rare lesion that is mainly located in the subcutaneous sacrococcygeal region. We describe the first case of MPE that presented as an intramuscular tumor mass located in the lumbar area. Absence of the visible connection with the spinal cord and lack of any other tumors in the reported case argue for the primary ectopic origin of the MPE. The differential diagnosis of MPE is discussed. Additionally, we evaluated the expression level of molecular biomarkers that have a prognostic value in central nervous system tumors.	[Shelekhova, Ksenya V.; Egorenkov, Vitaly V.; Kheinstein, Valery A.; Konstantinova, Anastasia M.; Imyanitov, Evgeny N.; Matsko, Marina V.; Matsko, Dmitry E.] Clin Res & Pract Ctr Specialized Oncol Care, St Petersburg, Russia; [Shelekhova, Ksenya V.; Kheinstein, Valery A.; Konstantinova, Anastasia M.; Matsko, Dmitry E.] St Petersburg Medicosocial Inst, St Petersburg, Russia; [Konstantinova, Anastasia M.; Imyanitov, Evgeny N.; Matsko, Marina V.] St Petersburg State Univ, St Petersburg, Russia; [Iyevleva, Aglaya; Imyanitov, Evgeny N.] NN Petrov Inst Oncol, St Petersburg, Russia; [Matsko, Marina V.; Matsko, Dmitry E.] Polenov Russian Neurosurg Inst, Branch Almazov NWFMRC, St Petersburg, Russia	Shelekhova, KV (reprint author), Clin Res & Pract Ctr Specialized Oncol Care, Dept Pathol, Leningradskaja Str 68a, St Petersburg 197758, Russia.	ksenshelekhova@gmail.com	Konstantinova, Anastasia/P-7221-2014	Konstantinova, Anastasia/0000-0002-2595-2249	Russian Scientific FundRussian Science Foundation (RSF) [17-15-01384]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work has been supported by the Russian Scientific Fund (Grant 17-15-01384).	Arivazhagan A, 2012, J NEURO-ONCOL, V107, P289, DOI 10.1007/s11060-011-0758-3; Boccard SG, 2015, ONCOTARGET, V6, P29456, DOI 10.18632/oncotarget.4909; Ferrandina G, 2006, CLIN CANCER RES, V12, P2774, DOI 10.1158/1078-0432.CCR-05-2715; Helbig D, 2016, J CUTAN PATHOL, V43, P71, DOI 10.1111/cup.12590; HELWIG EB, 1984, AM J CLIN PATHOL, V81, P156, DOI 10.1093/ajcp/81.2.156; Koos B, 2010, NEUROPATH APPL NEURO, V36, P356, DOI 10.1111/j.1365-2990.2010.01077.x; von Zangen IL, 2007, ACTA NEUROPATHOL, V113, P325, DOI 10.1007/s00401-006-0190-5; Ma YT, 2006, BRIT J RADIOL, V79, P445, DOI 10.1259/bjr/61959899; Mallory FB, 1902, J MED RES, V8, P1; McLendon RE, 2016, WHO CLASSIFICATION T, P104; Moreno L, 2013, J NEURO-ONCOL, V111, P169, DOI 10.1007/s11060-012-0996-z; Pajtler KW, 2015, CANCER CELL, V27, P728, DOI 10.1016/j.ccell.2015.04.002; Puputti M, 2010, BRAIN PATHOL, V20, P763, DOI 10.1111/j.1750-3639.2009.00357.x; Reifenberger G, 2017, NAT REV CLIN ONCOL, V14, P434, DOI 10.1038/nrclinonc.2016.204; Satti Mohammed, 2005, Ann Diagn Pathol, V9, P215, DOI 10.1016/j.anndiagpath.2005.04.015; Takano T, 2005, INT J GYNECOL CANCER, V15, P1138, DOI 10.1111/j.1525-1438.2005.00187.x; Whittemore DE, 2005, ARCH PATHOL LAB MED, V129, P1338; Yust Katz S, J CLIN NEUROSCI, DOI [10.1016/j.jocn.2017.10.026., DOI 10.1016/J.JOCN.2017.10.026.]; Zavalhia LS, 2012, DIS MARKERS, V33, P61, DOI 10.3233/DMA-2012-0905	19	3	3	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	JUN	2018	26	4					364	369		10.1177/1066896917748195			6	Pathology; Surgery	Pathology; Surgery	GF9BK	WOS:000432270900015	29254456				2019-10-28	
J	McCarthy, WA; Makhijani, R; Miller, K; Rojas, K; Beffa, L; Mathews, C; Robison, K; Quddus, MR				McCarthy, Whitney A.; Makhijani, Reeva; Miller, Katherine; Rojas, Kristin; Beffa, Lindsey; Mathews, Cara; Robison, Katina; Quddus, M. Ruhul			Gastric-Type Endometrial Adenocarcinoma: Report of Two Cases in Patients From the United States	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						gastric-type; endometrioid adenocarcinoma; endometrium	MUCINOUS ADENOCARCINOMA; LESIONS	Gastric-type adenocarcinomas of the uterine cervix have been described within the literature in detail; however, the description of gastric-type endometrial adenocarcinomas is a recent development, with only two cases originating from Japan in the world literature to date. According to these prior reports, the recognition of this pattern of differentiation is critical, as it is often associated with deep myoinvasion, positive regional lymph nodes, and poor outcome despite appropriate adjuvant treatment. We present two cases of endometrial adenocarcinoma with gastric-type differentiation in patients from the United States with superficial myoinvasion and positive patient outcomes. Gastric-type differentiation in endometrial adenocarcinomas is rare and likely underrecognized. Continued reporting of these cases is necessary to further understand the natural history and clinical implications of this entity.	[McCarthy, Whitney A.; Makhijani, Reeva; Miller, Katherine; Rojas, Kristin; Beffa, Lindsey; Mathews, Cara; Robison, Katina; Quddus, M. Ruhul] Women & Infants Hosp Rhode Isl, Providence, RI 02905 USA; [McCarthy, Whitney A.; Makhijani, Reeva; Miller, Katherine; Rojas, Kristin; Beffa, Lindsey; Mathews, Cara; Robison, Katina; Quddus, M. Ruhul] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA; [McCarthy, Whitney A.; Makhijani, Reeva; Miller, Katherine; Rojas, Kristin; Beffa, Lindsey; Mathews, Cara; Robison, Katina; Quddus, M. Ruhul] Brown Univ, Providence, RI 02912 USA	Quddus, MR (reprint author), Women & Infants Hosp Rhode Isl, Dept Pathol & Lab Med, 101 Dudley St, Providence, RI 02905 USA.	mquddus@wihri.org		Mathews, Cara/0000-0001-8461-4568			Abiko K, 2010, PATHOL INT, V60, P42, DOI 10.1111/j.1440-1827.2009.02473.x; Buell-Gutbrod R, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-128; Carleton C, 2016, AM J SURG PATHOL, V40, P636, DOI 10.1097/PAS.0000000000000578; Hino M, 2016, MOL CLIN ONCOL, V4, P699, DOI 10.3892/mco.2016.789; Karamurzin YS, 2015, AM J SURG PATHOL, V39, P1449, DOI 10.1097/PAS.0000000000000532; Kojima A, 2007, AM J SURG PATHOL, V31, P664, DOI 10.1097/01.pas.0000213434.91868.b0; Mikami Y, 2013, ADV ANAT PATHOL, V20, P227, DOI 10.1097/PAP.0b013e31829c2d66; Mikami Y, 2009, HISTOPATHOLOGY, V54, P184, DOI 10.1111/j.1365-2559.2008.03202.x	8	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	JUN	2018	26	4					377	381		10.1177/1066896917743010			5	Pathology; Surgery	Pathology; Surgery	GF9BK	WOS:000432270900017	29281925				2019-10-28	
J	Tamas, J; Vereczkey, I; Toth, E; Csernak, E; Purcsi, K; Pete, I				Tamas, Judit; Vereczkey, Ildiko; Toth, Erika; Csernak, Erzsebet; Purcsi, Katalin; Pete, Imre			Mixed Ovarian Tumor Composed of Brenner Tumor and Adult-Type Granulosa Cell Tumor: A Case Report of a Very Rare Mixed Ovarian Tumor and a Review of the Literature	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Review						ovarian mixed tumor; Brenner tumor; adult-type granulosa cell tumor	CARCINOMA; MUTATION; FOXL2; CYSTADENOMA; NEOPLASMS; TERATOMA; STRUMA	A combination of ovarian tumors with the same histogenetic origin but different histologic subtype is relatively common, whereas a co-occurrence of tumors with different histogenetic origin is rare. We report a case of mixed ovarian tumor composed of Brenner tumor and adult-type granulosa cell tumor, a combination that to the best of our knowledge has not been reported in the literature until now.	[Tamas, Judit; Vereczkey, Ildiko; Toth, Erika; Csernak, Erzsebet; Purcsi, Katalin; Pete, Imre] Natl Inst Oncol, Budapest, Hungary	Tamas, J (reprint author), Natl Inst Oncol, Dept Surg & Mol Pathol, 7-9 Rath Gyorgy St, H-1122 Budapest, Hungary.	judittamas86@gmail.com					Burg J, 2002, INT J GYNECOL PATHOL, V21, P74, DOI 10.1097/00004347-200201000-00014; Gupta N, 2011, J CLIN DIAGN RES, V5, P1651; Jaafar H, 2006, MALAYS J MED SCI, V13, P4; Jamieson S, 2010, MODERN PATHOL, V23, P1477, DOI 10.1038/modpathol.2010.145; Kurman RJ, 2014, WHO CLASSIFICATION T; Kushida Y, 2005, PATHOL INT, V55, P797, DOI 10.1111/j.1440-1827.2005.01909.x; McCluggage WG, 2012, J CLIN PATHOL, V65, P293, DOI 10.1136/jclinpath-2011-200352; McKenna M, 2005, INT J GYNECOL PATHOL, V24, P224, DOI 10.1097/01.pgp.0000158532.90747.e7; Pejovic T, 1999, GYNECOL ONCOL, V74, P134, DOI 10.1006/gyno.1999.5402; Prat J., 2004, PATHOLOGY OF THE OVA, P185; Schoolmeester JK, 2012, INT J GYNECOL PATHOL, V31, P538, DOI 10.1097/PGP.0b013e31824d354f; Seidman JD, 2008, ARCH PATHOL LAB MED, V132, P1753, DOI 10.1043/1543-2165-132.11.1753; Seidman JD, 2011, BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT, SIXTH EDITION, P679, DOI 10.1007/978-1-4419-0489-8_14; Shah SP, 2009, NEW ENGL J MED, V360, P2719, DOI 10.1056/NEJMoa0902542; Singh N, 2014, HISTOPATHOLOGY, V64, P626, DOI 10.1111/his.12314; Sundar SB, 2015, INT J MED RES HEALTH, V4, P248, DOI 10.5958/2319-5886.2015.00045.4; Trivedi P, 2009, INDIAN J PATHOL MICR, V52, P559, DOI 10.4103/0377-4929.56166; Wilberger A, 2015, INT J SURG PATHOL, V23, P393, DOI 10.1177/1066896915573569; Yoshida M, 2004, PATHOL INT, V54, P793, DOI 10.1111/j.1440-1827.2004.01757.x; Young RH, 2011, BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT, SIXTH EDITION, P785, DOI 10.1007/978-1-4419-0489-8_15	20	0	0	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	JUN	2018	26	4					382	387		10.1177/1066896917744877			6	Pathology; Surgery	Pathology; Surgery	GF9BK	WOS:000432270900018	29198156				2019-10-28	
J	Konishi, T; Shimada, Y; Lee, LH; Cavalcanti, MS; Hsu, M; Smith, JJ; Nash, GM; Temple, LK; Guillem, JG; Paty, PB; Garcia-Aguilar, J; Vakiani, E; Gonen, M; Shia, J; Weiser, MR				Konishi, Tsuyoshi; Shimada, Yoshifumi; Lee, Lik Hang; Cavalcanti, Marcela S.; Hsu, Meier; Smith, Jesse Joshua; Nash, Garrett M.; Temple, Larissa K.; Guillem, Jose G.; Paty, Philip B.; Garcia-Aguilar, Julio; Vakiani, Efsevia; Gonen, Mithat; Shia, Jinru; Weiser, Martin R.			Poorly Differentiated Clusters Predict Colon Cancer Recurrence An In-Depth Comparative Analysis of Invasive-Front Prognostic Markers	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						colon cancer; invasive front; prognostic markers; poorly differentiated clusters	COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; CLINICAL-SIGNIFICANCE; CONSENSUS CONFERENCE; PERINEURAL INVASION; LYMPHOID REACTION; AMERICAN SOCIETY; METASTASIS; MICROENVIRONMENT; RECOMMENDATIONS	This study aimed to compare common histologic markers at the invasive front of colon adenocarcinoma in terms of prognostic accuracy and interobserver agreement. Consecutive patients who underwent curative resection for stages I to III colon adenocarcinoma at a single institution in 2007 to 2014 were identified. Poorly differentiated clusters (PDCs), tumor budding, perineural invasion, desmoplastic reaction, and Crohn-like lymphoid reaction at the invasive front, as well as the World Health Organization (WHO) grade of the entire tumor, were analyzed. Prognostic accuracies for recurrence-free survival (RFS) were compared, and interobserver agreement among 3 pathologists was assessed. The study cohort consisted of 851 patients. Although all the histologic markers except WHO grade were significantly associated with RFS (PDCs, tumor budding, perineural invasion, and desmoplastic reaction: P < 0.001; Crohn-like lymphoid reaction: P=0.021), PDCs (grade 1 [G1]: n=581; G2: n=145; G3: n=125) showed the largest separation of 3-year RFS in the full cohort (G1: 94.1%; G3: 63.7%; hazard ratio [HR], 6.39; 95% confidence interval [CI], 4.11-9.95; P < 0.001), stage II patients (G1: 94.0%; G3: 67.3%; HR, 4.15; 95% CI, 1.96-8.82; P < 0.001), and stage III patients (G1: 89.0%; G3: 59.4%; HR, 4.50; 95% CI, 2.41-8.41; P < 0.001). PDCs had the highest prognostic accuracy for RFS with the concordance probability estimate of 0.642, whereas WHO grade had the lowest. Interobserver agreement was the highest for PDCs, with a weighted kappa of 0.824. The risk of recurrence over time peaked earlier for worse PDCs grade. Our findings indicate that PDCs are the best invasive-front histologic marker in terms of prognostic accuracy and interobserver agreement. PDCs may replace WHO grade as a prognostic indicator.	[Konishi, Tsuyoshi; Shimada, Yoshifumi; Smith, Jesse Joshua; Nash, Garrett M.; Temple, Larissa K.; Guillem, Jose G.; Paty, Philip B.; Garcia-Aguilar, Julio; Weiser, Martin R.] Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA; [Lee, Lik Hang; Cavalcanti, Marcela S.; Vakiani, Efsevia; Shia, Jinru] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA; [Hsu, Meier; Gonen, Mithat] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, 1275 York Ave, New York, NY 10021 USA; [Konishi, Tsuyoshi] Japanese Fdn Canc Res, Dept Surg Gastroenterol, Canc Inst Hosp, Tokyo, Japan; [Shimada, Yoshifumi] Niigata Univ, Grad Sch Med & Dent Sci, Div Digest & Gen Surg, Niigata, Japan	Shia, J (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA.; Weiser, MR (reprint author), Mem Sloan Kettering Canc Ctr, Dept Surg, Colorectal Serv, New York, NY 10065 USA.	shiaj@mskcc.org; weiser1@mskcc.org	Gonen, Mithat/E-4826-2012	Gonen, Mithat/0000-0001-8683-8477; Smith, Jesse Joshua/0000-0003-2538-5456	National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 C008748]	Supported by National Cancer Institute grant P30 C008748.	Barresi V, 2017, CLIN COLORECTAL CANC, V16, P9, DOI 10.1016/j.clcc.2016.06.002; Barresi V, 2015, HUM PATHOL, V46, P1722, DOI 10.1016/j.humpath.2015.07.013; Benson AB, 2004, J CLIN ONCOL, V22, P3408, DOI 10.1200/JCO.2004.05.063; Bonetti LR, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0481-7; Brierley JD, 2017, TNM CLASSIFICATION M; Compton C, 2000, CANCER-AM CANCER SOC, V88, P1739, DOI 10.1002/(SICI)1097-0142(20000401)88:7<1739::AID-CNCR30>3.0.CO;2-T; Compton CC, 2000, ARCH PATHOL LAB MED, V124, P979; Fleiss J, 2003, STAT METHODS RATES P, P598, DOI DOI 10.1002/0471445428; FLEISS JL, 1973, EDUC PSYCHOL MEAS, V33, P613, DOI 10.1177/001316447303300309; Gonen M, 2005, BIOMETRIKA, V92, P965, DOI 10.1093/biomet/92.4.965; Hamilton SR, 2010, WHO CLASSIFICATION T, P134; Hess KR, 1999, STAT MED, V18, P3075, DOI 10.1002/(SICI)1097-0258(19991130)18:22<3075::AID-SIM244>3.0.CO;2-6; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Karagiannis GS, 2012, MOL CANCER RES, V10, P1403, DOI 10.1158/1541-7786.MCR-12-0307; Kawachi H, 2015, MODERN PATHOL, V28, P872, DOI 10.1038/modpathol.2015.36; Kim JH, 2015, J CLIN PATHOL, V68, P22, DOI 10.1136/jclinpath-2014-202603; Koelzer VH, 2015, TRANSL RES, V166, P207, DOI 10.1016/j.trsl.2015.02.008; LIGHT RJ, 1971, PSYCHOL BULL, V76, P365, DOI 10.1037/h0031643; Lugli A, 2009, BRIT J CANCER, V101, P1382, DOI 10.1038/sj.bjc.6605318; Lugli A, 2017, MODERN PATHOL, V30, P1299, DOI 10.1038/modpathol.2017.46; McAllister SS, 2010, J CLIN ONCOL, V28, P4022, DOI 10.1200/JCO.2010.28.4257; Meyerhardt JA, 2013, J CLIN ONCOL, V31, P4465, DOI 10.1200/JCO.2013.50.7442; MULLER HG, 1994, BIOMETRICS, V50, P61, DOI 10.2307/2533197; Okamura T, 2016, DIS COLON RECTUM, V59, P396, DOI 10.1097/DCR.0000000000000567; Prall F, 2007, HISTOPATHOLOGY, V50, P151, DOI 10.1111/j.1365-2559.2006.02551.x; Puppa G, 2012, HISTOPATHOLOGY, V61, P562, DOI 10.1111/j.1365-2559.2012.04270.x; Rozek LS, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw027; Schmoll HJ, 2012, ANN ONCOL, V23, P2479, DOI 10.1093/annonc/mds236; Shia J, 2003, AM J SURG PATHOL, V27, P1407, DOI 10.1097/00000478-200311000-00002; Shia J, 2008, HUM PATHOL, V39, P116, DOI 10.1016/j.humpath.2007.05.022; Shimada Y, 2015, SURG TODAY, V45, P1493, DOI 10.1007/s00595-014-1096-9; Shimada Yoshifumi, 2008, Acta Medica et Biologica, V56, P19; Shinto E, 2005, HISTOPATHOLOGY, V47, P25, DOI 10.1111/j.1365-2559.2005.02162.x; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Ueno H, 2004, GASTROENTEROLOGY, V127, P385, DOI 10.1053/S0016-5085(04)00717-6; Ueno H, 2014, BRIT J CANCER, V111, P2082, DOI 10.1038/bjc.2014.509; Ueno H, 2015, SURGERY, V157, P899, DOI 10.1016/j.surg.2014.12.025; Ueno H, 2015, ANN SURG ONCOL, V22, P1504, DOI 10.1245/s10434-014-4149-9; Ueno H, 2014, AM J SURG PATHOL, V38, P197, DOI 10.1097/PAS.0000000000000113; Ueno H, 2013, AM J SURG PATHOL, V37, P1542, DOI 10.1097/PAS.0b013e318297ef6e; Ueno H, 2013, AM J CLIN PATHOL, V139, P434, DOI 10.1309/AJCPWHUEFTGBWKE4; Warrens MJ, 2010, ADV DATA ANAL CLASSI, V4, P271, DOI 10.1007/s11634-010-0073-4; Washington MK, 2009, ARCH PATHOL LAB MED, V133, P1539, DOI 10.1043/1543-2165-133.10.1539; Weiser MR, 2008, J CLIN ONCOL, V26, P380, DOI 10.1200/JCO.2007.14.1291; Yagi R, 2016, ANN SURG ONCOL, V23, P552, DOI 10.1245/s10434-016-5379-9; Zlobec I, 2007, J PATHOL, V212, P260, DOI 10.1002/path.2164; Zlobec I, 2009, WORLD J GASTROENTERO, V15, P5898, DOI 10.3748/wjg.15.5898	47	7	7	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUN	2018	42	6					705	714		10.1097/PAS.0000000000001059			10	Pathology; Surgery	Pathology; Surgery	GF8NF	WOS:000432228900002	29624511	Green Accepted			2019-10-28	
J	Saldanha, G; Yarrow, J; Pancholi, J; Flatman, K; Teo, KW; Elsheik, S; Harrison, R; O'Riordan, M; Bamford, M				Saldanha, Gerald; Yarrow, Jeremy; Pancholi, Jay; Flatman, Katarina; Teo, Kah Wee; Elsheik, Somaia; Harrison, Rebecca; O'Riordan, Marie; Bamford, Mark			Breslow Density Is a Novel Prognostic Feature That Adds Value to Melanoma Staging	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						melanoma; prognosis; biomarker; Breslow density; REMARK	MALIGNANT-MELANOMA; PREDICTION MODELS; VOLUME; VALIDATION	Histomorphologic prognostic biomarkers that can be measured using only an hematoxylin and eosin stain are very attractive because they are simple and cheap. We conceived an entirely novel biomarker of this type, the Breslow density (BD), which measures invasive melanoma cell density at the site where Breslow thickness (BT) is measured. This study assessed BD's prognostic value. In this study, BD was measured in 1329 melanoma patients. Measurement accuracy and precision was assessed using intraclass correlation coefficient (ICC). Survival was assessed with a primary end-point of melanoma-specific survival (MSS) and also overall survival and metastasis-free survival. We found that BD measurement was accurate compared with gold standard image analysis (ICC, 0.84). Precision was excellent for 3 observers with different experience (ICC, 0.93) and for an observer using only written instructions (ICC, 0.93). BD was a highly significant predictor in multivariable analysis for overall survival, MSS, and metastasis-free survival (each, P<0.001) and it explained MSS better than BT, but BT and BD together had best explanatory capability. A BD cut point of 65% was trained in 970 melanomas and validated in 359. This cut point showed promise as a novel way to upstage melanoma from T stage "a" to "b." BD was combined with BT to create a targeted burden score. This was a validated as an adjunct to American Joint Committee on Cancer stage. In summary, BD can be measured accurately and precisely. It demonstrated independent prognostic value and explained MSS better than BT alone. Notably, we demonstrated ways that BD could be used with American Joint Committee on Cancer version 8 staging.	[Saldanha, Gerald; Yarrow, Jeremy; Pancholi, Jay; Flatman, Katarina; Teo, Kah Wee] Univ Leicester, Leicester Canc Res Ctr, Leicester, Leics, England; [Harrison, Rebecca; O'Riordan, Marie; Bamford, Mark] Univ Hosp Leicester NHS Trust, Dept Cellular Pathol, Leicester, Leics, England; [Elsheik, Somaia] Nottingham Univ Hosp, Dept Cellular Pathol, Nottingham, England	Saldanha, G (reprint author), Univ Leicester, Inst Adv Studies, Leicester Royal Infirm, Level 3,Robert Kilpatrick Bldg, Leicester LE1 5WW, Leics, England.	gss4@le.ac.uk			British Skin Foundation; Hope Foundation; Pathological Society of Great Britain and Ireland; Cancer Research UKCancer Research UK	Supported by the British Skin Foundation, the Hope Foundation, the Pathological Society of Great Britain and Ireland and Cancer Research UK.	Babyak MA, 2004, PSYCHOSOM MED, V66, P411, DOI 10.1097/01.psy.0000127692.23278.a9; Bahmer FA, 1996, AM J DERMATOPATH, V18, P159, DOI 10.1097/00000372-199604000-00009; Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799; Berger AC, 2016, CURR MED RES OPIN, V32, P1599, DOI 10.1080/03007995.2016.1192997; Burnham KP, 2011, BEHAV ECOL SOCIOBIOL, V65, P23, DOI 10.1007/s00265-010-1029-6; CLARK WH, 1984, HUM PATHOL, V15, P1147, DOI 10.1016/S0046-8177(84)80310-X; FRIEDMAN RJ, 1991, DERMATOL CLIN, V9, P643; Gershenwald JE, 2017, CA-CANCER J CLIN, V67, P472, DOI 10.3322/caac.21409; Glazer AM, 2017, JAMA DERMATOL, V153, P225, DOI 10.1001/jamadermatol.2016.4512; Lo JA, 2014, SCIENCE, V346, P945, DOI 10.1126/science.1253735; Long GV, 2017, NEW ENGL J MED, V377, P1813, DOI 10.1056/NEJMoa1708539; McShane LM, 2005, BRIT J CANCER, V93, P387, DOI 10.1038/sj.bjc.6602678; R Core Team, 2015, R LANG ENV STAT COMP; Rahman MS, 2017, BMC MED RES METHODOL, V17, DOI 10.1186/s12874-017-0336-2; Rashed H, 2017, HISTOPATHOLOGY, V70, P264, DOI 10.1111/his.13060; Rothberg BEG, 2014, METHODS MOL BIOL, V1102, P227, DOI 10.1007/978-1-62703-727-3_13; Royston P, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-33; RStudio Team, 2015, RSTUDIO INT DEV R; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Steyerberg E, 2009, CLIN PREDICTION MODE, P83; Steyerberg EW, 2014, EUR HEART J, V35, P1925, DOI 10.1093/eurheartj/ehu207; Volpe VO, 2017, J AM ACAD DERMATOL, V77, P356, DOI 10.1016/j.jaad.2017.04.1126; Voss B, 2014, DERMATOLOGY, V228, P66, DOI 10.1159/000356121; Wang JX, 2016, J CELL COMMUN SIGNAL, V10, P191, DOI 10.1007/s12079-016-0349-3; Weber J, 2017, NEW ENGL J MED, V377, P1824, DOI 10.1056/NEJMoa1709030	25	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUN	2018	42	6					715	725		10.1097/PAS.0000000000001034			11	Pathology; Surgery	Pathology; Surgery	GF8NF	WOS:000432228900003	29462090	Green Accepted			2019-10-28	
J	Gru, AA; Kim, J; Pulitzer, M; Guitart, J; Battistella, M; Wood, GS; Cerroni, L; Kempf, W; Willemze, R; Pawade, J; Querfeld, C; Schaffer, A; Pincus, L; Tetzlaff, M; Duvic, M; Scarisbrick, J; Porcu, P; Mangold, AR; DiCaudo, DJ; Shinohara, M; Hong, EK; Horton, B; Kim, YH				Gru, Alejandro A.; Kim, Jinah; Pulitzer, Melissa; Guitart, Joan; Battistella, Maxime; Wood, Gary S.; Cerroni, Lorenzo; Kempf, Werner; Willemze, Rein; Pawade, Joya; Querfeld, Christiane; Schaffer, Andras; Pincus, Laura; Tetzlaff, Michael; Duvic, Madeleine; Scarisbrick, Julia; Porcu, Pierluigi; Mangold, Aaron R.; DiCaudo, David J.; Shinohara, Michi; Hong, Eric K.; Horton, Bethany; Kim, Youn H.			The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and Sezary Syndrome A Multi-institutional and International Pathology Study	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						mycosis fungoides; Sezary syndrome; cutaneous lymphoma; T-cell lymphoma; pathology	CUTANEOUS T-CELL; PROGNOSTIC-FACTORS; BRENTUXIMAB VEDOTIN; CLINICOPATHOLOGICAL FEATURES; CD30 EXPRESSION; LYMPHOMA; SURVIVAL; PROPOSAL; CLASSIFICATION; ORGANIZATION	This pathology PILOT study aims to define the role and feasibility of centralized pathology review in a cohort of 75 patients from different centers in the United States and Europe using digital slide scanning. The pathologic material from 75 patients who had been diagnosed with mycosis fungoides/Sezary syndrome and were clinically staged as IIb or above was retrieved from 11 participating centers. Each pathology reviewer was provided with the pathologic diagnosis (by the referring pathologist), and the following list of histopathologic criteria (presence or absence) from the initial report: epidermotropism, folliculotropism (FT), large cell transformation, syringotropism, and granulomas. Patients with advance stage were selected for this study as this is a population where there is significant variability in the diagnosis of pathologic prognostic and predictive biomarkers. The slides were digitally scanned with an Aperio scanner and consensus review of cases occurred when major or minor discrepancies between the referral diagnosis and central pathology review occurred. Among the 75 cases, 70 (93.3%) had a final consensus diagnosis between the 3 central review pathologists. The overall agreement between the consensus review and the referring pathologist was 60%. The overall agreement was also higher between the reviewers and consensus review, compared with the referring pathologist and consensus. 65.3% of cases had some type of discrepancy (major or minor) between the outside and consensus review. Major discrepancies were seen in 34 of 73 cases (46.6%; 73 cases indicated a yes or no response). Minor discrepancies were seen in 32 of 75 (42.7%) of cases. Most of the major discrepancies were accounted by a difference in interpretation in the presence or absence of large cell transformation or FT. Most minor discrepancies were explained by a different interpretation in the expression of CD30. We found digital slide scanning to be a beneficial, reliable, and practical for a methodical approach to perform central pathology review in the context of a large clinical prospective study.	[Gru, Alejandro A.] Univ Virginia, Dept Pathol & Dermatol, Charlottesville, VA 22908 USA; [Horton, Bethany] Univ Virginia, Dept Publ Hlth Sci, Charlottesville, VA USA; [Kim, Jinah] Stanford Univ, Dept Pathol, Palo Alto, CA 94304 USA; [Hong, Eric K.; Kim, Youn H.] Stanford Univ, Dept Dermatol, Palo Alto, CA 94304 USA; [Querfeld, Christiane] City Hope Natl Med Ctr, Div Dermatol, Duarte, CA USA; [Pincus, Laura] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [Pulitzer, Melissa] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Guitart, Joan] Northwestern Univ, Dept Dermatol, Chicago, IL 60611 USA; [Battistella, Maxime] Hosp St Louis, Dept Pathol, Paris, France; [Wood, Gary S.] Univ Wisconsin, Dept Dermatol, Madison, WI USA; [Cerroni, Lorenzo] Karl Franzens Univ Graz, Dept Dermatol, Graz, Austria; [Kempf, Werner] Kempf & Pfaltz, Diagnost Histopathol, Zurich, Switzerland; [Willemze, Rein] Leiden Univ, Dept Dermatol, Leiden, Netherlands; [Pawade, Joya] Univ Hosp Birmingham, Dept Pathol, Birmingham, W Midlands, England; [Scarisbrick, Julia] Univ Hosp Birmingham, Dept Dermatol, Birmingham, W Midlands, England; [Schaffer, Andras] Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; [Tetzlaff, Michael] MD Anderson Canc Ctr, Dept Pathol, Houston, TX USA; [Duvic, Madeleine] MD Anderson Canc Ctr, Dept Dermatol, Houston, TX USA; [Porcu, Pierluigi] Thomas Jefferson Univ, Div Hematol Malignancies & Hematopoiet Stem Cell, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Mangold, Aaron R.; DiCaudo, David J.] Mayo Clin, Dept Dermatol, Scottsdale, AZ USA; [Shinohara, Michi] Univ Washington, Dept Dermatol, Seattle, WA 98195 USA	Gru, AA (reprint author), Univ Virginia, Dept Pathol & Dermatol, Charlottesville, VA 22908 USA.	Aag4b@virginia.edu	Battistella, Maxime/K-2949-2012	Battistella, Maxime/0000-0002-7053-7431			Agar NS, 2010, J CLIN ONCOL, V28, P4730, DOI 10.1200/JCO.2009.27.7665; Bagot M, 2017, INDIAN J DERMATOL, V62, P142, DOI 10.4103/ijd.IJD_73_17; Barberio E, 2007, BRIT J DERMATOL, V157, P284, DOI 10.1111/j.1365-2133.2007.08008.x; Bellei M, 2017, HEMATOL ONCOL, V35, P630, DOI 10.1002/hon.2316; Benner MF, 2012, BLOOD, V119, P1643, DOI 10.1182/blood-2011-08-376319; Benton EC, 2013, EUR J CANCER, V49, P2859, DOI 10.1016/j.ejca.2013.04.018; Berger GK, 2017, CRIT REV ONCOL HEMAT, V109, P42, DOI 10.1016/j.critrevonc.2016.11.009; Diamandidou E, 1999, J AM ACAD DERMATOL, V40, P914, DOI 10.1016/S0190-9622(99)70079-4; Duvic M, 2015, J CLIN ONCOL, V33, P3759, DOI 10.1200/JCO.2014.60.3787; Edinger JT, 2009, AM J SURG PATHOL, V33, P1860, DOI 10.1097/PAS.0b013e3181bf677d; Florell SR, 2006, AM J CLIN PATHOL, V125, P727, DOI 10.1309/3JK2H6Y988NUAY37; Gerami P, 2008, ARCH DERMATOL, V144, P738, DOI 10.1001/archderm.144.6.738; Guitart J, 2001, J CUTAN PATHOL, V28, P174, DOI 10.1034/j.1600-0560.2001.028004174.x; Herrera AF, 2014, CANCER-AM CANCER SOC, V120, P1993, DOI 10.1002/cncr.28676; Kadin ME, 2012, J INVEST DERMATOL, V132, P703, DOI 10.1038/jid.2011.351; Kim YH, 2003, ARCH DERMATOL, V139, P857, DOI 10.1001/archderm.139.7.857; Kim YH, 2015, J CLIN ONCOL, V33, P3750, DOI 10.1200/JCO.2014.60.3969; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Olsen E, 2007, BLOOD, V110, P1713, DOI 10.1182/blood-2007-03-055749; Pulitzer M, 2014, PATHOLOGY, V46, P610, DOI 10.1097/PAT.0000000000000166; Scarisbrick JJ, 2014, BRIT J DERMATOL, V170, P1226, DOI 10.1111/bjd.12909; Scarisbrick JJ, 2015, J CLIN ONCOL, V33, P3766, DOI 10.1200/JCO.2015.61.7142; Swerdlow SH, 2008, WHO CLASSIFICATION T; Virmani P, 2017, EXPERT REV HEMATOL, V10, P111, DOI 10.1080/17474086.2017.1270201; Vose JM, 2008, J CLIN ONCOL, V26, P4124, DOI 10.1200/JCO.2008.16.4558; Whittaker S, 2016, BLOOD, V127, P3142, DOI 10.1182/blood-2015-12-611830; Willemze R, 2005, BLOOD, V105, P3768, DOI 10.1182/blood-2004-09-3502	27	1	1	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUN	2018	42	6					726	734		10.1097/PAS.0000000000001041			9	Pathology; Surgery	Pathology; Surgery	GF8NF	WOS:000432228900004	29543675				2019-10-28	
J	Baneckova, M; Agaimy, A; Andreasen, S; Vanecek, T; Steiner, P; Slouka, D; Svoboda, T; Miesbauerova, M; Michal, M; Skalova, A				Baneckova, Martina; Agaimy, Abbas; Andreasen, Simon; Vanecek, Tomas; Steiner, Petr; Slouka, David; Svoboda, Tomas; Miesbauerova, Marketa; Michal, Michael, Jr.; Skalova, Alena			Mammary Analog Secretory Carcinoma of the Nasal Cavity Characterization of 2 Cases and Their Distinction From Other Low-grade Sinonasal Adenocarcinomas	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						nasal cavity; mammary analog secretory carcinoma; MASC; low-grade sinonasal adenocarcinoma; ETV6-NTRK3	LOW-GRADE ADENOCARCINOMA; ETV6-NTRK3 GENE FUSION; SALIVARY-GLANDS; SINONASAL-TRACT; THYROID-GLAND; FEATURES; MASC; DIFFERENTIATION; REARRANGEMENTS; TRANSLOCATION	Secretory carcinoma, originally described as mammary analog secretory carcinoma (MASC), is a low-grade salivary gland tumor characterized by a t(12;15)(p13;q25) translocation, resulting in an ETV6-NTRK3 gene fusion. Most MASCs are localized to the parotid gland and intraoral minor salivary glands. Moreover, ETV6-rearranged carcinomas with secretory features have been reported recently in the thyroid (with and without a history of radiation exposure), skin, and in very rare instances in the sinonasal tract. Here, we describe 2 cases of primary MASC in the sinonasal tract and provide a detailed clinical and histopathologic characterization of their morphology, immunohistochemical profile, and genetic background and highlight features allowing for its separation from its recently described molecular mimicker, ETV6-rearranged low-grade sinonasal adenocarcinoma.	[Baneckova, Martina; Steiner, Petr; Miesbauerova, Marketa; Michal, Michael, Jr.; Skalova, Alena] Charles Univ Prague, Dept Pathol, Fac Med Plzen, Oncol Clin, Plzen, Czech Republic; [Slouka, David] Charles Univ Prague, Dept Otorhinolaryngol, Fac Med Plzen, Oncol Clin, Prague, Czech Republic; [Svoboda, Tomas] Charles Univ Prague, Dept Oncol & Radiotherapy, Fac Med Plzen, Oncol Clin, Prague, Czech Republic; [Baneckova, Martina; Miesbauerova, Marketa; Michal, Michael, Jr.; Skalova, Alena] Biopt Lab Ltd, Plzen, Czech Republic; [Vanecek, Tomas; Steiner, Petr] Biopt Lab Ltd, Dept Mol Pathol, Plzen, Czech Republic; [Agaimy, Abbas] Friedrich Alexander Univ, Inst Pathol, Erlangen, Germany; [Andreasen, Simon] Koge Univ Hosp, Dept Otorhinolaryngol & Maxillofacial Surg, Koge, Denmark; [Andreasen, Simon] Rigshosp, Dept Otolaryngol Head & Neck Surg, Copenhagen, Denmark	Skalova, A (reprint author), Charles Univ Prague, Sikls Dept Pathol, Med Fac, Fac Hosp, E Benese 13, Plzen 30599, Czech Republic.	skalova@fnplzen.cz	Michal, Michael/I-3497-2017; Baneckova, Martina/Q-1052-2017	Michal, Michael/0000-0003-4403-7027; Andreasen, Simon/0000-0002-1528-4988; Baneckova, Martina/0000-0002-5829-5572	National Sustainability Program I (NPU I) [LO1503]; Ministry of Education, Youth and Sports of the Czech RepublicMinistry of Education, Youth & Sports - Czech Republic [260 391, SVV-2017]	Supported by the National Sustainability Program I (NPU I) Nr. LO1503 and by the grant SVV-2017 No. 260 391 provided by the Ministry of Education, Youth and Sports of the Czech Republic. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Agaimy A, 2017, AM J SURG PATHOL, V41, P458, DOI 10.1097/PAS.0000000000000797; Amin SM, 2016, AM J DERMATOPATH, V38, P842, DOI 10.1097/DAD.0000000000000590; Andreasen S, 2017, AM J SURG PATHOL, V41, P1552, DOI 10.1097/PAS.0000000000000912; Andreasen S, 2017, HISTOPATHOLOGY, V70, P880, DOI 10.1111/his.13162; Antonescu CR, 2000, DIAGN MOL PATHOL, V9, P1, DOI 10.1097/00019606-200003000-00001; Bishop JA, 2017, AM J SURG PATHOL, V41, P1690, DOI 10.1097/PAS.0000000000000944; Bishop JA, 2017, AM J SURG PATHOL, V41, P62, DOI 10.1097/PAS.0000000000000734; Bishop JA, 2016, HEAD NECK PATHOL, V10, P23, DOI 10.1007/s12105-016-0688-7; Bishop JA, 2013, AM J SURG PATHOL, V37, P1053, DOI 10.1097/PAS.0b013e3182841554; Bishop JA, 2013, HEAD NECK PATHOL, V7, P35, DOI 10.1007/s12105-013-0429-0; Bourgeois JM, 2000, AM J SURG PATHOL, V24, P937, DOI 10.1097/00000478-200007000-00005; Chenevert J, 2012, MODERN PATHOL, V25, P919, DOI 10.1038/modpathol.2012.57; Chiosea SI, 2012, HISTOPATHOLOGY, V61, P387, DOI 10.1111/j.1365-2559.2012.04232.x; Chiosea SI, 2012, AM J SURG PATHOL, V36, P343, DOI 10.1097/PAS.0b013e318242a5b0; Dettloff J, 2017, HEAD NECK PATHOL, V11, P124, DOI 10.1007/s12105-016-0741-6; Dogan S, 2016, MODERN PATHOL, V29, P985, DOI 10.1038/modpathol.2016.115; Drilon A, 2016, ANN ONCOL, V27, P920, DOI 10.1093/annonc/mdw042; El-Naggar AK, 2017, WHO CLASSIFICATION H, P11; Gaffney R, 2003, J MOL DIAGN, V5, P127, DOI 10.1016/S1525-1578(10)60462-X; HEFFNER DK, 1982, CANCER, V50, P312, DOI 10.1002/1097-0142(19820715)50:2<312::AID-CNCR2820500225>3.0.CO;2-Z; Hyrcza MD, 2015, DIAGN HISTOPATHOL, V21, P481; Ito Y, 2015, AM J SURG PATHOL, V39, P602, DOI 10.1097/PAS.0000000000000392; Leivo I, 2016, HEAD NECK PATHOL, V10, P68, DOI 10.1007/s12105-016-0694-9; Luna MA, 2005, ADV ANAT PATHOL, V12, P109, DOI 10.1097/01.pap.0000163961.18730.ba; Lurquin E, 2015, HISTOPATHOLOGY, V67, P749, DOI 10.1111/his.12702; Murphy DA, 2017, APPL IMMUNOHISTO M M, V25, P513, DOI 10.1097/PAI.0000000000000360; Skalova A, 2003, VIRCHOWS ARCH, V443, P152, DOI 10.1007/s00428-003-0844-9; Skalova A, 2017, WHO CLASSIFICATION H, P177; Skalova A, 2018, AM J SURG PATHOL, V42, pE11, DOI 10.1097/PAS.0000000000000980; Skalova A, 2016, AM J SURG PATHOL, V40, P3, DOI 10.1097/PAS.0000000000000537; Skalova A, 2013, HEAD NECK PATHOL, V7, pS30, DOI 10.1007/s12105-013-0455-y; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Stevens TM, 2015, MODERN PATHOL, V28, P1084, DOI 10.1038/modpathol.2015.64; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; Viswanatha DS, 2000, MODERN PATHOL, V13, P825, DOI 10.1038/modpathol.3880144; WENIG BM, 1988, AM J SURG PATHOL, V12, P946, DOI 10.1097/00000478-198812000-00005; Xu B, 2018, HEAD NECK PATHOL, V12, P274, DOI 10.1007/s12105-017-0855-5	37	6	6	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUN	2018	42	6					735	743		10.1097/PAS.0000000000001048			9	Pathology; Surgery	Pathology; Surgery	GF8NF	WOS:000432228900005	29543674				2019-10-28	
J	Marrano, P; Shago, M; Somers, GR; Thorner, PS				Marrano, Paula; Shago, Mary; Somers, Gino R.; Thorner, Paul S.			Fluorescent In Situ Hybridization for TP53 in the Diagnosis of Pediatric Osteogenic Sarcoma	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						osteosarcoma; TP53; FISH; sarcoma; p53	ROTHMUND-THOMSON-SYNDROME; P53 MUTATIONS; MDM2 GENES; CLINICOPATHOLOGICAL FEATURES; GENOMIC INSTABILITY; HUMAN OSTEOSARCOMAS; TUMOR-SUPPRESSOR; BREAST-CANCER; PREDISPOSITION; RETINOBLASTOMA	Osteogenic sarcoma (OS) is the most common malignant bone tumor in children and adolescents. Despite advances in molecular genetic characterization of pediatric and adult tumors, the diagnosis of OS still depends almost entirely on light microscopy. The lack of consistent genetic changes in OS has greatly hindered the development of any diagnostic molecular test. Recently, whole-genome sequencing has shown that similar to 50% of cases of OS have a translocation involving the TP53 gene with breakpoints confined to the first intron. We developed a 2 color break-apart fluorescent in situ hybridization (FISH) probe for intron 1 of TP53 and applied it to an archived series to assess its diagnostic utility. The study group included 37 cases of OS (including osteoblastic, chondroblastic, and fibroblastic), as well as 53 cases of non-OS pediatric sarcomas (including Ewing sarcoma, rhabdomyosarcoma, undifferentiated small cell sarcoma, CCNB3-BCOR sarcoma, CIC-DUX sarcoma, synovial sarcoma, and malignant peripheral nerve sheath tumor) and 27 cases of benign bone lesions (including osteoblastoma, chondromyxoid fibroma, fibrous dysplasia, and fibro-osseous dysplasia). A rearranged signal was found in 20/37 cases (54%) of OS and in none of the other sarcomas or benign bone lesions, giving the FISH test 100% specificity for a diagnosis of OS. p53 immunostaining was generally not predictive of the results obtained by FISH and could not substitute for this test. This FISH probe offers a simple and specific genetic test to aid in the diagnosis of OS, despite the genetic complexity of this tumor.	[Marrano, Paula; Somers, Gino R.; Thorner, Paul S.] Univ Toronto, Div Pathol, Toronto, ON, Canada; [Shago, Mary] Univ Toronto, Div Genome Diagnost, Hosp Sick Children, Toronto, ON, Canada; [Somers, Gino R.; Thorner, Paul S.] Univ Toronto, Dept Pathobiol & Lab Med, Toronto, ON, Canada	Thorner, PS (reprint author), Hosp Sick Children, Div Pathol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	paul.thorner@utoronto.ca					Bayani J, 2003, GENE CHROMOSOME CANC, V36, P7, DOI 10.1002/gcc.10132; Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003; Geller David S, 2010, Clin Adv Hematol Oncol, V8, P705; Gokgoz N, 2001, CANCER, V92, P2181, DOI 10.1002/1097-0142(20011015)92:8<2181::AID-CNCR1561>3.0.CO;2-3; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; Hicks MJ, 2007, J CLIN ONCOL, V25, P370, DOI 10.1200/JCO.2006.08.4558; Joseph CG, 2014, GENE CHROMOSOME CANC, V53, P15, DOI 10.1002/gcc.22114; Kleinerman RA, 2005, J CLIN ONCOL, V23, P2272, DOI 10.1200/JCO.2005.05.054; Lau CC, 2004, GENE CHROMOSOME CANC, V39, P11, DOI 10.1002/gcc.10291; Lonardo F, 1997, CANCER, V79, P1541, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1541::AID-CNCR15>3.0.CO;2-Y; Lopez-Guerrero JA, 2004, DIAGN MOL PATHOL, V13, P81; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Manning AL, 2012, NAT REV CANCER, V12, P220, DOI 10.1038/nrc3216; Martin Jeff W., 2012, Sarcoma, P627254, DOI 10.1155/2012/627254; MCINTYRE JF, 1994, J CLIN ONCOL, V12, P925, DOI 10.1200/JCO.1994.12.5.925; Meek DW, 2009, NAT REV CANCER, V9, P714, DOI 10.1038/nrc2716; MILLER CW, 1990, CANCER RES, V50, P7950; Miller CW, 1996, J CANCER RES CLIN, V122, P559, DOI 10.1007/BF01213553; Mirabello L., 2015, JNCI-J NATL CANCER I, V107, P1; Mohaghegh P, 2001, HUM MOL GENET, V10, P741, DOI 10.1093/hmg/10.7.741; Ottaviani G, 2009, CANC TREAT, V152, P3, DOI 10.1007/978-1-4419-0284-9_1; Overholtzer M, 2003, P NATL ACAD SCI USA, V100, P11547, DOI 10.1073/pnas.1934852100; Pellin A, 1997, DIAGN MOL PATHOL, V6, P333, DOI 10.1097/00019606-199712000-00005; Selvarajah S, 2008, CYTOGENET GENOME RES, V122, P5, DOI 10.1159/000151310; Sztan Marianna, 1997, Pathol Oncol Res, V3, P115; Tsuchiya T, 2000, CANCER GENET CYTOGEN, V120, P91, DOI 10.1016/S0165-4608(99)00255-1; Wang LL, 2003, J NATL CANCER I, V95, P669, DOI 10.1093/jnci/95.9.669; Watanabe G, 2015, AM J SURG PATHOL, V39, P1026, DOI 10.1097/PAS.0000000000000386; Wunder JS, 2005, J CLIN ONCOL, V23, P1483, DOI 10.1200/JCO.2005.04.074; Yemelyanova A, 2011, MODERN PATHOL, V24, P1248, DOI 10.1038/modpathol.2011.85; Zielenska M, 2004, CYTOGENET GENOME RES, V107, P77, DOI 10.1159/000079574; Zielenska M, 2001, CANCER GENET CYTOGEN, V130, P14, DOI 10.1016/S0165-4608(01)00461-7	32	0	0	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUN	2018	42	6					744	749		10.1097/PAS.0000000000001054			6	Pathology; Surgery	Pathology; Surgery	GF8NF	WOS:000432228900006	29543677				2019-10-28	
J	Xing, DY; Zheng, G; Schoolmeester, JK; Li, ZB; Pallavajjala, A; Haley, L; Conner, MG; Vang, R; Hung, CF; Wu, TC; Ronnett, BM				Xing, Deyin; Zheng, Gang; Schoolmeester, John Kenneth; Li, Zaibo; Pallavajjala, Aparna; Haley, Lisa; Conner, Michael G.; Vang, Russell; Hung, Chien-Fu; Wu, Tzyy-Choou; Ronnett, Brigitte M.			Next-generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						next-generation sequencing; small cell neuroendocrine carcinoma; human papillomavirus; mutations; uterine cervix	HUMAN-PAPILLOMAVIRUS INFECTION; RELAPSED OVARIAN-CANCER; PROGNOSTIC-FACTORS; THERAPEUTIC CHALLENGE; ONCOGENIC MUTATIONS; BRCA1/2 MUTATION; ENDOCRINE TUMORS; P53 MUTATIONS; DOUBLE-BLIND; EXPRESSION	Small cell neuroendocrine carcinoma (SCNEC) of the uterine cervix is a rare but extremely aggressive tumor. While high-risk human papillomavirus (HPV) is involved at an early stage of oncogenesis in many tumors, additional driving events have been postulated to facilitate the progression of SCNECs. Identification of oncogenic drivers could guide targeted therapy of this neoplasm. Clinicopathologic features of 10 cervical SCNECs are reported. Analyses included immunohistochemical evaluation of p16, p53, synaptophysin, and chromogranin expression; in situ hybridizations and polymerase chain reaction for high-risk HPV and/or HPV 18; and next-generation sequencing based on a 637-gene panel. The patients ranged in age from 28 to 68 years (mean, 45.6y; median, 40.5y). All tumors had diffuse p16 and synaptophysin expression. All but 1 tumor was positive for chromogranin (extent of staining ranged from focal to diffuse). HPV 18 was detected in 6 tumors and HPV 35 in 1 tumor. At least 1 driver mutation was detected in 8 tumors. Four cases harbored TP53 somatic mutations, 3 of which correlated with an aberrant p53 staining pattern. Four PIK3CA mutations (p.G106A, p.N345T, p.E545K, and p.E545D) were detected in 3 tumors, 2 of which also harbored TP53 mutations. Oncogenic driver mutations involving KRAS, Erbb2, c-Myc, NOTCH1, BCL6, or NCOA3 were detected in 4 tumors. Mutations in caretaker tumor suppressors PTEN, RB1, BRCA1, BRCA2, and ARID1B were also identified in 4 tumors that commonly coharbored activating oncogenic mutations. Targeted next-generation gene sequencing identified genetic alterations involving the MAPK, PI3K/AKT/mTOR, and TP53/BRCA pathways in SCNECs. The presence of genetic alterations that are amenable to targeted therapy in SCNECs offers the potential for individualized management strategies for treatment of this aggressive tumor.	[Xing, Deyin; Zheng, Gang; Pallavajjala, Aparna; Haley, Lisa; Vang, Russell; Hung, Chien-Fu; Wu, Tzyy-Choou; Ronnett, Brigitte M.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; [Schoolmeester, John Kenneth] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA; [Li, Zaibo] Ohio State Univ, Wexner Med Ctr, Dept Pathol, Columbus, OH 43210 USA; [Conner, Michael G.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA	Xing, DY (reprint author), Johns Hopkins Univ Hosp, Dept Pathol, Weinberg 2242,401 N Broadway, Baltimore, MD 21231 USA.	dxing2@jhmi.edu		Zheng, Gang/0000-0003-0276-9430	Cervical Cancer SPORE program at Johns Hopkins	Career Development Award by the Cervical Cancer SPORE program at Johns Hopkins (D.X.).	ABELER VM, 1994, CANCER, V73, P672, DOI 10.1002/1097-0142(19940201)73:3<672::AID-CNCR2820730328>3.0.CO;2-R; Abidin Aidalena Z, 2010, Ther Adv Med Oncol, V2, P25, DOI 10.1177/1758834009356014; Atienza-Amores M, 2014, GYNECOL ONCOL, V134, P410, DOI 10.1016/j.ygyno.2014.05.017; Bermudez A, 2001, GYNECOL ONCOL, V82, P32, DOI 10.1006/gyno.2001.6201; Bose R, 2013, CANCER DISCOV, V3, P224, DOI 10.1158/2159-8290.CD-12-0349; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chan JK, 2003, CANCER, V97, P568, DOI 10.1002/cncr.11086; Chen J, 2008, OBSTET GYNECOL, V111, P1394, DOI 10.1097/AOG.0b013e318173570b; Cho SY, 2017, ONCOTARGET, V8, P8095, DOI 10.18632/oncotarget.14098; Cohen JG, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.04.019; Conner Michael G, 2002, Ann Diagn Pathol, V6, P345, DOI 10.1053/adpa.2002.36661; Dougherty BA, 2017, ONCOTARGET, V8, P43653, DOI 10.18632/oncotarget.17613; EVANDER M, 1992, J CLIN MICROBIOL, V30, P987; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fruman DA, 2017, CELL, V170, P605, DOI 10.1016/j.cell.2017.07.029; Frumovitz M, 2016, GYNECOL ONCOL, V141, P588, DOI 10.1016/j.ygyno.2016.04.001; Gadducci A, 2017, GYNECOL ONCOL, V144, P637, DOI 10.1016/j.ygyno.2016.12.003; Ganesan R, 2016, INT J SURG PATHOL, V24, P490, DOI 10.1177/1066896916643385; Gondek LP, 2016, LEUKEMIA, V30, P1916, DOI 10.1038/leu.2016.63; Hales EC, 2014, CELL SIGNAL, V26, P149, DOI 10.1016/j.cellsig.2013.09.021; Henken FE, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-71; Herrington CS, 1999, HUM PATHOL, V30, P906, DOI 10.1016/S0046-8177(99)90243-5; Hodgson A, 2017, MODERN PATHOL, V30, P1633, DOI 10.1038/modpathol.2017.80; Horn LC, 2006, INT J GYNECOL PATHOL, V25, P182, DOI 10.1097/01.pgp.0000185406.85685.df; Howitt BE, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0617-2; Ihle NT, 2012, JNCI-J NATL CANCER I, V104, P228, DOI 10.1093/jnci/djr523; Intaraphet S, 2014, ONCOTARGETS THER, V7, P1205, DOI 10.2147/OTT.S64714; Ishida GM, 2004, INT J GYNECOL PATHOL, V23, P366, DOI 10.1097/01.pgp.0000139637.01977.61; KAELBLING M, 1992, LANCET, V340, P140, DOI 10.1016/0140-6736(92)93214-8; Kim YT, 1996, HUM PATHOL, V27, P389, DOI 10.1016/S0046-8177(96)90113-6; Kurman RJ, 2014, WHO CLASSIFICATION T; Ledermann JA, 2016, LANCET ONCOL, V17, P1579, DOI 10.1016/S1470-2045(16)30376-X; Lyons YA, 2014, GYNECOL ONCOL REP, V10, P28, DOI 10.1016/j.gore.2014.09.003; Mannion C, 1998, CANCER, V83, P1391, DOI 10.1002/(SICI)1097-0142(19981001)83:7<1391::AID-CNCR17>3.0.CO;2-#; Masumoto N, 2003, HUM PATHOL, V34, P778, DOI 10.1016/S0046-8177(03)00284-3; Matulonis UA, 2016, ANN ONCOL, V27, P1013, DOI 10.1093/annonc/mdw133; O'Neill CJ, 2007, HISTOPATHOLOGY, V50, P851, DOI 10.1111/j.1365-2559.2007.02699.x; Ojesina AI, 2014, NATURE, V506, P371, DOI 10.1038/nature12881; PAO CC, 1994, J SURG ONCOL, V57, P87, DOI 10.1002/jso.2930570204; PAQUETTE RL, 1993, CANCER-AM CANCER SOC, V72, P1272, DOI 10.1002/1097-0142(19930815)72:4<1272::AID-CNCR2820720420>3.0.CO;2-Q; Pujade-Lauraine E, 2017, LANCET ONCOL, V18, P1274, DOI 10.1016/S1470-2045(17)30469-2; Samuels Y, 2004, CELL CYCLE, V3, P1221, DOI 10.4161/cc.3.10.1164; Satoh T, 2014, INT J GYNECOL CANCER, V24, pS102, DOI 10.1097/IGC.0000000000000262; Scholes AGM, 1997, INT J CANCER, V71, P796, DOI 10.1002/(SICI)1097-0215(19970529)71:5<796::AID-IJC17>3.0.CO;2-6; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Small W, 2017, CANCER-AM CANCER SOC, V123, P2404, DOI 10.1002/cncr.30667; STOLER MH, 1991, AM J SURG PATHOL, V15, P28, DOI 10.1097/00000478-199101000-00003; Straughn JM, 2001, GYNECOL ONCOL, V83, P216, DOI 10.1006/gyno.2001.6385; Tommasino M, 2003, HUM MUTAT, V21, P307, DOI 10.1002/humu.10178; Wang HLL, 2004, AM J SURG PATHOL, V28, P901, DOI 10.1097/00000478-200407000-00009; Wang KL, 2012, EUR J CANCER, V48, P1484, DOI 10.1016/j.ejca.2011.12.014; Wistuba II, 1999, GYNECOL ONCOL, V72, P3, DOI 10.1006/gyno.1998.5248; Wright AA, 2013, CANCER-AM CANCER SOC, V119, P3776, DOI 10.1002/cncr.28288; Xing DY, 2016, AM J SURG PATHOL, V40, P529, DOI 10.1097/PAS.0000000000000565; Yang SW, 2009, CANCER EPIDEMIOL, V33, P118, DOI 10.1016/j.canep.2009.05.003; Yemelyanova A, 2009, AM J SURG PATHOL, V33, P1504, DOI 10.1097/PAS.0b013e3181ac35f5; Zhang XY, 2005, J BIOL CHEM, V280, P33165, DOI 10.1074/jbc.M505124200; Zhang YX, 2016, CLIN CANCER RES, V22, P4735, DOI 10.1158/1078-0432.CCR-16-0323; Zivanovic O, 2009, GYNECOL ONCOL, V112, P590, DOI 10.1016/j.ygyno.2008.11.010	60	4	5	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUN	2018	42	6					750	760		10.1097/PAS.0000000000001042			11	Pathology; Surgery	Pathology; Surgery	GF8NF	WOS:000432228900007	29505425	Green Accepted			2019-10-28	
J	Terra, SBSP; Aesif, SW; Maleszewski, JJ; Folpe, AL; Boland, JM				Terra, Simone B. S. P.; Aesif, Scott W.; Maleszewski, Joseph J.; Folpe, Andrew L.; Boland, Jennifer M.			Mediastinal Synovial Sarcoma Clinicopathologic Analysis of 21 Cases With Molecular Confirmation	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						synovial sarcoma; mediastinum; thorax	SYT-SSX; FUSION GENE; FEATURES; TUMORS; IDENTIFICATION; NERVE	Synovial sarcoma (SS), a translocation-associated sarcoma characterized by SS18-SSX1/2 fusion, presents most often in the extremities of young adults. While SS regularly occurs in the pleuropulmonary parenchyma, the mediastinum is an exceedingly rare primary site; the literature on this subject is predominantly composed of case reports and small series, mostly without molecular confirmation. Cases of mediastinal SS were selected from our institutional and consultation archives. Diagnoses were confirmed by either SS18 fluorescence in situ hybridization (n = 6) or reverse transcription polymerase chain reaction for SS18-SSX1/2 (n = 15). Mediastinal SSs occurred in 21 patients (15 men; mean age, 38y; range, 21 to 75). Only 1 patient was older than 50 years. Average tumor size was 13.5cm (range: 6.4 to 23cm). One tumor was biphasic and the rest were monophasic, 11 of which were poorly differentiated (52%). Of 10 cases with known fusion transcripts, 6 had SS18-SSX2 and 4 had SS18-SSX1. Follow-up was known for 16 patients (mean: 18.9mo; range: 5 to 45): 14 had local disease progression or recurrence, and 6 had metastasis. Death from disease occurred in 11 of 16 patients (69%) at 5 to 32 months, and 5 (36%) were alive with disease at last follow-up (6 to 45mo). Mediastinal SS is a rare and aggressive malignancy most common in patients younger than 50 years. Most are monophasic and reach large size before detection. Poorly differentiated morphology is common. SS should be included in the differential diagnosis of spindle cell, biphasic and poorly differentiated mediastinal tumors. Because of the rarity of SS at this site, molecular testing is recommended to confirm the diagnosis.	[Terra, Simone B. S. P.; Aesif, Scott W.; Maleszewski, Joseph J.; Folpe, Andrew L.; Boland, Jennifer M.] Mayo Clin, Rochester, MN USA; [Aesif, Scott W.] Univ Wisconsin, Madison, WI USA	Boland, JM (reprint author), Mayo Clin, Div Anat Pathol, 200 First St SW, Rochester, MN 55905 USA.	boland.jennifer@mayo.edu		Boland, Jennifer/0000-0002-2723-9586; Aesif, Scott/0000-0002-4798-7290			Begueret H, 2005, AM J SURG PATHOL, V29, P339; Bergh P, 1999, CANCER-AM CANCER SOC, V85, P2596, DOI 10.1002/(SICI)1097-0142(19990615)85:12<2596::AID-CNCR16>3.0.CO;2-K; Brodin B, 2001, GENE, V268, P173, DOI 10.1016/S0378-1119(01)00412-7; Chan JA, 2003, HISTOPATHOLOGY, V43, P72, DOI 10.1046/j.1365-2559.2003.01643.x; Coindre JM, 2003, CANCER-AM CANCER SOC, V98, P2700, DOI 10.1002/cncr.11840; de Silva MVC, 2003, HISTOPATHOLOGY, V43, P220, DOI 10.1046/j.1365-2559.2003.01668.x; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; Duband S, 2008, AM J PERINAT, V25, P517, DOI 10.1055/s-0028-1085074; Essary LR, 2002, CANCER, V94, P459, DOI 10.1002/cncr.10188; Fisher C, 2004, HISTOPATHOLOGY, V45, P245, DOI 10.1111/j.1365-2559.2004.01950.x; Fletcher C, 2013, WHO CLASSIFICATION T; Folpe AL, 2009, AM J SURG PATHOL, V33, P1179, DOI 10.1097/PAS.0b013e31819e61c8; Guillou L, 2001, HUM PATHOL, V32, P105, DOI 10.1053/hupa.2001.21130; Hartel PH, 2007, MODERN PATHOL, V20, P760, DOI 10.1038/modpathol.3800795; Kawai A, 1998, NEW ENGL J MED, V338, P153, DOI 10.1056/NEJM199801153380303; Ladanyi M, 2002, CANCER RES, V62, P135; Lewis JJ, 2000, J CLIN ONCOL, V18, P2087, DOI 10.1200/JCO.2000.18.10.2087; MAJESTE RM, 1988, CANCER, V61, P2527, DOI 10.1002/1097-0142(19880615)61:12<2527::AID-CNCR2820611223>3.0.CO;2-6; Miettinen M, 2000, VIRCHOWS ARCH, V437, P275, DOI 10.1007/s004280000238; Motoi T, 2010, HUM PATHOL, V41, P1397, DOI 10.1016/j.humpath.2010.02.009; Olsen SH, 2006, MODERN PATHOL, V19, P659, DOI 10.1038/modpathol.3800569; Pelmus M, 2002, AM J SURG PATHOL, V26, P1434, DOI 10.1097/00000478-200211000-00005; Poo WC, 2011, AM J CLIN PATHOL, V135, P839, DOI 10.1309/AJCP45SSNAOPXYXU; Salah Samer, 2014, ISRN Oncol, V2014, P412527, DOI 10.1155/2014/412527; Sandberg AA, 2002, CANCER GENET CYTOGEN, V133, P1, DOI 10.1016/S0165-4608(01)00626-4; Scheithauer BW, 2011, HUM PATHOL, V42, P568, DOI 10.1016/j.humpath.2010.08.019; Sharma S, 2017, PATHOL RES PRACT, V213, P868, DOI 10.1016/j.prp.2017.03.005; Storlazzi CT, 2003, GENE CHROMOSOME CANC, V37, P195, DOI 10.1002/gcc.10210; Sultan I, 2009, CANCER-AM CANCER SOC, V115, P3537, DOI 10.1002/cncr.24424; Suster S, 2005, AM J SURG PATHOL, V29, P569, DOI 10.1097/01.pas.0000157934.50936.3e; Ten Heuvel SE, 2008, APPL IMMUNOHISTO M M, V16, P246, DOI 10.1097/PAI.0b013e31815349f5; Trupiano JK, 2002, ANN THORAC SURG, V73, P628, DOI 10.1016/S0003-4975(01)03110-1; van de Rijn M, 1999, AM J SURG PATHOL, V23, P106, DOI 10.1097/00000478-199901000-00012; Weiss SW, 2014, ENZINGER WEISSS SOFT; WITKIN GB, 1989, AM J SURG PATHOL, V13, P490, DOI 10.1097/00000478-198906000-00005; Xu P, 2017, OPHTHALMOL EYE DIS, V9, P1, DOI 10.1177/1179172117701732	36	1	1	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUN	2018	42	6					761	766		10.1097/PAS.0000000000001050			6	Pathology; Surgery	Pathology; Surgery	GF8NF	WOS:000432228900008	29543673				2019-10-28	
J	Ren, Q; Wang, L; Al-Ahmadie, HA; Fine, SW; Gopalan, A; Sirintrapun, SJ; Tickoo, SK; Reuter, VE; Chen, YB				Ren, Qinghu; Wang, Lu; Al-Ahmadie, Hikmat A.; Fine, Samson W.; Gopalan, Anuradha; Sirintrapun, Sahussapont J.; Tickoo, Satish K.; Reuter, Victor E.; Chen, Ying-Bei			Distinct Genomic Copy Number Alterations Distinguish Mucinous Tubular and Spindle Cell Carcinoma of the Kidney From Papillary Renal Cell Carcinoma With Overlapping Histologic Features	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						mucinous tubular and spindle cell carcinoma; papillary renal cell carcinoma; chromosomal aberration; SNP array; Hippo-YAP signaling	LOW-GRADE; SOLID VARIANT; METANEPHRIC ADENOMA; MOLECULAR ANALYSIS; GENETIC FEATURES; DIFFERENTIATION; COMPONENTS; NEOPLASMS	Mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney is a rare type of renal cell carcinoma that frequently exhibits histologic and immunophenotypic features overlapping with type 1 papillary renal cell carcinoma (PRCC). To clarify molecular attributes that can be used for this difficult differential diagnosis, we sought to delineate the genome-wide copy number alterations in tumors displaying classic histologic features of MTSCC in comparison to the solid variant of type 1 PRCC and indeterminate cases with overlapping histologic features. The study included 11 histologically typical MTSCC, 9 tumors with overlapping features between MTSCC and PRCC, and 6 cases of solid variant of type 1 PRCC. DNA samples extracted from macrodissected or microdissected tumor areas were analyzed for genome-wide copy number alterations using an SNP-array platform suitable for clinical archival material. All cases in the MTSCC group exhibited multiple chromosomal losses, most frequently involving chromosomes 1, 4, 6, 8, 9, 13, 14, 15, and 22, while lacking trisomy 7 or 17. In contrast, cases with overlapping morphologic features of MTSCC and PRCC predominantly showed multiple chromosomal gains, most frequently involving chromosomes 7, 16, 17, and 20, similar to the chromosomal alteration pattern that was seen in the solid variant of type 1 PRCC cases. Morphologic comparison of these molecularly characterized tumors identified histologic features that help to distinguish MTSCC from PRCC, but immunohistochemical profiles of these tumors remained overlapping, including a marker for Hippo-Yes-associated protein signaling. Characteristic patterns of genome-wide copy number alterations strongly support MTSCC and PRCC as distinct entities despite their immunohistochemical and certain morphologic overlap, and help define histologic features useful for the classification of questionable cases.	[Ren, Qinghu; Wang, Lu; Al-Ahmadie, Hikmat A.; Fine, Samson W.; Gopalan, Anuradha; Sirintrapun, Sahussapont J.; Tickoo, Satish K.; Reuter, Victor E.; Chen, Ying-Bei] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA	Chen, YB (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA.	cheny@mskcc.org	Wang, Lu/N-8128-2018	Wang, Lu/0000-0002-0073-0666	Cycle for Survival of Memorial Sloan Kettering Cancer Center; NIH/NCI Cancer Center Support Grant [P30 CA008748]	Supported by Cycle for Survival of Memorial Sloan Kettering Cancer Center (Y.-B.C.). L.W., H.A.A.-A., S.W.F., A.G., S.J.S., S.K.T., V.E.R., and Y.-B.C. were funded in part by an NIH/NCI Cancer Center Support Grant (P30 CA008748). The remaining authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Alexiev BA, 2014, PATHOL RES PRACT, V210, P454, DOI 10.1016/j.prp.2014.03.002; Arafah Maha, 2013, Saudi J Kidney Dis Transpl, V24, P557; Argani P, 2008, AM J SURG PATHOL, V32, P1353, DOI 10.1097/PAS.0b013e31816a1c34; Brandal P, 2006, MODERN PATHOL, V19, P186, DOI 10.1038/modpathol.3800499; Bulimbasic S, 2009, HUM PATHOL, V40, P906, DOI 10.1016/j.humpath.2009.03.004; Cantley R, 2010, ARCH PATHOL LAB MED, V134, P1210, DOI 10.1043/2009-0464-CR.1; Cao WL, 2014, INT J CLIN EXP PATHO, V7, P4350; Chen YB, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13131; Cossu-Rocca P, 2006, MODERN PATHOL, V19, P488, DOI 10.1038/modpathol.3800565; Dhillon J, 2009, AM J SURG PATHOL, V33, P44, DOI 10.1097/PAS.0b013e3181829ed5; Eble J. N. S. G., 2004, WHO CLASSIFICATION T; Farghaly H, 2012, ANN DIAGN PATHOL, V16, P59, DOI 10.1016/j.anndiagpath.2010.10.001; Ferlicot S, 2005, VIRCHOWS ARCH, V447, P978, DOI 10.1007/s00428-005-0036-x; Fine SW, 2006, AM J SURG PATHOL, V30, P1554, DOI 10.1097/01.pas.0000213271.15221.e3; Hes O, 2002, HISTOPATHOLOGY, V41, P549, DOI 10.1046/j.1365-2559.2002.01515.x; Kenney PA, 2015, BJU INT, V116, P85, DOI 10.1111/bju.12992; Kinney SN, 2015, MODERN PATHOL, V28, P1236, DOI 10.1038/modpathol.2015.81; Kuroda N, 2008, HISTOL HISTOPATHOL, V23, P1517, DOI 10.14670/HH-23.1517; Linehan WM, 2016, NEW ENGL J MED, V374, P135, DOI 10.1056/NEJMoa1505917; MacLennan GT, 1997, UROLOGY, V50, P679, DOI 10.1016/S0090-4295(97)00335-X; Padilha M, 2013, HISTOPATHOLOGY, V62, P941, DOI 10.1111/his.12106; Mehra R, 2016, CANCER DISCOV, V6, P1258, DOI 10.1158/2159-8290.CD-16-0267; Moch H, 2016, WHO CLASSIFICATION T; Okon Krzysztof, 2007, Polish Journal of Pathology, V58, P227; Paner GP, 2006, AM J SURG PATHOL, V30, P13, DOI 10.1097/01.pas.0000180443.94645.50; Parwani AV, 2001, HUM PATHOL, V32, P506, DOI 10.1053/hupa.2001.24320; Peckova K, 2015, ANN DIAGN PATHOL, V19, P226, DOI 10.1016/j.anndiagpath.2015.04.004; Pillay N, 2008, HUM PATHOL, V39, P966, DOI 10.1016/j.humpath.2007.10.006; Qi XL, 2016, INT J CLIN EXP PATHO, V9, P2451; Rakozy C, 2002, MODERN PATHOL, V15, P1162, DOI 10.1097/01.MP.0000031709.40712.46; Renshaw AA, 1997, AM J SURG PATHOL, V21, P1203, DOI 10.1097/00000478-199710000-00011; Sadimin ET, 2017, HISTOPATHOLOGY, V71, P719, DOI 10.1111/his.13298; Shen SS, 2007, ANN DIAGN PATHOL, V11, P13, DOI 10.1016/j.anndiagpath.2006.09.005; Simon RA, 2008, INT J CLIN EXP PATHO, V1, P180; Srigley J, 2002, LAB INVEST, V82, p182A; Srigley JR, 1999, MODERN PATHOL, V12, P107; Ursani NA, 2011, HUM PATHOL, V42, P444, DOI 10.1016/j.humpath.2010.07.018; Weber A, 2003, PATHOLOGE, V24, P453, DOI 10.1007/s00292-003-0657-2; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhang YL, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0194-8	40	6	6	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUN	2018	42	6					767	777		10.1097/PAS.0000000000001038			11	Pathology; Surgery	Pathology; Surgery	GF8NF	WOS:000432228900009	29462091	Green Accepted			2019-10-28	
J	Feasel, P; Al-Ibraheemi, A; Fritchie, K; Zreik, RT; Wang, WL; Demicco, E; Saeb-Lima, M; Goldblum, JR; Rubin, BP; McKenney, JK; Ko, JS; Billings, SD				Feasel, Patrick; Al-Ibraheemi, Alyaa; Fritchie, Karen; Zreik, Riyam T.; Wang, Wei-Lien; Demicco, Elizabeth; Saeb-Lima, Marcela; Goldblum, John R.; Rubin, Brian P.; McKenney, Jesse K.; Ko, Jennifer S.; Billings, Steven D.			Superficial Solitary Fibrous Tumor A Series of 26 Cases	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						solitary fibrous tumor; skin; skin neoplasms; immunohistochemistry; STAT6	OF-THE-LITERATURE; DERMATOFIBROSARCOMA PROTUBERANS; RISK-ASSESSMENT; SKIN; GENETICS; EXPRESSION; DIAGNOSIS; VARIANTS; LIPOMAS; MIMICS	While superficial (cutaneous/subcutaneous) solitary fibrous tumor (SFT) have been described, definitive diagnosis is difficult due to overlapping features with other tumors. We describe the largest series to date of superficial SFT. For inclusion, SFT had to arise in dermis or subcutis. Twenty-six cases were identified. Patients ranged from 16 to 80 years (mean, 47y) with a marked female predominance (19 F; 7 M). Tumors involved the head (11), thigh (7), back (3), shoulder (2), upper arm (1), ankle (1), and great toe (1). Mean size was 2.9cm (range, 1.0 to 7.0cm). The majority (n=19) had typical histologic features (cellular SFT) with irregular fascicles of spindled cells, staghorn-like blood vessels, and variable amounts of collagen. Necrosis was evident in 3 cases (all <25%). Mitotic activity ranged from 0 to 10 mitotic figures/10 high-power fields (mean, 2 mitotic figures/10 high-power fields). Seventeen of the 18 were positive for STAT6, whereas 21/22 expressed CD34. All were low risk (23/23) by proposed criteria (Demicco and colleagues), including 2 cases with malignant histology. Three could not be risk stratified due to lack of information on tumor size. Follow-up, available on 7 cases, showed no recurrence/metastasis (mean follow-up, 100mo; range, 2 to 241mo). Cutaneous SFT are more common in women and most often involve the head. They are usually low risk by proposed criteria and appear to behave in an indolent manner, though larger studies are needed to confirm this. Recognition that SFT may present as a superficial mass will avoid misclassification as other CD34-positive neoplasms that frequently arise in the skin and subcutaneous tissue.	[Feasel, Patrick; Goldblum, John R.; Rubin, Brian P.; McKenney, Jesse K.; Ko, Jennifer S.; Billings, Steven D.] Cleveland Clin, Dept Pathol, 9500 Euclid Ave,L25, Cleveland, OH 44195 USA; [Al-Ibraheemi, Alyaa] Boston Childrens Hosp, Dept Pathol, Boston, MA USA; [Fritchie, Karen] Mayo Clin, Dept Pathol, Rochester, MN USA; [Zreik, Riyam T.] Baylor Scott & White Mem Hosp, Dept Pathol, Temple, TX USA; [Wang, Wei-Lien] MD Anderson Canc Ctr, Dept Pathol, Houston, TX USA; [Demicco, Elizabeth] Mt Sinai Hosp, Dept Pathol, Toronto, CA USA; [Saeb-Lima, Marcela] Natl Inst Med Sci & Nutr Salvador Zubiran, Dept Dermatol, Mexico City, DF, Mexico	Billings, SD (reprint author), Cleveland Clin, Dept Pathol, 9500 Euclid Ave,L25, Cleveland, OH 44195 USA.	billins@ccf.org					Billings SD, 2007, AM J DERMATOPATH, V29, P437, DOI 10.1097/DAD.0b013e31813735df; Cheah A, 2015, HISTOPATHOLOGY, V66, P430, DOI 10.1111/his.12548; Cheah AL, 2014, PATHOLOGY, V46, P389, DOI 10.1097/PAT.0000000000000122; Cowper SE, 1999, AM J DERMATOPATH, V21, P213, DOI 10.1097/00000372-199906000-00001; Creytens D, 2016, APPL IMMUNOHISTO M M, V24, pE12, DOI 10.1097/PAI.0000000000000166; Demicco EG, 2017, MODERN PATHOL, V30, P1433, DOI 10.1038/modpathol.2017.54; Demicco EG, 2015, AM J CLIN PATHOL, V143, P672, DOI 10.1309/AJCPN25NJTOUNPNF; Doyle LA, 2014, MODERN PATHOL, V27, P390, DOI 10.1038/modpathol.2013.164; Doyle LA, 2013, ANN SURG ONCOL, V20, P4055, DOI 10.1245/s10434-013-3243-8; Erdag G, 2007, J CUTAN PATHOL, V34, P844, DOI 10.1111/j.1600-0560.2006.00728.x; Fletcher C, 2013, WHO CLASSIFICATION T; Fritchie KJ, 2012, AM J CLIN PATHOL, V137, P963, DOI 10.1309/AJCPQEG6YNN6CNAL; Goldblum JR, 2013, ENZINGER WEISSS SOFT; Hardisson D, 2002, J AM ACAD DERMATOL, V46, pS37, DOI 10.1067/mjd.2002.106359; Okamura JM, 1997, AM J DERMATOPATH, V19, P515, DOI 10.1097/00000372-199710000-00104; Sandberg AA, 2002, CANCER GENET CYTOGEN, V133, P1, DOI 10.1016/S0165-4608(01)00626-4; Sigel JE, 2001, AM J DERMATOPATH, V23, P275, DOI 10.1097/00000372-200106000-00027; Simon MP, 1997, NAT GENET, V15, P95, DOI 10.1038/ng0197-95; Sirvent N, 2003, GENE CHROMOSOME CANC, V37, P1, DOI 10.1002/gcc.10202; Soldano AC, 2008, AM J DERMATOPATH, V30, P54, DOI 10.1097/DAD.0b013e31815b9bed; Thway K, 2016, INT J SURG PATHOL, V24, P281, DOI 10.1177/1066896915627485; van Houdt WJ, 2013, ANN SURG ONCOL, V20, P4090, DOI 10.1245/s10434-013-3242-9; Wilky BA, 2013, ANN SURG ONCOL, V20, P4080, DOI 10.1245/s10434-013-3241-x; Wood L, 2010, AM J DERMATOPATH, V32, P764, DOI 10.1097/DAD.0b013e3181d0c587; Yoshida A, 2014, AM J SURG PATHOL, V38, P552, DOI 10.1097/PAS.0000000000000137	25	3	4	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUN	2018	42	6					778	785		10.1097/PAS.0000000000001027			8	Pathology; Surgery	Pathology; Surgery	GF8NF	WOS:000432228900010	29438169				2019-10-28	
J	Verrill, C; Perry-Keene, J; Srigley, JR; Zhou, M; Humphrey, PA; Lopez-Beltran, A; Egevad, L; Ulbright, TM; Tickoo, SK; Epstein, JI; Comperat, E; Berney, DM				Verrill, Clare; Perry-Keene, Joanna; Srigley, John R.; Zhou, Ming; Humphrey, Peter A.; Lopez-Beltran, Antonio; Egevad, Lars; Ulbright, Thomas M.; Tickoo, Satish K.; Epstein, Jonathan I.; Comperat, Eva; Berney, Daniel M.		ISUP Testicular Tumor Panel	Intraoperative Consultation and Macroscopic Handling The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						testis; germ cell tumor; guidelines	GERM-CELL TUMORS; STAGE-I SEMINOMA; FROZEN-SECTION EXAMINATION; TESTIS-SPARING SURGERY; SPERMATIC CORD; LYMPHOVASCULAR INVASION; PROGNOSTIC-FACTORS; PROSTATE-CANCER; SURVEILLANCE; ORCHIECTOMY	The International Society of Urological Pathology held a conference on issues in testicular and penile pathology in Boston in March 2015, which included a presentation by the testis macroscopic features working group. The presentation focused on current published guidance for macroscopic handling of testicular tumors and retroperitoneal lymph node dissections with a summary of results from an online survey of members preceding the conference. The survey results were used to initiate discussions, but decisions on practice were made by expert consensus rather than voting. The importance of comprehensive assessment at the time of gross dissection with confirmation of findings by microscopic assessment was underscored. For example, the anatomic landmarks denoting the distinction of hilar soft tissue invasion (pT2) from spermatic cord invasion (pT3 category) can only be determined by careful macroscopic assessment in many cases. Other recommendations were to routinely sample epididymis, rete testis, hilar soft tissue, and tunica vaginalis in order to confirm macroscopic invasion of these structures or if not macroscopically evident, to exclude subtle microscopic invasion. Tumors 2cm or less in greatest dimension should be completely embedded. If the tumor is > 2cm in greatest dimension, 10 blocks or a minimum of 1 to 2 additional blocks per centimeter should be taken (whichever is greater).	[Verrill, Clare] Univ Oxford, Nuffield Dept Surg Sci, Oxford, England; [Verrill, Clare] Univ Oxford, NIHR Oxford Biomed Res Ctr, Oxford, England; [Berney, Daniel M.] Queen Mary Univ London, Dept Mol Oncol, Barts Canc Inst, London, England; [Perry-Keene, Joanna] Sunshine Coast Univ Hosp, Aquesta Specialised Uropathol, Sunshine Coast, Qld, Australia; [Perry-Keene, Joanna] Sunshine Coast Univ Hosp, Dept Pathol, Sunshine Coast, Qld, Australia; [Srigley, John R.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Zhou, Ming] NYU, Sch Med, Dept Pathol, New York, NY USA; [Tickoo, Satish K.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Humphrey, Peter A.] Yale Sch Med, Dept Pathol, New Haven, CT USA; [Lopez-Beltran, Antonio] Univ Cordoba, Dept Pathol, Cordoba, Spain; [Egevad, Lars] Karolinska Hosp, Dept Pathol & Cytol, Stockholm, Sweden; [Ulbright, Thomas M.] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA; [Epstein, Jonathan I.] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD USA; [Comperat, Eva] Univ Pierre & Marie Curie Paris VI, Dept Pathol, Hop Tenon, Paris, France	Verrill, C (reprint author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg Sci, Oxford OX3 9DU, England.	Clare.Verrill@OUH.nhs.uk			Orchid; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) (Molecular Diagnostics Theme/Multimodal Pathology Subtheme)	The International Society of Urological Pathology (ISUP) 2015 consultation on testis and penile cancer was generously supported by Orchid. Clare Verrill's research time is supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) (Molecular Diagnostics Theme/Multimodal Pathology Subtheme). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Afroz Nishat, 2004, Indian Journal of Pediatrics, V71, P939, DOI 10.1007/BF02830842; Aparicio J, 2014, ANN ONCOL, V25, P2173, DOI 10.1093/annonc/mdu437; Berney D, 2014, ROYAL COLL PATHOLOGI; Berney DM, 2017, HISTOPATHOLOGY, V70, P26, DOI 10.1111/his.13078; Berney DM, 2015, HISTOPATHOLOGY, V67, P313, DOI 10.1111/his.12657; Berney DM, 2017, NEOPLASIA TESTIS RET; Brimo F, 2016, AJCC CANC STAGING MA; Brunocilla E, 2013, ANTICANCER RES, V33, P5205; Camacho N, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007001; Chung P, 2015, CANCER MED-US, V4, P155, DOI 10.1002/cam4.324; Chung PWM, 2011, HEMATOL ONCOL CLIN N, V25, P529, DOI 10.1016/j.hoc.2011.03.009; Delahunt B, 2017, HISTOPATHOLOGY, V71, P5, DOI 10.1111/his.13200; Dry SM, 1999, AM J CLIN PATHOL, V111, P534; Ehrlich Y, 2009, J UROLOGY, V181, P1114, DOI 10.1016/j.juro.2008.11.025; Einaga N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176280; Elert A, 2002, EUR UROL, V41, P290, DOI 10.1016/S0302-2838(02)00004-0; Favilla V, 2015, CLIN GENITOURIN CANC, V13, pE31, DOI 10.1016/j.clgc.2014.06.009; Favilla V, 2014, INT UROL NEPHROL, V46, P1131, DOI 10.1007/s11255-013-0617-6; Feldman DR, 2009, WORLD J UROL, V27, P463, DOI 10.1007/s00345-009-0431-z; Gatta LB, 2012, EUR J HISTOCHEM, V56, P63, DOI [10.4081/ejh.2012.e12, 10.4081/ejh.2012.12]; Genomics England, 2015, 100 000 GEN PROJ PRO; Gentile G, 2013, CLIN GENITOURIN CANC, V11, P522, DOI 10.1016/j.clgc.2013.04.033; Gordetsky J, 2017, AM J SURG PATHOL, V41, P1397, DOI 10.1097/PAS.0000000000000917; Gundem G, 2015, NATURE, V520, P353, DOI 10.1038/nature14347; Heidenreich A, 2001, J UROLOGY, V166, P2161, DOI 10.1016/S0022-5347(05)65526-7; Kavoussi PK, 2016, CAMPBELL WALSH UROLO, P498; Lawrentschuk N, 2011, J UROLOGY, V185, P508, DOI 10.1016/j.juro.2010.09.072; Lawrentschuk N, 2009, WORLD J UROL, V27, P433, DOI 10.1007/s00345-009-0430-0; McCleskey BC, 2017, ARCH PATHOL LAB MED, V141, P824, DOI 10.5858/arpa.2016-0226-OA; Moch H, 2016, WHO CLASSIFICATION T; Moore K. L., 2014, CLIN ORIENTED ANATOM; Mortensen MS, 2014, EUR UROL, V66, P1172, DOI 10.1016/j.eururo.2014.07.001; Nazeer T, 1996, MODERN PATHOL, V9, P762; Nguyen CT, 2011, HEMATOL ONCOL CLIN N, V25, P593, DOI 10.1016/j.hoc.2011.03.002; Nguyen CT, 2010, J CLIN ONCOL, V28, P119, DOI 10.1200/JCO.2009.22.0400; Parker C, 2002, EUR J CANCER, V38, P2014, DOI 10.1016/S0959-8049(02)00235-6; Purshouse K, 2017, CLIN GENITOURIN CANC, V15, P152, DOI [10.1016/j.clgc.2016.05.005, 10.10164/j.clgc.2016.05.005]; Royal College of Pathologists of Australasia, 2011, RCPA TEST TUM STRUCT; Sanfrancesco JM, 2018, AM J SURG PATHOL, V42, P306, DOI 10.1097/PAS.0000000000001008; Scandura G, 2017, BJU INT; Silverio PC, 2015, ANN DIAGN PATHOL, V19, P99, DOI 10.1016/j.anndiagpath.2014.12.006; Sobin LH, 2010, UICC INT UNION CANC; Steiner H, 2003, UROLOGY, V62, P508, DOI 10.1016/S0090-4295(03)00465-5; Subik MK, 2012, HUM PATHOL, V43, P1514, DOI 10.1016/j.humpath.2011.11.013; Tickoo SK, 2011, PROTOCOL EXAMINATION; Verrill C, 2017, AM J SURG PATHOL, V41, pE22, DOI 10.1097/PAS.0000000000000844; VONDERMAASE H, 1993, EUR J CANCER, V29A, P1931, DOI 10.1016/0959-8049(93)90446-M; Warde P, 2002, J CLIN ONCOL, V20, P4448, DOI 10.1200/JCO.2002.01.038; Winstanley AM, 2004, EUR UROL, V45, P564, DOI 10.1016/j.eururo.2003.10.015; Znaor A, 2014, EUR UROL, V65, P1095, DOI 10.1016/j.eururo.2013.11.004	51	3	3	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUN	2018	42	6					E33	E43		10.1097/PAS.0000000000001049			11	Pathology; Surgery	Pathology; Surgery	GF8NF	WOS:000432228900001	29579010				2019-10-28	
J	Owosho, AA; Estilo, CL; Huryn, JM; Chi, P; Antonescu, CR				Owosho, Adepitan A.; Estilo, Cherry L.; Huryn, Joseph M.; Chi, Ping; Antonescu, Cristina R.			A Clinicopathologic Study of Head and Neck Malignant Peripheral Nerve Sheath Tumors	HEAD & NECK PATHOLOGY			English	Article						Malignant peripheral nerve sheath tumor; NF1; H3K27me3; Polycomb repressor complex 2	SOFT-TISSUE; SINGLE INSTITUTION; TREATMENT OUTCOMES; SYNOVIAL SARCOMAS; MARKER; H3K27; MANAGEMENT; IMMUNOHISTOCHEMISTRY; METHYLATION; EXPRESSION	Head and neck high grade malignant peripheral nerve sheath tumors (HN-MPNSTs) are rare highly aggressive soft tissue sarcomas that show overlapping morphologic and immunophenotypic features with melanoma and other high grade sarcomas, resulting in diagnostic challenges, particularly in sporadic settings. Recent discoveries have implicated loss of function mutations in the polycomb repressive complex 2 (PRC2) components, including EED or SUZ12 genes, as one of the leading pathogenetic mechanisms in high grade MPNST. MPNSTs with PRC2 loss are associated with complete loss of trimethylation at lysine 27 of histone H3 (H3K27me3), which emerged as a reliable immunohistochemical marker in the diagnosis of sporadic and radiation induced MPNST. As the diagnosis of MPNST in the HN is particularly challenging to distinguish from melanoma and other sarcoma types, we carried out a clinicopathologic analysis on HN-MPNST patients managed at our institution over a 20-year period (1997-2016), using the latest diagnostic criteria including H3K27me3 staining and other molecular investigations. The overall survival of HN-MPNST was compared with other HN soft tissue sarcomas. The diagnosis of HN-MPNST was confirmed in 13 patients (seven males and six females), with a mean age of 31 years; with 3 (23%) patients being of pediatric age. The most common site was the neck soft tissue (77%). Two-thirds of patients (n = 9) had stigmata of NF1, three had prior radiotherapy and only one developed a de novo MPNST. All except one tumor (86%) tested showed loss of H3K27me3 expression, including all non-NF1 patients. The 2 and 5-year DSS rates were 50 and 30%. The 2-year DFS rate was 21%. Adverse predictors on DSS included adult age (p = 0.011), prior-history of RT (p = 0.003) and recurrence (p = 0.003). Compared to other molecularly confirmed subsets of HN sarcomas (Ewing and Ewing-like sarcoma, rhabdomyosarcoma and synovial sarcoma), HN-MPNST had the worst overall survival (p < 0.0001). We conclude that HN-MPNSTs are highly aggressive sarcomas associated with an unfavorable outcome and the utility of H3K27me3 IHC stains in the evaluation of MPNST is a reliable ancillary diagnostic adjunct.	[Owosho, Adepitan A.] Univ New England, Coll Dent Med, Portland, ME 04103 USA; [Owosho, Adepitan A.; Estilo, Cherry L.; Huryn, Joseph M.] Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA; [Chi, Ping] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA; [Chi, Ping] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA; [Antonescu, Cristina R.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA	Antonescu, CR (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA.	antonesc@mskcc.org			NIH/NCI Cancer Center Support Grant [P50-CA140146-01]; Cycle for Survival; Kristen Ann Carr Foundation [P30-CA008748]	Supported in part by NIH/NCI Cancer Center Support Grant P50-CA140146-01 (CRA), Cycle for Survival (CRA); P30-CA008748, Kristen Ann Carr Foundation (CRA).	Anghileri M, 2006, CANCER-AM CANCER SOC, V107, P1065, DOI 10.1002/cncr.22098; Antonescu CR, 2017, AM J SURG PATHOL, V41, P941, DOI 10.1097/PAS.0000000000000846; Arshi A, 2015, ORAL ONCOL, V51, P1088, DOI 10.1016/j.oraloncology.2015.08.012; Asano N, 2017, HISTOPATHOLOGY, V70, P385, DOI 10.1111/his.13072; Bahrami A, 2010, AM J SURG PATHOL, V34, P1504, DOI 10.1097/PAS.0b013e3181ef70b6; Bishop AJ, 2018, AM J CLIN ONCOL-CANC, V41, P465, DOI 10.1097/COC.0000000000000303; Cleven AHG, 2016, MODERN PATHOL, V29, P582, DOI 10.1038/modpathol.2016.45; DAGOSTINO AN, 1963, CANCER, V16, P1003, DOI 10.1002/1097-0142(196308)16:8<1003::AID-CNCR2820160807>3.0.CO;2-S; DASGUPTA TK, 1970, ANN SURG, V171, P419, DOI 10.1097/00000658-197003000-00016; De Raedt T, 2014, NATURE, V514, P247, DOI 10.1038/nature13561; DECOU JM, 1995, ANN SURG ONCOL, V2, P524, DOI 10.1007/BF02307086; DUCATMAN BS, 1986, CANCER-AM CANCER SOC, V57, P2006, DOI 10.1002/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6; Fletcher CDM, 2013, WHO CLASSIFICATION T, P134; Gladdy RA, 2010, J CLIN ONCOL, V28, P2064, DOI 10.1200/JCO.2009.25.1728; Hrehorovich PA, 2003, RADIOGRAPHICS, V23, P790, DOI 10.1148/rg.233025153; Karamchandani JR, 2012, APPL IMMUNOHISTO M M, V20, P445, DOI 10.1097/PAI.0b013e318244ff4b; Kroep JR, 2011, ANN ONCOL, V22, P207, DOI 10.1093/annonc/mdq338; LaFemina J, 2013, ANN SURG ONCOL, V20, P66, DOI 10.1245/s10434-012-2573-2; Lee W, 2014, NAT GENET, V46, P1227, DOI 10.1038/ng.3095; Ma C, 2014, INT J ORAL MAX SURG, V43, P924, DOI 10.1016/j.ijom.2014.03.006; Miettinen M, 2015, AM J SURG PATHOL, V39, P826, DOI 10.1097/PAS.0000000000000398; Minovi A, 2007, HEAD NECK-J SCI SPEC, V29, P439, DOI 10.1002/hed.20537; Nonaka D, 2008, J CUTAN PATHOL, V35, P1014, DOI 10.1111/j.1600-0560.2007.00953.x; Nonaka D, 2008, AM J SURG PATHOL, V32, P1291, DOI 10.1097/PAS.0b013e3181658c14; Owosho AA, 2017, HEAD NECK PATHOL, DOI [10.1007/s12105-017-0808-2, DOI 10.1007/S12105-017-0808-2]; Owosho AA, 2017, ORAL ONCOL, V66, P46, DOI 10.1016/j.oraloncology.2016.12.021; Owosho AA, 2016, ORAL ONCOL, V61, P89, DOI 10.1016/j.oraloncology.2016.08.017; Owosho AA, 2016, ORAL ONCOL, V58, pE6, DOI 10.1016/j.oraloncology.2016.05.009; Pasmant E, 2017, AM J SURG PATHOL, V41, P283, DOI 10.1097/PAS.0000000000000791; Patel TD, 2016, OTOLARYNG HEAD NECK, V154, P113, DOI 10.1177/0194599815606700; Peng KA, 2014, OTOLARYNG HEAD NECK, V151, P627, DOI 10.1177/0194599814545747; Porter D. E., 2009, Sarcoma, P1, DOI 10.1155/2009/756395; Prieto-Granada CN, 2016, AM J SURG PATHOL, V40, P479, DOI 10.1097/PAS.0000000000000564; Rodriguez FJ, 2012, ACTA NEUROPATHOL, V123, P295, DOI 10.1007/s00401-012-0954-z; Rohrich M, 2016, ACTA NEUROPATHOL, V131, P877, DOI 10.1007/s00401-016-1540-6; Schaefer IM, 2016, MODERN PATHOL, V29, P4, DOI 10.1038/modpathol.2015.134; Scheithauer BW, 2009, AM J SURG PATHOL, V33, P325, DOI 10.1097/PAS.0b013e31818d6470; Valentin T, 2016, EUR J CANCER, V56, P77, DOI 10.1016/j.ejca.2015.12.015; VEGE DS, 1994, J SURG ONCOL, V55, P100, DOI 10.1002/jso.2930550208; Wong WW, 1998, INT J RADIAT ONCOL, V42, P351, DOI 10.1016/S0360-3016(98)00223-5; Zhang M, 2014, NAT GENET, V46, P1170, DOI 10.1038/ng.3116; Zou CY, 2009, ANN SURG, V249, P1014, DOI 10.1097/SLA.0b013e3181a77e9a	42	1	1	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	JUN	2018	12	2					151	159		10.1007/s12105-017-0841-y			9	Pathology	Pathology	GG0GC	WOS:000432355500001	28762137	Green Published			2019-10-28	
J	Gill, AS; Amdur, R; Joshi, AS				Gill, Amarbir S.; Amdur, Richard; Joshi, Arjun S.			Importance of FNA Technique for Decreasing Non-diagnostic Rates in Thyroid Nodules	HEAD & NECK PATHOLOGY			English	Article						Thyroid nodule; Fine needle aspiration; FNA; Aspiration technique; Capillary action; Non diagnostic rates	FINE-NEEDLE-ASPIRATION; DIAGNOSTIC-ACCURACY; BETHESDA SYSTEM; CYTOLOGICAL MATERIAL; SAMPLE ADEQUACY; BIOPSY; SIZE; CYTOPATHOLOGY; TRIAL	To identify potential interventions that may lower the high non-diagnostic rates associated with ultrasound guided (US) fine needle aspiration (FNA) biopsy of the thyroid nodule. A case series of 164 thyroid nodule US-guided FNA was identified retrospectively. The following variables were analyzed in regards to diagnostic and non-diagnostic sampling: patient age, gender, size of nodule, biopsy technique (capillary vs. aspiration), needle gauge (23 vs. 25), and physician experience. The FNA diagnosis, and final pathology, when applicable, was recorded for each sample using the Bethesda criteria. Data was analyzed using the Fisher's exact test or the chi square test. After multivariate logistic regression, capillary action was independently associated with lower non-diagnostic rates (p = 0.01), while increasing patient age was associated with higher non-diagnostic rates (p = 0.018). Physician experience (p = 0.014) was not independently associated with lower non-diagnostic rates. Nodules that were "cystic > 50%" were significantly more likely to yield a non-diagnostic result (p < 0.0001). After taking into account confounding variables, including physician experience, our data reveals a statistically significant decrease in non-diagnostic rates with the use of capillary action vs. aspiration technique in US-guided FNA. A major focus in healthcare today is providing cost-effective and minimally invasive care to the patient. In the setting of a rising incidence of thyroid disease, we believe our study demonstrates the need for a prospective analysis of the relationship between technique and non-diagnostic rates.	[Gill, Amarbir S.] Univ Calif Davis, Div Otolaryngol Head & Neck Surg, 2521 Stockton Blvd 7200, Sacramento, CA 95817 USA; [Amdur, Richard; Joshi, Arjun S.] George Washington Univ, Div Otolaryngol Head & Neck Surg, Washington, DC USA	Gill, AS (reprint author), Univ Calif Davis, Div Otolaryngol Head & Neck Surg, 2521 Stockton Blvd 7200, Sacramento, CA 95817 USA.	amgill@ucdavis.edu					Baloch Zubair W, 2004, Endocr Pract, V10, P234; Bhatki AM, 2008, OTOLARYNG HEAD NECK, V139, P27, DOI 10.1016/j.otohns.2008.04.006; Bongiovanni M, 2012, ACTA CYTOL, V56, P333, DOI 10.1159/000339959; Brennan PA, 2007, HEAD NECK-J SCI SPEC, V29, P919, DOI 10.1002/hed.20601; Carmeci C, 1998, THYROID, V8, P283, DOI 10.1089/thy.1998.8.283; Cesur M, 2006, THYROID, V16, P555, DOI 10.1089/thy.2006.16.555; Cibas ES, 2008, DIAGN CYTOPATHOL, V36, P390, DOI 10.1002/dc.20827; Cibas ES, 2009, THYROID, V19, P1159, DOI 10.1089/thy.2009.0274; Cooper DS, 2009, THYROID, V19, P1167, DOI 10.1089/thy.2009.0110; de Carvalho GA, 2009, ENDOCR PATHOL, V20, P204, DOI 10.1007/s12022-009-9092-0; Degirmenci B, 2007, CLIN RADIOL, V62, P798, DOI 10.1016/j.crad.2007.01.024; DEY P, 1993, CYTOPATHOLOGY, V4, P299, DOI 10.1111/j.1365-2303.1993.tb00105.x; GHARIB H, 1994, MAYO CLIN PROC, V69, P44, DOI 10.1016/S0025-6196(12)61611-5; Gumus M, 2012, DIAGN INTERV RADIOL, V18, P102, DOI 10.4261/1305-3825.DIR.4340-11.1; Inci MF, 2013, ENDOCRINE, V43, P424, DOI 10.1007/s12020-012-9784-y; MAZZAFERRI EL, 1993, NEW ENGL J MED, V328, P553; Moon HJ, 2011, ULTRASOUND MED BIOL, V37, P549, DOI 10.1016/j.ultrasmedbio.2011.01.015; Naim C, 2013, CAN ASSOC RADIOL J, V64, P220, DOI 10.1016/j.carj.2012.03.003; Robitschek J, 2010, OTOLARYNG HEAD NECK, V142, P306, DOI 10.1016/j.otohns.2009.11.011; Schoedel KE, 2008, DIAGN CYTOPATHOL, V36, P787, DOI 10.1002/dc.20896; Tangpricha V, 2001, THYROID, V11, P973, DOI 10.1089/105072501753211055; Tauro Leo F, 2012, Oman Med J, V27, P151, DOI 10.5001/omj.2012.31; Tublin ME, 2007, J ULTRAS MED, V26, P1697, DOI 10.7863/jum.2007.26.12.1697; Williams BA, 2013, J OTOLARYNGOL-HEAD N, V42, DOI 10.1186/1916-0216-42-61; Wong LQ, 2012, ADV ANAT PATHOL, V19, P313, DOI 10.1097/PAP.0b013e3182666398; Zhou JQ, 2014, CANCER CYTOPATHOL, V122, P266, DOI 10.1002/cncy.21382	26	0	2	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	JUN	2018	12	2					160	165		10.1007/s12105-017-0844-8			6	Pathology	Pathology	GG0GC	WOS:000432355500002	28819755	Green Published			2019-10-28	
J	Upadhyaya, JD; Cohen, DM; Islam, MN; Bhattacharyya, I				Upadhyaya, Jasbir D.; Cohen, Donald M.; Islam, Mohammed N.; Bhattacharyya, Indraneel			Hybrid Central Odontogenic Fibroma with Giant Cell Granuloma like Lesion: A Report of Three Additional Cases and Review of the Literature	HEAD & NECK PATHOLOGY			English	Review						Central odontogenic fibroma; Central giant cell granuloma; Hybrid central odontogenic fibroma with giant cell granuloma-like lesion; World Health Organization	TUMORS; JAWS	Central odontogenic fibroma (COF) is an uncommon intraosseous neoplasm of the gnathic bones which is composed of fibrous connective tissue, with or without calcifications, and variable amounts of inactive odontogenic epithelium. It makes up less than 5% of odontogenic tumors and is more commonly seen in females. Central giant cell granuloma (CGCG) is a locally destructive but benign lesion of the jaws containing osteoclast-like multinucleated giant cells in a fibrovascular stroma. CGCG makes up approximately 10% of all benign jaw tumors and typically occurs in females younger than 30 years of age. A hybrid lesion with histologic features of both COF and CGCG is very rare and was first described in 1992. To date, fewer than 50 cases of this lesion have been reported. In this study, we present three additional cases of COF developing in conjunction with giant cell granuloma-like lesion, as well as provide a comprehensive literature review. Two of the lesions presented in our study were located in the posterior mandible and one occurred in the anterior mandible. Buccal and/or lingual expansion was noted in two patients and no recurrence was reported. Histologically, all three lesions demonstrated a blend of odontogenic epithelial islands with numerous multinucleated giant cells in a highly cellular connective tissue stroma. Immunohistochemical staining with CK19 and CD68 highlighted the odontogenic epithelium and multinucleated giant cells respectively. The precise nature of these hybrid lesions remains obscure and additional molecular studies may be of help in understanding their pathogenesis.	[Upadhyaya, Jasbir D.; Cohen, Donald M.; Islam, Mohammed N.; Bhattacharyya, Indraneel] Univ Florida, Coll Dent, Dept Oral & Maxillofacial Diagnost Sci, 1395 Ctr Dr, Gainesville, FL 32610 USA	Upadhyaya, JD (reprint author), Univ Florida, Coll Dent, Dept Oral & Maxillofacial Diagnost Sci, 1395 Ctr Dr, Gainesville, FL 32610 USA.	jupadhyaya@dental.ufl.edu	Upadhyaya, Jasbir/L-4724-2019				ALLEN CM, 1992, ORAL SURG ORAL MED O, V73, P62, DOI 10.1016/0030-4220(92)90156-K; ANDERSEN L, 1973, ACTA PATH MICRO IM A, VA 81, P606; Barnes L., 2005, PATHOLOGY GENETICS H; Brannon Robert B, 2004, Oral Maxillofac Surg Clin North Am, V16, P359, DOI 10.1016/j.coms.2004.03.004; DAMM DD, 2013, GEN DENT, V61, P77; Daniels JSM, 2004, ORAL SURG ORAL MED O, V98, P295, DOI 10.1016/j.tripleo.2004.01.017; Eliot C, 2015, OR SURG OR MED OR PA, V119, pE289, DOI 10.1016/j.oooo.2014.11.021; Eversole LR, 2011, HEAD NECK PATHOL, V5, P335, DOI 10.1007/s12105-011-0279-6; Fowler C, 1993, ORAL SURG ORAL MED O, V76, P587; GARDNER DG, 1980, ORAL SURG ORAL MED O, V50, P425, DOI 10.1016/S0030-4220(80)80011-9; Gardner DG, 1996, J ORAL PATHOL MED, V25, P556, DOI 10.1111/j.1600-0714.1996.tb01731.x; GUNHAN O, 1991, BRIT J ORAL MAX SURG, V29, P42, DOI 10.1016/0266-4356(91)90173-3; GUNHAN O, 1990, AUST DENT J, V35, P518; HANDLERS JP, 1991, J ORAL MAXIL SURG, V49, P46, DOI 10.1016/0278-2391(91)90265-N; Hassan S, 2008, 62 ANN M AM AC OR MA; Ikeshima Atsushi, 2005, J Oral Sci, V47, P149, DOI 10.2334/josnusd.47.149; KAWAKAMI T, 1989, J ORAL MAXIL SURG, V47, P737, DOI 10.1016/S0278-2391(89)80017-5; Kessler HP, 2006, W SOC TEACHERS ORAL; Kim J, 1993, J ORAL MAXILLOFAC SU, V51, P7; Leite T, 2017, ANN M AM AC OR MAX P; Mosqueda-Taylor A, 2011, ORAL SURG ORAL MED O, V112, P349, DOI 10.1016/j.tripleo.2011.03.021; de Lima MDM, 2008, OTOLARYNG HEAD NECK, V139, P867, DOI 10.1016/j.otohns.2008.08.013; Neville B. W., 2016, ORAL MAXILLOFACIAL P; Odell EW, 1997, HISTOPATHOLOGY, V30, P165, DOI 10.1046/j.1365-2559.1997.d01-585.x; REGEZI JA, 1978, J ORAL SURG, V36, P771; Regezi JA, 2002, MODERN PATHOL, V15, P331, DOI 10.1038/modpathol.3880527; Schultz K, 2017, ANN M AM AC OR MAX P; Taylor AM, 1999, J ORAL MAXIL SURG, V57, P1258, DOI 10.1016/S0278-2391(99)90500-1; Tosios KI, 2008, HEAD NECK PATHOL, V2, P333, DOI 10.1007/s12105-008-0076-z; VINCENT SD, 1987, ORAL SURG ORAL MED O, V63, P715, DOI 10.1016/0030-4220(87)90376-8; WESLEY RK, 1975, ORAL SURG ORAL MED O, V40, P235, DOI 10.1016/0030-4220(75)90155-3; Wright JM, 2017, HEAD NECK PATHOL, V11, P68, DOI 10.1007/s12105-017-0794-1; Younis RH, 2008, HEAD NECK PATHOL, V2, P222, DOI 10.1007/s12105-008-0063-4	33	1	1	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	JUN	2018	12	2					166	174		10.1007/s12105-017-0845-7			9	Pathology	Pathology	GG0GC	WOS:000432355500003	28785965	Green Published			2019-10-28	
J	Layfield, EM; Schmidt, RL; Esebua, M; Layfield, LJ				Layfield, Eleanor M.; Schmidt, Robert L.; Esebua, Magda; Layfield, Lester J.			Frozen Section Evaluation of Margin Status in Primary Squamous Cell Carcinomas of the Head and Neck: A Correlation Study of Frozen Section and Final Diagnoses	HEAD & NECK PATHOLOGY			English	Article						Frozen section; Diagnostic accuracy; Head and neck carcinomas	PATHOLOGISTS Q-PROBES; OVARIAN-TUMORS; CANCER SURGERY; TONGUE CANCER; ACCURACY; CONSULTATION; RESECTION; INSTITUTIONS; HOSPITALS; UTILITY	Frozen section is routinely used for intraoperative margin evaluation in carcinomas of the head and neck. We studied a series of frozen sections performed for margin status of head and neck tumors to determine diagnostic accuracy. All frozen sections for margin control of squamous carcinomas of the head and neck were studied from a 66 month period. Frozen and permanent section diagnoses were classified as negative or malignant. Correlation of diagnoses was performed to determine accuracy. One thousand seven hundred and ninety-six pairs of frozen section and corresponding permanent section diagnoses were obtained. Discordances were found in 55 (3.1%) pairs. In 35 pairs (1.9%), frozen section was reported as benign, but permanent sections disclosed carcinoma. In 21 cases, the discrepancy was due to sampling and in the remaining cases it was an interpretive error. In 20 cases (1.1%), frozen section was malignant, but the permanent section was interpreted as negative. Frozen section is an accurate method for evaluation of operative margins for head and neck carcinomas with concordance between frozen and permanent results of 97%. Most errors are false negative results with the majority of these being due to sampling issues.	[Layfield, Eleanor M.] Univ Missouri, Dept Radiol, Columbia, MO USA; [Schmidt, Robert L.] Univ Utah Hlth Care, Dept Pathol & Lab Med, Salt Lake City, UT USA; [Schmidt, Robert L.] ARUP Labs, Salt Lake City, UT USA; [Esebua, Magda; Layfield, Lester J.] Univ Missouri, Dept Pathol & Anat Sci, One Hosp Dr,M263 Med Sci Bldg, Columbia, MO 65212 USA	Layfield, LJ (reprint author), Univ Missouri, Dept Pathol & Anat Sci, One Hosp Dr,M263 Med Sci Bldg, Columbia, MO 65212 USA.	layfieldl@health.missouri.edu					Abudukadeer A, 2016, EUR J GYNAECOL ONCOL, V37, P216; Amit M, 2016, HEAD NECK-J SCI SPEC, V38, pE1803, DOI 10.1002/hed.24320; Black C, 2006, CANCER, V107, P2792, DOI 10.1002/cncr.22347; BYERS RM, 1978, AM J SURG, V136, P525, DOI 10.1016/0002-9610(78)90275-1; Cooley ML, 2002, HEAD NECK-J SCI SPEC, V24, P262, DOI 10.1002/hed.10024; DANKWA EK, 1985, J CLIN PATHOL, V38, P1235, DOI 10.1136/jcp.38.11.1235; DiNardo LJ, 2000, LARYNGOSCOPE, V110, P1773, DOI 10.1097/00005537-200010000-00039; Du E, 2016, LARYNGOSCOPE, V126, P1768, DOI 10.1002/lary.25899; GANDOUREDWARDS RF, 1993, HEAD NECK-J SCI SPEC, V15, P33, DOI 10.1002/hed.2880150108; Gephardt GN, 1996, ARCH PATHOL LAB MED, V120, P804; Gorisek B, 2009, J INT MED RES, V37, P1173, DOI 10.1177/147323000903700423; Hatami Hossein, 2015, Iran J Pathol, V10, P295; HOWANITZ PJ, 1990, ARCH PATHOL LAB MED, V114, P355; Khan AH, 2016, J PAK MED ASSOC, V66, P143; Liu SL, 2016, J CLIN ONCOL, V34, P307, DOI 10.1200/JCO.2015.63.4907; Liu YJ, 2016, INT J SURG PATHOL, V24, P108, DOI 10.1177/1066896915605911; Mahe E, 2013, CAN J SURG, V56, pE13, DOI 10.1503/cjs.011112; Maxwell JH, 2015, JAMA OTOLARYNGOL, V141, P1104, DOI 10.1001/jamaoto.2015.1351; Meier JD, 2005, HEAD NECK-J SCI SPEC, V27, P952, DOI 10.1002/hed.20269; Nigrisoli E., 1994, Pathologica (Genoa), V86, P191; Novis DA, 1996, ARCH PATHOL LAB MED, V120, P1087; Onajin O, 2015, J CUTAN PATHOL, V42, P459, DOI 10.1111/cup.12498; Ord RA, 1997, J ORAL MAXIL SURG, V55, P663, DOI 10.1016/S0278-2391(97)90570-X; Pinto PBC, 2001, GYNECOL ONCOL, V81, P230, DOI 10.1006/gyno.2001.6133; ROGERS C, 1987, ARCH PATHOL LAB MED, V111, P514; Spiro RH, 1999, HEAD NECK-J SCI SPEC, V21, P408, DOI 10.1002/(SICI)1097-0347(199908)21:5<408::AID-HED5>3.0.CO;2-E; St John ER, 2017, ANN SURG, V265, P300, DOI 10.1097/SLA.0000000000001897; Varvares MA, 2016, LARYNGOSCOPE, V126, P2426, DOI 10.1002/lary.26081; Wendum D, 2003, ANN PATHOL, V23, P393; Wenig BM, 2008, HEAD NECK PATHOL, V2, P131, DOI 10.1007/s12105-008-0053-6; White VA, 2008, ARCH PATHOL LAB MED, V132, P29, DOI 10.1043/1543-2165(2008)132[29:IFDCRT]2.0.CO;2; Williams MD, 2016, CURR ONCOL REP, V18, DOI 10.1007/s11912-016-0540-y; Yahalom R, 2008, J SURG ONCOL, V98, P572, DOI 10.1002/jso.21034; Yeh YC, 2015, HISTOPATHOLOGY, V66, P922, DOI 10.1111/his.12468; ZARBO RJ, 1991, ARCH PATHOL LAB MED, V115, P1187	35	4	4	1	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	JUN	2018	12	2					175	180		10.1007/s12105-017-0846-6			6	Pathology	Pathology	GG0GC	WOS:000432355500004	28836224	Green Published			2019-10-28	
J	Thompson, LDR; Jo, VY; Agaimy, A; Llombart-Bosch, A; Morales, GN; Machado, I; Flucke, U; Wakely, PE; Miettinen, M; Bishop, JA				Thompson, Lester D. R.; Jo, Vickie Y.; Agaimy, Abbas; Llombart-Bosch, Antonio; Morales, Gema Nieto; Machado, Isidro; Flucke, Uta; Wakely, Paul E., Jr.; Miettinen, Markku; Bishop, Justin A.			Sinonasal Tract Alveolar Rhabdomyosarcoma in Adults: A Clinicopathologic and Immunophenotypic Study of Fifty-Two Cases with Emphasis on Epithelial Immunoreactivity	HEAD & NECK PATHOLOGY			English	Article						Nasal cavity; Paranasal sinus neoplasms/pathology; Rhabdomyosarcoma, alveolar; Adult; Keratins; Immunohistochemistry	HEALTH-ORGANIZATION CLASSIFICATION; CELL NEUROENDOCRINE CARCINOMA; SOFT-TISSUE SARCOMA; NECK TUMORS TUMORS; PARANASAL SINUSES; INTERGROUP-RHABDOMYOSARCOMA; NASAL CAVITY; DIFFERENTIAL-DIAGNOSIS; 4TH EDITION; HEAD	Sinonasal tract (SNT) alveolar rhabdomyosarcoma (ARMS) are frequently misdiagnosed, especially in adults. Fifty-two adult (>= 18 years) patients with SNT ARMS were reviewed and characterized by immunohistochemistry and molecular studies. Twenty-six females and 26 males (18-72 years; mean 43.2 years), presented after a short duration (mean 2.6 months) with a large (mean 5.5 cm) destructive nasal cavity mass, involving multiple contiguous paranasal sites (n = 46) and with cervical adenopathy (n = 41). The tumors showed an alveolar, nested to solid growth pattern below an intact, but often involved (n = 9) epithelium with frequent necrosis (n = 37), destructive bone invasion (n = 30), and lymphovascular invasion (n = 25). The neoplastic cells were dyshesive and dilapidated, with crush artifacts. Rhabdoid features (n = 36) and tumor cell multinucleation (n = 28) were common. Mitotic counts were high (mean 17/10 HPFs). The neoplastic cells showed the following immunohistochemical positive findings: desmin (100%), myogenin (100%), MYOD1 (100%), MSA (96%), SMA (52%), CAM5.2 (50%), AE1/AE3 (36%); other positive markers included S100 protein (27%), CD56 (100%), synaptophysin (35%), and chromogranin (13%). Overall, 54% show epithelial marker reactivity. Molecular studies showed FOXO1 translocations (81%) with PCR demonstrating PAX3 in 72.7% tested. Patients presented with high stage (IV 24; III 26) and metastatic disease (lymph nodes n = 41; distant metastases n = 25) (IRSG grouping). Surgery (n = 16), radiation (n = 41) and chemotherapy (n = 45) yielded an overall survival of 36.1 months (mean; range 2.4-286); 18 alive without disease (mean 69.6 months); 7 alive with disease (mean 11.0 months); 1 dead without disease (63.7 months); and 26 dead with disease (mean 18.5 months). SNT ARMS frequently present in adults as a large, destructive midline mass of short symptom duration, with high stage disease. The alveolar to solid pattern of growth of cells with rhabdoid-plasmacytoid features suggests the diagnosis, but epithelial immunohistochemistry markers are present in 54% of cases, leading to misdiagnosis as carcinomas if muscle markers are not also performed. Overall survival of 36.1 months is achieved with multimodality therapy, but 64% have incurable disease (16.9 months). Mixed anatomic site (p = 0.02) was a significant adverse prognostic indicator, while stage (0.06) and tumor size > 5 cm (0.06) approached marginal significance.	[Thompson, Lester D. R.] Woodland Hills Med Ctr, Dept Pathol, Southern Calif Permanente Med Grp, 5601 De Soto Ave, Woodland Hills, CA 91365 USA; [Jo, Vickie Y.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Jo, Vickie Y.] Harvard Med Sch, Boston, MA USA; [Agaimy, Abbas] Friedrich Alexander Univ Erlangen Nuremberg, Univ Hosp, Inst Pathol, Erlangen, Germany; [Llombart-Bosch, Antonio; Morales, Gema Nieto] Univ Valencia, Valencia, Spain; [Machado, Isidro] Inst Valenciano Oncol, Valencia, Spain; [Flucke, Uta] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands; [Wakely, Paul E., Jr.] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA; [Miettinen, Markku] NCI, NIH, Bethesda, MD 20892 USA; [Bishop, Justin A.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA	Thompson, LDR (reprint author), Woodland Hills Med Ctr, Dept Pathol, Southern Calif Permanente Med Grp, 5601 De Soto Ave, Woodland Hills, CA 91365 USA.	Lester.D.Thompson@kp.org					Agaimy A, 2017, AM J SURG PATHOL, V41, P458, DOI 10.1097/PAS.0000000000000797; Akyuz C, 2012, PEDIATR HEMAT ONCOL, V29, P38, DOI 10.3109/08880018.2011.650836; Babin E, 2006, J LARYNGOL OTOL, V120, P289, DOI 10.1017/S0022215106000594; Bahrami A, 2008, MODERN PATHOL, V21, P795, DOI 10.1038/modpathol.2008.86; Barr FG, 2006, J MOL DIAGN, V8, P202, DOI 10.2353/jmoldx.2006.050124; Bishop JA, 2016, HEAD NECK PATHOL, V10, P23, DOI 10.1007/s12105-016-0688-7; Bishop JA, 2015, HEAD NECK PATHOL, V9, P507, DOI 10.1007/s12105-015-0624-2; Bishop JA, 2015, AM J SURG PATHOL, V39, P1267, DOI 10.1097/PAS.0000000000000460; Bishop JA, 2014, AM J SURG PATHOL, V38, P1282, DOI 10.1097/PAS.0000000000000285; Bisogno G, 2012, CANCER-AM CANCER SOC, V118, P821, DOI 10.1002/cncr.26355; CALLENDER TA, 1995, OTOLARYNG HEAD NECK, V112, P252, DOI 10.1016/S0194-5998(95)70246-6; Chapman-Fredricks J, 2009, APPL IMMUNOHISTO M M, V17, P207, DOI 10.1097/PAI.0b013e31818fc85c; Cordes B, 2009, HUM PATHOL, V40, P283, DOI 10.1016/j.humpath.2008.07.019; Dias P, 2000, AM J PATHOL, V156, P399, DOI 10.1016/S0002-9440(10)64743-8; Downs-Kelly E, 2009, DIAGN MOL PATHOL, V18, P138, DOI 10.1097/PDM.0b013e31818c2ea4; Ejaz A, 2005, ADV ANAT PATHOL, V12, P134, DOI 10.1097/01.pap.0000163958.29032.56; Esnaola NF, 2001, ANN SURG, V234, P215, DOI 10.1097/00000658-200108000-00012; Ferrari A, 2003, CANCER-AM CANCER SOC, V98, P571, DOI 10.1002/cncr.11550; FU YS, 1976, CANCER-AM CANCER SOC, V37, P364, DOI 10.1002/1097-0142(197601)37:1<364::AID-CNCR2820370147>3.0.CO;2-Y; Houreih MA, 2009, INT J SURG PATHOL, V17, P135, DOI 10.1177/1066896908319444; Iezzoni Julia C, 2005, Am J Clin Pathol, V124 Suppl, pS110; Luna-Ortiz K, 2004, THYROID, V14, P363, DOI 10.1089/105072504774193195; MIETTINEN M, 1982, AM J PATHOL, V108, P246; MIETTINEN M, 1989, AM J SURG PATHOL, V13, P120, DOI 10.1097/00000478-198902000-00005; Mills SE, 2002, MODERN PATHOL, V15, P264, DOI 10.1038/modpathol.3880522; Ognjanovic S, 2009, CANCER-AM CANCER SOC, V115, P4218, DOI 10.1002/cncr.24465; Patel TD, 2015, INT FORUM ALLERGY RH, V5, P448, DOI 10.1002/alr.21497; Raney R B, 2001, Sarcoma, V5, P9, DOI 10.1080/13577140120048890; Raney RB, 2008, PEDIATR BLOOD CANCER, V50, P958, DOI 10.1002/pbc.21447; Raney RB, 1999, MED PEDIATR ONCOL, V33, P362, DOI 10.1002/(SICI)1096-911X(199910)33:4<362::AID-MPO4>3.0.CO;2-I; Sanghvi S, 2013, AM J OTOLARYNG, V34, P682, DOI 10.1016/j.amjoto.2013.04.012; Sebire NJ, 2005, APPL IMMUNOHISTO M M, V13, P1, DOI 10.1097/00129039-200503000-00001; Smith SM, 2015, HEAD NECK PATHOL, V9, P165, DOI 10.1007/s12105-014-0553-5; Stelow EB, 2017, HEAD NECK PATHOL, V11, P3, DOI 10.1007/s12105-017-0791-4; Su SY, 2014, INT ARCH OTORHINOLAR, V18, pS149, DOI 10.1055/s-0034-1390014; Szablewski V, 2015, LARYNGOSCOPE, V125, P615, DOI 10.1002/lary.24910; Thompson LDR, 2009, PATHOLOGY, V41, P8; Thompson LDR, 2017, HEAD NECK PATHOL, V11, P78, DOI 10.1007/s12105-017-0790-5; Thompson LDR, 2017, MODERN PATHOL, V30, pS1, DOI 10.1038/modpathol.2016.119; Thompson LDR, 2012, HEAD NECK PATHOL, V6, P75, DOI 10.1007/s12105-012-0336-9; Turner JH, 2011, OTOLARYNG HEAD NECK, V145, P967, DOI 10.1177/0194599811417063; Weinreb I, 2007, HEAD NECK PATHOL, V1, P21, DOI 10.1007/s12105-007-0004-7; Wenig BM, 2009, ARCH PATHOL LAB MED, V133, P699, DOI 10.1043/1543-2165-133.5.699; Win KT, 2014, INT J CLIN EXP PATHO, V7, P451; Wooff JC, 2011, AM J SURG PATHOL, V35, P1786, DOI 10.1097/PAS.0b013e3182363b78; Wu YT, 2014, J CRANIOFAC SURG, V25, P922, DOI 10.1097/SCS.0000000000000704; Wurm J, 2005, OTOLARYNG HEAD NECK, V133, P42, DOI 10.1016/j.otohns.2005.03.023	47	4	4	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	JUN	2018	12	2					181	192		10.1007/s12105-017-0851-9			12	Pathology	Pathology	GG0GC	WOS:000432355500005	28875443	Green Published			2019-10-28	
J	Fowler, CB; Damm, DD				Fowler, Craig B.; Damm, Douglas D.			Sialadenoma Papilliferum: Analysis of Seven New Cases and Review of the Literature	HEAD & NECK PATHOLOGY			English	Review						Sialadenoma papilliferum; Salivary gland neoplasm; Syringocystadenoma; Papilliferum	SALIVARY-GLAND TUMORS; SYRINGOCYSTADENOCARCINOMA PAPILLIFERUM; PAROTID-GLAND; ORAL-CAVITY; HARD PALATE; IN-SITU; ULTRASTRUCTURE; CARCINOMA; FEATURES; MUCOSA	Sialadenoma papilliferum (SP) is a rare benign salivary gland neoplasm that comprises from 0.4 to 1.2% of all salivary gland tumors. The tumor is so named because of its microscopic resemblance to the syringocystadenoma papilliferum, an uncommon benign tumor of sweat gland origin. The purpose of this paper is to report the clinical and microscopic features of seven new cases of SP and combine them with cases previously reported in the English language literature to further define this unusual lesion. Combining our cases with acceptable cases from the literature, the palate (especially the hard palate) was the most common site, with 80% of the cases occurring in this location. Other locations in decreasing order were buccal mucosa, upper lip, retromolar pad, and parotid gland. Age at diagnosis ranged from 18 to 87 years with a peak in the 6th decade and an average age of 56.4 years. Microscopically, the lesions demonstrated a papillary surface morphology, and the papillary projections varied from long and pointed to short and blunted. The supporting connective tissue contained a variable number of convoluted ductal structures, which often fused with the overlying surface epithelium. The ductal structures exhibited papillary infoldings and were lined by a double layer of epithelium consisting of basal cell layer and a luminal layer of cuboidal-to-columnar ductal cells. Immunohistochemical reactivity with p63 and p40 indicated that the basal cell layer was comprised predominantly of neoplastic myoepithelial cells. The luminal cells were immunoreactive with epithelial membrane antigen characteristic of ductal cell differentiation. Conservative surgical treatment was accomplished in most cases and appears to be adequate treatment as only two recurrences were documented. Several case reports of purported malignant transformation in SP have been reported in the literature, but in our opinion, there is insufficient evidence in the publications to unequivocally determine whether any of the malignancies truly originated within a pre-existing SP.	[Fowler, Craig B.; Damm, Douglas D.] Univ Kentucky, Coll Dent, Div Oral & Maxillofacial Pathol, Lexington, KY 40506 USA	Fowler, CB (reprint author), Univ Kentucky, Coll Dent, Div Oral & Maxillofacial Pathol, Lexington, KY 40506 USA.	craig.fowler@uky.edu					ABRAMS AM, 1969, CANCER, V24, P1057, DOI 10.1002/1097-0142(196911)24:5<1057::AID-CNCR2820240529>3.0.CO;2-L; Argyres MI, 1999, J CUTAN PATHOL, V26, P259, DOI 10.1111/j.1600-0560.1999.tb01840.x; Asahina I, 1997, J ORAL MAXIL SURG, V55, P1000, DOI 10.1016/S0278-2391(97)90078-1; Bondi R, 1996, HISTOPATHOLOGY, V28, P475, DOI 10.1046/j.1365-2559.1996.t01-4-297345.x; Brannon RB, 2001, ORAL SURG ORAL MED O, V92, P68, DOI 10.1067/moe.2001.115978; Chi AC, 2015, HEAD NECK PATHOL, V9, P244, DOI 10.1007/s12105-014-0572-2; CLEARY KR, 1990, ANN OTO RHINOL LARYN, V99, P756, DOI 10.1177/000348949009900918; DRUMMOND JF, 1978, ORAL SURG ORAL MED O, V45, P72, DOI 10.1016/0030-4220(78)90225-6; Ellis GL, 2008, SERIES, P148; FANTASIA JE, 1986, ARCH PATHOL LAB MED, V110, P523; FREEDMAN PD, 1978, ORAL SURG ORAL MED O, V45, P88, DOI 10.1016/0030-4220(78)90228-1; Gomes APN, 2004, INT J ORAL MAX SURG, V33, P621, DOI 10.1016/j.ijom.2003.10.019; GRUSHKA M, 1984, LARYNGOSCOPE, V94, P231, DOI 10.1288/00005537-198402000-00018; Ide F, 2010, J CLIN PATHOL, V63, P362, DOI 10.1136/jcp.2009.072660; Ishida-Yamamoto A, 2001, J AM ACAD DERMATOL, V45, P755, DOI 10.1067/mjd.2001.117723; JENSEN JL, 1973, ORAL SURG ORAL MED O, V35, P521, DOI 10.1016/0030-4220(73)90009-1; KRONENBERG J, 1989, J LARYNGOL OTOL, V103, P1089, DOI 10.1017/S0022215100111089; Kubota Y, 2012, J ORAL MAXIL SURG, V70, P1609, DOI 10.1016/j.joms.2011.08.012; Liu W, 2009, HEAD NECK PATHOL, V3, P59, DOI 10.1007/s12105-009-0106-5; Loehn B, 2013, HEAD NECK-J SCI SPEC, V35, pE74, DOI 10.1002/hed.21879; Mahajan D, 2007, ORAL SURG ORAL MED O, V103, pE51, DOI 10.1016/j.tripleo.2006.01.012; Maiorano E, 1996, J ORAL PATHOL MED, V25, P336, DOI 10.1111/j.1600-0714.1996.tb00273.x; Markopoulos A, 1997, J ORAL MAXIL SURG, V55, P1181, DOI 10.1016/S0278-2391(97)90305-0; MCCOY JM, 1980, J ORAL SURG, V38, P691; MITRE BK, 1986, J ORAL MAXIL SURG, V44, P469, DOI 10.1016/S0278-2391(86)80014-3; NAKAHATA A, 1990, J ORAL PATHOL MED, V19, P313, DOI 10.1111/j.1600-0714.1990.tb00851.x; NASU M, 1981, J ORAL SURG, V39, P367; NUMATA M, 1985, J CUTAN PATHOL, V12, P3, DOI 10.1111/j.1600-0560.1985.tb00422.x; Owosho AA, 2016, APPL IMMUNOHISTO M M, V24, P501, DOI 10.1097/PAI.0000000000000222; PAPANICOLAOU S J, 1987, Journal of Oral Medicine, V42, P57; Patterson JW, 2016, WEEDENS SKIN PATHOLO, P944; PIMENTEL MTY, 1995, J LARYNGOL OTOL, V109, P787, DOI 10.1017/S0022215100131330; Ponniah I, 2007, ORAL SURG ORAL MED O, V104, pE27, DOI 10.1016/j.tripleo.2006.06.053; PUTS JJG, 1984, J MAXILLOFAC SURG, V12, P90, DOI 10.1016/S0301-0503(84)80218-0; REGEZI JA, 1985, CANCER-AM CANCER SOC, V55, P108, DOI 10.1002/1097-0142(19850101)55:1<108::AID-CNCR2820550118>3.0.CO;2-2; RENNIE JS, 1984, INT J ORAL MAXILLOF, V13, P452, DOI 10.1016/S0300-9785(84)80074-5; Shimoda M, 2004, VIRCHOWS ARCH, V445, P641, DOI 10.1007/s00428-004-1091-4; SHIRASUNA K, 1984, CANCER, V53, P468, DOI 10.1002/1097-0142(19840201)53:3<468::AID-CNCR2820530317>3.0.CO;2-R; SOLOMON MP, 1978, CANCER, V42, P1859, DOI 10.1002/1097-0142(197810)42:4<1859::AID-CNCR2820420425>3.0.CO;2-C; Ubaidat MA, 2001, ARCH PATHOL LAB MED, V125, P1595; VANDERWAL JE, 1992, INT J ORAL MAX SURG, V21, P104, DOI 10.1016/S0901-5027(05)80543-0; WALDRON CA, 1988, ORAL SURG ORAL MED O, V66, P323, DOI 10.1016/0030-4220(88)90240-X; WERTHEIMER FW, 1983, INT J ORAL MAXILLOF, V12, P190, DOI 10.1016/S0300-9785(83)80066-0; WHITTAKER JS, 1976, J CLIN PATHOL, V29, P795, DOI 10.1136/jcp.29.9.795; Woestenborghs H, 2006, HISTOPATHOLOGY, V48, P869, DOI 10.1111/j.1365-2559.2006.02421.x	45	2	2	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	JUN	2018	12	2					193	201		10.1007/s12105-017-0852-8			9	Pathology	Pathology	GG0GC	WOS:000432355500006	28887760	Green Published			2019-10-28	
J	Sato, K; Thompson, LDR; Miyai, K; Kono, T; Tsuda, H				Sato, Kimiya; Thompson, Lester D. R.; Miyai, Kosuke; Kono, Takako; Tsuda, Hitoshi			Ectopic Hamartomatous Thymoma: A Review Of The Literature With Report Of New Cases And Proposal Of A New Name: Biphenotypic Branchioma	HEAD & NECK PATHOLOGY			English	Review						Ectopic hamartomatous thymoma; Biphenotypic branchioma; Carcinoma; Branchial pouch; Head and neck; Soft tissue	ANDROGEN RECEPTORS; CARCINOMA; DIFFERENTIATION; TUMOR	Ectopic hamartomatous thymoma (EHT) is a rare benign neoplasm of the lower neck suggesting branchial origin. Despite use of the term thymoma in the nomenclature, there is no evidence of thymic origin or differentiation. It affects middle-aged adults with a remarkable male predominance. To date less than 80 cases have been reported in the English literature. We present here two additional cases of EHT. The first is a benign case in a 31-year-old man, showing typical histological features. The second is a malignant case in a 70-year-old woman, showing intraductal carcinoma arising in intimate association with an EHT. These cases are presented in the context of a review of cases reported in the English literature. The exact origin has not been identified, but is considered to be of branchial apparatus, creating a quandary about the best terminology. Recently, the designation "branchial anlage mixed tumor" or "thymic anlage tumor" were proposed, but do not quite reflect the true nature of the neoplasm. To avoid taxonomic confusion, international consensus on terminology is desired. As this entity is a neoplasm that shows dual mesoderm and endoderm derivation/differentiation, we propose a new name "biphenotypic branchioma.".	[Sato, Kimiya; Kono, Takako; Tsuda, Hitoshi] Natl Def Med Coll, Dept Basic Pathol, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan; [Thompson, Lester D. R.] Woodland Hills Med Ctr, Dept Pathol, 5601 De Soto Ave, Woodland Hills, CA 91367 USA; [Miyai, Kosuke] Japan Self Def Forces Cent Hosp, Dept Pathol, Setagaya Ku, 1-2-24 Ikejiri, Tokyo 1548532, Japan	Sato, K (reprint author), Natl Def Med Coll, Dept Basic Pathol, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.	kimiya@ndmc.ac.jp	Thompson, Lester D. R./J-8404-2016	Thompson, Lester D. R./0000-0003-3714-1432			ARMOUR A, 1993, J LARYNGOL OTOL, V107, P155, DOI 10.1017/S0022215100122509; Ceng YS, 2013, CHINESE MED J-PEKING, V126, P798, DOI 10.3760/cma.j.issn.0366-6999.20122610; Chan J. K. C., 2013, WHO CLASSIFICATION T, P201; CHAN JKC, 1991, HUM PATHOL, V22, P349, DOI 10.1016/0046-8177(91)90083-2; Choi JH, 2007, ACTA CYTOL, V51, P672; Doctor Vatsala M., 1993, Indian Journal of Cancer, V30, P192; Eulderink F, 1998, EUR J SURG, V164, P629; FETSCH JF, 1990, HUM PATHOL, V21, P662, DOI 10.1016/S0046-8177(96)90014-3; Fetsch JF, 2004, AM J SURG PATHOL, V28, P1360, DOI 10.1097/01.pas.0000135518.27224.3f; Franzen A, 2018, LARYNGOSCOPE, V128, P646, DOI 10.1002/lary.26775; Fukunaga M, 2002, APMIS, V110, P565, DOI 10.1034/j.1600-0463.2002.11007808.x; Henderson CJA, 2000, PATHOLOGY, V32, P142, DOI 10.1080/003130200104420; Hirokawa M, 1999, ACTA CYTOL, V43, P232, DOI 10.1159/000330983; Huang L, 2014, NIGER J CLIN PRACT, V17, P814, DOI 10.4103/1119-3077.144407; Hwang HC, 1998, MODERN PATHOL, V11, P1122; Iida E, 2006, SCAND J PLAST RECONS, V40, P249, DOI 10.1080/0284431051003592; Jing HB, 2015, INT J CLIN EXP PATHO, V8, P11776; Kazakov DV, 2004, HISTOPATHOLOGY, V45, P202, DOI 10.1111/j.1365-2559.2004.01866.x; Kim JM, 1990, KOREAN J PATHOL, V24, P50; Koljonen V, 2013, J EUR ACAD DERMATOL, V27, P884, DOI 10.1111/j.1468-3083.2012.04600.x; Kondo T, 2017, CASE REP OTOLARYNGOL, DOI 10.1155/2017/1672919; Kushida Y, 2006, J CUTAN PATHOL, V33, P369, DOI 10.1111/j.0303-6987.2006.00424.x; Lee Shi Nae, 2003, Arch Pathol Lab Med, V127, pe378; Liang PI, 2013, HISTOPATHOLOGY, V62, P518, DOI 10.1111/his.12022; Marschall J, 2002, HEAD NECK-J SCI SPEC, V24, P800, DOI 10.1002/hed.10091; Michal M, 1996, HISTOPATHOLOGY, V29, P549, DOI 10.1046/j.1365-2559.1996.d01-533.x; Michal M, 1996, PATHOL RES PRACT, V192, P610, DOI 10.1016/S0344-0338(96)80113-0; Michal M, 1999, HISTOPATHOLOGY, V35, P89; Michal Michal, 1993, Zentralblatt fuer Pathologie, V139, P381; Parihar Shivani, 2016, BMJ Case Rep, V2016, DOI 10.1136/bcr-2016-215789; Reusens H, 2015, ACTA CHIR BELG, V115, P418; ROSAI J, 1984, AM J SURG PATHOL, V8, P501, DOI 10.1097/00000478-198407000-00002; Roychoudhuri R, 2006, CANCER CAUSE CONTROL, V17, P655, DOI 10.1007/s10552-005-0615-9; SAEED IT, 1990, HISTOPATHOLOGY, V17, P572, DOI 10.1111/j.1365-2559.1990.tb00800.x; Sakurai H, 2010, SURG TODAY, V40, P146, DOI 10.1007/s00595-009-4019-4; Shim DB, 2012, AURIS NASUS LARYNX, V39, P110, DOI 10.1016/j.anl.2011.07.016; SMITH PS, 1982, J CLIN PATHOL, V35, P1074, DOI 10.1136/jcp.35.10.1074; Weinreb I, 2007, HUM PATHOL, V38, P1092, DOI 10.1016/j.humpath.2007.01.029; Weissferdt A, 2016, AM J SURG PATHOL, V40, P1571, DOI 10.1097/PAS.0000000000000699; Williams L, 2015, AM J SURG PATHOL, V39, P705, DOI 10.1097/PAS.0000000000000413; Yoruk O, 2014, SURG RADIOL ANAT, V36, P239, DOI 10.1007/s00276-013-1176-3; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zhao C, 2000, VIRCHOWS ARCH, V437, P643, DOI 10.1007/s004280000309; Zhou J, 2008, ARCH HISTOPATHOL DIF, V15, P13; 석상희, 2006, The Korean Journal of Pathology, V40, P292	45	3	3	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	JUN	2018	12	2					202	209		10.1007/s12105-017-0854-6			8	Pathology	Pathology	GG0GC	WOS:000432355500007	28879635	Green Published			2019-10-28	
J	Haase, C; Lethaus, B; Knuchel-Clarke, R; Holzle, F; Cassataro, A; Braunschweig, T				Haase, Claudia; Lethaus, Bernd; Knuechel-Clarke, Ruth; Hoelzle, Frank; Cassataro, Angela; Braunschweig, Till			Development of a Rapid Analysis Method for Bone Resection Margins for Oral Squamous Cell Carcinoma by Immunoblotting	HEAD & NECK PATHOLOGY			English	Article						Oral squamous cell carcinoma; Head and neck; Immunofluorescence; Intraoperative care; Frozen section; Bone; Surgical margin	INTRAOPERATIVE EVALUATION; FROZEN-SECTION; RECONSTRUCTION; SURGERY; TISSUE; HEAD	The purpose of this proof-of-principle study was to develop a rapid and approachable method to analyse bone resection margins in patients with oral squamous cell carcinoma (OSCC) in an intraoperative setting, similar to assessing frozen sections of soft tissue. Bone excision and risk of remaining tumour cells could be minimised, thus improving reconstruction measures and facilitating convalescence. Frozen, sawed wafers of porcine bone artificially combined with porcine skin (simulating OSCC properties) were used to develop and evaluate a new molecular method: protein transfer from non-decalcified, sawed wafers onto a membrane stained by immunofluorescence (Tissue-ProtTrans). Tissue-ProtTrans was based on the detection of keratin 5/6 as a marker of tumour cells. The results were compared to standard immunohistochemistry (IHC) and H&E results of the same wafers after decalcification. Tissue-ProtTrans resulted in a total assay time of 3.5 h using the Trans-Blot(A (R)) Turbo (TM) Transfer System (Bio-Rad) for protein transfer. Amersham Protran(A (R)) Premium Nitrocellulose Membranes 0.2 A mu m (GE Healthcare) were stained with a primary antibody to keratin 5/6 (Dako Agilent) and a secondary antibody labelled with IRDye(A (R)) 800CW (LI-COR). Visualisation was performed with an infrared laser scanner (Odyssey). Upon comparison, five independent experiments on porcine specimens processed with the Tissue-ProtTrans showed similar results to standard IHC and H&E analysis. In comparison to standard IHC results (requiring several days due to decalcification) Tissue-ProtTrans provided similar results, but was much faster (3.5 h). This highly promising method has good potential for further time reduction and will be suitable for intraoperative assessment.	[Haase, Claudia; Knuechel-Clarke, Ruth; Cassataro, Angela; Braunschweig, Till] RWTH Aachen Univ Hosp, Inst Pathol, Aachen, Germany; [Lethaus, Bernd; Hoelzle, Frank] RWTH Aachen Univ Hosp, Dept Oral & Maxillofacial Surg, Aachen, Germany	Braunschweig, T (reprint author), RWTH Aachen Univ Hosp, Inst Pathol, Aachen, Germany.	tbraunschweig@ukaachen.de		Braunschweig, Till/0000-0001-9166-2912			[Anonymous], 2016, ORAL CANC FACTS; [Anonymous], 2009, ED GUIDE IMMUNOHISTO; [Anonymous], 2015, GLOB CANC FACTS FIGS; [Anonymous], 2010, TRANS BLOT TURBOTM B, P40; Bak M, 2010, ORAL ONCOL, V46, P71, DOI 10.1016/j.oraloncology.2009.11.006; Bilodeau EA, 2011, HEAD NECK PATHOL, V5, P216, DOI 10.1007/s12105-011-0264-0; Camuzard O, 2017, EUR ARCH OTO-RHINO-L, V274, P441, DOI 10.1007/s00405-016-4219-7; Chung JY, 2015, METHODS MOL BIOL, V1312, P175, DOI 10.1007/978-1-4939-2694-7_21; Deutsche Gesellschaft fur Mund- Kiefer-und Gesichtschirurgie, 2012, LEITL LANGV LEITL ON, P119; Ferreira JJ, 2015, PROSTHET ORTHOT INT, V39, P182, DOI 10.1177/0309364613520032; Forrest LA, 1997, AM J OTOLARYNG, V18, P396; FORREST LA, 1995, LARYNGOSCOPE, V105, P475; Gellrich NC, 2004, J ORAL MAXIL SURG, V62, P186, DOI 10.1016/j.joms.2003.04.012; Green B, 2014, BRIT J ORAL MAX SURG, V52, P675, DOI 10.1016/j.bjoms.2014.06.010; Hausamen J-E, 2012, MUND KIEFER GEGSICHT, V4; Jerjes W, 2005, ARCH ORAL BIOL, V50, P361, DOI 10.1016/j.archoralbio.2004.08.003; Mahmood S, 2001, J ORAL MAXIL SURG, V59, P1138, DOI 10.1053/joms.2001.26710; Mayer A, 2015, AM J OTOLARYNG, V36, P324, DOI 10.1016/j.amjoto.2014.04.012; Nieberler M, 2014, CANCER CYTOPATHOL, V122, P646, DOI 10.1002/cncy.21428; Oxford LE, 2006, OTOLARYNG HEAD NECK, V134, P138, DOI 10.1016/j.otohns.2005.09.007; Pfister DG, 2013, NCCN CLIN PRACTICE G; Rao Roopa S, 2014, J Contemp Dent Pract, V15, P127; Reid PD, 1992, TISSUE PRINTING TOOL; Rivera C, 2015, INT J CLIN EXP PATHO, V8, P11884; Santamaria E, 2016, CLIN PLAST SURG, V43, P719, DOI 10.1016/j.cps.2016.05.011; SHOCKLEY WW, 1991, ARCH OTOLARYNGOL, V117, P745; TAYLOR R, 1993, PLANT PHYSIOL, V102, P1027, DOI 10.1104/pp.102.3.1027; Weisberger EC, 2001, ARCH OTOLARYNGOL, V127, P790; Weitz J, 2016, INT J ORAL MAX SURG, V45, P1366, DOI 10.1016/j.ijom.2016.06.023; Wysluch A, 2010, HEAD NECK-J SCI SPEC, V32, P1473, DOI 10.1002/hed.21350	30	0	0	1	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	JUN	2018	12	2					210	220		10.1007/s12105-017-0856-4			11	Pathology	Pathology	GG0GC	WOS:000432355500008	28929330	Green Published			2019-10-28	
J	Scognamiglio, T; Chen, YT				Scognamiglio, Theresa; Chen, Yao-Tseng			Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma	HEAD & NECK PATHOLOGY			English	Article						PD-L1; Squamous cell carcinoma; HPV; Immunohistochemistry	HPV-ASSOCIATED HEAD; LUNG-CANCER; IMMUNE MODULATION; PEMBROLIZUMAB; IMMUNOHISTOCHEMISTRY; BIOMARKERS; NIVOLUMAB; RECURRENT; BLOCKADE; THERAPY	Anti-PD1 antibody has been approved for metastatic squamous cell carcinoma of the head and neck (SCCHN) and objective response rates of approximately 20% have been reported. Defining PD-L1 expression at >= 1% tumor cells as positive, PD-L1-positive tumors showed a higher response rate. However, it is unclear whether 1% is the optimal cutoff, and studies on lung cancer suggested 50% cutoff as a stronger predictive biomarker. 96 primary SCCHN from oropharynx and oral cavity and 34 corresponding metastatic lesions were typed for membranous PD-L1 expression. p16 immunohistochemistry was used as a surrogate marker for HPV status in SCCHN from the oropharynx. Fifty-two of 96 (54%) tumors were PD-L1-positive, 72% if PD-L1 expression in tumor-infiltrating immunocytes was also included as positive. Fifteen of 34 primary-metastasis tumor pairs differed in PD-L1 expression, and p16(+) cases more frequently showed PD-L1 expression in immunocytes than p16(-) cases (82 vs. 45%, p < 0.05). PD-L1-positive SCCHN showed two distinct patterns of expression. In the induced pattern of expression, PD-L1-positive tumor cells were limited to the periphery of tumor nests at the tumor-immunocyte interface, comprising < 5% of tumor cells, and were almost always associated with PD-L1-positive immunocytes. In contrast, tumors with constitutive PD-L1 expression had a higher percentage of positive tumor cells, often diffusely distributed throughout the tumor, and often were not accompanied by PD-L1-positive immunocytes. We propose that distinguishing these two biologically distinctive patterns of PD-L1 expression and typing metastatic instead of primary lesions might better predict immunotherapeutic response to anti-PD1/PD-L1 regimens beyond just the percentage of PD-L1-positive tumor cells.	[Scognamiglio, Theresa] Weill Cornell Med, Dept Pathol & Lab Med, 525 East 68th St,Starr 1005, New York, NY 10065 USA; [Chen, Yao-Tseng] Weill Cornell Med, Dept Pathol & Lab Med, 525 East 68th St, New York, NY 10065 USA	Scognamiglio, T (reprint author), Weill Cornell Med, Dept Pathol & Lab Med, 525 East 68th St,Starr 1005, New York, NY 10065 USA.	ths9004@med.cornell.edu; ytchen@med.cornell.edu					Badoual C, 2013, CANCER RES, V73, P128, DOI 10.1158/0008-5472.CAN-12-2606; Bauml J, 2017, J CLIN ONCOL, V35, P1542, DOI 10.1200/JCO.2016.70.1524; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Chow LQM, 2016, J CLIN ONCOL, V34, P3838, DOI 10.1200/JCO.2016.68.1478; Feldman R, 2016, HEAD NECK-J SCI SPEC, V38, pE1625, DOI 10.1002/hed.24290; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Festino L, 2016, DRUGS, V76, P925, DOI 10.1007/s40265-016-0588-x; Garber K, 2015, NAT BIOTECHNOL, V33, P1217, DOI 10.1038/nbt1215-1217; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Kim HS, 2016, CANCER RES TREAT, V48, P527, DOI 10.4143/crt.2015.249; Kim HR, 2016, SCI REP-UK, V6, DOI 10.1038/srep36956; Lyford-Pike S, 2013, CANCER RES, V73, P1733, DOI 10.1158/0008-5472.CAN-12-2384; Malm IJ, 2015, HEAD NECK-J SCI SPEC, V37, P1088, DOI 10.1002/hed.23706; Okazaki T, 2007, INT IMMUNOL, V19, P813, DOI 10.1093/intimm/dxm057; Page DB, 2014, ANNU REV MED, V65, P185, DOI 10.1146/annurev-med-092012-112807; Rebelatto MC, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0545-8; Scheel AH, 2016, MODERN PATHOL, V29, P1165, DOI 10.1038/modpathol.2016.117; Seiwert TY, 2016, LANCET ONCOL, V17, P956, DOI 10.1016/S1470-2045(16)30066-3; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Straub M, 2016, ONCOTARGET, V7, P12024, DOI 10.18632/oncotarget.7593; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Topalian SL, 2016, NAT REV CANCER, V16, P275, DOI 10.1038/nrc.2016.36; Ukpo OC, 2013, HEAD NECK PATHOL, V7, P113, DOI 10.1007/s12105-012-0406-z; Yao S, 2013, NAT REV DRUG DISCOV, V12, P130, DOI 10.1038/nrd3877	25	3	3	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	JUN	2018	12	2					221	229		10.1007/s12105-017-0857-3			9	Pathology	Pathology	GG0GC	WOS:000432355500009	28948509	Green Published			2019-10-28	
J	Kakkar, A; Antony, VM; Irugu, DVK; Adhikari, N; Jain, D				Kakkar, Aanchal; Antony, Vijay Mariadas; Irugu, David Victor Kumar; Adhikari, Narayan; Jain, Deepali			NUT Midline Carcinoma: A Series of Five Cases, Including One with Unusual Clinical Course	HEAD & NECK PATHOLOGY			English	Article						NUT; Poorly differentiated carcinoma; Squamous cell carcinoma; Sinonasal; Lacrimal fossa; Head and neck	BRD4-NUT FUSION ONCOGENE; REARRANGEMENT; ANTIBODY	NUT midline carcinomas (NMCs) are rare, poorly differentiated tumors with aggressive biological behavior and a characteristic molecular signature. Availability of NUT antibody has facilitated diagnosis of NMC without molecular testing. We report a series of head and neck NMCs diagnosed using NUT IHC at our institute, including one case with an unusual course. Immunohistochemistry for NUT was performed in nasal and sinonasal tumors with diagnoses of undifferentiated carcinoma, poorly differentiated squamous cell carcinoma and malignant neoplasm, not otherwise specified, to identify cases of NMC. Clinicopathological features were reviewed. Five cases of NMC were identified, accounting for 9.6% of poorly differentiated/undifferentiated carcinomas of the sinonasal region. These patients had a sex ratio of 2:3, and ranged in age from of 10 to 31 years (mean: 25.2 years). Patient 4 had previously been diagnosed with basal cell carcinoma arising in left nasolacrimal duct, and inverted papilloma of nasal cavity. She presented to us with a left lacrimal fossa mass extending into nasal cavity, which was diagnosed as NMC. NMC is a rare neoplasm, the awareness of which is imperative for pathologists to identify cases in which NUT IHC should be ordered. NUT IHC should be performed in all cases of a poorly differentiated carcinoma, particularly those with foci of squamous differentiation, irrespective of patient age and unusual tumor location, as seen in one of our cases. Although considered a highly aggressive and lethal neoplasm, NMC can have a more prolonged clinical course on occasion.	[Kakkar, Aanchal; Antony, Vijay Mariadas; Jain, Deepali] All India Inst Med Sci, Dept Pathol, New Delhi 110029, India; [Irugu, David Victor Kumar] All India Inst Med Sci, Dept Otorhinolaryngol & Head & Neck Surg, New Delhi 110029, India; [Adhikari, Narayan] All India Inst Med Sci, Dept Radiat Oncol, New Delhi 110029, India	Jain, D (reprint author), All India Inst Med Sci, Dept Pathol, New Delhi 110029, India.	deepalijain76@gmail.com					Bauer DE, 2012, CLIN CANCER RES, V18, P5773, DOI 10.1158/1078-0432.CCR-12-1153; D'Ambrosio L, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3262-0; den Bakker MA, 2009, AM J SURG PATHOL, V33, P1253, DOI 10.1097/PAS.0b013e3181abe120; Engleson J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-69; Evans AG, 2012, AM J SURG PATHOL, V36, P1222, DOI 10.1097/PAS.0b013e318258f03b; French CA, 2008, ONCOGENE, V27, P2237, DOI 10.1038/sj.onc.1210852; French CA, 2004, J CLIN ONCOL, V22, P4135, DOI 10.1200/JCO.2004.02.107; French CA, 2003, CANCER RES, V63, P304; Gokmen-Polar Y, 2014, MODERN PATHOL, V27, P1649, DOI 10.1038/modpathol.2014.63; Haack H, 2009, AM J SURG PATHOL, V33, P984, DOI 10.1097/PAS.0b013e318198d666; Jain D, 2015, DIAGN CYTOPATHOL, V43, P456, DOI 10.1002/dc.23250; Odashiro AN, 2015, DIAGNOSTIC SURG PATH, P6451; Seim NB, 2017, HEAD NECK PATHOL, V11, P460, DOI 10.1007/s12105-017-0809-y; Shaikh F, 2015, CUREUS, V7, DOI 10.7759/cureus.288; Stelow EB, 2009, ADV ANAT PATHOL, V16, P92, DOI 10.1097/PAP.0b013e31819923e4; Ziai J, 2010, HEAD NECK PATHOL, V4, P163, DOI 10.1007/s12105-010-0174-6	16	8	8	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	JUN	2018	12	2					230	236		10.1007/s12105-017-0858-2			7	Pathology	Pathology	GG0GC	WOS:000432355500010	28948459	Green Published			2019-10-28	
J	Woo, HY; Choi, EC; Yoon, SO				Woo, Ha Young; Choi, Eun Chang; Yoon, Sun Och			Diagnostic Approaches for Salivary Gland Tumors with Secretory and Microcystic Features	HEAD & NECK PATHOLOGY			English	Article						Secretory carcinoma; Salivary gland tumor; S-100; Mammaglobin; ETV6-NTRK3	ETV6-NTRK3 GENE FUSION; ACINIC CELL-CARCINOMA; RECENTLY DESCRIBED ENTITY; MAMMAGLOBIN IMMUNOHISTOCHEMISTRY; DOG1; TRANSLOCATION; EXPRESSION; SPECTRUM; MIMICS; ORIGIN	Secretory carcinoma (SC) of the salivary gland is a new entity that shares the unique morphologic features and cytogenetic characteristics of the ETV6-NTRK3 fusion gene with its breast counterpart. Before identification of SC of the salivary gland, it was most frequently diagnosed as acinic cell carcinoma (AciCC). We retrospectively reviewed our own database of salivary gland tumors harboring microcystic and papillary architecture and/or secretory features that were originally diagnosed as AciCC. We selected nine cases of AciCC showing diffuse S-100 expression on immunohistochemistry (IHC). A recently diagnosed case of SC was included in the study as a reference sample. We performed IHC of S-100 and mammaglobin and ETV6 gene fluorescence in situ hybridization (FISH) in all cases. Seven cases were positive for both S-100 and mammaglobin, while five of the seven (71.4%) demonstrated ETV6 gene translocation by FISH. In the cases which did not co-express either S-100 or mammaglobin on IHC, ETV6 gene rearrangement was not shown on FISH. In conclusion, if a salivary gland tumor has morphologic features of SC with co-expression of S-100 and mammaglobin, ETV6 FISH can be performed to confirm the diagnosis of SC of the salivary gland.	[Woo, Ha Young; Yoon, Sun Och] Yonsei Univ, Dept Pathol, Coll Med, 50 Yonsei Ro, Seoul 120752, South Korea; [Choi, Eun Chang] Yonsei Univ, Dept Otorhinolaryngol, Coll Med, 50 Yonsei Ro, Seoul 120752, South Korea	Yoon, SO (reprint author), Yonsei Univ, Dept Pathol, Coll Med, 50 Yonsei Ro, Seoul 120752, South Korea.	soyoon@yuhs.ac		Yoon, Sun Och/0000-0002-5115-1402; Woo, Hayoung/0000-0002-3078-6484	National Research Foundation of Korea (NRF)-Ministry of Education [NRF-2015R1D1A1A09059399]	The study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (NRF-2015R1D1A1A09059399).	Bishop JA, 2013, HUM PATHOL, V44, P1982, DOI 10.1016/j.humpath.2013.03.017; Bishop JA, 2013, AM J SURG PATHOL, V37, P1053, DOI 10.1097/PAS.0b013e3182841554; Bishop JA, 2013, CANCER CYTOPATHOL, V121, P228, DOI 10.1002/cncy.21245; Bishop JA, 2013, HEAD NECK PATHOL, V7, P35, DOI 10.1007/s12105-013-0429-0; Bourgeois JM, 2000, AM J SURG PATHOL, V24, P937, DOI 10.1097/00000478-200007000-00005; Chenevert J, 2012, MODERN PATHOL, V25, P919, DOI 10.1038/modpathol.2012.57; Chiosea SI, 2012, HISTOPATHOLOGY, V61, P387, DOI 10.1111/j.1365-2559.2012.04232.x; Chiosea SI, 2012, AM J SURG PATHOL, V36, P343, DOI 10.1097/PAS.0b013e318242a5b0; Connor A, 2012, AM J SURG PATHOL, V36, P27, DOI 10.1097/PAS.0b013e318231542a; Fehr A, 2011, AM J SURG PATHOL, V35, P1600, DOI 10.1097/PAS.0b013e31822832c7; Hemminger J, 2012, HISTOPATHOLOGY, V61, P170, DOI 10.1111/j.1365-2559.2011.04150.x; Lei Y, 2012, HEAD NECK PATHOL, V6, P166, DOI 10.1007/s12105-011-0312-9; Li W, 2017, J PATHOL TRANSL MED, V51, P17, DOI 10.4132/jptm.2016.09.23; Pinto A, 2014, MODERN PATHOL, V27, P30, DOI 10.1038/modpathol.2013.84; Said-Al-Naief N, 2017, INT J SURG PATHOL, V25, P127, DOI 10.1177/1066896916670005; Shah AA, 2015, HEAD NECK PATHOL, V9, P85, DOI 10.1007/s12105-014-0557-1; Skalova A, 2013, HEAD NECK PATHOL, V7, pS30, DOI 10.1007/s12105-013-0455-y; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; TAVASSOLI FA, 1980, CANCER, V45, P2404, DOI 10.1002/1097-0142(19800501)45:9<2404::AID-CNCR2820450928>3.0.CO;2-8; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; Urano M, 2015, HUM PATHOL, V46, P94, DOI 10.1016/j.humpath.2014.09.012; Wang L, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-28	22	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	JUN	2018	12	2					237	243		10.1007/s12105-017-0864-4			7	Pathology	Pathology	GG0GC	WOS:000432355500011	29139086	Green Published			2019-10-28	
J	Ginat, DT; Johnson, DN; Shogan, A; Cipriani, NA				Ginat, Daniel T.; Johnson, Daniel N.; Shogan, Andrea; Cipriani, Nicole A.			Cervical Chondrocutaneous Branchial Remnants	HEAD & NECK PATHOLOGY			English	Article						Cervical chondrocutaneous branchial remnant; Choristoma; CT; Ultrasound		Cervical chondrocutaneous branchial remnants are rare congenital choristomas. These lesions contain a cartilage core surrounded by skin with adnexal structures and subcutaneous fat. Correspondingly, on ultrasound there is a tubular hypoechoic core surrounded by hyperechoic, while on CT there is central intermediate attenuation surrounded by fat attenuation tissues. These features are exemplified in this sine qua non radiology-pathology correlation article. Management includes complete surgical resection and evaluating for potential associated anomalies, such as other branchial apparatus anomalies, as well as cardiac anomalies.	[Ginat, Daniel T.] Univ Chicago, Dept Radiol, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Johnson, Daniel N.; Cipriani, Nicole A.] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Shogan, Andrea] Univ Chicago, Dept Surg, Sect Otolaryngol, 5841 S Maryland Ave, Chicago, IL 60637 USA	Ginat, DT (reprint author), Univ Chicago, Dept Radiol, 5841 S Maryland Ave, Chicago, IL 60637 USA.	ginatd01@gmail.com			University of Chicago Office of Faculty Affairs through Faculty Initiatives Fund	We are grateful for support received from the University of Chicago Office of Faculty Affairs through the Faculty Initiatives Fund for our Head and Neck Radiology-Pathology Trainee Conference, during which this case was presented.	Atlan G, 1997, PLAST RECONSTR SURG, V100, P32, DOI 10.1097/00006534-199707000-00006; Begovic N, 2014, INT J PEDIATR OTORHI, V78, P1961, DOI 10.1016/j.ijporl.2014.08.038; Braun H, 2003, INT J PEDIATR OTORHI, V67, P89, DOI 10.1016/S0165-5876(02)00362-2; Chander B, 2014, TURK J PATHOL, V30, P195, DOI 10.5146/tjpath.2014.01264; Nasser HA, 2011, J PEDIATR SURG, V46, P998, DOI 10.1016/j.jpedsurg.2011.01.015; Dang NP, 2013, BRIT J ORAL MAX SURG, V51, pE288, DOI 10.1016/j.bjoms.2013.03.006	6	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	JUN	2018	12	2					244	246		10.1007/s12105-017-0834-x			3	Pathology	Pathology	GG0GC	WOS:000432355500012	28685414	Green Published			2019-10-28	
J	Sultan, AS; Mostoufi, B; Papadimitriou, JC; Koka, R; Basile, J; Younis, RH				Sultan, Ahmed S.; Mostoufi, Behzad; Papadimitriou, John C.; Koka, Rima; Basile, John; Younis, Rania H.			Large Cell Transformation of Oral Mycosis Fungoides	HEAD & NECK PATHOLOGY			English	Article						Mycosis fungoides; Sezary syndrome; T-cell lymphoma; Large cell transformation; Oral cavity	LYMPHOMA; MUCOSA; INVOLVEMENT; DIAGNOSIS	Mycosis fungoides (MF) accounts for approximately 50% of all primary cutaneous lymphomas. MF occurrence in the oral cavity is extremely rare with approximately 45 cases reported to date. We present a case of a 68 year-old man with a raised nodular lesion of the ventral tongue with clinical impression of irritational fibroma. Histopathologic and immunohistochemical (IHC) examination revealed a phenotype consistent with MF with large cell transformation in the context of Sezary syndrome. The histological diagnosis of oral MF requires a high index of suspicion and IHC panel to rule out large cell transformation. To our knowledge, only four cases of large cell transformation of oral MF have been reported in the English literature. The clinical and histopathologic features of a rare case of intra-oral MF with large cell transformation are exemplified in this article.	[Sultan, Ahmed S.; Basile, John; Younis, Rania H.] Univ Maryland, Sch Dent, Dept Oncol & Diagnost Sci, Baltimore, MD 21201 USA; [Mostoufi, Behzad] Univ Maryland, Sch Dent, Dept Oral & Maxillofacial Surg, Baltimore, MD 21201 USA; [Papadimitriou, John C.; Koka, Rima] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Basile, John; Younis, Rania H.] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA	Sultan, AS (reprint author), Univ Maryland, Sch Dent, Dept Oncol & Diagnost Sci, Baltimore, MD 21201 USA.	asultan@umaryland.edu		Younis, Rania/0000-0001-5781-5460; Sultan, Ahmed S./0000-0001-5286-4562; Koka, Madhurima/0000-0002-0457-8489			ALHothali GI, 2013, INT J HEALTH SCI-IJH, V7, P220, DOI 10.12816/0006045; BARNETT ML, 1985, J PERIODONTOL, V56, P690, DOI 10.1902/jop.1985.56.11.690; Bassuner Juri, 2016, Case Rep Dermatol Med, V2016, P5857935, DOI 10.1155/2016/5857935; Benner MF, 2012, BLOOD, V119, P1643, DOI 10.1182/blood-2011-08-376319; Bittencourt AL, 2015, INT J DERMATOL, V54, pE327, DOI 10.1111/ijd.12875; Cheng Y., 2016, INT J ANTENN PROPAG, V2016, P5, DOI DOI 10.1016/J.BIOPSYCH.2016.05.016; Chi AC, 2016, ORAL MAXILLOFACIAL P; Chua Margaret S-T, 2002, Australas Radiol, V46, P336, DOI 10.1046/j.1440-1673.2002.01000.x; DAMM DD, 1984, ORAL SURG ORAL MED O, V58, P413, DOI 10.1016/0030-4220(84)90335-9; Ficarra G, 1997, ORAL ONCOL, V33, P375; Goldsmith SM, 2014, OR SURG OR MED OR PA, V118, pE48, DOI 10.1016/j.oooo.2013.10.005; Gomez-de la Fuente E, 2000, ACTA DERM-VENEREOL, V80, P299; Harman M, 1998, J EUR ACAD DERMATOL, V10, P253; Hata T, 1998, INT J ORAL MAX SURG, V27, P127, DOI 10.1016/S0901-5027(98)80311-1; Kadin ME, 2014, J AM ACAD DERMATOL, V70, P374, DOI 10.1016/j.jaad.2013.09.007; Kunishige J, 2006, INTERNET J DERMATOL, V5, P1; May SA, 2007, AM J DERMATOPATH, V29, P62, DOI 10.1097/01.dad.0000246949.49071.17; Postorino M, 2016, ANN HEMATOL, V95, P153, DOI 10.1007/s00277-015-2503-z; SALHANY KE, 1988, AM J PATHOL, V132, P265; Scherfler S, 2012, J CRANIO MAXILL SURG, V40, pE211, DOI 10.1016/j.jcms.2011.10.021; SIROIS DA, 1993, ORAL SURG ORAL MED O, V75, P700, DOI 10.1016/0030-4220(93)90426-5; Swerdlow SH, 2008, WHO CLASSIFICATION T; Wain EM, 2003, CLIN EXP DERMATOL, V28, P499, DOI 10.1046/j.1365-2230.2003.01348.x; Zapater E, 2010, ORAL DIS, V16, P119, DOI 10.1111/j.1601-0825.2009.01586.x	24	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	JUN	2018	12	2					247	251		10.1007/s12105-017-0840-z			5	Pathology	Pathology	GG0GC	WOS:000432355500013	28741231	Green Published			2019-10-28	
J	Welter, SM; DeLuca-Johnson, J; Thompson, K				Welter, Shannon M.; DeLuca-Johnson, Javier; Thompson, Keith			Histologic Review of Sarcoidosis in a Neck Lymph Node	HEAD & NECK PATHOLOGY			English	Review						Sarcoidosis; Lymph node; Granuloma; Schaumann bodies; Hamazaki-Wesenbergbodies; Noncaseating; Epithelioid macrophages; Multinucleated giant cells		Sarcoidosis is a multisystem granulomatous disease of unknown etiology. It may occur at any age, but is most commonly seen in young to middle age adults. Sarcoidosis remains more common in women regardless of geographic or racial boundaries. Although the etiology remains unclear, the most common explanation is that sarcoidosis is a disease of immunologic dysregulation triggered by an as yet unidentified environmental or microbial antigen in genetically susceptible persons. We review a case of sarcoidosis with was initially diagnosed in a neck lymph node that was removed for evaluation of metastatic squamous cell carcinoma with a discussion on the clinical and histologic characteristic of the disease.	[Welter, Shannon M.; DeLuca-Johnson, Javier; Thompson, Keith] Naval Med Ctr San Diego, Dept Anat Pathol, 34800 Bob Wilson Dr, San Diego, CA 92134 USA	Welter, SM (reprint author), Naval Med Ctr San Diego, Dept Anat Pathol, 34800 Bob Wilson Dr, San Diego, CA 92134 USA.	shannon.m.welter.mil@mail.mil					Asano S, 2012, J CLIN EXP HEMATOP, V52, P1; Iannuzzi MC, 2007, NEW ENGL J MED, V357, P2153, DOI 10.1056/NEJMra071714; Ioachim HL, 2002, SARCOIDOSIS LYMPHADE, P203; Lazar CA, 2010, SEMIN RESP CRIT CARE, V31, P501, DOI 10.1055/s-0030-1262218; Nunes H, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-46; O'Malley DP, 2009, ATLAS NONTUMOR PATHO; Saidha Shiv, 2012, Yale Journal of Biology and Medicine, V85, P133	7	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	JUN	2018	12	2					255	258		10.1007/s12105-017-0847-5			4	Pathology	Pathology	GG0GC	WOS:000432355500015	28852977	Green Published			2019-10-28	
J	Ashrafian, H				Ashrafian, Hutan			Early Depiction of a Parotid Tumour in the "School of Athens" (1509-1511) by Raphael (1483-1520)	HEAD & NECK PATHOLOGY			English	Editorial Material									[Ashrafian, Hutan] Imperial Coll London, St Marys Hosp, Dept Surg & Canc, 10th Floor Queen Elizabeth Queen Mother QEQM Bldg, London W2 1NY, England	Ashrafian, H (reprint author), Imperial Coll London, St Marys Hosp, Dept Surg & Canc, 10th Floor Queen Elizabeth Queen Mother QEQM Bldg, London W2 1NY, England.	h.ashrafian@imperial.ac.uk		Ashrafian, Hutan/0000-0003-1668-0672				0	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	JUN	2018	12	2					259	260		10.1007/s12105-017-0848-4			2	Pathology	Pathology	GG0GC	WOS:000432355500016	28864999	Green Published, Other Gold			2019-10-28	
J	Wasserman, JK; Gravel, D; Purgina, B				Wasserman, Jason K.; Gravel, Denis; Purgina, Bibianna			Chordoma of the Head and Neck: A Review	HEAD & NECK PATHOLOGY			English	Review						Chordoma; Chondrosarcoma; Skull base; Brachyury; Head and neck	SKULL BASE CHORDOMA; BRACHYURY EXPRESSION; SOFT-TISSUE; CHONDROID CHORDOMA; CRANIAL CHORDOMAS; TUMOR RECURRENCE; SPINAL CHORDOMA; CHONDROSARCOMA; CHILDHOOD; SURVIVAL	Chordoma is a rare malignant bone tumor that can arise anywhere along the central neural axis and many involve head and neck sites, most commonly the skull base. The relative rarity of these tumors, combined with the complex anatomy of the head and neck, pose diagnostic challenges to pathologists. This article describes the pertinent clinical, pathologic, and molecular features of chordomas and describes how these features can be used to aid in formulating a differential diagnosis. Emphasis is placed on key diagnostic pitfalls and the importance of incorporating immunohistochemical information into the diagnosis.	[Wasserman, Jason K.; Gravel, Denis; Purgina, Bibianna] Univ Ottawa, Ottawa Hosp, Dept Pathol & Lab Med, Div Anat Pathol, 501 Smyth Rd,4th Floor CCW, Ottawa, ON K1H 8L6, Canada	Purgina, B (reprint author), Univ Ottawa, Ottawa Hosp, Dept Pathol & Lab Med, Div Anat Pathol, 501 Smyth Rd,4th Floor CCW, Ottawa, ON K1H 8L6, Canada.	bpurgina@ottawahospital.on.ca					Akhavan-Sigari R, 2014, ANTICANCER RES, V34, P623; Almefty K, 2007, CANCER-AM CANCER SOC, V110, P2457, DOI 10.1002/cncr.23073; Amary MF, 2011, J PATHOL, V224, P334, DOI 10.1002/path.2913; Arai M, 2012, BRAIN TUMOR PATHOL, V29, P201, DOI 10.1007/s10014-012-0085-1; Bayrak OF, 2013, J NEURO-ONCOL, V115, P143, DOI 10.1007/s11060-013-1211-6; Bloch OG, 2009, J CLIN NEUROSCI, V16, P1547, DOI 10.1016/j.jocn.2009.05.003; Bohman LE, 2014, WORLD NEUROSURG, V82, P806, DOI 10.1016/j.wneu.2014.07.005; Borba LAB, 1996, J NEUROSURG, V84, P584, DOI 10.3171/jns.1996.84.4.0584; Brandal P, 2005, CANCER GENET CYTOGEN, V160, P15, DOI 10.1016/j.cancergencyto.2004.11.016; CHAMBERS PW, 1979, AM J CLIN PATHOL, V72, P765; Chavez JA, 2014, CLIN NEUROPATHOL, V33, P418, DOI 10.5414/NP300724; Chen KW, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0886-7; Cho YH, 2008, NEUROSURG REV, V31, P35, DOI 10.1007/s10143-007-0099-z; COFFIN CM, 1993, ARCH PATHOL LAB MED, V117, P927; Colli B O, 2001, Neurosurg Focus, V10, pE1; Di Maio S, 2011, J NEUROSURG, V115, P1094, DOI 10.3171/2011.7.JNS11355; Fischer C, 2015, J CANCER, V6, P984, DOI 10.7150/jca.11371; Fletcher C, 2013, WHO CLASSIFICATION T; Folpe AL, 1999, AM J SURG PATHOL, V23, P1059, DOI 10.1097/00000478-199909000-00008; FORSYTH PA, 1993, J NEUROSURG, V78, P741, DOI 10.3171/jns.1993.78.5.0741; GAY E, 1995, NEUROSURGERY, V36, P887, DOI 10.1227/00006123-199505000-00001; Gladstone HB, 1998, OTOLARYNG HEAD NECK, V118, P104, DOI 10.1016/S0194-5998(98)70384-5; Hasselblatt M, 2016, ACTA NEUROPATHOL, V132, P149, DOI 10.1007/s00401-016-1574-9; HEFFELFINGER MJ, 1973, CANCER-AM CANCER SOC, V32, P410, DOI 10.1002/1097-0142(197308)32:2<410::AID-CNCR2820320219>3.0.CO;2-S; Hindi N, 2015, EUR J CANCER, V51, P2609, DOI 10.1016/j.ejca.2015.07.038; Hoch BL, 2006, AM J SURG PATHOL, V30, P811, DOI 10.1097/01.pas.0000209828.39477.ab; Jambhekar NA, 2010, ARCH PATHOL LAB MED, V134, P1181, DOI 10.1043/2009-0476-OA.1; Jian BJ, 2011, BRIT J NEUROSURG, V25, P446, DOI 10.3109/02688697.2010.546896; Jian BJ, 2010, J NEURO-ONCOL, V98, P101, DOI 10.1007/s11060-009-0068-1; KANEKO Y, 1991, NEUROSURGERY, V29, P442, DOI 10.1227/00006123-199109000-00019; Kataria Sant Prakash, 2013, J Neurosci Rural Pract, V4, pS95, DOI 10.4103/0976-3147.116426; Khurram SA, 2016, HEAD NECK PATHOL, V10, P400, DOI 10.1007/s12105-016-0712-y; Lauer SR, 2013, AM J SURG PATHOL, V37, P719, DOI 10.1097/PAS.0b013e31827813e7; Launay SG, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-423; Le LP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018846; Lee-Jones L, 2004, GENE CHROMOSOME CANC, V41, P80, DOI 10.1002/gcc.20052; Long C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066676; Lynn-Macrae Alastair, 2005, Ear Nose Throat J, V84, P593; Martin JJ, 2007, J NEUROSURG, V107, P758, DOI 10.3171/JNS-07/10/0758; Marucci G, 2014, J NEURO-ONCOL, V118, P271, DOI 10.1007/s11060-014-1445-y; MATSUMOTO J, 1989, PEDIATR RADIOL, V20, P28, DOI 10.1007/BF02010629; McMaster ML, 2001, CANCER CAUSE CONTROL, V12, P1, DOI 10.1023/A:1008947301735; Miettinen M, 2015, AM J SURG PATHOL, V39, P1305, DOI 10.1097/PAS.0000000000000462; MITCHELL A, 1993, CANCER, V72, P2943, DOI 10.1002/1097-0142(19931115)72:10<2943::AID-CNCR2820721014>3.0.CO;2-6; Mobley BC, 2010, ACTA NEUROPATHOL, V120, P745, DOI 10.1007/s00401-010-0767-x; Mukherjee D, 2011, J NEUROSURG-SPINE, V14, P143, DOI 10.3171/2010.10.SPINE10189; Nguyen RP, 2009, AM J NEURORADIOL, V30, P803, DOI 10.3174/ajnr.A1446; Oakley GJ, 2008, MODERN PATHOL, V21, P1461, DOI 10.1038/modpathol.2008.144; Pamir MN, 2006, EUR J RADIOL, V58, P461, DOI 10.1016/j.ejrad.2006.03.020; Pillay N, 2012, NAT GENET, V44, P1185, DOI 10.1038/ng.2419; Presneau N, 2011, J PATHOL, V223, P327, DOI 10.1002/path.2816; Romeo S, 2006, J PATHOL, V209, P143, DOI 10.1002/path.1987; Rosenberg AE, 1999, AM J SURG PATHOL, V23, P1370, DOI 10.1097/00000478-199911000-00007; ROSENBERG AE, 1994, AM J CLIN PATHOL, V101, P36, DOI 10.1093/ajcp/101.1.36; Sangoi AR, 2011, MODERN PATHOL, V24, P425, DOI 10.1038/modpathol.2010.196; Sangoi AR, 2009, AM J SURG PATHOL, V33, P669, DOI 10.1097/PAS.0b013e318194c566; Scheil S, 2001, GENE CHROMOSOME CANC, V32, P203, DOI 10.1002/gcc.1184; Scheipl S, 2016, J PATHOL, V239, P320, DOI 10.1002/path.4729; Singhal N, 2009, ANTI-CANCER DRUG, V20, P953, DOI 10.1097/CAD.0b013e328330c7f0; Smoll NR, 2013, CANCER-AM CANCER SOC, V119, P2029, DOI 10.1002/cncr.28032; Stacchiotti S, 2012, J CLIN ONCOL, V30, P914, DOI 10.1200/JCO.2011.35.3656; Tao ZZ, 2005, INT J PEDIATR OTORHI, V69, P1415, DOI 10.1016/j.ijporl.2005.03.027; Tirabosco R, 2008, AM J SURG PATHOL, V32, P572, DOI 10.1097/PAS.0b013e31815b693a; Vujovic S, 2006, J PATHOL, V209, P157, DOI 10.1002/path.1969; Yadav R, 2014, NEURO-ONCOLOGY, V16, P372, DOI 10.1093/neuonc/not228; Yang C, 2009, MOL CANCER THER, V8, P2597, DOI 10.1158/1535-7163.MCT-09-0504; Yang XHR, 2009, NAT GENET, V41, P1176, DOI 10.1038/ng.454; Zhang K, 2015, INT J CLIN EXP PATHO, V8, P608; Zou MX, 2015, EUR SPINE J, V24, P1738, DOI 10.1007/s00586-015-3927-9	69	3	3	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	JUN	2018	12	2					261	268		10.1007/s12105-017-0860-8			8	Pathology	Pathology	GG0GC	WOS:000432355500017	28980142	Green Published			2019-10-28	
J	Hill, K; Diaz, J; Hagemann, IS; Chernock, RD				Hill, Kirk; Diaz, Jason; Hagemann, Ian S.; Chernock, Rebecca D.			Multiple Myeloma Presenting as Massive Amyloid Deposition in a Parathyroid Gland Associated with Amyloid Goiter: A Medullary Thyroid Carcinoma Mimic on Intra-operative Frozen Section	HEAD & NECK PATHOLOGY			English	Article						Amyloid; Amyloid goiter; Parathyroid; Medullary thyroid carcinoma; Frozen section	MANIFESTATION; INVOLVEMENT	Clinical examples of amyloid deposition in parathyroid glands are exceedingly rare and usually present as an incidental finding in a patient with amyloid goiter. Here, we present the first histologically documented case of parathyroid amyloid deposition that presented as a mass. The patient did not have hyperparathyroidism. The parathyroid gland was submitted for intra-operative frozen section and concern for medullary thyroid carcinoma was raised. An important histologic clue arguing against medullary thyroid carcinoma was the evenly dispersed nature of the amyloid. Histologic perinuclear clearing and parathyroid hormone immunohistochemistry confirmed parathyroid origin on permanent sections. The patient was also found to have associated amyloid goiter. Mass spectrometry of the amyloid showed it to be composed of kappa light chains. On further work-up, the patient was diagnosed with multiple myeloma. Awareness of parathyroid amyloid deposition is important as it is a histologic mimic of medullary thyroid carcinoma, especially on frozen section. Amyloid typing with evaluation for multiple myeloma in any patient with kappa or lambda light chain restriction is also important.	[Hill, Kirk; Hagemann, Ian S.; Chernock, Rebecca D.] Washington Univ, Sch Med, Dept Pathol & Immunol, 660 S Euclid Ave,Campus Box 8118, St Louis, MO 63130 USA; [Diaz, Jason] Ear Nose & Throat Ctr Utah, Salt Lake City, UT USA; [Chernock, Rebecca D.] Washington Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, St Louis, MO 63110 USA	Chernock, RD (reprint author), Washington Univ, Sch Med, Dept Pathol & Immunol, 660 S Euclid Ave,Campus Box 8118, St Louis, MO 63130 USA.; Chernock, RD (reprint author), Washington Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, St Louis, MO 63110 USA.	rchernock@path.wustl.edu					Abdou AG, 2009, ENDOCR PATHOL, V20, P243, DOI 10.1007/s12022-009-9089-8; ANDERSON TJ, 1974, J CLIN PATHOL, V27, P656, DOI 10.1136/jcp.27.8.656; Aydin B, 2016, CASE REP ENDOCRINOL, DOI 10.1155/2016/3240585; ELLIS HA, 1984, ARCH PATHOL LAB MED, V108, P689; Febrero B, 2012, ENDOCR PATHOL, V23, P260, DOI 10.1007/s12022-012-9220-0; Franc B, 1998, HUM PATHOL, V29, P1078, DOI 10.1016/S0046-8177(98)90417-8; HAMED G, 1995, AM J CLIN PATHOL, V104, P306; HAZARD JB, 1977, AM J PATHOL, V88, P213; KOELMEYER TD, 1977, NEW ZEAL MED J, V85, P372; Lagha EK, 2010, EUR ANN OTORHINOLARY, V127, P108, DOI [10.1016/j.anorl.2010.02.013, 10.1016/j.anorl.210.02.013]; LEEDHAM PW, 1970, J CLIN PATHOL, V23, P811, DOI 10.1136/jcp.23.9.811; ORDONEZ NG, 1983, AM J SURG PATHOL, V7, P535, DOI 10.1097/00000478-198309000-00004; Ori Y, 2012, ISR MED ASSOC J, V14, P232; Ozdemir D, 2010, ENDOCR PRACT, V16, P1056, DOI 10.4158/EP10095.RA; Siddiqui MA, 2007, THYROID, V17, P77, DOI 10.1089/thy.2006.0045; Vanguri VK, 2008, ENDOCR PATHOL, V19, P66, DOI 10.1007/s12022-008-9020-8; Villamil CF, 2000, ARCH PATHOL LAB MED, V124, P281; WILLIAMS ED, 1966, J CLIN PATHOL, V19, P103, DOI 10.1136/jcp.19.2.103	18	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	JUN	2018	12	2					269	273		10.1007/s12105-017-0853-7			5	Pathology	Pathology	GG0GC	WOS:000432355500018	28879586	Green Published			2019-10-28	
J	Xu, B; Aryeequaye, R; Wang, L; Katabi, N				Xu, Bin; Aryeequaye, Ruth; Wang, Lu; Katabi, Nora			Sinonasal Secretory Carcinoma of Salivary Gland with High Grade Transformation: A Case Report of this Under-Recognized Diagnostic Entity with Prognostic and Therapeutic Implications	HEAD & NECK PATHOLOGY			English	Article						Secretory carcinoma; Sinonasal non-intestinal type adenocarcinoma; High grade transformation; ETV6-NTRK3 fusion	KINASE INHIBITOR LOXO-101; ETV6 GENE REARRANGEMENT; IMMUNOHISTOCHEMICAL SPECTRUM; ALK INHIBITOR; ADENOCARCINOMA; ENTRECTINIB; UPDATE; FUSION; ORIGIN; EGFR	Secretory carcinoma (SC) is a recently described salivary gland carcinoma with characteristic ETV6-NTRK3 fusion. In this case report, we described a SC of the maxillary sinus that underwent high grade transformation in a 61-year-old patient. The diagnosis was confirmed by the presence of ETV6 translocation. Within the sinonasal tract, SC is an important differential diagnosis especially of sinonasal adenocarcinoma, non-intestinal type (non-ITAC), as these two entities bears histologic and immunophenotypic similarity. Distinction between these two tumors can be challenging based on the morphology alone and may require additional immunohistochemical and molecular studies. It is important to recognize that SC can occur in the sinonasal tract as correctly diagnosing SC may be prognostic relevant and may provide new targeted therapeutic avenues for these patients.	[Xu, Bin; Aryeequaye, Ruth; Wang, Lu; Katabi, Nora] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA	Katabi, N (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA.	Bin1.xu@sunnybrook.ca; rutha@mskcc.org; huluwawa2002@gmail.com; katabin@mskcc.org	Wang, Lu/N-8128-2018	Wang, Lu/0000-0002-0073-0666; Xu, Bin/0000-0003-4638-9835	Cancer Center Support Grant of the National Institutes of Health/National Cancer Institute [P30CA008748]	This study was funded in part by the Cancer Center Support Grant of the National Institutes of Health/National Cancer Institute under award number P30CA008748. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Andreasen S, 2017, AM J SURG PATHOL, V41, P1552, DOI 10.1097/PAS.0000000000000912; Antonescu CR, 2011, GENE CHROMOSOME CANC, V50, P559, DOI 10.1002/gcc.20881; Ardini E, 2016, MOL CANCER THER, V15, P628, DOI 10.1158/1535-7163.MCT-15-0758; Bhaijee F, 2011, ANN DIAGN PATHOL, V15, P181, DOI 10.1016/j.anndiagpath.2010.10.002; Bhayani MK, 2014, HEAD NECK-J SCI SPEC, V36, P1490, DOI 10.1002/hed.23485; Cipriani NA, 2017, INT J SURG PATHOL, V25, P613, DOI 10.1177/1066896917709350; Connor A, 2012, AM J SURG PATHOL, V36, P27, DOI 10.1097/PAS.0b013e318231542a; Doebele RC, 2015, CANCER DISCOV, V5, P1049, DOI 10.1158/2159-8290.CD-15-0443; Drilon A, 2016, ANN ONCOL, V27, P920, DOI 10.1093/annonc/mdw042; El-Naggar AK, 2017, WHO CLASSIFICATION T; Garcia-Inclan C, 2012, CELL ONCOL, V35, P443, DOI 10.1007/s13402-012-0103-7; Jung MJ, 2013, KOREAN J PATHOL, V47, P36, DOI 10.4132/KoreanJPathol.2013.47.1.36; Leivo I, 2016, HEAD NECK PATHOL, V10, P68, DOI 10.1007/s12105-016-0694-9; Luo WY, 2014, INT J CLIN EXP PATHO, V7, P9008; Lurquin E, 2015, HISTOPATHOLOGY, V67, P749, DOI 10.1111/his.12702; Majewska H, 2015, VIRCHOWS ARCH, V466, P245, DOI 10.1007/s00428-014-1701-8; Nagao T, 2013, HEAD NECK PATHOL, V7, pS37, DOI 10.1007/s12105-013-0458-8; Nagasubramanian R, 2016, PEDIATR BLOOD CANCER, V63, P1468, DOI 10.1002/pbc.26026; Pinto A, 2014, MODERN PATHOL, V27, P30, DOI 10.1038/modpathol.2013.84; Projetti F, 2015, J ORAL PATHOL MED, V44, P244, DOI 10.1111/jop.12226; Rolfo C, 2015, EXPERT OPIN INV DRUG, V24, P1493, DOI 10.1517/13543784.2015.1096344; Sethi R, 2014, LARYNGOSCOPE, V124, P188, DOI 10.1002/lary.24254; Skalova A, 2016, AM J SURG PATHOL, V40, P3, DOI 10.1097/PAS.0000000000000537; Skalova A, 2014, AM J SURG PATHOL, V38, P23, DOI 10.1097/PAS.0000000000000088; Skalova A, 2013, HEAD NECK PATHOL, V7, pS30, DOI 10.1007/s12105-013-0455-y; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Stevens TM, 2015, MODERN PATHOL, V28, P1084, DOI 10.1038/modpathol.2015.64; Szablewski V, 2013, INT J MOL SCI, V14, P5170, DOI 10.3390/ijms14035170; Weinreb I, 2014, NAT GENET, V46, P1166, DOI 10.1038/ng.3096	29	2	2	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	JUN	2018	12	2					274	278		10.1007/s12105-017-0855-5			5	Pathology	Pathology	GG0GC	WOS:000432355500019	28980201	Green Published			2019-10-28	
J	Islam, MN; Chehal, H; Smith, MH; Islam, S; Bhattacharyya, I				Islam, Mohammed N.; Chehal, Hardeep; Smith, Molly Housley; Islam, Sarah; Bhattacharyya, Indraneel			Merkel Cell Carcinoma of the Buccal Mucosa and Lower Lip	HEAD & NECK PATHOLOGY			English	Article						Merkel cell carcinoma; Dermal neoplasm; Neuroendocrine tumor; Trabecular cell carcinoma	OF-THE-LITERATURE; ORAL-MUCOSA; TRABECULAR CARCINOMA; YOUNG-ADULT; SKIN; TUMOR	Merkel cell carcinoma (MCC) is an uncommon relatively aggressive neuroendocrine dermal neoplasm first described in 1972 as a tumor of the sun exposed skin. Although most MCC affect the skin of the head and neck, rare primarily oral mucosal cases have been documented. Merkel cells are nondendritic neuroendocrine cells that are found not only in the skin but also the oral mucosa and give rise to MCC. Neuroendocrine cells may be found as aggregates in organs or as diffuse or isolated cells within organs and their epithelial lining. They contain peptide hormones and biogenic amines and occur in two forms: dendritic, which are not associated with nerve fibers and non-dendritic, which are associated with nerve fibers. Merkel cells as well as MCC express simple epithelium-type Cytokeratins (8, 18, 19, 20), neurosecretory substances; chromogranin A, synaptophysin, neuron-specific enolase (NSE), adhesion molecules, and villin (intermediate filament). Though weakly, they also express neural markers such as S-100 protein. Cytokeratin 20, and Cluster of differentiation 56, are the two key diagnostic markers for Merkel cells and MCC. Etiology includes UV radiation, the recently described Merkel cell polyomavirus, and long term systemic immunosuppression. The cutaneous and mucosal variants of MCC are considered aggressive tumors with a high risk for local recurrence and metastasis and should be considered in the differential diagnosis of head and neck mucosal lesions. We present two cases of primary Merkel cell carcinoma, one on the buccal mucosa and the other on the lower lip, and discuss the salient histologic, immunohistochemical and clinical features.	[Islam, Mohammed N.; Smith, Molly Housley; Bhattacharyya, Indraneel] Univ Florida, Coll Dent, Dept Oral & Maxillofacial Surg & Diagnost Sci, Gainesville, FL 32610 USA; [Chehal, Hardeep] Creighton Univ, Sch Dent, Dept Oral Diagnost Sci, Omaha, NE 68178 USA; [Islam, Sarah] Indiana Univ Sch Med, 8600 Univ Blvd, Evansville, IN 47712 USA	Islam, MN (reprint author), Univ Florida, Coll Dent, Dept Oral & Maxillofacial Surg & Diagnost Sci, Gainesville, FL 32610 USA.	mislam@dental.ufl.edu					Baker P, 1999, J ORAL MAXIL SURG, V57, P1143, DOI 10.1016/S0278-2391(99)90344-0; BOYSEN M, 1989, J LARYNGOL OTOL, V103, P519, DOI 10.1017/S0022215100156762; Caren H, 2007, BRIT J CANCER, V97, P1416, DOI 10.1038/sj.bjc.6604032; Chang Y, 2012, ANNU REV PATHOL-MECH, V7, P123, DOI 10.1146/annurev-pathol-011110-130227; DOLEZAL RF, 1988, J SURG ONCOL, V37, P123, DOI 10.1002/jso.2930370212; DRIJKONINGEN M, 1986, HUM PATHOL, V17, P301, DOI 10.1016/S0046-8177(83)80224-X; ENGLISH KB, 1990, AM J DERMATOPATH, V12, P589, DOI 10.1097/00000372-199012000-00010; Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586; Foote M, 2012, J AM ACAD DERMATOL, V67, P395, DOI 10.1016/j.jaad.2011.09.009; Hanly AJ, 2000, J CUTAN PATHOL, V27, P118, DOI 10.1034/j.1600-0560.2000.027003118.x; HAYTER JP, 1991, BRIT J ORAL MAX SURG, V29, P114, DOI 10.1016/0266-4356(91)90096-N; Hendrikx SMGA, 2005, ORAL ONCOL EXTRA, V41, P202; Houben R, 2013, J INVEST DERMATOL, V133, P2453, DOI 10.1038/jid.2013.169; Inoue T, 1997, ORAL ONCOL, V33, P226, DOI 10.1016/S0964-1955(96)00078-4; KARAM F, 1990, SOUTHERN MED J, V83, P1354, DOI 10.1097/00007611-199011000-00035; Longo F, 1999, J ORAL PATHOL MED, V28, P88; Mahomed F, 2010, J ORAL PATHOL MED, V39, P121, DOI 10.1111/j.1600-0714.2009.00834.x; MIR R, 1988, ORAL SURG ORAL MED O, V65, P71, DOI 10.1016/0030-4220(88)90195-8; Munde Prashant Balasaheb, 2013, J Oral Maxillofac Pathol, V17, P408, DOI 10.4103/0973-029X.125208; Nagy J, 2005, VIRCHOWS ARCH, V446, P278, DOI 10.1007/s00428-004-1176-0; Neville B. W., 2015, ORAL MAXILLOFACIAL P; Orsini G, 2000, J ORAL MAXIL SURG, V58, P1044, DOI 10.1053/joms.2000.8749; Prabhu S, 2010, BRIT J ORAL MAX SURG, V48, P48, DOI 10.1016/j.bjoms.2008.12.005; Righi A, 2006, INT J SURG PATHOL, V14, P206, DOI 10.1177/1066896906290053; ROENIGK RK, 1986, J DERMATOL SURG ONC, V12, P332, DOI 10.1111/j.1524-4725.1986.tb01918.x; Roy S, 2015, INDIAN J PATHOL MICR, V58, P214, DOI 10.4103/0377-4929.155318; Tai Patricia, 2013, ISRN Surg, V2013, P850797, DOI 10.1155/2013/850797; TANG CK, 1978, CANCER, V42, P2311, DOI 10.1002/1097-0142(197811)42:5<2311::AID-CNCR2820420531>3.0.CO;2-L; TANG CK, 1979, MT SINAI J MED, V46, P516; Tanio S, 2015, MOL CLIN ONCOL, V3, P1301, DOI 10.3892/mco.2015.629; TOKER C, 1972, ARCH DERMATOL, V105, P107, DOI 10.1001/archderm.105.1.107; VIGNESWARAN N, 1992, ORAL SURG ORAL MED O, V74, P193, DOI 10.1016/0030-4220(92)90382-Z; WARNER TFCS, 1983, CANCER, V52, P238, DOI 10.1002/1097-0142(19830715)52:2<238::AID-CNCR2820520209>3.0.CO;2-W; Zeng M, 2015, ONCOL LETT, V10, P887, DOI 10.3892/ol.2015.3298	34	1	1	1	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	JUN	2018	12	2					279	285		10.1007/s12105-017-0859-1			7	Pathology	Pathology	GG0GC	WOS:000432355500020	28980225	Green Published			2019-10-28	
J	Cracolici, V; Grogan, RH; Sukhanova, M; Cheng, JX; Gurbuxani, S; Cipriani, NA				Cracolici, Vincent; Grogan, Raymon H.; Sukhanova, Madina; Cheng, Jason X.; Gurbuxani, Sandeep; Cipriani, Nicole A.			A Herald of Plasma Cell Myeloma: A Report of Malignant Plasma Cells Identified in Parathyroid Adenoma and a Review of Non-parathyroid Malignancies in Parathyroid Glands	HEAD & NECK PATHOLOGY			English	Article						Parathyroid adenoma; Myeloma; Hypercalcemia; Incidental	METASTATIC BREAST-CARCINOMA; TO-TUMOR METASTASIS; PRIMARY HYPERPARATHYROIDISM; MULTIPLE-MYELOMA; HYPERCALCEMIA	Involvement of the parathyroid glands by non-parathyroid neoplasia is an infrequent event. Rare cases of metastases to the parathyroid gland have been reported in parathyroidectomies and autopsies of patients with known solid or hematopoietic malignancies. Here, we present a case of atypical clonal plasma cells incidentally identified within a parathyroid adenoma resected for hyperparathyroidism and hypercalcemia, which served as the sentinel event for a subsequent diagnosis of plasma cell myeloma. To our knowledge, this is the only reported case of a hematopoietic malignancy involving a parathyroid adenoma and the only reported case of malignant hematopoietic cells initially detected in parathyroidectomy.	[Cracolici, Vincent; Cheng, Jason X.; Gurbuxani, Sandeep; Cipriani, Nicole A.] Univ Chicago, Med Ctr, Dept Pathol, 5841 South Maryland Ave, Chicago, IL 60637 USA; [Grogan, Raymon H.] Univ Chicago, Med Ctr, Dept Surg, 5841 South Maryland Ave, Chicago, IL 60637 USA; [Sukhanova, Madina] Univ Chicago, Med Ctr, Dept Med, 5841 South Maryland Ave, Chicago, IL 60637 USA	Cracolici, V (reprint author), Univ Chicago, Med Ctr, Dept Pathol, 5841 South Maryland Ave, Chicago, IL 60637 USA.	vincent.cracolici@uchospitals.edu					Applewhite MK, 2016, ANN SURG ONCOL, V23, P4310, DOI 10.1245/s10434-016-5439-1; Bauer JL, 2017, HEAD NECK PATHOL, DOI [10.1007/s/12105-017-0850-x, DOI 10.1007/S/12105-017-0850-X]; BENISOVICH VI, 1991, CANCER, V68, P1106, DOI 10.1002/1097-0142(19910901)68:5<1106::AID-CNCR2820680534>3.0.CO;2-3; BOIXEDA D, 1991, DIAGN ONCOL, V1, P316; DeLellis RA, 2011, MODERN PATHOL, V24, pS78, DOI 10.1038/modpathol.2010.132; Fery-Blanco C, 2007, REV MED INTERNE, V28, P504, DOI 10.1016/j.revmed.2007.02.007; Fraser WD, 2009, LANCET, V374, P145, DOI 10.1016/S0140-6736(09)60507-9; Fulciniti F, 2011, DIAGN CYTOPATHOL, V39, P681, DOI 10.1002/dc.21528; GOTO S, 1995, INTERNAL MED, V34, P988, DOI 10.2169/internalmedicine.34.988; Hill K, 2018, HEAD NECK PATHOL, V12, P269, DOI 10.1007/s12105-017-0853-7; Horowitz CA, 1972, AM J MED, DOI [10.1016/0002-9343(72)90086-1, DOI 10.1016/0002-9343(72)90086-1]; Hussain N, 2013, CASE REP ONCOL MED, DOI 10.1155/2013/420565; INOSHITA T, 1985, MIL MED, V150, P323; Khandwala Hasnain M, 2004, Endocr Pract, V10, P345; Kyle RA, 2003, MAYO CLIN PROC, V78, P21, DOI 10.4065/78.1.21; Lee HE, 2011, PATHOL INT, V61, P593, DOI 10.1111/j.1440-1827.2011.02707.x; Lee SH, 2013, J CLIN ENDOCR METAB, V98, P3127, DOI 10.1210/jc.2013-1227; MARGOLIS CI, 1969, NEW YORK STATE J MED, V69, P702; Otsuka F, 1997, ENDOCR J, V44, P105, DOI 10.1507/endocrj.44.105; SCHWARTZ IS, 1982, MT SINAI J MED, V49, P499; Shifrin A, 2015, J CLIN ENDOCR METAB, V100, pE478, DOI 10.1210/jc.2014-2760; Varettoni M, 2010, ANN ONCOL, V21, P325, DOI 10.1093/annonc/mdp329; Venkatraman L, 2007, J CLIN PATHOL, V60, P1058, DOI 10.1136/jcp.2005.035352; WOOLNER LB, 1958, CANCER, V11, P975, DOI 10.1002/1097-0142(195809/10)11:5<975::AID-CNCR2820110518>3.0.CO;2-N; Zarebczan B, 2010, SURGERY, V148, P1075, DOI 10.1016/j.surg.2010.09.032	25	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	JUN	2018	12	2					286	290		10.1007/s12105-017-0861-7			5	Pathology	Pathology	GG0GC	WOS:000432355500021	29030756	Green Published			2019-10-28	
J	Agaimy, A				Agaimy, Abbas			Colonic-type Adenocarcinoma of the Tongue and Oral Cavity (CATOC)	HEAD & NECK PATHOLOGY			English	Letter							INTESTINAL-TYPE ADENOCARCINOMA; CYST; RARE		[Agaimy, Abbas] Friedrich Alexander Univ Erlangen Nuremberg, Inst Pathol, Erlangen, Germany	Agaimy, A (reprint author), Friedrich Alexander Univ Erlangen Nuremberg, Inst Pathol, Erlangen, Germany.	abbas.agaimy@uk-erlangen.de					Agaimy A, 2007, VIRCHOWS ARCH, V450, P479, DOI 10.1007/s00428-007-0369-8; Bell D, 2009, HUM PATHOL, V40, P1798, DOI 10.1016/j.humpath.2009.01.028; Franchi A, 2015, VIRCHOWS ARCH, V466, P161, DOI 10.1007/s00428-014-1696-1; LIPSETT J, 1993, ORAL SURG ORAL MED O, V75, P626, DOI 10.1016/0030-4220(93)90238-Y; McDaniel AS, 2013, JAMA OTOLARYNGOL, V139, P653, DOI 10.1001/jamaoto.2013.3240a; Rahimi S, 2017, HEAD NECK PATHOL, V11, P186, DOI 10.1007/s12105-016-0759-9; Slova D, 2012, HEAD NECK PATHOL, V6, P250, DOI 10.1007/s12105-011-0301-z; Smith SM, 2017, HEAD NECK PATHOL, V11, P234, DOI 10.1007/s12105-016-0740-7; Volchok J, 2007, ARCH OTOLARYNGOL, V133, P717, DOI 10.1001/archotol.133.7.717	9	4	4	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	JUN	2018	12	2					291	293		10.1007/s12105-017-0843-9			3	Pathology	Pathology	GG0GC	WOS:000432355500022	28779466	Green Published			2019-10-28	
J	Bell, D				Bell, Diana			Response to "Colonic-Type Adenocarcinoma of the Tongue and Oral Cavity (CATOC)"	HEAD & NECK PATHOLOGY			English	Letter							INTESTINAL-TYPE ADENOCARCINOMA; CYST; RARE		[Bell, Diana] Univ Texas MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA	Bell, D (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	Diana.bell@mdanderson.org					Agaimy A, 2017, HEAD NECK PATHOL, P1; Agaimy A, 2007, VIRCHOWS ARCH, V450, P479, DOI 10.1007/s00428-007-0369-8; Bell D, 2009, HUM PATHOL, V40, P1798, DOI 10.1016/j.humpath.2009.01.028; McDaniel AS, 2013, JAMA OTOLARYNGOL, V139, P653, DOI 10.1001/jamaoto.2013.3240a; Rahimi S, 2017, HEAD NECK PATHOL, V11, P186, DOI 10.1007/s12105-016-0759-9; Slova D, 2012, HEAD NECK PATHOL, V6, P250, DOI 10.1007/s12105-011-0301-z; Smith SM, 2017, HEAD NECK PATHOL, V11, P234, DOI 10.1007/s12105-016-0740-7; Volchok J, 2007, ARCH OTOLARYNGOL, V133, P717, DOI 10.1001/archotol.133.7.717	8	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	JUN	2018	12	2					294	295		10.1007/s12105-017-0865-3			2	Pathology	Pathology	GG0GC	WOS:000432355500023	29128950	Green Published			2019-10-28	
J	Agaimy, A				Agaimy, Abbas			In Reply: Colonic-Type Adenocarcinoma of the Tongue and Oral Cavity (CATOC)	HEAD & NECK PATHOLOGY			English	Letter							CYST		[Agaimy, Abbas] Friedrich Alexander Univ Erlangen Nuremberg, Inst Pathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany	Agaimy, A (reprint author), Friedrich Alexander Univ Erlangen Nuremberg, Inst Pathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany.	abbas.agaimy@uk-erlangen.de					Agaimy A, 2007, VIRCHOWS ARCH, V450, P479, DOI 10.1007/s00428-007-0369-8; Agaimy A, 2018, HEAD NECK PATHOL, V12, P291, DOI 10.1007/s12105-017-0843-9; Bell D., 2017, HEAD NECK PATHOL, DOI [10.1007/s12105-017-0843-9, DOI 10.1007/S12105-017-0843-9]; Bell D, 2009, HUM PATHOL, V40, P1798, DOI 10.1016/j.humpath.2009.01.028; Smith SM, 2017, HEAD NECK PATHOL, V11, P234, DOI 10.1007/s12105-016-0740-7; Volchok J, 2007, ARCH OTOLARYNGOL, V133, P717, DOI 10.1001/archotol.133.7.717	6	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	JUN	2018	12	2					296	297		10.1007/s12105-017-0866-2			2	Pathology	Pathology	GG0GC	WOS:000432355500024	29139085	Green Published			2019-10-28	
J	Ide, F; Matsumoto, N; Kikuchi, K; Kusama, K				Ide, Fumio; Matsumoto, Naoyuki; Kikuchi, Kentaro; Kusama, Kaoru			Hybrid Central Odontogenic Fibroma/Central Giant Cell Lesion: A Missing Report	HEAD & NECK PATHOLOGY			English	Letter							FIBROMA		[Ide, Fumio; Kikuchi, Kentaro; Kusama, Kaoru] Meikai Univ, Sch Dent, Dept Diagnost & Therapeut Sci, Div Pathol, 1-1 Keyakidai, Sakado, Saitama 3500283, Japan; [Ide, Fumio; Matsumoto, Naoyuki] Tsurumi Univ, Sch Dent Med, Dept Diagnost Pathol, Tsurumi Ku, 2-1-3 Tsurumi, Yokohama, Kanagawa 2308501, Japan	Ide, F (reprint author), Meikai Univ, Sch Dent, Dept Diagnost & Therapeut Sci, Div Pathol, 1-1 Keyakidai, Sakado, Saitama 3500283, Japan.; Ide, F (reprint author), Tsurumi Univ, Sch Dent Med, Dept Diagnost Pathol, Tsurumi Ku, 2-1-3 Tsurumi, Yokohama, Kanagawa 2308501, Japan.	idef@dent.meikai.ac.jp					ALLEN CM, 1992, ORAL SURG ORAL MED O, V73, P62, DOI 10.1016/0030-4220(92)90156-K; American Academy of Oral & Maxillofacial Pathology (AAOMP), 2014, CLIN PATH C CAS 1; Busch H P, 1988, Dtsch Z Mund Kiefer Gesichtschir, V12, P193; Cortes Castillo G, 2011, REV ODONTOL MEX, V15, P124; Domarus H, 1976, Dtsch Zahnarztl Z, V31, P260; Eliot C, 2015, OR SURG OR MED OR PA, V119, pE289, DOI 10.1016/j.oooo.2014.11.021; Kessler HP, 2006, W SOC TEACHERS ORAL; Molina RB, 2011, J CLIN EXP DENT, V3, pe348; Mosqueda-Taylor A, 2011, ORAL SURG ORAL MED O, V112, P349, DOI 10.1016/j.tripleo.2011.03.021; Piesold J, 1997, Mund Kiefer Gesichtschir, V1, P174; PREIN J, 1985, ATLAS TUMOREN GESICH; Remmele W, 2013, PATHOLOGIE; Tosios KI, 2008, HEAD NECK PATHOL, V2, P333, DOI 10.1007/s12105-008-0076-z; Upadhyaya JD, 2018, HEAD NECK PATHOL, V12, P166, DOI 10.1007/s12105-017-0845-7; Wangerin K, 1985, Dtsch Z Mund Kiefer Gesichtschir, V9, P227	15	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	JUN	2018	12	2					298	299		10.1007/s12105-017-0863-5			2	Pathology	Pathology	GG0GC	WOS:000432355500025	29340949	Green Published			2019-10-28	
J	Laposata, M				Laposata, Michael			Obtaining a Correct Diagnosis Rapidly in the United States Is Associated With Many Barriers Not Present in Other Countries	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Editorial Material									[Laposata, Michael] Univ Texas Med Branch, Dept Pathol, 301 Univ Blvd, Galveston, TX 77555 USA	Laposata, M (reprint author), Univ Texas Med Branch, Dept Pathol, 301 Univ Blvd, Galveston, TX 77555 USA.	milaposa@utmb.edu					Balogh E., 2015, IMPR DIAGN HLTH CAR, P1; Bhardwaj Anish, 2017, Hosp Pract (1995), V45, P81, DOI 10.1080/21548331.2017.1327302; Brill S., 2013, TIME, V181, P30; College of American Pathologists, 2017, PRACT CHAR SURV; Jauhar S., 2017, NY TIMES; Lowes R., MED EC; Makary MA, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2139; Smith BR, 2016, ACAD MED, V91, P107, DOI 10.1097/ACM.0000000000000817	8	2	2	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JUN	2018	149	6					458	460		10.1093/AJCP/AQY010			3	Pathology	Pathology	GE3UM	WOS:000431138400001	29635278				2019-10-28	
J	Benedict, MA; Lauwers, GY; Jain, D				Benedict, Mark A.; Lauwers, Gregory Y.; Jain, Dhanpat			Gastric Adenocarcinoma of the Fundic Gland Type Update and Literature Review	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Review							PARIETAL-CELL CARCINOMA; WELL-DIFFERENTIATED ADENOCARCINOMA; PREDOMINANT TYPE; CLINICOPATHOLOGICAL FEATURES; ONCOCYTIC ADENOCARCINOMA; STOMACH; GNAS; CARCINOGENESIS; EXPRESSION; MUTATIONS	Objectives: Gastric adenocarcinoma of the fundic gland type (GA-FG) is a newly described entity with a lack of awareness amongst general surgical pathologists and this review highlights the key features and controversies associated with this uncommon neoplasm. Methods: A literature search through PubMed using synonyms for GA-FG was conducted to obtain 111 cases. Results: GA-FG is a well-differentiated neoplasm of oxyntic mucosa, that is comprised of chief cells and parietal cells. Chief cell differentiation is highlighted with Muc-6, RUNX3, and pepsinogen. Parietal cells are highlighted with H+/ K+ ATPase and PDGFRA-a. Association with Helicobacter infection, chronic gastritis, intestinal metaplasia, or gastric atrophy is not seen. Most GA-FGs are confined to the mucosa. Deeper invasion, lymphovascular invasion, nodal metastasis, and extragastric spread are uncommon. Conclusions: GA-FGs are rare lesions that typically follow a benign course. However, despite features of malignancy in some cases, complete surgical excision, sometimes with endoscopic mucosal resection, seems adequate treatment.	[Benedict, Mark A.; Jain, Dhanpat] Yale Univ, Sch Med, Dept Pathol, 310 Cedar St, New Haven, CT 06520 USA; [Lauwers, Gregory Y.] H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, Tampa, FL USA	Jain, D (reprint author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St, New Haven, CT 06520 USA.	Dhanpat.Jain@yale.edu					Abe T, 2013, INTERNAL MED, V52, P1585, DOI 10.2169/internalmedicine.52.0361; Cha Hee Jeong, 2016, Case Rep Gastroenterol, V10, P292, DOI 10.1159/000444277; Chan K, 2016, HISTOPATHOLOGY, V68, P825, DOI 10.1111/his.12859; Chen WC, 2012, J GASTROINTEST CANC, V43, P262, DOI [10.1007/s12029-012-9416-z, DOI 10.1007/S12029-012-9416-Z]; Chiba T, 2016, DIGEST ENDOSC, V28, P722, DOI 10.1111/den.12676; Fujii M, 2015, CASE REP CLIN PATHOL, V2, P17, DOI [10.5430/crcp.v2n1p17, DOI 10.5430/CRCP.V2N1P17]; Fujimoto A, 2014, PROG DIG ENDOSC, V84, P100; Fujisawa T, 2011, GASTROENTEROL ENDOSC, V53, P3769; Fukatsu H, 2011, DIGEST ENDOSC, V23, P244, DOI 10.1111/j.1443-1661.2011.01125.x; GAFFNEY EF, 1987, HISTOPATHOLOGY, V11, P217; Hori K, 2015, ENDOSCOPY, V47, pE177, DOI 10.1055/s-0034-1391500; Jalving M, 2003, SCAND J GASTROENTERO, V38, P916, DOI 10.1080/00365520310005433; Joo M, 2016, J PATHOL TRANSL MED, V50, P71, DOI 10.4132/jptm.2015.07.14; Kato M, 2015, CLIN J GASTROENTEROL, V8, P393, DOI 10.1007/s12328-015-0619-2; Kawasaki K, 2016, INTERNAL MED, V55, P543, DOI 10.2169/internalmedicine.55.5706; Khor TS, 2012, AM J SURG PATHOL, V36, P331, DOI 10.1097/PAS.0b013e31823d08d6; Kushima R, 2013, PATHOL INT, V63, P318, DOI 10.1111/pin.12070; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lee SH, 2008, PATHOLOGY, V40, P95, DOI 10.1080/00313020701716375; Lewin E, 2015, AM J CLIN PATHOL, V144, pA391, DOI 10.1093/ajcp/144.suppl2.391; Mardi K, 2013, J CANCER RES THER, V9, P162, DOI 10.4103/0973-1482.110354; Matsubara A, 2013, J PATHOL, V229, P579, DOI 10.1002/path.4153; Miyaoka Y, 2011, GASTROENTEROL ENDOSC, V53, P1778; Miyazawa M, 2015, WORLD J GASTROENTERO, V21, P8208, DOI 10.3748/wjg.v21.i26.8208; Mochizuki K, 2015, PATHOL INT, V65, P148, DOI 10.1111/pin.12241; Nagini S, 2012, WORLD J GASTRO ONCOL, V4, P156, DOI 10.4251/wjgo.v4.i7.156; NAKAMURA K, 1968, GANN, V59, P251; Nomura R, 2014, HUM PATHOL, V45, P2488, DOI 10.1016/j.humpath.2014.08.016; Parikh ND, 2015, CLIN GASTROENTEROL H, V13, pXVII, DOI 10.1016/j.cgh.2015.07.023; Park ES, 2012, KOREAN J PATHOL, V46, P287, DOI 10.4132/KoreanJPathol.2012.46.3.287; RYCHTEROVA V, 1991, APMIS, V99, P1008, DOI 10.1111/j.1699-0463.1991.tb01293.x; Sato Y, 2016, CLIN J GASTROENTEROL, V9, P345, DOI 10.1007/s12328-016-0680-5; Singhi AD, 2012, AM J SURG PATHOL, V36, P1030, DOI 10.1097/PAS.0b013e31825033e7; Sterbini FP, 2016, APPL ENVIRON MICROB, V82, P6633, DOI 10.1128/AEM.01437-16; Takeda S, 2015, Acta Gastroenterol Belg, V78, P340; Takubo K, 2002, AM J SURG PATHOL, V26, P458, DOI 10.1097/00000478-200204000-00007; Terada T, 2011, INT J CLIN EXP PATHO, V4, P797; Tohda G, 2016, WORLD J GASTRO ENDOS, V8, P244, DOI 10.4253/wjge.v8.i4.244; Torbenson M, 2002, MODERN PATHOL, V15, P718, DOI 10.1097/01.MP.0000018976.15044.9B; Tsukamoto T, 2007, PATHOL INT, V57, P517, DOI 10.1111/j.1440-1827.2007.02134.x; Ueo T, 2014, DIGEST ENDOSC, V26, P293, DOI [10.1111/den.12210, 10.1111/den.12212]; Ueyama H, 2014, ENDOSCOPY, V46, P153, DOI 10.1055/s-0033-1359042; Wu HY, 2009, CANCER EPIDEM BIOMAR, V18, P1945, DOI 10.1158/1055-9965.EPI-09-0250; Yang GY, 2003, ULTRASTRUCT PATHOL, V27, P87, DOI 10.1080/01913120390179842; Zhang C, 2017, HEMATOL ONCOL CLIN N, V31, P389, DOI 10.1016/j.hoc.2017.01.002	45	3	4	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JUN	2018	149	6					461	473		10.1093/AJCP/AQY019			13	Pathology	Pathology	GE3UM	WOS:000431138400002	29648578	Bronze			2019-10-28	
J	Jiang, CY; Zhu, JH; Zhou, PC; Zhu, HJ; Wang, W; Jin, Q; Li, P				Jiang, Chunyi; Zhu, Jinhong; Zhou, Pengcheng; Zhu, Huijun; Wang, Wei; Jin, Qin; Li, Peng			Overexpression of FIBCD1 Is Predictive of Poor Prognosis in Gastric Cancer	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article							MAMMALIAN CHITINASE; L-FICOLIN; RECOGNITION; INFLAMMATION; EXPRESSION; BIOMARKERS; MORTALITY; SEQUENCE; THERAPY	Objectives: Fibrinogen C domain containing 1 (FIBCD1) is a newly identified acetyl group recognition receptor. The aim of this study was to evaluate the prognostic significance of FIBCD1 in gastric cancer. Methods: This study included 706 samples, and the clinical data of all patients were recorded in detail. We studied messenger RNA (mRNA) and protein expression of FIBCD1 in cancerous and normal tissues by quantitative real-time polymerase chain reaction (n = 54) and tissue microarray immunohistochemistry analysis (n = 706), respectively. Results: mRNA and protein expression levels of FIBCD1 were significantly higher in gastric cancer than in normal tissues. High FIBCD1 protein level showed significant correlations with age (P =.011), TNM stage (P <.001), serum carcinoembryonic antigen (CEA) level (P =.002), and the expression of human epidermal growth factor receptor 2 (P <.001). Kaplan-Meier survival analysis revealed that patients with gastric cancer with high levels of FIBCD1 had a significantly shorter survival time than those with low expression levels. In univariate analysis, high FIBCD1 expression, older age, histologic type, differentiation, TNM stage, serum CEA, and serum CA19-9 level correlated with overall survival. Multivariate analysis suggested that FIBCD1 expression was an independent prognostic factor. Conclusions: FIBCD1 may be a novel biomarker to evaluate the prognosis of gastric cancer.	[Jiang, Chunyi; Zhu, Huijun; Wang, Wei; Jin, Qin] Nantong Univ, Affiliated Hosp, Dept Pathol, Nantong, Jiangsu, Peoples R China; [Jiang, Chunyi] Nantong Univ, Affiliated Hosp, Dept Clin Biobank, Nantong, Jiangsu, Peoples R China; [Zhou, Pengcheng] Nantong Univ, Affiliated Hosp, Dept Emergency Surg, Nantong, Jiangsu, Peoples R China; [Li, Peng] Nantong Univ, Affiliated Hosp, Dept Gen Surg, Nantong, Jiangsu, Peoples R China; [Zhu, Jinhong] Harbin Med Univ, Canc Hosp, Mol Epidemiol Lab, Harbin, Heilongjiang, Peoples R China; [Zhu, Jinhong] Harbin Med Univ, Canc Hosp, Dept Lab Med, Harbin, Heilongjiang, Peoples R China	Li, P (reprint author), Nantong Univ, Affiliated Hosp, 20 XISI Rd, Nantong 226001, Jiangsu, Peoples R China.	lipeng121212@gmail.com		Zhu, Jinhong/0000-0002-0408-3101; Jin, Qin/0000-0002-7246-4651	National Natural Science Funds of ChinaNational Natural Science Foundation of China [81572390]	This work was supported by the National Natural Science Funds of China (81572390).	Balzarini P, 2013, DIGEST LIVER DIS, V45, P616, DOI 10.1016/j.dld.2013.01.024; Bussink AP, 2007, GENETICS, V177, P959, DOI 10.1534/genetics.107.075846; Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713; Cetin Bulent, 2016, J Gastrointest Cancer, V47, P125, DOI 10.1007/s12029-016-9806-8; Chen WQ, 2012, CHINESE J CANCER RES, V24, P171, DOI 10.1007/s11670-012-0171-2; Cunningham D, 2010, NEW ENGL J MED, V362, P858, DOI 10.1056/NEJMc0911925; Elieh Ali Komi D, CLIN REV ALLERGY IMM; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Garlatti V, 2007, J BIOL CHEM, V282, P35814, DOI 10.1074/jbc.M705741200; Garlatti V, 2007, EMBO J, V26, P623, DOI 10.1038/sj.emboj.7601500; HARRISON JD, 1995, WORLD J SURG, V19, P496, DOI 10.1007/BF00294709; Humphray SJ, 2004, NATURE, V429, P369, DOI 10.1038/nature02465; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115; Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437; Koretke KK, 1999, PROTEINS, P141; Krarup A, 2004, J BIOL CHEM, V279, P47513, DOI 10.1074/jbc.M407161200; Kurita K, 2006, MAR BIOTECHNOL, V8, P203, DOI 10.1007/s10126-005-0097-5; Mordente A, 2015, ADV EXP MED BIOL, V867, P9, DOI 10.1007/978-94-017-7215-0_2; Reese TA, 2007, NATURE, V447, P92, DOI 10.1038/nature05746; Rossi V, 1998, J BIOL CHEM, V273, P1232, DOI 10.1074/jbc.273.2.1232; Sands BE, 2015, GASTROENTEROLOGY, V149, P1275, DOI 10.1053/j.gastro.2015.07.003; Schlosser A, 2009, J IMMUNOL, V183, P3800, DOI 10.4049/jimmunol.0901526; Shibata Y, 2000, J IMMUNOL, V164, P1314, DOI 10.4049/jimmunol.164.3.1314; Shrive AK, 2014, J BIOL CHEM, V289, P2880, DOI 10.1074/jbc.M113.520577; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Thiel S, 2007, MOL IMMUNOL, V44, P3875, DOI 10.1016/j.molimm.2007.06.005; Thomsen T, 2010, J BIOL CHEM, V285, P1229, DOI 10.1074/jbc.M109.061523; Van Cutsem E, 2006, J CLIN ONCOL, V24, P4991, DOI 10.1200/JCO.2006.06.8429; Yuan DD, 2016, ONCOL REP, V35, P1245, DOI 10.3892/or.2015.4528; Zhang HL, 2014, SCI REP-UK, V4, DOI 10.1038/srep05811; Zhu Z, 2004, SCIENCE, V304, P1678, DOI 10.1126/science.1095336	32	1	2	2	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JUN	2018	149	6					474	483		10.1093/AJCP/AQY013			10	Pathology	Pathology	GE3UM	WOS:000431138400003	29659669				2019-10-28	
J	D'Angelo, R; Weiss, R; Wolfe, D; Chinnam, R; Murat, A; Gluesing, J; Somers, T				D'Angelo, Rita; Weiss, Ronald; Wolfe, David; Chinnam, Ratna; Murat, Alper; Gluesing, Julia; Somers, Toni			Facing the Inevitable Being Prepared for Regulatory Requirements for Laboratory Developed Tests	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article								Objectives: We introduce regulatory terms, definitions, and the Quality System Regulation as proposed by the US Food and Drug Administration in the 2014 draft guidance entitled Framework for Regulatory Oversight of Laboratory Developed Tests and explore medical device requirements applicable to a laboratory environment to design, develop, and validate laboratory developed tests (LDTs). Methods: We performed nine interviews with laboratory professionals to explore concerns and challenges regarding the draft, translated the results into operational factors, and surveyed professionals to test the factors that would comprise a regulatory quality management system framework. Results: Nine interviewees and 35 survey respondents shared concerns of risk classification, process validation, patient safety, and general ambiguity regarding the proposed requirements for development of LDTs. Conclusions: Respondents agree that a regulatory quality management system is needed in laboratories that develop LDTs, but the translation and method for design control to a clinical laboratory do not exist. As a result, laboratories are taking the wait-and-see approach.	[D'Angelo, Rita] DAngelo Advantage LLC, 30033 Pointe Dr, Rockwood, MI 48173 USA; [Weiss, Ronald; Wolfe, David] Coll Amer Pathologists, Northfield, IL USA; [Chinnam, Ratna; Murat, Alper; Gluesing, Julia; Somers, Toni] Wayne State Univ, Ind & Syst Engn, Detroit, MI USA	D'Angelo, R (reprint author), DAngelo Advantage LLC, 30033 Pointe Dr, Rockwood, MI 48173 USA.	dange-loadvantage@gmail.com	Somers, Toni M/E-5422-2016	Somers, Toni M/0000-0001-5880-7606			[Anonymous], 2012, 15189 ISO; [Anonymous], 2011, LAB QUAL MAN SYST; [Anonymous], 2011, QMS01A4 CLSI; Boonstra H, 2000, CONTRACEPTION, V61, P9, DOI 10.1016/S0010-7824(99)00121-3; Burd EM, 2010, CLIN MICROBIOL REV, V23, P550, DOI 10.1128/CMR.00074-09; *CLIN LAB STAND I, 2015, QUAL SYST REG LAB DE; *CMS, CLIA OV; *EM GROUP, LONG WILL IT TAK MY; Erickson B, 2010, CHEM ENG NEWS, V88, P24; Evans JP, 2015, JAMA-J AM MED ASSOC, V313, P669, DOI 10.1001/jama.2014.18145; *FDA, 2015, FDA PUBL WORKSH DISC; FDA, 2014, GUID IND FO IN PRESS; FDA Center for devices and radiological health, 1997, DES CONTR GUID MED D; *GEN LEG DEP, 2008, CIT PET REG IN VITR; KLEIN R, 2016, ARUP LAB U UTAH SEPT; *NEW YORK STAT DEP, LAB STAND; U.S. Food and Drug Administration/Center for Devices and Radiological Health, DISC PAP LAB DEV TES; Vance GH, 2011, ARCH PATHOL LAB MED, V135, P1432, DOI 10.5858/arpa.2011-0304-SA; Weiss RL, 2012, AM J CLIN PATHOL, V138, P20, DOI 10.1309/AJCP6OAULC3CMFEJ; Williams B, 2010, AUSTRALASIAN J PARAM, V8, P3, DOI DOI 10.33151/ajp.8.3.93	20	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JUN	2018	149	6					484	498		10.1093/AJCP/AQY014			15	Pathology	Pathology	GE3UM	WOS:000431138400004	29659675	Bronze			2019-10-28	
J	Chisholm, KM; Xu, M; Davis, B; Ogi, A; Pacheco, MC; Geddis, AE; Tsuchiya, KD; Rutledge, JC				Chisholm, Karen M.; Xu, Min; Davis, Billy; Ogi, Amy; Pacheco, M. Cristina; Geddis, Amy E.; Tsuchiya, Karen D.; Rutledge, Joe C.			Evaluation of the Utility of Bone Marrow Morphology and Ancillary Studies in Pediatric Patients Under Surveillance for Myelodysplastic Syndrome	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article							IN-SITU HYBRIDIZATION; ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC-CELL TRANSPLANTATION; MULTIPARAMETER FLOW-CYTOMETRY; FANCONI-ANEMIA; MYELOPROLIFERATIVE DISORDERS; CONVENTIONAL CYTOGENETICS; PREDISPOSING CONDITIONS; SCORING SYSTEM; FRAGILE SITE	Objectives: To evaluate the utility of flow cytometry, karyotype, and a fluorescence in situ hybridization (FISH) panel in screening children for myelodysplastic syndrome (MDS). Methods: Bone marrow morphology, flow cytometry, karyotype, and FISH reports from 595 bone marrow specimens (246 patients) were analyzed. Results: By morphology, 8.7% of cases demonstrated at least unilineage dysplasia and/or increased blasts. Flow cytometry identified definitive abnormalities in 2.8% of cases, all of which had abnormal morphology. Of the 42 cases (7.2%) with acquired karyotypic abnormalities, 26 had no morphologic dysplasia. With a 98.2% concordance between karyotype and MDS FISH, FISH only identified two additional cases, both with low-level (< 4%) abnormalities. Peripheral blood count evaluation only identified the absence of thrombocytopenia to correlate with an absence of abnormal ancillary tests. Conclusions: The combination of morphologic evaluation and karyotype with judicious use of flow cytometry and MDS FISH is sufficient to detect abnormalities for these indications.	[Chisholm, Karen M.; Xu, Min; Davis, Billy; Ogi, Amy; Pacheco, M. Cristina; Tsuchiya, Karen D.; Rutledge, Joe C.] Seattle Childrens Hosp, Dept Labs, OC 8-720,4800 Sand Point Way NE, Seattle, WA 98105 USA; [Geddis, Amy E.] Seattle Childrens Hosp, Canc & Blood Disorders Ctr, Seattle, WA USA; [Chisholm, Karen M.; Xu, Min; Tsuchiya, Karen D.; Rutledge, Joe C.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; [Pacheco, M. Cristina] Univ Washington, Dept Pathol, Seattle, WA 98195 USA; [Geddis, Amy E.] Univ Washington, Dept Pediat, Div Hematol & Oncol, Seattle, WA 98195 USA	Tsuchiya, KD (reprint author), Seattle Childrens Hosp, Dept Labs, OC 8-720,4800 Sand Point Way NE, Seattle, WA 98105 USA.	karen.chisholm@seattlechildrens.org		Chisholm, Karen/0000-0002-1898-1252			Aalbers AM, 2013, LEUKEMIA, V27, P1923, DOI 10.1038/leu.2013.81; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Ayas M, 2013, J CLIN ONCOL, V31, P1669, DOI 10.1200/JCO.2012.45.9719; Babushok DV, 2016, LEUKEMIA LYMPHOMA, V57, P520, DOI 10.3109/10428194.2015.1115041; BaderMeunier B, 1996, BRIT J HAEMATOL, V92, P344, DOI 10.1046/j.1365-2141.0000.d01-1480.x; BADERMEUNIER B, 1994, BRIT J HAEMATOL, V87, P381, DOI 10.1111/j.1365-2141.1994.tb04926.x; Brunning RD, 2008, WHO CLASSIFICATION T, P114; Cada M, 2015, HAEMATOLOGICA, V100, P633, DOI 10.3324/haematol.2014.117457; Churpek JE, 2015, BLOOD, V126, P2484, DOI 10.1182/blood-2015-04-641100; Clinical and Laboratory Standards Institute, 2013, MM07A2 CLSI; Coleman JF, 2011, AM J CLIN PATHOL, V135, P915, DOI [10.1309/AJCFW10YBRMWSWYE, 10.1309/AJCPW10YBRMWSWYE]; Connelly JA, 2012, CURR OPIN HEMATOL, V19, P44, DOI 10.1097/MOH.0b013e32834da96e; Costa D, 2010, LEUKEMIA RES, V34, P1437, DOI 10.1016/j.leukres.2010.02.019; Cremers EMP, 2016, EUR J CANCER, V54, P49, DOI 10.1016/j.ejca.2015.11.013; Debacker K, 2007, HUM MOL GENET, V16, pR150, DOI 10.1093/hmg/ddm136; Della Porta MG, 2012, HAEMATOL-HEMATOL J, V97, P1209, DOI 10.3324/haematol.2011.048421; Douet-Guilbert N, 2011, ANTICANCER RES, V31, P1007; Ganapathi KA, 2015, BLOOD, V125, P56, DOI 10.1182/blood-2014-06-580340; HASLE H, 1995, LEUKEMIA, V9, P1569; Hasle H, 1999, LEUKEMIA, V13, P376, DOI 10.1038/sj.leu.2401342; He R, 2016, AM J CLIN PATHOL, V146, P86, DOI 10.1093/ajcp/aqw077; Heeney MM, 2003, J PEDIATR-US, V143, P662, DOI 10.1067/S0022-3476(03)00445-1; Howlader N, 2017, SEER CANC STAT REV; Jiang H, 2012, LEUKEMIA RES, V36, P448, DOI 10.1016/j.leukres.2011.10.014; Kern W, 2010, CANCER-AM CANCER SOC, V116, P4549, DOI 10.1002/cncr.25353; Kussick SJ, 2005, AM J CLIN PATHOL, V124, P170, DOI 10.1309/6PBP78G4FBA1FDG6; Kussick SJ, 2003, ARCH PATHOL LAB MED, V127, P1140; Luna-Fineman S, 1999, BLOOD, V93, P459, DOI 10.1182/blood.V93.2.459.402k19_459_466; MacMillan ML, 2015, BLOOD, V125, P3798, DOI 10.1182/blood-2015-02-626002; Mandel K, 2002, J PEDIAT HEMATOL ONC, V24, P595; Mehta PA, 2010, CANCER GENET CYTOGEN, V203, P180, DOI 10.1016/j.cancergencyto.2010.07.127; Meyer S, 2011, BLOOD, V117, P6047, DOI 10.1182/blood-2011-03-343897; Mitchell R, 2014, BRIT J HAEMATOL, V164, P384, DOI 10.1111/bjh.12634; Mueller BU, 1996, J PEDIAT HEMATOL ONC, V18, P266, DOI 10.1097/00043426-199608000-00006; Niemeyer CM, 2017, SEMIN HEMATOL, V54, P69, DOI 10.1053/j.seminhematol.2017.04.002; Ogata K, 2009, HAEMATOL-HEMATOL J, V94, P1066, DOI 10.3324/haematol.2009.008532; Parmentier S, 2012, HAEMATOL-HEMATOL J, V97, P723, DOI 10.3324/haematol.2011.056879; PASSMORE SJ, 1995, BLOOD, V85, P1742, DOI 10.1182/blood.V85.7.1742.bloodjournal8571742; PETIT P, 1983, AM J HUM GENET, V35, P126; Pitchford CW, 2010, AM J CLIN PATHOL, V133, P260, DOI 10.1309/AJCPZ4JL5ZMRPFTD; Porter CC, 2017, CLIN CANCER RES, V23, pE14, DOI 10.1158/1078-0432.CCR-17-0428; Quentin S, 2011, BLOOD, V117, pE161, DOI 10.1182/blood-2010-09-308726; Rochowski A, 2012, PEDIATR BLOOD CANCER, V59, P922, DOI 10.1002/pbc.24168; Sasaki H, 2001, LEUKEMIA, V15, P1713, DOI 10.1038/sj.leu.2402271; Shimamura A, 2010, BLOOD REV, V24, P101, DOI 10.1016/j.blre.2010.03.002; Steensma DP, 2012, CURR HEMATOL MALIG R, V7, P310, DOI 10.1007/s11899-012-0140-3; TAYLOR AMR, 1983, AM J HUM GENET, V35, P123; Tonnies H, 2003, BLOOD, V101, P3872, DOI 10.1182/blood-2002-10-3243; Touliatou V, 2004, ANTICANCER RES, V24, P3945; van de Loosdrecht AA, 2008, BLOOD, V111, P1067, DOI 10.1182/blood-2007-07-098764; Walsh MF, 2017, CLIN CANCER RES, V23, pE23, DOI 10.1158/1078-0432.CCR-17-0465; Wells DA, 2003, BLOOD, V102, P394, DOI 10.1182/blood-2002-09-2768; Wlodarski MW, 2016, BLOOD, V127, P1387, DOI 10.1182/blood-2015-09-669937; Wood BL, 2007, CLIN LAB MED, V27, P551, DOI 10.1016/j.cll.2007.05.006; Yang W, 2010, LEUKEMIA RES, V34, P420, DOI 10.1016/j.leukres.2009.09.013; Yetgin S, 1997, AM J HEMATOL, V54, P166, DOI 10.1002/(SICI)1096-8652(199702)54:2<166::AID-AJH13>3.0.CO;2-D	56	0	0	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JUN	2018	149	6					499	513		10.1093/AJCP/AQY007			15	Pathology	Pathology	GE3UM	WOS:000431138400005	29659673				2019-10-28	
J	Hutchings, D; Maleki, Z; Rodriguez, EF				Hutchings, Danielle; Maleki, Zahra; Rodriguez, Erika F.			Pulmonary Non-Small Cell Carcinoma With Morphologic Features of Adenocarcinoma or "Non-Small Cell Carcinoma Favor Adenocarcinoma" in Cytologic Specimens Share Similar Clinical and Molecular Genetic Characteristics	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article							MALIGNANT PLEURAL EFFUSION; LUNG ADENOCARCINOMA; INTERNATIONAL ASSOCIATION; IASLC/ATS/ERS CLASSIFICATION; SMALL BIOPSIES; DIAGNOSIS; CANCER; TISSUE; TTF-1; PANEL	Objectives: Define if the presence of morphologic features of adenocarcinoma (ACA) in non-small cell lung carcinoma (NSCLC) on cytology specimens correlates with clinical and biologic features. Methods: A total of 209 cases of NSCLC diagnosed on fine-needle aspiration in a 3-year period were included. Results: After morphologic review, the cases were classified as ACA (n = 115), NSCLC favor ACA (n = 43), and NSCLC-not otherwise specified (NOS) (n = 18). Squamous cell (SCC) (n = 14) and NSCLC favor SCC (n = 19) were excluded from further analysis. Patients with EGFR-mutated tumors had longer overall survival than those with EGFR wild-type tumors (P =.01). When comparing cases with morphologic features of ACA, NSCLC favor ACA, and NSCLC-NOS, there were no differences in the presence or absence of tested mutations, clinical stage, or survival. Conclusion: Patients diagnosed with pulmonary ACA, NSCLC favor ACA, or NSCLC-NOS in cytology specimens have similar clinical stage, survival, and molecular alterations.	[Hutchings, Danielle; Maleki, Zahra; Rodriguez, Erika F.] Johns Hopkins Sch Med, Dept Pathol, Div Cytopathol, Baltimore, MD 21287 USA	Rodriguez, EF (reprint author), Johns Hopkins Sch Med, Dept Pathol, Carnegie Pathol 469, 600 North Wolfe St, Baltimore, MD 21287 USA.	erodri17@jhmi.edu					Bishop JA, 2012, MODERN PATHOL, V25, P405, DOI 10.1038/modpathol.2011.173; Carter J, 2017, ANN AM THORAC SOC, V14, P1169, DOI 10.1513/AnnalsATS.201609-709OC; Esterbrook G, 2013, LUNG CANCER, V80, P30, DOI 10.1016/j.lungcan.2012.12.017; Fatima N, 2012, DIAGN CYTOPATHOL, V40, P943, DOI 10.1002/dc.21678; Fatima N, 2011, CANCER CYTOPATHOL, V119, P127, DOI 10.1002/cncy.20135; Lin MT, 2014, AM J CLIN PATHOL, V141, P856, DOI 10.1309/AJCPMWGWGO34EGOD; Mukhopadhyay S, 2011, AM J SURG PATHOL, V35, P15, DOI 10.1097/PAS.0b013e3182036d05; Nicholson AG, 2010, J THORAC ONCOL, V5, P436, DOI 10.1097/JTO.0b013e3181c6ed9b; Ocque R, 2011, AM J CLIN PATHOL, V136, P81, DOI 10.1309/AJCPFKOLGL6PMOF3; Rekhtman N, 2011, MODERN PATHOL, V24, P1348, DOI 10.1038/modpathol.2011.92; Rekhtman N, 2011, J THORAC ONCOL, V6, P451, DOI 10.1097/JTO.0b013e31820517a3; Righi L, 2011, CANCER-AM CANCER SOC, V117, P3416, DOI 10.1002/cncr.25830; Rodriguez EF, 2017, ACTA CYTOL, V61, P214, DOI 10.1159/000477148; Rodriguez EF, 2015, CANCER CYTOPATHOL, V123, P306, DOI 10.1002/cncy.21532; Rooper LM, 2016, HUM PATHOL, V51, P139, DOI 10.1016/j.humpath.2015.12.025; Santos GD, 2012, LUNG CANCER, V77, P501, DOI 10.1016/j.lungcan.2012.05.091; Sethi S, 2012, CYTOJOURNAL, V9, DOI 10.4103/1742-6413.94570; Shiran I, 2017, CLIN LUNG CANCER, V18, P316, DOI 10.1016/j.cllc.2017.01.009; Sigel CS, 2011, J THORAC ONCOL, V6, P1849, DOI 10.1097/JTO.0b013e318227142d; Sterlacci W, 2012, AM J CLIN PATHOL, V137, P946, DOI 10.1309/AJCP77KMKJXNMPMS; Travis WD, 2015, WHO CLASSIFICATION T; Travis WE, 2004, PATHOLOGY GENETICS T; Travis WD, 2013, ARCH PATHOL LAB MED, V137, P668, DOI 10.5858/arpa.2012-0263-RA; Travis William D, 2011, Proc Am Thorac Soc, V8, P381, DOI 10.1513/pats.201107-042ST; Travis WD, 2011, SEMIN RESP CRIT CARE, V32, P22, DOI 10.1055/s-0031-1272866; Zakowski MF, 2016, ARCH PATHOL LAB MED, V140, P1116, DOI 10.5858/arpa.2015-0316-OA; ZUSMANHARACH SB, 1991, J CLIN PATHOL, V44, P997, DOI 10.1136/jcp.44.12.997	27	3	3	1	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JUN	2018	149	6					514	521		10.1093/AJCP/AQY018			8	Pathology	Pathology	GE3UM	WOS:000431138400006	29635384	Bronze			2019-10-28	
J	Amukele, TK; Jones, R; Elbireer, A				Amukele, Timothy K.; Jones, Robert; Elbireer, Ali			Test Cost and Test Accuracy in Clinical Laboratories in Kampala, Uganda	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article							SUB-SAHARAN AFRICA; QUALITY; PRICE; PERCEPTIONS	Objectives: To assess the accuracy and costs of laboratory tests in Kampala, Uganda. Methods: A random selection of 78 laboratories tested external quality assurance samples at market rates. There were 40 moderate-to high-complexity and 38 low-complexity laboratories. Four percent (3/78) of these laboratories were accredited and 94% (73/78) were private. The 40 moderate-to high-complexity laboratories performed malaria blood smear, urine human chorionic gonadotropin (hCG), human immunodeficiency virus (HIV), syphilis, glucose, and three-panel tests: CBC, liver function tests, and kidney function tests. The 38 low-complexity laboratories performed malaria blood smear, urine hCG, and syphilis testing only. Hematology, HIV, syphilis, and malarial proficiency testing samples were prepared by accredited laboratories in Kampala. All other samples were provided by the Royal College of Pathologists of Australia. Results: 77.1% of all results were accurate (met target values). It varied widely by laboratory (50%-100%), test identity (malaria blood smear, 96%; serum urea nitrogen, 38%), and test type (quantitative: 66% [31%-89%], qualitative: 91% [68%-97%]). Test prices varied by up to 3,600%, and there was no correlation between test cost and accuracy (r(2) = 0.02). Conclusions: There were large differences in accuracy and price across laboratories in Kampala. Price was not associated with quality.	[Amukele, Timothy K.; Jones, Robert] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Elbireer, Ali] Johns Hopkins Univ, Sch Med, Dept Med, Infect Dis, Baltimore, MD 21205 USA; [Amukele, Timothy K.; Elbireer, Ali] Makerere Univ Johns Hopkins Univ, Clin Core Lab, Infect Dis Inst, Kampala, Uganda; [Elbireer, Ali] ASLM, Addis, Ethiopia	Amukele, TK (reprint author), Johns Hopkins Univ, Sch Med, 4940 Eastern Ave AA Bldg,154B, Baltimore, MD 21287 USA.	tamukell@jhmi.edu		Elbireer, Ali/0000-0002-2513-3497			Amukele TK, 2015, AM J CLIN PATHOL, V143, P50, DOI 10.1309/AJCPCYA54DWZQPQT; Amukele TK, 2012, AM J CLIN PATHOL, V138, P720, DOI 10.1309/AJCP8PCM4JVLEEQR; Bates I, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-38; BAUER H, 1969, DIS COLON RECTUM, V12, P13, DOI 10.1007/BF02617189; BELK WP, 1947, AM J CLIN PATHOL, V17, P853; Born PH, 1998, J FAM PRACTICE, V46, P319; Cho H I, 1999, Southeast Asian J Trop Med Public Health, V30 Suppl 3, P32; Delorme L, 2015, Bull Soc Pathol Exot, V108, P36, DOI 10.1007/s13149-014-0378-1; Ehrmeyer SS, 2004, CLIN CHIM ACTA, V346, P37, DOI 10.1016/j.cccn.2003.12.033; Elbireer A, 2010, LABMEDICINE, V41, P429, DOI 10.1309/LMCZOZFR80QWIBEM; Elbireer AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064661; FREAN J, 2012, B WORLD HEALTH ORGAN, V90, pA191; Gershy-Damet GM, 2010, AM J CLIN PATHOL, V134, P393, DOI [10.1309/AJCPTUUC2V1WJOBM, 10.1309/AJCPTUUC2V1WJQBM]; Hsia RY, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005482; Larson B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035444; Libeer JC, 1996, EUR J CLIN CHEM CLIN, V34, P665; Nkrumah B, 2014, AFR J LAB MED, V3, DOI 10.4102/ajlm.v3i2.214; Opartkiattikul Nisarat, 2002, Rinsho Byori, V50, P121; Petti CA, 2006, CLIN INFECT DIS, V42, P377, DOI 10.1086/499363; RAO AR, 1989, J MARKETING RES, V26, P351, DOI 10.2307/3172907; Schroeder LF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134578; Schroeder LF, 2014, AM J CLIN PATHOL, V141, P791, DOI 10.1309/AJCPQ5KTKAGSSCFN; SUNDERMAN FW, 1992, CLIN CHEM, V38, P1205; TELLIS GJ, 1987, MARKET SCI, V6, P240, DOI 10.1287/mksc.6.3.240; WHITEHEAD TP, 1973, J CLIN PATHOL, V26, P435, DOI 10.1136/jcp.26.6.435; ZEITHAML VA, 1988, J MARKETING, V52, P2, DOI 10.2307/1251446; 1982, LANCET, V319, P442	27	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JUN	2018	149	6					522	529		10.1093/AJCP/AQY017			8	Pathology	Pathology	GE3UM	WOS:000431138400007	29659678				2019-10-28	
J	Riley, JD; Stanley, G; Wyllie, R; Kottke-Marchant, K; Procop, GW				Riley, Jacquelyn D.; Stanley, Glenn; Wyllie, Robert; Kottke-Marchant, Kandice; Procop, Gary W.			The Impact of an Electronic Expensive Test Notification	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article							DECISION-SUPPORT; CARE; COST; TRANSPARENCY; MANAGEMENT; GUIDANCE; DISPLAY	Objectives: The impact of clinical decision support tools (CDSTs) that display test cost information has been variable. Methods: We retrospectively analyzed the 3-year impact of a passive CDST that notified providers when the test order cost was $ 1,000 or more. We determined the most common expensive tests ordered, the frequency with which providers abandoned the order after notification, and the costs saved through this intervention. Results: The average monthly abandonment rate was 12.5% (2014), 12.9% (2015), and 14.3% (2016). The cost savings from tests not performed for this 3-year period was $ 696,007. Molecular hematopathology assays were the most frequently ordered tests, with variable abandonment rates. Conclusions: Although this CDST was passive (ie, could be overridden at the point of order entry) and was associated with a relatively low abandonment rate, it achieved a considerable cost savings each year since each abandoned test saved the institution $ 1,000 or more.	[Riley, Jacquelyn D.; Stanley, Glenn; Wyllie, Robert; Kottke-Marchant, Kandice; Procop, Gary W.] Cleveland Clin, Cleveland, OH 44106 USA	Procop, GW (reprint author), Cleveland Clin, Enterprise Test Utilizat Pathol & Lab Med Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	procopg@ccf.org					Baron JM, 2014, CLIN CHIM ACTA, V427, P196, DOI 10.1016/j.cca.2013.09.027; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Chen SL, 2017, ANN SURG ONCOL, V24, P2836, DOI 10.1245/s10434-017-5954-8; Chien AT, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-1507; Durand DJ, 2013, J AM COLL RADIOL, V10, P108, DOI 10.1016/j.jacr.2012.06.020; Goetz C, 2015, J GEN INTERN MED, V30, P835, DOI 10.1007/s11606-015-3226-5; Horn DM, 2014, J GEN INTERN MED, V29, P1332, DOI 10.1007/s11606-014-2945-3; Horn DM, 2014, J GEN INTERN MED, V29, P708, DOI 10.1007/s11606-013-2672-1; McLawhorn AS, 2017, CURR REV MUSCULOSKE, V10, P370, DOI 10.1007/s12178-017-9423-6; Miller K, 2015, ARCH PATHOL LAB MED, V139, P1020, DOI 10.5858/arpa.2013-0705-OA; Neilson EG, 2004, ANN INTERN MED, V141, P196, DOI 10.7326/0003-4819-141-3-200408030-00008; Porter ME, 2009, NEW ENGL J MED, V361, P109, DOI 10.1056/NEJMp0904131; Procop GW, 2015, AM J CLIN PATHOL, V143, P623, DOI 10.1309/AJCPJOJ3HKEBD3TU; Procop GW, 2014, AM J CLIN PATHOL, V141, P718, DOI 10.1309/AJCPOWHOIZBZ3FRW; Riley JD, 2015, J MOL DIAGN, V17, P225, DOI 10.1016/j.jmoldx.2015.01.003; Sedrak MS, 2017, JAMA INTERN MED, V177, P939, DOI 10.1001/jamainternmed.2017.1144; Silvestri MT, 2016, J HOSP MED, V11, P65, DOI 10.1002/jhm.2500	17	3	3	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JUN	2018	149	6					530	535		10.1093/AJCP/AQY021			6	Pathology	Pathology	GE3UM	WOS:000431138400008	29635311				2019-10-28	
J	Sanchez, I; Betsou, F; Culot, B; Frasquilho, S; McKay, SC; Pericleous, S; Smith, C; Thomas, G; Mathieson, W				Sanchez, Ignacio; Betsou, Fay; Culot, Benedicte; Frasquilho, Sonia; McKay, Siobhan C.; Pericleous, Stephanos; Smith, Colleen; Thomas, Gerry; Mathieson, William			RNA and microRNA Stability in PAXgene-Fixed Paraffin-Embedded Tissue Blocks After Seven Years' Storage	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article							NUCLEIC-ACIDS; FRESH-FROZEN; FORMALIN; FIXATION; QUALITY; CANCER; HISTOMORPHOLOGY; MORPHOLOGY; SYSTEM; FFPE	Objectives: To evaluate the stability of RNA and microRNA (miRNA) in PAXgene-fixed paraffin-embedded tissue blocks after 7 years' storage. Methods: RNA and miRNA were extracted from PAXgene-fixed paraffin-embedded (PFPE) blocks in 2009 then stored at -80 degrees C. Seven years later, RNA and miRNA were again extracted from the same blocks. RNA and miRNA integrity in the 2009 and 2016 extractions were compared using RNA integrity number (RIN), paraffin-embedded RNA metric (PERM), reverse transcription polymerase chain reaction (RT-PCR) for different amplicon lengths, and quantitative RT-PCR (qRT-PCR) for three mRNA and three miRNA targets. Results: In PFPE blocks, mRNA was poorer in 2016 extractions compared to the 2009 extractions in all blocks and all assays applied, with transcripts degrading at different rates in the same blocks. For miRNA, qRT-PCR showed no statistically significant differences between 2009 and 2016 extractions. Conclusions: mRNA in PFPE tissue blocks degrades at room temperature storage over 7 years.	[Sanchez, Ignacio; Betsou, Fay; Culot, Benedicte; Frasquilho, Sonia; Mathieson, William] Integrated Biobank Luxembourg, 1 Rue Louis Rech, L-3555 Dudelange, Luxembourg; [McKay, Siobhan C.; Pericleous, Stephanos; Thomas, Gerry] Imperial Coll London, Dept Surg & Canc, London, England; [Smith, Colleen] Singleton Hosp, Wales Canc Bank, Swansea, W Glam, Wales	Mathieson, W (reprint author), Integrated Biobank Luxembourg, 1 Rue Louis Rech, L-3555 Dudelange, Luxembourg.	William.Mathieson@ibbl.lu		Pericleous, Stephanos/0000-0002-9058-7946	Integrated Biobank of Luxembourg	This work was supported by internal funds from the Integrated Biobank of Luxembourg.	Aggerholm-Pedersen N, 2014, TRANSL ONCOL, V7, P687, DOI 10.1016/j.tranon.2014.09.012; Andersen GB, 2015, ANAL BIOCHEM, V468, P50, DOI 10.1016/j.ab.2014.09.012; Andreasson A, 2013, BIOPRESERV BIOBANK, V11, P366, DOI 10.1089/bio.2013.0038; Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110; Bao WG, 2013, ANN SURG ONCOL, V20, P1737, DOI 10.1245/s10434-012-2440-1; Belloni B, 2013, J CLIN PATHOL, V66, P124, DOI 10.1136/jclinpath-2012-200983; Buesa RJ, 2008, ANN DIAGN PATHOL, V12, P387, DOI 10.1016/j.anndiagpath.2008.07.004; Carithers LJ, 2015, BIOPRESERV BIOBANK, V13, P311, DOI 10.1089/bio.2015.0032; Chung JY, 2016, BIOTECHNIQUES, V60, P239, DOI 10.2144/000114415; Craft WF, 2014, PEERJ, V2, DOI 10.7717/peerj.377; Ergin B, 2010, J PROTEOME RES, V9, P5188, DOI 10.1021/pr100664e; Groelz D, 2014, VIRCHOWS ARCH, V465, pS322; Gundisch S, 2014, VIRCHOWS ARCH, V465, P509, DOI 10.1007/s00428-014-1624-4; Gundisch S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060638; Hognas G, 2018, AM J SURG PATHOL, V42, P103, DOI 10.1097/PAS.0000000000000961; Kap M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027704; Mathieson W, 2016, J CLIN PATHOL, V69, P1105, DOI 10.1136/jclinpath-2016-203697; Mathieson W, 2016, AM J CLIN PATHOL, V146, P25, DOI 10.1093/ajcp/aqw023; Oberauner-Wappis L, 2016, INT J EXP PATHOL, V97, P202, DOI 10.1111/iep.12185; Opitz L, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-36; Ravo M, 2008, LAB INVEST, V88, P430, DOI 10.1038/labinvest.2008.11; Srinivasan M, 2002, AM J PATHOL, V161, P1961, DOI 10.1016/S0002-9440(10)64472-0; Staff S, 2013, J CLIN PATHOL, V66, P807, DOI 10.1136/jclinpath-2012-201283; Stewart JP, 2017, BBA-REV CANCER, V1868, P258, DOI 10.1016/j.bbcan.2017.05.005; Strand C, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-38; Thompson KL, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-57; Tramm T, 2013, DIAGN MOL PATHOL, V22, P181, DOI 10.1097/PDM.0b013e318285651e; Urban C, 2018, BBA-GEN SUBJECTS, V1862, P51, DOI 10.1016/j.bbagen.2017.10.005; Viertler C, 2012, J MOL DIAGN, V14, P458, DOI 10.1016/j.jmoldx.2012.05.002	29	4	4	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JUN	2018	149	6					536	547		10.1093/AJCP/AQY026			12	Pathology	Pathology	GE3UM	WOS:000431138400009	29659661				2019-10-28	
J	Yu, BH; Li, BZ; Zhou, XY; Shi, DR; Yang, WT				Yu, Bao-Hua; Li, Bai-Zhou; Zhou, Xiao-Yan; Shi, Da-Ren; Yang, Wen-Tao			Cytoplasmic FOXP1 expression is correlated with ER and calpain II expression and predicts a poor outcome in breast cancer	DIAGNOSTIC PATHOLOGY			English	Article						Breast cancer; FOXP1; ER; Calpain II; AKT pathway; Immunohistochemistry; Survival	FORKHEAD TRANSCRIPTION FACTOR; PROSTATE-CANCER; CELL-MIGRATION; CHROMOSOME 3P; RECEPTOR; CARCINOMAS; SURVIVAL; SYSTEM; GENES; BETA	Background: Nuclear forkhead box protein P1 (N-FOXP1) expression in invasive breast cancer has been documented in the literature. However, the FOXP1 expression patterns at different stages of breast cancer progression are largely unknown, and the significance of cytoplasmic FOXP1 (C-FOXP1) expression in breast cancer has not been well illustrated. The aims of this study were to investigate FOXP1 expression patterns in invasive ductal carcinoma (IDC), ductal carcinoma in situ (DCIS), atypical ductal hyperplasia (ADH) and usual ductal hyperplasia (UDH), and to analyze the clinicopathological relevance of C-FOXP1 and its prognostic value in IDC. Methods: N-FOXP1 and C-FOXP1 expression in cases of IDC, DCIS, ADH and UDH was determined using immunohistochemistry. The correlation between C-FOXP1 expression and clinicopathological parameters as well as the overall survival (OS) and disease-free survival (DFS) rates of patients with IDC were analyzed. Results: Exclusive N-FOXP1 expression was found in 85.0% (17/20), 40.0%(8/20), 12.2% (5/41) and 10.8% (9/83) of UDH, ADH, DCIS, and IDC cases, respectively, and exclusive C-FOXP1 expression was observed in 0% (0/20), 0% (0/20), 4.9% (2/41), and 31.3% (26/83) of the cases, respectively. Both N-and C-FOXP1 staining were observed in 15.0% (3/20), 60.0% (12/20), 82.9% (34/41) and 48.2% (40/83) of the above cases, respectively, while complete loss of FOXP1 expression was observed in only 9.6% (8/83) of IDC cases. Estrogen receptor (ER) expression in C-FOXP1-positive IDC cases (31/66, 47.0%) was significantly lower than that in C-FOXP1-negative cases (13/17, 76.5%) (p = 0.030). Calpain II expression was observed in 83.3% (55/66) of C-FOXP1-positive IDC cases, which was significantly higher than that in C-FOXP1-negative cases (9/17, 52.9%) (p = 0.007). Calpain II was significantly associated with pAKT (p = 0.029), pmTOR (p = 0.011), p4E-BP1 (p < 0.001) and p-p70S6K (p = 0.003) expression levels. The 10-year OS and DFS rates of the C-FOXP1-positive patients were 60.5% and 48.7%, respectively, both of which were lower than those of the C-FOXP1-negative patients (93.3, 75.3%). The OS curve showed a dramatic impact of C-FOXP1 status on OS (p = 0.045). Conclusions: Cytoplasmic relocalization of FOXP1 protein was a frequent event in breast IDC. Calpain II might play an important role in nucleocytoplasmic trafficking of FOXP1 and the AKT pathway might be involved in this process. C-FOXP1 expression was inversely associated with ER expression and might be a predictor of poor OS in patients with IDC.	[Yu, Bao-Hua; Zhou, Xiao-Yan; Shi, Da-Ren; Yang, Wen-Tao] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Dong An Rd 270, Shanghai 200032, Peoples R China; [Yu, Bao-Hua; Zhou, Xiao-Yan; Shi, Da-Ren; Yang, Wen-Tao] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China; [Li, Bai-Zhou] Zhejiang Univ, Affiliated Hosp 2, Dept Pathol, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China	Zhou, XY (reprint author), Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Dong An Rd 270, Shanghai 200032, Peoples R China.; Zhou, XY (reprint author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China.	xyzhou100@163.com			youth project of National Nature Science Funding of China [81700195]; Shanghai Hospital Development Center Emerging Advanced Technology Joint Research Project [SHDC12014105]	This study was supported by grants from the youth project of National Nature Science Funding of China (No. 81700195) and Shanghai Hospital Development Center Emerging Advanced Technology Joint Research Project (SHDC12014105).	Ackermann S, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-840; Banham AH, 2001, CANCER RES, V61, P8820; Banham AH, 2007, PROSTATE, V67, P1091, DOI 10.1002/pros.20583; Bates GJ, 2008, BREAST CANCER RES TR, V111, P453, DOI 10.1007/s10549-007-9812-4; Delmas C, 2003, J BIOL CHEM, V278, P12443, DOI 10.1074/jbc.M209523200; Dey N, 2017, PHARMACOL THERAPEUT, V175, P91, DOI 10.1016/j.pharmthera.2017.02.037; Fox SB, 2004, CLIN CANCER RES, V10, P3521, DOI 10.1158/1078-0432.CCR-03-0461; Giatromanolaki A, 2006, MODERN PATHOL, V19, P9, DOI 10.1038/modpathol.3800494; Gil-Parrado S, 2002, J BIOL CHEM, V277, P27217, DOI 10.1074/jbc.M202945200; Goatly A, 2008, MODERN PATHOL, V21, P902, DOI 10.1038/modpathol.2008.74; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Guerrero-Zotano A, 2016, CANCER METAST REV, V35, P515, DOI 10.1007/s10555-016-9637-x; Guicciardi ME, 2003, CANCER BIOL THER, V2, P153, DOI 10.4161/cbt.2.2.349; Halacli SO, 2017, CELL BIOL INT, V41, P102, DOI 10.1002/cbin.10702; Halacli SO, 2015, ONCOL LETT, V9, P1482, DOI 10.3892/ol.2015.2885; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; Ho WC, 2012, J BIOL CHEM, V287, P15458, DOI 10.1074/jbc.M112.349308; Hu ZH, 2015, TUMOR BIOL, V36, P7269, DOI 10.1007/s13277-015-3383-5; Ijichi N, 2013, VITAM HORM, V93, P203, DOI 10.1016/B978-0-12-416673-8.00006-X; Ijichi N, 2012, HORM CANCER-US, V3, P147, DOI 10.1007/s12672-012-0111-0; Katoh M, 2013, CANCER LETT, V328, P198, DOI 10.1016/j.canlet.2012.09.017; Kim SJ, 2004, INT J MOL MED, V14, P289; Koon HB, 2007, EXPERT OPIN THER TAR, V11, P955, DOI 10.1517/14728222.11.7.955; Lakhani SREI, 2012, WHO CLASSIFICATION T; Li CL, 2017, ONCOL LETT, V13, P3889, DOI 10.3892/ol.2017.5896; Libertini SJ, 2005, CANCER RES, V65, P10700, DOI 10.1158/0008-5472.CAN-05-1666; Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3; Rayoo M, 2009, J CLIN PATHOL, V62, P896, DOI 10.1136/jcp.2009.065169; Rios-Doria J, 2004, CANCER RES, V64, P7237, DOI 10.1158/0008-5472.CAN-04-1048; Rios-Doria J, 2003, J BIOL CHEM, V278, P1372, DOI 10.1074/jbc.M208772200; Shigekawa Takashi, 2011, Hormones & Cancer, V2, P286, DOI 10.1007/s12672-011-0082-6; Shu WG, 2001, J BIOL CHEM, V276, P27488, DOI 10.1074/jbc.M100636200; Storr SJ, 2012, ANN ONCOL, V23, P2289, DOI 10.1093/annonc/mds176; Storr SJ, 2016, ONCOTARGET, V7, P47927, DOI 10.18632/oncotarget.10066; Storr SJ, 2015, PATHOBIOLOGY, V82, P133, DOI 10.1159/000430464; Takayama K, 2014, MOL ENDOCRINOL, V28, P2012, DOI 10.1210/me.2014-1171; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Wu N, 2018, TECHNOL CANCER RES T, V17, DOI 10.1177/1533033818758772; Xiao J, 2016, SCI REP-UK, V6, DOI 10.1038/srep30437; Xu LJ, 2004, J BIOL CHEM, V279, P53683, DOI 10.1074/jbc.M409889200; Xu T, 2017, J CANCER, V8, P3838, DOI 10.7150/jca.21051; Yu BH, 2011, ANN HEMATOL, V90, P701, DOI 10.1007/s00277-010-1124-9; Zhang YX, 2012, J CLIN PATHOL, V65, P528, DOI 10.1136/jclinpath-2011-200547; Zhao XS, 2004, BIOCHEM J, V378, P839, DOI 10.1042/BJ20031450	44	2	2	1	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	MAY 30	2018	13								36	10.1186/s13000-018-0715-y			9	Pathology	Pathology	GH9ER	WOS:000433972500001	29848352	DOAJ Gold, Green Published			2019-10-28	
J	Chkioua, L; Boudabous, H; Jaballi, I; Grissa, O; Ben Turkia, H; Tebib, N; Laradi, S				Chkioua, Latifa; Boudabous, Hela; Jaballi, Ibtissem; Grissa, Oussama; Ben Turkia, Hadhami; Tebib, Neji; Laradi, Sandrine			Novel splice site IDUA gene mutation in Tunisian pedigrees with hurler syndrome	DIAGNOSTIC PATHOLOGY			English	Article						Mucopolysaccharidosis type I; alpha-L-iduronidase; Splice site mutation; Homozygous; Compound heterozygote	ALPHA-L-IDURONIDASE; MUCOPOLYSACCHARIDOSIS TYPE; I PATIENTS; IDENTIFICATION	Background: The mucopolysaccharidosis type I (MPS I) is a lysosomal storage disease resulting from the defective activity of the enzyme alpha-L-iduronidase (IDUA). The disease has three major clinical subtypes (severe Hurler syndrome, intermediate Hurler-Scheie syndrome and attenuated Scheie syndrome). We aim to identify the genetic variants in MPS I patients and to investigate the effect of the novel splice site mutation on splicing of IDUA-mRNA variability using bioinformatics tools. Methods: The IDUA mutations were determined in four MPS I patients from four families from Northern Tunisia, by amplifying and sequencing each of the IDUA exons and intron-exon junctions. Results: One novel splice site IDUA mutation, c.1650+1G> T in intron 11 and two previously reported mutations, p.A75T and p.R555H, were detected. The patients in families 1 and 2 who have the Hurler phenotype were homozygotes for the novel splice site mutation c.1650 + 1G > T. The patient in family 3, who also had the Hurler phenotype, was a compound heterozygote for the novel splice site mutation c.1650 + 1G > T and for the previously reported missense mutation p.A75T. The patient in family 4 who had the Hurler-Scheie phenotype was a compound heterozygote for the novel splice site mutation c.1650 + 1G > T and for the previously reported missense mutation p.R555H. In addition, four known IDUA polymorphisms were identified. Bioinformatics tools allowed us to associate the variant c.1650 + 1G > T with the severe clinical phenotype of MPS I. This variant affects the essential nucleotide + 1 (G to T) of the donor splice site of IDUA intron 11. The G > T in intron 11 leads to wild type donor site broken with minus 19.97% value compared to normal value with 0%, hence the new splice site acceptor has plus 5.59%. Conclusions: The present findings indicate that the identified mutations facilitate the accurate carrier detection (genetic counseling of at-risk relatives) and the molecular prenatal diagnosis in Tunisia.	[Chkioua, Latifa; Jaballi, Ibtissem; Grissa, Oussama] Univ Monastir, Fac Pharm, Monastir 5000, Tunisia; [Boudabous, Hela; Ben Turkia, Hadhami; Tebib, Neji] La Rabta Hosp, Tunis 1007, Tunisia; [Laradi, Sandrine] French Natl Blood Syst EFS GIMAP EA 3064, Auvergne Rhone Alpes Reg Branch, F-42023 St Etienne, France; [Chkioua, Latifa] Univ Monastir, Fac Pharm Monastir, Ave Avicenne, Monastir 5019, Tunisia	Chkioua, L (reprint author), Univ Monastir, Fac Pharm, Monastir 5000, Tunisia.; Chkioua, L (reprint author), Univ Monastir, Fac Pharm Monastir, Ave Avicenne, Monastir 5019, Tunisia.	chkioualatifa2002@yahoo.fr					BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Chkioua L, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-113; Chkioua L, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-47; Chkioua L, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-39; CLARKE LA, 1994, HUM MUTAT, V3, P275, DOI 10.1002/humu.1380030316; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; HOPWOOD JJ, 1979, CLIN SCI, V57, P265, DOI 10.1042/cs0570265; Laradi S, 2005, J INHERIT METAB DIS, V28, P1019, DOI 10.1007/s10545-005-0197-4; Maniatis T., 1982, MOL CLONING LAB MANU; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Neufeld EF, 2001, METABOLIC MOL BASES, P3421; SCOTT HS, 1991, P NATL ACAD SCI USA, V88, P9695, DOI 10.1073/pnas.88.21.9695; SCOTT HS, 1995, HUM MUTAT, V6, P288, DOI 10.1002/humu.1380060403; Skjorringe T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018599; Stone JE, 1998, ANN CLIN BIOCHEM, V35, P207, DOI 10.1177/000456329803500204; Varon R, 2006, HUM MOL GENET, V15, P679, DOI 10.1093/hmg/ddi482; Venturi N, 2002, HUM MUTAT, V20, DOI 10.1002/humu.9051	17	1	1	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	MAY 29	2018	13								35	10.1186/s13000-018-0710-3			8	Pathology	Pathology	GH9EP	WOS:000433972300001	29843745	DOAJ Gold, Green Published			2019-10-28	
J	Moore, AM; Moshkin, O; Swain, GJ; Crocker, S; LeBrun, DP				Moore, Alison M.; Moshkin, Olga; Swain, Gordon J.; Crocker, Susan; LeBrun, David P.			High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma	DIAGNOSTIC PATHOLOGY			English	Article						Composite lymphoma; Double-hit lymphoma; High-grade B-cell lymphoma; Diffuse large B-cell lymphoma; Follicular lymphoma; Chronic lymphocytic leukemia; Small lymphocytic lymphoma; Cytogenetics; MYC; BCL2	FOLLICULAR LYMPHOMA; BICLONAL LYMPHOMAS; TRANSFORMATION	Background: We report the first case of composite lymphoma consisting of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), follicular lymphoma (FL) and high-grade B-cell lymphoma with MYC and BCL2 rearrangements within the same needle biopsy in which a clonal relationship between the FL and high-grade B-cell lymphoma components was demonstrated by molecular cytogenetics. Case presentation: An 85-year-old man presented with masses in his neck and right groin. Cutting needle biopsy of the inguinal mass revealed the three lymphoma types which were morphologically, immunophenotypically and topographically distinct. Fluorescence in situ hybridization (FISH) identified an IGH-BCL2 rearrangement in both the FL and high-grade B-cell components while a MYC rearrangement was detected in the high-grade B-cell component alone. Conclusions: Our findings suggest that the high-grade lymphoma with MYC and BCL2 translocations evolved through transformation of the FL by a process that entailed acquisition of the MYC translocation. No clonal relationship between the FL and CLL/SLL components was evident since the IGH-BCL2 rearrangement was present in in the former but not the latter. This unique case of co-localized FL, CLL/SLL, and high-grade B-cell lymphoma contributes to our understanding of the clonal relationships that may exist between the components of composite lymphomas.	[Moore, Alison M.; Crocker, Susan; LeBrun, David P.] Queens Univ, Dept Pathol & Mol Med, Kingston, ON, Canada; [Moshkin, Olga; Swain, Gordon J.] Peterborough Reg Hlth Ctr, Peterborough, ON, Canada	LeBrun, DP (reprint author), Queens Univ, Dept Pathol & Mol Med, Kingston, ON, Canada.	dpl1@queensu.ca					Abramson JS, 2016, HEMATOL ONCOL CLIN N, V30, P1239, DOI 10.1016/j.hoc.2016.07.005; Aukema SM, 2017, HISTOPATHOLOGY, V71, P960, DOI 10.1111/his.13316; Boiocchi L, 2012, AM J CLIN PATHOL, V137, P647, DOI 10.1309/AJCPHXO5UGW2OELA; Carlotti E, 2009, BLOOD, V113, P3553, DOI 10.1182/blood-2008-08-174839; diSibio G, 2010, EXP MOL PATHOL, V89, P260, DOI 10.1016/j.yexmp.2010.07.001; Fend F, 1999, AM J PATHOL, V154, P1857, DOI 10.1016/S0002-9440(10)65443-0; FOON KA, 1993, ANN INTERN MED, V119, P63, DOI 10.7326/0003-4819-119-1-199307010-00011; Koshy J, 2014, INT J CLIN EXP PATHO, V7, P407; Kuppers R, 2014, LANCET ONCOL, V15, pE435, DOI 10.1016/S1470-2045(14)70153-6; Pasqualucci L, 2014, CELL REP, V6, P130, DOI 10.1016/j.celrep.2013.12.027; Savage KJ, 2009, BLOOD, V114, P3533, DOI 10.1182/blood-2009-05-220095; Zhang H, 2011, J HEMATOP, V4, P165	12	0	0	1	1	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	MAY 24	2018	13								34	10.1186/s13000-018-0714-z			4	Pathology	Pathology	GH0QL	WOS:000433107000002	29793519	DOAJ Gold, Green Published			2019-10-28	
J	Ren, JL; Liu, TT; Han, Y; Wang, QZ; Chen, YZ; Li, G; Jiang, LH				Ren, Jialin; Liu, Tingting; Han, Yang; Wang, Qiongzi; Chen, Yanzhi; Li, Guang; Jiang, Lihong			GSK-3 beta inhibits autophagy and enhances radiosensitivity in non-small cell lung cancer	DIAGNOSTIC PATHOLOGY			English	Article						X-rays; Non-small cell lung cancer; GSK-3 beta; Autophagy; Radiosensitivity	BREAST-TUMOR CELLS; REGULATES AUTOPHAGY; PROSTATE-CANCER; RADIATION; CONTRIBUTES; PROMOTES; GROWTH; RADIORESISTANCE; DEGRADATION; VITAMIN-D-3	Background: Radiotherapy is one of the most common and effective treatment methods for cancer, and improving the radiosensitivity of tumor tissues during the treatment process is vital. We report the mechanisms of glycogen synthase kinase 3 (GSK-3) beta-regulated autophagy and the effects of autophagy on radiosensitivity in non-small cell lung cancer (NSCLC). Method: Immunohistochemical staining was performed to determine GSK-3 beta tissue expression in 89 NSCLC patients with follow-up data and the expression status of GSK-3 beta and autophagy in NSCLC tissues after X-ray radiotherapy. Western blots were used to quantitate changes in autophagy-related protein expression after A549 cells were treated with GSK-3 beta inhibitors and after H460 cells were transfected with GSK-3 beta mutants with different activities and X-ray irradiated. Clonogenic assays were used to measure the effect of autophagy on cellular proliferation. Results: GSK-3 beta expression positively correlated with NSCLC differentiation (P < 0.05), and GSK-3 beta negativity was associated with a better prognosis in 89 NSCLC patients. After X-ray irradiation, the expression levels of GSK-3 beta and p62 were decreased in NSCLC tissues, and the expression levels of the autophagy-related protein LC3 were increased. A549 and H460 cells were selected as representative GSK-3 beta-high and GSK-3 beta-low expression cell lines. After transfecting H460 cells with different GSK-3 beta mutants [wild type GSK-3 beta (GSK-3 beta-WT), constitutively active GSK-3 beta (GSK-3 beta-S9A), and catalytically inactive GSK-3 beta (GSK-3 beta-K85R)] and subjecting these cells to X-ray irradiation, AMPK and LC3 expression levels decreased, and p62 expression levels increased. These effects were particularly significant for the GSK-3 beta-S9A mutant. In A549 cells, after GSK-3 beta inhibition and X-ray irradiation, AMPK and LC3 protein expression levels increased. Moreover, when autophagy was inhibited, cell proliferation decreased. Conclusion: Our studies revealed that GSK-3 beta expression is associated with NSCLC differentiation, and patients with GSK-3 beta-negative tumors had a better prognosis. X-ray irradiation inhibited GSK-3 beta expression and promoted autophagy. Therefore, GSK-3 beta inhibits autophagy and enhances the radiosensitivity of NSCLC cells.	[Ren, Jialin; Han, Yang; Wang, Qiongzi] China Med Univ, Affiliated Hosp 1, Dept Pathol, Shenyang 110001, Peoples R China; [Ren, Jialin; Han, Yang; Wang, Qiongzi] China Med Univ, Coll Basic Med Sci, Shenyang 110001, Peoples R China; [Liu, Tingting] China Med Univ, Affiliated Hosp 1, Dept Surg, Shenyang, Liaoning, Peoples R China; [Chen, Yanzhi] China Med Univ, Affiliated Hosp 4, Dept Radiotherapy, Shenyang, Liaoning, Peoples R China; [Li, Guang] China Med Univ, Affiliated Hosp 1, Dept Radiotherapy, Shenyang, Liaoning, Peoples R China; [Jiang, Lihong] Gen Hosp Liaohe Oilfield, Dept Pathol, Panjin, Peoples R China	Han, Y (reprint author), China Med Univ, Affiliated Hosp 1, Dept Pathol, Shenyang 110001, Peoples R China.; Han, Y (reprint author), China Med Univ, Coll Basic Med Sci, Shenyang 110001, Peoples R China.	18900911058@189.cn			Liaoning Nature Science Foundation [2015020491]; National Nature Science Foundation of ChinaNational Natural Science Foundation of China [81000995]	This work was supported by the Liaoning Nature Science Foundation (grant No. 2015020491 to Yang Han) and the National Nature Science Foundation of China (grant No. 81000995 to Yang Han).	Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562; Azoulay-Alfaguter I, 2015, ONCOGENE, V34, P4613, DOI 10.1038/onc.2014.390; Bristol ML, 2012, AUTOPHAGY, V8, P739, DOI 10.4161/auto.19313; Bristol ML, 2013, J PHARMACOL EXP THER, V344, P544, DOI 10.1124/jpet.112.199802; Cao C, 2006, CANCER RES, V66, P10040, DOI 10.1158/0008-5472.CAN-06-0802; Cerniglia GJ, 2012, MOL PHARMACOL, V82, P1230, DOI 10.1124/mol.112.080408; Chang ZX, 2013, INT J MOL MED, V31, P1449, DOI 10.3892/ijmm.2013.1351; DeMasters G, 2006, MOL CANCER THER, V5, P2786, DOI 10.1158/1535-7163.MCT-06-0316; Fan QW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001017; Fujiwara K, 2007, INT J ONCOL, V31, P753; Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966; Gewirtz DA, 2009, RADIOTHER ONCOL, V92, P323, DOI 10.1016/j.radonc.2009.05.022; Gwak HS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047449; Han Y, 2009, INT J RADIAT ONCOL, V75, P518, DOI 10.1016/j.ijrobp.2009.05.040; Hu BC, 2017, J BIOL CHEM, V292, P3531, DOI 10.1074/jbc.M116.772392; Juzenas P, 2008, ADV DRUG DELIVER REV, V60, P1600, DOI 10.1016/j.addr.2008.08.004; Kenific CM, 2015, TRENDS CELL BIOL, V25, P37, DOI 10.1016/j.tcb.2014.09.001; Kitano A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055289; Liang B, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-213; Lin SY, 2012, SCIENCE, V336, P477, DOI 10.1126/science.1217032; Liu H, 2013, AUTOPHAGY, V9, P730, DOI 10.4161/auto.24039; Liu LY, 2011, AUTOPHAGY, V7, P112, DOI 10.4161/auto.7.1.14005; Luo J, 2009, CANCER LETT, V273, P194, DOI 10.1016/j.canlet.2008.05.045; Marchand B, 2015, J BIOL CHEM, V290, P5592, DOI 10.1074/jbc.M114.616714; Nagarajan D, 2012, FREE RADICAL BIO MED, V52, P983, DOI 10.1016/j.freeradbiomed.2011.11.024; O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066; Parr C, 2012, MOL CELL BIOL, V32, P4410, DOI 10.1128/MCB.00930-12; Peng PL, 2008, INT J RADIAT ONCOL, V70, P529, DOI 10.1016/j.ijrobp.2007.08.034; Qi YL, 2014, CANCER RES, V74, P3740, DOI 10.1158/0008-5472.CAN-13-3182; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Seok S, 2014, NATURE, V516, P108, DOI 10.1038/nature13949; Turner LS, 2011, PROSTATE CANCER P D, V14, P30, DOI 10.1038/pcan.2010.47; Wang P, 2013, GASTROENTEROLOGY, V145, P1133, DOI 10.1053/j.gastro.2013.07.048; Yang J, 2010, J CELL SCI, V123, P861, DOI 10.1242/jcs.060475; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Yang Y, 2012, INT J ONCOL, V41, P1782, DOI 10.3892/ijo.2012.1620; Yu L, 2012, NEOPLASIA, V14, P1203, DOI 10.1593/neo.121310; Zhang XD, 2014, ADV MATER, V26, P4565, DOI 10.1002/adma.201400866	38	2	2	0	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	MAY 24	2018	13								33	10.1186/s13000-018-0708-x			10	Pathology	Pathology	GH0QL	WOS:000433107000001	29793508	DOAJ Gold, Green Published			2019-10-28	
J	Agarwal, P; Kaushal, M; Dogra, S; Gupta, A; Sharma, N				Agarwal, Poojan; Kaushal, Manju; Dogra, Shruti; Gupta, Ankur; Sharma, Nishi			Retropharyngeal SOL:An unusual presentation of a multifaceted entity	CYTOJOURNAL			English	Editorial Material							PULMONARY TUBERCULOSIS; COLD ABSCESS; SPINE		[Agarwal, Poojan; Kaushal, Manju; Dogra, Shruti] Dr RML Hosp, PGIMER, Dept Pathol, New Delhi, India; [Gupta, Ankur; Sharma, Nishi] Dr RML Hosp, PGIMER, Dept ENT, New Delhi, India	Agarwal, P (reprint author), Dr RML Hosp, PGIMER, Dept Pathol, New Delhi, India.	poojanagarwal@gmail.com; manju_kaushal@yahoo.com; d.shrutidogra@gmail.com; gupta.ankur39@yahoo.co.in; drsharmanish@yahoo.co.in					Agrawal M, 2016, J CLIN DIAGN RES, V10, pDC9, DOI 10.7860/JCDR/2016/18837.7755; Asano S, 2012, J CLIN EXP HEMATOP, V52, P1; Ekka M, 2015, LUNG INDIA, V32, P262, DOI 10.4103/0970-2113.156247; Greenwood D, 2012, MED MICROBIOLOGY GUI; Harkani A, 2011, THESCIENTIFICWORLDJO, V11, P1623, DOI 10.1100/2011/915163; Kothari PR, 2002, PEDIATR SURG INT, V18, P165, DOI 10.1007/s003830100678; Long SS, 2012, PRINCIPLES PRACTICE; Marques Pedro Miguel dos Santos, 2009, Braz. j. otorhinolaryngol., V75, P826, DOI 10.1590/S1808-86942009000600009; Ogah OS, 2012, ANN TROP MED PUBLIC, V5, P587, DOI 10.4103/1755-6783.109286; Park Sang-Hee, 2014, Osong Public Health Res Perspect, V5, pS3, DOI 10.1016/j.phrp.2014.10.006; Patil C, 2011, ASIAN PAC J TROP MED, V4, P251, DOI 10.1016/S1995-7645(11)60080-1; Rao MJ, 2013, INDIAN J PATHOL MICR, V56, P480, DOI 10.4103/0377-4929.125400; Shariff S, 2016, PRINCIPLES INTERPRET; Singh J, 2012, S AFR J SURG, V50, P137, DOI [10.7196/sajs.1383, 10.7196/SAJS.1383]; Zumla A, 1996, CLIN INFECT DIS, V23, P146, DOI 10.1093/clinids/23.1.146	15	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	MAY 22	2018	15								12	10.4103/cytojournal.cytojournal_15_17			4	Pathology	Pathology	GH4QE	WOS:000433388200001	29937916	DOAJ Gold, Green Published			2019-10-28	
J	Chen, Y; Khanna, A; Chen, JQ; Zhang, HZ; Caraway, NP; Katz, RL				Chen, Ying; Khanna, Abha; Chen, Jie Qing; Zhang, Hua Zhong; Caraway, Nancy P.; Katz, Ruth L.			Cytologic features, immunocytochemical findings, and DNA ploidy in four rare cases of epithelioid hemangioendothelioma involving effusions	CYTOJOURNAL			English	Article						Cytology; DNA ploidy; effusion; epithelioid; hemangioendothelioma; immunocytochemistry; proliferation index	SOFT-TISSUE TUMORS; OF-THE-LITERATURE; IMAGE-ANALYSIS; PLEURAL EFFUSION; TRANSCRIPTION FACTOR; CARCINOMA; CYTOMETRY; FLUID; MESOTHELIOMA; ANEUPLOIDY	Background: Epithelioid hemangioendothelioma (EHE) involving serous effusion is extremely rare, and the diagnosis can be challenging. DNA ploidy quantitation of EHE in effusion fluids has not been previously described in the English-language literature. Methods: Specimens of cytological diagnosed with EHE in effusion fluids between 2002 and 2009 were retrieved from the pathology files at MD Anderson Cancer Center. A total of four cases of EHE involving or arising from effusion fluids were found, and we reviewed cytospin, smears, cell block sections, and immunostained slides. DNA image analysis for ploidy and proliferation evaluation was performed on a destained, papanicolaou-stained slide from each case. Results: The tumor cells were epithelioid with prominent cytoplasmic vacuolization and intracytoplasmic inclusions, which could resemble reactive mesothelial cells, mesothelioma, or adenocarcinoma. The tumor cells were positive for endothelial markers. DNA image analysis in three of the four cases revealed predominantly diploid and tetraploid subpopulations, with few aneuploid cells and fairly low proliferation indices, and these patients had fairly prolonged survival. Conclusions: DNA image analysis is useful for differentiating EHE from reactive mesothelial cells and high-grade carcinoma. For accurate diagnosis of EHE in effusion fluids, cytologic features should be considered together with clinical history and ancillary studies.	[Chen, Ying] Fudan Univ, Shanghai Canc Ctr, Dept Pathol, Shanghai, Peoples R China; [Chen, Ying] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China; [Khanna, Abha; Chen, Jie Qing; Zhang, Hua Zhong; Caraway, Nancy P.; Katz, Ruth L.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	Katz, RL (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.	yingwxd@163.com; akhanna@mdanderson.org; jieqing_chen03@hotmail.com; huazhongg@gmail.com; ncaraway@mdanderson.org; rkatz@mdanderson.org					ABATI A, 1994, DIAGN CYTOPATHOL, V11, P64, DOI 10.1002/dc.2840110115; Anderson T, 2015, AM J SURG PATHOL, V39, P132, DOI 10.1097/PAS.0000000000000346; AUER GU, 1980, ANAL QUANT CYTOL, V2, P161; Bahrami A, 2008, PATHOL INT, V58, P730, DOI 10.1111/j.1440-1827.2008.02301.x; Bisht B, 2014, MALAY J PATHOL, V36, P83; BUGGAGE RR, 1995, DIAGN CYTOPATHOL, V13, P54, DOI 10.1002/dc.2840130112; Caraway NP, 2007, CANCER CYTOPATHOL, V111, P323, DOI 10.1002/cncr.22950; Chen Ying, 2015, J Am Soc Cytopathol, V4, P148, DOI 10.1016/j.jasc.2014.12.001; ELNAGGAR AK, 1991, HUM PATHOL, V22, P972, DOI 10.1016/0046-8177(91)90005-A; Enbom ET, 2014, ACTA CYTOL, V58, P211, DOI 10.1159/000357967; Errani C, 2011, GENE CHROMOSOME CANC, V50, P644, DOI 10.1002/gcc.20886; ETO H, 1992, HUM PATHOL, V23, P1055, DOI 10.1016/0046-8177(92)90269-9; Folpe AL, 2001, AM J SURG PATHOL, V25, P1061, DOI 10.1097/00000478-200108000-00011; Fujii T, 2008, MODERN PATHOL, V21, P125, DOI 10.1038/modpathol.3800986; Guidozzi F, 1996, GYNECOL ONCOL, V61, P204, DOI 10.1006/gyno.1996.0125; Kalof AN, 2009, ADV ANAT PATHOL, V16, P62, DOI 10.1097/PAP.0b013e3181915e94; Krishnamurthy S, 2001, CANCER CYTOPATHOL, V93, P229, DOI 10.1002/cncr.9034; Kurisu Y, 2011, DIAGN CYTOPATHOL, V39, P124, DOI 10.1002/dc.21377; Lau K, 2011, CHEST, V140, P1312, DOI 10.1378/chest.11-0039; Makhlouf HR, 1999, CANCER, V85, P562, DOI 10.1002/(SICI)1097-0142(19990201)85:3<562::AID-CNCR7>3.0.CO;2-T; Miettinen M, 2011, AM J SURG PATHOL, V35, P432, DOI 10.1097/PAS.0b013e318206b67b; Motherby H, 1998, ANAL QUANT CYTOL, V20, P153; NOWELS KW, 1989, DIAGN CYTOPATHOL, V5, P75, DOI 10.1002/dc.2840050114; Osterheld MC, 2005, DIAGN CYTOPATHOL, V32, P173, DOI 10.1002/dc.20205; Petersen S, 2000, BRIT J CANCER, V82, P65; Posligua L, 2006, INT J SURG PATHOL, V14, P257, DOI 10.1177/1066896906290682; SALMON I, 1995, AM J CLIN PATHOL, V103, P568; Saqi A, 2007, DIAGN CYTOPATHOL, V35, P203, DOI 10.1002/dc.20620; Sayah M, 2015, DIAGN CYTOPATHOL, V43, P751, DOI 10.1002/dc.23315; Segers K, 1996, LUNG CANCER, V14, P229, DOI 10.1016/0169-5002(95)00549-8; Shidham VB, 2007, CYTOPATHOLOGIC DIAGN, P55; SIRGI KE, 1993, AM J SURG PATHOL, V17, P179, DOI 10.1097/00000478-199302000-00009; Sturgis CD, 1999, CANCER CYTOPATHOL, V87, P155, DOI 10.1002/(SICI)1097-0142(19990625)87:3<155::AID-CNCR9>3.0.CO;2-#; Sun W, 2004, ACTA CYTOL, V48, P119, DOI 10.1159/000326303; Walts A, 1997, DIAGN CYTOPATHOL, V16, P372, DOI 10.1002/(SICI)1097-0339(199704)16:4<372::AID-DC15>3.0.CO;2-H; WEISS SW, 1982, CANCER, V50, P970, DOI 10.1002/1097-0142(19820901)50:5<970::AID-CNCR2820500527>3.0.CO;2-Z; Woodall CE, 2008, AM SURGEON, V74, P64; Zhang X, 2008, AM J SURG PATHOL, V32, P1327, DOI 10.1097/PAS.0b013e31816b6459	38	0	0	2	2	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	MAY 22	2018	15								13	10.4103/cytojournal.cytojournal_46_17			9	Pathology	Pathology	GH4QE	WOS:000433388200002	29937917	DOAJ Gold, Green Published			2019-10-28	
J	Li, PF; Ma, J; Zhang, XM; Guo, Y; Liu, YX; Li, X; Zhao, DH; Wang, Z				Li, Peifeng; Ma, Jing; Zhang, Xiumin; Guo, Yong; Liu, Yixiong; Li, Xia; Zhao, Danhui; Wang, Zhe			Cervical small cell carcinoma frequently presented in multiple high risk HPV infection and often associated with other type of epithelial tumors	DIAGNOSTIC PATHOLOGY			English	Article						Human papillomavirus; p16; p53; Small cell carcinoma; Uterine cervix	UTERINE CERVIX; HUMAN-PAPILLOMAVIRUS; CANCER; P16	Background: Small cell carcinoma of the uterine cervix is a rare and highly malignant tumor, and its etiopathogenesis is strongly related to high-risk HPV infections. Methods: The clinicopathological data of 30 cases of cervical primary small cell carcinoma were retrospectively analyzed. In situ hybridization, polymerase chain reaction and reverse dot-blot hybridization were employed to detect HPV DNA in both small cell carcinoma and other coexisting epithelial tumors. Immunohistochemistry was used to detect the protein expression of p16 and p53. Results: Amongst 30 patients with cervical primary small cell carcinoma, 15 patients simultaneously exhibited other types of epithelial tumors, including squamous cell carcinoma, adenocarcinoma, squamous cell carcinoma in situ, and adenocarcinoma in situ. Most tumor cells infected with HPV presented integrated patterns in the nuclei by in situ hybridization. HPV DNA was detected in every small cell carcinoma case (100%) by polymerase chain reaction and reverse dot blot hybridization. 27 cases (90%) harbored type 18, and 15 (50%) displayed multiple HPV18 and 16 infections. The prevalence of HPV 18 infection in small cell carcinoma was higher than in cervical squamous and glandular epithelial neoplasms (P =0.002). However, similar infection rates of HPV 16 were detected in both tumors (P=0.383). Both small cell carcinoma and other types of epithelial tumors exhibited strong nuclear and cytoplasmic staining for p16 in all cases. Three cases of small cell carcinoma revealed completely negative p53 immunohistochemical expression in 15 cases of composite tumors, which suggested TP53 nonsense mutation pattern. The pure small cell carcinoma of uterine cervix had similar mutation or wild type pattern for TP53 compared with composite tumor (P=0.224). Conclusions: Cervical small cell carcinomas are often associated with squamous or glandular epithelial tumors, which might result from multiple HPV infections, especially HPV 16 infection. Multiple HPV infections were not correlated with tumor stage, size, lymphovascular invasion, lymph node metastasis, or prognosis. Furthermore, careful observation of specimens is very important in finding little proportion of small cell carcinoma in the composite lesions, specifically in cervical biopsy specimens, in order to avoid the missed diagnosis of small cell carcinoma.	[Wang, Zhe] Fourth Mil Med Univ, State Key Lab Canc Biol, Dept Pathol, Xijing Hosp, Changle West Rd 169, Xian 710032, Shaanxi, Peoples R China; Fourth Mil Med Univ, Sch Basic Med, Changle West Rd 169, Xian 710032, Shaanxi, Peoples R China	Wang, Z (reprint author), Fourth Mil Med Univ, State Key Lab Canc Biol, Dept Pathol, Xijing Hosp, Changle West Rd 169, Xian 710032, Shaanxi, Peoples R China.	zhwang@fmmu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81272651, 81570180]	The study was funded by grants from the National Natural Science Foundation of China (81272651 and 81570180 to Zhe Wang).	ABELER VM, 1994, CANCER, V73, P672, DOI 10.1002/1097-0142(19940201)73:3<672::AID-CNCR2820730328>3.0.CO;2-R; Ahmad A, 2017, CANCER BIOMARK, V19, P375, DOI 10.3233/CBM-160060; Atienza-Amores M, 2014, GYNECOL ONCOL, V134, P410, DOI 10.1016/j.ygyno.2014.05.017; Carlson JW, 2007, HISTOPATHOLOGY, V51, P305, DOI 10.1111/j.1365-2559.2007.02790.x; Carow Katrin, 2017, BMC Res Notes, V10, P532, DOI 10.1186/s13104-017-2846-8; Chan JK, 2003, CANCER, V97, P568, DOI 10.1002/cncr.11086; Dores GM, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1188-y; Emerson RE, 2016, INT J GYNECOL PATHOL, V35, P372, DOI 10.1097/PGP.0000000000000254; Gadducci A, 2017, GYNECOL ONCOL, V144, P637, DOI 10.1016/j.ygyno.2016.12.003; Horn LC, 2007, INT J GYNECOL PATHOL, V26, P269, DOI 10.1097/01.pgp.0b013e318047fffc; Ishida GM, 2004, INT J GYNECOL PATHOL, V23, P366, DOI 10.1097/01.pgp.0000139637.01977.61; Li N, 2011, INT J CANCER, V128, P927, DOI 10.1002/ijc.25396; Lu JF, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2328-6; Masumoto N, 2003, HUM PATHOL, V34, P778, DOI 10.1016/S0046-8177(03)00284-3; Mazarico E, 2014, EUR J GYNAECOL ONCOL, V35, P378; Satoh T, 2014, INT J GYNECOL CANCER, V24, pS102, DOI 10.1097/IGC.0000000000000262; Small W, 2017, CANCER-AM CANCER SOC, V123, P2404, DOI 10.1002/cncr.30667; Togami S, 2015, PATHOL ONCOL RES, V21, P487, DOI 10.1007/s12253-014-9854-y; Wang HLL, 2004, AM J SURG PATHOL, V28, P901, DOI 10.1097/00000478-200407000-00009; Zhou J, 2017, ONCOTARGET, V8, P40425, DOI 10.18632/oncotarget.16390; Zhou Xiao Hui, 2017, Asian Pac J Cancer Prev, V18, P1875	21	1	2	0	0	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	MAY 22	2018	13								31	10.1186/s13000-018-0709-9			10	Pathology	Pathology	GH0QI	WOS:000433106700002	29788963	DOAJ Gold, Green Published			2019-10-28	
J	Mizutani, K; Yamada, S; Guo, X; Futatsuya, C; Kumagai, M; Shioya, A; Aikawa, A; Nakada, S; Kurose, N; Minato, H; Nojima, T				Mizutani, Kenichi; Yamada, Sohsuke; Guo, Xin; Futatsuya, Chizuru; Kumagai, Motona; Shioya, Akihiro; Aikawa, Akane; Nakada, Satoko; Kurose, Nozomu; Minato, Hiroshi; Nojima, Takayuki			An autopsy case of peripheral T cell lymphoma occurring in a postpartum woman: a unique case suggesting changes in the immunocharacteristics of lymphoma cells before and after delivery	DIAGNOSTIC PATHOLOGY			English	Article						Peripheral T cell lymphoma (PTCL); Autopsy; CD4; CD8; T helper 1 (Th1); T helper 2 (Th2); Pregnancy; Delivery	PREGNANCY; BREAST	Background: The occurrence of malignant lymphoma after delivery is an extremely rare event. Although several cases of Hodgkin lymphoma and B cell lymphoma and a few cases of peripheral T cell lymphoma (PTCL) after delivery have been reported, there are no report of autopsy cases of PTCL in the puerperal period. Case presentation: A 32-year-old Japanese woman with a past medical history of atopic dermatitis and bronchial asthma presented with generalized eruptions four days after the delivery of her first child; generalized skin induration and lymphadenopathy subsequently emerged. A skin biopsy specimen showed the diffuse proliferation of atypical lymphoid cells that were immunohistochemically-positive for CD4 but negative for CD8. She was diagnosed as PTCL, not otherwise specified (PTCL, NOS). She died one year and three months after the onset of symptoms. At autopsy, the systemic infiltration of lymphoma cells into the whole body was observed. Unexpectedly, these lymphoma cells were immuno-reactive with CD8 but not with CD4. Conclusion: The occurrence and development of PTCL after delivery with the shift from CD4 positivity to CD8 positivity may be associated with not only the selection of resistant subclone as a result of chemotherapy but also the changes of immune status before and after delivery.	[Mizutani, Kenichi; Yamada, Sohsuke; Guo, Xin; Futatsuya, Chizuru; Kumagai, Motona; Shioya, Akihiro; Aikawa, Akane; Nakada, Satoko; Kurose, Nozomu] Kanazawa Med Univ, Dept Pathol & Lab Med, 1-1 Daigaku, Kahoku, Ishikawa 9200293, Japan; [Mizutani, Kenichi] Kagoshima Univ, Dept Pathol, Grad Sch Med & Dent Sci, Field Oncol, 8-35-1 Sakuragaoka, Kagoshima, Kagoshima 8908544, Japan; [Minato, Hiroshi] Ishikawa Prefectural Cent Hosp, Dept Pathol, 2-1 Kuratsukihigashi, Kanazawa, Ishikawa 9208530, Japan; [Nojima, Takayuki] Kanazawa Univ Hosp, Dept Orthopaed Surg, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan	Mizutani, K (reprint author), Kanazawa Med Univ, Dept Pathol & Lab Med, 1-1 Daigaku, Kahoku, Ishikawa 9200293, Japan.; Mizutani, K (reprint author), Kagoshima Univ, Dept Pathol, Grad Sch Med & Dent Sci, Field Oncol, 8-35-1 Sakuragaoka, Kagoshima, Kagoshima 8908544, Japan.	mizutani@kanazawa-med.ac.jp		/0000-0001-5709-1968			Antoniou SA, 2010, EUR J OBSTET GYN R B, V152, P111, DOI 10.1016/j.ejogrb.2010.05.015; DURODOLA J I, 1976, International Journal of Gynecology and Obstetrics, V14, P225; Kato M, 2001, INT J HEMATOL, V74, P186, DOI 10.1007/BF02982003; Negahban S, 2010, MOL DIAGN THER, V14, P243, DOI 10.2165/11539350-000000000-00000; Nomizu T, 1986, Gan No Rinsho, V32, P1023; Raghupathy R, 1997, IMMUNOL TODAY, V18, P478, DOI 10.1016/S0167-5699(97)01127-4; Szegedi K, 2017, EXP DERMATOL, P1; Zwitter M, 1996, BRIT J CANCER, V73, P246, DOI 10.1038/bjc.1996.43	8	0	0	0	0	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	MAY 22	2018	13								32	10.1186/s13000-018-0707-y			5	Pathology	Pathology	GH0QI	WOS:000433106700003	29788970	DOAJ Gold, Green Published			2019-10-28	
J	Wang, HY; Li, ZW; Dong, B; Sun, W; Yang, X; Liu, RP; Zhou, LX; Huang, XZ; Jia, L; Lin, DM				Wang, Haiyue; Li, Zhongwu; Dong, Bin; Sun, Wei; Yang, Xin; Liu, Ruping; Zhou, Lixin; Huang, Xiaozheng; Jia, Ling; Lin, Dongmei			Prognostic significance of PD-L1 expression and CD8+T cell infiltration in pulmonary neuroendocrine tumors	DIAGNOSTIC PATHOLOGY			English	Article						Pulmonary neuroendocrine tumor; PD-L1; CD8+TILs	CANCER-IMMUNOTHERAPY; IMMUNE RESISTANCE; BREAST-CANCER; LUNG-CANCER; ANTI-PD-1; BLOCKADE; MELANOMA; PATHWAY; LYMPHOCYTES; ANTIBODIES	Background: Recent research supports a significant role of immune checkpoint inhibitors in the treatment of solid tumors. However, relevant reports for programmed death-ligand 1 (PD-L1) and CD8+ tumor-infiltrating lymphocytes (TILs) in pulmonary neuroendocrine tumors (PNETs) have not been fully studied. Therefore, we investigated PNETs for the expression of PD-L1 and infiltration by CD8+ TILs as well as the prognostic value of both factors. Methods: In total, 159 specimens of PNETs (35 TC, 2 AC, 28 LCNEC, 94 SCLC) were included in this study. Immunohistochemistry (IHC) was used to detect the expression of PD-L1 in these cases. Cases demonstrating >= 5% tumor cell expression or any expression (> 1%) of PD-L1 on immune cells were considered positive. CD8 + TILs both within stroma and tumor areas of invasive carcinoma were analyzed using whole-slide digital imaging. Manual regional annotation and machine cell counts were performed for each case. Results: Positive expression of PD-L1 was observed in 72 cases (45.3%), including 9 cases (5.7%) with expression exclusively on tumor cells, 46 cases (28.9%) with expression exclusively on immune cells, and 17 cases (10.7%) with the expression on tumor cells and immune cells. PD-L1 expression was associated with necrosis (p < 0.001), high pathologic grade (p < 0.001) and histologic type (p < 0.001). No correlation was observed with overall survival (OS) (p = 0.158) or progression-free survival (PFS) (p = 0.315). In contrast, higher CD8+ T cell density was associated with the absence of vascular invasion (p = 0.004), histologic type (p = 0.005), negative lymph node metastasis (p = 0.005) and lower clinical staging (p = 0.007). Moreover, multivariate analysis revealed that CD8+ stromal TIL was an independent prognostic factor for improved OS (p = 0.009) and PFS (p = 0.002). Conclusion: PD-L1 was expressed in approximately half of the PNETs. The majority of the expression was observed in immune cells. Positive expression of PD-L1 showed no correlation with OS or PFS, while higher CD8+ TILs within stroma was proved to be an independent prognostic factor for favorable OS and PFS of PNETs.	[Wang, Haiyue; Li, Zhongwu; Sun, Wei; Yang, Xin; Zhou, Lixin; Huang, Xiaozheng; Jia, Ling; Lin, Dongmei] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ, Dept Pathol, 52 Fucheng Rd, Beijing 100142, Peoples R China; [Dong, Bin] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ, Dept Cent Lab, Beijing 100142, Peoples R China; [Liu, Ruping] Beijing Inst Graph Commun, Beijing 102600, Peoples R China	Lin, DM (reprint author), Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ, Dept Pathol, 52 Fucheng Rd, Beijing 100142, Peoples R China.	lindm100142@163.com			Beijing Municipal Science and Technology Commission NOVA program [2010 B033]; Beijing Municipal Science and Technology Commission Capital Characteristic Clinical Application Research [Z141107002514077]; National Nature Science Foundation of ChinaNational Natural Science Foundation of China [61501039]; Beijing Cancer Hospital [13-11]	This study was supported by the Beijing Municipal Science and Technology Commission NOVA program (NO. 2010 B033), the Beijing Municipal Science and Technology Commission Capital Characteristic Clinical Application Research (No. Z141107002514077), the National Nature Science Foundation of China (No. 61501039), and grants from the funding of the Beijing Cancer Hospital (approval #:13-11).	Aerts JG, 2013, CANCER RES, V73, P2381, DOI 10.1158/0008-5472.CAN-12-3932; Bertino EM, 2009, CANCER-AM CANCER SOC, V115, P4434, DOI 10.1002/cncr.24498; Domagala-Kulawik J, 2015, TRANSL LUNG CANCER R, V4, P177, DOI 10.3978/j.issn.2218-6751.2015.01.11; Dushyanthen S, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0431-3; Fan YW, 2016, ONCOTARGETS THER, V9, P6075, DOI 10.2147/OTT.S115054; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Khoja L, 2016, BRIT J CANCER, V115, P1186, DOI 10.1038/bjc.2016.308; Lyford-Pike S, 2013, CANCER RES, V73, P1733, DOI 10.1158/0008-5472.CAN-12-2384; Metro G, 2012, EXPERT OPIN EMERG DR, V17, P31, DOI 10.1517/14728214.2012.656588; Ohaegbulam KC, 2015, TRENDS MOL MED, V21, P24, DOI 10.1016/j.molmed.2014.10.009; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Ramos-Esquivel A., 2017, ESMO OPEN, V2, DOI [10.1136/esmoopen-2017-000236, DOI 10.1136/ESMOOPEN-2017-000236]; Rekhtman N, 2010, ARCH PATHOL LAB MED, V134, P1628, DOI 10.1043/2009-0583-RAR.1; Schultheis AM, 2015, EUR J CANCER, V51, P421, DOI 10.1016/j.ejca.2014.12.006; Taube JM, 2015, CLIN CANCER RES, V21, P3969, DOI 10.1158/1078-0432.CCR-15-0244; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Teng MWL, 2015, CANCER RES, V75, P2139, DOI 10.1158/0008-5472.CAN-15-0255; Thompson ED, 2017, GUT, V66, P794, DOI 10.1136/gutjnl-2015-310839; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Travis WD, 2010, ANN ONCOL, V21, P65, DOI 10.1093/annonc/mdq380; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Twyman-Saint Victor C, 2015, NATURE, V520, P373, DOI 10.1038/nature14292; Vollbrecht C, 2015, BRIT J CANCER, V113, P1704, DOI 10.1038/bjc.2015.397; Yamaguchi R, 2012, HUM PATHOL, V43, P1688, DOI 10.1016/j.humpath.2011.12.013	26	3	3	0	6	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	MAY 22	2018	13								30	10.1186/s13000-018-0712-1			10	Pathology	Pathology	GH0QI	WOS:000433106700001	29789013	DOAJ Gold, Green Published			2019-10-28	
J	[Anonymous]				[Anonymous]			Abstracts of the 50th Anniversary Association of Pathology Chairs Annual Meeting: Pathology and Population Health Abstracts	ACADEMIC PATHOLOGY			English	Article																	0	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	MAY 22	2018	5								UNSP 2374289518769905	10.1177/2374289518769905			17	Pathology	Pathology	GG7GX	WOS:000432867600001		DOAJ Gold, Green Published			2019-10-28	
J	Huang, YX; Lei, Y; Wang, Q; Li, DZ; Ma, LL; Guo, LL; Tang, MS; Liu, GL; Yan, QW; Shen, L; Tong, GH; Jing, ZL; Zhang, Y; Deng, YJ				Huang, Yingxin; Lei, Yan; Wang, Qi; Li, Dazhou; Ma, Lili; Guo, Lili; Tang, Minshan; Liu, Guanglong; Yan, Qianwen; Shen, Lan; Tong, Guihui; Jing, Zhiliang; Zhang, Yan; Deng, Yongjian			Telepathology consultation for frozen section diagnosis in China	DIAGNOSTIC PATHOLOGY			English	Article						Telepathology; Intraoperative consultation of pathology; Frozen section; Diagnosis	SURGICAL PATHOLOGY; INTRAOPERATIVE CONSULTATION; ROBOTIC TELEPATHOLOGY; ACCURACY; SYSTEM; FEASIBILITY; EXPERIENCE; NETWORKING; TRIAL	Background: Telepathology (TP) provides remote pathology services for primary diagnosis practices, including intraoperative consultation of surgical pathology; it has not been widely implemented in China. In this study, the results of an implementation were reported, which lasted for two and a half years, and demonstrated the experience of the diagnosis of the intraoperative frozen sections by using TP consultation platform of Southern Medical University and Guangzhou Huayin Medical Laboratory Center (SMU-HUAYIN TP) in China. Methods: The SMU-HUAYIN TP consultation platform connects 71 participating basic hospitals and 11 senior pathologists. Nanfang Hospital is a high-level hospital located in a large city in China. This retrospective study summarizes the experience and results of TP for frozen section diagnosis by comparing the data of the platform and Nanfang Hospital over a period of 2.5 years from January 2015 to June 2017. Results: A total of 5233 cases were submitted to the platform, including 1019 cases in 2015, 2320 cases in 2016, and 1894 cases in 2017. The most common cases were breast (30.42%), followed by thyroid (29.05%) and gynecological (24.86%). Average turn-around time (TAT) of the cases from the platform in 2015 and 2016 was controlled within 30 min. In most W cases (90.31%) and cases from Nanfang Hospital (86.14%), a definitive diagnosis was provided. The coincidence rate was 99.77% in the TP cases and 99.35% in the cases from Nanfang Hospital. The false positive and false negative rates of W cases were 0.04 and 0.19%, respectively and no significant difference was found among different senior pathologists (P = 0.974, P = 0.989, P > 0.05). Similarly, there was no significant difference between W cases and cases from Nanfang Hospital that were diagnosed by the same senior pathologist (P > 0.05). Conclusions: Our results indicate that TP in frozen section diagnosis could improve patient care and solve the problem of unevenly distributed pathology resources in China. We believe that in the near future, TP in frozen section diagnosis will become an important component of telemedicine and will play a significant role in health care reform in China.	[Deng, Yongjian] Southern Med Univ, Nanfang Hosp, Dept Pathol, 1838 Guangzhou North Rd, Guangzhou 510515, Guangdong, Peoples R China; Southern Med Univ, Sch Basic Med Sci, 1838 Guangzhou North Rd, Guangzhou 510515, Guangdong, Peoples R China	Deng, YJ (reprint author), Southern Med Univ, Nanfang Hosp, Dept Pathol, 1838 Guangzhou North Rd, Guangzhou 510515, Guangdong, Peoples R China.	dengyj@smu.edu.cn					Chen J, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-S1-S2; Demichelis F, 2001, AM J CLIN PATHOL, V116, P744; Dunn B E, 1997, Telemed J, V3, P1, DOI 10.1089/tmj.1.1997.3.1; Dunn BE, 1999, TELEMED J, V5, P323, DOI 10.1089/107830299311899; Dunn BE, 2001, HUM PATHOL, V32, P1300, DOI 10.1053/hupa.2001.29644; Dunn BE, 2000, TELEMED J E-HEALTH, V6, P349, DOI 10.1089/153056200750040200; Evans AJ, 2009, HUM PATHOL, V40, P1070, DOI 10.1016/j.humpath.2009.04.012; Frierson HF, 2007, HUM PATHOL, V38, P1330, DOI 10.1016/j.humpath.2007.02.006; Horbinski C, 2007, J NEUROPATH EXP NEUR, V66, P750, DOI 10.1097/nen.0b013e318126c179; Kaplan KJ, 2002, MODERN PATHOL, V15, P1197, DOI 10.1097/01.MP.0000033928.11585.42; KAUFMAN Z, 1986, CANCER, V57, P377, DOI 10.1002/1097-0142(19860115)57:2<377::AID-CNCR2820570231>3.0.CO;2-M; LESSELLS AM, 1976, BRIT J SURG, V63, P327, DOI 10.1002/bjs.1800630418; Li XX, 2008, HUM PATHOL, V39, P236, DOI 10.1016/j.humpath.2007.06.008; Li XX, 2007, HUM PATHOL, V38, P1842, DOI 10.1016/j.humpath.2007.04.019; Liang WY, 2008, HUM PATHOL, V39, P56, DOI 10.1016/j.humpath.2007.04.023; Moser PL, 2003, J TELEMED TELECARE, V9, P130, DOI 10.1258/135763303767149915; Tripodi SA, 2012, J CLIN PATHOL, V65, P635, DOI 10.1136/jclinpath-2011-200551; Weinstein RS, 2001, HUM PATHOL, V32, P1283, DOI 10.1053/hupa.2001.29643; WEINSTEIN RS, 1987, ARCH PATHOL LAB MED, V111, P646; WEINSTEIN RS, 1991, HUM PATHOL, V22, P511, DOI 10.1016/0046-8177(91)90225-E; Winokur TS, 2000, HUM PATHOL, V31, P781, DOI 10.1053/hupa.2000.8452	21	2	2	0	4	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	MAY 14	2018	13								29	10.1186/s13000-018-0705-0			6	Pathology	Pathology	GF8UC	WOS:000432247900001	29759085	DOAJ Gold, Green Published			2019-10-28	
J	Matsui, T; Maeda, T; Kusakabe, S; Arita, H; Yagita, K; Morii, E; Kanakura, Y				Matsui, Takahiro; Maeda, Tetsuo; Kusakabe, Shinsuke; Arita, Hideyuki; Yagita, Kenji; Morii, Eiichi; Kanakura, Yuzuru			A case report of granulomatous amoebic encephalitis by Group 1 Acanthamoeba genotype T18 diagnosed by the combination of morphological examination and genetic analysis	DIAGNOSTIC PATHOLOGY			English	Article						Granulomatous amoebic encephalitis; Acanthamoeba; Genotype T18; Cerebrospinal fluid	STEM-CELL TRANSPLANTATION; FREE-LIVING AMEBAS; IDENTIFICATION; INFECTIONS; RECIPIENT; PATIENT; DISEASE; HUMANS; DNA; PCR	Background: The diagnosis of granulomatous amoebic encephalitis is challenging for clinicians because it is a rare and lethal disease. Previous reports have indicated that Acanthamoeba with some specific genotypes tend to cause the majority of human infections. We report a case of granulomatous amoebic encephalitis caused by Acanthamoeba spp. with genotype T18 in an immunodeficient patient in Japan after allogenic bone marrow transplantation, along with the morphological characteristics and genetic analysis. Case presentation: A 52-year old man, who had undergone allogenic bone marrow transplantation, suffered from rapid-growing brain masses in addition to pneumonia and died within 1 month from the onset of the symptoms including fever, headache and disorientation. Infection with Acanthamoeba in the brain and lung was confirmed by histological evaluation; immunohistochemical staining and polymerase chain reaction analysis using autopsy samples also indicated the growth of Acanthamoeba in the brain. Gene sequence analysis indicated that this is the second documented case of infection with Acanthamoeba spp. with genotype 118 in a human host. Postmortem retrospective evaluation of cerebrospinal fluid sample in our case, as well as literature review, indicated that some cases of granulomatous amoebic encephalitis caused by Acanthamoeba may be diagnosable by cerebrospinal fluid examination. Conclusion: This case indicates that Acanthamoeba spp. with genotype T18 can also be an important opportunistic pathogen. For pathologists as well as physicians, increased awareness of granulomatous amoebic encephalitis is important for improving the poor prognosis along with the attempt to early diagnosis with cerebrospinal fluid.	[Matsui, Takahiro; Maeda, Tetsuo; Kusakabe, Shinsuke; Kanakura, Yuzuru] Osaka Univ, Dept Hematol & Oncol, Grad Sch Med, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan; [Matsui, Takahiro; Morii, Eiichi] Osaka Univ, Dept Pathol, Grad Sch Med, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan; [Arita, Hideyuki] Osaka Univ, Dept Neurosurg, Grad Sch Med, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan; [Yagita, Kenji] Natl Inst Infect Dis, Dept Parasitol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan	Matsui, T (reprint author), Osaka Univ, Dept Hematol & Oncol, Grad Sch Med, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.; Matsui, T (reprint author), Osaka Univ, Dept Pathol, Grad Sch Med, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.	matsuit@molpath.med.osaka-u.ac.jp					Akpek G, 2011, TRANSPL INFECT DIS, V13, P366, DOI 10.1111/j.1399-3062.2011.00612.x; Booton GC, 2005, J CLIN MICROBIOL, V43, P1689, DOI 10.1128/JCM.43.4.1689-1693.2005; Feingold JM, 1998, BONE MARROW TRANSPL, V22, P297, DOI 10.1038/sj.bmt.1701320; Fuerst PA, 2015, J EUKARYOT MICROBIOL, V62, P69, DOI 10.1111/jeu.12186; Kaul DR, 2008, TRANSPL INFECT DIS, V10, P437, DOI 10.1111/j.1399-3062.2008.00335.x; Krol-Turminska K, 2017, ANN AGR ENV MED, V24, P254, DOI 10.5604/12321966.1233568; Marciano-Cabral F, 2003, CLIN MICROBIOL REV, V16, P273, DOI 10.1128/CMR.16.2.273-307.2003; Qvarnstrom Y, 2013, J EUKARYOT MICROBIOL, V60, P626, DOI 10.1111/jeu.12069; Satlin MJ, 2013, TRANSPL INFECT DIS, V15, P619, DOI 10.1111/tid.12131; Schroeder JM, 2001, J CLIN MICROBIOL, V39, P1903, DOI 10.1128/JCM.39.5.1903-1911.2001; Schuster FL, 2002, CLIN MICROBIOL REV, V15, P342, DOI 10.1128/CMR.15.3.342-354.2002; Walia R, 2007, TRANSPL INFECT DIS, V9, P51, DOI 10.1111/j.1399-3062.2006.00159.x; Yagi S, 2007, J CLIN MICROBIOL, V45, P2090, DOI 10.1128/JCM.02435-06	13	3	3	0	1	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	MAY 10	2018	13								27	10.1186/s13000-018-0706-z			6	Pathology	Pathology	GF8UA	WOS:000432247700001	29747695	DOAJ Gold, Green Published			2019-10-28	
J	Nakayama, R; Togashi, Y; Baba, S; Kaku, Y; Teramoto, Y; Sakurai, T; Haga, H; Takeuchi, K				Nakayama, Ryuko; Togashi, Yuki; Baba, Satoko; Kaku, Yo; Teramoto, Yuki; Sakurai, Takaki; Haga, Hironori; Takeuchi, Kengo			Epithelioid cell histiocytoma with SQSTM1-ALK fusion: a case report	DIAGNOSTIC PATHOLOGY			English	Article						Epithelioid cell histiocytoma; Fibrous histiocytoma; ALK gene rearrangement; SQSTM1-ALK gene fusion	IN-SITU HYBRIDIZATION; FIBROUS HISTIOCYTOMA; ALK REARRANGEMENT; CANCER; OVEREXPRESSION; LYMPHOMA; TUMORS	Background: Epithelioid cell histiocytoma (ECH), which is also known as epithelioid benign fibrous histiocytoma, has been classified as a rare variant of fibrous histiocytoma (FH). However, the recent detection of ALK protein expression and/or ALK gene rearrangement in ECH suggests that it might be biologically different from conventional FH. Case presentation: A 27-year-old male presented with nodule on his left foot, which had been present for 5 years. A macroscopic examination revealed an exophytic, hyperkeratotic nodule on the dorsum of the left foot Tumorectomy was performed, and a microscopic examination showed a subepidermal lesion composed of sheets of tumor cells with oval to round nuclei and ill-defined eosinophilic cytoplasm. The tumor cells were diffusely positive for factor Xllla and ALK, but were negative for AE1/AE3 keratin, alpha-smooth muscle actin, CD30, CD34, CD68, PU.1, melan A, MITF, and S-100 protein. ALK immunostaining showed a diffuse cytoplasmic staining pattern. ALK fluorescence in situ hybridization demonstrated break-apart signals, which was suggestive of ALK rearrangement A 5'-rapid amplification of cDNA ends assay detected SQSTMI -ALK fusion, in which exon 5 of the SQSTM1 gene was fused to exon 20 of the ALK gene. The patient was free from recurrence and distant metastasis at the 1-year of follow-up. Conclusion: We were able to demonstrate the SQSTM1-ALK fusion gene in ECH. Practically, detecting immunopositivity for ALK and appropriate cell-lineage markers are the key to diagnosing ECH.	[Nakayama, Ryuko; Teramoto, Yuki; Sakurai, Takaki; Haga, Hironori] Kyoto Univ Hosp, Dept Diagnost Pathol, Kyoto, Japan; [Togashi, Yuki; Baba, Satoko; Takeuchi, Kengo] Japanese Fdn Canc Res, Canc Inst, Pathol Project Mol Targets, Tokyo, Japan; [Kaku, Yo] Kyoto Univ Hosp, Dept Dermatol, Kyoto, Japan	Haga, H (reprint author), Kyoto Univ Hosp, Dept Diagnost Pathol, Kyoto, Japan.	haga@kuhp.kyoto-u.ac.jp					BeylotBarry M, 1996, AM J PATHOL, V149, P483; Cangelosi JJ, 2008, AM J DERMATOPATH, V30, P373, DOI 10.1097/DAD.0b013e31817330e9; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; Creytens D, 2017, APPL IMMUNOHISTO M M, V25, pE46, DOI 10.1097/PAI.0000000000000418; Dickson BC, 2018, MODERN PATHOL, V31, P753, DOI 10.1038/modpathol.2017.191; Doyle LA, 2015, MODERN PATHOL, V28, P904, DOI 10.1038/modpathol.2015.49; Doyle LA, 2013, AM J SURG PATHOL, V37, P484, DOI 10.1097/PAS.0b013e31827070d4; Gleason BC, 2008, AM J SURG PATHOL, V32, P354, DOI 10.1097/PAS.0b013e31813c6b85; Glusac EJ, 1999, AM J DERMATOPATH, V21, P1, DOI 10.1097/00000372-199902000-00001; Iyevleva AG, 2015, CANCER LETT, V362, P116, DOI 10.1016/j.canlet.2015.03.028; Jedrych J, 2015, BRIT J DERMATOL, V172, P1427, DOI 10.1111/bjd.13548; JONES EW, 1989, BRIT J DERMATOL, V120, P185; Kazakov DV, 2018, AM J DERMATOPATH, V40, P805, DOI 10.1097/DAD.0000000000001085; Luzar B, 2010, HISTOPATHOLOGY, V56, P148, DOI 10.1111/j.1365-2559.2009.03447.x; Mano H, 2012, CANCER DISCOV, V2, P495, DOI 10.1158/2159-8290.CD-12-0009; Selinger CI, 2013, MODERN PATHOL, V26, P1545, DOI 10.1038/modpathol.2013.87; Togashi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031323; Walther C, 2015, LAB INVEST, V95, P1071, DOI 10.1038/labinvest.2015.83; Yeh I, 2015, AM J SURG PATHOL, V39, P581, DOI 10.1097/PAS.0000000000000387	19	0	0	0	1	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	MAY 10	2018	13								28	10.1186/s13000-018-0704-1			5	Pathology	Pathology	GF8UA	WOS:000432247700002	29747676	DOAJ Gold, Green Published			2019-10-28	
J	Alekseyev, YO; Fazeli, R; Yang, S; Basran, R; Maher, T; Miller, NS; Remick, D				Alekseyev, Yuriy O.; Fazeli, Roghayeh; Yang, Shi; Basran, Raveen; Maher, Thomas; Miller, Nancy S.; Remick, Daniel			A Next-Generation Sequencing PrimerHow Does It Work and What Can It Do?	ACADEMIC PATHOLOGY			English	Review						diagnostic test; microbiology; mutation; oncology; sequencing	NONSMALL CELL LUNG; FOR-MOLECULAR-PATHOLOGY; PERSONALIZED MEDICINE; SOLID TUMORS; DNA-SEQUENCE; HEREDITARY PHEOCHROMOCYTOMA; CLINICAL-APPLICATION; PRECISION MEDICINE; COLORECTAL-CANCER; SOMATIC VARIANTS	Next-generation sequencing refers to a high-throughput technology that determines the nucleic acid sequences and identifies variants in a sample. The technology has been introduced into clinical laboratory testing and produces test results for precision medicine. Since next-generation sequencing is relatively new, graduate students, medical students, pathology residents, and other physicians may benefit from a primer to provide a foundation about basic next-generation sequencing methods and applications, as well as specific examples where it has had diagnostic and prognostic utility. Next-generation sequencing technology grew out of advances in multiple fields to produce a sophisticated laboratory test with tremendous potential. Next-generation sequencing may be used in the clinical setting to look for specific genetic alterations in patients with cancer, diagnose inherited conditions such as cystic fibrosis, and detect and profile microbial organisms. This primer will review DNA sequencing technology, the commercialization of next-generation sequencing, and clinical uses of next-generation sequencing. Specific applications where next-generation sequencing has demonstrated utility in oncology are provided.	[Alekseyev, Yuriy O.; Fazeli, Roghayeh; Yang, Shi; Basran, Raveen; Maher, Thomas; Miller, Nancy S.; Remick, Daniel] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; [Alekseyev, Yuriy O.; Fazeli, Roghayeh; Yang, Shi; Basran, Raveen; Maher, Thomas; Miller, Nancy S.; Remick, Daniel] Boston Med Ctr, Boston, MA 02118 USA	Remick, D (reprint author), Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA.; Remick, D (reprint author), Boston Med Ctr, Boston, MA 02118 USA.	remickd@bu.edu		Maher, Thomas/0000-0002-6083-9487; Remick, Daniel/0000-0002-2615-3713	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 AI112887-01, R01GM117519, T32 GM86308]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported in part by NIH grant R21 AI112887-01, R01GM117519, and T32 GM86308 (DGR).	Ackerman Sara L, 2018, AJOB Empir Bioeth, V9, P48, DOI 10.1080/23294515.2017.1405095; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Alikian Mary, 2017, Biomol Detect Quantif, V11, P4, DOI 10.1016/j.bdq.2017.01.001; Allyse M, 2013, TRENDS BIOTECHNOL, V31, P439, DOI 10.1016/j.tibtech.2013.04.006; Aparisi MJ, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023-014-0168-7; Astolfi A, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1982-6; Au CH, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0456-8; Badal B, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92102; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; Belardinilli F, 2015, CLIN BIOCHEM, V48, P908, DOI 10.1016/j.clinbiochem.2015.04.003; Bentley DR, 2008, NATURE, V456, P53, DOI 10.1038/nature07517; Boycott K, 2015, J MED GENET, V52, P431, DOI 10.1136/jmedgenet-2015-103144; Burnichon N, 2016, CURR OPIN ONCOL, V28, P5, DOI 10.1097/CCO.0000000000000249; Bustos BDU, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00606-w; Carlson JA, 2017, AM J DERMATOPATH, V39, P1, DOI 10.1097/DAD.0000000000000729; Castera L, 2014, EUR J HUM GENET, V22, P1305, DOI 10.1038/ejhg.2014.16; Chang FQ, 2013, CANCER GENET-NY, V206, P413, DOI 10.1016/j.cancergen.2013.10.003; Chen CY, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00305; Coco S, 2015, CURR DRUG TARGETS, V16, P47, DOI 10.2174/1389450116666141210094640; Corro C, 2017, EXP MOL PATHOL, V102, P255, DOI 10.1016/j.yexmp.2017.02.009; Coyne GO, 2017, CURR PROB CANCER, V41, P182, DOI 10.1016/j.currproblcancer.2017.02.001; Curras-Freixes M, 2017, J MOL DIAGN, V19, P575, DOI 10.1016/j.jmoldx.2017.04.009; D'Haene N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138245; Daoud H, 2016, CAN MED ASSOC J, V188, pE254, DOI 10.1503/cmaj.150823; Darwanto A, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3328-z; de Abreu FB, 2016, CLIN CHEM LAB MED, V54, P761, DOI 10.1515/cclm-2015-1190; De Luca F, 2016, ONCOTARGET, V7, P26107, DOI 10.18632/oncotarget.8431; Deurenberg RH, 2017, J BIOTECHNOL, V243, P16, DOI 10.1016/j.jbiotec.2016.12.022; DiBardino DM, 2016, CLIN LUNG CANCER, V17, P517, DOI 10.1016/j.cllc.2016.05.017; Dubbink HJ, 2016, J MOL DIAGN, V18, P775, DOI 10.1016/j.jmoldx.2016.06.002; Easton DF, 2015, NEW ENGL J MED, V372, P2243, DOI 10.1056/NEJMsr1501341; Fisher KE, 2016, J MOL DIAGN, V18, P299, DOI 10.1016/j.jmoldx.2015.11.006; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; Giefing M, 2016, EUR J CANCER, V55, P147, DOI 10.1016/j.ejca.2015.10.070; Gleeson FC, 2015, CLIN GASTROENTEROL H, V13, P202, DOI 10.1016/j.cgh.2014.06.024; Gogol-Doring A, 2012, METHODS MOL BIOL, V802, P249, DOI 10.1007/978-1-61779-400-1_16; Green ED, 2011, NATURE, V470, P204, DOI 10.1038/nature09764; Gyvyte U, 2017, ONCOTARGET, V8, P37225, DOI 10.18632/oncotarget.16664; Hagemann IS, 2015, CANCER-AM CANCER SOC, V121, P631, DOI 10.1002/cncr.29089; Heather JM, 2016, GENOMICS, V107, P1, DOI 10.1016/j.ygeno.2015.11.003; Hixson L, 2015, JALA-J LAB AUTOM, V20, P562, DOI 10.1177/2211068214564595; Hovelson DH, 2015, NEOPLASIA, V17, P385, DOI 10.1016/j.neo.2015.03.004; HUNKAPILLER T, 1991, SCIENCE, V254, P59, DOI 10.1126/science.1925562; Hynes SO, 2017, BRIT J CANCER, V116, P553, DOI 10.1038/bjc.2016.452; JACKSON DA, 1972, P NATL ACAD SCI USA, V69, P2904, DOI 10.1073/pnas.69.10.2904; Jamuar SS, 2015, HUM GENOMICS, V9, DOI 10.1186/s40246-015-0031-5; Jennings LJ, 2017, J MOL DIAGN, V19, P341, DOI 10.1016/j.jmoldx.2017.01.011; Jeon YK, 2017, J PATHOL TRANSL MED, V51, P224, DOI 10.4132/jptm.2017.04.09; Johnson DB, 2014, ONCOLOGIST, V19, P616, DOI 10.1634/theoncologist.2014-0011; Judkins T, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1224-y; Kalia SS, 2017, GENET MED, V19, P249, DOI 10.1038/gim.2016.190; Kamps R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020308; Kim HS, 2017, ONCOTARGET, V8, P38389, DOI 10.18632/oncotarget.16409; Kline CN, 2017, NEURO-ONCOLOGY, V19, P699, DOI 10.1093/neuonc/now254; Koshimizu E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074167; Kotrova M, 2017, MOL DIAGN THER, V21, P481, DOI 10.1007/s40291-017-0277-9; LaDuca H, 2014, GENET MED, V16, P830, DOI 10.1038/gim.2014.40; Lalani SR, 2017, PEDIATR NEONATOL, V58, P111, DOI 10.1016/j.pedneo.2016.07.002; Lalloo F, 2016, RECENT RESULTS CANC, V205, P105, DOI 10.1007/978-3-319-29998-3_7; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee H, 2014, JAMA-J AM MED ASSOC, V312, P1880, DOI 10.1001/jama.2014.14604; Lefterova MI, 2015, J MOL DIAGN, V17, P623, DOI 10.1016/j.jmoldx.2015.07.004; Levy S, 2007, PLOS BIOL, V5, P2113, DOI 10.1371/journal.pbio.0050254; Li G, 2017, J THORAC DIS, V9, pS9, DOI 10.21037/jtd.2016.08.17; Li MM, 2017, J MOL DIAGN, V19, P4, DOI 10.1016/j.jmoldx.2016.10.002; Lim SM, 2016, ONCOTARGET, V7, P24172, DOI 10.18632/oncotarget.8138; Lindquist KE, 2017, ONCOTARGET, V8, P34796, DOI 10.18632/oncotarget.16276; Lo Iacono M, 2016, ONCOTARGET, V7, P14394, DOI 10.18632/oncotarget.7343; Loman NJ, 2012, NAT REV MICROBIOL, V10, P599, DOI 10.1038/nrmicro2850; LUCKEY JA, 1990, NUCLEIC ACIDS RES, V18, P4417, DOI 10.1093/nar/18.15.4417; Luthra R, 2017, J MOL DIAGN, V19, P255, DOI 10.1016/j.jmoldx.2016.09.011; Luthra R, 2015, CANCERS, V7, P2023, DOI 10.3390/cancers7040874; Manson-Bahr D, 2015, J CLIN PATHOL, V68, P212, DOI 10.1136/jclinpath-2014-202754; Mardis ER, 2016, DIS MODEL MECH, V9, P483, DOI 10.1242/dmm.025585; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Matthijs G, 2016, EUR J HUM GENET, V24, P1515, DOI 10.1038/ejhg.2016.63; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; McCarthy JJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005785; McNeil C., 2015, J NATL CANC I, V107; Misyura M, 2016, J MOL DIAGN, V18, P842, DOI 10.1016/j.jmoldx.2016.06.004; Miyazaki K, 2016, J CLIN EXP HEMATOP, V56, P79; Morey M, 2013, MOL GENET METAB, V110, P3, DOI 10.1016/j.ymgme.2013.04.024; Nikiforov YE, 2015, THYROID, V25, P1217, DOI 10.1089/thy.2015.0305; Nikiforova MN, 2013, J CLIN ENDOCR METAB, V98, pE1852, DOI 10.1210/jc.2013-2292; Pant S, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00078; Parsons HA, 2016, ADV EXP MED BIOL, V882, P259, DOI 10.1007/978-3-319-22909-6_11; Pentsova EI, 2016, J CLIN ONCOL, V34, P2404, DOI 10.1200/JCO.2016.66.6487; Picarsic JL, 2016, PEDIATR DEVEL PATHOL, V19, P115, DOI 10.2350/15-07-1667-OA.1; Pillai S, 2017, EXP MOL PATHOL, V102, P41, DOI 10.1016/j.yexmp.2016.12.007; Pinto R, 2016, ONCOTARGET, V7, P25135, DOI 10.18632/oncotarget.7175; PROBER JM, 1987, SCIENCE, V238, P336, DOI 10.1126/science.2443975; Quinn AM, 2015, J THORAC ONCOL, V10, P784, DOI 10.1097/JTO.0000000000000473; Reifenberger G, 2017, NAT REV CLIN ONCOL, V14, P434, DOI 10.1038/nrclinonc.2016.204; Reuter JA, 2015, MOL CELL, V58, P586, DOI 10.1016/j.molcel.2015.05.004; Reynolds JP, 2017, CANCER CYTOPATHOL, V125, P178, DOI 10.1002/cncy.21812; Richer AL, 2015, PHARMACOGEN PERS MED, V8, P63, DOI 10.2147/PGPM.S52845; Rizzo G, 2015, ORAL DIS, V21, pE11, DOI 10.1111/odi.12246; Rothberg JM, 2011, NATURE, V475, P348, DOI 10.1038/nature10242; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sanger F, 1992, Biotechnology, V24, P104; Sawyer SL, 2016, CLIN GENET, V89, P275, DOI 10.1111/cge.12654; Sethi N, 2016, HEAD NECK-J SCI SPEC, V38, pE2395, DOI 10.1002/hed.24085; Shin S, 2017, ONCOTARGET, V8, P34858, DOI 10.18632/oncotarget.16799; Short NJ, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0565-x; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; Stadler ZK, 2016, J CLIN ONCOL, V34, P2141, DOI 10.1200/JCO.2015.65.1067; Stavropoulos DJ, 2016, NPJ GENOM MED, V1, DOI 10.1038/npjgenmed.2015.12; Stockley TL, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0364-2; Strom CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136419; Sugita S, 2017, J ORTHOP SCI, V22, P601, DOI 10.1016/j.jos.2017.02.004; SWERDLOW H, 1990, NUCLEIC ACIDS RES, V18, P1415, DOI 10.1093/nar/18.6.1415; Syn NLX, 2016, EXPERT OPIN DRUG MET, V12, P911, DOI 10.1080/17425255.2016.1196187; Toledo RA, 2015, CURR OPIN ENDOCRINOL, V22, P169, DOI 10.1097/MED.0000000000000150; Tops BBJ, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1015-5; Tuna M, 2017, ONCOTARGET, V8, P8877, DOI 10.18632/oncotarget.12830; van Dijk EL, 2014, TRENDS GENET, V30, P418, DOI 10.1016/j.tig.2014.07.001; Vasan N, 2014, ONCOLOGIST, V19, P453, DOI 10.1634/theoncologist.2013-0377; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Verri C, 2017, J THORAC ONCOL, V12, P922, DOI 10.1016/j.jtho.2017.03.001; Wagle N, 2012, CANCER DISCOV, V2, P82, DOI 10.1158/2159-8290.CD-11-0184; Wang J, 2017, CLIN TRANSL MED, V6, DOI 10.1186/s40169-017-0139-4; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; Watson M, 2014, GENOME BIOL, V15, DOI 10.1186/gb4165; Wei CH, 2016, APPL IMMUNOHISTOCHEM; Wheeler DA, 2008, NATURE, V452, P872, DOI 10.1038/nature06884; Wilson MR, 2014, NEW ENGL J MED, V370, P2408, DOI 10.1056/NEJMoa1401268; Wright CF, 2015, LANCET, V385, P1305, DOI 10.1016/S0140-6736(14)61705-0; Xie N, 2017, EXP THER MED, V14, P338, DOI 10.3892/etm.2017.4464; Yadav SS, 2015, UROLONCOL, V33, DOI [10.1016/j.urolonc.2015.02.009, DOI 10.1016/J.UROLONC.2015.02.009]; Yohe S, 2017, ARCH PATHOL LAB MED, V141, P1544, DOI 10.5858/arpa.2016-0501-RA; Zacher A, 2017, BRAIN PATHOL, V27, P146, DOI 10.1111/bpa.12367; Zhu WJ, 2017, CELL MOL LIFE SCI, V74, P869, DOI 10.1007/s00018-016-2368-x	134	7	7	2	17	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	MAY 6	2018	5								UNSP 2374289518766521	10.1177/2374289518766521			11	Pathology	Pathology	GF4RN	WOS:000431951000001	29761157	DOAJ Gold, Green Published			2019-10-28	
J	Kosmidis, P; Mankel, B; Fend, F; Adam, P				Kosmidis, Perikles; Mankel, Barbara; Fend, Falko; Adam, Patrick			The t(14;18) translocation is absent from endothelial and follicular dendritic cells o follicular lymphoma (FL) and shows heterogeneous presence in preserved FL mantle zones	DIAGNOSTIC PATHOLOGY			English	Article						T(14;18); Microenvironment cells; Follicular lymphoma	INTERPHASE CYTOGENETICS; TUMOR; TRANSDIFFERENTIATION; ABNORMALITIES; NEOPLASMS; SARCOMAS; FICTION	Background: The translocation t(14;18)(q32;q21) is the genetic hallmark of follicular lymphoma (FL) and can be observed in 85-90% of cases. Whether the translocation is restricted to cells with germinal center B-cell phenotype or can be observed in other cell types of the microenvironment remains debated. Of interest, cases of associated histiocytic and dendritic cell sarcomas arising in the background of FL have been shown to be clonally related and carry the t(14;18), suggesting a "transdifferentiation" of the malignant FL clone into a neoplasm of a different hematopoietic lineage. Methods: We analyzed the presence of the t(14;18)(q32;q21) as a surrogate marker of the malignant clone in cells of the FL microenvironment using combined fluorescence immunophenotyping and interphase cytogenetics targeting the BCL2 gene locus. In addition to non-lymphoid cells in FL, we analysed FL with preserved IgD+ mantle zones and cases of in situ follicular neoplasia (ISFN) to investigate whether cells of non-germinal center B-cell phenotype are part of the malignant clone. Results: Six (40%) of 15 manifest FL cases with preserved IgD+ mantle zones did not harbour the t(14;18)(q32;q21) translocation. In all t(14;18) + FL cases, follicular dendritic cells and endothelial cells lacked the t(14;18) translocation. 2/9 FL revealed t(14;18)- IgD+ mantle zone B-cells. In the seven ISFN cases, the t(14;18) translocation was strictly confined to germinal center cells. Conclusions: The t(14;18) translocation in follicular lymphoma is limited to B-cells. The origin of IgD+ mantle cells is heterogeneous, in the majority of cases belonging to the neoplastic clone, whereas a minority of cases of manifest FL show nonneoplastic mantle zones, similar to ISFN.	[Adam, Patrick] Eberhard Karls Univ Tubingen, Inst Pathol & Neuropathol, Liebermeisterstr 8, D-72076 Tubingen, Germany; Eberhard Karls Univ Tubingen, Comprehens Canc Ctr CCC, Liebermeisterstr 8, D-72076 Tubingen, Germany	Adam, P (reprint author), Eberhard Karls Univ Tubingen, Inst Pathol & Neuropathol, Liebermeisterstr 8, D-72076 Tubingen, Germany.	patrick.adam@uni-tuebingen.de			IZKF FORTUNE Program of the University of Tubingen [1927-0-0]; Karl - Thiemig - Stiftung; DFGGerman Research Foundation (DFG) [FE 597/4-1]	P.K. was supported through a grant from the IZKF FORTUNE Program (Project 1927-0-0), of the University of Tubingen.; P.A. was supported by the Karl - Thiemig - Stiftung.; FF was supported by the DFG, grant FE 597/4-1.	Abaza Hala M H, 2015, Hematol Oncol Stem Cell Ther, V8, P56, DOI 10.1016/j.hemonc.2015.04.002; Adam P, 2013, HUM PATHOL, V44, P1817, DOI 10.1016/j.humpath.2013.02.004; Akino T, 2009, AM J PATHOL, V175, P2657, DOI 10.2353/ajpath.2009.090202; Bakhirev AG, 2014, ARCH PATHOL LAB MED, V138, P538, DOI 10.5858/arpa.2012-0663-OA; Chen W, 2009, AM J SURG PATHOL, V33, P863, DOI 10.1097/PAS.0b013e31819287b8; Feldman AL, 2008, BLOOD, V111, P5433, DOI 10.1182/blood-2007-11-124792; Gatta LB, 2012, APPL IMMUNOHISTO M M, V20, P413, DOI 10.1097/PAI.0b013e31823fb322; Grogg KL, 2004, AM J SURG PATHOL, V28, P988, DOI 10.1097/01.pas.0000112536.76973.7f; Hida K, 2004, CANCER RES, V64, P8249, DOI 10.1158/0008-5472.CAN-04-1567; Streubel B, 2004, NEW ENGL J MED, V351, P250, DOI 10.1056/NEJMoa033153; Swerdlow SH, 2008, WHO CLASSIFICATION T; Vasef MA, 1995, AM J CLIN PATHOL, V104, P696; Wang ED, 2011, AM J SURG PATHOL, V35, P457, DOI 10.1097/PAS.0b013e3182098799; WEBERMATTHIESEN K, 1993, J HISTOCHEM CYTOCHEM, V41, P1641, DOI 10.1177/41.11.7691932; WEBERMATTHIESEN K, 1992, J HISTOCHEM CYTOCHEM, V40, P171, DOI 10.1177/40.2.1552161; West DS, 2013, AM J SURG PATHOL, V37, P978, DOI 10.1097/PAS.0b013e318283099f; Zhang D, 2009, INT J HEMATOL, V89, P529, DOI 10.1007/s12185-009-0300-y	17	0	0	0	0	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	MAY 2	2018	13								25	10.1186/s13000-018-0703-2			7	Pathology	Pathology	GE9IY	WOS:000431544600001	29720207	DOAJ Gold, Green Published			2019-10-28	
J	Li, HF; Huang, WH; Luo, RC				Li, Huifen; Huang, Weihua; Luo, Rongcheng			RETRACTION: The microRNA-325 inhibits hepatocellular carcinoma progression by targeting high mobility group box 1 (Retraction of Vol 10, art no 117, 2015)	DIAGNOSTIC PATHOLOGY			English	Retraction									[Li, Huifen] Zhongshan Peoples Hosp, Dept Chemotherapy, Zhongshan 528400, Guangdong, Peoples R China; [Huang, Weihua; Luo, Rongcheng] Southern Med Univ, TCM Integrated Hosp, Canc Ctr, 13 Shiliugang Rd, Guangzhou 510315, Guangdong, Peoples R China	Luo, RC (reprint author), Southern Med Univ, TCM Integrated Hosp, Canc Ctr, 13 Shiliugang Rd, Guangzhou 510315, Guangdong, Peoples R China.	manuluorongcheng@163.com					Budhu A, 2008, HEPATOLOGY, V47, P897, DOI 10.1002/hep.22160; Li H, 2015, SHOCK VIB, V2015, P1, DOI DOI 10.1002/CEAT.201400379; Li HF, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0323-z; Yao SH, 2015, BIOMED PHARMACOTHER, V70, P72, DOI 10.1016/j.biopha.2015.01.013	4	0	0	0	7	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	MAY 2	2018	13								26	10.1186/s13000-018-0701-4			1	Pathology	Pathology	GE9IY	WOS:000431544600002	29720204	DOAJ Gold, Green Published			2019-10-28	
J	Buckley, L; Jackett, L; Clark, J; Gupta, R				Buckley, Lisa; Jackett, Louise; Clark, Jonathan; Gupta, Ruta			HPV-related Oropharyngeal Carcinoma: A Review of Clinical and Pathologic Features With Emphasis on Updates in Clinical and Pathologic Staging	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						human papilloma virus; oropharyngeal squamous cell carcinoma; pathology; staging; differential diagnoses	SQUAMOUS-CELL CARCINOMA; AMERICAN JOINT COMMITTEE; FINE-NEEDLE-ASPIRATION; HUMAN-PAPILLOMAVIRUS; NEUROENDOCRINE CARCINOMA; NECK-CARCINOMA; UNITED-STATES; ORAL-CAVITY; HEAD; CANCER	There has been a sharp increase in the incidence of the human papilloma virus-related oropharyngeal squamous cell carcinoma, partly due to the increasingly widespread awareness and recognition of this entity. This review assimilates the recent histopathologic classifications, staging systems, rapidly expanding research base and developments in management of human papilloma virus-related oropharyngeal squamous cell carcinoma and summarizes their implications for routine diagnostic practice. Differential diagnoses and their cytologic appearances are detailed and the utility of p16 staining and other immunohistochemistry testing is discussed.	[Buckley, Lisa] Liverpool Hosp, Liverpool, Australia; [Jackett, Louise; Gupta, Ruta] Royal Prince Alfred Hosp, Dept Tissue Pathol & Diagnost Oncol, Camperdown, NSW, Australia; [Jackett, Louise] Melanoma Inst Australia, Wollstonecraft, NSW, Australia; [Clark, Jonathan; Gupta, Ruta] Univ Sydney, Cent Clin Sch, Sydney, NSW, Australia; [Clark, Jonathan] Chris OBrien Lifehouse, Dept Head & Neck Surg, Camperdown, NSW, Australia; [Clark, Jonathan] Univ New South Wales, South Western Sydney Clin Sch, Sydney, NSW, Australia	Buckley, L (reprint author), POB 355, Forestville, NSW 2087, Australia.	lisa.buckley15@gmail.com		Gupta, Ruta/0000-0003-2940-313X			American Joint Committee on Cancer, 2017, IMPL AJCC 8 ED CANC; Amin MB, 2017, AJCC CANC STAGING MA; An Yi, 2016, Cancers Head Neck, V1, P18, DOI 10.1186/s41199-016-0016-7; An Y, 2017, CANCER-AM CANCER SOC, V123, P2762, DOI 10.1002/cncr.30598; Bates T, 2014, HEAD NECK PATHOL, V8, P127, DOI 10.1007/s12105-013-0471-y; Bernadt CT, 2017, DIAGN CYTOPATHOL, V45, P221, DOI 10.1002/dc.23668; Bishop JA, 2015, SEMIN DIAGN PATHOL, V32, P344, DOI 10.1053/j.semdp.2015.02.013; Bishop JA, 2011, AM J SURG PATHOL, V35, P1679, DOI 10.1097/PAS.0b013e3182299cde; Chaturvedi AK, 2013, J CLIN ONCOL, V31, P4550, DOI 10.1200/JCO.2013.50.3870; Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596; Chernock RD, 2009, HEAD NECK PATHOL, V3, P186, DOI 10.1007/s12105-009-0126-1; Davison JM, 2010, RADIOLOGY, V255, P578, DOI 10.1148/radiol.10091479; El-Mofty SK, 2014, MED ORAL PATOL ORAL, V19, pE377, DOI 10.4317/medoral.20184; El-Naggar A, 2017, WHO CLASSIFICATION H; El-Naggar AK, 2012, HEAD NECK-J SCI SPEC, V34, P459, DOI 10.1002/hed.21974; Fisseler-Eckhoff Annette, 2012, Cancers (Basel), V4, P777, DOI 10.3390/cancers4030777; HAVRE PA, 1995, CANCER RES, V55, P4420; Howard JD, 2012, SEMIN RADIAT ONCOL, V22, P187, DOI 10.1016/j.semradonc.2012.03.002; Huang SH, 2015, J CLIN ONCOL, V33, P836, DOI 10.1200/JCO.2014.58.6412; Isayeva T, 2015, MODERN PATHOL, V28, P631, DOI 10.1038/modpathol.2014.149; Jalaly JB, 2015, CANCER CYTOPATHOL, V123, P723, DOI 10.1002/cncy.21600; Krane JF, 2013, ACTA CYTOL, V57, P117, DOI 10.1159/000346715; Lewis JS, 2012, AM J SURG PATHOL, V36, P1036, DOI 10.1097/PAS.0b013e3182583678; Lydiatt WM, 2017, CA-CANCER J CLIN, V67, P122, DOI 10.3322/caac.21389; Masand RP, 2011, HEAD NECK PATHOL, V5, P108, DOI 10.1007/s12105-011-0245-3; Mehrad M, 2016, HEAD NECK PATHOL, V10, P486, DOI 10.1007/s12105-016-0727-4; Mirghani H, 2015, INT J CANCER, V136, P1494, DOI 10.1002/ijc.28847; O'Sullivan B, 2016, LANCET ONCOL, V17, P440, DOI 10.1016/S1470-2045(15)00560-4; Rooper LM, 2016, ORAL ONCOL, V55, P11, DOI 10.1016/j.oraloncology.2016.02.008; Roy-Chowdhuri S, 2015, SEMIN DIAGN PATHOL, V32, P250, DOI 10.1053/j.semdp.2014.12.006; Seethala RR, 2013, PROTOCOL EXAMINATION; Stein AP, 2015, CANCER J, V21, P138, DOI 10.1097/PPO.0000000000000115; Steinau M, 2014, EMERG INFECT DIS, V20, P822, DOI 10.3201/eid2005.131311; Stenmark MH, 2014, INT J RADIAT ONCOL, V88, P580, DOI 10.1016/j.ijrobp.2013.11.246; Thompson ED, 2016, AM J SURG PATHOL, V40, P471, DOI 10.1097/PAS.0000000000000580; Xu B, 2016, HUM PATHOL, V54, P193, DOI 10.1016/j.humpath.2016.04.002	36	2	2	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	MAY	2018	25	3					180	188		10.1097/PAP.0000000000000179			9	Pathology	Pathology	GD2II	WOS:000430322900003	29394171				2019-10-28	
J	Kakar, S				Kakar, Sanjay			Pathologic Staging of Colorectal Adenocarcinoma: Changes and Updates in the American Joint Committee on Cancer (AJCC) 8th Edition and College of American Pathologists' Cancer Protocol	AJSP-REVIEWS AND REPORTS			English	Review						adenocarcinoma; colorectal; staging	ISOLATED TUMOR-CELLS; LYMPH-NODE METASTASIS; II COLON-CANCER; POOR PROGNOSTIC INDICATOR; ELASTIC LAMINA INVASION; RECTAL-CANCER; RISK-FACTORS; MICROSATELLITE INSTABILITY; PERITONEAL INVOLVEMENT; DISEASE RECURRENCE	The eighth edition of the AJCC Cancer Staging Manual has been published, and the new staging schemes will be applicable in 2018. The College of American Pathologists has also released an updated protocol incorporating these changes. While the overall T and N categories are similar to the seventh edition, the definitions of intramucosal adenocarcinoma, T4a category, and tumor deposits have been made more precise. The category of M1c has been created for peritoneal metastasis because of its worse outcome. In the College of American Pathologists protocol, tumor budding and venous invasion have been incorporated as recommended (optional) elements, the scoring of tumor regression has been updated, and the importance of screening for microsatellite instability/mismatch repair proteins has been emphasized. This review provides a brief description and rationale for these changes and updates.	[Kakar, Sanjay] Univ Calif San Francisco, Dept Pathol, 505 Parnassus Ave,M590, San Francisco, CA 94143 USA	Kakar, S (reprint author), Univ Calif San Francisco, Dept Pathol, 505 Parnassus Ave,M590, San Francisco, CA 94143 USA.	sanjay.kakar@ucsf.edu					Alexander J, 2001, AM J PATHOL, V158, P527, DOI 10.1016/S0002-9440(10)63994-6; Allegra CJ, 2016, J CLIN ONCOL, V34, P179, DOI 10.1200/JCO.2015.63.9674; Amin MB, 2017, AJCC CANC STAGING MA; Asayama N, 2016, J GASTROENTEROL, V51, P702, DOI 10.1007/s00535-015-1144-2; Betge J, 2012, CANCER-AM CANCER SOC, V118, P628, DOI 10.1002/cncr.26310; Bosch SL, 2013, ENDOSCOPY, V45, P827, DOI 10.1055/s-0033-1344238; Brown IS, 2016, J CLIN PATHOL, V69, P292, DOI 10.1136/jclinpath-2015-203203; Chen VW, 2014, CANCER-AM CANCER SOC, V120, P3793, DOI 10.1002/cncr.29056; Chetty R, 2012, HUM PATHOL, V43, P1917, DOI 10.1016/j.humpath.2012.01.020; Choi DH, 2009, DIS COLON RECTUM, V52, P438, DOI 10.1007/DCR.0b013e318197e37f; COOPER HS, 1995, GASTROENTEROLOGY, V108, P1657, DOI 10.1016/0016-5085(95)90126-4; Egashira Y, 2004, MODERN PATHOL, V17, P503, DOI 10.1038/modpathol.3800030; Faerden AE, 2011, DIS COLON RECTUM, V54, P200, DOI 10.1007/DCR.0b013e3181fd4c7c; Franko J, 2012, J CLIN ONCOL, V30, P263, DOI 10.1200/JCO.2011.37.1039; Galon J, 2014, J PATHOL, V232, P199, DOI 10.1002/path.4287; Gavioli M, 2005, DIS COLON RECTUM, V48, P1851, DOI 10.1007/s10350-005-0133-6; Graham RP, 2015, AM J SURG PATHOL, V39, P1340, DOI 10.1097/PAS.0000000000000504; Grin A, 2013, HUM PATHOL, V44, P2696, DOI 10.1016/j.humpath.2013.07.013; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; HAGGITT RC, 1985, GASTROENTEROLOGY, V89, P326; Jin M, 2015, AM J SURG PATHOL, V39, P109, DOI 10.1097/PAS.0000000000000320; Kenney Barton C., 2008, Yale Journal of Biology and Medicine, V81, P103; Kim JH, 2013, WORLD J GASTROENTERO, V19, P3895, DOI 10.3748/wjg.v19.i24.3895; Kirsch R, 2013, AM J SURG PATHOL, V37, P200, DOI 10.1097/PAS.0b013e31826a92cd; Koelzer VH, 2016, HUM PATHOL, V47, P4, DOI 10.1016/j.humpath.2015.08.007; Kojima M, 2010, AM J SURG PATHOL, V34, P1351, DOI 10.1097/PAS.0b013e3181ecfe98; Ladabaum U, 2011, ANN INTERN MED, V155, P69, DOI 10.7326/0003-4819-155-2-201107190-00002; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Lewin MR, 2007, AM J SURG PATHOL, V31, P1882, DOI 10.1097/PAS.0b013e318057fac2; Liang WY, 2013, AM J SURG PATHOL, V37, P1565, DOI 10.1097/PAS.0b013e31828ea2de; Lin Q, 2015, ONCOTARGETS THER, V8, P233, DOI 10.2147/OTT.S71414; Lugli A, 2017, MODERN PATHOL, V30, P1299, DOI 10.1038/modpathol.2017.46; Mayo E, 2016, HISTOPATHOLOGY, V69, P230, DOI 10.1111/his.12936; Mescoli C, 2012, J CLIN ONCOL, V30, P965, DOI 10.1200/JCO.2011.35.9539; Messenger DE, 2012, HUM PATHOL, V43, P965, DOI 10.1016/j.humpath.2011.11.015; Nagayoshi K, 2014, DIS COLON RECTUM, V57, P467, DOI 10.1097/DCR.0000000000000059; Nagtegaal ID, 2011, J CLIN ONCOL, V29, P2487, DOI 10.1200/JCO.2011.34.6429; Nascimbeni R, 2002, DIS COLON RECTUM, V45, P200, DOI 10.1007/s10350-004-6147-7; Panarelli NC, 2013, AM J SURG PATHOL, V37, P1252, DOI 10.1097/PAS.0b013e3182960e7c; Petersen VC, 2002, GUT, V51, P65, DOI 10.1136/gut.51.1.65; Petrelli F, 2015, J Gastrointest Cancer, V46, P212, DOI 10.1007/s12029-015-9716-1; Protic M, 2015, J AM COLL SURGEONS, V221, P643, DOI 10.1016/j.jamcollsurg.2015.05.007; Puppa G, 2007, MODERN PATHOL, V20, P843, DOI 10.1038/modpathol.3800791; Puppa G, 2011, AM J SURG PATHOL, V35, P465, DOI 10.1097/PAS.0b013e31820ac84a; Puppa G, 2009, MODERN PATHOL, V22, P410, DOI 10.1038/modpathol.2008.198; Rahbari NN, 2012, J CLIN ONCOL, V30, P60, DOI 10.1200/JCO.2011.36.9504; Rock JB, 2014, ARCH PATHOL LAB MED, V138, P636, DOI 10.5858/arpa.2013-0166-OA; Roxburgh CSD, 2014, ANN SURG, V259, P1156, DOI 10.1097/SLA.0000000000000229; Ryan R, 2005, HISTOPATHOLOGY, V47, P141, DOI 10.1111/j.1365-2559.2005.02176.x; Sargent DJ, 2010, J CLIN ONCOL, V28, P3219, DOI 10.1200/JCO.2009.27.1825; Shepherd NA, 1997, GASTROENTEROLOGY, V112, P1096, DOI 10.1016/S0016-5085(97)70119-7; SHEPHERD NA, 1995, J CLIN PATHOL, V48, P849, DOI 10.1136/jcp.48.9.849; Shia J, 2008, AM J SURG PATHOL, V32, P1586, DOI 10.1097/PAS.0b013e31817ec2cd; Shinto E, 2004, DIS COLON RECTUM, V47, P467, DOI 10.1007/s10350-003-0083-9; Sloothaak DAM, 2017, EJSO-EUR J SURG ONC, V43, P1456, DOI 10.1016/j.ejso.2017.04.012; Sloothaak DAM, 2014, EJSO-EUR J SURG ONC, V40, P263, DOI 10.1016/j.ejso.2013.12.002; Song YX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034087; Teutsch SM, 2009, GENET MED, V11, P3, DOI 10.1097/GIM.0b013e318184137c; Ueno H, 2004, GASTROENTEROLOGY, V127, P385, DOI 10.1053/S0016-5085(04)00717-6; Ueno H, 1997, SURG TODAY, V27, P617, DOI 10.1007/BF02388217; Ueno H, 2007, AM J CLIN PATHOL, V127, P287, DOI 10.1309/903UT10VQ3LC7B8L; Ueno H, 2014, AM J SURG, V207, P70, DOI 10.1016/j.amjsurg.2013.04.009; Ueno H, 2011, J CLIN ONCOL, V29, P2550, DOI 10.1200/JCO.2010.33.7725; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; Weixler B, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2130-7	65	0	0	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	MAY-JUN	2018	23	3					138	144		10.1097/PCR.0000000000000243			7	Pathology	Pathology	GL9XG	WOS:000437696100009					2019-10-28	
J	Wheeler, FC; Kim, AS; Mosse, CA; Shaver, AC; Yenamandra, A; Seegmiller, AC				Wheeler, Ferrin C.; Kim, Annette S.; Mosse, Claudio A.; Shaver, Aaron C.; Yenamandra, Ashwini; Seegmiller, Adam C.			Limited Utility of Fluorescence In Situ Hybridization for Recurrent Abnormalities in Acute Myeloid Leukemia at Diagnosis and Follow-up	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Acute myeloid leukemia; Cytogenetics; FISH	WORLD-HEALTH-ORGANIZATION; BONE-MARROW; MYELODYSPLASTIC SYNDROMES; CLINICAL-PRACTICE; MLL GENE; CLASSIFICATION; REARRANGEMENTS; CYTOGENETICS; NEOPLASMS; REVISION	Acute myeloid leukemia (AML) is classified in part by recurrent cytogenetic abnormalities, often detected by both fluorescent in situ hybridization (FISH) and karyotype. The goal of this study was to assess the utility of FISH and karyotyping at diagnosis and follow-up. Adult AML samples at diagnosis or follow-up with karyotype and FISH were identified. Concordance was determined, and clinical characteristics and outcomes for discordant results were evaluated. Karyotype and FISH results were concordant in 193 (95.0%) of 203 diagnostic samples. In 10 cases, FISH detected an abnormality, but karyotype was normal. Of these, one had a FISH result with clinical significance. In follow-up cases, 17 (8.1%) of 211 showed FISH-positive discordant results; most were consistent with low-level residual disease. Clinically significant discordance between karyotype and AML FISH is uncommon. Consequently, FISH testing can safely be omitted from most of these samples. Focused FISH testing is more useful at follow-up, for minimal residual disease detection.	[Wheeler, Ferrin C.; Mosse, Claudio A.; Shaver, Aaron C.; Yenamandra, Ashwini; Seegmiller, Adam C.] Vanderbilt Univ, Med Ctr, Dept Pathol & Lab Med, 1301 Med Ctr Dr, Nashville, TN 37232 USA; [Kim, Annette S.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA	Seegmiller, AC (reprint author), Vanderbilt Univ, Med Ctr, Dept Pathol & Lab Med, 1301 Med Ctr Dr, Nashville, TN 37232 USA.	adam.seegmiller@vanderbilt.edu			NCATS/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000011]	The REDCap database tool is maintained by the Vanderbilt Institute for Clinical and Translational Research supported by grant UL1TR000011 from NCATS/NIH.	Abdou SMH, 2002, LEUKEMIA LYMPHOMA, V43, P89, DOI 10.1080/10428190290000437; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; BOWER M, 1994, BLOOD, V84, P3776, DOI 10.1182/blood.V84.11.3776.bloodjournal84113776; Caligiuri MA, 1998, CANCER RES, V58, P55; Coleman JF, 2011, AM J CLIN PATHOL, V135, P915, DOI [10.1309/AJCFW10YBRMWSWYE, 10.1309/AJCPW10YBRMWSWYE]; Frohling S, 2002, J CLIN ONCOL, V20, P2480, DOI 10.1200/JCO.2002.08.155; He R, 2015, AM J CLIN PATHOL, V143, P873, DOI 10.1309/AJCPP6LVMQG4LNCK; Jiang H, 2012, LEUKEMIA RES, V36, P448, DOI 10.1016/j.leukres.2011.10.014; Kim AS., 2014, WINTROBES CLIN HEMAT, P1801; McGowan-Jordan J, 2016, ISCN INT SYSTEM HUMA; O'Donnell MR, 2012, J NATL COMPR CANC NE, V10, P984, DOI 10.6004/jnccn.2012.0103; Othman MAK, 2015, J HISTOCHEM CYTOCHEM, V63, P384, DOI 10.1369/0022155415576201; Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192; Patel JP, 2012, NEW ENGL J MED, V366, P1079, DOI 10.1056/NEJMoa1112304; Pitchford CW, 2010, AM J CLIN PATHOL, V133, P260, DOI 10.1309/AJCPZ4JL5ZMRPFTD; Seegmiller AC, 2016, AM J CLIN PATHOL, V146, P585, DOI [10.1093/AJCP/AQW180, 10.1093/ajcp/aqw180]; Seegmiller AC, 2014, LEUKEMIA LYMPHOMA, V55, P601, DOI 10.3109/10428194.2013.801470; Seegmiller AC, 2013, AM J CLIN PATHOL, V140, P643, DOI 10.1309/AJCP8CKE9NEINQFL; Vardiman JW, 2009, BLOOD, V114, P937, DOI 10.1182/blood-2009-03-209262; Wiktor AE, 2006, GENET MED, V8, P16, DOI 10.1097/01.gim.0000195645.00446.61; Wolff DJ, 2007, J MOL DIAGN, V9, P134, DOI 10.2353/jmoldx.2007.060128	21	1	1	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	MAY	2018	149	5					418	424		10.1093/ajcp/aqy002			7	Pathology	Pathology	GC0FX	WOS:000429453400007	29538617	Bronze, Green Published			2019-10-28	
J	Gagnon, L; Leduc, M; Thibodeau, JF; Zhang, MZ; Grouix, B; Sarra-Bournet, F; Gagnon, W; Hince, K; Tremblay, M; Geerts, L; Kennedy, CRJ; Hebert, RL; Gutsol, A; Holterman, CE; Kamto, E; Gervais, L; Ouboudinar, J; Richard, J; Felton, A; Laverdure, A; Simard, JC; Letourneau, S; Cloutier, MP; Leblond, FA; Abbott, SD; Penney, C; Duceppe, JS; Zacharie, B; Dupuis, J; Calderone, A; Nguyen, QT; Harris, RC; Laurin, P				Gagnon, Lyne; Leduc, Martin; Thibodeau, Jean-Francois; Zhang, Ming-Zhi; Grouix, Brigitte; Sarra-Bournet, Francois; Gagnon, William; Hince, Kathy; Tremblay, Mikael; Geerts, Lilianne; Kennedy, Christopher R. J.; Hebert, Richard L.; Gutsol, Alex; Holterman, Chet E.; Kamto, Eldjonai; Gervais, Liette; Ouboudinar, Jugurtha; Richard, Jonathan; Felton, Alexandra; Laverdure, Alexandre; Simard, Jean-Christophe; Letourneau, Sylvie; Cloutier, Marie-Pier; Leblond, Francois A.; Abbott, Shaun D.; Penney, Christopher; Duceppe, Jean-Simon; Zacharie, Boulos; Dupuis, Jocelyn; Calderone, Angelino; Nguyen, Quang T.; Harris, Raymond C.; Laurin, Pierre			A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors GPR40 and GPR84	AMERICAN JOURNAL OF PATHOLOGY			English	Article							PROTEIN-COUPLED-RECEPTOR; BETA-ARRESTIN RECRUITMENT; BIASED-AGONISM; GPR40; CELLS; ACTIVATION; GPR84; EXPRESSION; FIBROSIS; LIGANDS	Numerous clinical conditions can lead to organ fibrosis and functional failure. There is a great need for therapies that could effectively target pathophysiological pathways involved in fibrosis. GPR40 and GPR84 are G protein-coupled receptors with free fatty acid ligands and are associated with metabolic and inflammatory disorders. Although GPR40 and GPR84 are involved in diverse physiological processes, no evidence has demonstrated the relevance of GPR40 and GPR84 in fibrosis pathways..Using PBI-4050 (3-pentylbenzeneacetic acid sodium salt), a synthetic analog of a medium-chain fatty acid that displays agonist and antagonist ligand affinity toward GPR40 and GPR84, respectively, we uncovered an anti fibrotic pathway involving these receptors. In experiments using Gpr40- and Gpr84-knockout mice in models of kidney fibrosis (unilateral ureteral obstruction, long-term post-acute ischemic injury, and adenine-induced chronic kidney disease), we found that GPR40 is protective and GPR84 is deleterious in these diseases. Moreover, through binding to GPR40 and GPR84, PBI-4050 significantly attenuated fibrosis in many injury contexts, as evidenced by the antifibrotic activity observed in kidney, liver, heart, lung, pancreas, and skin fibrosis models. Therefore, GPR40 and GPR84 may represent promising molecular targets in fibrosis pathways. We conclude that PBI-4050 is a first-in-class compound that may be effective for managing inflammatory and fibrosis-related diseases.	[Gagnon, Lyne; Leduc, Martin; Thibodeau, Jean-Francois; Grouix, Brigitte; Sarra-Bournet, Francois; Gagnon, William; Hince, Kathy; Tremblay, Mikael; Geerts, Lilianne; Gervais, Liette; Ouboudinar, Jugurtha; Richard, Jonathan; Felton, Alexandra; Laverdure, Alexandre; Simard, Jean-Christophe; Letourneau, Sylvie; Cloutier, Marie-Pier; Leblond, Francois A.; Abbott, Shaun D.; Penney, Christopher; Duceppe, Jean-Simon; Zacharie, Boulos; Laurin, Pierre] Promet BioSci Inc, 500 Blvd Cartier Ouest,Ste 150, Laval, PQ H7V 5B7, Canada; [Thibodeau, Jean-Francois; Kennedy, Christopher R. J.; Gutsol, Alex; Holterman, Chet E.; Kamto, Eldjonai] Ottawa Hosp, Res Inst, Kidney Res Ctr, Ottawa, ON, Canada; [Thibodeau, Jean-Francois; Kennedy, Christopher R. J.; Hebert, Richard L.] Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON, Canada; [Zhang, Ming-Zhi; Harris, Raymond C.] Vanderbilt Univ, Sch Med, Dept Med, Div Nephrol & Hypertens, Nashville, TN 37212 USA; [Dupuis, Jocelyn; Calderone, Angelino; Nguyen, Quang T.] Montreal Heart Inst, Montreal, PQ, Canada; [Dupuis, Jocelyn] Univ Montreal, Dept Med, Montreal, PQ, Canada; [Calderone, Angelino] Univ Montreal, Dept Pharmacol & Physiol, Montreal, PQ, Canada	Gagnon, L (reprint author), Promet BioSci Inc, 500 Blvd Cartier Ouest,Ste 150, Laval, PQ H7V 5B7, Canada.	l.gagnon@prometic.com	Dupuis, Jocelyn/C-6613-2013	Dupuis, Jocelyn/0000-0002-3193-1014; Holterman, Chet/0000-0002-9002-6073; Thibodeau, Jean-Francois/0000-0002-9322-4868; Leduc, Martin/0000-0001-9286-9456	Prometic BioSciences Inc; Mitacs Accelerate scholarship; Mitacs Elevate scholarship	Supported by Prometic BioSciences Inc, a Mitacs Accelerate scholarship (J.-F.T.), and a Mitacs Elevate scholarship (J.C.S.).	Bouchard C, 2007, GLIA, V55, P790, DOI 10.1002/glia.20506; Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200; Burant CF, 2012, LANCET, V379, P1403, DOI 10.1016/S0140-6736(11)61879-5; Cartoni C, 2010, J NEUROSCI, V30, P8376, DOI 10.1523/JNEUROSCI.0496-10.2010; Chung MJ, 2007, J PATHOL, V212, P180, DOI 10.1002/path.2161; Edfalk S, 2008, DIABETES, V57, P2280, DOI 10.2337/db08-0307; Fujita T, 2011, J INVEST DERMATOL, V131, P1660, DOI 10.1038/jid.2011.123; Gales C, 2006, NAT STRUCT MOL BIOL, V13, P778, DOI 10.1038/nsmb1134; Goebel M, 2011, PHYSIOL GENOMICS, V43, P237, DOI 10.1152/physiolgenomics.00193.2010; Hara T, 2009, MOL PHARMACOL, V75, P85, DOI 10.1124/mol.108.052225; Hardy S, 2005, J BIOL CHEM, V280, P13285, DOI 10.1074/jbc.M410922200; Ichimura A, 2009, PROSTAG OTH LIPID M, V89, P82, DOI 10.1016/j.prostaglandins.2009.05.003; Itoh Y, 2005, HEPATOL RES, V33, P171, DOI 10.1016/j.hepres.2005.09.028; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; Keir LS, 2015, NEPHRON, V129, P128, DOI 10.1159/000369816; Kotarsky K, 2003, BIOCHEM BIOPH RES CO, V301, P406, DOI 10.1016/S0006-291X(02)03064-4; Laurin P, 2016, PBI 4050 REDUCES CAR; Liou AP, 2011, GASTROENTEROLOGY, V140, P903, DOI 10.1053/j.gastro.2010.10.012; Loening AM, 2006, PROTEIN ENG DES SEL, V19, P391, DOI 10.1093/protein/gzl023; Longo PA, 2013, METHOD ENZYMOL, V529, P227, DOI 10.1016/B978-0-12-418687-3.00018-5; Ma SK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0113130; Ma SK, 2014, INT J MOL MED, V34, P1117, DOI 10.3892/ijmm.2014.1874; Mancini AD, 2015, J BIOL CHEM, V290, P21131, DOI 10.1074/jbc.M115.644450; Nagasaki H, 2012, FEBS LETT, V586, P368, DOI 10.1016/j.febslet.2012.01.001; Nakamoto K, 2012, BRAIN RES, V1432, P74, DOI 10.1016/j.brainres.2011.11.012; Nicol LSC, 2015, J NEUROSCI, V35, P8959, DOI 10.1523/JNEUROSCI.3558-14.2015; Panse M, 2015, CELL PHYSIOL BIOCHEM, V35, P1537, DOI 10.1159/000373969; Parker I, 2017, PBI 4050 IS SAFE WEL; Qian J, 2014, CELL SIGNAL, V26, P2412, DOI 10.1016/j.cellsig.2014.07.019; Sauliere A, 2012, NAT CHEM BIOL, V8, P622, DOI [10.1038/NCHEMBIO.961, 10.1038/nchembio.961]; Southern C, 2013, J BIOMOL SCREEN, V18, P599, DOI 10.1177/1087057113475480; Suzuki M, 2013, J BIOL CHEM, V288, P10684, DOI 10.1074/jbc.M112.420042; Tamura M, 2009, HISTOCHEM CELL BIOL, V131, P483, DOI 10.1007/s00418-009-0557-5; Tardif K, 2015, AM J PHYSIOL-HEART C, V308, pH1265, DOI 10.1152/ajpheart.00804.2014; Venkataraman C, 2005, IMMUNOL LETT, V101, P144, DOI 10.1016/j.imlet.2005.05.010; Wang JH, 2006, J BIOL CHEM, V281, P34457, DOI 10.1074/jbc.M608019200; Wittenberger T, 2001, J MOL BIOL, V307, P799, DOI 10.1006/jmbi.2001.4520; Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807; Yonezawa T, 2004, BIOCHEM BIOPH RES CO, V314, P805, DOI 10.1016/j.bbrc.2003.12.175; Yonezawa T, 2013, CURR MED CHEM, V20, P3855; Zhang Q, 2016, J PHARMACOL EXP THER, V357, P337, DOI 10.1124/jpet.116.232033; Zhang Xia, 2008, Curr Protoc Immunol, VChapter 14, DOI 10.1002/0471142735.im1401s83	42	14	14	2	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAY	2018	188	5					1132	1148		10.1016/j.ajpath.2018.01.009			17	Pathology	Pathology	GD6TK	WOS:000430641100004	29454750	Other Gold			2019-10-28	
J	Alexeev, EE; Lanis, JM; Kao, DJ; Campbell, EL; Kelly, CJ; Battista, KD; Gerich, ME; Jenkins, BR; Walk, ST; Kominsky, DJ; Colgan, SP				Alexeev, Erica E.; Lanis, Jordi M.; Kao, Daniel J.; Campbell, Eric L.; Kelly, Caleb J.; Battista, Kayla D.; Gerich, Mark E.; Jenkins, Brittany R.; Walk, Seth T.; Kominsky, Douglas J.; Colgan, Sean P.			Microbiota-Derived Indole Metabolites Promote Human and Murine Intestinal Homeostasis through Regulation of Interleukin-10 Receptor	AMERICAN JOURNAL OF PATHOLOGY			English	Article							ARYL-HYDROCARBON RECEPTOR; INFLAMMATORY-BOWEL-DISEASE; GUT MICROBIOTA; TRYPTOPHAN-METABOLITES; IL-10 RECEPTOR; AH RECEPTOR; CELLS; ACTIVATION; INDUCTION; EPITHELIA	Interactions between the gut microbiota and the host are important for health, where dysbiosis has emerged as a likely component of mucosal disease. The specific constituents of the microbiota that contribute to mucosal disease are not well defined. The authors sought to define microbial components that regulate homeostasis within the intestinal mucosa. Using an unbiased, metabolomic profiling approach, a selective depletion of indole and indole-derived metabolites was identified in murine and human colitis. Indole-3-propionic acid (IPA) was selectively diminished in circulating serum from human subjects with active colitis, and IPA served as a biomarker of disease remission. Administration of indole metabolites showed prominent induction of IL-10R1 on cultured intestinal epithelia that was explained by activation of the aryl hydrocarbon receptor. Colonization of germ-free mice with wild-type Escherichia coli, but not E. coli mutants unable to generate indole, induced colonic epithelial IL-10R1. Moreover, oral administration of IPA significantly ameliorated disease in a chemically induced murine colitis model. This work defines a novel role of indole metabolites in anti-inflammatory pathways mediated by epithelial IL-10 signaling and identifies possible avenues for utilizing indoles as novel therapeutics in mucosal disease.	[Alexeev, Erica E.; Lanis, Jordi M.; Kao, Daniel J.; Kelly, Caleb J.; Battista, Kayla D.; Gerich, Mark E.; Colgan, Sean P.] Univ Colorado, Mucosal Inflammat Program, Anschutz Med Campus,12700 E 19th Ave,MS B-146, Aurora, CO 80045 USA; [Alexeev, Erica E.; Lanis, Jordi M.; Kao, Daniel J.; Kelly, Caleb J.; Battista, Kayla D.; Gerich, Mark E.] Univ Colorado, Dept Med, Anschutz Med Campus, Aurora, CO USA; [Campbell, Eric L.] Queens Univ Belfast, Ctr Expt Med, Belfast, Antrim, North Ireland; [Jenkins, Brittany R.; Walk, Seth T.; Kominsky, Douglas J.] Montana State Univ, Dept Microbiol & Immunol, 109 Lewis Hall, Bozeman, MT 59717 USA	Colgan, SP (reprint author), Univ Colorado, Mucosal Inflammat Program, Anschutz Med Campus,12700 E 19th Ave,MS B-146, Aurora, CO 80045 USA.; Kominsky, DJ (reprint author), Montana State Univ, Dept Microbiol & Immunol, 109 Lewis Hall, Bozeman, MT 59717 USA.	douglas.kominsky@montana.edu; sean.colgan@ucdenver.edu	; Campbell, Eric/N-5357-2015	Kelly, Caleb/0000-0003-4861-1479; Campbell, Eric/0000-0003-0744-6577	NIH grantsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DK1047893, DK50189, DK095491, DK103639, DK103712]; VA Merit grant [BX002182]; Bill and Melinda Gates FoundationGates Foundation	Supported by NIH grants DK1047893, DK50189, DK095491, DK103639, and DK103712 (S.P.C.) and VA Merit grant BX002182 (S.P.C.). Funding for generating and maintaining the human intestinal organoids was provided by the Bill and Melinda Gates Foundation (D.J.Ko.).	Albrecht E, 2014, METABOLOMICS, V10, P141, DOI 10.1007/s11306-013-0565-2; Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Bessede A, 2014, NATURE, V511, P184, DOI 10.1038/nature13323; Butto LF, 2016, INT J MED MICROBIOL, V306, P302, DOI 10.1016/j.ijmm.2016.02.010; Cervantes-Barragan L, 2017, SCIENCE, V357, P806, DOI 10.1126/science.aah5825; Chaudhry A, 2011, IMMUNITY, V34, P566, DOI 10.1016/j.immuni.2011.03.018; Cheng J, 2012, TRENDS PHARMACOL SCI, V33, P323, DOI 10.1016/j.tips.2012.03.003; COLGAN SP, 1994, AM J PHYSIOL, V267, pC402; De Preter V, 2015, GUT, V64, P447, DOI 10.1136/gutjnl-2013-306423; Devlin AS, 2016, CELL HOST MICROBE, V20, P709, DOI 10.1016/j.chom.2016.10.021; Dieleman LA, 1998, CLIN EXP IMMUNOL, V114, P385; Eeckhaut V, 2013, GUT, V62, P1745, DOI 10.1136/gutjnl-2012-303611; Engelhardt KR, 2014, CURR TOP MICROBIOL, V380, P1, DOI 10.1007/978-3-662-43492-5_1; Frank DN, 2007, P NATL ACAD SCI USA, V104, P13780, DOI 10.1073/pnas.0706625104; Gaitanis G, 2008, J INVEST DERMATOL, V128, P1620, DOI 10.1038/sj.jid.5701252; Heath-Pagliuso S, 1998, BIOCHEMISTRY-US, V37, P11508, DOI 10.1021/bi980087p; Hopkins FG, 1903, J PHYSIOL-LONDON, V29, P451; Hubbard TD, 2015, DRUG METAB DISPOS, V43, P1522, DOI 10.1124/dmd.115.064246; Hubbard TD, 2015, SCI REP-UK, V5, DOI 10.1038/srep12689; Huttenhower C, 2014, IMMUNITY, V40, P843, DOI 10.1016/j.immuni.2014.05.013; Innocentin YLS, 2011, CELL, V147, P629, DOI 10.1016/j.cell.2011.09.025; Jin UH, 2014, MOL PHARMACOL, V85, P777, DOI 10.1124/mol.113.091165; Kimura A, 2008, P NATL ACAD SCI USA, V105, P9721, DOI 10.1073/pnas.0804231105; Kominsky DJ, 2014, J IMMUNOL, V192, P1267, DOI 10.4049/jimmunol.1301757; Kominsky DJ, 2011, J IMMUNOL, V186, P6505, DOI 10.4049/jimmunol.1002805; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Lanis JM, 2017, MUCOSAL IMMUNOL, V10, P1133, DOI 10.1038/mi.2016.133; Lee JH, 2015, TRENDS MICROBIOL, V23, P707, DOI 10.1016/j.tim.2015.08.001; Lee JH, 2010, FEMS MICROBIOL REV, V34, P426, DOI 10.1111/j.1574-6976.2009.00204.x; Lo R, 2012, TOXICOL SCI, V130, P349, DOI 10.1093/toxsci/kfs253; Lozupone CA, 2012, NATURE, V489, P220, DOI 10.1038/nature11550; Machiels K, 2014, GUT, V63, P1275, DOI 10.1136/gutjnl-2013-304833; Manichanh C, 2012, NAT REV GASTRO HEPAT, V9, P599, DOI 10.1038/nrgastro.2012.152; Martin K, 1998, J BACTERIOL, V180, P107; Mascanfroni ID, 2015, NAT MED, V21, P638, DOI 10.1038/nm.3868; Mathieu MC, 2001, J BIOL CHEM, V276, P4819, DOI 10.1074/jbc.M008495200; McCracken KW, 2011, NAT PROTOC, V6, P1920, DOI 10.1038/nprot.2011.410; Monteleone I, 2011, GASTROENTEROLOGY, V141, P237, DOI 10.1053/j.gastro.2011.04.007; Muniz LR, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00310; NEWTON WA, 1964, P NATL ACAD SCI USA, V51, P382, DOI 10.1073/pnas.51.3.382; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Sartor RB, 2008, GASTROENTEROLOGY, V134, P577, DOI 10.1053/j.gastro.2007.11.059; Shimada Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080604; Sokol H, 2009, INFLAMM BOWEL DIS, V15, P1183, DOI 10.1002/ibd.20903; Spence JR, 2011, NATURE, V470, P105, DOI 10.1038/nature09691; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Venkatesh M, 2014, IMMUNITY, V41, P296, DOI 10.1016/j.immuni.2014.06.014; Vlachos C, 2012, BRIT J DERMATOL, V167, P496, DOI 10.1111/j.1365-2133.2012.11014.x; Wikoff WR, 2009, P NATL ACAD SCI USA, V106, P3698, DOI 10.1073/pnas.0812874106; Wlodarska M, 2017, CELL HOST MICROBE, V22, P25, DOI 10.1016/j.chom.2017.06.007; Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005; Zelante T, 2013, IMMUNITY, V39, P372, DOI 10.1016/j.immuni.2013.08.003	52	18	18	2	24	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAY	2018	188	5					1183	1194		10.1016/j.ajpath.2018.01.01			12	Pathology	Pathology	GD6TK	WOS:000430641100008	29454749				2019-10-28	
J	Totoki, T; Alessandro-Gabazza, CND; Toda, M; Tonto, PB; Takeshita, A; Yasuma, T; Nishihama, K; Iwasa, M; Horiki, N; Takei, Y; Gabazza, EC				Totoki, Toshiaki; Alessandro-Gabazza, Corina N. D'; Toda, Masaaki; Tonto, Prince Baffour; Takeshita, Atsuro; Yasuma, Taro; Nishihama, Kota; Iwasa, Motoh; Horiki, Noriyuki; Takei, Yoshiyuki; Gabazza, Esteban C.			Protein S Exacerbates Chronic Liver Injury and Fibrosis	AMERICAN JOURNAL OF PATHOLOGY			English	Article							K-DEPENDENT PROTEIN; TAM RECEPTORS; ANTICOAGULANT; INFLAMMATION; EXPRESSION; DISEASE; CELLS	Protein S is a vitamin K-dependent glycoprotein produced mainly in the liver with anticoagulant, anti-inflammatory, immune-modulatory, and antiapoptotic properties. Protein S exacerbates acute liver injury by prolonging the survival of liver immune cells. However, the effect of protein Son chronic liver injury and fibrosis is unknown. Here, we investigated whether human protein S can affect chronic liver injury and fibrosis. Liver injury/fibrosis was induced by carbon tetrachloride injection in mice overexpressing human protein S and in wild-type mice. Human protein S transgenic mice receiving carbon tetrachloride showed significantly higher circulating levels of liver transaminases, increased liver expression of inflammatory cytokines, significantly more extended liver fibrosis, and areas with DNA breakage after chronic injury compared with wild-type mice. Wild-type mice infused with exogenous human protein S exhibited exacerbated liver injury and increased number of hepatic stellate cells compared with untreated mice. Human protein S inhibited apoptosis and increased Akt pathway activation in hepatic stellate cells. The anti-apoptotic activity of protein S may play a role in chronic liver injury and subsequent liver fibrosis.	[Totoki, Toshiaki; Iwasa, Motoh; Horiki, Noriyuki; Takei, Yoshiyuki] Mie Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Tsu, Mie, Japan; [Alessandro-Gabazza, Corina N. D'; Toda, Masaaki; Tonto, Prince Baffour; Yasuma, Taro; Gabazza, Esteban C.] Mie Univ, Grad Sch Med, Dept Immunol, Tsu, Mie, Japan; [Takeshita, Atsuro; Yasuma, Taro; Nishihama, Kota] Mie Univ, Grad Sch Med, Dept Diabet Metab & Endocrinol, Tsu, Mie, Japan	Gabazza, EC (reprint author), Mie Univ, Sch Med, Dept Immunol, Edobashi 2-174, Tsu, Mie 5148507, Japan.	gabazza@doc.medic.mie-u.ac.jp		Gabazza, Esteban/0000-0001-5748-1499	Ministry of Education, Culture, Sports, Science, and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)	Supported in part by grant from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (E.C.G.).	Anderson HA, 2003, NAT IMMUNOL, V4, P87, DOI 10.1038/ni871; Baccouche H, 2017, BLOOD COAGUL FIBRIN, V28, P139, DOI 10.1097/MBC.0000000000000561; Chelakkot-Govindalayathil AL, 2015, J THROMB HAEMOST, V13, P142, DOI 10.1111/jth.12789; Ge PS, 2016, NEW ENGL J MED, V375, P2104, DOI 10.1056/NEJMc1612334; Giri TK, 2002, J BIOL CHEM, V277, P15099, DOI 10.1074/jbc.M103036200; Griffin JH, 2012, INT J HEMATOL, V95, P333, DOI 10.1007/s12185-012-1059-0; Hafizi S, 2006, FEBS J, V273, P5231, DOI 10.1111/j.1742-4658.2006.05529.x; Hammerich L, 2014, HEPATOLOGY, V59, P630, DOI 10.1002/hep.26697; Hataji O, 2002, LUNG, V180, P47, DOI 10.1007/s004080000080; Hinz B, 2012, AM J PATHOL, V180, P1340, DOI 10.1016/j.ajpath.2012.02.004; JAMISON CS, 1995, THROMB RES, V78, P407, DOI 10.1016/0049-3848(95)00074-2; Kanthou C, 2000, ADV EXP MED BIOL, V476, P155; Nguyen KQ, 2013, AUTOIMMUNITY, V46, P294, DOI 10.3109/08916934.2013.794515; Kopec AK, 2016, J THROMB HAEMOST, V14, P1337, DOI 10.1111/jth.13327; KRACHMAINICOFF A, 1990, CLIN CHEM, V36, P43; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Lisman T, 2010, J HEPATOL, V53, P362, DOI 10.1016/j.jhep.2010.01.042; MAILLARD C, 1992, ENDOCRINOLOGY, V130, P1599, DOI 10.1210/en.130.3.1599; Marengo A, 2016, ANNU REV MED, V67, P103, DOI 10.1146/annurev-med-090514-013832; Rothlin CV, 2007, CELL, V131, P1124, DOI 10.1016/j.cell.2007.10.034; Shimokawa T, 2001, THROMB HAEMOSTASIS, V86, P623; Silva EAC, 2013, IMMUNITY, V39, P160, DOI 10.1016/j.immuni.2013.06.010; Suleiman L, 2013, CRIT REV ONCOL HEMAT, V88, P637, DOI 10.1016/j.critrevonc.2013.07.004; Takagi T, 2009, J THROMB HAEMOST, V7, P2053, DOI 10.1111/j.1538-7836.2009.03642.x; Tischendorf M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155337; Urawa M, 2016, J THROMB HAEMOST, V14, P1588, DOI 10.1111/jth.13362; Vilaseca M, 2017, HEPATOLOGY, V65, P2031, DOI 10.1002/hep.29084; Webb JH, 2002, J IMMUNOL, V169, P2580, DOI 10.4049/jimmunol.169.5.2580; Yasuma T, 2016, DIABETES, V65, P1940, DOI 10.2337/db15-1404; Zhong ZH, 2010, J NEUROSCI, V30, P15521, DOI 10.1523/JNEUROSCI.4437-10.2010	30	1	1	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAY	2018	188	5					1195	1203		10.1016/j.ajpath.2018.01.007			9	Pathology	Pathology	GD6TK	WOS:000430641100009	29454753	Bronze			2019-10-28	
J	Masemann, D; Dantas, RL; Sitnik, S; Schied, T; Nordhoff, C; Ludwig, S; Wixler, V				Masemann, Doerthe; Dantas, Rafael Leite; Sitnik, Siarhei; Schied, Tanja; Nordhoff, Carolin; Ludwig, Stephan; Wixler, Viktor			The Four-and-a-Half LIM Domain Protein 2 Supports Influenza A Virus-Induced Lung Inflammation by Restricting the Host Adaptive Immune Response	AMERICAN JOURNAL OF PATHOLOGY			English	Article							T-CELL RESPONSES; ALVEOLAR MACROPHAGES; DENDRITIC CELLS; BETA-CATENIN; NS1 PROTEIN; INFECTION; FHL2; COACTIVATOR; DEFICIENCY; RESOLUTION	Four-and-a-half LIM domain protein 2 (FHL2) is a multifunctional adaptor protein with fine-tuning adjustment properties. It acts as a regulator of signaling cascades but also as a cofactor of transcription and controls several anti-inflammatory immune responses. Recently, we described FHL2 as a novel regulator of influenza A virus propagation. We have shown that in vitro FHL2 restricts viral replication by accelerating the interferon regulatory factor 3-dependent transcription of the Ifnb1 gene. In this work, we unraveled an ambiguous role of FHL2 during influenza A virus infection in vivo. Although FHL2 restrained viral replication during the first 24 hours of infection, it significantly delayed viral clearance afterward. Comparison of lung immune status of wild-type and FHL2 knockout mice during influenza virus infection did not acknowledge significant differences in the innate host immune response but revealed an improved migration of dendritic cells from infected lungs into draining lymph nodes as well as increased levels of activated CD8(+) T lymphocytes accumulated in the lungs of FHL2 knockout mice.	[Masemann, Doerthe; Dantas, Rafael Leite; Sitnik, Siarhei; Schied, Tanja; Nordhoff, Carolin; Ludwig, Stephan; Wixler, Viktor] Westfaelische Wilhelms Univ, Inst Mol Virol, Von Esmarch Str 56, D-48149 Munster, Germany; [Ludwig, Stephan] Westfaelische Wilhelms Univ, Cluster Excellence Cells Mot, Munster, Germany	Wixler, V (reprint author), Westfaelische Wilhelms Univ, Inst Mol Virol, Von Esmarch Str 56, D-48149 Munster, Germany.	vwixler@uni-muenster.de		Ludwig, Stephan/0000-0003-4490-3052	Coordination for the Improvement of Higher Education Personnel (CAPES) BrazilCAPES [99999.013234/2013-07]; IZKF Muenster grants [Wix2/005/10, Lud2/008/17]; Deutsche Forschungsgemeinschaft grantsGerman Research Foundation (DFG) [SFB 492, SFB 1009 B02]	Supported by Coordination for the Improvement of Higher Education Personnel (CAPES) Brazil grant 99999.013234/2013-07 (R.L.D.), IZKF Muenster grants Wix2/005/10 (V.W.) and Lud2/008/17 (S.L.), and Deutsche Forschungsgemeinschaft grants SFB 492 All (V.W.) and SFB 1009 B02 (S.L.).	Alnajar A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081356; Ayllon J, 2015, CURR TOP MICROBIOL, V386, P73, DOI 10.1007/82_2014_400; Bai S, 2008, J BIOL CHEM, V283, P30861, DOI 10.1074/jbc.M802525200; Ballesteros-Tato A, 2010, NAT IMMUNOL, V11, P216, DOI 10.1038/ni.1838; Borgeling Y, 2014, J BIOL CHEM, V289, P13, DOI 10.1074/jbc.M113.469239; Chakrabarti AK, 2013, VIROLOGY, V440, P97, DOI 10.1016/j.virol.2013.02.025; Dahan J, 2013, MOL CELL BIOL, V33, P3299, DOI 10.1128/MCB.00105-13; Dantas RL, 2017, AM J PATHOL, V187, P2388, DOI 10.1016/j.ajpath.2017.07.015; Dudek SE, 2011, BIOL CHEM, V392, P1135, DOI [10.1515/BC-2011-174, 10.1515/BC.2011.174]; Durbin RK, 2013, IMMUNOL REV, V255, P25, DOI 10.1111/imr.12101; Ehrhardt C, 2010, MICROBES INFECT, V12, P81, DOI 10.1016/j.micinf.2009.09.007; Forster R, 2008, NAT REV IMMUNOL, V8, P362, DOI 10.1038/nri2297; GeurtsvanKessel CH, 2008, J EXP MED, V205, P1621, DOI 10.1084/jem.20071365; Ghoneim HE, 2013, J IMMUNOL, V191, P1250, DOI 10.4049/jimmunol.1300014; Grant EJ, 2016, CURR OPIN VIROL, V16, P132, DOI 10.1016/j.coviro.2016.01.016; Herold S, 2015, EUR RESPIR J, V45, P1463, DOI 10.1183/09031936.00186214; Herold S, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00065; Hussell T, 2014, NAT REV IMMUNOL, V14, P81, DOI 10.1038/nri3600; Johannessen M, 2006, CELL MOL LIFE SCI, V63, P268, DOI 10.1007/s00018-005-5438-z; Kawai T, 2006, NAT IMMUNOL, V7, P131, DOI 10.1038/ni1303; Kleiber K, 2007, ANTICANCER RES, V27, P55; Konig K, 2010, J IMMUNOL, V185, P1466, DOI 10.4049/jimmunol.0903449; Kother K, 2014, FASEB J, V28, P4235, DOI 10.1096/fj.14-249599; Kong YF, 2001, CIRCULATION, V103, P2731; Krug RM, 2015, CURR OPIN VIROL, V12, P1, DOI 10.1016/j.coviro.2015.01.007; Legge KL, 2003, IMMUNITY, V18, P265, DOI 10.1016/S1074-7613(03)00023-2; Liu M, 2015, SCI REP-UK, V5, DOI 10.1038/srep14171; Ludwig S, 2006, CELL MICROBIOL, V8, P375, DOI 10.1111/j.1462-5822.2005.00678.x; Ludwig S, 2014, INT J MED MICROBIOL, V304, P894, DOI 10.1016/j.ijmm.2014.08.016; Martin B, 2002, J CELL BIOL, V159, P113, DOI 10.1083/jcb.200202075; Newton AH, 2016, SEMIN IMMUNOPATHOL, V38, P471, DOI 10.1007/s00281-016-0558-0; Nordhoff C, 2012, CELL MICROBIOL, V14, P1135, DOI 10.1111/j.1462-5822.2012.01787.x; Openshaw PJM, 2005, CLIN MICROBIOL REV, V18, P541, DOI 10.1128/CMR.18.3.541-555.2005; Park J, 2008, FASEB J, V22, P2508, DOI 10.1096/fj.07-095521; Peteranderl C, 2016, SEMIN RESP CRIT CARE, V37, P487, DOI 10.1055/s-0036-1584801; Pommerenke C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041169; Wei Y, 2003, J BIOL CHEM, V278, P5188, DOI 10.1074/jbc.M207216200; Wixler V, 2007, J CELL BIOL, V177, P163, DOI 10.1083/jcb.200606043; Wixler V, 2015, ANN RHEUM DIS, V74, P2216, DOI 10.1136/annrheumdis-2013-205061; Wu HY, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-172	40	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAY	2018	188	5					1236	1245		10.1016/j.ajpath.2018.02.004			10	Pathology	Pathology	GD6TK	WOS:000430641100013	29458009	Bronze			2019-10-28	
J	Dzikiewicz-Krawczyk, A; Diepstra, A; Rutgers, B; Kortman, G; de Jong, D; Koerts, J; Bulthuis, M; van der Sluis, T; Seitz, A; Visser, L; Kok, K; Kluiver, J; van den Berg, A				Dzikiewicz-Krawczyk, Agnieszka; Diepstra, Arjan; Rutgers, Bea; Kortman, Gertrud; de Jong, Debora; Koerts, Jasper; Bulthuis, Marian; van der Sluis, Tineke; Seitz, Annika; Visser, Lydia; Kok, Klaas; Kluiver, Joost; van den Berg, Anke			Argonaute 2 RNA Immunoprecipitation Reveals Distinct miRNA Targetomes of Primary Burkitt Lymphoma Tumors and Normal B Cells	AMERICAN JOURNAL OF PATHOLOGY			English	Article							LARGE GENE LISTS; EXPRESSION; MICRORNA; CLUSTER; CLASSIFICATION; MIR-17-92; HODGKIN; PATHWAY; REPRESSION; COMPONENTS	miRNAs are small noncoding RNAs involved in the posttranscriptional regulation of gene expression. Deregulated miRNA levels have been linked to Burkitt lymphoma (BL) pathogenesis. To date, the number of known pathogenesis-related miRNA-target gene interactions is limited. Here, we determined for the first time the miRNA targetomes of primary BL tumors and normal B cells. AG02-RNA immunoprecipitation of two frozen diagnostic BL tissue samples and three CD19(+) B-cell samples isolated from routinely removed tonsils showed distinct miRNA targetomes of BL and normal B cells. In contrast to normal B cells, miRNA target genes in BL were enriched for targets of the oncogenic miR-17 to 92 cluster, and were involved mainly in cell cycle and cell death. Immunohistochemistry on BL and tonsil tissues confirmed altered protein levels for two of six selected miRNA targets, in line with the differential AG02-IP enrichment between BL and normal B cells. A comparison of AG02-IP-enriched genes in primary BL cases with BL cell lines indicated that despite a considerable overlap, the miRNA targetomes of BL cell lines show substantial differences with the targetomes of primary BL tumors. In summary, we identified distinct miRNA targetomes of BL and normal B cells, and showed both the necessity and feasibility of studying miRNA-target gene interactions in primary tumors.	[Dzikiewicz-Krawczyk, Agnieszka; Diepstra, Arjan; Rutgers, Bea; Kortman, Gertrud; de Jong, Debora; Koerts, Jasper; Bulthuis, Marian; van der Sluis, Tineke; Seitz, Annika; Visser, Lydia; Kluiver, Joost; van den Berg, Anke] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Hanzepl 1, NL-9700 RB Groningen, Netherlands; [Kok, Klaas] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Hanzepl 1, NL-9700 RB Groningen, Netherlands; [Dzikiewicz-Krawczyk, Agnieszka] Polish Acad Sci, Inst Human Genet, Poznan, Poland	van den Berg, A (reprint author), Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Hanzepl 1, NL-9700 RB Groningen, Netherlands.	a.van.den.berg01@umcg.nl	Dzikiewicz-Krawczyk, Agnieszka/X-2135-2019; van den Berg, Anke/H-1718-2011	Dzikiewicz-Krawczyk, Agnieszka/0000-0001-7633-2114; van den Berg, Anke/0000-0002-8894-2638	Pediatric Oncology Foundation Groningen grant [SKOG 11-001]	Supported by Pediatric Oncology Foundation Groningen grant SKOG 11-001 (J.K. and A.v.d.B.).	Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Alexander DD, 2007, INT J CANCER, P1, DOI 10.1002/ijc.22719; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bartolome-Izquierdo N, 2017, BLOOD, V129, P2408, DOI 10.1182/blood-2016-08-731166; Browne CD, 2010, P NATL ACAD SCI USA, V107, P18944, DOI 10.1073/pnas.1007558107; Bueno MJ, 2011, BLOOD, V117, P6255, DOI 10.1182/blood-2010-10-315432; Dews M, 2010, CANCER RES, V70, P8233, DOI 10.1158/0008-5472.CAN-10-2412; Dzikiewicz-Krawczyk A, 2017, LEUKEMIA, V31, P1470, DOI 10.1038/leu.2017.94; HARRIS NL, 1994, BLOOD, V84, P1361; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hezaveh K, 2016, HAEMATOLOGICA, V101, P1380, DOI 10.3324/haematol.2016.143891; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Iizuka M, 2009, GENE, V436, P108, DOI 10.1016/j.gene.2009.01.020; Iqbal J, 2015, BLOOD, V125, P1137, DOI 10.1182/blood-2014-04-566778; Jin HY, 2013, EMBO J, V32, P2377, DOI 10.1038/emboj.2013.178; Kluiver J, 2006, GENE CHROMOSOME CANC, V45, P147, DOI 10.1002/gcc.20273; Kluiver Joost, 2013, Methods Mol Biol, V971, P265, DOI 10.1007/978-1-62703-269-8_15; Landais S, 2007, CANCER RES, V67, P5699, DOI 10.1158/0008-5472.CAN-06-4478; Li J, 2016, NEOPLASIA, V18, P339, DOI 10.1016/j.neo.2016.04.005; lizuka M, 2008, MOL CELL BIOL, V28, P140; Luo QF, 2013, INT J ONCOL, V43, P1212, DOI 10.3892/ijo.2013.2034; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; Martin HC, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-3-r51; Mestdagh P, 2010, MOL CELL, V40, P762, DOI 10.1016/j.molcel.2010.11.038; Molyneux EM, 2012, LANCET, V379, P1234, DOI 10.1016/S0140-6736(11)61177-X; Mu P, 2009, GENE DEV, V23, P2806, DOI 10.1101/gad.1872909; Olive V, 2013, ELIFE, V2, DOI 10.7554/eLife.00822; Olive V, 2009, GENE DEV, V23, P2839, DOI 10.1101/gad.1861409; Riley KJ, 2012, EMBO J, V31, P2207, DOI 10.1038/emboj.2012.63; Robaina MC, 2015, EXP MOL PATHOL, V98, P200, DOI 10.1016/j.yexmp.2015.03.006; Robaina MC, 2016, ANN HEMATOL, V95, P881, DOI 10.1007/s00277-016-2653-7; Robertus JL, 2010, BRIT J HAEMATOL, V149, P896, DOI 10.1111/j.1365-2141.2010.08111.x; Sander S, 2008, BLOOD, V112, P4202, DOI 10.1182/blood-2008-03-147645; Schneider C, 2014, P NATL ACAD SCI USA, V111, P8185, DOI 10.1073/pnas.1322466111; Scott DW, 2014, NAT REV CANCER, V14, P517, DOI 10.1038/nrc3774; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Seo S, 2005, J IMMUNOL, V175, P3492, DOI 10.4049/jimmunol.175.6.3492; Skalsky RL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002484; Slezak-Prochazka I, 2016, ONCOTARGET, V7, P2391, DOI 10.18632/oncotarget.6165; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Sylvestre Y, 2007, J BIOL CHEM, V282, P2135, DOI 10.1074/jbc.M608939200; Tan LP, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp715; Tan LP, 2009, LAB INVEST, V89, P708, DOI 10.1038/labinvest.2009.26; Wang M, 2014, EXP MOL PATHOL, V96, P261, DOI 10.1016/j.yexmp.2014.02.015; Yuan Y, 2017, AM J PATHOL, V187, P1343, DOI 10.1016/j.ajpath.2017.02.016; Zhang J, 2009, BLOOD, V113, P4586, DOI 10.1182/blood-2008-09-178186; Zhang N, 2010, P NATL ACAD SCI USA, V107, P21629, DOI 10.1073/pnas.1016299107; Zhang X, 2012, ONCOGENE, V31, P3002, DOI 10.1038/onc.2011.470	50	0	1	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAY	2018	188	5					1289	1299		10.1016/j.ajpath.2018.01.018			11	Pathology	Pathology	GD6TK	WOS:000430641100017	29458013	Bronze			2019-10-28	
J	Kao, YC; Owosho, AA; Sung, YS; Zhang, L; Fujisawa, Y; Lee, JC; Wexler, L; Argani, P; Swanson, D; Dickson, BC; Fletcher, CDM; Antonescu, CR				Kao, Yu-Chien; Owosho, Adepitan A.; Sung, Yun-Shao; Zhang, Lei; Fujisawa, Yumi; Lee, Jen-Chieh; Wexler, Leonard; Argani, Pedram; Swanson, David; Dickson, Brendan C.; Fletcher, Christopher D. M.; Antonescu, Cristina R.			BCOR-CCNB3 Fusion Positive Sarcomas A Clinicopathologic and Molecular Analysis of 36 Cases With Comparison to Morphologic Spectrum and Clinical Behavior of Other Round Cell Sarcomas	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						round cell sarcoma; Ewing sarcoma; BCOR; CCNB3; fusions	CLEAR-CELL-SARCOMA; DIFFERENTIATED SYNOVIAL SARCOMA; TUMOR STUDY-GROUP; ROUND-CELL; HISTOLOGIC MIMICS; PCGF HOMOLOGS; HUMAN CANCERS; HOX GENES; BCOR; KIDNEY	BCOR-CCNB3 sarcoma (BCS) is a recently defined genetic entity among undifferentiated round cell sarcomas, which was initially classified as and treated similarly to the Ewing sarcoma (ES) family of tumors. In contrast to ES, BCS shows consistent BCOR overexpression, and preliminary evidence suggests that these tumors share morphologic features with other tumors harboring BCOR genetic alterations, including BCOR internal tandem duplication (ITD) and BCOR-MAML3. To further investigate the pathologic features, clinical behavior, and their relationship to other round cell sarcomas, we collected 36 molecularly confirmed BCSs for a detailed histologic and immunohistochemical analysis. Four of the cases were also analyzed by RNA sequencing (RNAseq). An additional case with BCOR overexpression but negative CCNB3 abnormality showed a novel KMT2D-BCOR fusion by targeted RNAseq. The patients ranged in age from 2 to 44 years old (mean and median, 15), with striking male predominance (M:F = 31:5). The tumor locations were slightly more common in bone (n = 20) than soft tissue (n = 14), with rare visceral (kidney, n = 2) involvement. Histologically, BCS showed a spectrum of round to spindle cells with variable cellularity, monomorphic nuclei and fine chromatin pattern, delicate capillary network, and varying amounts of myxoid or collagenous stroma. The morphologic features and immunoprofile showed considerable overlap with other round cell sarcomas with BCOR oncogenic upregulation, that is, BCOR-MAML3 and BCOR ITD. Follow-up available in 22 patients showed a 5-year overall survival of 72%, which was relatively similar to ES (79%, P = 0.738) and significantly better than CIC-DUX4 sarcomas (43%, P = 0.005) control groups. Local recurrences occurred in 6 patients and distant metastases (lung, soft tissue/bone, pancreas) in 4. Seven of 9 cases treated with an ES chemotherapy regimen with evaluable histologic response showed >60% necrosis in posttherapy resections. Unsupervised clustering by RNAseq data revealed that tumors with BCOR genetic alterations, including BCOR-CCNB3, BCOR-MAML3, and BCOR ITD, formed a tight genomic group distinct from ES and CIC-rearranged sarcomas.	[Kao, Yu-Chien; Sung, Yun-Shao; Zhang, Lei; Fujisawa, Yumi; Antonescu, Cristina R.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA; [Owosho, Adepitan A.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10065 USA; [Wexler, Leonard] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10065 USA; [Kao, Yu-Chien] Taipei Med Univ, Shuang Ho Hosp, Dept Pathol, Taipei, Taiwan; [Lee, Jen-Chieh] Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept & Grad Inst Pathol, Taipei, Taiwan; [Owosho, Adepitan A.] Univ New England, Coll Dent Med, Portland, ME USA; [Argani, Pedram] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; [Swanson, David; Dickson, Brendan C.] Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON, Canada; [Fletcher, Christopher D. M.] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA	Antonescu, CR (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA.	antonesc@mskcc.org		Lee, Jen-Chieh/0000-0001-7739-5934	Kristen Ann Carr Foundation; Cycle for Survival;  [P50 CA140146-01];  [P30 CA008748]	Supported in part by P50 CA140146-01 (C.R.A.), P30 CA008748 (C.R.A.), Kristen Ann Carr Foundation (C.R.A.), and Cycle for Survival (C.R.A.). The remaining authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Antonescu CR, 2017, AM J SURG PATHOL, V41, P941, DOI 10.1097/PAS.0000000000000846; Antonescu CR, 2014, GENE CHROMOSOME CANC, V53, P183, DOI 10.1002/gcc.22132; Argani P, 2000, AM J SURG PATHOL, V24, P4, DOI 10.1097/00000478-200001000-00002; Argani P, 2017, AM J SURG PATHOL, V41, P1702, DOI 10.1097/PAS.0000000000000926; Bhatlekar S, 2014, J MOL MED, V92, P811, DOI 10.1007/s00109-014-1181-y; Cohen-Gogo S, 2014, PEDIATR BLOOD CANCER, V61, P2191, DOI 10.1002/pbc.25210; Furtwangler R, 2013, EUR J CANCER, V49, P3497, DOI 10.1016/j.ejca.2013.06.036; Gao ZH, 2012, MOL CELL, V45, P344, DOI 10.1016/j.molcel.2012.01.002; Hamilton SN, 2017, AM J CLIN ONCOL-CANC, V40, P423, DOI 10.1097/COC.0000000000000176; Hung YP, 2016, MODERN PATHOL, V29, P1324, DOI 10.1038/modpathol.2016.140; Huynh KD, 2000, GENE DEV, V14, P1810; Junco SE, 2013, STRUCTURE, V21, P665, DOI 10.1016/j.str.2013.02.013; Kao YC, 2017, GENE CHROMOSOME CANC, V56, P296, DOI 10.1002/gcc.22435; Kao YC, 2016, AM J SURG PATHOL, V40, P1670, DOI 10.1097/PAS.0000000000000697; Kao YC, 2016, AM J SURG PATHOL, V40, P1009, DOI 10.1097/PAS.0000000000000629; Li WS, 2016, HISTOPATHOLOGY, V69, P792, DOI 10.1111/his.13001; Magro G, 2017, HUM PATHOL, V60, P58, DOI 10.1016/j.humpath.2016.07.038; Nakayama R, 2010, AM J SURG PATHOL, V34, P1599, DOI 10.1097/PAS.0b013e3181f7ce2c; Ng D, 2004, NAT GENET, V36, P411, DOI 10.1038/ng1321; Nguyen TB, 2002, J BIOL CHEM, V277, P41960, DOI 10.1074/jbc.M203951200; Owosho AA, 2017, ORAL ONCOL, V66, P46, DOI 10.1016/j.oraloncology.2016.12.021; Panagopoulos I, 2013, GENE CHROMOSOME CANC, V52, P610, DOI 10.1002/gcc.22057; Paret C, 2016, ONCOTARGET, V7, P83378, DOI 10.18632/oncotarget.13092; Pearson JC, 2005, NAT REV GENET, V6, P893, DOI 10.1038/nrg1726; Peters TL, 2015, MODERN PATHOL, V28, P575, DOI 10.1038/modpathol.2014.139; Pierron G, 2012, NAT GENET, V44, P461, DOI 10.1038/ng.1107; Poo WC, 2011, AM J CLIN PATHOL, V135, P839, DOI 10.1309/AJCP45SSNAOPXYXU; Puls F, 2014, AM J SURG PATHOL, V38, P1307, DOI 10.1097/PAS.0000000000000223; Righi A, 2015, AM J SURG PATHOL, V39, P691, DOI 10.1097/PAS.0000000000000412; Rux DR, 2017, DEV DYNAM, V246, P310, DOI 10.1002/dvdy.24482; Seki M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8557; Shibayama T, 2015, PATHOL INT, V65, P410, DOI 10.1111/pin.12319; Specht K, 2016, AM J SURG PATHOL, V40, P433, DOI 10.1097/PAS.0000000000000591; Sturm D, 2016, CELL, V164, P1060, DOI 10.1016/j.cell.2016.01.015; Ueno-Yokohata H, 2015, NAT GENET, V47, P861, DOI 10.1038/ng.3338; Wong SJ, 2016, STRUCTURE, V24, P1795, DOI 10.1016/j.str.2016.07.011; Yamamoto Y, 2014, MOL CANCER RES, V12, P479, DOI 10.1158/1541-7786.MCR-13-0596; Yamamoto Y, 2010, BLOOD, V116, P4274, DOI 10.1182/blood-2010-01-264432	38	20	20	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAY	2018	42	5					604	615		10.1097/PAS.0000000000000965			12	Pathology; Surgery	Pathology; Surgery	GD3LD	WOS:000430404500006	29300189	Green Accepted			2019-10-28	
J	Dickson, BC; Sung, YS; Rosenblum, MK; Reuter, VE; Harb, M; Wunder, JS; Swanson, D; Antonescu, CR				Dickson, Brendan C.; Sung, Yun-Shao; Rosenblum, Marc K.; Reuter, Victor E.; Harb, Mohammed; Wunder, Jay S.; Swanson, David; Antonescu, Cristina R.			NUTM1 Gene Fusions Characterize a Subset of Undifferentiated Soft Tissue and Visceral Tumors	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						NUT midline carcinoma; NUTM1; BCORL1; BRD3; BRD4; MXD1; fusions	ROUND-CELL SARCOMAS; MIDLINE CARCINOMA; AGGRESSIVE CARCINOMA; DIFFERENTIATION; TRANSCRIPTION; MAX; REARRANGEMENT; EXPRESSION; MECHANISM; PROTEINS	NUT midline carcinoma is an aggressive tumor that occurs mainly in the head and neck and, less frequently, the mediastinum and lung. Following identification of an index case of a NUTM1 fusion positive undifferentiated soft tissue tumor, we interrogated additional cases of primary undifferentiated soft tissue and visceral tumors for NUTM1 abnormalities. Targeted next-generation sequencing was performed on RNA extracted from formalin-fixed paraffin-embedded tissue, and results validated by fluorescence in situ hybridization using custom bacterial artificial chromosome probes. Six patients were identified: mean age of 42 years (range, 3 to 71y); equal sex distribution; and, tumors involved the extremity soft tissues (N = 2), kidney (N = 2), stomach, and brain. On systemic work-up at presentation all patients lacked a distant primary tumor. Morphologically, the tumors were heterogenous, with undifferentiated round-epithelioid-rhabdoid cells arranged in solid sheets, nests, and cords. Mitotic activity was generally brisk. Four cases expressed pancytokeratin, but in only 2 cases was this diffuse. Next-generation sequencing demonstrated the following fusions: BRD4-NUTM1 (3 cases), BRD3-NUTM1, MXD1-NUTM1, and BCORL1-NUTM1. Independent testing by fluorescence in situ hybridization confirmed the presence of NUTM1 and partner gene rearrangement. This study establishes that NUT-associated tumors transgress the midline and account for a subset of primitive neoplasms occurring in soft tissue and viscera. Tumors harboring NUTM1 gene fusions are presumably underrecognized, and the extent to which they account for undifferentiated mesenchymal, neuroendocrine, and/or epithelial neoplasms is unclear. Moreover, the relationship, if any, between NUT-associated tumors in soft tissue and/or viscera, and conventional NUT carcinoma, remains to be elucidated.	[Dickson, Brendan C.; Swanson, David] Univ Toronto, Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON, Canada; [Wunder, Jay S.] Univ Toronto, Mt Sinai Hosp, Univ Musculoskeletal Oncol Unit, Toronto, ON, Canada; [Dickson, Brendan C.; Swanson, David] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Wunder, Jay S.] Univ Toronto, Dept Surg, Div Orthopaed, Toronto, ON, Canada; [Dickson, Brendan C.; Wunder, Jay S.] Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada; [Harb, Mohammed] Horizon Hlth Network, Dept Med Oncol, Moncton, NB, Canada; [Harb, Mohammed] Dalhousie Univ, Dept Med Oncol, Halifax, NS, Canada; [Sung, Yun-Shao; Rosenblum, Marc K.; Reuter, Victor E.; Antonescu, Cristina R.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA	Dickson, BC (reprint author), Mt Sinai Hosp, Dept Pathol & Lab Med, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	brendan.dickson@sinaihealthsystem.ca			Kristen Ann Carr Foundation; Cycle for Survival;  [P50 CA140146-01];  [P30-CA008748]	Supported in part by: P50 CA140146-01 (CRA); P30-CA008748 (CRA); Kristen Ann Carr Foundation (CRA); Cycle for Survival (CRA). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Alekseyenko AA, 2015, GENE DEV, V29, P1507, DOI 10.1101/gad.267583.115; Allen AJ, 2017, GYNECOL ONCOL REP, V20, P51, DOI 10.1016/j.gore.2017.03.002; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; [Anonymous], HGNC DAT; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Bauer DE, 2012, CLIN CANCER RES, V18, P5773, DOI 10.1158/1078-0432.CCR-12-1153; Bishop JA, 2016, CANCER CYTOPATHOL, V124, P901, DOI 10.1002/cncy.21761; Chau NG, 2016, CANCER-AM CANCER SOC, V122, P3632, DOI 10.1002/cncr.30242; Chen XY, 2016, BIOINFORMATICS, V32, P1220, DOI 10.1093/bioinformatics/btv710; Comino-Mendez I, 2011, NAT GENET, V43, P663, DOI 10.1038/ng.861; den Bakker MA, 2009, AM J SURG PATHOL, V33, P1253, DOI 10.1097/PAS.0b013e3181abe120; Evans AG, 2012, AM J SURG PATHOL, V36, P1222, DOI 10.1097/PAS.0b013e318258f03b; French CA, 2008, ONCOGENE, V27, P2237, DOI 10.1038/sj.onc.1210852; French CA, 2004, J CLIN ONCOL, V22, P4135, DOI 10.1200/JCO.2004.02.107; French CA, 2003, CANCER RES, V63, P304; French CA, 2001, AM J PATHOL, V159, P1987, DOI 10.1016/S0002-9440(10)63049-0; French CA, 2017, WHO CLASSIFICATION H, P20; French C, 2014, NAT REV CANCER, V14, P149, DOI 10.1038/nrc3659; French CA, 2014, CANCER DISCOV, V4, P928, DOI 10.1158/2159-8290.CD-14-0014; French CA, 2010, J CLIN PATHOL, V63, P492, DOI 10.1136/jcp.2007.052902; French CA, 2010, CANCER GENET CYTOGEN, V203, P16, DOI 10.1016/j.cancergencyto.2010.06.007; Haack H, 2009, AM J SURG PATHOL, V33, P984, DOI 10.1097/PAS.0b013e318198d666; Kao YC, 2017, AM J SURG PATHOL, V41, P482, DOI 10.1097/PAS.0000000000000788; Kao YC, 2017, GENE CHROMOSOME CANC, V56, P42, DOI 10.1002/gcc.22400; KEES UR, 1991, AM J PEDIAT HEMATOL, V13, P459; KUBONISHI I, 1991, CANCER RES, V51, P3327; Lemelle L, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26693; Li WS, 2016, HISTOPATHOLOGY, V69, P792, DOI 10.1111/his.13001; Liu S, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1234; MOLL R, 1987, AM J PATHOL, V127, P288; Pagan JK, 2007, J BIOL CHEM, V282, P15248, DOI 10.1074/jbc.M700246200; Schaefer IM, 2017, MODERN PATHOL, V30, P539, DOI 10.1038/modpathol.2016.230; Sholl LM, 2015, J THORAC ONCOL, V10, P951, DOI 10.1097/JTO.0000000000000545; Sirohi D, 2017, HISTOPATHOLOGY; Specht K, 2016, AM J SURG PATHOL, V40, P433, DOI 10.1097/PAS.0000000000000591; Sturm D, 2016, CELL, V164, P1060, DOI 10.1016/j.cell.2016.01.015; Suzuki S, 2015, PATHOL RES PRACT, V211, P404, DOI 10.1016/j.prp.2014.10.013; Tanaka M, 2012, AM J SURG PATHOL, V36, P381, DOI 10.1097/PAS.0b013e31824230a8; Thompson LDR, 2017, VIRCHOWS ARCH; Thompson-Wicking K, 2013, ONCOGENE, V32, P4664, DOI 10.1038/onc.2012.487; Totoki Y, 2011, NAT GENET, V43, P464, DOI 10.1038/ng.804; Yamada Y, 2017, VIRCHOWS ARCH, V470, P373, DOI 10.1007/s00428-017-2072-8	42	13	13	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAY	2018	42	5					636	645		10.1097/PAS.0000000000001021			10	Pathology; Surgery	Pathology; Surgery	GD3LD	WOS:000430404500009	29356724	Green Accepted			2019-10-28	
J	Mengoli, MC; Rossi, G; Cavazza, A; Franco, R; Marino, FZ; Migaldi, M; Gnetti, L; Silini, EM; Ampollini, L; Tiseo, M; Lococo, F; Fournel, L; Spagnolo, P; Cottin, V; Colby, TV				Mengoli, Maria Cecilia; Rossi, Giulio; Cavazza, Alberto; Franco, Renato; Marino, Federica Zito; Migaldi, Mario; Gnetti, Letizia; Silini, Enrico Maria; Ampollini, Luca; Tiseo, Marcello; Lococo, Filippo; Fournel, Ludovic; Spagnolo, Paolo; Cottin, Vincent; Colby, Thomas V.			Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) Syndrome and Carcinoid Tumors With/Without NECH A Clinicopathologic, Radiologic, and Immunomolecular Comparison Study	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						DIPNECH; neuroendocrine cell hyperplasia; carcinoid; mTOR; immunohistochemistry	LUNG-DISEASE; OBLITERATIVE BRONCHIOLITIS; INTRALOBAR SEQUESTRATION; ENDOCRINE-CELLS; PROLIFERATIONS; EXPRESSION; SPECTRUM; RECEPTOR; INFANCY; TRANSPLANTATION	The diagnostic criteria of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) are not well defined, and DIPNECH can be mistaken for carcinoids associated with neuroendocrine cell hyperplasia (NECH). In this study, we compared clinical, radiologic, histologic, immunohistochemical, and molecular features of DIPNECH and isolated carcinoids with/without NECH. The study population included 151 cases (77 female patients and 74 male patients), 19 with DIPNECH and 132 with carcinoids with/without NECH. None of the cases displayed molecular alterations or anaplastic lymphoma kinase expression. Compared with individuals with carcinoids with/without NECH, patients with DIPNECH were more likely to be female individuals (P < 0.0001), nonsmokers (P = 0.021), and symptomatic, and to have an obstructive/mixed respiratory defect, peripheral location of the lesions, and air trapping (P < 0.0001) on chest computed tomography, and constrictive bronchiolitis on histology (P < 0.0001). Among immunohistochemical markers, DIPNECH was associated with higher expression of thyroid transcription factor-1, CD10, and gastrin-releasing peptide/bombesin-like peptide (P < 0.0001). Yet, when a purely histopathologic definition of DIPNECH was applied, 40% of isolated carcinoids also met the diagnostic criteria for DIPNECH, even in the absence of symptoms and/or radiologic abnormalities. Therefore, as DIPNECH represents a distinct clinical syndrome, we suggest the term DIPNECH be limited to cases presenting with respiratory symptoms, functional and/or radiologic abnormalities, and constrictive bronchiolitis on histology.	[Mengoli, Maria Cecilia; Cavazza, Alberto] Arcispedale Santa Maria Nuova IRCCS, Unit Pathol, Reggio Emilia, Italy; [Lococo, Filippo] IRCCS Arcispedale Santa Maria Nuova, Unit Thorac Surg, Viale Risorgimento 80, I-42124 Reggio Emilia, Italy; [Rossi, Giulio] Azienda USL Valle Aosta, Reg Hosp Parini, Pathol Anat, Aosta, Italy; [Franco, Renato; Marino, Federica Zito] SUN, Pathol Unit, Naples, Italy; [Migaldi, Mario] Azienda Osped Univ Policlin Modena, Unit Pathol, Modena, Italy; [Gnetti, Letizia; Silini, Enrico Maria] Univ Hosp Parma, Sect Pathol Anat, Parma, Italy; [Ampollini, Luca] Univ Hosp Parma, Unit Thorac Surg, Parma, Italy; [Tiseo, Marcello] Univ Hosp Parma, Oncol Unit, Parma, Italy; [Spagnolo, Paolo] Univ Padua, Dept Cardiac Thorac & Vasc Sci, Sect Resp Dis, Padua, Italy; [Fournel, Ludovic] Rene Descartes Univ, Cochin Hosp Paris, AP HP, Dept Thorac Surg, Paris, France; [Cottin, Vincent] Hop Louis Pradel, Hosp Civils Lyon, Natl Reference Ctr Rare Pulm Dis, Lyon, France; [Cottin, Vincent] Claude Bernard Lyon 1 Univ, Univ Lyon, Lyon, France; [Cottin, Vincent] INRA, Lyon, France; [Colby, Thomas V.] Mayo Clin, Lab Med, Pathol Unit, Scottsdale, AZ USA	Lococo, F (reprint author), IRCCS Arcispedale Santa Maria Nuova, Unit Thorac Surg, Viale Risorgimento 80, I-42124 Reggio Emilia, Italy.	filippo_lococo@yahoo.it	SILINI, ENRICO MARIA/AAB-8747-2019; Cavazza, Alberto/K-2531-2018; Tiseo, Marcello/K-6119-2016; Mengoli, Maria Cecilia/J-7335-2015	SILINI, ENRICO MARIA/0000-0003-2578-3059; Cavazza, Alberto/0000-0003-3590-319X; Tiseo, Marcello/0000-0002-9553-8465; Mengoli, Maria Cecilia/0000-0002-1437-8747; Gnetti, Letizia/0000-0002-6982-5188			Adams H, 2006, RESPIRATION, V73, P690, DOI 10.1159/000088007; AGUAYO SM, 1992, NEW ENGL J MED, V327, P1285, DOI 10.1056/NEJM199210293271806; Aubry MC, 2007, CHEST, V131, P1635, DOI 10.1378/chest.06-2788; Baniak NM, 2016, PATHOL RES PRACT, V212, P125, DOI 10.1016/j.prp.2015.12.006; BONIKOS DS, 1976, CANCER-AM CANCER SOC, V37, P1977, DOI 10.1002/1097-0142(197604)37:4<1977::AID-CNCR2820370450>3.0.CO;2-4; Brown MJ, 1997, AM J ROENTGENOL, V168, P1561, DOI 10.2214/ajr.168.6.9168724; Carr LL, 2016, CLIN CHEST MED, V37, P579, DOI 10.1016/j.ccm.2016.04.018; Carr LL, 2015, CHEST, V147, P415, DOI 10.1378/chest.14-0711; Chassagnon G, 2015, CLIN RADIOL, V70, P317, DOI 10.1016/j.crad.2014.10.012; Chauhan A, 2015, LUNG, V193, P653, DOI 10.1007/s00408-015-9754-2; Davies SJ, 2007, THORAX, V62, P248, DOI 10.1136/thx.2006.063065; Degan S, 2008, ANN NY ACAD SCI, V1144, P136, DOI 10.1196/annals.1418.022; Dewan M, 2000, J R SOC PROMO HEALTH, V120, P192, DOI 10.1177/146642400012000310; Du EZ, 2004, HUM PATHOL, V35, P825, DOI 10.1016/j.humpath.2004.02.016; Edge SB, 2010, AJCC CANC STAGING MA; Falkenstern-Ge RF, 2011, J CANCER RES CLIN, V137, P1495, DOI 10.1007/s00432-011-1015-z; FELTON WL, 1953, CANCER, V6, P555, DOI 10.1002/1097-0142(195305)6:3<555::AID-CNCR2820060312>3.0.CO;2-T; Fernandez-Cuesta L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4518; Ferolla P, 2009, J THORAC ONCOL, V4, P383, DOI 10.1097/JTO.0b013e318197f2e7; Foran PJ, 2015, CLIN IMAG, V39, P243, DOI 10.1016/j.clinimag.2014.10.017; Fukuizumi A, 2015, J THORAC ONCOL, V10, pE104, DOI 10.1097/JTO.0000000000000635; Gorshtein A, 2012, CANCER-AM CANCER SOC, V118, P612, DOI 10.1002/cncr.26200; Gosney JR, 2011, HISTOPATHOLOGY, V59, P751, DOI 10.1111/j.1365-2559.2011.03992.x; GOSNEY JR, 1989, J PATHOL, V157, P127, DOI 10.1002/path.1711570207; He P, 2012, J THORAC DIS, V4, P655, DOI 10.3978/j.issn.2072-1439.2012.06.11; HEATH D, 1990, HISTOPATHOLOGY, V16, P21, DOI 10.1111/j.1365-2559.1990.tb01055.x; JOHNSON DE, 1982, PEDIATR RES, V16, P446, DOI 10.1203/00006450-198206000-00009; JOHNSON DE, 1988, AM REV RESPIR DIS, V137, P123, DOI 10.1164/ajrccm/137.1.123; Kuruva M, 2016, CLIN NUCL MED, V41, P239, DOI 10.1097/RLU.0000000000001079; Lee JS, 2002, J COMPUT ASSIST TOMO, V26, P180, DOI 10.1097/00004728-200203000-00003; Marchevsky AM, 2015, HUM PATHOL, V46, P176, DOI 10.1016/j.humpath.2014.10.019; MILLER MA, 1978, AM J MED, V65, P373, DOI 10.1016/0002-9343(78)90835-5; MILLER RR, 1995, AM J SURG PATHOL, V19, P653, DOI 10.1097/00000478-199506000-00005; Nakajima M, 2016, INTERNAL MED, V55, P3151, DOI 10.2169/internalmedicine.55.6738; Nassar AA, 2011, AM J RESP CRIT CARE, V184, P8, DOI 10.1164/rccm.201010-1685PP; PELOSI G, 1992, ARCH PATHOL LAB MED, V116, P1167; Righi L, 2010, ANN ONCOL, V21, P548, DOI 10.1093/annonc/mdp334; Righi L, 2010, ENDOCR-RELAT CANCER, V17, P977, DOI 10.1677/ERC-10-0157; Rizvi SMH, 2009, HISTOPATHOLOGY, V55, P332, DOI 10.1111/j.1365-2559.2009.03371.x; Rossi G, 2016, EUR RESPIR J, V47, P1829, DOI 10.1183/13993003.01954-2015; Rossi G, 2012, AM J RESP CRIT CARE, V185, P341, DOI 10.1164/ajrccm.185.3.341; Sachithanandan N, 2005, CANCER-AM CANCER SOC, V103, P509, DOI 10.1002/cncr.20825; Sauer R, 2017, J Med Case Rep, V11, P95, DOI 10.1186/s13256-017-1254-y; Schirosi L, 2012, ANN ONCOL, V23, P2409, DOI 10.1093/annonc/mdr626; SHEERIN N, 1995, THORAX, V50, P207, DOI 10.1136/thx.50.2.207; Simbolo M, 2017, J PATHOL, V241, P488, DOI 10.1002/path.4853; Sturm N, 2002, HUM PATHOL, V33, P175, DOI 10.1053/hupa.2002.31299; Sunday ME, 1996, ENDOCR PATHOL, V7, P173, DOI 10.1007/BF02739921; Travis WD, 2015, WHO CLASSIFICATION T; Trisolini R, 2016, LUNG, V194, P243, DOI 10.1007/s00408-016-9854-7; Volante M, 2007, MODERN PATHOL, V20, P1172, DOI 10.1038/modpathol.3800954; Wang VE, 2017, ONCOLOGIST, V22, P768, DOI 10.1634/theoncologist.2017-0054; Wirtschafter E, 2015, LUNG, V193, P659, DOI 10.1007/s00408-015-9755-1; Young LR, 2013, CHEST, V144, P1199, DOI 10.1378/chest.13-0811; Young LR, 2011, CHEST, V139, P1060, DOI 10.1378/chest.10-1304; Zhou HJ, 2014, J BRONCHOL INTERN PU, V21, P342, DOI 10.1097/LBR.0000000000000098; Zhou JH, 2003, CLIN CANCER RES, V9, P4953	57	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAY	2018	42	5					646	655		10.1097/PAS.0000000000001033			10	Pathology; Surgery	Pathology; Surgery	GD3LD	WOS:000430404500010	29438170				2019-10-28	
J	Acosta, AM; Al Rasheed, MRH; Rauscher, GH; Vormittag, E; Mon, KS; Sharif, A; Kajdacsy-Balla, A; Mohapatra, G				Acosta, Andres M.; Al Rasheed, Mohamed R. H.; Rauscher, Garth H.; Vormittag, Erica; Mon, Khin Su; Sharif, Asma; Kajdacsy-Balla, Andre; Mohapatra, Gayatry			Tumor necrosis in radical prostatectomies with high-grade prostate cancer is associated with multiple poor prognostic features and a high prevalence of residual disease	HUMAN PATHOLOGY			English	Article						Prostate cancer; Tumor necrosis; Gleason; Biochemical recurrence; PSA	ISUP CONSENSUS CONFERENCE; GLEASON SCORE; INTERNATIONAL-SOCIETY; ADENOCARCINOMA; CARCINOMA; ANTIGEN; INVOLVEMENT; CRIBRIFORM; PATTERNS; PREDICT	The Gleason grading system and the recently defined Grade Groups are strong, well-established predictors of outcome in prostate cancer. Each Gleason score, however, is the result of a sum of categories (Gleason patterns or GPs) that are intrinsically heterogeneous, as each individual pattern encompasses several tumor morphologies. Although the prognostic value of specific morphologic components of GP4 has recently been demonstrated, the significance of the different patterns of GP5 is largely unknown. We reviewed 344 consecutive prostatectomies performed at the Hospital of the University of Illinois at Chicago between 2011 and 2016 and selected 56 cases with primary or secondary GP5 with archival material available for review. Subsequently, we sorted the cases according to the presence or absence of tumor necrosis in invasive adenocarcinoma GP5-designated G5 (+N) and G5 (-N), respectively-for comparison of histopathologic and clinical characteristics. The GP5 (+N) group demonstrated higher prevalence of biochemical recurrence (P = .0006) and seminal vesicle invasion (P = .02), with a trend toward a higher frequency of lymph node metastases (P = .07) and multifocal surgical margin involvement (P = .09). Also, G5 (+N) patients showed higher preoperative prostate-specific antigen values (P = .005) and a larger percentage of submitted tissue involved by tumor (P < .0001). Our results show that GP5 with tumor necrosis is associated with poor prognostic histopathologic features and high rates of residual disease after prostatectomy. (C) 2017 Elsevier Inc. All rights reserved.	[Acosta, Andres M.; Al Rasheed, Mohamed R. H.; Vormittag, Erica; Mon, Khin Su; Sharif, Asma; Kajdacsy-Balla, Andre; Mohapatra, Gayatry] Univ Illinois, Dept Pathol, 820 S Wood St,Suite 130 CSN, Chicago, IL 60612 USA; [Rauscher, Garth H.] Univ Illinois, Sch Publ Hlth, Dep Epidemiol, Chicago, IL 60612 USA	Acosta, AM; Mohapatra, G (reprint author), Univ Illinois, Dept Pathol, 820 S Wood St,Suite 130 CSN, Chicago, IL 60612 USA.	amacosta@uic.edu; gayamoha@uic.edu		Haroon Al Rasheed, Mohamed Rizwan/0000-0002-0572-0387; Acosta, Andres/0000-0003-0164-5911	Depattment of Pathology of the University of Illinois at Chicago	This study was supported by intradepartmental funds from the Depattment of Pathology of the University of Illinois at Chicago. A. M. A. and G. M. were responsible for the design/experimental approach of the project and contributed equally to this manuscript. A. M. A., M. R. H. A. R., E. V., K. S. M., and A. S. reviewed the histology slides and gathered all the clinical and histopathologic data. A. M. A., G. M., and G. R. performed the data analysis. A. K. B. provided advice for the design of the project. G. M., A. M. A., G. R., and A. K. B. reviewed the results of the data analysis.	DAMICO AV, 1995, J UROLOGY, V154, P131, DOI 10.1016/S0022-5347(01)67248-3; Epstein JI, 2005, AM J SURG PATHOL, V29, P1228, DOI 10.1097/01.pas.0000173646.99337.b1; Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530; Epstein JI, 2016, EUR UROL, V69, P428, DOI 10.1016/j.eururo.2015.06.046; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; GLEASON DONALD F., 1966, CANCER CHEMO THERAP REP, V50, P125; Gottipati S, 2012, AM J SURG PATHOL, V36, P900, DOI 10.1097/PAS.0b013e3182495dee; Han M, 2001, UROL CLIN N AM, V28, P555, DOI 10.1016/S0094-0143(05)70163-4; Harding-Jackson N, 2016, J UROLOGY, V196, P1076, DOI 10.1016/j.juro.2016.05.105; Hattab EM, 2006, J UROLOGY, V175, P1695, DOI 10.1016/S0022-5347(05)00998-5; Kweldam CF, 2017, MODERN PATHOL, V30, P1126, DOI 10.1038/modpathol.2017.29; Kweldam CF, 2015, MODERN PATHOL, V28, P457, DOI 10.1038/modpathol.2014.116; Lim SK, 2013, ANN SURG ONCOL, V20, P3127, DOI 10.1245/s10434-013-2996-4; Mahal BA, 2016, BJU INT, V118, P95, DOI 10.1111/bju.13239; Mohler JL, 2017, NATL COMPREHENSIVE C; Partin AW, 1997, JAMA-J AM MED ASSOC, V277, P1445, DOI 10.1001/jama.277.18.1445; Pichler M, 2012, AM J CLIN PATHOL, V137, P283, DOI 10.1309/AJCPLBK9L9KDYQZP; Pierorazio PM, 2013, BJU INT, V111, P753, DOI 10.1111/j.1464-410X.2012.11611.x; Richards CH, 2011, FUTURE ONCOL, V7, P1223, DOI [10.2217/fon.11.99, 10.2217/FON.11.99]; Sauter G, 2016, EUR UROL, V69, P592, DOI 10.1016/j.eururo.2015.10.029; Swanson GP, 2008, J UROLOGY, V180, P2453, DOI 10.1016/j.juro.2008.08.037; Uhlman MA, 2010, UROLOGY, V75, P460, DOI 10.1016/j.urology.2009.06.059	22	4	4	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAY	2018	75						1	9		10.1016/j.humpath.2017.11.015			9	Pathology	Pathology	GI2YQ	WOS:000434238200001	29180249				2019-10-28	
J	Tabbo, F; Nottegar, A; Guerrera, F; Migliore, E; Luchini, C; Maletta, F; Veronese, N; Montagna, L; Gaudiano, M; Di Giacomo, F; Filosso, PL; Delsedime, L; Ciccone, G; Scarpa, A; Sapino, A; Oliaro, A; Ruffini, E; Inghirami, G; Chilosi, M				Tabbo, Fabrizio; Nottegar, Alessia; Guerrera, Francesco; Migliore, Enrica; Luchini, Claudio; Maletta, Francesca; Veronese, Nicola; Montagna, Licia; Gaudiano, Marcello; Di Giacomo, Filomena; Filosso, Pier Luigi; Delsedime, Luisa; Ciccone, Giovannino; Scarpa, Aldo; Sapino, Anna; Oliaro, Alberto; Ruffini, Enrico; Inghirami, Giorgio; Chilosi, Marco			Cell of origin markers identify different prognostic subgroups of lung adenocarcinoma	HUMAN PATHOLOGY			English	Article						Lung adenocarcinoma; Biomarkers; Immunohistochemistry; Morphology; Genetic mutations; Survival analysis	INTERNATIONAL-ASSOCIATION; PULMONARY ADENOCARCINOMA; PATIENT SURVIVAL; STEM-CELLS; K-RAS; CLASSIFICATION; CANCER; EGFR; CARCINOMAS; RECURRENCE	Strong prognostic markers able to stratify lung adenocarcinoma (ADC) patients are lacking. We evaluated whether a six-immunohistochemical markers panel (TTF1, SP-A, Napsin A, MUC5AC, CDX2 and CK5), defining the putative neoplastic "cell of origin," allows to identify prognostic subgroups among lung ADC. We screened a large cohort of ADC specimens (2003-2013) from Torino Institutional Repository identifying: (i) marker positivity by immunohistochemistry, (ii) main morphological appearance by light microscopy, (iii) presence of "hotspot" mutations of candidate genes by Sequenom technology. To evaluate possible predictors of survival and time to recurrence, uni- and multivariable-adjusted comparisons were performed. We identified 4 different subgroups: "alveolar," "bronchiolar," "mixed" and "null type." Alveolar-differentiated ADC were more common in young (P = .065), female (P = .083) patients, frequently harboring EGFR-mutated (P = .003) tumors with acinar pattern (P < .001). Bronchiolar differentiated ADC were more associated with mucinous and solid pattern (P < .001), higher degree of vascular invasion (P =.01) and KRAS gene mutations (P = .07). Bronchiolar, mixed, and null types were independent negative predictors for overall survival, and the latter two had a shorter time to recurrence. This "Cell of Origin" classifier is more predictable than morphology and genetics and is an independent predictor of survival on a multivariate analysis. (C) 2018 Elsevier Inc. All rights reserved.	[Tabbo, Fabrizio; Di Giacomo, Filomena; Inghirami, Giorgio] Univ Torino, Dept Mol Biotechnol & Hlth Sci, Turin, Italy; [Tabbo, Fabrizio; Di Giacomo, Filomena; Inghirami, Giorgio] Univ Torino, Ctr Expt Res & Med Studies, Turin, Italy; [Tabbo, Fabrizio; Gaudiano, Marcello; Di Giacomo, Filomena; Inghirami, Giorgio] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY 10021 USA; [Nottegar, Alessia; Luchini, Claudio; Montagna, Licia; Scarpa, Aldo] Univ & Hosp Trust Verona, Dept Diagnost & Publ Hlth, I-37134 Verona, Italy; [Guerrera, Francesco; Filosso, Pier Luigi; Oliaro, Alberto; Ruffini, Enrico] AOU Citta Salute & Sci Torino, Dept Thorac Surg, I-10126 Turin, Italy; [Migliore, Enrica; Ciccone, Giovannino] AOU Citta Salute & Sci Torino, Unit Canc Epidemiol, I-10126 Turin, Italy; [Migliore, Enrica; Ciccone, Giovannino] CPO Piemonte, I-10126 Turin, Italy; [Luchini, Claudio] Univ & Hosp Trust Verona, ARC Net Res Ctr, I-37134 Verona, Italy; [Luchini, Claudio] Santa Chiara Hosp, Dept Pathol, I-38100 Trento, Italy; [Maletta, Francesca; Delsedime, Luisa] Univ Torino, Dept Med Sci, I-10126 Turin, Italy; [Veronese, Nicola] CNR, Natl Res Council, I-38121 Padua, Italy; [Veronese, Nicola] Inst Clin Res & Educ Med, I-38121 Padua, Italy; [Sapino, Anna] IRCCS, Candiolo Canc Inst FPO, I-10060 Candiolo, To, Italy; [Inghirami, Giorgio] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; [Inghirami, Giorgio] NYU, Sch Med, NYU Canc Ctr, New York, NY 10016 USA; [Chilosi, Marco] Pederzoli Hosp, Dept Pathol, I-37134 Verona, Italy	Tabbo, F (reprint author), Univ Torino, Dept Oncol, Reg Gonzole 10, I-10043 Orbassano, TO, Italy.	fabrizio.tabbo@unito.it	Guerrera, Francesco/M-9391-2014; Luchini, Claudio/O-2187-2019; Guerrera, Francesco/L-4400-2019; Luchini, Claudio/Q-4922-2016	Guerrera, Francesco/0000-0002-4125-4379; Luchini, Claudio/0000-0003-4901-4908; Luchini, Claudio/0000-0003-4901-4908; Maletta, Francesca/0000-0002-7877-030X			Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Chilosi M, 2010, ARCH PATHOL LAB MED, V134, P55, DOI 10.1043/1543-2165-134.1.55; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Fisher LD, 1993, BIOSTATISTICS METHOD, P801; Guerrera F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145100; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hardavella G, 2016, TRANSL LUNG CANCER R, V5, P272, DOI 10.21037/tlcr.2016.02.01; Hashimoto T, 2000, AM J PATHOL, V157, P2133, DOI 10.1016/S0002-9440(10)64851-1; Hung JJ, 2014, J CLIN ONCOL, V32, P2357, DOI 10.1200/JCO.2013.50.1049; Kadota K, 2014, AM J SURG PATHOL, V38, P1118, DOI 10.1097/PAS.0000000000000246; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Krawczyk P, 2014, J CANCER RES CLIN, V140, P2047, DOI 10.1007/s00432-014-1756-6; Luchini C, 2016, APPL IMMUNOHISTO M M, V24, P215, DOI 10.1097/PAI.0000000000000175; Luchini C, 2015, PLACENTA, V36, P1318, DOI 10.1016/j.placenta.2015.09.012; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Marchetti A, 1996, J PATHOL, V179, P254, DOI 10.1002/(SICI)1096-9896(199607)179:3<254::AID-PATH589>3.0.CO;2-J; Meador CB, 2014, CLIN CANCER RES, V20, P2264, DOI 10.1158/1078-0432.CCR-13-1591; Meng XJ, 2017, CANCER LETT, V405, P29, DOI 10.1016/j.canlet.2017.06.033; Nottegar A, 2016, APPL IMMUNOHISTOCHEM, V7; Nottegar A, 2017, EXP MOL PATHOL, V102, P276, DOI 10.1016/j.yexmp.2017.02.014; Okada A, 2010, CANCER SCI, V101, P1745, DOI 10.1111/j.1349-7006.2010.01585.x; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Rock JR, 2009, P NATL ACAD SCI USA, V106, P12771, DOI 10.1073/pnas.0906850106; Russell PA, 2011, J THORAC ONCOL, V6, P1496, DOI 10.1097/JTO.0b013e318221f701; Russo A, 2015, ONCOTARGET, V6, P26814, DOI 10.18632/oncotarget.4254; Sica G, 2010, AM J SURG PATHOL, V34, P1155, DOI 10.1097/PAS.0b013e3181e4ee32; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Snyder EL, 2013, MOL CELL, V50, P185, DOI 10.1016/j.molcel.2013.02.018; Takeuchi T, 2006, J CLIN ONCOL, V24, P1679, DOI 10.1200/JCO.2005.03.8224; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Travis WD, 2011, CLIN CHEST MED, V32, P669, DOI 10.1016/j.ccm.2011.08.005; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Yatabe Y, 2005, AM J SURG PATHOL, V29, P633, DOI 10.1097/01.pas.0000157935.28066.35	34	1	1	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAY	2018	75						167	178		10.1016/j.humpath.2018.01.017			12	Pathology	Pathology	GI2YQ	WOS:000434238200021	29409837				2019-10-28	
J	Lee, C; Kim, B; Song, B; Park, JH; Moon, KC				Lee, Cheol; Kim, Bohyun; Song, Boram; Park, Jeong Hwan; Moon, Kyung Chul			Clinicopathologic Features of Benign Neurogenic Tumor of Urinary Bladder	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						urinary bladder; neurofibroma; neurilemmoma; ganglioneuroma; granular cell tumor	PLEXIFORM NEUROFIBROMA; DIFFUSE GANGLIONEUROMATOSIS; CHOROIDAL GANGLIONEUROMA; PATIENT; TYPE-1; PHEOCHROMOCYTOMA; CRITERIA; DISEASE	Background. Benign neurogenic tumor involving the urinary bladder is a very rare and heterogeneous disease group. The clinical and radiological diagnosis may be difficult because of the disease's rarity and the histological similarities of each disease especially in needle biopsy specimens. However, accurate diagnosis is very important because the clinical course of each disease, even within the same diseases, is quite variable. In this study, we investigated 7 benign neurogenic tumors to better understand the rare disease entity in the urinary bladder by analyzing histological and immunohistochemical findings and comparing clinicopathologic features. Methods. We collected the cases by searching the medical records database of Seoul National University Hospital from 2000 to 2016. Results. We identified 3 ganglioneuromas, 2 schwannomas, 1 neurofibroma, and 1 granular cell tumor involving the urinary bladder. There were some limitations for the initial clinical and radiological diagnosis and even pathologic diagnosis using needle biopsy specimens. One infant patient was diagnosed radiologically with rhabdomyosarcoma, but the final diagnosis changed to ganglioneuromatosis. The initial needle biopsy diagnosis of 2 ganglioneuroma cases showed neurofibroma. All patients underwent a local resection, and 1 granular cell tumor patient suffered with pain because of a recurrent tumor. One neurofibromatosis patient had a lesion appear 34 months after the bladder operation, so he underwent repeated debulking operations, but he was diagnosed with malignant transformation after 8 years. Conclusions. An understanding of benign neurogenic tumors involving the urinary bladder and the sharing of rare experiences surrounding them are required to provide accurate diagnoses.	[Lee, Cheol; Kim, Bohyun; Song, Boram; Moon, Kyung Chul] Seoul Natl Univ, Seoul, South Korea; [Park, Jeong Hwan] Metropolitan Govt Boramae Hosp, Seoul, South Korea	Moon, KC (reprint author), Seoul Natl Univ, Kidney Res Inst, Dept Pathol, Med Res Ctr,Coll Med, 103 Daehak Ro, Seoul 110799, South Korea.	blue7270@snu.ac.kr			Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [2016R1D1A1A02937001]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2016R1D1A1A02937001).	Abbas Farhat, 2007, World J Surg Oncol, V5, P33, DOI 10.1186/1477-7819-5-33; Bacci C, 2010, CLIN GENET, V77, P293, DOI 10.1111/j.1399-0004.2009.01292.x; Cheng L, 1999, CANCER-AM CANCER SOC, V86, P505, DOI 10.1002/(SICI)1097-0142(19990801)86:3<505::AID-CNCR20>3.0.CO;2-A; CHETTY R, 1993, AM J SURG PATHOL, V17, P837, DOI 10.1097/00000478-199308000-00009; Fanburg-Smith JC, 1998, AM J SURG PATHOL, V22, P779, DOI 10.1097/00000478-199807000-00001; Fletcher C, 2013, WHO CLASSIFICATION T; Geraci AP, 1998, J CHILD NEUROL, V13, P356, DOI 10.1177/088307389801300712; Gutmann DH, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.4; Hartman C, 2015, UROLOGY, V85, P467, DOI 10.1016/j.urology.2014.10.027; Hwang John S, 2011, Orthopedics, V34, pe428, DOI 10.3928/01477447-20110627-31; Kang HW, 2010, KOREAN J UROL, V51, P291, DOI 10.4111/kju.2010.51.4.291; Kyoshima K, 2004, SURG NEUROL, V61, P468, DOI 10.1016/S0090-3019(03)00393-8; Lockhart ME, 2000, AM J ROENTGENOL, V175, P132, DOI 10.2214/ajr.175.1.1750132; Moch H, 2016, WHO CLASSIFICATION T; NASSIRI M, 1994, ARCH PATHOL LAB MED, V118, P938; Ozgun G, 2014, KAOHSIUNG J MED SCI, V30, P215, DOI 10.1016/j.kjms.2013.02.001; RAVICH A, 1945, ANN SURG, V121, P361, DOI 10.1097/00000658-194503000-00010; Salvitti M, 2013, J PEDIATR UROL, V9, pE131, DOI 10.1016/j.jpurol.2013.01.006; Scheithauer BW, 2008, HUM PATHOL, V39, P1708, DOI 10.1016/j.humpath.2008.02.019; SHEPHARD RH, 1958, BRIT J SURG, V45, P304; Shimada H, 1999, CANCER, V86, P349, DOI 10.1002/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.3.CO;2-P; Shome D, 2006, EYE, V20, P1450, DOI 10.1038/sj.eye.6702320; Wang Jian, 2004, Zhonghua Bing Li Xue Za Zhi, V33, P497; Wang WL, 2008, AM J SURG PATHOL, V32A, P907, DOI 10.1097/PAS.0b013e31815b0c9a; Xu WH, 2014, INT J MOL MED, V34, P53, DOI 10.3892/ijmm.2014.1756; Yazici B, 2014, OPHTHAL PLAST RECONS, V30, pE140, DOI 10.1097/IOP.0b013e3182a74e55	26	0	0	1	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	MAY	2018	26	3					221	228		10.1177/1066896917742722			8	Pathology; Surgery	Pathology; Surgery	GD1AD	WOS:000430231500003	29172920				2019-10-28	
J	Majumdar, K; Sakhuja, P; Puri, AS; Gaur, K; Haider, A; Gondal, R				Majumdar, Kaushik; Sakhuja, Puja; Puri, Amarender Singh; Gaur, Kavita; Haider, Aiman; Gondal, Ranjana			Coeliac disease and the liver: spectrum of liver histology, serology and treatment response at a tertiary referral centre	JOURNAL OF CLINICAL PATHOLOGY			English	Article						celiac; hepatitis; steatosis; liver; chronic; autoimmune	GLUTEN-FREE DIET; AUTOIMMUNE HEPATITIS; DIAGNOSIS; HYPERTRANSAMINASEMIA; DYSFUNCTION; ANTIGLIADIN; PREVALENCE; ANTIBODIES; DISORDERS	Background Coeliac disease (CD) is a gluten-sensitive enteropathy diagnosed on the basis of ESPGHAN criteria and clinical response to gluten-free diet (GFD). Histological abnormalities on liver biopsy have been noted in CD but have seldom been described. Aims To assess the histological spectrum of coeliac hepatitis' and possibility of reversal of such features after a GFD. Methods Twenty-five patients with concomitant CD and hepatic derangement were analysed for clinical profile, laboratory investigations and duodenal and liver biopsy. A histological comparison of pre- and post-GFD duodenal and liver biopsies was carried out, wherever possible. Results Fifteen patients presenting with CD subsequently developed abnormal liver function tests; 10 patients presenting with liver disease were found to have tissue positive transglutaminase in 70% and antigliadin antibodies in 60%. Serological markers for autoimmune liver disease (AILD) were positive in eight patients. Liver histology ranged from mild reactive hepatitis, chronic hepatitis, steatosis to cirrhosis. Liver biopsies after a GFD were available in six cases, of which five showed a decrease in steatosis, portal and lobular inflammation and fibrosis score. Conclusion Coeliac hepatitis could be a distinct entity and the patients may present with either CD or secondary hepatic derangement. Evaluation for the presence of CD is recommended for patients presenting with AILD, unexplained transaminasaemia or anaemia. This is one of the very few studies demonstrating the continuum of liver histological changes in coeliac hepatitis'. Trial of a GFD may result in clinicopathological improvement of coeliac hepatitis'.	[Majumdar, Kaushik; Sakhuja, Puja; Gaur, Kavita; Haider, Aiman; Gondal, Ranjana] GB Pant Inst Postgrad Med Educ & Res, Dept Pathol, Acad Block, New Delhi 110002, India; [Puri, Amarender Singh] GB Pant Inst Postgrad Med Educ & Res, Dept Gastroenterol, New Delhi, India	Majumdar, K (reprint author), GB Pant Inst Postgrad Med Educ & Res, Dept Pathol, Acad Block, New Delhi 110002, India.	pujasak@gmail.com					Bardella MT, 1999, HEPATOLOGY, V29, P654, DOI 10.1002/hep.510290318; BARDELLA MT, 1995, HEPATOLOGY, V22, P833, DOI 10.1016/0270-9139(95)90305-4; Chalasani N, 2012, AM J GASTROENTEROL, V107, P811, DOI 10.1038/ajg.2012.128; Davison S, 2002, ARCH DIS CHILD, V87, P293, DOI 10.1136/adc.87.4.293; Drastich P, 2012, WORLD J GASTROENTERO, V18, P6255, DOI 10.3748/wjg.v18.i43.6255; Fasano A, 2001, GASTROENTEROLOGY, V120, P636, DOI 10.1053/gast.2001.22123; Franzese A, 2001, J PEDIATR GASTR NUTR, V33, P329, DOI 10.1097/00005176-200109000-00019; Gaur K, 2016, SAUDI J GASTROENTERO, V22, P461, DOI 10.4103/1319-3767.195554; Green PHR, 2005, BEST PRACT RES CL GA, V19, P389, DOI 10.1016/j.bpg.2005.02.006; HAGANDER B, 1977, LANCET, V2, P270; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; JACOBSEN MB, 1990, SCAND J GASTROENTERO, V25, P656, DOI 10.3109/00365529008997589; Kaukinen K, 2002, GASTROENTEROLOGY, V122, P881, DOI 10.1053/gast.2002.32416; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; LINDBERG T, 1978, LANCET, V1, P390; Mounajjed T, 2011, AM J CLIN PATHOL, V136, P128, DOI 10.1309/AJCPDOMY5RI5TPMN; Mulder C, 1998, GUT, V42, P594, DOI 10.1136/gut.42.4.594; NASCHITZ JE, 1987, AM J GASTROENTEROL, V82, P1186; POLLOCK DJ, 1977, HISTOPATHOLOGY, V1, P421, DOI 10.1111/j.1365-2559.1977.tb01681.x; Puri Amrinder Singh, 2004, Indian Pediatr, V41, P822; Rostami K, 1999, AM J GASTROENTEROL, V94, P888; Rubio-Tapia A, 2007, HEPATOLOGY, V46, P1650, DOI 10.1002/hep.21949; Ventura A, 1999, GASTROENTEROLOGY, V117, P297, DOI 10.1053/gast.1999.0029900297; Villalta D, 2005, J CLIN LAB ANAL, V19, P6, DOI 10.1002/jcla.20047; Volta U, 2002, AM J GASTROENTEROL, V97, P2609, DOI 10.1016/S0002-9270(02)04389-7; Volta U, 1998, DIGEST DIS SCI, V43, P2190, DOI 10.1023/A:1026650118759; WALKERSMITH JA, 1990, ARCH DIS CHILD, V65, P909	27	6	6	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAY	2018	71	5					412	419		10.1136/jclinpath-2017-204647			8	Pathology	Pathology	GD9LV	WOS:000430835100005	28970297				2019-10-28	
J	Kurihara-Shimomura, M; Sasahira, T; Nakamura, H; Nakashima, C; Kuniyasu, H; Kirita, T				Kurihara-Shimomura, Miyako; Sasahira, Tomonori; Nakamura, Hiroshi; Nakashima, Chie; Kuniyasu, Hiroki; Kirita, Tadaaki			Zinc finger AN1-type containing 4 is a novel marker for predicting metastasis and poor prognosis in oral squamous cell carcinoma	JOURNAL OF CLINICAL PATHOLOGY			English	Article						ZFAND4; metastasis; prognosis; oral cancer	MELANOMA INHIBITORY-ACTIVITY; LONG-TERM SURVIVAL; DISTANT METASTASIS; CANCER STATISTICS; NODAL METASTASIS; LYMPHANGIOGENESIS; EXPRESSION; INVASION	Aims Head and neck cancer, including oral squamous cell carcinoma (OSCC), is the sixth most common cancer worldwide and has a high potential for locoregional invasion and nodal metastasis. Therefore, discovery of a useful molecular biomarker capable of predicting tumour progression and metastasis of OSCC is crucial. We have previously reported zinc finger AN1-type containing 4 (ZFAND4) as one of the most upregulated genes in recurrent OSCC using a cDNA microarray analysis. Although ZFAND4 has been shown to promote cell proliferation of gastric cancer, its expression and clinicopathological roles in OSCC remain unclear. Methods In this study, we examined ZFAND4 expression by immunohistochemistry in 214 cases of OSCC. Results High cytoplasmic expression of ZFAND4 was observed in 45 out of 214 (21%) patients with OSCC. Expression levels of ZFAND4 were strongly associated with metastasis to the lymph nodes (p=0.0429) and distant organs (p=0.0068). Cases with high expression of ZFAND4 had a significantly unfavourable prognosis compared with patients with low expression of ZFAND4 (p<0.0001). Furthermore, ZFAND4 overexpression was an independent poor prognostic factor for OSCC as determined by multivariate analysis using the Cox proportional hazards model (p<0.0001). Conclusions These results suggest that ZFAND4 is a useful marker for predicting metastasis and poor prognosis in patients with OSCC.	[Kurihara-Shimomura, Miyako; Nakamura, Hiroshi; Nakashima, Chie; Kirita, Tadaaki] Nara Med Univ, Dept Mol Pathol, Kashihara, Nara 6348521, Japan; [Sasahira, Tomonori; Kuniyasu, Hiroki] Nara Med Univ, Dept Mol Pathol, Kashihara, Nara, Japan	Sasahira, T (reprint author), Nara Med Univ, Dept Mol Pathol, Kashihara, Nara, Japan.	sasa@naramed-u.ac.jp			Japan Society for the Promotion of Science, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science	This work was supported in part by Grant-in-Aid for Scientific Research from Japan Society for the Promotion of Science, Japan.	Allred DC, 1998, MODERN PATHOL, V11, P155; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Husni RE, 2016, LUNG CANCER, V97, P59, DOI 10.1016/j.lungcan.2016.04.018; Kang HS, 2016, J CANCER RES CLIN, V142, P295, DOI 10.1007/s00432-015-2043-x; Kowalski LP, 2005, ORAL ONCOL, V41, P534, DOI 10.1016/j.oraloncology.2005.01.012; Kuang P, 2017, TRANSL ONCOL, V10, P367, DOI 10.1016/j.tranon.2017.02.010; Kurihara M, 2013, BRIT J CANCER, V108, P1460, DOI 10.1038/bjc.2013.27; Leikauf GD, 2013, AM J RESP CELL MOL, V49, P368, DOI 10.1165/rcmb.2012-0337OC; Liao CT, 2007, CANCER, V110, P1501, DOI 10.1002/cncr.22959; McBride SM, 2014, ORAL ONCOL, V50, P208, DOI 10.1016/j.oraloncology.2013.10.020; Sakamoto N, 2010, CANCER SCI, V101, P1038, DOI 10.1111/j.1349-7006.2009.01477.x; Sasahira T, 2008, CANCER SCI, V99, P1806, DOI 10.1111/j.1349-7006.2008.00894.x; Sasahira T, 2017, HISTOPATHOLOGY, V70, P539, DOI 10.1111/his.13097; Sasahira T, 2016, VIRCHOWS ARCH, V469, P163, DOI 10.1007/s00428-016-1955-4; Sasahira T, 2016, ONCOTARGET, V7, P31137, DOI 10.18632/oncotarget.9082; Sasahira T, 2016, BRIT J CANCER, V115, P52, DOI 10.1038/bjc.2016.167; Sasahira T, 2016, ONCOTARGET, V7, P26751, DOI 10.18632/oncotarget.8495; Sasahira T, 2014, EUR J CANCER, V50, P2142, DOI 10.1016/j.ejca.2014.05.006; Sasahira T, 2010, EUR J CANCER, V46, P2285, DOI 10.1016/j.ejca.2010.04.027; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Takahashi Miho, 2014, Tokai J Exp Clin Med, V39, P178; Tang L, 2015, ONCOL REP, V33, P1707, DOI 10.3892/or.2015.3798; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yokobori T, 2013, CANCER RES, V73, P2059, DOI 10.1158/0008-5472.CAN-12-0326; Zhou CJ, 2009, ORAL ONCOL, V45, P883, DOI 10.1016/j.oraloncology.2009.03.002	26	4	5	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAY	2018	71	5					436	441		10.1136/jclinpath-2017-204770			6	Pathology	Pathology	GD9LV	WOS:000430835100008	29074611				2019-10-28	
J	Wang, HK; Liang, JF; Zheng, HX; Xiao, H				Wang, Hong-kun; Liang, Jian-fang; Zheng, Hui-xia; Xiao, Hong			Expression and prognostic significance of ECT2 in invasive breast cancer	JOURNAL OF CLINICAL PATHOLOGY			English	Article						breast cancer; ECT2; immunohistochemistry; prognosis	CELL TRANSFORMING SEQUENCE-2; POOR-PROGNOSIS; METASTASIS	Aims To investigate the expression of epithelial cell transforming sequence 2 (ECT2) in invasive breast cancer and its prognostic significance. Methods ECT2 immunohistochemical detection was performed in 165 breast cancer specimens and 100 normal control tissues. Univariable and multivariable Cox proportional hazards regression model analysis was used to confirm independent prognostic factors. The PHREG procedure linear hypotheses testing method was used to analyse survival data. Results Expression of ECT2 in breast cancer was significantly higher than that of the normal control group (p<0.001), and it was related to tumour grade, the status of lymph node metastasis, TNM staging, recurrence status, menopausal status, and the Ki-67 proliferation index (p<0.05), and not related to age, tumour size, tumour type, expression of estrogen receptor, progesterone receptor and human epidermal growth factor 2, and triple-negative disease (p>0.05). Univariable analysis showed that expression of ECT2, the status of lymph node metastasis, triple-negative disease and Ki-67 proliferation index were related to the overall survival of patients with breast cancer (p<0.001, p=0.006, p=0.001, p=0.041, respectively). PHREG procedure linear hypotheses testing results for overall survival revealed that high expression of ECT2, lymph node metastasis, triple-negative disease and high Ki-67 proliferation index predicted lower overall survival rates. Multivariable Cox regression indicated that high expression of ECT2 and triple-negative disease were independent prognostic factors for patients with breast cancer (p<0.001, p=0.004, respectively). Conclusions Expression of ECT2 may be one of the main causes of the occurrence and development of breast cancer, and high expression of ECT2 as an independent prognostic factor predicts a poor prognosis. ECT2 could also be a potential molecular target for designing therapeutic strategies for breast cancer.	[Wang, Hong-kun; Liang, Jian-fang; Zheng, Hui-xia; Xiao, Hong] Shanxi Med Univ, Dept Pathol, Hosp 1, Taiyuan 030001, Shanxi, Peoples R China	Zheng, HX (reprint author), Shanxi Med Univ, Dept Pathol, Hosp 1, Taiyuan 030001, Shanxi, Peoples R China.	huixiazheng62@126.com					Bianchini G, 2016, NAT REV CLIN ONCOL, V13, P674, DOI 10.1038/nrclinonc.2016.66; Breslow N, 1972, J R STAT SOC B, V34, P216; Cheng YS, 2014, NEUROL INDIA, V62, P406, DOI 10.4103/0028-3886.141278; Guo ZH, 2017, MED ONCOL, V34, DOI 10.1007/s12032-016-0872-3; Hirata D, 2009, CLIN CANCER RES, V15, P256, DOI 10.1158/1078-0432.CCR-08-1672; Iyoda M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014082; Jin Y, 2014, INT J CLIN EXP PATHO, V7, P8724; Luo Y, 2015, BIOMED PHARMACOTHER, V73, P135, DOI 10.1016/j.biopha.2015.06.007; Mansour M, 2016, CANCER RES, V76, P4236, DOI 10.1158/0008-5472.CAN-15-1553; Miah S, 2017, MOL BIOSYST, V13, P42, DOI 10.1039/c6mb00639f; Sano M, 2006, ONCOL REP, V16, P1093; Scoumanne A, 2006, CANCER RES, V66, P6271, DOI 10.1158/0008-5472.CAN-06-0121; Tan HY, 2016, EXP THER MED, V12, P2088, DOI 10.3892/etm.2016.3584; Tanabe K, 2017, ONCOTARGET, V8, P6353, DOI 10.18632/oncotarget.14087; Wang HB, 2016, CLIN TRANSL ONCOL, V18, P735, DOI 10.1007/s12094-015-1428-2; Yao H, 2017, ONCOTARGET, V8, P1913, DOI 10.18632/oncotarget.12284; Zhang ML, 2008, HEPATOB PANCREAT DIS, V7, P533	17	5	6	1	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAY	2018	71	5					442	445		10.1136/jclinpath-2017-204569			4	Pathology	Pathology	GD9LV	WOS:000430835100009	29051317				2019-10-28	
J	Khanh, NP; Tan, SW; Yeap, SK; Lee, HJ; Choi, KS; Hair-Bejo, M; Bich, TN; Omar, AR				Khanh, N. P.; Tan, S. W.; Yeap, S. K.; Lee, H. J.; Choi, K. S.; Hair-Bejo, M.; Bich, T. N.; Omar, A. R.			Comparative Pathogenicity of Malaysian QX-like and Variant Infectious Bronchitis Virus Strains in Chickens at Different Age of Exposure to the Viruses	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						chicken; infectious bronchitis virus; Malaysian QX-Iike and variant strains; pathogenicity	MOLECULAR CHARACTERIZATION; PHYLOGENETIC ANALYSIS; GENOTYPE; SEROTYPE; ANTIGENICITY; NEPHROPATHOGENICITY; IDENTIFICATION; PATHOGENESIS; IBV	Infectious bronchitis viruses (IBVs) circulating in Malaysia arc classified into two groups as Malaysian QX-like and variant strains. In this study, the pathogenicity of IBS130/2015 (QX-like) and IBS037A/2014 (variant) IBVs in 1-day-old and 30-day-old specific pathogen free (SPF) chickens was characterized. Both strains caused respiratory and kidney infections based on immunohistochemistry (IHC), real-time quantitative polymerasc chain reaction (qPCR) and a ciliostasis study; however, the results showed that the QX-like strain was more pathogenic, caused higher mortality and showed higher tissue tropism for the kidney than the variant strain. In contrast, despite causing low or no mortality depending on the age of the infected chickens, the Malaysian variant strain showed high tissue tropism for the respiratory tract compared with the QX-like strain. IHC and qPCR indicated the presence of both IBV strains in the epithelial lining of villi in the jejunum and the caccal tonsil; however, no pathological changes were detected in these organs. Both the Malaysian QX-like and variant IBV strains arc able to infect the respiratory tract and kidney of chickens irrespective of age. (C) 2018 Elsevier Ltd. All rights reserved.	[Khanh, N. P.; Tan, S. W.; Yeap, S. K.; Hair-Bejo, M.; Omar, A. R.] Univ Putra Malaysia, Inst Biosci, Serdang, Selangor, Malaysia; [Hair-Bejo, M.; Omar, A. R.] Univ Putra Malaysia, Fac Vet Med, Serdang, Selangor, Malaysia; [Khanh, N. P.; Bich, T. N.] Can Tho Univ, Fac Agr & Appl Biol, Ninh Kieu, Can Tho, Vietnam; [Lee, H. J.; Choi, K. S.] Avian Dis Div, 177 Hyeoksin 8-Ro, Gimcheon Si, Gyeongsangbuk, South Korea	Omar, AR (reprint author), Univ Putra Malaysia, Inst Biosci, Serdang, Selangor, Malaysia.; Omar, AR (reprint author), Univ Putra Malaysia, Fac Vet Med, Serdang, Selangor, Malaysia.	aro@upm.edu.my			IBS HICoE from the Ministry of Higher Education, Government of Malaysia [6369101]; APQA, Republic of Korea [I-1543084-2017-19-01]; PhD programme of the Vietnam International Education Development, Ministry of Education and Training	The study was supported by an IBS HICoE Grant (number 6369101) from the Ministry of Higher Education, Government of Malaysia and APQA Grant no I-1543084-2017-19-01, Republic of Korea. N. P. Khanh was supported by a PhD programme of the Vietnam International Education Development, Ministry of Education and Training.	Abolnik C, 2015, INFECT GENET EVOL, V32, P416, DOI 10.1016/j.meegid.2015.03.033; Abro SH, 2012, ARCH VIROL, V157, P1211, DOI 10.1007/s00705-012-1284-0; ALBASSAM MA, 1986, AVIAN DIS, V30, P468, DOI 10.2307/1590408; Almeida DO, 2012, POULTRY SCI, V91, P3052, DOI 10.3382/ps.2012-02476; AMBALI AG, 1990, AVIAN DIS, V34, P809, DOI 10.2307/1591367; AVELLANEDA GE, 1994, AVIAN DIS, V38, P589, DOI 10.2307/1592083; Benyeda Z, 2010, J COMP PATHOL, V143, P276, DOI 10.1016/j.jcpa.2010.04.007; Benyeda Z, 2009, AVIAN PATHOL, V38, P449, DOI 10.1080/03079450903349196; Boroomand Z, 2012, SCI WORLD J, P1, DOI 10.1100/2012/402537; Chacon JL, 2014, BRIT POULTRY SCI, V55, P271, DOI 10.1080/00071668.2014.903558; Chacon JL, 2011, AVIAN PATHOL, V40, P153, DOI 10.1080/03079457.2010.544641; Chen BY, 1997, AVIAN PATHOL, V26, P607, DOI 10.1080/03079459708419238; Chen YQ, 2017, VET MICROBIOL, V198, P108, DOI 10.1016/j.vetmic.2016.12.017; Choi KS, 2009, J VET SCI, V10, P357, DOI 10.4142/jvs.2009.10.4.357; CRINION RAP, 1972, AVIAN DIS, V16, P351, DOI 10.2307/1588800; de Wit JJ, 2011, AVIAN PATHOL, V40, P463, DOI 10.1080/03079457.2011.599060; Dolz R, 2012, VET MICROBIOL, V156, P256, DOI 10.1016/j.vetmic.2011.11.001; Domanska-Blicharz K, 2006, VET REC, V158, P808, DOI 10.1136/vr.158.23.808-c; Ducatez MF, 2009, J GEN VIROL, V90, P2679, DOI 10.1099/vir.0.012476-0; Fabricant J, 1998, AVIAN DIS, V42, P648, DOI 10.2307/1592697; Feng JL, 2012, EMERG INFECT DIS, V18, P1994, DOI 10.3201/eid1812.120552; Gough RE, 2008, VET REC, V162, P99, DOI 10.1136/vr.162.3.99; Ignjatovic J, 2002, J COMP PATHOL, V126, P115, DOI 10.1053/jcpa.2001.0528; Jackwood M. W., 2013, DIS POULTRY, P139, DOI 10.1002/9781119421481; Jackwood MW, 2012, AVIAN DIS, V56, P634, DOI 10.1637/10227-043012-Review.1; Khanh NP, 2017, AVIAN DIS, V61, P442, DOI [10.1637/11637-032817-reg.1, 10.1637/11637-032817-Reg.1]; Khataby K, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0711-y; Landman W. J, 2005, P 14 WORLD VET POULT, V369, P2005; Lee EK, 2008, AVIAN DIS, V52, P332, DOI 10.1637/8117-092707-ResNote.1; Lin SY, 2016, SCI REP-UK, V6, DOI 10.1038/srep37725; Liu SW, 2004, AVIAN PATHOL, V33, P321, DOI 10.1080/0307945042000220697; MACDONALD JW, 1980, AVIAN PATHOL, V9, P245, DOI 10.1080/03079458008418410; Mase M, 2004, ARCH VIROL, V149, P2069, DOI 10.1007/s00705-004-0369-9; Najafi H, 2017, VET RES FORUM, V8, P35; Pohuang T, 2013, THAI J VET MED, V42, P7; Pohuang T, 2011, VIRUS GENES, V43, P254, DOI 10.1007/s11262-011-0635-3; Raj GD, 1997, AVIAN PATHOL, V26, P677, DOI 10.1080/03079459708419246; Shimazaki Y, 2008, AVIAN DIS, V52, P618, DOI 10.1637/8359-051408-Reg.1; Stevens A, 2007, THEORY PRACTICE HIST, P107; Terregino C, 2008, AVIAN PATHOL, V37, P487, DOI 10.1080/03079450802356938; Uenaka T, 1998, J VET MED SCI, V60, P495, DOI 10.1292/jvms.60.495; Villarreal LYB, 2007, AVIAN DIS, V51, P974, DOI 10.1637/7983-041307.1; Wang YuDong, 1998, Chinese Journal of Animal Quarantine, V15, P1; WINTERFIELD RW, 1984, POULTRY SCI, V63, P2358, DOI 10.3382/ps.0632358; Worthington KJ, 2008, AVIAN PATHOL, V37, P247, DOI 10.1080/03079450801986529; Yan SH, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01653; Yan SH, 2017, VET MICROBIOL, V203, P167, DOI 10.1016/j.vetmic.2017.03.010; Yu L, 2001, AVIAN DIS, V45, P416, DOI 10.2307/1592981; Zulperi ZM, 2009, VIRUS GENES, V38, P383, DOI 10.1007/s11262-009-0337-2	49	2	2	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	MAY	2018	161						43	54		10.1016/j.jcpa.2018.04.006			12	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GO1TA	WOS:000439737800006	30173857				2019-10-28	
J	Cagnoli, C; Brussino, A; Mancini, C; Ferrone, M; Orsi, L; Salmin, P; Pappi, P; Giorgio, E; Pozzi, E; Cavalieri, S; Di Gregorio, E; Ferrero, M; Filla, A; De Michele, G; Gellera, C; Mariotti, C; Nethisinghe, S; Giunti, P; Stevanin, G; Brusco, A				Cagnoli, Claudia; Brussino, Alessandro; Mancini, Cecilia; Ferrone, Marina; Orsi, Laura; Salmin, Paola; Pappi, Patrizia; Giorgio, Elisa; Pozzi, Elisa; Cavalieri, Simona; Di Gregorio, Eleonora; Ferrero, Marta; Filla, Alessandro; De Michele, Giuseppe; Gellera, Cinzia; Mariotti, Caterina; Nethisinghe, Suran; Giunti, Paola; Stevanin, Giovanni; Brusco, Alfredo			Spinocerebellar Ataxia Tethering PCR A Rapid Genetic Test for the Diagnosis of Spinocerebellar Ataxia Types 1, 2, 3, 6, and 7 by PCR and Capillary Electrophoresis	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							DOMINANT CEREBELLAR ATAXIAS; LARGE PATHOGENIC EXPANSIONS; CAG REPEAT EXPANSIONS; CHAIN-REACTION ASSAY; CLINICAL CORRELATIONS; INFANTILE PHENOTYPE; 7 SCA7; FAMILIES; FREQUENCY; DISEASE	Spinocerebellar ataxia (SCA) types 1, 2, 3, 6, and 7, associated with a (CAG)(n) repeat expansion in coding sequences, are the most prevalent autosomal dominant ataxias worldwide (approximately 60% of the cases). In addition, the phenotype of SCA2 expansions has been now extended to Parkinson disease and amyotrophic lateral sclerosis. Their diagnosis is currently based on a PCR to identify small expanded alleles, followed by a second-level test whenever a false normal homozygous or a CAT interruption in SCA1 needs to be verified. Next-generation sequencing still does not allow efficient detection of these repeats. Here, we show the efficacy of a novel, rapid, and cost-effective method to identify and size pathogenic expansions in SCA1, 2, 3, 6, and 7 and recognize large alleles or interruptions without a second-level test. Twenty-five healthy controls and 33 expansion carriers were analyzed: alleles migrated consistently in different PCRs and capillary runs, and homozygous individuals were always distinguishable from heterozygous carriers of both common and large (>100 repeats) pathogenic CAG expansions. Repeat number could be calculated counting the number of peaks, except for the Largest SCA2 and SCA7 alleles. Interruptions in SCA1 were always visible. Overall, our method allows a simpler, cost-effective, and sensibly faster SCA diagnostic protocol compared with the standard technique and to the still unadapted next-generation sequencing.	[Cagnoli, Claudia; Brussino, Alessandro; Mancini, Cecilia; Ferrone, Marina; Giorgio, Elisa; Pozzi, Elisa; Cavalieri, Simona; Di Gregorio, Eleonora; Ferrero, Marta; Brusco, Alfredo] Univ Turin, Dept Med Sci, Via Santena 19, I-10126 Turin, Italy; [Ferrone, Marina; Salmin, Paola; Pappi, Patrizia; Brusco, Alfredo] Citta Salute & Sci Univ Hosp, Med Genet Unit, Dept Lab Med, Turin, Italy; [Orsi, Laura] Citta Salute & Sci Univ Hosp, Neurol Div 1, Dept Neurosci & Mental Hlth, Turin, Italy; [Filla, Alessandro; De Michele, Giuseppe] Univ Federico II, Dept Neurosci Odontostomatol & Reprod Sci, Naples, Italy; [Gellera, Cinzia; Mariotti, Caterina] Fdn IRCCS Carlo Besta Neurol Inst, Unit Genet Neurodegenerat & Metab Dis, Milan, Italy; [Nethisinghe, Suran; Giunti, Paola] UCL, Ataxia Ctr, Dept Mol Neurosci, Inst Neurol, London, England; [Stevanin, Giovanni] INSERM, U1127, Inst Cerveau & Moelle Epiniere, Paris, France; [Stevanin, Giovanni] CNRS, UMR 7225, Paris, France; [Stevanin, Giovanni] Sorbonne Univ, UMRS 1127, Univ Pierre & Marie Curie Paris 06, Paris, France; [Stevanin, Giovanni] PSL Res Univ, Ecole Prat Hautes Etud, Paris, France; [Stevanin, Giovanni] Hop La Pitie Salpetriere, AP HP, Ctr Reference Neurogenet, Paris, France	Brusco, A (reprint author), Univ Turin, Dept Med Sci, Via Santena 19, I-10126 Turin, Italy.	alfredo.brusco@unito.it	Nethisinghe, Suran/E-2318-2011; Giorgio, Elisa/K-4740-2018; Stevanin, Giovanni/P-9223-2019; Stevanin, Giovanni/E-5038-2016; Giunti, Paola/E-5526-2012; Mancini, Cecilia/AAB-7442-2019	Nethisinghe, Suran/0000-0002-4272-9292; Giorgio, Elisa/0000-0003-4076-4649; Stevanin, Giovanni/0000-0001-9368-8657; Giunti, Paola/0000-0003-3508-4788; Mancini, Cecilia/0000-0003-1282-0404; Brusco, Alfredo/0000-0002-8318-7231; Mariotti, Caterina/0000-0003-2405-3564	MURSTMinistero dell' Istruzione, dell' Universita e della Ricerca (MIUR); Department of Health's National Institute for Health Research Biomedical Research Centres funding schemeNational Institute for Health Research (NIHR)	Supported by MURST local research grant (A.Brusc.). S.N. and P.G. work at University College London Hospitals/University College London, which receives a proportion of funding from the Department of Health's National Institute for Health Research Biomedical Research Centres funding scheme.	Ansorge O, 2004, ANN NEUROL, V56, P448, DOI 10.1002/ana.20230; Benton CS, 1998, NEUROLOGY, V51, P1081, DOI 10.1212/WNL.51.4.1081; Brusco A, 2004, ARCH NEUROL-CHICAGO, V61, P727, DOI 10.1001/archneur.61.5.727; Cagnoli C, 2006, J MOL DIAGN, V8, P128, DOI 10.2353/jmoldx.2006.050043; Cagnoli C, 2004, J MOL DIAGN, V6, P96, DOI 10.1016/S1525-1578(10)60496-5; Cancel G, 1997, HUM MOL GENET, V6, P709, DOI 10.1093/hmg/6.5.709; Charles P, 2007, NEUROLOGY, V69, P1970, DOI 10.1212/01.wnl.0000269323.21969.db; Corrado L, 2011, HUM GENET, V130, P575, DOI 10.1007/s00439-011-1000-2; Coutelier M, 2017, BRAIN, V140, P1579, DOI 10.1093/brain/awx081; David G, 1998, HUM MOL GENET, V7, P165, DOI 10.1093/hmg/7.2.165; Day JW, 2003, NEUROLOGY, V60, P657, DOI 10.1212/01.WNL.0000054481.84978.F9; Durr A, 2010, LANCET NEUROL, V9, P885, DOI 10.1016/S1474-4422(10)70183-6; Globas C, 2008, MOVEMENT DISORD, V23, P2232, DOI 10.1002/mds.22288; HARDING AE, 1982, ANN NEUROL, V12, P419, DOI 10.1002/ana.410120503; Jama M, 2013, J MOL DIAGN, V15, P255, DOI 10.1016/j.jmoldx.2012.09.005; Jiang Miao, 2004, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V21, P83; Johansson J, 1998, HUM MOL GENET, V7, P171, DOI 10.1093/hmg/7.2.171; Koefoed P, 1997, EUR J NEUROL, V4, P586, DOI 10.1111/j.1468-1331.1997.tb00410.x; Kraus-Perrotta Cara, 2016, Cerebellum Ataxias, V3, P20; Lattante S, 2014, NEUROLOGY, V83, P990, DOI 10.1212/WNL.0000000000000778; Mao R, 2002, AM J MED GENET, V110, P338, DOI 10.1002/ajmg.10467; Martin JJ, 1999, J NEUROL SCI, V168, P37, DOI 10.1016/S0022-510X(99)00176-8; Maruyama H, 2002, AM J MED GENET, V114, P578, DOI 10.1002/ajmg.10514; Matilla-Duenas A, 2014, CEREBELLUM, V13, P269, DOI 10.1007/s12311-013-0539-y; Matsuura T, 2002, ADV EXP MED BIOL, V516, P79; Moretti P, 2004, AM J MED GENET A, V124A, P392, DOI 10.1002/ajmg.a.20428; Moseley ML, 1998, NEUROLOGY, V51, P1666, DOI 10.1212/WNL.51.6.1666; Paulson H., 1998, GENEREVIEWS; Riess O, 1997, NEUROGENETICS, V1, P59, DOI 10.1007/s100480050009; Rossi M, 2014, EUR J NEUROL, V21, P607, DOI 10.1111/ene.12350; Saleem Q, 2000, HUM GENET, V106, P179, DOI 10.1007/s004390051026; Saluto A, 2005, J MOL DIAGN, V7, P605, DOI 10.1016/S1525-1578(10)60594-6; Schols L, 2004, LANCET NEUROL, V3, P291, DOI 10.1016/S1474-4422(04)00737-9; Schols L, 1997, ANN NEUROL, V42, P924, DOI 10.1002/ana.410420615; Sequeiros J, 2010, EUR J HUM GENET, V18, P1173, DOI 10.1038/ejhg.2010.8; Shimizu Y, 2004, J HUM GENET, V49, P610, DOI 10.1007/s10038-004-0196-6; Silveira I, 2002, ARCH NEUROL-CHICAGO, V59, P623, DOI 10.1001/archneur.59.4.623; Sproviero W, 2017, NEUROBIOL AGING, V51, DOI 10.1016/j.neurobiolaging.2016.11.010; Stevanin G, 2000, EUR J HUM GENET, V8, P4, DOI 10.1038/sj.ejhg.5200403; Stevanin G, 1998, HUM MOL GENET, V7, P1809, DOI 10.1093/hmg/7.11.1809; Storey E, 2000, AM J MED GENET, V95, P351, DOI 10.1002/1096-8628(20001211)95:4<351::AID-AJMG10>3.0.CO;2-R; Tang BS, 2000, ARCH NEUROL-CHICAGO, V57, P540, DOI 10.1001/archneur.57.4.540; Vallat JM, 2016, REV NEUROL-FRANCE, V172, P339, DOI 10.1016/j.neurol.2016.04.005; van de Warrenburg BPC, 2002, NEUROLOGY, V58, P702, DOI 10.1212/WNL.58.5.702; van de Warrenburg BPC, 2001, J NEUROL, V248, P911, DOI 10.1007/s004150170082; Wang LS, 2015, NEUROLOGY, V85, P1283, DOI 10.1212/WNL.0000000000002016; Warner JP, 1996, J MED GENET, V33, P1022, DOI 10.1136/jmg.33.12.1022; Yu DX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016818; Zortea M, 2004, NEUROEPIDEMIOLOGY, V23, P275, DOI 10.1159/000080092	49	2	2	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAY	2018	20	3					289	297		10.1016/j.jmoldx.2017.12.006			9	Pathology	Pathology	GE3EF	WOS:000431095900004	29462666				2019-10-28	
J	Brauninger, A; Blau, W; Kunze, K; Desch, AK; Brobeil, A; Tur, MK; Etschmann, B; Gunther, U; Korholz, D; Schliesser, G; Kabisch, A; Kiehl, M; Rummel, M; Gattenlohner, S				Brauninger, Andreas; Blau, Wolfgang; Kunze, Kristin; Desch, Ann-Kathrin; Brobeil, Alexander; Tur, Mehmet K.; Etschmann, Benjamin; Guenther, Ulrich; Koerholz, Dieter; Schliesser, Georg; Kaebisch, Andreas; Kiehl, Michael; Rummel, Mathias; Gattenlohner, Stefan			Targeted Next-Generation Sequencing Is a Sensitive Tool for Differential Diagnosis of Myelodysplastic Syndromes in Bone Marrow Trephines	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							ACUTE MYELOID-LEUKEMIA; STEM-CELL TRANSPLANTATION; INTEGRATIVE GENOMICS VIEWER; SOMATIC MUTATIONS; DNMT3A; MDS; AML; PROGRESSION; LANDSCAPE; COMMON	Myelodysplastic syndromes are hematological neoplasias in which immunohistologic examination of bone marrow trephines is important for a definite diagnosis. Unequivocal distinction from reactive bone marrow changes is, however, sometimes difficult. Because neoplastic clones in myelodysplastic syndrome carry mutations in recurrent genes, mutation detection by targeted next-generation sequencing may be a useful support for differential diagnosis. To elucidate the accuracy of this approach in the clinical diagnostic setting, we analyzed single and consecutive bone marrow trephines processed for immunohistologic examination from 145 patients by targeted next-generation sequencing of 12 genes recurrently mutated in myelodysplastic syndromes. Of 110 patients with immunohistologic unequivocal diagnosis, 41 of 47 with myelodysplastic syndrome carried mutations. In 14 consecutive samples available from these patients, remissions were accompanied by loss of mutations and ongoing disease with persisting mutations. Of 35 samples with indefinite immunohistologic appearance, 22 developed clinical unequivocal myelodysplastic syndrome in the further course, and 19 carried mutations already in the initial biopsy, which persisted in consecutive samples available from 13 patients. No mutation was detected in any initial and consecutive sample of 13 patients with indefinite immunohistologic appearance without clinical unequivocal myelodysplastic syndrome in the further course. We conclude that targeted next-generation sequencing is an accurate tool for differential diagnosis of myelodysplastic syndrome in the clinical diagnostic setting.	[Brauninger, Andreas; Kunze, Kristin; Desch, Ann-Kathrin; Brobeil, Alexander; Tur, Mehmet K.; Etschmann, Benjamin; Gattenlohner, Stefan] Justus Liebig Univ Giessen, Inst Pathol, Langhansstr 10, D-35392 Giessen, Germany; [Blau, Wolfgang; Rummel, Mathias] Justus Liebig Univ Giessen, Div Hematol, Dept Internal Med, Giessen, Germany; [Guenther, Ulrich] Hosp Waltershausen Friedrichsroda, Dept Internal Med 2, Friedrichsroda, Germany; [Koerholz, Dieter] Univ Giessen, Dept Pediat Oncol & Hematol, Giessen, Germany; [Schliesser, Georg; Kaebisch, Andreas] Joint Practice Hematol & Oncol Giessen, Giessen, Germany; [Kiehl, Michael] Klinikum Frankfurt Oder, Div Hematooncol, Frankfurt, Oder, Germany	Brauninger, A (reprint author), Justus Liebig Univ Giessen, Inst Pathol, Langhansstr 10, D-35392 Giessen, Germany.	andreas.braeuninger@patho.med.uni-giessen.de		Tur, Mehmet Kemal/0000-0002-9259-6723	pool Rhon Klinikum [RKA FL_21]	Supported by pool Rhon Klinikum RKA FL_21.	Abdel-Wahab O, 2012, CANCER CELL, V22, P180, DOI 10.1016/j.ccr.2012.06.032; Bartels S, 2016, ONCOTARGET, V7, P30084, DOI 10.18632/oncotarget.8310; Bejar R, 2017, LEUKEMIA, V31, P1869, DOI 10.1038/leu.2017.181; Bejar R, 2014, J CLIN ONCOL, V32, P2691, DOI 10.1200/JCO.2013.52.3381; Bejar R, 2011, NEW ENGL J MED, V364, P2496, DOI 10.1056/NEJMoa1013343; Brunning RD, 2008, WHO CLASSIFICATION T, P87; Cargo CA, 2015, BLOOD, V126, P2362, DOI 10.1182/blood-2015-08-663237; Cazzola M, 2013, BLOOD, V122, P4021, DOI 10.1182/blood-2013-09-381665; Duncavage EJ, 2016, LEUKEMIA, V30, P2422, DOI 10.1038/leu.2016.247; Duncavage EJ, 2017, BLOOD, V129, P1397, DOI 10.1182/blood-2016-10-745273; Gangat N, 2016, AM J HEMATOL, V91, P76, DOI 10.1002/ajh.24253; Haferlach T, 2014, LEUKEMIA, V28, P241, DOI 10.1038/leu.2013.336; Keel SB, 2016, HAEMATOLOGICA, V101, P1343, DOI 10.3324/haematol.2016.149476; Kim SJ, 2013, BLOOD, V122, P4086, DOI 10.1182/blood-2013-02-483487; Kunze K, 2014, CANCER RES, V74, P6173, DOI 10.1158/0008-5472.CAN-14-1162; Kunze K, 2014, PATHOL RES PRACT, V210, P369, DOI 10.1016/j.prp.2014.02.006; Kwok B, 2015, BLOOD, V126, P2355, DOI 10.1182/blood-2015-08-667063; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; Lindsley RC, 2017, NEW ENGL J MED, V376, P536, DOI 10.1056/NEJMoa1611604; Makishima H, 2017, NAT GENET, V49, P204, DOI 10.1038/ng.3742; Malcovati L, 2017, BLOOD, V129, P3371, DOI 10.1182/blood-2017-01-763425; Mossner M, 2016, BLOOD, V128, P1246, DOI 10.1182/blood-2015-11-679167; Orazi A, 2007, PATHOBIOLOGY, V74, P97, DOI 10.1159/000101709; Papaemmanuil E, 2013, BLOOD, V122, P3616, DOI 10.1182/blood-2013-08-518886; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Russler-Germain DA, 2014, CANCER CELL, V25, P442, DOI 10.1016/j.ccr.2014.02.010; Scharenberg C, 2017, HAEMATOLOGICA, V102, P498, DOI 10.3324/haematol.2016.152025; Sperling AS, 2017, NAT REV CANCER, V17, P5, DOI 10.1038/nrc.2016.112; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Verburgh E, 2003, J CLIN ONCOL, V21, P273, DOI 10.1200/JCO.2003.04.182; Walter MJ, 2012, NEW ENGL J MED, V366, P1090, DOI 10.1056/NEJMoa1106968; Yeh P, 2017, BLOOD, V129, P1685, DOI 10.1182/blood-2016-09-740308; Yoshizato T, 2017, BLOOD, V129, P2347, DOI 10.1182/blood-2016-12-754796	33	2	2	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAY	2018	20	3					344	354		10.1016/j.jmoldx.2018.01.006			11	Pathology	Pathology	GE3EF	WOS:000431095900010	29471115	Bronze			2019-10-28	
J	Kim, M; Kim, JE; Kim, HJ; Chung, YR; Kwak, Y; Park, SY				Kim, Milim; Kim, Joung Eun; Kim, Hyun Jeong; Chung, Yul Ri; Kwak, Yoonjin; Park, So Yeon			Cytologic Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features and Its Impact on the Risk of Malignancy in the Bethesda System for Reporting Thyroid Cytopathology: An Institutional Experience	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Thyroid; Fine-needle aspiration cytology; Encapsulated follicular variant of papillary thyroid carcinoma; Noninvasive follicular thyroid neoplasm with papillary-like nuclear features; Risk of malignancy; Bethesda system	FINE-NEEDLE-ASPIRATION; NIFTP; CARCINOMA; VARIANT; PARADIGM; CANCER	Background: This study was performed to analyze cytologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) and its impact on the risk of malignancy (ROM) in the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). Methods: Five thousand five hundred and forty-nine cases of thyroid fine-needle aspiration cytology (FNAC) diagnosed between 2012 and 2014 were included in this study. Diagnostic categories based on TBSRTC were compared with final surgical diagnoses, and the ROM in each category was calculated both when NIFTP was included in malignant lesions and when excluded from malignant lesions. Results: Of the 5,549 thyroid FNAC cases, 1,891 cases underwent surgical resection. In final diagnosis, 1,700 cases were revealed as papillary thyroid carcinoma (PTC), and 25 cases were reclassified as NIFTP. The cytologic diagnoses of NIFTP were non-diagnostic in one, benign in five, atypia of undetermined significance (AUS) in 14, follicular neoplasm in two, and suspicious for malignancy in three cases. Collectively, NIFTP/encapsulated follicular variant of PTC (EFVPTC) were more frequently classified as benign, AUS, or follicular neoplasm and less frequently categorized as malignant compared to conventional PTCs. Exclusion of NIFTP from malignant diagnoses resulted in a slight decrease in malignancy rates in non-diagnostic, benign, AUS, follicular neoplasm, and suspicious for malignancy categories without any statistical significance. Conclusions: The decrease in the ROM was not significant when NIFTP was excluded from malignant lesions. In thyroid FNACs, NIFTP/EFVPTCs were mostly classified into indeterminate categories. Therefore, it might be feasible to separate NIFTP/EFVPTC from conventional PTC on FNAC to guide clinicians to conservative management for patients with NIFTP/EFVPTC.	[Kim, Milim; Kim, Hyun Jeong; Chung, Yul Ri; Park, So Yeon] Seoul Natl Univ, Bundang Hosp, Dept Pathol, 82 Gumi Ro 173beon Gil, Seongnam 13620, South Korea; [Kim, Milim; Chung, Yul Ri; Kwak, Yoonjin; Park, So Yeon] Seoul Natl Univ, Coll Med, Dept Pathol, Seoul, South Korea; [Kim, Joung Eun] Seoul Natl Univ, Coll Med, Seoul, South Korea	Park, SY (reprint author), Seoul Natl Univ, Bundang Hosp, Dept Pathol, 82 Gumi Ro 173beon Gil, Seongnam 13620, South Korea.	sypmd@snu.ac.kr					Baloch ZW, 2016, CANCER CYTOPATHOL, V124, P616, DOI 10.1002/cncy.21744; Brandler TC, 2017, CANCER CYTOPATHOL, V125, P378, DOI 10.1002/cncy.21848; Bychkov A, 2017, THYROID, V27, P983, DOI 10.1089/thy.2017.0079; Chandler JB, 2017, CANCER CYTOPATHOL, V125, P865, DOI 10.1002/cncy.21910; Cibas ES, 2017, THYROID, V27, P1341, DOI 10.1089/thy.2017.0500; Cibas ES, 2009, THYROID, V19, P1159, DOI 10.1089/thy.2009.0274; Faquin WC, 2016, CANCER CYTOPATHOL, V124, P181, DOI 10.1002/cncy.21631; Hauch A, 2014, ANN SURG ONCOL, V21, P3844, DOI 10.1245/s10434-014-3846-8; Hirokawa M, 2017, ENDOCR J, V64, P1149, DOI 10.1507/endocrj.EJ17-0214; Hung YP, 2018, HISTOPATHOLOGY, V72, P53, DOI 10.1111/his.13363; Iyer NG, 2011, CANCER-AM CANCER SOC, V117, P4439, DOI 10.1002/cncr.26070; Jung CK, 2014, J CLIN ENDOCR METAB, V99, pE276, DOI 10.1210/jc.2013-2503; Kiernan CM, 2018, SURGERY, V163, P55, DOI 10.1016/j.surg.2017.04.041; Li WH, 2018, DIAGN CYTOPATHOL, V46, P148, DOI 10.1002/dc.23866; Mainthia R, 2018, SURGERY, V163, P60, DOI 10.1016/j.surg.2017.04.037; Maletta F, 2016, HUM PATHOL, V54, P134, DOI 10.1016/j.humpath.2016.03.014; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Ohori NP, 2017, CANCER CYTOPATHOL, V125, P692, DOI 10.1002/cncy.21892; Singh R, 2017, ANN SURG ONCOL, V24, P3300, DOI 10.1245/s10434-017-6038-5; Strickland KC, 2016, THYROID, V26, P1466, DOI 10.1089/thy.2016.0280; Strickland KC, 2015, THYROID, V25, P987, DOI 10.1089/thy.2014.0612; Zhou HJ, 2018, CANCER CYTOPATHOL, V126, P20, DOI 10.1002/cncy.21926	22	4	4	0	1	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	MAY	2018	52	3					171	178		10.4132/jptm.2018.04.03			8	Pathology	Pathology	GF6GU	WOS:000432065900005	29614546	DOAJ Gold, Green Published			2019-10-28	
J	Moon, JH; Lee, K; Yang, HK; Kim, WH				Moon, Ji Hye; Lee, Kyoungbun; Yang, Han-Kwang; Kim, Woo Ho			Duodenal Adenocarcinoma of Brunner Gland Origin: A Case Report	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Brunner glands; Adenocarcinoma; Duodenum		We report a case of adenocarcinoma originating from the duodenal Brunner glands in a 47-year-old female patient. The lesion was 0.8 cm in extent and located at the posterior wall of the first part of the duodenum. Histologically, the tumor showed transition from non-neoplastic Brunner glands through dysplastic epithelium into adenocarcinoma. The carcinoma cells were strongly positive for MUC6 protein, which is an epithelial marker for the Brunner glands. Tumor protein p53 was overexpressed in the carcinoma cells, but not in the non-neoplastic or dysplastic epithelium. Dystrophic calcification was predominant. This is the first case report of duodenal adenocarcinoma of Brunner gland origin in Korea.	[Moon, Ji Hye; Lee, Kyoungbun; Kim, Woo Ho] Seoul Natl Univ, Coll Med, Dept Pathol, 103 Daehak Ro, Seoul 03080, South Korea; [Yang, Han-Kwang] Seoul Natl Univ, Coll Med, Dept Surg, Seoul, South Korea; [Yang, Han-Kwang; Kim, Woo Ho] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea	Kim, WH (reprint author), Seoul Natl Univ, Coll Med, Dept Pathol, 103 Daehak Ro, Seoul 03080, South Korea.	woohokim@snu.ac.kr	Lee, Kyoung-Bun/J-2571-2016	Lee, Kyoung-Bun/0000-0001-8427-3003			Chang HK, 2010, HUM PATHOL, V41, P1087, DOI 10.1016/j.humpath.2010.01.006; Fenoglio-Preiser CM, 2008, GASTROINTESTINAL PAT, P471; Iwamuro M, 2017, CASE REP GASTROINTES, V2017; Kamei Keiko, 2013, Case Rep Gastroenterol, V7, P433, DOI 10.1159/000355881; Kim K, 2013, DIGEST DIS SCI, V58, P194, DOI 10.1007/s10620-012-2320-3; Kitagori K, 2010, CLIN GASTROENTEROL H, V8, pXXVI, DOI 10.1016/j.cgh.2009.05.027; Koizumi Masaru, 2007, Case Rep Gastroenterol, V1, P103, DOI 10.1159/000108944; Ohta Y, 2008, SURG TODAY, V38, P756, DOI 10.1007/s00595-007-3707-1	8	0	0	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	MAY	2018	52	3					179	182		10.4132/jptm.2017.10.09			4	Pathology	Pathology	GF6GU	WOS:000432065900006	29281782	DOAJ Gold, Green Published			2019-10-28	
J	Rhee, YY; Kim, SH; Kim, EK; Kim, SH				Rhee, Ye-Young; Kim, Soo Hee; Kim, Eun Kyung; Kim, Se Hoon			Merkel Cell Carcinoma Metastatic to Pleural Fluid: A Case Report	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Carcinoma, Merkel cell; Neoplasm metastasis; Pleural fluid; Liquid-based cytology		Merkel cell carcinoma (MCC) is a rare aggressive neuroendocrine carcinoma of the skin that shows locoregional or distant metastasis. Metastasis of MCC to body cavity effusion is extremely rare; only three cases have been reported so far. Metastatic MCC in effusion cytology shows small blue round cells with fine stippled chromatin like other small blue round cell tumors such as small cell lung carcinoma or lymphoma. The diagnosis of metastatic MCC can grant patients good chances at recently advanced therapeutic options. Here, we present a case of metastatic MCC to pleural effusion with characteristic single file-like pattern.	[Rhee, Ye-Young; Kim, Soo Hee] Seegene Med Fdn, Pathol Ctr, Seoul, South Korea; [Kim, Eun Kyung; Kim, Se Hoon] Yonsei Univ, Coll Med, Dept Pathol, Severance Hosp, 50-1 Yonsei Ro, Seoul 03722, South Korea	Kim, SH (reprint author), Yonsei Univ, Coll Med, Dept Pathol, Severance Hosp, 50-1 Yonsei Ro, Seoul 03722, South Korea.	paxco@yuhs.ac; paxco@yuhs.ac	; Kim, Eun-Kyung/E-5211-2017	Kim, Se Hoon/0000-0001-7516-7372; Kim, Eun-Kyung/0000-0002-3368-5013			Allen PJ, 2005, J CLIN ONCOL, V23, P2300, DOI 10.1200/JCO.2005.02.329; Barksdale SK, 2017, PATHOLOGY, V49, P568, DOI 10.1016/j.pathol.2017.07.003; Eng TY, 2007, AM J CLIN ONCOL-CANC, V30, P624, DOI 10.1097/COC.0b013e318142c882; Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586; Fitzgerald TL, 2015, AM SURGEON, V81, P802; Hodgson NC, 2005, J SURG ONCOL, V89, P1, DOI 10.1002/jso.20167; Payne M. M., 2004, CYTOJOURNAL, V1, P5; Policarpio-Nicolas MLC, 2015, CYTOJOURNAL, V12, DOI 10.4103/1742-6413.162775; Pulitzer Melissa, 2017, Surg Pathol Clin, V10, P399, DOI 10.1016/j.path.2017.01.013; Pulitzer MP, 2009, ADV ANAT PATHOL, V16, P135, DOI 10.1097/PAP.0b013e3181a12f5a; Robertson JP, 2015, BRIT J DERMATOL, V173, P835, DOI 10.1111/bjd.13782; TOKER C, 1972, ARCH DERMATOL, V105, P107, DOI 10.1001/archderm.105.1.107; WATSON CW, 1985, ACTA CYTOL, V29, P397	13	0	0	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	MAY	2018	52	3					206	209		10.4132/jptm.2017.11.10			4	Pathology	Pathology	GF6GU	WOS:000432065900012	29166764	DOAJ Gold, Green Published			2019-10-28	
J	Dickson, BC; Swanson, D; Charames, GS; Fletcher, CDM; Hornick, JL				Dickson, Brendan C.; Swanson, David; Charames, George S.; Fletcher, Christopher D. M.; Hornick, Jason L.			Epithelioid fibrous histiocytoma: molecular characterization of ALK fusion partners in 23 cases	MODERN PATHOLOGY			English	Article							INFLAMMATORY MYOFIBROBLASTIC TUMORS; B-CELL LYMPHOMA; ETV6-NTRK3 GENE FUSION; LUNG-CANCER; KINASE FUSIONS; SPITZ TUMORS; IDENTIFICATION; REARRANGEMENT; CARCINOMA; EML4-ALK	Epithelioid fibrous histiocytoma is a rare and distinctive cutaneous neoplasm. Most cases harbor ALK rearrangement and show ALK overexpression, which distinguish this neoplasm from conventional cutaneous fibrous histiocytoma and variants. SQSTM1 and VCL have previously been shown to partner with ALK in one case each of epithelioid fibrous histiocytoma. The purpose of this study was to examine a large cohort of epithelioid fibrous histiocytomas by next-generation sequencing to characterize the nature and prevalence of ALK fusion partners. A retrospective archival review was performed to identify cases of epithelioid fibrous histiocytoma (2012-2016). Immunohistochemistry was performed to confirm ALK expression. Targeted next-generation sequencing was applied on RNA extracted from formalin-fixed paraffin-embedded tissue to identify the fusion partners. Twenty-three cases fulfilled inclusion criteria. The mean patient age was 39 years (range, 874), there was no sex predilection, and 475% of cases involved the lower extremities. The most common gene fusions were SQSTM1-ALK (N=12; 52%) and VCL-ALK (N=7; 30%); the other four cases harbored novel fusion partners (DCTN1, ETV6, PPFIBP1, and SPECC1L). The pattern of ALK immunoreactivity was usually granular cytoplasmic (N=12; 52%) or granular cytoplasmic and nuclear (N=10; 43%); the case containing an ETV6 fusion partner showed nuclear staining alone. There was no apparent relationship between tumor morphology and the ALK fusion partner. In summary, SQSTM1 and VCL are the most common ALK fusion partners in epithelioid fibrous histiocytoma; DCTN1, ETV6, PPFIBP1, and SPECC1L represent rare fusion partners. The proteins encoded by these genes play diverse roles in scaffolding, cell adhesion, signaling, and transcription (among others) without clear commonalities. These findings expand the oncogenic promiscuity of many of these ALK fusion genes, which drive neoplasia in tumors of diverse lineages with widely varied clinical behavior. This is the first documented account of ETV6-ALK and SPECC1L-ALK translocations in neoplasms.	[Dickson, Brendan C.; Swanson, David; Charames, George S.] Mt Sinai Hosp, Dept Pathol & Lab Med, 600 Univ Ave,Suite 6-500-12-5, Toronto, ON M5G 1X5, Canada; [Dickson, Brendan C.; Charames, George S.] Univ Toronto, Dept Pathobiol & Lab Med, Toronto, ON, Canada; [Dickson, Brendan C.; Swanson, David; Charames, George S.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada; [Fletcher, Christopher D. M.; Hornick, Jason L.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Fletcher, Christopher D. M.; Hornick, Jason L.] Harvard Med Sch, Boston, MA USA	Dickson, BC (reprint author), Mt Sinai Hosp, Dept Pathol & Lab Med, 600 Univ Ave,Suite 6-500-12-5, Toronto, ON M5G 1X5, Canada.; Hornick, JL (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	Brendan.Dickson@sinaihealthsystem.ca; jhornick@bwh.harvard.edu	Charames, George/J-2328-2016; Dickson, Brendan/J-2347-2016	Charames, George/0000-0002-5937-9276; Dickson, Brendan/0000-0003-2269-6216			Alassiri AH, 2016, AM J SURG PATHOL, V40, P1051, DOI 10.1097/PAS.0000000000000677; Amin SM, 2017, AM J SURG PATHOL, V41, P491, DOI 10.1097/PAS.0000000000000761; Andreasen S, 2017, AM J SURG PATHOL, V41, P1552, DOI 10.1097/PAS.0000000000000912; Antonescu CR, 2015, AM J SURG PATHOL, V39, P957, DOI 10.1097/PAS.0000000000000404; Bays JL, 2017, CELL MOL LIFE SCI, V74, P2999, DOI 10.1007/s00018-017-2511-3; Brenca M, 2016, J PATHOL, V238, P543, DOI 10.1002/path.4677; Bridge JA, 2001, AM J PATHOL, V159, P411, DOI 10.1016/S0002-9440(10)61711-7; Busam KJ, 2014, AM J SURG PATHOL, V38, P925, DOI 10.1097/PAS.0000000000000187; Chen XY, 2016, BIOINFORMATICS, V32, P1220, DOI 10.1093/bioinformatics/btv710; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; Chou A, 2015, AM J SURG PATHOL, V39, P652, DOI 10.1097/PAS.0000000000000368; Davis JL, 2017, PEDIAT DEV PATHOL; De Braekeleer E, 2012, LEUKEMIA RES, V36, P945, DOI 10.1016/j.leukres.2012.04.010; Debelenko LV, 2011, MODERN PATHOL, V24, P430, DOI 10.1038/modpathol.2010.213; Doyle LA, 2015, MODERN PATHOL, V28, P904, DOI 10.1038/modpathol.2015.49; Doyle LA, 2011, J CUTAN PATHOL, V38, P697, DOI 10.1111/j.1600-0560.2011.01747.x; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; Gfrerer L, 2014, PLAST RECONSTR SURG, V134, P748, DOI 10.1097/PRS.0000000000000517; GOMEZ CS, 1994, HISTOPATHOLOGY, V24, P123, DOI 10.1111/j.1365-2559.1994.tb01290.x; Hallberg B, 2013, NAT REV CANCER, V13, P685, DOI 10.1038/nrc3580; Han SP, 2013, NAT CELL BIOL, V15, P238, DOI 10.1038/ncb2700; Iyama K, 2017, THYROID, V27, P811, DOI 10.1089/thy.2016.0673; Iyevleva AG, 2015, CANCER LETT, V362, P116, DOI 10.1016/j.canlet.2015.03.028; Jedrych J, 2015, BRIT J DERMATOL, V172, P1427, DOI 10.1111/bjd.13548; JONES EW, 1989, BRIT J DERMATOL, V120, P185; Kardon JR, 2009, NAT REV MOL CELL BIO, V10, P854, DOI 10.1038/nrm2804; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Lee JC, 2017, J PATHOL, V241, P316, DOI 10.1002/path.4836; Leeman-Neill RJ, 2014, CANCER-AM CANCER SOC, V120, P799, DOI 10.1002/cncr.28484; Liu S, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1234; Lovly CM, 2014, CANCER DISCOV, V4, P889, DOI 10.1158/2159-8290.CD-14-0377; Maeda M, 1997, CIRCULATION, V95, P17, DOI 10.1161/01.CIR.95.1.17; Mano H, 2008, CANCER SCI, V99, P2349, DOI 10.1111/j.1349-7006.2008.00972.x; Marino-Enriquez A, 2011, GENE CHROMOSOME CANC, V50, P146, DOI 10.1002/gcc.20839; Marino-Enriquez A, 2011, AM J SURG PATHOL, V35, P135, DOI 10.1097/PAS.0b013e318200cfd5; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Nakamura Y, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.86; Onciu M, 2003, BLOOD, V102, P2642, DOI 10.1182/blood-2003-04-1095; Pan ZG, 2017, AM J SURG PATHOL, V41, P25, DOI 10.1097/PAS.0000000000000753; Rea SL, 2014, EXP CELL RES, V325, P27, DOI 10.1016/j.yexcr.2014.01.020; Rubin BP, 1998, AM J PATHOL, V153, P1451, DOI 10.1016/S0002-9440(10)65732-X; Saadi I, 2011, AM J HUM GENET, V89, P44, DOI 10.1016/j.ajhg.2011.05.023; Sakamoto K, 2016, INT J HEMATOL, V103, P399, DOI 10.1007/s12185-016-1934-1; Shimada Y, 2017, ONCOLOGIST, V22, P158, DOI 10.1634/theoncologist.2016-0194; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Subbiah V, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0160-2; Sugawara E, 2012, CANCER-AM CANCER SOC, V118, P4427, DOI 10.1002/cncr.27391; Takeuchi K, 2011, CLIN CANCER RES, V17, P3341, DOI 10.1158/1078-0432.CCR-11-0063; Takeuchi K, 2011, HAEMATOL-HEMATOL J, V96, P464, DOI 10.3324/haematol.2010.033514; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; Wei ZY, 2011, MOL CELL, V43, P586, DOI 10.1016/j.molcel.2011.07.021; Wiesner T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4116; Yamamoto H, 2016, HISTOPATHOLOGY, V69, P72, DOI 10.1111/his.12910; Yeh I, 2016, J PATHOL, V240, P282, DOI 10.1002/path.4775; Yu WJ, 2017, HISTOPATHOLOGY, V71, P53, DOI 10.1111/his.13185; Zhang MY, 2015, NAT GENET, V47, P180, DOI 10.1038/ng.3177	56	1	1	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAY	2018	31	5					753	762		10.1038/modpathol.2017.191			10	Pathology	Pathology	GE9VN	WOS:000431579000006	29327718				2019-10-28	
J	Croce, S; Ducoulombier, A; Ribeiro, A; Lesluyes, T; Noel, JC; Amant, F; Guillou, L; Stoeckle, E; Devouassoux-Shisheboran, M; Penel, N; Floquet, A; Arnould, L; Guyon, F; Mishellany, F; Chakiba, C; Cuppens, T; Zikan, M; Leroux, A; Frouin, E; Farre, I; Genestie, C; Valo, I; MacGrogan, G; Chibon, F				Croce, Sabrina; Ducoulombier, Agnes; Ribeiro, Agnes; Lesluyes, Tom; Noel, Jean-Christophe; Amant, Frederic; Guillou, Louis; Stoeckle, Eberhard; Devouassoux-Shisheboran, Mojgan; Penel, Nicolas; Floquet, Anne; Arnould, Laurent; Guyon, Frederic; Mishellany, Florence; Chakiba, Camille; Cuppens, Tine; Zikan, Michal; Leroux, Agnes; Frouin, Eric; Farre, Isabelle; Genestie, Catherine; Valo, Isabelle; MacGrogan, Gaetan; Chibon, Frederic			Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors	MODERN PATHOLOGY			English	Article							STAGE-I; PROGNOSTIC-FACTORS; LEIOMYOSARCOMA; SARCOMAS; LEIOMYOMAS; DIFFERENTIATION; SURVIVAL; UTERUS; IMPACT; PROGRESSION	The diagnosis of a uterine smooth muscle lesion is, in the majority of cases, straightforward. However, in a small number of cases, the morphological criteria used in such lesions cannot differentiate with certainty a benign from a malignant lesion and a diagnosis of smooth muscle tumor with uncertain malignant potential (STUMP) is made. Uterine leiomyosarcomas are often easy to diagnose but it is difficult or even impossible to identify a prognostic factor at the moment of the diagnosis with the exception of the stage. We hypothesize, for uterine smooth muscle lesions, that there is a gradient of genomic complexity that correlates to outcome. We first tested this hypothesis on STUMP lesions in a previous study and demonstrated that this 'gray category' could be split according to genomic index into two groups. A benign group, with a low to moderate alteration rate without recurrence and a malignant group, with a highly rearranged profile akin to uterine leiomyosarcomas. Here, we analyzed a large series of 77 uterine smooth muscle lesions (from 76 patients) morphologically classified as 19 leiomyomas, 14 STUMP and 44 leiomyosarcomas with clinicopathological and genomic correlations. We confirmed that genomic index with a cut-off=10 is a predictor of recurrence (P<0.0001) and with a cut-off=35 is a marker for poor overall survival (P=0.035). For the tumors confined to the uterus, stage as a prognostic factor was not useful in survival prediction. At stage I, among the tumors reclassified as molecular leiomyosarcomas (ie, genomic index >= 10), the poor prognostic markers were: 5p gain (overall survival P=0.0008), genomic index at cut-off=35 (overall survival P=0.0193), 13p loss including RB1 (overall survival P=0.0096) and 17p gain including MYOCD gain (overall survival P=0.0425). Based on these findings (and the feasibility of genomic profiling by array-comparative genomic hybridization), genomic index, 5p and 17p gains prognostic value could be evaluated in future prospective chemotherapy trials.	[Croce, Sabrina; Ribeiro, Agnes; MacGrogan, Gaetan; Chibon, Frederic] Inst Bergonie, Ctr Comprehens Canc, Dept Biopathol, Bordeaux, France; [Croce, Sabrina; Lesluyes, Tom; Chibon, Frederic] INSERM, U1218, Bordeaux, France; [Ducoulombier, Agnes; Penel, Nicolas] Ctr Oscar Lambret, Dept Oncol, Ctr Comprehens Canc, Lille, France; [Ducoulombier, Agnes] Ctr Antoine Lacassagne, Ctr Comprehens Canc, Oncol Dept, Nice, France; [Lesluyes, Tom] Univ Bordeaux, Bordeaux, France; [Noel, Jean-Christophe] Erasme Univ Hosp, Dept Pathol, Clin Gynecopathol & Senol, Brussels, Belgium; [Amant, Frederic; Cuppens, Tine] Univ Leuven, KU Leuven, Dept Oncol, Gynaecol Oncol, Leuven, Belgium; [Amant, Frederic; Cuppens, Tine] Univ Hosp Leuven, Dept Obstet & Gynaecol, Leuven, Belgium; [Amant, Frederic] Antoni Van Leeuwenhoek Netherlands Canc Inst, CGOA, Amsterdam, Netherlands; [Guillou, Louis] Argot Lab, Lausanne, Switzerland; [Guillou, Louis] Inst Univ Pathol, Lausanne, Switzerland; [Stoeckle, Eberhard; Guyon, Frederic] Inst Bergonie, Ctr Comprehens Canc, Dept Surg, Bordeaux, France; [Devouassoux-Shisheboran, Mojgan] Hop Univ Lyon Sud, Dept Pathol, Pierre Benite, France; [Floquet, Anne; Chakiba, Camille] Inst Bergonie, Ctr Comprehens Canc, Dept Med Oncol, Bordeaux, France; [Arnould, Laurent] Ctr JF Leclerc, Ctr Comprehens Canc, Dept Pathol, Dijon, France; [Mishellany, Florence] Ctr Jean Perrin, Ctr Comprehens Canc, Dept Pathol, Clermont Ferrand, France; [Zikan, Michal] Charles Univ Prague, Fac Med 1, Dept Obstet & Gynaecol, Gynaecol Oncol Ctr, Prague, Czech Republic; [Zikan, Michal] Gen Univ Hosp, Prague, Czech Republic; [Leroux, Agnes] Ctr Alexis Vautrin, Ctr Comprehens Canc, Dept Pathol, Vandoeuvre Les Nancy, France; [Frouin, Eric] Univ Hosp, Dept Pathol, Poitiers, France; [Farre, Isabelle] Ctr Oscar Lambret, Ctr Comprehens Canc, Dept Pathol, Lille, France; [Genestie, Catherine] Inst Gustave Roussy, Ctr Comprehens Canc, Dept Pathol, Villejuif, France; [Valo, Isabelle] ICO Site Paul Papin, Ctr Comprehens Canc, Dept Pathol, Angers, France	Croce, S (reprint author), Inst Bergonie, Dept Pathol, 229 Cours Argonne, F-33000 Bordeaux, France.	s.croce@bordeaux.unicancer.fr	Lesluyes, Tom/AAB-6229-2019; Amant, Frederic/W-7436-2019; chibon, frederic/A-2651-2013	Lesluyes, Tom/0000-0003-2251-5884; Amant, Frederic/0000-0002-5452-4905; PENEL, Nicolas/0000-0001-5243-1548; Chakiba, Camille/0000-0002-6383-9589	ARCFondation ARC pour la Recherche sur le CancerAustralian Research Council; Ligue Regionale contre le cancerLigue nationale contre le cancer	This study was supported by the grants from ARC and la Ligue Regionale contre le cancer. We thank Dr Ravi Nookala of Institut Bergonie for the medical writing service and Magali Philip, Quitterie Fontanges, Patrick Murat and Virginie Duvignau for photographs. FA is senior researcher for the Research Fund Flanders (F.W.O.).	Agaram NP, 2016, GENE CHROMOSOME CANC, V55, P124, DOI 10.1002/gcc.22318; Amant Frederic, 2015, Sarcoma, P704124, DOI 10.1155/2015/704124; Amant F, 2009, LANCET ONCOL, V10, P1188, DOI 10.1016/S1470-2045(09)70226-8; Baird DD, 2003, AM J OBSTET GYNECOL, V188, P100, DOI 10.1067/mob.2003.99; BELL SW, 1994, AM J SURG PATHOL, V18, P535, DOI 10.1097/00000478-199406000-00001; Croce S, 2015, MODERN PATHOL, V28, P1001, DOI 10.1038/modpathol.2015.3; Croce S, 2014, AM J SURG PATHOL, V38, P1330, DOI 10.1097/PAS.0000000000000249; Davidson B, 2016, AM J CLIN PATHOL, V145, P449, DOI 10.1093/ajcp/aqw030; Downes KA, 1997, AM J SURG PATHOL, V21, P1261, DOI 10.1097/00000478-199711000-00001; El-Rifai W, 1998, AM J PATHOL, V153, P985, DOI 10.1016/S0002-9440(10)65640-4; Garcia C, 2015, INT J GYNECOL CANCER, V25, P622, DOI 10.1097/IGC.0000000000000370; HEMPLING RE, 1995, AM J CLIN ONCOL-CANC, V18, P282, DOI 10.1097/00000421-199508000-00002; Hensley ML, 2009, GYNECOL ONCOL, V112, P563, DOI 10.1016/j.ygyno.2008.11.027; Hu J, 2001, GENE CHROMOSOME CANC, V31, P117, DOI 10.1002/gcc.1125.abs; Iasonos A, 2013, CANCER-AM CANCER SOC, V119, P1816, DOI 10.1002/cncr.27971; Kimura Y, 2010, CANCER RES, V70, P501, DOI 10.1158/0008-5472.CAN-09-1469; Lagarde P, 2012, CLIN CANCER RES, V18, P826, DOI 10.1158/1078-0432.CCR-11-1610; Larramendy ML, 2006, CANCER GENET CYTOGEN, V169, P94, DOI 10.1016/j.cancergencyto.2006.01.008; Liegl-Atzwanger B, 2016, MODERN PATHOL, V29, P1262, DOI 10.1038/modpathol.2016.107; Lim D, 2013, AM J SURG PATHOL, V37, P650, DOI 10.1097/PAS.0b013e3182851162; Makinen N, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005850; Mehine M, 2013, NEW ENGL J MED, V369, P2160, DOI 10.1056/NEJMc1310230; Mehine M, 2013, NEW ENGL J MED, V369, P43, DOI 10.1056/NEJMoa1302736; NORDAL RR, 1995, ACTA ONCOL, V34, P797, DOI 10.3109/02841869509127189; Oliva E, 2014, WHO CLASSIFICATION T, P135; Oliva E, 2016, MODERN PATHOL, V29, pS104, DOI 10.1038/modpathol.2015.139; OMURA GA, 1985, J CLIN ONCOL, V3, P1240, DOI 10.1200/JCO.1985.3.9.1240; Pautier P, 2000, CANCER, V88, P1425, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1425::AID-CNCR21>3.3.CO;2-V; Pelmus M, 2009, INT J GYNECOL CANCER, V19, P385, DOI 10.1111/IGC.0b013e3181a1bfbc; Perot G, 2014, MODERN PATHOL, V27, P840, DOI 10.1038/modpathol.2013.205; Perot G, 2009, CANCER RES, V69, P2269, DOI 10.1158/0008-5472.CAN-08-1443; Reed NS, 2008, EUR J CANCER, V44, P808, DOI 10.1016/j.ejca.2008.01.019; Ricci S, 2017, GYNECOL ONCOL, V145, P208, DOI 10.1016/j.ygyno.2017.02.019; ROSE PG, 1987, AM J OBSTET GYNECOL, V156, P660, DOI 10.1016/0002-9378(87)90072-X; Skorstad M, 2016, ACTA OBSTET GYN SCAN, V95, P984, DOI 10.1111/aogs.12930; Sorbe B, 2008, INT J ONCOL, V32, P1111; Wang WL, 2011, AM J SURG PATHOL, V35, P522, DOI 10.1097/PAS.0b013e31820ca624; Zhang Q, 2014, CANCER-AM CANCER SOC, V120, P3165, DOI 10.1002/cncr.28900; Zivanovic O, 2012, CANCER-AM CANCER SOC, V118, P660, DOI 10.1002/cncr.26333	39	7	7	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAY	2018	31	5					816	828		10.1038/modpathol.2017.185			13	Pathology	Pathology	GE9VN	WOS:000431579000012	29327710	Bronze			2019-10-28	
J	Rocken, C				Roecken, C.			Digital Medicine 2018	PATHOLOGE			German	Editorial Material									[Roecken, C.] Christian Albrechts Univ Kiel, Inst Pathol, Arnold Heller Str 3-14, D-24105 Kiel, Germany	Rocken, C (reprint author), Christian Albrechts Univ Kiel, Inst Pathol, Arnold Heller Str 3-14, D-24105 Kiel, Germany.	christoph.roecken@uksh.de	Rocken, Christoph/A-9239-2010					0	0	0	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	MAY	2018	39	3					215	215		10.1007/s00292-018-0443-9			1	Pathology	Pathology	GF0UY	WOS:000431647800001	29696369	Bronze			2019-10-28	
J	Hanchev, KS; Abramov, AV				Hanchev, K. S.; Abramov, A. V.			Disturbance of nitric oxide synthase constitutive isoforms expression as a pathogenetic factor of complications development after tooth extraction in experimental diabetes mellitus	PATHOLOGIA			Russian	Article						nitric oxide synthase; tooth extraction complications; experimental diabetes mellitus; rats		The role of constitutive NOS isoforms (endothelial and neuronal) in pathogenesis of complications development and repair processes disturbances in periodontium after tooth extraction in experimental diabetes mellitus is not studied completely. The aim of work - to find out the features of constitutive NOS isoforms (endothelial and neuronal) indices alterations in periodontal tissue of rats with experimental streptozotocin-induced diabetes mellitus on different terms (1st, 7th and 14th day) after mandibular 1st molar extraction. Materials and methods. Immunohistochemical study of endothelial and neuronal NOS isoforms expression indices (content, concentration, area of immunoreactive material distribution) in periodontium tissue was conducted on 120 male rats 8-10 months-old (8 experimental groups). Results. In rats with experimental diabetes mellitus (EDM) without tooth extraction content and concentration of both constitutive NOS isoforms in periodontium were lower than in control group of animals. The extraction of tooth in rats with EDM resulted in significant increase of all indices of both isoforms expression in comparison with EDM rats without tooth extraction. On the 7th day after tooth extraction nNOS content and area of distribution was also increased by 24.3 % and 14.2 % respectively, and concentration decreased by 58.3 %. Indices of eNOS were not reliably changed in comparison with the 1st day after tooth extraction. On the 14th day after tooth extraction in rats with EDM, a significant decrease in all the indices of expression of constitutive NOS was observed, moreover, the concentration and area of nNOS distribution and the content, concentration and area of eNOS become significantly lower than in the corresponding control group. Conclusions. In rats with EDM in periodontal tissues the content and concentration of NOS constitutive isoforms are reduced. Extraction of the tooth in the animal with EDM leads to a moderate increase in the content and concentration of nNOS and eNOS from the 1st to the 7th day. On the 14th day after the extraction, the expression indices of both isoforms decrease lower than in the corresponding control groups, that indicates a low content of endothelial and neuronal isoforms in the periodontium of rats with EDM and probably plays an important role in the pathogenesis of long-term complications development after surgery along with violation of repair processes.	[Hanchev, K. S.] Zaporizhzhia State Med Univ, Dept Propaedeut & Surg Dent, Zaporizhia, Ukraine; [Abramov, A. V.] Zaporizhzhia State Med Univ, Dept Pathol Physiol, Zaporizhia, Ukraine	Abramov, AV (reprint author), Zaporizhzhia State Med Univ, Dept Pathol Physiol, Zaporizhia, Ukraine.	Abramov@zsmu.pp.ua	Andrii, Abramov/AAC-5575-2019	Andrii, Abramov/0000-0001-8520-2258			Engebretson S, 2013, J CLIN PERIODONTOL, V40, pS153, DOI [10.1111/jcpe.12084, 10.1902/jop.2013.1340017]; Khmil E., 2013, VISNYK PROBLEM BIOLO, V1, P306; Kolesnik Y., 2005, PATHOLOGIA, V2, P20; Stancic A, 2018, MECH AGEING DEV, V172, P21, DOI 10.1016/j.mad.2017.08.018	4	0	0	1	1	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	MAY-AUG	2018		2					148	152		10.14739/2310-1237.2018.2.141407			5	Pathology	Pathology	GU7BJ	WOS:000445473200004		DOAJ Gold			2019-10-28	
J	Jiang, JH; Pi, J; Jin, H; Yang, F; Cai, JY				Jiang, Jin-Huan; Pi, Jiang; Jin, Hua; Yang, Fen; Cai, Ji-Ye			Chinese herb medicine matrine induce apoptosis in human esophageal squamous cancer KYSE-150 cells through increasing reactive oxygen species and inhibiting mitochondrial function	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Matrine; Apoptosis; KYSE-150 cells; Mitochondrial membrane potential; ROS	DOWN-REGULATION; OXIDATIVE STRESS; UP-REGULATION; MCF-7 CELLS; PATHWAY; ALKALOIDS; MOLECULES; AUTOPHAGY; ADHESION; ACTIN	Matrine, as a natural alkaloid isolated from the traditional herb medicine sophora flavescens, has been proved to possess excellent biological activities, including anticancer effects. Now, this research aims to assess the anticancer activities and the mechanism of matrine against esophageal cancer cells, we investigated the proliferative inhibition, apoptosis induction, as well as the underlying mechanism of matrine on esophageal cancer KYSE-150 cells. It was found that matrine could suppress KYSE-150 cell proliferation and significantly mediate cell apoptosis in a dose-dependent relation by increasing intracellular reactive oxygen species level and triggering mitochondrial membrane potential disruption. More precise mechanism studies demonstrated that matrine could up-regulate the expression of Bax proteins and down-regulate the expression of Bcl-2 proteins, as well as the activation about caspase-3, 8 and 9 in KYSE-150 cells. The morphological analysis of KYSE-150 cells exhibited that matrine could destroy the F-actin and nuclei structures and induce morphological damage with increased surface height distribution and roughness of cell membrane. These results not only demonstrated the potential anticancer activity mechanism of matrine at nanoscale, but also provide preliminary guidance for the treatment of esophageal cancer using matrine.	[Jiang, Jin-Huan; Pi, Jiang; Jin, Hua; Yang, Fen; Cai, Ji-Ye] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau, Peoples R China; [Cai, Ji-Ye] Jinan Univ, Dept Chem, Guangzhou, Guangdong, Peoples R China	Cai, JY (reprint author), Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau, Peoples R China.; Cai, JY (reprint author), Jinan Univ, Dept Chem, Guangzhou, Guangdong, Peoples R China.	tjycai@jnu.edu.cn		pi, jiang/0000-0003-4418-1248	Macao Science and Technology Development Fund [028/2014/A1]	This work was supported by a Macao Science and Technology Development Fund; Contract grant number: 028/2014/A1.	Abu N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105244; Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Alia G., 2014, NANOTECHNOLOGY, V25; Chikara S, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-016-1512-3; Fu Q, 2014, FITOTERAPIA, V94, P183, DOI 10.1016/j.fitote.2013.12.014; Funaya N, 2012, J CHROMATOGR A, V1248, P18, DOI 10.1016/j.chroma.2012.05.081; Guo CY, 2013, NEURAL REGEN RES, V8, P2003, DOI 10.3969/j.issn.1673-5374.2013.21.009; Hezova R, 2016, TUMOR BIOL, V37, P8007, DOI 10.1007/s13277-015-4656-8; Jung H, 2016, ARCH PHARM RES, V39, P855, DOI 10.1007/s12272-016-0760-6; Kan QC, 2013, IMMUNOL RES, V56, P189, DOI 10.1007/s12026-013-8393-z; Kato H, 2013, GEN THORAC CARDIOVAS, V61, P330, DOI 10.1007/s11748-013-0246-0; Kim H, 2017, COLLOID SURFACE B, V155, P366, DOI 10.1016/j.colsurfb.2017.04.039; Kim KS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030066; Kong Qiongman, 2005, Purinergic Signal, V1, P337, DOI 10.1007/s11302-005-7145-5; Kwon H. -Y., 2013, EVID-BASED COMPL ALT, V2013, P10; Lee JH, 2013, MOL CELL BIOCHEM, V379, P133, DOI 10.1007/s11010-013-1635-5; Li HJ, 2015, INT J CLIN EXP PATHO, V8, P14793; Li Q, 2016, ONCOL REP, V35, P375, DOI 10.3892/or.2015.4341; Liang CZ, 2012, CANCER CHEMOTH PHARM, V69, P317, DOI 10.1007/s00280-011-1699-4; Liu R., 2017, CELL PHYSL BIOCH, V41; Liu Y. Q., 2014, ASIAN PAC J CANC PRE, V15; Ma ZJ, 2018, EUR J PHARMACOL, V821, P1, DOI 10.1016/j.ejphar.2017.12.027; Masuelli L, 2017, ONCOTARGET, V8, P34405, DOI 10.18632/oncotarget.14907; Mileo AM, 2012, J CELL PHYSIOL, V227, P3301, DOI 10.1002/jcp.24029; Moghadamtousi S. Z., 2014, AHEM MED, V14; Moghimipour E, 2018, LIFE SCI, V194, P104, DOI 10.1016/j.lfs.2017.12.026; Mu HY, 2014, ONCOL REP, V32, P1087, DOI 10.3892/or.2014.3273; Napier KJ, 2014, WORLD J GASTRO ONCOL, V6, P112, DOI 10.4251/wjgo.v6.i5.112; Pan QM, 2015, J NAT PROD, V78, P1683, DOI 10.1021/acs.jnatprod.5b00325; Pi J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140935; Pi J, 2014, NANOSCALE, V6, P12229, DOI 10.1039/c4nr04195j; Pi J, 2013, BIOORG MED CHEM LETT, V23, P6296, DOI 10.1016/j.bmcl.2013.09.078; Pinkhien T, 2016, ANTICANCER RES, V36, P6327, DOI 10.21873/anticanres.11229; Principe M, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-016-0385-8; Rao PC, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317694565; Sabatino L., 2015, J ENV SCI HLTH B, V50; Sarbadhikary P, 2017, CHEM-BIOL INTERACT, V277, P137, DOI 10.1016/j.cbi.2017.09.011; Shao HM, 2013, ONCOL LETT, V6, P517, DOI 10.3892/ol.2013.1399; Short MW, 2017, AM FAM PHYSICIAN, V95, P22; Sit ST, 2011, J CELL SCI, V124, P679, DOI 10.1242/jcs.064964; Stowe DF, 2009, ANTIOXID REDOX SIGN, V11, P1373, DOI [10.1089/ars.2008.2331, 10.1089/ARS.2008.2331]; Wang HQ, 2015, ONCOL REP, V33, P2561, DOI 10.3892/or.2015.3844; Wasim L., 2017, CELL ONCOL, P1; Wu GJ, 2017, ONCOTARGET, V8, P11621, DOI 10.18632/oncotarget.14598; Wu PP, 2011, ONCOL REP, V25, P551, DOI 10.3892/or.2010.1080; Yu WB, 2017, BIOMARK MED, V11, P213, DOI 10.2217/bmm-2017-0019; Zhang JQ, 2010, WORLD J GASTROENTERO, V16, P4281, DOI 10.3748/wjg.v16.i34.4281	47	7	7	1	7	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAY	2018	214	5					691	699		10.1016/j.prp.2018.03.015			9	Pathology	Pathology	GJ5NF	WOS:000435427500013	29567333				2019-10-28	
J	Lee, A; Lee, SH; Jung, CK; Park, G; Lee, KY; Choi, HJ; Min, KO; Kim, TJ; Lee, EJ; Lee, YS				Lee, Ahwon; Lee, Sung-Hak; Jung, Chan Kwon; Park, Gyungsin; Lee, Kyo Young; Choi, Hyun Joo; Min, Ki Ouk; Kim, Tae Jung; Lee, Eun Jung; Lee, Youn Soo			Use of the Ion AmpliSeq Cancer Hotspot Panel in clinical molecular pathology laboratories for analysis of solid tumours: With emphasis on validation with relevant single molecular pathology tests and the Oncomine Focus Assay	PATHOLOGY RESEARCH AND PRACTICE			English	Article						High-throughput nucleotide sequencing; Molecular diagnostic techniques; Malignant neoplasm	TRIALS	Targeted application of next-generation sequencing (NGS) technology allows detection of specific mutations that can provide treatment opportunities for cancer patients. We evaluated the applicability of the Ion AmpliSeq Cancer Hotspot Panel V2 (CHV2) using formalin-fixed, paraffin-embedded (FFPE) tissue of clinical specimens. Thirty-five FFPE tumour samples with known mutational status were collected from four different hospitals and sequenced with CHV2 using an Ion Chef System and Ion S5 XL system. Out of 35 cases, seven were sequenced with Oncomine focus Assay Panel for comparison. For the limit of detection test, we used an FFPE reference standard, a cell line that included an engineered 50% EGFR 1790 M in an RKO cell line background. Coverage analysis results including number of mapped reads, on target percent, mean depth, and uniformity were not different according to hospitals. Sensitivity for mutation detection down to 3% was demonstrated. NGS results showed 100% concordance with the results from single molecular pathology tests Assay in 30 cases with 24 known positive mutations and 14 known negative mutations, and another NGS panel of the Oncomine focus in seven cases. The CHV2 NGS test for solid tumours using Ion chef system and S5 XL system in clinical molecular pathology laboratories for analysis of solid tumours could be routinely used and could replace some single molecular pathology tests after a stringent and thorough validation process.	[Lee, Ahwon; Lee, Sung-Hak; Jung, Chan Kwon; Park, Gyungsin; Lee, Kyo Young; Lee, Youn Soo] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Hosp Pathol, 222 Banpo Daero, Seoul 06591, South Korea; [Lee, Ahwon; Jung, Chan Kwon] Catholic Univ Korea, Coll Med, Canc Res Inst, Seoul, South Korea; [Choi, Hyun Joo] Catholic Univ Korea, Coll Med, St Vincents Hosp, Dept Hosp Pathol, Seoul, South Korea; [Min, Ki Ouk] Catholic Univ Korea, Coll Med, St Pauls Hosp, Dept Hosp Pathol, Seoul, South Korea; [Kim, Tae Jung; Lee, Eun Jung] Catholic Univ Korea, Coll Med, Yeouido St Marys Hosp, Dept Hosp Pathol, Seoul, South Korea	Lee, YS (reprint author), Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Hosp Pathol, 222 Banpo Daero, Seoul 06591, South Korea.	lys9908@catholic.ac.kr	Jung, Chan Kwon/C-7578-2014	Jung, Chan Kwon/0000-0001-6843-3708	Department of Hospital Pathology Fund of the Catholic University of Korea	This study was supported by a grant of the Department of Hospital Pathology Fund of the Catholic University of Korea made in the program year of 2016.	Coyne GO, 2017, CURR PROB CANCER, V41, P182, DOI 10.1016/j.currproblcancer.2017.02.001; Deans ZC, 2017, VIRCHOWS ARCH, V470, P5, DOI 10.1007/s00428-016-2025-7; Goodwin S, 2016, NAT REV GENET, V17, P333, DOI 10.1038/nrg.2016.49; Kim JH, 2017, J PATHOL TRANSL MED, V51, P191, DOI 10.4132/jptm.2017.03.14; Koitzsch U, 2017, J CLIN PATHOL, V70, P725, DOI 10.1136/jclinpath-2017-204342; Massard C, 2017, CANCER DISCOV, V7, P586, DOI 10.1158/2159-8290.CD-16-1396; Meric-Bernstam F, 2015, J CLIN ONCOL, V33, P2753, DOI 10.1200/JCO.2014.60.4165; Park HS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154133; Singh RR, 2016, EXPERT REV PRECIS ME, V1, P109, DOI 10.1080/23808993.2015.1120401; Tsongalis GJ, 2014, CLIN CHEM LAB MED, V52, P707, DOI 10.1515/cclm-2013-0883	10	3	3	0	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAY	2018	214	5					713	719		10.1016/j.prp.2018.03.009			7	Pathology	Pathology	GJ5NF	WOS:000435427500016	29615338				2019-10-28	
J	Li, PP; Yin, HX; Meng, FL; Liu, S; Liu, HX; Ma, R				Li, Panpan; Yin, Hexuan; Meng, Fanling; Liu, Shuang; Liu, Haixia; Ma, Rong			High TRIM44 expression in endometrial carcinoma is associated with a poorer patient outcome	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Tripartite motif-containing protein 44; TRIM44; Endometrial cancer; Metastasis; Prognosis	CANCER STATISTICS; CELL-PROLIFERATION; MIGRATION; INVASION	Background: Tripartite motif-containing protein 44 (TRIM44) has been recently identified as a novel oncogene that is overexpressed in several types of human cancers; however, its role in endometrial cancer (EC) remains unknown. The purpose of the current study was to investigate the TRIM44 protein expression and dinicopathological significance of TRIM44 in EC. Methods: Paraffin-embedded surgical specimens were collected from 143 patients with EC for the immunohistochemical analysis of TRIM44 expression. Western blotting was performed to evaluate differences in TRIM44 protein expression in EC and normal endometrial tissues. Results: TRIM44 expression was low in normal tissues and high in EC tissues (P < 0.001). TRIM44 over expression was significantly associated with the Federation of Gynecology and Obstetrics (FIGO) stage, histological grade, depth of myometrial invasion and lymph node metastasis (P < 0.05). Moreover, TRIM44 expression was an independent prognostic factor for both overall survival and disease-free survival in patients with EC (both P < 0.05). Conclusions: The present study provides evidence that TRIM44 predicts the risk of development and prognosis of EC, highlighting its potential application as a therapeutic target for this malignancy.	[Li, Panpan; Yin, Hexuan; Meng, Fanling; Liu, Shuang; Liu, Haixia; Ma, Rong] Hatbin Med Univ, Canc Hosp, Dept Gynecol, Harbin 150081, Heilongjiang, Peoples R China	Ma, R (reprint author), Hatbin Med Univ, Canc Hosp, Dept Gynecol, Harbin 150081, Heilongjiang, Peoples R China.	dr_marong2017@126.com			Science and Technology Department returned fund for study abroad of Heilongjiang Province [LC2012C14]	This work was supported by grants of the Science and Technology Department returned fund for study abroad of Heilongjiang Province (LC2012C14).	Benedet JL, 2000, INT J GYNECOL OBSTET, V70, P209; Bradford L. S., 2015, AM J CLIN ONCOL, V38; Kashimoto K., CANC SCI, V103; Luo QQ, 2015, INT J CLIN ONCOL, V20, P508, DOI 10.1007/s10147-014-0752-9; Ong CAJ, 2013, J CLIN ONCOL, V31, P1576, DOI 10.1200/JCO.2012.45.9636; Ong CAJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju050; Penzel R, 2003, INT J CANCER, V105, P494, DOI 10.1002/ijc.11101; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Tan YY, 2017, ONCOL RES, V25, P1253, DOI 10.3727/096504017X14854310794561; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Xing Y, 2016, ONCOTARGET, V7, P30479, DOI 10.18632/oncotarget.8586; Yamada Y, 2017, CANCER SCI, V108, P32, DOI 10.1111/cas.13105; Zhu XH, 2016, TUMOR BIOL, V37, P14615, DOI 10.1007/s13277-016-5316-3	14	1	1	0	4	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAY	2018	214	5					727	731		10.1016/j.prp.2018.03.007			5	Pathology	Pathology	GJ5NF	WOS:000435427500018	29526558				2019-10-28	
J	Fan, YB; Shen, ZJ				Fan, Yibing; Shen, Zongji			The clinical value of HPV E6/E7 and STAT3 mRNA detection in cervical cancer screening	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Human papillomavirus (HPV) E6/E7; Signal transducer and activator of transcription 3 (STAT3); Survivin; Cervical cancer; Fluorescence in situ hybridization (FISH)	SURVIVIN EXPRESSION; WOMEN; PREVENTION; BIOMARKERS; CYTOLOGY; CELLS; E6	Objective: To explore the value of human papillomavirus (HPV) E6/E7 and signal transducer and activator of transcription 3 (STAT3) mRNA detection in the screening of cervical lesions. Methods: 192 patients with abnormal ThinPrep cytology test (TCT) results and/or high-risk HPV infection were screened to identify possible cervical lesions in cases. Diagnoses were confirmed by histopathology. Fluorescence in situ hybridization (FISH) was performed to detect and qualify the mRNAs of HPV E6/E7, STAT3, and Survivin in cervical exfoliated cells. In addition, the performance of separate and combined mRNA detection methods were compared with TCT, HR-HPV DNA schemes respectively. Results: 1. Compared with HPVE6/E7 and STAT3 mRNA methods, Survivin mRNA assay had poor specificity (Sp), Youden index (Y1) and concordance rate. 2. HPV E6/E7, STAT3, and STAT3 + HR-HPV methods had the best Sp, concordance rate and positive predictive value (PPV) for cervical lesions screening and atypical squamous cells of undetermined significance (ASCUS) triage. For screening of high grade squamous intraepithelial lesions or greater (HSILs +), no difference was observed in the Se of mRNA detection methods in comparison with that of TCT, HR-HPV and TCT + HR-HPV, whereas the false positive rate (FPR) decreased by 41.48%! 55.99%/17.19% and the colposcopy referral rate reduced by about 20.00%/25.00%/11.17%. For triage of women with ASCUS, no difference was observed in the Se of mRNA detection methods as compared to that of HR-HPV (x(2) = 1.05, P > 0.75), while the FPR decreased by 45.83%/37.50%/41.66% and the colposcopy referral rate reduced by 32.42%/22.60%/25.28%, respectively. The Se, YI, and PPV of the combined methods increased in comparison to each method alone. 3. Compared with the TCT + HR-HPV method, HPV E6/ E7 + STAT3 method had perfect Sp (95.92%) and PPV (95.40%) for screening HSILs +, the FPR and colposcopy referral rate decreased by 31.06% and 22.48% respectively. Conclusions: 1. The expression of HPV E6/E7 and STAT3 mRNA confirmed using FISH assay is expected to be a new method and molecular marker for cervical lesions screening. Survivin mRNA was excluded due to its poor performance. 2. HPV E6/E7, STAT3, and STAT3 + HR-HPV assays could be new approaches for cervical cancer screening and ASCUS triage, and the efficiency of combined screening program was better than that of a separate one. 3. HPV E6/E7 + STAT3 regimen is expected to be a diagnostic strategy for cervical lesions.	[Fan, Yibing] Soochow Univ, Affiliated Hosp 1, Suzhou 215006, Peoples R China; [Shen, Zongji] Yangzhou Univ, Dept Obstet & Gynecol, Clin Med Coll 5, Peoples Hosp Changshu City 2, Suzhou 215006, Peoples R China	Shen, ZJ (reprint author), Yangzhou Univ, Dept Obstet & Gynecol, Clin Med Coll 5, Peoples Hosp Changshu City 2, Suzhou 215006, Peoples R China.	yunguicao@yeah.net			Sci-Tech Development Project of Changshu City, Suzhou, Jiangsu, China [CS201515]	This study was supported by funding (No. CS201515) from the Sci-Tech Development Project of Changshu City, Suzhou, Jiangsu, China.	Cao XQ, 2014, ASIAN PAC J CANCER P, V15, P5271, DOI 10.7314/APJCP.2014.15.13.5271; Castle PE, 2015, J CLIN VIROL, V69, P52, DOI 10.1016/j.jcv.2015.05.006; Chen CL, 2007, BRIT J CANCER, V96, P591, DOI 10.1038/sj.bjc.6603597; Cibas ES, 2009, AM J CLIN PATHOL, V132, P658, DOI 10.1309/AJCPPHLWMI3JV4LA; Demir F., 2014, EUR J GYNAEC ONCOL I, V35, P2014; Galgano MT, 2010, AM J SURG PATHOL, V34, P1077, DOI 10.1097/PAS.0b013e3181e8b2c4; Heselmeyer-Haddad K, 2005, AM J PATHOL, V166, P1229, DOI 10.1016/S0002-9440(10)62341-3; Honegger A, 2013, INT J CANCER, V133, P1631, DOI 10.1002/ijc.28164; Insinga RP, 2008, CANCER EPIDEM BIOMAR, V17, P1611, DOI 10.1158/1055-9965.EPI-07-2922; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; Kailash U, 2006, BRIT J CANCER, V95, P1250, DOI 10.1038/sj.bjc.6603375; Liu HN, 2014, GENE, V550, P27, DOI 10.1016/j.gene.2014.08.009; Mishra GA, 2011, INDIAN J MED PAEDIAT, V32, P125, DOI 10.4103/0971-5851.92808; Nakayama Y, 2015, EUR J GYNAECOL ONCOL, V36, P192; de Arellano AR, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0234-9; Reid JL, 2015, AM J CLIN PATHOL, V144, P473, DOI 10.1309/AJCPHVD7MIP3FYVV; Sankaranarayanan R, 2015, WOMENS HEALTH, V11, P201, DOI [10.2217/whe.14.70, 10.2217/WHE.14.70]; Saslow D, 2012, CA-CANCER J CLIN, V62, P147, DOI 10.3322/caac.21139; Seed P. T., 2001, STATA TECHN B, V10; Shukla S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067849; Shukla S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-282; Sokolova I, 2007, J MOL DIAGN, V9, P604, DOI 10.2353/jmoldx.2007.070007; Stoler MH, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2012.12.003; Stoler MH, 2011, AM J CLIN PATHOL, V135, P468, DOI 10.1309/AJCPZ5JY6FCVNMOT; Suh DH, 2014, J GYNECOL ONCOL, V25, P236, DOI 10.3802/jgo.2014.25.3.236; Tyagi A, 2016, CLIN CANCER RES, V22, P4170, DOI 10.1158/1078-0432.CCR-15-2574; VOUSDEN K, 1993, FASEB J, V7, P872; Wang CJ, 2009, APPL IMMUNOHISTO M M, V17, P530, DOI 10.1097/PAI.0b013e3181a13bf2; Wang H, 2015, J HUAZHONG U SCI-MED, V35, P891, DOI 10.1007/s11596-015-1524-0; Wright TC, 2016, AM J CLIN PATHOL, V146, P391, DOI [10.1093/AJCP/AQW125, 10.1093/ajcp/aqw125]; Zhao FH, 2012, CANCER EPIDEMIOL, V36, P384, DOI 10.1016/j.canep.2012.01.009	31	4	4	0	9	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAY	2018	214	5					767	775		10.1016/j.prp.2018.02.003			9	Pathology	Pathology	GJ5NF	WOS:000435427500021	29655523				2019-10-28	
J	Li, M; Bian, ZH; Yao, SR; Zhang, J; Jin, GY; Wang, X; Yin, Y; Huang, ZH				Li, Min; Bian, Zehua; Yao, Surui; Zhang, Jia; Jin, Guoying; Wang, Xue; Yin, Yuan; Huang, Zhaohui			Up-regulated expression of SNHG6 predicts poor prognosis in colorectal cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Colorectal cancer; Long non-coding RNA; Small nucleolar RNA host gene 6 (SNHG6); Prognosis	LONG NONCODING RNA; CELL-PROLIFERATION; GASTRIC-CANCER; PROMOTES; OVEREXPRESSION; METASTASIS; STATISTICS; RESISTANCE; INVASION	Long non-coding RNAs (lncRNAs) have been shown to play important roles in tumor formation and development. Small nucleolar RNA host gene 6 (SNHG6) is a recently identified cancer-related lncRNA, and its role in colorectal cancer (CRC) remains to be explored. The aim of this study was to evaluate the expression and function of SNHG6 in CRC. The expression of SNHG6 was detected by real time quantitative RT-PCR (qRT-PCR) in 74 CRC tissues and matched noncancerous tissues (NCTs). Relationships between the expression levels of SNHG6 and various clinicopathological features were analyzed by Chi-square test. The Kaplan-Meier method and log-rank test were applied to compare the survival distribution between different groups. CCK8 assay and colony formation assay were used to measure the effect of SNGH6 on cell proliferation. Flow cytometric analysis was performed to measure the effect of SNHG6 on cell cycle and apoptosis. Our results showed that SNHG6 was up -regulated more than 1.5-fold in 50.0% (37/74) of CRC tissues compared with paired NCTs (P < 0.0001). High level of SNHG6 expression was strongly associated with advanced tumor stage (P = 0.026) and predicted poor prognosis of CRC (P = 0.0215). The Cox proportional hazards model demonstrated that SNHG6 expression was an independent prognostic factor for CRC (HR, 2.568; 95% CI, 1.055-6.252; P = 0.038). Furthermore, SNHG6 knockdown by siRNA could inhibit cell proliferation, cell cycle progression, and induce apoptosis. Taken together, SNHG6 functions as an oncogene in CRC and appears as a novel prognositic factor for CRC patients.	[Li, Min; Bian, Zehua; Yao, Surui; Zhang, Jia; Jin, Guoying; Yin, Yuan; Huang, Zhaohui] Jiangnan Univ, Affiliated Hosp, Wuxi Canc Inst, 200 Hui He Rd, Wuxi 214062, Jiangsu, Peoples R China; [Bian, Zehua; Wang, Xue; Yin, Yuan; Huang, Zhaohui] Jiangnan Univ, Wuxi Med Sch, Canc Epigenet Program, Wuxi 214122, Jiangsu, Peoples R China	Huang, ZH (reprint author), Jiangnan Univ, Affiliated Hosp, Wuxi Canc Inst, 200 Hui He Rd, Wuxi 214062, Jiangsu, Peoples R China.	hzhwacsy@126.com	Huang, Zhaohui/S-9410-2019	Huang, Zhaohui/0000-0002-0117-9976	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81672328, 81272299, 81772636]; Natural Science Foundation of Jiangsu ProvinceJiangsu Planned Projects for Postdoctoral Research FundsNatural Science Foundation of Jiangsu Province [BK20150004, BK20151108]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [NOJUSRP51619B, JUSRP51710A]; Medical Key Professionals Program of Jiangsu Province [AF052141]; Medical Innovation Team Program of Wuxi [CXTP003]; Hospital Management Centre of Wuxi [YGZXZ1401]; Postgraduate Research & Practice Innovation Program of Jiangsu Province [KYCX17_1497]	This study was partially supported by grants from the National Natural Science Foundation of China (81672328, 81272299 and 81772636), Natural Science Foundation of Jiangsu Province (BK20150004 and BK20151108), Fundamental Research Funds for the Central Universities (NOJUSRP51619B and JUSRP51710A), Medical Key Professionals Program of Jiangsu Province (AF052141), Medical Innovation Team Program of Wuxi (CXTP003), Hospital Management Centre of Wuxi (YGZXZ1401) and Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX17_1497).	Bian Z., 2017, ONCOGENESIS, V6, P1; Bian ZH, 2016, TUMOR BIOL, V37, P6619, DOI 10.1007/s13277-015-3814-3; Bian ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep23892; Cao C, 2017, ONCOGENE, V36, P1112, DOI 10.1038/onc.2016.278; Chang L, 2016, CANCER LETT, V383, P183, DOI 10.1016/j.canlet.2016.09.034; Chen G, 2013, NUCLEIC ACIDS RES, V41, pD983, DOI 10.1093/nar/gks1099; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Fu Z., 2017, CANC LETT; Han Y, 2014, PATHOLOGY, V46, P396, DOI 10.1097/PAT.0000000000000125; Holoch D, 2015, NAT REV GENET, V16, P71, DOI 10.1038/nrg3863; Lian YF, 2017, ONCOTARGET, V8, P59435, DOI 10.18632/oncotarget.19738; Liu FT, 2017, CELL PHYSIOL BIOCHEM, V43, P1077, DOI 10.1159/000481719; Liu YW, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0588-9; Malakar P, 2017, CANCER RES, V77, P1155, DOI 10.1158/0008-5472.CAN-16-1508; McHugh CA, 2015, NATURE, V521, P232, DOI 10.1038/nature14443; Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349; Peng WX, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2016.91; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Wang WL, 2016, PATHOL RES PRACT, V212, P690, DOI 10.1016/j.prp.2016.05.003; Wang YY, 2015, CELL STEM CELL, V16, P413, DOI 10.1016/j.stem.2015.03.003; Xu MD, 2017, CLIN CANCER RES, V23, P2071, DOI 10.1158/1078-0432.CCR-16-0742; Yan K, 2017, CELL PHYSIOL BIOCHEM, V42, P999, DOI 10.1159/000478682; Yang BY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0722-8; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010	24	9	10	0	6	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAY	2018	214	5					784	789		10.1016/j.prp.2017.12.014			6	Pathology	Pathology	GJ5NF	WOS:000435427500023	29506878				2019-10-28	
J	Borel, N; Polkinghorne, A; Pospischil, A				Borel, Nicole; Polkinghorne, Adam; Pospischil, Andreas			A Review on Chlamydial Diseases in Animals: Still a Challenge for Pathologists?	VETERINARY PATHOLOGY			English	Review						Chlamydiales; Chlamydiaceae; Chlamydia; Chlamydia-related bacteria; host range; molecular techniques; review; zoonosis	CHLAMYDOPHILA-PNEUMONIAE; WADDLIA-CHONDROPHILA; FAMILY CHLAMYDIACEAE; MOLECULAR EVIDENCE; GUINEA-PIG; ANTIBIOTIC-RESISTANCE; LABORATORY DIAGNOSIS; PSITTACI INFECTION; PECORUM INFECTIONS; ORDER CHLAMYDIALES	Chlamydiae have a worldwide distribution causing a wide range of diseases in human hosts, livestock, and companion animals as well as in wildlife and exotic species. Moreover, they can persist in their hosts as asymptomatic infections for extended periods of time. The introduction of molecular techniques has revolutionized the Chlamydia field by expanding the host range of known chlamydial species but also by discovering new species and even new families of bacteria in the broader order Chlamydiales. The wide range of hosts, diseases, and tissues affected by chlamydiae complicate the diagnosis such that standard diagnostic approaches for these bacteria are rare. Bacteria of the Chlamydiales order are small and their inclusions are difficult to detect by standard microscopy. With the exception of avian and ovine chlamydiosis, macroscopic and/or histologic changes might not be pathognomic or indicative for a chlamydial infection or even not present at all. Moreover, detection of chlamydial DNA in specimens in the absence of other methods or related pathological lesions questions the significance of such findings. The pathogenic potential of the majority of recently identified Chlamydia-related bacteria remains largely unknown and awaits investigation through experimental or natural infection models including histomorphological characterization of associated lesions. This review aims to summarize the historical background and the most important developments in the field of animal chlamydial research in the past 5 years with a special focus on pathology. It will summarize the current nomenclature, present critical thoughts about diagnostics, and give an update on chlamydial infections in domesticated animals such as livestock, companion animals and birds, as well as free-ranging and captive wild animals such as reptiles, fish, and marsupials.	[Borel, Nicole; Pospischil, Andreas] Univ Zurich, Inst Vet Pathol, Dept Pathobiol, Zurich, Switzerland; [Polkinghorne, Adam] Univ Sunshine Coast, Fac Sci Hlth Educ & Engn, Ctr Anim Hlth Innovat, Sippy Downs, Qld, Australia	Borel, N (reprint author), Univ Zurich, Inst Vet Pathol, Vetsuisse Fac, Winterthurerstr 268, CH-8057 Zurich, Switzerland.	N.Borel@access.uzh.ch	; Borel, Nicole/M-6204-2016	Polkinghorne, Adam/0000-0002-6567-2962; Borel, Nicole/0000-0002-1556-9262			Aaziz R, 2015, VET MICROBIOL, V181, P318, DOI 10.1016/j.vetmic.2015.10.018; AbdelRahman YM, 2005, FEMS MICROBIOL REV, V29, P949, DOI 10.1016/j.femsre.2005.03.002; Ammerdorffer A, 2017, CURR OPIN INFECT DIS, V30, P289, DOI 10.1097/QCO.0000000000000369; Appino S, 2015, REPROD DOMEST ANIM, V50, P526, DOI 10.1111/rda.12505; Bainbridge FA, 1912, LANCET, V1, P705; Baker JA, 1942, SCIENCE, V96, P475, DOI 10.1126/science.96.2499.475; Baker JA, 1944, J EXP MED, V79, P159, DOI 10.1084/jem.79.2.159; Barkallah M, 2016, J MICROBIOL METH, V125, P64, DOI 10.1016/j.mimet.2016.04.001; Barkallah M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091549; Barkallah M, 2013, VET MICROBIOL, V164, P101, DOI 10.1016/j.vetmic.2013.01.036; Bart M, 2000, VET J, V159, P220, DOI 10.1053/tvjl.1999.0451; Bavoil P, 2013, PATHOG DIS, V67, P89, DOI 10.1111/2049-632X.12026; Bavoil PM, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00027; Bedson SP, 1932, BRIT J EXP PATHOL, V13, P461; Berger L, 1999, J CLIN MICROBIOL, V37, P2378; Blaha EA, 1909, BERL TIERARZTL WSCHR, V25, P879; Blumer C, 2007, VET PATHOL, V44, P144, DOI 10.1354/vp.44-2-144; Blumer S, 2011, VET MICROBIOL, V152, P385, DOI 10.1016/j.vetmic.2011.05.024; BOCKLISCH H, 1991, BERL MUNCH TIERARZTL, V104, P119; Bodetti TJ, 2002, SYST APPL MICROBIOL, V25, P146, DOI 10.1078/0723-2020-00086; Borel N, 2007, EMERG INFECT DIS, V13, P1904, DOI 10.3201/eid1312.070655; Borel N, 2016, CURR CLIN MICROBIOL, V3, P10, DOI 10.1007/s40588-016-0028-4; Borel N, 2014, VET J, V200, P218, DOI 10.1016/j.tvjl.2014.03.015; Branley J, 2016, SCI REP-UK, V6, DOI 10.1038/srep30019; BRUMPT E., 1938, ANN PARASI TOL HUMAINE ET COMP, V16, P153; Burach F, 2014, VET MICROBIOL, V172, P230, DOI 10.1016/j.vetmic.2014.04.022; Burnard D, 2016, VET MICROBIOL, V196, P78, DOI 10.1016/j.vetmic.2016.10.018; Burnet F, 1935, BRIT J PATHOLOGY, V40, P479; BUXTON D, 1990, J COMP PATHOL, V102, P221; Casson N, 2008, MICROB PATHOGENESIS, V45, P92, DOI 10.1016/j.micpath.2008.04.003; Chan J, 2017, ONE HEALTH, V3, P29, DOI 10.1016/j.onehlt.2017.02.003; Choroszy-Krol I, 2014, ADV CLIN EXP MED, V23, P123, DOI 10.17219/acem/37035; Coles AC, 1930, LANCET, V1, P1011; Cope I, 2014, VET REC CASE REP, V2, P1, DOI [10.1136/vetreccr-2014-000086, DOI 10.1136/VETRECCR-2014-000086]; Crespo S, 1999, DIS AQUAT ORGAN, V37, P61, DOI 10.3354/dao037061; DAGNALL GJR, 1990, VET MICROBIOL, V21, P233, DOI 10.1016/0378-1135(90)90034-S; De Puysseleyr K, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0560-x; De Puysseleyr K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096704; De Puysseleyr L, 2017, TRANSBOUND EMERG DIS, V64, P826, DOI 10.1111/tbed.12446; Dean D, 2013, EMERG INFECT DIS, V19, P1948, DOI 10.3201/eid1912.130656; Deuchande R, 2010, VET REC, V166, P598, DOI 10.1136/vr.c2435; DILBECK PM, 1990, J CLIN MICROBIOL, V28, P814; Draghi A, 2004, J CLIN MICROBIOL, V42, P5286, DOI 10.1128/JCM.42.11.5286-5297.2004; Essig A, 2015, CURR CLIN MICROBIOL, V2, P22, DOI 10.1007/s40588-015-0014-2; Everett KDE, 1999, INT J SYST BACTERIOL, V49, P415, DOI 10.1099/00207713-49-2-415; Frutos MC, 2015, AVIAN PATHOL, V44, P50, DOI 10.1080/03079457.2014.993593; Frutos MC, 2014, REV ARGENT MICROBIOL, V46, P45, DOI 10.1016/S0325-7541(14)70047-1; Giannitti F, 2016, J VET DIAGN INVEST, V28, P184, DOI 10.1177/1040638715625729; Guo WN, 2016, SCI REP-UK, V6, DOI 10.1038/srep19638; Gupta S, 2015, LETT APPL MICROBIOL, V60, P135, DOI 10.1111/lam.12362; Guscetti F, 2009, VET MICROBIOL, V135, P157, DOI 10.1016/j.vetmic.2008.09.038; Halberstaedter, 1907, DEUT MED WOCHENSCHR, V33, P1285; Harkinezhad T, 2009, VET MICROBIOL, V135, P68, DOI 10.1016/j.vetmic.2008.09.046; Hemsley S, 1997, J COMP PATHOL, V116, P273, DOI 10.1016/S0021-9975(97)80003-5; Henning K, 2000, DEUT TIERARZTL WOCH, V107, P49; Henning K, 2002, VET MICROBIOL, V85, P285, DOI 10.1016/S0378-1135(01)00510-7; Higgins DP, 2005, J COMP PATHOL, V133, P164, DOI 10.1016/j.jcpa.2005.04.005; Hoffmann KQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134091; Holzer M, 2016, GENOME ANNOUNC, V4; HOMER BL, 1994, VET PATHOL, V31, P1; HOOVER EA, 1978, AM J VET RES, V39, P541; Huchzermeyer FW, 2008, J S AFR VET ASSOC, V79, P99; HUCHZERMEYER FW, 1994, J S AFR VET ASSOC, V65, P20; Hulin V, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv005; Hunt H, 2016, NEW ZEAL VET J, V64, P364, DOI 10.1080/00480169.2016.1208781; Jackson M, 1999, VET MICROBIOL, V65, P225; Jacobson E, 2002, J VET DIAGN INVEST, V14, P487, DOI 10.1177/104063870201400607; Jacobson ER, 2004, J VET DIAGN INVEST, V16, P153, DOI 10.1177/104063870401600211; JACOBSON ER, 1990, J WILDLIFE DIS, V26, P572, DOI 10.7589/0090-3558-26.4.572; JACOBSON ER, 1989, J ZOO WILDLIFE MED, V20, P364; Jelocnik M, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2016.135; Jelocnik M, 2014, VET MICROBIOL, V174, P214, DOI 10.1016/j.vetmic.2014.08.018; Jelocnik M, 2014, BMC VET RES, V10, DOI 10.1186/1746-6148-10-121; Jeong J, 2017, J VET MED SCI, V79, P1204, DOI 10.1292/jvms.16-0516; Johnston SD, 2015, VET PATHOL, V52, P1254, DOI 10.1177/0300985815570069; JONES BR, 1975, T OPHTHAL SOC UK, V95, P16; JONES H, 1945, J INFECT DIS, V76, P55, DOI 10.1093/infdis/76.1.55; Joseph SJ, 2015, GENOME BIOL EVOL, V7, P3070, DOI 10.1093/gbe/evv201; Kabeya H, 2015, MICROBIOL IMMUNOL, V59, P507, DOI 10.1111/1348-0421.12287; Katharios P, 2015, SCI REP-UK, V5, DOI 10.1038/srep17609; Knittler MR, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftu007; Kreizinger Z, 2015, J VET DIAGN INVEST, V27, P206, DOI 10.1177/1040638714563566; Kumar S, 2007, J CLIN MICROBIOL, V45, P392, DOI 10.1128/JCM.01726-06; Laroucau K, 2009, INFECT GENET EVOL, V9, P1240, DOI 10.1016/j.meegid.2009.08.005; Lazarus AS, 1939, J BACTERIOL, V38, P121; Lenart J, 2001, ANTIMICROB AGENTS CH, V45, P2198, DOI 10.1128/AAC.45.8.2198-2203.2001; Leonard CA, 2014, CURR CLIN MICROBIOL, V1, P61, DOI 10.1007/s40588-014-0005-8; LEVADITI JC, 1964, ANN I PASTEUR PARIS, V107, P656; Levinthal W, 1930, KLIN WOCHENSCHR, V9, P654; Li J, 2016, VET MICROBIOL, V193, P93, DOI 10.1016/j.vetmic.2016.08.008; Li ZC, 2015, BIOMED RES INT, DOI 10.1155/2015/658519; Lillie RD, 1930, PUBLIC HEALTH REP, V45, P773, DOI 10.2307/4579610; Livingstone M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177653; Lohr M, 2015, PATHOG DIS, V73, DOI 10.1111/2049-632X.12201; Longbottom D, 2003, J COMP PATHOL, V128, P217, DOI 10.1053/jcpa.2002.0629; Longbottom D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057950; Longbottom D, 2013, VET J, V195, P257, DOI 10.1016/j.tvjl.2012.06.018; Lutz-Wohlgroth L, 2006, J VET MED A, V53, P185, DOI 10.1111/j.1439-0442.2006.00819.x; Mackie JT, 2016, J COMP PATHOL, V155, P356, DOI 10.1016/j.jcpa.2016.07.011; MCCHESNEY SL, 1982, CORNELL VET, V72, P92; Meyer KF, 1933, P SOC EXP BIOL MED, V30, P484; MEYER KF, 1953, ANN NY ACAD SCI, V56, P545, DOI 10.1111/j.1749-6632.1953.tb30244.x; Mitchell CM, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-442; Mitchell CM, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000903; Mitchell CM, 2009, VET MICROBIOL, V136, P91, DOI 10.1016/j.vetmic.2008.10.008; MONNICKENDAM MA, 1980, BRIT J OPHTHALMOL, V64, P279, DOI 10.1136/bjo.64.4.279; MONNICKENDAM MA, 1980, BRIT J OPHTHALMOL, V64, P284, DOI 10.1136/bjo.64.4.284; Morange A, 1895, PSITTACOSE INFECT SP; MURRAY ES, 1964, J INFECT DIS, V114, P1, DOI 10.1093/infdis/114.1.1; Nemeth NM, 2016, J COMP PATHOL, V155, P105, DOI 10.1016/j.jcpa.2016.05.006; O'Connell CM, 2016, MICROB CELL, V3, P390, DOI 10.15698/mic2016.09.525; Ortega N, 2016, IRISH VET J, V69, DOI 10.1186/s13620-016-0067-4; Paavonen J, 2012, ANN MED, V44, P18, DOI 10.3109/07853890.2010.546365; PAGE L. A., 1966, INT J SYST BACTERIOL, V16, P223; PAGE L. A., 1968, INT J SYST BACTERIOL, V18, P51; Pantchev A, 2010, COMP IMMUNOL MICROB, V33, P473, DOI 10.1016/j.cimid.2009.08.002; Perry HM, 1920, BRIT J EXP PATHOL, V1, P131; Pilloux L, 2015, MICROBES INFECT, V17, P755, DOI 10.1016/j.micinf.2015.08.007; Polkinghorne A, 2017, CLIN MICROBIOL INFEC, V23, P693, DOI 10.1016/j.cmi.2017.05.025; Polkinghorne A, 2009, VET MICROBIOL, V135, P142, DOI 10.1016/j.vetmic.2008.09.034; Polkinghorne A, 2013, VET MICROBIOL, V165, P214, DOI 10.1016/j.vetmic.2013.02.026; POSPISCHIL A, 1987, VET PATHOL, V24, P568, DOI 10.1177/030098588702400617; Pospischil A, 2009, DRUG TODAY, V45, P141; Poudel A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044961; Radomski N, 2016, FEBS LETT, V590, P3920, DOI 10.1002/1873-3468.12295; Ramsey KH, 2016, PATHOG DIS, V74, DOI 10.1093/femspd/ftv129; RANK RG, 1992, AM J PATHOL, V140, P927; RANK RG, 1994, METHOD ENZYMOL, V235, P69; Reed KD, 2000, EMERG INFECT DIS, V6, P196, DOI 10.3201/eid0602.000216; Reinhold P, 2011, VET J, V189, P257, DOI 10.1016/j.tvjl.2010.09.003; Ritter J., 1879, DTSCH ARCH KLIN MED, V25, P53; Robertson T, 2010, VET MICROBIOL, V145, P373, DOI 10.1016/j.vetmic.2010.04.007; Rodolakis A, 2015, VET MICROBIOL, V181, P107, DOI 10.1016/j.vetmic.2015.07.010; Rogers DG, 2000, J VET DIAGN INVEST, V12, P233, DOI 10.1177/104063870001200306; Rogers DG, 1996, J VET DIAGN INVEST, V8, P433, DOI 10.1177/104063879600800405; Roulis E, 2014, MICROBIOL RESOUR ANN, V2, DOI 10.1128/genomeA.01223-13; Roulis E, 2013, TRENDS MICROBIOL, V21, P120, DOI 10.1016/j.tim.2012.10.009; Ruegg SR, 2015, VET J, V205, P424, DOI 10.1016/j.tvjl.2015.05.007; Ruhl S, 2008, EMERG INFECT DIS, V14, P1966, DOI 10.3201/eid1412.080582; Ruhl S, 2009, VET MICROBIOL, V135, P169, DOI 10.1016/j.vetmic.2008.09.049; Sachse K, 2015, CURR CLIN MICROBIOL, V2, P10, DOI 10.1007/s40588-014-0010-y; Sachse K, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftu008; Sachse K, 2015, SYST APPL MICROBIOL, V38, P99, DOI 10.1016/j.syapm.2014.12.004; Sachse K, 2014, SYST APPL MICROBIOL, V37, P79, DOI 10.1016/j.syapm.2013.12.004; Sachse K, 2012, VET MICROBIOL, V157, P476, DOI 10.1016/j.vetmic.2012.01.002; Sachse K, 2009, VET MICROBIOL, V135, P2, DOI 10.1016/j.vetmic.2008.09.040; Sammin D, 2009, VET MICROBIOL, V135, P90, DOI 10.1016/j.vetmic.2008.09.054; Sargison ND, 2015, NEW ZEAL VET J, V63, P284, DOI 10.1080/00480169.2015.1018365; SCHACHTER J, 1969, LANCET, V1, P1063; Schautteet K, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-29; Seth-Smith HMB, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3657-y; Seth-Smith HMB, 2017, GENOME BIOL EVOL, V9, P750, DOI 10.1093/gbe/evx043; Seth-Smith HMB, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00508; Seth-Smith HMB, 2016, ISME J, V10, P1791, DOI 10.1038/ismej.2015.223; Soldati G, 2004, VET PATHOL, V41, P388, DOI 10.1354/vp.41-4-388; Speight KN, 2016, J WILDLIFE DIS, V52, P301, DOI 10.7589/2015-05-120; Stoner BP, 2015, CLIN INFECT DIS, V61, pS865, DOI 10.1093/cid/civ756; STOREY C, 1993, J GEN MICROBIOL, V139, P2621, DOI 10.1099/00221287-139-11-2621; Stride MC, 2014, VET MICROBIOL, V171, P258, DOI 10.1016/j.vetmic.2014.03.022; Strik NI, 2005, VET CLIN PATH, V34, P169, DOI 10.1111/j.1939-165X.2005.tb00034.x; STUDDERT MJ, 1981, AUST VET J, V57, P515, DOI 10.1111/j.1751-0813.1981.tb05787.x; Sykes JE, 2005, CLIN TECH SMALL AN P, V20, P129, DOI 10.1053/j.ctsap.2004.12.018; Szeredi L, 2005, VET RES COMMUN, V29, P37, DOI 10.1007/s11259-005-0835-1; Szymanska-Czerwinska M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174599; Szymanska-Czerwinska M, 2016, VECTOR-BORNE ZOONOT, V16, P1, DOI 10.1089/vbz.2015.1839; Taylor HR, 2008, TRACHOMA BLINDING SC; Taylor HR, 2014, LANCET, V384, P2142, DOI 10.1016/S0140-6736(13)62182-0; Taylor-Brown A., 2017, New Microbes and New Infections, V18, P28, DOI 10.1016/j.nmni.2017.04.004; Taylor-Brown A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10757-5; Taylor-Brown A, 2017, ENVIRON MICROBIOL, V19, P1899, DOI 10.1111/1462-2920.13694; Taylor-Brown A, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3055-x; Taylor-Brown A, 2015, VET MICROBIOL, V178, P88, DOI 10.1016/j.vetmic.2015.04.021; Taylor-Brown A, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftu009; TerWee J, 1998, VET MICROBIOL, V59, P259, DOI 10.1016/S0378-1135(97)00185-5; Theegarten D, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-14; Vorimore F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074823; Walker E, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0832-3; Walker E, 2015, VET J, V206, P252, DOI 10.1016/j.tvjl.2015.09.022; Wallensten A, 2014, EUROSURVEILLANCE, V19, P42; Wan C, 2011, AUST VET J, V89, P409, DOI 10.1111/j.1751-0813.2011.00827.x; Wanninger S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166917; Wardrop S, 1997, THESIS; Warren K, 2005, J ZOO WILDLIFE MED, V36, P100, DOI 10.1638/02-067; Wheelhouse N, 2015, VET REC, V176, P465, DOI 10.1136/vr.103075; Wheelhouse N, 2016, SCI REP-UK, V6, DOI 10.1038/srep37150; Wheelhouse N, 2014, VET REC, V174, DOI 10.1136/vr.g3567; Wheelhouse N, 2013, VET REC, V172, P110, DOI 10.1136/vr.f469; Wheelhouse N, 2010, VACCINE, V28, P5657, DOI 10.1016/j.vaccine.2010.04.114; Wheelhouse N, 2015, CURR CLIN MICROBIOL, V2, P1, DOI 10.1007/s40588-014-0011-x; Wheelhouse N, 2012, VET J, V193, P586, DOI 10.1016/j.tvjl.2012.01.008; Zocevic A, 2012, ENVIRON MICROBIOL, V14, P2212, DOI 10.1111/j.1462-2920.2012.02800.x	191	10	11	2	16	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAY	2018	55	3					374	390		10.1177/0300985817751218			17	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GC7MI	WOS:000429977000004	29310550	Bronze			2019-10-28	
J	Muscatello, LV; Avallone, G; Serra, F; Seuberlich, T; Mandara, MT; Siso, S; Brunetti, B; Oevermann, A				Muscatello, Luisa Vera; Avallone, Giancarlo; Serra, Fabienne; Seuberlich, Torsten; Mandara, Maria Teresa; Siso, Silvia; Brunetti, Barbara; Oevermann, Anna			Glomeruloid Microvascular Proliferation, Desmoplasia, and High Proliferative Index as Potential Indicators of High Grade Canine Choroid Plexus Tumors	VETERINARY PATHOLOGY			English	Article						angiogenic growth factors; central nervous system; choroid plexus carcinoma; choroid plexus papilloma; dog; histology; immunohistochemistry; microvascular proliferation	BRAIN-TUMORS; E-CADHERIN; EXPRESSION; ANGIOGENESIS; CARCINOMAS; PERICYTES; CANCER; PAPILLOMAS; CHILDREN; BETA	Choroid plexus tumors (CPT) are intraventricular neoplasms accounting for 10% of all primary central nervous system tumors in dogs. They are frequently classified according to the human WHO classification into choroid plexus papilloma (CPP, grade I), atypical CPP (aCPP, grade II), and choroid plexus carcinoma (CPC, grade III). Histological features observed in canine CPT such as increased vascular density (IVD) and glomeruloid microvascular proliferation (GMVP) are not part of the WHO classification. This multi-centric study aimed to investigate tumor-associated vascular hyperplasia in dogs by determining the prevalence of GMVP and IVD in 52 canine CPT and their association with tumor grade. In addition, the expression of angiogenic factors was assessed by immunohistochemistry in 25 tumors to investigate the pathogenesis of tumor-associated vascular hyperplasia. Based on the classical histological hallmarks, this study of 52 CPT identified 22 (42%) CPP (grade I) and 30 of (58%) CPC (grade III). GMVP was more prevalent in CPC (13/30; 43%) than CPP (1/22; 4%), whereas IVD occurred to a similar extent in CPP and CPC. Desmoplasia was more common in CPC (19/30; 63%) than CPP (2/22; 9%), and similarly, the proliferative index (PI) of neoplastic epithelium was significantly higher in CPC (5.14%) than CPP (0.94%). The majority of CPT expressed platelet-derived growth factor (PDGF), PDGFR, PDGFR, and vascular endothelial growth factor (VEGF) irrespective of tumor grade or tumor-associated vascular hyperplasia. These results suggest that tumor-associated GMVP, desmoplasia, and PI may serve as histological indicators of malignancy in CPT.	[Muscatello, Luisa Vera; Avallone, Giancarlo; Brunetti, Barbara] Univ Bologna, Dept Vet Med Sci DIMEVET, Bologna, Italy; [Serra, Fabienne; Seuberlich, Torsten; Oevermann, Anna] Univ Bern, Vetsuisse Fac, Div Neurol Sci, Dept Clin Res & Vet Publ Hlth, Bremgartenstr 109 A, CH-3001 Bern, Switzerland; [Mandara, Maria Teresa] Univ Perugia, Dept Vet Med, Perugia, Italy; [Siso, Silvia] UC Davis Sch Vet Med, Davis, CA USA; [Siso, Silvia] Biomarin Pharmaceut Inc, Novato, CA USA	Oevermann, A (reprint author), Univ Bern, Vetsuisse Fac, Div Neurol Sci, Dept Clin Res & Vet Publ Hlth, Bremgartenstr 109 A, CH-3001 Bern, Switzerland.	anna.oevermann@vetsuisse.unibe.ch	Siso, Silvia/X-7690-2019	AVALLONE, Giancarlo/0000-0002-5203-7679			Akslen LA, 2011, BRIT J CANCER, V105, P9, DOI 10.1038/bjc.2011.203; Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7; Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001; Barreto ASCD, 2004, ARQ NEURO-PSIQUIAT, V62, P600, DOI 10.1590/S0004-282X2004000400007; Brat DJ, 2001, AM J PATHOL, V158, P789, DOI 10.1016/S0002-9440(10)64025-4; Carlotti CG, 2002, ACTA NEUROPATHOL, V103, P1; Choi EJ, 2016, J VET DIAGN INVEST, V28, P464, DOI 10.1177/1040638716650239; Dome B, 2003, J NEUROPATH EXP NEUR, V62, P655; Gerhardt H, 2008, J MOL MED-JMM, V86, P135, DOI 10.1007/s00109-007-0258-2; Higgins RJ, 2016, TUMOR DOMESTIC ANIMA, P853; Koos B, 2009, AM J PATHOL, V175, P1631, DOI 10.2353/ajpath.2009.081022; Kumar V., 2015, ROBBINS COTRAN PATHO, P265; Lam S, 2013, PEDIATR NEUROSURG, V49, P331, DOI 10.1159/000367974; Louis D. N., 2016, WHO IARC CLASSIFICAT; Maharaj ASR, 2008, J EXP MED, V205, P491, DOI 10.1084/jem.20072041; Maharaj ASR, 2006, AM J PATHOL, V168, P639, DOI 10.2353/ajpath.2006.050834; Nentwig A, 2012, J VET DIAGN INVEST, V24, P14, DOI 10.1177/1040638711425940; Nupponen NN, 2008, MODERN PATHOL, V21, P265, DOI 10.1038/modpathol.3800989; Raica M, 2010, PHARMACEUTICALS, V3, P572, DOI 10.3390/ph3030572; Reginato A, 2016, VET PATHOL, V53, P788, DOI 10.1177/0300985815620844; RIBAS JL, 1989, VET PATHOL, V26, P55, DOI 10.1177/030098588902600109; Ribatti D, 2011, INT J DEV BIOL, V55, P261, DOI 10.1387/ijdb.103167dr; Rickert CH, 2001, MICROSC RES TECHNIQ, V52, P104; Rossmeisl JH, 2017, ONCOTARGETS THER, V10, P2077, DOI 10.2147/OTT.S132964; Safaee M, 2013, NEURO-ONCOLOGY, V15, P255, DOI 10.1093/neuonc/nos289; Stiver SI, 2004, FRONT BIOSCI, V9, P3105, DOI 10.2741/1463; Straume O, 2002, CANCER RES, V62, P6808; Sun MZ, 2014, NEUROSURG REV, V37, P179, DOI 10.1007/s10143-013-0499-1; Sundberg C, 2001, AM J PATHOL, V158, P1145, DOI 10.1016/S0002-9440(10)64062-X; Tanaka F, 2003, CANCER RES, V63, P6791; Westworth DR, 2008, J VET INTERN MED, V22, P1157, DOI 10.1111/j.1939-1676.2008.0170.x; Wrede B, 2009, J NEURO-ONCOL, V95, P383, DOI 10.1007/s11060-009-9936-y; Yang J, 2010, J NEUROL SCI, V296, P39, DOI 10.1016/j.jns.2010.06.012; Zecchin A, 2015, CURR OPIN HEMATOL, V22, P234, DOI 10.1097/MOH.0000000000000138	34	3	3	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAY	2018	55	3					391	401		10.1177/0300985817754124			11	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GC7MI	WOS:000429977000005	29402204	Bronze			2019-10-28	
J	Suarez-Santana, CM; Sierra, E; Diaz-Delgado, J; Zucca, D; de Quiros, YB; Puig-Lozano, R; Camara, N; De la Fuente, J; de los Monteros, AE; Rivero, M; Arbelo, M; Fernandez, A				Suarez-Santana, Cristian M.; Sierra, Eva; Diaz-Delgado, Josue; Zucca, Daniele; Bernaldo de Quiros, Yara; Puig-Lozano, Raquel; Camara, Nakita; De la Fuente, Jesus; Espinosa de los Monteros, Antonio; Rivero, Miguel; Arbelo, Manuel; Fernandez, Antonio			Prostatic Lesions in Odontocete Cetaceans	VETERINARY PATHOLOGY			English	Article						benign prostatic hyperplasia; cetacean; Crassicauda; dolphins; morbillivirus; prostate gland; prostatitis; urogenital system; whales	WHALE BALAENOPTERA-PHYSALUS; CANARY-ISLANDS; CYTOMEGALOVIRUS PROSTATITIS; MEDITERRANEAN-SEA; CRASSICAUDA SP; MORBILLIVIRUS; MORTALITY; DOLPHINS; NEMATODA; SPAIN	The prostate is the only accessory male genital gland described in cetaceans. Although few studies describe the gross and histologic anatomy of the prostate in cetaceans, there is no information on pathological findings involving this organ. The prostate glands of 45 cetaceans, including 8 different odontocete species (n = 44) and 1 mysticete, were evaluated. The main pathologic diagnoses were verminous prostatitis, septic prostatitis, viral prostatitis, benign prostatic hyperplasia, and prostatitis of unknown etiology. Verminous prostatitis (n = 12) was caused by nematodes of the genus Crassicauda, and different presentations were observed. Septic prostatitis, identified in 2 cases, both involved nematode infestation and Clostridium spp coinfection. One case of viral prostatitis was identified and was associated with morbillivirus infection. In prostatitis of unknown cause (n = 7), varying degrees of prostatic lesions, mostly chronic inflammation, were identified. Impacts at individual levels (eg, localized disease, loss of reproductive capacity) and population levels (eg, decreased reproductive success) are plausible. Our results indicate a high occurrence of prostatic lesions in free-ranging odontocetes. For this reason, the prostate should be routinely inspected and sampled during necropsy of odontocete cetaceans.	[Suarez-Santana, Cristian M.; Sierra, Eva; Diaz-Delgado, Josue; Zucca, Daniele; Bernaldo de Quiros, Yara; Puig-Lozano, Raquel; Camara, Nakita; De la Fuente, Jesus; Espinosa de los Monteros, Antonio; Rivero, Miguel; Arbelo, Manuel; Fernandez, Antonio] Univ Las Palmas Gran Canaria, Inst Anim Hlth & Food Secur IUSA, Sch Vet, Div Histol & Anim Pathol, Las Palmas Gran Canaria 35413, Canary Islands, Spain	Sierra, E (reprint author), Univ Las Palmas Gran Canaria, Inst Anim Hlth & Food Secur IUSA, Sch Vet, Div Histol & Anim Pathol, Las Palmas Gran Canaria 35413, Canary Islands, Spain.	manuel.arbelo@ulpgc.es	Fernandez, Antonio/G-3448-2015; Sierra, Eva/H-9352-2015; de Quiros, Yara Bernaldo/A-3628-2015; Camara, Nakita/P-8624-2019; laspalmas, MARS/S-2676-2018; Arbelo, Manuel/D-6789-2013	Fernandez, Antonio/0000-0001-5281-0521; Sierra, Eva/0000-0003-3749-8845; de Quiros, Yara Bernaldo/0000-0002-2611-0406; Camara, Nakita/0000-0001-8307-3915; Arbelo, Manuel/0000-0002-1623-5010; Suarez-Santana, Cristian M/0000-0002-0409-6156	University of Las Palmas of Gran Canaria; national project "Embolic Pathology in Cetaceans" [CGL2015-71498-P]	We thank all the people who indirectly participated in this work, including volunteers and personnel of the Government of Canarias. We greatly acknowledge Ana Afonso Almeda and Idaira Felipe Jimenez for technical assistance, the partner nongovernmental organizations SECAC and Canarias Conservation, and Binter Canarias. This study is part of a PhD program supported by the University of Las Palmas of Gran Canaria through a predoctoral fellowship for students (Contrato Predoctoral Convocatoria del 2012 programa propio de la ULPG, BOULPGC Ano VI num. 6). Partial funding came from the national project "Embolic Pathology in Cetaceans" (ref. CGL2015-71498-P).	Balbuena JA, 2014, DIS AQUAT ORGAN, V108, P83, DOI 10.3354/dao02694; Bateman TF, ANN M SOC INT COMP B, V55, P17; Brown D.L., 2017, PATHOLOGIC BASIS VET, P412; Carvalho VL, 2010, VET PARASITOL, V173, P116, DOI 10.1016/j.vetpar.2010.06.023; Cozzi B, 2017, ANATOMY OF DOLPHINS: INSIGHTS INTO BODY STRUCTURE AND FUNCTION, P369, DOI 10.1016/B978-0-12-407229-9.00009-9; Dejucq N, 2001, MICROBIOL MOL BIOL R, V65, P208, DOI 10.1128/MMBR.65.2.208-231.2001; Diaz-Delgado J, 2016, VET PATHOL, V53, P1233, DOI 10.1177/0300985816642228; Epstein JI, 2015, ROBBINS COTRAN PATHO, P959; Esperon F, 2008, DIS AQUAT ORGAN, V81, P73, DOI 10.3354/dao01915; Foster RA, 2017, PATHOLOGIC BASIS VET, P1194; Garcia-Alvarez N, 2014, SCI TOTAL ENVIRON, V493, P22, DOI 10.1016/j.scitotenv.2014.05.125; Geraci JR, 2005, MARINE MAMMALS ASHOR; Harrison RJ, 1972, FUNCTIONAL ANATOMY M, P361; Kuiken Thijs, 1991, P1; La Vignera S, 2011, INT J ANDROL, V34, pE330, DOI 10.1111/j.1365-2605.2011.01200.x; Lair S, 2016, VET PATHOL, V53, P22, DOI 10.1177/0300985815604726; LAMBERTSEN RH, 1986, J MAMMAL, V67, P353, DOI 10.2307/1380889; LAMBERTSEN RH, 1985, J PARASITOL, V71, P485, DOI 10.2307/3281543; Lane EP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107038; Matthews L. H., 1950, Atlantide Report (Sci Res Danish Exp Coasts Trop W Africa 1945-1946), V1, P223; Musso D, 2016, CLIN MICROBIOL REV, V29, P487, DOI 10.1128/CMR.00072-15; RAGA JA, 1990, ANN PARASIT HUM COMP, V65, P255, DOI 10.1051/parasite/1990655255; Raga JA, 2008, EMERG INFECT DIS, V14, P471, DOI 10.3201/eid1403.071230; Reynolds JE, 1999, BIOL MARINE MAMMALS, P15; Rouphael NG, 2011, AM J TRANSPLANT, V11, P1330, DOI 10.1111/j.1600-6143.2011.03519.x; Sierra E, 2016, EMERG INFECT DIS, V22, P740, DOI 10.3201/eid2204.150954; Van Bressem MFO, 2006, DIS AQUAT ORGAN, V68, P149, DOI 10.3354/dao068149; Van Bressem MF, 2014, VIRUSES-BASEL, V6, P5145, DOI 10.3390/v6125145; Wasser SK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179824; Yablokov AV, 1974, WHALES DOLPHINS KITY, V1, P174; Yoon GS, 2010, INT J SURG PATHOL, V18, P55, DOI 10.1177/1066896908321182; You L, 1999, TOXICOL APPL PHARM, V161, P258, DOI 10.1006/taap.1999.8804	32	1	1	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAY	2018	55	3					466	472		10.1177/0300985818755252			7	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GC7MI	WOS:000429977000015	29402205	Bronze			2019-10-28	
J	Bledsoe, JR; Wallace, ZS; Stone, JH; Deshpande, V; Ferry, JA				Bledsoe, Jacob R.; Wallace, Zachary S.; Stone, John H.; Deshpande, Vikram; Ferry, Judith A.			Lymphomas in IgG4-related disease: clinicopathologic features in a Western population	VIRCHOWS ARCHIV			English	Article						IgG4-related disease; IgG4-RD; Lymphoma	B-CELL LYMPHOMA; IGG4-POSITIVE PLASMA-CELLS; AUTOIMMUNE PANCREATITIS; SCLEROSING DISEASE; LYMPHADENOPATHY; ASSOCIATION; RISK	Lymphomas that occur in the setting of IgG4-related disease (IgG4-RD) are uncommon. Most reported cases derive from Asia and are MALT lymphomas occurring in orbital IgG4-RD. The spectrum of lymphomas among IgG4-RD patients in the Western world remains poorly defined. The aim of this study was to report our experience with lymphomas occurring in IgG4-RD. Eight cases were identified from the pathology and consultation files. The median age was 61 years (range 22-68) at IgG4-RD diagnosis and 63.5 years (range 33-79) at lymphoma diagnosis, with a M:F ratio of 4:4. The diagnosis of lymphoma and IgG4-RD was concurrent in three cases and asynchronous in five (interval 4.3-16.4 years). Concurrent cases included a MALT lymphoma and a diffuse large B cell lymphoma (DLBCL) occurring with IgG4-related sialadenitis and a follicular lymphoma occurring with orbital IgG4-RD. Asynchronous cases included a lymphoplasmacytic lymphoma with large cell transformation and intervening IgG4-related pancreatitis, a MALT lymphoma after lacrimal IgG4-RD, two DLBCLs after multiorgan IgG4-RD, and a DLBCL after IgG4-related sialadenitis. Our findings suggest that lymphomas in IgG4-RD are more varied in location and type than the experience reported from Asia to date. Pathologists should be aware of the potential for lymphoma to develop in patients with IgG4-RD and should have a high degree of suspicion when lymphadenopathy or extranodal masses persist despite appropriate therapy for IgG4-RD. The co-occurrence of IgG4-RD and lymphoma that is reported here and previously suggests a possible etiologic association.	[Bledsoe, Jacob R.] Univ Massachusetts, Mem Med Ctr, Dept Pathol, Worcester, MA 01605 USA; [Wallace, Zachary S.; Stone, John H.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; [Deshpande, Vikram; Ferry, Judith A.] Massachusetts Gen Hosp, James Homer Wright Pathol Labs, Boston, MA 02114 USA	Bledsoe, JR (reprint author), Univ Massachusetts, Mem Med Ctr, Dept Pathol, Worcester, MA 01605 USA.	jacob.bledsoe@umassmemorial.org; zswallace@mgh.harvard.edu; jhstone@mgh.harvard.edu; vdeshpande@mgh.harvard.edu; jferry@mgh.harvard.edu					Asano N, 2012, J CLIN EXP HEMATOP, V52, P57; Bledsoe JR, 2017, AM J CLIN PATHOL, V148, P215, DOI 10.1093/AJCP/AQX067; Cheuk W, 2008, AM J SURG PATHOL, V32, P1159, DOI 10.1097/PAS.0b013e31816148ad; Cheuk W, 2008, AM J SURG PATHOL, V32, P671, DOI 10.1097/PAS.0b013e318157c068; Cheuk W, 2012, SEMIN DIAGN PATHOL, V29, P226, DOI 10.1053/j.semdp.2012.07.001; Deshpande V, 2012, MODERN PATHOL, V25, P1181, DOI 10.1038/modpathol.2012.72; Ferry JA, 2013, DIAGN HISTOPATHOL, V19, P128, DOI [DOI 10.1016/J.MPDHP.2013.01.005, 10.1016/j.mpdhp.2013.01.005]; Ferry JA, 2015, AM J SURG PATHOL, V39, P1688, DOI 10.1097/PAS.0000000000000497; Geyer JT, 2014, MODERN PATHOL, V27, P375, DOI 10.1038/modpathol.2013.159; Gupta R, 2013, PANCREAS, V42, P506, DOI 10.1097/MPA.0b013e31826bef91; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; Ishida M, 2013, INT J CLIN EXP PATHO, V6, P2560; Johnson NA, 2012, J CLIN ONCOL, V30, P3452, DOI 10.1200/JCO.2011.41.0985; Kanda G, 2011, INTERNAL MED, V50, P155, DOI 10.2169/internalmedicine.50.4413; Kim T, 2008, J GASTROINTEST SURG, V12, P1566, DOI 10.1007/s11605-008-0543-6; Kubota T, 2010, J CLIN PATHOL, V63, P1059, DOI 10.1136/jcp.2010.082156; Menon MP, 2014, HISTOPATHOLOGY, V64, P455, DOI 10.1111/his.12274; Rollins-Raval MA, 2012, INT J SURG PATHOL, V20, P47, DOI 10.1177/1066896911420562; Sato Y, 2008, PATHOL INT, V58, P465, DOI 10.1111/j.1440-1827.2008.02257.x; Sato Y, 2010, J CLIN PATHOL, V63, P1084, DOI 10.1136/jcp.2010.082958; Stone JH, 2012, NEW ENGL J MED, V366, P539, DOI 10.1056/NEJMra1104650; Strehl JD, 2011, J CLIN PATHOL, V64, P237, DOI 10.1136/jcp.2010.085613; Swerdlow SH, 2008, WHO CLASSIFICATION T; Takahashi N, 2009, PANCREAS, V38, P523, DOI 10.1097/MPA.0b013e31819d73ca; Uehara T, 2012, INTERNAL MED, V51, P419, DOI 10.2169/internalmedicine.51.5713; Wallace ZS, 2016, ARTHRITIS RHEUMATOL, V68, P2283, DOI 10.1002/art.39773; Wallace ZS, 2015, ARTHRITIS RHEUMATOL, V67, P2466, DOI 10.1002/art.39205; Yamamoto M, 2012, MOD RHEUMATOL, V22, P414, DOI 10.1007/s10165-011-0520-x	28	5	5	1	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAY	2018	472	5					839	852		10.1007/s00428-017-2286-9			14	Pathology	Pathology	GG9NI	WOS:000433027400015	29285637				2019-10-28	
J	Hryhorovskyi, VV; Kalashnykov, AV; Kuziv, YL; Apukhovska, LI				Hryhorovskyi, V. V.; Kalashnykov, A. V.; Kuziv, Ye. L.; Apukhovska, L. I.			Histopathology, morphometric indices of bones, articular and epiphyseal cartilages in experimental glucocorticoid-induced osteochondropathy	PATHOLOGIA			Russian	Article						glucocorticoids; articular cartilage; epiphyses; experiment; vitamin D; vitamin E	VITAMIN-D SUPPLEMENTATION; RANDOMIZED CLINICAL-TRIAL; KNEE OSTEOARTHRITIS; GROWTH-PLATE; TRIAMCINOLONE; METAANALYSIS; VOLUME; PAIN	Research objective - to define parametres of vitamins D and. influence on changes of articular (AC) and epiphyseal (EC) cartilage structural-functional condition indices in glucocorticoid-induced osteochondropathy (GIOCP) in experiment. Materials and methods. Series (7 rats each): 1) intact; 2) prednisolone in a dose of 5,0 mg/kg per os daily; 3) prednisolone in combination with vitamin D 100 IU; 4) prednisolone in combination with vitamin D 100 IU and vitamin E of 0,6 mg. Observation during 30 days. Indicators: weight of tibia, length and thickness of femur, thickness of proximal femoral AC and EC on a frontal tissue section, specific chondrocyte (ChC) number per unit of the section area, number of large places of cartilage matrix in sections of AC and EC. Results. The thickness of AC in GIOCP decreases, and in the conditions of vitamins D and E preventive administration tends to normalization though does not reach values of intact animals series. Specific ChC quantity per section area unit and large places of matrix quantity in GIOCP increase; in series where vitamin D was administrated, the tendency to decrease of parameters of both indices was observed, and in a series where both vitamins were administrated, the number of large places of matrix nevertheless remains above, than norm. The thickness of EC at GIOCP decreases, despite preventive application of vitamins. In GIOCP specific ChC quantity per unit of EC area and large places of matrix number increase, however in series where both vitamins D and E were preventively applied, the tendency to normalization of mean parameters of these indicators is observed. It gives evidence of steady character of glucocorticoid influence on EC chondrocytes and metaphyseal zone of ossification osteoblasts. Conclusions. Preventive administration of vitamins D and. during GIOCP-modelling leads to restoration (or to intact animals parameters approximation) of the majority of osteometric indices level, and also introduces positive changes in AC and EC of proximal femoral epimetaphysis histomorphometric indicators.	[Hryhorovskyi, V. V.] NAMS Ukraine, SI Res Inst Traumatol & Orthopaed, Highest Category, Kiev, Ukraine; [Hryhorovskyi, V. V.] NAMS Ukraine, SI Res Inst Traumatol & Orthopaed, Pathomorphol Dept, Kiev, Ukraine; [Kalashnykov, A. V.] NAMS Ukraine, SI Res Inst Traumatol & Orthopaed, Kiev, Ukraine; [Kalashnykov, A. V.] NAMS Ukraine, SI Res Inst Traumatol & Orthopaed, Dept Traumat Injuries & Problems Osteosynth, Kiev, Ukraine; [Kuziv, Ye. L.] Mil Med Ctr Cent Reg, Vinnytsia, Ukraine; [Apukhovska, L. I.] Natl Acad Sci Ukraine, Palladin Inst Biochem, Kiev, Ukraine	Hryhorovskyi, VV (reprint author), NAMS Ukraine, SI Res Inst Traumatol & Orthopaed, Highest Category, Kiev, Ukraine.; Hryhorovskyi, VV (reprint author), NAMS Ukraine, SI Res Inst Traumatol & Orthopaed, Pathomorphol Dept, Kiev, Ukraine.	val_grigorov@bigmir.net					Apukhovs'ka L I, 2009, Ukr Biokhim Zh (1999), V81, P50; Batura I. O., 2008, THESIS; Bodick N, 2015, J BONE JOINT SURG AM, V97A, P877, DOI 10.2106/JBJS.N.00918; Boyan BD, 2001, STEROIDS, V66, P363, DOI 10.1016/S0039-128X(00)00162-8; Cao YL, 2013, RHEUMATOLOGY, V52, P1323, DOI 10.1093/rheumatology/ket132; Diao NC, 2017, CLIN BIOCHEM, V50, P1312, DOI 10.1016/j.clinbiochem.2017.09.001; Gao XR, 2017, INT J SURG, V46, P14, DOI 10.1016/j.ijsu.2017.08.010; Garfinkel RJ, 2017, ORTHOP J SPORTS MED, V5, DOI 10.1177/2325967117711376; Hartmann K, 2016, PHYSIOL REV, V96, P409, DOI 10.1152/physrev.00011.2015; Hryhorovskyi V. V., 2018, VISNYK ORTOPEDII TRA, V1, P15; Ivanov Yu. I., 1990, STAT OBRABOTKA PEZUL; Jin XZ, 2016, JAMA-J AM MED ASSOC, V315, P1005, DOI 10.1001/jama.2016.1961; Kalashnikov A. V., 2017, VISNYK MORFOLOHII, V23, P207; Lu YHCS, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3456; Lui JC, 2011, ENDOCR DEV, V20, P187, DOI 10.1159/000321244; McAlindon TE, 2017, JAMA-J AM MED ASSOC, V317, P1967, DOI 10.1001/jama.2017.5283; Morozkina T. S., 2002, VITAMINY; Smink JJ, 2003, OSTEOARTHR CARTILAGE, V11, P864, DOI 10.1016/S1063-4584(03)00187-0; Wenying Zhu, 2015, THESIS; Wernecke C, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115581163	20	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	MAY-AUG	2018		2					128	135		10.14739/2310-1237.2018.2.141415			8	Pathology	Pathology	GU7BJ	WOS:000445473200001		DOAJ Gold			2019-10-28	
J	Mykhailovska, NS; Stetsiuk, IO				Mykhailovska, N. S.; Stetsiuk, I. O.			The indicators of the bone tissue mineralization abnormalities in women with coronary artery disease in the post-menopausal period	PATHOLOGIA			English	Article						coronary artery disease; postmenopausal period; osteoporosis; osteopenia; metabolic diseases; correlation of data		Objective. To determine the indicators of the bone mineral density (BMD) abnormalities in women with coronary artery disease (CAD) in the post-menopausal period. Methods. An open cross-sectional study in parallel groups involved 80 women with coronary artery disease (CAD): stable exertional angina of II-III functional class (mean age 64.59 +/- 1.02 years). Depending on the degree of BMD they were divided into 3 groups: group 1 - 19 CAD women with normal BMD; group 2 - 27 CAD women with osteopenia; group 3 - 34 CAD women with osteoporosis. The control selected group consisted of 11 healthy women of the corresponding age. With the help of ultrasound densitometry, FRAX algorithm and bone biomarkers levels assessment we investigated structural and functional state of the bone tissue. Results. It was acknowledged that in women with CAD in the postmenopausal period, depending on the severity of BMD loss, there is a significant decrease in the T-and Z-criteria and an increase in the 10-year risk of developing osteoporosis fractures. The development of postmenopausal osteoporosis (PMOS) combined with CAD was accompanied with an increase in the level of inflammation, neoangiogenesis and bone remodeling biomarkers (osteoprotegerin, ostecalcin, VEGF-A), which also have multi-directional correlative interrelationships with the structural and functional indicators of the BMD state (T, Z-criterion, 10-year risk of osteoporosis fractures). ROC-analysis results show the cut-off values at the osteopenia and osteoporosis stage for osteoprotegerin level equal to 223.76 pg/ml and 224.44 pg/ml; for osteocalcin level - 15.89 ng/ml and 16.71 ng/ml, for VEGF-A level - 112.52 pg/ml and 123.31 pg/ml correspondingly. Conclusions. The levels of osteoprotegerin and/or ostecalcine and/or VEGF-A can be used as a screening method for early diagnosis of BMD loss and stratification of patients in the category of increased risk of osteopenia and osteoporosis.	[Mykhailovska, N. S.; Stetsiuk, I. O.] Zaporizhzhia State Med Univ, Dept Gen Practice Family Med, Zaporizhia, Ukraine	Mykhailovska, NS (reprint author), Zaporizhzhia State Med Univ, Dept Gen Practice Family Med, Zaporizhia, Ukraine.	iryna.zsmu@gmail.com	Mykhailovska, Natalia/K-3284-2017; Stetsiuk, Iryna O./K-4030-2017	Mykhailovska, Natalia/0000-0001-6781-9406; Stetsiuk, Iryna O./0000-0002-3698-0181			Barna O. M., 2009, LIKY UKRAINY, V3, P43; Fuster K., 2010, I MED COMMITTEE PREV; Gavisova A. A., 2012, RUSSKIJ MEDICINSKIJ, V20, P1110; Grasgruber P, 2016, FOOD NUTR RES, V60, DOI 10.3402/fnr.v60.31694; Grosso A, 2017, FRONT BIOENG BIOTECH, V5, DOI 10.3389/fbioe.2017.00068; Horbas I. M., 2009, ZDOROVIA UKRAINY, V3, P34; Karpova I. S., 2012, KARDIOLOGIYA BELARUS, V1, P98; Koval S. N., 2012, ARTERIALNAYA GIPERTE, V4; Kovalenko V. M., 2016, UKRAINSKYI KARDIOLOH, V3, P5; Kovalenko V. M., 2016, PROBLEMY ZDOROVIA ME; Mohylnytska L. A., 2015, KLIN ENDOKRYNOLOHIIA, V3, P23; Mykhailovska N. S., 2016, SCIENCERISE MED SCI, V8, P51; Pankratova Yu. V., 2013, OZHIRENIE I METABOLI, V2, P11; Povoroznyuk V. V., 2012, PROBLEMY OSTEOLOHII, V15, P53; Sagalovsky S., 2012, MIZHNARONYI MEDYCHNY, V18, P71; Toropcova N. V., 2012, ZDOROVE ZHENSCHINY, V1, P87; Townsend N, 2016, EUR HEART J, V37, P3232, DOI 10.1093/eurheartj/ehw334; Vertkin A. L., 2012, OSTEOPOROZ KAK KOMPO; Wilkins E, 2017, EUROPEAN CARDIOVASCU; Zhavrid E. A., 2010, ONKOLOGICHESKIJ ZH, V4, P23	20	1	1	0	1	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	MAY-AUG	2018		2					136	141		10.14739/2310-1237.2018.2.141408			6	Pathology	Pathology	GU7BJ	WOS:000445473200002		DOAJ Gold			2019-10-28	
J	Badiuk, MI; Mykyta, OO; Semeniv, IP; Rygan, MM; Kosarchuk, VV				Badiuk, M. I.; Mykyta, O. O.; Semeniv, I. P.; Rygan, M. M.; Kosarchuk, V. V.			The structure of urgent conditions of servicemen of the Armed Forces of Ukraine in modern conditions	PATHOLOGIA			Russian	Article						emergencies; wounds and injuries; algorithms; clinical protocols; standard of care; military personnel; Ukraine		Purpose: to study the structure of urgent conditions of servicemen with combat injuries and diseases in modern conditions in order to substantiate the development of promising algorithms and medical aid protocols adapted to NATO standards. Materials and methods. The paper presents the results of analysis of the structure and nature of urgent conditions of modern combat pathology and diseases among military personnel who were on treatment at the National Military Medical Clinical Center "Main Military Clinical Hospital" from 1999 to 2018 (191 731 disease histories). Results. The article analyzes the structure of emergency conditions for servicemen of the Armed Forces of Ukraine, who were admitted the National Military Medical Clinical Center "MMCH" in the period from 1999 to 2013 compared with the corresponding indicators for 2014-2017 years. The trends in the dynamics of the indicators of the structure of emergency conditions of servicemen with injuries (including combat ones) and diseases during the period of armed conflict compared to the previous period (1999-2013) were studied. The most urgent conditions of servicemen with combat trauma and serious illnesses are identified, which are the priority for the development and implementation of modern algorithms and protocols for the provision of medical assistance in combat conditions in the Armed Forces of Ukraine. A list of algorithms and protocols for the provision of medical assistance to servicemen of the Armed Forces of Ukraine under the main emergency conditions in today's conditions is proposed. Conclusions. The basic nosological forms of combat injuries and illnesses of military personnel are established in which emergencies are formed: the XIX class - injuries and head and brain injuries (27.3 %), abdominal injuries (18.2 %), chest injuries and ribs (12.9 %); X class - pneumonia (75.9 %); IX class - strokes (40.1 %), myocardial infarction (30.1 %) and hypertensive disease (12.5 %). The main classes, whose nosological forms are accompanied by severe and extremely serious conditions, are the XIX. class - traumas, poisonings and some other consequences of external causes (48.5 %), class X - respiratory diseases (12.1 %), class IX - Diseases of the circulatory system (7.4 %) and class V - disorders of the psyche and behavior (6.1 %). Identified urgent conditions of servicemen, arising from appropriate nosological forms and included in the described classes of diseases, are priority for the development of priority algorithms and protocols for the provision of medical assistance to servicemen in combat conditions according to NATO standards.	[Badiuk, M. I.; Kosarchuk, V. V.] Armed Forces Ukrainian Mil Med Acad, Dept Med Support Org, Kiev, Ukraine; [Mykyta, O. O.] Ukrainian Mil Med Acad, Dept Mil Prevent Med, Kiev, Ukraine; [Semeniv, I. P.] Feofaniya Clin Hosp, Kiev, Ukraine; [Rygan, M. M.] LLC Inst Sport Traumatol, Med Ctr, Kiev, Ukraine	Badiuk, MI (reprint author), Armed Forces Ukrainian Mil Med Acad, Dept Med Support Org, Kiev, Ukraine.	mikita_o@ukr.net					[Anonymous], 2011, NATO STANAG 2549 AME; Badiuk M. I., 2018, EKSTRENNA MEDYCHNA D; Badiuk M. I., 2015, STANDART PIDHOTOVKY; Bilyi V.Y, 2016, MEDYCHNE ZABEZPECHEN, P77; Mykyta O. O., 2016, PROBLEMY VIISKOVOI O, V45, P9; Verba A. V., 2015, UKRAINA ZDOROVIA NAT, V3, P19	6	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	MAY-AUG	2018		2					142	147		10.14739/2310-1237.2018.2.141431			6	Pathology	Pathology	GU7BJ	WOS:000445473200003		DOAJ Gold			2019-10-28	
J	Trubka, IO; Rossokha, ZI; Kyriachenko, SP; Savychuk, NO; Gorovenko, NG				Trubka, I. O.; Rossokha, Z. I.; Kyriachenko, S. P.; Savychuk, N. O.; Gorovenko, N. G.			Genetic predictors of development risk of combined caries and chronic catarrhal gingivitis course in children	PATHOLOGIA			Russian	Article						dental caries; gingivitis; polymorphism genetic; child	DENTAL-CARIES; CHILDHOOD CARIES; PERIODONTITIS; POLYMORPHISM; ASSOCIATION; SALIVA	The purpose of this work was to determine the role of the genetic component in the development of the combined course of caries and gingivitis in children. Materials and methods. The study involved 49 schoolchildren aged 7-15 years. Dental examination was carried out according to the generally accepted method. The children were divided according to the carious process activity into two groups: 0-4 (compensated caries-comparison group) and 5-8 (subcompensated caries - main group). Chronic generalized catarrhal gingivitis (CGCG) was detected in these groups with frequency: 8 (29.62 %) of 27 patients and 15 (68.18 %) of 22 patients, respectively. Biochemical analysis of the oral fluid parameters, which included an assessment of calcium, phosphorus content, the activity of acid and alkaline phosphatases, malondialdehyde (MDA), catalase, was carried out for children. Molecular genetic research was based on the genomic DNA isolation from the buccal epithelium. To determine the polymorphic variants of GSTT1, GSTM1 genes the method of multiplex polymerase chain reaction (PCR) was used and for the IL-1 beta (C3953T, rs1143634) and MMP13 (A77G, rs2252070) gene s-PCR followed by restriction fragment length polymorphism analysis. Results. The development chance of caries in children was associated with the GSTM1 gene deletion polymorphism in combination with the 3953CT polymorphic variant in the IL-1 beta gene. It was shown, that the development of caries was associated with CGCG, and this combined dental pathology was more reliably detected in patients with 3953TT and 3953TT genotypes in the IL-1 beta gene. Significantly increased index of malonic dialdehyde and decreased catalase activity in the presence of 3953TT and 3953TT polymorphic variants in the IL-1 beta gene are determined. Conclusions. Genetic predictors of increased development chance of combined dental pathology - subcompensated caries and CGCG, pathogenetically combined with increased activity and intensity of periodontal tissue damage among children, were revealed.	[Trubka, I. O.; Savychuk, N. O.] Shupyk Natl Med Acad Postgrad Educ, Dept Childrens Dent, Kiev, Ukraine; [Rossokha, Z. I.] Publ Hlth Minist Ukraine, State Inst Reference Ctr Mol Diagnost, Kiev, Ukraine; [Kyriachenko, S. P.] Publ Hlth Minist Ukraine, State Inst Reference Ctr Mol Diagnost, Mol Genet Lab, Kiev, Ukraine; [Savychuk, N. O.] Shupyk Natl Med Acad Postgrad Educ, Sci, Kiev, Ukraine; [Gorovenko, N. G.] Shupyk Natl Med Acad Postgrad Educ, Dept Med & Lab Genet, Kiev, Ukraine; [Gorovenko, N. G.] Shupyk Natl Med Acad Postgrad Educ, NAMS Ukraine, Kiev, Ukraine	Trubka, IO (reprint author), Shupyk Natl Med Acad Postgrad Educ, Dept Childrens Dent, Kiev, Ukraine.	itrubka@ukr.net	Savychuk, Nataliia/L-5171-2019; Savychuk, Natali O/X-9305-2018; Rossokha, Zoia/C-8783-2019; Gorovenko, Natalia/W-5699-2018	Savychuk, Nataliia/0000-0001-9532-665X; Savychuk, Natali O/0000-0001-9532-665X; Rossokha, Zoia/0000-0002-4767-7364; Gorovenko, Natalia/0000-0003-4227-7166			Ahmadi-Motamayel F, 2013, MED ORAL PATOL ORAL, V18, pE553, DOI 10.4317/medoral.18762; Antunes LAA, 2017, CARIES RES, V51, P102, DOI 10.1159/000451037; Dabra Sarita, 2012, Dent Res J (Isfahan), V9, P41, DOI 10.4103/1735-3327.92942; Divaris Kimon, 2017, Dent Clin North Am, V61, P619, DOI 10.1016/j.cden.2017.02.008; Gasyuk N. V., 2013, SVIT MEDYTSYNY TA BI, V2, P207; Goryachkovskij A. M., 2005, KLIN BIOKHIMIYA LAB; Jain Atul, 2015, J Oral Biol Craniofac Res, V5, P212, DOI 10.1016/j.jobcr.2015.06.015; Karimbux NY, 2012, J PERIODONTOL, V83, P1407, DOI 10.1902/jop.2012.110655; Khomenko L. O., 2011, KLIN STOMATOLOHIIA, V1-2, P53; Kuchler EC, 2017, CARIES RES, V51, P225, DOI 10.1159/000450764; McDevitt MJ, 2000, J PERIODONTOL, V71, P156, DOI 10.1902/jop.2000.71.2.156; Opal S, 2015, AUST DENT J, V60, P2, DOI 10.1111/adj.12262; Penes NO, 2017, ROM J MORPHOL EMBRYO, V58, P53; Piekoszewska-Zietek P, 2017, CARIES RES, V51, P425, DOI 10.1159/000476075; Popovych Z. B., 2010, VISNYK STOMATOLOHII, V2, P32; Savichuk N., 2015, SOVREMENNAYA STOMATO, V3, P46; Shaffer JR, 2011, J DENT RES, V90, P1457, DOI 10.1177/0022034511422910; Sirak S. V., 2013, STOMATOLOGIYA DETSKO, V12, P61; Spinei A., 2015, CURIERUL MED, V58, P3; Tannure PN, 2012, CARIES RES, V46, P401, DOI 10.1159/000339379; Tothova L., 2015, CELL INFECT MICROBIO, V5, P73, DOI [10.3389/fcimb.2015.00073, DOI 10.3389/FCIMB.2015.00073]; Wang X, 2012, CARIES RES, V46, P177, DOI 10.1159/000337282; Yildiz G, 2016, J DENT RES, V95, P74, DOI 10.1177/0022034515605281; Zhan YB, 2014, J PERIODONTOL, V85, P1059, DOI 10.1902/jop.2014.130523	24	0	0	0	1	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	MAY-AUG	2018		2					154	160		10.14739/2310-1237.2018.2.141341			7	Pathology	Pathology	GU7BJ	WOS:000445473200005		DOAJ Gold			2019-10-28	
J	Shumna, TY; Kamyshnyi, OM; Zinchenko, TP				Shumna, T. Ye.; Kamyshnyi, O. M.; Zinchenko, T. P.			Research of distribution pattern of allelic genes and genotypes of C/A polymorphism of COL1A1_1 collagen gene (RS1107946) in children with nasal obstruction of allergic genesis and orthodontic pathology	PATHOLOGIA			English	Article						alleles; genotype; collagen; distal occlusion; allergic rhinitis; children	EHLERS-DANLOS SYNDROMES; OSTEOGENESIS IMPERFECTA	Purpose. Determination of the genotypes of C/A polymorphism of COL1A1_1 collagen gene (rs1107946) and patterns of distribution of allelic genes in children with nasal obstruction and orthodontic pathology. Materials and methods. A molecular-genetic study for determination of C/A polymorphism of COL1A1_1 collagen gene (rs1107946) was performed in 99 children at the age of 6 to 17 years, for 11 months and 30 days inclusive; 30 children of which had nasal obstruction due to allergic rhinitis without abnormal distal occlusion (the first group); 23 children had just the distal occlusion (the second group); 26 children had allergic rhinitis and distal occlusion (the third group); 20 almost healthy children (the fourth group). Genotyping was performed by the polymerase chain reaction method (Applied Biosystems, USA) using the total DNA samples isolated from whole venous blood using a set of reagents SNP-Screen (Syntol manufacturer) on the CFX96TM Real-Time PCR Detection Systems amplifier (Bio-Rad Laboratories, Inc., USA). Non-parametric statistic methods of the licensed software package Statistica for Windows 6.1.RU, serial number AXXR712D833214SAN5 was used for processing the research results. Results. Molecular-genetic study of the distribution patterns of allelic genes and genotypes of the C/A polymorphism of the COL1A1_1 (rs1107946) collagen gene in the examined children showed that the frequency of occurrence of the C allele was significantly higher than the A allele (71.72 % and 28.28 %, respectively). In this case, the homozygous C/C genotype was registered most often (68.69 %), homozygous genotype A/A (25.25 %) was rarely registered and heterozygous C/A (6.06 %) was very rarely registered. In the observation groups, in children with allergic rhinitis, distal occlusion and a combination of allergic and orthodontic pathology, the genotypes had the following distribution: the C/C genotype - 76.67 %; 34.78 %; 73.00 %; A/A genotype - 20.00 %; 56.52 %; 17.39 %; A/C genotype - 3.33 %; 8.70 %; 11.54 %. The occurrence frequency of alleles of the C/A polymorphism of the COL1A1_1 collagen gene (rs1107946) in the examined children showed that the children with distal occlusion were significantly frequent carriers of A allele (60.87 %), whereas the carriers of C allele were predominantly children with allergic rhinitis (78.33 %), with combined allergic and orthodontic pathology (78.85 %) and healthy (90.00 %), P < 0.05. The correlation between the results of the study conducted in groups of children with the distal occlusion and practically healthy showed that the sensitivity of the presence of A allelic gene was equal to 60.87 %, specificity - 90.00 %, accuracy - 61.54 %. Since the sensitivity and specificity of the diagnostic test exceeded 50.00 %, the prognostic value for the positive result was equal to 87.50 % and for the negative result - 66.67 % and confirm this prognostic significance for the development of the orthodontic pathology in children. This will allow improving the preventive measures in children with orthodontic pathology. Conclusions. The molecular-genetic studies for determining the A allele (rs1107946) of the COL1A1_1 collagen gene in children could be recommended to determine the risk of development and the need for early prevention of the distal occlusion in children.	[Shumna, T. Ye.] Zaporizhzhia State Med Univ, Dept Fac Pediat, Zaporizhia, Ukraine; [Kamyshnyi, O. M.] Zaporizhzhia State Med Univ, Dept Microbiol Virol & Immunol, Zaporizhia, Ukraine; [Kamyshnyi, O. M.] Zaporizhzhia State Med Univ, Mol Genet Res Div, Med & Lab Ctr, Zaporizhia, Ukraine; [Zinchenko, T. P.] Zaporizhzhia State Med Univ, Dept Therapeut Orthoped & Pediat Dent, Zaporizhia, Ukraine	Shumna, TY (reprint author), Zaporizhzhia State Med Univ, Dept Fac Pediat, Zaporizhia, Ukraine.	tshumnaya72@gmail.com					Abashidze N., 2012, DENT ART; Asanov A. Y., 2008, HENETYKA PEDYATRYY, V8, P31; Belozerov Yu. M., 2008, DETSKAYA KARDIOLOGIY; Boitsaniuk S. I., 2017, MOLODYI VCHENYI, V5, P57; Brady AF, 2017, AM J MED GENET C, V175, P70, DOI 10.1002/ajmg.c.31550; Brozek JL, 2017, J ALLERGY CLIN IMMUN, V140, P950, DOI 10.1016/j.jaci.2017.03.050; Eimar H, 2016, J DENT RES, V95, P761, DOI 10.1177/0022034516637045; Flis P. S., 2007, ORTODONTIIA; Hubskyi Yu. I., 2016, BIOL BIOORHANICHNA K; Jabbour Z, 2018, ORTHOD CRANIOFAC RES, V21, P71, DOI 10.1111/ocr.12218; Lindahl K, 2015, EUR J HUM GENET, V23, P1042, DOI 10.1038/ejhg.2015.81; Luchynskyi M. A., 2017, KLIN STOMATOLOHIIA, V2, P4, DOI [10.11603/2311-9624.2017.2.7936, DOI 10.11603/2311-9624.2017.2.7936]; Lukianenko N. S., 2015, ZDOROV E REBENKA, V2, P80; Malfait F, 2017, AM J MED GENET C, V175, P8, DOI 10.1002/ajmg.c.31552; Malfait F, 2013, ORPHANET J RARE DIS, V8, DOI [10.1186/1750-1172-8-78, 10.1186/1750-1172-8-154]; Mandel B. R., 2016, OSNOVY SOVREMENNOJ G; Marushko Yu. V., 2012, ZDOROVIA UKRAINY, P33; Naumovych S. A., MARKERY NEDIFFERENCI; Nesterenko Z. V., 2010, ZDOROVE REBENKA, V4, P136; Nesterenko Z. V., 2010, ZDOROVE REBENKA, V5, P131; Rebrova O. Y, 2006, STAT ANALIZ MED DANN; Sesorova I. S., 2016, SOVREMENNYE PROBLEMY, V6; Storozhenko K. V., 2016, VISNYK STOMATOLOHII, V1, P16; Zhytnik L, 2017, HUM GENOMICS, V11, DOI 10.1186/s40246-017-0115-5	24	0	0	0	1	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	MAY-AUG	2018		2					161	168		10.14739/2310-1237.2018.2.141355			8	Pathology	Pathology	GU7BJ	WOS:000445473200006		DOAJ Gold			2019-10-28	
J	Sakovych, OO; Zhebel, VM; Polishchuk, TV; Franchuk, SV; Sursaieva, LM				Sakovych, O. O.; Zhebel, V. M.; Polishchuk, T. V.; Franchuk, S. V.; Sursaieva, L. M.			Polymorphism of the second type angiotensin II receptor's gene in women with essential hypertension and the corresponding features of structural and functional parameters of myocardium	PATHOLOGIA			Russian	Article						essential hypertension; polymorphism genetic; left ventricular's hypertrophy	BLOOD-PRESSURE; ASSOCIATION; UPDATE	Objective. To improve the diagnosis of predisposition to Essential arterial hypertension (EH) and Chronic heart failure (CHF) in postmenopausal age's women by determining the polymorphic genotypes of the first type angiotensin II receptor's gene (AT1-R) and the corresponding structural and functional state of myocardium. Materials and methods. The study involved 180 women of postmenopausal age, they were residents of Podillya Region of Ukraine. 80 women without signs of cardiovascular diseases were the control group, 100 women with EH included the main study's group. Genotyping of AT1-R was carried out using the polymerase chain reaction. The distribution of the frequencies of genotypes AT1-R was checked in accordance with the Hardy-Weinberg equilibrium law. The structural and functional parameters of myocardium were evaluated using an echocardiography. The left ventricular's systolic function was preserved in cases where the left ventricular's ejection fraction was more than 40 %. Mathematical processing was performed using the standard statistic package Statistica 6.0. Results. In patients with EH genotype AC was detected most often (49 %), AA and AC genotypes weer determined in 40 % and 11 % of patients (PAA-CC <= 0.05, PAC-CC <= 0.05) respectively. Carrying allele C of the AT1-P gene was associated with a higher probability of future occurrence of CHF in patients with EH, more significant structural disorders of myocardium and disturbances of systolic and diastolic functions of left ventricle (LV) such as pseudonormal and restrictive types. Conclusions. Allele C associates with the presence of EH and a greater probability of occurrence of CHF in postmenopausal women, residents of Podillya Region, more pronounced disturbances in the structure of myocardium, with diastolic and systolic dysfunctions of LV. Developed mathematical models help to determine approximately the structure of AT1-R according to the parameters of cardiac hemodynamics in the case of impossibility of laboratory investigation.	[Sakovych, O. O.; Zhebel, V. M.; Polishchuk, T. V.; Franchuk, S. V.; Sursaieva, L. M.] Natl Pirogov Mem Med Univ, Fac Med 2, Dept Internal Med, Vinnytsa, Ukraine	Sakovych, OO (reprint author), Natl Pirogov Mem Med Univ, Fac Med 2, Dept Internal Med, Vinnytsa, Ukraine.	elena.sakovich0804@gmail.com	С, Елена/Q-8083-2017; Polishchuk, Tetiana/F-2479-2019	С, Елена/0000-0003-0284-5069; 			Dzyak G. V., 2008, UKRAINSKYI KARDIOLOH, V4, P34; Imaizumi T, 2017, CLIN EXP NEPHROL, V21, P457, DOI 10.1007/s10157-016-1315-3; Kajdashev I. P., 2005, CITOLOGIYA GENETIKA, V5, P51; Kornatskyi V. M, 2014, KHVOROBY SYSTEMY KRO; Mancia G, 2013, J HYPERTENS, V31, P1281, DOI [10.1097/01.hjh.0000431740.32696.cc, 10.1093/eurheartj/eht151]; Mishra Avshesh, 2015, Indian Heart J, V67, P214, DOI 10.1016/j.ihj.2015.04.013; Nagueh SF, 2016, J AM SOC ECHOCARDIOG, V29, P277, DOI 10.1016/j.echo.2016.01.011; Padmanabhan S, 2017, PHARMACOL RES, V121, P219, DOI 10.1016/j.phrs.2017.04.031; Pashkov I. P., 2016, VISNYK VINNYTSKOHO N, V20, P165; Saidov M. Z., 2017, ROSSIJSKIJ KARDIOLOG, V22, P76, DOI [10.15829/1560-4071-2017-10-76-84, DOI 10.15829/1560-4071-2017-10-76-84]; Sakovych O. O., 2011, ZAPOROZHYE MED J, V13, P44; Shalimova A. S., 2015, KARDIOLOGIYA OT NAUK, V3, P22; Sydorchuk LP, 2011, NEW ARMEN MED J, V5, P35; Tong JW, 2017, J OCCUP ENVIRON MED, V59, P412, DOI 10.1097/JOM.0000000000000970; Tseluyko V. J., 2013, UKRAINSKYI KARDIOLOH, V4, P21; Tykhonova S. A., 2008, UKRAINSKYI TERAPEVTY, V3, P61; Voronkov L. H., 2017, SERTSEVA NEDOSTATNIS, V1, P6; Warren HR, 2017, NAT GENET, V49, P1558, DOI [10.1038/ng.3768, 10.1038/ng1017-1558a]; Zeller T, 2012, CLIN CHEM, V58, P92, DOI 10.1373/clinchem.2011.170431; Zhebel V. M., 2009, ARTERIALNAYA GIPERTE, V1, P24; [Зотова Татьяна Юрьевна Zotova T.Yu.], 2017, [Клиническая медицина, Klinicheskaya meditsina], V95, P404, DOI 10.18821/0023-2149-2017-95-5-404-407	21	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	MAY-AUG	2018		2					169	175		10.14739/2310-1237.2018.2.141398			7	Pathology	Pathology	GU7BJ	WOS:000445473200007		DOAJ Gold			2019-10-28	
J	Hancheva, OV; Tishchenko, SV; Ivanenko, TV				Hancheva, O. V.; Tishchenko, S. V.; Ivanenko, T. V.			Quantitative characteristics of the neurotensin content in the hypothalamic arcuate nucleus in arterial hypertension of different etiologies	PATHOLOGIA			English	Article						hypothalamus; arcuate nucleus; neurotensin; hypertension; rats	SYSTEM; RATS; BRAIN	The aim of this work is to determine the features of the neurotensin content in the hypothalamic ARC in Wistar rat and SHR strains in arterial hypertension of different etiology: endocrine-salt and essential. Materials and methods. The study was performed on 24 adult male rats at the age of 13-14 months, weight of 250-270 g, which were divided into three experimental groups of 8 animals each. The 1st group (control) - Wistar rats with normal BP indices (Psys / Pdias = 110/75 +/- 5 mm Hg), the 2nd - Wistar rats with endocrine-salt model of hypertension (Psys/Pdias = 145/110 +/- 10 mm Hg); the 3rd - SHR with spontaneous arterial hypertension (Psys/Pdias = 150/110 +/- 10 mm Hg). An immunohistochemical method was used to study the content of neurotensin in the arcuate nucleus, analyzed by digital processing with Image J and EXCEL-7.0. Results. Persistent increase in BP is accompanied by an increase in the content and concentration of neurotensin in the hypothalamic ARC, does not depend on the etiology of hypertension and has a compensatory character. In SHR with essential hypertension there is a higher expression of neurotensin in the hypothalamic ARC in comparison with the endocrine-salt model of hypertension, but the number of neurons involved in the synthesis and accumulation of the neurohormone is significantly lower, which characterizes the morphological features of cellular populations in the hypothalamus of the animals of this strain and can play a role in the development and progression of hypertension.	[Hancheva, O. V.; Tishchenko, S. V.; Ivanenko, T. V.] Zaporizhzhia State Med Univ, Dept Pathol Physiol, Zaporizhia, Ukraine	Hancheva, OV (reprint author), Zaporizhzhia State Med Univ, Dept Pathol Physiol, Zaporizhia, Ukraine.	gancheva@zsmu.pp.ua	Hancheva, Olha/X-9959-2019				CHRONWALL BM, 1985, PEPTIDES, V6, P1, DOI 10.1016/0196-9781(85)90128-7; Garlow SJ, 2006, NEUROPSYCHOPHARMACOL, V31, P535, DOI 10.1038/sj.npp.1300870; Gerasimova A. S., 2008, MED NAUKI OBZORY LIT, V3; Kawabe T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045180; Littlejohn NK, 2013, AM J PHYSIOL-REG I, V304, pR818, DOI 10.1152/ajpregu.00082.2013; MERCHENTHALER I, 1991, ENDOCRINOLOGY, V129, P2875, DOI 10.1210/endo-129-6-2875; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; NELSON DO, 1981, BRAIN RES, V226, P119, DOI 10.1016/0006-8993(81)91087-8; NEMEROFF CB, 1980, TRENDS NEUROSCI, V3, P212, DOI 10.1016/0166-2236(80)90080-6; Osadchuk M. A., 2011, ROSSIJSKIJ ZH GASTRO, V21, P30; QUIRION R, 1980, LIFE SCI, V27, P1889, DOI 10.1016/0024-3205(80)90435-X; SUMNERS C, 1982, HYPERTENSION, V4, P888, DOI 10.1161/01.HYP.4.6.888	12	0	0	2	2	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	MAY-AUG	2018		2					176	179		10.14739/2310-1237.2018.2.141399			4	Pathology	Pathology	GU7BJ	WOS:000445473200008		DOAJ Gold			2019-10-28	
J	Mykhaliuk, YL; Hunina, LM				Mykhaliuk, Ye. L.; Hunina, L. M.			The state of bioelectric activity of myocardium in handball players	PATHOLOGIA			Russian	Article						athletes; electrocardiography; syndrome of early repolarization ventricles; bundle branch block	ELECTROCARDIOGRAM; REPOLARIZATION; HEART	The aim of the work was to study the parameters of the electrocardiogram electrocardiogram in highly skilled handball players and compare the data obtained among athletes with different qualifications. Materials and methods. A comparison of electrocardiographic indicators of 49 handball players of the level of master of sports-master of sports of international class (MS-MSIC) and 22 - qualification of candidate for master of sports-1 category (CMS-1category). Results. It has been established that in handball players of the MS-MSIC level with a significantly longer training experience, a sinus bradycardia occurs more often - 69.4 % vs. 38.1 % (P = 0.003), there is more than twice less the heart rate within the range of 61-67 beats/ min - 30,6 % vs. 63,7 % (P = 0,009) in comparison with the athletes of qualification C.S-1 category. They are also more often manifesting the phenomenon of the SEVR - 71.4 % vs. 18.2 % (P < 0.00001) and there are significantly more individuals with ECG changes (P = 0.023). Conclusions. Elite handball players were older, had more experience of handball, body weight, persons with sinus bradycardia, changes in ECG and athletes with the SEVR.	[Mykhaliuk, Ye. L.] Zaporizhzhia State Med Univ, Dept Phys Rehabil Sports Med Phys Educ & Hlth, Zaporizhia, Ukraine; [Hunina, L. M.] AS Makarenko Sumy State Pedag Univ, Dept Human & Anim Biol, Sumy, Ukraine; [Hunina, L. M.] Natl Antidoping Ctr Ukraine, Sumy, Ukraine	Mykhaliuk, YL (reprint author), Zaporizhzhia State Med Univ, Dept Phys Rehabil Sports Med Phys Educ & Hlth, Zaporizhia, Ukraine.	evg.mikhalyuk@gmail.com					Buchina E. V., 2012, VESTNIK SPORTIVNOJ N, V5, P19; Chichkov M. Y., 2016, SOVREMENNYE PROBLEMY, V5, P89; Chichkova M.A., 2017, UCHENYE ZAPISKI U IM, V7, P203; Corrado D, 2010, EUR HEART J, V31, P243, DOI 10.1093/eurheartj/ehp473; Crouse SF, 2009, CLIN CARDIOL, V32, P37, DOI 10.1002/clc.20452; Filyavich A. E., 1982, ELEKTROKARDIOGRAFICH; Gorokhov S. S., 2013, VOENNAYA MED, V4, P117; Haissaguerre M, 2008, NEW ENGL J MED, V358, P2016, DOI 10.1056/NEJMoa071968; Ivanova N. V., 2018, AKTUALNYE PROBLEMY B, P239; Kottsova O. N., 2017, POTENCIAL SOVREMENNO, V2, P43; Kottsova O. N., 2017, KLIN ELEKTROKARDIOLO, P48; Lellouche N, 2011, J CARDIOVASC ELECTR, V22, P131, DOI 10.1111/j.1540-8167.2010.01871.x; Makarov L. M., 2015, PRIKLADNAYA SPORTIVN, V2, P108; Maron BJ, 2009, CIRCULATION, V119, P1085, DOI 10.1161/CIRCULATIONAHA.108.804617; Mikhalyuk E. L., 2017, PRIKLADNAYA SPORTIVN, V1, P69; Mikhalyuk E. L., 2014, MED OBESPECHENIE SPO, P126; Mikhalyuk E. L., 2012, AKTUALNI PROBLEMY FI, P186; Mikhalyuk E. L., 2017, NAUKOVO PEDAHOHICH K, V3, P296; Mkrtychan L. A., 2017, SPORTMED 2017 P 12 I, P104; PARK RC, 1985, CURR PROB CARDIOLOGY, V10, P1; Pelliccia A, 2000, CIRCULATION, V102, P278; Rautaharju PM, 2009, J AM COLL CARDIOL, V53, P982, DOI 10.1016/j.jacc.2008.12.014; Svetlichkina A. A., 2016, UCHENYE ZAPISKI U IM, V3, P214, DOI [10.5930/issn.1994-4683.2016.03.133.p214-217, DOI 10.5930/ISSN.1994-4683.2016.03.133.P214-217]; Swiatowiec A, 2009, KARDIOL POL, V67, P1095; Tuyev A.V., 2003, ROSSIJSKIJ KARDIOLOG, V8, P11; Yagoda A. V., 2003, VESTNIK ARITMOLOGII, V32, P75; Zemcovskij E'. V., 1995, SPORTIVNAYA KARDIOLO	27	1	1	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	MAY-AUG	2018		2					180	186		10.14739/2310-1237.2018.2.141346			7	Pathology	Pathology	GU7BJ	WOS:000445473200009		DOAJ Gold			2019-10-28	
J	Liubomyrska, KS; Kamyshnyi, OM; Krut, YY				Liubomyrska, K. S.; Kamyshnyi, O. M.; Krut, Yu. Ya.			Association between single nucleotide polymorphism of immunoregulatory genes and preterm premature rupture of membranes in preterm labour	PATHOLOGIA			English	Article						preterm labour; preterm premature rupture of membranes; single nucleotide polymorphism	BIRTH	Aim. Investigation of the association between SNP genes of IL4 (rs2243250), IL10 (rs1800896 and rs1800872) and RLN2 (rs4742076 and rs3758239) and preterm premature rupture of membranes in 26-34 weeks of gestation in Zaporizhzhia population. Materials and methods. We have investigated markers of cytokines genes in 50 women with PPROM in 26-34 weeks of gestation period and 50 pregnant women with physiological pregnancy and term labour without complications. The genotyping using TaqMan tests was done on amplifier CFX96 T Real-Time PCR Detection Systems (Bio-Rad Laboratories, Inc., USA. The combined effect of the studied locus of the analyzed genes on the appearance of PPROM, PTL in the population was initiated using the Multifactory Dimensionality Reduction (MDR) method (software MDR ver. 3.0.2). Results. The distribution of the rs2243250 gene polymorphism alleles of the IL4 gene of the main study group - TT homozygotes were determined in 4 % cases, CT heterozygotes were found in 22 %, CC homozygotes - in 74 % cases. We have got statistically significant differences of rs4742076 polymorphisms (TT, CT, and CC) of the RLN2 gene in the study groups. We also detected statistically significant differences in all the alleles of rs3758239 polymorphism (AA, GG and AG) of the gene RLN2 - chi(2) = 23.86, OR(AA) = 12.57; 95 % CI: 3.68-42.98; OR(GG)= 0.08; 95 % CI: 0.02-0.27; and OR(AG)= 0.11; 95 % CI: 0.03-0.42, respectively, P < 0.05, indicating the reliability of the received prognostic markers. The nature of interlocal interaction between the genes is at the level of "independent effects" of influence (IL4-IL10 rs1800896 = -23.08 %, IL10 rs1800896 -IL10 rs1800872 = -19.94 %, IL10 rs1800872-IL-4 = -19.34 %). The percentage of entropy of the investigated polymorphism of each gene for the case-control status was 14.15 % for the IL4 gene, 23.08 % for the IL10 rs1800896 gene and 9.34 % for the IL10 rs1800872 gene. Conclusions. Combination of IL4 rs2243250, IL10 rs1800896 and rs1800872 supports the role for functional polymorphisms in immunoregulatory genes in the development of PPROM and PTL. Reliable clinical association of rs4742076 and rs3758239 gene RLN2 was established with the PPROM in 26-34 weeks' gestation in Zaporizhzhia population.	[Liubomyrska, K. S.; Krut, Yu. Ya.] Zaporizhzhia State Med Univ, Dept Obstet & Gynecol, Zaporizhia, Ukraine; [Kamyshnyi, O. M.] Zaporizhzhia State Med Univ, Dept Microbiol Virol & Immunol, Zaporizhia, Ukraine; [Kamyshnyi, O. M.] Zaporizhzhia State Med Univ, Med & Lab Ctr, Mol Genet Res Div, Zaporizhia, Ukraine	Liubomyrska, KS (reprint author), Zaporizhzhia State Med Univ, Dept Obstet & Gynecol, Zaporizhia, Ukraine.	lubomirskaae@gmail.com					Bukowski R, 2017, PEERJ, V5, DOI 10.7717/peerj.3685; Ramos BRD, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0823-1; Heinzmann A, 2009, NEONATOLOGY, V96, P175, DOI 10.1159/000210091; Musilova I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133929; *NAT CTR BIOT INF, DBSNP DAT; Rocha FG, 2013, AM J OBSTET GYNECOL, V209, DOI 10.1016/j.ajog.2013.05.020; Salem H, 2018, GENE, V649, P58, DOI 10.1016/j.gene.2018.01.097; Sheikh IA, 2015, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3089-0; Stonek F, 2008, ACTA OBSTET GYN SCAN, V87, P430, DOI 10.1080/00016340801995657; Tchirikov M, 2018, J PERINAT MED, V46, P465, DOI 10.1515/jpm-2017-0027; Vogel I, 2009, IN VIVO, V23, P1005; Wang YY, 2018, MOL MED REP, V18, P113, DOI 10.3892/mmr.2018.8967; Zare-Bidaki Majid, 2017, J Reprod Infertil, V18, P218	13	0	0	0	1	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	MAY-AUG	2018		2					187	193		10.14739/2310-1237.2018.2.141400			7	Pathology	Pathology	GU7BJ	WOS:000445473200010		DOAJ Gold			2019-10-28	
J	Loskutova, TO				Loskutova, T. O.			New approaches to the prognosis of pre-eclampsia in pregnant woman	PATHOLOGIA			Russian	Article						pregnancy; pre-eclampsia; genetic polymorphism; antibodies; prognosis		Objective - development and evaluation of the effectiveness of the method for predicting pre-eclamapsia in pregnant women by testing thrombophilia genes, measuring the levels of antibodies to beta 2 glycoprotein-1, D-dimer and coefficient of atherogenicity. Materials and methods. This retrospective, case - control study was conducted on 156 patients who were in third trimester of pregnancy: 112 with PE and 44 healthy normotensive pregnant women. A combined approach to the prognosis of preeclampsia which is based on the level of D-dimer (immunoturbodimetric analysis), the value of the atherogenicity coefficient, the number of antibodies to beta 2 glycoprotein-1 (ELISA-analysis), the presence of polymorphism 455 G -> A in the gene of fibrinogen beta and 675 4G/5G in the gene of the plasminogen activator inhibitor type 1 (PCR) was proposed. Results. It was established that the sensitivity of the proposed prognostic model was 82.5 % (95 % CI 74.2-88.9 %), specificity 90.9 % (95 % CI 78.3-97.5 %). The model takes into account the role in pre-eclampsia development not only of each individual factor, but also of their combination. Approbation of the prognostic model in the group of pregnant women in the first trimester of pregnancy showed its high efficacy: the incidence of PE in the group with a predicted low risk of developing PE was 2.5 % versus 57.1 % in the group with a predictable high risk (P < 0.05). Conclusions. The proposed model has good prognostic features, which allow assessing the risk of pre-eclampsia development in pregnant women with high probability beginning from first trimester of pregnancy.	[Loskutova, T. O.] Minist Hlth Ukraine, State Inst Dnipropetrovsk Med Acad, Dept Obstet & Gynecol, Dnipro, Ukraine	Loskutova, TO (reprint author), Minist Hlth Ukraine, State Inst Dnipropetrovsk Med Acad, Dept Obstet & Gynecol, Dnipro, Ukraine.	Loskutovata@gmail.com	Loskutova, Tetiana/F-3002-2017	Loskutova, Tetiana/0000-0002-9844-5520			Brusch A, 2016, ANTIBODIES, V5, DOI 10.3390/antib5020016; Dawood F., 2013, J BLOOD DISORDERS TR, V4, P164, DOI 10.4172/2155-9864.1000164; Gathiram P, 2016, CARDIOVASC J AFR, V27, P71, DOI 10.5830/CVJA-2016-009; Morgan JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056907; Simcox LE, 2015, INT J MOL SCI, V16, P28418, DOI 10.3390/ijms161226104; Singh M, 2015, J CLIN DIAGN RES, V9, DOI 10.7860/JCDR/2015/13505.6241; Sonek J, 2018, AM J OBSTET GYNECOL, V218, DOI 10.1016/j.ajog.2017.10.024	7	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	MAY-AUG	2018		2					194	198		10.14739/2310-1237.2018.2.141336			5	Pathology	Pathology	GU7BJ	WOS:000445473200011		DOAJ Gold			2019-10-28	
J	Holotiuk, VV; Kryzhanivska, AY; Sadovyi, IY; Tataryn, BB				Holotiuk, V. V.; Kryzhanivska, A. Ye.; Sadovyi, I. Ya.; Tataryn, B. B.			Predictive value and changes of inducible nitric oxide synthase expression in patients with rectal cancer under the influence of antitumor therapy	PATHOLOGIA			English	Article						inducible nitric oxide synthase; rectal cancer; pathology; chemotherapy; radiotherapy; L-arginine; tegafur		The aim of investigation - to establish the features of iNOS expression in the rectum wall under the influence of various neoadjuvant therapy options in patients with rectal cancer (RC) and to find out its predictive significance. Materials and methods. In 88 patients with stage II-III rectal adenocarcinoma we established iNOS expression in the tumor before and after neoadjuvant radiotherapy (NRT), therapeutic pathomorphosis grade and density of immune cell infiltrates. Patients were divided into 3 groups: 1 - patients after the course of NRT on the tumor site; 2 - patients who underwent chemoradiomodification of the NRT with drug tegafur; 3 - patients who underwent chemoradiomodification of the NRT with tegafur and L-arginine. Results. In the tumors of rectal cancer the level of iNOS expression by 4.5 times exceeded that in the intact rectum wall (P < 0.001), correlated with metastatic lesion of the regional lymph nodes (r = 0.55; P = 0.026) and depended on the type of growth of RC. The level of iNOS expression in the tumor prior to treatment in Group 3 patients, in which the high efficacy of NRT was reported, was 54.61 +/- 3.55 versus 35.10 +/- 2.28 CU in the rest of the patients (P = 0.01). After NRT, most Groups 1-2 patients reduced the iNOS expression in the RC tissue - on the average to 37.30 +/- 4.13 CU, more in the residual parenchyma as compared to the tumor stroma, while Group 1 patients showed the lowest total immunosensitivity intensity of iNOS -24.34 +/- 3.10 CU, and Group 3 patients - the highest -45.35 +/- 5.84 CU. Conclusions. After the use of NRT, iNOS expression in the residual parenchyma of the RC decreased, but in the stroma the marker expression remained unchanged or there was an increase in the marker expression, which was most inherent to therapeutic pathomorphosis grades III-IV. iNOS expression in the RC stroma was highest in patients after NRT with radiomodification using tegafur and L-arginine and positively correlated with the density of immune cell infiltrates in the tumor. Evaluation of the preoperative level of iNOS in patients with RC can serve as a predictive test of advisability of NRT used on the background of radiomodification with L-arginine.	[Holotiuk, V. V.; Kryzhanivska, A. Ye.; Sadovyi, I. Ya.; Tataryn, B. B.] SHEI Ivano Frankivsk Natl Med Univ, Ivano Frankivsk, Ukraine	Holotiuk, VV (reprint author), SHEI Ivano Frankivsk Natl Med Univ, Ivano Frankivsk, Ukraine.	golotiuk1@ukr.net					Blaise GA, 2005, TOXICOLOGY, V208, P177, DOI 10.1016/j.tox.2004.11.032; Bonavida B., 2015, NITRIC OXIDE CANC PA, DOI [10.1007/978-3-319-13611-0, DOI 10.1007/978-3-319-13611-0]; Choudhari SK, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-118; Gochman E, 2012, ACTA HISTOCHEM, V114, P827, DOI 10.1016/j.acthis.2012.02.004; Grimm EA, 2013, CLIN CANCER RES, V19, P5557, DOI 10.1158/1078-0432.CCR-12-1554; Huerta S, 2008, INT J ONCOL, V33, P909, DOI 10.3892/ijo_00000079; Rahat MA, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00144; Stuehr DJ, 2004, J NUTR, V134, p2748S, DOI 10.1093/jn/134.10.2748S; Wink DA, 2011, J LEUKOCYTE BIOL, V89, P873, DOI 10.1189/jlb.1010550; Zafirellis K, 2010, APMIS, V118, P115, DOI 10.1111/j.1600-0463.2009.02569.x	10	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	MAY-AUG	2018		2					199	203		10.14739/2310-1237.2018.2.141349			5	Pathology	Pathology	GU7BJ	WOS:000445473200012		DOAJ Gold			2019-10-28	
J	Herasymova, OV; Protsiuk, TL; Protsiuk, LO; Surkova, NM; Kotsur, LD; Kuleshov, OV				Herasymova, O. V.; Protsiuk, T. L.; Protsiuk, L. O.; Surkova, N. M.; Kotsur, L. D.; Kuleshov, O. V.			The influence of bronchial asthma control level on the quality of life indices	PATHOLOGIA			English	Article						bronchial asthma; quality of life; children	IMPACT	Objective - to study the indices of general and specific quality of life in schoolchildren, depending on the level of bronchial asthma control. Materials and methods. Quality of life parameters of 189 in-patients with BA, aged 6-17 years and 95 controls were studied. Parallel questioning with subsequent analysis of quality of life indices in 189 parents of BA children and 95 parents of the control group children was performed. General QL was evaluated using PedsQL (Pediatric Quality of Life Inventory 4.0). Specific quality of life was evaluated using specific quality of life questionnaire for the children ill with bronchial asthma - PAQLQ (Pediatric Asthma Quality of Life Questionnaire). Statistical analysis of the data obtained was done by variance statistical methods using the standard program package of multivariate statistical analysis Statistica 6.0 Results. The study found the index of physical functioning to be 43.6 [31.3-62.5] points in the children with UC BA, 53.1 [37.5-68.2] points in those with PC BA, being significantly lower as compared to the control group children -79.6 [56.0-100.0] points (P < 0.001). Physical functioning index in the children with UC BA was 1.7 times lower as compared to those with C BA. Comparison of the indices in those with PC BA -53,1 [37.5-68.2] points and C BA -74.1 [50.0-76.0] points, showed that physical activity in the children with PC BA was significantly lower as compared to those with C BA (P < 0.001). The analysis showed no significant difference between the answers of the children with asthma and their parents. No significant difference between the answers of healthy children's parents and the children themselves was revealed as well (P > 0.05). The cumulative index of QL was dependent on the level of BA control. It was 2.5 [1.4-3.6] points in the children with UC BA, being significantly lower as compared to those with PC BA -3.9 [2.8-4.9] points, and C BA -6.2 [5.6-6.8] points (P < 0.001); and in the children with PC BA this index was significantly lower as compared to those with C BA (P < 0.01). Conclusions. Along with traditional methods of assessment of respiratory function and laboratory indices of inflammatory process activity in bronchial asthma, study of physical and mental health, social activity, general wellbeing and many other parameters of quality of life, as well as the influence of treatment on these parameters should be carried out.	[Herasymova, O. V.; Protsiuk, T. L.] Natl Pirogov Mem Med Univ, Dept Pediat 1, Vinnytsia, Ukraine; [Protsiuk, L. O.] Natl Pirogov Mem Med Univ, Dept Hyg & Ecol, Vinnytsia, Ukraine; [Kotsur, L. D.; Kuleshov, O. V.] Natl Pirogov Mem Med Univ, Dept Propedeut Pediat Dis Patient Care, Vinnytsia, Ukraine; [Surkova, N. M.] Vinnytsia Reg Childrens Clin Hosp, Vinnytsia, Ukraine	Herasymova, OV (reprint author), Natl Pirogov Mem Med Univ, Dept Pediat 1, Vinnytsia, Ukraine.	rossata@ukr.net					Al-Gewely MS, 2013, EGYPT J PEDIATR ALLE, V11, P83; Cerovic S, 2009, J ASTHMA, V46, P936, DOI 10.3109/02770900903265812; Chroma Jana, 2011, Cas Lek Cesk, V150, P660; Dean BB, 2009, J ASTHMA, V46, P861, DOI 10.3109/02770900903184237; Elshazly H. M., 2015, MENOUFIA MED J, V28, P442; Gopal S., 2016, IJHSR, V6, P293; Heethal J. P., 2014, British Journal of Medicine and Medical Research, V4, P1187; Juniper EF, 1996, QUAL LIFE RES, V5, P27, DOI 10.1007/BF00435966; Klymenko V.A, 2014, ASTMA TA ALERHIA, V3, P27; Luskin AT, 2014, J ALLER CL IMM-PRACT, V2, P544, DOI 10.1016/j.jaip.2014.02.011; Matsunaga NY, 2015, J BRAS PNEUMOL, V41, P502, DOI 10.1590/S1806-37562015000000186; Nair S., 2014, INDIAN J ALLERGY AST, V28, P13; Protsiuk T. L., 2013, CURRENT ISSUES PHARM, V3, P66; Trzcieniecka-Green A., 2015, INT J CHILD ADOLESCE, V8, P351; Varni JW, 2003, AMBUL PEDIATR, V3, P329, DOI 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2; Wander A., 2017, J PEDIATRRES, V4, P382; Zandieh Fariborz, 2006, Iran J Allergy Asthma Immunol, V5, P79	17	0	0	1	1	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	MAY-AUG	2018		2					204	209		10.14739/2310-1237.2018.2.141394			6	Pathology	Pathology	GU7BJ	WOS:000445473200013		DOAJ Gold			2019-10-28	
J	Zubchenko, SO; Maruniak, SR				Zubchenko, S. O.; Maruniak, S. R.			Evaluation of quality of life of patients with pollen allergy before and after sublingual immunotherapy course	PATHOLOGIA			English	Article						pollen allergy; allergic rhinitis; quality of life; sublingual allergy immunotherapy	MUGWORT	In Ukraine, there are over 1.5 thousand types of weeds, which may provoke the development of allergic reactions. Based on our observation, most commonly sensitization to Artemisia and less often to Ambrosia is recorded in patients of Lviv region. The presence of clinical symptoms significantly deteriorates life quality of patients with pollen allergy and requires conduction of proper allergy immunotherapy. Aim. To analyze QOL of patients with allergy to weed pollen before and after conduction of sublingual immunotherapy based on a specialized questionnaire MiniRQLQ. Materials and methods. Totally, 485 individuals, 24.0 +/- 4.5 years old were examined. Clinical diagnosis of AR was made according to ARIA criteria (2014). SPT to standard inhaled allergens (Diater-Laboratories, Spain), total serum and specific immunoglobulins IgE, IFA, type-specific components of allergens, immunofluorescent method immunoCAP ("Phadia AB", Sweden) were determined. Analysis of life quality was performed based on questionnaire MiniMRQLQ. Results. Among patients of Lviv region with pollen allergy, the most commonly detected positive SPT were to Artemisia - in 62.3 %, less to Ambrosia -13.9 % of individuals, combined sensitization -23.8 % of patients. Among them, genuine allergy to Artemisia was confirmed in 88.1 %, to Ambrosia -88.2 % of individuals, co-sensitization - in 21 patients. According to the results of molecular investigations, SLIT was performed for 69.6 % of patients (the 1st group), 30.4 % of individuals were treated symptomatically (the 2nd group). Based on questionnaire MiniRQLQ, it was revealed that QOL indices in patients with pollen allergy, who underwent SLIT, were reliably lower after the first and the second years of treatment compared to the indices before SLIT. Reliable changes were not detected in patients of the second group. Conclusions. Improvement of QOL indices after a course of SLIT indicated the high efficacy of this treatment method in patients with pollen allergy.	[Zubchenko, S. O.] Danylo Halytsky Lviv Natl Med Univ, Dept Clin Immunol & Allergol, Lvov, Ukraine; [Maruniak, S. R.] Shupyk Natl Med Acad Postgrad Educ, Anesthesiol & Intens Care, Kiev, Ukraine	Zubchenko, SO (reprint author), Danylo Halytsky Lviv Natl Med Univ, Dept Clin Immunol & Allergol, Lvov, Ukraine.	svitlana_zu@meta.ua	Maruniak, Stepan/S-6088-2019	Maruniak, Stepan/0000-0001-7538-2443			Bousquet J, 2012, ALLERGY, V67, P18, DOI 10.1111/j.1398-9995.2011.02728.x; do Amaral CSF, 2012, AN BRAS DERMATOL, V87, P717, DOI 10.1590/S0365-05962012000500008; Leonard R, 2010, J BIOL CHEM, V285, P27192, DOI 10.1074/jbc.M110.127118; Moverare R, 2011, INT ARCH ALLERGY IMM, V154, P164, DOI 10.1159/000320231; Niederberger V, 2009, IMMUNOL LETT, V122, P131, DOI 10.1016/j.imlet.2008.11.012; Pherwani A, 2008, INDIAN J OTOLARYNGOL, V60, P20, DOI 10.1007/s12070-008-0008-y	6	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	MAY-AUG	2018		2					210	214		10.14739/2310-1237.2018.2.141395			5	Pathology	Pathology	GU7BJ	WOS:000445473200014		DOAJ Gold			2019-10-28	
J	Riabokon, OV; Khelemendyk, AB; Riabokon, YY				Riabokon, O. V.; Khelemendyk, A. B.; Riabokon, Yu. Yu.			Monitoring of patients with chronic hepatitis B without liver cirrhosis while determining the tactics of treatment	PATHOLOGIA			English	Article						chronic hepatitis B; antiviral agents	HEPATOCELLULAR-CARCINOMA; VIRUS INFECTION; RISK; GUIDELINES; MANAGEMENT; GENOTYPES; THERAPY; LEVEL	Aim. The purpose of the work is to reveal the features of CHB without liver cirrhosis when assessing the need for the appointment of antiviral therapy for the implementation of the State Target Program; to compare the criteria for monitoring CHB patients without cirrhosis in existing international recommendations. Material and methods. When assessing the features of the course of CHB in 286 patients without cirrhosis, the recommendations of NICE (2013) and WHO (2015) were taken into account to determine the need for antiviral treatment, which is the basis of the clinical protocol in Ukraine. The work analyzes the international guidelines for monitoring CHB patients without cirrhosis: the American Association for the Study of the Liver Diseases (2016), the European Association for the Study of the Liver (2012), the National institute for Health and Care Excellence (2013), World Health Organization (2015). Results. In the work, we analyzed the features of the course of CHB without cirrhosis using criteria for the distribution of patients depending on the indications for antiviral treatment, which are set out in the clinical protocol in Ukraine and are based on the international recommendations of NICE (2013) and WHO (2015). It is shown that 8.0 % (23 of 286) of patients require priority antiviral treatment according to laboratory criteria. The course of CHB in these patients is characterized by more frequent astheno-vegetative manifestations, more pronounced cytolytic syndrome and more frequent detection of HBeAg. Among 38.1 % (109 of 286) patients with CHB without cirrhosis with a low viral load < 2000 IU / ml, which is not recommended for antiviral drugs, one third has cytolytic syndrome (34.3 %), one tenth is HBeAg-positive (10.5 %), and one fourth has liver fibrosis of F 2-3 stages (27.3 %), which requires an improvement in the monitoring of these patients. The analysis of international recommendations showed complex and different approaches to monitoring CHB patients without cirrhosis of the liver when deciding on the appointment of antiviral treatment. The AASLD recommendations (2016) differ from the others in the mandatory determination of the patient's HBeAg status and the clearly established norm of ALT. The EASL (2012) recommendations do not require mandatory determination of HBeAg status, with the main criterion being the amount of HBV-DNA in the blood. NICE recommendations (2013) determine the mandatory identification of a combination of factors in addressing this issue, taking into account the patient's age, viral load, the severity of the cytolytic syndrome. WHO recommendations (2015) are the most adapted for countries with limited resources. Conclusion. When using the recommendations of NICE 2013 and WHO 2015 among 38.1 % of CHB patients without cirrhosis with a low viral load < 2000 IU/ml, which is not recommended for antiviral therapy, 34.3 % have cytolytic syndrome, 10.5 % are HBeAg-positive, and 27.3 % have liver fibrosis F 2-3 stages, which makes it necessary to improve monitoring of these patients. Monitoring CHB patients without cirrhosis in determining the need for antiviral treatment in the world remains a complex issue and has no unambiguous approaches to the solution, as evidenced by the existence of several international clinical recommendations: AASLD 2016, EASL 2012, NICE 2013, WHO 2015.	[Riabokon, O. V.; Khelemendyk, A. B.] Zaporizhzhia State Med Univ, Dept Infect Dis, Zaporizhia, Ukraine; [Riabokon, Yu. Yu.] Zaporizhzhia State Med Univ, Dept Children Infect Dis, Zaporizhia, Ukraine	Riabokon, OV (reprint author), Zaporizhzhia State Med Univ, Dept Infect Dis, Zaporizhia, Ukraine.	RyabokonZSMU@gmail.com	Khelemendyk, Anastasiia/Z-3470-2019; Riabokon, Yurii/Z-3191-2019	Khelemendyk, Anastasiia/0000-0003-4724-6465; Riabokon, Yurii/0000-0002-2273-8511			[Anonymous], 2013, HEPATITIS B CHRONIC; Chen CJ, 2006, JAMA-J AM MED ASSOC, V295, P65, DOI 10.1001/jama.295.1.65; Cornberg M, 2011, Z GASTROENTEROL, V49, P871, DOI 10.1055/s-0031-1273462; Golubovska O., 2017, KLIN INFEKTOLOGIYA P, V6, P270; Hadziyannis SJ, 2001, HEPATOLOGY, V34, P617, DOI 10.1053/jhep.2001.27834; Iloeje UH, 2006, GASTROENTEROLOGY, V130, P678, DOI 10.1053/j.gastro.2005.11.016; Kao JH, 2003, INTERVIROLOGY, V46, P400, DOI 10.1159/000074999; Keeffe EB, 2008, CLIN GASTROENTEROL H, V6, P1315, DOI 10.1016/j.cgh.2008.08.021; Kravchenko V. V., 2016, UNIFIKOVANYI KLIN PR; Lobzin Yu. V., 2012, VIRUSNYE GEPATITY; McMahon BJ, 2001, ANN INTERN MED, V135, P759, DOI 10.7326/0003-4819-135-9-200111060-00006; Papatheodoridis G, 2012, J HEPATOL, V57, P167, DOI 10.1016/j.jhep.2012.02.010; Schaefer S, 2007, WORLD J GASTROENTERO, V13, P14, DOI 10.3748/wjg.v13.i1.14; Schiff ER, 2011, CLIN GASTROENTEROL H, V9, P274, DOI 10.1016/j.cgh.2010.11.040; Terrault NA, 2016, HEPATOLOGY, V63, P261, DOI 10.1002/hep.28156; Varbobitis I, 2016, CLIN MOL HEPATOL, V22, P319, DOI 10.3350/cmh.2016.0045; Zhang Yao, 2013, Chin Med Sci J, V27, P243	17	0	0	0	1	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	MAY-AUG	2018		2					215	220		10.14739/2310-1237.2018.2.141428			6	Pathology	Pathology	GU7BJ	WOS:000445473200015		DOAJ Gold			2019-10-28	
J	Shyshkin, MA; Tumanskyi, VO				Shyshkin, M. A.; Tumanskyi, V. O.			Features of CDH1, CTNNB1 genes transcriptional activity and expression levels of E-cadherin, beta-catenin proteins coded by these genes on the I, II, III, IV stages of colorectal adenocarcinoma development	PATHOLOGIA			Russian	Article						colorectal cancer; CTNNB1 human protein; CDH1 human protein; beta catenin; E-cadherin	CANCER CELLS; METASTASIS; PROMOTES; GENETICS; PATHWAY; GROWTH	Aim - analysis of CDH1 and CTNNB1 genes mRNA expression levels and expression levels of E-cadherin, beta-catenin proteins coded by these genes, and also their correlations with KRAS gene transcriptional activity level on the I, II, III, IV stages (pTNM) of colorectal adenocarcinoma (CRA) development. Materials and methods. Parallel immunohistochemical and molecular-genetic, pathohistological studies of operational material of CRA from 40 patients (4 study groups - I, II, III, IV stages according to pTNM classification - 10 cases in each group) with diagnosis of colorectal adenocarcinoma, and sectional material of 10 fragments of distal colonic wall with normal histological structure were conducted. Results. In comparison with unchanged mucosa of distal colon CRA is characterized by the decreased CDH1 gene transcriptional activity. There is the tendency to reducing of CDH1 gene mRNA expression in the study groups - from the I to the IV stages of the tumor development. CRA is characterized by the low E-cadherin expression level, which also has the tendency to reducing in the study groups. Moreover, in comparison with unchanged mucosa of distal colon CRA is characterized by the increased CTNNB1 gene transcriptional activity and the high beta-catenin expression level. There aren't statistically significant differences between the CTNNB1 gene mRNA, beta-catenin expression levels in the study groups. There are direct correlations between the expression levels of the studied genes and the molecules, coded by these genes, and also reverse correlations between the KRAS and CDH1 genes mRNA expression levels, the KRAS gene mRNA expression level and the E-cadherin expression level, direct correlation between the KRAS gene mRNA expression level and the beta-catenin expression level. Conclusions. CRA is characterized by the decreased CDH1 gene transcriptional activity that correlates with the low E-cadherin expression level, and by the increased CTNNB1 gene transcriptional activity that correlates with the high beta-catenin expression level. The CDH1 gene transcriptional activity and the expression level of E-cadherin, which is coded by this gene, decrease during the CRA progression from the I to the IV stages. CRA is characterized by reverse correlations between the KRAS and CDH1 genes mRNA expression levels, the KRAS gene mRNA expression level and the E-cadherin expression level, direct correlation between the KRAS gene mRNA expression level and the beta-catenin expression level.	[Shyshkin, M. A.; Tumanskyi, V. O.] Zaporizhzha State Med Univ, Dept Pathol Anat & Forens Med, Zaporizhia, Ukraine	Shyshkin, MA (reprint author), Zaporizhzha State Med Univ, Dept Pathol Anat & Forens Med, Zaporizhia, Ukraine.	shishkin.stomat@gmail.com					Bourroul GM, 2016, EINSTEIN-SAO PAULO, V14, P135, DOI 10.1590/S1679-45082016AO3678; Boutin AT, 2017, GENE DEV, V31, P370, DOI 10.1101/gad.293449.116; Bruun J, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00118; Buda A, 2011, CELL COMMUN ADHES, V18, P131, DOI 10.3109/15419061.2011.636465; Chen XB, 2012, MOL BIOL REP, V39, P6707, DOI 10.1007/s11033-012-1494-2; Christou N, 2017, ONCOL LETT, V13, P4571, DOI 10.3892/ol.2017.6063; Church J, 2016, SEMIN COLON RECTAL S, V27, P172, DOI 10.1053/j.scrs.2016.04.013; He X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070858; Isaeva A. V., 2015, VESTNIK RAMN, V70, P475, DOI [DOI 10.15690/VRAMN.V70.I4.1415, 10.15690/vramn.v70.i4.1415]; Kim SA, 2016, BRIT J CANCER, V114, P199, DOI 10.1038/bjc.2015.347; Lemieux E, 2015, ONCOGENE, V34, P4914, DOI 10.1038/onc.2014.416; Lu MH, 2012, CLIN CANCER RES, V18, P6416, DOI 10.1158/1078-0432.CCR-12-0832; Manzi J. P., 2015, EXPLORING CANC PROLI; Morin PJ, 2016, CANCER RES, V76, P5587, DOI 10.1158/0008-5472.CAN-16-2387; Nakamoto K, 2013, ONCOL LETT, V5, P1295, DOI 10.3892/ol.2013.1187; Rasband WS, 1997, IMAGE; Shyshkin MA, 2018, PATHOLOGIA, P49, DOI 10.14739/2310-1237.2018.1.129447; Sobin LH, 2009, INT UNION CANC UICC; Tumanskyi V. O., 2015, BIULETEN, V10; Wong SHM, 2018, CRIT REV ONCOL HEMAT, V121, P11, DOI 10.1016/j.critrevonc.2017.11.010; Yoshida N, 2015, ANTICANCER RES, V35, P4403	21	0	0	0	1	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	MAY-AUG	2018		2					221	228		10.14739/2310-1237.2018.2.141432			8	Pathology	Pathology	GU7BJ	WOS:000445473200016		DOAJ Gold			2019-10-28	
J	Vorotyntsev, SI; Hrynovska, MB; Sofilkanych, MM; Zakharchuk, OV				Vorotyntsev, S. I.; Hrynovska, M. B.; Sofilkanych, M. M.; Zakharchuk, O. V.			Efficacy of regional analgesia techniques in abdominal surgery patients with obesity	PATHOLOGIA			English	Article						obesity; surgical procedures; analgesia and anesthesia	RECTUS SHEATH CATHETERS; RANDOMIZED CONTROLLED-TRIAL; BARIATRIC SURGERY; ENHANCED RECOVERY; EPIDURAL ANALGESIA; PLANE BLOCK; LAPAROSCOPY; GUIDELINES; ANESTHESIA; SOCIETY	The use of regional anesthetic techniques in abdominal surgery is an essential component of the multimodal approach to perioperative analgesia, yet data on their use in obese patients remains limited. The aim of this study is to determine the effectiveness of the epidural analgesia (EA) and the transversus abdominis plane block (TAP-block) in laparoscopic obese patients, as well as to evaluate the possibility of using the rectus sheath block (RSB) as a "rescue" anesthetic technique after laparotomy in obese patients. Materials and methods. The data on the 102 obese patients operated on esophageal hiatal diaphramgmatic hernia, colon tumor, postoperative ventral hernia, morbid obesity and choledocholithiasis were analyzed. In laparoscopic surgery 20 patients received EA (EA group), 21 patients - TAP-block (TAP group), 21 patients - opioids and non-steroidal anti-inflammatory drugs (NSAIDs) without any regional anesthesia techniques (group TIVA(1)). In laparotomic surgery 16 patients received RSB (RSB group) and 24 patients - only opioids and NSAIDs (TIVA(2) group). After the surgery the following was estimated: the time of extubation, the total dose of opioids, the level of pain according to the 10-point numeric range score (NRS), the incidence of dyspnea using the monitor Utas 300 (Ukraine), the incidence of postoperative nausea and vomiting (PONV), the time of active patient mobilization, and the level of satisfaction with analgetic regimen. For the RSB group, the complexity of the RSB and the mean time to achieve adequate analgesia (pain intensity <= 3 points per NRS) were determined additionally. The statistical analysis was performed using the Statistica for Windows version 6.0 software. Results. In the EA group, the intraoperative dose of fentanyl was twice lower, and patients were extubated two times faster than in the TAP, TIVA(1), RSB, TIVA(2) groups (P < 0.05). At the same time, none of the patients in the EA group required the restoration of neuromuscular conduction with neostigmine (P < 0.05). After the surgery, the pain level was 2-3 times higher in the TIVA(1), RSB, and TIVA(2) groups than in the EA and TAP groups (P < 0.05). "Rescue" analgesia in the RSB group was performed from the first attempt in all the patients in 5-10 minutes and provided an adequate effect in 3 (2-4) min. The complexity level of RSB was defined as "easy" in 12 (75 %) patients, as "average" in 4 (25 %) patients (P < 0.05). The incidence of dyspnea and opioid doses after surgery in the EA, TAP and RSB groups of patients were 2 times lower, and the incidence of PONV was 3 to 4 times lower than in the TIVA(1) and TIVA(2) patients' groups (P < 0.05). In the EA and TAP groups, patients became mobile after 8-13 hours after surgery, in the group TIVA(1) - after 16-22 hours, in the group RSB - after 18-36 hours, in the group TIVA(2) - after 48-96 hours (P < 0.05). 100 % of the respondents from the EA, TAP and RSB groups were satisfied with the analgesic regimen at the "excellent - good" level. In the TIVA(1) and TIVA(2) groups, 20-25 % of respondents identified analgesic comfort as "good", 60-65 % of respondents - as "satisfactorily", about 15 % of respondents - as "unsatisfactorily" (P < 0.05). Conclusions. In laparoscopic surgery the use of EA or TAP-block in obese patients significantly reduces the level of postoperative pain, the need for opioids, the incidence of dyspnea and PONV, which leads to the possibility of patients' mobilization within 8-13 hours after surgery. After laparotomic surgery in obese patients RSB effectively "rescues" from pain and prevents excessive use of opioids, which reduces the number of adverse reactions and increases satisfaction with the quality of analgesia.	[Vorotyntsev, S. I.] Zaporizhzhia State Med Univ, Postgrad Educ Fac, Dept Surg & Anesthesiol, Zaporizhia, Ukraine; [Sofilkanych, M. M.; Zakharchuk, O. V.] Zaporizhzhia State Med Univ, Dept Fac Surg, Zaporizhia, Ukraine; [Hrynovska, M. B.] Ivano Frankivsk Natl Med Univ, Dept Anesthesiol & Intens Care, Ivano Frankivsk, Ukraine	Vorotyntsev, SI (reprint author), Zaporizhzhia State Med Univ, Postgrad Educ Fac, Dept Surg & Anesthesiol, Zaporizhia, Ukraine.	vorotyntsev_s@ukr.net					Beard TL, 2011, J GASTROINTEST SURG, V15, P1259, DOI 10.1007/s11605-011-1500-3; Carmichael JC, 2017, DIS COLON RECTUM, V60, P761, DOI 10.1097/DCR.0000000000000883; Fiorini F., 2016, J ANESTH CRIT CARE O, V4, DOI 10.15406/jaccoa.2016.04.00145; Godden AR, 2013, ANN ROY COLL SURG, V95, P591, DOI 10.1308/003588413X13629960049270; Helander EM, 2017, CURR PAIN HEADACHE R, V21, DOI 10.1007/s11916-017-0607-y; Kim S. B., 2001, KOREAN J ANESTHESIOL, V41, P66, DOI 10.4097/kjae.2001.41.1.66; Mulier JP, 2016, CURR OPIN ANESTHESIO, V29, P129, DOI 10.1097/ACO.0000000000000281; Nguyen NT, 2013, SURG OBES RELAT DIS, V9, P15, DOI 10.1016/j.soard.2012.07.002; Quek KHY, 2014, SINGAP MED J, V55, pE39; Reoch J, 2011, ARCH SURG-CHICAGO, V146, P1314, DOI 10.1001/archsurg.2011.270; Ruiz-Tovar J, 2017, SURG ENDOSC, V31, P231, DOI 10.1007/s00464-016-4961-3; Sinha A, 2013, OBES SURG, V23, P548, DOI 10.1007/s11695-012-0819-5; Thorell A, 2016, WORLD J SURG, V40, P2065, DOI 10.1007/s00268-016-3492-3; Tudor ECG, 2015, ANN ROY COLL SURG, V97, P530, DOI 10.1308/rcsann.2015.0018; Vorotyntsev S., GSL J ANESTHESIOLOGY; Vorotyntsev S. I., 2017, KLIN KHIRURGIIA, V6, P21; Wassef M, 2013, J PAIN RES, V6, P837, DOI 10.2147/JPR.S50561; Wilkinson KM, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-400; Willschke H, 2006, BRIT J ANAESTH, V97, P244, DOI 10.1093/bja/ael143; Yamamoto S, 2014, ANN SURG, V260, P23, DOI 10.1097/SLA.0000000000000499; Yassin HM, 2017, ANESTH PAIN MED, V7, DOI [10.5812/aapm.14244, DOI 10.5812/AAPM.14244]	21	0	0	1	6	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	MAY-AUG	2018		2					229	235		10.14739/2310-1237.2018.2.141426			7	Pathology	Pathology	GU7BJ	WOS:000445473200017		DOAJ Gold			2019-10-28	
J	Pivtorak, VI; Monastyrskyi, VM				Pivtorak, V. I.; Monastyrskyi, V. M.			Features of the topography of a single kidney after removal of contralateral one	PATHOLOGIA			Russian	Article						single kidney; nephrectomy; somatotypes; kidney; medical topography; magnetic resonance imaging	SOLITARY KIDNEY; MANAGEMENT	Changes in the topographic anatomy of the kidney after radical nephrectomies of the contralateral kidney remain unexplored for today. Aim of the study was to determine the characteristics of the angles of a single kidney after contralateral nephrectomy in the frontal, sagittal and horizontal planes in patients of different somatotypes, on the basis of magnetic resonance tomography. Materials and methods. A comprehensive examination of 189 patients of the first and second adulthood was performed, there were 124 patients with a single kidney and different postoperative period after kidney removal and 65 patients with two kidneys who had no kidney and urinary tract diseases among them. The studies were carried out using the magnetic resonance tomograph Philips Intera-1.5T. Results. The performed studies of the angles of the slope of the only kidney remaining after contralateral nephrectomy in the frontal, sagittal and horizontal planes with the help of magnetic resonance imaging show certain regularities depending on the somatotype. It was revealed that the smallest angle of inclination is created in the left single kidney of the women of the ectomorphic somatotype in the frontal plane (19.6 +/- 2.1 degrees), and the largest one - in the left single kidney of the men of the mesomorphic somatotype in the horizontal plane (61.4 degrees +/- 4.5 degrees). The angles of the slope of the single kidney in representatives of all the somatotypes in the horizontal plane were statistically significantly larger as compared to similar parameters in persons with two kidneys who had no diseases of the kidneys and urinary tract. In the sagittal plane, the angles of inclination of the left and right single kidney in members of all somatotypes were statistically significant, whereas in the frontal plane they differed (P < 0.05) only in patients with mesomorphic somatotype. Conclusion. In patients after 2-5 years after the removal of the contralateral kidney significantly less angles of inclination of the right single kidney in the frontal plane are observed as compared to parameters in patients with two kidneys, who had diseases of the kidneys and urinary tract. Angles of the inclination of the right and left single kidneys of patients with all the somatotypes in the horizontal plane are statistically significantly larger in comparison with those in patients with two kidneys who did not have kidney and urinary tract diseases. The angles of inclination of the left single kidney of patients with all the somatotypes in the sagittal plane are statistically significantly less than the parameters of the right single kidney.	[Pivtorak, V. I.] Natl MI Pirogov Mem Med Univ, Dept Clin Anat & Operat Surg, Vinnytsia, Ukraine; [Monastyrskyi, V. M.] Natl MI Pirogov Mem Med Univ, Fac Postgrad Educ, Dept Surg, Vinnytsia, Ukraine	Pivtorak, VI (reprint author), Natl MI Pirogov Mem Med Univ, Dept Clin Anat & Operat Surg, Vinnytsia, Ukraine.	pivtorakv@gmail.com	Pivtorak, Vladimir/F-2188-2017	Pivtorak, Vladimir/0000-0001-7234-3596			Averyanova N. I., 2006, PERMSKIJ MED ZH, V23, P32; Carter JEL, 1990, SOMATOTYPING DEV APP, Vxiv; Cleper Roxana, 2018, Harefuah, V157, P58; Godron-Dubrasquet A, 2017, ARCH PEDIATRIE, V24, P1158, DOI 10.1016/j.arcped.2017.08.016; Johnson S, 2011, CLIN J AM SOC NEPHRO, V6, P70, DOI 10.2215/CJN.00030110; Klatte T, 2015, EUR UROL, V68, P980, DOI 10.1016/j.eururo.2015.04.010; Kupajski M, 2012, VIDEOSURGERY MINIINV, V7, P1, DOI 10.5114/wiitm.2011.25641; [Лященко Сергей Николаевич Lyashchenko S.N.], 2017, [Морфология, Morfologiya], V152, P74; Lyashchenko S. N., 2014, NAUKA MOLODYKH, V3, P30; Mahmoud H, 2016, CURR OPIN NEPHROL HY, V25, P487, DOI 10.1097/MNH.0000000000000266; Mavinkurve-Groothuis AMC, 2016, PEDIATR NEPHROL, V31, P435, DOI 10.1007/s00467-015-3215-2; Monastirskiy V. M., 2017, DTSCH WISSEN SCHAFTS, V5, P31, DOI [10.19221/201759, DOI 10.19221/201759]; Monastyrsky V. M., 2018, VISNYK PROBLEM BIOL, V2, P311, DOI [10.29254/2077-4214-2018-1-2-143-311-316, DOI 10.29254/2077-4214-2018-1-2-143-311-316]; Monina Yu.V, 2014, KREATIVNAYA KHIRURGI, V3, P52; Myoller T. B., 2008, NORMA KT I MRT ISSLE; Oparin A. A., 2016, SKHIDNOIEVROPEISKYI, V1, P57; Tatevosyan A. S., 2013, Urologiya (Moscow), P24; Tatevosyan A. S., 2005, EKOLOGICHESKIJ VESTN, V1, P85; Tonyan A. G., 2015, ISSLEDOVANIYA PRAKTI, V2, P43, DOI [10.17709/2409-2231-2015-2-3-43-50, DOI 10.17709/2409-2231-2015-2-3-43-50]	19	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	MAY-AUG	2018		2					236	241		10.14739/2310-1237.2018.2.141369			6	Pathology	Pathology	GU7BJ	WOS:000445473200018		DOAJ Gold			2019-10-28	
J	Stefanchuk, RO; Yanchuk, AO; Stefanchuk, MM; Stefanchuk, MO				Stefanchuk, R. O.; Yanchuk, A. O.; Stefanchuk, M. M.; Stefanchuk, M. O.			The codification of medical legislation in Ukraine: the question of the formulation of the problem	PATHOLOGIA			Russian	Review						filing; medical legislation; health care		The purpose of the research is to study and propose an integrated approach to the formation of legal health policy. National medical law is not systemic. Obsolete, duplicate and contradictory legal acts of varying legal force, excessive number of subordinate ministerial and departmental acts require the systematization of medical legislation, the creation of a coherent, logical and intra-contradictory system. It is necessary to combine the efforts and knowledge of lawyers and doctors to create an appropriate viable regulatory framework and improve the efficiency and quality of the law-making process. When developing its own legal and regulatory framework, it is necessary to take into account the international legal standards in the field of health protection, the experience of foreign countries in medical legislation, as well as national peculiarities, traditions and realities. Codification is a special and the most perfect and highest form of systematization of legislation. That is a streamlining of the legislative material, which is aimed at processing by eliminating repetitions, contradictions, filling gaps, transforming the nature and direction of the material, to the maximum extent provided by internal coherence, integrity, consistency and completeness of legal regulation of existing social relations. An urgent task is the creation of the Medical Code of Ukraine, which would meet the general standards of human rights and relevant international legal acts, which is dominated by directives and other acts of the World Health Organization.	[Stefanchuk, R. O.] Kharkov Natl Univ, Kharkov, Ukraine; [Yanchuk, A. O.] Minist Hlth Ukraine, State Secretary, Kiev, Ukraine; [Stefanchuk, M. M.] Kyiv Natl Econ Univ, State Higher Educ Estab, Kiev, Ukraine; [Stefanchuk, M. O.] Taras Shevchenko Natl Univ, Fac Law, Kiev, Ukraine	Stefanchuk, RO (reprint author), Kharkov Natl Univ, Kharkov, Ukraine.		Stefanchuk, Mykola/Q-1540-2016	Stefanchuk, Mykola/0000-0002-2983-2770			Alekseev S. S., 1999, PRAVO AZBUKA TEORIYA; Bolotina N. B., 2001, MEDYCHNE PRAVO UKRAY; Kerimov D. A, 2001, METODOLOGIYA PRAVA P; Korsakov S. A., 1999, MED VESTNIK, V8, P15; Krasytska L. V., 2002, TSYVILNO PRAVOVE REH; Lyubinets O. V., 2006, UKRAINSKYI MEDYCHNYI, V3; Ministerstvo okhorony zdorovia Ukrayiny, 2002, NORM PRAV DOK PYT NA; Moskalenko V. F., 2000, B ZAKONODAVSTA YURYD, V7; Nersesyanc V. S., 1999, PROBLEMY OBSHHEJ TEO; Pigolkin A. S., 2003, SISTEMATIZACIYA ZAKO; Polyakov A. V., 2003, OBSHHAYA TEORIYA PRA; Tikhomirov A. V., MED PRAVO	12	0	0	0	1	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	MAY-AUG	2018		2					242	247		10.14739/2310-1237.2018.2.141429			6	Pathology	Pathology	GU7BJ	WOS:000445473200019		DOAJ Gold			2019-10-28	
J	Ivchenko, DV; Miroshnikov, VV				Ivchenko, D. V.; Miroshnikov, V. V.			Autologous platelet-rich plasma application for the optimization of bone tissue reparative regeneration in osteopenia	PATHOLOGIA			Russian	Article						platelet-rich plasma; bone regeneration; osteogenesis; bone remodeling; mineral metabolism; osteoporosis	RANDOMIZED-CONTROLLED-TRIAL; GROWTH-FACTORS; IN-VITRO; GEL	Objective: analysis of scientific literature on the effectiveness of using Plateled-Rich Plasma to optimize the treatment of compression fractures of vertebral bodies of thoracic and lumbar localization against the background of postmenopausal and senile osteoporosis. All the methods of using Platelet-Rich Plasma, described in the literature, can be divided into several main groups. Platelet-Rich Plasma can be mixed with bone material; is applied to the lesion site before application of bone material; is applied over the bone material; used as a biological membrane. Platelet-Rich Plasma contain fibrillar and cellular components and is able to act as a carrier of cells which are important for the regeneration of soft and bony tissues. It can strengthen the attachment of human osteoblasts to membranes and, as a consequence, induce osteogenesis. Many authors are the supporters of the stimulating effect of Platelet-Rich Plasma on reparative osteogenesis. After injection of Platelet-Rich Plasma in the case of complicated fracture the following was observed: odema in the damaged tissues is less pronounced, there are less signs of acute and chronic inflammation, the phase of alteration is changing more quickly by regenerative-reparative processes. The natural clot contains fibrin, fibronectin and vitronectin, they are also called adhesion molecules necessary for cell migration, osteoconduction, epithelialization and osseointegration. Biological properties of Platelet-Rich Plasma are due not only to the presence of growth factors (TGF-beta and PDGF), but without them it immediately induces the formation of a fibrin clot, followed by stimulation of cell adhesion and collagen synthesis. Conclusion. Based on the published literature, a high potential of plasma therapy by Platelet-Rich Plasma for bone tissue regeneration is demonstrated. No adequate clinical studies on the effectiveness of Platelet-Rich Plasma therapy that would meet all modern criteria have yet been conducted. Therapy of Platelet-Rich Plasma is a promising branch in medicine and deserves further research in terms of new effective and safe method of application in medical practice.	[Ivchenko, D. V.] Zaporizhzhia State Med Univ, Dept Traumatol & Orthoped, Zaporizhzhia, Ukraine; [Miroshnikov, V. V.] City Clin Hosp Emergency & Med Care, Dept Traumatol Polytrauma Beds, Zaporizhzhia, Ukraine	Ivchenko, DV (reprint author), Zaporizhzhia State Med Univ, Dept Traumatol & Orthoped, Zaporizhzhia, Ukraine.	globalmedms@gmail.com					Akeda K, 2006, OSTEOARTHR CARTILAGE, V14, P1272, DOI 10.1016/j.joca.2006.05.008; Badr M, 2010, EUR J ORAL IMPLANTOL, V3, P233; Berchenko G. N., 2010, TRAVMA, V11, P7; Bielecki TM, 2007, J BONE JOINT SURG BR, V89B, P417, DOI 10.1302/0301-620X.89B3.18491; Borzykh A. V., 2013, LITOPYS TRAVMATOLOHI, V3-4, P9; Brekhov V. L., 2007, THESIS; Buryanov O. A., 2017, VISNYK PROBLEM BIOL, V1, P96; Chang T, 2007, AUST DENT J, V52, P227, DOI 10.1111/j.1834-7819.2007.tb00493.x; Chen LW, 2013, ORTHOPEDICS, V36, pE687, DOI [10.3928/01477447-20130523-10, 10.3928/01477447-20130523]; Civinini R, 2011, CLIN CASES MINER BON, V8, P25; de Vos RJ, 2010, JAMA-J AM MED ASSOC, V303, P144, DOI 10.1001/jama.2009.1986; Dozza B, 2017, J BIOMED MATER RES A, V105, P1019, DOI 10.1002/jbm.a.35975; Glukhov A. A., 2013, VESTNIK NOVYKH MED T, V20, P108; Grigorovsky V. V., 2013, UKRAINSKYI NEIROKHIR, V2, P28; Hatakeyama M, 2008, ORAL SURG ORAL MED O, V105, pE13, DOI 10.1016/j.tripleo.2007.07.033; Hee HT, 2003, EUR SPINE J, V12, P400, DOI 10.1007/s00586-003-0548-5; Kawase T, 2005, J PERIODONTOL, V76, P760, DOI 10.1902/jop.2005.76.5.760; Keceli HG, 2008, J CLIN PERIODONTOL, V35, P255, DOI 10.1111/j.1600-051X.2007.01181.x; Kholodkova O. L., 2015, ZDOBUTKY KLIN EKSPER, V4, P66; Kholodkova O. L., 2013, UKRAINSKYI MORFOLOHI, V11, P63; Kirilova I. L., 2008, TRAVMATOLOGIYA ORTOP, V3, P64; Klimovickij V. G., 2011, TRAVMA, V12, P93; Klimovitsky V. G., 2013, LITOPYS TRAVMATOLOHI, V3-4, P58; Korzh N. A., 2006, ORTHOPAEDY TRAUMATOL, V1, P77; Kulytska O. V., 2015, VISNYK NAUKOVYKH DOS, V4, P68, DOI [10.11603/1681-276..2015.4.5648, DOI 10.11603/1681-276..2015.4.5648]; Lai YX, 2018, BIOMATERIALS, V153, P1, DOI 10.1016/j.biomaterials.2017.10.025; Lazishvili G. D., 2016, KHIRURGICHESKAYA PRA, V1, P46; Lazishvili G. D., 2016, KLIN PRAKTIKA, V3, P54; Lazishvili G. D., 2016, KAFEDRA TRAVMATOLOGI, V1, P40; Lowery JW, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a022327; Marunych V. V., 2012, OSNOVNI POKAZNYKY IN; Mebarki M, 2017, ACTA BIOMATER, V59, P94, DOI 10.1016/j.actbio.2017.06.018; Moojen DJF, 2008, J ORTHOP RES, V26, P404, DOI 10.1002/jor.20519; Osawa Y, 2017, BONE, V105, P42, DOI 10.1016/j.bone.2017.05.016; Pavlenko K. V., 2015, J ED HLTH SPORT, V5, P279, DOI [10.5281/zenodo.16453, DOI 10.5281/ZENODO.16453]; Pavlenko K. V., 2016, THESIS; Perut F, 2016, CURR PHARM BIOTECHNO, V17, P1079, DOI 10.2174/1389201017666160719100437; Popsuishapka A. K., 2014, ORTOPEDIYA TRAVMATOL, V1, P34; Por YC, 2007, ANN ACAD MED SINGAP, V36, P911; Samodaj V. G., 2007, AKTUALNYE VOPROSY TK, P148; Schaaf H, 2008, VOX SANG, V94, P64, DOI 10.1111/j.1423-0410.2007.00997.x; Schwartz-Arad D, 2007, Refuat Hapeh Vehashinayim (1993), V24, P51; Schwartz- Arad D., 2007, REFUAT HAPEH VEHASHI, V24, P84; Shteinle A. V., 2010, SIBIRSKIJ MED ZH, V25, P114; Simman R, 2008, ANN PLAS SURG, V61, P337, DOI 10.1097/SAP.0b013e318157a185; Stanton T., 2012, HIGH CONCENTRATE PRP; Tao H, 2016, BIOMED REP, V5, P357, DOI 10.3892/br.2016.731; Tryfanenko S. I., 2012, BUKOVYNSKYI MEDYCHNY, V4, P162; Uggeri J, 2007, J PERIODONTOL, V78, P1985, DOI 10.1902/jop.2007.070116; Viny AD, 2015, J EXP MED, V212, P1819, DOI 10.1084/jem.20151317; Zhao Yao, 2010, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V24, P1004; Zubenko A. H., 2011, THESIS	52	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	MAY-AUG	2018		2					248	258		10.14739/2310-1237.2018.2.141333			11	Pathology	Pathology	GU7BJ	WOS:000445473200020		DOAJ Gold			2019-10-28	
J	Hryhoriichuk, VI; Kuzyk, YI; Boiko, OI				Hryhoriichuk, V. I.; Kuzyk, Yu. I.; Boiko, O. I.			Common arterial trunk: pathomorphological changes of unoperated cardiac defect in adulthood	PATHOLOGIA			Russian	Review						persistent truncus arteriosus; congenital heart defects; ventricular heart septal defects	CONGENITAL HEART-DISEASE	Congenital heart defects in adulthood constitute the sufficient proportion of cardiac pathology. The common arterial trunk (CAT) is one of the congenital cardiac defects that is described in the adult population. Without surgical intervention, patients who survived become inoperable quickly due to the development of early congestive heart insufficiency and pulmonary hypertension. The purpose of the research is to analyze the autopsy case of unoperated congenital cardiac defects in adulthood. Materials and methods. The pathomorphological analysis of the case of death of a 33-year-old male with untreated complex congenital heart defect - CAT, ventricular septal defect, Eisenmenger's syndrome was made using standard and elective histological techniques. Results. In the forensic examination of the body of the deceased 33-year-old male, congenital heart defect was diagnosed as CAT and ventricular septal defect. Coronary, pulmonary and major arteries of a large circle of blood circulate from the CAT. Congenital heart defect has been complicated by the development of cardiomegaly (heart weight 1500 g) with myocardial hypertrophy of both ventricles and led to decompensation of cardiac activity. During the pathohistological examination of the valve of the CAT we determined the foci of fibrinoid necrosis, myxomatosis, single accumulation of lymphocytes, focal fibrosis. In the myocardium of the right and left ventricles we observed hypertrophy, focal contraction and fragmentation of cardiomyocytes, expressed intramusc ular edema, sclerosis of the walls of the small intramural arteries with perifocal areas of vacuolar degeneration of cardiomyocytes, stromal cardiosclerosis, isolated interstitial infiltration of lymphocytes, dilatation of lymphatic vessels. In the pulmonary tissue diffuse hemosiderosis, multiple intravalveolar hemorrhages, sclerosis of the small pulmonary arteries with the formation of two-and three-sided lumen, sclerosis of interalveolar membranes were detected. Morphological changes in the myocardium and lungs confirm prolonged congestive heart failure and pulmonary hypertension. Conclusions. We describe a unique case of long-term survival of a patient with CAT without surgical intervention. The complex of pathomorphological changes of the described case testifies to cardiovascular remodeling, which is the base of hemodynamic evolution of complex congenital heart disease and allowed the man to live up to 33 years without surgical intervention.	[Hryhoriichuk, V. I.; Kuzyk, Yu. I.; Boiko, O. I.] Danylo Halytsky Lviv Natl Med Univ, Dept Pathol Anat & Forens Med, Lvov, Ukraine; [Hryhoriichuk, V. I.] CI Lviv Reg Off Forens Med Examinat, Dept Forens Examinat Corpses, Lvov, Ukraine; [Kuzyk, Yu. I.; Boiko, O. I.] CI Lviv Reg Pathol Bur, Lvov, Ukraine	Kuzyk, YI (reprint author), Danylo Halytsky Lviv Natl Med Univ, Dept Pathol Anat & Forens Med, Lvov, Ukraine.; Kuzyk, YI (reprint author), CI Lviv Reg Pathol Bur, Lvov, Ukraine.	juliakuzyk21@gmail.com					Benjamin EJ, 2017, CIRCULATION, V135, pE146, DOI 10.1161/CIR.0000000000000485; COLLETT RW, 1949, SURG CLIN N AM, V29, P1245; Frank DB, 2015, MINERVA PEDIATR, V67, P169; Ivanov Y. Yu., 2013, NEONATALOHIIA KHIRUR, V3, P89; Kim Hyung-Seop, 2015, J Cardiovasc Ultrasound, V23, P32, DOI 10.4250/jcu.2015.23.1.32; Lebid I G., 2017, KARDIOKHIRURHIIA TA, V1, P6; Matushov V. N., 2013, SIBIRSKIJ MED ZH, V28, P14; Naidu P, 2017, INT J CARDIOL, V245, P125, DOI 10.1016/j.ijcard.2017.05.132; Szoke Z, 2017, J CARDIOVASC EMERG, V3, P138, DOI 10.1515/jce-2017-0018; VANPRAAGH R, 1965, AM J CARDIOL, V16, P406, DOI 10.1016/0002-9149(65)90732-0	10	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	MAY-AUG	2018		2					259	264		10.14739/2310-1237.2018.2.141338			6	Pathology	Pathology	GU7BJ	WOS:000445473200021		DOAJ Gold			2019-10-28	
J	Sihvo, HK; Airas, N; Linden, J; Puolanne, E				Sihvo, H. -K.; Airas, N.; Linden, J.; Puolanne, E.			Pectoral Vessel Density and Early Ultrastructural Changes in Broiler Chicken Wooden Breast Myopathy	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						broiler chicken; electron microscopy; vessel density; wooden breast myopathy	SKELETAL-MUSCLE CHARACTERISTICS; MAJOR MUSCLE; SARCOPLASMIC-RETICULUM; EGG-PRODUCTION; GROWTH; MEAT; MYODEGENERATION; CAPILLARY; HYPOXIA; FIBERS	In wooden breast myopathy (WBM) of broiler chickens, the pectoralis major muscles show abnormally hard consistency and microscopical myodegeneration of unknown aetiology. To date, previous studies have focused primarily on chronic WBM and ultrastructural descriptions of early WBM are lacking. The aim of this study was to elucidate the pathogenesis of WBM by light microscopical morphometry of vessel density and the ultra structural description of early WBM changes with transmission electron microscopy. The pectoral vessel density was compared between unaffected chickens (n = 14) and two areas of focal WBM in affected chickens (n = 14). The transverse myofibre area per vessel was highest in the unaffected area of muscle from cases of focal WBM, significantly higher (P = 0.01) than in macroscopically unaffected tissue, indicating that relatively decreased blood supply may trigger the development of WBM. The ultrastructural study included unaffected chickens (n = 3), two areas offocal WBM from affected chickens (n = 3) and areas of diffuse WBM from affected chickens (n = 3). The morphologically least affected myofibres within the WBM lesion areas in light microscopy exhibited ultrastructural changes of increased sarcoplasmic reticulum diameter and mitochondrial hyperplasia. Such changes originate typically from osmotic imbalance, for which the most likely aetiologies in WBM include tissue hypoxia or myodegencration of the surrounding myofibres. The findings suggest that a relative reduction of blood supply in the major pectoral muscle occurs in the early phase of WBM, which may be linked to the ultrastructural changes of osmotic imbalance. (C) 2018 Elsevier Ltd. All rights reserved.	[Sihvo, H. -K.; Airas, N.; Linden, J.] Univ Helsinki, Dept Vet Biosci, POB 66, FI-00014 Helsinki, Finland; [Sihvo, H. -K.; Puolanne, E.] Univ Helsinki, Dept Food & Environm Sci, POB 66, FI-00014 Helsinki, Finland	Sihvo, HK (reprint author), Univ Helsinki, Dept Vet Biosci, POB 66, FI-00014 Helsinki, Finland.; Sihvo, HK (reprint author), Univ Helsinki, Dept Food & Environm Sci, POB 66, FI-00014 Helsinki, Finland.	hanna-kaisa.sihvo@helsinki.fi		Linden, Jere/0000-0001-9872-3626	Finnish Foundation of Veterinary Research [10-86824]; Niemi Foundation [161015]	This work was supported by the Finnish Foundation of Veterinary Research (grant number 10-86824) and the Niemi Foundation (grant number 161015).	Abasht B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153750; Cheville NF, 2009, ULTRASTRUCT PATHOL, P75; Clark DL, 2016, POULTRY SCI, V95, P2930, DOI 10.3382/ps/pew243; de Brot S, 2016, VET REC, V178, P141, DOI 10.1136/vr.103561; Duhamel TA, 2004, J APPL PHYSIOL, V97, P188, DOI 10.1152/japplphysiol.00958.2003; Franzini-Armstrong C, 2012, MUSCLE, P763; Frias JA, 2005, BBA-BIOMEMBRANES, V1668, P64, DOI 10.1016/j.bbamem.2004.11.006; FUJISAWA K, 1975, J NEUROL SCI, V24, P447, DOI 10.1016/0022-510X(75)90170-7; GHADIALLY FN, 1997, ULTRASTRUCT PATHOL, P195; Ghadially FN, 1997, ULTRASTRUCT PATHOL, P433; Ghadially FN, 1997, ULTRASTRUCT PATHOL, P887; Hoving-Bolink AH, 2000, MEAT SCI, V56, P397, DOI 10.1016/S0309-1740(00)00071-1; HUDLICKA O, 1985, J EXP BIOL, V115, P215; Jacobs RA, 2016, J PHYSIOL-LONDON, V594, P1151, DOI 10.1113/JP271118; Joiner KS, 2014, AVIAN DIS, V58, P377, DOI 10.1637/10733-112513-Reg.1; Klasing K, 2008, DIS POULTRY, P1121; Macrae VE, 2006, BRIT POULTRY SCI, V47, P264, DOI 10.1080/00071660600753615; Mutryn MF, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1623-0; Papah MB, 2017, AVIAN PATHOL, V46, P623, DOI 10.1080/03079457.2017.1339346; PAPINAHO PA, 1996, J APPL POULTRY RES, V5, P126; Radaelli G, 2017, POULTRY SCI, V96, P309, DOI 10.3382/ps/pew270; REMIGNON H, 1995, J MUSCLE RES CELL M, V16, P95, DOI 10.1007/BF00122527; Revuelta-Lopez E, 2015, J MOL CELL CARDIOL, V85, P25, DOI 10.1016/j.yjmcc.2015.04.028; Sewry C. A., 2002, CURR DIAGN PATHOL, V8, P225; Sihvo HK, 2017, VET PATHOL, V54, P119, DOI 10.1177/0300985816658099; Sihvo HK, 2014, VET PATHOL, V51, P619, DOI 10.1177/0300985813497488; Soglia F, 2016, POULTRY SCI, V95, P651, DOI 10.3382/ps/pev353; Soike D, 1998, J VET MED A, V45, P169, DOI 10.1111/j.1439-0442.1998.tb00813.x; Soike D, 1998, J VET MED A, V45, P161, DOI 10.1111/j.1439-0442.1998.tb00812.x; Velleman SG, 2015, AVIAN DIS, V59, P410, DOI 10.1637/11097-042015-Reg.1; Zambonelli P, 2016, POULTRY SCI, V95, P2771, DOI 10.3382/ps/pew268	31	6	6	3	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	MAY	2018	161						1	10		10.1016/j.jcpa.2018.04.002			10	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GO1TA	WOS:000439737800001	30173852				2019-10-28	
J	Domenis, L; Spedicato, R; Pepe, E; Orusa, R; Robetto, S				Domenis, L.; Spedicato, R.; Pepe, E.; Orusa, R.; Robetto, S.			Caseous Lymphadenitis Caused by Corynebacterium pseudotuberculosis in Alpine Chamois (Rupicapra r. rupicapra): a Review of 98 Cases	JOURNAL OF COMPARATIVE PATHOLOGY			English	Review						caseous lymphadcnitis; chamois; Corynebacterium pseudotuberculosis; Rupicapra r. rupicapra	SHEEP; PREVALENCE; PHENOTYPE; ABATTOIR; PATIENT; LESIONS; FLOCKS; GOATS	Cognebacterium pseudotuberculosis is the causative agent of caseous lymphadenitis (CLA) in domestic and wild ruminants. Here we describe CLA in alpine chamois (Rupicapra r. rupicapra) based on a series of 98 cases of C. pseudotuberculosis infection confirmed by bacteriology and gene sequence analysis. The population included 53 males and 45 females distributed within three age groups: up to 18 months (n = 14), 18 months to 4 years (n = 11) and over 4 years (n = 73). Four different gross lesion distribution patterns, observed individually or variably combined in the same animal, were defined: (1) cutaneous/external (i.e. subcutaneous lymph nodes with or without muscle involvement, n = 34); (2) abdominal visceral (i.e. only abdominal organs involved: liver and/or spleen and/or kidney and/or lymph nodes, n = 35); (3) thoracic visceral (i.e. only thoracic organs involved: lung and/or heart and/or lymph nodes, n = 26); and (4) generalized visceral (i.e. abdominal and thoracic organs involved, n = 26). In six particularly severe cases, mammary gland, testis, vertebral hone and the central nervous system were also affected. Macroscopically, most abscesses were characterized by fluid pus, confirmed by microscopy that showed the absence of distinct concentric layers and coagulative necrosis, which are typically seen in sheep and goats raised in areas where the infection is endemic. In three cases amyloid deposits were observed in the liver and kidney. The C. pseudotuberculosis strains isolated were highly homologous to the reference strain ATCC 19410, except for some variability in their ability to ferment maltose and mannitol. Based on the production of nitrate reductase, 95 strains were attributed to the ovis biovar (nitrate reduction negative) and three to the equi biovar (nitrate reduction positive). All strains were sensitive to antibiotics, except to ampicillin (62.3% resistant strains) and gentamicin (83.7% resistant strains). Using an indirect enzyme-linked immunosorbent assay designed for CLA in sheep and goats, seven (58.3%) of 12 scrum samples tested positive for antibodies. (C) 2018 Elsevier Ltd. All rights reserved.	[Domenis, L.; Spedicato, R.; Pepe, E.; Orusa, R.; Robetto, S.] Natl Reference Ctr Wildlife Dis, Valle Aosta Dept, Ist Zooprofilatt Sperimentale Piemonte Liguria &, Reg Amer 7G, Quart, Italy	Domenis, L (reprint author), Natl Reference Ctr Wildlife Dis, Valle Aosta Dept, Ist Zooprofilatt Sperimentale Piemonte Liguria &, Reg Amer 7G, Quart, Italy.	lorenzo.domenis@izsto.it					Abebe D, 2015, LETT APPL MICROBIOL, V61, P469, DOI 10.1111/lam.12482; Baird GJ, 2007, J COMP PATHOL, V137, P179, DOI 10.1016/j.jcpa.2007.07.002; Bassano B., 1993, IBEX J MOUNT ECOL, V1, P31; BATEY RG, 1986, AM J VET RES, V47, P482; BIBERSTEIN EL, 1971, VET REC, V89, P691, DOI 10.1136/vr.89.26.691; Binns SH, 2007, VET MICROBIOL, V123, P169, DOI 10.1016/j.vetmic.2007.02.015; BOOMKER J, 1980, S AFR J WILDL RES, V10, P63; Britz E, 2014, VET J, V200, P282, DOI 10.1016/j.tvjl.2014.03.009; Brown C. C., 1987, Veterinary Bulletin, V57, P1; Cadena-Colom A, 2014, ACTA VET SCAND, V56, P1; Chirino-Zarraga C, 2006, SMALL RUMINANT RES, V65, P170, DOI 10.1016/j.smallrumres.2005.06.017; CLARK K A, 1972, Journal of Wildlife Diseases, V8, P67; CLSI, 2016, METH ANT DIL DISK SU; Domenis L, 2017, J COMP PATHOL, V156, P101; Dorella FA, 2006, VET RES, V37, P201, DOI 10.1051/vetres:2005056; Eckersall Peter D, 2007, BMC Vet Res, V3, P35, DOI 10.1186/1746-6148-3-35; Fontaine MC, 2008, SMALL RUMINANT RES, V76, P42, DOI 10.1016/j.smallrumres.2007.12.025; Heggelund L, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv053; Join-Lambert OF, 2006, PEDIATR INFECT DIS J, V25, P848, DOI 10.1097/01.inf.0000234071.93044.77; Kelly EJ, 2012, J WILDLIFE DIS, V48, P803, DOI 10.7589/0090-3558-48.3.803; Literak I, 1999, SMALL RUMINANT RES, V32, P107, DOI 10.1016/S0921-4488(98)00174-6; Matos AC, 2015, J WILDLIFE DIS, V51, P793, DOI 10.7589/2014-09-240; Morales N, 2017, J WILDLIFE DIS, V53, P621, DOI 10.7589/2016-09-213; Muller B, 2011, VET MICROBIOL, V147, P340, DOI 10.1016/j.vetmic.2010.07.017; Nocard E, 1896, ANN I PASTEUR, V10, P609; Olender A, 2012, ANTIBIOTIC RESISTANT BACTERIA - A CONTINUOUS CHALLENGE IN THE NEW MILLENNIUM, P387; PATON MW, 1988, ACTA VET SCAND, P101; PEPIN M., 1994, CURR TOP VET RES, V1, P63; Perez L, 1996, 14 REUN GROUP ET EC; PREICZ H, 1891, J MED VET ZOOT, V16, P563; Raez-Bravo A, 2015, PARASITOL RES, V114, P4005, DOI 10.1007/s00436-015-4628-3; Romero-Perez JC, 2004, REV CLIN ESP, V204, P388, DOI 10.1016/S0014-2565(04)71494-0; ROTH HH, 1966, BRIT VET J, V122, P296, DOI 10.1016/S0007-1935(17)40506-9; Schroder W., 1985, BIOL MANAGEMENT MOUN, P67; Silinski S, 2004, P 5 SCI M EUR ASS ZO, P321; SONGER JG, 1988, AM J VET RES, V49, P223; STAUBER E, 1973, Journal of Wildlife Diseases, V9, P56; STOOPS SG, 1984, AM J VET RES, V45, P557; Tarello W, 2008, VET REC, V162, P862, DOI 10.1136/vr.162.26.862; Valli VEO, 1993, PATHOLOGY DOMESTIC A, V3, P238; Zavoshti F. R., 2012, Comparative Clinical Pathology, V21, P667, DOI 10.1007/s00580-010-1154-7	41	1	1	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	MAY	2018	161						11	19		10.1016/j.jepa.2018.01.003			9	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GO1TA	WOS:000439737800002	30173853				2019-10-28	
J	Dzimira, S; Wydooghe, E; Van Soom, A; Van Brantegem, L; Nowacka-Woszuk, J; Szczerbal, I; Switonski, M				Dzimira, S.; Wydooghe, E.; Van Soom, A.; Van Brantegem, L.; Nowacka-Woszuk, J.; Szczerbal, I.; Switonski, M.			Sertoli Cell Tumour and Uterine Leiomyoma in Miniature Schnauzer Dogs with Persistent Miillerian Duct Syndrome Caused by Mutation in the AMHR2 Gene	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						dog; leiomyoma; persistent Miillerian duct syndrome; Sertoli cell tumour	SEX DEVELOPMENT; CRYPTORCHIDISM; DISORDERS; NEOPLASIA; SEMINOMA	Disorders of sex development (DSD) arc a serious health problem in dogs. Different types of DSD have been described, including persistent Mullerian duct syndrome (PMDS), for which the molecular background has been identified in miniature schnauzers. Human patients with PMDS are at increased risk for cancers of the gonads (predominantly) or the Mullerian duct structures (rarely). This report describes two miniature schnauzer dogs with PMDS caused by a known nonsense mutation in the AMHR2 gene, with concurrent development of genital ncoplasia. The first case (78,XY and SR gamma-positive) had unilateral cryptorchidism and a Sertoli cell tumour in the abdominal testicle. The second case (mosaic karyotype 77,XY,rob/78,XY and SR gamma-positive) had both gonads descended in the scrotum and developed an abdominal mass derived from the uterine wall, which showed histological features typical of leiomyoma. (C) 2018 Elsevier Ltd. All rights reserved.	[Dzimira, S.] Wroclaw Univ Environm & Life Sci, Dept Pathol, Wroclaw, Poland; [Wydooghe, E.; Van Soom, A.] Univ Ghent, Clin Small Anim Reprod, Dept Reprod Obstet & Herd Hlth, Merelbeke, Belgium; [Van Brantegem, L.] Univ Ghent, Dept Pathol Bacteriol & Poultry Dis, Fac Vet Med, Merelbeke, Belgium; [Nowacka-Woszuk, J.; Szczerbal, I.; Switonski, M.] Poznan Univ Life Sci, Dept Genet & Anim Breeding, Poznan, Poland	Switonski, M (reprint author), Poznan Univ Life Sci, Dept Genet & Anim Breeding, Poznan, Poland.	switonsk@up.poznan.pl	Dzimira, Stanislaw/S-5801-2016	Dzimira, Stanislaw/0000-0001-7203-2392; Szczerbal, Izabela/0000-0002-4238-0414; Nowacka-Woszuk, Joanna/0000-0002-1041-3576; Switonski, Marek/0000-0003-2539-9508	National Science Center, Poland [2016/23/B/NZ9/03424]	This study was financed by the National Science Center, Poland, grant number 2016/23/B/NZ9/03424. The first two authors contributed equally to the study.	Alam MR, 2007, VET MED-CZECH, V52, P74, DOI 10.17221/2056-VETMED; Bigliardi E, 2011, REPROD BIOL ENDOCRIN, V9, DOI 10.1186/1477-7827-9-12; Breshears MA, 2011, VET PATHOL, V48, P1038, DOI 10.1177/0300985810396104; Cahua U Jacqueline, 2015, Rev. investig. vet. Perú, V26, P705, DOI 10.15381/rivep.v26i4.11208; Dzimira S, 2015, PATHOL RES PRACT, V211, P772, DOI 10.1016/j.prp.2015.07.010; Hagel T, 2010, KLEINTIERPRAXIS, V55, P547; Iannuzzi L, 2008, J APPL GENET, V49, P357, DOI 10.1007/BF03195634; Johnston J, 2016, REV ELECT VET, V17; Jonen H, 1996, KLEINTIERPRAXIS, V41, P911; Juniarto AZ, 2013, J CLIN PATHOL, V66, P198, DOI 10.1136/jclinpath-2012-201062; Kovachev SM, 2014, ISR MED ASSOC J, V16, P735; Kuiper H, 2004, DEUT TIERARZTL WOCH, V111, P251; Kurpisz M, 2010, REPROD BIOL, V10, P19, DOI 10.1016/S1642-431X(12)60035-7; Madureira R, 2017, SEMIN-CIENC AGRAR, V38, P2831, DOI [10.5433/1679-0359.2017v38n4suplp2831, 10.5433/1679-0359.2017v38n4Supl1p2831]; Matsuu A, 2009, J VET MED SCI, V71, P379, DOI 10.1292/jvms.71.379; MEYERSWALLEN VN, 1989, BIOL REPROD, V41, P881, DOI 10.1095/biolreprod41.5.881; Park EJ, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1068-6; Picard JY, 2017, SEX DEV, V11, P109, DOI 10.1159/000475516; Pleskacova J, 2010, SEX DEV, V4, P259, DOI 10.1159/000314536; Schmerbach K, 2005, TIERAERZTL PRAX K H, V33, P280; Smit MM, 2018, REPROD DOMEST ANIM, V53, P371, DOI 10.1111/rda.13116; Switonski M, 2012, SEX DEV, V6, P128, DOI 10.1159/000330921; Switonski M, 1996, CHROMOSOME RES, V4, P306, DOI 10.1007/BF02263682; Szczerbal I, 2014, REPROD DOMEST ANIM, V49, pe31, DOI 10.1111/rda.12318; Thiel David D, 2005, J Pediatr Surg, V40, pe29, DOI 10.1016/j.jpedsurg.2005.05.071; Vegter AR, 2010, REPROD DOMEST ANIM, V45, P447, DOI 10.1111/j.1439-0531.2008.01223.x; Whyte A, 2009, ANIM REPROD SCI, V115, P328, DOI 10.1016/j.anireprosci.2008.11.008; Wu XF, 2009, J ANDROL, V30, P46, DOI 10.2164/jandrol.108.005736	28	2	2	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	MAY	2018	161						20	24		10.1016/j.jcpa.2018.04.004			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GO1TA	WOS:000439737800003	30173854				2019-10-28	
J	Huang, S; Wang, M; Rehman, MU; Zhang, L; Tong, X; Shen, Y; Li, J				Huang, S.; Wang, M.; Rehman, M. U.; Zhang, L.; Tong, X.; Shen, Y.; Li, J.			Role of Angiopoietin-like 4 on Bone Vascularization in Chickens Exposed to High-altitude Hypoxia	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						ANGPTL4; bone vascularization; chicken; high-altitude hypoxia	INDUCED TIBIAL DYSCHONDROPLASIA; INDUCIBLE FACTORS; GROWTH-PLATE; ANGIOGENESIS; EXPRESSION; PROTEINS; CARTILAGE; SURVIVAL; FACTOR-1; THERAPY	The aim of this study was to investigate the role and expression of a novel angiogenic factor (angiopoietin-like 4, ANGPTL4) in tibial growth plates of broiler chickens exposed to high-altitude hypoxia. One-day-old healthy broiler chickens (n = 120) were transported from lowland to a high-altitude hypoxic region (nearly 3,000 m above sea level) and were reared under hypoxic- (natural lower oxygen content) and normoxic conditions (nearly 21% oxygen content) for 14 days. The effect of hypoxia on angiogenesis in the tibial growth plates and hypoxia-inducible factor (HIF)-1 alpha and ANGPTL4 expressions were determined by histological examination, quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), western blot and enzyme-linked immunosorbent assay (ELISA) techniques. The increase in vascular distribution to the hypertrophic chondrocyte zone of tibial growth plates contributed to promoting growth and development of the tibia under hypoxic conditions, which was highly correlated with the upregulation of ANGPTL4 at both the mRNA and protein levels together with activation of HIF-1 alpha under hypoxic conditions. These findings demonstrate that angiogenic factor ANGPTL4 upregulation is involved in tibial growth plate angiogenesis to promote the development of the tibia in broiler chickens under hypoxic conditions. They also suggest that ANGPTL4 may serve as a new molecular therapeutic target for ameliorating tibial dyschondroplasia chicken bone vascularization. (C) 2018 Elsevier Ltd. All rights reserved.	[Huang, S.; Rehman, M. U.; Zhang, L.; Tong, X.; Shen, Y.; Li, J.] Huazhong Agr Univ, Coll Vet Med, Wuhan, Hubei, Peoples R China; [Li, J.] Tibet Agr & Anim Husb Coll, Lab Detect & Monitoring Highland Anim Dis, Linzhi, Tibet, Peoples R China	Shen, Y; Li, J (reprint author), Huazhong Agr Univ, Coll Vet Med, Wuhan, Hubei, Peoples R China.; Li, J (reprint author), Tibet Agr & Anim Husb Coll, Lab Detect & Monitoring Highland Anim Dis, Linzhi, Tibet, Peoples R China.	yshen@mail.hzau.edu.cn; lijk210@sina.com	Rehman, Mujeeb Ur/L-3379-2019	Rehman, Mujeeb Ur/0000-0002-5078-5657	National Key Research and Development Program of China [2017YFD0502200]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [31460682]	The study was supported by the National Key Research and Development Program of China (number 2017YFD0502200) and the National Natural Science Foundation of China (number 31460682). In addition, the authors sincerely acknowledge and thank the Tibet Agriculture and Animal Husbandry College for permission to conduct the experiments and for providing the experimental site.	Costache MI, 2017, J GASTROINTEST LIVER, V26, P51, DOI 10.15403/jgld.2014.1121.261.eus; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Genin O, 2012, POULTRY SCI, V91, P1619, DOI 10.3382/ps.2012-02207; Gerber HP, 2000, TRENDS CARDIOVAS MED, V10, P223, DOI 10.1016/S1050-1738(00)00074-8; Groves PJ, 2017, ANIMAL, V11, P112, DOI 10.1017/S1751731116001105; Harper J, 1999, NAT MED, V5, P617, DOI 10.1038/9460; Hato T, 2008, TRENDS CARDIOVAS MED, V18, P6, DOI 10.1016/j.tcm.2007.10.003; Hausman MR, 2001, BONE, V29, P560, DOI 10.1016/S8756-3282(01)00608-1; Herzog A, 2011, AM J PHYSIOL-REG I, V301, pR140, DOI 10.1152/ajpregu.00134.2011; Hickey MM, 2006, CURR TOP DEV BIOL, V76, P217, DOI 10.1016/S0070-2153(06)76007-0; Hu K, 2016, ONCOTARGET, V7, P7816, DOI 10.18632/oncotarget.6868; Huang SC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22109-y; Huang SC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09664-6; Huang SC, 2018, J VET SCI, V19, P107, DOI 10.4142/jvs.2018.19.1.107; Huang SC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173698; Jayson GC, 2016, LANCET, V388, P518, DOI 10.1016/S0140-6736(15)01088-0; Katoh Y, 2006, INT J MOL MED, V17, P1145; Knowles HJ, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00080; Krzykawska-Serda M, 2017, ADV EXP MED BIOL, V977, P319, DOI 10.1007/978-3-319-55231-6_42; Kubo H, 2016, ONCOL LETT, V11, P1026, DOI 10.3892/ol.2015.4011; La PL, 2017, PPAR RES; Le Jan S, 2003, AM J PATHOL, V162, P1521, DOI 10.1016/S0002-9440(10)64285-X; Lienau J, 2009, J ORTHOP RES, V27, P1133, DOI 10.1002/jor.20870; Murata M, 2009, J ORTHOP RES, V27, P50, DOI 10.1002/jor.20703; Oike Y, 2005, TRENDS MOL MED, V11, P473, DOI 10.1016/j.molmed.2005.08.002; Ortmann B, 2014, CELL MOL LIFE SCI, V71, P3569, DOI 10.1007/s00018-014-1645-9; Pelicia K, 2012, BRAZ J POULTRY SCI, V14, P129, DOI 10.1590/S1516-635X2012000200007; Portal-Nunez S, 2012, HISTOL HISTOPATHOL, V27, P559, DOI 10.14670/HH-27.559; Pufe T, 2005, SCAND J MED SCI SPOR, V15, P211, DOI 10.1111/j.1600-0838.2005.00465.x; Rath NC, 2007, POULTRY SCI, V86, P2390, DOI 10.3382/ps.2007-00219; Schipani E, 2001, GENE DEV, V15, P2865; Schmittnaegel M, 2017, SCI TRANSL MED, V9, P385; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Street J., 2005, EUR J ORTHOP SURG TR, V15, P214; Tan MJ, 2012, MOL CANCER RES, V10, P677, DOI 10.1158/1541-7786.MCR-11-0519; Tian WX, 2009, AVIAN PATHOL, V38, P161, DOI 10.1080/03079450902737789; Xiong XR, 2015, ANIM BIOTECHNOL, V26, P222, DOI 10.1080/10495398.2014.1002563; Ya NL, 2017, CLIN NEUROL NEUROSUR, V153, P102, DOI 10.1016/j.clineuro.2016.11.020; Zelzer E, 2004, DEVELOPMENT, V131, P2161, DOI 10.1242/dev.01053; Zhu PC, 2012, BIOSCIENCE REP, V32, P211, DOI 10.1042/BSR20110102	40	0	0	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	MAY	2018	161						25	33		10.1016/j.jcpa.2018.04.007			9	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GO1TA	WOS:000439737800004	30173855				2019-10-28	
J	Miniscalco, B; Poggi, A; Martini, V; Morello, E; Sulce, M; Melega, M; Borrelli, A; Tarducci, A; Riondato, F				Miniscalco, B.; Poggi, A.; Martini, V.; Morello, E.; Sulce, M.; Melega, M.; Borrelli, A.; Tarducci, A.; Riondato, F.			Flow Cytometric Characterization of S-phase Fraction and Ploidy in Lymph Node Aspirates from Dogs with Lymphoma	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						DNA content; dog; lymphoma; proliferation rate	CANINE MALIGNANT-LYMPHOMAS; PROGNOSTIC-SIGNIFICANCE; DNA-PLOIDY; CELL-CYCLE; CLASSIFICATION; GRADE; KI67; PROLIFERATION; TUMOR; HALLMARKS	Canine lymphoma is a multifaceted disease encompassing numerous entities with different prognosis. Objective assessment of the proliferation rate is of importance from the pathological and clinical perspectives. Different methods have been described in the literature to assess proliferation rate, including evaluation of Ki67 expression in fresh lymph node (LN) aspirates measured by flow cytometry (FC). This test has a high accuracy in discriminating between low- and high-grade lymphomas, and provides prognostic information among highgrade B-cell lymphomas. DNA content analysis is less expensive and suitable for well-preserved samples. We describe DNA-content analysis using LN aspirates from 112 dogs with lymphoma. S-phase fraction (SPF) accurately discriminated between low- and high-grade lymphomas, with 3.15% being the best discriminating cut-off value. SPF values strongly correlated with Ki67 expression as assessed by FC. Survival analyses were restricted to 33 dogs with high-grade B-cell lymphoma receiving standardized multi-agent chemotherapy, but no significant result was obtained for SPF. We also describe a subset of aneuploid cases and their respective follow-up. We conclude that DNA content analysis may be combined with morphological examination of LN aspirates to improve the objectivity in lymphoma subtype classification in dogs. Further studies are needed to assess the possible prognostic role of SPF and ploidy status within specific lymphoma subtypes in dogs. (C) 2018 Elsevier Ltd. All rights reserved.	[Miniscalco, B.; Poggi, A.; Morello, E.; Sulce, M.; Melega, M.; Borrelli, A.; Tarducci, A.; Riondato, F.] Univ Turin, Dept Vet Sci, Largo Braccini 2, Turin, Italy; [Martini, V.] Univ Milan, Dept Vet Med, Via Celoria 10, Milan, Italy	Riondato, F (reprint author), Univ Turin, Dept Vet Sci, Largo Braccini 2, Turin, Italy.	fulvio.riondato@unito.it		Sulce, Majlind/0000-0001-8827-2876; TARDUCCI, Alberto/0000-0002-0485-6258; MELEGA, MAVERICK/0000-0003-0640-536X; BORRELLI, Antonio/0000-0003-2431-4680			Aresu L, 2015, VET COMP ONCOL, V13, P348, DOI 10.1111/vco.12048; AYL RD, 1992, VET PATHOL, V29, P386, DOI 10.1177/030098589202900503; BAUER KD, 1993, CYTOMETRY, V14, P486, DOI 10.1002/cyto.990140506; Bauer NB, 2007, J VET INTERN MED, V21, P928, DOI 10.1892/0891-6640(2007)21[928:ANORAK]2.0.CO;2; BOLON B, 1990, VET PATHOL, V27, P96, DOI 10.1177/030098589002700204; Burkhard MJ, 2015, CLIN LAB MED, V35, P591, DOI 10.1016/j.cll.2015.05.008; CLEMO FAS, 1994, VET PATHOL, V31, P207, DOI 10.1177/030098589403100208; Comazzi S, 2011, VET J, V188, P149, DOI 10.1016/j.tvjl.2010.03.011; Darzynkiewicz Z, 2017, CURRENT PROTOCOLS CY, V82; Devitt JJ, 2009, CYTOGENET GENOME RES, V124, P12, DOI 10.1159/000200083; Dictor M, 1999, AM J CLIN PATHOL, V112, pS40; Fouad YA, 2017, AM J CANCER RES, V7, P1016; FournelFleury C, 1997, J COMP PATHOL, V117, P35, DOI 10.1016/S0021-9975(97)80065-5; FOX MH, 1990, CANCER RES, V50, P6176; Garrett LD, 2002, J VET INTERN MED, V16, P704, DOI 10.1892/0891-6640(2002)016<0704:EOACPW>2.3.CO;2; Gelain ME, 2008, VET IMMUNOL IMMUNOP, V121, P179, DOI 10.1016/j.vetimm.2007.09.018; Golias CH, 2004, INT J CLIN PRACT, V58, P1134, DOI 10.1111/j.1742-1241.2004.00284.x; GREENLEE PG, 1990, CANCER-AM CANCER SOC, V66, P480, DOI 10.1002/1097-0142(19900801)66:3<480::AID-CNCR2820660314>3.0.CO;2-X; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HELLMEN E, 1993, VET PATHOL, V30, P20, DOI 10.1177/030098589303000103; JOENSUU H, 1991, CANCER, V68, P1564, DOI 10.1002/1097-0142(19911001)68:7<1564::AID-CNCR2820680718>3.0.CO;2-#; Kaufman DG, 2007, ADV ENZYME REGUL, V47, P127, DOI 10.1016/j.advenzreg.2006.12.015; Kim Kang Ho, 2015, Curr Protoc Mol Biol, V111, DOI 10.1002/0471142727.mb2806s111; Kiupel M, 1998, J COMP PATHOL, V119, P407, DOI 10.1016/S0021-9975(98)80035-2; Kiupel M, 1999, VET PATHOL, V36, P292, DOI 10.1354/vp.36-4-292; Lackowska B, 2012, POL J PATHOL, V63, P18; Lackowska Bozena, 1999, Polish Journal of Pathology, V50, P23; Martini V, 2016, VET COMP ONCOL, V14, P117, DOI 10.1111/vco.12155; Ormcrod MG, 1998, ANAL CELL PATHOL, V17, P103; Owen L, 1980, TNM CLASSIFICATION T, P46; Phillips BS, 2000, J VET DIAGN INVEST, V12, P111, DOI 10.1177/104063870001200202; Pinto AE, 2003, DIAGN CYTOPATHOL, V29, P194, DOI 10.1002/dc.10298; Poggi A, 2017, VET COMP ONCOL, V15, P431, DOI 10.1111/vco.12184; Poggi A, 2015, VET COMP ONCOL, V13, P475, DOI 10.1111/vco.12078; Ponce F, 2004, VET J, V167, P158, DOI 10.1016/j.tvjl.2003.10.009; Regan RC, 2013, VET COMP ONCOL, V11, P287, DOI 10.1111/j.1476-5829.2012.00318.x; REHN S, 1990, HEMATOL ONCOL, V8, P1, DOI 10.1002/hon.2900080102; Sansregret L, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a028373; Sayag D, 2018, VET COMP ONCOL, V16, P12, DOI 10.1111/vco.12320; Sun YL, 2016, BIOANALYSIS, V8, P2399, DOI 10.4155/bio-2016-0194; TESKE E, 1994, EXP HEMATOL, V22, P1179; Teske E, 1996, VET QUART, V18, P112, DOI 10.1080/01652176.1996.9694630; TESKE E, 1993, EXP HEMATOL, V21, P579; Vail DM, 2010, VET COMP ONCOL, V8, P28, DOI 10.1111/j.1476-5829.2009.00200.x; Valli VE, 2013, VET PATHOL, V50, P738, DOI 10.1177/0300985813478210; Valli VE, 2011, VET PATHOL, V48, P198, DOI 10.1177/0300985810379428; Villamil JA, 2009, J CANCER EPIDEMIOL, DOI 10.1155/2009/591753; VINCENT MD, 1987, MED HYPOTHESES, V24, P151, DOI 10.1016/0306-9877(87)90098-3; Wilkerson MJ, 2012, VET CLIN N AM-SMALL, V42, P53, DOI 10.1016/j.cvsm.2011.09.012; Willis R. A., 1952, SPREAD TUMORS HUMAN; Wiman KG, 2017, J INTERN MED, V281, P483, DOI 10.1111/joim.12609; Winter JN, 1996, BLOOD, V88, P3919, DOI 10.1182/blood.V88.10.3919.bloodjournal88103919	52	0	0	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	MAY	2018	161						34	42		10.1016/j.jcpa.2018.01.005			9	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GO1TA	WOS:000439737800005	30173856				2019-10-28	
J	Lin, AW; Vapniarsky, N; Cissell, DD; Verstraete, FJM; Lin, CH; Hatcher, DC; Arzi, B				Lin, A. W.; Vapniarsky, N.; Cissell, D. D.; Verstraete, F. J. M.; Lin, C. H.; Hatcher, D. C.; Arzi, B.			The Temporomandibular Joint of the Domestic Dog (Canis lupus familiaris) in Health and Disease	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						cartilage; dog; osteoarthritis; temporomandibular joint degeneration	INTERNAL DERANGEMENT; DISC; DISORDERS; OSTEOARTHRITIS; ATTACHMENTS; PREVALENCE; DIAGNOSIS; ETIOLOGY	This study aimed to characterize the histological, biomechanical and biochemical properties of the temporomandibular joint (TMJ) of the domestic dog in health and disease. In addition, we sought to identify structure-function relationships and to characterize TMJ degenerative lesions that may be found naturally in this species. TMJs (n = 20) from fresh cadaver heads (n = 10) of domestic dogs were examined macroscopically and microscopically and by cone-beam computed tomography. The TMJ discs were evaluated for their mechanical and biochemical properties. If TMJ arthritic changes were found, pathological characteristics were described and compared with healthy joints. Five (50%) dogs demonstrated macroscopically normal fibrocartilaginous articular surfaces and fibrous discs and five (50%) dogs exhibited degenerative changes that were observed either in the articular surfaces or the discs. In the articulating surfaces, these changes included erosions, conformational changes and osteophytes. In the discs, degenerative changes were represented by full thickness perforations. Histologically, pathological specimens demonstrated fibrillations with or without erosions, subchondral bone defects and subchondral bone sclerosis. Significant anisotropy in the TMJ discs was evident on histology and tensile mechanical testing. Specifically, the discs were significantly stiffer and stronger in the rostrocaudal direction compared with the mediolateral direction. No significant differences were detected in compressive properties of different disc regions. Biochemical analyses showed high collagen content and low glycosaminoglycan (GAG) content. No significant differences in biochemical composition, apart from GAG, were detected among the disc regions. GAG concentration was significantly higher in the central region as compared with the caudal (posterior) region. The TMJ of the domestic dog exhibits similarities, but also differences, compared with other mammals with regards to structure-function relationships. The TMJ articular surfaces and the disc exhibit degenerative changes as seen in other species, including perforation of the disc as seen in man. The degenerative changes had greater effects on the mechanical properties compared with the biochemical properties of the TMJ components. Translational motion of the TMJ does occur in dogs, but is limited. (C) 2018 Elsevier Ltd. All rights reserved.	[Lin, A. W.; Cissell, D. D.; Verstraete, F. J. M.; Hatcher, D. C.; Arzi, B.] Univ Calif Davis, Dept Surg & Radiol Sci, Davis, CA 95616 USA; [Vapniarsky, N.] Univ Calif Davis, Sch Vet Med, Dept Pathol Microbiol & Immunol, Davis, CA 95616 USA; [Lin, C. H.] Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA	Arzi, B (reprint author), Univ Calif Davis, Dept Surg & Radiol Sci, Davis, CA 95616 USA.; Vapniarsky, N (reprint author), Univ Calif Davis, Sch Vet Med, Dept Pathol Microbiol & Immunol, Davis, CA 95616 USA.	natarzi@gmail.com; barzi@ucdavis.edu			Faculty discretionary funds of B. Arzi, University of California, Davis; National Center for Advancing Translational Sciences, National Institute of Health, Institutional Career Development [KL2 TR001859]	This research was funded by Faculty discretionary funds of B. Arzi, University of California, Davis. The funding sources had no role in the study design or in the collection, analysis and interpretation of data, in the writing of the manuscript or in the decision to submit the manuscript for publication. While working on this manuscript, N. Vapniarsky was supported by the National Center for Advancing Translational Sciences, National Institute of Health, Institutional Career Development Grant number KL2 TR001859.	Allen KD, 2006, TISSUE ENG, V12, P1183, DOI 10.1089/ten.2006.12.1183; Aryaei A, 2016, CURR OSTEOPOROS REP, V14, P269, DOI 10.1007/s11914-016-0327-y; Arzi B, 2015, ARCH ORAL BIOL, V60, P208, DOI 10.1016/j.archoralbio.2014.09.004; Arzi B, 2013, JAVMA-J AM VET MED A, V242, P69, DOI 10.2460/javma.242.1.69; Arzi B, 2012, EUR J WILDLIFE RES, V58, P451, DOI 10.1007/s10344-011-0595-x; BROOKS SL, 1992, ORAL SURG ORAL MED O, V73, P118, DOI 10.1016/0030-4220(92)90168-P; Brown BN, 2012, J ORAL MAXIL SURG, V70, P2656, DOI 10.1016/j.joms.2011.12.030; Curth S, 2017, ZOOLOGY, V125, P1, DOI 10.1016/j.zool.2017.06.002; DEBONT LGM, 1986, J ORAL MAXIL SURG, V44, P634, DOI 10.1016/S0278-2391(86)80075-1; Detamore MS, 2003, J ORAL MAXIL SURG, V61, P494, DOI 10.1053/joms.2003.50096; Dijkgraaf LC, 1999, J ORAL MAXIL SURG, V57, P255, DOI 10.1016/S0278-2391(99)90669-9; Evans HE, 2012, MILLERS ANATOMY DOG, P161; Fazaeli S, 2016, OSTEOARTHR CARTILAGE, V24, P1292, DOI 10.1016/j.joca.2016.01.138; Ficklin T, 2007, J BIOMECH, V40, P3607, DOI 10.1016/j.jbiomech.2007.06.005; Gatchel RJ, 2006, J AM DENT ASSOC, V137, P339, DOI 10.14219/jada.archive.2006.0183; Herring S. W., 2003, Journal of Musculoskeletal & Neuronal Interactions, V3, P391; Kalpakci KN, 2011, J DENT RES, V90, P193, DOI 10.1177/0022034510381501; Kristensen KD, 2011, J ORAL PATHOL MED, V40, P111, DOI 10.1111/j.1600-0714.2010.00934.x; Lantz GC, 2012, ORAL MAXILLOFACIAL S, P531; Matuska AM, 2016, ARCH ORAL BIOL, V64, P72, DOI 10.1016/j.archoralbio.2016.01.003; McDonald M, 2015, ARCH ORAL BIOL, V60, P582, DOI 10.1016/j.archoralbio.2015.01.005; MOFFETT BC, 1964, AM J ANAT, V115, P119, DOI 10.1002/aja.1001150108; Murphy MK, 2013, J DENT RES, V92, P753, DOI 10.1177/0022034513494817; Murphy MK, 2013, INT J ORAL MAX IMPL, V28, pE393, DOI 10.11607/jomi.te20; NAKANO T, 1989, ARCH ORAL BIOL, V34, P749, DOI 10.1016/0003-9969(89)90082-4; Nanci A, 2017, T CATES ORAL HISTOLO, P311; OBERG T, 1971, ACTA ODONTOL SCAND, V29, P349, DOI 10.3109/00016357109026526; Shen P, 2014, J CRANIO MAXILL SURG, V42, P874, DOI 10.1016/j.jcms.2014.01.001; Shengyi T, 1991, J Craniomandib Disord, V5, P28; Sindelar BJ, 2000, ARCH BIOCHEM BIOPHYS, V379, P64, DOI 10.1006/abbi.2000.1855; SOLBERG WK, 1979, J AM DENT ASSOC, V98, P25, DOI 10.14219/jada.archive.1979.0008; Tanaka E, 2008, J DENT RES, V87, P296, DOI 10.1177/154405910808700406; Tanaka E, 2003, CRIT REV ORAL BIOL M, V14, P138, DOI 10.1177/154411130301400207; Vapniarsky N, 2017, TISSUE ENG PART C-ME, V23, P700, DOI [10.1089/ten.tec.2017.0149, 10.1089/ten.TEC.2017.0149]; Vollmerhaus B, 1996, ANAT HISTOL EMBRYOL, V25, P145, DOI 10.1111/j.1439-0264.1996.tb00073.x; Willard VP, 2012, ARCH ORAL BIOL, V57, P599, DOI 10.1016/j.archoralbio.2011.10.004; Zarb GA, 1999, J OROFAC PAIN, V13, P295	37	2	2	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	MAY	2018	161						55	67		10.1016/j.jcpa.2018.05.001			13	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GO1TA	WOS:000439737800007	30173858	Green Published			2019-10-28	
J	Otis, CN				Otis, Christopher N.			Introduction to Updates in the Reporting of Selected Tumor Sites	AJSP-REVIEWS AND REPORTS			English	Editorial Material									[Otis, Christopher N.] UMass Baystate, Springfield, MA USA	Otis, CN (reprint author), Baystate Med Ctr, Dept Pathol, 759 Chestnut St, Springfield, MA 01199 USA.	christopher.otis@umassmed.edu						0	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	MAY-JUN	2018	23	3					105	106		10.1097/PCR.0000000000000248			2	Pathology	Pathology	GL9XG	WOS:000437696100002					2019-10-28	
J	Otis, CN				Otis, Christopher N.			A Perspective on Standardized Tumor Staging, Tumor Nomenclature, and Surgical Pathology Reports	AJSP-REVIEWS AND REPORTS			English	Editorial Material							POINT-COUNTERPOINT		[Otis, Christopher N.] Univ Massachusetts, Baystate Hlth, 759 Chestnut St, Springfield, MA 01199 USA; [Otis, Christopher N.] Tufts Univ, Sch Med, Boston, MA 02111 USA	Otis, CN (reprint author), Univ Massachusetts, Baystate Hlth, 759 Chestnut St, Springfield, MA 01199 USA.	Christopher.otis@umass.med.edu					Ackerman AB, 2004, AM J CLIN PATHOL, V122, P815; Edge SB, 2017, AJCC CANC STAGING MA; Ellis DW, 2016, VIRCHOWS ARCH, V468, P51, DOI 10.1007/s00428-015-1834-4; Otis CN, 2004, AM J CLIN PATHOL, V122, P817; Rosai J., 1997, GUIDING SURGEONS HAN; SINARD JH, 2006, PRACTICAL PATHOLOGY; Srigley JR, 2009, J SURG ONCOL, V99, P517, DOI 10.1002/jso.21282	7	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	MAY-JUN	2018	23	3					107	108		10.1097/PCR.0000000000000249			2	Pathology	Pathology	GL9XG	WOS:000437696100003					2019-10-28	
J	Ellis, DW; Judge, M; Srigley, JR				Ellis, David W.; Judge, Meagan; Srigley, John R.			International Harmonization of Cancer Diagnosis, Staging, and Data Sets for Pathology Reporting-The Role of the International Collaboration on Cancer Reporting	AJSP-REVIEWS AND REPORTS			English	Editorial Material									[Ellis, David W.; Judge, Meagan] Royal Coll Pathologists Australasia, Sydney, NSW, Australia; [Ellis, David W.] Clinpath Labs, Adelaide, SA, Australia; [Srigley, John R.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Srigley, John R.] Trillium Hlth Partners, Mississauga, ON, Canada	Ellis, DW (reprint author), Clinpath Labs, 19 Fullarton Rd, Kent Town, SA 5067, Australia.	david_ellis@me.com					College of American Pathologists, 2017, CANC PROT CHECKL; Delahunt B, 2017, HISTOPATHOLOGY, V71, P5, DOI 10.1111/his.13200; Ellis DW, 2016, VIRCHOWS ARCH, V468, P51, DOI 10.1007/s00428-015-1834-4; International Collaboration on Cancer Reporting, 2017, GUID DEV ICCR DAT; Merlin T, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-34; RCPA (Royal College of Pathologists of Australasia), 2017, CANC PROT; Royal College of Pathologists, 2017, CANC DAT TISS PATHW; Srigley JR, 2009, J SURG ONCOL, V99, P517, DOI 10.1002/jso.21282	8	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	MAY-JUN	2018	23	3					109	112		10.1097/PCR.0000000000000246			4	Pathology	Pathology	GL9XG	WOS:000437696100004					2019-10-28	
J	Sanders, MA; Wong, SM; Iorgulescu, JB; Lester, SC				Sanders, Mary Ann; Wong, Stephanie M.; Iorgulescu, Julian Bryan; Lester, Susan C.			Changes and Clarifications in the Eighth Edition of the AJCC Cancer Staging System for Breast Cancer	AJSP-REVIEWS AND REPORTS			English	Review						AJCC cancer staging system; breast cancer; TNM system	CARCINOMA IN-SITU; NEOADJUVANT CHEMOTHERAPY; RESIDUAL DISEASE; CLASSIFICATION; PURE	In the eighth edition of the American Joint Committee on Cancer staging system for breast cancer, the definitions for T (tumor), N (nodes), and M (metastases) remain substantially unchanged but with clarifications for certain categories that may have been problematic for pathologists and clinicians. The principal change is the decision to exclude lobular carcinoma in situ from T classification. In contrast, there is a major change in how stage is determined by introducing a new clinical prognostic stage and a new pathological prognostic stage. These prognostic stages incorporate information about grade, estrogen receptor expression, progesterone receptor expression, human epidermal growth factor receptor 2 expression, and, in some cases, the Oncotype Dx Recurrence Score, in addition to T, N, and M, to create groups of cancers predicted to have a similar survival at 3 years based on information from the National Cancer Database. This review highlights the changes and notable clarifications to the TNM system and how these relate to standard pathology reporting.	[Sanders, Mary Ann] Univ Louisville, Dept Pathol & Lab Med, Louisville, KY 40292 USA; [Wong, Stephanie M.] McGill Univ, Ctr Hlth, Dept Surg, Montreal, PQ, Canada; [Iorgulescu, Julian Bryan; Lester, Susan C.] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA	Lester, SC (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	slester@bwh.harvard.edu					Bagaria SP, 2014, JAMA SURG, V149, P125, DOI 10.1001/jamasurg.2013.3181; Beahrs OH, 1977, MANUAL STAGING CANC; Boffa DJ, 2017, JAMA ONCOL, V3, P1722, DOI 10.1001/jamaoncol.2016.6905; Bossuyt V, 2015, ANN ONCOL, V26, P1280, DOI 10.1093/annonc/mdv161; Brown M, 2008, CANCER-AM CANCER SOC, V112, P737, DOI 10.1002/cncr.23243; Chavez-Macgregor M, 2017, ONCOLOGIST, V22, P1292, DOI 10.1634/theoncologist.2017-0116; Cheng E, 2017, AM J SURG PATHOL, V41, P1275, DOI 10.1097/PAS.0000000000000896; Cowell CF, 2013, MOL ONCOL, V7, P859, DOI 10.1016/j.molonc.2013.07.005; Fouad TM, 2017, LANCET ONCOL, V18, pE228, DOI 10.1016/S1470-2045(17)30192-4; Gradisher WJ, 2017, VERSION 2 2017 NATL; Groen EJ, 2017, BREAST, V31, P274, DOI 10.1016/j.breast.2016.09.001; Gruber G, 2004, INT J CANCER, V109, P144, DOI 10.1002/ijc.11684; Guth U, 2007, BREAST, V16, P625, DOI 10.1016/j.breast.2007.05.006; Guilbert MC, 2018, AM J SURG PATHOL, V2018; Guth U, 2005, ANN ONCOL, V16, P1618, DOI 10.1093/annonc/mdi319; Haagensen C, 1956, DISEASES BREAST, P533; Hortobagyi GN, 2017, AJCC CANC STAGING MA, P589; Orucevic A, 2015, BREAST J, V21, P147, DOI 10.1111/tbj.12367; Pieri A, 2014, WORLD J CLIN ONCOL, V5, P546, DOI 10.5306/wjco.v5.i3.546; Rabban JT, 2009, AM J SURG PATHOL, V33, P256, DOI 10.1097/PAS.0b013e31817fbdb4; Sahoo Sunati, 2012, Surg Pathol Clin, V5, P749, DOI 10.1016/j.path.2012.06.005; Sakr RA, 2016, MOL ONCOL, V10, P360, DOI 10.1016/j.molonc.2015.11.001	22	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	MAY-JUN	2018	23	3					113	117		10.1097/PCR.0000000000000239			5	Pathology	Pathology	GL9XG	WOS:000437696100005					2019-10-28	
J	Hagemann, IS; Cole, LL; Cosin, JA; Gress, DM; Mutch, DG; Olawaiye, AB				Hagemann, Ian S.; Cole, Lisa L.; Cosin, Jonathan A.; Gress, Donna M.; Mutch, David G.; Olawaiye, Alexander B.			Controversies in Gynecologic Cancer Staging: An AJCC Cancer Staging Manual, Eighth Edition Perspective	AJSP-REVIEWS AND REPORTS			English	Review						AJCC; biomarkers; cancer staging; cervical cancer; endometrial cancer; gynecology; ovarian cancer; registries; uterine sarcoma; vulvar cancer	SENTINEL LYMPH-NODE; INVASIVE CERVICAL-CANCER; SQUAMOUS-CELL CARCINOMA; POSITIVE PERITONEAL CYTOLOGY; EPITHELIAL OVARIAN-CANCER; ENDOMETRIAL CANCER; PROGNOSTIC-FACTORS; HUMAN-PAPILLOMAVIRUS; LYMPHADENECTOMY; CHEMOTHERAPY	Staging systems provide a common language to support clinical research and decision making in patients with cancer. The eighth edition of the AJCC Cancer Staging Manual incorporates updates that reflect evolving clinical practices and scientific insights. The present article summarizes changes that have been made for gynecologic subsites and outlines continued challenges. Gynecologic American Joint Committee on Cancer/International Union Against Cancer staging continues to conform closely to current International Federation of Obstetrics and Gynecology staging. The eighth edition is aligned with the major revision made to International Federation of Obstetrics and Gynecology staging of ovarian cancer in 2014 and contains a unified staging system for ovarian, fallopian tube, and primary peritoneal cancer. Continuing challenges for ovarian cancer include determining the relative significance of intraoperative rupture, surface involvement, and positive washings, which are rank ordered in the new staging system. Another challenge is assignment of a tubal versus ovarian primary site for high-grade serous carcinoma, which cannot be done in a reliable way. In uterine carcinoma, endometrial intraepithelial carcinoma is now recognized as a T1 cancer, and nodal micrometastases have been defined with their own N stage. Also, isolated tumor cells in lymph nodes have been incorporated in the staging of all gynecologic carcinomas. The staging of uterine sarcoma is largely unchanged. Future revisions may consider grouping these tumors with soft tissue sarcomas at large. Staging of cervical cancer is largely unchanged. Nomenclature of early invasive carcinoma and the challenges in defining tumor dimension in cervical carcinoma are discussed. The nodal staging of vulvar cancer now incorporates a vocabulary for isolated tumor cells and micrometastases. Despite the current interest in molecular staging, the eighth edition expert panel did not identify any specific biomarkers for inclusion in stage classification, but several are recommended for collection as ancillary data elements, including p16 status in vulvar, vaginal, and cervical tumors. In the eighth edition, as in the seventh, anatomic factors remain the cornerstone of gynecologic cancer staging.	[Hagemann, Ian S.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA; [Hagemann, Ian S.; Mutch, David G.] Washington Univ, Sch Med, Dept Obstet & Gynecol, St Louis, MO USA; [Cole, Lisa L.] Univ Massachusetts, Med Sch Baystate, Dept Pathol, Springfield, MA USA; [Cosin, Jonathan A.] Hartford Healthcare Canc Inst, New Britain, CT USA; [Gress, Donna M.] Amer Joint Comm Canc, Chicago, IL USA; [Olawaiye, Alexander B.] Univ Pittsburgh, Dept Obstet & Gynecol, Pittsburgh, PA USA	Hagemann, IS (reprint author), 425 S Euclid Ave,Campus Box 8118, St Louis, MO 63110 USA.	hagemani@wustl.edu					Aalders JG, 2007, GYNECOL ONCOL, V104, P222, DOI 10.1016/j.ygyno.2006.10.013; Abu-Rustum NR, 2009, GYNECOL ONCOL, V113, P163, DOI 10.1016/j.ygyno.2009.01.003; Alvarado-Cabrero I, 2017, INT J GYNECOL PATHOL, V36, P476, DOI 10.1097/PGP.0000000000000357; Amendola MA, 2005, J CLIN ONCOL, V23, P7454, DOI 10.1200/JCO.2004.00.5397; American College of Surgeons Commission on Cancer, 2016, CANC PROGR STAND; Amin MB, 2017, AJCC CANC STAGING MA; Bakkum-Gamez JN, 2009, OBSTET GYNECOL, V113, P11, DOI 10.1097/AOG.0b013e3181917a0c; Bernard B, 2013, GYNECOL ONCOL, V131, P634, DOI 10.1016/j.ygyno.2013.09.011; Berney DM, 2016, BRIT J CANCER, V114, P1078, DOI 10.1038/bjc.2016.86; Beyer J, 2010, J CLIN ONCOL, V28, P4906, DOI 10.1200/JCO.2009.26.8128; Bidard FC, 2013, CANCER METAST REV, V32, P179, DOI 10.1007/s10555-012-9398-0; Bohm S, 2015, J CLIN ONCOL, V33, P2457, DOI 10.1200/JCO.2014.60.5212; Brachova P, 2015, INT J ONCOL, V46, P607, DOI 10.3892/ijo.2014.2747; Broders AC, 1926, ARCH PATHOL LAB MED, V2, P376; Chan JK, 2008, CANCER-AM CANCER SOC, V112, P2202, DOI 10.1002/cncr.23390; Cherniack AD, 2017, CANCER CELL, V31, P411, DOI 10.1016/j.ccell.2017.02.010; College of American Pathologists, 2017, PROT EX SPEC PAT PRI; Creasman W, 2009, INT J GYNECOL OBSTET, V105, P109, DOI 10.1016/j.ijgo.2009.02.010; Darragh TM, 2012, ARCH PATHOL LAB MED, V136, P1266, DOI 10.5858/arpa.LGT200570; Day E, 2016, INT J GYNECOL PATHOL, V35, P467, DOI 10.1097/PGP.0000000000000269; DEMBO AJ, 1990, OBSTET GYNECOL, V75, P263; Edge SB, 2010, AJCC CANC STAGING MA; Eifel P. J., 2008, CANC PRINCIPLES PRAC; Einhorn LH, 2007, NEW ENGL J MED, V357, P340, DOI 10.1056/NEJMoa067749; Epstein JI, 2016, EUR UROL, V69, P428, DOI 10.1016/j.eururo.2015.06.046; Eriksson AGZ, 2016, GYNECOL ONCOL, V140, P394, DOI 10.1016/j.ygyno.2015.12.028; Ferrandina G, 2007, GYNECOL ONCOL, V107, P154, DOI 10.1016/j.ygyno.2007.05.016; Field MG, 2014, CURR OPIN OPHTHALMOL, V25, P234, DOI 10.1097/ICU.0000000000000051; Foote J, IS PERITONEAL CYTOLO; Garg G, 2013, GYNECOL ONCOL, V128, P77, DOI 10.1016/j.ygyno.2012.09.026; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Giuliano AE, 2017, CA-CANCER J CLIN, V67, P291, DOI 10.3322/caac.21393; Greene FL, 2005, CANCER, V103, P647, DOI 10.1002/cncr.20808; Greene FL, 2002, AJCC CANC STAGING MA; Grigsby PW, 2008, CANCER IMAGING, V8, P146, DOI 10.1102/1470-7330.2008.0022; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Herrington CS, 1999, J PATHOL, V189, P1; Horn LC, 2008, GYNECOL ONCOL, V108, P63, DOI 10.1016/j.ygyno.2007.08.086; Horn LC, 2006, INT J GYNECOL PATHOL, V25, P182, DOI 10.1097/01.pgp.0000185406.85685.df; Hui P, 2005, MODERN PATHOL, V18, P75, DOI 10.1038/modpathol.3800271; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115; Kidd EA, 2010, J CLIN ONCOL, V28, P2108, DOI 10.1200/JCO.2009.25.4151; Kizer NT, 2009, GYNECOL ONCOL, V114, P310, DOI 10.1016/j.ygyno.2009.04.018; Kommoss F, 2017, J CANCER RES CLIN, V143, P255, DOI 10.1007/s00432-016-2276-3; Kumar V, 2015, ROBBINS COTRAN PATHO; Kurman RJ, 2010, AM J SURG PATHOL, V34, P433, DOI 10.1097/PAS.0b013e3181cf3d79; Li N, 2011, INT J CANCER, V128, P927, DOI 10.1002/ijc.25396; Mariani A, 2000, AM J OBSTET GYNECOL, V182, P1506, DOI 10.1067/mob.2000.107335; McAlpine JN, 2017, HISTOPATHOLOGY, V71, P238, DOI 10.1111/his.13205; McCluggage WG, 2015, MODERN PATHOL, V28, P1101, DOI 10.1038/modpathol.2015.77; McCluggage WG, 2017, INT J GYNECOL PATHOL; MILOSEVIC MF, 1992, INT J GYNECOL CANCER, V2, P225, DOI 10.1046/j.1525-1438.1992.02050225.x; Mitchell DG, 2009, GYNECOL ONCOL, V112, P95, DOI 10.1016/j.ygyno.2008.10.005; MORTON DG, 1961, AM J OBSTET GYNECOL, V81, P1115, DOI 10.1016/S0002-9378(15)33341-X; National Comprehensive Cancer Network, 2017, NCCN GUID AC MYEL LE; National Comprehensive Cancer Network, 2017, NCCN GUID AN CARC; National Comprehensive Cancer Network, 2016, NCCN GUID VULV CANC; Ngan HYS, 2006, INT J GYNECOL OBSTET, V95, pS193, DOI 10.1016/S0020-7292(06)60034-9; Onda T, 1998, CANCER, V83, P1555, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1555::AID-CNCR10>3.0.CO;2-R; Oonk MH, 2010, LANCET ONCOL, V11, P646, DOI 10.1016/S1470-2045(10)70104-2; ORIGONI M, 1992, GYNECOL ONCOL, V45, P313, DOI 10.1016/0090-8258(92)90311-6; Petereit DG, 2000, CLIN RAD ONCOLOGY; Pirog EC, 2000, AM J PATHOL, V157, P1055, DOI 10.1016/S0002-9440(10)64619-6; Prat J, 2014, INT J GYNECOL OBSTET, V124, P1, DOI 10.1016/j.ijgo.2013.10.001; Preti M, 2017, J GYNECOL ONCOL, V28, DOI 10.3802/jgo.2017.28.e27; Roma AA, 2015, AM J SURG PATHOL, V39, P667, DOI 10.1097/PAS.0000000000000402; Rossi EC, 2017, LANCET ONCOL, V18, P384, DOI 10.1016/S1470-2045(17)30068-2; Schwab M., 2011, ENCY CANC; Sedlis A, 1999, GYNECOL ONCOL, V73, P177, DOI 10.1006/gyno.1999.5387; Seidman JD, 2015, GYNECOL ONCOL, V136, P336, DOI 10.1016/j.ygyno.2014.12.018; Seidman JD, 2010, INT J GYNECOL PATHOL, V29, P1, DOI 10.1097/PGP.0b013e3181af2372; Shah C, 2005, GYNECOL ONCOL, V99, P564, DOI 10.1016/j.ygyno.2005.06.011; Spencer WT, 1882, OVARIAN UTERINE TUMO; SREENAN JJ, 1995, AM J SURG PATHOL, V19, P666, DOI 10.1097/00000478-199506000-00007; STENDAHL U, 1983, INT J GYNECOL PATHOL, V2, P42, DOI 10.1097/00004347-198301000-00004; Swerdlow SH, 2017, WHO CLASSIFICATION T; Tangen IL, 2017, BR J CANC; Tebeu PM, 2004, BRIT J CANCER, V91, P720, DOI 10.1038/sj.bjc.6602035; Touhami O, 2015, GYNECOL ONCOL, V138, P41, DOI 10.1016/j.ygyno.2015.04.008; Vergote I, 2001, LANCET, V357, P176, DOI 10.1016/S0140-6736(00)03590-X; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F; ZALOUDEK CJ, 1981, CANCER-AM CANCER SOC, V48, P354, DOI 10.1002/1097-0142(19810715)48:2<354::AID-CNCR2820480222>3.0.CO;2-Q	82	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	MAY-JUN	2018	23	3					118	128		10.1097/PCR.0000000000000240			11	Pathology	Pathology	GL9XG	WOS:000437696100006					2019-10-28	
J	Spruill, LS; Bruner, ET; Smith, MT				Spruill, Laura S.; Bruner, Evelyn T.; Smith, Michael Timothy			Genitourinary Updates in the Eighth Edition of the AJCC Cancer Staging Manual	AJSP-REVIEWS AND REPORTS			English	Review						AJCC; bladder; genitourinary; kidney; penis; prostate; staging; testis; urethra	SQUAMOUS-CELL CARCINOMA; UROTHELIAL CARCINOMA; PROGNOSTIC-FACTORS; BLADDER-CANCER; BIOCHEMICAL RECURRENCE; RADICAL PROSTATECTOMY; INVASION; LYMPHADENECTOMY; SYSTEM; PENIS	The new, eighth edition of the AJCC Cancer Staging Manual has been published, and there are many and significant changes in the staging for genitourinary organs. Pathologists will necessarily need to study the manual to acquire fluency in the staging. The staging changes and philosophy will be applicable in 2018. The TNM process involved remains the same, but some specific definition changes are present. Prostate staging is now very different; whereas prior staging included pT2a, pT2b, and pT2c, now all organ-confined disease is pT2 without consideration of half gland involvement. Staging of penis cancer previously considered urethral involvement but now corpus spongiosum involvement is considered pT2, and corpus cavernosum involvement is considered pT3 disease irrespective of the urethral involvement based on literature evidence. Invasion of the epididymis as a component of testis staging is now considered pT2 rather than pT1. These are just some of the new changes that will require understanding on the part of the pathologist. This article describes the changes and some of the background supportive literature and provides appropriate explanatory illustrations.	[Spruill, Laura S.; Bruner, Evelyn T.; Smith, Michael Timothy] Med Univ South Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Spruill, Laura S.; Smith, Michael Timothy] Med Univ South Carolina, Dept Urol Surg, Charleston, SC 29425 USA	Smith, MT (reprint author), Med Univ South Carolina, 171 Ashley Ave,MSC 908, Charleston, SC 29425 USA.	smithti@musc.edu					Brimo F, 2013, HUM PATHOL, V44, P95, DOI 10.1016/j.humpath.2012.04.020; Caso JR, 2010, BJU INT, V106, P1623, DOI 10.1111/j.1464-410X.2010.09439.x; Chun FKH, 2006, EUR UROL, V49, P273, DOI 10.1016/j.eururo.2005.12.009; da Costa WH, 2015, INT J UROL, V22, P669, DOI 10.1111/iju.12759; Edge SB, 2010, AJCC CANC STAGING MA; Fine SW, 2012, EUR UROL, V62, P20, DOI 10.1016/j.eururo.2012.02.055; Freedland SJ, 2004, CANCER-AM CANCER SOC, V100, P1646, DOI 10.1002/cncr.20145; Gillan A, 2015, BIOMED RES INT, DOI 10.1155/2015/547586; Gupta R, 2008, ADV ANAT PATHOL, V15, P127, DOI 10.1097/PAP.0b013e31817145a9; Hu ZH, 2014, ANN DIAGN PATHOL, V18, P49, DOI 10.1016/j.anndiagpath.2013.11.002; Leijte JAP, 2008, J UROLOGY, V180, P933, DOI 10.1016/j.juro.2008.05.011; Leissner J, 2004, J UROLOGY, V171, P139, DOI 10.1097/01.ju.0000102302.26806.fb; Lughezzani G, 2014, J UROLOGY, V191, P977, DOI 10.1016/j.juro.2013.10.140; Mahul B, 2017, AJCC CANC STAGING MA; MCDOUGAL WS, 1995, J UROLOGY, V154, P1364, DOI 10.1016/S0022-5347(01)66863-0; Paner GP, 2017, ADV ANAT PATHOL, V24, P113, DOI 10.1097/PAP.0000000000000152; SOLSONA E, 1992, EUR UROL, V22, P115; Soria JC, 1997, ANN ONCOL, V8, P1089, DOI 10.1023/A:1008248319036; van Rhijn BWG, 2012, EUR UROL, V61, P378, DOI 10.1016/j.eururo.2011.10.026	19	0	0	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	MAY-JUN	2018	23	3					129	133		10.1097/PCR.0000000000000241			5	Pathology	Pathology	GL9XG	WOS:000437696100007					2019-10-28	
J	Butnor, KJ				Butnor, Kelly J.			Accurate Assessment of Histologic Parameters That Impact Lung Cancer Staging: Implications for the American Joint Committee on Cancer Eighth Edition TNM Classification	AJSP-REVIEWS AND REPORTS			English	Review						lung cancer; staging; visceral pleura	VISCERAL PLEURAL INVASION; INTERNATIONAL-ASSOCIATION; ELASTIC STAINS; IN-SITU; ADENOCARCINOMA; CARCINOMAS; CRITERIA; PROPOSAL; TUMORS	The eighth edition of the American Joint Committee on Cancer TNM Classification represents a paradigm shift in lung cancer staging. Some staging parameters, such as the visceral pleural invasion, have not changed. Others are a significant departure from the prior edition, including tumor size used to assign T category, which for the first time is based solely on the invasive component, excluding any lepidic component. Understanding how to assess these histologic parameters will allow pathologists to contribute to the improved care of lung cancer patients through accurate pathologic staging.	[Butnor, Kelly J.] Univ Vermont, Med Ctr, Dept Pathol & Lab Med, 111 Colchester Ave,ACC Bldg,EP2-120, Burlington, VT 05401 USA	Butnor, KJ (reprint author), Univ Vermont, Med Ctr, Dept Pathol & Lab Med, 111 Colchester Ave,ACC Bldg,EP2-120, Burlington, VT 05401 USA.	kelly.butnor@uvmhealth.org					Amin MB, 2017, AJCC CANC STAGING MA; Borczuk AC, 2012, MODERN PATHOL, V25, pS1, DOI 10.1038/modpathol.2011.151; Bunker ML, 1999, AM J CLIN PATHOL, V112, P777; Detterbeck FC, 2016, J THORAC ONCOL, V11, P651, DOI 10.1016/j.jtho.2016.01.025; Edge SB, 2010, AJCC CANC STAGING MA; Girard N, 2009, AM J SURG PATHOL, V33, P1752, DOI 10.1097/PAS.0b013e3181b8cf03; Goldstraw P., 2009, INT ASS STUDY LUNG C; Kadota K, 2014, AM J SURG PATHOL, V38, P448, DOI 10.1097/PAS.0000000000000134; MARTINI N, 1975, J THORAC CARDIOV SUR, V70, P606; Otsuka H, 2010, J THORAC ONCOL, V5, P1571, DOI 10.1097/JTO.0b013e3181eba931; Rami-Porta R, 2015, J THORAC ONCOL, V10, P990, DOI 10.1097/JTO.0000000000000559; Rossi G, 2004, AM J SURG PATHOL, V28, P442, DOI 10.1097/00000478-200404000-00003; Russell PA, 2011, J THORAC ONCOL, V6, P1496, DOI 10.1097/JTO.0b013e318221f701; Shimizu K, 2004, J THORAC CARDIOV SUR, V127, P1574, DOI 10.1016/j.jtcvs.2003.11.017; Travis WD, 2015, WHO CLASSIFICATION T; Travis WD, 2016, J THORAC ONCOL, V11, P1204, DOI 10.1016/j.jtho.2016.03.025; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Travis WD, 2008, J THORAC ONCOL, V3, P1384, DOI 10.1097/JTO.0b013e31818e0d9f; Yoshizawa A, 2011, MODERN PATHOL, V24, P653, DOI 10.1038/modpathol.2010.232	19	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	MAY-JUN	2018	23	3					134	137		10.1097/PCR.0000000000000242			4	Pathology	Pathology	GL9XG	WOS:000437696100008					2019-10-28	
J	Berg, AN; Seethala, RR				Berg, Aaron N.; Seethala, Raja R.			The American Joint Committee on Cancer Eighth Edition: Changes in Thyroid Carcinoma Staging and an Update on Reporting	AJSP-REVIEWS AND REPORTS			English	Review						AJCC 8th edition; NIFTP; staging; thyroid	DIFFERENTIATED CARCINOMA; EXTRATHYROIDAL EXTENSION; NODE-METASTASIS; WELL; IMPACT; CUTOFF; SYSTEM	The AJCC Cancer Staging Manual, Eighth Edition (AJCC 8th edition) contains a number of significant changes, many of which affect the reporting of clinicopathologic parameters in thyroid cancers. The first key change is the separation of medullary thyroid carcinoma into its own chapter. Within differentiated and anaplastic thyroid carcinomas, anaplastic carcinomas are now assigned a T stage similar to differentiated thyroid carcinomas. However, this is largely cosmetic because these are still assigned stage group IV. Perhaps the most significant alteration from a reporting standpoint is revision of extrathyroidal extension (ETE) in terms of T staging. Pathologic stage pT3 is now subdivided into pT3a (by size) and pT3b (by ETE). Under AJCC 8th edition, pT3b is now defined by gross (clinical, radiologic, and/or macroscopic) ETE. Other key changes are the inclusion of level VII (anterior mediastinal) lymph nodes as N1a and changes in stage groupings, particularly with a new age cutoff of 55 years, and a downshift in several stage groups. Inmedullary thyroid carcinoma, the potential prognostic value of nonanatomic factors (ie, serum calcitonin, carcinoembryonic antigen, RET mutation status) is officially recognized, although not yet part of staging. The advent of the new terminology noninvasive follicular thyroid neoplasm with papillary-like nuclear features will remove a subset of tumors that qualify for this new designation from formal AJCC staging altogether.	[Berg, Aaron N.; Seethala, Raja R.] Univ Pittsburgh, Dept Pathol, Med Ctr Presbyterian, Pittsburgh, PA USA	Seethala, RR (reprint author), Dept Pathol, A614X UPMC Presbyterian,200 Lothrop St, Pittsburgh, PA 15213 USA.	seethalarr@upmc.edu					Amin MB, 2017, AJCC CANC STAGING MA; ANDERSEN PE, 1995, AM J SURG, V170, P467, DOI 10.1016/S0002-9610(99)80331-6; Bellantone R, 1998, J SURG ONCOL, V68, P237, DOI 10.1002/(SICI)1096-9098(199808)68:4<237::AID-JSO6>3.0.CO;2-5; DeLellis RA, 2004, PATHOLOGY GENETICS T; Elisei R, 2012, NAT REV ENDOCRINOL, V8, P466, DOI 10.1038/nrendo.2012.38; Ganly I, 2015, THYROID, V25, P1106, DOI 10.1089/thy.2015.0104; Ghossein R, 2009, ARCH PATHOL LAB MED, V133, P683, DOI 10.1043/1543-2165-133.5.683; Hay ID, 2016, SURGERY, V159, P11, DOI 10.1016/j.surg.2015.05.046; Hofstra RM, 1994, NATURE, V367; Hughes CJ, 1996, HEAD NECK-J SCI SPEC, V18, P127, DOI 10.1002/(SICI)1097-0347(199603/04)18:2<127::AID-HED3>3.3.CO;2-H; Ito Y, 2006, WORLD J SURG, V30; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Nixon IJ, 2016, THYROID, V26, P373, DOI 10.1089/thy.2015.0315; Nixon IJ, 2016, ANN SURG ONCOL, V23, P410, DOI 10.1245/s10434-015-4762-2; Nixon IJ, 2014, SURGERY, V156, P137, DOI 10.1016/j.surg.2014.03.027; Nixon IJ, 2011, SURGERY, V150, P1242, DOI 10.1016/j.surg.2011.09.007; Park JS, 2017, ORAL ONCOL, V72, P183, DOI 10.1016/j.oraloncology.2017.02.008; Park YM, 2017, ORAL ONCOL, V75, P1, DOI 10.1016/j.oraloncology.2017.10.012; Perrier ND, 2018, CA-CANCER J CLIN, V68, P56, DOI 10.3322/caac.21439; Randolph GW, 2012, THYROID, V22, P1144, DOI 10.1089/thy.2012.0043; Roh JL, 2008, ANN SURG ONCOL, V15, P2482, DOI 10.1245/s10434-008-0044-6; Rosen JE, 2017, AJCC CANC STAGING MA, Vxvii; Seethala RR, 2018, MODERN PATHOL, V31, P39, DOI 10.1038/modpathol.2017.130; Tuttle RM, 2017, THYROID, V27, P751, DOI 10.1089/thy.2017.0102; Tuttle RM, 2017, AJCC CANC STAGING MA, Vxvii; Vergez S, 2010, EJSO-EUR J SURG ONC, V36, P777, DOI 10.1016/j.ejso.2010.06.015; Wang LY, 2015, THYROID, V25, P993, DOI 10.1089/thy.2015.0141; Yin DT, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005794	28	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	MAY-JUN	2018	23	3					145	148		10.1097/PCR.0000000000000244			4	Pathology	Pathology	GL9XG	WOS:000437696100010					2019-10-28	
J	Laurini, JA; Cooper, K				Laurini, Javier A.; Cooper, Kumarasen			Pathologic Staging of Bone and Soft Tissue Tumors: What Is New in the Eighth Edition of the American Joint Committee on Cancer Staging Manual?	AJSP-REVIEWS AND REPORTS			English	Review						bone tumors; grade; prognosis; soft tissue sarcoma; staging	NONMETASTATIC EWINGS-SARCOMA; HIGH-GRADE OSTEOSARCOMA; PROGNOSTIC-FACTORS; SINGLE INSTITUTION; ADULT PATIENTS; FRENCH FEDERATION; LOCAL RECURRENCE; CENTERS SARCOMA; CHEMOTHERAPY; SURVIVAL	The recently published eighth edition of the AJCC Cancer Staging Manual addresses and incorporates a substantial number of advances in our understanding of bone and soft tissue sarcomas. A greater emphasis has been placed on the anatomic site of origin resulting in new staging systems. In addition, modifications to the existing AJCC prognostic stage groups and implementation of new prognostic stage groups for certain anatomic sites and tumor types were made. Minor changes in the biologic grading of bone sarcomas were also included. For retroperitoneal soft tissue sarcomas, a nomogram providing additional prognostic information has been endorsed by the AJCC PrecisionMedicine Core and is included as a risk assessmentmodel. Pathologists play a central role in tumor staging and therefore should become familiar with these changes.	[Laurini, Javier A.] Wake Forest Sch Med, Dept Pathol, Winston Salem, NC USA; [Cooper, Kumarasen] Hosp Univ Penn, Pathol & Lab Med, 3400 Spruce St,6 Founders, Philadelphia, PA 19104 USA	Cooper, K (reprint author), Hosp Univ Penn, Pathol & Lab Med, 3400 Spruce St,6 Founders, Philadelphia, PA 19104 USA.	Kumarasen.Cooper@uphs.upenn.edu					Allison Daniel C., 2012, Sarcoma, P704872, DOI 10.1155/2012/704872; Amin MB, 2017, AJCC CANC STAGING MA; Bacci G, 2000, J CLIN ONCOL, V18, P4, DOI 10.1200/JCO.2000.18.1.4; Bacci G, 2009, EUR SPINE J, V18, P1091, DOI 10.1007/s00586-009-0921-0; Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776; Boriani S, 1997, SPINE, V22, P1036, DOI 10.1097/00007632-199705010-00020; Carpentieri DF, 2005, ARCH PATHOL LAB MED, V129, P866; Coindre JM, 2006, ARCH PATHOL LAB MED, V130, P1448; Coindre JM, 1996, J CLIN ONCOL, V14, P869, DOI 10.1200/JCO.1996.14.3.869; COLLIN C, 1987, ANN SURG, V205, P331, DOI 10.1097/00000658-198704000-00001; COSTA J, 1984, CANCER, V53, P530, DOI 10.1002/1097-0142(19840201)53:3<530::AID-CNCR2820530327>3.0.CO;2-D; Duchman KR, 2015, CANCER EPIDEMIOL, V39, P593, DOI 10.1016/j.canep.2015.05.001; Edge S. B., 2009, AJCC CANC STAGING MA; ENNEKING WF, 1980, CLIN ORTHOP RELAT R, P106; Fletcher C.D.M., 2013, WHO CLASSIFICATION S; Gronchi A, 2013, J CLIN ONCOL, V31, P1649, DOI 10.1200/JCO.2012.44.3747; Gronchi A, 2010, ANN SURG, V251, P506, DOI 10.1097/SLA.0b013e3181cf87fa; Guillou L, 1997, J CLIN ONCOL, V15, P350, DOI 10.1200/JCO.1997.15.1.350; Gupta AA, 2010, CANCER-AM CANCER SOC, V116, P3189, DOI 10.1002/cncr.25144; HUVOS AG, 1977, ARCH PATHOL LAB MED, V101, P14; Liu CY, 2010, ANN SURG ONCOL, V17, P2102, DOI 10.1245/s10434-010-0997-0; Maki RG, 2013, ANN SURG ONCOL, V20, P3377, DOI 10.1245/s10434-013-3052-0; Mattavelli D, 2013, ANN ONCOL, V24, P2181, DOI 10.1093/annonc/mdt126; Park JT, 2015, ANN SURG ONCOL, V22, P248, DOI 10.1245/s10434-014-3870-8; Penel N, 2008, INT J ORAL MAX SURG, V37, P428, DOI 10.1016/j.ijom.2008.01.019; Picci P, 1997, J CLIN ONCOL, V15, P1553, DOI 10.1200/JCO.1997.15.4.1553; PICCI P, 1994, J CLIN ONCOL, V12, P2699, DOI 10.1200/JCO.1994.12.12.2699; Raut CP, 2016, CANCER-AM CANCER SOC, V122, P1417, DOI 10.1002/cncr.29931; RAYMOND AK, 1987, SEMIN DIAGN PATHOL, V4, P212; Rubin BP, 2010, ARCH PATHOL LAB MED, V134, pE1, DOI 10.1043/1543-2165-134.4.e1; Sabolch A, 2012, AM J CLIN ONCOL-CANC, V35, P151, DOI 10.1097/COC.0b013e318209cd72; WINKLER K, 1990, CANCER, V66, P1703, DOI 10.1002/1097-0142(19901015)66:8<1703::AID-CNCR2820660809>3.0.CO;2-V	32	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	MAY-JUN	2018	23	3					149	156		10.1097/PCR.0000000000000245			8	Pathology	Pathology	GL9XG	WOS:000437696100011					2019-10-28	
J	Rangan, A; Oliveira, JL; Jevremovic, D; Morice, WG; Chen, D; Shi, M				Rangan, Aruna; Oliveira, Jennifer L.; Jevremovic, Dragan; Morice, William G.; Chen, Dong; Shi, Min			Pure Red Cell Aplasia Due to T-Cell Large Granular Lymphocytic Leukemia After Hematopoietic Stem Cell Transplantation	AJSP-REVIEWS AND REPORTS			English	Article						hematopoietic stem cell transplant; large granular lymphocyte; pure red cell aplasia; T-cell large granular lymphocytic leukemia	BONE-MARROW-TRANSPLANTATION; DONOR ORIGIN; EXPANSION; RECONSTITUTION; REACTIVATION; REPERTOIRE; DISEASE; SCT	Although reactive polytypic large granular lymphocyte (LGL) expansions after hematopoietic stem cell transplant (HSCT) due to viral infection are common, T-cell large granular lymphocytic leukemia (T-LGLL) is extremely rare and usually clinically indolent and requires no treatment in the post-HSCT setting. In contrast, here we present a case of post-HSCT donor-derived T-LGLL that led to pure red cell aplasia with severe patient morbidity. After diagnosis, the patient received immunosuppressive treatment with a dramatic response and has been transfusion independent for more than a year. To our knowledge, this is the first case of a post-HSCT T-LGLL with a documented significant adverse clinical impact requiring and responding to therapeutic intervention. It underscores the importance of recognizing such a rare entity in posttransplant patients.	[Rangan, Aruna; Oliveira, Jennifer L.; Jevremovic, Dragan; Morice, William G.; Chen, Dong; Shi, Min] Mayo Clin, Dept Lab Med & Pathol, Div Hematopathol, 200 1st St SW, Rochester, MN 55901 USA	Shi, M (reprint author), Mayo Clin, Dept Lab Med & Pathol, Div Hematopathol, 200 1st St SW, Rochester, MN 55901 USA.	shi.min@mayo.edu	Chen, Dong/V-8825-2019		Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic	Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic.	Au WY, 2003, AM J CLIN PATHOL, V120, P626, DOI 10.1309/VA755A0PVRV9XDT; Bahceci E, 2003, BRIT J HAEMATOL, V122, P934, DOI 10.1046/j.1365-2141.2003.04522.x; Cieri N, 2015, BLOOD, V125, P2865, DOI 10.1182/blood-2014-11-608539; DOLSTRA H, 1995, BRIT J HAEMATOL, V90, P300, DOI 10.1111/j.1365-2141.1995.tb05150.x; Gill H, 2012, BONE MARROW TRANSPL, V47, P952, DOI 10.1038/bmt.2011.212; Go RS, 2001, BLOOD, V98, P483, DOI 10.1182/blood.V98.2.483; Guerrero A, 2012, BIOL BLOOD MARROW TR, V18, P66, DOI 10.1016/j.bbmt.2011.05.010; Kim D, 2013, BONE MARROW TRANSPL, V48, P1104, DOI 10.1038/bmt.2013.5; Kusumoto S, 2007, CLIN LYMPHOMA MYELOM, V7, P475, DOI 10.3816/CLM.2007.n.031; Lacy MQ, 1996, BLOOD, V87, P3000, DOI 10.1182/blood.V87.7.3000.bloodjournal8773000; Lamy T, 2011, BLOOD, V117, P2764, DOI 10.1182/blood-2010-07-296962; Miller CB, 2001, BONE MARROW TRANSPL, V27, P1011, DOI 10.1038/sj.bmt.1703022; Mohty M, 2002, LEUKEMIA, V16, P2129, DOI 10.1038/sj.leu.2402645; Nann-Rutti S, 2012, BIOL BLOOD MARROW TR, V18, P1765, DOI 10.1016/j.bbmt.2012.07.007; Shi M, 2016, LEUKEMIA LYMPHOMA, V57, P1230, DOI 10.3109/10428194.2015.1081191; Stussi G, 2009, HAEMATOL-HEMATOL J, V94, P239, DOI 10.3324/haematol.13356; Suessmuth Y, 2015, BLOOD, V125, P3835, DOI 10.1182/blood-2015-03-631853	17	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	MAY-JUN	2018	23	3					E1	E4		10.1097/PCR.0000000000000247			4	Pathology	Pathology	GL9XG	WOS:000437696100001					2019-10-28	
J	Uzun, E; Sarioglu, S				Uzun, Evren; Sarioglu, Sulen			Techniques for Maximizing the Performance of Molecular Pathology Testing: Responsibilities of All Pathologists	TURKISH JOURNAL OF PATHOLOGY			English	Review						Molecular Pathology; Tissue saving; Tumor enrichment; Tumor percentage	IN-SITU HYBRIDIZATION; FINE-NEEDLE-ASPIRATION; CELL LUNG-CANCER; CIRCULATING TUMOR-CELLS; GROWTH-FACTOR RECEPTOR; POLYMERASE-CHAIN-REACTION; METASTATIC BREAST-CANCER; KRAS MUTATION ANALYSIS; LIQUID-BASED CYTOLOGY; GASTROINTESTINAL STROMAL TUMORS	Molecular pathological analysis has an expanding role in patient diagnosis and management. The performance of these techniques relies on excellent laboratory procedures. However, the crucial step is obtaining the best samples for molecular analysis. Archiving and selection of these are the responsibilities of all pathologists even if they are not working at a center with molecular pathological facilities. This review focuses on the features of different types of materials for molecular pathological analysis. Many steps that might affect the results, including communication between the pathologist and the oncology team, features of different types of materials (cytological, tissue blocks, biopsy, circulating tumor cells (CTCs) and cell-free circulating nucleic acids), effects of tissue processing, methods for selecting the best material, and tissue saving and tumor enrichment methods are discussed. The procedures for referral to a center for molecular pathological analysis are also mentioned. Awareness of the importance of the cytopathological and histopathological material of the patients for future molecular pathological analysis by pathologists is of the utmost importance.	[Uzun, Evren; Sarioglu, Sulen] Dokuz Eylul Univ, Fac Med, Dept Pathol, Izmir, Turkey	Uzun, E (reprint author), Dokuz Eylul Univ, Fac Med, Dept Pathol, Izmir, Turkey.	drevrenuzun@gmail.com					Abati A, 1999, CANCER CYTOPATHOL, V87, P231, DOI 10.1002/(SICI)1097-0142(19990825)87:4<231::AID-CNCR11>3.0.CO;2-A; Aisner DL, 2013, DIAGN CYTOPATHOL, V41, P316, DOI 10.1002/dc.21851; Aisner DL, 2012, AM J CLIN PATHOL, V138, P332, DOI 10.1309/AJCPFR12WJKCEEZZ; Aisner DL, 2012, DIAGN CYTOPATHOL, V40, P511, DOI 10.1002/dc.22820; Aisner DL, 2016, ARCH PATHOL LAB MED; Alix-Panabieres Catherine, 2014, Klin Lab Diagn, P60; Alix-Panabieres C, 2013, CLIN CHEM, V59, P110, DOI 10.1373/clinchem.2012.194258; Apple SK, 1996, AM J CLIN PATHOL, V105, P321; Arcila ME, 2011, CLIN CANCER RES, V17, P1169, DOI 10.1158/1078-0432.CCR-10-2277; Arentsen HC, 2007, EXPERT REV MOL DIAGN, V7, P11, DOI 10.1586/14737159.7.1.11; Bai H, 2009, J CLIN ONCOL, V27, P2653, DOI 10.1200/JCO.2008.17.3930; Bass BP, 2014, ARCH PATHOL LAB MED, V138, P1520, DOI 10.5858/arpa.2013-0691-RA; Beadling C, 2011, J MOL DIAGN, V13, P504, DOI 10.1016/j.jmoldx.2011.04.003; Beatty BG, 2004, AM J CLIN PATHOL, V122, P246, DOI 10.1309/X8UP920UF4XM1C5C; Beaty MW, 1997, CANCER CYTOPATHOL, V81, P180, DOI 10.1002/(SICI)1097-0142(19970625)81:3<180::AID-CNCR8>3.0.CO;2-V; BENEZRA J, 1991, J HISTOCHEM CYTOCHEM, V39, P351, DOI 10.1177/39.3.1704393; Betz BL, 2011, AM J CLIN PATHOL, V136, P564, DOI 10.1309/AJCP84TUTQOSUONG; Bidard FC, 2014, LANCET ONCOL, V15, P406, DOI 10.1016/S1470-2045(14)70069-5; Bozzetti C, 2003, CANCER CYTOPATHOL, V99, P310, DOI 10.1002/cncr.11731; Bozzetti C, 2002, ANN ONCOL, V13, P1398, DOI 10.1093/annonc/mdf217; Bozzetti C, 2013, DIAGN CYTOPATHOL, V41, P595, DOI 10.1002/dc.22905; Bozzetti C, 2013, LUNG CANCER, V80, P35, DOI 10.1016/j.lungcan.2013.01.007; Brevet M, 2011, LUNG CANCER, V73, P96, DOI 10.1016/j.lungcan.2010.10.014; Burton MP, 1998, BIOTECHNIQUES, V24, P86, DOI 10.2144/98241st01; Cajulis RS, 1996, DIAGN CYTOPATHOL, V14, P178, DOI 10.1002/(SICI)1097-0339(199603)14:2<178::AID-DC14>3.3.CO;2-#; Canfell K, 2004, CYTOPATHOLOGY, V15, P276, DOI 10.1111/j.1365-2303.2004.00164.x; Cantara S, 2010, J CLIN ENDOCR METAB, V95, P1365, DOI 10.1210/jc.2009-2103; Chang GA, 2016, MOL ONCOL, V10, P157, DOI 10.1016/j.molonc.2015.09.005; Cheema PK, 2017, J ONCOL PRACT, V13, pE130, DOI 10.1200/JOP.2016.014019; Choi SE, 2015, J PATHOL TRANSL MED, V49, P236, DOI 10.4132/jptm.2015.03.16; Chudova D, 2010, J CLIN ENDOCR METAB, V95, P5296, DOI 10.1210/jc.2010-1087; Chung CTS, 2010, J CLIN PATHOL, V63, P630, DOI 10.1136/jcp.2010.076794; Clark DP, 2009, CANCER CYTOPATHOL, V117, P289, DOI 10.1002/cncy.20045; Cree IA, 2014, J CLIN PATHOL, V67, P923, DOI 10.1136/jclinpath-2014-202404; Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261; Dejmek A, 2013, CANCER CYTOPATHOL, V121, P344, DOI 10.1002/cncy.21276; Dias-Santagata D, 2010, EMBO MOL MED, V2, P146, DOI 10.1002/emmm.201000070; Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219; Dijkstra JR, 2013, VIRCHOWS ARCH, V462, P39, DOI 10.1007/s00428-012-1356-2; Dillon DA, 2002, ACTA CYTOL, V46, P841, DOI 10.1159/000327057; Ferreira MM, 2016, MOL ONCOL, V10, P374, DOI 10.1016/j.molonc.2016.01.007; Fiegl M, 2004, BRIT J CANCER, V91, P558, DOI 10.1038/sj.bjc.6601942; Fiegl M, 2000, HUM PATHOL, V31, P448, DOI 10.1053/hp.2000.6550; Fumagalli D, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-101; Gailey MP, 2015, CANCER CYTOPATHOL, V123, P30, DOI 10.1002/cncy.21476; Gerlinger M, 2013, NEW ENGL J MED, V369, P1172, DOI 10.1056/NEJMc1309091; Gibson Jane, 2014, J Am Soc Cytopathol, V3, P280, DOI 10.1016/j.jasc.2014.08.002; Goswami RS, 2016, AM J CLIN PATHOL, V145, P222, DOI 10.1093/ajcp/aqv023; GREER CE, 1991, AM J CLIN PATHOL, V95, P117, DOI 10.1093/ajcp/95.2.117; Guo JA, 2010, J CANCER RES CLIN, V136, P1341, DOI 10.1007/s00432-010-0785-z; Nishino HT, 2011, CANCER CYTOPATHOL, V119, P219, DOI 10.1002/cncy.20161; Halling KC, 2008, ADV ANAT PATHOL, V15, P279, DOI 10.1097/PAP.0b013e3181832320; Hodgkinson CL, 2014, NAT MED, V20, P897, DOI 10.1038/nm.3600; Hofman P, 2016, VIRCHOWS ARCH, V469, P601, DOI 10.1007/s00428-016-2004-z; Hofman V, 2012, CYTOPATHOLOGY, V23, P30, DOI 10.1111/j.1365-2303.2010.00835.x; Hofman V, 2011, CLIN CANCER RES, V17, P827, DOI 10.1158/1078-0432.CCR-10-0445; Huang Q, 2005, BIOTECH HISTOCHEM, V80, P147, DOI 10.1080/10520290500382806; Hubbard RA, 2003, ARCH PATHOL LAB MED, V127, P940; Hung Ming-Szu, 2006, Chang Gung Med J, V29, P373; Hunt JL, 2008, ARCH PATHOL LAB MED, V132, P248, DOI 10.1043/1543-2165(2008)132[248:MPIAPP]2.0.CO;2; Jiang F, 2002, DIAGN MOL PATHOL, V11, P47, DOI 10.1097/00019606-200203000-00009; Kapila K, 2011, J CYTOL, V28, P54, DOI 10.4103/0970-9371.80731; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kawahara A, 2014, CANCER CYTOPATHOL, V122, P145, DOI 10.1002/cncy.21355; Keegan H, 2005, CYTOPATHOLOGY, V16, P82, DOI 10.1111/j.1365-2303.2005.00239.x; Kiernan Kmiec Z. J. A., 2016, FOLIA HISTOCHEM CYTO, V54, P58; Killian JK, 2010, J MOL DIAGN, V12, P739, DOI 10.2353/jmoldx.2010.090238; Kilpatrick SE, 2001, AM J CLIN PATHOL, V115, P59; Kimura H, 2006, BRIT J CANCER, V95, P1390, DOI 10.1038/sj.bjc.6603428; Kipp BR, 2010, J MOL DIAGN, V12, P780, DOI 10.2353/jmoldx.2010.100016; Krishnamurthy S, 2007, CANCER CYTOPATHOL, V111, P106, DOI 10.1002/cncr.22489; Lewandowska MA, 2013, ONCOL REP, V30, P1045, DOI 10.3892/or.2013.2579; Lhermitte B, 2017, VIRCHOWS ARCH, V470, P21, DOI 10.1007/s00428-016-2042-6; Li WB, 2016, ONCOTARGET, V7, P8332, DOI 10.18632/oncotarget.6671; Lin CC, 2015, EXPERT REV MOL DIAGN, V15, P1427, DOI 10.1586/14737159.2015.1094379; Lurkin I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008802; Malapelle U, 2012, J CLIN PATHOL, V65, P87, DOI 10.1136/jclinpath-2011-200296; Malapelle U, 2011, DIAGN CYTOPATHOL, V39, P703, DOI 10.1002/dc.21512; Monsonego J, 2001, BRIT J CANCER, V84, P360, DOI 10.1054/bjoc.2000.1588; Morrow CJ, 2016, ANN ONCOL, V27, P1155, DOI 10.1093/annonc/mdw122; Muller C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009095; Murase T, 2000, MODERN PATHOL, V13, P147, DOI 10.1038/modpathol.3880028; Nakamura T, 2012, J THORAC ONCOL, V7, P1369, DOI 10.1097/JTO.0b013e31825f2821; Newman AM, 2014, NAT MED, V20, P552, DOI 10.1038/nm.3519; Nikiforov YE, 2009, J CLIN ENDOCR METAB, V94, P2092, DOI 10.1210/jc.2009-0247; Nizzoli R, 2005, ACTA CYTOL, V49, P27, DOI 10.1159/000326091; Pantel K, 2016, MOL ONCOL, V10, P371, DOI 10.1016/j.molonc.2016.01.009; Pantel K, 2013, CANCER RES, V73, P6384, DOI 10.1158/0008-5472.CAN-13-2030; Paterlini-Brechot P, 2007, CANCER LETT, V253, P180, DOI 10.1016/j.canlet.2006.12.014; Pugliese V, 2001, GASTROINTEST ENDOSC, V54, P595, DOI 10.1067/mge.2001.119220; Rader AE, 2001, CANCER CYTOPATHOL, V93, P269, DOI 10.1002/cncr.9041; Rafael OC, 2014, CANCER CYTOPATHOL, V122, P454, DOI 10.1002/cncy.21426; Rait VK, 2006, J HISTOCHEM CYTOCHEM, V54, P301, DOI 10.1369/jhc.5A6125.2005; Rekhtman N, 2011, J THORAC ONCOL, V6, P451, DOI 10.1097/JTO.0b013e31820517a3; Santos GD, 2011, CANCER CYTOPATHOL, V119, P80, DOI 10.1002/cncy.20150; Sarosdy MF, 2006, J UROLOGY, V176, P44, DOI 10.1016/S0022-5347(06)00576-3; Savic S, 2010, CHEST, V138, P137, DOI 10.1378/chest.09-1951; Scarpino S, 2015, LUNG CANCER, V87, P8, DOI 10.1016/j.lungcan.2014.10.012; Schenk T, 1997, CHEST, V111, P1691, DOI 10.1378/chest.111.6.1691; Schwarzenbach H, 2014, NAT REV CLIN ONCOL, V11, P145, DOI 10.1038/nrclinonc.2014.5; Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066; Shih JY, 2006, INT J CANCER, V118, P963, DOI 10.1002/ijc.21458; Siravegna G, 2016, MOL ONCOL, V10, P475, DOI 10.1016/j.molonc.2015.12.005; Smits AJJ, 2014, MODERN PATHOL, V27, P168, DOI 10.1038/modpathol.2013.134; Srinivasan M, 2002, AM J PATHOL, V161, P1961, DOI 10.1016/S0002-9440(10)64472-0; Su ZL, 2011, J MOL DIAGN, V13, P74, DOI 10.1016/j.jmoldx.2010.11.010; Suciu BA, 2016, ROM J MORPHOL EMBRYO, V57, P495; Sun PL, 2013, CANCER CYTOPATHOL, V121, P311, DOI 10.1002/cncy.21260; Tan CS, 2016, LUNG CANCER, V93, P59, DOI 10.1016/j.lungcan.2016.01.003; Tarkowski TA, 2001, MOL DIAGN, V6, P125, DOI 10.1054/modi.2001.25320; Tisserand P, 2003, CANCER CYTOPATHOL, V99, P223, DOI 10.1002/cncr.11258; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; van der Heijden HFM, 2012, THORAC CANCER, V3, P201, DOI 10.1111/j.1759-7714.2012.00116.x; van Eijk R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017791; Vivero Marina, 2017, J Am Soc Cytopathol, V6, P16, DOI 10.1016/j.jasc.2016.06.002; von Smolinski D, 2005, HISTOCHEM CELL BIOL, V124, P177, DOI 10.1007/s00418-005-0013-0; Williams C, 1999, AM J PATHOL, V155, P1467, DOI 10.1016/S0002-9440(10)65461-2; Willmore C, 2004, AM J CLIN PATHOL, V122, P206, DOI 10.1309/4E6UYBY62N2FCA6N; Witt BL, 2012, DIAGN CYTOPATHOL, V40, P556, DOI 10.1002/dc.22858; Wu HH, 2016, ARCH PATHOL LAB MED, V140, P1383, DOI 10.5858/arpa.2015-0454-OA; Yamaguchi K, 2005, HEPATO-GASTROENTEROL, V52, P713; Yamashita K, 1998, AM J CLIN PATHOL, V109, P704; Yokobori T, 2013, CANCER RES, V73, P2059, DOI 10.1158/0008-5472.CAN-12-0326; Zojer N, 1997, BRIT J CANCER, V75, P403, DOI 10.1038/bjc.1997.65	125	1	1	0	0	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	MAY	2018	34	2					113	126		10.5146/tjpath.2017.01420			14	Pathology	Pathology	GL0AM	WOS:000436622700001	29235614	DOAJ Gold			2019-10-28	
J	Kus Ozturk, S; Erden, E				Kus Ozturk, Sonay; Erden, Esra			Do the Well Known Prognostic Parameters in Pancreatic Ductal Adenocarcinoma Really Reflect Survival?	TURKISH JOURNAL OF PATHOLOGY			English	Article						Pancreatic ductal carcinoma; Survival; Mitosis; Grade; Peripancreatic invasion; Tumor size	LYMPH-NODE RATIO; SINGLE-INSTITUTION EXPERIENCE; TUMOR SIZE; CURATIVE RESECTION; 5-YEAR SURVIVORS; CANCER; IMPACT; INDICATORS; CARCINOMA; PROPOSAL	Objective: Pancreatic ductal adenocarcinoma is an aggressive tumor with short survival. In this study we aimed to investigate the effect of well-known prognostic parameters on survival in these tumors. Material and Method: A total of 56 pancreatic ductal adenocarcinoma cases diagnosed between 2005 and 2014 were included in the study. Survival data were obtained and histopathological parameters were re-evaluated in each patient. Results: Tumor size (p=0.029), mitotic count (p=0.030), lymph node metastasis (p=0.003), metastatic lymph node ratio (p<0.001) and ampullary invasion (p=0.044) had a statistically significant relationship with survival. However, there was no relationship between survival and tumor grade, lymphovascular and perineural invasion, and peripancreatic soft tissue invasion. Conclusion: Our results showed that existent 2010 WHO pancreatic ductal adenocarcinoma grading parameters excluding mitotic count are subjective and not applicable. Considering that almost all of the tumors in our series were larger than 2 cm, we think that the 2 cm cut-off in tumor size is insufficient to make the tumor stage pT2. Peripancreatic soft tissue invasion, which is a common finding in pancreatic ductal adenocarcinoma, should also not be assessed like adjacent tissue invasion and make the tumor reach pT3 stage independent of tumor size. It is clear that the existent WHO tumor grading and pT staging parameters need to be revised and the mitotic count, which correlates with survival, should be presented in pathology reports.	[Kus Ozturk, Sonay; Erden, Esra] Ankara Univ, Dept Surg Pathol, Sch Med, Ankara, Turkey	Kus Ozturk, S (reprint author), Ankara Univ, Dept Surg Pathol, Sch Med, Ankara, Turkey.	sonayku@gmail.com					Adsay NV, 2005, AM J SURG PATHOL, V29, P724, DOI 10.1097/01.pas.0000163360.40357.f1; Amin MB, 2017, AJCC CANC STAGING MA; Ashfaq A, 2014, J GASTROINTEST SURG, V18, P1929, DOI 10.1007/s11605-014-2566-5; Basturk O, 2015, ANN SURG ONCOL, V22, pS1187, DOI 10.1245/s10434-015-4861-0; Bosman FT, 2010, WHO CLASSIFICATION T, P280; Brower S T, 1993, HPB Surg, V7, P1, DOI 10.1155/1993/83609; Cleary SP, 2004, J AM COLL SURGEONS, V198, P722, DOI 10.1016/j.jamcollsurg.2004.01.008; Conlon KC, 1996, ANN SURG, V223, P273, DOI 10.1097/00000658-199603000-00007; Fortner JG, 1996, ANN SURG, V223, P147, DOI 10.1097/00000658-199602000-00006; GEER RJ, 1993, AM J SURG, V165, P68, DOI 10.1016/S0002-9610(05)80406-4; House MG, 2007, J GASTROINTEST SURG, V11, P1549, DOI 10.1007/s11605-007-0243-7; Kang MJ, 2014, ANN SURG ONCOL, V21, P1545, DOI 10.1245/s10434-013-3473-9; La Torre M, 2011, J SURG ONCOL, V104, P629, DOI 10.1002/jso.22013; Lim JE, 2003, ANN SURG, V237, P74, DOI 10.1097/00000658-200301000-00011; Luttges J, 2000, J PATHOL, V191, P154; Nakagohri T, 2006, HEPATO-GASTROENTEROL, V53, P447; OHTA T, 1993, INT SURG, V78, P208; Park H, 2014, HUM PATHOL, V45, P2341, DOI 10.1016/j.humpath.2014.06.030; Pawlik TM, 2007, SURGERY, V141, P610, DOI 10.1016/j.surg.2006.12.013; Riediger H, 2009, J GASTROINTEST SURG, V13, P1337, DOI 10.1007/s11605-009-0919-2; Robinson SM, 2012, EJSO-EUR J SURG ONC, V38, P333, DOI 10.1016/j.ejso.2011.12.020; Rochefort MM, 2013, ANN SURG ONCOL, V20, P4322, DOI 10.1245/s10434-013-3159-3; Saka B, 2016, ANN SURG ONCOL, V23, P2010, DOI 10.1245/s10434-016-5093-7; Shimada K, 2006, PANCREAS, V33, P233, DOI 10.1097/01.mpa.0000232917.78890.01; Sohn TA, 2000, J GASTROINTEST SURG, V4, P567, DOI 10.1016/S1091-255X(00)80105-5; Sperti C, 1997, WORLD J SURG, V21, P195, DOI 10.1007/s002689900215; Sperti C, 1997, J AM COLL SURGEONS, V185, P255, DOI 10.1016/S1072-7515(01)00925-5; Sperti C, 1996, BRIT J SURG, V83, P625, DOI 10.1002/bjs.1800830512; Strobel O, 2015, ANN SURG, V261, P961, DOI 10.1097/SLA.0000000000000814; Takai S, 2003, PANCREAS, V26, P243, DOI 10.1097/00006676-200304000-00007; Winter JM, 2006, J GASTROINTEST SURG, V10, P1199, DOI 10.1016/j.gassur.2006.08.018	31	0	0	0	0	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	MAY	2018	34	2					127	133		10.5146/tjpath.2017.01414			7	Pathology	Pathology	GL0AM	WOS:000436622700002	28984346	DOAJ Gold			2019-10-28	
J	Can, N; Tastekin, E; Deniz Yalta, T; Sut, N; Korkmaz, S; Usta, U; Oz Puyan, F; Genc, E; Cezik, M; Binboga Tutug, B; Kostek, O; Tozkir, H				Can, Nuray; Tastekin, Ebru; Deniz Yalta, Tulin; Sut, Necdet; Korkmaz, Selma; Usta, Ufuk; Oz Puyan, Fulya; Genc, Ezgi; Cezik, Mert; Binboga Tutug, Busem; Kostek, Osman; Tozkir, Hilmi			BRAF V600 Mutation Profile of Metastatic Melanoma in the Thrace Region of Turkey	TURKISH JOURNAL OF PATHOLOGY			English	Article						Malignant melanoma; BRAF mutation; Clinicopathological features	PRIMARY CUTANEOUS MELANOMA; DABRAFENIB; TRIAL; MEDICINE; FEATURES; CANCER; TUMORS; NRAS	Objective: BRAF is the most common mutation in melanoma. The most common subtype is BRAF V600E, followed by V600K. Initially, the authors aimed to investigate whether clinicopathological features of melanoma are associated with BRAF mutations. We then aimed to present the relationships between the clinicopathological features and the mutated subtype (V600E vs V600K). Material and Method: 61 patients with metastatic malignant melanoma (affecting the lymph node or other distant sites) were selected. Patient data regarding age at the time of diagnosis, sex, metastatic site (lymph node, distant metastasis or both) and primary tumour site were obtained from the hospital's database. Tissue samples containing at least 30% tumour cells were isolated from the specimens of 61 patients (24 samples from primary tumours and 37 from metastatic foci) for BRAF analysis. Comparisons between the BRAF V600 mutation and clinicopathological and histopathological features were performed. Results: BRAF V600 mutation was detected in 34 (55.7%) patients. The subtype was BRAF V600E in 22 (64.7%) patients, BRAF V600K in 11(32.4%) patients and BRAF V600R in 1(2.9%) patient. The crucial results of the present study may be summarized as follows: i) BRAF V600 mutation was more common in older patients and tumors with BRAF V600 mutation revealed necrosis and LVI more commonly than wild-type tumors, ii) BRAF V600K mutation was more common in older patients and BRAF V600K mutated tumors exhibited ulceration more commonly than tumors with BRAF V600E mutation (close to significant). Conclusion: The BRAF V600 mutation may have interactions with prognostic clinicoptahological features of melanoma including necrosis and lymphovascular invasion. V600K mutation may be more common than expected and may have different associations with properties of the tumor such as tumor ulceration and patient age. Investigation of the mutated subtype of the BRAF gene may therefore reveal more detailed data about the management of melanoma and may also prevent missing of candidates for BRAF inhibitor therapies.	[Can, Nuray; Tastekin, Ebru; Deniz Yalta, Tulin; Usta, Ufuk; Oz Puyan, Fulya; Genc, Ezgi; Cezik, Mert; Binboga Tutug, Busem] Trakya Univ, Fac Med, Dept Pathol, Balkan Campus, TR-22030 Edirne, Turkey; [Sut, Necdet] Trakya Univ, Fac Med, Dept Biostat, Balkan Campus, Edirne, Turkey; [Korkmaz, Selma] Suleyman Demirel Univ, Fac Med, Dept Dermatol, Isparta, Turkey; [Kostek, Osman] Trakya Univ, Fac Med, Dept Internal Med, Div Med Oncol, Balkan Campus, Edirne, Turkey; [Tozkir, Hilmi] Trakya Univ, Fac Med, Dept Med Genet, Balkan Campus, Edirne, Turkey	Can, N (reprint author), Trakya Univ, Fac Med, Dept Pathol, Balkan Campus, TR-22030 Edirne, Turkey.	nuraycan@ymail.com	Puyan, Fulya/V-7074-2019; Kostek, Osman/AAA-3604-2019	Puyan, Fulya/0000-0001-5853-0109; Kostek, Osman/0000-0002-1901-5603			Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Akman T, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0440-7; Bello DM, 2013, CANCER CONTROL, V20, P261, DOI 10.1177/107327481302000404; Brose MS, 2002, CANCER RES, V62, P6997; Bucheit AD, 2013, CANCER-AM CANCER SOC, V119, P3821, DOI 10.1002/cncr.28306; Chen G, 2016, JAMA ONCOL, V2, P1056, DOI 10.1001/jamaoncol.2016.0509; Cirenajwis H, 2017, MOL ONCOL, V11, P438, DOI 10.1002/1878-0261.12050; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Falchook GS, 2012, LANCET, V379, P1893, DOI 10.1016/S0140-6736(12)60398-5; Ferrara G, 2016, AM J DERMATOPATH, V38, P253, DOI 10.1097/DAD.0000000000000380; Griewank KG, 2014, JNCI-J NATL CANCER I, P106, DOI DOI 10.1093/JNCI/DJU246; Hong JW, 2014, ANN DERMATOL, V26, P195, DOI 10.5021/ad.2014.26.2.195; Hugdahl E, 2016, BRIT J CANCER, V114, P801, DOI 10.1038/bjc.2016.44; Inumaru JSS, 2014, GENET MOL RES, V13, P2840, DOI 10.4238/2014.January.22.8; Jakob JA, 2012, CANCER-AM CANCER SOC, V118, P4014, DOI 10.1002/cncr.26724; Junkins-Hopkins JM, 2010, J AM ACAD DERMATOL, V63, P329, DOI 10.1016/j.jaad.2010.04.044; Long GV, 2012, LANCET ONCOL, V13, P1087, DOI 10.1016/S1470-2045(12)70431-X; Long GV, 2011, J CLIN ONCOL, V29, P1239, DOI 10.1200/JCO.2010.32.4327; Meckbach D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089218; Meckbach D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086194; Menzies AM, 2012, CLIN CANCER RES, V18, P3242, DOI 10.1158/1078-0432.CCR-12-0052; Rajkumar S, 2016, BRIT J CANCER, V115, P145, DOI 10.1038/bjc.2016.195; Roh MR, 2015, PIGM CELL MELANOMA R, V28, P661, DOI 10.1111/pcmr.12412; Satzger I, 2015, ONCOTARGET, V6, P37895, DOI 10.18632/oncotarget.5634; Sener E, 2017, PATHOL RES PRACT, V213, P522, DOI 10.1016/j.prp.2017.01.010; Siroy AE, 2015, J INVEST DERMATOL, V135, P508, DOI 10.1038/jid.2014.366; Tsao H, 2012, GENE DEV, V26, P1131, DOI 10.1101/gad.191999.112; Vallarelli AF, 2016, ONCOTARGET, V7, P53127, DOI 10.18632/oncotarget.10634; Yaman B, 2016, AM J DERMATOPATH, V38, P113, DOI 10.1097/DAD.0000000000000404; Yaman B, 2015, AM J DERMATOPATH, V37, P389, DOI 10.1097/DAD.0000000000000241; Yilmaz I, 2015, INDIAN J PATHOL MICR, V58, P279, DOI 10.4103/0377-4929.162831	31	0	0	1	3	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	MAY	2018	34	2					134	142		10.5146/tjpath.2018.01422			9	Pathology	Pathology	GL0AM	WOS:000436622700003		DOAJ Gold			2019-10-28	
J	Hafez, NH; Shaaban, HM				Hafez, Nesreen H.; Shaaban, HebatAllah M.			Can GATA3 Immunocytochemistry be Utilized as a Reliable Diagnostic Marker for Metastatic Breast Carcinoma in Cytological Materials? A Comparative Study with Mammaglobin and GCDFP-15 Expression	TURKISH JOURNAL OF PATHOLOGY			English	Article						GATA3; Immunostaining; Metastatic breast carcinoma; Cytology	UROTHELIAL CARCINOMAS; IMMUNOHISTOCHEMISTRY; SPECIMENS; CANCER; TISSUES; TUMORS	Objective: Cytomorphologic differentiation of metastatic breast carcinoma from non breast metastases in cytological materials can be difficult. Current breast immunocytochemical markers have low sensitivities. Transcription factor GATA3 is a promising marker for detecting breast differentiation in cytological materials. The aim of the study was to assess the diagnostic value of GATA3 as a breast differentiation marker in metastatic cytological materials and to compare it with expression of mammaglobin and gross cystic disease fluid protein-15 (GCDFP-15). Material and Method: We retrospectively retrieved 133 cases of metastatic breast carcinoma from the archive the of Cytology Unit between December 2013 and June 2015. They included 77 fine needle aspiration and 56 serous effusion samples. Forty-five cytological materials from non mammary metastatic tumors were used as a control. Immunostaining was performed on cell blocks for the presence of GATA3, mammaglobin and GCDFP-15. Results: GATA3 nuclear staining was detected in 82.7% of metastatic breast carcinomas, and 11.1% of metastatic non mammary adenocarcinomas (p <0.001). GATA3 sensitivity, specificity, positive predictive value, negative predictive value and accuracy were 82.7%, 88.9%, 95.7%, 63.5% and 84.3%, respectively. Mammaglobin and GCDFP-15 staining of metastatic breast carcinoma cases was positive in 70.7% and 47.1%, respectively. GATA3 staining was significantly higher compared with mammaglobin and GCDFP-15 (p<0.001). Conclusion: GATA3 is more sensitive marker than mammaglobin and GCDFP-15 for diagnosing metastatic breast carcinoma in cytological cell block materials. Adding mammaglobin to GATA3 resulted in improvement in its sensitivity. GATA3 was occasionally positive in some metastatic non mammary carcinoma that may cause misdiagnosis.	[Hafez, Nesreen H.; Shaaban, HebatAllah M.] Cairo Univ, Dept Pathol, Natl Canc Inst, Cairo, Egypt	Hafez, NH (reprint author), Cairo Univ, Dept Pathol, Natl Canc Inst, Cairo, Egypt.	nesreennci@hotmail.com					Banet N, 2015, AM J SURG PATHOL, V39, P101, DOI 10.1097/PAS.0000000000000315; Braxton DR, 2015, DIAGN CYTOPATHOL, V43, P271, DOI 10.1002/dc.23206; Cimino-Mathews A, 2013, HUM PATHOL, V44, P1341, DOI 10.1016/j.humpath.2012.11.003; Deftereos G, 2015, AM J SURG PATHOL, V39, P1282, DOI 10.1097/PAS.0000000000000505; Dyhdalo Kathryn S, 2015, J Am Soc Cytopathol, V4, P218, DOI 10.1016/j.jasc.2015.01.008; Gown AM, 2016, HISTOPATHOLOGY, V68, P86, DOI 10.1111/his.12877; Kandalaft PL, 2016, ARCH PATHOL LAB MED, V140, P508, DOI 10.5858/arpa.2015-0173-CP; Kandalaft PL, 2016, APPL IMMUNOHISTO M M, V24, P609, DOI 10.1097/PAI.0000000000000237; Krings G, 2014, HUM PATHOL, V45, P2225, DOI 10.1016/j.humpath.2014.06.022; Leng Bing, 2017, J Am Soc Cytopathol, V6, P73, DOI 10.1016/j.jasc.2016.12.002; Lew M, 2015, CANCER CYTOPATHOL, V123, P576, DOI 10.1002/cncy.21574; Liu HY, 2012, AM J CLIN PATHOL, V138, P57, DOI 10.1309/AJCP5UAFMSA9ZQBZ; Mariotto AB, 2017, CANCER EPIDEM BIOMAR, V26, P809, DOI [10.1158/1055-9965.epi-16-0889, 10.1158/1055-9965.EPI-16-0889]; Miettinen M, 2014, AM J SURG PATHOL, V38, P13, DOI 10.1097/PAS.0b013e3182a0218f; Ordonez NG, 2013, ADV ANAT PATHOL, V20, P352, DOI 10.1097/PAP.0b013e3182a28a68; Sangoi AR, 2016, APPL IMMUNOHISTO M M, V24, P229, DOI 10.1097/PAI.0000000000000186; Shield PW, 2014, CANCER CYTOPATHOL, V122, P307, DOI 10.1002/cncy.21393; Verduin L, 2016, APPL IMMUNOHISTO M M, V24, P509, DOI 10.1097/PAI.0000000000000221; Yan Z, 2009, DIAGN CYTOPATHOL, V37, P475, DOI 10.1002/dc.21039	19	0	0	0	1	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	MAY	2018	34	2					143	149		10.5146/tjpath.2017.01419			7	Pathology	Pathology	GL0AM	WOS:000436622700004	29235613	DOAJ Gold			2019-10-28	
J	Fathy, A; Abdelrahman, AE				Fathy, Anan; Abdelrahman, Aziza E.			EZH2, Endothelin-1, and CD34 as Biomarkers of Aggressive Cervical Squamous Cell Carcinoma: An Immunohistochemical Study	TURKISH JOURNAL OF PATHOLOGY			English	Article						EZH2; Endothelin-1; CD34; Immunohistochemistry; Uterine cervical cancer	LYMPH-NODE METASTASIS; CANCER; EXPRESSION; PROGNOSIS; AXIS	Objective: Cervical cancer has an increasing incidence in developing countries with a predominance of squamous cell carcinoma. In this work, we aimed to analyze the role of EZH2, Endothelin-1, and CD34 as indicators of the aggressiveness in cervical squamous cell carcinoma. Material and Method: Immunohistochemical expression of EZH2, Endothelin-1, and CD34 was studied in 54 paraffin-embedded tissue specimens of cervical squamous cell carcinoma. Their correlation to the clinicopathologic features and the potential angiogenic role were analyzed. Results: High EZH2 expression was noted in 78% of cervical squamous cell carcinoma with a significant relation with tumor grade, FIGO stage and lymph node metastasis (p=<0.001, p=0.007, p=0.03 respectively). Endothelin-1 overexpression was detected in 63% of the studied cases with a significant association with tumor size, FIGO stage and lymph node metastasis (p=0.009, p=0.002, p=0.02 respectively). High CD34 expression (MVD) was noted in 56% of the cases and associated with the tumor size, FIGO stage and lymph node metastasis (p<0.001, p<0.001, p=0.04 respectively). The three markers were significantly associated (p<0.05). Conclusion: EZH2, ET-1, and CD34 may act as biomarkers of aggressive cervical squamous cell carcinoma. They may contribute to the signaling pathway of angiogenesis. Therefore, they could potentially be used in targeted therapy.	[Fathy, Anan; Abdelrahman, Aziza E.] Zagazig Univ, Fac Med, Dept Pathol, Zagazig 44519, Egypt	Abdelrahman, AE (reprint author), Zagazig Univ, Fac Med, Dept Pathol, Zagazig 44519, Egypt.	azaelsayed@gmail.com	Abdelrahman, Aziza E./I-3399-2019	Abdelrahman, Aziza E./0000-0003-4074-4779			Ancuta C, 2010, ROM J MORPHOL EMBRYO, V51, P289; Asgari Mojgan, 2017, Iran J Pathol, V12, P171; Azizmohammadi S, 2017, ONCOL RES, V25, P495, DOI 10.3727/096504016X14749735594687; Benazzi C, 2014, SCI WORLD J, DOI 10.1155/2014/919570; Cairns R, 2006, MOL CANCER RES, V4, P61, DOI 10.1158/1541-7786.MCR-06-0002; Cao XQ, 2014, ASIAN PAC J CANCER P, V15, P5271, DOI 10.7314/APJCP.2014.15.13.5271; Chen SQ, 2014, INT J GYNECOL CANCER, V24, P1653, DOI 10.1097/IGC.0000000000000273; Chen ZH, 2015, ONCOL LETT, V10, P723, DOI 10.3892/ol.2015.3348; Crea F, 2012, CANCER METAST REV, V31, P753, DOI 10.1007/s10555-012-9387-3; Huang CN, 2016, INT J CLIN EXP PATHO, V9, P11697; Irani S, 2014, CRIT REV ONCOL HEMAT, V89, P314, DOI 10.1016/j.critrevonc.2013.08.011; Jin MF, 2015, ONCOL LETT, V10, P857, DOI 10.3892/ol.2015.3319; Liu YY, 2014, INT J GYNECOL PATHOL, V33, P218, DOI 10.1097/PGP.0b013e31829c6574; Lu J, 2014, ONCOTARGET, V5, P11319, DOI 10.18632/oncotarget.2435; Matsika A, 2015, PATHOLOGY, V47, P622, DOI 10.1097/PAT.0000000000000325; Miller RA, 2015, ARCH PATHOL LAB MED, V139, P776, DOI 10.5858/arpa.2014-0202-OA; Mohamed H, 2016, J ADENOCARCINOMA, V1, P1; Papanikolaou S, 2017, UROL ANNALS, V9, P372, DOI 10.4103/UA.UA_43_17; Pecorelli S, 2009, INT J GYNECOL OBSTET, V105, P107, DOI 10.1016/j.ijgo.2009.02.009; Pyakurel D, 2014, J PATHOLOGY NEPAL, V4, P570; Rofstad EK, 2014, NEOPLASIA, V16, P586, DOI 10.1016/j.neo.2014.07.003; Rosano L, 2013, NAT REV CANCER, V13, P637, DOI 10.1038/nrc3546; Shahsavari Fatemeh, 2015, J Contemp Dent Pract, V16, P458; Sun B, 2015, INT J CLIN EXP PATHO, V8, P1783; Vieira SC, 2005, PATHOL RES PRACT, V201, P313, DOI 10.1016/j.prp.2005.01.010; Wang SZ, 2016, ONCOL LETT, V11, P3366, DOI 10.3892/ol.2016.4406; Wulfing P, 2003, CLIN CANCER RES, V9, P4125; Zhang Q, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06920-7; Zhang ZY, 2017, ONCOL LETT, V13, P4390, DOI 10.3892/ol.2017.6027	29	0	0	0	1	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	MAY	2018	34	2					150	157		10.5146/tjpath.2018.01425			8	Pathology	Pathology	GL0AM	WOS:000436622700005	29630085	DOAJ Gold			2019-10-28	
J	Jeiroodi, N; Bagherpour, M; Zare, R; Torabi Ardakani, S; Andisheh Tadbir, A				Jeiroodi, Naghmeh; Bagherpour, Mahshid; Zare, Razieh; Torabi Ardakani, Shima; Andisheh Tadbir, Azadeh			Evaluation of Midkine Expression in Dentigerous Cysts, Odontogenic Keratocysts and Different Types of Ameloblastoma	TURKISH JOURNAL OF PATHOLOGY			English	Article						Dentigerous Cysts; Odontogenic Keratocyst; Ameloblastoma; Unicystic; Multicystic	SQUAMOUS-CELL CARCINOMA; GROWTH; TUMORS; CANCER; METAANALYSIS; PARAMETERS; HEAD	Objective: Midkine is a heparin-binding growth factor whose expression is increased in most tumors, namely ameloblastomas. This study aimed to compare Midkine expression in different odontogenic lesions. Material and Method: This analytical cross-sectional study was performed on 52 definitely diagnosed odontogenic lesions including 15 dentigerous cysts, 13 odontogenic keratocysts, and 17 unicystic and 5 multicystic ameloblastomas archived from 1997 to 2015. Midkine expression was examined in tissue samples through immunohistochemistry. The nonparametric Kruskal-Wallis and Mann-Whitney tests were run as appropriate (P < 0.05). Results: The frequency of Midkine expression was < 20% in 7.7%, 20-50% in 25%, and > 50 % in 67.3% of the samples, indicating significant differences among the groups (P = 0.002). Moreover, the expression intensity was strong in 63.5%, moderate in 23.1%, and weak in 13.5% of odontogenic lesion samples (P = 0.071). The total staining score was weak in 3.8%, moderate in 48.1%, and strong in 48.1% of the cells, displaying significant differences between the study groups in this regard (P = 0.043). Conclusion: Midkine can be considered as both a differentiating factor and a molecular-targeted therapy in odontogenic lesions. Yet, further studies are required to approve the role of this cytokine in different biological and pathological stages of the tumors.	[Jeiroodi, Naghmeh; Bagherpour, Mahshid; Zare, Razieh; Torabi Ardakani, Shima] Shiraz Univ Med Sci, Sch Dent, Dept Oral & Maxillofacial Pathol, Shiraz, Iran; [Andisheh Tadbir, Azadeh] Shiraz Univ Med Sci, Sch Dent, Dept Oral & Dent Dis, Shiraz, Iran	Andisheh Tadbir, A (reprint author), Shiraz Univ Med Sci, Sch Dent, Dept Oral & Dent Dis, Shiraz, Iran.	jeiroodi@yahoo.com	zare, razieh/R-8161-2018; jeiroodi, naghmeh/S-8814-2018	zare, razieh/0000-0001-8542-5718; jeiroodi, naghmeh/0000-0002-8167-9849	Shiraz University of Medical Science [8895166]	The authors thank the Vice-Chancellery of Shiraz University of Medical Science for supporting this research (Grant# 8895166). This manuscript is based on the thesis of Mahshid Bagherpour for partial fulfillment of DDS degree. The authors are grateful to Dr. M. Vossoughi from the Dental Research Development Center of the Dental School for the statistical analysis and Ms. Farzaneh Rasouli for her help with the English editing of the manuscript.	Almeida RDC, 2016, INT J ORAL MAX SURG, V45, P359, DOI 10.1016/j.ijom.2015.12.016; Chen Jun, 2016, Hua Xi Kou Qiang Yi Xue Za Zhi, V34, P189; Cheng YSL, 2014, CLIN TRANSL MED, V3, DOI 10.1186/2001-1326-3-3; Chiu TJ, 2013, BIOMARKERS, V18, P687, DOI 10.3109/1354750X.2013.846412; Choi YW, 2015, HUM PATHOL, V46, P1557, DOI 10.1016/j.humpath.2015.06.018; Fujita S, 2008, HUM PATHOL, V39, P694, DOI 10.1016/j.humpath.2007.09.014; Gaitan-Cepeda LA, 2010, ORAL DIS, V16, P185, DOI 10.1111/j.1601-0825.2009.01625.x; Gramage E, 2014, BRIT J PHARMACOL, V171, P913, DOI 10.1111/bph.12495; Gunawardhana KSND, 2014, J INVESTIG CLIN DENT, V5, P220, DOI 10.1111/jicd.12071; Hatori K, 2011, J ENDODONT, V37, P781, DOI 10.1016/j.joen.2011.03.009; Haynes L, 2001, Prog Brain Res, V132, P313; Sanchez OH, 2008, MED ORAL PATOL ORAL, V13, pE730; Jham BC, 2012, J ORAL PATHOL MED, V41, P21, DOI 10.1111/j.1600-0714.2011.01049.x; Jin Z, 2008, CLIN CANCER RES, V14, P5033, DOI 10.1158/1078-0432.CCR-08-0092; Kadomatsu KJ, 2004, CANCER LETT, V204, P127, DOI 10.1016/S0304-3835(03)00450-6; Lascane Nelise Alexandre da Silva, 2014, Braz. Dent. J., V25, P253, DOI 10.1590/0103-6440201300024; Li FG, 2015, TUMOR BIOL, V36, P9789, DOI 10.1007/s13277-015-3710-x; Ruan M, 2007, INT J ORAL MAX SURG, V36, P159, DOI 10.1016/j.ijom.2006.09.004; Sandra F, 2004, ORAL ONCOL, V40, P274, DOI 10.1016/j.oraloncology.2003.08.011; Sasaki R, 2010, ORAL SURG ORAL MED O, V110, pE41, DOI 10.1016/j.tripleo.2010.04.006; Scheper MA, 2012, OR SURG OR MED OR PA, V114, P497, DOI 10.1016/j.oooo.2012.06.013; Seethala RR, 2017, HEAD NECK PATHOL, V11, P55, DOI 10.1007/s12105-017-0795-0; Shao H, 2014, ENDOCRINE, V46, P285, DOI 10.1007/s12020-013-0068-y; Tong Y, 2007, J NEUROCHEM, V100, P1097, DOI 10.1111/j.1471-4159.2006.04276.x; Wu GQ, 2016, ONCOTARGET, DOI 10.18632/oncotarget.8532	25	0	0	2	4	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	MAY	2018	34	2					158	164		10.5146/tjpath.2017.01421			7	Pathology	Pathology	GL0AM	WOS:000436622700006	29383694	DOAJ Gold			2019-10-28	
J	Sungu, N; Kiran, MM; Tatli Dogan, H; Kilicarslan, A; Karakok, E; Akyol, M				Sungu, Nuran; Kiran, Merve Meryem; Tatli Dogan, Hayriye; Kilicarslan, Aydan; Karakok, Emre; Akyol, Mesut			Evaluation of p53 and Ki67 Expression Profiles in Basal Cell Carcinomas in a Usual and an Unusual Location	TURKISH JOURNAL OF PATHOLOGY			English	Article						Basal cell carcinoma; p53; Ki67; Location	HISTOLOGIC VARIANTS	Objective: Owing to their importance in cell proliferation in cutaneous malignancies, we aimed to immunohistochemically compare the expression profiles of p53 and Ki67 in basal cell carcinoma (BCC) cases in both a usual and an unusual locations in this study. Material and Method: In this study we included 12 in an unusual location of BCC cases and 21 BCC cases in a usual location. Immunohistochemical expression of p53 and Ki67 antibodies were studied in 33 paraffin-embedded tissue specimens of basal cell carcinoma. We compared the p53 and Ki67 staining scores with clinicopathologic features. Results: The tumor size was found to be greater in BCC cases in an unusual location than those in a usual location. The relationship between age and tumor size was also evaluated in both groups and it was found that tumor size increased with age. A comparative study between the two groups showed no difference p53 and Ki67 expression percentages. There was a linear correlation between the Ki67 and p53 marker staining rates (rho=0.420; p=0.015). In the samples taken from cases in a usual region, there was a linear and moderate relationship between the markers (rho=0.513; p=0.017). Median tumor diameter results were similar to the marker staining score (p>0.05). Conclusion: This is the first study comparing the expression profiles of p53 and Ki67 of BCC cases in an unusual and a usual location. No significant difference was found concerning Ki67 and p53 expression levels between the two groups.	[Sungu, Nuran; Kiran, Merve Meryem; Tatli Dogan, Hayriye; Kilicarslan, Aydan; Karakok, Emre] Ankara Yildirim Beyazit Univ, Ankara Ataturk Res & Training Hosp, Dept Pathol, Ankara, Turkey; [Akyol, Mesut] Ankara Yildirim Beyazit Univ, Ankara Ataturk Res & Training Hosp, Dept Biostat, Ankara, Turkey	Sungu, N (reprint author), Ankara Yildirim Beyazit Univ, Ankara Ataturk Res & Training Hosp, Dept Pathol, Ankara, Turkey.	nuransungu@gmail.com					Abeldano A, 2010, DERMATOL ARGENT, V16, P25; Ansarin H, 2006, EUR J DERMATOL, V16, P543, DOI 10.1684/ejd.2006.0027; Borgohain M, 2015, INDIAN J MED CASE RE, V4, P23; Bulus H, 2014, TURK J GASTROENTEROL, V25, P239, DOI 10.5152/tjg.2014.6251; Dagatti MS, 2006, ARCH ARGENT DERMATOL, V56, P55; Demirkan  N C, 2000, Pathol Oncol Res, V6, P272; DEROSA G, 1993, J CUTAN PATHOL, V20, P429; Dourmishev Lyubomir A, 2013, Indian Dermatol Online J, V4, P12, DOI 10.4103/2229-5178.105456; Ghaderi Reza, 2005, Iran J Allergy Asthma Immunol, V4, P167; Jacob A, 1827, DUBLIN HOSP REP, V4, P232; Khodaeiani Effat, 2013, Indian J Dermatol, V58, P181, DOI 10.4103/0019-5154.110824; Koseoglu RD, 2009, J CUTAN PATHOL, V36, P958, DOI [10.1111/j.1600-0560.2009.01204.x, 10.1111/j.1600-0560.2008.01204.x]; Kramer E, 2014, ISR MED ASSOC J, V16, P229; LeBoit PE, 2006, PATHOLOGY GENETIC SK; MARGO CE, 1993, SURV OPHTHALMOL, V38, P169, DOI 10.1016/0039-6257(93)90100-L; Mateoiu C, 2011, ROM J MORPHOL EMBRYO, V52, P315; Mercut R, 2014, ROM J MORPHOL EMBRYO, V55, P263; Pisani C, 2006, J EUR ACAD DERMATOL, V20, P446, DOI 10.1111/j.1468-3083.2006.01456.x; Sungu N, 2017, TURK DERMATOL DERG, V11, P109, DOI 10.4274/tdd.3243; Telfer NR, 2008, BRIT J DERMATOL, V159, P35, DOI 10.1111/j.1365-2133.2008.08666.x; Vantuchova Y, 2006, SCRIPTA MED FACULTAT, V79, P261; Yalcin UK, 2012, TURK J PATHOL, V28, P119, DOI 10.5146/tjpath.2012.01110	22	1	1	0	0	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	MAY	2018	34	2					165	170		10.5146/tjpath.2018.01424			6	Pathology	Pathology	GL0AM	WOS:000436622700007	29630084	DOAJ Gold			2019-10-28	
J	Khera, R; Ahmed, F; Mundada, M; Nambaru, L; Murthy, SS; Devi, GS; Rajappa, SJ; Mallavarapu, KM; Santa, A; Kumar, P				Khera, Rachna; Ahmed, Faiq; Mundada, Manasi; Nambaru, Lavanya; Murthy, Sudha S.; Devi, Sandhya G.; Rajappa, Senthil J.; Mallavarapu, Krishna Mohan; Santa, A.; Kumar, Pavan			Acute Myeloid Leukaemia with Gene Mutation: A Correlation with Haematological and Immunophenotypic Characteristics and Our Experience in a Tertiary Care Cancer Center in South India	TURKISH JOURNAL OF PATHOLOGY			English	Article						Acute myeloid leukemia; FLT3; NPM1; South India	NPM1 MUTATIONS; PROGNOSTIC IMPACT; FLT3	Objective: Molecular genetic analysis of FLT3, NPM1, and CEBPA is already the standard of care in patients with acute myeloid leukaemia (AML) and represents the most frequent genetic alterations and important diagnostic and prognostic indicators. This study was undertaken to determine the frequency of FLT3 and NPM1 gene mutations in our institution and to characterize the association between gene mutations and haematological parameters as well as immunophenotypic features. Material and Method: Morphological, haematological and immunophenotypic characteristics of NPM1 and FLT3 mutations in 126 patients of de novo AML including adults and children were studied. Apart from the French American British (FAB) method for classification, blasts were assessed for cuplike morphology as per strict definition for cuplike nuclei, >= 10% blasts with nuclear invaginations >= 25% of the nuclear area. Results: FLT3 mutation in 31/126 (25%) and NPM1 mutation was found in 17/126 (13.4%) of the AML patients. 6 (5%) samples were positive for both NPM1 and FLT3/ITD mutations. Associations between the FLT3 and NPM1 gene mutations with haematological and immunophenotypic characteristics are reported. Conclusion: The results suggest that presence of distinct morphology and haematological and immunophenotypic characteristics together may serve as important indicators and surrogate for NPM1 and FLT3/ITD mutations. Further, comprehensive studies on the biological effects of NPM1 and FLT3/ITD mutations and their interactions with other genetic alterations are needed to gain insight into the molecular mechanism of these mutations involved in the pathogenesis of AML.	[Khera, Rachna; Ahmed, Faiq; Mundada, Manasi; Nambaru, Lavanya; Murthy, Sudha S.; Devi, Sandhya G.] Basavatarakam Indo Amer Canc Hosp & Res Inst, Dept Lab Med, Hyderabad, Telangana, India; [Rajappa, Senthil J.; Mallavarapu, Krishna Mohan; Santa, A.; Kumar, Pavan] Basavatarakam Indo Amer Canc Hosp & Res Inst, Dept Med Oncol, Hyderabad, Telangana, India	Khera, R (reprint author), Basavatarakam Indo Amer Canc Hosp & Res Inst, Dept Lab Med, Hyderabad, Telangana, India.	rachnakhera@yahoo.com					Boonthimat C, 2008, HAEMATOL-HEMATOL J, V93, P1565, DOI 10.3324/haematol.12937; Chauhan PS, 2013, DIS MARKERS, DOI 10.1155/2013/582569; Dohner K, 2005, BLOOD, V106, P3740, DOI 10.1182/blood-2005-05-2164; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Kiyoi H, 2002, ONCOGENE, V21, P2555, DOI 10.1038/sj.onc.1205332; Paietta E, 2004, BLOOD, V104, P558, DOI 10.1182/blood-2004-01-0168; Park BG, 2013, ANN HEMATOL, V92, P451, DOI 10.1007/s00277-012-1645-5; Rausei-Mills V, 2008, AM J CLIN PATHOL, V129, P624, DOI 10.1309/NRTX9AKXHR5JBT93; Suzuki T, 2005, BLOOD, V106, P2854, DOI 10.1182/blood-2005-04-1733; Thiede C, 2006, BLOOD, V107, P4011, DOI 10.1182/blood-2005-08-3167	10	0	0	0	0	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	MAY	2018	34	2					171	174		10.5146/tjpath.2017.01415			4	Pathology	Pathology	GL0AM	WOS:000436622700008	28984348	DOAJ Gold			2019-10-28	
J	Azatcam, M; Altun, E; Avci, V				Azatcam, Meltem; Altun, Eren; Avci, Veli			Histopathological Diagnostic Dilemma in Retrorectal Developmental Cysts: Report of a Case and Review of the Literature	TURKISH JOURNAL OF PATHOLOGY			English	Review						Cyst; Developmental; Duplication; Rectal	TAILGUT CYST; HAMARTOMA	Retrorectal developmental cysts are lesions that are classified according to their histopathological characteristics and origins. The major types are epidermoid cyst, dermoid cyst, rectal duplication cyst, rectal cystic hamartoma and teratoma. These cysts grow slowly and the majority of cases are asymptomatic. Total excision is required and histopathological examination should be carefully performed for retrorectal localized developmental cysts, since the cystic lesions may show malignant transformation. Here, a 3-year-old male patient with retrorectal mass, which was histopathologically compatible with tailgut cyst, is presented and the differential diagnosis of retrorectal developmental cysts is discussed.	[Azatcam, Meltem; Altun, Eren] Bingol Matern & Childrens Hosp, Dept Med Pathol, Bingol, Turkey; [Avci, Veli] Bingol Matern & Childrens Hosp, Dept Pediat Surg Clin, Bingol, Turkey	Altun, E (reprint author), Bingol Kadm Dogum & Cocuk Hastaliklari Hastanesi, Patol Lab, Bingol, Turkey.	erenaltun@hotmail.com	ALTUN, EREN/P-1338-2019	ALTUN, EREN/0000-0001-9110-8364			Akbulut S, 2013, EUR REV MED PHARMACO, V17, P1688; Akillioglu I, 2011, 29 UL COC CERR K HAR, P133; Baumann JL, 2014, CASE REP GASTROINTES, DOI 10.1155/2014/790326; Blank G, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-55; Dahan H, 2001, RADIOGRAPHICS, V21, P575, DOI 10.1148/radiographics.21.3.g01ma13575; Fenoglio-Preiser C. M., 2008, GASTROINTESTINAL PAT; Galluzzo ML, 2007, PEDIATR DEVEL PATHOL, V10, P325, DOI 10.2350/06-09-0166.1; Glasgow Sean C, 2006, Clin Colon Rectal Surg, V19, P61, DOI 10.1055/s-2006-942346; Hassan Imran, 2009, Clin Colon Rectal Surg, V22, P84, DOI 10.1055/s-0029-1223839; Husain AN, 2011, COLOR ATLAS PEDIAT P; Killingsworth C, 2005, AM SURGEON, V71, P666; Lianos G, 2013, J CANCER RES THER, V9, P343, DOI 10.4103/0973-1482.119297; Neale Jeffrey A, 2011, Clin Colon Rectal Surg, V24, P149, DOI 10.1055/s-0031-1285999; Park WH, 2009, J KOREAN SURG SOC, V77, P69, DOI 10.4174/jkss.2009.77.1.69; Petras RE, 2010, STERNBERGS DIAGNOSTI, P1352; Prasad AR, 2000, ARCH PATHOL LAB MED, V124, P725; Unlu M, 2010, DEU TIP FAKULTESI DE, V24, P143	17	2	2	0	0	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	MAY	2018	34	2					175	178		10.5146/tjpath.2015.01306			4	Pathology	Pathology	GL0AM	WOS:000436622700009	28272655	DOAJ Gold			2019-10-28	
J	Nangia, A; Sehgal, S; Agarwal, K				Nangia, Anita; Sehgal, Shivali; Agarwal, Kiran			Masson's Tumor Masquerading as a Papillary Adenocarcinoma on Fine Needle Aspiration Cytology: A Case Report	TURKISH JOURNAL OF PATHOLOGY			English	Article						Masson's tumor; Papillary adenocarcinoma; Fine needle aspiration	ENDOTHELIAL HYPERPLASIA; MALIGNANCY; PITFALL	Intravascular papillary endothelial hyperplasia, previously known as Masson's tumor, is a relatively uncommon reactive endothelial proliferation that occurs most commonly in the vessels of the head, neck, and extremities. We report a case of intravascular papillary endothelial hyperplasia in the neck in a 40-year-old female that was misdiagnosed as papillary adenocarcinoma on fine needle aspiration. The cytologic picture of intravascular papillary endothelial hyperplasia is diverse, making a pinpoint diagnosis of this entity difficult on fine needle aspiration.	[Nangia, Anita; Sehgal, Shivali; Agarwal, Kiran] Lady Hardinge Med Coll & Hosp, Dept Pathol, Delhi, India	Sehgal, S (reprint author), Lady Hardinge Med Coll & Hosp, Dept Pathol, Delhi, India.	shivalisehgal@gmail.com					Choi YD, 2013, KOREAN J PATHOL, V47, P499, DOI 10.4132/KoreanJPathol.2013.47.5.499; CLEARKIN KP, 1976, ARCH PATHOL LAB MED, V100, P441; GARCIAMACIAS MC, 1990, ACTA CYTOL, V34, P175; Handa U, 2012, ACTA CYTOL, V56, P199, DOI 10.1159/000332355; Jain S, 2012, CYTOPATHOLOGY, V23, P198, DOI 10.1111/j.1365-2303.2011.00857.x; Karim RZ, 2007, ACTA CYTOL, V51, P207, DOI 10.1159/000325718; Kovalovsky A, 2013, J CYTOL, V30, P42, DOI 10.4103/0970-9371.107512; Novak JA, 1999, ACTA CYTOL, V43, P663, DOI 10.1159/000331163; Suh KS, 2003, DIAGN CYTOPATHOL, V29, P14, DOI 10.1002/dc.10207; Weiss SW, 2008, ENZINGER WEISSS SOFT, P668	10	0	0	0	0	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	MAY	2018	34	2					179	181		10.5146/tjpath.2015.01334			3	Pathology	Pathology	GL0AM	WOS:000436622700010	28272657	DOAJ Gold			2019-10-28	
J	Onaygil, E; Songur, A; Kutlubay, Z; Demirkesen, C				Onaygil, Emel; Songur, Abdullah; Kutlubay, Zekayi; Demirkesen, Cuyan			Early Stage Prurigo Pigmentosa : A Case Report	TURKISH JOURNAL OF PATHOLOGY			English	Article						Prurigo Pigmentosa; Diet; Histopathology	DISEASE	Prurigo pigmentosa is a rare inflammatory dermatosis that primarily affects adolescents and young adults. Even though it is most commonly seen in Japanese women, other countries have reported cases with increasing frequency. It is characterized by erythematous papules and macules on the trunk, neck and chest that resolve leaving a reticulate hyperpigmentation. Some endogenous factors related with ketosis like fasting, diet, diabetes, pregnancy and exogenous agents like chrome, nickel, para-amino compounds have been accused of playing a role in etiology. Here we would like to present a case of a 16-year-old female patient who was referred to our clinic with pruritic lesions on the trunk and neck, consistent with the initial phase of prurigo pigmentosa, after a period of strict diet. Prurigo pigmentosa is a disease with distinctive histologic and clinical features. Due to its rare occurrence, an accurate diagnosis may be particularly challenging. Clinicopathological correlation is therefore crucial in the diagnosis of the disease in its early phase.	[Onaygil, Emel; Demirkesen, Cuyan] Istanbul Univ, Cerrahpasa Fac Med, Dept Pathol, Istanbul, Turkey; [Songur, Abdullah] Sanliurfa Balikligol Hosp, Dept Dermatol, Sanliurfa, Turkey; [Kutlubay, Zekayi] Istanbul Univ, Cerrahpasa Fac Med, Dept Dermatol, Istanbul, Turkey	Onaygil, E (reprint author), Istanbul Univ, Cerrahpasa Fac Med, Dept Pathol, Istanbul, Turkey.	emel_dm@hotmail.com	Demirkesen, Cuyan/A-6355-2019	Demirkesen, Cuyan/0000-0002-3045-9942			Atasoy M, 2009, J EUR ACAD DERMATOL, V23, P228, DOI 10.1111/j.1468-3083.2008.02811.x; Baykal C, 2006, INT J DERMATOL, V45, P1164, DOI 10.1111/j.1365-4632.2006.02857.x; Boer A, 2003, AM J DERMATOPATH, V25, P117, DOI 10.1097/00000372-200304000-00005; Erbagci Z, 2002, ACTA DERM-VENEREOL, V82, P302, DOI 10.1080/000155502320323324; Hijazi M, 2014, AM J DERMATOPATH, V36, P800, DOI 10.1097/DAD.0000000000000182; JOYCE AP, 1989, ARCH DERMATOL, V125, P1551, DOI 10.1001/archderm.125.11.1551; Keel PK, 2007, J ABNORM PSYCHOL, V116, P422, DOI 10.1037/0021-843X.116.2.422; Kim JK, 2012, J DERMATOL, V39, P891, DOI 10.1111/j.1346-8138.2012.01640.x; Kim MH, 2001, CONTACT DERMATITIS, V44, P289, DOI 10.1034/j.1600-0536.2001.440507.x; Kubota Y, 1998, EUR J DERMATOL, V8, P439; Lu PH, 2011, INT J DERMATOL, V50, P36, DOI 10.1111/j.1365-4632.2010.04625.x; Meas T, 2005, DIABETES METAB, V31, P299, DOI 10.1016/S1262-3636(07)70198-2; Murao K, 1996, BRIT J DERMATOL, V134, P379, DOI 10.1111/j.1365-2133.1996.tb07643.x; NAGASHIMA M, 1978, Journal of Dermatology (Tokyo), V5, P61; Nakada T, 1998, CLIN EXP DERMATOL, V23, P25; Park JY, 2000, KOR J DERMATOL, V38, P980; Teraki Yuichi, 2005, J Dtsch Dermatol Ges, V3, P9, DOI 10.1046/j.1439-0353.2005.04076.x	17	0	0	0	1	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	MAY	2018	34	2					182	185		10.5146/tjpath.2015.01333			4	Pathology	Pathology	GL0AM	WOS:000436622700011	28272658	DOAJ Gold			2019-10-28	
J	Haberal Reyhan, AN				Haberal Reyhan, Asuman Nihan			Solitary Fibrous Tumor of the Vagina with Potentially Malignant Features: A Case Report and Review of the Literature	TURKISH JOURNAL OF PATHOLOGY			English	Review						Solitary fibrous tumor; Vagina; Hemangiopericytoma; Female genital neoplasms		Extrapleural solitary fibrous tumors are being increasingly reported. The retroperitoneum, deep soft tissues of the proximal extremities, abdominal cavity, trunk, head and neck are among the most common extraserosal locations reported. A recurrent solitary fibrous tumor involving the vagina of a 25-year-old woman is reported. Microscopically, the tumor was hypercellular and composed of mitotically active spindle cells. Immunohistochemically, the tumor cells were positive for vimentin, CD34, and bcl-2. Four cases of solitary fibrous tumors involving the vagina have been reported previously. To the best of our knowledge, this is the first case with clinical and histological features suggestive of a malignant behavior.	[Haberal Reyhan, Asuman Nihan] Baskent Univ, Dept Pathol, Fac Med, Ankara, Turkey	Haberal Reyhan, AN (reprint author), Baskent Univ, Dept Pathol, Fac Med, Ankara, Turkey.	asumannihan@yahoo.com					Akiyama Y, 2000, PATHOL INT, V50, P327, DOI 10.1046/j.1440-1827.2000.01042.x; Demicco EG, 2012, MODERN PATHOL, V25, P1298, DOI 10.1038/modpathol.2012.83; Gold JS, 2002, CANCER, V94, P1057, DOI 10.1002/cncr.10328; Hasegawa T, 1999, HUM PATHOL, V30, P1464, DOI 10.1016/S0046-8177(99)90169-7; Ide F, 2005, VIRCHOWS ARCH, V446, P646, DOI 10.1007/s00428-005-1261-z; Iyengar Pratibha, 2007, J Low Genit Tract Dis, V11, P50, DOI 10.1097/01.lgt.0000230205.73365.5e; Nascimento AG, 1996, ADV ANAT PATHOL, V3, P388; Placide N, 2012, INT J SURG PATHOL, V20, P101, DOI 10.1177/1066896911413577; SUSTER S, 1995, AM J SURG PATHOL, V19, P1257, DOI 10.1097/00000478-199511000-00005; Vadmal MS, 2000, AM J DERMATOPATH, V22, P83, DOI 10.1097/00000372-200002000-00017; Vallat-Decouvelaere AV, 1998, AM J SURG PATHOL, V22, P1501, DOI 10.1097/00000478-199812000-00007	11	1	1	0	0	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	MAY	2018	34	2					186	189		10.5146/tjpath.2015.01309			4	Pathology	Pathology	GL0AM	WOS:000436622700012	28272656	DOAJ Gold			2019-10-28	
J	Bianchi, C; Bianchi, T				Bianchi, Claudio; Bianchi, Tommaso			Non-Hodgkin Lymphoma and Pleural Mesothelioma in a Person Exposed to Asbestos	TURKISH JOURNAL OF PATHOLOGY			English	Article						Non-Hodgkin Lymphoma; Mesothelioma; Asbestos	MALIGNANT MESOTHELIOMA; WORKERS; OCCUPATION; DISORDERS; PATIENT; CANCER; CELLS	Non-Hodgkin lymphoma and pleural mesothelioma may co-exist in the same patient. A large cell non-Hodgkin lymphoma of the inguinal lymph nodes was diagnosed in a 73-year-old woman. The patient was treated by chemotherapy. She did not receive radiotherapy. The patient had been exposed to asbestos having worked in a cotton mill and in a distillery. Four years after the diagnosis of lymphoma, she presented with a left pleural effusion. Large biopsies of the pleura showed a malignant mesothelioma, biphasic type, and pleural plaques. Epidemiological studies about the asbestos-lymphoma relationship gave conflicting results. The lymphoma-mesothelioma association is not exceptional, and suggests that asbestos plays a role in the etiology of both malignancies.	[Bianchi, Claudio; Bianchi, Tommaso] Italian League Canc, Ctr Study Environm Canc, Monfalcone, Italy	Bianchi, C (reprint author), Hosp Monfalcone, Ctr Study Environm Canc, Ctr Study Environm Canc, Monfalcone, Italy.	legatumori1@interfree.it					Ascoli V, 2014, CANCER EPIDEMIOL, V38, P273, DOI 10.1016/j.canep.2014.02.014; Becker N, 2001, INT ARCH OCC ENV HEA, V74, P459, DOI 10.1007/s004200100253; Bianchi C, 2004, IND HEALTH, V42, P235, DOI 10.2486/indhealth.42.235; Bianchi C, 2004, MED LAV, V95, P276; Bianchi C, 1983, ACTA NEUROL, V5, P308; Bianchi C, 1984, 47 C SOC IT MED LAV, P1077; Bianchi C, 2007, TUMORI J, V93, P19; Bianchi Claudio, 2013, Indian J Occup Environ Med, V17, P122, DOI 10.4103/0019-5278.130865; Bianchi C, 2010, EUR J ONCOL, V15, P167; Bianchi Claudio, 2008, Indian J Occup Environ Med, V12, P57, DOI 10.4103/0019-5278.43261; de Klerk N, 2013, INT J CANCER, V132, P1423, DOI 10.1002/ijc.27758; EFREMIDIS AP, 1985, CANCER, V55, P1056, DOI 10.1002/1097-0142(19850301)55:5<1056::AID-CNCR2820550522>3.0.CO;2-V; Froom P, 2000, J OCCUP ENVIRON MED, V42, P19, DOI 10.1097/00043764-200001000-00007; GERBER MA, 1970, AM J CLIN PATHOL, V53, P204; Hayashi Y, 1989, Nihon Naika Gakkai Zasshi, V78, P1611; KAGAN E, 1983, AM J CLIN PATHOL, V80, P14, DOI 10.1093/ajcp/80.1.14; Li X, 2015, ARCH PATHOL LAB MED, V139, P1129, DOI 10.5858/arpa.2014-0569-OA; LIEBEN J, 1966, ARCH ENVIRON HEALTH, V13, P619, DOI 10.1080/00039896.1966.10664628; Longo MS, 1983, RIV OSPEDALE SAMPIER, V21, P29; Mester B, 2006, OCCUP ENVIRON MED, V63, P17, DOI 10.1136/oem.2005.020453; Nishimura Y, 2009, INT J IMMUNOPATH PH, V22, P579, DOI 10.1177/039463200902200304; Oksa P, 1997, AM J IND MED, V31, P693, DOI 10.1002/(SICI)1097-0274(199706)31:6<693::AID-AJIM4>3.0.CO;2-S; Otsuki T, 2007, CELL MOL IMMUNOL, V4, P261; PERRY MC, 1978, MED PEDIATR ONCOL, V5, P205, DOI 10.1002/mpo.2950050128; Pukkala E, 2009, ACTA ONCOL, V48, P646, DOI 10.1080/02841860902913546; ROSS R, 1982, LANCET, V2, P1118; Seidler A, 2010, INT ARCH OCC ENV HEA, V83, P563, DOI 10.1007/s00420-009-0502-x; Stewart BW, 2003, WORLD CANC REPORT; Weisenburger DD, 2002, CLIN LYMPHOMA, V3, P36, DOI 10.3816/CLM.2002.n.009	29	0	0	0	0	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	MAY	2018	34	2					190	193		10.5146/tjpath.2015.01332			4	Pathology	Pathology	GL0AM	WOS:000436622700013	28272659	DOAJ Gold			2019-10-28	
J	Yigit, N; Celik, E; Yavan, I				Yigit, Nuri; Celik, Ertugrul; Yavan, Ibrahim			Prominent Signet Ring Cell Morphology in a Pulmonary Squamous Cell Carcinoma	TURKISH JOURNAL OF PATHOLOGY			English	Article						Signet ring cells; Intracytoplasmic vacuoles; Squamous cell carcinoma; Lung		In daily practice, signet ring cell morphology immediately brings to the mind the possibility of an adenocarcinoma at first glance. The signet ring cell appearance has been described and is well-known in a wide variety of some other neoplasms as well. Surprisingly however, neoplastic cells having the same morphology can unexpectedly be encountered in not previously well-documented tumors. Here, we present an 85-year-old man diagnosed with primary pulmonary squamous cell carcinoma and a large signet ring cell population. Examination of the lobectomy specimen and further radiological workup was consistent with stage I disease. Signet ring cell variant of squamous cell carcinoma is a very infrequent tumor and has been reported in only eight cases from skin, cervical and oral cavity biopsies as well as in one case of pulmonary acantholytic variant of squamous cell carcinoma with focal signet ring cells. To be aware of this entity is crucial for pathologists to reach the correct diagnosis, particularly in cytological samples, because of its potentially modifying effect on treatment options and patient management compared to adenocarcinomas. Our patient remained in clinical remission during the 9-month follow-up.	[Yigit, Nuri; Yavan, Ibrahim] Gulhane Mil Med Acad & Sch Med, Dept Pathol, Ankara, Turkey; [Celik, Ertugrul] Izmir Mil Hosp, Dept Pathol, Izmir, Turkey	Yigit, N (reprint author), Gulhane Mil Med Acad & Sch Med, Dept Pathol, Ankara, Turkey.	nyigitsum@gmail.com					Alves MO, 2014, HEAD NECK ONCOL, V6, P11; Bogusz AM, 2013, INT J SURG PATHOL, V21, P399, DOI 10.1177/1066896912474342; CRAMER SF, 1989, AM J CLIN PATHOL, V91, P488, DOI 10.1093/ajcp/91.4.488; El Demellawy D, 2011, J CUTAN PATHOL, V38, P306, DOI 10.1111/j.1600-0560.2009.01418.x; Grier DD, 2012, AM J HEMATOL, V87, P625, DOI 10.1002/ajh.22155; Iwasaki H, 2015, VIRCHOWS ARCH, V466, P453, DOI 10.1007/s00428-015-1721-z; Karabagli P, 2013, BREAST CANCER-TOKYO, V20, P363, DOI 10.1007/s12282-010-0210-0; KUPRYJANCZYK J, 1992, INT J GYNECOL CANCER, V2, P152, DOI 10.1046/j.1525-1438.1992.02030152.x; Lortscher David N, 2012, Dermatol Online J, V18, P3; McKinley E, 1998, J CUTAN PATHOL, V25, P176, DOI 10.1111/j.1600-0560.1998.tb01712.x; Mehrad M, 2013, AM J SURG PATHOL, V37, P1349, DOI 10.1097/PAS.0b013e318290427d; Nakajima K, 2013, CASE REP DERMATOL, V5, P215, DOI 10.1159/000354536; Park HS, 2015, HISTOPATHOLOGY; Saito T, 2015, INT J CLIN EXP PATHO, V8, P2267; Salviato T, 2013, AM J DERMATOPATH, V35, P671, DOI 10.1097/DAD.0b013e3182892261; Terada T, 2012, MED ONCOL, V29, P2866, DOI 10.1007/s12032-011-0122-7	16	0	0	1	2	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	MAY	2018	34	2					194	197		10.5146/tjpath.2015.01337			4	Pathology	Pathology	GL0AM	WOS:000436622700014	28272660	DOAJ Gold			2019-10-28	
J	Castellanos, MR; Nehru, VM; Pirog, EC; Optiz, L				Castellanos, Mario R.; Nehru, Vijeyaluxmy Motilal; Pirog, Edyta C.; Optiz, Lynne			Fluorescence microscopy of H&E stained cervical biopsies to assist the diagnosis and grading of CIN	PATHOLOGY RESEARCH AND PRACTICE			English	Review						Diagnostic imaging; Fluorescence imaging; Cervical neoplasia; Hematoxylin and eosin	INTRAEPITHELIAL NEOPLASIA; CONFOCAL MICROSCOPY; NATURAL-HISTORY; HEMATOXYLIN-EOSIN; SECTIONS; CANCER; SPECTROSCOPY; REGRESSION; DYSPLASIA; CARCINOMA	Background: Prevention of cervical cancer is based upon the accurate diagnosis and grading of cervical lesions identified during screening. The pathological classification of cervical intraepithelial neoplasia (CIN) is problematic, as it relies on subjective criteria and is known to have high interobserver variability and low reproducibility. These limitations can result in either over or under treatment of patients. Biomarkers to improve CIN diagnosis have not overcome all these challenges. Main body: Here we review the use of a promising optical imaging method using eosin-based fluorescence spectroscopy. This technique is able to perform fluorescent analysis of cervical biopsies directly from hematoxylin and eosin (H&E) stained tissues. Eosin is a brominated derivative of fluorescein. Fluorescence characteristics of protein-eosin complexes can demonstrate tissue changes associated with dysplasia and cancer. In this article we review the progress made towards developing eosin-based fluorescence spectroscopy. We describe the various morphologies seen among the CIN grades with this optical method and highlight the progress made to quantitate the spectral image characteristics. Conclusion: Eosin-based fluorescence spectroscopy can be used to directly examine H&E stained tissue slides. Relevant areas can be imaged and spectral analysis done to obtain objective data to identify and grade cervical lesions.	[Castellanos, Mario R.; Nehru, Vijeyaluxmy Motilal] Staten Isl Univ Hosp Northwell Hlth, Dept Med, Div Res, 475 Seaview Ave, Staten Isl, NY 10305 USA; [Pirog, Edyta C.] Weill Cornell Med Coll, Dept Pathol, 525 East 68th St, New York, NY 10065 USA; [Optiz, Lynne] Staten Isl Univ Hosp Northwell Hlth, Dept Pathol & Lab Med, 475 Seaview Ave, Staten Isl, NY 10305 USA	Castellanos, MR (reprint author), Staten Isl Univ Hosp Northwell Hlth, Dept Med, Div Res, 475 Seaview Ave, Staten Isl, NY 10305 USA.	mcastellan@northwell.edu; vmotil2@uic.edu; ecpirog@med.cornell.edu; lopitz@northwell.edu					Birla L, 2004, SPECTROCHIM ACTA A, V60, P551, DOI 10.1016/S1386-1425(03)00261-0; BONSIB SM, 1990, MODERN PATHOL, V3, P204; Buys TPH, 2012, GENDER MED, V9, pS7, DOI 10.1016/j.genm.2011.08.002; Carlson K, 2005, GYNECOL ONCOL, V99, pS84, DOI 10.1016/j.ygyno.2005.07.049; Carreon JD, 2007, INT J GYNECOL PATHOL, V26, P441, DOI 10.1097/pgp.ob013e31805152ab; Castellanos MR, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0343-8; Castellanos MR, 2012, INT J GYNECOL PATHOL, V31, P1, DOI 10.1097/PGP.0b013e3182230df7; Castle PE, 2009, OBSTET GYNECOL, V113, P18, DOI 10.1097/AOG.0b013e31818f5008; Ceballos KM, 2008, INT J GYNECOL PATHOL, V27, P101, DOI 10.1097/pgp.0b013e31814fb1da; Chadwick C.S., 1958, IMMUNOLOGY, V31, P5; de Oliveira ERZM, 2006, INT J GYNECOL CANCER, V16, P1055, DOI 10.1111/j.1525-1438.2006.00462.x; deCarvalho HF, 1996, HISTOCHEM CELL BIOL, V106, P587, DOI 10.1007/s004180050080; Dinish U.S., 2008, P SOC PHOTO-OPT INS, P6859; Doorbar J, 2006, CLIN SCI, V110, P525, DOI 10.1042/CS20050369; Elston DM, 2002, J AM ACAD DERMATOL, V47, P777, DOI 10.1067/mjd.2002.120623; ESPADA J, 1993, HISTOCHEMISTRY, V99, P385, DOI 10.1007/BF00717051; Esselen KM, 2013, CLIN OBSTET GYNECOL, V56, P55, DOI 10.1097/GRF.0b013e3182823797; Ginsburg O, 2016, LANCET; Gu J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125706; Gu J, 2014, J BIOPHOTONICS, V7, P483, DOI 10.1002/jbio.201200202; Ikeda K, 2008, GYNECOL ONCOL, V108, P598, DOI 10.1016/j.ygyno.2007.11.042; Jakubovsky J, 2002, ACTA HISTOCHEM, V104, P353, DOI 10.1078/0065-1281-00684; Koeneman MM, 2015, EXPERT REV MOL DIAGN, V15, P527, DOI 10.1586/14737159.2015.1012068; McCredie MRE, 2008, LANCET ONCOL, V9, P425, DOI 10.1016/S1470-2045(08)70103-7; McMahon JT, 2002, MODERN PATHOL, V15, P988, DOI 10.1097/01.MP.0000027202.51385.85; Monici M, 2005, BIOTECHNOL ANN REV, V11, P227, DOI 10.1016/S1387-2656(05)11007-2; OSTOR AG, 1993, INT J GYNECOL PATHOL, V12, P186; Pavlova I, 2003, PHOTOCHEM PHOTOBIOL, V77, P550, DOI 10.1562/0031-8655(2003)077<0550:MABOON>2.0.CO;2; Ragazzi M, 2016, ADV ANAT PATHOL, V23, P159, DOI 10.1097/PAP.0000000000000114; Ramanujam N, 2000, NEOPLASIA, V2, P89, DOI 10.1038/sj.neo.7900077; Schiller John T, 2010, Gynecol Oncol, V118, pS12, DOI 10.1016/j.ygyno.2010.04.004; Sheikhzadeh F, 2015, BIOMED ENG ONLINE, V14, DOI 10.1186/s12938-015-0093-6; Sokolov K, 2002, CURR OPIN CHEM BIOL, V6, P651, DOI 10.1016/S1367-5931(02)00381-2; STEINBERG BM, 1990, ARCH OTOLARYNGOL, V116, P1167; Stoler MH, 2015, AM J SURG PATHOL, V39, P729, DOI 10.1097/PAS.0000000000000381; Stoler MH, 2001, JAMA-J AM MED ASSOC, V285, P1500, DOI 10.1001/jama.285.11.1500; Syrjanen K., 2000, EPIDEMIOLOGY GENITAL, P117; Syrjanen KJ, 1996, EUR J OBSTET GYN R B, V65, P45, DOI 10.1016/0028-2243(95)02303-A; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Trimble CL, 2005, CLIN CANCER RES, V11, P4717, DOI 10.1158/1078-0432.CCR-04-2599; Waheed AA, 2000, ANAL BIOCHEM, V287, P73, DOI 10.1006/abio.2000.4793; Wilson RH, 2011, TECHNOL CANCER RES T, V10, P121, DOI 10.7785/tcrt.2012.500187; Wright T., 2011, PRECANCEROUS LESIONS; Zheng W, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2975866	44	2	2	2	5	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAY	2018	214	5					605	611		10.1016/j.prp.2018.03.021			7	Pathology	Pathology	GJ5NF	WOS:000435427500001	29627221				2019-10-28	
J	Chen, XY; Ding, B; Zhang, P; Geng, SQ; Xu, J; Han, B				Chen, Xinyi; Ding, Bin; Zhang, Ping; Geng, Shaoqing; Xu, Jing; Han, Bo			Intraductal carcinoma of the prostate: What we know and what we do not know	PATHOLOGY RESEARCH AND PRACTICE			English	Review						Intraductal carcinoma of the prostate; Diagnostic parameters; Differential diagnosis; Incidence; Morphology; Clinical significance	ATYPICAL CRIBRIFORM LESIONS; GENITAL ORGANS-PART; HIGH-GRADE PIN; INTRAEPITHELIAL NEOPLASIA; DUCTAL ADENOCARCINOMA; NEEDLE-BIOPSY; CLINICOPATHOLOGICAL FEATURES; ENDOMETRIOID ADENOCARCINOMA; INVASIVE ADENOCARCINOMA; CANCER PROGRESSION	Intraductal carcinoma of the prostate (IDC-P) is a malignant, clonal proliferation of cells growing within the basement membrane-bound structures of the prostate. IDC-P is usually associated with unfavorable clinicopathologic parameters such as large tumor volume, high-grade Gleason score, extra prostatic extension and seminal vesicle invasion. Majority of laboratory and patient data suggest that IDC-P represents intraductal spread of invasive carcinoma, rather than a precursor lesion. Additionally, relationship of IDC-P and adjacent invasive carcinoma has been investigated in a series of molecular studies. The differential diagnosis of IDC-P from other lesions is critical for patient management. In this article, we summarize current literatures regarding what we know about IDC-P, including its pathological morphology, incidence, differential diagnosis, molecular features and clinical significance. In addition, we propose several issues that we currently do not know about IDC-P. Further research is needed to better understand the biological nature of IDC-P.	[Chen, Xinyi; Xu, Jing; Han, Bo] Shandong Univ, QiLu Med Coll, Sch Basic Med Sci, Dept Pathol, Jinan 250012, Shandong, Peoples R China; [Chen, Xinyi; Ding, Bin; Geng, Shaoqing; Xu, Jing] Qingdao Univ, Med Coll, Qingdao Cent Hosp, Dept Pathol, Qingdao, Peoples R China; [Zhang, Ping] Qingdao Univ, Med Coll, Affiliated Hosp 2, Dept Radiol,Qingdao Cent Hosp, Qingdao, Peoples R China; [Han, Bo] Shandong Univ, Qilu Hosp, Dept Pathol, Jinan 250012, Shandong, Peoples R China	Han, B (reprint author), Shandong Univ, Qilu Hosp, Dept Pathol, Jinan 250012, Shandong, Peoples R China.	boh@sdu.edu.cn		Xu, Jing/0000-0003-2438-3045	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81672554, 81472417]; Specific Key Project for Research and Development of Shandong Province [2016GSF201170]	We thank Youxin Ji for valuable comments on the draft of this manuscript, and Yinan Li, Jing Xu for helpful suggestions. This work was supported by National Natural Science Foundation of China (Grants No. 81672554 and 81472417 to BH). The Specific Key Project for Research and Development of Shandong Province (2016GSF201170 to BH).	AYALA AG, 1986, AM J SURG PATHOL, V10, P665, DOI 10.1097/00000478-198610000-00001; Bettendorf O, 2008, GENE CHROMOSOME CANC, V47, P565, DOI 10.1002/gcc.20560; Bostwick DG, 2004, MODERN PATHOL, V17, P360, DOI 10.1038/modpathol.3800053; BOSTWICK DG, 1985, AM J SURG PATHOL, V9, P595, DOI 10.1097/00000478-198508000-00004; Chen ZB, 2015, PROSTATE, V75, P1247, DOI 10.1002/pros.23005; Chua MLK, 2017, EUR UROL, V72, P665, DOI 10.1016/j.eururo.2017.04.034; Cohen RJ, 1998, BRIT J UROL, V81, P413; Cohen RJ, 2000, PROSTATE, V43, P11, DOI 10.1002/(SICI)1097-0045(20000401)43:1<11::AID-PROS3>3.0.CO;2-B; Cohen RJ, 2007, ARCH PATHOL LAB MED, V131, P1103; Dawkins HJS, 2000, PROSTATE, V44, P265; Drake W M Jr, 1974, Urology, V3, P621, DOI 10.1016/S0090-4295(74)80262-1; DUBE VE, 1973, CANCER, V32, P402, DOI 10.1002/1097-0142(197308)32:2<402::AID-CNCR2820320218>3.0.CO;2-Q; Epstein JI, 2014, AM J SURG PATHOL, V38, pE6, DOI 10.1097/PAS.0000000000000238; Epstein JI, 2010, INT J SURG PATHOL, V18, p142S, DOI 10.1177/1066896910370616; Facher EA, 1998, J MED GENET, V35, P790, DOI 10.1136/jmg.35.9.790-a; Guo CC, 2006, MODERN PATHOL, V19, P1528, DOI 10.1038/modpathol.3800702; Haffner MC, 2016, J PATHOL, V238, P31, DOI 10.1002/path.4628; Han B, 2010, AM J SURG PATHOL, V34, P478, DOI 10.1097/PAS.0b013e3181d6827b; Herawi M, 2007, AM J SURG PATHOL, V31, P889, DOI 10.1097/01.pas.0000213447.16526.7f; Hickman RA, 2017, AM J SURG PATHOL, V41, P550, DOI 10.1097/PAS.0000000000000794; Humphrey PA, 2016, EUR UROL, V70, P106, DOI 10.1016/j.eururo.2016.02.028; Kato M, 2016, MODERN PATHOL, V29, P166, DOI 10.1038/modpathol.2015.146; Kimura K, 2014, PROSTATE, V74, P680, DOI 10.1002/pros.22786; Korsten H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147500; KOVI J, 1985, CANCER, V56, P1566, DOI 10.1002/1097-0142(19851001)56:7<1566::AID-CNCR2820560717>3.0.CO;2-Y; Kronz JD, 2001, AM J SURG PATHOL, V25, P147, DOI 10.1097/00000478-200102000-00002; LEE SS, 1994, J SURG ONCOL, V55, P235, DOI 10.1002/jso.2930550407; Lindberg J, 2015, EUR UROL, V67, P819, DOI 10.1016/j.eururo.2014.09.006; Lotan TL, 2013, MODERN PATHOL, V26, P587, DOI 10.1038/modpathol.2012.201; Magers M, 2015, ARCH PATHOL LAB MED, V139, P1234, DOI 10.5858/arpa.2015-0206-RA; McNeal JE, 1996, AM J SURG PATHOL, V20, P802, DOI 10.1097/00000478-199607000-00003; Millar EKA, 1996, HISTOPATHOLOGY, V29, P11, DOI 10.1046/j.1365-2559.1996.d01-483.x; Miyai K, 2014, HUM PATHOL, V45, P1572, DOI 10.1016/j.humpath.2014.03.011; Miyai K, 2014, INT J CLIN EXP PATHO, V7, P2518; Moch H, 2016, EUR UROL, V70, P93, DOI 10.1016/j.eururo.2016.02.029; Morais CL, 2016, HUM PATHOL, V55, P117, DOI 10.1016/j.humpath.2016.04.017; Morais CL, 2015, AM J SURG PATHOL, V39, P169, DOI 10.1097/PAS.0000000000000348; Narod SA, 2008, BRIT J CANCER, V99, P371, DOI 10.1038/sj.bjc.6604453; Park K, 2014, J CLIN ONCOL, V32, P206, DOI 10.1200/JCO.2013.49.8386; Pettaway C A, 1998, Tech Urol, V4, P35; Risbridger GP, 2015, EUR UROL, V67, P496, DOI 10.1016/j.eururo.2014.08.007; Rischmann P, 2017, EUR UROL, V71, P267, DOI 10.1016/j.eururo.2016.09.039; Robinson B, 2012, ARCH PATHOL LAB MED, V136, P418, DOI 10.5858/arpa.2011-0519-RA; Robinson BD, 2010, J UROLOGY, V184, P1328, DOI 10.1016/j.juro.2010.06.017; Seipel AH, 2016, PATHOLOGY, V48, P398, DOI 10.1016/j.pathol.2016.04.001; Shah RB, 2010, AM J SURG PATHOL, V34, P470, DOI 10.1097/PAS.0b013e3181cfc44b; Taris M, 2014, PROSTATE, V74, P1481, DOI 10.1002/pros.22863; Taylor RA, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13671; Teng LH, 2013, UROLOGY, V82, P394, DOI 10.1016/j.urology.2013.03.029; Tomlins SA, 2012, ARCH PATHOL LAB MED, V136, P935, DOI 10.5858/arpa.2011-0424-OA; Tu SM, 2009, CANCER-AM CANCER SOC, V115, P2872, DOI 10.1002/cncr.24326; Van der Kwast T, 2012, EUR J CANCER, V48, P1318, DOI 10.1016/j.ejca.2012.02.003; Watts K, 2013, HISTOPATHOLOGY, V63, P574, DOI 10.1111/his.12198; Weier C, 2013, J PATHOL, V230, P174, DOI 10.1002/path.4186; Wobker SE, 2016, AM J SURG PATHOL, V40, pE67, DOI 10.1097/PAS.0000000000000609; Zhong C, 2006, CANCER RES, V66, P2188, DOI 10.1158/0008-5472.CAN-05-3440	56	0	2	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAY	2018	214	5					612	618		10.1016/j.prp.2018.03.003			7	Pathology	Pathology	GJ5NF	WOS:000435427500002	29628124				2019-10-28	
J	Lee, A; Won, KY; Lim, SJ; Cho, SY; Han, SA; Park, S; Song, JY				Lee, Anbok; Won, Kyu Yeoun; Lim, Sung-Jig; Cho, Sun Young; Han, Sang-Ah; Park, SaeGwang; Song, Jeong-Yoon			ALDH1 and tumor infiltrating lymphocytes as predictors for neoadjuvant chemotherapy response in breast cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Breast; Neoplastic stem cells; Tumor infiltrating lymphocytes; Neoadjuvant chemotherapy; Prognosis	STEM-CELLS; EXPRESSION; THERAPY; RESISTANCE; SURVIVAL; CD133	Many studies have reported that Aldehyde dehydrogenase 1 (ALDH1) and tumor-infiltrating lymphocytes (TIL) are related to breast cancer prognosis. However, the clinical significance of ALDH1 and tumor-infiltrating immune cells in breast cancer has not been fully investigated in patients who received neoadjuvant chemotherapy (NAC). We studied the significance of the expression of ALDH1 and the population of TIL for predicting the prognosis and chemotherapeutic response of patients with breast cancer who had received NAC. Forty patients who underwent NAC were enrolled in this study. ALDH1 and TIL (T cells and tumor associated macrophages) were evaluated before and after NAC. The influences of ALDH1 expression status and TIL populations on both prognosis and chemotherapeutic response were evaluated. ALDH1 positivity was related to estrogen receptor (p = 0.026) and progesterone receptor negativity (p = 0.025). Positive change of ALDH1 after NAC tended to be associated with a poor NAC response (p = 0.078). Patients with more CD8 + T cells before NAC and fewer CD68 (+) macrophages after NAC tended to have better OS, respectively (p = 0.086, p = 0.096). The chemotherapeutic response and prognosis of patients with breast cancer who received NAC are thought to be determined by the tumor microenvironment. Further research with more patients and a longer study period is needed.	[Lee, Anbok] INJE Univ, Coll Med, Busan Paik Hosp, Dept Surg, Busan, South Korea; [Won, Kyu Yeoun; Lim, Sung-Jig] Kyung Hee Univ, Coll Med, Kyung Hee Univ Hosp Gangdong, Dept Pathol, Seoul, South Korea; [Cho, Sun Young] Kyung Hee Univ, Coll Med, Med Ctr, Dept Lab Med, Seoul, South Korea; [Han, Sang-Ah; Song, Jeong-Yoon] Kyung Hee Univ, Coll Med, Kyung Hee Univ Hosp Gangdong, Dept Surg, Seoul, South Korea; [Park, SaeGwang] INJE Univ, Coll Med, Dept Microbiol & Immunol, Busan, South Korea	Song, JY (reprint author), Kyung Hee Univ Hosp Gangdong, Dept Surg, Seoul 134727, South Korea.	jeonguni01@hanmail.net					Andre F, 2010, CURR OPIN ONCOL, V22, P547, DOI 10.1097/CCO.0b013e32833fb384; Aomatsu N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045865; Campbell MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079114; Castaneda CA, 2016, WORLD J CLIN ONCOL, V7, P387, DOI 10.5306/wjco.v7.i5.387; Collina F, 2015, BIOMED RES INT, DOI 10.1155/2015/158682; deLeeuw RJ, 2012, CLIN CANCER RES, V18, P3022, DOI 10.1158/1078-0432.CCR-11-3216; Dragu DL, 2015, WORLD J STEM CELLS, V7, P1185, DOI 10.4252/wjsc.v7.i9.1185; Duhen T, 2012, BLOOD, V119, P4430, DOI 10.1182/blood-2011-11-392324; Fedyanin M, 2017, CURR STEM CELL RES T, V12, P19, DOI 10.2174/1574888X11666160905092938; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Kapucuoglu N, 2015, PATHOL RES PRACT, V211, P740, DOI 10.1016/j.prp.2015.05.011; Kida K, 2016, BREAST CANCER RES TR, V156, P261, DOI 10.1007/s10549-016-3738-7; Kim SJ, 2015, J BREAST CANCER, V18, P347, DOI 10.4048/jbc.2015.18.4.347; Ladoire S, 2011, J PATHOL, V224, P389, DOI 10.1002/path.2866; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Medrek C, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-306; Miller M, 2014, ANN SURG ONCOL, V21, P3317, DOI 10.1245/s10434-014-3922-0; Mitrofanova I, 2017, IMMUNOBIOLOGY, V222, P101, DOI 10.1016/j.imbio.2016.08.001; Molofsky AV, 2004, CURR OPIN CELL BIOL, V16, P700, DOI 10.1016/j.ceb.2004.09.004; Morrison SJ, 1997, DEVELOPMENT, V124, P1929; Park CK, 2016, J PATHOL TRANSL MED, V50, P173, DOI 10.4132/jptm.2016.02.02; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Seo AN, 2013, BRIT J CANCER, V109, P2705, DOI 10.1038/bjc.2013.634; Tanei T, 2009, CLIN CANCER RES, V15, P4234, DOI 10.1158/1078-0432.CCR-08-1479; Ward RJ, 2007, ANNU REV PATHOL-MECH, V2, P175, DOI 10.1146/annurev.pathol.2.010506.091847; Zhang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076147; Zhou LL, 2016, JMMB, V16, P1	27	2	2	0	2	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAY	2018	214	5					619	624		10.1016/j.prp.2018.04.006			6	Pathology	Pathology	GJ5NF	WOS:000435427500003	29685462				2019-10-28	
J	Li, RD; Tang, YH; Wang, HL; Yang, D; Sun, LJ; Li, W				Li, Rui-Dong; Tang, Yan-Hua; Wang, Hui-Li; Yang, Dong; Sun, Li-Jun; Li, Wei			The SMYD3 VNTR 3/3 polymorphism confers an increased risk and poor prognosis of hepatocellular carcinoma in a Chinese population	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Hepatocellular carcinoma; SMYD3 gene; Polymorphism; Risk factors; Drinking history; Family history of hepatocellular carcinoma; Cirrhosis; Hepatitis B virus	DOMAIN-CONTAINING PROTEIN-3; FAMILY-HISTORY; LIVER-CANCER; CHOLANGIOCARCINOMA; ASSOCIATION; SURVIVAL; GENE; SET	Objective: Hepatocellular carcinoma (HCC) is one of the most lethal human malignancies in China, and the genetic link of hepatocarcinogenesis remains to be defined. Thus, we explored the role of SET and myeloid translocation protein 8, Nervy, and DEAF1 (MYND) domain containing protein 3 (SMYD3) gene polymorphism on risk and prognosis of HCC. Methods: A total of 236 patients with HCC who received treatment in Affiliated Hospital of Jining Medical University for the first time and 230 healthy individuals were enrolled in the study. After DNA extraction for all the subjects, polymerase chain reaction (PCR) was used to amplify and sequence variable numbers of tandem repeat (VNTR) loci of SMYD3 gene. SMYD3 gene was genotyped and its frequency distribution was calculated. Age, education level, income, smoking and drinking history, HCC family history, tumor node metastasis (TNM) staging, maximum tumor diameter, lymph node metastasis (LNM) etc. were investigated. Correlation of SMYD3 gene polymorphism and other risk factors with the occurrence and prognosis of HCC was analyzed. Results: The family history of HCC, drinking history, cirrhosis, and HBV or/and HCV infection, SMYD3 VNTR 3/3 were more frequently observed in subjects with HCC. Patients with SMYD3 VNTR 3/3 genotype, drinking history, family history of HCC, cirrhosis and hepatitis B virus (HBV), TNM staging, maximum tumor diameter, LNM were more vulnerable to HCC. Besides, patients with SMYD3 VNTR 3/3 genotype had lower 2- and 3-year survival rate. The COX regression analysis revealed that drinking history, family history of HCC, SMYD3 VNTR 3/3 genotype, TNM staging, and LNM were all related to the prognosis of HCC. Conclusion: This study indicates that drinking history, family history of HCC and SMYD3 VNTR 3/3, NM staging, maximum tumor diameter, LNM might be risk factors for HCC, and SMYD3 VNTR 3/3 might contribute to a lower 2- and 3-year survival rate of patients with HCC.	[Li, Rui-Dong; Tang, Yan-Hua; Wang, Hui-Li; Yang, Dong; Sun, Li-Jun; Li, Wei] Jining Med Univ, Affiliated Hosp, Dept Oncol, 89 Guhuai Rd, Jining 272009, Shandong, Peoples R China	Wang, HL (reprint author), Jining Med Univ, Affiliated Hosp, Dept Oncol, 89 Guhuai Rd, Jining 272009, Shandong, Peoples R China.	drwanghuili@yeah.net					Al-Bahrani R, 2015, PATHOL ONCOL RES, V21, P901, DOI 10.1007/s12253-015-9918-7; Bai HQ, 2016, MED SCI MONITOR, V22, P1773, DOI 10.12659/MSM.895548; Chan SL, 2016, J CLIN ONCOL, V34, P83, DOI 10.1200/JCO.2015.61.5724; Cock-Rada AM, 2012, CANCER RES, V72, P810, DOI 10.1158/0008-5472.CAN-11-1052; Cui XJ, 2015, J VIROL, V89, P9021, DOI 10.1128/JVI.01261-15; Donato F, 1999, CANCER CAUSE CONTROL, V10, P417, DOI 10.1023/A:1008989103809; Eberle CA, 2014, VIROLOGY, V462, P34, DOI 10.1016/j.virol.2014.05.016; Foreman KW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022290; Gao J, 2012, ASIAN PAC J CANCER P, V13, P743, DOI 10.7314/APJCP.2012.13.3.743; Guo ZJ, 2012, INT J CANCER, V131, P1318, DOI 10.1002/ijc.27352; Han MA, 2012, J CLIN ONCOL, V30, P701, DOI 10.1200/JCO.2011.35.3078; Huang L, 2017, AM J TRANSL RES, V9, P1; Ismail BES, 2013, CHIN CLIN ONCOL, V2, DOI 10.3978/j.issn.2304-3865.2013.09.03; Jin GA, 2011, CANCER SCI, V102, P144, DOI 10.1111/j.1349-7006.2010.01782.x; Kar P, 2014, J CLIN EXP HEPATOL, V4, pS34, DOI 10.1016/j.jceh.2014.02.155; Kim JM, 2015, NUCLEIC ACIDS RES, V43, P8868, DOI 10.1093/nar/gkv874; Lafaro K, 2016, J SURG ONCOL, V113, P296, DOI 10.1002/jso.24123; Lee Sang Seok, 2012, Korean J Hepatol, V18, P48, DOI 10.3350/kjhep.2012.18.1.48; Lin ZY, 2015, CLIN LAB, V61, P1435, DOI 10.7754/Clin.Lab.2015.150104; Liu C, 2013, JNCI-J NATL CANCER I, V105, P1719, DOI 10.1093/jnci/djt304; Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108391; Liu TT, 2016, MED SCI MONITOR, V22, P5131, DOI 10.12659/MSM.898095; Ma SJ, 2018, BIOSCIENCE REP, V38, DOI [10.1042/bsr20170656, 10.1042/BSR20170656]; Pais R, 2015, CLIN GASTROENTEROL H, V13, P992, DOI 10.1016/j.cgh.2014.10.011; Park CH, 2012, WORLD J GASTROENTERO, V18, P2661, DOI [10.3748/wjg.v18121.2661, 10.3748/wjg.v18.i21.2661]; Peserico A, 2015, J CELL PHYSIOL, V230, P2447, DOI 10.1002/jcp.24975; Sidharthan S, 2014, HEPATOL INT, V8, pS452, DOI 10.1007/s12072-013-9494-4; Turati F, 2012, HEPATOLOGY, V55, P1416, DOI 10.1002/hep.24794; Ukawa S, 2017, J EPIDEMIOL, V27, pS43, DOI 10.1016/j.je.2016.12.007; Van Aller GS, 2012, EPIGENETICS-US, V7, P340, DOI 10.4161/epi.19506; Wang MM, 2018, CANCER MED-US, V7, P646, DOI 10.1002/cam4.1341; Wong GLH, 2013, ALIMENT PHARM THER, V37, P517, DOI 10.1111/apt.12207; Xu H, 2012, ASIAN PAC J CANCER P, V13, P1895, DOI 10.7314/APJCP.2012.13.5.1895; Yoon YI, 2016, J GASTROINTEST SURG, V20, P411, DOI 10.1007/s11605-015-3045-3; Yu YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074870	35	3	3	0	4	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAY	2018	214	5					625	630		10.1016/j.prp.2018.04.005			6	Pathology	Pathology	GJ5NF	WOS:000435427500004	29691085				2019-10-28	
J	Dang, YW; Lin, P; Liu, LM; He, RQ; Zhang, LJ; Peng, ZG; Li, XJ; Chen, G				Dang, Yi-wu; Lin, Peng; Liu, Li-min; He, Rong-quan; Zhang, Li-jie; Peng, Zhi-gang; Li, Xiao-jiao; Chen, Gang			In silico analysis of the potential mechanism of telocinobufagin on breast cancer MCF-7 cells	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Breast cancer; Telocinobufagin; MCF-7 cells; Gene profile	TRADITIONAL CHINESE MEDICINE; CANDIDATE GENES; CHAN SU; EXPRESSION; APOPTOSIS; BINDING; CHEMOTHERAPY; METAANALYSIS; COMBINATION; METASTASIS	Backgrounds and aims: The extractives from a ChanSu, traditional Chinese medicine, have been discovered to possess anti-inflammatory and tumor-suppressing abilities. However, the molecular mechanism of telocinobufagin, a compound extracted from ChanSu, on breast cancer cells has not been clarified. The aim of this study is to investigate the underlying mechanism of telocinobufagin on breast cancer cells. Methods and materials: The differentially expressed genes after telocinobufagin treatment on breast cancer cells were searched and downloaded from Gene Expression Omnibus (GEO), ArrayExpress and literatures. Bioinformatics tools were applied to further explore the potential mechanism of telocinobufagin in breast cancer using the Kyoto Encyclopedia of genes and genomes (KEGG) pathway, Gene ontology (GO) enrichment, panther, and protein-protein interaction analyses. To better comprehend the role of telocinobufagin in breast cancer, we also queried the Connectivity Map using the gene expression profiles of telocinobufagin treatment. Results: One GEO accession (GSE85871) provided 1251 differentially expressed genes after telocinobufagin treatment on MCF-7 cells. The pathway of neuroactive ligand-receptor interaction, cell adhesion molecules (CAMs), intestinal immune network for IgA production, hematopoietic cell lineage and calcium signaling pathway were the key pathways from KEGG analysis. IGF1 and KSR1, owning to higher protein levels in breast cancer tissues, IGF1 and KSR1 could be the hub genes related to telocinobufagin treatment. It was indicated that the molecular mechanism of telocinobufagin resembled that of fenspiride. Conclusions: Telocinobufagin might regulate neuroactive ligand-receptor interaction pathway to exert its influences in breast cancer MCF-7 cells, and its molecular mechanism might share some similarities with fenspiride. This study only presented a comprehensive picture of the role of telocinobufagin in breast cancer MCF-7 cells using big data. However, more thorough and deeper researches are required to add to the validity of this study.	[Dang, Yi-wu; Chen, Gang] Guangxi Med Univ, Affiliated Hosp 1, Dept Pathol, Nanning 530021, Guangxi Zhuang, Peoples R China; [Lin, Peng; Zhang, Li-jie] Guangxi Med Univ, Affiliated Hosp 1, Ultrason Div, Radiol Dept, Nanning 530021, Guangxi Zhuang, Peoples R China; [Liu, Li-min] Guangxi Med Univ, Coll Pharm, Dept Toxicol, Nanning 530021, Guangxi Zhuang, Peoples R China; [He, Rong-quan; Peng, Zhi-gang] Guangxi Med Univ, Affiliated Hosp 1, Dept Med Oncol, Nanning 530021, Guangxi Zhuang, Peoples R China; [Li, Xiao-jiao] Guangxi Med Univ, Affiliated Hosp 1, Dept PET CT, Nanning 530021, Guangxi Zhuang, Peoples R China	Chen, G (reprint author), Guangxi Med Univ, Affiliated Hosp 1, Dept Pathol, Nanning 530021, Guangxi Zhuang, Peoples R China.	chengang@gxmu.edu.cn		Chen, Gang/0000-0002-4864-1451	Medical Excellence Award - Creative Research Development Grant from the First Affiliated Hospital of Guangxi Medical University	The current paper was supported by the Medical Excellence Award Funded by the Creative Research Development Grant from the First Affiliated Hospital of Guangxi Medical University.	Azuma K, 2011, BIOCHEM BIOPH RES CO, V407, P219, DOI 10.1016/j.bbrc.2011.03.002; Bjorner S, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00332; Campbell TM, 2018, CANCER RES, V78, P410, DOI 10.1158/0008-5472.CAN-17-1153; Cao BR, 2017, ONCOTARGET, V8, P53642, DOI 10.18632/oncotarget.10949; Cao YG, 2009, FUND CLIN PHARMACOL, V23, P457, DOI 10.1111/j.1472-8206.2009.00696.x; Chen H, 2015, FITOTERAPIA, V104, P1, DOI 10.1016/j.fitote.2015.05.011; Collina F, 2016, AM J TRANSL RES, V8, P3530; Dai YH, 2018, J ASIAN NAT PROD RES, V20, P581, DOI 10.1080/10286020.2017.1339697; Darmani NA, 2001, NEUROPSYCHOPHARMACOL, V24, P198, DOI 10.1016/S0893-133X(00)00197-4; Dees ND, 2012, GENOME RES, V22, P1589, DOI 10.1101/gr.134635.111; Emam H, 2017, ONCOL LETT, V14, P1035, DOI 10.3892/ol.2017.6256; Engel SR, 2001, INT REV NEUROBIOL, V46, P321; Fan QW, 2016, MED SCI MONITOR, V22, P5163, DOI 10.12659/MSM.902615; Gao L, 2017, AM J TRANSL RES, V9, P4574; Han DY, 2016, AM J TRANSL RES, V8, P871; Harryman WL, 2016, AM J TRANSL RES, V8, P940; Huang JC, 2016, CELL PHYSIOL BIOCHEM, V39, P1955, DOI 10.1159/000447892; Huang Y, 2017, ONCOL LETT, V13, P167, DOI 10.3892/ol.2016.5447; Kang KH, 2017, ONCOL LETT, V14, P853, DOI 10.3892/ol.2017.6223; Kim BY, 2017, SCI REP-UK, V7, DOI 10.1038/srep41711; Li YP, 2017, AM J TRANSL RES, V9, P2038; Li YF, 2017, MED SCI MONITOR, V23, P4321, DOI 10.12659/MSM.903272; Liang Shun-Tian, 2016, Nan Fang Yi Ke Da Xue Xue Bao, V36, P921; Liao JQ, 2016, AM J TRANSL RES, V8, P2438; Liu J, 2015, TUMOR BIOL, V36, P1849, DOI 10.1007/s13277-014-2787-y; Liu WH, 2017, CELL PHYSIOL BIOCHEM, V43, P969, DOI 10.1159/000481650; Liu XH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179037; Miyahara K, 2016, INT J ONCOL, V49, P1848, DOI 10.3892/ijo.2016.3673; Ougland R, 2016, CELL PHYSIOL BIOCHEM, V38, P173, DOI 10.1159/000438619; Pal J, 2018, CLIN CANCER RES, V24, P1448, DOI 10.1158/1078-0432.CCR-17-1901; Pan ZY, 2016, CELL PHYSIOL BIOCHEM, V38, P1975, DOI 10.1159/000445558; Park JH, 2016, INT J ONCOL, V49, P471, DOI 10.3892/ijo.2016.3540; Safari-Alighiarloo N, 2016, PEERJ, V4, DOI 10.7717/peerj.2775; Schmeda-Hirschmann G, 2016, TOXICON, V121, P119, DOI 10.1016/j.toxicon.2016.09.004; Soria JC, 2014, ANN ONCOL, V25, P2244, DOI 10.1093/annonc/mdu390; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tolba MF, 2018, CRIT REV ONCOL HEMAT, V122, P202, DOI 10.1016/j.critrevonc.2018.01.005; Touat M, 2015, CLIN CANCER RES, V21, P2684, DOI 10.1158/1078-0432.CCR-14-2329; Vaz-Luis I, 2018, NAT REV CLIN ONCOL, V15, P249, DOI 10.1038/nrclinonc.2017.207; Wang P, 2016, ONCOL LETT, V12, P4605, DOI 10.3892/ol.2016.5288; Wu SC, 2015, INT IMMUNOPHARMACOL, V25, P353, DOI 10.1016/j.intimp.2015.02.005; Xia JF, 2017, AM J CHINESE MED, V45, P1537, DOI 10.1142/S0192415X17500835; Xie SS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160734; Xu HX, 2016, INT J ONCOL, V49, P1343, DOI 10.3892/ijo.2016.3639; Xu WJ, 2015, ONCOTARGET, V6, P30017, DOI 10.18632/oncotarget.5013; Yang HX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06897-3; Yuan ZT, 2017, ONCOL REP, V37, P1815, DOI 10.3892/or.2017.5410; Zhang HY, 2016, CELL PHYSIOL BIOCHEM, V40, P807, DOI 10.1159/000453140; Zhang X, 2011, PHYTOCHEMISTRY, V72, P1779, DOI 10.1016/j.phytochem.2011.05.004; Zhou HY, 2016, INT J ONCOL, V49, P2442, DOI 10.3892/ijo.2016.3718	50	4	4	7	11	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAY	2018	214	5					631	643		10.1016/j.prp.2018.03.029			13	Pathology	Pathology	GJ5NF	WOS:000435427500005	29656985				2019-10-28	
J	Xie, ZC; Li, TT; Gan, BL; Gao, X; Gao, L; Chen, G; Hu, XH				Xie, Zu-cheng; Li, Tian-tian; Gan, Bin-liang; Gao, Xiang; Gao, Li; Chen, Gang; Hu, Xiao-hua			Investigation of miR-136-5p key target genes and pathways in lung squamous cell cancer based on TCGA database and bioinformatics analysis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						miR-136-5p; Lung squamous cell cancer; TCGA; Target gene; Signaling pathway; Bioinformatics	HEPATOCELLULAR-CARCINOMA; MIRNA DETECTION; POLYMORPHISMS; RISK; ASSOCIATION; EXPRESSION; UGT1A7; GLUCURONIDATION; METASTASIS; ADENOCARCINOMA	Background: Lung squamous cell cancer (LUSC) is a common but challenging malignancy. It is important to illuminate the molecular mechanism of LUSC. Thus, we aim to explore the molecular mechanism of miR-136-5p in relation to LUSC. Methods: We used the Cancer Genome Atlas (TCGA) database to investigate the expression of miR-136-5p in relation to LUSC. Then, we identified the possible miR-136-5p target genes through intersection of the predicted miR-136-5p target genes and LUSC upregulated genes from TCGA. Bioinformatics analysis was performed to determine the key miR-136-5p targets and pathways associated with LUSC. Finally, the expression of hub genes, correlation between miR-136-5p and hub genes, and expected significance of hub genes were evaluated via the TCGA and Genotype-Tissue Expression (GTEx) project. Results: MiR-136-5p was significantly downregulated in LUSC patients. Glucuronidation, glucuronosyltransferase, and the retinoic acid metabolic process were the most enriched metabolic interactions in LUSC patients. Ascorbate and aldarate metabolism, pentose and glucuronate interconversions, and retinol metabolism were identified as crucial pathways. Seven hub genes (UGT1A1, UGT1A3, UGT1A6, UGT1A7, UGT1A10, SRD5A1, and ADH7) were found to be upregulated, and UGT1A1, UGT1A3, UGT1A6, UGT1A7, and ADH7 were negatively correlated with miR-136-5p. UGT1A7 and ADH7 were the most significantly involved miR-136-5p target genes, and high expression of these genes was correlated with better overall survival and disease-free survival of LUSC patients. Conclusions: Downregulated miR-136-5p may target UGT1A7 and ADH7 and participate in ascorbate and aldarate metabolism, pentose and glucuronate interconversions, and retinol metabolism. High expression of UGT1A7 and ADH7 may indicate better prognosis of LUSC patients.	[Xie, Zu-cheng; Li, Tian-tian; Gan, Bin-liang; Gao, Xiang; Hu, Xiao-hua] Guangxi Med Univ, Affiliated Hosp 1, Dept Med Oncol, 6 Shuangyong Rd, Nanning 530021, Guangxi Zhuang, Peoples R China; [Gao, Li; Chen, Gang] Guangxi Med Univ, Affiliated Hosp 1, Dept Pathol, 6 Shuangyong Rd, Nanning 530021, Guangxi Zhuang, Peoples R China	Hu, XH (reprint author), Guangxi Med Univ, Affiliated Hosp 1, Dept Med Oncol, 6 Shuangyong Rd, Nanning 530021, Guangxi Zhuang, Peoples R China.	gxmuhxh@163.com					Araki J, 2005, EUR J CANCER, V41, P2360, DOI 10.1016/j.ejca.2005.04.043; Cadoni G, 2012, ACTA OTORHINOLARYNGO, V32, P1; Chen SJ, 2013, P NATL ACAD SCI USA, V110, P19143, DOI 10.1073/pnas.1319123110; Chen WH, 2014, J NEURO-ONCOL, V120, P43, DOI 10.1007/s11060-014-1535-x; Chen WJ, 2017, PATHOL RES PRACT, V213, P364, DOI 10.1016/j.prp.2017.01.007; Deng M, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-0917-9; Dolly SO, 2017, DRUGS, V77, P813, DOI 10.1007/s40265-017-0732-2; Dweep H, 2015, NAT METHODS, V12, P697, DOI 10.1038/nmeth.3485; Feng Fei-Yue, 2005, Ai Zheng, V24, P1085; Gan TQ, 2017, MED SCI MONITOR, V23, P2453, DOI 10.12659/MSM.901460; Ganju A, 2017, DRUG DISCOV TODAY, V22, P424, DOI 10.1016/j.drudis.2016.10.014; Han SX, 2012, CANCER EPIDEMIOL, V36, pE201, DOI 10.1016/j.canep.2012.02.004; Hashibe M, 2008, NAT GENET, V40, P707, DOI 10.1038/ng.151; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Kong SY, 2008, CANCER SCI, V99, P340, DOI 10.1111/j.1349-7006.2007.00693.x; Kuznetsova ES, 2016, MOL BIOL+, V50, P220, DOI 10.1134/S0026893316020138; Lazarus P., 2014, J PHARMACOL EXP THER, V348, P465; Liu CJ, 2015, INT J CLIN EXP PATHO, V8, P15245; Liu Jian, 2009, Zhonghua Yi Xue Za Zhi, V89, P3122; Lu PH, 2011, CANCER INVEST, V29, P645, DOI 10.3109/07357907.2011.626477; Margaillan G, 2016, J STEROID BIOCHEM, V155, P85, DOI 10.1016/j.jsbmb.2015.09.021; Mazerska Z, 2016, PHARMACOL THERAPEUT, V159, P35, DOI 10.1016/j.pharmthera.2016.01.009; Mishra S, 2016, CRIT REV ONCOL HEMAT, V98, P12, DOI 10.1016/j.critrevonc.2015.10.003; Naidu S, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0162-0; Oguri T, 2004, ANTICANCER RES, V24, P2893; Osawa K, 2012, ASIAN PAC J CANCER P, V13, P2311, DOI 10.7314/APJCP.2012.13.5.2311; Papageorgiou I, 2017, BIOCHEM PHARMACOL, V146, P199, DOI 10.1016/j.bcp.2017.09.013; Papageorgiou I, 2017, BIOCHEM PHARMACOL, V137, P93, DOI 10.1016/j.bcp.2017.04.017; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Sharma R, 2010, ORAL DIS, V16, P760, DOI 10.1111/j.1601-0825.2010.01683.x; Shen SN, 2014, TUMOR BIOL, V35, P631, DOI 10.1007/s13277-013-1087-2; Stucker I, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-214; Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Torre Lindsey A, 2016, Adv Exp Med Biol, V893, P1, DOI 10.1007/978-3-319-24223-1_1; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Tseng CS, 2005, AM J GASTROENTEROL, V100, P1758, DOI 10.1111/j.1572-0241.2005.41857.x; Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507; Uso M, 2014, FUTURE ONCOL, V10, P2279, DOI 10.2217/fon.14.93; Wu H, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0173-0; Yan MS, 2016, ONCOL REP, V36, P65, DOI 10.3892/or.2016.4767; Yang Li-Hua, 2012, Yichuan, V34, P651, DOI 10.3724/SP.J.1005.2012.00651; Yang Y, 2013, ONCOL RES, V21, P345, DOI 10.3727/096504014X14024160459285; Yilmaz Latif, 2015, Asian Pac J Cancer Prev, V16, P1651; Yuan QG, 2017, GENE, V628, P48, DOI 10.1016/j.gene.2017.07.031; Zhang N, 2016, INT J ONCOL, V49, P1360, DOI 10.3892/ijo.2016.3632; Zhao C, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0757-5; Zhao LZ, 2017, MOL MED REP, V16, P1232, DOI 10.3892/mmr.2017.6699; Zheng JC, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317695020	50	3	3	4	16	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAY	2018	214	5					644	654		10.1016/j.prp.2018.03.028			11	Pathology	Pathology	GJ5NF	WOS:000435427500006	29650443				2019-10-28	
J	Li, HX; Sun, XY; Yang, SM; Wang, Q; Wang, ZY				Li, Huan-Xi; Sun, Xiang-Yu; Yang, Shi-Ming; Wang, Qing; Wang, Zhen-Yu			Peroxiredoxin 1 promoted tumor metastasis and angiogenesis in colorectal cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Peroxiredoxin 1; Metastasis; Angiogenesis; Colorectal cancer	EPITHELIAL-MESENCHYMAL TRANSITION; MATRIX METALLOPROTEINASES; SIGNALING PATHWAY; MICROVASCULAR DENSITY; INVASION; VEGF; EXPRESSION; GROWTH; ROLES; PROGRESSION	Peroxiredoxinl (Prdx1) is a member of the PrdxS family, and it regulates cellular signaling and differentiation. The role of Prdx1in colorectal cancer (CRC) remains unclear. In this study, we investigated the relevance of Prdx1 in the metastasis and angiogenesis of CRC. The expression of Prdx1 in 60 cases human CRC tissues was detected through immunohistochemistry. The tumors that highly expressed Prdx1 (42/60) exhibited higher tumor grade and lymph node metastasis than those with low expression of Prdx1 (18/60) (p < 0.05). Kaplan-Meier survival analysis showed that the survival time of thePrdx1-positive group was shorter than that of thePrdx1-negative group (p = 0.046).Moreover, a statistically significant correlation was observed between the Prdx1 expression and microvessel density (p = 0.004). Transwell migration assay revealed that Prdx1 was down regulated in the CRC cell line HCT116, thereby suppressing the invasion and migration capacities of tumor cells, whereas Prdx1was up-regulated in HT29 cells, thereby increasing the invasion and migration capacities of tumor cells. The tube formation capacity of human umbilical vein endothelial cells cultured in 3D medium was increased after conditioned medium from overexpressed Prdx1 cancer cells was added relative to that when down regulated Prdx1 cell medium was added (p < 0.05). In addition, up-regulated Prdx1 increased the protein expression of MMP2, MMP9, and VEGFA. These data suggested that Prdx1 expression predicted poor prognosis by regulating the tumor metastasis and angiogenesis of CRC. Therefore, Prdx1 may serve as a potential therapeutic target.	[Li, Huan-Xi; Sun, Xiang-Yu; Wang, Qing; Wang, Zhen-Yu] Tianjin Nankai Hosp, Dept Minimally Invas Surg, 122 San Wei Rd, Tianjin 300100, Peoples R China; [Yang, Shi-Ming] Tianjin Nankai Hosp, Dept Gastrointestinal Surg, Tianjin 300100, Peoples R China	Li, HX (reprint author), Tianjin Nankai Hosp, Dept Minimally Invas Surg, 122 San Wei Rd, Tianjin 300100, Peoples R China.	lihuanxi1101@163.com					Abe R, 2008, CURR PHARM DESIGN, V14, P3779, DOI 10.2174/138161208786898671; Anannamcharoen Sahaphol, 2012, Journal of the Medical Association of Thailand, V95, P1041; Araujo RF, 2015, PATHOL RES PRACT, V211, P71, DOI 10.1016/j.prp.2014.09.007; Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Balch C, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00267; Brown GT, 2015, J PATHOL, V237, P273, DOI 10.1002/path.4586; Carmeliet P, 2005, ONCOLOGY-BASEL, V69, P4, DOI 10.1159/000088478; Chu GH, 2016, AM J TRANSL RES, V8, P842; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8; Ding CB, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0524-2; Ding CB, 2017, J CELL MOL MED, V21, P193, DOI 10.1111/jcmm.12955; Ferrara N, 2005, EXP SUPPL, V94, P209; Ha B, 2012, BIOCHEM BIOPH RES CO, V421, P33, DOI 10.1016/j.bbrc.2012.03.103; Hampton MB, 2018, ANTIOXID REDOX SIGN, V28, P591, DOI 10.1089/ars.2017.7422; Hu YY, 2012, ADV EXP MED BIOL, V727, P186, DOI 10.1007/978-1-4614-0899-4_14; Jiao L, 2016, TUMOR BIOL, V37, P8413, DOI 10.1007/s13277-015-4736-9; Leme Marcelo Betim Paes, 2006, Acta Cir. Bras., V21, P392, DOI 10.1590/S0102-86502006000600007; Lin HM, 2007, ONCOL REP, V17, P1541; Lu WD, 2014, CANCER LETT, V343, P190, DOI 10.1016/j.canlet.2013.10.002; Ozerdem U, 2013, PATHOL INT, V63, P277, DOI 10.1111/pin.12056; Papadopoulos V, 2016, CLIN COLORECTAL CANC, V15, P116, DOI 10.1016/j.clcc.2016.02.010; Peng LL, 2017, ONCOTARGET, V8, P15057, DOI 10.18632/oncotarget.14801; Sawa M, 2016, EXPERT OPIN THER TAR, V20, P419, DOI 10.1517/14728222.2016.1098619; Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220; Sun YL, 2015, WORLD J GASTROENTERO, V21, P10840, DOI 10.3748/wjg.v21.i38.10840; Sundov Z, 2013, HEPATO-GASTROENTEROL, V60, P432, DOI 10.5754/hge12826; Taniuchi K, 2015, PANCREAS, V44, P331, DOI 10.1097/MPA.0000000000000270; van Rensburg HJJ, 2016, CELL SIGNAL, V28, P1761, DOI 10.1016/j.cellsig.2016.08.004; Vinson KE, 2016, INT J CANCER, V138, P1835, DOI 10.1002/ijc.29800; Zeng ZS, 1999, CARCINOGENESIS, V20, P749, DOI 10.1093/carcin/20.5.749; Zhang SR, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0414-9; Zhang YY, 2012, ASIAN PAC J CANCER P, V13, P2437, DOI 10.7314/APJCP.2012.13.6.2437	33	6	6	1	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAY	2018	214	5					655	660		10.1016/j.prp.2018.03.026			6	Pathology	Pathology	GJ5NF	WOS:000435427500007	29673884				2019-10-28	
J	Ma, C; Jin, RM; Chen, KJ; Hao, T; Li, BS; Zhao, DH; Jiang, H				Ma, Chong; Jin, Ri-Ming; Chen, Ke-Ji; Hao, Tao; Li, Bao-Song; Zhao, Da-Hua; Jiang, Hong			Low expression of B-Cell-Associated protein 31 is associated with unfavorable prognosis in human colorectal cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Colorectal cancer; B cell-associated protein 31; X-tile; Prognosis	HEPATOCELLULAR-CARCINOMA; POOR-PROGNOSIS; APOPTOSIS; BIOMARKER; RESECTION	Colorectal cancer (CRC) is one of the most common cancers worldwide. B cell-associated protein 31 (BAP31) was shown to participate in the apoptosis, and to be an immunotherapy target and a, prognostic factor for cancer, but its role in CRC has not been elucidated. In this study, we examined the expression of BAP31 in CRC to evaluate its prognostic values. We investigated the BAP31 expression level in 142 tissues (108 CRC and 17 paired human adjacent normal mucosa, and 17 liver metastatic CRC tissues) from 108 patients, using tissue microarray-based immunohistochemistry. We further investigated the association between BAP31 expression and overall survival (OS) and disease-free survival (DFS) in 77 CRC patients using Kaplan-Meier analysis. Univariate and multivariate Cox regression analyses were applied to evaluate the potential prognostic value of BAP31 in CRC patients. BAP31 expression level was significantly increased in CRC tissues (p = 0.0014) and liver metastatic CRC tissues (p < 0.0001) compared with corresponding adjacent normal mucosa. BAP31 expression was also significantly increased in liver metastatic CRC tissues compared with corresponding primary CRC tissues (p = 0.0116). Kaplan-Meier analyses showed that CRC patients with low BAP31 expression had significantly lower survival rate (p = 0.001) and lower disease-free survival rate (P = 0.009). Furthermore, multivariate Cox analysis showed that BAP31 was an independent prognostic factor for OS (hazard ratio = 0.410, 95% confidence interval = 0.195-0.862, p = 0.019). Conclusions: Our study demonstrated that BAP31 is a potential prognostic marker for CRC patients after surgery.	[Ma, Chong; Hao, Tao; Li, Bao-Song; Jiang, Hong] Binzhou Med Univ Hosp, Dept Colorectal & Gen Surg, Binzhou 256603, Peoples R China; [Jin, Ri-Ming; Chen, Ke-Ji] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Liver Surg 1, Shanghai 200438, Peoples R China; [Zhao, Da-Hua] Binzhou Med Univ Hosp, Dept Pathol, Binzhou 256603, Peoples R China	Jiang, H (reprint author), Binzhou Med Univ Hosp, Dept Colorectal & Gen Surg, 522 Huanghe Sanlu, Binzhou City 256603, Shandong, Peoples R China.	bzbh519@163.com			Binzhou City Science and Technology Development Plan [2014ZC0107]	This study was supported by the Binzhou City Science and Technology Development Plan (2014ZC0107).	Bai DS, 2009, HEPATOLOGY, V49, P460, DOI 10.1002/hep.22638; Cai MY, 2011, GUT, V60, P967, DOI 10.1136/gut.2010.231993; Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Dawood O, 2009, EUR J CANCER, V45, P2947, DOI 10.1016/j.ejca.2009.08.011; Delom F, 2007, CELL DEATH DIFFER, V14, P586, DOI 10.1038/sj.cdd.4402012; Drusco A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096670; Gibson TB, 2006, CLIN COLORECTAL CANC, V6, P29, DOI 10.3816/CCC.2006.n.01; Hurwitz HI, 2005, J CLIN ONCOL, V23, P3502, DOI 10.1200/JCO.2005.10.017; Jin GZ, 2013, J HEPATOL, V59, P510, DOI 10.1016/j.jhep.2013.04.028; Jin GZ, 2011, J PROTEOME RES, V10, P3418, DOI 10.1021/pr200482t; Lee DW, 2015, ANN SURG ONCOL, V22, P187, DOI 10.1245/s10434-014-3826-z; Li XX, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0356-7; Lian SJ, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004328; Matroule JY, 2001, ONCOGENE, V20, P4070, DOI 10.1038/sj.onc.1204546; Ochiai T, 2014, ONCOL REP, V32, P887, DOI 10.3892/or.2014.3299; Pan CW, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0359-z; Papamichael D, 2015, ANN ONCOL, V26, P463, DOI 10.1093/annonc/mdu253; Sun LC, 2012, ANN SURG ONCOL, V19, P2411, DOI 10.1245/s10434-011-2177-2; Tan N, 2016, HISTOPATHOLOGY, V68, P221, DOI 10.1111/his.12738; Tokunaga R, 2015, DIS COLON RECTUM, V58, P1048, DOI 10.1097/DCR.0000000000000458; Vallbohmer D, 2005, J CLIN ONCOL, V23, P3536, DOI 10.1200/JCO.2005.09.100; Yang XR, 2009, CLIN CANCER RES, V15, P5518, DOI 10.1158/1078-0432.CCR-09-0151; Yoo PS, 2006, CLIN COLORECTAL CANC, V6, P202, DOI 10.3816/CCC.2006.n.036; Yu SJ, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0153-6	25	1	1	0	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAY	2018	214	5					661	666		10.1016/j.prp.2018.03.023			6	Pathology	Pathology	GJ5NF	WOS:000435427500008	29653744				2019-10-28	
J	Wang, G; Bi, C				Wang, Gang; Bi, Cong			Correlations of pri-Let-7 gene polymorphisms with the recurrence and metastasis of primary liver cancer after transcatheter arterial chemoembolization	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Pri-let-7a-1 rs10739971; Pri-let-7a-2 rs629367; Primary liver cancer; Transcatheter arterial chemoembolization; Recurrence; Metastasis	POTENTIALLY FUNCTIONAL POLYMORPHISM; PRIMARY HEPATOCELLULAR-CARCINOMA; CHINESE POPULATION; PROMOTER REGION; LET-7 FAMILY; LUNG-CANCER; RISK; BIOGENESIS; MICRORNAS; SUSCEPTIBILITY	Background and aim: Single nucleotide polymorphisms (SNPs) within miRNAs could change their production or affinity with target genes, thus leading to malignant diseases. This study aims to explore correlations of pri-let-7 gene polymorphisms with the recurrence and metastasis of primary liver cancer (PLC) after a transcatheter arterial chemoembolization (TACE) surgical procedure. Materials and methods: A total of 302 PLC patients treated with hepatoprotective therapies after TACE were selected to and assigned into recurrent and non-recurrent groups. Genotypes of pri-let-7a-1 rs1073997 and prilet-7a-2 rs629367 were analyzed by Taqman assay. The relationship between PLC with the mutation of each SNP was determined by a multivariate logistic regression analyses. Moreover, the association between survival and pri-let-7 gene polymorphisms was analyzed by the Kaplan-Meier method. The Progress Free Survival (PFS) curve, correlation of pri-let-7a-1 rs629367 with alcohol, HBsAg-positive and TNM III/IV were analyzed by a stratified analysis. Additionally, the risk factors for the recurrence of PLC were analyzed by a multivariate logistic regression analyses. Results: Results showed that the allelic frequency of the pri-let-7a-2 rs629367 SNP in the recurrent group was higher than that of the non-recurrent group. The distribution of CC genotype was significantly higher than non CC genotype in the recurrent group. Alcohol consumption, positive expression of hepatitis B surface antigen (HBsAg), AC + CC genotype of rs629367 and TNM III/IV were determined to be the risk factors for the recurrence and metastasis of PLC after TACE. We found a positive correlation between pri-let-7a-2 rs629367 with alcohol consumption, HBsAg-positive and TNM III/IV. The median PFS of HBsAg-positive and TNM III/IV patients with the AC + CC genotype of rs629367 was shorter than those with non-AC + CC genotype. Conclusion: Our findings provide evidence that patients with PLC that carry the AC + CC genotype of pri-let-7a2 rs629367 after TACE have a worse prognosis than those who carry the AA genotype. We speculate that the prilet-7 rs629367 SNP could be used as a predictor of recurrence and metastasis after TACE for patients with PLC.	[Wang, Gang] China Med Univ, Affiliated Hosp 4, Dept Radiol, 4 Chongshan East Rd, Shenyang 110032, Liaoning, Peoples R China; [Bi, Cong] China Med Univ, Hosp 1, Dept Radiol, Shenyang 110001, Liaoning, Peoples R China	Wang, G (reprint author), China Med Univ, Affiliated Hosp 4, Dept Radiol, 4 Chongshan East Rd, Shenyang 110032, Liaoning, Peoples R China.	Drwanggang17@163.com					Akao Y, 2006, BIOL PHARM BULL, V29, P903, DOI 10.1248/bpb.29.903; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Arisawa T, 2012, HUM IMMUNOL, V73, P747, DOI 10.1016/j.humimm.2012.04.011; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Chen PS, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-90; Cong WM, 2015, CANCER LETT, V368, P14, DOI 10.1016/j.canlet.2015.07.043; Cui LH, 2012, MED ONCOL, V29, P1837, DOI 10.1007/s12032-011-0066-y; Dzikiewicz-Krawczyk A, 2015, CRIT REV ONCOL HEMAT, V93, P1, DOI 10.1016/j.critrevonc.2014.08.006; Feng L, 2015, INDIAN J CANCER, V52, pE99, DOI 10.4103/0019-509X.172523; de Larrea CF, 2012, CLIN CANCER RES, V18, P3697, DOI 10.1158/1078-0432.CCR-12-0191; Gao J, 2012, ASIAN PAC J CANCER P, V13, P743, DOI 10.7314/APJCP.2012.13.3.743; He Y, 2010, J NEUROSCI, V30, P10251, DOI 10.1523/JNEUROSCI.2419-10.2010; Inamura K, 2007, LUNG CANCER, V58, P392, DOI 10.1016/j.lungcan.2007.07.013; Jin W, 2015, INT J CLIN EXP MED, V8, P18954; Kim CW, 2012, NUCLEIC ACIDS RES, V40, P3856, DOI 10.1093/nar/gkr1302; Lee H, 2016, PROTEIN CELL, V7, P100, DOI 10.1007/s13238-015-0212-y; Li H, 2013, ONCOL LETT, V5, P1195, DOI 10.3892/ol.2013.1163; Liu Meng-Zhong, 2005, Ai Zheng, V24, P82; Mohr AM, 2015, SEMIN LIVER DIS, V35, P3, DOI 10.1055/s-0034-1397344; Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2; Nicastro G, 2012, NAT STRUCT MOL BIOL, V19, P1282, DOI 10.1038/nsmb.2427; Peter ME, 2009, CELL CYCLE, V8, P843, DOI 10.4161/cc.8.6.7907; Shin KM, 2016, GENE, V577, P148, DOI 10.1016/j.gene.2015.11.036; Song MJ, 2016, KOREAN J INTERN MED, V31, P242, DOI 10.3904/kjim.2015.112; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Tao MH, 2007, CANCER EPIDEM BIOMAR, V16, P943, DOI 10.1158/1055-9965.EPI-06-1012; Wang ZM, 2014, BIOMED RES INT, DOI 10.1155/2014/468605; Wittekind C, 2010, PATHOLOGE, V31, P331, DOI 10.1007/s00292-010-1349-3; Xie KP, 2013, CANCER EPIDEMIOL, V37, P998, DOI 10.1016/j.canep.2013.09.005; Xie P, 2016, CLIN LUNG CANCER, V17, pE95, DOI 10.1016/j.cllc.2016.03.010; Xu Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095249; Xu Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089203; Xu Y, 2011, INT J CANCER, V128, P412, DOI 10.1002/ijc.25342; Yan YX, 2015, ENDOCR J, V62, P887, DOI 10.1507/endocrj.EJ15-0236; Yang Haitao, 2017, Asian Pac J Cancer Prev, V18, P2695; Zhou J, 2012, DNA CELL BIOL, V31, P524, DOI 10.1089/dna.2011.1340; Zhu JB, 2015, INT J CLIN EXP PATHO, V8, P7332	37	0	0	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAY	2018	214	5					667	672		10.1016/j.prp.2018.03.022			6	Pathology	Pathology	GJ5NF	WOS:000435427500009	29627220				2019-10-28	
J	Khan, F; Esnakula, A; Ricks-Santi, LJ; Zafar, R; Kanaan, Y; Naab, T				Khan, Farhan; Esnakula, Ashwini; Ricks-Santi, Luisel J.; Zafar, Rabia; Kanaan, Yasmine; Naab, Tammey			Loss of PTEN in high grade advanced stage triple negative breast ductal cancers in African American women	PATHOLOGY RESEARCH AND PRACTICE			English	Article						PTEN Phosphatidyl inositol 3-kinase (P13k)/AKT; signal transduction pathway; Mammalian target of rapamycin (mTOR); Triple-negative breast cancer; African American	TRASTUZUMAB RESISTANCE; EXPRESSION; PATHWAY; MUTATIONS; SUBTYPES; GENE; INHIBITION; ACTIVATION; CARCINOMA	Introduction: PTEN is a tumor suppressor gene that inhibits cell proliferation by inhibiting the phosphoinositide 3-kinase (PI3 K) signaling pathway. The significance of PTEN mutations resulting in variable PTEN expression and their impact on prognosis of breast cancer is not well established. The objective of our study was to correlate the immunohistochemical expression of PTEN in the four major subtypes of breast carcinoma (Luminal A, Luminal B, HER2 positive, and Triple Negative) in a population of 202 African-American (AA) females with other clinicopathological factors. Materials and methods: Tissue microarrays (TMAs) were constructed from FFPE tumor blocks from primary ductal breast carcinomas in 202 African-American females. Five micrometer sections were stained with a mouse monoclonal antibody against PTEN. The sections were evaluated for the intensity of cytoplasmic and nuclear reactivity. Bivariate analysis was done via chi(2) analysis and survivability data was calculated via the generation of Kaplan-Meier curves (SPSS v19). Results: Loss of PTEN expression was associated with ER negative (p = 0.021), PR negative (p = 0.024) and triple negative (p = 0.0024) breast ductal cancers. It was marginally associated with distant metastasis (p = 0.074). There was no association between PTEN loss and recurrence-free survival or overall survival. Conclusion: In our study, a statistically significant association between PTEN loss and the triple negative breast cancers (TNBC) was found in AA women. PTEN inhibits PI3 K resulting in decreased activation of downstream effector, mammalian target of rapamycin (mTOR). Loss of PTEN results in cell proliferation through activation of mTOR. Targeted therapy with mTOR inhibitors might be useful in the treatment of TNBC.	[Khan, Farhan; Esnakula, Ashwini; Zafar, Rabia; Naab, Tammey] Howard Univ, Coll Med, Dept Pathol, Washington, DC 20059 USA; [Kanaan, Yasmine] Howard Univ, Coll Med, Dept Microbiol, Washington, DC USA; [Ricks-Santi, Luisel J.] Hampton Univ, Canc Res Ctr, Hampton, VA 23668 USA	Khan, F (reprint author), Howard Univ, Coll Med, Dept Pathol, Washington, DC 20059 USA.	farhan.khan@wustl.edu			National Center for Research Resources (NCRR), National Institutes of Health through the Clinical and Translational Science Awards Program (CTSA) [UL1RR031975]; DHHS; Roadmap Initiative; Re-Engineering the Clinical Research Enterprise; RCMI Program at Howard University [G12 RR003048]; Division of Research Infrastructure, National Center for Research Resources, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR); Howard University Cancer Center/Johns Hopkins Cancer Center Partnership, National Cancer Institute, NIH [U54 CA091431]	This project has been funded in whole or in part with Federal funds (UL1RR031975) from the National Center for Research Resources (NCRR), National Institutes of Health, through the Clinical and Translational Science Awards Program (CTSA), a trademark of DHHS, part of the Roadmap Initiative, "Re-Engineering the Clinical Research Enterprise," (G12 RR003048) from the RCMI Program at Howard University, Division of Research Infrastructure, National Center for Research Resources, NIH and (U54 CA091431) the Howard University Cancer Center/Johns Hopkins Cancer Center Partnership, National Cancer Institute, NIH.	American Cancer Society, 2009, CANC FACTS FIG AFR A; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Charafe-Jauffret E, 2005, INT J ONCOL, V27, P1307; DeSantis C. E., 2015, BREAST CANC STAT CO, DOI [10.3322/caac.21320/epdf, DOI 10.3322/CAAC.21320/EPDF]; Eng C, 1998, NAT GENET, V19, P223, DOI 10.1038/897; Fouque A, 2016, RECENT PAT ANTI-CANC, V11, P283, DOI 10.2174/1574892811666160519113731; Horiuchi D, 2012, J EXP MED, V209, P679, DOI 10.1084/jem.20111512; Jerusalem G, 2014, BREAST CANCER-TARGET, V6, P43, DOI 10.2147/BCTT.S38679; Kalinsky K., 2014, J CLIN ONCOL, V32; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Levine RL, 1998, CANCER RES, V58, P3254; Li ST, 2017, ONCOTARGET, V8, P32043, DOI 10.18632/oncotarget.16761; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Massihnia D, 2016, ONCOTARGET, V7, P60712, DOI 10.18632/oncotarget.10858; Mayer IA, 2014, CANC RES S, V73; McMenamin ME, 1999, CANCER RES, V59, P4291; Meric-Bernstam F, 2009, J CLIN ONCOL, V27, P2278, DOI 10.1200/JCO.2008.20.0766; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Slingerland J., 2016, J CELL PHYSL, V183, P10; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tashiro H, 1997, CANCER RES, V57, P3935; Wang SI, 1997, CANCER RES, V57, P4183; Wu YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078259; Zhou XP, 2002, AM J PATHOL, V161, P439, DOI 10.1016/S0002-9440(10)64200-9	29	5	6	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAY	2018	214	5					673	678		10.1016/j.prp.2018.03.020			6	Pathology	Pathology	GJ5NF	WOS:000435427500010	29653745	Green Accepted			2019-10-28	
J	Khanna, G; Pathak, P; Suri, V; Sharma, MC; Chaturvedi, S; Ahuja, A; Bhardwaj, M; Garg, A; Sarkar, C; Sharma, R				Khanna, Gaurav; Pathak, Pankaj; Suri, Vaishali; Sharma, Mehar Chand; Chaturvedi, Sujata; Ahuja, Arvind; Bhardwaj, M.; Garg, Ajay; Sarkar, Chitra; Sharma, Rajeev			Immunohistochemical and molecular genetic study on epithelioid glioblastoma: Series of seven cases with review of literature	PATHOLOGY RESEARCH AND PRACTICE			English	Review						BRAFV600E; Epithelioid glioblastoma; EGFR amplification; TERT	BRAF V600E MUTATION; ASTROCYTOMA	Epithelioid glioblastoma (e-gbm) is a recently described variant of glioblastoma (GBM) which is associated with short survival and now added as a provisional entity to WHO 2016 classification of CNStumors. About half of these tumors show characteristic BRAF-V600E mutation. However, unlike conventional GBMs, e-gbm lack specific diagnostic and prognostic markers. Hence, we aimed to molecularly characterize these tumors. An extensive review of literature was performed.In a multi-institutional effort, all the cases of glioblastoma of year 2017 were reviewed. Cases with predominant epithelioid morphology were analysed. Seven cases of e-gbm (adults:4 and pediatric: 3) were identified. Duration of symptoms varied from 2 weeks to one month. Radiologically, all cases were supratentorial, contrast enhancing with solid and cystic appearance. Majority of the cases were immunopositive for GFAP (71%), EMA (71%), S100 (71%) and vimentin (85%). All the cases showed ATRX, INI-1 and H3K27me3 expression. BRAFV600Emutation was seen in 28% of cases. TERT mutation was seen in 40% cases, while one case showed EGFR amplification. H3F3A mutations and PTEN deletions were seen in none. Although e-gbms are rare, epithelioid morphology of a CNS tumor in a young adult or children with areas of necrosis needs thorough histomorphological and genetic workup.	[Khanna, Gaurav; Pathak, Pankaj; Suri, Vaishali; Sharma, Mehar Chand; Sarkar, Chitra] AIIMS, Dept Pathol, New Delhi 110029, India; [Chaturvedi, Sujata] Inst Human Behav & Allied Sci, Dept Pathol, New Delhi, India; [Ahuja, Arvind; Bhardwaj, M.] PGIMER, Dept Pathol, New Delhi, India; [Ahuja, Arvind; Bhardwaj, M.] Dr RML Hosp, New Delhi, India; [Garg, Ajay] AIIMS, Dept Neuroradiol, New Delhi, India; [Sharma, Rajeev] AIIMS, Dept Neurosurg, New Delhi, India	Suri, V (reprint author), AIIMS, Dept Pathol, New Delhi 110029, India.	khannagaurav13186@gmail.com; pankgem@gmail.com; surivaishali@yahoo.co.in; sharmamehar@yahoo.co.in; drsujatacv@gmail.com; drarvindahuja@gmail.com; minakshi.bh@gmail.com; drajaygarg@gmail.com; sarkar.chitra@gmail.com; rajufbd79@gmail.com	Ahuja, Arvind/F-3531-2015	Ahuja, Arvind/0000-0001-7003-5952; Pathak, Pankaj/0000-0001-8753-7385			Alexandrescu S, 2016, BRAIN PATHOL, V26, P215, DOI 10.1111/bpa.12295; Broniscer A, 2014, NEUROPATH APPL NEURO, V40, P327, DOI 10.1111/nan.12093; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Dias-Santagata D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017948; Dougherty MJ, 2010, NEURO-ONCOLOGY, V12, P621, DOI 10.1093/neuonc/noq007; Funata N, 2016, BRAIN TUMOR PATHOL, V33, P57, DOI 10.1007/s10014-015-0239-z; Gupta R. K., 2017, ANN PATHOL LAB MED, V4, P10; Jha P, 2011, DIAGN MOL PATHOL, V20, P225, DOI 10.1097/PDM.0b013e31821c30bc; KEPES JJ, 1982, CLIN NEUROPATHOL, V1, P139; Kleinschmidt-DeMasters BK, 2013, AM J SURG PATHOL, V37, P685, DOI 10.1097/PAS.0b013e31827f9c5e; Korshunov A, 2018, BRAIN PATHOL, V28, P656, DOI 10.1111/bpa.12566; Kuroda JI, 2016, NEUROPATHOLOGY, V36, P181, DOI 10.1111/neup.12258; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Marc C., 2013, J NEUROONCOL, V114, P237; Matsumura N, 2017, NEUROPATHOLOGY, V37, P58, DOI 10.1111/neup.12318; Nakajima N, 2018, BRAIN PATHOL, V28, P663, DOI 10.1111/bpa.12572; Nobusawa S, 2014, BRAIN PATHOL, V24, P239, DOI 10.1111/bpa.12114; Robinson GW, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-258; Schindler G, 2011, ACTA NEUROPATHOL, V121, P397, DOI 10.1007/s00401-011-0802-6; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Sugimoto K, 2016, BRAIN TUMOR PATHOL, V33, P137, DOI 10.1007/s10014-015-0243-3; Tanaka S, 2014, BRAIN TUMOR PATHOL, V31, P172, DOI 10.1007/s10014-014-0192-2	22	3	3	0	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAY	2018	214	5					679	685		10.1016/j.prp.2018.03.019			7	Pathology	Pathology	GJ5NF	WOS:000435427500011	29615337				2019-10-28	
J	Han, F; Zhang, SX; Liang, J; Qiu, WZ				Han, Fei; Zhang, Suxia; Liang, Jun; Qiu, Weizhe			Clinicopathological and predictive significance of SIRT1 and peroxisome proliferator-activated receptor gamma in esophageal squamous cell carcinoma: The correlation with EGFR and Survivin	PATHOLOGY RESEARCH AND PRACTICE			English	Article						SIRT1; PPAR Y; EGFR; Survivin; ESCC	EXPRESSION; OVEREXPRESSION; TRANSCRIPTION; INHIBITION; PROTEIN; GENE	SIRT1 (silent mating type information regulation 2 homolog 1) is an enzyme that deacetylates proteins that contributes to cell survival and angiogenesis. Peroxisome proliferator-activated receptor Y (PPAR Y) is a member of the nuclear steroid hormone receptor superfamily and regulates cell apoptosis and proliferation. The functional roles of SIRT1 and PPAR Y in tumor progression remain controversy. This study aims to investigate the roles of SIRT1 and PPAR Y in esophageal squamous cell carcinoma (ESCC), as well as correlation with expression of EGFR and Survivin. Here, we analyzed the protein expression of SIRT1 and PPAR Y in tumor microarray with ESCC and its associations with clinicopathological parameters and overall survival. Both SIRT1 and PPAR Y were highly expressed in tumor tissues comparing with non-cancerous epithelium. High expression of SIRT1 was positively correlated with advanced TNM stage and poor outcome, while high expression of PPAR Y was positively related with tumor grading, not with patients' prognosis. In addition, the high expression of SIRT1 was positively correlated with overexpression of EGFR, not related with PPAR Y or Survivin expression status. These data suggests SIRT1 may serve as a predictor of poor prognosis in ESCC, and its mediated tumor-promoting role might be associated with the overexpression of EGFR protein in ESCC.	[Han, Fei] Washington Univ, Sch Med, Div Radiol Sci, St Louis, MO 63110 USA; [Han, Fei; Zhang, Suxia; Liang, Jun; Qiu, Weizhe] Tongji Univ, Sch Med, Tongji Hosp, Dept Pathol, Shanghai 200065, Peoples R China	Han, F (reprint author), Mallinckrodt Inst Radiol, Campus Box 8225,4566 Scott Ave, St Louis, MO 63110 USA.	feihan@wustl.edu			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81201838]	This study was supported by a grant from the National Natural Science Foundation of China (No. 81201838) for Dr. Fei Han.	Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; Han F, 2017, PATHOL RES PRACT, V213, P1519, DOI 10.1016/j.prp.2017.09.023; Hanawa M, 2006, INT J CANCER, V118, P1173, DOI 10.1002/ijc.21454; Hida Y, 2007, ARCH DERMATOL RES, V299, P103, DOI 10.1007/s00403-006-0725-6; Huffman DM, 2007, CANCER RES, V67, P8423; Ikenoue T, 2008, CANCER RES, V68, P6908, DOI 10.1158/0008-5472.CAN-08-1107; Li C, 2015, ONCOTARGETS THER, V8, P977, DOI 10.2147/OTT.S82378; Li D, 2016, AM J TRANSL RES, V8, P1601; Li YM, 2016, ONCOTARGET, V7, P29255, DOI 10.18632/oncotarget.8711; Marshall GM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002135; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nosho K, 2009, MODERN PATHOL, V22, P922, DOI 10.1038/modpathol.2009.49; Pantazi E., 2015, BIOMED RES INT, V2015, DOI DOI 10.1155/2015/894679; Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850; Rosato A, 2006, INT J CANCER, V119, P1717, DOI 10.1002/ijc.21923; Rumi MAK, 2002, J LAB CLIN MED, V140, P17, DOI 10.1067/mlc.2002.125055; Stenzinger A, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-450; Takahashi H, 2006, CANCER SCI, V97, P854, DOI 10.1111/j.1349-7006.2006.00250.x; Takashima T, 2005, ONCOL REP, V13, P601; Vallbohmer D, 2010, J GASTROINTEST SURG, V14, P75, DOI 10.1007/s11605-009-1021-5; Wang W, 2010, ONCOL RES, V19, P141, DOI 10.3727/096504011X12935427587849; Wu SJ, 2017, ONCOTARGET, V8, P62589, DOI 10.18632/oncotarget.19880; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Zhang Y., 2008, ONCOGENE, V28, P445	25	3	3	0	0	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAY	2018	214	5					686	690		10.1016/j.prp.2018.03.018			5	Pathology	Pathology	GJ5NF	WOS:000435427500012	29625788				2019-10-28	
J	Gao, ZJ; Yuan, WD; Yuan, JQ; Yuan, K; Wang, Y				Gao, Zhao-jia; Yuan, Wei-dong; Yuan, Jun-qiang; Yuan, Kai; Wang, Yong			miR-486-5p functions as an oncogene by targeting PTEN in non-small cell lung cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						miR-486-5p; Oncogene; Non-small cell lung cancer; PTEN; Therapy	EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-SUPPRESSOR; OVARIAN-CANCER; CARCINOMA; PROLIFERATION; METASTASIS; STATISTICS; MICRORNA; GROWTH; ACTS	Purpose: Lung cancer, the leading cause of cancer-related death worldwide, shows a poor 5-year overall survival rate. In our previous study, we demonstrated that miR-486-5p can be a potential blood-based biomarker for early diagnosis and recurrence prediction of non-small cell lung cancer (NSCLC). The aim of the present study was to investigate the possible roles and related target genes of miR-486-5p in NSCLC progression. Methods: pcDNA3.1(+)/Pri-miR486 recombinant plasmid and miR-486-5p inhibitor were transfected into NSCLC cells and theirs effects were evaluated by qRT-PCR. Then, MTT assay and Colony formation assay were performed to determine the potential roles of miR-486-5p played on NSCLC cellular proliferation and cloning in vitro. We also initially investigated the target genes of miR-486-5p by using bioinformatic methods, qRT-PCR and western blot. Results: pcDNA3.1( +)/Pri-miR486 recombinant plasmid significantly upregulated the expression of miR-486-5p, while miR-486-5p inhibitor significantly downregulated its expression. Upregulation of miR-486-5p promoted the cellular proliferation and cloning, while miR-486-5p silencing restrained the cellular proliferation and cloning. Furthermore, four potential target genes (PIK3R1, PTEN, MAP3K7 and FOXO1) of miR-486-5p were screened out. Finally, we found that upregulation of miR-486-5p in NSCLC cells significantly reduced PTEN and increased AKT expression levels, whereas miR-486-5p silencing increased PTEN and reduced AKT expression. Therefore, we believe that miR-486-5p can regulate PTEN-PI3 K/AKT signaling. Conclusions: miR-486-5p acts as an oncogene in the progression of NSCLC by influencing PTEN-P13 K/AKT signaling. miR-486-5p may provide potential therapeutic targets for NSCLC.	[Gao, Zhao-jia; Yuan, Wei-dong; Yuan, Jun-qiang; Yuan, Kai; Wang, Yong] Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Div Thorac Surg, 29 Xinglong Lane, Changzhou 213003, Jiangsu, Peoples R China; [Gao, Zhao-jia; Yuan, Kai] Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Heart & Lung Dis Lab, Changzhou, Jiangsu, Peoples R China	Yuan, K; Wang, Y (reprint author), Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Div Thorac Surg, 29 Xinglong Lane, Changzhou 213003, Jiangsu, Peoples R China.	yuankai1978@163.com; doctor_wang1960@163.com			Basic research project of Changzhou [CJ20140041]; High-Level Medical Talents Training Project [2016CZBJ042]; Jiangsu Provincial Medical Youth Talent (Jiangsu Health Scientific Education) [3]; Jiangsu Planned Projects for Postdoctoral Research FundsJiangsu Planned Projects for Postdoctoral Research Funds	This research was supported by Basic research project of Changzhou (Grant number. CJ20140041), High-Level Medical Talents Training Project (Grant number. 2016CZBJ042), Jiangsu Provincial Medical Youth Talent (Jiangsu Health Scientific Education[2017]No.3), Jiangsu Planned Projects for Postdoctoral Research Funds.	Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Akcakaya P, 2011, INT J ONCOL, V39, P311, DOI 10.3892/ijo.2011.1043; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Cai YJ, 2017, ONCOL REP, V37, P2787, DOI 10.3892/or.2017.5548; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Eyking A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156871; Gustafson D, 2016, BEST PRACT RES CL EN, V30, P563, DOI 10.1016/j.beem.2016.07.002; Hu ZB, 2010, J CLIN ONCOL, V28, P1721, DOI 10.1200/JCO.2009.24.9342; Li WS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134220; Liang C, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.145; Liu CX, 2016, ONCOTARGETS THER, V9, P2865, DOI 10.2147/OTT.S103460; Liu G, 2014, J PATHOL, V233, P308, DOI 10.1002/path.4348; Ma HY, 2016, ONCOTARGET, V7, P10594, DOI 10.18632/oncotarget.7236; Mees ST, 2009, ANN SURG ONCOL, V16, P2339, DOI 10.1245/s10434-009-0531-4; Mi HY, 2017, NUCLEIC ACIDS RES, V45, pD183, DOI 10.1093/nar/gkw1138; Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349; Mo DP, 2017, BIOTECHNOL LETT, V39, P701, DOI 10.1007/s10529-017-2290-9; Musilova K, 2015, LEUKEMIA, V29, P1004, DOI 10.1038/leu.2014.351; Peng Y, 2013, P NATL ACAD SCI USA, V110, P15043, DOI 10.1073/pnas.1307107110; Pu HY, 2017, ONCOL LETT, V13, P2403, DOI 10.3892/ol.2017.5684; Ramalingam SS, 2011, CA-CANCER J CLIN, V61, P91, DOI 10.3322/caac.20102; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Song LB, 2013, CELL RES, V23, P274, DOI 10.1038/cr.2012.174; Subramaniam Sangeetha, 2013, J Carcinog, V12, P3, DOI 10.4103/1477-3163.107958; Sun YC, 2016, CELL PROLIFERAT, V49, P636, DOI 10.1111/cpr.12288; Wang J, 2014, ONCOGENE, V33, P1181, DOI 10.1038/onc.2013.42; Wink KCJ, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00292; Wu HL, 2009, EXPERT OPIN THER TAR, V13, P1439, DOI 10.1517/14728220903338777; Xu WT, 2014, DRUG DES DEV THER, V8, P1745, DOI 10.2147/DDDT.S71061; Yi YF, 2016, EXP THER MED, V12, P3411, DOI 10.3892/etm.2016.3783; Yin Z, 2017, GENE, V620, P46, DOI 10.1016/j.gene.2017.04.007; Youness RA, 2016, ONCOL LETT, V12, P2567, DOI 10.3892/ol.2016.4914; Zhang GQ, 2014, TUMOR BIOL, V35, P11137, DOI 10.1007/s13277-014-2412-0; Zhang GW, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0415-9; Zhang XG, 2016, ONCOTARGETS THER, V9, P6909, DOI 10.2147/OTT.S117338; Zhu ZJ, 2017, BIOCHEM BIOPH RES CO, V486, P49, DOI [10.1016/j.bbrc.2017.02.1210006-291X, 10.1016/j.bbrc.2017.02.121]	37	10	10	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAY	2018	214	5					700	705		10.1016/j.prp.2018.03.013			6	Pathology	Pathology	GJ5NF	WOS:000435427500014	29567332				2019-10-28	
J	Yao, XY; Zhou, JD; Yang, J; Zhang, W; Ma, JC; Wen, XM; Yao, DM; Xu, ZJ; Wu, DH; He, PF; Qian, J; Lin, J				Yao, Xin-yu; Zhou, Jing-dong; Yang, Jing; Zhang, Wei; Ma, Ji-chun; Wen, Xiang-mei; Yao, Dong-ming; Xu, Zi-jun; Wu, De-hong; He, Pin-fang; Qian, Jun; Lin, Jiang			SETBP1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome	PATHOLOGY RESEARCH AND PRACTICE			English	Article						AML; HRMA; Mutation; MDS; SETBP1	CHRONIC MYELOMONOCYTIC LEUKEMIA; DISEASE PROGRESSION; MALIGNANCIES	Background: Somatic mutations in SETBP1 gene have recently been detected in hematologic malignancies. The present study aimed to explore the frequency and clinical correlations of SETBP1 mutations in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Methods: In this study, we used high-resolution melting analysis (HRMA) to detect the SETBP1 mutations in a cohort of 363 patients with AML or MDS. Results: A total of 1.2% (3/249) of AML and 1.8% (2/114) of MDS patients were found with heterozygous SETBP1 mutations. In AML, patients with SETBP1 mutations showed higher hemoglobin (P = 0.004) and were more frequently recurrent in AML-M4 subtype (P = 0.034). All five SETBP1 mutated patients had normal karyotypes. The patients with SETBP1 mutations had significantly higher incidences of concurrent SRSF2 mutations (P = 0.002). HRMA could detect SETBP1 mutations with 5% sensitivity, obviously higher than 25% of Sanger sequencing. Conclusions: We established a rapid, inexpensive, high-throughput and sensitive method to screen SETBP1 mutations. SETBP1 mutations were a rare molecular event in AML and MDS patients.	[Yao, Xin-yu; Zhou, Jing-dong; Yang, Jing; Zhang, Wei; Qian, Jun] Jiangsu Univ, Affiliated Peoples Hosp, Dept Hematol, 8 Dianli Rd, Zhenjiang 212002, Jiangsu, Peoples R China; [Ma, Ji-chun; Wen, Xiang-mei; Yao, Dong-ming; Xu, Zi-jun; He, Pin-fang; Lin, Jiang] Jiangsu Univ, Affiliated Peoples Hosp, Lab Ctr, Zhenjiang 212013, Jiangsu, Peoples R China; [Zhou, Jing-dong; Yang, Jing; Zhang, Wei; Ma, Ji-chun; Wen, Xiang-mei; Xu, Zi-jun; He, Pin-fang; Qian, Jun; Lin, Jiang] Key Lab Precis Diag & Treatment Zhenjiang City, Zhenjiang, Jiangsu, Peoples R China; [Wu, De-hong] Third Peoples Hosp KunShan City, Dept Hematol, 615 Zizhu Rd, Kunshan 215300, Jiangsu, Peoples R China	Qian, J (reprint author), Jiangsu Univ, Affiliated Peoples Hosp, Dept Hematol, 8 Dianli Rd, Zhenjiang 212002, Jiangsu, Peoples R China.; Lin, J (reprint author), Jiangsu Univ, Affiliated Peoples Hosp, Lab Ctr, 8 Dianli Rd, Zhenjiang 212002, Peoples R China.	qianjun0007@hotmail.com; linjiangmail@sina.com		Yao, Xinyu/0000-0003-2150-0904	National Natural Science foundation of ChinaNational Natural Science Foundation of China [81270630]; Medical Innovation Team of Jiangsu Province [CXTDB2017002]; 333 Project of Jiangsu ProvinceNatural Science Foundation of Jiangsu Province [BRA2016131]; Six talent peaks project in Jiangsu Province [2015-WSN-115]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2016M601747]; Postgraduate Research & Practice Innovation Program of Jiangsu Province [KYCX17_1821]; Social Development Foundation of Zhenjiang [SH2015058, SH2016045]	This study was supported by National Natural Science foundation of China (81270630), Medical Innovation Team of Jiangsu Province (CXTDB2017002), 333 Project of Jiangsu Province (BRA2016131), Six talent peaks project in Jiangsu Province (2015-WSN-115), China Postdoctoral Science Foundation (2016M601747), Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX17_1821), Social Development Foundation of Zhenjiang (SH2015058, SH2016045).	BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Cristobal I, 2010, BLOOD, V115, P615, DOI 10.1182/blood-2009-06-227363; Damm F, 2013, LEUKEMIA, V27, P1401, DOI 10.1038/leu.2013.35; Dohner H, 2011, HEMATOL-AM SOC HEMAT, P36, DOI 10.1182/asheducation-2011.1.36; Fernandez-Mercado M, 2013, BRIT J HAEMATOL, V163, P235, DOI 10.1111/bjh.12491; Hoischen A, 2010, NAT GENET, V42, P483, DOI 10.1038/ng.581; Hou HA, 2014, AM J HEMATOL, V89, P181, DOI 10.1002/ajh.23611; Hu WQ, 2015, CLIN CASE REP, V3, P448, DOI 10.1002/ccr3.243; Laborde RR, 2013, LEUKEMIA, V27, P2100, DOI 10.1038/leu.2013.97; Lin J., PLOS ONE, V9; Lin J., PLOS ONE, V6; Lin J, 2012, ANN HEMATOL, V91, P519, DOI 10.1007/s00277-011-1352-7; Linder K, 2017, BIOMARK RES, V5, DOI 10.1186/s40364-017-0113-8; Makishima H, 2013, NAT GENET, V45, P942, DOI 10.1038/ng.2696; Marcucci G, 2011, J CLIN ONCOL, V29, P475, DOI 10.1200/JCO.2010.30.2554; Meggendorfer M., 2013, LEUKEMIA, V27; Ouyang Y, 2017, ONCOTARGET, V8, P20834, DOI 10.18632/oncotarget.15355; Piazza R, 2013, NAT GENET, V45, P18, DOI 10.1038/ng.2495; Qian J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045760; Qian J, 2010, CLIN CHIM ACTA, V411, P2097, DOI 10.1016/j.cca.2010.08.020; Shi YS, 2006, MOL CELL, V23, P819, DOI 10.1016/j.molcel.2006.07.022; Swerdlow SH, 2008, WHO CLASSIFICATION T; Tefferi A, 2017, AM J HEMATOL, V92, P1311, DOI 10.1002/ajh.24901; Thol F, 2013, LEUKEMIA, V27, P2072, DOI 10.1038/leu.2013.145; Winkelmann N, 2017, J CANCER RES CLIN, V143, P2511, DOI 10.1007/s00432-017-2518-z; Yang J, 2013, CLIN BIOCHEM, V46, P701, DOI 10.1016/j.clinbiochem.2013.01.023	26	1	1	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAY	2018	214	5					706	712		10.1016/j.prp.2018.03.010			7	Pathology	Pathology	GJ5NF	WOS:000435427500015	29549983				2019-10-28	
J	Hoffman, SJ; Wu, MLC				Hoffman, Sara J.; Wu, Mark Li-cheng			Phenotypic and genotypic differences in colorectal carcinoma among Caucasians, Asians, and Hispanics lack statistical significance	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Colorectal carcinoma; Microsatellite instability; Colon; BRAF; KRAS; Ethnicity	MICROSATELLITE INSTABILITY; LYNCH SYNDROME; CANCER; MUTATION; FREQUENCY; SURVIVAL; FEATURES; COLON; JAPAN	Colorectal carcinoma (CRC) has been shown to have both genetic and environmental factors that can promote carcinoma development. Previous studies have found ethnic differences in the distribution of molecular phenotypes of CRC. Very little specific data exist regarding Hispanic CRC, and these data primarily focus on epidemiology or location of carcinoma. Our retrospective study analyzed 562 Caucasian, Asian, and Hispanic CRC patients at the UCI Medical Center from 2004 to 2012. The results showed that there were no statistically significant differences with respect to mean age, gender or site of carcinoma among the three ethnic groups. There were no statistically significant differences among the three ethnicities with respect to rates of MSI, mutated BRAF, and mutated KRAS. The Caucasian group had a non-significant higher rate of MSI (15%) and BRAF mutation (12%) than the Asian and Hispanic groups. Hispanics had a non-significant higher rate of KRAS mutation (59%) than Caucasians (38%) and Asians (37%). The results of this study demonstrated a higher rate of MSI and BRAF mutation in the Caucasian group and a higher rate of KRAS mutation in the Hispanic group, however differences were not statistically significant.	[Hoffman, Sara J.] Univ Calif Irvine, Dept Pediat, Div Genet & Genom Med, Irvine Sch Med, Irvine, CA 92717 USA; [Wu, Mark Li-cheng] Univ Calif Irvine, Dept Pathol & Lab Med, Irvine Sch Med, Irvine, CA USA	Hoffman, SJ (reprint author), Sutter Pacific Med Fdn, 3883 Airway Dr,Ste 300, Santa Rosa, CA 95403 USA.	professional.sh@aol.com					Backes FJ, 2011, CLIN OBSTET GYNECOL, V54, P199, DOI 10.1097/GRF.0b013e3182185a41; Bellizzi AM, 2009, ADV ANAT PATHOL, V16, P405, DOI 10.1097/PAP.0b013e3181bb6bdc; Bhatnagar BNS, 2004, CLIN ANAT, V17, P236, DOI 10.1002/ca.10204; Burt Randall, 2007, Drug Discov Today Dis Mech, V4, P293, DOI 10.1016/j.ddmec.2008.05.004; Chang SC, 2010, SURGERY, V147, P720, DOI 10.1016/j.surg.2009.10.069; Chien C, 2005, CANCER, V104, P629, DOI 10.1002/cncr.21204; Ciardiello F, 2011, TARGET ONCOL, V6, P133, DOI 10.1007/s11523-011-0181-x; De Jesus-Monge WE, 2010, FAM CANCER, V9, P155, DOI 10.1007/s10689-009-9310-4; Doi T, 2011, JPN J CLIN ONCOL, V41, P210, DOI 10.1093/jjco/hyq229; Edkins S, 2006, CANCER BIOL THER, V5, P928, DOI 10.4161/cbt.5.8.3251; Goodenberger M, 2011, J CLIN GASTROENTEROL, V45, P488, DOI 10.1097/MCG.0b013e318206489c; Gupta S, 2010, CANCER-AM CANCER SOC, V116, P4965, DOI 10.1002/cncr.25486; Hawk ET, 2005, J CLIN ONCOL, V23, P378, DOI 10.1200/JCO.2005.08.097; Hayashi T, 2006, DIS COLON RECTUM, V49, pS23, DOI 10.1007/s10350-006-0722-z; Ishikubo T, 2004, CANCER LETT, V216, P55, DOI 10.1016/j.canlet.2004.07.017; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]; Kang GH, 2011, ARCH PATHOL LAB MED, V135, P698, DOI 10.1043/2010-0523-RA.1; Laghi L, 2012, DIGEST DIS, V30, P304, DOI 10.1159/000337003; Lee S, 2008, PATHOL INT, V58, P104, DOI 10.1111/j.1440-1827.2007.02197.x; Nakaji S, 2002, INT J COLORECTAL DIS, V17, P365, DOI 10.1007/s00384-002-0403-x; Phipps AI, 2012, CANCER EPIDEM BIOMAR, V21, P1792, DOI 10.1158/1055-9965.EPI-12-0674; Rim SH, 2009, CANCER-AM CANCER SOC, V115, P1967, DOI 10.1002/cncr.24216; Saunders BP, 1996, GASTROINTEST ENDOSC, V43, P124, DOI 10.1016/S0016-5107(06)80113-6; Tan C, 2012, WORLD J GASTROENTERO, V18, P5171, DOI 10.3748/wjg.v18.i37.5171; Uy GB, 2004, WORLD J SURG, V28, P117, DOI 10.1007/s00268-003-7281-4; Vasovcak P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024114; Watson AJM, 2011, DIGEST DIS, V29, P222, DOI 10.1159/000323926; Zeller John L, 2008, JAMA, V300, P2816, DOI 10.1001/jama.300.23.2816	28	0	0	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAY	2018	214	5					720	726		10.1016/j.prp.2018.03.008			7	Pathology	Pathology	GJ5NF	WOS:000435427500017	29650442				2019-10-28	
J	Gao, L; Zhang, LJ; Li, SH; Wei, LL; Luo, B; He, RQ; Xia, S				Gao, Li; Zhang, Li-jie; Li, Sheng-hua; Wei, Li-li; Luo, Bin; He, Rong-quan; Xia, Shuang			Role of miR-452-5p in the tumorigenesis of prostate cancer: A study based on the Cancer Genome Atl(TCGA), Gene Expression Omnibus (GEO), and bioinformatics analysis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Bioinformatics analysis; GEO; miR-452-5p; Prostate cancer; Target gene; TCGA	PI3K/AKT PATHWAY; DNA METHYLATION; DOWN-REGULATION; CELL MIGRATION; STEM-CELLS; METASTASIS; MICRORNAS; PROMOTES; ACTIVATION; CARCINOMA	Background: MiR-452-5p has been reported to be down-regulated in prostate cancer, affecting the development of this type of cancer. However, the molecular mechanism of miR-452-5p in prostate cancer remains unclear. Therefore, we investigated the network of target genes of miR-452-5p in prostate cancer using bioinformatics analyses. Materials and methods: We first analyzed the expression profiles and prognostic value of miR-452-5p in prostate cancer tissues from a public database. Gene Ontology (GO), the Kyoto Encyclopedia of Genes and Genomes (KEGG), PANTHER pathway analyses, and a disease ontology (DG) analysis were performed to find the molecular functions of the target genes from GSE datasets and miRWalk. Finally, we validated hub genes from the protein-protein interaction (PPI) networks of the target genes In the Human Protein Atlas (HPA) database and Gene Expression Profiling Interactive Analysis (GEPIA). Narrowing down the optimal target genes was conducted by seeking the common parts of up-regulated genes from GEPIA, down-regulated genes from GSE datasets, and predicted genes in miRWalk. Results: Based on mining of GEO and ArrayExpress microarray chips and miRNA-Seq data in the TCGA database, which includes 1007 prostate cancer samples and 387 non-cancer samples, miR-452-5p is shown to be down regulated in prostate cancer. GO, KEGG, and PANTHER pathway analyses suggested that the target genes might participate in important biological processes, such as transforming growth factor beta signaling and the positive regulation of brown fat cell differentiation and mesenchymal cell differentiation, as well as the Ras signaling pathway and pathways regulating the pluripotency of stem cells and arrhythmogenic right ventricular cardiomyopathy (ARVC). Nine genes-GABBR, PNISR, NTSR1, DOCK1, EREG, SFRP1, PTGS2, LEF1, and BMP2-were defined as hub genes in the PPI network. Three genes-FAM174B, SLC30A4, and SLIT1-were jointly shared by GEPIA, the GSE datasets, and miRWalk. Conclusions: Down-regulated miR-452-5p might play an essential role in the tumorigenesis of prostate cancer.	[Gao, Li; Zhang, Li-jie; Wei, Li-li; Xia, Shuang] Guangxi Med Univ, Dept Human Anat, 22 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China; [Li, Sheng-hua; Luo, Bin] Guangxi Med Univ, Affiliated Hosp 1, Dept Med Oncol, 6 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China; [He, Rong-quan] Guangxi Med Univ, Dept Biochem, 22 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China	Xia, S (reprint author), Guangxi Med Univ, Dept Human Anat, 22 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.; He, RQ (reprint author), Guangxi Med Univ, Dept Biochem, 22 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.	herongquan@gxmu.edu.cn; xiassxia@163.com			Fund of the Promoting Project of Basic Capacity for Young and Middle-aged University Teachers in Guangxi [KY2016LX034]	The study was supported by the Fund of the Promoting Project of Basic Capacity for Young and Middle-aged University Teachers in Guangxi (KY2016LX034).	Alifano M, 2010, BIOCHIMIE, V92, P164, DOI 10.1016/j.biochi.2009.11.004; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bailey CL, 2009, CANCER RES, V69, P4962, DOI 10.1158/0008-5472.CAN-08-4269; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Boguslawska J, 2014, MOL CELL ENDOCRINOL, V384, P61, DOI 10.1016/j.mce.2014.01.006; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chang L, 2016, ONCOL LETT, V11, P69, DOI 10.3892/ol.2015.3873; Cheaib B, 2015, CHIN J CANCER, V34, P4, DOI 10.5732/cjc.014.10289; Chen DJ, 2016, DRUG DES DEV THER, V10, DOI 10.2147/DDDT.S101998; Dallavalle C, 2016, J CLIN INVEST, V126, P4585, DOI 10.1172/JCI86505; Danielsen SA, 2015, BBA-REV CANCER, V1855, P104, DOI 10.1016/j.bbcan.2014.09.008; Dupouy S, 2011, BIOCHIMIE, V93, P1369, DOI 10.1016/j.biochi.2011.04.024; Gao L, 2017, ONCOTARGETS THER, V10, P3667, DOI 10.2147/OTT.S137433; Goswami Chirayu Pankaj, 2012, J Clin Bioinforma, V2, P23, DOI 10.1186/2043-9113-2-23; Goto Y, 2016, BRIT J CANCER, V114, P1135, DOI 10.1038/bjc.2016.95; He ZC, 2015, CELL PHYSIOL BIOCHEM, V37, P387, DOI 10.1159/000430362; Hu CM, 2017, ONCOL LETT, V13, P4769, DOI 10.3892/ol.2017.6098; Huo Hong-Nan, 2013, Shengli Xuebao, V65, P323; Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329; Kang PC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090308; Kee JY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176937; Kim J, 2017, INT J GENOMICS, DOI 10.1155/2017/5789769; Kristensen H, 2014, CLIN CANCER RES, V20, P2169, DOI 10.1158/1078-0432.CCR-13-2642; Lai TH, 2008, PROSTATE, V68, P1341, DOI 10.1002/pros.20799; Latil A, 2003, INT J CANCER, V103, P306, DOI 10.1002/ijc.10821; Li DY, 2017, ONCOL LETT, V13, P2607, DOI 10.3892/ol.2017.5761; Li J. J., 2014, YI XUE BAN J PEKING, V46, P868; Li RZ, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0900-y; Lin JZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076169; Lin SC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11418; Liu C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14270; Liu C, 2012, CANCER RES, V72, P3393, DOI 10.1158/0008-5472.CAN-11-3864; Liu LP, 2013, CLIN CANCER RES, V19, P3429, DOI 10.1158/1078-0432.CCR-12-3794; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Luo Y, 2016, OXID MED CELL LONGEV, DOI 10.1155/2016/1469693; Manzo-Merino J, 2014, ARCH MED RES, V45, P525, DOI 10.1016/j.arcmed.2014.10.008; Markowska A, 2014, WSPOLCZESNA ONKOL, V18, P143, DOI 10.5114/wo.2014.43154; Mitsui Y, 2015, ONCOTARGET, V6, P9577, DOI 10.18632/oncotarget.3445; Nawshad A, 2007, J CELL SCI, V120, P1646, DOI 10.1242/jcs.003129; Ouyang Q, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0290-8; Piletic K, 2016, ARCH TOXICOL, V90, P2405, DOI 10.1007/s00204-016-1815-7; Puerta-Gil P, 2012, AM J PATHOL, V180, P1808, DOI 10.1016/j.ajpath.2012.01.034; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Stock D, 2008, UROL CLIN N AM, V35, P117, DOI 10.1016/j.ucl.2007.09.006; Strand SH, 2014, INT J MOL SCI, V15, P16544, DOI 10.3390/ijms150916544; Su W, 2017, ONCOTARGET, V8, P4449, DOI 10.18632/oncotarget.13879; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Udomprasert A., 2017, CANC SCI; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; van Schooneveld E, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3127; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Wang KZ, 2017, EXP THER MED, V13, P3239, DOI 10.3892/etm.2017.4378; Wilhite SE, 2012, METHODS MOL BIOL, V802, P41, DOI 10.1007/978-1-61779-400-1_3; Wu W, 2016, ONCOTARGET, V7, P21631, DOI 10.18632/oncotarget.7795; Wu WH, 2013, CAN J NEUROL SCI, V40, P355, DOI 10.1017/S031716710001430X; Yun J, 2012, LAB INVEST, V92, P1033, DOI 10.1038/labinvest.2012.61; Zhang B, 2016, NEUROPATHOL APPL NEU; Zhang W, 2002, CELL RES, V12, P9, DOI 10.1038/sj.cr.7290105; Zhang YQ, 2017, ONCOL LETT, V13, P4252, DOI 10.3892/ol.2017.6028; Zhang YL, 2017, CANCER BIOL MED, V14, P90, DOI 10.20892/j.issn.2095-3941.2016.0086; Zheng L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118276; Zheng QL, 2014, MOL CELL BIOCHEM, V389, P187, DOI 10.1007/s11010-013-1940-z; Zhou TJ, 2017, THERANOSTICS, V7, P1389, DOI 10.7150/thno.17647	64	5	5	3	15	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAY	2018	214	5					732	749		10.1016/j.prp.2018.03.002			18	Pathology	Pathology	GJ5NF	WOS:000435427500019	29559248				2019-10-28	
J	Li, TT; Gao, X; Gao, L; Gan, BL; Xie, ZC; Zeng, JJ; Chen, G				Li, Tian-tian; Gao, Xiang; Gao, Li; Gan, Bin-liang; Xie, Zu-cheng; Zeng, Jing-jing; Chen, Gang			Role of upregulated miR-136-5p in lung adenocarcinoma: A study of 1242 samples utilizing bioinformatics analysis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Lung adenocarcinoma; miR-136a-5p; Meta-analysis; Bioinformatics; Cell adhesion molecules	EXPRESSION PROFILES; CELL-PROLIFERATION; CANCER STATISTICS; POOR-PROGNOSIS; MESSENGER-RNA; METASTASIS; MICRORNA; IDENTIFICATION; ASSOCIATION; RESISTANCE	Background: It is generally acknowledged that miRNAs play pivotal roles in the initiation and development of cancer. The aim of the current study is to investigate the clinicopathological role of miR-136-5p in lung adenocarcinoma and its underlying molecular mechanism. Materials and methods: Data of a cohort of 1242 samples were provided by the Gene Expression Omnibus and The Cancer Genome Atlas to evaluate miR-136-5p expression in lung adenocarcinoma. A comprehensive meta analysis integrating the expression data from all sources was performed, followed by a summary receiver operating curve plotted to appraise the upregulated expression of miR-136-5p in lung adenocarcinoma. Candidate targets of miR-136-5p were launched by the intersection of differentially expressed genes in The Cancer Genome Atlas and genes predicted by 12 web-based platforms. Then, hub genes were illustrated by a protein-protein interaction network. Furthermore, Kyoto Encyclopedia of Genes and Genomes, Gene Ontology and Protein Analysis Through Evolutionary Relationships analyses of potential target genes were carried out via bioinformatics tools. Results: MiR-136-5p expression was upregulated in lung adenocarcinoma versus normal tissues (standard mean difference = 0.43, 95% confidence interval: 0.27-0.58). The summary receiver operating characteristic curve further verified the upregulation of miR-136-5p in lung adenocarcinoma (area under curve = 0.7459). A total of 311 candidate target genes of miR-136-5p were gathered to create a protein-protein interaction network. Molecular mechanism analysis unveiled the potential miR-136-5p target genes participated in cell adhesion molecules, focal adhesion, complement and coagulation cascades and blood coagulation. Conclusion: MiR-136-5p is overexpressed in lung adenocarcinoma and is involved in the molecular mechanism of lung adenocarcinoma via suppressing the expressions of downstream targets, especially claudin-18, sialophorin and syndecan 2 that participate in cell adhesion.	[Li, Tian-tian; Gao, Xiang; Gao, Li; Gan, Bin-liang; Xie, Zu-cheng; Zeng, Jing-jing; Chen, Gang] Guangxi Med Univ, Affiliated Hosp 1, Dept Pathol, 6 Shuangyong Rd, Nanning 530021, Guangxi Zhuang, Peoples R China	Zeng, JJ (reprint author), Guangxi Med Univ, Affiliated Hosp 1, Dept Pathol, 6 Shuangyong Rd, Nanning 530021, Guangxi Zhuang, Peoples R China.	zjj_gxmuyfy_patho@163.com		Chen, Gang/0000-0002-4864-1451			Acunzo Mario, 2015, Adv Biol Regul, V57, P1, DOI 10.1016/j.jbior.2014.09.013; Arima C, 2014, CARCINOGENESIS, V35, P2224, DOI 10.1093/carcin/bgu127; Bjaanaes MM, 2014, INT J CANCER, V135, P1812, DOI 10.1002/ijc.28828; Carvalho S, 2016, TRENDS CANCER, V2, P519, DOI 10.1016/j.trecan.2016.08.003; Castro D, 2017, ONCOTARGET, V8, P81679, DOI 10.18632/oncotarget.20955; Chen WH, 2014, J NEURO-ONCOL, V120, P43, DOI 10.1007/s11060-014-1535-x; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Dacic S, 2016, ONCOTARGET, V7, P82943, DOI 10.18632/oncotarget.12705; Danza K, 2017, ONCOTARGET, V8, P50715, DOI 10.18632/oncotarget.14899; Daugaard I, 2017, EXP MOL PATHOL, V102, P484, DOI 10.1016/j.yexmp.2017.05.012; De Grandis M, 2017, CANCER RES, V77, P6627, DOI 10.1158/0008-5472.CAN-17-1223; Deng G, 2017, MOL MED REP, V16, P2835, DOI 10.3892/mmr.2017.6901; Faehling M, 2017, ONCOTARGET, V8, P77897, DOI 10.18632/oncotarget.20857; Fu QW, 2013, INT J CANCER, V132, P1761, DOI 10.1002/ijc.27873; Gan TQ, 2017, MED SCI MONITOR, V23, P2453, DOI 10.12659/MSM.901460; Gao HY, 2017, ONCOTARGETS THER, V10, P205, DOI 10.2147/OTT.S116178; Geng Y, 2016, ONCOTARGETS THER, V9, P4605, DOI 10.2147/OTT.S103430; Hao SN, 2014, TUMOR BIOL, V35, P5675, DOI 10.1007/s13277-014-1751-1; Hayes J, 2014, TRENDS MOL MED, V20, P460, DOI 10.1016/j.molmed.2014.06.005; He CL, 2015, INT J CLIN EXP PATHO, V8, P8348; Hiemer SE, 2014, J BIOL CHEM, V289, P13461, DOI 10.1074/jbc.M113.529115; Huan JL, 2017, AM J TRANSL RES, V9, P1977; Huang QY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175501; Huang WT, 2016, ONCOTARGETS THER, V9, P5163, DOI 10.2147/OTT.S108828; Jeong JY, 2017, CANCER LETT, V386, P168, DOI 10.1016/j.canlet.2016.11.017; Kim MH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160996; Lee H, 2011, BIOCHEM BIOPH RES CO, V409, P148, DOI 10.1016/j.bbrc.2011.04.135; Li J, 2015, CELL PHYSIOL BIOCHEM, V37, P1847, DOI 10.1159/000438546; Li Y. J., 2017, FUTURE ONCOL; Liang L., 2017, PATHOL RES PRACT; Lin K, 2016, ONCOTARGETS THER, V9, P5679, DOI 10.2147/OTT.S111241; Liu LP, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0620-0; Liu WH, 2017, CELL PHYSIOL BIOCHEM, V43, P969, DOI 10.1159/000481650; Lopes-Ramos CM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181153; Lou NN, 2016, ONCOTARGET, V7, P65185, DOI 10.18632/oncotarget.11218; Lu XL, 2016, TUMOR BIOL, V37, P253, DOI 10.1007/s13277-015-3792-5; Lv Q, 2017, CANCER BIOL THER, V18, P142, DOI 10.1080/15384047.2017.1281497; Ma XB, 2015, HUM PATHOL, V46, P593, DOI 10.1016/j.humpath.2015.01.002; Merikallio H, 2011, INT J CLIN EXP PATHO, V4, P667; Nymark P, 2011, GENE CHROMOSOME CANC, V50, P585, DOI 10.1002/gcc.20880; Oh T, 2013, J MOL DIAGN, V15, P498, DOI 10.1016/j.jmoldx.2013.03.004; Opilka Mieszko Norbert, 2014, Pol Przegl Chir, V86, P151, DOI 10.2478/pjs-2014-0028; Othman N, 2017, INT J ONCOL, V51, P1757, DOI 10.3892/ijo.2017.4174; Patnaik S. K., 2012, PLOS ONE; Patnaik SK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181926; Reineri S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168639; Ren FH, 2015, INT J CLIN EXP MED, V8, P17377; Ren FH, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0227-8; Robles AI, 2015, J THORAC ONCOL, V10, P1037, DOI 10.1097/JTO.0000000000000560; Seike M, 2009, P NATL ACAD SCI USA, V106, P12085, DOI 10.1073/pnas.0905234106; Sekimoto N, 2017, MOL MED REP, V15, P534, DOI 10.3892/mmr.2016.6053; Shen SN, 2014, TUMOR BIOL, V35, P631, DOI 10.1007/s13277-013-1087-2; Shimobaba S, 2016, BBA-MOL CELL RES, V1863, P1170, DOI 10.1016/j.bbamcr.2016.02.015; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Song B, 2016, EXP THER MED, V12, P2455, DOI 10.3892/etm.2016.3648; Sui J, 2016, INT J ONCOL, V49, P2023, DOI 10.3892/ijo.2016.3716; Sun Y., 2017, PATHOL RES PRACT; Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937; Tang RX, 2015, MED SCI MONITOR, V21, P2514, DOI 10.12659/MSM.894372; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Torre Lindsey A, 2016, Adv Exp Med Biol, V893, P1, DOI 10.1007/978-3-319-24223-1_1; Tsonis AI, 2013, FEBS J, V280, P2248, DOI 10.1111/febs.12162; Uhlen M, 2010, NAT BIOTECHNOL, V28, P1248, DOI 10.1038/nbt1210-1248; van Jaarsveld MTM, 2014, MOL ONCOL, V8, P458, DOI 10.1016/j.molonc.2013.12.011; Wang L, 2016, CELL PHYSIOL BIOCHEM, V38, P2389, DOI 10.1159/000445591; Wu H, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0173-0; Wu YS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166378; Xie XJ, 2016, INT J ONCOL, V48, P1617, DOI 10.3892/ijo.2016.3357; Yamamoto G, 2017, INT J ONCOL, V50, P1579, DOI 10.3892/ijo.2017.3935; Yan MS, 2016, ONCOL REP, V36, P65, DOI 10.3892/or.2016.4767; Yang J, 2016, EXP THER MED, V12, P1490, DOI 10.3892/etm.2016.3464; Yang Y, 2013, ONCOL RES, V21, P345, DOI 10.3727/096504014X14024160459285; Ye ZH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163162; Yu X, 2015, AM J TRANSL RES, V7, P2536; Yuan QG, 2017, GENE, V628, P48, DOI 10.1016/j.gene.2017.07.031; Zhang X, 2016, EXP THER MED, V12, P2095, DOI 10.3892/etm.2016.3613; Zhang Y, 2016, ONCOTARGETS THER, V9, P4959, DOI 10.2147/OTT.S105225; Zhao HN, 2015, ONCOL REP, V33, P591, DOI 10.3892/or.2014.3640; Zhao J, 2014, DNA CELL BIOL, V33, P715, DOI 10.1089/dna.2014.2376; Zheng JC, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317695020; Zhuo CJ, 2016, CELL PHYSIOL BIOCHEM, V40, P1316, DOI 10.1159/000453184	81	3	3	0	4	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAY	2018	214	5					750	766		10.1016/j.prp.2018.02.017			17	Pathology	Pathology	GJ5NF	WOS:000435427500020	29526559				2019-10-28	
J	Xu, LM; Xu, XT; Huang, HL; Ma, ZH; Zhang, SM; Niu, PP; Chen, YR; Ping, JL; Lu, P; Yu, CH; Min, LS; Chen, J; Dai, LC; Dong, SL				Xu, Limin; Xu, Xuting; Huang, Huilian; Ma, Zhihong; Zhang, Shuangmei; Niu, Pingping; Chen, Yingrong; Ping, Jinliang; Lu, Ping; Yu, Caihua; Min, Lishan; Chen, Jing; Dai, Licheng; Dong, Shunli			MiR-1260b promotes the migration and invasion in non-small cell lung cancer via targeting PTPRK	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Non-small cell lung cancer; miR-1260b; PTPRK; Migration; Invasion	DOWN-REGULATES ONCO-MIR-1260B; COLORECTAL-CANCER; BREAST-CANCER; MICRORNA; LYMPHOMA; GENES; PROLIFERATION; METASTASIS; STATISTICS; PROGNOSIS	Objective: Non-small cell lung cancer (NSCLC) accounts for 80-85% of lung cancer cases which cause most of cancer-related deaths globally. As our previous study discovered miR-1260b can be regarded as a specific signature for metastasis in NSCLC patients. However, the molecular mechanisms of miR-1260b underlying NSCLC progression and metastasis remain dismal. Methods: The expression of miR-1260b in NSCLC tissues and cell lines were examined by real-time PCR, the effects of miR-1260b on cell migration, invasion and proliferation were evaluated in vitro. Furthermore, luciferase reporter assay was performed to identify the targets of miR-1260b, and the association between miR1260b and its target gene was determined by real-time PCR and western blot assay. Results: The results showed that miR-1260b was significantly upregulated in NSCLC cell lines. The inhibition of miR-1260b expression decreased the migratory and invasive rates in A549 cells while miR-1260b overexpression had the opposite effect. Furthermore, PTPRK was identified as a direct target of miR-1260b, and PTPRK expression was inversely correlated with miR-1260b in NSCLC cell lines and clinical tissues. Conclusions: These results suggested that miR-1260b may play an important role in NSCLC metastasis progression and could serve as a putative target for diagnosis and treatment of NSCLC.	[Xu, Limin; Xu, Xuting; Huang, Huilian; Ma, Zhihong; Niu, Pingping; Chen, Yingrong; Min, Lishan; Chen, Jing; Dai, Licheng; Dong, Shunli] Huzhou Cent Hosp, Huzhou Key Lab Mol Med, Huzhou 313000, Zhejiang, Peoples R China; [Zhang, Shuangmei] Huzhou Cent Hosp, Resp Med, Huzhou 313000, Zhejiang, Peoples R China; [Ping, Jinliang; Lu, Ping] Huzhou Cent Hosp, Dept Pathol, Huzhou 313000, Zhejiang, Peoples R China; [Yu, Caihua] Huzhou Cent Hosp, Dept Thorac Surg, Huzhou 313000, Zhejiang, Peoples R China	Dai, LC; Dong, SL (reprint author), Huzhou Cent Hosp, Huzhou Key Lab Mol Med, Huzhou 313000, Zhejiang, Peoples R China.	dlc171@hzhospital.com; dongshunli@hzhospital.com			Natural Science Foundation of Zhejiang ProvinceNatural Science Foundation of Zhejiang Province [LY16H160002]; Public Technology Applied Research Program [2015GZ15]; Public Applied Research Program [2016GY22, 2016GY30]	The research was supported by the grants from Natural Science Foundation of Zhejiang Province (No. LY16H160002), the Public Technology Applied Research Program (Key Program No.2015GZ15), the Public Applied Research Program (No. 2016GY22, 2016GY30).	Agarwal S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062852; Cady FM, 2008, J CLIN ONCOL, V26, P4814, DOI 10.1200/JCO.2008.16.1455; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chen YW, 2015, BLOOD, V125, P1589, DOI 10.1182/blood-2014-07-588970; Craig SEL, 2015, SEMIN CELL DEV BIOL, V37, P108, DOI 10.1016/j.semcdb.2014.09.004; Del Vescovo V, 2014, WORLD J CLIN ONCOL, V5, P604, DOI 10.5306/wjco.v5.i4.604; Ge H, 2015, INT J CLIN EXP PATHO, V8, P800; Hirata H, 2014, BRIT J CANCER, V110, P1645, DOI 10.1038/bjc.2014.48; Hirata H, 2013, BRIT J CANCER, V108, P2070, DOI 10.1038/bjc.2013.173; Inamura K, 2017, CANCERS, V9, DOI 10.3390/cancers9050049; Lanczky A, 2016, BREAST CANCER RES TR, V160, P439, DOI 10.1007/s10549-016-4013-7; Li Wei-Min, 2017, Sichuan Da Xue Xue Bao Yi Xue Ban, V48, P331; Liang Z, 2017, ONCOTARGET, V8, P47389, DOI 10.18632/oncotarget.17650; Lin PY, 2010, BRIT J CANCER, V103, P1144, DOI 10.1038/sj.bjc.6605901; Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932; Liu DR, 2016, MED SCI MONITOR, V22, P2417, DOI 10.12659/MSM.898733; Markou A, 2013, LUNG CANCER, V81, P388, DOI 10.1016/j.lungcan.2013.05.007; Markou A, 2016, LUNG CANCER-TARGETS, V7, P19, DOI 10.2147/LCTT.S60341; McKiernan PJ, 2016, EXPERT REV MOL DIAGN, V16, P173, DOI 10.1586/14737159.2016.1122526; Meng W, 2013, CLIN CANCER RES, V19, P5423, DOI 10.1158/1078-0432.CCR-13-0320; Nakamura M, 2003, CANCER RES, V63, P737; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Sarver AL, 2010, CANCER RES, V70, P9570, DOI 10.1158/0008-5472.CAN-10-2074; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Starr TK, 2009, SCIENCE, V323, P1747, DOI 10.1126/science.1163040; Sun CC, 2016, ONCOTARGET, V7, P8341, DOI 10.18632/oncotarget.7071; Sun CC, 2016, BIOCHEM BIOPH RES CO, V471, P82, DOI 10.1016/j.bbrc.2016.01.175; Sun CC, 2015, ONCOTARGET, V6, P25533, DOI 10.18632/oncotarget.4575; Sun PH, 2013, J CANCER RES CLIN, V139, P1129, DOI 10.1007/s00432-013-1421-5; Sun YJ, 2015, ONCOTARGET, V6, P8244, DOI 10.18632/oncotarget.3135; Tonks NK, 2006, NAT REV MOL CELL BIO, V7, P833, DOI 10.1038/nrm2039; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wang LD, 2014, CANCER SCI, V105, P592, DOI 10.1111/cas.12388; Woodard GA, 2016, CANCER TREAT RES, V170, P47, DOI 10.1007/978-3-319-40389-2_3; Xu LM, 2015, AGING DIS, V6, P478, DOI 10.14336/AD.2015.0620; Yang JQ, 2013, PATHOL RES PRACT, V209, P490, DOI 10.1016/j.prp.2013.04.018; Yang Y, 2015, CANCER GENE THER, V22, P23, DOI 10.1038/cgt.2014.66; Zhang J, 2015, CLIN TRANSL ONCOL, V17, P209, DOI 10.1007/s12094-014-1213-7; Zhu WJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103373	39	8	8	1	6	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAY	2018	214	5					776	783		10.1016/j.prp.2018.02.002			8	Pathology	Pathology	GJ5NF	WOS:000435427500022	29628123				2019-10-28	
J	Xu, B; Zhang, XP; Wang, SS; Shi, BL				Xu, Bin; Zhang, Xiping; Wang, Shanshan; Shi, Bailing			MiR-449a suppresses cell migration and invasion by targeting PLAGL2 in breast cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						MiR-449a; Migration; Invasion; PLAGL2; Breast cancer	ZINC-FINGER PROTEIN; METASTASIS; ACTIVATION; EXPRESSION; PROGRESSION	Background: Breast cancer is one of the most common malignancies worldwide. However, the detailed molecular mechanisms underlying breast cancer metastasis are still incompletely clear. MicroRNAs (miRNAs) play a crucial role in cancer metastasis. In this study, we aimed to analyze the expression and function of miR-449a in breast cancer. Material and methods: A total of 15 human primary breast cancer tissues and adjacent non-cancerous tissues (10 pairs) were obtained. MiR-449a was examined in tumor tissues and adjacent nontumorous tissues of breast cancer patients and cell lines by real-time PCR. The protein expression levels were analyzed by western blot and immunohistochemistry staining. Luciferase reporter assays was used to validate the target of miR-449a. The effect of miR-449a on breast cancer cell migration and invasion were studied in vitro and in vivo. Results: The expression levels of miR-449a were significantly decreased in breast cancer tissues and cell lines. Overexpression of miR-449a suppressed breast cancer cell proliferation, clone formation, migration, invasion and metastasis in vitro and in vivo. Pleomorphic adenoma gene like-2 (PLAGL2) was identified as a major target of miR-449a. Both overexpression of miR-449a inhibited the expression of PLAGL2 significantly and the knockdown of PLAGL2 expression inhibited the breast cancer cell proliferation and metastasis. Conclusion: We demonstrate the miR-449a tumor suppressor role in breast cancer cell migration and invasion via targeting PLAGL2. These findings suggesting that miR-449a/PLAGL2 could serve as a therapeutic strategy for targeting breast cancer.	[Xu, Bin; Wang, Shanshan] Zhejiang Rehabil Med Ctr, Dept Surg, Hangzhou 310053, Zhejiang, Peoples R China; [Zhang, Xiping] Zhejiang Canc Hosp, Dept Tumor Surg, Hangzhou 310022, Zhejiang, Peoples R China; [Shi, Bailing] Zhejiang Chinese Med Univ, Dept Surg, Affiliated Hosp 3, Hangzhou 310005, Zhejiang, Peoples R China	Xu, B (reprint author), Zhejiang Rehabil Med Ctr, 2828 Bin Sheng Rd, Hangzhou, Zhejiang, Peoples R China.	xubin789654@sina.com			Zhejiang Provincial Natural Science Foundation of ChinaNatural Science Foundation of Zhejiang Province [Y16H150023]	This research was supported by Zhejiang Provincial Natural Science Foundation of China under Grant No.Y16H150023.	Bordinhao ALR, 2016, ONCOL REP, V36, P3197, DOI 10.3892/or.2016.5153; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen SP, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1738-3; Chikh A, 2016, ONCOTARGET, V7, P18325, DOI 10.18632/oncotarget.7761; Furukawa T, 2001, ONCOGENE, V20, P4718, DOI 10.1038/sj.onc.1204647; Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317; Iorio MV, 2009, CANCER RES, V69, P2195, DOI 10.1158/0008-5472.CAN-08-2920; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kumar P, 2016, ONCOTARGET, V7, P22791, DOI 10.18632/oncotarget.8061; Landrette SF, 2005, BLOOD, V105, P2900, DOI 10.1182/blood-2004-09-3630; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li BL, 2017, CHEM-BIOL INTERACT, V277, P33, DOI 10.1016/j.cbi.2017.08.014; Li Q, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0435-5; Mizutani A, 2002, J BIOL CHEM, V277, P15851, DOI 10.1074/jbc.M111431200; Monroig PD, 2015, ADV DRUG DELIVER REV, V81, P104, DOI 10.1016/j.addr.2014.09.002; Nicolini A, 2006, BIOMED PHARMACOTHER, V60, P548, DOI 10.1016/j.biopha.2006.07.086; Qian BY, 2009, BREAST CANCER RES TR, V117, P131, DOI 10.1007/s10549-008-0219-7; Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200; Sekiya R, 2014, CARCINOGENESIS, V35, P1993, DOI 10.1093/carcin/bgu081; Shi W, 2016, ONCOTARGET, V7, P18906, DOI 10.18632/oncotarget.7753; Shi W, 2011, CANCER RES, V71, P2926, DOI 10.1158/0008-5472.CAN-10-3369; Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808; Yao YL, 2015, MOL ONCOL, V9, P640, DOI 10.1016/j.molonc.2014.11.003; You JC, 2015, AM J CANCER RES, V5, P2730; Zhang G., 2016, BIOCH BIOPHYS RES CO, V469; Zhang H, 2010, ONCOGENE, V29, P937, DOI 10.1038/onc.2009.406; Zheng HW, 2010, CANCER CELL, V17, P497, DOI 10.1016/j.ccr.2010.03.020; Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007	29	1	1	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAY	2018	214	5					790	795		10.1016/j.prp.2017.12.012			6	Pathology	Pathology	GJ5NF	WOS:000435427500024	29653747				2019-10-28	
J	Miura, A; Mori, T; Yoshida, A; Watanabe, Y; Sunami, K; Watanabe, S; Kohno, T; Tsuta, K				Miura, Akihiro; Mori, Taisuke; Yoshida, Akihiko; Watanabe, Yukio; Sunami, Kuniko; Watanabe, Shunichi; Kohno, Takashi; Tsuta, Koji			Primary adenocarcinoma of the trachea revealing a mucinous bronchial gland cell origin	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Tracheal tumors; Salivary gland tumors; Nkx3.1	LUNG-CANCER; TUMORS; NATIONWIDE; NKX3.1		[Miura, Akihiro; Mori, Taisuke; Yoshida, Akihiko; Watanabe, Yukio; Tsuta, Koji] Natl Canc Ctr, Dept Pathol, Tokyo, Japan; [Miura, Akihiro; Mori, Taisuke; Yoshida, Akihiko; Watanabe, Yukio; Tsuta, Koji] Natl Canc Ctr, Clin Lab, Tokyo, Japan; [Miura, Akihiro; Watanabe, Yukio; Watanabe, Shunichi] Natl Canc Ctr, Dept Thorac Surg, Tokyo, Japan; [Miura, Akihiro] Okayama Univ, Dept Thorac Surg, Okayama, Japan; [Sunami, Kuniko; Kohno, Takashi] Natl Canc Ctr, Dept Genome Biol, Res Inst, Tokyo, Japan; [Tsuta, Koji] Kansai Med Univ, Dept Pathol & Lab Med, 2-5-1 Shinmachi, Hirakata, Osaka 5731010, Japan	Tsuta, K (reprint author), Kansai Med Univ, Dept Pathol & Lab Med, 2-5-1 Shinmachi, Hirakata, Osaka 5731010, Japan.; Miura, A (reprint author), Okayama Univ, Dept Thorac Surg, Kita Ku, 5-1 Shikata 2 Chome, Okayama 7008558, Japan.	akmiura0930@okayama-u.ac.jp; tsutakoji@hirakata.kmu.ac.jp		san pu, zhang bo/0000-0002-1217-7220			Ahn Y, 2009, J THORAC ONCOL, V4, P635, DOI 10.1097/JTO.0b013e31819d18f9; Barnes L, 2005, WHO CLASSIFICATION T; De S, 2009, LUNG INDIA, V26, P162, DOI 10.4103/0970-2113.56358; ElNayal A, 2013, AM J ROENTGENOL, V201, pW57, DOI 10.2214/AJR.12.9579; Gaissert HA, 2006, ANN THORAC SURG, V82, P268, DOI 10.1016/j.athoracsur.2006.01.065; Gurel B, 2010, AM J SURG PATHOL, V34, P1097, DOI 10.1097/PAS.0b013e3181e6cbf3; Honings J, 2007, ANN SURG ONCOL, V14, P968, DOI 10.1245/s10434-006-9229-z; Kang DY, 2011, LUNG CANCER, V72, P250, DOI 10.1016/j.lungcan.2010.08.021; Kiryu T, 2001, CHEST, V119, P768, DOI 10.1378/chest.119.3.768; Licht PB, 2001, EUR J CARDIO-THORAC, V19, P339, DOI 10.1016/S1010-7940(01)00597-8; MANNINEN MP, 1991, ACTA OTO-LARYNGOL, V111, P1162, DOI 10.3109/00016489109138466; Molina JR, 2007, CANCER-AM CANCER SOC, V110, P2253, DOI 10.1002/cncr.23048; Schneider A, 2000, MECH DEVELOP, V95, P163, DOI 10.1016/S0925-4773(00)00355-5; Sunami K, 2016, J THORAC ONCOL, V11, P203, DOI 10.1016/j.jtho.2015.10.005; Urdaneta AI, 2011, AM J CLIN ONCOL-CANC, V34, P32, DOI 10.1097/COC.0b013e3181cae8ab; Zhu F, 2013, J THORAC ONCOL, V8, P1578, DOI 10.1097/JTO.0b013e3182a7d272	16	1	1	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAY	2018	214	5					796	799		10.1016/j.prp.2018.03.006			4	Pathology	Pathology	GJ5NF	WOS:000435427500025	29549985				2019-10-28	
J	Huglo, D; Semah, F				Huglo, D.; Semah, F.			A word of the President	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Editorial Material									[Huglo, D.; Semah, F.] CHRU Lille, Serv Med Nucl, F-59037 Lille, France	Huglo, D (reprint author), CHRU Lille, Serv Med Nucl, F-59037 Lille, France.	damien.huglo@chru-lille.fr; franck.semah@chru-lille.fr						0	0	0	0	2	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	MAY-JUN	2018	42	3					125	125		10.1016/j.mednuc.2018.04.001			1	Pathology	Pathology	GI1AS	WOS:000434102200001					2019-10-28	
J	Bombois, S				Bombois, S.			Etiological diagnosis of cognitive disorders and biomarkers. In which situations molecular imaging is indicated?	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Review						Alzheimer disease; Biomarkers; PET	ALZHEIMERS ASSOCIATION WORKGROUPS; DISEASE BIOMARKERS; NATIONAL INSTITUTE; RECOMMENDATIONS; IMPAIRMENT; PET; GUIDELINES; CRITERIA; TAU	The development of biomarkers had led to characterise Alzheimer disease as a clinico-biological entity, the cognitive disorders being associated with the evidence of the presence of the pathological lesions of the disease. The etiological diagnosis is essentially clinical. If MRI is systematic to explore any cognitive deficit, the use of PET or cerebrospinal fluid biomarkers is not systematic. The main indications of these examinations are the presence of a non-amnesic cognitive disorder, an atypical clinical evolution and an early onset of disorders. (C) 2018 Published by Elsevier Masson SAS.	[Bombois, S.] Univ Lille, Ctr Natl Reference Patients Alzheimer Jeunes, Ctr Memoire Ressources & Rech, CHU,Inserm 01171,Troubles Cognitifs Degeneratifs, F-59000 Lille, France	Bombois, S (reprint author), Hop Roger Salengro, CMRR, 1 Rue Emile Laine, F-59037 Lille, France.	stephanie.bombois@chru-lille.fr	Bombois, Stephanie/N-5534-2018	Bombois, Stephanie/0000-0003-3117-1833			Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008; [Anonymous], 1998, Neurobiol Aging, V19, P109; Blennow K, 2003, LANCET NEUROL, V2, P605, DOI 10.1016/S1474-4422(03)00530-1; Coleman RE, 2005, NEUROIMAG CLIN N AM, V15, P837, DOI 10.1016/j.nic.2005.09.007; Delacourte A, 2002, NEUROLOGY, V59, P398, DOI 10.1212/WNL.59.3.398; Denis A, 2017, MED NUCL, V41, P299, DOI 10.1016/j.mednuc.2017.06.008; Dubois B, 2007, LANCET NEUROL, V6, P734, DOI 10.1016/S1474-4422(07)70178-3; Dubois B, 2014, LANCET NEUROL, V13, P614, DOI 10.1016/S1474-4422(14)70090-0; Dupont AC, 2017, MED NUCL, V41, P27, DOI 10.1016/j.mednuc.2016.12.002; Gosche KM, 2002, NEUROLOGY, V58, P1476, DOI 10.1212/WNL.58.10.1476; Herukka SK, 2017, ALZHEIMERS DEMENT, V13, P285, DOI 10.1016/j.jalz.2016.09.009; Ikonomovic MD, 2008, BRAIN, V131, P1630, DOI 10.1093/brain/awn016; Jack CR, 2011, ARCH NEUROL-CHICAGO, V68, P1526, DOI 10.1001/archneurol.2011.183; Josephs KA, 2006, BRAIN, V129, P1385, DOI 10.1093/brain/awl078; Lebouvier T, 2017, CURR OPIN NEUROL, V30, P589, DOI 10.1097/WCO.0000000000000502; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; Mendez MF, 2012, AM J ALZHEIMERS DIS, V27, P413, DOI 10.1177/1533317512454711; Rohrer JD, 2012, NEUROBIOL AGING, V33, P744, DOI 10.1016/j.neurobiolaging.2010.05.020; Sarazin M, 2007, NEUROLOGY, V69, P1859, DOI 10.1212/01.wnl.0000279336.36610.f7; Schneider LS, 2010, ALZHEIMERS DEMENT, V6, P367, DOI 10.1016/j.jalz.2010.07.004; Semah F, 2016, MED NUCL, V40, P364, DOI 10.1016/j.mednuc.2016.08.001; Tapiola T, 2009, ARCH NEUROL-CHICAGO, V66, P382, DOI 10.1001/archneurol.2008.596; van der Flier WM, 2011, LANCET NEUROL, V10, P280, DOI 10.1016/S1474-4422(10)70306-9; Vercruysse O, 2018, CURR ALZHEIMER RES; Villemagne VL, 2018, NAT REV NEUROL	26	0	0	0	1	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	MAY-JUN	2018	42	3					185	189		10.1016/j.mednuc.2018.03.131			5	Pathology	Pathology	GI1AS	WOS:000434102200003					2019-10-28	
J	Semah, F				Semah, F.			Molecular imaging of Alzheimer's disease	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Review						Positron emission tomography; FDG; Amyloid	FRONTOTEMPORAL DEMENTIA; F-18-FDG PET; LEWY BODIES; FDG-PET; DIAGNOSIS; MRI; SPECT	Molecular imaging plays an important role in the diagnosis of patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. Positron emission tomography with FDG is the major technique used for clinical routine. The role of amyloid agents needs to be evaluated as diagnostic procedure. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Semah, F.] CHU Lille, Serv Med Nucl, F-59000 Lille, France; [Semah, F.] INSERM, U1171, F-59000 Lille, France	Semah, F (reprint author), CHU Lille, Serv Med Nucl, F-59000 Lille, France.; Semah, F (reprint author), INSERM, U1171, F-59000 Lille, France.	franck.semah@chru-lille.fr					BEAURAIN J, 1994, MAGN RESON IMAGING, V12, P139, DOI 10.1016/0730-725X(94)92361-2; Bombois S, 2008, STROKE, V39, P2046, DOI 10.1161/STROKEAHA.107.505206; Bombois S, 2013, CURR ALZHEIMER RES, V10, P357, DOI 10.2174/1567205011310040002; DELEON MJ, 1983, AM J NEURORADIOL, V4, P553; Denis A, 2017, MED NUCL, V41, P299, DOI 10.1016/j.mednuc.2017.06.008; Duara R, 2008, NEUROLOGY, V71, P1986, DOI 10.1212/01.wnl.0000336925.79704.9f; Dupont AC, 2017, MED NUCL, V41, P27, DOI 10.1016/j.mednuc.2016.12.002; Dupont AC, 2016, MED NUCL, V40, P72, DOI 10.1016/j.mednuc.2016.01.001; Foster NL, 2007, BRAIN, V130, P2616, DOI 10.1093/brain/awm177; Frisoni GB, 2013, NEUROLOGY, V81, P487, DOI 10.1212/WNL.0b013e31829d86e8; Gelosa G, 2012, EUR J NUCL MED MOL I, V39, P1207, DOI 10.1007/s00259-012-2108-x; Herholz K, 2011, LANCET NEUROL, V10, P667, DOI 10.1016/S1474-4422(11)70123-5; Jack CR, 2013, NEUROLOGY, V80, P890, DOI 10.1212/WNL.0b013e3182840bbe; JACK CR, 1995, MAGN RESON IMAGING, V13, P1057, DOI 10.1016/0730-725X(95)02013-J; Koric L, 2016, REV NEUROL-FRANCE, V172, P725, DOI 10.1016/j.neurol.2016.10.009; Le Bouc R, 2012, BRAIN, V135, P3026, DOI 10.1093/brain/aws237; Lenfant P, 2011, MED NUCL, V35, P136, DOI 10.1016/j.mednuc.2011.01.005; McKeith I, 2007, LANCET NEUROL, V6, P305, DOI 10.1016/S1474-4422(07)70057-1; O'Brien JT, 2014, J NUCL MED, V55, P1959, DOI 10.2967/jnumed.114.143347; O'Brien JT, 2004, ARCH NEUROL-CHICAGO, V61, P919, DOI 10.1001/archneur.61.6.919; Sabri O, 2015, ALZHEIMERS DEMENT; Semah F, 2016, MED NUCL, V40, P364, DOI 10.1016/j.mednuc.2016.08.001; Theysohn JM, 2011, J MAGN RESON IMAGING, V33, P782, DOI 10.1002/jmri.22513; Tosun D, 2013, ANN NEUROL; Vanhoutte M, 2017, NEUROBIOL AGING, V59, P184, DOI 10.1016/j.neurobiolaging.2017.08.009; Verclytte S, 2016, J NEUROIMAGING, V26, P207, DOI 10.1111/jon.12264	26	0	0	1	5	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	MAY-JUN	2018	42	3					190	193		10.1016/j.mednuc.2018.03.132			4	Pathology	Pathology	GI1AS	WOS:000434102200004					2019-10-28	
J	Imbert, L				Imbert, L.			Overview on whole body CZT cameras: The key points for the physicist	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Review						CZT; Whole body; Performance; Quality image	MYOCARDIAL-PERFUSION SPECT; PERFORMANCE; SYSTEM	Whole body CZT cameras might clearly enhance single photon emission imaging not only through the optimization of acquisition protocols but also through the development of SPECT tracers with the objective of reaching an image quality comparable to that of PET imaging but with much lower costs and technical constraints. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Imbert, L.] Inst Cancerol Lorraine, F-54000 Nancy, France; [Imbert, L.] CHRU Nancy, Plateforme Nancyclotep, Rue Morvan, F-54500 Vandoeuvre Les Nancy, France; [Imbert, L.] Univ Lorraine, INSERM, UMR IADI 1254, F-54000 Nancy, France	Imbert, L (reprint author), Inst Cancerol Lorraine, F-54000 Nancy, France.; Imbert, L (reprint author), CHRU Nancy, Plateforme Nancyclotep, Rue Morvan, F-54500 Vandoeuvre Les Nancy, France.; Imbert, L (reprint author), Univ Lorraine, INSERM, UMR IADI 1254, F-54000 Nancy, France.	l.imbert@chru-nancy.fr					Bocher M, 2010, EUR J NUCL MED MOL I, V37, P1887, DOI 10.1007/s00259-010-1488-z; Erlandsson K, 2009, PHYS MED BIOL, V54, P2635, DOI 10.1088/0031-9155/54/9/003; Imbert L, 2016, J NUCL CARDIOL, V23, P894, DOI 10.1007/s12350-015-0216-2; Imbert L, 2012, J NUCL MED, V53, P1897, DOI 10.2967/jnumed.112.107417; Slomka PJ, 2009, J NUCL CARDIOL, V16, P255, DOI 10.1007/s12350-009-9052-6; Tissot H, 2017, MED NUCL, V41, P83, DOI 10.1016/j.mednuc.2017.02.008	6	1	1	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	MAY-JUN	2018	42	3					194	195		10.1016/j.mednuc.2018.03.133			2	Pathology	Pathology	GI1AS	WOS:000434102200005					2019-10-28	
J	Hutton, BF				Hutton, B. F.			Introduction aux cameras TEP-TDM digitales	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			English	Editorial Material						Digital PET/CT	RECONSTRUCTION; ATTENUATION; TIME		[Hutton, B. F.] UCL, Inst Nucl Med, Level 5,Univ Coll 235 Euston Rd, London NW1 2BU, England	Hutton, BF (reprint author), UCL, Inst Nucl Med, Level 5,Univ Coll 235 Euston Rd, London NW1 2BU, England.	b.hutton@ucl.ac.uk			Siemens Healthineers; GE HealthcareGE Healthcare	The author has no competing interest, but acknowledges research support from Siemens Healthineers and GE Healthcare and previous collaboration with Mediso and Spectrum Dynamics.	Bertolli O, 2016, P IEEE NUCL SCI S ME, DOI [10.1109/NSSMIC.2016.8069426, DOI 10.1109/NSSMIC.2016.8069426]; Bousse A, 2016, PHYS MED BIOL, V61, pL11, DOI 10.1088/0031-9155/61/3/L11; Casey M, 2017, EUR J NUCL MED MOL I, V44, pS303; Cherry SR, 2018, J NUCL MED, V59, P3, DOI 10.2967/jnumed.116.184028; Delso G, 2014, EJNMMI PHYS, V1, DOI 10.1186/2197-7364-1-7; Delso G, 2011, J NUCL MED, V52, P1914, DOI 10.2967/jnumed.111.092726; Hutton BF, 2018, BRIT J RADIOL, V91, DOI 10.1259/bjr.20160690; Liu Z, 2016, J INSTRUM, V1; Rezaei A, 2012, IEEE T MED IMAGING, V31, P2224, DOI 10.1109/TMI.2012.2212719; Surti S, 2011, PHYS MED BIOL, V56, P2667, DOI 10.1088/0031-9155/56/9/002; Tashima H, 2016, PHYS MED BIOL, V61, P7295; Yang J, 2014, MED PHYS, V41	12	0	0	0	1	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	MAY-JUN	2018	42	3					196	197		10.1016/j.mednuc.2018.03.134			2	Pathology	Pathology	GI1AS	WOS:000434102200006					2019-10-28	
J	Singh, V; Eldin, K; Timmons, C; Bush, J; Rabah, R				Singh, Vivekanand; Eldin, Karen; Timmons, Charles; Bush, Jonathan; Rabah, Raja			Pediatric Pathology Fellowship Recruitment-Report of a Survey Conducted by the Fellowship Committee of the Society for Pediatric Pathology	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						pediatric pathology; fellowship; recruitment; training; job; vacancy	RESIDENTS	Pediatric pathology (PP) is a subspecialty of pathology encompassing disease states during human development from the fetus to the young adult. Despite the existence of ACGME-accredited fellowship programs and opportunity for pediatric pathology subspecialty board certification, many pediatric pathology fellowship positions remain unfilled in North America. We sought to understand the difficulties in recruitment to the PP training programs by conducting a survey. A 3-pronged survey targeting pathology residents (PR), PP fellows and recent fellowship graduates (F&G), and PP training programs was conducted. Three separate questionnaires were prepared, one for each group; and administered online via SurveyMonkey. There were 175 responses to PR survey, 29 to F&G and 19 to programs survey. The results of the PR and F&G survey revealed that trainees select a subspecialty early in their residency training, primarily based on their interest, followed by prospects of employment. Nearly half of resident respondents had discounted pediatric pathology subspecialty training without prior exposure to the specialty. Senior residents and faculty members were reported as the main source for fellowship information for residents choosing subspecialty training and the choice of the training program was mostly dictated by geographic location. Most fellow recruits are racially diverse, female, and American medical graduates. Pathology residents decide on subspecialty training based on their interest; however, many are not exposed to pediatric pathology early on in training. The survey results suggest that existing PP fellowship positions likely will continue to exceed demand for subspecialty training. The results of the study could aid in developing strategies to boost recruitment to PP.	[Singh, Vivekanand] Childrens Mercy Hosp, Dept Pathol & Lab Med, 2401 Gillham Rd, Kansas City, MO 64108 USA; [Eldin, Karen] Texas Childrens Hosp, Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Timmons, Charles] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Childrens Med Ctr, Dallas, TX USA; [Bush, Jonathan] Childrens & Womens Hosp BC, Vancouver, BC, Canada; [Rabah, Raja] CS Mott Childrens Hosp, Dept Pathol, Ann Arbor, MI USA; [Rabah, Raja] Univ Michigan, Med Ctr, Ann Arbor, MI USA	Singh, V (reprint author), Childrens Mercy Hosp, Dept Pathol & Lab Med, 2401 Gillham Rd, Kansas City, MO 64108 USA.	vsingh@cmh.edu		Bush, Jonathan/0000-0001-9432-2390			Bernacki KD, 2012, AM J CLIN PATHOL, V137, P543, DOI 10.1309/AJCP2YNIJ0ZPMJNE; Comstock J, 2015, PEDIATR DEVEL PATHOL, V18, P257, DOI 10.2350/15-02-1608-LET.1; Eldin K, 2009, PEDIAT DEV PATHOL, V12, P30; Lagwinski N, 2009, ARCH PATHOL LAB MED, V133, P1431, DOI 10.1043/1543-2165-133.9.1431; Robboy SJ, 2013, ARCH PATHOL LAB MED, V137, P1723, DOI 10.5858/arpa.2013-0200-OA	5	0	0	0	0	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	MAY-JUN	2018	21	3					279	284		10.1177/1093526617722905			6	Pathology; Pediatrics	Pathology; Pediatrics	GI7NL	WOS:000434689100001	28840791				2019-10-28	
J	Di Guglielmo, MD; Perdue, L; Adeyemi, A; van Golen, KL; Corao, DU				Di Guglielmo, Matthew D.; Perdue, Lacey; Adeyemi, Adebowale; van Golen, Kenneth L.; Corao, Diana U.			Immunohistochemical Staining for Uroguanylin, a Satiety Hormone, is Decreased in Intestinal Tissue Specimens From Female Adolescents With Obesity	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						gastrointestinal; pediatric; basic research; PediPath; metabolic; endocrine	EATING SELF-REGULATION; GASTROINTESTINAL HORMONES; ENTEROENDOCRINE CELLS; COLORECTAL-CANCER; CHILDHOOD OBESITY; WEIGHT STATUS; CHILDREN; PREVENTION; GHRELIN; AXIS	Gastrointestinal tract-secreted satiety hormones play a significant role in one of the largest health-care challenges for children and adults, obesity. Recent studies in mice identified a novel role for uroguanylin, the endogenous intestinal hormone that binds guanylyl cyclase C (GUCY2C), in regulating satiety via a gut-brain signaling pathway. Mice bred without GUCY2C receptors over-ate and developed obesity. We hypothesized that intestinal uroguanylin expression in pediatric patients with obesity would be lower than patients without obesity, and we attempted to examine the difference with immunohistochemistry. Retrospective chart review of gastrointestinal endoscopic procedures at an academic children's hospital identified patients with normal pathology findings on biopsy. Children aged 8-17 were included in the review; we analyzed biopsy samples from 20 matched pairs that differed only by body mass index (BMI)-for-age (average: 25%-75% vs. high: >95%). Biopsies of the duodenum, terminal ileum, ascending colon, and descending colon were subjected to immunohistochemistry for GUCY2C, uroguanylin, and the endogenous colonic hormone, guanylin. Intensity staining of all specimens was scored by a blinded pathologist. The overall staining intensity for females with high BMI-for-age was less for uroguanylin and guanylin as compared to average BMI-for-age females while GUCY2C staining was equal. Males did not exhibit different staining intensities for uroguanylin or guanylin. More matched female pairs had greater uroguanylin and guanylin staining in the average BMI-for-age cohort. The intestinal expression of uroguanylin, a key satiety hormone, appears to be diminished in female pediatric patients in the setting of obesity.	[Di Guglielmo, Matthew D.; Adeyemi, Adebowale] Nemours Alfred I duPont Hosp Children, Dept Pediat, Wilmington, DE 19803 USA; [Perdue, Lacey] Univ Delaware, Dept Biomed Engn, Newark, DE USA; [van Golen, Kenneth L.] Univ Delaware, Dept Mol Biosci, Newark, DE USA; [Corao, Diana U.] Nemours Alfred I duPont Hosp Children, Dept Pathol, Wilmington, DE 19803 USA	Di Guglielmo, MD (reprint author), Nemours Alfred I duPont Hosp Children, Div Gastroenterol & Nutr, 1600 Rockland Rd, Wilmington, DE 19803 USA.	Matthew.DiGuglielmo@nemours.org		Di Guglielmo, Matthew/0000-0001-9853-0437	Institutional Development Award from the National Institute of General Medical Sciences of the National Institutes of Health [U54-GM104941]; Nemours Summer Undergraduate Research Scholars Program	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by an Institutional Development Award from the National Institute of General Medical Sciences of the National Institutes of Health under grant number U54-GM104941 (PI: S. Binder-Macleod). The authors wish to acknowledge the Nemours Summer Undergraduate Research Scholars Program which supported one of the co-authors (LP).	Bascietto C, 2012, J PEDIATR ENDOCR MET, V25, P255, DOI 10.1515/jpem-2011-0478; Birch LL, 2014, AM J CLIN NUTR, V99, p723S, DOI 10.3945/ajcn.113.069047; Birch LL, 1998, PEDIATRICS, V101, P539; Blake-Lamb TL, 2016, AM J PREV MED, V50, P780, DOI 10.1016/j.amepre.2015.11.010; Blaut M, 2015, P NUTR SOC, V74, P227, DOI 10.1017/S0029665114001700; Blomain ES, 2016, MOL PHARMACOL, V90, P199, DOI 10.1124/mol.115.103192; Blomain ES, 2016, EXPERT REV ANTICANC, V16, P465, DOI 10.1586/14737140.2016.1162102; Boutelle KN, 2014, APPETITE, V76, P95, DOI 10.1016/j.appet.2014.01.076; Brown CL, 2015, PEDIATR CLIN N AM, V62, P1241, DOI 10.1016/j.pcl.2015.05.013; Brown CL, 2016, OBESITY, V24, P446, DOI 10.1002/oby.21370; Connaughton RM, 2016, P NUTR SOC, V3, P1; Daniels SR, 2015, PEDIATRICS, V136, pE275, DOI 10.1542/peds.2015-1558; Dewey KG, 2001, PEDIATR CLIN N AM, V48, P87, DOI 10.1016/S0031-3955(05)70287-X; Egerod KL, 2012, ENDOCRINOLOGY, V153, P5782, DOI 10.1210/en.2012-1595; Faith MS, 2013, HUM HERED, V75, P80, DOI 10.1159/000353879; Folgueira C, 2016, EUR J NUTR, V55, P529, DOI 10.1007/s00394-015-0869-2; Folgueira C, 2016, DIABETES, V65, P421, DOI 10.2337/db15-0889; Fruhbeck G, 2012, NAT REV ENDOCRINOL, V8, P5, DOI 10.1038/nrendo.2011.206; Gortmaker SL, 2014, NEW ENGL J MED, V370, P475, DOI 10.1056/NEJMe1315169; Guedes TP, 2015, SURG OBES RELAT DIS, V11, P1323, DOI 10.1016/j.soard.2015.02.011; Horner K, 2015, APPL PHYSIOL NUTR ME, V40, P1089, DOI 10.1139/apnm-2015-0050; Hughes SO, 2015, APPETITE, V89, P1, DOI 10.1016/j.appet.2015.01.009; Huh SY, 2011, PEDIATRICS, V127, pE544, DOI 10.1542/peds.2010-0740; Ip Edward Haksing, 2016, BMC Obes, V3, P9, DOI 10.1186/s40608-016-0090-8; Kim GW, 2016, NUTR DIABETES, V6, DOI 10.1038/nutd.2016.18; Lin JRE, 2016, CANCER RES, V76, P339, DOI 10.1158/0008-5472.CAN-15-1467-T; Lomenick JP, 2008, OBESITY, V16, P547, DOI 10.1038/oby.2007.129; Lomenick JP, 2009, J CLIN ENDOCR METAB, V94, P4463, DOI 10.1210/jc.2009-0949; Lumeng JC, 2015, JAMA PEDIATR, V169, P484, DOI 10.1001/jamapediatrics.2014.3554; McAllister EJ, 2009, CRIT REV FOOD SCI, V49, P868, DOI 10.1080/10408390903372599; Moran GW, 2012, J CROHNS COLITIS, V6, P871, DOI 10.1016/j.crohns.2012.01.013; Ogden CL, 2014, JAMA-J AM MED ASSOC, V311, P806, DOI 10.1001/jama.2014.732; Ramanathan ASK, 2016, J FAM COMMUNITY MED, V23, P38, DOI 10.4103/2230-8229.172232; Rau TT, 2013, J PHYSIOL PHARMACOL, V64, P719; Rodriguez A, 2016, INT J OBESITY, V40, P1405, DOI 10.1038/ijo.2016.66; Scaglioni S, 2011, AM J CLIN NUTR, V94, p2006S, DOI 10.3945/ajcn.110.001685; Seeley RJ, 2011, J CLIN INVEST, V121, P3384, DOI 10.1172/JCI58297; Singhal A, 2007, OBES REV, V8, P51, DOI 10.1111/j.1467-789X.2007.00318.x; Spieker EA, 2016, PRIMARY CARE, V43, P83, DOI 10.1016/j.pop.2015.08.013; Taut D, 2015, APPL PSYCHOL-HLTH WE, V7, P4, DOI 10.1111/aphw.12035; Taveras EM, 2009, PEDIATRICS, V123, P1177, DOI 10.1542/peds.2008-1149; Valentino MA, 2011, J CLIN INVEST, V121, P3578, DOI 10.1172/JCI57925; Voss JD, 2015, REV MED VIROL, V25, P379, DOI 10.1002/rmv.1852; Woo Baidal JA, 2016, AM J PREV MED, V15	44	3	3	0	3	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	MAY-JUN	2018	21	3					285	295		10.1177/1093526617722912			11	Pathology; Pediatrics	Pathology; Pediatrics	GI7NL	WOS:000434689100002	28847213	Green Accepted			2019-10-28	
J	Wang, AA; Ernst, LM; Miller, ES				Wang, Ann A.; Ernst, Linda M.; Miller, Emily S.			Basal Plate Myometrial Fibers and Hypertensive Disorders of Pregnancy: A Case-Control Study	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						placenta; basal plate myometrial fibers; preeclampsia; hypertension; pregnancy; spiral arteries; vascular; fetal; pathology	PLACENTA-ACCRETA; TROPHOBLAST INVASION; GROWTH-RETARDATION; RISK	Introduction: Basal plate myometrium (BPMYO), the pathological presence of myometrial fibers in the basal plate, is a common finding on pathological examination of the placenta, yet its clinical correlates are not well studied. As myometrial fibers are frequently located in proximity to poorly converted maternal spiral arteries, our objective was to determine whether BPMYO is associated with hypertensive disorders of pregnancy (HDP), a well-known clinical sequela of abnormal maternal artery remodeling. Methods: This case-control study included women who delivered a live-born singleton gestation whose placentas were sent for pathological examination. Cases were women with HDP (gestational hypertension, preeclampsia, or HELLP syndrome) as defined by American College of Obstetricians and Gynecologists. Controls were women without HDP. Women with chronic hypertension were excluded. The primary outcome was the presence of BPMYO. Secondary outcomes included the pathologic stage of BPMYO and the incidence of pathologically defined accreta. Each outcome was compared between cases and controls in bivariable and multivariable analyses. Results: Of the 306 women who met inclusion criteria, 230 (75%) had HDP. BPMYO was present in 99 (32%) of placentas. Compared to controls, cases were younger, had higher body mass index, and were more likely to have diabetes, be nulliparous, deliver preterm, and have had a prior cesarean. There were no differences in the incidence of BPMYO, stage of BPMYO, or incidence of pathologically defined accreta between cases and controls. These findings persisted after controlling for potential confounders. Conclusions: Although BPMYO may be more common in the setting of abnormal placental vasculature, there is no significant association between BPMYO and HDP.	[Wang, Ann A.; Ernst, Linda M.; Miller, Emily S.] Northwestern Univ, Feinberg Sch Med, Arthur J Rubloff Bldg,420 E Super St, Chicago, IL 60611 USA; [Ernst, Linda M.] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; [Miller, Emily S.] Northwestern Univ, Dept Obstet & Gynecol, Feinberg Sch Med, Chicago, IL 60611 USA	Wang, AA (reprint author), Northwestern Univ, Feinberg Sch Med, Arthur J Rubloff Bldg,420 E Super St, Chicago, IL 60611 USA.	ann.wang@northwestern.edu					BROSENS I, 1977, BRIT J OBSTET GYNAEC, V84, P656; Brosens I A, 1972, Obstet Gynecol Annu, V1, P177; Kaufmann P, 2003, BIOL REPROD, V69, P1, DOI 10.1095/biolreprod.102.014977; Khong TY, 2001, AM J CLIN PATHOL, V116, P703; Linn RL, 2015, PLACENTA, V36, P1419, DOI 10.1016/j.placenta.2015.10.004; Miller ES, 2016, BJOG-INT J OBSTET GY, V123, P2140, DOI 10.1111/1471-0528.13579; Sherer DM, 1996, OBSTET GYNECOL, V87, P444, DOI 10.1016/0029-7844(95)00426-2; Stanek J, 2007, PEDIATR DEVEL PATHOL, V10, P266, DOI 10.2350/06-10-0174.1	8	0	0	0	2	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	MAY-JUN	2018	21	3					296	299		10.1177/1093526617730185			4	Pathology; Pediatrics	Pathology; Pediatrics	GI7NL	WOS:000434689100003	28893157				2019-10-28	
J	Xu, M; Chisholm, KM; Fan, G; Stevens, AM; Rutledge, JC				Xu, Min; Chisholm, Karen M.; Fan, Guang; Stevens, Anne M.; Rutledge, Joe C.			Hematoxylin Bodies in Pediatric Bone Marrow Aspirates and their Utility in the Diagnosis of Systemic Lupus Erythematosus	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						hemotoxylin bodies; bone marrow; systemic lupus erythematosus; antinuclear antibodies; anti-double stranded DNA; lupus nephritis	PLEURAL EFFUSION; LE CELLS; CLASSIFICATION; CRITERIA; FLUIDS	In our recent case report, the finding of lupus erythematosus (LE) cells in a bone marrow aspirate led to the diagnosis of systemic lupus erythematosus (SLE) and appropriate treatment, although the patient was not clinically suspected to have SLE. To determine whether LE cells are present in the bone marrow aspirates of SLE patients, but overlooked in routine bone marrow morphology review, bone marrow aspirates from 30 pediatric patients (15 with SLE and 15 with other diagnoses) evaluated by rheumatologists were reviewed. LE cells were found in the bone marrow aspirates of only I SLE patient and none in non-SLE patients. However, hematoxylin bodies were identified in 53% (8/15) of SLE patients. Neither hematoxylin bodies nor LE cells were found in the aspirates from patients with other disorders. Three additional pediatric patients identified prospectively were found to have hematoxylin bodies in the bone marrow aspirates. Although the diagnosis was not initially suspected, 2 of the 3 patients were subsequently diagnosed with SLE. All patients with hematoxylin bodies and SLE had antinuclear antibody titers >= 1:640 with a homogeneous staining pattern. In addition, bone marrow aspirates of 9 adult patients were reviewed, and neither LE cells nor hematoxylin bodies were identified. In summary, hematoxylin bodies were present in the bone marrow aspirates of many pediatric SLE patients, while LE cells were rare. The finding of hematoxylin bodies in pediatric bone marrow aspirates is a helpful and specific diagnostic clue that may lead to the diagnosis of SLE when other clinical features are nonspecific.	[Xu, Min; Chisholm, Karen M.; Rutledge, Joe C.] Seattle Childrens Hosp, Dept Labs, OC 8-731,4800 Sand Point Way NE, Seattle, WA 98105 USA; [Xu, Min; Chisholm, Karen M.; Rutledge, Joe C.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; [Fan, Guang] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR USA; [Stevens, Anne M.] Seattle Childrens Hosp, Div Pediat Rheumatol, Seattle, WA 98105 USA; [Stevens, Anne M.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Stevens, Anne M.] Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, Seattle, WA USA	Xu, M (reprint author), Seattle Childrens Hosp, Dept Labs, OC 8-731,4800 Sand Point Way NE, Seattle, WA 98105 USA.	min.xu@seattlechildrens.org		Chisholm, Karen/0000-0002-1898-1252			Altit G, 2012, JCR-J CLIN RHEUMATOL, V18, P273, DOI 10.1097/RHU.0b013e3182642527; ARTERBERRY JD, 1964, JAMA-J AM MED ASSOC, V187, P389, DOI 10.1001/jama.1964.03060190005001; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Chan JKC, 2014, INT J SURG PATHOL, V22, P12, DOI 10.1177/1066896913517939; Chang WT, 2013, J MICROBIOL IMMUNOL, V46, P139, DOI 10.1016/j.jmii.2011.12.032; DUBOES EDMUND L., 1954, CALIFORNIA MED, V80, P154; FRIES JF, 1973, ANN RHEUM DIS, V32, P171, DOI 10.1136/ard.32.2.171; Gulhane S, 2012, J CYTOL, V29, P77, DOI 10.4103/0970-9371.93232; Hakkim A, 2010, P NATL ACAD SCI USA, V107, P9813, DOI 10.1073/pnas.0909927107; HARGRAVES MM, 1948, P STAFF M MAYO CLIN, V23, P25; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; Park JY, 2007, DIAGN CYTOPATHOL, V35, P806, DOI 10.1002/dc.20758; Petri M, 2012, ARTHRITIS RHEUM-US, V64, P2677, DOI 10.1002/art.34473; Pujani M, 2013, ACTA CYTOL, V57, P652, DOI 10.1159/000354966; Schmidt-Acevedo S, 2000, J AUTOIMMUN, V15, P15, DOI 10.1006/jaut.2000.0381; Smith CK, 2015, CURR OPIN RHEUMATOL, V27, P448, DOI 10.1097/BOR.0000000000000197; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; Tay SH, 2015, INT J RHEUM DIS, V18, P99, DOI 10.1111/1756-185X.12546; Voulgarelis M, 2006, AM J HEMATOL, V81, P590, DOI 10.1002/ajh.20593; Xu M, 2016, PEDIATR DEVEL PATHOL, V19, P424, DOI 10.2350/15-08-1695-CR.1; Yu C, 2014, J AUTOIMMUN, V48-49, P10, DOI 10.1016/j.jaut.2014.01.004; Zhuang HY, 2014, ARTHRITIS RHEUMATOL, V66, P140, DOI 10.1002/art.38189	22	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	MAY-JUN	2018	21	3					300	307		10.1177/1093526617734948			8	Pathology; Pediatrics	Pathology; Pediatrics	GI7NL	WOS:000434689100004	28990859				2019-10-28	
J	Campbell, J; Armstrong, K; Palaniappan, N; Maher, E; Glancy, M; Porteous, M; Mckenzie, KJ; Evans, MJ				Campbell, Jamie; Armstrong, Kristy; Palaniappan, Nithiya; Maher, Eddy; Glancy, Mary; Porteous, Mary; Mckenzie, Kathryn J.; Evans, Margaret J.			In a Genomic Era, Placental Pathology Still Holds the Key in the Nondysmorphic Stillbirth	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						intrauterine growth restriction; microarray; placenta; stillbirth; postmortem; nondysmorphic	FETAL-GROWTH RESTRICTION; GESTATIONAL-AGE; PREGNANCY LOSS; FOOT LENGTH; AUTOPSY; DEATH; CLASSIFICATION; MICROARRAYS; POSTMORTEM; CONSENSUS	Objective: To explore the relative utility of genetic testing in contrast to placental pathology in explaining causation of death in the structurally normal stillborn population. Methods: A retrospective review of a structurally normal stillborn infant cohort in South East Scotland between 2011 and 2015, defined by death at or after 24 weeks of gestation. We reviewed pathology reports and collected demographic data on cases. This information was collated with genetic test results (quantitative fluorescent polymerase chain reaction and microarray analysis) and placental pathology to create a database for analysis. Primary Results: Within the structurally normal population (n= 131), there were 125 genetic tests performed and 11 abnormal results. Sixty-six microarray analyses were performed, and 2 (3%) of the results were thought likely to reflect cause of stillbirth (I case of incomplete trisomy 4 and I case of deletion of chromosome Xp in a female). Analysis was significantly limited in 2 cases as parental samples were not available. The placental pathology was available in a total of 129 cases; significant findings were identified in 100 cases; 79 (61%) showed changes that were considered to have caused death (including cord "accidents"), and a further 21 (16%) showed findings likely to influence the management of subsequent pregnancies. Conclusions: We reaffirm the utility of placental examination in the investigation of stillbirth. In cases of nondysmorphic stillbirth where placental pathology does not explain the cause of stillbirth, microarray analysis of fetal DNA can add further diagnostic information in 3% of cases but can add further diagnostic confusion, and it is important that parental bloods are taken to minimize this risk.	[Campbell, Jamie; Porteous, Mary] Western Gen Hosp, Dept Clin Genet, Edinburgh, Midlothian, Scotland; [Armstrong, Kristy; Mckenzie, Kathryn J.; Evans, Margaret J.] Royal Infirm Edinburgh NHS Trust, Dept Pathol, Edinburgh, Midlothian, Scotland; [Palaniappan, Nithiya] Royal Infirm Edinburgh NHS Trust, Dept Obstet & Gynaecol, Edinburgh, Midlothian, Scotland; [Maher, Eddy; Glancy, Mary] Western Gen Hosp, Ctr Genom & Expt Med, Cytogenet Labs Serv, Edinburgh, Midlothian, Scotland	Campbell, J (reprint author), Univ Edinburgh, MRC Inst Genet & Mol Med, Western Gen Hosp, Ctr Genom & Expt Med, Crewe Rd South, Edinburgh EH4 2XR, Midlothian, Scotland.	jamie.campbell@nhs.net					Bukowski R, 2011, JAMA-J AM MED ASSOC, V306, P2459, DOI 10.1001/jama.2011.1823; Clausson B, 2001, BRIT J OBSTET GYNAEC, V108, P830, DOI 10.1111/j.1471-0528.2001.00205.x; De Jong CLD, 2000, ULTRASOUND OBST GYN, V15, P36, DOI 10.1046/j.1469-0705.2000.00001.x; Flenady V, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-24; Gardosi J, 2005, BMJ-BRIT MED J, V331, P1113, DOI 10.1136/bmj.38629.587639.7C; GARDOSI J, 1995, ULTRASOUND OBST GYN, V6, P168, DOI 10.1046/j.1469-0705.1995.06030168.x; GARDOSI J, 1992, LANCET, V339, P283, DOI 10.1016/0140-6736(92)91342-6; Goldenberg R L, 2004, J Matern Fetal Neonatal Med, V16, P79; Heazell AEP, 2012, BJOG-INT J OBSTET GY, V119, P987, DOI 10.1111/j.1471-0528.2012.03357.x; Hutchinson JC, 2016, ARCH DIS CHILDHOOD-E, V101, P54, DOI 10.1136/archdischild-2015-309321; Information and Statistics Division NHS Scotland, SCOTT PER INF MORT M; Information Services Division, 2012, SCOTT PER INF MORT M; Kharbanda M, 2015, ARCH DIS CHILDHOOD-E, V100, P24, DOI 10.1136/archdischild-2014-306022; Khong TY, 2016, ARCH PATHOL LAB MED, V140, P698, DOI 10.5858/arpa.2015-0225-CC; Lawn JE, 2016, LANCET, V387, P587, DOI 10.1016/S0140-6736(15)00837-5; MACHIN GA, 1975, J CLIN PATHOL, V28, P428, DOI 10.1136/jcp.28.6.428; Man J, 2016, ULTRASOUND OBST GYN, V48, P566, DOI 10.1002/uog.16016; MERCER BM, 1987, AM J OBSTET GYNECOL, V156, P350, DOI 10.1016/0002-9378(87)90282-1; Mistry H, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-236; Page JM, 2017, OBSTET GYNECOL, V129, P699, DOI [10.1097/AOG.0000000000001937, 10.1097/aog.0000000000001937]; Pasztor N, 2014, FETAL PEDIATR PATHOL, V33, P49, DOI 10.3109/15513815.2013.850132; Pinar H, 2014, OBSTET GYNECOL, V123, P325, DOI 10.1097/AOG.0000000000000100; Ptacek I, 2014, PLACENTA, V35, P552, DOI 10.1016/j.placenta.2014.05.011; Reddy UM, 2012, NEW ENGL J MED, V367, P2185, DOI 10.1056/NEJMoa1201569; Reddy UM, 2012, PRENATAL DIAG, V32, P371, DOI 10.1002/pd.3825; Reddy UM, 2009, OBSTET GYNECOL, V114, P901, DOI 10.1097/AOG.0b013e3181b8f6e4; Redline RW, 2015, AM J OBSTET GYNECOL, V213, pS21, DOI 10.1016/j.ajog.2015.05.056; Rosenfeld JA, 2015, ULTRASOUND OBST GYN, V46, P478, DOI 10.1002/uog.14866; Sahoo T, 2017, GENET MED, V19, P83, DOI 10.1038/gim.2016.69; Salihoglu O, 2016, FETAL PEDIATR PATHOL, V35, P231, DOI 10.3109/15513815.2016.1173749; Sankaran S, 2009, BEST PRACT RES CL OB, V23, P765, DOI 10.1016/j.bpobgyn.2009.05.003; Sebire NJ, 2014, ULTRASOUND OBST GYN, V43, P241, DOI 10.1002/uog.13295; Van Wyk L, 2016, J TROP PEDIATRICS, V62, P144, DOI 10.1093/tropej/fmv093; Wapner RJ, 2010, CLIN OBSTET GYNECOL, V53, P628, DOI 10.1097/GRF.0b013e3181ee2793; Wozniak J, 2009, ARCH PERINAT MED, V15, P215	35	1	1	0	0	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	MAY-JUN	2018	21	3					308	318		10.1177/1093526617733373			11	Pathology; Pediatrics	Pathology; Pediatrics	GI7NL	WOS:000434689100005	28990860				2019-10-28	
J	Powis, Z; Chamberlin, AC; Alamillo, CL; Ceulemans, S; Bird, LM; Tang, S				Powis, Zoe; Chamberlin, Adam C.; Alamillo, Christina L.; Ceulemans, Sophia; Bird, Lynne M.; Tang, Sha			Postmortem Diagnostic Exome Sequencing Identifies a De Novo TUBB3 Alteration in a Newborn With Prenatally Diagnosed Hydrocephalus and Suspected Walker Warburg Syndrome	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						TUBB3 protein; human; exome; clinical diagnostic sequencing; postmortem diagnosis; Walker-Warburg syndrome; abnormal brain; hydrocephalus	MUTATIONS; PREDICTION	Objective: Herein, we report a case of a deceased newborn with prenatally detected hydrocephalus. Postnatal findings included abnormal brain imaging and electroencephalogram, optic nerve abnormalities, and elevated creatine kinase (CK). No underlying genetic etiology had been previously identified for the proband, despite testing with a congenital muscular dystrophy gene panel. Methods: Diagnostic exome sequencing (DES) was performed on the proband-parents trio, and candidate alterations were confirmed using automated fluorescence dideoxy sequencing. Results: Exome sequencing of the proband, mother and father identified a previously unreported apparently de novo heterozygous tubulin, beta-3 (TUBB3) c.523G>C (p.V175L) alteration in the proband. Conclusion: Overall, DES established a likely molecular genetic diagnosis for a postmortem case after traditional testing methods were uninformative. The DES results allowed for reproductive options, such as preimplantation genetic diagnosis and/or prenatal diagnosis, to be available to the parents in future pregnancies.	[Powis, Zoe; Chamberlin, Adam C.; Alamillo, Christina L.; Tang, Sha] Ambry Genet, 15 Argonaut, Aliso Viejo, CA 92656 USA; [Ceulemans, Sophia; Bird, Lynne M.] Rady Childrens Hosp, Div Genet, San Diego, CA USA; [Bird, Lynne M.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA	Powis, Z (reprint author), Ambry Genet, 15 Argonaut, Aliso Viejo, CA 92656 USA.	zpowis@ambrygen.com					Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421; Craddock TJA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037251; Fallet-Bianco C, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-69; Farwell KD, 2015, GENET MED, V17, P578, DOI 10.1038/gim.2014.154; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Kim DE, 2004, NUCLEIC ACIDS RES, V32, pW526, DOI 10.1093/nar/gkh468; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Mignot I, 2012, J BIOL CHEM, V287, P31085, DOI 10.1074/jbc.M112.383869; Niwa S, 2013, EMBO J, V32, P1352, DOI 10.1038/emboj.2013.59; Poirier K, 2010, HUM MOL GENET, V19, P4462, DOI 10.1093/hmg/ddq377; Schymkowitz JWH, 2005, P NATL ACAD SCI USA, V102, P10147, DOI 10.1073/pnas.0501980102; Tischfield MA, 2011, CURR OPIN GENET DEV, V21, P286, DOI 10.1016/j.gde.2011.01.003; Tischfield MA, 2010, CELL, V140, P74, DOI 10.1016/j.cell.2009.12.011	15	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	MAY-JUN	2018	21	3					319	323		10.1177/1093526617698611			5	Pathology; Pediatrics	Pathology; Pediatrics	GI7NL	WOS:000434689100006	29187032				2019-10-28	
J	Dunham, C; McFadden, D; Dahlgren, L; Butler, B; Hamilton, S; McKinnon, M				Dunham, C.; McFadden, D.; Dahlgren, L.; Butler, B.; Hamilton, S.; McKinnon, M.			Congenital Hypothalamic "Hamartoblastoma" Versus "Hamartoma": Suggestions for Neuropathologic Terminology Emanating From a Mid-gestational Autopsy Case of Pallister-Hall Syndrome	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						Pallister-Hall syndrome; congenital hypothalamic hamartoblastoma; hypothalamic hamartoma; GLI3; fetus; autopsy	IMPERFORATE ANUS; GLI3; MUTATIONS; HYPOPITUITARISM; DELINEATION; ANOMALIES; VARIANT	Pallister-Hall syndrome (PHS) is a rare malformative disorder that is due to truncating functional repressor mutations in GLI3. Since the seminal publication in 1980, hypothalamic tumors have been recognized to be a cardinal feature of PHS. In their original description of the neuropathologic features of PHS, Clarren et al. coined the term "hamartoblastoma" to characterize what they deemed to be a dual malformative and neoplastic mass of the hypothalamus. In subsequent published cases/series of PHS, the term "hamartoma" was often substituted for hamartoblastoma given what appeared to be a benign natural history of this lesion. Additional confusion in the literature has ensued since most hypothalamic hamartomas (HH) encountered on the clinical neuropathology service are "isolated" in nature (ie, no other congenital malformations) and present in a very different and stereotypical fashion with gelastic seizures and/or precocious puberty. While genomic investigations of isolated HH have begun to uncover a mutational profile of these cases, GLI3 mutations have only been recognized in a small subset of isolated HH. Herein, we describe the autopsy findings from a 21-week gestational age fetus with features of PHS. Moreover, we provide a detailed description of the hypothalamic tumor affecting this fetus and propose a novel subclassification of HH, distinguishing syndromic from isolated forms based upon the presence or absence of neocortical-like areas.	[Dunham, C.; McFadden, D.] Children & Womens Hlth Ctr BC, Dept Pathol & Lab Med, Vancouver, BC, Canada; [Dahlgren, L.; Butler, B.] Children & Womens Hlth Ctr BC, Dept Obstet & Gynecol, Vancouver, BC, Canada; [Hamilton, S.; McKinnon, M.] Children & Womens Hlth Ctr BC, Dept Med Genet, Vancouver, BC, Canada	Dunham, C (reprint author), Children & Womens Hlth Ctr BC, Div Anat Pathol, 4500 Oak St, Vancouver, BC V6H 3N1, Canada.	cdunham@cw.bc.ca		McKinnon, Margaret/0000-0002-3161-414X			Castori M, 2007, AM J MED GENET A, V143A, P277, DOI 10.1002/ajmg.a.31591; CLARREN SK, 1980, AM J MED GENET, V7, P75, DOI 10.1002/ajmg.1320070111; Coons SW, 2007, J NEUROPATH EXP NEUR, V66, P131, DOI 10.1097/nen.0b013e3180302090; Demurger F, 2015, EUR J HUM GENET, V23, P92, DOI 10.1038/ejhg.2014.62; FINNIGAN DP, 1991, AM J MED GENET, V40, P395, DOI 10.1002/ajmg.1320400403; Graham J M Jr, 1985, Prog Clin Biol Res, V200, P163; Graham J M Jr, 1986, Am J Med Genet Suppl, V2, P53; Haddad-Tovolli R, 2015, FRONT NEUROANAT, V9, DOI 10.3389/fnana.2015.00034; Hall JG, 2016, GENE, V589, P100, DOI 10.1016/j.gene.2016.01.003; HALL JG, 1980, AM J MED GENET, V7, P47, DOI 10.1002/ajmg.1320070110; Hall JG, 2014, AM J MED GENET C, V166, P414, DOI 10.1002/ajmg.c.31419; Hildebrand MS, 2016, AM J HUM GENET, V99, P423, DOI 10.1016/j.ajhg.2016.05.031; HUFF DS, 1982, NEW ENGL J MED, V306, P430; IAFOLLA K, 1989, AM J MED GENET, V33, P489, DOI 10.1002/ajmg.1320330416; Jaiman S, 2012, INDIAN J PATHOL MICR, V55, P100, DOI 10.4103/0377-4929.94873; Kang S, 1997, NAT GENET, V15, P266, DOI 10.1038/ng0397-266; LOW M, 1995, CLIN GENET, V48, P209; Magnani D, 2013, CEREB CORTEX, V23, P2542, DOI 10.1093/cercor/bhs237; McPherson E, 2013, AM J MED GENET A, V161, P2666, DOI 10.1002/ajmg.a.36117; Norman M. G., 1995, CONGENITAL MALFORMAT; PALLISTER PD, 1989, AM J MED GENET, V33, P500, DOI 10.1002/ajmg.1320330417; Quinn JC, 2009, DEV BIOL, V327, P204, DOI 10.1016/j.ydbio.2008.12.008; Rash BG, 2011, DEV BIOL, V359, P242, DOI 10.1016/j.ydbio.2011.08.026; Saitsu H, 2016, ANN CLIN TRANSL NEUR, V3, P356, DOI 10.1002/acn3.300; Saxonhouse MA, 2005, J NEUROSURG, V103, P277, DOI 10.3171/ped.2005.103.3.0277; SILLS IN, 1994, AM J MED GENET, V52, P251, DOI 10.1002/ajmg.1320520231; SILLS IN, 1993, AM J MED GENET, V47, P321, DOI 10.1002/ajmg.1320470305; SQUIRES LA, 1995, PEDIATR NEUROSURG, V22, P303, DOI 10.1159/000120920; Tsugu H, 1998, PEDIATR NEUROSURG, V29, P290, DOI 10.1159/000028739; VERLOES A, 1995, CLIN DYSMORPHOL, V4, P208; Wang H, 2014, CELL REP, V8, P1093, DOI 10.1016/j.celrep.2014.07.006; Yu WY, 2009, DEV BIOL, V334, P264, DOI 10.1016/j.ydbio.2009.07.026	32	0	0	0	1	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	MAY-JUN	2018	21	3					324	331		10.1177/1093526617701338			8	Pathology; Pediatrics	Pathology; Pediatrics	GI7NL	WOS:000434689100007	28429635				2019-10-28	
J	Chen, LN; Espinel, A; Reilly, B; Luca, DC				Chen, Leonard N.; Espinel, Alexandra; Reilly, Brian; Luca, Dragos C.			Extramedullary Hematopoiesis Presenting as Bilateral Glomus Tympanicum-First Case Report in a Pediatric Patient and With Bilateral Presentation	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						extramedullary hematopoiesis; glomus tympanicum; middle ear	MIDDLE-EAR	To the best of our knowledge, this is the first case report of middle ear extramedullary hematopoiesis (EMH) in a pediatric patient as well as the first bilateral presentation reported in both children and adults. We report a 13-year-old African-American female with sickle cell disease who developed bilateral hearing loss, with magnetic resonance imaging findings consistent with bilateral glomus tympanicum (GT). Upon excisional biopsy, however, EMH was diagnosed histologically. Besides its novelty, this case highlights the importance of considering EMH in the differential diagnosis of GT including cases with bilateral presentation that may be otherwise highly suggestive of the familial form of GT.	[Chen, Leonard N.] Medstar Georgetown Univ Hosp, Dept Pathol, Washington, DC USA; [Espinel, Alexandra; Reilly, Brian] Childrens Natl Med Ctr, Dept Otolaryngol, Washington, DC 20010 USA; [Luca, Dragos C.] Childrens Natl Med Ctr, Dept Pathol, 111 Michigan Ave NW, Washington, DC 20010 USA	Luca, DC (reprint author), Childrens Natl Med Ctr, Dept Pathol, 111 Michigan Ave NW, Washington, DC 20010 USA.	dcluca@childrensnational.org					ALFORD BOB R., 1962, LARYNGOSCOPE, V72, P765; APPLEBAUM EL, 1989, AM J OTOLARYNG, V10, P287, DOI 10.1016/0196-0709(89)90010-0; Aronsohn MS, 2003, OTOL NEUROTOL, V24, P963, DOI 10.1097/00129492-200311000-00027; GILTMAN LI, 1986, AM J OTOL, V7, P218; Meara JG, 1998, AM J OTOLARYNG, V19, P287, DOI 10.1016/S0196-0709(98)90134-X; Orphanidou-Vlachou E, 2014, SEMIN ULTRASOUND CT, V35, P255, DOI 10.1053/j.sult.2013.12.001; Sohawon D, 2012, J MED IMAG RADIAT ON, V56, P538, DOI 10.1111/j.1754-9485.2012.02397.x; Sweeney AD, 2015, OTOLARYNG CLIN N AM, V48, P293, DOI 10.1016/j.otc.2014.12.004; TALI ET, 1991, NEURORADIOLOGY, V33, P171, DOI 10.1007/BF00588261	9	0	0	0	0	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	MAY-JUN	2018	21	3					332	334		10.1177/1093526617704267			3	Pathology; Pediatrics	Pathology; Pediatrics	GI7NL	WOS:000434689100008	28488469				2019-10-28	
J	Swarz, JA; Anilkumar, AC; Miller, DC; Litofsky, NS; Tanaka, T				Swarz, Jeffrey A.; Anilkumar, Arayamparambil C.; Miller, Douglas C.; Litofsky, N. Scott; Tanaka, Tomoko			An Unusual Presentation of a Cervical Paraspinal Leiomyoma in an Adolescent Female	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						leiomyoma; cervical spine; Li-Fraumeni Syndrome; hereditary leiomyomatosis and renal cell cancer	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; UTERINE FIBROIDS; MUTATIONS; LEIOMYOSARCOMA; POPULATION; CANCER; TUMORS	Objective: We describe an apparently unique case of an extra-uterine leiomyoma in the cervical paraspinal tissue including its evaluation and management. Methods: A 14-year-old girl was referred to the neurology clinic for an abnormal head CT following a concussion. MRI revealed a homogenously enhancing left cervical paraspinal mass. The patient underwent complete resection and subsequent genetic testing and counseling were obtained to determine the presence of Li-Fraumeni Syndrome (LFS) or Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) mutations. Result: Histopathological examination proved that the tumor was a benign leiomyoma. Genomic testing for Fumarate Hydratase Gene, HLRCC, TP53 mutations or deletions, and LFS sequencing were negative. Further testing showed no immunosuppression. Conclusions: To the best of our knowledge, this is the only case of paraspinal leiomyoma to have been reported to date. We emphasize the importance of considering immunosuppression, LFS, or HLRCC as an underlying cause in extra-uterine leiomyata.	[Swarz, Jeffrey A.] Univ Missouri, Sch Med, Columbia, MO 65212 USA; [Anilkumar, Arayamparambil C.] Univ Missouri, Sch Med, Dept Child Hlth, Pediat Neurol, Columbia, MO 65212 USA; [Miller, Douglas C.] Univ Missouri, Sch Med, Dept Pathol & Anat Sci, Columbia, MO 65212 USA; [Litofsky, N. Scott; Tanaka, Tomoko] Univ Missouri, Sch Med, Div Neurol Surg, One Hosp Dr,MC 321, Columbia, MO 65212 USA	Tanaka, T (reprint author), Univ Missouri, Sch Med, Div Neurol Surg, One Hosp Dr,MC 321, Columbia, MO 65212 USA.	tanakat@health.missouri.edu					Aksoy DY, 2002, SPINE, V27, P301; Alam NA, 2003, HUM MOL GENET, V12, P1241, DOI 10.1093/hmg/ddg148; Anker MC, 2003, AM J MED GENET A, V119A, P381, DOI 10.1002/ajmg.a.20019; Arishima H, 2013, PEDIATR DERMATOL, V30, pe27, DOI 10.1111/j.1525-1470.2011.01719.x; Carney JA, 2009, J CLIN ENDOCR METAB, V94, P3656, DOI 10.1210/jc.2009-1156; Choi SH, 1997, NEUROSURGERY, V40, P1080, DOI 10.1097/00006123-199705000-00038; Kazarin O, 2013, ANN THORAC SURG, V95, P1429, DOI 10.1016/j.athoracsur.2012.08.081; KRANSDORF MJ, 1995, AM J ROENTGENOL, V164, P395, DOI 10.2214/ajr.164.2.7839977; Litofsky NS, 1998, J NEURO-ONCOL, V40, P179, DOI 10.1023/A:1006167629968; Makinen N, 2011, SCIENCE, V334, P252, DOI 10.1126/science.1208930; Malhotra Purnima, 2010, Indian J Dermatol, V55, P337, DOI 10.4103/0019-5154.74535; Park KY, 2007, KOR J SPINE, V4, P134; Peng Y, 2008, MOL CANCER RES, V6, P663, DOI 10.1158/1541-7786.MCR-07-0370; Spitzer AL, 2004, ARCH SURG-CHICAGO, V139, P262, DOI 10.1001/archsurg.139.3.262; Stewart EA, 2001, LANCET, V357, P293, DOI 10.1016/S0140-6736(00)03622-9; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Varley JM, 2003, HUM MUTAT, V21, P313, DOI 10.1002/humu.10185; Ylisaukko-oja SK, 2006, INT J CANCER, V119, P283, DOI 10.1002/ijc.21798	18	1	1	0	0	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	MAY-JUN	2018	21	3					335	340		10.1177/1093526617706815			6	Pathology; Pediatrics	Pathology; Pediatrics	GI7NL	WOS:000434689100009	28429638				2019-10-28	
J	Nair, V; Nigam, JS; Deshpande, AH; Bharti, JN; Patil, NP				Nair, Vivek; Nigam, Jitendra Singh; Deshpande, Archana Hemant; Bharti, Jyotsna Naresh; Patil, Nilesh Prakash			Curious Tale of Human Tail	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Letter							LIPOMA		[Nair, Vivek; Nigam, Jitendra Singh; Deshpande, Archana Hemant; Bharti, Jyotsna Naresh] Andaman & Nicobar Isl Inst Med Sci, Dept Pathol, Port Blair 744104, Andaman & Nicob, India; [Patil, Nilesh Prakash] Andaman & Nicobar Isl Inst Med Sci, Dept Surg, Port Blair, Andaman & Nicob, India	Bharti, JN (reprint author), Andaman & Nicobar Isl Inst Med Sci, Dept Pathol, Port Blair 744104, Andaman & Nicob, India.	jyotsnamamc@gmail.com		BHARTI, JYOTSNA NARESH/0000-0002-5233-8594; NIGAM, JITENDRA SINGH/0000-0003-0725-0494			Donovan DJ, 2005, PEDIATR NEUROSURG, V41, P35, DOI 10.1159/000084863; LEDLEY FD, 1982, NEW ENGL J MED, V306, P1212, DOI 10.1056/NEJM198205203062006; Mukhopadhyay Biswanath, 2012, J Indian Assoc Pediatr Surg, V17, P23, DOI 10.4103/0971-9261.91082; Park SH, 2005, PEDIATR NEUROSURG, V41, P158, DOI 10.1159/000085876; Puvabanditsin S, 2013, J CHILD NEUROL, V28, P124, DOI 10.1177/0883073812439436	5	0	0	0	0	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	MAY-JUN	2018	21	3					341	342		10.1177/1093526617707857			2	Pathology; Pediatrics	Pathology; Pediatrics	GI7NL	WOS:000434689100010	28478738				2019-10-28	
J	Williamson, SR; Hornick, JL; Eble, JN; Gupta, NS; Rogers, CG; True, L; Grignon, DJ; Cheng, L				Williamson, Sean R.; Hornick, Jason L.; Eble, John N.; Gupta, Nilesh S.; Rogers, Craig G.; True, Lawrence; Grignon, David J.; Cheng, Liang			Renal cell carcinoma with angioleiomyoma-like stroma and clear cell papillary renal cell carcinoma: exploring SDHB protein immunohistochemistry and the relationship to tuberous sclerosis complex	HUMAN PATHOLOGY			English	Article						Renal cell carcinoma; Tuberous sclerosis; Succinate dehydrogenase; Clear cell papillary renal cell carcinoma; Immunohistochemistiy	SMOOTH-MUSCLE STROMA; ANGIOMYOADENOMATOUS TUMOR; DISTINCT-ENTITY; FEATURES; CLASSIFICATION	Renal cell carcinoma (RCC) with angioleiomyoma-like stroma appears to be molecularly distinct from clear cell RCC; however, its relationship to clear cell papillary RCC remains debated. Recent studies have found that similar tumors sometimes occur in patients with tuberous sclerosis complex (TSC), of which 1 study found unexpectedly negative succinate dehydrogenase B (SDHB) immunostaining. We evaluated immunohistochemistry for SDHB in 12 apparently sporadic RCCs with angioleiomyoma-like stroma and correlated with clinical information for stigmata of TSC. Tumors were compared with a group of 16 clear cell papillary RCCs and 6 unclassified tumors with prominent stroma. With the exception of 1 unclassified tumor, all exhibited at least focal cytoplasmic staining for SDHB protein, often requiring high magnification and better appreciated with increased antibody concentration. Detailed history information was available for 9 of 11 patients with smooth muscle rich tumors, revealing no stigmata of undiagnosed TSC. Electron microscopy performed on 1 of these tumors revealed mitochondria to be very sparse, potentially accounting for the weak immunohistochemical labeling for SDHB protein. Weak SDHB immunostaining may represent another shared feature of RCC with angioleiomyoma-like stroma and clear cell papillary RCC, likely due to sparse mitochondria, strengthening the possible relationship of these entities. Although smooth muscle rich tumors have been recently reported in patients with TSC, absence of staining in tumors with this pattern may not be specific for TSC. In tumors with pale or clear cytoplasm, immunohistochemical staining for SDHB should be interpreted with caution as evidence of abnormality in the SDH pathway. (C) 2017 Elsevier Inc. All rights reserved.	[Williamson, Sean R.; Gupta, Nilesh S.] Henry Ford Hlth Syst, Dept Pathol & Lab Med, Detroit, MI 48202 USA; [Williamson, Sean R.; Gupta, Nilesh S.] Henry Ford Hlth Syst, Henry Ford Canc Inst, Detroit, MI 48202 USA; [Williamson, Sean R.] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; [Hornick, Jason L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Hornick, Jason L.] Harvard Med Sch, Boston, MA 02115 USA; [Eble, John N.; Grignon, David J.; Cheng, Liang] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 48202 USA; [Rogers, Craig G.] Henry Ford Hlth Syst, Vattikutti Urol Inst, Detroit, MI 48202 USA; [True, Lawrence] Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Williamson, SR (reprint author), Henry Ford Hosp, Dept Pathol, K6,2799 W Grand Blvd, Detroit, MI 48202 USA.	swilli25@hflis.org		Williamson, Sean/0000-0002-3898-1460			Alexiev BA, 2014, PATHOL RES PRACT, V210, P234, DOI 10.1016/j.prp.2013.12.009; Aron M, 2015, AM J SURG PATHOL, V39, P873, DOI 10.1097/PAS.0000000000000446; Barletta JA, 2012, ADV ANAT PATHOL, V19, P193, DOI 10.1097/PAP.0b013e31825c6bc6; Cornejo KM, 2015, HUM PATHOL, V46, P820, DOI 10.1016/j.humpath.2015.02.013; Deml KF, 2015, AM J SURG PATHOL, V39, P889, DOI 10.1097/PAS.0000000000000456; Gill AJ, 2014, AM J SURG PATHOL, V38, P1588, DOI 10.1097/PAS.0000000000000292; Guo J, 2014, AM J SURG PATHOL, V38, P1457, DOI 10.1097/PAS.0000000000000248; Hes O, 2016, ANN DIAGN PATHOL, V21, P59, DOI 10.1016/j.anndiagpath.2015.11.003; Iczkowski KA, 2013, HISTOPATHOLOGY, V62, P522, DOI 10.1111/his.12040; Kuhn E, 2006, AM J SURG PATHOL, V30, P1372, DOI 10.1097/01.pas.0000213277.45715.82; Kuroda N, 2011, ANN DIAGN PATHOL, V15, P202, DOI 10.1016/j.anndiagpath.2010.03.003; Kuroda N, 2009, PATHOL INT, V59, P689, DOI 10.1111/j.1440-1827.2009.02429.x; Michal M, 2000, Ann Diagn Pathol, V4, P311, DOI 10.1053/adpa.2000.17890; Michal M, 2009, VIRCHOWS ARCH, V454, P89, DOI 10.1007/s00428-008-0697-3; Moch H, 2016, WHO CLASSIFICATION T, P14; Peckova K, 2014, ANN DIAGN PATHOL, V18, P291, DOI 10.1016/j.anndiagpath.2014.08.004; Sahni VA, 2012, CUAJ-CAN UROL ASSOC, V6, pE140, DOI 10.5489/cuaj.11072; Sarungbam J, 2016, MODERN PATHOL, V29, p260A; Shannon BA, 2009, HUM PATHOL, V40, P425, DOI 10.1016/j.humpath.2008.05.021; Singh C, 2012, ANN DIAGN PATHOL, V16, P470, DOI 10.1016/j.anndiagpath.2012.01.006; Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1; Srigley JR, 2016, WHO CLASSIFICATION T, P40; Trpkov K, 2017, AM J SURG PATHOL, V41, P1299, DOI 10.1097/PAS.0000000000000838; Trpkov K, 2016, AM J SURG PATHOL, V40, P60, DOI 10.1097/PAS.0000000000000508; Verine J, 2009, VIRCHOWS ARCH, V454, P479, DOI 10.1007/s00428-009-0741-y; Verkarre V, 2015, LAB INVEST, V95, p266A; Williamson S. R., 2016, UROL ONCOL, V34, P292; Williamson SR, 2015, MODERN PATHOL, V28, P279, DOI 10.1038/modpathol.2014.105; Williamson SR, 2015, MODERN PATHOL, V28, P80, DOI 10.1038/modpathol.2014.86; Williamson SR, 2013, MODERN PATHOL, V26, P697, DOI 10.1038/modpathol.2012.204; Yang P, 2014, AM J SURG PATHOL, V38, P895, DOI 10.1097/PAS.0000000000000237; Zhou HJ, 2014, HUM PATHOL, V45, P59, DOI 10.1016/j.humpath.2013.08.004	32	5	5	1	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAY	2018	75						10	15		10.1016/j.humpath.2017.11.013			6	Pathology	Pathology	GI2YQ	WOS:000434238200002	29180251				2019-10-28	
J	Li, CY; Cao, L; Xu, C; Liu, F; Xiang, GM; Liu, XZ; Jiao, J; Niu, Y				Li, Congying; Cao, Lu; Xu, Cong; Liu, Fang; Xiang, Guomin; Liu, Xiaozhen; Jiao, Jiao; Niu, Yun			The immunohistochemical expression and potential prognostic value of HDAC6 and AR in invasive breast cancer	HUMAN PATHOLOGY			English	Article						Histone deacetylase 6; Androgen receptor; Breast cancer; ER-negative breast cancer; Prognosis	ANDROGEN RECEPTOR EXPRESSION; HISTONE DEACETYLASE 6; DISEASE; DIFFERENTIATION; IDENTIFICATION; INHIBITORS; PROTEINS; TUMORS; ROLES	Previous studies have investigated the role of histone deacetylase 6 (HDAC6) in the regulation of androgen receptor (AR) in prostate cancer; however, the role of HDAC6 has not yet been clearly identified in breast cancer. The aim of this study was to examine the expression of HDAC6 and AR, determine the correlation between HDAC6 and AR, and assess the prognostic value of HDAC6 and AR in breast cancer. A total of 228 cases of invasive breast cancer were randomly selected. The expression of HDAC6 and AR was analyzed by immunohistochemistry. chi(2) Tests were performed to determine the association between conventional clinicopathological factors and HDAC6, AR, and HDAC6/AR co-expression. Spearman correlation methods were performed to determine the correlation between HDAC6 and AR, and Kaplan-Meier analyses were performed to determine the prognostic impact of HDAC6, AR and HDAC6/AR co-expression; 58.8% (134/228) patients exhibited high expression of HDAC6. High HDAC6 expression was significantly associated with high histologic grade (G3) (P < .001) and p53 overexpression (P = .002). HDAC6 and AR expression levels were significantly associated (r = 0.382, P < .01). In estrogen receptor (ER) negative samples, high expression of HDAC6 was more common in the AR+ groups (P < .001) and correlated with high histologic grade (G3) (P = .009), as well as higher HER2 (P = .006) and p53 levels (P = .012). Higher expression of AR and HDAC6 and HDAC6/AR co-expression had a worse clinical prognosis. The expression levels of HDAC6 and AR are correlated in breast cancer; moreover, HDAC6 and AR have prognostic value in predicting the overall survival (OS) of ER-negative breast cancer patients. (C) 2017 Elsevier Inc. All rights reserved.	[Niu, Yun] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Breast Canc Pathol, West Huanhu Rd, Tianjin 300060, Peoples R China; [Niu, Yun] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Res Lab, West Huanhu Rd, Tianjin 300060, Peoples R China; Key Lab Canc Prevent & Therapy Tianjin, West Huanhu Rd, Tianjin 300060, Peoples R China; Tianjins Clin Res Ctr Canc, West Huanhu Rd, Tianjin 300060, Peoples R China; Tianjin Med Univ, Minist Educ, Key Lab Breast Canc Prevent & Therapy, West Huanhu Rd, Tianjin 300060, Peoples R China	Niu, Y (reprint author), Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Breast Canc Pathol, West Huanhu Rd, Tianjin 300060, Peoples R China.; Niu, Y (reprint author), Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Res Lab, West Huanhu Rd, Tianjin 300060, Peoples R China.	yunniu2017@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81172532]	This work was financially supported by National Natural Science Foundation of China (81172532).	Agoff SN, 2003, AM J CLIN PATHOL, V120, P725, DOI 10.1309/42F00D0DJD0J5EDT; Ai JK, 2009, MOL ENDOCRINOL, V23, P1963, DOI 10.1210/me.2009-0188; Aldana-Masangkay GI, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/875824; Aleskandarany MA, 2016, BREAST CANCER RES TR, V159, P215, DOI 10.1007/s10549-016-3934-5; D'Amato NC, 2016, MOL CANCER RES, V14, P1054, DOI 10.1158/1541-7786.MCR-16-0167; Chuffa LGD, 2017, STEROIDS, V118, P93, DOI 10.1016/j.steroids.2016.12.011; Delcuve GP, 2012, CLIN EPIGENETICS, V4, DOI 10.1186/1868-7083-4-5; Denkert C, 2010, BREAST CARE, V5, P185; Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Hayashi S, 2005, CANCER CHEMOTH PHARM, V56, pS27, DOI 10.1007/s00280-005-0096-2; KuenenBoumeester V, 1996, EUR J CANCER, V32A, P1560, DOI 10.1016/0959-8049(96)00112-8; Lee YS, 2008, CANCER RES, V68, P7561, DOI 10.1158/0008-5472.CAN-08-0188; Liu XZ, 2016, ONCOTARGET, V7, P48905, DOI 10.18632/oncotarget.10211; Liu XZ, 2016, TUMOR BIOL, V37, P8027, DOI 10.1007/s13277-015-4712-4; Moinfar F, 2003, CANCER-AM CANCER SOC, V98, P703, DOI 10.1002/cncr.11532; Muller BM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-215; Niemeier LA, 2010, MODERN PATHOL, V23, P205, DOI 10.1038/modpathol.2009.159; Ogawa Y, 2008, INT J CLIN ONCOL, V13, P431, DOI 10.1007/s10147-008-0770-6; Park YH, 2015, J BREAST CANCER, V18, P249, DOI 10.4048/jbc.2015.18.3.249; Rahim B, 2017, CANCERS, P9; Rechoum Y, 2014, BREAST CANCER RES TR, V147, P473, DOI 10.1007/s10549-014-3082-8; Rey M, 2011, EUR J CELL BIOL, V90, P128, DOI 10.1016/j.ejcb.2010.09.004; Ryu HW, 2017, CANCER LETT, V391, P162, DOI 10.1016/j.canlet.2017.01.033; Saji S, 2005, ONCOGENE, V24, P4531, DOI 10.1038/sj.onc.1208646; Seidel C, 2016, BIOCHEM PHARMACOL, V99, P31, DOI 10.1016/j.bcp.2015.11.005; Seidel C, 2015, EPIGENOMICS-UK, V7, P103, DOI [10.2217/epi.14.69, 10.2217/EPI.14.69]; Subramanian C, 2011, NEOPLASIA, V13, P726, DOI 10.1593/neo.11558; Verdel A, 2000, CURR BIOL, V10, P747, DOI 10.1016/S0960-9822(00)00542-X; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Yoshida N, 2004, CANCER SCI, V95, P496, DOI 10.1111/j.1349-7006.2004.tb03239.x; Zhang ZH, 2004, CLIN CANCER RES, V10, P6962, DOI 10.1158/1078-0432.CCR-04-0455	34	3	3	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAY	2018	75						16	25		10.1016/j.humpath.2017.11.010			10	Pathology	Pathology	GI2YQ	WOS:000434238200003	29180246				2019-10-28	
J	Gupta, K; Jogunoori, S; Satapathy, A; Salunke, P; Kumar, N; Radotra, BD; Vasishta, RK				Gupta, Kirti; Jogunoori, Swathi; Satapathy, Ayusman; Salunke, Pravin; Kumar, Narendra; Radotra, Bishan Dass; Vasishta, Rakesh Kumar			Medulloblastoma with myogenic and/or melanotic differentiation does not align immunohistochemically with the genetically defined molecular subgroups	HUMAN PATHOLOGY			English	Article						Medulloblastoma; Molecular subgroups; Medullomyoblastoma; Myogenic differentiation; Melanotic medullomyoblastoma	MEDULLOMYOBLASTOMA; CLASSIFICATION; SURVIVAL	The World Health Organization classification of central nervous system neoplasms (2016 update) recognizes 4 histological variants and genetically defined molecular subgroups within medulloblastoma (MB). MB with myogenic differentiation is one of the rare variants, which is usually recognized as a pattern alongside the known histological variants. Because of its rarity, less is known about its molecular landscape and importantly about its placement in the current molecular schema. We aimed to analyze this rare variant for expression of 3 immunohistochemical markers conventionally used in molecular stratification of MB. Demographic profile and imaging details with survival outcome were also analyzed. Sixty-five MB cases were molecularly stratified using immunohistochemical markers (YAP1, GAB1, beta-catenin). MB with myogenic differentiation and MB cases showing variable immunoreactivity with the above 3 antibodies were further evaluated for smooth muscle actin, desmin, myogenin, and HMB45. Seven cases were categorized as MB with myogenic and/or melanotic differentiation. Age ranged from 2 to 40 years with a male-to-female ratio of 1:1.3. In 4 cases, myogenic or melanotic differentiation was evident on histology, whereas in 3, differentiation was highlighted only with muscle markers. Interestingly, all 7 cases showed variable immunoreactivity with 3 molecular markers and did not follow the conventionally accepted algorithm used for molecular stratification. Follow-up period ranged from 9 to 57 months. Overall survival revealed a varied pattern, with 3 deaths and 4 patients being alive with no evidence of disease at last follow-up. Our results provide evidence that these variants are distinct and do not align immunohistochemically with the currently recognized genetic subgroups. (C) 2018 Elsevier Inc. All rights reserved.	[Gupta, Kirti; Jogunoori, Swathi; Radotra, Bishan Dass; Vasishta, Rakesh Kumar] PGIMER, Dept Histopathol, Chandigarh, India; [Satapathy, Ayusman; Salunke, Pravin] PGIMER, Dept Neurosurg, Chandigarh, India; [Kumar, Narendra] PGIMER, Dept Radiotherapy, Chandigarh, India	Gupta, K (reprint author), PGIMER, Dept Histopathol, Chandigarh, India.	kirtigupta10@yahoo.co.in					Bergmann M, 1998, ACTA NEUROPATHOL, V95, P205, DOI 10.1007/s004010050788; Borcek AO, 2011, TURK NEUROSURG, V21, P438, DOI 10.5137/1019-5149.JTN.2964-10.2; Ellison DW, 2011, ACTA NEUROPATHOL, V121, P381, DOI 10.1007/s00401-011-0800-8; Ellison DW, 2016, WHO CLASSIFICATION T, P184; Gajjar A, 2006, LANCET ONCOL, V7, P813, DOI 10.1016/S1470-2045(06)70867-1; Granese J, 2008, NEUROPATH APPL NEURO, V34, P671, DOI 10.1111/j.1365-2990.2008.00955.x; Helton KJ, 2004, CANCER-AM CANCER SOC, V101, P1445, DOI 10.1002/cncr.20450; Huang PI, 2017, CHILD NERV SYST, V33, P1285, DOI 10.1007/s00381-017-3435-9; Jaiswal AK, 2005, J CLIN NEUROSCI, V12, P961, DOI 10.1016/j.jocn.2004.11.019; Kaur K, 2016, BRAIN PATHOL, V26, P334, DOI 10.1111/bpa.12293; Leonard JR, 2001, J NEUROSURG, V95, P82, DOI 10.3171/jns.2001.95.1.0082; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Mehta A, 2006, ARCH PATHOL LAB MED, V130, P565; Pietsch T, 2016, CLIN NEUROPATHOL, V35, P344; Polydorides AD, 2008, J NEURO-ONCOL, V88, P193, DOI 10.1007/s11060-008-9548-y; Rajeshwari M, 2016, NEUROPATHOLOGY, V36, P372, DOI 10.1111/neup.12281; Rattenberry W, 2011, J NEURO-ONCOL, V105, P659, DOI 10.1007/s11060-011-0626-1; Sachdeva MUS, 2008, DIAGN PATHOL, V3, DOI 10.1186/1746-1596-3-18; Stefanits H, 2014, CLIN NEUROPATHOL, V33, P122, DOI 10.5414/NP300675; Taylor MD, 2012, ACTA NEUROPATHOL, V123, P465, DOI 10.1007/s00401-011-0922-z; Wright KD, 2012, PEDIATR BLOOD CANCER, V59, P561, DOI 10.1002/pbc.24002	21	0	0	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAY	2018	75						26	33		10.1016/j.humpath.2018.01.014			8	Pathology	Pathology	GI2YQ	WOS:000434238200004	29412177				2019-10-28	
J	Lin, XQ; Laskin, WB; Lu, XY; Zhang, YX				Lin, Xiaoqi; Laskin, William B.; Lu, Xinyan; Zhang, Yaxia			Expression of MDM2 and p16 in angiomyolipoma	HUMAN PATHOLOGY			English	Article						Angiomyolipoma; Liposarcoma; Lipoma; Histomorphology; Cytomorphology; Immunohistochemistry; Fluorescence in situ hybridization for MDM2	WELL-DIFFERENTIATED LIPOSARCOMA; POTENTIAL DIAGNOSTIC PITFALL; IN-SITU HYBRIDIZATION; SOFT-TISSUE; LIPOMATOUS TUMOR; AMPLIFICATION; CDK4; IMMUNOHISTOCHEMISTRY; MANAGEMENT; NEOPLASMS	Angiomyolipoma (AML) arises primarily from the kidney but may grow into the retroperitoneal space mimicking a primary retroperitoneal tumor. Fine needle aspiration (FNA) and core needle biopsy of AML, particularly the fat-predominant variant, may be difficult to distinguish from retroperitoneal well differentiated liposarcoma (WDLS) or lipoma. Commonly used immunomarkers, MDM2 and p16, have proven useful in diagnosing WDLS and dedifferentiated liposarcoma (DDLS), while HMB45 and MelanA are melanocyte-related markers characteristically expressed in AML. In this study, we investigated the utility of MDM2 and p16 along with HMB45 and Melan-A immunohistochemical analysis in distinguishing AML from WDL/DDLS or lipoma. Immunohistochemically, AMLs demonstrated focal MDM2 expression (40% of cases) and focal/diffuse expression of p16 (60%). AMLs marked focally or diffusely with HMB45 (76% of cases) and Melan-A (96%). These latter two immunomarkers were not expressed in any of the WDLS/DDLSs or lipomas tested. WDLS/DDLSs showed focal/diffuse expression of MDM2 (91% of cases) and p16 (97%). While focal expression of MDM2 and p16 was observed in 14% and 67% of lipomas, respectively, no lipoma exhibited diffuse MDM2 positivity. In our hands, MDM2 expression by itself cannot exclude the diagnosis of AML or lipoma, and p16 alone is not helpful in separating AML and conventional lipoma from WDLS/DDLS. However, along with morphology, an immunohistochemical battery including HMB45, Melan-A, MDM2 and p16 are useful in distinguishing AML from WDLS/DDLS or lipoma. For equivocal cases, fluorescence in situ hybridization for MDM2 should be performed. (C) 2018 Elsevier Inc. All rights reserved.	[Lin, Xiaoqi; Lu, Xinyan] Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA; [Laskin, William B.] Yale Sch Med, Dept Pathol, New Haven, CT 06520 USA; [Zhang, Yaxia] Hosp Special Surg, Dept Pathol, New York, NY 10021 USA; [Lin, Xiaoqi] Northwestern Univ, Northwestern Mem Hosp, 251 East Huron St,Galter Pavil 7-132F, Chicago, IL 60611 USA	Lin, XQ (reprint author), Northwestern Univ, Northwestern Mem Hosp, 251 East Huron St,Galter Pavil 7-132F, Chicago, IL 60611 USA.	xlin@northwestem.edu					Asch-Kendrick RJ, 2016, HUM PATHOL, V57, P7, DOI 10.1016/j.humpath.2016.06.014; Bhatt JR, 2016, EUR UROL, V70, P85, DOI 10.1016/j.eururo.2016.01.048; Binh MBN, 2005, AM J SURG PATHOL, V29, P1340, DOI 10.1097/01.pas.0000170343.09562.39; Cappellesso R, 2016, HUM PATHOL, V47, P64, DOI 10.1016/j.humpath.2015.08.019; Clay MR, 2016, AM J SURG PATHOL, V40, P1647, DOI 10.1097/PAS.0000000000000713; Creytens D, 2017, HUM PATHOL, V64, P232, DOI 10.1016/j.humpath.2016.12.033; Creytens D, 2015, APPL IMMUNOHISTO M M, V23, P126, DOI 10.1097/PDM.0000000000000041; Erickson-Johnson MR, 2009, MODERN PATHOL, V22, P1541, DOI 10.1038/modpathol.2009.149; Flum AS, 2016, J UROLOGY, V195, P834, DOI 10.1016/j.juro.2015.07.126; Folpe AL, 2005, AM J SURG PATHOL, V29, P1558, DOI 10.1097/01.pas.0000173232.22117.37; Folpe AL, 2002, PATHOLOGY GENETICS T, P221; Folpe AL, 2010, HUM PATHOL, V41, P1, DOI 10.1016/j.humpath.2009.05.011; He M, 2009, APPL IMMUNOHISTO M M, V17, P51, DOI 10.1097/PAI.0b013e3181719223; Hornick JL, 2006, HISTOPATHOLOGY, V48, P75, DOI 10.1111/j.1365-2559.2005.02316.x; Israel GM, 2002, AM J ROENTGENOL, V179, DOI 10.2214/ajr.179.3.1790769; Martignoni G, 2004, WHO CLASSIFICATION T, P65; Nelson CP, 2002, J UROLOGY, V168, P1315, DOI 10.1097/01.ju.0000028200.86216.b2; Ng W, 2015, INT J SURG PATHOL, V23, P544, DOI 10.1177/1066896915595465; Oliner J. D., 2016, COLD SPRING HARB PER, V6; PEDEUTOUR F, 1994, GENE CHROMOSOME CANC, V10, P85, DOI 10.1002/gcc.2870100203; Pilotti S, 2000, BRIT J CANCER, V82, P1271; Putri RI, 2014, INDIAN J PATHOL MICR, V57, P558, DOI 10.4103/0377-4929.142663; Roma AA, 2007, ARCH PATHOL LAB MED, V131, P122; Sasaki T, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-468; Shimada S, 2006, PATHOL INT, V56, P638, DOI 10.1111/j.1440-1827.2006.02021.x; Sirvent N, 2007, AM J SURG PATHOL, V31, P1476, DOI 10.1097/PAS.0b013e3180581fff; Thway K, 2012, AM J SURG PATHOL, V36, P462, DOI 10.1097/PAS.0b013e3182417330; Venyo AKG, 2016, INT J SURG ONCOL, DOI 10.1155/2016/6347136; Weaver J, 2009, MODERN PATHOL, V22, P66, DOI 10.1038/modpathol.2008.153	29	2	3	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAY	2018	75						34	40		10.1016/j.humpath.2018.01.022			7	Pathology	Pathology	GI2YQ	WOS:000434238200005	29432785				2019-10-28	
J	Xu, Y; Yu, WM; Yang, TT; Zhang, MZ; Liang, C; Cai, XL; Shao, QS				Xu, Yuan; Yu, Weiming; Yang, Taotao; Zhang, Miaozun; Liang, Chao; Cai, Xianlei; Shao, Qinshu			Overexpression of BCAT1 is a prognostic marker in gastric cancer	HUMAN PATHOLOGY			English	Article						Gastric cancer; BCAT1; Diagnosis; Prognosis; Biomarker	PROMOTES CELL-PROLIFERATION; C-MYC REGULATION; HEPATOCELLULAR-CARCINOMA; EXPRESSION; TARGET; GENE; MIGRATION; ECA39; INVASION; GROWTH	As one form of branched-chain amino-acid transaminase (BCAT) enzymes, It has been found that up-regulation of BCAT1 is associated with poor prognosis in numerous types of tumors, but studies on the role of BCAT1 expression in gastric cancer (GC) are rare. The aims of this study were to detect BCAT1 expression in GC and to analyze its association with prognosis of GC patients. Microarray experiments were performed on the Affymetrix U133 plus 2.0 GeneChip Array. The protein and messenger RNA levels of BCAT1 were validated by immunohistochemistry and real-time quantitative polymerase chain reaction in GC tissues and adjacent noncancerous tissues. Our study shows that the expression of BCAT1 significantly increased in human GC. Furthermore, it can also be found that BCAT1 overexpression was associated with TNM stage (P < .05), local invasion (P < .05), Lauren type (P < .05), tumor classification (P < .05), lymph node metastasis (P < .05), and presence of distant metastasis (P < .05). Kaplan-Meier survival analysis revealed that high BCAT1 expression predicted significantly worse overall survival (P < .05), whereas multivariate Cox regression analysis showed that BCAT1 affects GC independently. In conclusion, up regulation of BCAT1 indicated a poor survival rate of GC and may serve as a useful marker for predicting the outcome of patients with GC. (C) 2018 Elsevier Inc. All rights reserved.	[Xu, Yuan; Yu, Weiming; Zhang, Miaozun; Liang, Chao; Cai, Xianlei] Lihuili Hosp, Ningbo City Med Ctr, Dept Gastrointestinal Surg, Ningbo 315000, Zhejiang, Peoples R China; [Yang, Taotao] Lihuili Hosp, Ningbo City Med Ctr, Dept Pharm, Ningbo 315000, Zhejiang, Peoples R China; [Shao, Qinshu] Zhejiang Prov Peoples Hosp, Dept Gastrointestinal Surg, Hangzhou 310014, Zhejiang, Peoples R China	Xu, Y (reprint author), Lihuili Hosp, Ningbo City Med Ctr, Dept Gastrointestinal Surg, Ningbo 315000, Zhejiang, Peoples R China.	xu565831937@163.com					Ben-Yosef T, 1998, MAMM GENOME, V9, P595, DOI 10.1007/s003359900825; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; CAVALIERI F, 1987, MOL CELL BIOL, V7, P3554, DOI 10.1128/MCB.7.10.3554; de Bont JM, 2008, NEURO-ONCOLOGY, V10, P648, DOI 10.1215/15228517-2008-032; Eden A, 1996, J BIOL CHEM, V271, P20242, DOI 10.1074/jbc.271.34.20242; Eden A, 1999, FEBS LETT, V457, P255, DOI 10.1016/S0014-5793(99)01054-6; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; HALL TR, 1993, J BIOL CHEM, V268, P3092; Karimi P, 2014, CANCER EPIDEM BIOMAR, V23, P700, DOI 10.1158/1055-9965.EPI-13-1057; Oktyabri D, 2016, BIOCHIMIE, V123, P20, DOI 10.1016/j.biochi.2016.01.005; Papathanassiu AE, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16040; Pereboom TC, 2014, EXP HEMATOL, V42, P394, DOI 10.1016/j.exphem.2013.12.010; Schuldiner O, 1996, P NATL ACAD SCI USA, V93, P7143, DOI 10.1073/pnas.93.14.7143; Takahashi Tsunehiro, 2013, Cancers (Basel), V5, P48, DOI 10.3390/cancers5010048; Tonjes M, 2013, NAT MED, V19, P901, DOI 10.1038/nm.3217; Xu M, 2016, ONCOL LETT, V12, P2648, DOI 10.3892/ol.2016.4969; Yoshikawa R, 2006, WORLD J GASTROENTERO, V12, P5884, DOI 10.3748/wjg.v12.i36.5884; Zhang L, 2017, BIOCHEM BIOPH RES CO, V486, P224, DOI 10.1016/j.bbrc.2017.02.101; Zheng YH, 2016, LIVER INT, V36, P1836, DOI 10.1111/liv.13178; Zhou W, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-53	20	2	2	2	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAY	2018	75						41	46		10.1016/j.humpath.2018.02.003			6	Pathology	Pathology	GI2YQ	WOS:000434238200006	29447920				2019-10-28	
J	Pan, M; Zhang, J; You, XH; Li, D; Lv, YQ; Zhang, J; Ding, XK; Li, ZY; Xu, FF; Chen, CS				Pan, Min; Zhang, Ji; You, Xiaohan; Li, Duo; Lv, Yinqiu; Zhang, Jianna; Ding, Xiaokai; Li, Zhanyuan; Xu, Feifei; Chen, Chaosheng			Renal outcomes in primary IgA nephropathy patients with segmental glomerular necrosis: a case-control study	HUMAN PATHOLOGY			English	Article						IgA nephropathy; Segmental glomerular necrosis; Chronic kidney disease; Oxford classification; Renal outcomes	OXFORD CLASSIFICATION; ACTIVATION; EXPRESSION; CRESCENTS; LESIONS; INJURY	The renal prognosis and treatment of primary IgA nephropathy (IgAN) patients with segmental glomerular necrosis (SGN) remain controversial. Patients with primary IgAN confirmed by renal biopsy were enrolled. Patients with SGN on renal biopsy were selected as the necrosis group, and a propensity score matching method was used to match a control group according to age, gender, weight, height and follow-up time. A total of 825 IgAN patients were enrolled in the present study. Seventy-three (8.8%) patients with SGN were selected as the necrosis group, and 292 patients without SGN were matched as the control group. Compared to the control group, a significantly increased serum fibrinogen level (3.97 g/L vs 3.54 g/L, P = .002) and proportion of patients with macroscopic hematuria (35.6% vs 14.7%, P<.001) was observed in the necrosis group. According to the new IgA pathological classification system, crescent formation was more pronounced in the necrosis group (P = .001). The average estimated glomerular filtration rate was obviously higher in the necrosis group and decreased more slowly during follow-up. However, the time-averaged urine protein-to-creatinine ratio remained low in the necrotic group, whereas it gradually increased in the control group. SGN suggests an active renal inflammatory state, but it was not an independent risk factor for a poor renal outcome in patients treated with immunosuppressive therapy. Furthermore, patients with SGN had a more stable renal function and low urinary protein excretion during follow-up, which may be attributable to aggressive immunotherapy. (C) 2018 Elsevier Inc. All rights reserved.	[Pan, Min; Li, Zhanyuan] Wenzhou Med Univ, Affiliated Hosp 2, Dept Nephrol, Wenzhou 325000, Zhejiang, Peoples R China; [Pan, Min; Li, Zhanyuan] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 325000, Zhejiang, Peoples R China; [Zhang, Ji; You, Xiaohan; Li, Duo; Lv, Yinqiu; Zhang, Jianna; Ding, Xiaokai; Xu, Feifei; Chen, Chaosheng] Wenzhou Med Univ, Affiliated Hosp 1, Dept Nephrol, Wenzhou 325000, Zhejiang, Peoples R China	Chen, CS (reprint author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Nephrol, Wenzhou 325000, Zhejiang, Peoples R China.	wzccs8@163.com	Zhang, Ji/O-7822-2017	Zhang, Ji/0000-0002-5194-1412	Wenzhou Science & Technology Bureau [Y20170300]	This study was supported by Wenzhou Science & Technology Bureau (Grant number Y20170300 for Min Pan).	Amdur RL, 2016, CLIN J AM SOC NEPHRO, V11, P1546, DOI 10.2215/CJN.13121215; Asgeirsdottir SA, 2012, AM J PHYSIOL-RENAL, V302, pF1630, DOI 10.1152/ajprenal.00400.2011; Cattran DC, 2009, KIDNEY INT, V76, P534, DOI 10.1038/ki.2009.243; D'Amico G, 2001, KIDNEY INT, V59, P682, DOI 10.1046/j.1523-1755.2001.059002682.x; Donadio JV, 1997, J AM SOC NEPHROL, V8, P1324; Finsterbusch M, 2016, P NATL ACAD SCI USA, V113, pE5172, DOI 10.1073/pnas.1606253113; FLOEGE J, 1992, KIDNEY INT, V41, P297, DOI 10.1038/ki.1992.42; Goicoechea M, 2008, KIDNEY INT, V74, pS67, DOI 10.1038/ki.2008.519; [关利铭 Guan Limin], 2006, [中国超声医学杂志, Chinese Journal of Ultrasonic in Medical], V22, P5; Haas M, 2017, J AM SOC NEPHROL, V28, P691, DOI 10.1681/ASN.2016040433; Ho DE, 2011, J STAT SOFTW, V42, p[8, 1], DOI DOI 10.18637/JSS.V042.I08; Hogan SL, 1996, J AM SOC NEPHROL, V7, P23; Koyama A, 1999, NEPHRON, V82, P205; Kusano T, 2016, HUM PATHOL, V49, P135, DOI 10.1016/j.humpath.2015.10.013; Lai KN, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.1; Le WB, 2014, AM J NEPHROL, V40, P43, DOI 10.1159/000364954; LEE SMK, 1982, HUM PATHOL, V13, P314, DOI 10.1016/S0046-8177(82)80221-9; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; LI HL, 1990, KIDNEY INT, V37, P1552, DOI 10.1038/ki.1990.148; Peschel A, 2014, J AM SOC NEPHROL, V25, P455, DOI 10.1681/ASN.2013030320; Pillebout E, 2002, J AM SOC NEPHROL, V13, P1271, DOI 10.1097/01.ASN.0000013883.99976.22; SHOUNO Y, 1993, ACTA PATHOL JAPON, V43, P723; Tan M, 2016, AM J NEPHROL, V43, P341, DOI 10.1159/000445759; Team RC, 2017, R LANG ENV STAT COMP; Tesar V, 2015, J AM SOC NEPHROL, V26, P2248, DOI 10.1681/ASN.2014070697; Tomiyoshi Y, 2001, INTERNAL MED, V40, P862, DOI 10.2169/internalmedicine.40.862; Trimarchi H, 2017, KIDNEY INT, V91, P1014, DOI 10.1016/j.kint.2017.02.003; Weening JJ, 2004, KIDNEY INT, V65, P521, DOI 10.1111/j.1523-1755.2004.00443.x; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wyatt RJ, 2013, NEW ENGL J MED, V368, P2402, DOI 10.1056/NEJMra1206793	30	0	0	1	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAY	2018	75						47	54		10.1016/j.humpath.2018.01.026			8	Pathology	Pathology	GI2YQ	WOS:000434238200007	29410298				2019-10-28	
J	Bosch, DE; Farjah, F; Wood, DE; Schmidt, RA				Bosch, Dustin E.; Farjah, Farhood; Wood, Douglas E.; Schmidt, Rodney A.			Regional lymph node sampling in lung carcinoma: a single institutional and national database comparison	HUMAN PATHOLOGY			English	Article						Lung carcinoma; Regional lymph nodes; Quality metrics; Cancer staging; National cancer database	AMERICAN-COLLEGE; SURGEONS COMMISSION; LYMPHADENECTOMY; NUMBER; LOBECTOMY; RESECTION; CANCER	Assessing regional lymph node metastasis is a key component of lung carcinoma staging and prognostication. Recent guidelines have suggested a quality metric of 10 total regional lymph nodes sampled with each stage I-II primary lung carcinoma resection. However, the extent of mediastinal lymph node sampling remains controversial. We assessed factors contributing to regional lymph node counts and effect on overall patient survival in an institutional cohort of 888 cases and the Surveillance, Epidemiology, and End Results national cancer registry (10 856 cases). The distribution of total lymph node counts in lobectomy and pneumonectomy cases was variable with a median of 10 and an interquartile range of 7 to 14. Multiple clinical and pathologic factors correlated with total regional node counts. Total lymph node counts of at least 10 in the institutional cohort did not correlate with significant differences in overall survival as compared with node counts of less than 10 (P = .38). In the Surveillance, Epidemiology, and End Results database, although 0 regional lymph nodes were correlated with reduced overall survival (hazard ratio, 1.47; P < .01), no significant difference was detected for 1 to 9 versus at least 10 nodes (P = .8). In conclusion, lymph node counts for primary lung carcinoma are driven by surgical, pathologic, and biologic variability. We find no evidence for a meaningful quality metric of 10 total regional lymph nodes at the institutional and national registry levels. (C) 2018 Elsevier Inc. All rights reserved.	[Bosch, Dustin E.; Schmidt, Rodney A.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA; [Farjah, Farhood; Wood, Douglas E.] Univ Washington, Dept Surg, Div Cardiothorac Surg, Seattle, WA 98195 USA; [Bosch, Dustin E.; Schmidt, Rodney A.] 1959 NE Pacific St,Box 357470, Seattle, WA 98195 USA	Schmidt, RA (reprint author), 1959 NE Pacific St,Box 357470, Seattle, WA 98195 USA.	schmidtr@uw.edu					ACOS, 2017, COC QUAL CAR MEAS; Darling GE, 2011, CHEST, V139, P1124, DOI 10.1378/chest.10-0859; Darling GE, 2011, J THORAC CARDIOV SUR, V141, P662, DOI 10.1016/j.jtcvs.2010.11.008; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Handy JR, 2016, ANN THORAC SURG, V102, P1040, DOI 10.1016/j.athoracsur.2016.06.020; Liu JB, 2017, J AM COLL SURGEONS, V224, P180, DOI 10.1016/j.jamcollsurg.2016.10.053; Ludwig MS, 2005, CHEST, V128, P1545, DOI 10.1378/chest.128.3.1545; Mokhles S, 2017, EUR J CARDIO-THORAC, V51, P1149, DOI 10.1093/ejcts/ezw439; Ou SHI, 2008, J THORAC ONCOL, V3, P880, DOI 10.1097/JTO.0b013e31817dfced; Schmidt Júnior Aurelino Fernandes, 2007, J. bras. pneumol., V33, P134, DOI 10.1590/S1806-37132007000200006; Silvestri GA, 2013, CHEST, V143, pE211, DOI 10.1378/chest.12-2355; Therneau T.M., 2000, STAT BIOL HEALTH; Varlotto JM, 2009, CANCER-AM CANCER SOC, V115, P851, DOI 10.1002/cncr.23985	13	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAY	2018	75						55	62		10.1016/j.humpath.2018.02.002			8	Pathology	Pathology	GI2YQ	WOS:000434238200008	29447922				2019-10-28	
J	Boto, A; Harigopal, M				Boto, Agedi; Harigopal, Malini			Strong androgen receptor expression can aid in distinguishing GATA3+metastases	HUMAN PATHOLOGY			English	Article						Androgen receptor; GATA3; Breast cancer; Urothelial cancer; Metastasis	BREAST-CANCER; ESTROGEN-RECEPTOR; GATA3 EXPRESSION; GENE-EXPRESSION; MAMMARY-GLAND; CARCINOMA; DIFFERENTIATION; UTILITY; TUMORS; STAGE	GATA3 is a transcription factor used clinically as a marker of breast or urothelial differentiation. A marker is yet needed to distinguish this in the case of the GATA3-positive tumor of unknown origin. We tested classical markers of breast differentiation and hormonal signaling to see which correlated strongest with GATA3 expression in breast cancer and thus which could help correctly identify breast origin in the case of the GATA3-positive tumor of unknown origin. GATA3, estrogen receptor, progesterone receptor, androgen receptor (AR), HER2, GCDFP15, and mammaglobin expression was intercorrelated in a histologically diverse 259-case breast cancer tissue microarray. We show herein a uniquely high level of correlation between GATA3 and AR expression (r = 0.61; 95% confidence interval 0.52-0.68) that was strongest among lobular carcinomas (r = 1; 95% confidence interval 0.73-1) and stronger than any other correlation studied. Separate AR staining of 10 metastatic GATA3+ carcinomas of urothelial origin and 13 metastatic GATA3+ carcinomas of breast origin showed that strong AR staining (>60% of tumor cells) has a sensitivity of 54% and a specificity of 100% for correctly distinguishing GATA3+ carcinoma of mammary origin from urothelial origin in the metastatic setting. Androgen receptor expression is strongly correlated with GATA3 in breast cancer, particularly in tumors with lobular morphology. Strong AR expression (>60% of tumor cells) is an excellent test to rule out urothelial carcinoma in the GATA3+ metastatic setting (specificity 100%) and will effectively identify breast origin in approximately 50% of cases. (C) 2018 Elsevier Inc. All rights reserved.	[Boto, Agedi; Harigopal, Malini] Yale New Haven Med Ctr, Dept Pathol, New Haven, CT 06515 USA	Boto, A (reprint author), Yale New Haven Med Ctr, Dept Pathol, New Haven, CT 06515 USA.	agedi.boto@yale.edu; malini.harigopal@yale.edu					Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Augello MA, 2011, EMBO J, V30, P3885, DOI 10.1038/emboj.2011.340; Bieche I, 2001, CARCINOGENESIS, V22, P1521, DOI 10.1093/carcin/22.9.1521; Boorjian S, 2004, UROLOGY, V64, P383, DOI 10.1016/j.urology.2004.03.025; Cimino-Mathews A, 2013, HUM PATHOL, V44, P1341, DOI 10.1016/j.humpath.2012.11.003; Cimino-Mathews A, 2012, HUM PATHOL, V43, P1003, DOI 10.1016/j.humpath.2011.08.007; Dimitrakakis C, 2003, MENOPAUSE, V10, P292, DOI 10.1097/01.GME.0000055522.67459.89; Dolled-Filhart M, 2006, CANCER RES, V66, P5487, DOI 10.1158/0008-5472.CAN-06-0100; Downes MR, 2013, J CLIN PATHOL, V66, P779, DOI 10.1136/jclinpath-2013-201586; Dydensborg AB, 2009, ONCOGENE, V28, P2634, DOI 10.1038/onc.2009.126; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Engelsen IB, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.04.043; Grillo F, 2017, J CLIN PATHOL, V70, P988, DOI 10.1136/jclinpath-2017-204387; Hah N, 2011, CELL, V145, P622, DOI 10.1016/j.cell.2011.03.042; Kanhere A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2260; Kim S, 2016, HUM PATHOL, V55, P190, DOI 10.1016/j.humpath.2016.04.013; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Krieger N, 2015, NPJ BREAST CANCER, V1, DOI 10.1038/npjbcancer.2015.16; KUENENBOUMEESTER V, 1992, INT J CANCER, V52, P581, DOI 10.1002/ijc.2910520415; Liu HY, 2012, AM J CLIN PATHOL, V138, P57, DOI 10.1309/AJCP5UAFMSA9ZQBZ; Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Peters AA, 2009, CANCER RES, V69, P6131, DOI 10.1158/0008-5472.CAN-09-0452; Riva C, 2005, VIRCHOWS ARCH, V447, P695, DOI 10.1007/s00428-005-0003-6; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Voduc D, 2008, CANCER EPIDEM BIOMAR, V17, P365, DOI 10.1158/1055-9965.EPI-06-1090; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Zadeh SL, 2018, INT J GYNECOL PATHOL, V37, P167, DOI 10.1097/PGP.0000000000000401	28	1	1	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAY	2018	75						63	70		10.1016/j.humpath.2018.01.024			8	Pathology	Pathology	GI2YQ	WOS:000434238200009	29408697				2019-10-28	
J	Liu, YF; Chang, K; Fu, KX; Dong, XJ; Chen, XS; Liu, JX; Cui, N; Ni, JS				Liu, Yafang; Chang, Kai; Fu, Kexin; Dong, Xinjie; Chen, Xiaoshuai; Liu, Jixuan; Cui, Ni; Ni, Jinsong			DNA demethylation of claudin-4 suppresses migration and invasion in laryngeal squamous carcinoma cells	HUMAN PATHOLOGY			English	Article						CLDN4; Methylation; Migration; Invasion; Laryngeal squamous carcinoma	TIGHT JUNCTION; HEPATOCELLULAR-CARCINOMA; CANCER; EXPRESSION; METHYLATION; PROGRESSION; PROTEINS; METASTASIS; DIAGNOSIS; PROMOTES	Claudin-4 (CLDN4) is a member of the claudin transmembrane protein family, which consists of integral membrane proteins that are components of the epithelial cell tight junctions; these tight junctions regulate movement of solutes and ions through the paracellular space. CLDN4 is also a differentiation marker and is believed to indicate an epithelial phenotype. However, the role of CLDN4 in laryngeal squamous carcinoma is still unclear. Here, we showed that CLDN4 expression was down-regulated in laryngeal squamous carcinoma tissues and negatively correlated with methyl-CpG-binding protein 2. In addition, CLDN4 was hypermethylated in HEp-2 cells. DNA demethylation of CLDN4 by 5-aza-2'-deoxycytidine suppressed migration and invasion of HEp-2 cells, whereas CLDN4 silencing restored the migration and invasion of HEp-2 cells. Therefore, CLDN4 plays a key role in laryngeal squamous carcinoma progression. (C) 2018 Elsevier Inc. All rights reserved.	[Liu, Yafang; Chang, Kai; Fu, Kexin; Dong, Xinjie; Chen, Xiaoshuai; Liu, Jixuan; Ni, Jinsong] Jilin Univ, Bethune Hosp 1, Dept Pathol, 3302 Jilin Rd, Changchun 130021, Jilin, Peoples R China; [Chang, Kai] Sichuan Acad Med Sci, Chengdu 610000, Sichuan, Peoples R China; [Chang, Kai] Sichuan Prov Peoples Hosp, Chengdu 610000, Sichuan, Peoples R China; [Cui, Ni] Jilin Univ, China Japan Union Hosp, Dept Gastrointestinal Colorectal & Surg, Changchun 130031, Jilin, Peoples R China	Ni, JS (reprint author), Jilin Univ, Bethune Hosp 1, Dept Pathol, 3302 Jilin Rd, Changchun 130021, Jilin, Peoples R China.	41869653@qq.com; cknyn@foxmail.com; fukexin19910227@126.com; dongdong1823@126.com; 476207312@qq.com; 153909833@qq.com; 312063516@qq.com; nijs@jlu.edu.cn			Health and Family Planning Commission of Jilin Province [20152037]	This work was supported by the Health and Family Planning Commission of Jilin Province (Grant No. 20152037).	Agarwal R, 2005, CANCER RES, V65, P7378, DOI 10.1158/0008-5472.CAN-05-1036; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Boireau S, 2007, CARCINOGENESIS, V28, P246, DOI 10.1093/carcin/bg1120; Dandrea M, 2009, NUCLEIC ACIDS RES, V37, P6681, DOI 10.1093/nar/gkp723; English DP, 2013, INT J MOL SCI, V14, P10412, DOI 10.3390/ijms140510412; Georges R, 2012, J CELL MOL MED, V16, P260, DOI 10.1111/j.1582-4934.2011.01289.x; Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006; Gonzalez-Mariscal L, 2007, PROG HISTOCHEM CYTO, V42, P1, DOI 10.1016/j.proghi.2007.01.001; Haass NK, 2004, J MOL HISTOL, V35, P309; Hicks DA, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2799-7; Higashi Y, 2007, J SURG RES, V139, P68, DOI 10.1016/j.jss.2006.08.038; Li W, 2016, SCI REP-UK, V6, DOI 10.1038/srep37534; Lin XJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067496; Liu YF, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0396-x; Lu SL, 2013, MODERN PATHOL, V26, P485, DOI 10.1038/modpathol.2012.187; Martin TA, 2009, BBA-BIOMEMBRANES, V1788, P872, DOI 10.1016/j.bbamem.2008.11.005; Michl P, 2003, CANCER RES, V63, P6265; Morin PJ, 2005, CANCER RES, V65, P9603, DOI 10.1158/0008-5472.CAN-05-2782; Nakayama F, 2008, PATHOBIOLOGY, V75, P177, DOI 10.1159/000124978; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nelhubel GA, 2014, PATHOL ONCOL RES, V20, P99, DOI 10.1007/s12253-013-9665-6; Piontek J, 2008, FASEB J, V22, P146, DOI 10.1096/fj.07-8319com; Schaefer IM, 2017, MODERN PATHOL, V30, P539, DOI 10.1038/modpathol.2016.230; Shang XY, 2012, NEOPLASIA, V14, P974, DOI 10.1593/neo.12942; Song YX, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00304-1; Stebbing J, 2013, ONCOGENE, V32, P4871, DOI 10.1038/onc.2012.591; Steed E, 2010, TRENDS CELL BIOL, V20, P142, DOI 10.1016/j.tcb.2009.12.002; Turksen K, 2011, BBA-REV CANCER, V1816, P73, DOI 10.1016/j.bbcan.2011.04.001; Williams K, 2012, EMBO REP, V13, P28, DOI 10.1038/embor.2011.233	29	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAY	2018	75						71	80		10.1016/j.humpath.2018.02.005			10	Pathology	Pathology	GI2YQ	WOS:000434238200010	29447921				2019-10-28	
J	Ye, Q; Wang, CL; Xian, J; Zhang, M; Cao, YJ; Cao, YD				Ye, Qian; Wang, Chenglong; Xian, Jie; Zhang, Ming; Cao, Yijia; Cao, Youde			Expression of programmed cell death protein 1 (PD-1) and indoleamine 2,3-dioxygenase (IDO) in the tumor microenvironment and in tumor-draining lymph nodes of breast cancer	HUMAN PATHOLOGY			English	Article						PD-1; IDO; Breast cancer; Tumor microenvironment (TME); Tumor-draining lymph nodes (TDLNs); TCGA dataset	POOR-PROGNOSIS; CARCINOMA; IMMUNITY; IMMUNOTHERAPY; LYMPHOCYTES; PATHWAYS; THERAPY	Programmed cell death protein 1 (PD-1) and indoleamine 2,3-dioxygenase (IDO) are both immunosuppressive proteins. Here, we investigated the relationship between PD-1 and IDO in the tumor micro environment (TME) and in tumor-draining lymph nodes (TDLNs) in breast cancer patients. First, the protein and mRNA expression levels of PD-1 and IDO in 20 frozen tissues were examined using Western blotting and real-time polymerase chain reaction. Second, 151 paraffin-embedded breast samples and 52 lymph node samples were analyzed by immunohistochemistry. Third, correlation and survival data for PD-1 and IDO in 963 breast tumor patients were mined using the cBio Cancer Genomics Portal. We found that the protein expression level of IDO was significantly increased in frozen tumor tissues (P = .005). From paraffin embedded samples in the TME, PD-1(+) cells were only located in the stroma, while IDO was expressed in myoepithelial, stromal, and tumor cells. PD-1 and stromal IDO in the TME showed increased expression in tumors (P < .001 and P < .001, respectively). In TDLNs, PD-1(+) cells were primarily located in the germinal centers (GCs), and IDO+ cells were primarily located in the paracortex. Normal lymph nodes expressed PD-1 and IDO at the same level as non-metastatic and metastatic lymph nodes (P = .151 and P = .812, respectively). According to cBioPortal, the correlation analysis showed that IDO and PD-1 had high correlation coefficients (r = 0.83). These findings suggest that there is a positive correlation between the expression of PD-1 and IDO and that blocking both PD-1 and IDO pathways may represent an attractive therapeutic strategy in breast cancer treatment. (C) 2018 Elsevier Inc. All rights reserved.	[Ye, Qian; Wang, Chenglong; Xian, Jie; Zhang, Ming; Cao, Yijia; Cao, Youde] Chongqing Med Univ, Coll Basic Med, Dept Pathol, 1 Yixueyuan Rd, Chongqing 400016, Peoples R China	Cao, YD (reprint author), Chongqing Med Univ, Coll Basic Med, Dept Pathol, 1 Yixueyuan Rd, Chongqing 400016, Peoples R China.	420306100@qq.com			Chongqing Science and Technology Commission (CN) [x4454]	This work was financially supported through grants from the Chongqing Science and Technology Commission (CN) [grant numbers: x4454].	Baumeister SH, 2016, ANNU REV IMMUNOL, V34, P539, DOI 10.1146/annurev-immunol-032414-112049; Fransen MF, 2013, INT J CANCER, V132, P1971, DOI 10.1002/ijc.27755; Gangadhar TC, 2016, 2016 EUR SOC MED ONC; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Hsu MC, 2010, MODERN PATHOL, V23, P1393, DOI 10.1038/modpathol.2010.130; Jacquemier J, 2012, INT J CANCER, V130, P96, DOI 10.1002/ijc.25979; Lakhani SREI, 2012, WHO CLASSIFICATION T; Lee JR, 2003, LAB INVEST, V83, P1457, DOI 10.1097/01.LAB.0000090158.68852.D1; Markwick LJL, 2015, GASTROENTEROLOGY, V148, P590, DOI 10.1053/j.gastro.2014.11.041; McNutt M, 2013, SCIENCE, V342, P1417, DOI 10.1126/science.1249481; Moreno BH, 2015, BRIT J CANCER, V112, P1421, DOI 10.1038/bjc.2015.124; Muenst S, 2013, BREAST CANCER RES TR, V139, P667, DOI 10.1007/s10549-013-2581-3; Muenst S, 2009, HUM PATHOL, V40, P1715, DOI 10.1016/j.humpath.2009.03.025; Muller AJ, 2005, NAT MED, V11, P312, DOI 10.1038/nm1196; Munn DH, 2016, CURR OPIN IMMUNOL, V39, P1, DOI 10.1016/j.coi.2015.10.009; Munn DH, 2016, TRENDS IMMUNOL, V37, P193, DOI 10.1016/j.it.2016.01.002; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Nardone V, 2016, CANCER BIOL THER, V17, P1213, DOI 10.1080/15384047.2016.1235666; Perez RP, 2017, J CLIN ONCOL S, V35; Sakuishi K, 2010, J EXP MED, V207, P2187, DOI 10.1084/jem.20100643; Savas P, 2016, NAT REV CLIN ONCOL, V13, P228, DOI 10.1038/nrclinonc.2015.215; Terme M, 2011, CANCER RES, V71, P5393, DOI 10.1158/0008-5472.CAN-11-0993; The ASCO Post, 2017, THE ASCO POST; Thompson E, 2016, MODERN PATHOL, V29, P249, DOI 10.1038/modpathol.2015.158; Thompson RH, 2007, CLIN CANCER RES, V13, P1757, DOI 10.1158/1078-0432.CCR-06-2599; Vigneron N, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2014.1003012; Wolchok JD, 2015, CELL, V162, P937, DOI 10.1016/j.cell.2015.07.045	27	3	3	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAY	2018	75						81	90		10.1016/j.humpath.2018.02.004			10	Pathology	Pathology	GI2YQ	WOS:000434238200011	29447919				2019-10-28	
J	Yasuda, F; Mii, A; Morita, M; Aoki, M; Tagawa, M; Aratani, S; Kaneko, T; Sakai, Y; Shimizu, A				Yasuda, Fumihiko; Mii, Akiko; Morita, Megumi; Aoki, Michiko; Tagawa, Masako; Aratani, Sae; Kaneko, Tomohiro; Sakai, Yukinao; Shimizu, Akira			Importance of frequency and morphological characteristics of nodular diabetic glomerulosclerosis in diabetic nephropathy	HUMAN PATHOLOGY			English	Article						Diabetes mellitus; Diabetic nephropathy; Glomerular lesion; Nodular glomerulosclerosis; Renal structural-functional relationships; Pathology	EXPERIMENTAL PROLIFERATIVE GLOMERULONEPHRITIS; RENAL PROGNOSIS; MESANGIOLYSIS; LESIONS; CLASSIFICATION; APOPTOSIS; MELLITUS; REPAIR	The Renal Pathology Society proposed a pathological classification for diabetic nephropathy (DN) (RPS 2010). We retrospectively examined the renal structural-functional relationships using the RPS 2010 classification in 49 DN cases. We also evaluated the importance of the percentage of glomeruli with nodular diabetic glomerulosclerosis and their morphological characteristics (cellular, cellular and extracellular matrix [ECM] or ECM types) in the pathology of DN. The classes of DN (RPS 2010) were significantly correlated with the duration of diabetes mellitus (DM), degree of proteinuria, a decreased estimated glomerular filtration rate (eGFR), and the stages of Japanese clinical DM and chronic kidney disease (CKD). When the percentage of glomeruli with nodular glomerulosclerosis (IIIA <25%, 1111B 25-50%, MC 50-75%, and IIID >75%) was added to class III in this classification, the classes of DN had a greater correlation with the levels of proteinuria. The morphological characteristics of nodular glomerulosclerosis such as cellular, cellular and ECM, or ECM type were associated with several clinical parameters including the duration of DM, degree of proteinuria, a decreased eGFR, and/or the stages of clinical DM and CKD. Mesangial red blood cell fragments that is indicative of microvascular injury was found in cellular or cellular and ECM types of nodular glomerulosclerosis. The RPS 2010 classification is useful as a DN pathological classification that indicates a good correlation with the clinical characteristics of DN. In addition, the frequency and morphological characteristics of nodular diabetic glomerulosclerosis is important for the evaluation of the pathology in DN. (C) 2018 Elsevier Inc. All rights reserved.	[Yasuda, Fumihiko; Aoki, Michiko; Tagawa, Masako; Aratani, Sae; Shimizu, Akira] Nippon Med Sch, Dept Analyt Human Pathol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan; [Mii, Akiko; Morita, Megumi; Aratani, Sae; Kaneko, Tomohiro; Sakai, Yukinao] Nippon Med Sch, Dept Nephrol, Bunkyo Ku, Tokyo 1138603, Japan	Shimizu, A (reprint author), Nippon Med Sch, Dept Analyt Human Pathol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan.	ashimizu@nms.ac.jp			Japanese Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [B23790963, C24591217, C17K09717]	This study was supported by Grants-in-Aid for Scientific Research (B23790963 to A.M. and C24591217 and C17K09717 to A.S.) from the Japanese Society for the Promotion of Science.	An Y, 2014, NEPHROL DIAL TRANSPL, P1; Dalla Vestra M, 2000, DIABETES METAB, V26, P8; de Boer IH, 2015, KIDNEY INT S, V5, P2; Fioretto P, 2010, NAT REV NEPHROL, V6, P508, DOI 10.1038/nrneph.2010.96; Hanafusa N, 2015, KIDNEY INT SUPPL, V5, P15, DOI 10.1038/kisup.2015.5; Lane Pascale, 1991, Journal of Diabetic Complications, V5, P69, DOI 10.1016/0891-6632(91)90021-G; Masuda Y, 2001, AM J PATHOL, V159, P599, DOI 10.1016/S0002-9440(10)61731-2; Matsumae T, 1999, NEPHRON, V81, P41, DOI 10.1159/000045244; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; Mise K, 2017, DIABETES RES CLIN PR, V127, P187, DOI 10.1016/j.diabres.2017.03.006; Mise K, 2015, DIABETES-METAB RES, V31, P572, DOI 10.1002/dmrr.2633; Najafian B, 2012, SEMIN NEPHROL, V32, P415, DOI 10.1016/j.semnephrol.2012.07.003; Nakai S, 2014, THER APHER DIAL, V18, P535, DOI 10.1111/1744-9987.12281; Oh SW, 2012, DIABETES RES CLIN PR, V97, P418, DOI 10.1016/j.diabres.2012.03.016; Okada T, 2012, NEPHROLOGY, V17, P68, DOI 10.1111/j.1440-1797.2011.01525.x; Paueksakon P, 2002, KIDNEY INT, V61, P2142, DOI 10.1046/j.1523-1755.2002.00384.x; Sahay M, 2014, Indian J Nephrol, V24, P226, DOI 10.4103/0971-4065.132999; SAITO Y, 1988, KIDNEY INT, V34, P389, DOI 10.1038/ki.1988.193; Shimizu A, 1998, NEPHRON, V79, P206, DOI 10.1159/000045026; SHIMIZU A, 1995, KIDNEY INT, V47, P114, DOI 10.1038/ki.1995.13; STOUT LC, 1993, HUM PATHOL, V24, P77; Tervaert TWC, 2010, J AM SOC NEPHROL, V21, P556, DOI 10.1681/ASN.2010010010; Wada T, 2014, DIABETES, P613; Wada T, 2013, CLIN EXP NEPHROL, V17, P3, DOI 10.1007/s10157-012-0711-6	24	1	1	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAY	2018	75						95	103		10.1016/j.humpath.2018.01.019			9	Pathology	Pathology	GI2YQ	WOS:000434238200012	29408640				2019-10-28	
J	Souza, PD; Dondo, PS; Souza, G; Lopes, D; Moscardi, M; Martinho, VD; Lourenco, RDD; Prieto, T; Balancin, ML; Assato, AK; Teodoro, WR; Rodrigues, S; Lima, M; Castellano, MV; Coletta, E; Parra, ER; Capelozzi, VL				Souza, Paola da Costa; Dondo, Patricia Suemi; Souza, Gabriela; Lopes, Deborah; Moscardi, Marcel; Martinho, Vinicius de Miranda; de Mattos Lourenco, Rodolfo Daniel; Prieto, Tabatha; Balancin, Marcelo Luiz; Assato, Aline Kawassaki; Teodoro, Walcy Rosolia; Rodrigues, Silvia; Lima, Mariana; Castellano, Maria Vera; Coletta, Ester; Parra, Edwin Roger; Capelozzi, Vera Luiza			Comprehensive analysis of immune, extracellular matrices and pathogens profile in lung granulomatosis of unexplained etiology	HUMAN PATHOLOGY			English	Article						Granuloma; Immunohistochemistry; Immunofluorescence; PCR; Morphometry; Immune cells; Collagens	BRONCHOALVEOLAR LAVAGE; PULMONARY-FIBROSIS; HYPERSENSITIVITY; TUBERCULOSIS	This study analyzed the type 1 and type 2 T helper (Th1/Th2) cytokines (including interleukins), immune cellular, matrix profile, and pathogens in granulomas with unexplained etiology compared to those with infectious and noninfectious etiology. Surgical lung biopsies from 108 patients were retrospectively reviewed. Histochemistry, immunohistochemistry, immunofluorescence, morphometry and polymerase chain reaction were used, respectively, to evaluate total collagen and elastin fibers, collagen I and III, immune cells, cytokines, matrix metalloproteinase-9, myofibroblasts, and multiple usual and unusual pathogens. No relevant polymerase chain reaction expression was found in unexplained granulomas. A significant difference was found between the absolute number of eosinophils, macrophages, and lymphocytes within granulomas compared to uninvolved lung tissue. Granulomas with unexplained etiology (UEG) presented increased number of eosinophils and high expression of interleukins (ILs) IL-4/IL-5 and transforming growth factor-beta. In sarcoidosis, CD4/CD8 cell number was significantly higher within and outside granulomas, respectively; the opposite was detected in hypersensitivity pneumonitis. Again, a significant difference was found between the high number of myofibroblasts and matrix metalloproteinase-9 in UEG, hypersensitivity pneumonitis, and sarcoidosis compared to granulomas of tuberculosis. Granulomas of paracoccidioisis exhibited increased type I collagen and elastic fibers. Th1 immune cellular profile was similar among granulomas with unexplained, infectious, and noninfectious etiology. In contrast, modulation of Th2 and matrix remodeling was associated with more fibroelastogenesis and scarring of lung tissue in UEG compared to infectious and noninfectious. We concluded that IL-4/IL-5 and transforming growth factor-beta might be used as surrogate markers of early fibrosis, reducing the need for genotyping, and promise therapeutic target in unexplained granulomas. (C) 2018 Elsevier Inc. All rights reserved.	[Souza, Paola da Costa; Dondo, Patricia Suemi; Souza, Gabriela; Lopes, Deborah; Moscardi, Marcel; Martinho, Vinicius de Miranda; de Mattos Lourenco, Rodolfo Daniel; Prieto, Tabatha; Balancin, Marcelo Luiz; Assato, Aline Kawassaki; Capelozzi, Vera Luiza] Univ Sao Paulo, Fac Med, Dept Pathol, Av Dr Arnaldo 455,Room 1143, BR-01246903 Sao Paulo, SP, Brazil; [Teodoro, Walcy Rosolia] Univ Sao Paulo, Fac Med, Rheumatol Div, BR-01246903 Sao Paulo, Brazil; [Rodrigues, Silvia; Lima, Mariana; Castellano, Maria Vera; Coletta, Ester] Hosp Servidor Publ Estadual, Div Resp Dis, BR-04029000 Sao Paulo, Brazil; [Parra, Edwin Roger] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA	Capelozzi, VL (reprint author), Univ Sao Paulo, Fac Med, Dept Pathol, Av Dr Arnaldo 455,Room 1143, BR-01246903 Sao Paulo, SP, Brazil.	vera.capelozzi@fm.usp.br	CAPELOZZI, VERA LUIZA/N-1737-2019; Teodoro, Walcy Paganelli Rosolia/H-5133-2017	CAPELOZZI, VERA LUIZA/0000-0001-9732-5853; Teodoro, Walcy Paganelli Rosolia/0000-0002-7846-7730; delmonte, samuel/0000-0002-3289-4577; Balancin, Marcelo/0000-0003-3798-8414; prieto, tabatha/0000-0002-2615-6922	Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [FAPESP 2014-19921, 2014-17053-2, 13359-0, 12959-3]; Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational Council for Scientific and Technological Development (CNPq) [CNPq 483005/2012-6, CNPq 150625/2013-8]	The authors received research grants from Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP 2014-19921, 2014-17053-2, 13359-0, 12959-3) and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq 483005/2012-6, CNPq 150625/2013-8).	Al Shammari B, 2015, J INFECT DIS, V212, P463, DOI 10.1093/infdis/jiv076; Caillaud Denis M., 2012, Inflammation & Allergy Drug Targets, V11, P15; Dorhoi A, 2016, SEMIN IMMUNOPATHOL, V38, P153, DOI 10.1007/s00281-015-0531-3; Fallowfield Jonathan A, 2006, Clin Liver Dis, V10, P481, DOI 10.1016/j.cld.2006.08.022; Gentilini MV, 2011, IMMUNOBIOLOGY, V216, P1054, DOI 10.1016/j.imbio.2011.02.002; Goldsby R, 2004, KUBY IMMUNOLOGY; HEINZEL FP, 1995, CURR OPIN INFECT DIS, V8, P151, DOI 10.1097/00001432-199506000-00002; Issa R, 2004, GASTROENTEROLOGY, V126, P1795, DOI 10.1053/j.gastro.2004.03.009; Johansson A, 2002, CANCER-AM CANCER SOC, V94, P1306, DOI 10.1002/cncr.10301; Knudsen L, 2017, CELL TISSUE RES, V367, P607, DOI 10.1007/s00441-016-2543-2; Kobayashi K, 2001, MICROSC RES TECHNIQ, V53, P241, DOI 10.1002/jemt.1090; Kunkel SL, 1996, SARCOIDOSIS VASC DIF, V13, P120; Liang ZZ, 2017, GENET MOL RES, V16, DOI 10.4238/gmr16019329; Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189; Mukhopadhyay S, 2010, ARCH PATHOL LAB MED, V134, P667, DOI 10.1043/1543-2165-134.5.667; Oda K, 2014, RESPIR INVESTIG, V52, P179, DOI 10.1016/j.resinv.2013.12.003; Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007; Ricard-Blum S, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004978; Rosen Y, 2015, ARCH PATHOL LAB MED, V139, P252, DOI 10.5858/arpa.2014-0051-RA; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Thannickal VJ, 2004, ANNU REV MED, V55, P395, DOI 10.1146/annurev.55.091902.103810; ULBRIGHT TM, 1980, AM J SURG PATHOL, V4, P13, DOI 10.1097/00000478-198004010-00002; WILLIAMS GT, 1983, J CLIN PATHOL, V36, P723, DOI 10.1136/jcp.36.7.723	23	1	1	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAY	2018	75						104	115		10.1016/j.humpath.2018.01.018			12	Pathology	Pathology	GI2YQ	WOS:000434238200013	29410258				2019-10-28	
J	Li, GH; Dong, TT; Yang, D; Gao, AQ; Luo, JD; Yang, HY; Wang, LL				Li, Guanhua; Dong, Taotao; Yang, Dong; Gao, Aiqin; Luo, Judong; Yang, Hongyan; Wang, Linlin			Progranulin promotes lymphangiogenesis through VEGF-C and is an independent risk factor in human esophageal cancers	HUMAN PATHOLOGY			English	Article						Progranulin; VEGF-C; Lymphangiogenesis; Esophageal cancer; Nomogram	ENDOTHELIAL GROWTH-FACTOR; LYMPH-NODE METASTASIS; SQUAMOUS-CELL CARCINOMAS; TUMOR LYMPHANGIOGENESIS; SIGNALING PATHWAYS; INVASION; ERK; ANGIOGENESIS; RECURRENCE; EXPRESSION	Lymph node metastasis is one of the most important predictors of the prognosis for esophageal cancer (EC) patients. However, the mechanism underlying the lymph node metastasis is largely unknown. Progranulin (PGRN) is shown to be highly expressed in various types of cancers and could promote the angiogenesis and epithelial-mesenchymal transition of cancer cells in previous studies. However, the expression status of PGRN and its effects on the lymphangiogenesis in EC are largely unclear. In this study, we show for the first time that PGRN is expressed in EC tissue samples and cell lines and could promote the expression of VEGF-C in vitro, a well-known lymphangiogenesis inducer, through the putative signaling transducers p-ERK and p-AKT. Besides, increased levels of PGRN are correlated with lymph node metastasis, high levels of lymph microvessel density, and lymph vessel space invasion in tissue samples of EC patients. In addition, Cox proportional risk model shows that patients with high levels of PGRN would have 2-fold increases in 5-year mortality compared with patients with low levels of PGRN. Finally, we establish a clinically useful nomogram to predict the possibility of mortality for individual EC patients. In conclusion, PGRN may play an important role in the lymphangiogenesis through activation of VEGF-C in the EC patients. (C) 2018 Elsevier Inc. All rights reserved.	[Li, Guanhua] Shandong Univ, Jinan Cent Hosp, Dept Resp, Jinan 250013, Shandong, Peoples R China; [Dong, Taotao] Shandong Univ, Qilu Hosp, Dept Gynecol & Obstet, Jinan 250012, Shandong, Peoples R China; [Yang, Dong] Jining Med Univ, Affiliated Hosp, Dept Oncol, Jining 272129, Shandong, Peoples R China; [Gao, Aiqin; Yang, Hongyan; Wang, Linlin] Shandong Univ, Jinan Cent Hosp, Dept Oncol, Jinan 250013, Shandong, Peoples R China; [Luo, Judong; Wang, Linlin] Shandong Univ, Shandong Acad Med Sci, Shandong Canc Hosp, Dept Radiat Oncol, Jinan 250117, Shandong, Peoples R China	Wang, LL (reprint author), Shandong Univ, Shandong Acad Med Sci, Shandong Canc Hosp, Dept Radiat Oncol, Jinan 250117, Shandong, Peoples R China.	wanglinlinatjn@163.com			Project of Postdoctoral Science Foundation of China [2016M590640, 2016M592199]; Project of Postdoctoral Innovation of Shandong Province [201501010, 201601006]; Project of Medical and Health Technology Development Program in Shandong Province [2014WS0003]; Natural Science Foundation of Shandong ProvinceNatural Science Foundation of Shandong Province [ZR2016HM41]; Project of the National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81402299]	This research work was supported by the Project of Postdoctoral Science Foundation of China (Grant Nos. 2016M590640 and 2016M592199), the Project of Postdoctoral Innovation of Shandong Province (Grant Nos. 201501010 and 201601006), the Project of Medical and Health Technology Development Program in Shandong Province (Grant No. 2014WS0003), the Natural Science Foundation of Shandong Province (Grant No. ZR2016HM41), and the Project of the National Natural Science Foundation of China (Grant No. 81402299).	Achen MG, 2008, ANN NY ACAD SCI, V1131, P225, DOI 10.1196/annals.1413.020; Choi JU, 2017, BIOMATERIALS, V139, P56, DOI 10.1016/j.biomaterials.2017.05.026; Daly JM, 2000, J AM COLL SURGEONS, V190, P573, DOI 10.1016/S1072-7515(00)00275-1; Daly JM, 2000, J AM COLL SURGEONS, V190, P562, DOI 10.1016/S1072-7515(00)00238-6; Deng Y, 2013, CELL CYCLE, V12, P1157, DOI 10.4161/cc.24491; Dong TT, 2016, EXP MOL PATHOL, V100, P17, DOI 10.1016/j.yexmp.2015.11.021; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Feng YK, 2011, EUR J CANCER, V47, P2353, DOI 10.1016/j.ejca.2011.05.006; He YL, 2002, J NATL CANCER I, V94, P819, DOI 10.1093/jnci/94.11.819; Hirakawa S, 2007, BLOOD, V109, P1010, DOI 10.1182/blood-2006-05-021758; Huang HL, 2015, INT J CLIN EXP PATHO, V8, P8809; Joukov V, 1996, EMBO J, V15, P290; Karpanen T, 2001, CANCER RES, V61, P1786; Kimura H, 1999, DIS ESOPHAGUS, V12, P205; Kitadai Y, 2001, INT J CANCER, V93, P662, DOI 10.1002/ijc.1379; Kitano H, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1241-5; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; Li K, 2002, INT J CANCER, V102, P271, DOI 10.1002/jhc.10706; Lin C, 2015, ONCOGENE, V34, P332, DOI 10.1038/onc.2013.559; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Mariette C, 2003, CANCER-AM CANCER SOC, V97, P1616, DOI 10.1002/cncr.11228; Ooki A, 2007, WORLD J SURG, V31, P2184, DOI 10.1007/s00268-007-9198-9; Palma LMA, 2015, CRIT REV ONCOL HEMAT, V93, P225, DOI 10.1016/j.critrevonc.2014.10.007; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Sato T, 2006, INT J ONCOL, V28, P1043; Schoppmann SF, 2013, SURGERY, V153, P526, DOI 10.1016/j.surg.2012.10.007; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Su JL, 2006, CANCER CELL, V9, P209, DOI 10.1016/j.ccr.2006.02.018; Wang LL, 2017, ONCOTARGET, V8, P26323, DOI 10.18632/oncotarget.15461; Yang D, 2015, AM J CANCER RES, V5, P3085; Zhang XD, 2012, AM J REPROD IMMUNOL, V67, P216, DOI 10.1111/j.1600-0897.2011.01080.x; Zlotnik A, 2015, STATA J, V15, P537, DOI 10.1177/1536867X1501500212	32	1	1	1	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAY	2018	75						116	124		10.1016/j.humpath.2018.02.008			9	Pathology	Pathology	GI2YQ	WOS:000434238200014	29452214				2019-10-28	
J	McCroskey, Z; Koen, TM; Lim, DJ; Divatia, MK; Shen, SS; Ayala, AG; Ro, JY				McCroskey, Zulfia; Koen, Trade M.; Lim, David J.; Divatia, Mukul K.; Shen, Steven S.; Ayala, Alberto G.; Ro, Jae Y.			Prostatic adenocarcinoma in the setting of persistent mullerian duct syndrome: a case report	HUMAN PATHOLOGY			English	Article						Persistent mullerian duct syndrome; Rudimentary uterus; Cryptorchidism; Prostate cancer		Persistent mullerian duct syndrome (PMDS) is a form of disordered sex development in which rudimentary mullerian structures are identified in phenotypically and genotypically normal males. It is caused by defects in the anti-mullerian hormone (AMH) system. Since patients with PMDS present with undescended testes, testosterone production by Leydig cells later in life is often decreased. The role of androgens in prostate cancerogenesis is well known. Cryptorchid testes and diminished testosterone levels in post-pubertal life in patients with PMDS play a protective role against prostate cancer, and hence, prostate cancer is a rare event in patients with PMDS. Herein, we present a patient who underwent prostatectomy for high-grade prostatic adenocarcinoma with persistent mullerian structures (such as rudimentary uterus, fallopian tubes, and cervix) identified during surgery. To our knowledge, this is the second case reported in the English language literature where PMDS was associated with prostate cancer. (C) 2017 Elsevier Inc. All rights reserved.	[McCroskey, Zulfia; Koen, Trade M.; Divatia, Mukul K.; Shen, Steven S.; Ayala, Alberto G.; Ro, Jae Y.] Cornell Univ, Weill Med Coll, Houston Methodist Hosp, Dept Pathol & Genom Med, 6565 Fannin St, Houston, TX 77030 USA; [Lim, David J.] Houston Methodist Hosp, Dept Urol, Houston, TX 77030 USA	Ro, JY (reprint author), Cornell Univ, Weill Med Coll, Houston Methodist Hosp, Dept Pathol & Genom Med, 6565 Fannin St, Houston, TX 77030 USA.	zulfia.mccroskey@mykolab.com; TMKoen@houstonmethodist.org; davidjblim@yahoo.com; mdivatia@hustonmethodist.org; stevenshen@houstonmethodist.org; aayala@hostonmethodist.org; jaero@houstonmethodist.org					Berkmen F, 1997, BRIT J UROL, V79, P122, DOI 10.1046/j.1464-410X.1997.27226.x; Bosland MC, 2006, ANN NY ACAD SCI, V1089, P168, DOI 10.1196/annals.1386.040; Bosland Maarten C, 2015, Curr Pharmacol Rep, V1, P258; Boyle P, 2016, BJU INT, V118, P731, DOI 10.1111/bju.13417; Dueilas A, 2001, REV INVEST CLIN, V2, P193; El-Sherbiny M, 2013, ARAB J UROL, V11, P19, DOI 10.1016/j.aju.2012.11.005; Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530; Finlayson C, 2017, J UROLOGY, V197, P937, DOI 10.1016/j.juro.2016.08.108; Karavitakis M, 2011, PROSTATE CANCER P D, V14, P46, DOI 10.1038/pcan.2010.16; Kovachev SM, 2014, ISR MED ASSOC J, V16, P735; Lang-Muritano M, 2001, EUR J PEDIATR, V160, P652, DOI 10.1007/s004310100840; Lee PA, 2002, J UROLOGY, V167, P1824, DOI 10.1016/S0022-5347(05)65241-X; Loeb S, 2017, J CLIN ONCOL, V35, P1430, DOI 10.1200/JCO.2016.69.5304; Manjunath BG, 2010, INDIAN J SURG, V72, P20, DOI 10.1007/s12262-010-0003-x; Matuszczak E, 2013, INT J ENDOCRINOL, DOI 10.1155/2013/128907; Mitre AI, 2002, UROLOGY, V4, P698; Nayak Vaibhav J, 2014, Int J Appl Basic Med Res, V4, P125, DOI 10.4103/2229-516X.136805; Ohnesorg T, 2014, SEX DEV, V8, P262, DOI 10.1159/000357956; Slater S, 2000, DRUG AGING, V17, P431, DOI 10.2165/00002512-200017060-00001; van der Zwan YG, 2012, SEX DEV, V6, P279, DOI 10.1159/000339704; Vandersteen DR, 1997, UROLOGY, V49, P941, DOI 10.1016/S0090-4295(97)00104-0; Wu JA, 2014, UROLOGY, V83, P915, DOI 10.1016/j.urology.2013.10.006; Wuerstle M, 2007, J PEDIATR SURG, V42, P2116, DOI 10.1016/j.jpedsurg.2007.09.003	23	0	0	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAY	2018	75						125	131		10.1016/j.humpath.2017.10.033			7	Pathology	Pathology	GI2YQ	WOS:000434238200015	29137935				2019-10-28	
J	Taneja, K; Arora, S; Rogers, CG; Gupta, NS; Cheng, L; Williamson, SR				Taneja, Kanika; Arora, Sohrab; Rogers, Craig G.; Gupta, Nitesh S.; Cheng, Liang; Williamson, Sean R.			Unclassified hemangioma-like renal cell carcinoma: a potential diagnostic pitfall	HUMAN PATHOLOGY			English	Article						Hemangioma; Clear cell renal cell carcinoma; Unclassified renal cell carcinoma; Kidney cancer; Partial nephrectomy; Immunohistochemistry	TUMOR-LIKE LESIONS; BENIGN VASCULAR TUMORS; BREAK-APART FISH; CLINICOPATHOLOGICAL ANALYSIS; ANASTOMOSING HEMANGIOMA; KIDNEY; DISTINCT; ENTITY; TFE3	Recently, rare renal cell carcinomas (RCCs) have been reported to closely mimic hemangioma; however, these have been largely recognizable as clear cell RCC. Conversely, true hemangiomas of the kidney are also increasingly recognized. We report a 62-year-old woman who underwent partial nephrectomy for a hemangioma-like RCC without appreciable clear cell morphology. Immunohistochemistry revealed luminal structures that stained positively for cytokeratin, cytokeratin 7, carbonic anhydrase IX, PAX8, and high-molecular-weight keratin, admixed with a CD34-positive, CD31-positive, and ERG-positive complex network of vessels. Staining was minimal for alpha-methyl-acyl-coA-racemase and EMA, and absent for GATA3, HMB45, melan-A, and cathepsin K. Fluorescence in situ hybridization revealed no TFE3 or TFEB rearrangement, 3p deletion, or trisomy 7 or 17. This case adds to the spectrum of hemangioma-like RCC with differing morphology and immunophenotype. Further study will determine whether this represents a distinct entity or an unusual pattern of degenerative changes in an existing entity. (C) 2017 Elsevier Inc. All rights reserved.	[Taneja, Kanika; Gupta, Nitesh S.; Williamson, Sean R.] Henry Ford Hlth Syst, Dept Pathol & Lab Med, Detroit, MI 48202 USA; [Taneja, Kanika; Gupta, Nitesh S.; Williamson, Sean R.] Henry Ford Hlth Syst, Henry Ford Canc Inst, Detroit, MI 48202 USA; [Arora, Sohrab; Rogers, Craig G.] Henry Ford Hlth Syst, Vattikuti Urol Inst, Detroit, MI 48202 USA; [Cheng, Liang] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA; [Williamson, Sean R.] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Williamson, SR (reprint author), Henry Ford Hosp, Dept Pathol, K6,2799 W Grand Blvd, Detroit, MI 48202 USA.	swilli25@hfhs.org					Brown JG, 2010, AM J SURG PATHOL, V34, P942, DOI 10.1097/PAS.0b013e3181e4f32a; Green WM, 2013, AM J SURG PATHOL, V37, P1150, DOI 10.1097/PAS.0b013e31828a69ae; John I, 2016, AM J SURG PATHOL, V40, P1084, DOI 10.1097/PAS.0000000000000627; Kryvenko ON, 2014, HISTOPATHOLOGY, V65, P309, DOI 10.1111/his.12394; Kryvenko ON, 2013, ARCH PATHOL LAB MED, V137, P251, DOI 10.5858/arpa.2011-0615-OA; Kryvenko ON, 2011, AM J CLIN PATHOL, V136, P450, DOI 10.1309/AJCPJPW34QCQYTMT; Mantilla JG, 2017, HUM PATHOL, V66, P152, DOI 10.1016/j.humpath.2017.06.016; Martignoni G, 2017, PATHOLOGY, V49, P10, DOI 10.1016/j.pathol.2016.05.014; Matsuzaki K, 2015, CUAJ-CAN UROL ASSOC, V9, pE33, DOI 10.5489/cuaj.2272; Mehta V, 2012, VIRCHOWS ARCH, V461, P669, DOI 10.1007/s00428-012-1333-9; Montgomery E, 2009, AM J SURG PATHOL, V33, P1364, DOI 10.1097/PAS.0b013e3181ad30a7; Rao Q, 2013, AM J SURG PATHOL, V37, P804, DOI 10.1097/PAS.0b013e31827e17cb; Tran T, 2016, HISTOPATHOLOGY, V68, P850, DOI 10.1111/his.12840; Verine J, 2013, VIRCHOWS ARCH, V462, P365, DOI 10.1007/s00428-013-1379-3; Williamson SR, 2015, MODERN PATHOL, V28, P279, DOI 10.1038/modpathol.2014.105; Williamson SR, 2013, MODERN PATHOL, V26, P697, DOI 10.1038/modpathol.2012.204	16	2	2	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAY	2018	75						132	136		10.1016/j.humpath.2017.09.015			5	Pathology	Pathology	GI2YQ	WOS:000434238200016	29104112				2019-10-28	
J	Xu, TX; Ma, M; Dai, J; Yu, SF; Wu, XW; Tang, H; Yu, JY; Yan, JY; Yu, H; Chi, ZH; Si, L; Sheng, XA; Cui, CL; Kong, Y; Guo, J				Xu, Tianxiao; Ma, Meng; Dai, Jie; Yu, Sifan; Wu, Xiaowen; Tang, Huan; Yu, Jiayi; Yan, Junya; Yu, Huan; Chi, Zhihong; Si, Lu; Sheng, Xinan; Cui, Chuanliang; Kong, Yan; Guo, Jun			Gene expression screening identifies CDCA5 as a potential therapeutic target in acral melanoma	HUMAN PATHOLOGY			English	Article						Microarray gene expression; Acral melanoma; Lymph node metastasis; Cell division cycle-associated 5 (CDCA5); Therapeutic target	SISTER-CHROMATID COHESION; CYCLE-ASSOCIATED 5; METASTATIC MELANOMA; CUTANEOUS MELANOMA; CELL-DIVISION; NODE BIOPSY; BRAF; SORORIN; CHINESE; PHOSPHORYLATION	Acral melanoma (AM) is a rapidly progressing subtype of melanoma with poor prognosis. The complete array of molecular changes that occur during AM metastasis remains unclear. In this study, we compared the gene expression profiles of 6 primary and 12 lymph node metastatic AM samples by tissue microarray analysis. We found that the expression levels of 396 genes were increased and that of 766 genes were decreased in the metastatic tissues compared with that in the primary tumors. The top 19 genes upregulated in the metastatic tissue specimens were selected for high-content short interfering RNA screening. We found that inhibition of cell division cycle associated 5 (CDCA5) significantly suppressed AM cell migration and invasion. Furthermore, we demonstrated that upregulation of CDCA5 was correlated with higher tumor-node-metastases stages (P = .025) and a shorter disease-free survival in patients with AM (P = .038). Cox regression analyses showed that high CDCA5 expression was also an independent factor of disease-free survival for patients with AM (hazard ratio =1.86, P = .041). Overall, our data define the gene expression signature of AM metastasis and indicate that CDCA5 is a potential therapeutic target in AM. (C) 2018 Elsevier Inc. All rights reserved.	[Xu, Tianxiao; Ma, Meng; Dai, Jie; Yu, Sifan; Wu, Xiaowen; Tang, Huan; Yu, Jiayi; Yan, Junya; Yu, Huan; Chi, Zhihong; Si, Lu; Sheng, Xinan; Cui, Chuanliang; Kong, Yan; Guo, Jun] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Renal Canc & Melanoma, Minist Educ Beijing, 52 Fucheng Rd, Beijing 100142, Peoples R China	Kong, Y; Guo, J (reprint author), Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Renal Canc & Melanoma, Minist Educ Beijing, 52 Fucheng Rd, Beijing 100142, Peoples R China.	k-yan08@163.com; guoj307@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81672696, 81772912]; Beijing Municipal Natural Science FoundationBeijing Natural Science Foundation [7152033]; Beijing Baiqianwan Talents Project; Beijing Municipal Administration of Hospitals [ZYLX201603]; Beijing Municipal Science and Technology Commission Beijing, ChinaBeijing Municipal Science & Technology Commission [Z151100003915074]	This work was supported by grants from National Natural Science Foundation of China (81672696; 81772912), Beijing Municipal Natural Science Foundation (7152033), Beijing Baiqianwan Talents Project, Beijing Municipal Administration of Hospitals Clinical Medicine Development of special funding support (ZYLX201603), and Beijing Municipal Science and Technology Commission (Z151100003915074) Beijing, China..	Antonov J, 2005, LAB INVEST, V85, P1040, DOI 10.1038/labinvest.3700303; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bidkhori G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067552; Braeuer RR, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12172; Carvajal RD, 2011, JAMA-J AM MED ASSOC, V305, P2327, DOI 10.1001/jama.2011.746; Chang IW, 2015, AM J TRANSL RES, V7, P710; Chi ZH, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-85; Chiang IT, 2015, ONCOL REP, V34, P1853, DOI 10.3892/or.2015.4159; Dreier MR, 2011, J CELL SCI, V124, P2976, DOI 10.1242/jcs.085431; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Hayward NK, 2017, NATURE, V545, P175, DOI 10.1038/nature22071; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Ito T, 2015, J AM ACAD DERMATOL, V72, P71, DOI 10.1016/j.jaad.2014.10.008; Johnson DB, 2015, ONCOLOGIST, V20, P648, DOI 10.1634/theoncologist.2014-0468; Kato T, 2016, INT J ONCOL, V49, P2411, DOI 10.3892/ijo.2016.3765; Koh SS, 2012, MODERN PATHOL, V25, P828, DOI 10.1038/modpathol.2012.32; Kong Y, 2017, CLIN CANCER RES, V23, P6946, DOI 10.1158/1078-0432.CCR-17-0070; Kong Y, 2011, CLIN CANCER RES, V17, P1684, DOI 10.1158/1078-0432.CCR-10-2346; Ladurner R, 2016, EMBO J, V35, P635, DOI 10.15252/embj.201592532; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Manola J, 2000, J CLIN ONCOL, V18, P3782, DOI 10.1200/JCO.2000.18.22.3782; Morton DL, 2006, NEW ENGL J MED, V355, P1307, DOI 10.1056/NEJMoa060992; Nguyen MH, 2010, CANCER RES, V70, P5337, DOI 10.1158/0008-5472.CAN-09-4372; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Saldanha G, 2006, CLIN CANCER RES, V12, P4499, DOI 10.1158/1078-0432.CCR-05-2447; Schmitz J, 2007, CURR BIOL, V17, P630, DOI 10.1016/j.cub.2007.02.029; Sebastian M, 2010, J THORAC ONCOL, V5, P1060, DOI 10.1097/JTO.0b013e3181d95dd4; Si L, 2013, CURR OPIN ONCOL, V25, P160, DOI 10.1097/CCO.0b013e32835dafcc; Si L, 2012, EUR J CANCER, V48, P94, DOI 10.1016/j.ejca.2011.06.056; Tanaka TU, 2000, NAT CELL BIOL, V2, P492; Tokuzen N, 2016, ONCOTARGET, V7, P2343, DOI 10.18632/oncotarget.6148; Tsao H, 2004, NEW ENGL J MED, V351, P998, DOI 10.1056/NEJMra041245; Turajlic S, 2012, GENOME RES, V22, P196, DOI 10.1101/gr.125591.111; Walker MG, 2001, CURR CANCER DRUG TAR, V1, P73, DOI 10.2174/1568009013334241	35	2	2	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAY	2018	75						137	145		10.1016/j.humpath.2018.02.009			9	Pathology	Pathology	GI2YQ	WOS:000434238200017	29452217				2019-10-28	
J	Adewuyi, EE; Deschenes, J; Lopez-Campistrous, A; Kattar, MM; Ghosh, S; McMullen, TPW				Adewuyi, Esther Ekpe; Deschenes, Jean; Lopez-Campistrous, Ana; Kattar, Mireille M.; Ghosh, Sunita; McMullen, Todd P. W.			Autocrine activation of platelet-derived growth factor receptor alpha in metastatic papillary thyroid cancer	HUMAN PATHOLOGY			English	Article						Platelet derived growth factor alpha; PDGFR alpha; Metastases; Autocrine; Diagnostic; Oncogene	GASTROINTESTINAL STROMAL TUMORS; SQUAMOUS-CELL CARCINOMA; FACTOR-AA; PDGF; EXPRESSION; MUTATIONS; MICROENVIRONMENT; TUMORIGENESIS; RECURRENCE; DIAGNOSIS	Metastatic dissemination of papillary thyroid cancer has been reported to be strongly associated with expression of platelet-derived growth factor (PDGFR) alpha and altered TTF1 function. However, the status of PDGF ligands in papillary thyroid cancer and the potential role of these ligands in metastatic disease are obscure. We assessed the prevalence of PDGF ligands in benign and malignant thyroid tumors to determine if ligand upregulation is associated with alpha-isoform (PDGF-AA or PDGF-BB) or the beta-isoform (PDGF-BB or PDGF-DD) of PDGFR in individual tumors. The immunohistochemical expression of PDGFR alpha, PDGF-AA, PDGF-BB, and PDGF-DD was surveyed in follicular adenomas (n = 55), papillary thyroid carcinomas (103 with and 59 without nodal metastases), and lymph node metastasis (n = 12). There is an augmented tendency for PDGF-AA expression in node-positive papillary thyroid cancer metastases (P < .0001). Although PDGF-BB and -DD were commonly identified, there was no relationship between the presence of these cytokines and malignant disease or metastases. Logistic regression demonstrated that PDGF-AA expression was significantly associated with the presence of PDGFR alpha (odds ratio = 4.6, P = .004) and recurrent disease. When either PDGFRa or PDGF-AA was used to predict the presence of metastases, the sensitivity achieved was 86% and 88%, respectively, whereas specificities were lower at 71% and 61%, respectively. The augmented coexpression of PDGF-AA and PDGFRa in metastatic papillary thyroid cancers suggests that an autocrine signaling loop may contribute to nodal infiltration. Combined testing for the expression of PDGF-AA and PDGFR alpha may identify those patients with papillary thyroid cancer at risk of metastatic disease and resistance to therapy. (C) 2018 Elsevier Inc. All rights reserved.	[Adewuyi, Esther Ekpe; Lopez-Campistrous, Ana; McMullen, Todd P. W.] Univ Alberta, Dept Surg, Edmonton, AB T6G 2H7, Canada; [Deschenes, Jean; Kattar, Mireille M.] Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB T6G 2H7, Canada; [Ghosh, Sunita; McMullen, Todd P. W.] Univ Alberta, Dept Oncol, Edmonton, AB T6G 2H7, Canada	McMullen, TPW (reprint author), Cross Canc Inst, Div Surg Oncol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.; McMullen, TPW (reprint author), Univ Alberta, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.	todd.mcmullen@ualberta.ca					Al-Hilli Z, 2016, AM J SURG, V212, P1147, DOI 10.1016/j.amjsurg.2016.09.014; Ball SG, 2007, J CELL BIOL, V177, P489, DOI 10.1083/jcb.200608093; Barnhill RL, 1996, BRIT J DERMATOL, V135, P898, DOI 10.1046/j.1365-2133.1996.d01-1092.x; Barreca A, 2011, MOL MED REP, V4, P3, DOI 10.3892/mmr.2010.399; Beaudenon-Huibregtse S, 2014, THYROID, V24, P1479, DOI 10.1089/thy.2013.0640; Chen KT, 2006, CANCER LETT, V231, P192, DOI 10.1016/j.canlet.2005.01.039; Delitto D, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1820-x; Dima M, 2016, ENDOCRINE, V53, P145, DOI 10.1007/s12020-015-0739-y; Duh QY, 2017, THYROID, V27, P1215, DOI 10.1089/thy.2016.0656; Ekpe-Adewuyi E, 2016, ONCOTARGET, V7, P83684, DOI 10.18632/oncotarget.13299; Eustatia-Rutten CFA, 2004, CLIN ENDOCRINOL, V61, P61, DOI 10.1111/j.1365-2265.2004.02060.x; Fredriksson L, 2004, CYTOKINE GROWTH F R, V15, P197, DOI 10.1016/j.cytogfr.2004.03.007; Gonzalez-Campora R, 2011, ANAL QUANT CYTOL, V33, P1; Heldin CH, 2018, J INTERN MED, V283, P16, DOI 10.1111/joim.12690; Holzer TR, 2016, J HISTOCHEM CYTOCHEM, V64, P785, DOI 10.1369/0022155416673979; Ito Y, 2006, WORLD J SURG, V30, P91, DOI 10.1007/s00268-005-0113-y; Ito Y, 2008, WORLD J SURG, V32, P729, DOI 10.1007/s00268-007-9315-9; Jung CK, 2014, J CLIN ENDOCR METAB, V99, pE276, DOI 10.1210/jc.2013-2503; Kim MJ, 2012, MOL MED REP, V5, P1267, DOI 10.3892/mmr.2012.784; Kitahara CM, 2016, NAT REV ENDOCRINOL, V12, P646, DOI 10.1038/nrendo.2016.110; Lopez-Campistrous A, 2016, EBIOMEDICINE, V12, P86, DOI 10.1016/j.ebiom.2016.09.007; Machens A, 2002, WORLD J SURG, V26, P22; Malkomes P, 2011, LANGENBECK ARCH SURG, V396, P1165, DOI 10.1007/s00423-011-0799-2; MAZZAFERRI EL, 1994, AM J MED, V97, P418, DOI 10.1016/0002-9343(94)90321-2; Otaka Y, 2017, CLIN CANCER RES, V23, P3442, DOI 10.1158/1078-0432.CCR-16-1815; Pan HD, 2017, WORLD J GASTROENTERO, V23, P1233, DOI 10.3748/wjg.v23.i7.1233; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Rotstein L, 2009, J SURG ONCOL, V99, P186, DOI 10.1002/jso.21234; Sulzbacher I, 2000, MODERN PATHOL, V13, P632, DOI 10.1038/modpathol.3880109; Topstad Dawnelle, 2017, CMAJ Open, V5, pE612, DOI 10.9778/cmajo.20160162; Watts TL, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1091-6; Yu GZ, 2015, ONCOTARGET, V6, P11281, DOI 10.18632/oncotarget.3596; Zhang JD, 2012, J PATHOL, V228, P241, DOI 10.1002/path.4069	33	0	0	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAY	2018	75						146	153		10.1016/j.humpath.2018.01.0025			8	Pathology	Pathology	GI2YQ	WOS:000434238200018	29408504				2019-10-28	
J	Conant, JL; Rabinowitz, I; Zhang, QY				Conant, Joanna L.; Rabinowitz, Ian; Zhang, Qian-Yun			Transient monoclonal gammopathy induced by Candida fungemia	HUMAN PATHOLOGY			English	Article						Transient MGUS; Candida albicans; MGUS Transient gammopathy; Reactive gammopathy; Candida; Fungemia	INFECTION	A 41-year-old woman was admitted for Candida fungemia. On hospital day 4, a routine complete blood count and peripheral smear showed circulating plasma cells. Initial workup showed an M-component on serum protein electrophoresis with 6% lambda-predominate plasma cells by flow cytometry. The patient was treated with intravenous antifungal therapy. Her 6-month follow-up laboratory evaluation revealed resolution of the M-component and only rare polyclonal plasma cells in peripheral blood by flow cytometry. This case illustrates that transient monoclonal gammopathy can be induced by fungal infection. It is important to exclude a plasma cell neoplasm or a B-cell lymphoma and to follow the patient until resolution of abnormal findings. (C) 2017 Elsevier Inc. All rights reserved.	[Conant, Joanna L.; Zhang, Qian-Yun] Univ New Mexico, Dept Hematopathol, Albuquerque, NM 87102 USA; [Rabinowitz, Ian] Univ New Mexico, Dept Hematol & Oncol, Albuquerque, NM 87106 USA	Conant, JL (reprint author), Univ New Mexico, Dept Hematopathol, 1001 Woodward PI NE, Albuquerque, NM 87113 USA.	jconant@salud.unm.edu		Conant, Joanna/0000-0001-8282-7172			Lu CYM, 2003, NEW ENGL J MED, V349, P1192, DOI 10.1056/NEJM200309183491222; McKenna RW, 2017, WHO CLASSIFICATION T, P241; Seve P, 2006, AM J HEMATOL, V81, P115, DOI 10.1002/ajh.20499; Stoimenis D, 2012, CASE REP MED, DOI 10.1155/2012/607104; Strobel SL, 2003, ANN CLIN LAB SCI, V33, P265; Vaiopoulos G, 2002, INFECTION, V30, P249, DOI 10.1007/s15010-002-2119-9; VODOPICK H, 1974, BLOOD, V44, P189, DOI 10.1182/blood.V44.2.189.189	7	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAY	2018	75						154	158		10.1016/j.humpath.2017.11.012			5	Pathology	Pathology	GI2YQ	WOS:000434238200019	29180248				2019-10-28	
J	Erickson, A; Sandeman, K; Landensuo, K; Nordling, S; Kallajoki, M; Seikkula, H; Butzow, A; Vasarainen, H; Bostrom, PJ; Taimen, P; Rannikko, A; Mirtti, T				Erickson, Andrew; Sandeman, Kevin; Landensuo, Kanerva; Nordling, Stig; Kallajoki, Markku; Seikkula, Heikki; Butzow, Anna; Vasarainen, Hanna; Bostrom, Peter J.; Taimen, Pekka; Rannikko, Antti; Mirtti, Tuomas			New prostate cancer grade grouping system predicts survival after radical prostatectomy	HUMAN PATHOLOGY			English	Article						Grade Group; Gleason grade; Prostate cancer; Survival; Competing risk analysis	ISUP CONSENSUS-CONFERENCE; 2014 INTERNATIONAL SOCIETY; TERM-FOLLOW-UP; UROLOGICAL-PATHOLOGY; VALIDATION; CARCINOMA; ANTIGEN; RECURRENCE; MANAGEMENT; OUTCOMES	Histological Gleason grading of prostate cancer has been through modifications and conjoined into a Grade Grouping system recently. The aim of this study was to determine whether the new Grade Grouping system predicts disease-specific and all-cause mortality after radical prostatectomy. We constructed a clinical database consisting of all consecutively radical prostatectomy treated men between 1983 and 1998 and between 2000 and 2005 at the Helsinki University Hospital and at the Turku University Hospital, respectively. Patients' all-cause and prostate cancer specific mortality information was updated in November 2015 from the Finnish Cancer Registry. Secondary therapy information was also available from the patients' records at Helsinki. Univariate and multivariate statistical analyses were performed to assess predictive significance of the Grade Grouping system. Grade Grouping associated independently with increased risk of prostate cancer specific mortality within 15 years of follow-up in a multivariable model containing age at operation, diagnostic prostate-specific antigen, pathological stage and lymph node status at operation. Additionally, the all-cause mortality-free survival time and time to secondary therapies were different between the Grade Groups, emphasized in the subanalysis of Grade Groups 1-2 versus Grade Groups 3-5. We can conclude that the new Grade Grouping system is feasible in predicting prostate cancer specific survival after radical surgical treatment. Grade Grouping offers a simpler way to interpret the predicted course of the disease to individual patients and thus may help in justifying more conservative follow-up approaches, especially in the lower Grade Group patients. (C) 2018 The Authors. Published by Elsevier Inc.	[Erickson, Andrew; Sandeman, Kevin; Nordling, Stig; Mirtti, Tuomas] Univ Helsinki, Dept Pathol, Med, FIN-00014 Helsinki, Finland; [Erickson, Andrew; Mirtti, Tuomas] Univ Helsinki, Inst Mol Med Finland FIMM, FIN-00014 Helsinki, Finland; [Sandeman, Kevin; Mirtti, Tuomas] Helsinki Univ Hosp, HUSLAB, Dept Pathol, Helsinki 00029, Finland; [Landensuo, Kanerva; Vasarainen, Hanna; Rannikko, Antti] Univ Helsinki, Clinicum, Dept Urol, FIN-00014 Helsinki, Finland; [Landensuo, Kanerva; Vasarainen, Hanna; Rannikko, Antti] Helsinki Univ Hosp, Helsinki 00014, Finland; [Kallajoki, Markku; Taimen, Pekka] Univ Turku, Dept Pathol, Turku 20521, Finland; [Kallajoki, Markku; Seikkula, Heikki; Bostrom, Peter J.; Taimen, Pekka] Turku Univ Hosp, Turku 20521, Finland; [Seikkula, Heikki; Bostrom, Peter J.] Univ Turku, Dept Urol, Turku 20521, Finland; [Butzow, Anna] United Medix Labs, Pathol, Helsinki 00310, Finland	Mirtti, T (reprint author), Helsinki Univ Hosp, Dept Pathol, HUSLAB, Med, Finland POB 400, FI-00029 Helsinki, Finland.; Mirtti, T (reprint author), Helsinki Univ Hosp, Inst Mol Med Finland FIMM, Finland POB 400, FI-00029 Helsinki, Finland.; Mirtti, T (reprint author), Univ Helsinki, Finland POB 400, FI-00029 Helsinki, Finland.	tuomas.mirtti@helsinki.fi		Rannikko, Antti/0000-0002-4261-3484; Mirtti, Tuomas/0000-0003-0455-9891	Cancer Society of Finland; Finnish Medical Foundation; Paivikki ja Sakari Sohlberg Foundation	We'd like to thank Anna But and Paula Bergman for their advice on statistical analysis, as well as Oscar Bruck and Dmitrii Bychov for their technical advice in R. This study was supported by Cancer Society of Finland, Finnish Medical Foundation (TM) and Paivikki ja Sakari Sohlberg Foundation (PT).	Abdollah F, 2015, EUR UROL, V68, P497, DOI 10.1016/j.eururo.2015.06.020; Amin MB, 2014, ARCH PATHOL LAB MED, V138, P1387, DOI 10.5858/arpa.2014-0219-SA; Baras AS, 2017, HUM PATHOL, V63, P27, DOI 10.1016/j.humpath.2016.12.008; Beauval JB, 2016, BMC UROL, V16, DOI 10.1186/s12894-016-0146-6; Berney DM, 2016, BRIT J CANCER, V114, P1078, DOI 10.1038/bjc.2016.86; Bjartell A, 2016, SCAND J UROL, V50, P255, DOI 10.1080/21681805.2016.1183226; Brimo F, 2013, EUR UROL, V63, P892, DOI 10.1016/j.eururo.2012.10.015; Dell'Oglio P, 2017, BRIT J CANCER, V116, pE2, DOI 10.1038/bjc.2016.346; Dell'Oglio P, 2017, PROSTATE, V77, P263, DOI 10.1002/pros.23265; Eggener SE, 2011, J UROLOGY, V185, P869, DOI 10.1016/j.juro.2010.10.057; Epstein JI, 2005, AM J SURG PATHOL, V29, P1228, DOI 10.1097/01.pas.0000173646.99337.b1; Epstein JI, 2017, AM J SURG PATHOL, V41, pE1, DOI 10.1097/PAS.0000000000000820; Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530; Epstein JI, 2016, EUR UROL, V69, P428, DOI 10.1016/j.eururo.2015.06.046; Epstein JI, 2010, J UROLOGY, V183, P433, DOI 10.1016/j.juro.2009.10.046; GLEASON DONALD F., 1966, CANCER CHEMO THERAP REP, V50, P125; Gordetsky JB, 2016, AM J SURG PATHOL, V40, P490, DOI 10.1097/PAS.0000000000000546; Grogan J, 2017, BJU INT, V120, P651, DOI 10.1111/bju.13857; He JM, 2017, EUR UROL, V71, P760, DOI 10.1016/j.eururo.2016.11.031; KURIYAMA M, 1981, CANCER RES, V41, P3874; Lahdensuo K, 2016, MODERN PATHOL, V29, P1565, DOI 10.1038/modpathol.2016.154; Lahdensuo K, 2015, SCAND J UROL, V49, P90, DOI 10.3109/21681805.2014.936494; LANGE PH, 1989, UROLOGY, V33, P13, DOI 10.1016/S0090-4295(89)80003-2; Loeb S, 2016, EUR UROL, V69, P1135, DOI 10.1016/j.eururo.2015.11.036; Lokman U, 2017, EUR UROL FOCUS, DOI [10.1016/j.euf2017.03.004, DOI 10.1016/j.euf2017.03.004]; Mathieu R, 2017, PROSTATE CANCER P D, V20, P197, DOI 10.1038/pcan.2016.66; Moch H, 2016, WHO CLASSIFICATION T; OESTERLING JE, 1988, J UROLOGY, V139, P766, DOI 10.1016/S0022-5347(17)42630-9; Pierorazio PM, 2013, BJU INT, V111, P753, DOI 10.1111/j.1464-410X.2012.11611.x; Spratt DE, 2016, PROSTATE CANCER P D, V19, P292, DOI 10.1038/pcan.2016.18; Spratt DE, 2016, BJU INT, V118, P763, DOI 10.1111/bju.13488; Stark JR, 2009, J CLIN ONCOL, V27, P3459, DOI 10.1200/JCO.2008.20.4669; Stephenson AJ, 2007, J CLIN ONCOL, V25, P2035, DOI 10.1200/JCO.2006.08.9607; Wright JL, 2009, J UROLOGY, V182, P2702, DOI 10.1016/j.juro.2009.08.026	34	4	4	2	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAY	2018	75						159	166		10.1016/j.humpath.2018.01.027			8	Pathology	Pathology	GI2YQ	WOS:000434238200020	29447924	Green Published			2019-10-28	
J	Yang, Y; Wu, QY; Li, N; Che, SL; Jin, TF; Nan, YZ; Lin, ZH; Chen, LY				Yang, Yang; Wu, Qunying; Li, Nan; Che, Shuanlong; Jin, Tiefeng; Nan, Yunze; Lin, Zhenhua; Chen, Liyan			Upregulation of Tiam1 contributes to cervical cancer disease progression and indicates poor survival. outcome	HUMAN PATHOLOGY			English	Article						Cervical cancer; Tiam1; Prognosis; Disease progression; Survival analysis	EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-CELL INVASION; COLORECTAL-CANCER; CARCINOMA; METASTASIS; EXPRESSION; BREAST; OVEREXPRESSION; ANGIOGENESIS; APOPTOSIS	T lymphoma invasion and metastasis 1 (Tiam 1), a guanine nucleotide exchange factor, is involved in the tumorigenesis of a number of malignancies. This study was aimed to explore the role of Tiam1 in cervical cancer progression, and evaluate the prognostic values. Tiam1 protein expression levels were detected by immunohistochemical (IHC) staining in 174 cervical cancer tissues, 92 of CINs (cervical intraepithelial neoplasia) and 32 of normal cervical epithelia tissues. Clinicopathological parameters and overall survival data were collected and compared between different Tiam 1 statuses. The role of Tiam1 in cervical cancer proliferation, migration and angiogenesis were detected using si-RNA (small interfering RNA) transfection. In results, Tiam1 protein showed a cytoplasmic and nuclear staining pattern in cervical cancer tissues. The strongly positive expression of Tiam1 protein was observed in 51.72% (90/174) of cervical cancers, which was significantly higher than in CINs and normal cervical epithelia tissues (9.38%, 3/32). High Tiam 1 protein expression was closely associated with advanced clinical stage, differentiation, lymph node (LN) metastasis, HPV infection and lower overall survival (OS) rates in cervical cancer. Multivariate analysis indicated that Tiam1 was an independent prognostic factor, along with clinical stage, in patients with cervical cancer. Additionally, Tiam1 depletion by RNAi in cervical cancer cells significantly decreased cell proliferation, migration and angiogenesis. In conclusion, our study demonstrated that upregulation of Tiam1 contributes to cervical cancer disease progression and indicates poor survival outcome. (C) 2018 Elsevier Inc. All rights reserved.	[Yang, Yang; Li, Nan; Che, Shuanlong; Jin, Tiefeng; Lin, Zhenhua; Chen, Liyan] Yanbian Univ, Med Coll, Dept Pathol, Yanji 133002, Peoples R China; [Yang, Yang; Li, Nan; Che, Shuanlong; Jin, Tiefeng; Lin, Zhenhua; Chen, Liyan] Yanbian Univ, Med Coll, Canc Res Ctr, Yanji 133002, Peoples R China; [Wu, Qunying] Yanbian Womens Hosp, Dept Pathol, Yanji 133000, Peoples R China; [Nan, Yunze] Yanbian Univ Hosp, Dept Gynecol, Yanji 133000, Peoples R China	Chen, LY (reprint author), Yanbian Univ, Med Coll, Dept Pathol, Yanji 133002, Peoples R China.; Chen, LY (reprint author), Yanbian Univ, Med Coll, Canc Res Ctr, Yanji 133002, Peoples R China.	313828301@qq.com; 884952098@qq.com; 834037558@qq.com; 285443936@qq.com; jintf@ybu.edu.cn; yznan@ybu.edu.cn; zhlin720@ybu.edu.cn; lychen@ybu.edu.cn			National Natural Science Funds of ChinaNational Natural Science Foundation of China [81660436]; Funds of Changbai Mountain Scholar Project	This study was supported by grants from National Natural Science Funds of China (No. 81660436) and The Funds of Changbai Mountain Scholar Project.	Bourguignon LYW, 2000, J CELL BIOL, V150, P177, DOI 10.1083/jcb.150.1.177; Chen QY, 2016, ONCOTARGET, V7, P18247, DOI 10.18632/oncotarget.7570; Cheng W, 2015, INT J CLIN EXP PATHO, V8, P15511; CVITKOVIC E, 1993, J CLIN ONCOL, V11, P2434, DOI 10.1200/JCO.1993.11.12.2434; Ding Y, 2014, ONCOL REP, V32, P607, DOI 10.3892/or.2014.3241; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Hou M, 2004, ACTA BIOCH BIOPH SIN, V36, P537, DOI 10.1093/abbs/36.8.537; Hsueh C, 2011, VIRCHOWS ARCH, V459, P587, DOI 10.1007/s00428-011-1164-0; Huang J, 2013, INT J CANCER, V132, P90, DOI 10.1002/ijc.27627; Jemal A, 2012, CANCER-AM CANCER SOC, V118, P4372, DOI 10.1002/cncr.27410; Joly MM, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0868-8; Li N, 2017, EXP MOL PATHOL, V102, P133, DOI 10.1016/j.yexmp.2017.01.009; Li ZL, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2724-0; Lin ZH, 2009, CLIN CANCER RES, V15, P570, DOI 10.1158/1078-0432.CCR-08-1813; Liu L, 2006, NEOPLASIA, V8, P917, DOI 10.1593/neo.06364; Minard ME, 2006, CLIN EXP METASTAS, V23, P301, DOI 10.1007/s10585-006-9040-z; Otsuki Y, 2003, J BIOL CHEM, V278, P5132, DOI 10.1074/jbc.M206733200; Shibayama-Imazu CHT, 2007, ANTICANCER RES, V27, P245; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Vici P, 2014, J CANCER, V5, P86, DOI 10.7150/jca.7963; Voulgari A, 2009, BBA-REV CANCER, V1796, P75, DOI 10.1016/j.bbcan.2009.03.002; Wang B, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.304; Xu K, 2010, ONCOGENE, V29, P6533, DOI 10.1038/onc.2010.385; Xu K, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0674-8; Yang H, 2015, CHIN J CANCER, V34, DOI 10.1186/s40880-015-0053-3; Zhang YT, 2017, HUM PATHOL, V65, P113, DOI 10.1016/j.humpath.2017.04.021; Zhong DP, 2009, CANCER BIOL THER, V8, P689, DOI 10.4161/cbt.8.8.7833	28	2	2	1	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAY	2018	75						179	188		10.1016/j.humpath.2018.02.006			10	Pathology	Pathology	GI2YQ	WOS:000434238200022	29452216				2019-10-28	
J	Cserni, G; Chmielik, E; Cserni, B; Tot, T				Cserni, Gabor; Chmielik, Ewa; Cserni, Balint; Tot, Tibor			The new TNM-based staging of breast cancer	VIRCHOWS ARCHIV			English	Review						Breast cancer; TNMstaging	NUCLEIC-ACID AMPLIFICATION; ISOLATED TUMOR-CELLS; LYMPH-NODES; CARCINOMA; SURVIVAL; MULTIFOCALITY; METAANALYSIS; DEFINITIONS; DISTINCTION; BIOMARKERS	This review describes the changes that have been implemented in the Tumor-Node-Metastasis (TNM)-based staging of breast cancers by the new, 8th editions of the relevant Union for International Cancer Control (UICC) and American Joint Committee on Cancer (AJCC) publications. After giving a background for TNM being the common language of cancer staging and related activities like cancer treatment and registration, it summarizes not only the changes but reviews some highlights important for pathologists, and lists and comments on the differences between the publications and diagnostic practices based on them. A section is dedicated to the prognostic stages of breast carcinomas introduced in the AJCC Cancer Staging Manual, but not mentioned in the UICC TNM classification of malignant tumors. A few issues that are not appropriately covered by TNM according to the authors' view (e.g., multifocal tumors, larger lymph node metastases identified by molecular methods, the heterogeneous prognosis of M1-defined stage IV disease) close the review with the final thoughts raising the vision of a potential loss of the common staging language.	[Cserni, Gabor] Bacs Kiskun Cty Teaching Hosp, Dept Pathol, Nyiri Ut 38, H-6000 Kecskemet, Hungary; [Cserni, Gabor] Univ Szeged, Dept Pathol, Allomas 1, H-6725 Szeged, Hungary; [Chmielik, Ewa] Maria Sklodowska Curie Mem Canc Ctr, Tumor Pathol Dept, PL-44101 Gliwice, Poland; [Chmielik, Ewa] Inst Oncol, Gliwice Branch, PL-44101 Gliwice, Poland; [Cserni, Balint] Univ Szeged, Dept Software Engn, Dugon Ter 13, H-6720 Szeged, Hungary; [Tot, Tibor] Falun Cty Hosp, Pathol & Cytol Dalarna, S-79182 Falun, Sweden	Cserni, G (reprint author), Bacs Kiskun Cty Teaching Hosp, Dept Pathol, Nyiri Ut 38, H-6000 Kecskemet, Hungary.; Cserni, G (reprint author), Univ Szeged, Dept Pathol, Allomas 1, H-6725 Szeged, Hungary.	cserni@freemail.hu		Cserni, Gabor/0000-0003-1344-7744	National Research, Development and Innovation Office [GINOP-2.3.2-15-2016-00020]	This work was partially funded by the National Research, Development and Innovation Office grant GINOP-2.3.2-15-2016-00020.	Amin MB, 2017, CA-CANCER J CLIN, V67, P93, DOI 10.3322/caac.21388; Brierley JD, 2017, TNM CLASSIFICATION M; Caliskan M, 2008, BREAST CANCER RES TR, V112, P513, DOI 10.1007/s10549-007-9880-5; COTTON DWK, 1991, HISTOPATHOLOGY, V19, P579, DOI 10.1111/j.1365-2559.1991.tb01517.x; Cserni G, 2008, EUR J CANCER, V44, P2185, DOI 10.1016/j.ejca.2008.06.033; Cserni G, 2012, J CLIN PATHOL, V65, P193, DOI 10.1136/jclinpath-2011-200301; Cserni G, 2011, EUR J CANCER, V47, P887, DOI 10.1016/j.ejca.2010.11.011; de Mascarel I, 2008, CANCER, V112, P1672, DOI 10.1002/cncr.23368; Duffy MJ, 2017, EUR J CANCER, V75, P284, DOI 10.1016/j.ejca.2017.01.017; Edge SB, 2010, AJCC CANC STAGING MA; Giuliano AE, 2017, CA-CANCER J CLIN, V67, P291, DOI 10.3322/caac.21393; Hendry S, 2017, ADV ANAT PATHOL, V24, P235, DOI 10.1097/PAP.0000000000000162; Hortobagyi G, 2017, AJCC CANC STAGING MA, P587, DOI DOI 10.1007/978-3-319-40618-3_48; Kattan MW, 2016, CA-CANCER J CLIN, V66, P370, DOI 10.3322/caac.21339; Look MP, 2002, J NATL CANCER I, V94, P116, DOI 10.1093/jnci/94.2.116; National Comprehensive Cancer Network, 2017, CLIN PRACT GUID ONC; Obralic N, 2006, J BUON, V11, P21; Senkus E, 2015, ANN ONCOL, V26, pV8, DOI 10.1093/annonc/mdv298; Shi F, 2017, BRIT J CANCER, V117, P1185, DOI 10.1038/bjc.2017.262; Sobin LH, 2009, TNM CLASSIFICATION M; Sparano JA, 2015, NEW ENGL J MED, V373, P2005, DOI 10.1056/NEJMoa1510764; Symmans WF, 2007, J CLIN ONCOL, V25, P4414, DOI 10.1200/JCO.2007.10.6823; Tabar L, 1999, CANCER, V86, P449, DOI 10.1002/(SICI)1097-0142(19990801)86:3<449::AID-CNCR13>3.0.CO;2-Q; Tai P, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-60; Tamas Z, 2017, ORVOSI HETILAP, V158, P1373, DOI 10.1556/650.2017.30849; Tot T, 2016, VIRCHOWS ARCH, V468, P199, DOI 10.1007/s00428-015-1873-x; Tot T, 2012, INT J BREAST CANCER, DOI 10.1155/2012/395415; Tot T, 2011, HUM PATHOL, V42, P1761, DOI 10.1016/j.humpath.2011.02.002; Tot T, 2011, VIRCHOWS ARCH, V458, P125, DOI 10.1007/s00428-010-1005-6; Vera-Badillo FE, 2014, BREAST CANCER RES TR, V146, P235, DOI 10.1007/s10549-014-3018-3; Waziri U, 2016, ONCOL LETT, V12, P4863, DOI 10.3892/ol.2016.5331; Wells CA, 2012, EUROPEAN GUIDELINES, P73; Wells CAAI, 2006, EUROPEAN GUIDELINES, P219	33	9	9	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAY	2018	472	5					697	703		10.1007/s00428-018-2301-9			7	Pathology	Pathology	GG9NI	WOS:000433027400001	29380126				2019-10-28	
J	Hellquist, H; Hunt, JL; Cardesa, A; Skalova, A; Slootweg, PJ; Rinaldo, A; Ferlito, A				Hellquist, H.; Hunt, J. L.; Cardesa, A.; Skalova, A.; Slootweg, P. J.; Rinaldo, A.; Ferlito, A.			Role of ancillary techniques in profiling unclassified laryngeal malignancies	VIRCHOWS ARCHIV			English	Review						Larynx; Unclassified malignancies; Immunohistochemistry; FISH; RT-PCR	OF-THE-LITERATURE; NUT MIDLINE CARCINOMA; SARCOMA/PRIMITIVE NEUROECTODERMAL TUMOR; EXTRASKELETAL EWINGS-SARCOMA; HIGH-GRADE TRANSFORMATION; ADENOID CYSTIC CARCINOMA; NEUROENDOCRINE NEOPLASMS; DEDIFFERENTIATED CHONDROSARCOMA; LYMPHOEPITHELIAL CARCINOMA; EMBRYONAL RHABDOMYOSARCOMA	Laryngeal biopsies, contrary to biopsies from many other sites of the body, very often contain minute amounts of tumour tissue that may consist of morphologically undifferentiated tumour only. In haematoxylin- and eosin-stained sections, there may be no indicative features of what specific tumour entity that is present. In the larynx, particularly small round cell neoplasms, primary or metastatic, often cause a diagnostic dilemma and where an incorrect diagnosis can induce substantial clinical consequences for the patient (e.g., primary neuroendocrine carcinomas vs metastatic variants, certain sarcomas). If sufficient/representative material has been obtained, the application of immunohistochemistry and/or molecular techniques should in virtually every case reveal the true nature of the malignancy. In cases with sparse amount of material, and therefore a limited number of sections to be cut, a careful and thoughtful stepwise approach is necessary to ascertain a reliable diagnosis, or at least guide the clinician to the most likely diagnoses. With today's advanced and widely available technology with an abundance of markers to discriminate different tumours, the use of the term "undifferentiated" should be largely unnecessary. In the exceptional, and indeed exceedingly rare cases, when a classification is not possible, even after repeat biopsy, we suggest that the laryngeal neoplasm is better termed "unclassified malignant neoplasm" rather than "undifferentiated malignant neoplasm".	[Hellquist, H.] Univ Algarve, Ctr Biomed Res, CBMR, Edificio 2, P-8005139 Faro, Portugal; [Hellquist, H.] Univ Algarve, Dept Biomed Sci & Med, Epigenet & Human Dis Lab, Faro, Portugal; [Hellquist, H.] Univ Algarve, Algarve Biomed Ctr, Campus Gambelas, Faro, Portugal; [Hunt, J. L.] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA; [Cardesa, A.] Univ Barcelona, Hosp Clin, Dept Anat Pathol, Barcelona, Spain; [Skalova, A.] Charles Univ Prague, Fac Med Plzen, Dept Pathol, Plzen, Czech Republic; [Slootweg, P. J.] Radboud Univ Nijmegen, Dept Pathol, Med Ctr, Nijmegen, Netherlands; [Rinaldo, A.] Univ Udine, Sch Med, Udine, Italy; [Ferlito, A.] Int Head & Neck Sci Grp, Padua, Italy	Hellquist, H (reprint author), Univ Algarve, Dept Biomed Sci & Med, Epigenet & Human Dis Lab, Faro, Portugal.; Hellquist, H (reprint author), Univ Algarve, Algarve Biomed Ctr, Campus Gambelas, Faro, Portugal.	henrikhellquist@gmail.com					ABRAMOWSKY CR, 1983, CANCER, V51, P1726, DOI 10.1002/1097-0142(19830501)51:9<1726::AID-CNCR2820510928>3.0.CO;2-W; Aggarwal Sumeet, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2015-211317; Alekseyenko AA, 2015, GENE DEV, V29, P1507, DOI 10.1101/gad.267583.115; Xu B, 2014, HEAD NECK PATHOL, V8, P24, DOI 10.1007/s12105-014-0531-y; Binh MBN, 2005, AM J SURG PATHOL, V29, P1340, DOI 10.1097/01.pas.0000170343.09562.39; Bishop JA, 2015, HEAD NECK PATHOL, V9, P507, DOI 10.1007/s12105-015-0624-2; Blanchard Adam, 2016, Ear Nose Throat J, V95, pE28; BLEIWEISS IJ, 1988, AM J SURG PATHOL, V12, P314, DOI 10.1097/00000478-198804000-00009; BRANDWEIN M, 1992, LARYNGOSCOPE, V102, P858, DOI 10.1288/00005537-199208000-00004; Burchill SA, 1997, EUR J CANCER, V33, P239, DOI 10.1016/S0959-8049(96)00463-7; Casiraghi Odile, 2004, Ann Diagn Pathol, V8, P189, DOI 10.1053/j.anndiagpath.2004.04.001; Chan JYK, 2016, HEAD NECK-J SCI SPEC, V38, pE1294, DOI 10.1002/hed.24215; Chin OY, 2017, LARYNGOSCOPE, V127, P430, DOI 10.1002/lary.26068; Coskun BU, 2005, AURIS NASUS LARYNX, V32, P189, DOI 10.1016/j.anl.2004.11.014; Cowan ML, 2016, HEAD NECK PATHOL, V10, P161, DOI 10.1007/s12105-015-0647-8; DOWNING JR, 1995, AM J PATHOL, V146, P626; Durai Rajaraman, 2006, Ear Nose Throat J, V85, P274; FERLITO A, 1991, ORL J OTO-RHINO-LARY, V53, P235, DOI 10.1159/000276222; FERLITO A, 1990, ORL J OTO-RHINO-LARY, V52, P63, DOI 10.1159/000276105; FERLITO A, 1988, ARCH OTOLARYNGOL, V114, P635; Ferlito A, 1997, ANN OTO RHINOL LARYN, V106, P437; FERLITO A, 1989, ANN OTO RHINOL LARYN, V98, P780, DOI 10.1177/000348948909801006; Ferlito A, 1999, INT J PEDIATR OTORHI, V49, P1, DOI 10.1016/S0165-5876(99)00038-5; FERLITO A, 1991, ORL J OTO-RHINO-LARY, V53, P185, DOI 10.1159/000276217; Ferlito A, 2009, HEAD NECK-J SCI SPEC, V31, P1634, DOI 10.1002/hed.21162; Ferry JA, 2017, WHO CLASSIFICATION H, P104; Fidai SS, 2016, HEAD NECK PATHOL, V10, P345, DOI 10.1007/s12105-015-0676-3; Flucke U, 2017, WHO CLASSIFICATION H, P100; Folpe AL, 2000, AM J SURG PATHOL, V24, P1657, DOI 10.1097/00000478-200012000-00010; Franchi A, 2017, WHO CLASSIFICATION H, P36; French CA, 2013, HEAD NECK PATHOL, V7, P11, DOI 10.1007/s12105-013-0428-1; French CA, 2004, J CLIN ONCOL, V22, P4135, DOI 10.1200/JCO.2004.02.107; French CA, 2003, CANCER RES, V63, P304; French CA, 2014, CANCER DISCOV, V4, P928, DOI 10.1158/2159-8290.CD-14-0014; French CA, 2012, ANNU REV PATHOL-MECH, V7, P247, DOI 10.1146/annurev-pathol-011811-132438; Furman J, 1996, AM J CLIN PATHOL, V106, P339; Garcia RE, 2002, LARYNGOSCOPE, V112, P1015, DOI 10.1097/00005537-200206000-00015; Gaulard P, 2017, WHO CLASSIFICATION H, P90; Ginsberg JP, 1999, J CLIN ONCOL, V17, P1809, DOI 10.1200/JCO.1999.17.6.1809; Haack H, 2009, AM J SURG PATHOL, V33, P984, DOI 10.1097/PAS.0b013e318198d666; Hafezi S, 2011, HEAD NECK PATHOL, V5, P8, DOI 10.1007/s12105-010-0227-x; Hanna E, 1997, ARCH OTOLARYNGOL, V123, P1318; Hellquist H, 2017, HISTOPATHOLOGY, V70, P861, DOI 10.1111/his.13143; Hellquist H, 2016, ADV THER, V33, P357, DOI 10.1007/s12325-016-0298-5; Hicks J, 2002, ORAL ONCOL, V38, P450, DOI 10.1016/S1368-8375(01)00105-1; HORNY HP, 1995, PATHOL RES PRACT, V191, P130, DOI 10.1016/S0344-0338(11)80562-5; Hung YP, 2016, MODERN PATHOL, V29, P370, DOI 10.1038/modpathol.2016.31; Hunt JL, 2017, ADV ANAT PATHOL, V24, P161, DOI 10.1097/PAP.0000000000000147; Ibrahimov M, 2013, J CRANIOFAC SURG, V24, P1049, DOI 10.1097/SCS.0b013e3182700cd9; Ijichi K, 2016, ONCOL LETT, V11, P1120, DOI 10.3892/ol.2015.4013; JONES JE, 1995, ARCH OTOLARYNGOL, V121, P1392; Kandukuri SR, 2017, ARCH PATHOL LAB MED, V141, P1014, DOI 10.5858/arpa.2016-0518-RA; Kimura N, 2017, WHO CLASSIFICATION H, P281; Leventhal Douglas D, 2010, Ear Nose Throat J, V89, pE8; Lewis JS, 2011, LARYNGOSCOPE, V121, P1187, DOI 10.1002/lary.21790; Little DJ, 2002, CANCER-AM CANCER SOC, V95, P377, DOI 10.1002/cncr.10669; Lynch MC, 2014, HEAD NECK PATHOL, V8, P225, DOI 10.1007/s12105-013-0492-6; Machado I, 2017, PATHOL RES PRACT, V213, P1048, DOI 10.1016/j.prp.2017.08.002; MacMillan C, 1996, HUM PATHOL, V27, P1172, DOI 10.1016/S0046-8177(96)90311-1; Marino-Enriquez A, 2010, AM J SURG PATHOL, V34, P1122, DOI 10.1097/PAS.0b013e3181e5dc49; McCuiston A, 2018, HEAD NECK PATHOL, V12, P89, DOI 10.1007/s12105-017-0830-1; Mills SE, 2002, MODERN PATHOL, V15, P264, DOI 10.1038/modpathol.3880522; Mungan S, 2016, CASE REP OTOLARYNGOL, DOI 10.1155/2016/8135967; NAKAYAMA M, 1993, ANN OTO RHINOL LARYN, V102, P785, DOI 10.1177/000348949310201009; NICOLAI P, 1990, ANN OTO RHINOL LARYN, V99, P515, DOI 10.1177/000348949009900704; Ohba S, 2012, AURIS NASUS LARYNX, V39, P326, DOI 10.1016/j.anl.2011.07.012; Perez-Ordonez B, 2017, WHO CLASSIFICATION H, P95; Pittore B, 2010, ACTA OTORHINOLARYNGO, V30, P52; Powitzky R, 2007, ANN OTO RHINOL LARYN, V116, P418, DOI 10.1177/000348940711600605; Purohit BS, 2014, LARYNGOSCOPE, V124, pE274, DOI 10.1002/lary.24518; Rinaggio J, 2004, ORAL SURG ORAL MED O, V97, P369, DOI 10.1016/j.tripleo.2003.09.015; Roy S, 2013, HEAD NECK PATHOL, V7, P263, DOI 10.1007/s12105-012-0402-3; Russell JO, 2015, AM J OTOLARYNG, V36, P277, DOI 10.1016/j.amjoto.2014.10.011; Sakai O, 2000, AM J NEURORADIOL, V21, P584; Schrock A, 2007, AURIS NASUS LARYNX, V34, P553, DOI 10.1016/j.anl.2007.02.009; Scotlandi K, 2000, INT J CANCER, V87, P328, DOI 10.1002/1097-0215(20000801)87:3<328::AID-IJC4>3.0.CO;2-1; Seethala RR, 2007, AM J SURG PATHOL, V31, P1683, DOI 10.1097/PAS.0b013e3180dc928c; Shayah A, 2007, ANN AFR MED, V6, P190, DOI 10.4103/1596-3519.55698; Shibuya R, 2014, VIRCHOWS ARCH, V465, P599, DOI 10.1007/s00428-014-1627-1; Terada T, 2007, AURIS NASUS LARYNX, V34, P105, DOI 10.1016/j.anl.2006.09.027; van der Laan TP, 2015, HEAD NECK-J SCI SPEC, V37, P707, DOI 10.1002/hed.23666; WEIDNER N, 1994, AM J SURG PATHOL, V18, P486, DOI 10.1097/00000478-199405000-00008; WENIG BM, 1995, CANCER, V75, P1568, DOI 10.1002/1097-0142(19950401)75:7<1568::AID-CNCR2820750704>3.0.CO;2-M; Wenig BM, 1993, NEOPLASMS LARYNX, P207; Wenig BM, 2005, PATHOLOGY GENETICS T, P160; Wenig BM, 2015, SEMIN DIAGN PATHOL, V32, P74, DOI 10.1053/j.semdp.2014.12.004; Wexler LH, 1996, CANCER, V78, P901; Windfuhr JP, 2004, ANN OTO RHINOL LARYN, V113, P533, DOI 10.1177/000348940411300705; Wygoda A, 2013, STRAHLENTHER ONKOL, V189, P586, DOI 10.1007/s00066-013-0356-8; Yang YS, 2004, J LARYNGOL OTOL, V118, P62, DOI 10.1258/002221504322731682; Yoshida A, 2012, AM J SURG PATHOL, V36, P993, DOI 10.1097/PAS.0b013e31824ee43c; Zaghi S, 2013, JAMA OTOLARYNGOL, V139, P739, DOI 10.1001/jamaoto.2013.3424; Zhang L, 2016, APMIS, V124, P624, DOI 10.1111/apm.12544; Zhu H, 2017, HEAD NECK PATHOL, V11, P146, DOI 10.1007/s12105-016-0747-0	94	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAY	2018	472	5					705	715		10.1007/s00428-018-2348-7			11	Pathology	Pathology	GG9NI	WOS:000433027400002	29623469				2019-10-28	
J	Tack, V; Ligtenberg, MJL; Siebers, AG; Rombout, PDM; Dabir, PD; Weren, RDA; van Krieken, JHJM; Dequeker, EMC				Tack, V.; Ligtenberg, M. J. L.; Siebers, A. G.; Rombout, P. D. M.; Dabir, P. D.; Weren, R. D. A.; van Krieken, J. H. J. M.; Dequeker, E. M. C.			RAS testing for colorectal cancer patients is reliable in European laboratories that pass external quality assessment	VIRCHOWS ARCHIV			English	Article						Reproducibility; Quality assurance; Molecular pathology; Biological markers; Colorectal neoplasms	PERSONALIZED MEDICINE; KRAS; PANITUMUMAB; MUTATIONS; PATHOLOGY; THERAPY; BRAF	Wild-type status of KRAS and the NRAS gene (exon 2, 3, and 4) in the tumor should be determined before treatment of metastatic colorectal cancer (mCRC) patients with EGFR-targeting agents. There is a large variation in test methods to determine RAS status, and more sensitive detection methods were recently introduced. Data from quality assessment programs indicate substantial error rates. This study assessed the completeness and correctness of RAS testing in European laboratories that successfully passed external quality assessment (EQA). Participants were requested to send material of their most recent ten patients with mCRC who had been tested for RAS status. Isolated DNA, a hematoxylin and eosin stained tissue slide with a marked area for macrodissection and accompanying patient reports were requested. Samples were reevaluated in a reference laboratory by using a next-generation sequencing approach. In total, 31 laboratories sent in the requested material (n = 309). Despite regulations for anti-EGFR therapy, one institute did not perform full RAS testing. Reanalysis was possible for 274 samples with sufficient DNA available. In the hotspot codons of KRAS and NRAS, seven discordant results were obtained in total, five of them leading to a different prediction of anti-EGFR therapy efficacy (2%; n = 274). Results show that oncologists can rely on the quality of laboratories with good performance in EQA. Oncologists need to be aware that the testing laboratory participates successfully in EQA programs. Some EQA providers list the good performing laboratories on their website.	[Tack, V.; Dequeker, E. M. C.] Univ Leuven, Dept Publ Hlth & Primary Care, Biomed Qual Assurance Res Unit, Kapucijnenvoer 35,Blok D, B-3000 Leuven, Belgium; [Ligtenberg, M. J. L.; Siebers, A. G.; Rombout, P. D. M.; Dabir, P. D.; Weren, R. D. A.; van Krieken, J. H. J. M.] Radboud Univ Nijmegen, Dept Pathol, Med Ctr, NL-GRID1041 Nijmegen, Netherlands; [Ligtenberg, M. J. L.] Radboud Univ Nijmegen, Dept Human Genet, Med Ctr, Nijmegen, Netherlands; [Dabir, P. D.] Randers Reg Hosp, Dept Pathol, Randers, Denmark	Dequeker, EMC (reprint author), Univ Leuven, Dept Publ Hlth & Primary Care, Biomed Qual Assurance Res Unit, Kapucijnenvoer 35,Blok D, B-3000 Leuven, Belgium.	els.dequeker@kuleuven.be	Ligtenberg, Marjolijn/N-9666-2013; van Krieken, Joannes H J M/D-4138-2009; Siebers, Albert/D-6300-2015; Dabir, Parag D/B-6893-2018; Dabir, Parag/N-4753-2019; Siebers, Albert/H-6974-2015	Ligtenberg, Marjolijn/0000-0003-1290-1474; van Krieken, Joannes H J M/0000-0001-6544-1040; Dabir, Parag D/0000-0002-9862-8132; Dabir, Parag/0000-0002-9862-8132; van Krieken, Joannes/0000-0002-8105-0450; Siebers, Albert/0000-0002-6085-0678	AmgenAmgen	This work was supported by Amgen.	Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; [Anonymous], 2012, 151892012 ISO; [Anonymous], COL EXT QUAL ASS SCH; [Anonymous], 2005, KWAL GEB LAB GEZ CCK; Boleij A, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2810-3; Boleij A, 2015, ONCOTARGET, V6, P15681, DOI 10.18632/oncotarget.3804; Ciardiello F, 2014, ANN ONCOL, V25, P1756, DOI 10.1093/annonc/mdu230; Dijkstra JR, 2013, VIRCHOWS ARCH, V462, P39, DOI 10.1007/s00428-012-1356-2; Douillard JY, 2014, ANN ONCOL, V25, P1346, DOI 10.1093/annonc/mdu141; Eijkelenboom A, 2016, J MOL DIAGN, V18, P851, DOI 10.1016/j.jmoldx.2016.06.010; EMA, 2013, VECT EPAR SUMM PUBL; European Medicine Agency (EMA), 2013, ERB EPAR SUMM PUBL 2; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Heinemann V, 2013, CANCER TREAT REV, V39, P592, DOI 10.1016/j.ctrv.2012.12.011; Ihle MA, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-13; Molinari F, 2011, CLIN CANCER RES, V17, P4901, DOI 10.1158/1078-0432.CCR-10-3137; Normanno N, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0655-1; Richman SD, 2017, J CLIN PATHOL, V70, P58, DOI 10.1136/jclinpath-2016-203822; Stintzing S, 2015, HEMATOL ONCOL CLIN N, V29, P43, DOI 10.1016/j.hoc.2014.09.009; Tack V, 2015, ONCOLOGIST, V20, P257, DOI 10.1634/theoncologist.2014-0382; van Krieken JH, 2013, VIRCHOWS ARCH, V462, P27, DOI 10.1007/s00428-012-1354-4; Vaughn CP, 2011, GENE CHROMOSOME CANC, V50, P307, DOI 10.1002/gcc.20854	22	1	1	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAY	2018	472	5					717	725		10.1007/s00428-017-2291-z			9	Pathology	Pathology	GG9NI	WOS:000433027400003	29333594	Green Published			2019-10-28	
J	Aggelou, H; Chadla, P; Nikou, S; Karteri, S; Maroulis, I; Kalofonos, HP; Papadaki, H; Bravou, V				Aggelou, Helen; Chadla, Panagiota; Nikou, Sofia; Karteri, Sofia; Maroulis, Ioannis; Kalofonos, Haralabos P.; Papadaki, Helen; Bravou, Vasiliki			LIMK/cofilin pathway and Slingshot are implicated in human colorectal cancer progression and chemoresistance	VIRCHOWS ARCHIV			English	Article						Cofilin; LIMK; Slingshot; Colorectal cancer; Chemoresistance; EMT	LIM KINASE; DRUG-RESISTANCE; DOWN-REGULATION; ACTIN DYNAMICS; COFILIN 1; CELLS; PROTEINS; OVEREXPRESSION; EXPRESSION; GROWTH	Cofilin phospho-regulation is important for actin filament turnover and is implicated in cancer. Phosphorylation of cofilin is mediated by LIM kinases (LIMKs) and dephosphorylation by Slingshot phosphatases (SSH). LIMKs and SSH promote cancer cell invasion and metastasis and represent novel anti-cancer targets. However, little is known regarding LIMK/cofilin and SSH in human colorectal cancer (CRC). In this study, we aimed to address their expression and significance in human CRC. We evaluated expression of non-phosphorylated (active) and phosphorylated cofilin, LIMK1, LIMK2, and SSH1 by immunohistochemistry in 143 human CRC samples in relation to clinicopathologic parameters, response of metastatic disease to chemotherapy, and epithelial-mesenchymal transition (EMT) markers beta-catenin, E-cadherin, and ZEB. We show that active cofilin, LIMK1, LIMK2, and SSH1 are overexpressed in human CRC and are associated with tumor progression parameters. SSH1 is an independent predictor of lymph node metastasis by multivariate analysis. LIMK1 and SSH1 expression is also higher in non-responders to chemotherapy, and SSH1 is shown by multivariate analysis to independently predict response of metastatic disease to chemotherapy. Active cofilin, LIMK1, LIMK2, and SSH1 also correlated with the EMT markers examined. In addition, immunofluorescence analysis showed increased expression of active cofilin, LIMK1, LIMK2, and SSH1 in HT29 colon cancer cells resistant to 5-fluorouracil compared to parental HT29 cells. Our results suggest that F-actin regulators LIMK/cofilin pathway and SSH1 are associated with CRC progression and chemoresistance representing promising tumor biomarkers and therapeutic targets in CRC.	[Aggelou, Helen; Chadla, Panagiota; Nikou, Sofia; Karteri, Sofia; Papadaki, Helen; Bravou, Vasiliki] Univ Patras, Sch Med, Dept Anat Histol Embryol, Patras 26500, Greece; [Maroulis, Ioannis] Univ Patras, Dept Surg, Sch Med, Patras, Greece; [Kalofonos, Haralabos P.] Univ Patras, Div Oncol, Sch Med, Patras, Greece	Bravou, V (reprint author), Univ Patras, Sch Med, Dept Anat Histol Embryol, Patras 26500, Greece.	vibra@upatras.gr		Nikou, Sofia/0000-0002-2582-4634			Castro MAA, 2010, CANCER-AM CANCER SOC, V116, P3645, DOI 10.1002/cncr.25125; Amin MB, 2017, AJCC CANC STAGING MA, DOI [10.1007/978-3-319-40618-3, DOI 10.1007/978-3-319-40618-3]; Arber S, 1998, NATURE, V393, P805; Bamburg JR, 2002, TRENDS CELL BIOL, V12, P598, DOI 10.1016/S0962-8924(02)02404-2; Becker M, 2014, TUMOR BIOL, V35, P1233, DOI 10.1007/s13277-013-1164-6; Bosman FT, 2010, WHO CLASSIFICATION T; Bravou V, 2006, J PATHOL, V208, P91, DOI 10.1002/path.1860; Bravou V, 2015, CANCER INVEST, V33, P387, DOI 10.3109/07357907.2015.1047508; Chen C, 2017, ONCOTARGET, V8, P66195, DOI 10.18632/oncotarget.19855; Chen QY, 2012, ONCOL RES, V20, P491, DOI 10.3727/096504013X13657689382699; Cohen J., 1969, STAT POWER ANAL BEHA; Coley HM, 2004, METH MOLEC MED, V88, P267; Dallas NA, 2009, CANCER RES, V69, P1951, DOI 10.1158/0008-5472.CAN-08-2023; Davila M, 2003, J BIOL CHEM, V278, P36868, DOI 10.1074/jbc.M306196200; Davila M, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-40; Dos Remedios CG, 2003, PHYSIOL REV, V83, P433, DOI 10.1152/physrev.00026.2002; Estornes Y, 2007, INT J CANCER, V121, P2162, DOI 10.1002/ijc.22911; Horita Y, 2008, J BIOL CHEM, V283, P6013, DOI 10.1074/jbc.M706538200; Huang TY, 2006, CURR OPIN CELL BIOL, V18, P26, DOI 10.1016/j.ceb.2005.11.005; Johnson EO, 2012, J CELL SCI, V125, P1204, DOI 10.1242/jcs.092304; Karavias D, 2016, J GASTROINTEST SURG, V20, P568, DOI 10.1007/s11605-015-2960-7; Kim AY, 2015, TOX RESEARCH, V31, P151, DOI 10.5487/TR.2015.31.2.151; Lee SY, 2017, PHARMACOL RES, V119, P422, DOI 10.1016/j.phrs.2017.03.003; Lourenco FC, 2014, GUT, V63, P480, DOI 10.1136/gutjnl-2012-303883; Lu L, 2015, ONCOL LETT, V9, P2757, DOI 10.3892/ol.2015.3133; Mardilovich K, 2015, ONCOTARGET, V6, P38469, DOI 10.18632/oncotarget.6288; McConnell BV, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-75; Mizuno K, 2013, CELL SIGNAL, V25, P457, DOI 10.1016/j.cellsig.2012.11.001; Nishimura S, 2011, HUM PATHOL, V42, P516, DOI 10.1016/j.humpath.2010.07.019; Nishita M, 2005, J CELL BIOL, V171, P349, DOI 10.1083/jcb.200504029; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Nowak D, 2010, EUR J HISTOCHEM, V54, P59, DOI 10.4081/ejh.2010.e14; Peng XC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027309; Popow-Wozniak A, 2012, HISTOCHEM CELL BIOL, V138, P725, DOI 10.1007/s00418-012-0988-2; Prudent R, 2012, CANCER RES, V72, P4429, DOI 10.1158/0008-5472.CAN-11-3342; Prunier C, 2017, ONCOTARGET, V8, P41749, DOI 10.18632/oncotarget.16978; Prunier C, 2016, ONCOTARGET, V7, P50816, DOI 10.18632/oncotarget.10816; Prunier C, 2016, CANCER RES, V76, P3541, DOI 10.1158/0008-5472.CAN-15-1864; Shankar J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132759; Shishkin S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010010; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Su B, 2016, ONCOTARGET, V7, P10498, DOI 10.18632/oncotarget.7252; Su J, 2017, SCI REP-UK, V7, DOI 10.1038/srep45624; Suyama E, 2004, J GENE MED, V6, P357, DOI 10.1002/jgm.491; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Vlecken DH, 2009, ZEBRAFISH, V6, P433, DOI 10.1089/zeb.2009.0602; Wang HB, 2017, ONCOTARGET, V8, P39131, DOI 10.18632/oncotarget.16608; Wang YF, 2015, CANCER LETT, V360, P171, DOI 10.1016/j.canlet.2015.02.015; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Yan XD, 2007, J PROTEOME RES, V6, P772, DOI 10.1021/pr060402r; Yoshioka K, 2003, P NATL ACAD SCI USA, V100, P7247, DOI 10.1073/pnas.1232344100	52	8	8	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAY	2018	472	5					727	737		10.1007/s00428-018-2298-0			11	Pathology	Pathology	GG9NI	WOS:000433027400004	29352327				2019-10-28	
J	Kim, JY; Lee, SH; An, S; Kim, SJ; Sung, YN; Song, KB; Hwang, DW; Kim, SC; Hong, SM				Kim, Joo Young; Lee, Sang Hwa; An, Soyeon; Kim, Sung Joo; Sung, You-Na; Song, Ki-Byung; Hwang, Dae Wook; Kim, Song Cheol; Hong, Seung-Mo			Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival	VIRCHOWS ARCHIV			English	Article						Pancreas; Neuroendocrine tumor; Carbonic anhydrase 9; Vimentin; Immunohistochemistry; Prognosis	ENDOCRINE TUMORS; GRADING SYSTEM; VIMENTIN EXPRESSION; PROGNOSTIC MARKER; SMALL-CELL; HYPOXIA; CANCER; TELOMERES; CYTOKERATIN-19; PROGRESSION	Well-differentiated pancreatic neuroendocrine neoplasms/tumors (PanNETs) are rare neoplasms with diverse clinical behavior. Biomarker discovery is important for predicting clinical course and prognosis of PanNET patients. Carbonic anhydrase 9 (CA9) and vimentin are hypoxia and epithelial-mesenchymal transition-related proteins of which expression in many carcinomas has been associated with poor prognosis, but their significance in PanNET has yet to be determined. We assessed CA9 and vimentin expression in 164 PanNETs and compared this with clinicopathologic characteristics. CA9 expression was observed in normal islets, while neuroendocrine microadenomas and small (< 1 cm) PanNETs showed loss of CA9 expression. CA9 and vimentin expression was observed in 38 (23%) and 36 (22%) of PanNETs, respectively. CA9 expression was associated with larger size (p = 0.001), higher grade (p < 0.001), higher pT category (p < 0.001), lymph node (p = 0.003) and distant (p = 0.047) metastases, higher AJCC stage (p < 0.001), and lymphovascular (p < 0.001) and perineural (p = 0.002) invasion. PanNET patients with CA9 expression had a shorter recurrence-free survival (5-year survival rate 47%) than those without CA9 expression (76%) by univariate (p = 0.001) but not multivariate analysis. Vimentin expression correlated with CA9 expression (p < 0.001) but not with other clinicopathologic factors. In conclusion, CA9 expression was observed in normal islets, while neuroendocrine microadenomas and small (< 1 cm) PanNETs showed CA9 expression loss. CA9 expression gradually reappeared in larger PanNETs, and this was associated with clinical progression and decreased patient survival by univariate but not multivariate analysis.	[Kim, Joo Young] Eulji Univ, Dept Pathol, Nowon Eulji Med Ctr, Seoul, South Korea; [Lee, Sang Hwa] Seegene Life Sci Ctr, Seoul, South Korea; [An, Soyeon] Catholic Univ Korea, Incheon St Marys Hosp, Dept Pathol, Coll Med, Incheon, South Korea; [Kim, Sung Joo; Sung, You-Na; Hong, Seung-Mo] Univ Ulsan, Dept Pathol, Asan Med Ctr, Coll Med, 88 Olympic Ro 43-Gil, Seoul 05505, South Korea; [Song, Ki-Byung; Hwang, Dae Wook; Kim, Song Cheol] Univ Ulsan, Dept Surg, Asan Med Ctr, Coll Med, Seoul, South Korea	Hong, SM (reprint author), Univ Ulsan, Dept Pathol, Asan Med Ctr, Coll Med, 88 Olympic Ro 43-Gil, Seoul 05505, South Korea.	smhong28@gmail.com		Hong, Seung-Mo/0000-0002-8888-6007	Ministry of Education, Science and Technology of the Republic of KoreaMinistry of Education, Science and Technology, Republic of Korea [2016R1A2B4009381]; Asan Institute for Life Sciences, Seoul, Republic of Korea [2013-554]	Ministry of Education, Science and Technology of the Republic of Korea (2016R1A2B4009381) and the Asan Institute for Life Sciences (2013-554), Seoul, Republic of Korea.	Ali A, 2006, AM J SURG PATHOL, V30, P1588, DOI 10.1097/01.pas.0000213309.51553.01; Amin S, 2016, GASTROENTEROL CLIN N, V45, P83, DOI 10.1016/j.gtc.2015.10.007; Basturk O, 2015, AM J SURG PATHOL, V39, P683, DOI 10.1097/PAS.0000000000000408; Bernstein JM, 2015, LARYNGOSCOPE, V125, pE8, DOI 10.1002/lary.24933; Bilimoria KY, 2008, ANN SURG, V247, P490, DOI 10.1097/SLA.0b013e31815b9cae; Chen J, 2005, GUT, V54, P920, DOI 10.1136/gut.2004.047340; Couvelard A, 2005, BRIT J CANCER, V92, P94, DOI 10.1038/sj.bjc.6602245; Dauphin M, 2013, LUNG CANCER, V81, P117, DOI 10.1016/j.lungcan.2013.03.011; Deschamps L, 2012, NEUROENDOCRINOLOGY, V95, P214, DOI 10.1159/000329873; Deshpande V, 2004, AM J SURG PATHOL, V28, P1145, DOI 10.1097/01.pas.0000135525.11566.b4; Dogeas E, 2014, J AM COLL SURGEONS, V218, P628, DOI 10.1016/j.jamcollsurg.2014.01.001; Edge SB, 2010, AJCC CANC STAGING MA, P859, DOI [10.1097/PAS.0b013e31827fcc18, DOI 10.1097/PAS.0B013E31827FCC18]; Fesinmeyer MD, 2005, CANCER EPIDEM BIOMAR, V14, P1766, DOI 10.1158/1055-9965.EPI-05-0120; Fischer L, 2008, BRIT J SURG, V95, P627, DOI 10.1002/bjs.6051; Galvan JA, 2013, AM J CLIN PATHOL, V140, P61, DOI 10.1309/AJCPIV40ISTBXRAX; Halfdanarson TR, 2008, ANN ONCOL, V19, P1727, DOI 10.1093/annonc/mdn351; Han X, 2013, TUMOR BIOL, V34, P2881, DOI 10.1007/s13277-013-0850-8; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Heaphy CM, 2011, SCIENCE, V333, P425, DOI 10.1126/science.1207313; Javela S, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-1; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Kang HJ, 2015, VIRCHOWS ARCH, V466, P403, DOI 10.1007/s00428-014-1709-0; Karihtala P, 2013, BREAST CANCER RES TR, V138, P81, DOI 10.1007/s10549-013-2442-0; Kim JY, 2017, CLIN CANCER RES, V23, P1598, DOI 10.1158/1078-0432.CCR-16-1147; Kim JY, 2015, AM J SURG PATHOL, V39, P592, DOI 10.1097/PAS.0000000000000383; Kim SJ, 2017, J PATHOL TRANSL MED, V51, P388, DOI 10.4132/jptm.2017.03.19; Kockar F, 2012, WORLD J CLIN ONCOL, V3, P82, DOI 10.5306/wjco.v3.i6.82; Krausch M, 2011, HORM METAB RES, V43, P865, DOI 10.1055/s-0031-1291333; Kulke MH, 2015, J NATL COMPR CANC NE, V13, P78, DOI 10.6004/jnccn.2015.0011; La Rosa S, 2007, HISTOPATHOLOGY, V50, P597, DOI 10.1111/j.1365-2559.2007.02662.x; Lin JY, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0450-6; Liu TC, 2013, AM J SURG PATHOL, V37, P853, DOI 10.1097/PAS.0b013e31827fcc18; Lloyd RV, 2017, WHO CLASSIFICATION T; Marinoni I, 2014, GASTROENTEROLOGY, V146, P453, DOI 10.1053/j.gastro.2013.10.020; McDonald PC, 2012, ONCOTARGET, V3, P84, DOI 10.18632/oncotarget.422; O'Toole D, 2010, ENDOCR-RELAT CANCER, V17, P847, DOI 10.1677/ERC-09-0204; Otsuki S, 2011, ONCOL REP, V25, P1235, DOI 10.3892/or.2011.1185; Rindi G, 2006, VIRCHOWS ARCH, V449, P395, DOI 10.1007/s00428-006-0250-1; Sakai Y, 2017, HUM PATHOL, V61, P148, DOI 10.1016/j.humpath.2016.10.022; Scarpa A, 2017, NATURE, V543, P65, DOI 10.1038/nature21063; Shin HJ, 2011, J CELL SCI, V124, P1077, DOI 10.1242/jcs.072207; Son EM, 2015, J PATHOL TRANSL MED, V49, P30, DOI 10.4132/jptm.2014.10.23; Speisky D, 2012, CLIN CANCER RES, V18, P2838, DOI 10.1158/1078-0432.CCR-11-2759; Strosberg JR, 2011, J CLIN ONCOL, V29, P3044, DOI 10.1200/JCO.2011.35.1817; Svastova E, 2003, EXP CELL RES, V290, P332, DOI 10.1016/S0014-4827(03)00351-3; Tang LH, 2012, AM J SURG PATHOL, V36, P1761, DOI 10.1097/PAS.0b013e318263207c; Wang L, 2015, NEOPLASMA, V62, P484, DOI 10.4149/neo_2015_058; Watanabe A, 2005, EXPERT REV MOL DIAGN, V5, P171, DOI 10.1586/14737159.5.2.171; Yachida S, 2012, AM J SURG PATHOL, V36, P173, DOI 10.1097/PAS.0b013e3182417d36; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang LZ, 2009, AM J SURG PATHOL, V33, P1562, DOI 10.1097/PAS.0b013e3181ac675b	51	1	1	1	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAY	2018	472	5					739	748		10.1007/s00428-018-2353-x			10	Pathology	Pathology	GG9NI	WOS:000433027400005	29666945				2019-10-28	
J	Barth, I; Schneider, U; Grimm, T; Karl, A; Horst, D; Gaisa, NT; Knuchel, R; Garczyk, S				Barth, Isabella; Schneider, Ursula; Grimm, Tobias; Karl, Alexander; Horst, David; Gaisa, Nadine T.; Knuechel, Ruth; Garczyk, Stefan			Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications	VIRCHOWS ARCHIV			English	Article						Bladder Cancer; Carcinoma in situ (CIS); Molecular subtypes; Her2/neu; Estrogen receptor Beta (ER ss); Targeted therapy	COMPREHENSIVE MOLECULAR CHARACTERIZATION; ESTROGEN-RECEPTOR-BETA; BREAST-CANCER; HIGH-RISK; TISSUE MICROARRAYS; CLINICAL-PRACTICE; PROGNOSTIC-FACTOR; INTRAVESICAL BCG; NEU ONCOGENE; ER-BETA	The stratification of bladder cancer into luminal and basal tumors has recently been introduced as a novel prognostic system in patient cohorts of muscle-invasive bladder cancer or high-grade papillary carcinomas. Using a representative immunohistochemistry panel, we analyzed luminal and basal marker expression in a large case series (n = 156) of urothelial carcinoma in situ (CIS), a precancerous lesion that frequently progresses to muscle-invasive disease. The majority of CIS cases was characterized by a positivity for luminal markers (aberrant cytokeratin (CK) 20 85% (132/156), GATA3 median Remmele score (score of staining intensity (0-3) multiplied with percentage of positive cells (0-4)): 12, estrogen receptor (ER) beta Remmele score > 2: 88% (138/156), human epidermal growth factor receptor 2 (Her2) Dako score 3+ 32% (50/156), Her2 Dako score 2+ 33% (51/156)), and marginal expression of basal markers (CK5/6+ 2% (3/156), CK14+ 1% (2/156)). To further investigate phenotypic stability during disease progression, we compared 48 pairs of CIS and invasive tumors from the same biopsy. A highly significant loss of luminal marker expression (p < 0.001) was observed in the course of progression whereas an increase of basal marker expression (p < 0.01) was noted in the invasive compartment. Importantly, 91% of CIS cases demonstrated a positivity for at least one of the two predictive markers Her2 and ER beta, indicating that the analysis of Her2 and ER beta may help to identify CIS-patient subgroups prone to more efficient targeted treatment strategies. Larger prospective and biomarker-embedded clinical trials are needed to confirm and validate our preliminary findings.	[Barth, Isabella; Schneider, Ursula; Gaisa, Nadine T.; Knuechel, Ruth; Garczyk, Stefan] Univ Hosp RWTH Aachen, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany; [Grimm, Tobias; Karl, Alexander] LMU Munich Univ, Dept Urol, Marchioninistr 15, Munich 81377, Germany; [Horst, David] LMU Munich Univ, Inst Pathol, Thalkirchner Str 36, D-80337 Munich, Germany	Knuchel, R (reprint author), Univ Hosp RWTH Aachen, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany.	rknuechel-clarke@ukaachen.de			START-Program of the Faculty of Medicine, RWTH AachenAustrian Science Fund (FWF)	This research project is supported by the START-Program of the Faculty of Medicine, RWTH Aachen. Part of the data of this research project was presented at the "9th AUF Symposium 2017" (German Urologic Society) and awarded with the presentation prize.	Bang YJ, 2010, LANCET, V376, P1302; Brandt WD, 2009, CANCER METAST REV, V28, P291, DOI 10.1007/s10555-009-9187-6; Brausi M, 2014, EUR UROL, V65, P69, DOI 10.1016/j.eururo.2013.07.021; Chang SS, 2016, J UROLOGY, V196, P1021, DOI 10.1016/j.juro.2016.06.049; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Damrauer JS, 2014, P NATL ACAD SCI USA, V111, P3110, DOI 10.1073/pnas.1318376111; Gravalos C, 2008, ANN ONCOL, V19, P1523, DOI 10.1093/annonc/mdn169; Han BM, 2012, WORLD J UROL, V30, P861, DOI 10.1007/s00345-011-0819-4; Hanna WM, 2014, MODERN PATHOL, V27, P4, DOI 10.1038/modpathol.2013.103; Hedegaard J, 2016, CANCER CELL, V30, P27, DOI 10.1016/j.ccell.2016.05.004; Hofmann M, 2008, J CLIN PATHOL, V61, P89, DOI 10.1136/jcp.2006.043562; Holz S, 2017, RES REP UROL, V9, P195, DOI 10.2147/RRU.S143865; Hsu I, 2014, CARCINOGENESIS, V35, P651, DOI 10.1093/carcin/bgt348; Hsu IW, 2013, NAT REV UROL, V10, P317, DOI 10.1038/nrurol.2013.53; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Huguet J, 2005, EUR UROL, V48, P53, DOI 10.1016/j.eururo.2005.03.021; Jakse G, 2001, EUR UROL, V40, P144, DOI 10.1159/000049765; Jung S, 2014, ANN DIAGN PATHOL, V18, P27, DOI 10.1016/j.anndiagpath.2013.10.006; Kaufman PA, 2007, J CLIN ONCOL, V25; Kim HT, 2002, J BIOL CHEM, V277, P32510, DOI 10.1074/jbc.M202852200; Kirkali Z, 2005, UROLOGY, V66, P4, DOI 10.1016/j.urology.2005.07.062; Kiss B, 2017, SCI REP-UK, V7, DOI 10.1038/srep42713; Knowles MA, 2015, NAT REV CANCER, V15, P25, DOI 10.1038/nrc3817; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Lerner SP, 2016, BLADDER CANCER, V2, P165, DOI 10.3233/BLC-160053; Miyamoto H, 2012, BJU INT, V109, P1716, DOI 10.1111/j.1464-410X.2011.10706.x; Ochoa AE, 2016, ONCOTARGET, V7, P80164, DOI 10.18632/oncotarget.13284; Phillips GDL, 2008, CANCER RES, V68, P9280, DOI 10.1158/0008-5472.CAN-08-1776; REMMELE W, 1987, PATHOLOGE, V8, P138; Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007; Sanli O, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.22; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; Schraml P, 1999, CLIN CANCER RES, V5, P1966; Shabsigh A, 2009, EUR UROL, V55, P164, DOI 10.1016/j.eururo.2008.07.031; Shen SS, 2006, CANCER-AM CANCER SOC, V106, P2610, DOI 10.1002/cncr.21945; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sjodahl G, 2012, CLIN CANCER RES, V18, P3377, DOI 10.1158/1078-0432.CCR-12-0077-T; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Slaton JW, 2001, UROLOGY, V57, P852, DOI 10.1016/S0090-4295(01)00968-2; SPRUCK CH, 1994, CANCER RES, V54, P784; Sylvester RJ, 2005, UROLOGY, V66, P90, DOI 10.1016/j.urology.2005.06.135; Tang DH, 2015, THER ADV UROL, V7, P351, DOI 10.1177/1756287215599694; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Woldu SL, 2017, BJU INT, V119, P371, DOI 10.1111/bju.13760; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	47	5	5	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAY	2018	472	5					749	758		10.1007/s00428-018-2354-9			10	Pathology	Pathology	GG9NI	WOS:000433027400006	29654370	Other Gold, Green Published			2019-10-28	
J	Flockerzi, FA; Roggia, C; Langer, F; Holleczek, B; Bohle, RM				Flockerzi, Fidelis Andrea; Roggia, Cristiana; Langer, Frank; Holleczek, Bernd; Bohle, Rainer M.			FGFR1 gene amplification in squamous cell carcinomas of the lung: a potential favorable prognostic marker for women and for patients with advanced cancer	VIRCHOWS ARCHIV			English	Article						FGFR1; Squamous cell carcinoma of the lung; Non-small cell lung cancer; Prognosis; Women; Advanced cancer	IN-SITU HYBRIDIZATION; COPY NUMBER; METAANALYSIS; MUTATIONS; SENSITIVITY; ACTIVATION; THERAPY	In squamous cell carcinoma (SCC) of the lung, mutations within the genes of fibroblast growth factor receptors (FGFR) such as K660N/K660E in FGFR2 and R248C/S249C in FGFR3 and FGFR1 gene amplification have been described, but their prognostic relevance still remains unclear. In order to detect the mutation frequencies and to define their prognostic value for associated clinicopathologic features and survival of patients, resected Delta Np63/p40-positive SCC of the lung (n = 101) were screened for FGFR1 gene amplification by fluorescence in situ hybridization performed on formalin-fixed paraffin embedded tissues and for the presumed driver mutations in genes of FGFR2 and FGFR3 by PCR and Sanger sequencing. Twenty-two of 101 SCCs (22%) were positive for amplification based on a FGFR1/centromere (chromosome 8) ratio > 2.0 or higher. In advanced tumor stages (III-IV), the overall survival of patients carrying FGFR1 gene amplification was significantly higher (p = 0.006). Among women, FGFR1 gene amplification was significantly associated with longer overall survival (p = 0.023). The presence of FGFR1 gene amplification was associated with patient age (65 versus 69 years, p = 0.046), but not with gender, tumor stage, histologic subtype, tumor grade, or Delta Np63/p40 immunoreactivity. The S249C mutation in the FGFR3 gene was identified in one out of 101 SCCs (1%); the K600N, K660E, or R248C mutations were not identified. These results suggest that FGFR1 gene amplification is a frequent alteration in SCC of the lung and appears not to be a negative but rather a favorable prognostic marker for women and particularly for patients with advanced SCC of the lung (stage III-IV).	[Flockerzi, Fidelis Andrea; Roggia, Cristiana; Bohle, Rainer M.] Saarland Univ, Dept Pathol, Med Ctr, Bldg 26, D-66421 Homburg, Germany; [Langer, Frank] Saarland Univ, Dept Thorac & Cardiovasc Surg, Med Ctr, Homburg, Germany; [Holleczek, Bernd] Saarland Canc Registry, Saarbrucken, Germany; [Bohle, Rainer M.] Saarland Univ, Canc Ctr Saarland, Med Ctr, Homburg, Germany; [Roggia, Cristiana] Univ Hosp Tubingen, Dept Interdisciplinary, Div Neurooncol, Tubingen, Germany	Flockerzi, FA (reprint author), Saarland Univ, Dept Pathol, Med Ctr, Bldg 26, D-66421 Homburg, Germany.	Fidelis.Flockerzi@uks.eu			Federal Ministry of Education and Research (Germany)Federal Ministry of Education & Research (BMBF); CHIC [600841]	This work was supported by scholarship (Deutschlandstipendium) from Federal Ministry of Education and Research (Germany) to F. A. V. Flockerzi and by the FP7 European projects CHIC (grant no. 600841).	Bishop JA, 2011, MODERN PATHOL, V24, p405A; Bocker W, 2001, PATHOLOGIE, V2; Burke D, 1998, TRENDS BIOCHEM SCI, V23, P59, DOI 10.1016/S0968-0004(97)01170-5; Goeckenjan G, 2010, Pneumologie, V64 Suppl 2, pe1, DOI 10.1055/s-0029-1243837; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Heist RS, 2012, J THORAC ONCOL, V7, P1775, DOI 10.1097/JTO.0b013e31826aed28; Heist RS, 2012, J THORAC ONCOL, V7, P924, DOI 10.1097/JTO.0b013e31824cc334; Hernandez S, 2006, J CLIN ONCOL, V24, P3664, DOI 10.1200/JCO.2005.05.1771; Inamura K, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00193; Ipenburg NA, 2016, TARGET ONCOL, V11, P17, DOI 10.1007/s11523-015-0374-9; Kadota K, 2014, J THORAC ONCOL, V9, P1126, DOI 10.1097/JTO.0000000000000253; KIEVITS T, 1990, CYTOGENET CELL GENET, V53, P134, DOI 10.1159/000132913; Kim Y, 2014, J CLIN ONCOL, V32, P121, DOI 10.1200/JCO.2013.50.8556; Kinoshita T, 2014, J THORAC ONCOL, V9, P1779, DOI 10.1097/JTO.0000000000000338; Knights V, 2010, PHARMACOL THERAPEUT, V125, P105, DOI 10.1016/j.pharmthera.2009.10.001; Liao RG, 2012, LUNG CANCER MANAG, V1, P293, DOI 10.2217/LMT.12.40; Liao RG, 2013, CANCER RES, V73, P5195, DOI 10.1158/0008-5472.CAN-12-3950; Lim S, 2016, YONSEI MED J, V57, P831, DOI 10.3349/ymj.2016.57.4.831; Liu X, 2014, GENET MOL RES, V13, P1109, DOI 10.4238/2014.February.20.12; Miao JL, 2016, CHINESE MED J-PEKING, V129, P2868, DOI 10.4103/0366-6999.194649; Mohammadi M, 2005, CYTOKINE GROWTH F R, V16, P107, DOI 10.1016/j.cytogfr.2005.01.008; Nishino T, 2017, ESOPHAGUS-TOKYO, V14, P122, DOI 10.1007/s10388-016-0554-4; Pilotto S, 2015, J THORAC ONCOL, V10, P1341, DOI 10.1097/JTO.0000000000000628; Schildhaus HU, 2012, MODERN PATHOL, V25, P1473, DOI 10.1038/modpathol.2012.102; Shi YJ, 2016, ONCOTARGET, V7, P5063, DOI 10.18632/oncotarget.6563; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; STEWART BW, WORLD CANC REPORT; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Tiseo M, 2015, CANCER TREAT REV, V41, P527, DOI 10.1016/j.ctrv.2015.04.011; Travis WD, 2014, PATHOLOGE, V35, P188, DOI 10.1007/s00292-014-1974-3; von Loga K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141867; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; Weeden CE, 2017, MOL CANCER THER, V16, P1610, DOI 10.1158/1535-7163.MCT-17-0174; Weichert W, 2016, EUR RESPIR J, V47, P938, DOI 10.1183/13993003.00937-2015; Weiss J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001451; Whitson BA, 2012, J SURG RES, V177, P185, DOI 10.1016/j.jss.2012.05.022; WILKINSON D, 1992, SITU HYBRIDIZATION P; Wittekind C, 2010, TNM KLASSIFIKATION M; Wynes MW, 2014, CLIN CANCER RES, V20, P3299, DOI 10.1158/1078-0432.CCR-13-3060; Xie FJ, 2016, ONCOTARGETS THER, V9, DOI 10.2147/OTT.S91848; Yang W, 2014, J THORAC DIS, V6, P803, DOI 10.3978/j.issn.2072-1439.2014.05.02; Yuan Y, 2016, CANCER CELL, V29, P711, DOI 10.1016/j.ccell.2016.04.001; Zhao XY, 2015, J NANOMATER, DOI 10.1155/2015/104193	43	1	1	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAY	2018	472	5					759	769		10.1007/s00428-017-2282-0			11	Pathology	Pathology	GG9NI	WOS:000433027400007	29270870				2019-10-28	
J	Ali, RH; Taraboanta, C; Mohammad, T; Hayes, MM; Ionescu, DN				Ali, Rola H.; Taraboanta, Catalin; Mohammad, Tareq; Hayes, Malcolm M.; Ionescu, Diana N.			Metastatic non-small cell lung carcinoma a mimic of primary breast carcinoma-case series and literature review	VIRCHOWS ARCHIV			English	Review						Non-small cell; Lung; Breast; Metastatic carcinoma	NEEDLE-ASPIRATION-CYTOLOGY; TRANSCRIPTION FACTOR-I; EXTRAMAMMARY MALIGNANCIES; ESTROGEN-RECEPTOR; GATA3 EXPRESSION; NEOPLASMS; ADENOCARCINOMA; CANCER; IMMUNOHISTOCHEMISTRY; DIAGNOSIS	Metastatic tumors to the breast are rare but constitute a major diagnostic dilemma. Of these, non-mammary carcinomatous metastases to the breast are particularly challenging and, without a clinical history, may be extremely difficult to distinguish from primary breast carcinoma (PBC). We specifically studied metastatic tumors of pulmonary origin, as the lung is one of the major primary sites for carcinomatous metastasis to breast. Sixteen metastatic lung tumors to the breast were identified in our archives between 1996 and 2017 including 12 non-small cell lung carcinomas (NSCLC), one large-cell neuroendocrine, one atypical carcinoid, and two small-cell carcinomas. Adenocarcinoma was the most frequent amongst the NSCLCs (11/14). We retrieved the clinical information of these cases and reviewed the pathological characteristics to provide practical tools for pathologists to aid in their identification. Even in the absence of a clinical history of lung cancer, metastatic pulmonary adenocarcinoma to the breast should be considered in at least one of the following scenarios: (1) single or multiple well-circumscribed lesions of the breast that lack an in situ component and that are accompanied by distant metastases but negative axillary lymph nodes, (2) breast tumors that are triple negative yet not high-grade, or (3) breast tumors presenting as stage 4 disease and/or having an unusually aggressive clinical course on standard breast therapy. Accurate and timely diagnosis of these tumors is mandatory because of treatment and prognostic implications.	[Ali, Rola H.] Kuwait Univ, Dept Pathol, Hlth Sci Ctr, Kuwait, Kuwait; [Taraboanta, Catalin; Hayes, Malcolm M.; Ionescu, Diana N.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada; [Mohammad, Tareq] Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90024 USA; [Hayes, Malcolm M.; Ionescu, Diana N.] British Columbia Canc Agcy, Dept Pathol, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada	Ionescu, DN (reprint author), Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada.; Ionescu, DN (reprint author), British Columbia Canc Agcy, Dept Pathol, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada.	dionescu@bccancer.bc.ca			UBC Residency Training Program Research fund	This project has been approved by the UBC/BCCA Joint Institutional Ethical Research Board. The project has been funded internally from the UBC Residency Training Program Research fund.	ABRAMS HL, 1950, CANCER, V3, P74, DOI 10.1002/1097-0142(1950)3:1<74::AID-CNCR2820030111>3.0.CO;2-7; Ali G, 2008, HUM PATHOL, V39, P1465, DOI 10.1016/j.humpath.2008.02.011; Alva S, 1999, ARCH SURG-CHICAGO, V134, P450, DOI 10.1001/archsurg.134.4.450; Babu KS, 2009, J THORAC ONCOL, V4, P540, DOI 10.1097/JTO.0b013e31819c8556; Bishop JA, 2010, HUM PATHOL, V41, P20, DOI 10.1016/j.humpath.2009.06.014; BOHMAN LG, 1982, RADIOLOGY, V144, P309, DOI 10.1148/radiology.144.2.7089284; CHAIGNAUD B, 1994, J AM COLL SURGEONS, V179, P49; Cimino-Mathews A, 2013, HUM PATHOL, V44, P1341, DOI 10.1016/j.humpath.2012.11.003; Comperat E, 2005, MODERN PATHOL, V18, P1371, DOI 10.1038/modpathol.3800422; Dabbs DJ, 2002, ANN THORAC SURG, V73, P403, DOI 10.1016/S0003-4975(01)03358-6; Dang DN, 2015, HUM PATHOL, V46, P1829, DOI 10.1016/j.humpath.2015.07.023; DeLair DF, 2013, MODERN PATHOL, V26, P343, DOI 10.1038/modpathol.2012.191; DERCHI LE, 1985, J ULTRAS MED, V4, P69; Fulciniti F, 2008, ANN ONCOL, V19, P682, DOI 10.1093/annonc/mdm546; Georgiannos SN, 2001, CANCER-AM CANCER SOC, V92, P2259, DOI 10.1002/1097-0142(20011101)92:9<2259::AID-CNCR1571>3.0.CO;2-O; Gomez-Fernandez C, 2010, APPL IMMUNOHISTO M M, V18, P137, DOI 10.1097/PAI.0b013e3181bec23b; Gown AM, 2016, HISTOPATHOLOGY, V68, P86, DOI 10.1111/his.12877; HAJDU SI, 1972, CANCER-AM CANCER SOC, V29, P1691, DOI 10.1002/1097-0142(197206)29:6<1691::AID-CNCR2820290637>3.0.CO;2-4; Hejmadi RK, 2003, CYTOPATHOLOGY, V14, P191, DOI 10.1046/j.1365-2303.2003.00073.x; Huo L, 2015, HISTOPATHOLOGY, V67, P245, DOI 10.1111/his.12645; Kawaguchi KR, 2014, APPL IMMUNOHISTO M M, V22, P266, DOI 10.1097/PAI.0b013e318297cc0b; Klingen TA, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-80; Klingen TA, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-37; Klingen TA, 2009, APMIS, V117, P762, DOI 10.1111/j.1600-0463.2009.02529.x; Krings G, 2014, HUM PATHOL, V45, P2225, DOI 10.1016/j.humpath.2014.06.022; Lee AHS, 2007, J CLIN PATHOL, V60, P1333, DOI 10.1136/jcp.2006.046078; Lee SK, 2010, J SURG ONCOL, V101, P137, DOI 10.1002/jso.21453; MCCREA ES, 1983, AM J ROENTGENOL, V141, P685, DOI 10.2214/ajr.141.4.685; Miettinen M, 2014, AM J SURG PATHOL, V38, P13, DOI 10.1097/PAS.0b013e3182a0218f; Noguera JJ, 2007, AUSTRALAS RADIOL, V51, P133, DOI 10.1111/j.1440-1673.2007.01681.x; Ordonez NG, 2000, ADV ANAT PATHOL, V7, P123, DOI 10.1097/00125480-200007020-00007; Peng Y, 2017, ARCH PATHOL LAB MED; Rani S, 2002, ACTA CYTOL, V46, P1166; Robens J, 2010, AM J SURG PATHOL, V34, P1881, DOI 10.1097/PAS.0b013e3181f884e8; SANDISON AT, 1959, BRIT J SURG, V47, P54, DOI 10.1002/bjs.18004720111; Sauer T, 2010, CYTOJOURNAL, V7, DOI 10.4103/1742-6413.65056; Shukla R, 2005, DIAGN CYTOPATHOL, V32, P193, DOI 10.1002/dc.20198; Siami K, 2007, AM J SURG PATHOL, V31, P1759, DOI 10.1097/PAS.0b013e3181131e21; SNEIGE N, 1989, AM J CLIN PATHOL, V92, P27, DOI 10.1093/ajcp/92.1.27; TOOMBS BD, 1977, AM J ROENTGENOL, V129, P673, DOI 10.2214/ajr.129.4.673; Vitkovski T, 2016, INT J SURG PATHOL, V24, P377, DOI 10.1177/1066896916629781; Williams SA, 2007, CANCER-AM CANCER SOC, V110, P731, DOI 10.1002/cncr.22835; Wood B, 2008, PATHOLOGY, V40, P345, DOI 10.1080/00313020801911520; Yang M, 2010, MODERN PATHOL, V23, P654, DOI 10.1038/modpathol.2010.38; Ye JQ, 2011, APPL IMMUNOHISTO M M, V19, P313, DOI 10.1097/PAI.0b013e318205b059; Yeh CN, 2004, AM SURGEON, V70, P287	46	2	3	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAY	2018	472	5					771	777		10.1007/s00428-017-2262-4			7	Pathology	Pathology	GG9NI	WOS:000433027400008	29105026				2019-10-28	
J	Bai, YH; Guo, T; Huang, XZ; Wu, Q; Niu, DF; Ji, XQ; Feng, Q; Li, ZW; Kakudo, K				Bai, Yanhua; Guo, Ting; Huang, Xiaozheng; Wu, Qi; Niu, Dongfeng; Ji, Xinqiang; Feng, Qin; Li, Zhongwu; Kakudo, Kennichi			In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related	VIRCHOWS ARCHIV			English	Article						BRAF V600E; PD-L1; PD-1; Papillary thyroid carcinoma; Immunohistochemistry	CELL INFILTRATION; IMMUNE-SYSTEM; CANCER; MUTATION; ANTIBODY; IMMUNOTHERAPY; MELANOMA; PATHOGENESIS; BRAF(V600E); MECHANISM	Immune checkpoint inhibitor therapies targeting PD-L1/PD-1 have been shown to be effective in treating several types of human cancer. In papillary thyroid carcinoma (PTC), little is known about the expression of PD-L1/PD-1 in the tumor microenvironment or its potential correlation with BRAF V600E mutation status. In this study, we examined the expression of PD-L1, PD-1, and BRAF V600E in PTC by immunohistochemistry and investigated the clinical significance of expression status. We studied the expression of PD-L1, PD-1, and BRAF V600E by immunohistochemical staining in 110 cases of PTC with a diameter > 1 cm. Cases with a background of chronic lymphocytic thyroiditis (CLT) were excluded, as differentiating lymphocytes in the context of CLT from tumor-infiltrating lymphocytes (TILs) is difficult. We classified PD-L1+/PD-1+ expression as type 1 (41%), PD-L1-/PD-1- as type 2 (17%), PD-L1+/PD-1- as type 3 (5%), and PD-L1-/PD-1+ as type 4 (37%). Significant correlations were found between expression of BRAF V600E and that of PD-L1 and PD-1. The positive correlation observed between expression of BRAF V600E and PD-L1/PD-1 suggests that immunotherapies targeting PD-L1/PD-1 might be effective for PTC patients with the BRAF V600E mutation, which are refractory to radioiodine therapy.	[Bai, Yanhua; Huang, Xiaozheng; Wu, Qi; Niu, Dongfeng; Feng, Qin; Li, Zhongwu] Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ,Dept Pathol, Beijing 100142, Peoples R China; [Guo, Ting] Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ,Div Gastrointestinal Canc Translat Re, Beijing 100142, Peoples R China; [Ji, Xinqiang] Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ,Dept Med Stat, Beijing 100142, Peoples R China; [Kakudo, Kennichi] Kindai Univ, Fac Med, Dept Pathol, Nara Hosp, Nara 6300293, Japan	Bai, YH (reprint author), Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ,Dept Pathol, Beijing 100142, Peoples R China.	byh0425@sina.com			National Nature Science Foundation of ChinaNational Natural Science Foundation of China [81202114, 81301874, 81301879]; National Science Foundation of Beijing [7132051]; General Program, Research Fund for the Doctoral Program of Higher Education [2012001120135]	This work was supported by the National Nature Science Foundation of China (Nos. 81202114, 81301874, and 81301879), the National Science Foundation of Beijing (No. 7132051), and the General Program, Research Fund for the Doctoral Program of Higher Education (No. 2012001120135).	Ahn S, 2017, ENDOCR-RELAT CANCER, V24, P97, DOI 10.1530/ERC-16-0421; Angell TE, 2014, THYROID, V24, P1385, DOI 10.1089/thy.2014.0134; Atefi M, 2014, CLIN CANCER RES, V20, P3446, DOI 10.1158/1078-0432.CCR-13-2797; Bai Y, 2008, CANCER SCI, V99, P1908, DOI 10.1111/j.1349-7006.2008.00908.x; Bai Y, 2009, MODERN PATHOL, V22, P887, DOI 10.1038/modpathol.2009.38; Baquero P, 2013, CANCER LETT, V335, P232, DOI 10.1016/j.canlet.2013.02.033; Bastman JJ, 2016, J CLIN ENDOCR METAB, V101, P2863, DOI 10.1210/jc.2015-4227; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Brauner E, 2016, ONCOTARGET, V7, P17194, DOI 10.18632/oncotarget.7839; CARCANGIU ML, 1985, CANCER, V55, P805, DOI 10.1002/1097-0142(19850215)55:4<805::AID-CNCR2820550419>3.0.CO;2-Z; Chintakuntlawar AV, 2017, J CLIN ENDOCR METAB, V102, P1943, DOI 10.1210/jc.2016-3756; Chowdhury S, 2016, ONCOTARGET, V7, P32318, DOI 10.18632/oncotarget.8698; Clark CA, 2016, CANCER RES, V76, P6964, DOI 10.1158/0008-5472.CAN-16-0258; Cunha LL, 2013, ENDOCR-RELAT CANCER, V20, P103, DOI 10.1530/ERC-12-0313; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Ilie M, 2016, VIRCHOWS ARCH, V468, P511, DOI 10.1007/s00428-016-1910-4; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Kimura ET, 2003, CANCER RES, V63, P1454; Koperek O, 2012, AM J SURG PATHOL, V36, P844, DOI 10.1097/PAS.0b013e318246b527; Li ZW, 2016, HUM PATHOL, V55, P182, DOI 10.1016/j.humpath.2016.05.012; Liu H, 2014, PATHOL INT, V64, P601, DOI 10.1111/pin.12215; Massari F, 2015, CANCER TREAT REV, V41, P114, DOI 10.1016/j.ctrv.2014.12.013; Pyo JS, 2015, ENDOCR PATHOL, V26, P211, DOI 10.1007/s12022-015-9374-7; Ricarte-Filho JC, 2009, CANCER RES, V69, P4885, DOI 10.1158/0008-5472.CAN-09-0727; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Sun J, 2015, INT J CLIN EXP PATHO, V8, P15072; Sznol M, 2013, CLIN CANCER RES, V19, P1021, DOI 10.1158/1078-0432.CCR-12-2063; Tang HD, 2016, CANCER LETT, V370, P85, DOI 10.1016/j.canlet.2015.10.009; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Teng MWL, 2015, CANCER RES, V75, P2139, DOI 10.1158/0008-5472.CAN-15-0255; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Wu H, 2015, PATHOL ONCOL RES, V21, P695, DOI 10.1007/s12253-014-9876-5; Xing M, 2005, ENDOCR-RELAT CANCER, V12, P245, DOI 10.1677/erc.1.0978; Xing MZ, 2013, NAT REV CANCER, V13, P184, DOI 10.1038/nrc3431; Zhang TF, 2016, ONCOTARGET, V7, P73068, DOI 10.18632/oncotarget.12230; Zuo H, 2007, EJSO-EUR J SURG ONC, V33, P370, DOI 10.1016/j.ejso.2006.09.024; Zwaenepoel K, 2017, HISTOPATHOLOGY, V71, P357, DOI 10.1111/his.13230	37	5	5	1	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAY	2018	472	5					779	787		10.1007/s00428-018-2357-6			9	Pathology	Pathology	GG9NI	WOS:000433027400009	29651624				2019-10-28	
J	Siegler, L; Erber, R; Burghaus, S; Brodkorb, T; Wachter, D; Wilkinson, N; Bolton, J; Stringfellow, H; Haller, F; Beckmann, MW; Hartmann, A; Agaimy, A				Siegler, Lisa; Erber, Ramona; Burghaus, Stefanie; Brodkorb, Tobias; Wachter, David; Wilkinson, Nafisa; Bolton, James; Stringfellow, Helen; Haller, Florian; Beckmann, Matthias W.; Hartmann, Arndt; Agaimy, Abbas			Fumarate hydratase (FH) deficiency in uterine leiomyomas: recognition by histological features versus blind immunoscreening	VIRCHOWS ARCHIV			English	Article						Fumarate hydratase; HLRCC syndrome; Leiomyoma; Uterine; Uterus; Smooth muscle tumor; Immunohistochemistry; FH	RENAL-CELL CANCER; HEREDITARY LEIOMYOMATOSIS; CARCINOMA SYNDROME; MOLECULAR CHARACTERISTICS; GERMLINE MUTATIONS; HLRCC SYNDROME; FAMILIES; IMMUNOHISTOCHEMISTRY; GENE; SUCCINATION	Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome is a rare autosomal dominant disease caused by germline mutations in the fumarate hydratase (FH) gene. Affected individuals develop cutaneous and uterine leiomyomas and aggressive RCC. To date, only few publications described the frequency and morphology of FH-deficient uterine leiomyomas. We reviewed 22 cases collected over 8 years from routine and consultation files based on distinctive histological features. In addition, we screened 580 consecutive uterine leiomyomas from 484 patients, 23 extra-uterine and 8 uterine leiomyosarcomas, and 6 leiomyomas with bizarre nuclei for FH loss using immunohistochemistry (IHC) on tissue microarrays (TMAs). All 22 FH-deficient cases were suspected on H&E sections and confirmed by FH IHC. Patients' ages ranged from 25 to 70 years (median 36). Seventeen patients had multiple nodules (2-14) measuring up to 11.8 cm. None of the patients had stigmata or family history of the HLRCC syndrome. Histologically, all FH-deficient tumors showed consistent and reproducible features as reported previously. FH loss was detected in 2/534 evaluable leiomyomas (0.4%), but in none of leiomyosarcomas. Two of six leiomyomas with bizarre nuclei were FH-deficient. FH-deficient uterine leiomyomas are rare in routine material (= 0.4%). They can be reliably identified or suspected by consistent morphological features. Our data showed predictive morphology to be superior to blind IHC screening for detecting them. The relationship of FH-deficient uterine smooth muscle tumors to the HLRCC syndrome needs further clarification.	[Siegler, Lisa; Erber, Ramona; Wachter, David; Haller, Florian; Hartmann, Arndt; Agaimy, Abbas] Friedrich Alexander Univ Erlangen Nurnberg FAU, Inst Pathol, Univ Hosp Erlangen, Comprehens Canc Ctr ER EMN, Erlangen, Germany; [Burghaus, Stefanie; Brodkorb, Tobias; Beckmann, Matthias W.] Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Obstet & Gynecol, Univ Hosp Erlangen, Comprehens Canc Ctr ER EMN, Erlangen, Germany; [Wilkinson, Nafisa] Univ Coll London Hosp NHS Trust, Dept Cellular Pathol, London, England; [Wilkinson, Nafisa] Univ Leeds, Leeds Teaching Hosp NHS Trust, Dept Pathol, Leeds, W Yorkshire, England; [Bolton, James] Cent Manchester Univ Hosp NHS Fdn Trust, Dept Pathol, Manchester, Lancs, England; [Stringfellow, Helen] Lancashire Teaching Hosp NHS Trust, Dept Pathol, Preston, Lancs, England	Agaimy, A (reprint author), Friedrich Alexander Univ Erlangen Nurnberg FAU, Inst Pathol, Univ Hosp Erlangen, Comprehens Canc Ctr ER EMN, Erlangen, Germany.	abbas.agaimy@uk-erlangen.de					Ahvenainen T, 2008, CANCER GENET CYTOGEN, V183, P83, DOI 10.1016/j.cancergencyto.2008.01.010; Alam NA, 2005, ARCH DERMATOL, V141, P199, DOI 10.1001/archderm.141.2.199; Bennett JA, 2017, MODERN PATHOL, V30, P1476, DOI 10.1038/modpathol.2017.56; Buelow B, 2016, AM J SURG PATHOL, V40, P982, DOI 10.1097/PAS.0000000000000626; Chan I, 2005, CLIN EXP DERMATOL, V30, P75, DOI 10.1111/j.1365-2230.2004.01675.x; Chen YB, 2014, AM J SURG PATHOL, V38, P627, DOI 10.1097/PAS.0000000000000163; Chuang GS, 2005, J AM ACAD DERMATOL, V52, P410, DOI 10.1016/j.jaad.2004.08.051; Eng C, 2003, NAT REV CANCER, V3, P193, DOI 10.1038/nrc1013; Gardie B, 2011, J MED GENET, V48, P226, DOI 10.1136/jmg.2010.085068; Garg K, 2011, AM J SURG PATHOL, V35, P1235, DOI 10.1097/PAS.0b013e318223ca01; Harrison WJ, 2016, AM J SURG PATHOL, V40, P599, DOI 10.1097/PAS.0000000000000573; Joseph NM, 2015, AM J SURG PATHOL, V39, P1529, DOI 10.1097/PAS.0000000000000520; Launonen V, 2001, P NATL ACAD SCI USA, V98, P3387, DOI 10.1073/pnas.051633798; Lehtonen HJ, 2006, J MED GENET, V43, P523, DOI 10.1136/jmg.2005.036400; Lehtonen HJ, 2011, FAM CANCER, V10, P397, DOI 10.1007/s10689-011-9428-z; Linehan WM, 2013, CLIN CANCER RES, V19, P3345, DOI 10.1158/1078-0432.CCR-13-0304; Llamas-Velasco M, 2016, AM J DERMATOPATH, V38, P887, DOI 10.1097/DAD.0000000000000580; Makinen N, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0672-1; Martinek P, 2015, VIRCHOWS ARCH, V467, P185, DOI 10.1007/s00428-015-1783-y; Martinez-Mir A, 2003, J INVEST DERMATOL, V121, P741, DOI 10.1046/j.1523-1747.2003.12499.x; Merino MJ, 2007, AM J SURG PATHOL, V31, P1578, DOI 10.1097/PAS.0b013e31804375b8; Miettinen M, 2016, AM J SURG PATHOL, V40, P1661, DOI 10.1097/PAS.0000000000000703; Sanz-Ortega J, 2013, AM J SURG PATHOL, V37, P74, DOI 10.1097/PAS.0b013e31825ec16f; Schmidt LS, 2014, INT J NEPHROL RENOV, V7, P253, DOI 10.2147/IJNRD.S42097; Smit DL, 2011, CLIN GENET, V79, P49, DOI 10.1111/j.1399-0004.2010.01486.x; Stewart L, 2008, ARCH DERMATOL, V144, P1584, DOI 10.1001/archdermatol.2008.517; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Toro JR, 2003, AM J HUM GENET, V73, P95, DOI 10.1086/376435; Udager AM, 2014, AM J SURG PATHOL, V38, P567, DOI 10.1097/PAS.0000000000000127; Wei MH, 2006, J MED GENET, V43, P18, DOI 10.1136/jmg.2005.033506	30	5	5	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAY	2018	472	5					789	796		10.1007/s00428-018-2292-6			8	Pathology	Pathology	GG9NI	WOS:000433027400010	29332133				2019-10-28	
J	Pu, YM; Yang, Y; Wang, YJ; Ding, L; Huang, XF; Wang, ZY; Ni, YH; Hu, QG				Pu, Y. M.; Yang, Y.; Wang, Y. J.; Ding, L.; Huang, X. F.; Wang, Z. Y.; Ni, Y. H.; Hu, Q. G.			Postoperative radiotherapy is dispensable for OSCC patients with micrometastases in lymph nodes	VIRCHOWS ARCHIV			English	Article						Oral squamous cell carcinoma; Micrometastasis; Radiotherapy; Prognosis; Worst pattern of invasion	SQUAMOUS-CELL CARCINOMA; UPPER AERODIGESTIVE TRACT; ORAL-CAVITY; CLINICAL-SIGNIFICANCE; NODAL MICROMETASTASES; OCCULT METASTASES; PROGNOSTIC VALUE; WORST PATTERN; TUMOR-CELLS; NECK-CANCER	Lymph node metastasis is a decisive factor for performing postoperative radiotherapy for oral squamous cell carcinoma (OSCC). However, whether OSCC patients with only micrometastasis need postoperative radiotherapy is unclear. In this study, OSCC patients (n = 311) with negative (n = 247), only micrometastasis (n = 44) and macrometastasis (n = 20) were detected and selected by HE staining. Micrometastasis was re-assessed using immunohistochemical staining of cytokeratin (CK) in HE-negative patients to find out the false negative cases. The results indicated that, among the negative lymph node cases (n = 247), the positive rate of CK was 4.94% (n = 12). Besides, the clinical features of the primary tumor in relation to the only micrometastatic status and the value of the postoperative radiotherapy on the only micrometastasis patients were evaluated. Patients with only micrometastasis had higher T stage and inferior worst pattern of invasion (WPOI) than patients without micrometastasis, but they had longer overall survival (OS), metastasis-free survival (MFS), and disease-free survival (DFS) than macrometastasis patients. However, the survival time of only micrometastasis patients with or without postoperative radiotherapy was comparable, even in patients with inferior WPOI. Radiotherapy, however, may only benefit patients with IV/V levels of micrometastasis. These data indicated that postoperative radiotherapy is dispensable for only micrometastasis OSCC patients.	[Pu, Y. M.; Yang, Y.; Wang, Y. J.; Huang, X. F.; Wang, Z. Y.; Ni, Y. H.; Hu, Q. G.] Nanjing Univ, Dept Oral & Maxillofacial Surg, Nanjing Stomatol Hosp, Sch Med, 30 Zhongyang Rd, Nanjing 210008, Jiangsu, Peoples R China; [Ni, Y. H.] Nanjing Univ, Dept Cent Lab, Nanjing Stomatol Hosp, Sch Med, 30 Zhongyang Rd, Nanjing 210008, Jiangsu, Peoples R China; [Ding, L.] Nanjing Univ, Nanjing Stomatol Hosp, Sch Med, 22 Hankou Rd, Nanjing 210093, Jiangsu, Peoples R China; [Ding, L.] Nanjing Univ, State Key Lab Pharmaceut Biotechnol, Sch Med, Div Immunol, 22 Hankou Rd, Nanjing 210093, Jiangsu, Peoples R China	Ni, YH; Hu, QG (reprint author), Nanjing Univ, Dept Oral & Maxillofacial Surg, Nanjing Stomatol Hosp, Sch Med, 30 Zhongyang Rd, Nanjing 210008, Jiangsu, Peoples R China.; Ni, YH (reprint author), Nanjing Univ, Dept Cent Lab, Nanjing Stomatol Hosp, Sch Med, 30 Zhongyang Rd, Nanjing 210008, Jiangsu, Peoples R China.	niyanhong12@163.com; qghu@nju.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81402238, 81072213, 81271698]; Nanjing Medical Science & Research Project [YKK13145]; National Key Disciplines Constructional Project Funding; Nanjing Municipal Key Medical Laboratory Constructional Project Funding; Center of Nanjing Clinical Medicine of tumor project; Jiangsu Provincial Commission of Health and Family Planning Project, China [Z201516]; Nanjing Medical Science and Technique Development Foundation	This work was supported by a grant from the National Natural Science Foundation of China (Nos. 81402238, 81072213, and 81271698), the Nanjing Medical Science & Research Project (No. YKK13145), National Key Disciplines Constructional Project Funding (since 2011), Nanjing Municipal Key Medical Laboratory Constructional Project Funding (since 2012), Center of Nanjing Clinical Medicine of tumor project (since 2014), Jiangsu Provincial Commission of Health and Family Planning Project, China (Z201516) and Nanjing Medical Science and Technique Development Foundation.	Almangush A, 2014, HEAD NECK-J SCI SPEC, V36, P811, DOI 10.1002/hed.23380; AMBROSCH P, 1995, HEAD NECK-J SCI SPEC, V17, P473, DOI 10.1002/hed.2880170604; Brandwein-Gensler A, 2005, AM J SURG PATHOL, V29, P167; Broglie MA, 2013, HEAD NECK-J SCI SPEC, V35, P660, DOI 10.1002/hed.23017; BRYNE M, 1989, J ORAL PATHOL MED, V18, P432, DOI 10.1111/j.1600-0714.1989.tb01339.x; Carrau RL, 1995, INVAS METAST, V15, P197; Cho JH, 2016, HEAD NECK-J SCI SPEC, V38, pE1777, DOI 10.1002/hed.24314; CUNNINGHAM MJ, 1986, AM J SURG, V152, P361, DOI 10.1016/0002-9610(86)90305-3; Ferlito A, 2002, ORAL ONCOL, V38, P3, DOI 10.1016/S1368-8375(01)00037-9; Ferlito A, 2001, ACTA OTO-LARYNGOL, V121, P660, DOI 10.1080/00016480152583584; Genden EM, 2003, ORAL ONCOL, V39, P207, DOI 10.1016/S1368-8375(02)00049-0; Glickman JN, 1999, CANCER, V85, P769, DOI 10.1002/(SICI)1097-0142(19990215)85:4<769::AID-CNCR3>3.3.CO;2-9; Hamakawa H, 2000, VIRCHOWS ARCH, V437, P116, DOI 10.1007/s004280000199; Hermanek P, 1999, CANCER-AM CANCER SOC, V86, P2668, DOI 10.1002/(SICI)1097-0142(19991215)86:12<2668::AID-CNCR11>3.0.CO;2-R; Izbicki JR, 1997, NEW ENGL J MED, V337, P1188, DOI 10.1056/NEJM199710233371702; Liao CT, 2011, INT J RADIAT ONCOL, V81, P930, DOI 10.1016/j.ijrobp.2010.07.1988; Min KW, 1998, ARCH PATHOL LAB MED, V122, P222; Negm H, 2013, EUR ARCH OTO-RHINO-L, V270, P1085, DOI 10.1007/s00405-012-2094-4; Nieuwenhuis EJC, 2003, LAB INVEST, V83, P1233, DOI 10.1097/01.LAB.0000083532.46536.56; Patel V, 2013, ORAL ONCOL, V49, P93, DOI 10.1016/j.oraloncology.2012.08.001; Rhee D, 2002, LARYNGOSCOPE, V112, P1970, DOI 10.1097/00005537-200211000-00011; ROBBINS KT, 1991, ARCH OTOLARYNGOL, V117, P601; VANDENBREKEL MWM, 1992, EUR ARCH OTO-RHINO-L, V249, P349, DOI 10.1007/BF00179388; Velosa C, 2017, HEAD NECK-J SCI SPEC, V39, P2142, DOI 10.1002/hed.24900; Woolgar JA, 1999, BRIT J ORAL MAX SURG, V37, P181, DOI 10.1054/bjom.1999.0037; Woolgar JA, 1997, INT J ORAL MAX SURG, V26, P3, DOI 10.1016/S0901-5027(97)80837-5; Xu YA, 2008, OTOLARYNG HEAD NECK, V139, P436, DOI 10.1016/j.otohns.2008.04.023; Xu YN, 2012, AM J OTOLARYNG, V33, P402, DOI 10.1016/j.amjoto.2011.10.012; Yamazaki Y, 2005, HEAD NECK-J SCI SPEC, V27, P676, DOI 10.1002/hed.20200; Yang TL, 2008, HEAD NECK-J SCI SPEC, V30, P631, DOI 10.1002/hed.20758	30	0	0	2	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAY	2018	472	5					797	805		10.1007/s00428-018-2351-z			9	Pathology	Pathology	GG9NI	WOS:000433027400011	29629513				2019-10-28	
J	Gultekin, SE; Aziz, R; Heydt, C; Senguven, B; Zoller, J; Safi, AF; Kreppel, M; Buettner, R				Gultekin, Sibel Elif; Aziz, Reem; Heydt, Carina; Senguven, Burcu; Zoller, Joachim; Safi, Ali Farid; Kreppel, Matthias; Buettner, Reinhard			The landscape of genetic alterations in ameloblastomas relates to clinical features	VIRCHOWS ARCHIV			English	Article						Ameloblastoma; MAPKinase signaling; Hedgehog signaling; Mutational risk profiling; Genotype-phenotype correlation; Mutation-based risk stratification	MUTATIONS; PATHWAY	Ameloblastoma is a mostly benign, but locally invasive odontogenic tumor eliciting frequent relapses and significant morbidity. Recently, mutually exclusive mutations in BRAF and SMO were identified causing constitutive activation of MAPK and hedgehog signaling pathways. To explore further such clinically relevant genotype-phenotype correlations, we here comprehensively analyzed a large series of ameloblastomas (98 paraffin block of 76 patients) with respect to genomic alterations, clinical presentation, and histological features collected from the archives of three different pathology centers in France, Germany, and Turkey. In good agreement with previously published data, we observed BRAF mutations almost exclusively in mandibular tumors, SMO mutations predominantly in maxillary tumors, and single mutations in EGFR, KRAS, and NRAS. KRAS, NRAS, PIK3CA, PTEN, CDKN2A, FGFR, and CTNNB1 mutations co-occurred in the background of either BRAF or SMO mutations. Strikingly, multiple mutations were exclusively observed in European patients, in solid ameloblastomas and were associated with a very high risk for recurrence. In contrast, tumors with a single BRAF mutation revealed a lower risk for relapse. We here establish a comprehensive landscape of mutations in the MAPK and hedgehog signaling pathways relating to clinical features of ameloblastoma. Our data suggest that ameloblastomas harboring single BRAF mutations are excellent candidates for neo-adjuvant therapies with combined BRAF/MEK inhibitors and that the risk of recurrence maybe stratified based on the mutational spectrum.	[Gultekin, Sibel Elif; Senguven, Burcu] Gazi Univ, Dept Oral Pathol, Fac Dent, Ankara, Turkey; [Aziz, Reem; Heydt, Carina; Buettner, Reinhard] Univ Hosp Cologne, Cologne Inst Pathol, Kerpener Str 62, D-50937 Cologne, Germany; [Zoller, Joachim; Safi, Ali Farid; Kreppel, Matthias] Univ Hosp Cologne, Clin Oral & Maxillofacial Surg, Cologne, Germany	Buettner, R (reprint author), Univ Hosp Cologne, Cologne Inst Pathol, Kerpener Str 62, D-50937 Cologne, Germany.	Reinhard.Buettner@uk-koeln.de			Medical Faculty, University of Cologne	Professor Sibel Elif Gultekin (Ankara) was supported as a guest professor by the Medical Faculty, University of Cologne. No other source of funding was received.	Barnes LEJW, 2005, WHO CLASSIFICATION T, P296; Black CC, 2010, ORAL SURG ORAL MED O, V110, P585, DOI 10.1016/j.tripleo.2010.02.040; Brown Noah A, 2015, Biomark Cancer, V7, P19, DOI 10.4137/BIC.S29329; Brown NA, 2014, CLIN CANCER RES, V20, P5517, DOI 10.1158/1078-0432.CCR-14-1069; Brunner P, 2015, ORAL ONCOL, V51, pE77, DOI 10.1016/j.oraloncology.2015.07.010; Depew MJ, 2002, SCIENCE, V298, P381, DOI 10.1126/science.1075703; Ferguson CA, 2001, DEVELOPMENT, V128, P4605; Gomes DC, 2015, EUR J ENDOCRINOL, V172, P603, DOI 10.1530/EJE-14-0934; Heikinheimo K, 2015, J DENT RES, V94, P237, DOI 10.1177/0022034514560373; Kloth M, 2014, GENES-BASEL, V5, P444, DOI 10.3390/genes5020444; Kurppa KJ, 2014, J PATHOL, V232, P492, DOI 10.1002/path.4317; Mendenhall WM, 2007, AM J CLIN ONCOL-CANC, V30, P645, DOI 10.1097/COC.0b013e3181573e59; Qui M, 1997, DEV BIOL, V185, P165; Regezi J, 2012, ORAL PATHOLOGY CLIN, P270; Robinson LC, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.9.FOCUS16308; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; Sweeney RT, 2014, NAT GENET, V46, P722, DOI 10.1038/ng.2986; Tucker A, 2004, NAT REV GENET, V5, P499, DOI 10.1038/nrg1380; Wright JM, 2017, HEAD NECK PATHOL, V11, P68, DOI 10.1007/s12105-017-0794-1	19	6	7	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAY	2018	472	5					807	814		10.1007/s00428-018-2305-5			8	Pathology	Pathology	GG9NI	WOS:000433027400012	29388014	Green Published, Other Gold			2019-10-28	
J	Machado, I; Lopez-Guerrero, JA; Scotlandi, K; Picci, P; Llombart-Bosch, A				Machado, Isidro; Antonio Lopez-Guerrero, Jose; Scotlandi, Katia; Picci, Piero; Llombart-Bosch, Antonio			Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT)	VIRCHOWS ARCHIV			English	Article						Ewing sarcoma; PD-1; PD-L1; Immunohistochemistry; Prognostic factor	CELL LUNG-CANCER; RISK PEDIATRIC SARCOMAS; INFILTRATING LYMPHOCYTES; EXPRESSION; IMMUNOTHERAPY; CARCINOMA; MELANOMA; MICROENVIRONMENT; NIVOLUMAB; CHEMOTHERAPY	Ewing's sarcoma family of tumors (ESFT) are aggressive neoplasms with scant tumor-infiltrating lymphocytes. We analyzed the immunohistochemical (IHC) expression of PD-L1 and PD-1 and their prognostic significance in clinically localized neoplasms in a cohort of 370 ESFT. Slides prepared from tissue microarrays were stained for PD-L1, PD-1, and CD8. Membranous/cytoplasmic staining over 5% of tumor cells was regarded as positive for PD-L1 and PD-1. Prognostic analysis was done considering only clinically localized tumors (n = 217). PD-L1 expression was present in 19% of ESFT, while PD-1 was expressed in 26%. Forty-eight percent of tumors were negative and 12% were positive for both PD-L1 and PD-1. Metastatic tumors displayed higher expression of PD-L1 (p < 0.0001). Histological subtypes were not correlated with PD-L1 or PD-1 positivity. ESFT with elevated proliferation index (Ki-67) were associated with higher PD-L1 expression (p = 0.049). Regarding prognosis, no significant association was found between PD-L1 expression and progression-free survival (PFS) or overall survival (OS), whereas lack of PD-1 expression in tumor cells was correlated with both poor PFS (p = 0.02) and poor OS (p = 0.004). Tumor-infiltrating CD8(+) T lymphocytes were observed in 15.4% of ESFT with informative results (347 tumors). No correlation was found between tumor-infiltrating CD8(+) T lymphocytes and ESFT histological subtypes, tumor location, or PD-1 and PD-L1 expression, nor with PFS (p = 0.473) or OS (p = 0.087). PD-L1 expression was not significantly related to prognosis. PD-1 was expressed in 26% of ESFT tumor cells and may have prognostic and therapeutic implications. CD8 expression in tumor-infiltrating lymphocytes was not related to prognosis.	[Machado, Isidro] Inst Valenciano Oncol, Dept Pathol, Valencia, Spain; [Antonio Lopez-Guerrero, Jose] Inst Valenciano Oncol, Dept Mol Biol, Valencia, Spain; [Scotlandi, Katia; Picci, Piero] Ist Rizzoli, Expt Oncol Lab, Bologna, Italy; [Llombart-Bosch, Antonio] Univ Valencia, Dept Pathol, Valencia, Spain	Machado, I (reprint author), Inst Valenciano Oncol, Dept Pathol, Valencia, Spain.	Isidro.machado@uv.es	Scotlandi, Katia/J-9009-2016; LOPEZ-GUERRERO, JOSE ANTONIO/Z-4808-2019; Guerrero, Jose Antonio Lopez/Z-2413-2019	Scotlandi, Katia/0000-0001-6114-9499; LOPEZ-GUERRERO, JOSE ANTONIO/0000-0002-7369-8388; 	EuroBoNeTEuropean Commission Joint Research Centre [18814]; IVO Foundation; AIRCAssociazione Italiana per la Ricerca sul Cancro (AIRC) [IG18451]	This study was supported by grant no. 18814 from EuroBoNeT, grant from the IVO Foundation, and AIRC IG18451 (KS).	Ahmadzadeh M, 2009, BLOOD, V114, P1537, DOI 10.1182/blood-2008-12-195792; Ahmed SK, 2014, AM J CLIN ONCOL-CANC, V37, P423, DOI 10.1097/COC.0b013e31827de65e; Alessi C, 2017, MELANOMA RES, V27, P565, DOI 10.1097/CMR.0000000000000396; Altvater B, 2014, CANCER IMMUNOL IMMUN, V63, P1047, DOI 10.1007/s00262-014-1574-3; Amaral T, 2017, EXPERT OPIN BIOL TH, V17, P1523, DOI 10.1080/14712598.2017.1378640; Aoki T, 2016, PEDIATR BLOOD CANCER, V63, P1461, DOI 10.1002/pbc.26018; Arpaci E, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0469-z; Ashour M, 2017, J CANC THERAPY, V8, P764, DOI [10.4236/jct.2017.88066, DOI 10.4236/JCT.2017.88066]; Bacci G, 2000, J CLIN ONCOL, V18, P4, DOI 10.1200/JCO.2000.18.1.4; Berghuis D, 2011, J PATHOL, V223, P347, DOI 10.1002/path.2819; Berghuis D, 2009, J PATHOL, V218, P222, DOI 10.1002/path.2537; Botta GP, 2017, TRANSL CANCER RES, V6, P17, DOI 10.21037/tcr.2017.02.09; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Chen LP, 2015, J CLIN INVEST, V125, P3384, DOI 10.1172/JCI80011; Chowdhury F, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1029701; Cotterill SJ, 2000, J CLIN ONCOL, V18, P3108, DOI 10.1200/JCO.2000.18.17.3108; Crompton BD, 2014, CANCER DISCOV, V4, P1326, DOI [10.1158/2159-8290.00-13-1037, 10.1158/2159-8290.CD-13-1037]; D'Angelo SP, 2015, HUM PATHOL, V46, P357, DOI 10.1016/j.humpath.2014.11.001; D'Incecco A, 2015, BRIT J CANCER, V112, P95, DOI 10.1038/bjc.2014.555; Darb-Esfahani S, 2016, ONCOTARGET, V7, P1486, DOI 10.18632/oncotarget.6429; de Alava Enrique, 2017, Surg Pathol Clin, V10, P575, DOI 10.1016/j.path.2017.04.001; Espinosa E, ANN TRANSL MED, V5, P189; Folpe AL, 2005, AM J SURG PATHOL, V29, P1025; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gaspar N, 2015, J CLIN ONCOL, V33, P3036, DOI 10.1200/JCO.2014.59.5256; Gooden MJM, 2011, BRIT J CANCER, V105, P93, DOI 10.1038/bjc.2011.189; Jacquelot N, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00608-2; Kager L, 2016, CLIN SARCOMA RES, V6, DOI 10.1186/s13569-016-0043-5; Kim C, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2451-6; Kim J, 2013, 2013 5TH IEEE INTERNATIONAL CONFERENCE ON BROADBAND NETWORK & MULTIMEDIA TECHNOLOGY (IC-BNMT), P10, DOI 10.1109/ICBNMT.2013.6823905; Koirala P, 2016, SCI REP-UK, V6, DOI 10.1038/srep30093; Kovar H, 2016, ONCOTARGET, V7, P8613, DOI 10.18632/oncotarget.6937; Ladenstein R, 2010, J CLIN ONCOL, V28, P3284, DOI 10.1200/JCO.2009.22.9864; Leite KRM, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0414-x; Llombart-Bosch A, 2009, VIRCHOWS ARCH, V455, P397, DOI 10.1007/s00428-009-0842-7; Mackall CL, 2008, CLIN CANCER RES, V14, P4850, DOI 10.1158/1078-0432.CCR-07-4065; McCaughan GJB, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0278-x; Merchant MS, 2016, CLIN CANCER RES, V22, P3182, DOI 10.1158/1078-0432.CCR-15-2550; Pan HY, 2015, INT J RADIAT ONCOL, V92, P349, DOI 10.1016/j.ijrobp.2015.01.022; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Paydas S, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0807-z; Pinto N, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26613; Raj S, 2014, ANN ONCOL, V25, piv494; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Schmidt LH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136023; Scognamiglio G, 2016, INT J MOL SCI, V17, P21; Sholl LM, 2016, ARCH PATHOL LAB MED, V140, P341, DOI 10.5858/arpa.2015-0506-SA; Spurny C, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.26719; Takada K, 2017, LUNG CANCER, V104, P7, DOI 10.1016/j.lungcan.2016.12.006; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Uyeturk U, 2016, WSPOLCZESNA ONKOL, V20, P141, DOI 10.5114/wo.2016.58487; van Erp AEM, 2017, ONCOTARGET, V8, P71371, DOI 10.18632/oncotarget.19071; Wang X, 2016, ONCOTARGETS THER, V9, P5023, DOI 10.2147/OTT.S105862; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Zheng Peilin, 2015, Biomark Cancer, V7, P15, DOI 10.4137/BIC.S29325	55	7	7	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAY	2018	472	5					815	824		10.1007/s00428-018-2316-2			10	Pathology	Pathology	GG9NI	WOS:000433027400013	29445891				2019-10-28	
J	Kervarrec, T; Samimi, M; Gaboriaud, P; Gheit, T; Beby-Defaux, A; Houben, R; Schrama, D; Fromont, G; Tommasino, M; Le Corre, Y; Hainaut-Wierzbicka, E; Aubin, F; Bens, G; Maillard, H; Furudoi, A; Michenet, P; Touze, A; Guyetant, S				Kervarrec, Thibault; Samimi, Mahtab; Gaboriaud, Pauline; Gheit, Tarik; Beby-Defaux, Agnes; Houben, Roland; Schrama, David; Fromont, Gaelle; Tommasino, Massimo; Le Corre, Yannick; Hainaut-Wierzbicka, Eva; Aubin, Francois; Bens, Guido; Maillard, Herve; Furudoi, Adeline; Michenet, Patrick; Touze, Antoine; Guyetant, Serge			Detection of the Merkel cell polyomavirus in the neuroendocrine component of combined Merkel cell carcinoma	VIRCHOWS ARCHIV			English	Article						Merkel cell carcinoma; Merkel cell polyomavirus; Combined merkel cell carcinoma; Squamous carcinoma; Polyomavirus; Papillomavirus	MICROARRAY PRIMER EXTENSION; BETA-HUMAN PAPILLOMAVIRUSES; COMBINED TUMORS; STAGING SYSTEM; EYEBROW HAIRS; MULTIPLEX PCR; EXPRESSION; INFECTION; DNA; DIFFERENTIATION	Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin. The main etiological agent is Merkel cell polyomavirus (MCPyV), detected in 80% of cases. About 5% of cases, called combined MCC, feature an admixture of neuroendocrine and non-neuroendocrine tumor cells. Reports of the presence or absence of MCPyV in combined MCC are conflicting, most favoring the absence, which suggests that combined MCC might have independent etiological factors and pathogenesis. These discrepancies might occur with the use of different virus identification assays, with different sensitivities. In this study, we aimed to determine the viral status of combined MCC by a multimodal approach. We histologically reviewed 128 cases of MCC and sub-classified them as "combined" or "conventional." Both groups were compared by clinical data (age, sex, site, American Joint Committee on Cancer [AJCC] stage, immunosuppression, risk of recurrence, and death during follow-up) and immunochemical features (cytokeratin 20 and 7, thyroid transcription factor 1 [TTF1], p53, large T antigen [CM2B4], CD8 infiltrates). After a first calibration step with 12 conventional MCCs and 12 cutaneous squamous cell carcinomas as controls, all eight cases of combined MCC were investigated for MCPyV viral status by combining two independent molecular procedures. Furthermore, on multiplex genotyping assay, the samples were examined for the presence of other polyoma- and papillomaviruses. Combined MCC differed from conventional MCC in earlier AJCC stage, increased risk of recurrence and death, decreased CD8 infiltrates, more frequent TTF1 positivity (5/8), abnormal p53 expression (8/8), and frequent lack of large T antigen expression (7/8). With the molecular procedure, half of the combined MCC cases were positive for MCPyV in the neuroendocrine component. Beta papillomaviruses were detected in 5/8 combined MCC cases and 9/12 conventional MCC cases. In conclusion, the detection of MCPyV DNA in half of the combined MCC cases suggests similar routes of carcinogenesis for combined and conventional MCC.	[Kervarrec, Thibault; Fromont, Gaelle; Guyetant, Serge] Univ Tours, Ctr Hosp Univ Tours, Dept Pathol, F-37044 Tours 09, France; [Kervarrec, Thibault; Samimi, Mahtab; Gaboriaud, Pauline; Touze, Antoine; Guyetant, Serge] Univ Tours, Biol Infect Polyomavirus Team, INRA, UMR 1282,ISP, 31 Ave Monge, F-37200 Tours, France; [Kervarrec, Thibault; Houben, Roland; Schrama, David] Univ Hosp Wurzburg, Dept Dermatol Venereol & Allergol, Josef Schneider Str 2, D-97080 Wurzburg, Germany; [Samimi, Mahtab; Tommasino, Massimo] Univ Tours, Dept Dermatol, Ctr Hosp Univ Tours, F-37044 Tours 09, France; [Gheit, Tarik] Int Agcy Res Canc, Infect & Canc Biol Grp, 150 Cours Albert Thomas, F-69008 Lyon, France; [Beby-Defaux, Agnes] Univ Poitiers, Recepteurs & Regulat Cellules Tumorales Team 2RCT, 1 Rue Georges Bonnet, F-86073 Poitiers, France; [Beby-Defaux, Agnes] Univ Poitiers, Ctr Hosp Univ Poitiers, Dept Virol, 2 Rue Miletrie, F-86021 Poitiers, France; [Le Corre, Yannick] LUNAM Univ, Dept Dermatol, Ctr Hosp Univ Angers, 4 Rue Larrey, F-49933 Angers, France; [Hainaut-Wierzbicka, Eva] Univ Poitiers, Ctr Hosp Univ Poitiers, Dept Dermatol, 2 Rue Miletrie, F-86021 Poitiers, France; [Aubin, Francois] Univ Franche Comte, Dept Dermatol, Ctr Hosp Univ Besancon, EA3181, IFR133,2 Blvd Fleming, F-25030 Besancon, France; [Bens, Guido] Ctr Hosp Reg Orleans, Dept Dermatol, 14 Ave Hop,CS 86709, F-45067 Orleans 2, France; [Maillard, Herve] Ctr Hosp Reg Mans, Dept Dermatol, 194 Ave Rubillard, F-72037 Le Mans, France; [Furudoi, Adeline] Univ Bordeaux, Ctr Hosp Univ Bordeaux, Dept Pathol, Ave Magellan, F-33604 Pessac, France; [Michenet, Patrick] Ctr Hosp Reg Orleans, Dept Pathol, 14 Ave Hop,CS 86709, F-45067 Orleans 2, France	Kervarrec, T (reprint author), Univ Tours, Ctr Hosp Univ Tours, Dept Pathol, F-37044 Tours 09, France.; Kervarrec, T (reprint author), Univ Tours, Biol Infect Polyomavirus Team, INRA, UMR 1282,ISP, 31 Ave Monge, F-37200 Tours, France.; Kervarrec, T (reprint author), Univ Hosp Wurzburg, Dept Dermatol Venereol & Allergol, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	thibaultkervarrec@yahoo.fr	samimi, mahtab/V-3038-2019	Touze, antoine/0000-0002-9856-9945; Houben, Roland/0000-0003-4538-2324	project POCAME; Axe Immunotherapies; Canceropole Grand Ouest-Region Centre Val de Loire (France); Fond de recherche de la societe francaise de Pathologie	This work was funded by project POCAME, Axe Immunotherapies, Canceropole Grand Ouest-Region Centre Val de Loire (France) and by the Fond de recherche de la societe francaise de Pathologie 2016.	Asgari MM, 2014, JAMA DERMATOL, V150, P716, DOI 10.1001/jamadermatol.2013.8116; Bishop JA, 2011, AM J SURG PATHOL, V35, P1679, DOI 10.1097/PAS.0b013e3182299cde; Busam KJ, 2009, AM J SURG PATHOL, V33, P1378, DOI 10.1097/PAS.0b013e3181aa30a5; Carter MD, 2018, HUM PATHOL, V71, P117, DOI 10.1016/j.humpath.2017.10.014; Chen CH, 2015, CSEE J POWER ENERGY, V1, P10, DOI 10.17775/CSEEJPES.2015.00029; Chou TC, 2016, CLIN EXP DERMATOL, V41, P902, DOI 10.1111/ced.12954; Czapiewski P, 2016, AM J DERMATOPATH, V38, P513, DOI 10.1097/DAD.0000000000000464; Gonzalez-Vela MDC, 2017, J INVEST DERMATOL, V137, P197, DOI 10.1016/j.jid.2016.08.015; Di Bonito P, 2015, FOOD ENVIRON VIROL, V7, P1, DOI 10.1007/s12560-014-9168-y; Eid M, 2017, J INVEST DERMATOL, V137, P797, DOI 10.1016/j.jid.2016.12.024; Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586; Gardair C, 2015, NEUROENDOCRINOLOGY, V101, P223, DOI 10.1159/000381062; Gheit T, 2006, J CLIN MICROBIOL, V44, P2025, DOI 10.1128/JCM.02305-05; Gheit T, 2007, J CLIN MICROBIOL, V45, P2537, DOI 10.1128/JCM.00747-07; Hampras SS, 2015, INFECT AGENTS CANCER, V10, DOI 10.1186/s13027-015-0030-0; Harms KL, 2016, ANN SURG ONCOL, V23, P3564, DOI 10.1245/s10434-016-5266-4; Houben R, 2012, J INVEST DERMATOL, V132, P254, DOI 10.1038/jid.2011.260; Houben R, 2012, INT J CANCER, V130, P847, DOI 10.1002/ijc.26076; Iannacone MR, 2014, INT J CANCER, V134, P2231, DOI 10.1002/ijc.28552; Iwasaki T, 2013, HUM PATHOL, V44, P442, DOI 10.1016/j.humpath.2012.08.022; Lai JH, 2015, HUM PATHOL, V46, P1290, DOI 10.1016/j.humpath.2015.05.008; LeBoit PE, 2007, PATH GEN SKIN TUM RE; Lemos BD, 2010, J AM ACAD DERMATOL, V63, P751, DOI 10.1016/j.jaad.2010.02.056; Leroux-Kozal V, 2015, HUM PATHOL, V46, P443, DOI 10.1016/j.humpath.2014.12.001; Liu W, 2016, CELL HOST MICROBE, V19, P775, DOI 10.1016/j.chom.2016.04.024; Martin B, 2013, HISTOPATHOLOGY, V62, P711, DOI 10.1111/his.12091; Mehrad M, 2013, AM J SURG PATHOL, V37, P1349, DOI 10.1097/PAS.0b013e318290427d; Mitteldorf C, 2012, AM J DERMATOPATH, V34, P506, DOI 10.1097/DAD.0b013e31823b9b4e; Moshiri AS, 2017, J INVEST DERMATOL, V137, P819, DOI 10.1016/j.jid.2016.10.028; Ostrowski SM, 2015, DEVELOPMENT, V142, P2533, DOI 10.1242/dev.123141; Paulson KG, 2011, J CLIN ONCOL, V29, P1539, DOI 10.1200/JCO.2010.30.6308; Pulitzer MP, 2015, MODERN PATHOL, V28, P1023, DOI 10.1038/modpathol.2015.60; Rodig SJ, 2012, J CLIN INVEST, V122, P4645, DOI 10.1172/JCI64116; Rollison DE, 2012, CANCER EPIDEM BIOMAR, V21, P74, DOI 10.1158/1055-9965.EPI-11-0764; Tommasino M, 2017, VIRUS RES, V231, P128, DOI 10.1016/j.virusres.2016.11.013; Touze A, 2009, EMERG INFECT DIS, V15, P960, DOI 10.3201/eid1506.081463; Watanabe G, 2015, AM J SURG PATHOL, V39, P1026, DOI 10.1097/PAS.0000000000000386	37	1	1	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAY	2018	472	5					825	837		10.1007/s00428-018-2342-0			13	Pathology	Pathology	GG9NI	WOS:000433027400014	29594354				2019-10-28	
J	Nagesh, NM; Giurca, BC; Lishman, S				Nagesh, Navin Mukundu; Giurca, Bogdan Chiva; Lishman, Suzy			Innovating undergraduate pathology education through public engagement	VIRCHOWS ARCHIV			English	Article						Medical education; National PathologyWeek; Public engagement	MEDICAL-EDUCATION; CURRICULUM; STUDENTS; SCHOOL; ABC; UK	The trends in modern undergraduate medical education focus on a patient-centred approach through problem-based learning over the traditional modular curriculum. Integrating pathology into this style of learning has resulted in the dilution of core scientific principles which may have contributed to reduced understanding and interest in the subject. We aim to innovate pathology education by utilising National Pathology Week which is organised by the Royal College of Pathologists to develop the public engagement model which empowers students to learn pathology by teaching the public. Through this model, we hope to generate a greater interest in pathology at both undergraduate and postgraduate stages of education. We obtained funding from the Royal College of Pathologists to organise National Pathology Week at Exeter Medical School and the Royal Devon & Exeter Hospital. We involved 125 undergraduate student volunteers from health-related courses. We designed a curriculum aiming to educate both students and public on current topics such as cancer screening programmes, antibiotic resistance, diagnosis of inflammatory bowel disease and the role of pathologists. We hosted 15 pathologists, biomedical scientists and microbiologists to engage with students, share experiences and offer an insight into their careers. Through this project, we interacted with over 500 members of the public and 150 school students. The medical student volunteers developed a range of skills including competent use of microscopes to visualise pathology slides, effective communication with lay audiences to teach pathology and understanding of the clinical application of pathology. We believe the public engagement model of teaching undergraduate students has the potential to develop a greater interest in pathology whilst benefitting the wider community.	[Nagesh, Navin Mukundu; Giurca, Bogdan Chiva] Exeter Med Sch, Heavitree Rd, Exeter EX1 2LU, Devon, England; [Lishman, Suzy] Royal Coll Pathologists, 21 Prescot St,4th Floor, London E1 8BB, England	Nagesh, NM (reprint author), Exeter Med Sch, Heavitree Rd, Exeter EX1 2LU, Devon, England.	nn235@exeter.ac.uk; Bc299@exeter.ac.uk; Suzy.Lishman@rcpath.org		Mukundu Nagesh, Navin/0000-0001-7904-1013; Chiva Giurca, Bogdan/0000-0001-8262-4682			[Anonymous], 2016, PREVIOUS NATL PATHOL; Brice J, 2010, MED TEACH, V32, P727, DOI 10.3109/0142159X.2010.497828; BYERS JM, 1989, AM J CLIN PATHOL, V92, pS2; Howe A, 2004, BRIT MED J, V329, P327, DOI 10.1136/bmj.329.7461.327; Kaufman DM, 2003, BMJ-BRIT MED J, V326, P213, DOI 10.1136/bmj.326.7382.213; Kennedy C, 2015, BMJ CAREERS; Lambert T, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X583173; Laposata M, 2016, ACAD PATHOL, V3, DOI 10.1177/2374289516634108; Larsen DP, 2008, MED EDUC, V42, P959, DOI 10.1111/j.1365-2923.2008.03124.x; Lempp H, 2004, MED TEACH, V26, P276, DOI 10.1080/248-0142159042000192046; Misch DA, 2002, ADV HEALTH SCI EDUC, V7, P153, DOI 10.1023/A:1015790318032; Mostafa Soha R, 2006, J Egypt Public Health Assoc, V81, P99; Murad MH, 2010, MED EDUC, V44, P1057, DOI 10.1111/j.1365-2923.2010.03750.x; Murdoch-Eaton D, 2004, MED TEACH, V26, P33, DOI 10.1080/0142159032000150494; Tang TS, 2004, TEACH LEARN MED, V16, P60, DOI 10.1207/s15328015tlm1601_12; Turney BW, 2007, ANN ROY COLL SURG, V89, P104, DOI 10.1308/003588407X168244; van den Tweel JG, 2010, VIRCHOWS ARCH, V457, P3, DOI 10.1007/s00428-010-0934-4; Wayte A, 2016, WORKFORCE PLANNING R; Wood DF, 2003, BMJ-BRIT MED J, V326, P328, DOI 10.1136/bmj.326.7384.328; Yu TC, 2011, ADV MED EDUC PRACT, V2, P157, DOI 10.2147/AMEP.S14383	20	3	3	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAY	2018	472	5					853	863		10.1007/s00428-018-2299-z			11	Pathology	Pathology	GG9NI	WOS:000433027400016	29488009	Green Published, Other Gold			2019-10-28	
